<SEC-DOCUMENT>0001564590-21-016117.txt : 20210329
<SEC-HEADER>0001564590-21-016117.hdr.sgml : 20210329
<ACCEPTANCE-DATETIME>20210329160606
ACCESSION NUMBER:		0001564590-21-016117
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		108
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210329
DATE AS OF CHANGE:		20210329

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Frequency Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001703647
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				472324450
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39062
		FILM NUMBER:		21781751

	BUSINESS ADDRESS:	
		STREET 1:		19 PRESIDENTIAL WAY, SUITE 203
		CITY:			WOBURN
		STATE:			MA
		ZIP:			01801
		BUSINESS PHONE:		781-315-4600

	MAIL ADDRESS:	
		STREET 1:		19 PRESIDENTIAL WAY, SUITE 203
		CITY:			WOBURN
		STATE:			MA
		ZIP:			01801
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>freq-10k_20201231.htm
<DESCRIPTION>10-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
freq-10k_20201231.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;margin-top:2pt;border-top:Double 2.25pt;padding-top:1pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549 </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:42.86%;margin-right:42.86%;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 10-K<font style="font-weight:normal;"> </font></p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:42.86%;margin-right:42.86%;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Mark&#160;One) </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:4.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top"  style="width:95.24%;">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934 </p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the fiscal year ended December 31, 2020</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OR </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:4.76%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="width:95.24%;">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934 FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; TO &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commission File Number&#160;001-39062</p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:42.86%;margin-right:42.86%;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:21pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">FREQUENCY THERAPEUTICS, INC.</font><font style="color:#000000;"> </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as specified in its Charter) </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:42.86%;margin-right:42.86%;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Delaware</font></p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">47-2324450</font></p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">incorporation or organization)</p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:3pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:3pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">19 Presidential Way, 2nd Floor</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Woburn, MA</p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">01801</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code: <font style="Background-color:#FFFFFF;color:#000000;">(866)&#160;389-1970</font></p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:42.86%;margin-right:42.86%;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b) of the Act: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:41%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Symbol(s)</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:41%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top"  style="width:41%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Common Stock, $0.001 par value per share</font></p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:16%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">FREQ</font></p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:41%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The Nasdaq Global Select Market</font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(g) of the Act: <font style="font-weight:bold;">None </font></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;YES&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font> NO&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act. &#160;YES&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font> NO&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. &#160;YES&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font> NO&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the Registrant was required to submit such files). &#160;YES&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font> NO&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:10.8pt;">
<td valign="top"  style="width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large&#160;accelerated&#160;filer</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated&#160;filer</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr style="height:1.9pt;">
<td valign="top"  style="width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-accelerated filer</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
</tr>
<tr style="height:1.9pt;">
<td valign="top"  style="width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). &#160;YES&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font>NO&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.46%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under&#160;<font style="text-decoration:underline;">Section 404(b) of the Sarbanes-Oxley Act</font>&#160;(<font style="text-decoration:underline;">15 U.S.C. 7262(b)</font>) by the registered public accounting firm that prepared or issued its audit report.<font style="font-family:Segoe UI Symbol;"> &#9744;</font></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate market value of common stock held by non-affiliates of the registrant based on the closing price of the registrant&#8217;s common stock as reported on the Nasdaq Global Select Market on June 30, 2020, was $625.8 million.</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> The number of shares of Registrant&#8217;s Common Stock outstanding as of March&#160;19, 2021 was 34,177,771. </p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portions of the Proxy Statement for the registrant&#8217;s&#160;2021&#160;Annual Meeting of Stockholders are incorporated by reference into Part&#160;III of this Annual Report on Form 10-K.</p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU1"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Table of Contents</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:83%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#bbbbbb"><font style="text-decoration:underline;">Forward-Looking Statements</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#cccccccc"><font style="text-decoration:underline;">Risk Factors Summary</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_I"><font style="text-decoration:underline;">PART I</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_BUSINESS"><font style="text-decoration:underline;">Business</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1A.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS"><font style="text-decoration:underline;">Risk Factors</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1B.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1B_UNRESOLVED_STAFF_COMMENTS"><font style="text-decoration:underline;">Unresolved Staff Comments</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_PROPERTIES"><font style="text-decoration:underline;">Properties</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;3.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_LEGAL_PROCEEDINGS"><font style="text-decoration:underline;">Legal Proceedings</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;4.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_MINE_SAFETY_DISCLOSURES"><font style="text-decoration:underline;">Mine Safety Disclosures</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_II"><font style="text-decoration:underline;">PART&#160;II</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;5.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"><font style="text-decoration:underline;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;6.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_SELECTED_FINANCIAL_DATA"><font style="text-decoration:underline;">Selected Financial Data</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><font style="text-decoration:underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7A.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"><font style="text-decoration:underline;">Quantitative and Qualitative Disclosures About Market Risk</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;8.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"><font style="text-decoration:underline;">Financial Statements and Supplementary Data</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"><font style="text-decoration:underline;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9A.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9A_CONTROLS_PROCEDURES"><font style="text-decoration:underline;">Controls and Procedures</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9B.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9B_OR_INFORMATION"><font style="text-decoration:underline;">Other Information</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_III"><font style="text-decoration:underline;">PART&#160;III</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;10.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"><font style="text-decoration:underline;">Directors, Executive Officers and Corporate Governance</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;11.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_11_EXECUTIVE_COMPENSATION"><font style="text-decoration:underline;">Executive Compensation</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;12.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"><font style="text-decoration:underline;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;13.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"><font style="text-decoration:underline;">Certain Relationships and Related Transactions, and Director Independence</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;14.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"><font style="text-decoration:underline;">Principal Accounting Fees and Services</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_IV"><font style="text-decoration:underline;">PART&#160;IV</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;15.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"><font style="text-decoration:underline;">Exhibits, Financial Statement Schedules</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;16</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16_FORM_10K_SUMMARY"><font style="text-decoration:underline;">Form 10-K Summary</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="bbbbbb"></a><a name="bbbbbb"></a>FORWARD-LOOKING STATEMENTS</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K, or Annual Report, contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this Annual Report, including statements regarding our future results of operations and financial position, business strategy, product candidates, clinical development plans and expectations, prospective products, product approvals, research and development costs, timing and likelihood of success, and plans and objectives of management for future operations and results, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions. The forward-looking statements in this Annual Report are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Annual Report and are subject to a number of important factors that could cause actual results to differ materially from those in the forward-looking statements, including the risks, uncertainties and assumptions described under the sections in this Annual Report titled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; These forward-looking statements are subject to numerous risks, including, without limitation, the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the initiation, timing, progress and results of our preclinical and clinical trials and research and development of programs, including our ongoing Phase 1b and Phase 2a clinical trials and any planned additional Phase 2 clinical trials or Phase 3 clinical trials for FX-322 and our program to develop a product candidate for the treatment of multiple sclerosis, or MS;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the impact of the novel coronavirus, COVID-19, on our ongoing and planned clinical trials, our research and development activities and our business and financial markets;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our ability to continue to develop our progenitor cell activation, or PCA, platform and identify additional product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our ability to successfully complete clinical trials of any product candidate and obtain regulatory approval for it;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the timing or likelihood of regulatory filings and approvals, including our planned filing of an investigational new drug application for our MS product candidate;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the commercialization, marketing and manufacture of any product candidate, if approved;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the pricing and reimbursement of any product candidate, if approved;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the rate and degree of market acceptance and clinical utility of any products for which we receive regulatory approval;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the implementation of our strategic plans for our business, product candidates, and technology;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates, PCA platform, and technology;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">estimates of our expenses, future revenues, capital requirements, and our needs for additional financing;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our ability to maintain and establish collaborations, including our License and Collaboration Agreement with Astellas Pharma Inc.;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our financial performance and the sufficiency of our financial resources; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">developments relating to our competitors and our industry, including the impact of government regulation.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. As a result of these factors, we cannot assure you that the forward-looking statements in this Annual Report will prove to be accurate. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances, or otherwise.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You should read this Annual Report and the documents that we reference in this Annual Report completely and with the understanding that our actual future results may be materially different from what we expect. We qualify that all of our forward-looking statements by these cautionary statements.</p><a name="_AEIOULastRenderedPageBreakAEIOU3"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="cccccccc"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RI</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="cccccccc"></a>SK FACTO</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RS SUMMARY</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business is subject to numerous risks and uncertainties, including those described in Part I Item 1A. &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K. You should carefully consider these risks and uncertainties when investing in our common stock. The principal risks and uncertainties affecting our business include the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.57%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">We are heavily dependent on the success of FX-322, our lead product candidate, which is still under clinical development. If FX-322 does not receive regulatory approval or is not successfully commercialized, our business will be materially adversely harmed; </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">We utilize our PCA platform to develop product candidates that are designed to activate progenitor cells, which is a new approach to therapeutic intervention and, as a result, successful development, approval, and commercialization of our product candidates, including&#160;FX-322,&#160;is uncertain; </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Clinical trials are expensive, time consuming, and difficult to design and implement, and involve an uncertain outcome. The results of preclinical studies and early clinical trials are not always predictive of future results. Our interim Phase 2a results, for example, showed that four weekly injections in subjects with mild to moderately severe SNHL did not demonstrate improvements in hearing measures versus placebo. Any product candidate that we advance into clinical trials may not achieve favorable results in later clinical trials, if any, or receive marketing approval; </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time consuming, and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for FX-322 or any other product candidates, our business will be substantially harmed; </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">We may not be successful in our efforts to identify additional product candidates. Due to our limited resources and access to capital, we must prioritize development of certain product candidates, the choice of which may prove to be wrong and adversely affect our business; </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">If we fail to comply with our obligations in our intellectual property licenses and funding arrangements with third parties, or otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important to our business; </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">We will require additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of FX-322 and additional product candidates;&nbsp;&nbsp;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">We face significant competition from biotechnology, pharmaceutical, and medical device companies and our operating results will suffer if we fail to compete effectively; </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.14%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">If we are unable to establish sales and marketing capabilities either on our own or in collaboration with third parties, we may not be successful in commercializing any product candidate we develop, if approved; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The COVID-19 pandemic has caused and could continue to cause disruptions to our business, including our preclinical studies, clinical trials and operations and could adversely impact our financial condition and results of operations. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.14%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_I"></a><a name="PART_I"></a>PART I</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1_BUSINESS"></a><a name="ITEM_1_BUSINESS"></a>Item 1. Business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage biotechnology company focused on harnessing the body&#8217;s innate biology to repair or reverse damage caused by a broad range of degenerative diseases and a global leader in the science and development of medicines for inner-ear cellular regeneration and hearing restoration.&#160;Our initial focus is on advancing our lead product candidate, FX-322, through clinical studies with the goal of developing and commercializing a medicine to help millions of patients with the most common form of hearing loss and build upon the potential of regenerative therapeutics for hearing. We believe we are a leading company using mitotic regeneration for cochlear sensory hair cell regeneration and that FX-322 has the potential to meaningfully improve overall hearing function and enhance quality of life. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our proprietary approach, called Progenitor Cell Activation, or PCA, uses combinations of small molecules to activate progenitor cells within the body to create functional tissue.&nbsp;&nbsp;These progenitor cells, which are closely related to stem cells, are already resident in the targeted location in the body and programmed to develop and differentiate into specific cell types within an organ, which we believe provide us the opportunity to pursue multiple proposed indications and develop potential<font style="font-size:12pt;"> </font>treatments for an array of degenerative diseases throughout the body. To that end, in addition to our lead program in hearing, we are working to rapidly advance discovery efforts focused on using our PCA approach to potentially remyelinate nerves in patients with multiple sclerosis, or MS and are advancing this program in collaboration with The Scripps Research Institute, or Scripps, and Cambridge Enterprise Limited (the technology transfer arm of the University of Cambridge), or Cambridge. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk64904358"></a>Our hearing program is for a condition called sensorineural hearing loss, or SNHL, which is the most prevalent type of hearing loss, typically caused by permanent loss of sensory hair cells in the cochlea within the ear. Cochlear sensory hair cells can be lost by noise exposure, as a result of aging, certain viral infections or exposure to ototoxic drugs.  FX-322 aims to treat the underlying cause of SNHL by regenerating hair cells through the activation of progenitor cells already present in the cochlea. In July 2019, we entered into a license and collaboration agreement, or the Astellas Agreement, with Astellas Pharma Inc., or Astellas, under which we granted them rights to develop and commercialize FX-322 outside of the United States.&nbsp;&nbsp;In September 2019, at the annual meeting of the American Academy of Otolaryngology, the principal investigator from our Phase 1/2 clinical trial evaluating FX-322 in 23 patients with stable SNHL shared preclinical and clinical data that showed that FX-322 was well-tolerated with no serious adverse effects and that we observed statistically significant and clinically meaningful improvement in key measures of hearing loss, including word recognition, or WR, and clarity of sound<a name="_Hlk64904358"></a>. Specifically, thirty-three percent (33%) of these subjects achieved a ten percent (10%) or greater absolute improvement in WR scores in the treated ear. The study results were accepted for publication in the peer-reviewed journal <font style="font-style:italic;">Otology and Neurotology</font> and were published in February 2021. They were also presented at the 2021 Association for Research in Otolaryngology 44<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> Annual Mid-Winter Meeting in February 2021.&nbsp;&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk34906381"></a><a name="_Hlk34650132"></a>In October 2019, we commenced dosing in a Phase 2a clinical trial of FX-322 and the FDA granted FX-322 Fast Track designation.&nbsp;&nbsp;The goals of the trial are to further establish the hearing signal observed in the Phase 1/2 clinical trial, evaluate the impact of multiple doses and provide insights on endpoints and patient population for further studies. In March 2021, we announced topline, day-90 interim data from the Phase 2a clinical trial. The results showed that four weekly injections in subjects with mild to moderately severe SNHL did not demonstrate improvements in hearing measures versus placebo. While our interim data showed that WR scores increased across all groups, repeated weekly injections appeared to dampen the hearing benefit observed compared to other single injection-studies. The interim results also showed an unexpected apparent level of hearing benefit in the placebo group that did not occur in previous trials and exceeded well-established published standards. No treatment-related serious adverse events were observed in the study. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2020, we announced top-line data from an exploratory clinical study in Germany that we believe demonstrated that FX-322 effectively reached the cochlea at levels predicted, based on computer models, to be therapeutically active. Results from the exploratory study showed measurable concentrations of FX-322 in every sample analyzed and that anatomical factors did not prevent FX-322 from reaching the cochlea. The study results were based on analyzing samples of cochlear fluid, known as perilymph, taken intraoperatively from patients undergoing cochlear implant surgery. A total of seven patients received a single intratympanic injection of FX-322, enabling researchers to directly measure the level of FX-322 in perilymph, which is not otherwise feasible in inner-ear studies because accessing the cochlea involves an invasive surgical procedure. Study patients were followed for approximately 30 days after the procedure and no serious treatment related adverse events were observed.&nbsp;&nbsp;The results of this study were included in the article accepted for publication in <font style="font-style:italic;">Otology and Neurotology </font>and published in February 2021.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk67382394"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2020, we shared preliminary findings from a longer-term, follow-up study of certain patients that had been treated with FX-322 in the randomized portion of the Phase 1/2 clinical trial, where we observed improvements in certain key measures of hearing loss. WR tests were performed for five patients at timepoints between 12- and 21-months following FX-322 administration. Four of the patients that were observed to have statistically significant WR scores during the Phase 1/2 clinical </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trial </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk67382394"></a>were observed to have maintained the hearing benefit, three of which remained at statistically significant levels. An additional </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patient who did not achieve a statistically significant improvement in WR during the Phase 1/2 clinical trial was also retested and it was observe</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d that the WR score had returned to baseline. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The results of this study were presented at the American Academy of Otolaryngology &#8211; Head &amp; Neck Surgery meeting in September 2020.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2021, we announced new data from a Phase 1b clinical trial of FX-322 designed to evaluate the impact of injection conditions on tolerability. The data showed hearing improvement from a single injection of FX-322. In the multi-center, randomized study, subjects with mild to severe SNHL (n=33) were injected in one ear with FX-322 with the untreated ear as the control. Hearing function was tested over the course of 90 days following dosing. Thirty-two (n=32) subjects completed the 90 day clinical assessment period and, at day 90 following dosing, thirty-four percent (34%) of these subjects achieved a ten percent (10%) or greater absolute improvement in WR scores in the treated ear, which was clinically meaningful and statistically significant compared to the untreated ear (p &lt;0.05). This included a subset of subjects that more than doubled their WR scores. The single dose had a favorable safety profile and was well tolerated.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We commenced a Phase 1b clinical trial of FX-322 for age-related hearing loss in October 2020. The clinical trial is a double-blind, placebo-controlled, randomized multicenter safety study of up to 30 individuals aged 66-85 with mild to moderately severe age-related hearing loss. The primary objectives of the Phase 1b study are to assess the local and systemic safety of a single dose of FX-322 and evaluate hearing responses in an older adult cohort. Study participants will be randomized 4:1 to receive either FX-322 or placebo in one ear. Validated measures of hearing including WR, WIN, and pure tone audiometry will be used. Safety, otologic and audiologic assessments will be conducted at day 30 and 90 following administration of FX-322 or placebo. We expect to share results from this clinical trial in the second quarter of 2021.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We commenced a Phase 1b clinical trial of FX-322 in patients aged 18-65 with severe SNHL in November 2020. Severe SNHL is defined as a pure tone average deficit between 71-90 dB. Many patients with this clinical profile typically would be candidates for cochlear implants. This clinical trial employs a similar design to the age-related Phase 1b clinical trial that is currently underway. We expect to share results from this clinical trial in the third quarter of 2021.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, no drug therapies have been approved by the FDA or, to our knowledge, by other regulatory bodies, for the treatment of SNHL. Existing devices such as hearing aids amplify sounds but do not replace hair cells, which have roles in clarifying sound and improving speech intelligibility, particularly in noisy environments. Hearing aids also cannot repair the underlying pathology of hearing loss. While hearing loss is often thought to be caused by aging, the condition is strongly correlated with living in an industrialized society. According to the World Health Organization, or WHO, 1.5 billion people, 20% of the world&#8217;s population, suffer from some degree of hearing loss worldwide, and, according to the National Institutes of Health, or NIH, more than 90% of people with hearing loss have SNHL. Based on our estimates, we believe that 41 million people in the United States alone have SNHL. The WHO also estimates that 1.1&#160;billion children and adults ages 12 to 35 years old are at risk for hearing loss from recreational noise exposure. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk32674668"></a>Under the Astellas Agreement, Astellas is responsible for the development and commercialization of FX-322 outside of the United States. As consideration for the licensed rights under the Astellas Agreement, Astellas paid us an upfront payment of $80.0 million in July 2019 and has agreed to pay potential development milestone payments of <a name="_Hlk32674668"></a>up to $230.0 million. Specifically, we would receive development milestone payments of $65.0 million and $25.0 million upon the first dosing of a patient in a Phase 2b clinical trial for SNHL in Europe and Asia, respectively, and $100.0 million and $40.0 million upon the first dosing of a patient in a Phase 3 clinical trial for SNHL in Europe and Asia, respectively.&nbsp;&nbsp;If the Astellas licensed products are successfully commercialized, we would be eligible for up to $315.0 million in potential commercial milestone payments plus tiered royalties on any future product sales ranging from low- to mid-teen percentages. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our MS program focuses on activating oligodendrocyte progenitor cells in the central nervous system to repair the myelin sheath that protects nerves and may have the potential to reverse damage done by the disease. <font style="color:#000000;">We established an internal research program using PCA to drive remyelination as a potential therapy for MS and have identified compounds that display promising preliminary preclinical results in an </font><font style="font-style:italic;color:#000000;">in vivo</font><font style="color:#000000;"> model of remyelination. Our research efforts are focused on optimizing these compounds and identifying a lead therapeutic candidate to advance into clinical trials. We have obtained worldwide licenses for intellectual property from Scripps and Cambridge Enterprise on approaches to promote remyelination of nerve fibers and are engaged in sponsoring clinical research to validate this approach at Cambridge University.&#160;</font> </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Imp</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">act of COVID-19 </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our offices are located in states that are currently operating under a phased re-opening plan in response to the COVID-19 pandemic. As of the date of the filing of this Annual Report, the majority of our employees continue to work from home, while nearly a quarter to one-third of our workforce, consisting of mainly laboratory personnel, have periodically worked in rotating teams to ensure the continuation of essential experiments. Our Farmington, CT research site, co-located with the University of Connecticut, has resumed activity at a fifty percent level after a period of paused activity due to state lock down orders previously in effect. While we have resumed experiments at our Farmington site, we have transitioned certain key experiments to our offices in Woburn, MA and third parties and contract research organizations have been engaged to advance certain projects. We are also have taken steps consistent with the FDA&#8217;s updated industry guidance for conducting clinical trials.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 pandemic, and actions taken to mitigate it, have had and are expected to continue to have an adverse impact on the economies and financial markets of many countries, including the geographical area in which we operate, which could adversely impact our ability to raise additional capital when needed or on acceptable terms, if at all. In addition, while no significant disruptions have occurred, the COVID-19 pandemic may cause such disruptions in our business or operations, as well as the business and operations of our CMOs, CROs and other third parties with whom we conduct business. The COVID-19 pandemic may also adversely impact our clinical trials, which could impede, delay, limit or prevent the clinical development of our product candidates and ultimately lead to the delay or<font style="font-weight:bold;"> </font>denial of regulatory approval of our product candidates, which would materially adversely affect our business and operations, including our ability to generate revenue.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our product pipeline </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our PCA therapeutic candidate pipeline and discovery research programs: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><img src="gyycud3vz5ad000001.jpg" title="" alt="" style="width:602px;height:350px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our team and history </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our company was founded in 2014 with the goal of creating medicines based on breakthrough research focused on activating the body&#8217;s regenerative potential. In their groundbreaking research, Professors Robert S. Langer at the Massachusetts Institute of Technology and Jeffrey Karp at Harvard Medical School, decoded the natural signals between cells that make the intestine one of the most regenerative organs in the body through the continuous activation of progenitor cells. Recognizing that similar progenitor cells were present but inactive in other organs, they discovered how to adapt these natural signals using small molecules to temporarily activate progenitor cells in other organs, including the cochlea, and create a localized healing response. Using these insights, we are developing FX-322 for the treatment of SNHL, and, in a </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phase 1/2 trial of FX-322 in stable hearing loss patients, we have observed statistically significant improvement in WR, a key measure of hearing function. Further, we have identified several additional potential indications for our PCA platform and expanded our team to incorporate domain expertise to pursue our goal of becoming a fully integrated biotechnology company. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our leadership team includes experienced biotech executives David L. Lucchino, our Chief Executive Officer and co-founder, Christopher R. Loose, our Chief Scientific Officer and co-founder, Peter P. Pfreundschuh, our Chief Financial Officer, Carl P. LeBel, our Chief Development Officer, Dana C. Hilt, our Chief Medical Officer, Quentin McCubbin, our Chief Manufacturing Officer, Michael D. Bookman, our General Counsel, and Wendy S. Arnold, our Chief People Officer. We have also assembled a world-class team of leaders in regenerative biology, otology, drug development, and drug delivery. Our Clinical Advisory Board is comprised of leaders in hearing science and technology who shape how the community thinks about hearing function and restoration. Our Regenerative Medicine Advisory Board members are at the forefront of scientific discovery on the activation of progenitor cells and their potential application to therapeutic interventions in diseases of multiple tissues and organs. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our strategy </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to create and commercialize therapeutics to potentially transform the lives of patients by repairing or reversing damage done to cells, tissue, and organs. To do so, we are implementing the following strategies: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">Advance development of a single dose regimen of FX-322 for the treatment of SNHL</font><font style="font-size:10pt;color:#000000;">. We believe our lead product candidate has the potential to improve hearing function for the millions of patients affected by SNHL who currently have no therapeutic options. We now have two independent, single-dose studies in patients with mild to severe SNHL that showed a hearing signal with FX-322 and with statistically significant improvements in speech intelligibility. The interim results from our Phase 2a study demonstrated that four weekly injections in subjects with mild to moderately severe SNHL did not demonstrate improvements in hearing measures versus placebo. Therefore, we plan to advance further development of FX-322 as a single dose regimen.  </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">Establish our position as a global leader in the field of hearing function. </font><font style="font-size:10pt;color:#000000;">We plan to continue to grow our discovery organization and add experts in the field of otology to drive the optimization of our PCA approach for the treatment of hearing loss. We also plan to expand our presence in the field of hearing restoration and to work closely with the broader community of advocates, physicians, and payors to bring new treatments to patients globally. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Hlk34126144"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">Expand the opportunities of our PCA platform beyond hearing.</font><font style="font-size:10pt;color:#000000;"> We believe our PCA platform has the potential to address a wide range of clinical applications. We will continue to invest in research and development to enhance our PCA platform with the goal of delivering new therapeutics in additional indications, such as diseases of the muscle, gastrointestinal tract, skin, and bone. We identified MS as a disease where PCA has the potential to produce a restorative effect by stimulation of oligodendrocyte precursor cells (OPCs) to myelinate axons.<a name="_Hlk34126144"></a> We have obtained worldwide licenses for intellectual property from Scripps and Cambridge, on approaches to promote remyelination of nerve fibers. </font><font style="color:#000000;font-size:10pt;">We established an internal research program using PCA to drive remyelination as a potential therapy for MS and have identified compounds that display promising preliminary preclinical results in an </font><font style="font-style:italic;color:#000000;font-size:10pt;">in vivo</font><font style="color:#000000;font-size:10pt;"> model of remyelination. Our research efforts are focused on optimizing these compounds and identifying a lead therapeutic candidate to advance into clinical trials. We have obtained worldwide licenses for intellectual property from Scripps and Cambridge Enterprise on approaches to promote remyelination of nerve fibers and are engaged in sponsoring clinical research to validate this approach at Cambridge University.&#160;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">Continue to build strategic collaborative relationships</font><font style="font-size:10pt;color:#000000;">. Given the broad potential opportunity of our PCA platform, we believe entering into strategic research, development, and commercial collaborations in select therapeutic areas may provide an attractive avenue to facilitate the capital-efficient development of our PCA platform and product pipeline. We believe these strategic collaborations could potentially provide significant funding to advance our product candidates while allowing us to benefit from the development and therapeutic area expertise of our collaborators. We may collaborate with large pharmaceutical companies, biotechnology companies, and academic institutions to maximize the potential of our PCA platform to create new therapies for patients. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our approach: Progenitor cell activation within the body </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are pioneering a new class of small molecule therapeutics designed to activate progenitor cells already present within the body to create healthy functional tissues and organs. We developed our PCA platform to identify combinations of small molecules that selectively activate progenitor cells to regenerate tissues. Our initial therapeutic focus is SNHL. We believe that our preclinical and clinical studies in SNHL have validated the potential of our PCA platform to provide a new approach to regenerative medicine. Other potential applications of our PCA platform include, but are not limited to, diseases of the muscle, gastrointestinal tract, skin, and bone. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The graphic below illustrates the application of our PCA platform to activate progenitor cells and create healthy functioning target cells. Our small molecules are designed to activate key genes in a progenitor cell, which enable the cell to go through asymmetric division, leaving behind a copy of the progenitor cell as well as creating a functional cell, such as a hair cell. This asymmetric division process is a common mechanism used during the natural development and repair of tissues. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><img src="gyycud3vz5ad000002.jpg" title="" alt="" style="width:660px;height:375px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Relationship between stem cells and progenitor cells </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All cells in the human body arise from a single unspecialized, or undifferentiated, cell type called a pluripotent stem cell. Two of the key characteristics of pluripotent stem cells are their ability to renew themselves through cell division and the ability to differentiate into any cell type. Progenitor cells have similar self-renewal properties as pluripotent stem cells. However, progenitor cells are programmed to develop and differentiate into specific cell types within an organ. This process can be visualized using Waddington&#8217;s epigenetic landscape, which depicts a pluripotent stem cell as a ball rolling down a hill as development progresses (see graphic below). As the ball commits to specific valleys, the cell becomes more specialized and increasingly commits to a tissue-specific fate, such as a progenitor cell. The progenitor cells are programmed to create specific cell types, and, in some cases, allow mature tissue and organs to repair and renew. However, researchers have discovered that many organs throughout the human body that do not spontaneously regenerate do contain inactive progenitor cells that, if stimulated, are potentially available to drive regeneration. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Over the course of several decades, multiple attempts have been made to harness the regenerative potential of stem cells. More recently, the 2012 Nobel Prize in Physiology or Medicine was awarded to Dr.&#160;Shinya Yamanaka for discovering how to create induced pluripotent stem cells by adding four genetic factors to a fully differentiated cell, as illustrated by the solid black arrow in the graphic below. However, the Yamanaka factors cannot be applied <font style="font-style:italic;">in vivo</font>, and<font style="font-style:italic;"> </font>it has proven challenging to manufacture pluripotent or other human stem cells outside of the body and to control their differentiation to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">produce a particular cell type. Further, delivering and properly integrating these cells back into the body adds substantial complexity. Using another approach, some investigators have tried to force progenitor cells within the body to directly convert into other cell types through a process called trans-differentiation, as illustrated by the dotted black arrow in the graphic below. However, trans-differentiation may deplete progenitor cells, which reduces the target cell population for future treatments. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that our PCA approach bypasses the challenges presented by stem cell therapies by utilizing small molecule therapeutics to temporarily reactivate progenitor cells that are already located at the tissue target site within the body and are pre-programmed to make specific cell types. Our combinations of small molecules are designed to induce a progenitor cell to temporarily enter an active state, where it then divides asymmetrically, replacing itself (blue arrows) and regenerating a desired cell type (orange arrow). Asymmetric division occurs when organs naturally regenerate, so progenitor cells are thought to be maintained for future use. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gyycud3vz5ad000003.jpg" title="" alt="" style="width:672px;height:301px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">=</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Key attributes of our PCA platform </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our discoveries in regenerative medicine allow us to activate the innate and under-utilized capabilities of progenitor cells. We believe our PCA platform represents a transformative step in the evolution of regenerative medicine by providing the following key attributes: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">Activates progenitor cells in the right location</font><font style="font-size:10pt;color:#000000;">. We overcome the major challenge of delivering and integrating cells into the proper location within tissue. Our small molecule therapeutic candidates activate the body&#8217;s own progenitor cells at the desired location in targeted tissues. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">Enables ease of manufacturing</font><font style="font-size:10pt;color:#000000;">. We eliminate the need to remove and grow live cells </font><font style="font-style:italic;font-size:10pt;color:#000000;">ex vivo</font><font style="font-size:10pt;color:#000000;">, which can be costly and complex to manufacture, difficult to control quality, and may pose potential safety risks. In contrast, our small molecule therapeutic candidates will be produced using standard manufacturing methods. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">Avoids permanent genetic changes</font><font style="font-size:10pt;color:#000000;">.&#160;&#160;&#160;&#160;Instead of altering genes, our small molecules are designed to temporarily activate the innate genes that play a central role in the development of organs and tissues. This small molecule approach could create a disease-modifying or restorative effect without changing the body&#8217;s genetic code. In addition, we believe we avoid the risk of acquiring immune reactivity to our therapeutics, which is commonly associated with genetically modifying cells. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our therapeutic discovery process </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We utilize a proprietary process to identify small molecule combinations for activating progenitor cells. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">Discovery in the right context</font><font style="font-size:10pt;color:#000000;">. Traditional drug screening uses immortalized cell lines that are convenient for use in a laboratory but may not reflect the complex biology of tissue-specific cell types in the body. In our </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="font-size:10pt;color:#000000;">discovery process, we develop primary progenitor cell assays that are designed to maintain these cells in their natural state </font><font style="font-size:10pt;color:#000000;">in order to</font><font style="font-size:10pt;color:#000000;"> increase the likelihood of successful drug discovery and translation into an effective tissue-specific therapeutic. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">Decoding and controlling activation pathways for progenitor cells</font><font style="font-size:10pt;color:#000000;">. We use our accumulated insights into&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;progenitor cell signaling and aging to identify biological pathways that may activate a specific progenitor cell. We then select and apply combinations of small molecules from our proprietary toolbox of compounds to modulate the chosen biological pathways and achieve PCA.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By assessing our small molecule combinations in a highly relevant context, we and our collaborators have applied this discovery process to identify compounds that activate progenitor cells in numerous tissues. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our hearing program </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We first applied our PCA platform to create FX-322, our lead product candidate designed to restore hearing function in patients with SNHL. We completed a Phase 1/2 clinical trial in 23 patients with stable SNHL in which we observed a statistically significant improvement in WR, a key measure of hearing function, and FX-322 was observed to be well-tolerated. Specifically, thirty-three percent (33%) of these subjects achieved a ten percent (10%) or greater absolute improvement in WR scores in the treated ear. In May 2020, we shared clinical data that showed delivery of FX-322 to the cochlea at levels predicted to reach the therapeutically active range of the treatment. In September 2020, at the American Academy of Otolaryngology annual meeting, we presented data showing sustained improvements in speech intelligibility and audibility measures in patients up to 21 months after receiving an initial dose of FX-322 in our Phase 1/2 study. The Phase 1/2 and cochlear delivery study results were accepted for publication in the peer-reviewed journal <font style="font-style:italic;">Otology and Neurotology</font> and were published in February 2021. We believe that FX-322 has the potential to meaningfully improve overall hearing function and significantly enhance quality of life for patients with hearing loss.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk63697201"></a>In October 2019, we commenced dosing in a Phase 2a clinical trial of FX-322 and the FDA granted FX-322 Fast Track designation.&nbsp;&nbsp;The goals of the trial are to further establish the hearing signal observed in the Phase 1/2 clinical trial, evaluate the impact of multiple doses and provide insights on endpoints and patient population for further studies. In March 2021, we announced topline, day-90 interim data from the Phase 2a clinical trial. The results showed that four weekly injections in subjects with mild to moderately severe SNHL did not demonstrate improvements in hearing measures versus placebo. No treatment-related serious adverse events were observed in the study. In the four-arm Phase 2a study, 95 subjects aged 18-65 are being evaluated for hearing improvement using WR, Words-In-Noise, or WIN, pure tone audiometry and additional exploratory measures. All subjects were administered a total of four weekly intratympanic injections comprised of zero, one, two, or four doses of FX-322 with the balance of injections comprised of placebo doses. While our interim data showed that WR scores increased across all groups, repeated weekly injections appeared to dampen the hearing benefit observed compared to other single injection-studies. The Phase 2a interim results also showed an unexpected apparent level of hearing benefit in the placebo group that did not occur in previous trials and exceeded well-established published standards, potentially suggesting bias due to trial design. Given these challenges observed in the Phase 2a study design, the interim results showed no discernible hearing benefit of FX-322 over placebo. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2020, we announced top-line data from an exploratory clinical study in Germany that we believe demonstrated that FX-322 effectively reached the cochlea at levels predicted, based on computer models, to be therapeutically active. Top-line results from the exploratory study showed measurable concentrations of FX-322 in every sample analyzed and that anatomical factors did not prevent FX-322 from reaching the cochlea. The study results were based on analyzing samples of cochlear fluid, known as perilymph, taken intraoperatively from patients undergoing cochlear implant surgery. A total of seven patients received a single intratympanic injection of FX-322, enabling researchers to directly measure the level of FX-322 in perilymph, which is not otherwise feasible in inner-ear studies because accessing the cochlea involves an invasive surgical procedure. Study patients were followed for approximately 30 days after the procedure and no serious treatment related adverse events were observed. The study results were accepted for publication in the peer-reviewed journal <font style="font-style:italic;">Otology and Neurotology</font> and were published in February 2021.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk63697221"></a>In June 2020, we shared preliminary findings from a longer-term, follow-up study of certain patients that had been treated with FX-322 in the randomized portion of the Phase 1/2 clinical trial, where we observed improvements in certain key measures of hearing loss. WR tests were performed for five patients at timepoints between 12- and 21-months following FX-322 administration. Four of the patients that were observed to have statistically significant WR scores during the Phase 1/2 clinical trial were observed to have maintained the hearing benefit, three of which remained at statistically significant levels. An additional patient who did not achieve a statistically significant improvement in WR during the Phase 1/2 clinical trial was also retested and it was observed that the WR score had returned to baseline. The results of this study were presented at the American Academy of Otolaryngology &#8211; Head &amp; Neck Surgery meeting in September 2020.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2021, we announced new data from a Phase 1b clinical trial of FX-322 designed to evaluate the impact of injection conditions on tolerability. The data showed hearing improvement from a single injection of FX-322. In the multi-center, randomized study, subjects with mild to severe SNHL (n=33) were injected in one ear with FX-322 with the untreated ear as the control. Hearing function was tested over the course of 90 days following dosing. Thirty-two (n=32) subjects completed the 90 day clinical assessment period and, at day 90 following dosing, thirty-four percent (34%) of these subjects achieved a ten percent (10%) or greater absolute improvement in WR scores in the treated ear, which was clinically meaningful and statistically significant compared to the untreated ear (p &lt;0.05). This included a subset of subjects that more than doubled their WR scores. The single dose had a favorable safety profile and was well tolerated.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As shown in the graph below, we now have two independent, single-dose studies in patients with mild to severe SNHL that showed a hearing signal with FX-322 and with statistically significant improvements in speech intelligibility.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<img src="gyycud3vz5ad000004.jpg" title="" alt="" style="width:507px;height:344px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Impact and prevalence of hearing loss </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">According to the WHO, 1.5 billion people suffer from some degree of hearing loss worldwide, and, according to the NIH, more than 90% of people with hearing loss have SNHL. Based on our estimates, we believe that approximately 41&#160;million people in the United States alone have SNHL. The WHO also estimates that 1.1&#160;billion children and adults ages 12 to 35 years old are at risk for hearing loss from recreational noise exposure. In middle- and high-income countries, the WHO estimates that nearly 50% of people aged 12 to 35 listen to personal audio devices at unsafe sound levels. Moreover, damage from noise exposure in early childhood can render the ears more susceptible to the effects of aging. Noise exposure is difficult to avoid in modern society. Noise at restaurants, for example, routinely climbs into the high 70-decibel, or dB, range, equivalent to a canister vacuum cleaner, and sometimes to the mid-80 dB, as loud as a nearby diesel truck. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. prevalence of </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SNHL,</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ranging from mild to moderate to severe</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, is shown in the graph below, which is from</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> data from the National Center for Health Statistics (NCHS)</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each SNHL patient population is being studied in the current FX-322 clinical program. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gyycud3vz5ad000005.jpg" title="" alt="" style="width:598px;height:328px;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk63962166"></a>After a patient first complains of hearing loss, which is most often to their primary care physician, patients with SNHL are managed by audiologists and <a name="_Hlk63962166"></a>otolaryngologists, who are trained as ear, nose, and throat specialists, or ENTs. In the United States, there are about 13,000 audiologists and about 12,500 ENTs. Developing a therapeutic to potentially modify an underlying cause of SNHL may provide a critically important treatment option for this group of health-care providers and their patients. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are also further direct and indirect impacts on individuals suffering from SNHL. Hearing loss profoundly affects an individual&#8217;s ability to participate in the social interactions of daily life, which can lead to feelings of loneliness, isolation, and frustration. Untreated hearing loss is associated with a 50% increase in dementia and a 40% increase in depression. Adults with hearing loss also have higher unemployment rates than non-hearing-impaired adults, and a relationship between hearing loss and diminished employment and advancement opportunities has been reported. According to a 2020 study in the medical journal <font style="font-style:italic;">The Lancet</font>, hearing loss is the largest modifiable risk factor for developing dementia.</p><a name="_AEIOULastRenderedPageBreakAEIOU5"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Biology and measurement of hearing </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As shown in the figure below, we hear sounds when sound waves enter the inner ear and generate movement of the fluid in the cochlea, a portion of the inner ear that looks like a snail shell. This fluid movement causes hair cells within the cochlea to bend and in turn generate electrical signals that are transmitted to the brain via the auditory nerve. The cochlea is arranged so that hair cells at the base detect high frequencies and hair cells at the apex detect low frequencies. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gyycud3vz5ad000006.jpg" title="" alt="" style="width:595px;height:288px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Humans are born with about 15,000 hair cells in the cochlea of each ear. Hair cells are commonly lost due to noise exposure in work settings, travel or leisure activities, or as a result of aging, certain viral infections or exposure to ototoxic drugs. Lost hair cells do not spontaneously regenerate. Over time, hearing loss can accumulate with greater prevalence at high frequencies. The left panel of the figure below shows a picture of the inside of a healthy cochlea, with one row of inner hair cells, or IHCs, and three rows of outer hair cells, or OHCs. OHCs amplify or dampen sound volume and tune the cochlea to detect specific frequencies. IHCs convert sound waves into nerve impulses that are sent to the auditory nerve. Functional hair cells allow the auditory system to focus on a sound and filter it appropriately throughout the cochlea. The right panel in the below image, <font style="color:#000000;">adapted from Ryan AF PNAS 2000,</font> shows a cochlea after noise damage, with both IHCs and OHCs missing. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Healthy and Noise-Damaged Cochlea </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gyycud3vz5ad000007.jpg" title="" alt="" style="width:612px;height:175px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The two primary components for hearing testing are intelligibility, or the ability to understand spoken words, and the audibility or loudness of sound. While amplifying devices such as hearing aids can make sounds louder, they have limited ability to improve intelligibility, particularly in noisy environments. Intelligibility is particularly important to understand speech in social settings such as in meetings or at restaurants, where filtering sound is critical for communication. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intelligibility is typically measured by playing a list of words that are repeated back by the person being tested and scoring based on the number of words that the person gets correct. The two validated testing methods of speech intelligibility that are most widely used by audiologists are: word recognition, or WR, where patients are asked to identify monosyllabic words delivered at a loud, but conversational volume level, and words-in-noise, or WIN, where patients are asked to identify monosyllabic words in the presence of background, multi-talker noise. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk63961536"></a>Audibility is determined by measuring hearing function at different levels of loudness and pitch or frequency. Patients are most often tested using pure tone audiometry, in which a tone is played at a particular frequency and patients are asked to indicate whether they can hear the tone at varying levels of loudness. Loudness is recorded in dB HL. Frequency is recorded in Hertz, or Hz, and is generally measured in the range of 250 to 8000 Hz. According to the WHO, normal hearing is defined as the ability to hear sounds at a loudness value of less than 26 dB HL, which is the average of loudness values measured at a range of low, middle, and high frequencies, such as 500, 1000, 2000, and 4000 Hz. The larger the loudness value needed for a patient to hear sounds the greater the decline in hearing function, or more severe hearing loss. The graphic below depicts the severity of hearing loss across a range of frequencies based on the American Speech-Language-Hearing Association scale. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><img src="gyycud3vz5ad000008.jpg" title="" alt="" style="width:632px;height:326px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Limitations of current treatment options </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current treatment options for hearing loss have significant limitations and none are disease modifying. The only available treatments for hearing loss are hearing aids, or in extreme cases, cochlear implants. No drug therapies have been approved by the FDA or, to our knowledge, by other regulatory bodies, for the treatment of SNHL. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Hearing aids </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hearing aids help many patients cope with mild-to-moderate hearing loss and are used or have been tried by more than 10&#160;million patients in the United States. Only one in four patients with hearing loss has ever used hearing aids, and approximately half of patients who seek medical assistance for their hearing loss do not get hearing aids.&nbsp;&nbsp;Limitations of hearing aids include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-size:10pt;color:#000000;">Poor sound quality</font><font style="font-size:10pt;color:#000000;">. Hearing aids amplify sounds, allowing patients to perceive sounds that would otherwise be too soft for them to hear, but do not address the loss of hair cells, which determine sound quality and intelligibility, particularly in noisy environments. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-size:10pt;color:#000000;">Challenges in social settings</font><font style="font-size:10pt;color:#000000;">. The wide range of frequencies and sharp tuning provided by hair cells enables the auditory system to accurately recognize and distinguish different sounds, allowing the brain to focus on a single sound source. Hearing aids on the other hand typically amplify all sounds and do not enable this important </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="font-size:10pt;color:#000000;">sound-processing capability. As a result, interactions in social settings, which require distinguishing one speaker among many sound sources, are significantly impaired. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-size:10pt;color:#000000;">Difficulties with background noise</font><font style="font-size:10pt;color:#000000;">. Patients with hearing loss may become more sensitive to background noise, and many patients with hearing aids turn them off in noisy environments. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-size:10pt;color:#000000;">Stigma associated with wearing a visible device</font><font style="font-size:10pt;color:#000000;">.</font><font style="font-weight:bold;font-size:10pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">Some patients refuse to wear hearing aids, or do not wear them regularly, as they do not want to be stigmatized or identified as having a physical handicap. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-size:10pt;color:#000000;">Need for maintenance</font><font style="font-size:10pt;color:#000000;">.</font><font style="font-weight:bold;font-size:10pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">Hearing aids must be replaced, on average, every four to six years, need regular battery replacement, and can require repair due to damage during use. Medicare and most private insurance plans do not pay for hearing aids, and most patients must pay for these devices out of pocket. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Cochlear Implants </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patients with severe or profound hearing loss who have not been helped by hearing aids may be candidates for a cochlear implant. Of the roughly one million people in the United States who qualify, only about 100,000 patients have cochlear implants. Cochlear implants comprise an external microphone, sound processor and transmitter system, which receive sounds from the environment, and an implanted receiver and electrode system that directly stimulates the auditory nerve. Cochlear implants do not mimic natural hearing, and patients with cochlear implants need to learn to interpret the low-resolution electric signal produced by the device as sound. Cochlear implants also require an invasive, costly surgical procedure. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our lead product candidate: FX-322 </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Using our PCA platform, we are developing our lead product candidate, FX-322, for the treatment of SNHL. FX-322 is designed to treat the underlying cause of SNHL by regenerating hair cells through activation of progenitor cells already present in the cochlea. We believe that FX-322 has the potential to meaningfully improve overall hearing function and significantly enhance quality of life for patients with hearing loss. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Mechanism of Action </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By studying the most regenerative organ in the body, the intestine, we discovered that signaling for proliferation and differentiation among stem cells could be replicated with small molecules. Specifically, activating the Wnt pathway, which is fundamental for cell growth, using a glycogen synthase kinase 3, or GSK3, inhibitor and inhibiting histone deacetylase, or HDAC, caused intestinal stem cells expressing the protein Lgr5 to proliferate. The inner ear contains progenitor cells with the Lgr5 protein that do not regenerate on their own. On the hypothesis that these progenitor cells lacked the signals required for regeneration, we applied a GSK3 inhibitor and HDAC inhibitor to these cells and found that they proliferated and regenerated lost hair cells. Based on this discovery, we created FX-322, which is a proprietary combination of an FDA-approved HDAC inhibitor, sodium valproate, and a new chemical entity that inhibits GSK3. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Administration </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FX-322 is our proprietary thermoreversible polymer formulation that is administered through the eardrum, or intratympanically, into the middle ear in a procedure that takes approximately 10 to 15 minutes. The intratympanic administration procedure is generally well-tolerated and is routinely performed by ENTs as an office-based procedure. FX-322, which is liquid at room temperature, gels at body temperature inside the middle ear, allowing the active ingredients to diffuse into the inner ear and reach the cochlea. Similar thermoreversible polymer formulations have been used in FDA-approved products for other indications in the ear. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The image below shows delivery of FX-322 </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">via intratympanic injection</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><img src="gyycud3vz5ad000009.jpg" title="" alt="" style="width:362px;height:241px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Preclinical studies </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to commencing clinical trials, we tested FX-322 in multiple preclinical studies, including in human cells <font style="font-style:italic;">ex vivo</font> and functional hearing tests in mice <font style="font-style:italic;">in vivo</font>. In <font style="font-style:italic;">in vitro</font> testing of isolated human inner ear progenitor cells with the compounds comprising FX-322, we observed the formation of new progenitor cells and their subsequent conversion into hair cells. We also observed translation across species in our <font style="font-style:italic;">in vitro</font> studies of the inner ear progenitor cells from rhesus macaques in which a similar expansion of cell numbers were observed as in the <font style="font-style:italic;">in vitro</font> studies of human cells<font style="font-style:italic;">.</font> </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also conducted <font style="font-style:italic;">ex vivo</font> testing in intact cochlea isolated from mice. To cause hair cell loss, we exposed the cochlea for 16 hours to an aminoglycoside antibiotic that is toxic to hair cells. We then treated the cochlea for 72 hours with the compounds comprising the active agents in FX-322. Aminoglycoside treatment (left panel in the figure below) killed more than 80% of the hair cells in the cochlea (shown in green). By contrast, cochlea treated with the compounds in FX-322 (shown in the right panel) regenerated hair cells to a near native level, as shown graphically in the right panel. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restoration of Hair Cells in Mouse Cochlea </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gyycud3vz5ad000010.jpg" title="" alt="" style="width:624px;height:168px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:2pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gyycud3vz5ad000011.jpg" title="" alt="" style="width:191px;height:204px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also tested FX-322 in a mouse model of severe noise-induced hearing loss. Following noise exposure, 47 mice were treated with FX-322 and 37 were treated with placebo. Hearing function was measured using auditory brainstem response, or ABR, in which the signal generated by the auditory nerve upon sensing sound is detected by electrodes on the scalp. We performed ABR testing after 24&#160;hours, and measured hearing recovery after 30 days. The figure below shows the percentage of mice treated with FX-322 (shown in orange) or with placebo (shown in blue) that achieved a hearing recovery of at least 10 dB at 20000 Hz, a mid-range frequency for mice. The improvement observed in the placebo-treated mice was due to recovery of temporary effects not related to hair cell death, which is typical following acute hearing loss. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Hearing Recovery in Mice Treated with FX-322 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gyycud3vz5ad000012.jpg" title="" alt="" style="width:287px;height:185px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have also conducted pharmacokinetic tests in multiple species in which we observed that FX-322 administration achieved therapeutic levels of the active pharmaceutical ingredients in the cochlea. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Clinical results </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Phase 1/2 clinical trial </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted a Phase 1/2 clinical trial of FX-322 in which we enrolled 23 adult patients aged 33 to 64 with an established diagnosis of mild to moderately severe stable SNHL, defined as the average pure tone value of 26 to 70 dB at the 500, 1000, 2000 and 4000 Hz frequencies, who had no change of 10&#160;db or more at any frequency for more than six months. Fourteen patients had mild SNHL and nine patients had moderate to moderately severe SNHL. Of the nine moderate to moderately severe patients, six were randomized to FX-322 and three to placebo. In this trial, 15 patients were treated with a single injection of FX-322 and eight patients received placebo. Each patient had a documented medical history consistent with either noise-induced hearing loss, or NIHL, typically from noise exposure at work, or sudden SNHL, or SSNHL, which is characterized as a loss of 30 dB at three adjacent frequencies occurring over a 72-hour period. All patients had stable SNHL, meaning their hearing function at study entry was not significantly different based on a documented audiogram from at least six months prior to the study. Hearing function, specifically speech intelligibility, was assessed using WR and WIN. Hearing loudness was also measured using pure tone audiometry. Patients were randomized to a single injection of FX-322 or placebo administered at one of two different dose volumes (0.05 mL and 0.2 mL) to assess the safety of FX-322 administration and systemic exposure to FX-322. Follow-up visits occurred at 15, 30, 60, and 90 days after injection. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The objectives of the trial were to assess: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the systemic safety of FX-322; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the plasma pharmacokinetic profile to determine the systemic exposure to FX-322; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the effect of FX-322 on measures of ear health and hearing function. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FX-322 was observed to be well-tolerated in this trial. No serious adverse events were observed, and all treatment-related adverse events were mild, procedure-related, and generally resolved within minutes after dosing. We also observed limited concentrations of the FX-322 components in systemic circulation. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the prospective analysis, we conducted a prospective statistical analysis where we tested whether the Day 90 WR value for each patient fell outside of the 95% confidence interval compared to their baseline WR value. A confidence interval, or CI, is a range of values in which, statistically, there is a specified level of confidence where the result lies. In this patient-by-patient analysis, we observed statistically significant and clinically meaningful increases in WR in four of 15 patients treated with FX-322 at Day 90, who were among the six FX-322 patients that had moderate to moderately severe SNHL (as shown in the figure below).We also observed improvements for the two remaining FX-322 patients in the study that had moderate to moderately severe SNHL in the range of 30-50% from their baseline score, but these improvements were not statistically significant.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2020, we shared preliminary findings from a follow-up study we conducted that assessed durability of the WR improvements beyond 90 days at a single follow-up visit from 407 to 639 days post<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">-</font></font>FX-322 administration in five of the subjects that showed a response in the Phase 1/2 trial (the 6<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> patient was unable to participate in the follow-up study). The mean percentage of words correct in the treated ear was 38.4% at baseline, 69.6% at day 90, and 54.8% at follow-up. Three of five subjects showed statistically significant improvements in WR at the follow-up visit compared to baseline (see following figure). We believe that the results suggest that a single dose of FX-322 can result in durable improvements in speech intelligibility and support further investigation of the efficacy of FX-322.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There was no apparent association between WR improvements and whether the patients had stable NIHL, or stable SSNHL, and similar results were obtained with both dose volumes. This is consistent with published work showing drug delivery to the cochlea depends more on the concentration of the drug than the volume of injection. There were no clinically meaningful WR improvements observed in the placebo group. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gyycud3vz5ad000013.jpg" title="" alt="" style="width:640px;height:303px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also performed a <font style="font-style:italic;">post hoc</font> analysis on WR and WIN data for the Phase 1/2 study. The analysis showed a statistically significant improvement in WR by all FX-322-treated patients versus all placebo patients (p=0.010). A p value is the probability that the difference between two data sets was due to chance. The smaller the p value, the more likely the differences are not due to chance alone. In general, if the p value is less than or equal to 0.05, the outcome is statistically significant. The data in the figures below are presented as adjusted mean relative percent change from baseline. FX-322 treated patients saw improvements in WR as early as 15 days after treatment that were sustained over 90 days. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">shown in the figure below</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for WIN</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the adjusted mean relative percent change from baseline was assessed at 15, 30, 60, and 90 days after injection, and a trend in improvement was seen in FX-322-treated patients versus placebo. Also, there were non-statistically significant trends in improved WIN scores at Day 90 in the four FX-322, treated patients that had statistically significant and clinically meaningful improvements </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in WR in the </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prospective statistical analysis. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gyycud3vz5ad000014.jpg" title="" alt="" style="width:638px;height:291px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.9%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The same WR data was published in <font style="font-style:italic;">Otology and Neurotology </font>in February 2021, as shown in the figure below. In compliance with the publication&#8217;s policy, the data was presented with standard error, resulting in a slightly different adjusted mean and p value. Despite the change, the results were consistent with the figure above. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.9%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gyycud3vz5ad000015.jpg" title="" alt="" style="width:316px;height:314px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.9%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As shown in the figure below, published in <font style="font-style:italic;">Otology and Neurotology </font>in February 2021, speech recognition in a noisy background also improved over time for FX-322-treated patients versus placebo patients. Performance was quantified as the signal-to-noise ratio, or SNR, consistent with 50% correct WR, with lower SNR values indicating better speech perception in background noise. Analyses showed a significant improvement in average SNR from baseline to Day 90 in FX-322-treated patients versus placebo patients. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gyycud3vz5ad000016.jpg" title="" alt="" style="width:565px;height:294px;"></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.9%;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:2pt;text-indent:5.9%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also assessed audiometric changes from 250 Hz to 8000 Hz for all patients. Since drug enters closest to the high frequency region, the greatest drug exposure is expected to occur in the high frequency region. While no statistical differences were observed at any frequency when comparing pooled treatment groups, four of the moderate to moderately severe FX-322 patients showed a 10 dB threshold improvement at 8000 Hz at Day 90.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Phase 2a clinical trial </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on our analysis of the data from our Phase 1/2 clinical trial, we initiated a randomized, double-blind, placebo-controlled, single- and repeat-dose Phase 2a clinical trial of FX-322 in the fourth quarter of 2019. In September 2020, we completed enrollment of 95 patients across 16 sites in the Phase 2a clinical trial. As in the Phase 1/2 clinical trial, patients were required to have a documented medical history consistent with either stable NIHL or stable SSNHL, meaning that a patient&#8217;s hearing deficit has remained consistent over a defined period of time based on a patient&#8217;s audiograms. &nbsp;&nbsp;All subjects in the clinical trial have meaningful WR deficits including patients who are considered to have &#8220;mild&#8221; hearing loss. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To explore how a single dose compares to multiple doses of FX-322, we randomized patients to one of four groups, each of which received four injections, once per week at weekly intervals starting at the initial visit. Group 1 received one injection of FX-322 and three injections of placebo. Group two received two injections of FX-322 and two injections of placebo. Group three received four injections of FX-322. Group four received four injections of placebo. Patients have follow-up visits two weeks after dosing and then monthly for seven months. The efficacy endpoints of this trial are WR, WIN, and pure tone audiometry in the range of 250 to 8000 Hz. The exploratory efficacy endpoints are the TFI, the HHIA, and pure tone audiometry in the range of 9000 to 16000 Hz. The selection of the efficacy endpoints in this study builds on the learnings from the Phase 1/2 trial, and we believe will add to our knowledge on the potential ways in which FX-322 may improve hearing function. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2021, we announced topline, day-90 interim data from the Phase 2a clinical trial. The results showed that four weekly injections in subjects with mild to moderately severe SNHL did not demonstrate improvements in hearing measures versus placebo. No treatment-related serious adverse events were observed in the study. In the four-arm Phase 2a study, 95 subjects aged 18-65 were evaluated for hearing improvement using WR, WIN, pure tone audiometry and additional exploratory measures. All subjects were administered a total of four weekly intratympanic injections comprised of zero, one, two, or four doses of FX-322 with the balance of injections comprised of placebo doses. While WR scores increased across all groups, the interim data showed that repeated weekly injections appeared to dampen the hearing benefit observed compared to other single injection-studies. The Phase 2a interim results also showed an unexpected apparent level of hearing </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">benefit in the placebo group that did not occur in previous trials and exceeded well-established published standards, potentially suggesting bias due to trial design. Given these challenges observed in the Phase 2a study design, there was no discernible hearing benefit of FX-322 over placebo.</font><font style="font-size:12pt;"> </font><font style="color:#000000;">We plan to report an analysis of the end of Phase 2a data (210 days) late in the second quarter of 2021.</font><font style="color:#000000;"> </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Phase 1b clinical studies</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2021, we announced new data from a Phase 1b clinical trial of FX-322 designed to evaluate the impact of injection conditions on tolerability. The results showed hearing improvement from a single injection of FX-322. In the multi-center, randomized study, subjects with mild to severe SNHL (n=33) were injected in one ear with FX-322 with the untreated ear as the control. Hearing function was tested over the course of 90 days following dosing. Thirty-two (n=32) subjects completed the 90 day clinical assessment period and, at day 90 following dosing, thirty-four percent (34%) of these subjects achieved a ten percent (10%) or greater absolute improvement in WR scores in the treated ear, which was clinically meaningful and statistically significant compared to the untreated ear (p &lt;0.05). This included a subset of subjects that more than doubled their WR scores. The single dose had a favorable safety profile and was well tolerated.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We commenced a Phase 1b clinical trial of FX-322 for age-related hearing loss in October 2020. The clinical trial is a double-blind, placebo-controlled, randomized multicenter safety study of up to 30 individuals aged 66-85 with mild to moderately severe age-related hearing loss. The primary objectives of the Phase 1b study are to assess the local and systemic safety of a single dose of FX-322 and evaluate hearing responses in an older adult cohort. Study participants will be randomized 4:1 to receive either FX-322 or placebo in one ear. Validated measures of hearing including WR, WIN, and pure tone audiometry will be used. Safety, otologic and audiologic assessments will be conducted at day 30 and 90 following administration of FX-322 or placebo. We expect to share results from this clinical trial in the second quarter of 2021.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We commenced a Phase 1b clinical trial of FX-322 in patients aged 18-65 with severe SNHL in November 2020. Severe SNHL is defined as a pure tone average deficit between 71-90 dB. Many patients with this clinical profile typically would be candidates for cochlear implants. This clinical trial employs a similar design to the age-related Phase 1b clinical trial that is currently underway. We expect to share results from this clinical trial in the third quarter of 2021.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other Clinical Studies</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2020, we announced top-line data from an exploratory clinical study in Germany that we believe demonstrated that FX-322 effectively reached the cochlea at levels predicted, based on computer models, to be therapeutically active. Top-line results from the exploratory study showed measurable concentrations of FX-322 in every sample analyzed and that anatomical factors did not prevent FX-322 from reaching the cochlea. The study results were based on analyzing samples of cochlear fluid, known as perilymph, taken intraoperatively from patients undergoing cochlear implant surgery. A total of seven patients received a single intratympanic injection of FX-322, enabling researchers to directly measure the level of FX-322 in perilymph, which is not otherwise feasible in inner-ear studies because accessing the cochlea involves an invasive surgical procedure. Study patients were followed for approximately 30 days after the procedure and no serious treatment related adverse events were observed. The study results were included in the article accepted for publication in the journal <font style="font-style:italic;">Otology and Neurotology</font> and were published in February 2021.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our multiple sclerosis (MS) program </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have initiated a discovery and preclinical program in MS after identifying MS as a degenerative disease that has the potential to be treated with small molecules that activate oligodendrocyte progenitor cells, or OPCs, leading to remyelination. In 2017, we initiated a relationship with Scripps, where researchers had discovered that anti-muscarinic and other classes of pharmacologic agents activate OPCs in the brain. We are pursuing this and other approaches to stimulating myelination of axons in MS.<font style="font-size:12pt;"> </font>Oligodendrocytes are responsible for making myelin, which accelerates the conduction of information through the brain and provides metabolic support for axons. We believe that stimulating progenitor cells in the central nervous system to grow oligodendrocytes and remyelinate axons<font style="font-size:12pt;"> </font>could potentially reverse the damage caused by the immune system in MS. The presently approved therapies for MS suppress demyelination but do not repair the damage to myelin.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The potential for anti-muscarinic drugs to treat the symptoms of MS was supported by an independently-run, double-blinded Phase 2 cross-over study entitled Clemastine Fumarate as a Remyelinating Therapy for Multiple Sclerosis (ReBUILD), conducted at the University of California, San Francisco. In the ReBUILD study, 50 adult, relapsing-remitting MS patients with optic neuropathy were randomized to either clemastine, which has anti-muscarinic and anti-histaminic activity, or placebo, both in combination with standard of care. The primary endpoint of the study was visual evoked potential<font style="font-size:12pt;"> </font>latency, or VEP, a test commonly used for optic neuritis and other demyelinating events, such as MS. Patients </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">treated with </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clemastine</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> showed a</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">improvement in VEPs indicating remyelination of optic nerve axons.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The results of this study were published in the</font><font style="font-size:12pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">medical journal </font><font style="font-style:italic;">The</font><font style="font-style:italic;font-size:12pt;"> </font><font style="font-style:italic;">Lancet</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and showed a statistically significant improvement in </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">VEP in patients treated using a single agent, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clemastine</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other agents which have been reported to show remyelinating activity in MS patients include a Histamine receptor 3 (H3) inverse agonist and Bexarotene (an RXR antagonist). In </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">all of</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the above studies the remyelinating effects </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">were</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> reported based on measures of nerve function (electrophysiology) or imaging (MRI imaging).&nbsp;&nbsp;These methods </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are considered to be</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> measures or biomarkers of the degree of remyelination</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, supporting the idea that r</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">emyelination may be possible in MS patients.&nbsp;&nbsp; </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have been applying our expertise in finding synergistic combinations of small molecules for activating progenitor cells to the treatment of MS. We believe that combinations of the agents may be more active than single agents such as clemastine. The increased remyelination activity may lead to a clinical benefit in patients with MS. We have licensed the worldwide rights to the related Scripps patent estate and are continuing to advance this discovery both on our own and through a sponsored research arrangement with Scripps. Through this work we have discovered combinations that enhance both <font style="font-style:italic;">in vitro</font> and <font style="font-style:italic;">in vivo</font> remyelination over single agents, and have obtained a worldwide, exclusive license from Cambridge for one such combination. <font style="color:#000000;">We established an internal research program using PCA to drive remyelination as a potential therapy for MS and have identified compounds that display promising preliminary preclinical results in an </font><font style="font-style:italic;color:#000000;">in vivo</font><font style="color:#000000;"> model of remyelination. Our research efforts are focused on optimizing these compounds and identifying a lead therapeutic candidate to advance into clinical trials. We have obtained worldwide licenses for intellectual property from Scripps and Cambridge Enterprise on approaches to promote remyelination of nerve fibers and are engaged in sponsoring clinical research to validate this approach at Cambridge University.&#160;</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2020 we established an internal research and discovery effort to identify novel compounds that activate OPCs and induce remyelination in animal models of MS.  The goal of the program is to identify product candidates that are novel and that show significantly more remyelination activity than existing remyelination agents.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Overview of multiple sclerosis </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">According to the National Multiple Sclerosis Society, nearly one million people in the United States are living with MS. The symptoms of MS include numbness or tingling, weakness, dizziness and vertigo, spasticity, vision problems, sexual problems, bladder or bowel problems, pain, cognitive changes, emotional changes, and depression. Most MS is initially<font style="font-size:12pt;"> </font>relapsing-remitting MS in which patients experience periods of new or relapsing symptoms followed by recovery and periods of remission. Early in the disease course, the patients are able to remyelinate the demyelinated nerves at least in part. As the disease progresses the ability of the body to remyelinate axons significantly decreases. This leads to progressive and irreversible neurological deficits.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA has approved a number of<font style="font-size:12pt;"> </font>disease-modifying therapies for MS that reduce the immune system attack on myelin, which may reduce the number of relapses, delay progression of disability, and limit new disease activity. However, none of these products repair the central nervous system or lead to remyelination of the nerve fibers, and there is no cure for MS. There are no FDA approved remyelinating therapies for MS. Our program aims to induce OPCs to become functional myelinating oligodendrocytes leading to myelin repair.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Leveraging our PCA platform for future applications </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to our hearing and MS programs, we believe our PCA platform has the potential to address a wide range of clinical applications. In directing our internal research, research collaborations, and in-licensing efforts, we intend to target areas of high unmet medical need for which the underlying disease process involves loss or degeneration of key cells that could be reversed using PCA. We believe the PCA platform could further be applied to diseases of the muscle, gastrointestinal tract, skin, and bone. We intend to continue to identify areas with high unmet need where our PCA platform and novel approach to regenerative medicine could lead to potentially disease-modifying therapeutics that create healthy functional tissues and improve patients&#8217; lives. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates consist of small chemical compounds to stimulate cell and tissue regeneration <font style="font-style:italic;">in vivo</font>. As a result, we can rely on the well-established and available manufacturing and drug-delivery technologies developed over decades by the pharmaceutical industry. We source our active pharmaceutical ingredients from contract manufacturers with a track record of FDA-compliant manufacturing. After rigorous internal and external quality control testing, we release these materials to additional contract manufacturers for formulation and packaging into final drug product for use in clinical testing. We expect to use a similar hybrid of internal and contract resources for commercialization of our products, at least until our operations reach a scale sufficient to justify investment in internal manufacturing capacity. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commercialization </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to directly market and commercialize our lead product candidate, FX-322 for the treatment of SNHL, if approved in the United States, by developing our own sales and marketing force, targeting ENTs and audiologists. Under the Astellas Agreement, Astellas has the right to market and commercialize FX-322 for the treatment of SNHL, and any other products containing both a GSK-3 inhibitor and an HDAC inhibitor if approved, outside of the United States. For any other product candidates that are not part of the Astellas Agreement and that may be approved, we intend to establish marketing and commercialization strategies for each as we approach potential approval and expect to be able to leverage our then-existing sales and marketing force. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intellectual property </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We strive to protect and enhance the proprietary technology, inventions, and improvements that are commercially important to the development of our business, including by seeking, maintaining, and defending patent rights, whether developed internally or licensed from third parties. We also rely on trade secrets, know-how, continuing technological innovation, and in-licensing opportunities to develop, strengthen, and maintain our proprietary position in our field. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future commercial success depends, in part, on our ability to: obtain and maintain patent and other proprietary protection for commercially important technology, inventions, and know-how related to our business; defend and enforce our intellectual property rights, in particular our patent rights; preserve the confidentiality of our trade secrets; and operate without infringing, misappropriating, or violating the valid and enforceable patents and proprietary rights of third parties. Our ability to stop third parties from making, using, selling, offering to sell, or importing products identical or similar to ours may depend on the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent positions of biotechnology and pharmaceutical companies like ours are generally uncertain and can involve complex legal, scientific, and factual issues. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. We also cannot ensure that patents will issue with respect to any patent applications that we or our licensors may file in the future, nor can we ensure that any of our owned or licensed patents or future patents will be commercially useful in protecting our product candidates and methods of manufacturing the same. In addition, the coverage claimed in a patent application may be significantly reduced before a patent is issued, and its scope can be reinterpreted and even challenged after issuance. As a result, we cannot guarantee that any of our products will be protected or remain protectable by enforceable patents. Moreover, any patents that we hold may be challenged, circumvented, or invalidated by third parties. See &#8220;Risk factors&#8212;Risks related to our intellectual property&#8221; for a more comprehensive description of risks related to our intellectual property. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In an effort to secure our intellectual property positions we generally file patent applications directed to our programs.&nbsp;&nbsp;As of March 19, 2021, we owned, licensed, or have an option to license 38 patent families.&nbsp;&nbsp;These patent families include 6 pending Patent Cooperation Treaty (PCT) applications, 22 U.S. patents, 35 ex-U.S. patents, 83 pending ex-U.S. patent applications, and 27 pending U.S. utility applications. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The intellectual property portfolio for our lead programs as of February 28, 2021, are summarized below. Prosecution is a lengthy process, during which the scope of the claims initially submitted for examination by the U.S. Patent and Trademark Office may be significantly narrowed before issuance, if issued at all. We expect this may be the case with respect to some of our pending patent applications referred to below. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Hearing loss </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent portfolio for our Hearing Loss program is based upon our owned and in-licensed patent families that include patents and patent applications directed generally to compositions of matter, pharmaceutical compositions, and methods of using the same to treat hearing loss; and specifically directed to compositions of matter of our lead product FX-322, pharmaceutical compositions of FX-322 and methods of using the same to treat hearing loss. The in-licensed patents and patent applications are subject to license agreements with Massachusetts Institute of Technology and Massachusetts Eye and Ear Infirmary described herein. As of March 19, 2021, we have rights to, through ownership and in-licensing, 31 patent families, including 17 U.S. patents, 32 ex-U.S. patents, 21 pending U.S. utility patent applications, 65 pending ex-U.S. patent applications, and 5 pending PCT applications relate to treating hearing loss, both generally and related to FX-322. While we believe that the specific and generic claims contained in our issued U.S. patents provide protection for the composition of matter and the method of using FX-322 to treat hearing loss and/or diseases associated with the absence or lack of certain tissue cells, third parties may nevertheless challenge such claims in our patents. If any such claims are invalidated or rendered unenforceable for any reason, we will lose valuable intellectual property rights, and our ability to prevent others from competing with us would be impaired. Any U.S. or ex-U.S. patents that may issue from pending applications that we control, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if any, for our hearing program, including our lead product FX-322, are projected to have a statutory expiration date in between 2035 and 2040, excluding any additional term for patent term adjustments or patent term extensions, if applicable.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Multiple sclerosis program </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to use a similar intellectual property strategy when building protection with respect to other programs. Within our MS program, we advise on a portfolio of intellectual property directed to the treatment of MS, through ownership and exclusive in-licensing from Scripps and Cambridge Enterprise. As of March 19, 2021, no development candidate has been designated, but the intellectual property portfolio for our MS research program currently includes 4 patent families including 3 U.S. patents, 3 ex-U.S. patents, 4 pending U.S. utility patent applications, and 11 ex-U.S. patent applications. While we believe that the specific and generic claims, contained in our U.S. and ex-U.S. patents provide protection for the claimed pharmaceutical compositions and methods of use third parties may nevertheless challenge such claims. If any such claims are invalidated or rendered unenforceable for any reason, we will lose valuable intellectual property rights, and our ability to prevent others from competing with us would be impaired. Any U.S. or ex-U.S. patents that may issue from pending applications that we control, if any, for our MS are projected to have a statutory expiration date between 2032 and 2039, excluding any additional term for patent term adjustments or patent term extensions. The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20 years from the earliest date of filing a non-provisional patent application. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, the term of a patent covering an FDA-approved drug may, in certain cases, be eligible for a patent term extension under the Hatch-Waxman Act as compensation for the loss of patent term during the FDA regulatory review process. The period of extension may be up to five years, but cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. Only one patent among those eligible for an extension and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. Similar provisions are available in Europe and in certain other jurisdictions to extend the term of a patent that covers an approved drug. It is possible that issued U.S. patents covering the use of products from our intellectual property may be entitled to patent term extensions. If our use of drug candidates or the drug candidate itself receive FDA approval, we intend to apply for patent term extensions, if available, to extend the term of patents that cover the approved use or drug candidate. We also intend to seek patent term extensions in any jurisdictions where available, however, there is no guarantee that the applicable authorities, including the FDA, will agree with our assessment of whether such extensions should be granted, and, even if granted, the length of such extensions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to patent protection, we rely upon unpatented trade secrets and confidential know-how and continuing technological innovation to develop and maintain our competitive position. However, trade secrets and confidential know-how are difficult to protect. We seek to protect our proprietary information, in part, using confidentiality agreements with any collaborators, scientific advisors, employees and consultants and invention assignment agreements with our employees. We also have agreements requiring assignment of inventions with selected consultants, scientific advisors, and collaborators. These agreements may not provide meaningful protection. These agreements may also be breached, and we may not have an adequate remedy for any such breach. In addition, our trade secrets and/or confidential know-how may become known or be independently developed by a third party, or misused by any collaborator to whom we disclose such information. Despite any measures taken to protect our intellectual property, unauthorized parties may attempt to copy aspects of our products or obtain or use information that we regard as proprietary. Although we take steps to protect our proprietary information, third parties may independently develop the same or similar proprietary information or may otherwise gain access to our proprietary information. As a result, we may be unable to meaningfully protect our trade secrets and proprietary information. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success will also depend in part on not infringing upon the proprietary rights of third parties. It is uncertain whether the issuance of any third-party patent would require us to alter our development or commercial strategies, or our drugs or processes, obtain licenses, or cease certain activities. Our breach of any license agreements or failure to obtain a license to proprietary rights that we may require to develop or commercialize our future drugs may have an adverse impact on us. If third parties have prepared and filed patent applications prior to March&#160;16, 2013, in the United States that also claim technology to which we have rights, we may have to participate in interference proceedings in the United States Patent and Trademark Office, or USPTO, to determine priority of inventions. See &#8220;Risk factors&#8212;Risks related to our intellectual property&#8221; for a more comprehensive description of risks related to our intellectual property. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">License and collaboration agreements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Astellas Pharma Inc. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2019, we entered into the Astellas Agreement with Astellas, under which we granted Astellas an exclusive, royalty-bearing, sub-licensable, nontransferable license to certain patent rights to research, develop, manufacture, have manufactured, use, seek and secure regulatory approval for, commercialize, offer for sale, sell, have sold and import, and otherwise exploit licensed products containing both a GSK-3 inhibitor and an HDAC inhibitor, or the Astellas licensed </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">products, including our product candidate FX-322, outside of the United States. We also granted Astellas a right of first negotiation and a right of last refusal if we enter into any negotiation or agreement of any kind (other than an acquisition of </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">all of</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> our stock or assets) with any third party under which such third party would obtain the right to develop, manufacture, or commercialize Astellas licensed products in the United States. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and Astellas have agreed to jointly develop the Astellas licensed products, including potentially carrying out joint studies. Each party has agreed to use commercially reasonable efforts to carry out development activities assigned to it under an agreed-upon development plan. Astellas has agreed to use commercially reasonable efforts to obtain regulatory approval for at least one Astellas licensed product in SNHL and in age-related hearing loss, in each case, in one major Asian country and one major European country. We have agreed to use commercially reasonable efforts to obtain regulatory approval for at least one Astellas licensed product in the United States. Astellas has the sole right to commercialize the Astellas licensed products outside of the United States, and we have the sole right to commercialize the Astellas licensed products in the United States. Astellas has agreed to use commercially reasonable efforts to commercialize Astellas licensed products in a major Asian country and a major European country following receipt of regulatory approval in such countries. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As consideration for the licensed rights under the Astellas agreement, Astellas paid us an upfront payment of $80.0 million in July 2019 and has agreed to pay potential development milestone payments up to $230.0 million. Specifically, we would receive development milestone payments of $65.0 million and $25.0 million upon the first dosing of a patient in a Phase 2b clinical trial for SNHL in Europe and Asia, respectively, and $100.0 million and $40.0 million upon the first dosing of a patient in a Phase 3 clinical trial for SNHL in Europe and Asia, respectively.&nbsp;&nbsp;If the Astellas licensed products are successfully commercialized, we would be eligible for up to $315.0 million in potential commercial milestone payments and also tiered royalties at rates ranging from low- to mid-teen percentages.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Astellas Agreement remains in effect until the expiration of all royalty obligations. Royalties are paid on a licensed product-by-licensed product and country-by-country basis until the latest of (i) the expiration of the last valid claim in the licensed patent rights with respect to such Astellas licensed product in such country or (ii) a set number of years from the first commercial sale of such Astellas licensed product in such country. Astellas may terminate the Astellas Agreement at will upon 60 days&#8217; written notice. Each party has the right to terminate the Astellas Agreement due to the other party&#8217;s material breach if such breach remains uncured for 90 days (or 45 days in the case of nonpayment) or if the other party becomes bankrupt. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Massachusetts Institute of Technology </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2016, we entered into an Exclusive Patent License Agreement, or the MIT License, with the Massachusetts Institute of Technology, or MIT, under which we received an exclusive, worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, offer to sell, lease, and import products, or the MIT licensed products, and to develop and perform processes, or the MIT licensed processes, which incorporate the licensed technology for the treatment of disease, including, but not limited to, the prevention and remediation of hearing loss. We also have the right to grant sublicenses under the MIT License. MIT and Brigham and Women&#8217;s Hospital retain the right on behalf of themselves and all other nonprofit research institutions to practice the licensed patent rights for nonclinical research, teaching, and educational purposes. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are required to use diligent efforts to develop and commercialize the MIT licensed products or processes and to make such products or processes reasonably available to the public. We are also subject to certain development obligations with regards to a first MIT licensed product. We have satisfied certain obligations related to preclinical and clinical studies and the filing of an IND for a first MIT licensed product with our development activities related to FX-322. Our future development obligations are: (i)&#160;to commence a Phase III clinical trial for such product within five years of the IND filing for such product, (ii)&#160;to file a New Drug Application, or NDA, or equivalent with the FDA or comparable European regulatory agency for such product within nine years of the IND filing for such product, and (iii)&#160;to make a first commercial sale of such product within 11&#160;years of the IND filing for such product. We also have certain development obligations with regards to a second MIT licensed product. If we fail to meet our development obligations, other than those relating to a second MIT licensed product, MIT may terminate the MIT License. In the event that we have failed to fulfill our development timeline obligation with respect to a second MIT licensed product and fail to cure such breach within 90&#160;days of written notice by MIT, MIT may restrict the licensed field to the prevention and remediation of hearing loss in humans and animals. We do not have the right to control prosecution of the in-licensed patent applications, and our rights to enforce the in-licensed patents are subject to certain limitations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon entering the MIT License, we paid a $50&#160;thousand license fee payment and issued to MIT shares of our common stock equal to 5% of our then-outstanding capital stock. We are required to pay certain annual license maintenance fees ranging from $30 thousand to $0.1 million per year prior to first commercial sale of a MIT licensed product and an annual </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">license maintenance fee of $0.2 million every year afterwards, which may be credited to running royalties during the same calendar year, if any. We are also required to make potential milestone payments in an aggregate amount of up to $2.9&#160;million on each MIT licensed product or process. In addition, we agreed to pay a low single-digit royalty on the MIT licensed products and processes and a 20% royalty on sub-license revenues. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2019, we paid MIT $16.0 million dollars representing the royalty on the upfront payment received from Astellas.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The MIT License will remain in effect until the expiration or abandonment of all licensed issued patents and filed patent applications, unless terminated earlier. We have the right to terminate for any reason upon three months&#8217; prior written notice. MIT has the right to terminate immediately if we cease to carry on any business related to the MIT License. MIT may also terminate the MIT License for our material breach if such breach remains uncured for 90 days (or 30 days in the case of nonpayment). MIT may also terminate the MIT License if we or our affiliates commence any action against MIT to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or not infringed, or if our sub-licensee commences such actions and we do not terminate such sub-license within 30 days after MIT&#8217;s demand. MIT has the right to increase all payments due by us, instead of terminating the MIT License in the case of a patent challenge. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2019, the MIT License was amended to update the diligence milestones for a second MIT licensed product. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Massachusetts Eye and Ear (Formerly Massachusetts Eye and Ear Infirmary) </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2019, we entered into an Non-Exclusive Patent License Agreement, or the MEE License, with the Massachusetts Eye and Ear, or MEE, under which we received a non-exclusive, non-sub-licensable, worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, offer to sell, lease and import products and to develop and perform processes that incorporate the licensed technology for the treatment or prevention of hearing loss, or the MEE licensed products.<sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup>We are obligated to use diligent efforts to develop and commercialize the MEE licensed products. We met one of our milestone timeline obligations by dosing a first patient in a Phase&#160;II trial by December&#160;31, 2020. We are still subject to a milestone timeline obligation to dose a first patient in a Phase&#160;III trial by December&#160;31, 2024. We do not control the filing, prosecution, enforcement, and defense of any licensed patent rights. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon entering the MEE License, we made a $20&#160;thousand license fee payment. We are obligated to pay certain annual license maintenance fees between $5 thousand and $7.5 thousand per each MEE patent family case number included in the licensed MEE patent rights prior to first commercial sale of an MEE licensed product. We are also obligated to pay a minimum annual royalty payment of $15 thousand per each MEE patent family case number included in the licensed MEE patent rights after first commercial sale of an MEE licensed product. We are also obligated to make milestone payments up to $350&#160;thousand on each product or process that incorporates the licensed patent rights. In addition, we have agreed to pay a low single-digit royalty on products and processes that incorporate the licensed patent rights. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The MEE License remains in effect until all issued patents and filed patent applications within the licensed patent rights have expired or been abandoned, unless terminated earlier. We have the right to terminate the MEE License at will by 30 business days&#8217; advance written notice to MEE. MEE has the right to terminate the MEE License (i)&#160;if we fail to make any payment due within 30 business days after MEE notifies us of such failure, (ii)&#160;if we fail to maintain required insurance, (iii)&#160;upon 45 business days&#8217; written notice if we become insolvent, or (iv)&#160;for any other default by us that is not cured within 60 business days of receipt of written notice. MEE also has the right to terminate if we or our affiliates challenge the validity of the licensed patent rights. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The Scripps Research Institute (California Institute for Biomedical Research) </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2018, we entered into a license agreement, or the CALIBR License, with the California Institute for Biomedical Research, or CALIBR, a division of Scripps, under which we received an exclusive, worldwide, royalty-bearing license to certain patent rights to make, have made, use, sell, offer to sell, and import products, or the CALIBR licensed products, which incorporate licensed technology for the treatment of MS. We also have the right to grant sublicenses under the CALIBR License. CALIBR reserves the right to use for itself and the right to grant nonexclusive licenses to other nonprofit or academic institutions for any internal research and educational purposes. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have agreed to use commercially reasonable efforts to develop, manufacture, and sell at least one CALIBR licensed product. We are also subject to certain milestone timeline obligations, which may be extended in certain circumstances as set forth in the CALIBR License to: (i) submit an IND (or equivalent) for a CALIBR licensed product by the 30th month after the effective date of the CALIBR License, (ii) initiate a Phase II clinical trial (or equivalent) for a CALIBR licensed product by the fourth anniversary of the effective date of the CALIBR License, and (iii) initiate a Phase III clinical trial (or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">equivalent) for a CALIBR licensed product by the sixth anniversary of the effective date of the CALIBR License. We do not have the right to control prosecution of the in-licensed patent applications, and our rights to enforce the in-licensed patents are subject to certain limitations. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon entering the CALIBR license, we made a $1.0&#160;million license fee payment, and are required to make milestone payments in an aggregate amount of up to $26.0&#160;million for each category of CALIBR licensed products. Category&#160;1 is any CALIBR licensed products containing a compound that modulates any muscarinic receptor, and Category&#160;2 is any CALIBR licensed products not included in Category&#160;1 that could differentiate oligodendrocyte precursor cells from <font style="font-style:italic;">in vitro</font> studies and/or are active in animal models relevant to MS. We are also required to pay a mid-single-digit royalty on CALIBR licensed products and a royalty on sub-license revenues ranging from a low-teen percentage to 50%. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The CALIBR License continues in effect until expiration of all our obligations to pay royalties. Royalties are payable by us on a country-by-country and licensed-product-by-licensed product basis upon the later of (i)&#160;the expiration or abandonment of all valid claims of the licensed patent rights in such country and (ii)&#160;10&#160;years from the first commercial sale of each CALIBR licensed product in such country. We may terminate the CALIBR License at will upon 30 days&#8217; prior written notice. We may also elect to terminate our license to one or more licensed patents in any or all jurisdictions by giving 90 days&#8217; prior written notice to CALIBR. CALIBR may terminate the CALIBR License for our material breach if such breach remains uncured for 30&#160;days. CALIBR has the right to terminate or reduce the license to a non-exclusive license if we fail to use diligent efforts to develop and commercially exploit CALIBR licensed products. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The Scripps Research Institute </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2018, we entered into a Research Funding and Option Agreement, or the Scripps option agreement, with Scripps, under which we were granted an exclusive option to acquire an exclusive, sublicensable, worldwide license under certain intellectual property related to the treatment of MS. If we exercise such option, the CALIBR License shall be amended to include such intellectual property. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As consideration for the Scripps option agreement, we are required to make funding payments totaling $0.7 million to Scripps to support its research activities. Scripps has agreed to use reasonable efforts to perform the research program pursuant to the Scripps option agreement. The Scripps option agreement had a one-year term and was renewed for a second year by mutual written agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2020, we extended the term of the Scripps option agreement through the end of December 2021. As consideration for this extension, we are required to make additional funding payments of $0.6 million to Scripps through December 2021. We have the right to terminate by giving 90&#160;days&#8217; advance written notice. Scripps has the right to terminate in the event of nonpayment by us that remains uncured for 10&#160;days. Each party has the right to terminate in the event of the other party&#8217;s material breach that remains uncured for 60&#160;days or if the other party becomes bankrupt. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cambridge Enterprise Limited </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, we entered into an Exclusive Patent License Agreement, or the Cambridge License, with Cambridge, under which we received an exclusive, worldwide, royalty-bearing license to certain patent rights to make, have made, use, sell, offer to sell, and import products, or the Cambridge licensed products, which incorporate licensed technology for the treatment of demyelinating diseases. We also have the right to grant sublicenses under the Cambridge License. Cambridge reserves the right to use for itself (as well as for the inventors and the funder) and the right to grant nonexclusive licenses to other academic institutions for any academic publication, research and teaching and clinical patient care. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have agreed to use diligent and good faith efforts to develop and commercially exploit at least one Cambridge licensed product. Upon entering into the Cambridge License, we made a $50.0 thousand license fee payment. We are obligated to pay an annual license fee of $50.0 thousand. We are also obligated to make milestone payments up to $10.5 million on each Cambridge licensed product. In addition, we have agreed to pay a low single-digit royalty on products that incorporate the licensed patent rights, subject to offset in certain circumstances.&nbsp;&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Cambridge License continues in effect on a country-by-country basis until the expiration or revocation, without right of further appeal, of all licensed issued patents and filed patent applications, unless terminated earlier. We have the right to terminate for any reason upon 90 days&#8217; prior written notice. Each party has the right to terminate immediately if the other party ceases to carry on its business. Either party may also terminate the Cambridge License for material breach if such breach remains uncured for 30 days. Cambridge may also terminate the Cambridge License if we fail to diligently develop and commercially exploit at least one Cambridge licensed product or we or our affiliates or sub-licensees commence any action against Cambridge to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or not infringed.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Competition </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a clinical-stage biotechnology company, we face competition from a wide array of companies in the pharmaceutical, biotechnology, and medical device industries. These include both small companies and large companies with much greater financial and technical resources and far longer operating histories than our own. We also compete with the intellectual property, technology, and product development efforts of academic, governmental, and private research institutions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our competitors may have significantly greater financial resources, established presence in the market, expertise in research and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and reimbursement, and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified scientific, sales, marketing, and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The key competitive factors affecting the success of any product candidates that we develop, if approved, are likely to be their efficacy, safety, convenience, price, and the availability of reimbursement from government and other third-party payors. Our commercial opportunity for any of our product candidates could be reduced or eliminated if our competitors develop and commercialize products that are more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours and may commercialize products more quickly than we are able to. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are aware of the following treatment options in the areas that we are initially targeting: </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Hearing loss </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are dozens of hearing aid brands, although approximately 80% of these devices are manufactured by four leading companies. There are three manufacturers of cochlear implants that market in the United States. We are also aware of multiple companies developing therapeutics to treat various forms of hearing loss. There are two companies with potential therapies to regenerate hair cells currently in clinical trials. Novartis conducted a Phase 1/2 trial with intracochlear delivery of an adenovirus-based gene therapy in subjects with severe to profound hearing loss, the data from which has not been shared to date, and Audion Therapeutics is conducting a Phase 2 study of its notch inhibitor, LY3056480, and Pipeline Therapeutics is conducting a Phase 1/2 study of its gamma secretase inhibitor. In 2020 Otonomy, Inc. disclosed top level data from a Phase 1/2 study of OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor, in subjects with a condition described as speech-in-noise impairment. In addition, Sensorion, a clinical stage company is conducting a Phase 2 study to treat sudden SNHL. There are also multiple programs in early-stage or preclinical development by pharmaceutical and biotechnology companies. In addition, there are several companies with programs to regrow neurons in the cochlea to treat hearing loss, and companies developing otoprotective therapies, which are intended to reduce damage to hair cells. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Multiple sclerosis </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are multiple therapeutic options for treating the symptoms of MS, as well as the underlying disease. However, all approved therapies are directed at blocking demyelination, and, to our knowledge, there are no approved therapies which promote remyelination. We are aware of numerous efforts to identify drugs or biologics that can stimulate oligodendrocyte regeneration and myelin repair in the central nervous system. These include Acorda Therapeutics which has conducted two Phase 1 trials of its monoclonal antibody rHIgM22 in MS patients. Convelo Therapeutics is developing potential remyelinating compounds that inhibit enzymes in the brain involved in the production of cholesterol for which they planned </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to begin clinical trials in 2019</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, while Pipeline Therapeutics is developing a selective M1 receptor antagonist to treat multiple sclerosis and other demyelinating disorders</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. This is an active research area with </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a number of</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> entities researching compounds, antibodies, and protein which may enhance remyelination.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Government regulation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA and comparable regulatory authorities in state and local jurisdictions and in other countries impose substantial and burdensome requirements upon companies involved in the clinical development, manufacture, marketing, and distribution of drugs, such as those we are developing. These agencies and other federal, state, and local entities regulate, among other things, the research and development, testing, manufacture, quality control, safety, effectiveness, labeling, storage, record keeping, approval, advertising and promotion, distribution, post-approval monitoring and reporting, sampling, and export and import of our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">U.S. drug development process </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local, and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process, or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA&#8217;s refusal to approve pending NDAs, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement, or civil or criminal penalties. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process required by the FDA before a drug may be marketed in the United States generally involves the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">completion of preclinical laboratory tests and formulation studies, as well as animal safety studies, in compliance with the FDA&#8217;s good laboratory practice, or GLP, regulations, as appropriate; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">submission to the FDA of an IND which must become effective before human clinical trials may begin; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">approval by an independent institutional review board, or IRB, at each clinical site before each trial may be initiated; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">performance of adequate and well-controlled human clinical trials in accordance with good clinical practice, or GCP, requirements to establish the safety and efficacy of the proposed drug product for each indication; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">submission to the FDA of an NDA; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">endorsement by an FDA advisory committee, if applicable; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">satisfactory completion of an FDA inspection of the clinical site(s), and related services involved in the conduct of the clinical studies to assess compliance with good clinical practices, or GCP;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with current good manufacturing practice, or cGMP, requirements, and to assure that the facilities, methods, and controls are adequate to preserve the drug&#8217;s identity, strength, quality, and purity; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">FDA review and approval of the NDA prior to commercial marketing or sale of the drug in the United States; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy, or REMS, or to conduct a post-approval study or studies. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Preclinical studies </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical studies include laboratory evaluation of product chemistry, toxicity, and formulation, as well as animal studies to assess potential safety and efficacy. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, and any available clinical data or literature, among other things, to the FDA as part of an IND. Some preclinical testing may continue even after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to the submission including to one or more proposed clinical trials and places the clinical trial on a partial or full clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Clinical </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">holds also may be imposed by the FDA at any time before or during clinical trials due to safety concerns about on-going or proposed clinical trials or noncompliance with specific FDA requirements, and the trials may not begin or continue until the FDA notifies the sponsor that the hold has been lifted. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Clinical trials </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB at each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution. Information about certain clinical trials must be submitted within specific time frames to the National Institutes of Health, or NIH, for public dissemination on their www.clinicaltrials.gov website. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Phase 1: The drug is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion, and, if possible, to gain an early indication of its effectiveness. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Phase 2: The drug is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases, and to determine dosage tolerance and optimal dosage. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Phase 3: The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unreasonable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. In addition, some clinical trials are overseen by an independent group of qualified experts organized by the sponsor, known as a data safety monitoring board or committee. Depending on its charter, this group may determine whether a trial may move forward at designated check points based on access to certain data from the trial. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concurrent with clinical trials, companies usually complete additional animal studies, and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate, and, among other things, the manufacturer must develop methods for testing the identity, strength, quality, and purity of the final drug. In addition, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA, and more frequently if serious adverse events occur. Phase 1, Phase 2, and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. There are also requirements governing the registration of, reporting of ongoing clinical trials and completed trial results to public registries. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Marketing approval </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assuming successful completion of the required clinical testing, the results of the preclinical and clinical studies, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls, and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. In most cases, the submission of an NDA is subject to a substantial application user fee. Under the Prescription Drug User Fee Act, or PDUFA, guidelines that are currently in effect, the FDA has a goal of ten months from the date of &#8220;filing&#8221; of a standard NDA for a new molecular entity to review and act on the submission. This review typically takes 12&#160;months from the date the NDA is submitted to the FDA because the FDA has approximately two months to make a &#8220;filing&#8221; decision. Specifically, the FDA conducts a preliminary review of all NDAs within the first 60 days after submission, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews an NDA to determine, among other things, whether the </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">submitted information supports that the </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">drug is safe and effective and whether the facility in which it is manufactured, processed, packaged, or held meets standards designed to assure the product&#8217;s continued safety, quality, and purity. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA also may require submission of a REMS plan to ensure that for certain medications with serious safety concerns the benefits of the drug outweigh its risks. The REMS plan could include medication guides, physician communication plans, assessment plans, and/or elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates, and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a Complete Response Letter, or CRL. A CRL generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical or preclinical testing in order for the FDA to reconsider the application for approval. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#8217;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if the FDA approves a product, it may limit the approved indications for use of the product, require that contraindications, warnings, or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements and FDA review and approval. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Pediatric Research Equity Act, or PREA, requires a sponsor to conduct pediatric clinical trials for most drugs, for a new active ingredient, new indication, new dosage form, new dosing regimen, or new route of administration. Under PREA, original NDAs and supplements must contain a pediatric assessment unless the sponsor has received a deferral or waiver, or the indication sought is for an orphan condition. The required assessment must evaluate the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The sponsor or the FDA may request a deferral of pediatric clinical trials for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug is ready for approval for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric clinical trials begin. The FDA must send a noncompliance letter to any sponsor that fails to submit the required assessment, keep a deferral current, or fails to submit a request for approval of a pediatric formulation. In some situations, the requirement for studies in pediatric populations can be waived if there is no relevant use.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">FDA-expedited development and review programs </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA has various programs, including orphan drug designation, rare pediatric disease designation, fast track designation, accelerated approval priority review, and breakthrough therapy designation, which are intended to expedite or simplify the process for the development and the FDA review of drugs that are intended for the treatment of serious or life-</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">threatening diseases or conditions and demonstrate the potential to address unmet medical needs. The purpose of these programs is to provide important new drugs to patients earlier than under standard FDA review procedures. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To be eligible for a fast track designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or life-threatening disease or condition, demonstrates the potential to address an unmet medical need, and is actively developing the drug for the disease. The FDA will determine that a product will fill an unmet medical need if it will provide a therapy where none exists or provide a therapy that may be potentially superior to existing therapy based on efficacy or safety factors. The FDA may review sections of the NDA for a fast track product on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may give a priority review designation to drugs that offer major advances in treatment or provide a treatment where no adequate therapy exists. A priority review means that the goal for the FDA to review an application is six months, rather than the standard review of 10&#160;months under current PDUFA guidelines. Under the new PDUFA agreement, these six- and 10-month review periods are measured from the &#8220;filing&#8221; date rather than the receipt date for NDAs for new molecular entities, which typically adds approximately two months to the timeline for review and decision from the date of submission. Most products that are eligible for fast track designation are also likely to be considered appropriate to receive a priority review, and, if relevant, accelerated approval. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may be eligible for accelerated approval and may be approved on the basis of adequate and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require a sponsor of a drug receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the drug may be subject to accelerated withdrawal procedures. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, under the provisions of the Food and Drug Administration Safety and Innovation Act, or FDASIA, passed in July 2012, a sponsor can request designation of a product candidate as a &#8220;breakthrough therapy.&#8221; A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Drugs designated as breakthrough therapies are also eligible for priority review and accelerated approval. The FDA must take certain actions, such as holding timely meetings and providing advice, intended to expedite the development and review of an application for approval of a breakthrough therapy. The designation includes all the benefits of a fast track designation. The breakthrough therapy designation is a distinct status from both accelerated approval and priority review, which can also be granted to the same drug if relevant criteria are met. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. Furthermore, fast track designation, priority review, and breakthrough therapy designation do not change the standards for approval but may expedite the development or approval process. We may explore some of these opportunities for our product candidates as appropriate. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Post-approval requirements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion, and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications with clinical data. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may impose </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a number of</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state and local agencies and are subject to periodic unannounced inspections by government agencies for compliance with cGMP and other requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">safety alerts, Dear Healthcare Provider letters, press releases, or other communications containing warning or other safety information about the product; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">fines, warning letters, or holds on post-approval clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">product seizure or detention, or refusal to permit the import or export of products; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">injunctions or the imposition of civil or criminal penalties. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA strictly regulates marketing, labeling, advertising, and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drugs and drug samples at the federal level and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Marketing exclusivity </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Market exclusivity provisions under the FDCA can delay the submission or the approval of certain marketing applications. The FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not approve or even accept for review an abbreviated new drug application, or ANDA, or an NDA submitted under Section&#160;505(b)(2), or 505(b)(2) NDA, submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovative drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDCA alternatively provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA, if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application. This three-year exclusivity covers only the modification for which the drug received approval based on the new clinical investigations and does not prohibit the FDA </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from approving ANDAs or 505(b)(2) NDAs for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">all of</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pediatric exclusivity is another type of marketing exclusivity available in the United States. Pediatric exclusivity provides for an additional six months of marketing exclusivity attached to another period of exclusivity and extends patent life of a related patent if a sponsor conducts clinical trials in children in response to a written request from the FDA. The issuance of a written request does not require the sponsor to undertake the described clinical trials. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other healthcare laws and compliance requirements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the state, local, and foreign jurisdictions in which they conduct their business. Such laws include, without limitation, U.S. federal and state anti-kickback, fraud and abuse, false claims, consumer fraud, pricing reporting, and transparency laws and regulations, as well as similar foreign laws in the jurisdictions outside the U.S. State laws may require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, as well as require the registration of pharmaceutical sales representatives and the reporting of pricing information and marketing expenditures. Violations of such laws, or any other governmental regulations that apply, may result in penalties, including, without limitation, civil and criminal penalties, damages, fines, additional reporting and oversight obligations, the curtailment or restructuring of operations, exclusion from participation in governmental healthcare programs, and individual imprisonment. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Coverage and reimbursement </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of any pharmaceutical product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. Significant uncertainty exists as to the coverage and reimbursement status of any newly approved product. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. One third-party payor&#8217;s decision to cover a product does not ensure that other payors will also provide coverage for the product. As a result, the coverage determination process can require manufactures to provide scientific and clinical support for the use of a product to each payor separately, and can be a time-consuming process, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, third-party payors are increasingly reducing reimbursements for pharmaceutical products and services. The U.S. government and state legislatures have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement, and requirements for substitution of generic products. Third-party payors are more and more challenging the prices charged, examining the medical necessity, and reviewing the cost effectiveness of pharmaceutical products, in addition to questioning their safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases in third-party reimbursement for any product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand for the product. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product, or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Pharmaceutical products may face competition from lower-priced products in foreign countries that have placed price controls on pharmaceutical products and may also compete with imported foreign products. Furthermore, there is no assurance that a product will be considered medically reasonable and necessary for a specific indication, will be considered cost-effective by third-party payors, that an adequate level of reimbursement will be established even if coverage is available, or that the third-party payors&#8217; reimbursement policies will not adversely affect the ability of manufacturers to sell products profitably. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Healthcare reform </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States and certain foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system that could affect the pharmaceutical industry. In March 2010, the ACA was signed into law, which substantially changed the way healthcare is financed by both governmental and private insurers in the United States. The ACA contains a number of provisions of particular import to the pharmaceutical industry, including those governing enrollment in federal healthcare programs, reimbursement adjustments, and fraud and abuse changes. Additionally, the ACA increases the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1%; requires collection of rebates for drugs paid by Medicaid managed care organizations; imposes a nondeductible annual fee on pharmaceutical manufacturers or importers who sell &#8220;branded prescription drugs&#8221; to specified federal government programs; implements a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected; expands of eligibility criteria for Medicaid programs; creates a new Patient-Centered Outcomes Research Institute to oversee; identify priorities in, and conducts comparative clinical effectiveness research, along with funding for such research; and establishes a Center for Medicare Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. For example, in December 2018, a U.S. district court judge ruled that the ACA is unconstitutional in its entirety because the Tax Cuts and Jobs Act modified the individual mandate. On December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the district court&#8217;s decision that the individual mandate was unconstitutional but remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. The U.S. Supreme Court is currently reviewing the case, although it is unclear how the Supreme Court will rule. It is also unclear how other efforts, if any, to challenge, repeal or replace the ACA will impact the law.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legislative changes have been proposed and adopted since the ACA was enacted, including aggregate reductions of Medicare payments to providers of 2% per fiscal year, which was temporarily suspended from May 1, 2020 through March 31, 2021, and reduced payments to several types of Medicare providers. Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries, and proposed and enacted legislation designed, among other things, to bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. Individual states in the United States have also become increasingly active in implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, and marketing cost disclosure and transparency measures, and, in some cases, mechanisms to encourage importation from other countries and bulk purchasing. Furthermore, there has been increased interest by third-party payors and governmental authorities in reference-pricing systems and publication of discounts and list prices. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Foreign regulation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to regulations in the United States, we will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product, we must obtain approval by the comparable regulatory authorities of foreign countries before we can commence clinical trials in those countries, if relevant, and market application approval by foreign countries or economic areas, such as the European Union, or EU, before we may market products in those countries or areas. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing, and reimbursement vary greatly from place to place, and the time may be longer or shorter than that required for FDA approval. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the European Economic Area, or EEA, which is comprised of the Member States of the European Union plus Norway, Iceland and Liechtenstein, medicinal products can only be commercialized after obtaining a Marketing Authorization, or MA. There are two types of MAs: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Community MAs&#8212;These are issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, and are valid throughout the entire territory of the EEA. The Centralized Procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products, and medicinal products indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune, and viral diseases. The Centralized Procedure is optional for products containing a new active substance </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="font-size:10pt;color:#000000;">not yet authorized in the EEA; for products that constitute a significant therapeutic, </font><font style="font-size:10pt;color:#000000;">scientific</font><font style="font-size:10pt;color:#000000;"> or technical innovation; or for products that are in the interest of public health in the EU. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">National MAs&#8212;These are issued by the competent authorities of the Member States of the EEA and only cover their respective territory and are available for products not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized for marketing in a Member State of the EEA, this National MA can be recognized in another Member State through the Mutual Recognition Procedure. If the product has not received a National MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the Decentralized Procedure. Under the Decentralized Procedure, an identical dossier is submitted to the competent authorities of each of the Member States in which the MA is sought, one of which is selected by the applicant as the Reference Member State. The competent authority of the Reference Member State prepares a draft assessment report, a draft summary of the product characteristics, or SmPC, and a draft of the labeling and package leaflet, which are sent to the other Member States (referred to as the Member States Concerned) for their approval. If the Member States Concerned raise no objections, based on a potential serious risk to public health, to the assessment, SmPC, labeling or packaging proposed by the Reference Member State, the product is subsequently granted a National MA in all the Member States, i.e., in the Reference Member State and the Member States Concerned. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the above described procedures, before granting the MA, the EMA or the competent authorities of the Member States of the EEA assess the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety, and efficacy. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As in the United States, it may be possible in foreign countries to obtain a period of market and/or data exclusivity that would have the effect of postponing the entry into the marketplace of a competitor&#8217;s generic product. For example, if any of our products receive marketing approval in the EEA, we expect they will benefit from eight years of data exclusivity and 10&#160;years of marketing exclusivity. An additional noncumulative one-year period of marketing exclusivity is possible if during the data exclusivity period (the first eight years of the 10-year marketing exclusivity period) we obtain an authorization for one or more new therapeutic indications that are deemed to bring a significant clinical benefit compared to existing therapies. The data exclusivity period begins on the date of the product&#8217;s first marketing authorization in the EEA and prevents generics from relying on the marketing authorization holder&#8217;s pharmacological, toxicological, and clinical data for a period of eight years. After eight years, a generic product application may be submitted, and generic companies may rely on the marketing authorization holder&#8217;s data. However, a generic cannot launch until two years later (or a total of 10 years after the first marketing authorization in the EU of the innovator product), or three years later (or a total of 11 years after the first marketing authorization in the EU of the innovator product) if the marketing authorization holder obtains marketing authorization for a new indication with significant clinical benefit within the eight-year data exclusivity period. In Japan, our products may be eligible for eight years of data exclusivity. There can be no assurance that we will qualify for such regulatory exclusivity, or that such exclusivity will prevent competitors from seeking approval solely on the basis of their own studies. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When conducting clinical trials in the EU, we must adhere to the provisions of the European Union Clinical Trials Directive (Directive 2001/20/EC) and the laws and regulations of the EU Member States implementing them. These provisions require, among other things, that the prior authorization of an Ethics Committee and the competent Member State authority is obtained before commencing the clinical trial. In April 2014, the EU passed the Clinical Trials Regulation (Regulation 536/2014), which will replace the current Clinical Trials Directive. To ensure that the rules for clinical trials are identical throughout the European Union, the EU Clinical Trials Regulation was passed as a regulation that is directly applicable in all EU member states. All clinical trials performed in the European Union are required to be conducted in accordance with the Clinical Trials Directive until the Clinical Trials Regulation becomes applicable. According to the current plans of the EMA, the Clinical Trials Regulation is expected to become applicable sometime in 2020. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Data privacy and security laws </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_146"></a><a name="_Hlk35341521"></a>Numerous state, federal and foreign laws, including consumer protection laws and regulations, govern the collection, dissemination, use, access to, confidentiality and security of personal information, including health-related information. In the United States, numerous federal and state laws and regulations, including data breach notification laws, health information privacy and security laws, including the Health Insurance Portability and Accountability Act of 1996, as amended, or HIPAA, and federal and state consumer protection laws and regulations (e.g., Section 5 of the FTC Act), that govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our partners. In addition, certain state and non-U.S. laws, such as the California Consumer Privacy Act, or the CCPA, the California Privacy Rights Act, or the CPRA, and the European Union General Data Protection </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulation, or the GDPR, govern the privacy and security of personal information, including health-related information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation.&nbsp;&nbsp;Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing.</font></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_cp_text_1_147"></a>Employees<a name="_cp_text_1_147"></a> and Human Capital Resources</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.85%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Employees</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 19, 2021, we had 87 employees, including 83 full-time employees. Women represent approximately 46% of our employees with approximately 14% holding senior management level/leadership roles. Thirty-nine percent of our employees have an M.D. or a Ph.D. From time to time, we also retain independent contractors to support our organization. None of our employees are represented by a labor union or covered by collective bargaining agreements, and we believe our relationship with our employees is good.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:4.85%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Diversity &amp; Inclusion</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk64992293"></a>We are committed to creating and maintaining a workplace free from discrimination or harassment on the basis of color, race, sex, national origin, ethnicity, religion, age, disability, sexual orientation, gender identification or expression, or any other status protected by applicable law. Our management team and employees are expected to exhibit and promote honest, ethical<a name="_Hlk64992293"></a> and respectful conduct in the workplace. All of our employees must adhere to a code of conduct that sets standards for appropriate behavior and are required to attend training upon hire and at our request to help prevent, identify, report and stop any type of discrimination and harassment. Ongoing acknowledgement of our anti-harassment policy is required on an annual basis. Our recruitment, hiring, development, training, compensation and advancement at our company is based on qualifications, performance, skills and experience without regard to gender, race and ethnicity.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:4.85%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Competitive Pay &amp; Benefits</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We strive to provide pay, comprehensive benefits and services that help meet the varying needs of our employees. Our total rewards package includes competitive pay; comprehensive healthcare benefits package for employees, with family member healthcare benefits covered at 90%; a health savings account with company contribution; unlimited paid time off and paid holidays; family medical leave; and flexible work schedules. In addition, we offer every full-time employee, both exempt and non-exempt, the benefit of equity ownership in the company through stock option grants and our employee stock purchase plan. We also sponsor a 401(k) plan with a 5% match.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:4.85%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Employee Development &amp; Training</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We focus on attracting, retaining, and cultivating talented individuals. We emphasize employee development and training by providing access to a wide range of online and instructor led development and continual learning programs. Employees are encouraged to attend scientific, clinical and technological meetings and conferences and have access to broad resources they need to be successful.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:4.85%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Safety</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The safety, health and wellness of our employees is a top priority. In response to COVID-19, we have implemented a safety protocols including shift work scheduling to reduce number of people in the facility, requirements for the wearing of masks and for social distancing, increased cleaning procedures and readily available hand sanitizer. These protocols are designed to comply with health and safety standards as required by federal, state and local government agencies, taking into consideration guidelines of the Centers for Disease Control and Prevention and other public health authorities. In addition, we have provided work-at-home arrangements for employees who are able to do so.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_cp_text_1_148"></a>Our Corporate Information</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_149"></a>We were incorporated under the laws of the state of Delaware in November 2014. Our principal executive offices are located at 19 Presidential Way, Woburn, Massachusetts 01801 and our telephone number is (866) 389-1970. In the second quarter of 2021, our principal executive offices will be relocated to 75 Hayden Avenue, Lexington, Massachusetts 02421. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our corporate website address is </font><font style="font-style:italic;">www.frequencytx.com</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The information contained in, or accessible through, our website is not incorporated by reference into this Annual </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Report</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and you should not consider information on our website to be a part of this Annual Report. We have included our website address in this Annual Report solely as an inactive textual reference.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_cp_text_1_150"></a>Where you can find more information</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_151"></a><a name="_cp_field_47_152"></a>We are subject to the information requirements of the Securities Exchange Act of 1934, as amended. The SEC maintains an internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically, such as ourselves<a name="_cp_field_47_152"></a>, with the SEC at <font style="color:#000000;text-decoration:underline;">http://www.sec.gov</font>.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p><a name="_AEIOULastRenderedPageBreakAEIOU6"></a>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1A_RISK_FACTORS"></a><a name="ITEM_1A_RISK_FACTORS"></a>Item 1A. Risk Factors.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Our future operating results could differ materially from the results described in this Annual Report on Form&#160;10-K due to the risks and uncertainties described below. You should consider carefully the following information about risks below in evaluating our business. If any of the following risks actually occur, our business, financial conditions, results of operations and future growth prospects would likely be materially and adversely affected. <font style="color:#000000;">Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations</font> in these circumstances, the market price of our common stock would likely decline. In addition, we cannot assure investors that our assumptions and expectations will prove to be correct. Important factors could cause our actual results to differ materially from those indicated or implied by forward-looking statements. See &#8220;Forward Looking Statements&#8221; for a discussion of some of the forward-looking statements that are qualified by these risk factors. Factors that could cause or contribute to such differences include those factors discussed below.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks related to our financial position and need for additional capital </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have incurred significant losses since inception and anticipate that we will continue to incur losses for the foreseeable future. We are not currently profitable, and we may never achieve or sustain profitability. If we are unable to achieve or sustain profitability, the market value of our common stock will likely decline. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage biotechnology company with a limited operating history. As a result, we are not profitable and have incurred significant losses since our formation. We had net losses of $26.5 million and $19.8 million for the years ended December&#160;31, 2020 and 2019, respectively. As of December 31, 2020, we had an accumulated deficit of $95.4 million. Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to gain regulatory approval and become commercially viable. We have not commercialized any products and have never generated revenue from the commercialization of any product. To date, we have devoted most of our financial resources to licensing technologies and research and development, including our preclinical platform development activities and clinical trials. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to incur significant additional operating losses for the next several years, at least, as we advance FX-322 and any other product candidate through clinical development, complete clinical trials, seek regulatory approval and commercialize FX-322 or any other product candidate, if approved. The costs of advancing product candidates into each clinical phase tend to increase substantially over the duration of the clinical development process. Therefore, the total costs to advance any product candidate to marketing approval in even a single jurisdiction are substantial. Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to begin generating revenue from the commercialization of any product candidates or achieve or maintain profitability. Our expenses will also increase substantially if and as we: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">continue our Phase 2a trial of FX-322 in sensorineural hearing loss, or SNHL, our Phase 1b trial of FX-322 in age-related hearing loss, or ARHL, and severe SNHL, and commence additional clinical studies relating to FX-322, and any future pivotal Phase 3 studies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">expand our development programs based on our progenitor cell activation, or PCA, platform, including our program for a treatment for multiple sclerosis, or MS, and develop other product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">continue to develop our PCA platform; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">seek regulatory approvals for FX-322 and any other product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">expand the target indications and patient population for FX-322; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">secure a commercial manufacturing source and supply chain capacity sufficient to produce commercial quantities of any product candidate for which we obtain regulatory approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">establish a sales, marketing and distribution infrastructure to commercialize FX-322 for the treatment of SNHL, if approved, and for any other product candidates for which we may obtain marketing approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">maintain, expand, and protect our intellectual property portfolio; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">hire additional clinical, scientific, and commercial personnel; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">add operational, financial, and management personnel, including personnel to support our product development and planned future commercialization efforts, as well as to support operations as a public company; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">acquire or in-license other product candidates or technologies. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, our ability to successfully develop, commercialize and license any product candidates and generate product revenue is subject to substantial additional risks and uncertainties, as described under &#8220;&#8212;Risks related to development, clinical testing, manufacturing, and regulatory approval&#8221; and &#8220;&#8212;Risks related to commercialization.&#8221; As a result, we expect to continue to incur net losses and negative cash flows for the foreseeable future. These net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders&#8217; equity and working capital. The amount of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenues. If we are unable to develop and commercialize one or more product candidates, either alone or through collaborations, or if revenues from any product that receives marketing approval are insufficient, we will not achieve profitability. Even if we successfully commercialize FX-322, we may continue to incur substantial research and development and other expenses to identify and develop other product candidates. Even if we do achieve profitability, we may not be able to sustain profitability or meet outside expectations for our profitability. If we are unable to achieve or sustain profitability or to meet outside expectations for our profitability, the value of our common stock will be materially adversely affected. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We will require additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of FX-322 and additional product candidates. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to spend substantial amounts to complete the development of, seek regulatory approvals for and, if approved, commercialize FX-322. These expenditures include and will include, as the case may be, costs related to the Phase 2a trial of FX-322 for the treatment of SNHL, the Phase 1b trials of FX-322 for the treatment of ARHL and severe SNHL, respectively, and any additional trials we conduct to support the development of FX-322. In addition, we are obligated to make milestone and royalty payments in connection with the sale of resulting products and licensing revenues under our license agreements with Massachusetts Institute of Technology, or MIT, Massachusetts Eye and Ear, or MEE, the Scripps Research Institute, or Scripps, and Cambridge Enterprise Limited (the technology transfer arm of the University of Cambridge), or Cambridge. We also expect to spend substantial amounts to identify and develop new product candidates based on our PCA platform. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will require additional capital to enable us to develop additional product candidates based on our PCA platform, which we may acquire through equity offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or other sources. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative effect on our financial condition and our ability to pursue our business strategy. In addition, attempting to secure additional financing may divert the time and attention of our management from day-to-day activities and harm our development efforts. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based upon our current operating plan, we believe that our existing cash, cash equivalents, short-term investments of $220.3 million will enable us to fund our operating expenses and capital expenditure requirements into 2023. This estimate and our expectation regarding the sufficiency of our current financial resources to advance the clinical development of FX-322 and any other product candidates are based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect, or our clinical trials, including our Phase 2a trial of FX-322 for the treatment of SNHL, our Phase 1b trials of FX-322 for the treatment of ARHL and severe SNHL, respectively, and other planned clinical trials of FX-322,  may be more expensive, time consuming or difficult to design or implement than we currently anticipate. Changing circumstances, including any unanticipated expenses, could cause us to consume capital significantly faster than we currently anticipate, and we may need to spend more than currently expected because of circumstances beyond our control. Because the length of time and scope of activities associated with successful development of FX-322 or any product candidate we may develop is highly uncertain, we are unable to estimate the actual funds we will require for development and any marketing and commercialization activities. Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the initiation, progress, timing, costs and results of our clinical trials through all phases of development, including the Phase 2a trial and Phase 1b ARHL and severe SNHL trials for FX-322, our other planned clinical trials of FX-322, and the development of any other product candidates including any unforeseen costs we may incur as a result of clinical trials due to the COVID-19 global pandemic or other causes;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the outcome, timing and cost of meeting regulatory requirements established by the U.S. Food and Drug Administration, or the FDA, and other comparable foreign regulatory authorities, including any additional clinical trials required by the FDA or other comparable foreign regulatory authorities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the willingness of the FDA and other comparable foreign regulatory authorities to accept our clinical trial designs, as well as data from our completed and planned clinical trials and preclinical studies, as the basis for review and approval of FX-322 and any other product candidates; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="color:#000000;">the cost of filing, prosecuting, defending, and enforcing our patent claims and other intellectual property </font><font style="color:#000000;">rights;</font><font style="color:#000000;"> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the cost of defending potential intellectual property disputes, including patent infringement actions brought by third parties against us; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the effect of competing technological and market developments; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the cost and timing of completion of commercial-scale manufacturing activities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the costs of operating as a public company; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the cost of making royalty, milestone or other payments under current and any future in-license agreements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the extent to which we in-license or acquire other product candidates or technologies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the cost of establishing sales, marketing and distribution capabilities for our product candidates, if approved; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our ability to maintain our collaboration with Astellas Pharma Inc., or Astellas, including achievement of the development milestones and to establish new collaborations; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the initiation, progress, and timing of our commercialization of FX-322, if approved, or any other product candidate. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending on our business performance, the economic climate and market conditions, we may be unable to raise additional funds through any sources. Market volatility resulting from the COVID-19 global pandemic could also adversely impact our ability to access capital as and when needed. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of FX-322 or any other product candidate, or potentially discontinue operations. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have a limited operating history and no history of commercializing pharmaceutical products, which may make it difficult to evaluate the prospects for our future viability. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were established and began operations in 2014. Our operations to date have been limited to financing and staffing our company, licensing technologies, developing our PCA platform, developing and conducting preclinical and clinical studies of FX-322 for the treatment of SNHL, and developing a pipeline of preclinical and research programs, including our program for the treatment of MS. We have not yet demonstrated the ability to successfully complete a large-scale, pivotal clinical trial, obtain marketing approval, manufacture a commercial-scale product, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Consequently, predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing pharmaceutical products. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, as a business with a limited operating history, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown challenges. Our interim Phase 2a results, for example, showed that four weekly injections in subjects with mild to moderately severe SNHL did not demonstrate improvements in hearing measures versus placebo, which results were unexpected. We will eventually need to transition from a company with a research focus to a company capable of supporting commercial activities. We may not be successful in such a transition and, as a result, our business may be adversely affected. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As we continue to build our business, we expect our financial condition and operating results may fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, the results of any quarterly or annual period are not necessarily indicative of future operating performance. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our ability to use our net operating loss carryforwards to offset future taxable income, or tax credit carryforward to offset future income tax liabilities, may be subject to certain limitations. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, we had net operating loss carryforwards, or NOLs, of $67.9&#160;million for federal income tax purposes and $43.4&#160;million for state income tax purposes, which may be available to offset our future taxable income, if any. Our NOLs begin to expire in various amounts in 2037, provided that federal NOLs generated in taxable years beginning after December&#160;31, 2017 will not be subject to expiration. As of December&#160;31, 2020, we also had federal and state research and development and other tax credit carryforwards of approximately $3.0&#160;million and $1.2&#160;million, respectively, available to reduce future tax liabilities. Our tax credit carryforwards expire at various dates through 2040. These NOLs and tax credit </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">carryforwards could expire unused, to the extent subject to expiration, and be unavailable to offset future income tax liabilities. In addition, in general, under Sections&#160;382 and 383 of the U.S. Internal Revenue Code of 1986, as amended, or the Code, a corporation that undergoes an &#8220;ownership change&#8221; is subject to limitations on its ability to use its pre-change NOLs and tax credit carryforwards to offset future taxable income. For these purposes, an ownership change generally occurs where the aggregate stock ownership of one or more stockholders or groups of stockholders who owns at least 5% of a corporation&#8217;s stock increases its ownership by more than 50 percentage points over its lowest ownership percentage within a specified testing period. We believe we have experienced an ownership change </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in 2017 and 2019</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and may experience ownership changes in the future </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as a result of</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> future transactions in our stock, some of which may be outside our control. If we undergo </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">additional</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> ownership change</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, our ability to use our NOLs and tax credit carryforwards could be further limited. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of the changes in ownership in 2017 and 2019, $0.01 million and $0.04 million of NOL carryforwards are limited under Section 382. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For these reasons, we may not be able to use a material portion of our NOLs or tax credit carryforwards, even if we attain profitability. We have recorded a full valuation allowance related to our NOLs and other deferred tax assets due to the uncertainty of the ultimate realization of the future tax benefits of such assets. Furthermore, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOLs </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">generated in </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">periods beginning after December 31, 2017 may be carried forward indefinitely but may only be used</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to offset 80% of </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">taxable income</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in years beginning after December 31, 2020, which</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> may require us to pay federal income taxes in future years despite generating </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">federal NOLs</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in prior years. </font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks related to development, clinical testing, manufacturing, and regulatory approval </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are heavily dependent on the success of FX-322, our lead product candidate, which is still under clinical development, and if FX-322 does not receive regulatory approval or is not successfully commercialized, our business will be materially adversely harmed. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have invested a significant portion of our efforts and financial resources in the development of FX-322 for the treatment of SNHL. Our future success is substantially dependent on our ability to successfully complete clinical development for, obtain regulatory approval for, and successfully commercialize FX-322, which may never occur. We currently have no products that are approved for commercial sale and may never be able to develop a marketable product. We expect that a substantial portion of our efforts and expenditures over the next few years will continue to be devoted to FX-322, which will require additional clinical development, management of clinical and manufacturing activities, regulatory approval, establishing commercial scale manufacturing, and significant sales, marketing, and distribution efforts before we can generate any revenues from any commercial sales. We cannot be certain that we will be able to successfully complete any of these activities or that, even if it receives regulatory approval, FX-322 will be as effective as anticipated at treating SNHL. Our interim Phase 2a results, for example, showed that four weekly injections in subjects with mild to moderately severe SNHL did not demonstrate improvements in hearing measures versus placebo. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The research, testing, manufacturing, labeling, approval, sale, packaging, marketing, and distribution of drug products are subject to extensive regulation by the FDA and comparable regulatory authorities in other countries. We are not permitted to market FX-322 in the United States until we receive approval of a New Drug Application, or NDA, from the FDA, or in any foreign countries until our collaborator, Astellas, receives the requisite approval from such countries. We have not submitted an NDA to the FDA and Astellas has not submitted comparable applications to other regulatory authorities for FX-322. We or Astellas may not be in a position to do so for several years, if ever. If we or Astellas are unable to obtain the necessary regulatory approval for FX-322 in a country, including as a result of the COVID-19 pandemic, we or Astellas will not be able to commercialize FX-322 for the treatment of SNHL in that country. As a result, our financial position will be materially adversely affected, and we may not be able to generate sufficient revenue to continue our business. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We utilize our PCA platform to develop product candidates that are designed to activate progenitor cells, which is a new approach to therapeutic intervention and, as a result, successful development, approval, and commercialization of our product candidates, including FX-322, is uncertain. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We utilize our PCA platform to develop product candidates, including FX-322, for the treatment of SNHL. Our PCA platform is designed to identify pathways to activate progenitor cells already present in the body to treat conditions or diseases through cellular regeneration. We have not, nor to our knowledge has any other company, received regulatory approval utilizing this mechanism of cellular regeneration. Given the novelty of our approach, we could encounter a longer than expected regulatory review process, increased development costs, or unexpected delays in, or even prevention of, the regulatory approval and commercialization of our product candidates, and we cannot be certain that our approach will lead to the development of any approvable or marketable products. For example, the FDA-approved treatment options available for patients with SNHL are hearing aids and cochlear implants. Unlike FX-322, which is a therapeutic that targets the underlying </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">biology of SNHL, these treatment options are medical devices that are designed to target the symptoms of SNHL. As a result, these treatment options are not directly comparable to FX-322, and FDA requirements for marketing authorization of these treatment options may not be relevant for FX-322. While we are developing what we believe are appropriate measurements of efficacy for FX-322, we cannot be certain that the FDA will agree with our measurements or that they will be sufficient for approval. If we were to encounter any of the foregoing, our business and financial prospects could be materially harmed. </font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Clinical trials are expensive, time consuming, and difficult to design and implement, and involve an uncertain outcome. The results of preclinical studies and early clinical trials are not always predictive of future results. Any product candidate that we advance into clinical trials may not achieve favorable results in later clinical trials, if any, or receive marketing approval. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and completed clinical trials are not necessarily predictive of future results, and any product candidates we develop may not be further developed or may have additional unfavorable results in later studies or trials. Clinical trial failure may result from a multitude of factors, including, but not limited to, flaws in study design, dose selection, placebo effect, patient enrollment criteria, selection of patients based on patient misrepresentations, and failure to demonstrate favorable safety or efficacy traits. As such, failure in clinical trials can occur at any stage of testing. Several companies in the pharmaceutical industry have suffered setbacks in the advancement of their drug candidates into later-stage clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding favorable results in earlier preclinical studies or clinical trials. Our interim Phase 2a results, for example, showed that four weekly injections in subjects with mild to moderately severe SNHL did not demonstrate improvements in hearing measures versus placebo. Based upon negative or inconclusive results or a need for additional information, we may decide, or regulatory authorities may require us, to conduct additional clinical trials or preclinical studies. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may experience delays in initiating and completing any clinical trials that we intend to conduct, and we do not know whether our clinical trials will begin on time, need to be redesigned, enroll patients on time, or be completed on schedule, or at all. For example, a number of clinical trial sites for our ongoing Phase 2a clinical trial of FX-322 temporarily halted patient enrollment during the first and second quarter of 2020 in response to the COVID-19 pandemic. While we were able to complete enrollment of our Phase 2 clinical trial in September 2020, enrollment in other ongoing clinical trials could be adversely affected by the pandemic. Clinical trials can be delayed for a variety of reasons, including delays related to: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical studies;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">obtaining regulatory approval to commence a trial; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">reaching an agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">obtaining Institutional Review Board, or IRB, approval at each site within the United States, or Independent Ethics Committee, or IEC, approval at sites outside the United States; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">business interruptions resulting from the COVID-19 pandemic;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">recruiting suitable patients to participate in a trial in a timely manner and in sufficient numbers; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">having patients complete a trial or return for post-treatment follow-up; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">imposition of a clinical hold by regulatory authorities, including as a result of unforeseen safety issues or side effects or failure of trial sites or investigators to adhere to regulatory requirements or follow trial protocols; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">clinical sites deviating from the trial protocol or dropping out of a trial; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">addressing patient safety concerns that arise during a trial; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">adding a sufficient number of clinical trial sites; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">manufacturing sufficient quantities of a product candidate for use in clinical trials. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We could also encounter delays if a clinical trial is suspended or terminated by us, the IRBs or IECs of the institutions in which such trials are being conducted, the FDA or other regulatory authorities, or recommended for termination by a Data and Safety Monitoring Board, or DSMB, for such trial. Such authorities may impose a suspension or termination or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">recommend an alteration due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions, or lack of adequate funding to continue the clinical trial. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, we rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and, while we have agreements governing their committed activities, we have limited influence over their actual performance, as described in the section titled &#8220;&#8212;Risks related to our dependence on third parties.&#8221; </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our lead product candidate, FX-322, is still in development and will require the successful completion of one, and possibly more, Phase 3 trials before we are prepared to submit an NDA for regulatory approval by the FDA. In addition, we have been advised by the FDA that, while the nonclinical studies conducted by us to date suggest a pharmacodynamic interaction between the two active components of FX-322, the FDA has indicated that the results of such nonclinical studies do not preclude a human study and that inclusion of a factorial study in humans in future trials of FX-322 would thoroughly assess the effects attributable to each component drug of FX-322 in the combination so as to satisfy the FDA&#8217;s combination rule. The design and conduct of a factorial study in humans, including the development of each active component to administer in such study, may cause additional delays in the development of FX-322. We cannot predict with any certainty if or when we might complete the development of FX-322 and submit an NDA for regulatory approval by the FDA of FX-322 or whether any such NDA will be approved by the FDA. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we experience delays in the commencement or completion of any clinical trials, or if we terminate a clinical trial prior to completion, the commercial prospects of any product candidate we develop could be harmed, and our ability to generate revenues may be delayed. In addition, any delays in our clinical trials could increase our costs, slow the development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may materially harm our business, financial condition, and results of operations. In addition, many of the factors that may cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA. The FDA may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of a clinical trial. The FDA may therefore question the integrity of the data generated at the applicable clinical trial site, and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA and may ultimately lead to the denial of marketing approval of a product candidate. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time- consuming, and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for FX-322 or any other product candidates, our business will be substantially harmed. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The time required to obtain approval by the FDA and comparable foreign regulatory authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during a product candidate&#8217;s clinical development and may vary among jurisdictions. The approval process may also be delayed by changes in government regulation, the impact of the COVID-19 pandemic, future legislation or administrative action. We have not obtained regulatory approval for any product candidate and it is possible that we will never obtain regulatory approval for any product candidate. We are not permitted to market any of our product candidates in the United States until we receive approval of an NDA from the FDA. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authority, that such product candidates are safe and effective for their intended uses. In addition, data obtained from preclinical trials and clinical trials are susceptible to varying interpretations, and regulatory authorities may not interpret our data as favorably as we do, which may further delay, limit, or prevent development efforts, clinical trials, or marketing approval. Furthermore, as more competing drug candidates within a class of drugs proceed through clinical development to regulatory review and approval, the amount and type of clinical data that may be required by regulatory authorities may </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">increase or change. Even if we believe the preclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and other comparable regulatory authorities. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA or any foreign regulatory authority can delay, limit, or deny approval of FX-322 or any other product candidates that we develop or require us to conduct additional preclinical or clinical testing or abandon a program for many reasons, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">serious and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals using drugs similar to our product candidates, or other products containing an active ingredient in our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">negative or ambiguous results from our clinical trials or results that may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the data collected from clinical trials of our product candidates may not be acceptable or sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States or elsewhere, and we may be required to conduct additional clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the FDA&#8217;s or the applicable foreign regulatory authority&#8217;s disagreement regarding the formulation, the labeling, and/or the specifications of our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the FDA or comparable foreign regulatory authorities may fail to approve or find deficiencies with the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Of the large number of drugs in development, only a small percentage successfully complete the regulatory approval processes and are commercialized. This lengthy approval process, as well as the unpredictability of future clinical trial results, may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, results of operations, and prospects. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the FDA or the applicable foreign regulatory authority also may approve a product candidate for a more limited indication or patient population than we originally requested, and the FDA or applicable foreign regulatory authority may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing circumstances could materially harm the commercial prospects for our product candidates and our business. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion. We may encounter delays in enrolling, or be unable to enroll, a sufficient number of patients to complete any of our clinical trials, and even once enrolled, we may be unable to retain a sufficient number of patients to complete any of our trials.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patient enrollment and retention in clinical trials depends on many factors, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the extent of the ongoing COVID-19 pandemic, see --- </font><font style="font-style:italic;color:#000000;">The COVID-19 pandemic could adversely impact our business, including our preclinical studies, clinical trials and operations;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="color:#000000;">the patient eligibility criteria defined in the protocol, such as the requirement to establish stable hearing loss in our Phase 2a </font><font style="color:#000000;">and Phase 1b </font><font style="color:#000000;">clinical </font><font style="color:#000000;">trial</font><font style="color:#000000;">s</font><font style="color:#000000;">;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the size of the patient population required for analysis of the trial&#8217;s primary endpoints; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the nature of the trial protocol, trial design, side effects or other results that may arise in development; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the existing body of safety and efficacy data with respect to the product candidate; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the proximity of patients to clinical sites; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our ability to recruit clinical trial investigators with the appropriate competencies, motivation and experience; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs or medical devices that may be approved for the indications we are investigating; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">competing clinical trials being conducted by other companies or institutions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our ability to obtain and maintain patient consents; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the risk that patients enrolled in clinical trials will drop out of the trials before completion.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk40184183"></a>In addition, our clinical trials will compete with other clinical trials for product candidates and medical devices that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Furthermore, any negative results we may report in clinical trials of any product candidate may make it difficult or impossible to recruit and retain patients in other clinical trials of that same product candidate. Delays or failures in planned patient enrollment or retention may result in increased costs or program delays, which could have a harmful effect on our ability to develop a product candidate or could render further development impossible. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Results of preclinical studies, clinical trials, or analyses may not be indicative of results that may be obtained in later trials. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The results of preclinical studies, clinical trials, or analyses of the results from such trials, including our prospective and <font style="font-style:italic;">post hoc</font> analyses of the data from the Phase 1/2 trial of FX-322 for the treatment of SNHL, may not be predictive of the results of later clinical trials. Product candidates in later clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and prior clinical trials or having shown promising results based on analyses of data from earlier trials. A number of companies in the pharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding earlier promising results. Our interim Phase 2a results, for example, showed that four weekly injections in subjects with mild to moderately severe SNHL did not demonstrate improvements in hearing measures versus placebo. In addition, conclusions based on promising data from analyses of clinical results, such as the prospective and <font style="font-style:italic;">post hoc</font> analysis of results from our Phase 1/2 clinical trial of FX-322 for the treatment of SNHL, may be shown to be incorrect in subsequent clinical trials that have pre-specified end points or may not be considered adequate by regulatory authorities. Even if we complete later clinical trials as planned, we cannot be certain that their results will support the safety and efficacy requirements sufficient to obtain regulatory approval, and, as a result, our clinical development plans may be materially harmed. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Interim and preliminary &#8220;top-line&#8221; data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may publicly disclose interim, top-line or preliminary data from our clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the top-line or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Top-line or preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the top-line or preliminary data we previously published. As a result, top-line and preliminary data should be viewed with caution until the final data are available. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the interim, top-line or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Any product candidate or component of a product candidate that we develop or the administration thereof, may cause serious adverse events or undesirable side effects, which may halt their clinical development, delay or prevent marketing approval, or, if approved, require them to be taken off the market, include safety warnings, or otherwise limit their sales. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Serious adverse events or undesirable side effects caused by any product candidate or component of a product candidate we develop could cause us or regulatory authorities to interrupt, delay, or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign regulatory authorities. Results of any clinical trial we conduct could reveal a high and unacceptable severity and prevalence of side effects. In our clinical studies to date, subjects treated with FX-322 have experienced adverse events that include ear discomfort and ear pain that are considered to be associated with the intratympanic injection procedure. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If unacceptable side effects arise in the development of any product candidate, we, the FDA, or the IRBs or IECs at the institutions in which our studies are conducted, or the DSMB, if constituted for our clinical trials, could recommend a suspension or termination of our clinical trials, or the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of a product candidate for any or all targeted indications. In addition, drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete a trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We may have to train medical personnel regarding the proper administration protocol for our product candidates and to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may harm our business, financial condition, and prospects significantly. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, if FX-322 or any other product candidate we develop receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">regulatory authorities may suspend, withdraw, or limit approvals of such product, or seek an injunction against its manufacture or distribution; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">regulatory authorities may require us to recall a product or we may decide to initiate a voluntary recall of a product;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">regulatory authorities may require additional warnings on the label, such as a &#8220;black box&#8221; warning or contraindication;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">additional restrictions may be imposed on the marketing of the product or the manufacturing processes for the product or any component thereof; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">we may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or create a medication guide outlining the risks of such side effects for distribution to patients; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">we may be required to conduct post-market studies or agree to post marketing commitments; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">we could be sued and held liable for harm caused to patients; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the product may become less competitive; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our reputation may suffer. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these events could prevent us from achieving or maintaining market acceptance of a product candidate, if approved, and could significantly harm our business, results of operations, and prospects. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December&#160;22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Separately, in response to the COVID-19 pandemic, on March 10, 2020 the FDA announced its intention to postpone most inspections of foreign manufacturing facilities and on March 18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Subsequently, on July 10, 2020 the FDA announced its intention to resume certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA intends to use this risk-based assessment system to identify the categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic or issue guidance materially affecting the conduct of clinical trials. If a prolonged government shutdown occurs, or it global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns or delays could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not be successful in our efforts to identify additional product candidates. Due to our limited resources and access to capital, we must prioritize development of certain product candidates, the choice of which may prove to be wrong and adversely affect our business. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we intend to explore additional product candidates based on our PCA platform, we may fail to identify viable new product candidates for clinical development for several reasons. If we fail to identify additional potential product candidates, our business could be materially harmed. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research programs to develop additional product candidates based on our PCA platform require substantial technical, financial, and human resources whether or not they are ultimately successful. Our research programs may initially show promise in identifying potential indications or product candidates, yet fail to yield results for clinical development for several reasons, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the research methodology used may not be successful in identifying potential indications or product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">potential product candidates may, after further study, be shown to have harmful or unexpected adverse effects or other characteristics that indicate they are unlikely to be effective drugs; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">it may take greater human and financial resources than we possess to identify additional therapeutic opportunities for our product candidates or to develop suitable potential product candidates through internal research programs, thereby limiting our ability to develop, diversify, and expand our product portfolio. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we have limited financial and human resources, we intend to initially focus on research programs and product candidates for a limited set of indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that could have greater commercial potential or a greater likelihood of success. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accordingly, there can be no assurance that we will ever be able to identify additional therapeutic opportunities for our product candidates or to develop suitable potential product candidates through internal research programs, which could materially adversely affect our future growth and prospects. For example, we may encounter delays in the process of selecting a product candidate for the treatment of MS and we may not achieve the timeline we currently anticipate for submitting an IND or comparable foreign equivalent. We may focus our efforts and resources on potential product candidates or other potential programs that ultimately prove to be unsuccessful. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The market opportunities for FX-322, if approved, may be smaller than we anticipate and, as a result, our commercial opportunity may be limited. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to initially seek approval of FX-322 for the treatment of SNHL. Our projections of the number of eligible patients are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, patient foundations, and market research, and may prove to be incorrect. Further, new sources may reveal a change in the estimated number of eligible patients, and the number of patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for our current programs or future product candidates may be limited. For example, even if we obtain FDA approval for FX-322, it may be approved for a target population that is more limited than what we currently anticipate. Even if we obtain significant market share for any product candidate, if approved, if the potential target populations are smaller, we may never achieve profitability without obtaining marketing approval for additional indications. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have never obtained marketing approval for a product candidate and we may be unable to obtain, or may be delayed in obtaining, marketing approval for any product candidate. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never obtained marketing approval for a product candidate. It is possible that the FDA may refuse to accept for substantive review any NDAs that we submit for our product candidates or may conclude after review of our data that our applications are insufficient to obtain marketing approval of our product candidates. We believe our approach of activating progenitor cells to treat conditions or diseases through cellular regeneration is novel and, as a result, the process for, and the outcome of, FDA approval is especially uncertain. If the FDA does not accept or approve our NDAs for our product candidates, it may require that we conduct additional clinical, preclinical, or manufacturing validation studies and submit that data before it will reconsider our applications. Depending on the extent of these or any other FDA-required studies, approval of any NDA that we submit may be delayed or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be considered sufficient by the FDA to approve our NDAs. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any delay in obtaining, or an inability to obtain, marketing approvals would prevent us from commercializing our product candidates, generating revenues, and achieving and sustaining profitability. If any of these outcomes occur, we may be forced to abandon our development efforts for our product candidates, which could significantly harm our business. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if we obtain FDA approval for a product candidate in the United States, we or our collaborators may never obtain approval for or commercialize the product candidate in any other jurisdiction, which would limit our ability to realize its full market potential. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to market any product in a particular jurisdiction, we or our collaborators must establish and comply with numerous and varying regulatory requirements regarding safety and efficacy on a country-by-country basis. Approval by the FDA in the United States does not ensure approval by comparable regulatory authorities in other countries or jurisdictions. However, the failure to obtain approval in one jurisdiction may negatively impact our or our collaborators&#8217; ability to obtain approval elsewhere. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and increased costs for us and require additional preclinical studies or clinical trials which could be costly and time- consuming. Regulatory requirements </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">can vary widely from country to country and could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any jurisdiction, including in international markets, and we do not have experience in obtaining regulatory approval in international markets. If we or our collaborators fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reduced</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and we will be unable to realize the full market potential of any product we develop. </font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if we obtain regulatory approval for any product candidate, we will still face extensive and ongoing regulatory requirements and obligations, which may result in significant additional expense, and any product candidates, if approved, may face future development and regulatory difficulties.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any product candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, packaging, distribution, adverse event reporting, storage, recordkeeping, export, import, and advertising and promotional activities for such product, among other things, will be subject to extensive and ongoing requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, establishment registration and drug listing requirements, continued compliance with current Good Manufacturing Practice, or cGMP, requirements relating to manufacturing, quality control, quality assurance, and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping and Good Clinical Practice, or GCP, and requirements for any clinical trials that we conduct post-approval. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product candidate may be marketed or to the conditions of approval, including a requirement to implement a REMS. If a product candidate receives marketing approval, the accompanying label may limit the approved indicated use of the product, which could limit sales of the product. The FDA may also require costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a product. The FDA closely regulates the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding off-label use, and if we market our products for uses beyond their approved indications, we may be subject to enforcement action for off-label marketing. Violations of the Federal Food, Drug, and Cosmetic Act, or FDCA, relating to the promotion of prescription drugs, may lead to FDA enforcement actions and investigations alleging violations of federal and state healthcare fraud and abuse laws, as well as state consumer protection laws. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, later discovery of previously unknown adverse events or other problems with our products, manufacturers, or manufacturing processes or failure to comply with regulatory requirements, may yield various results, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">restrictions on manufacturing such products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">restrictions on the labeling or marketing of products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">restrictions on product distribution or use; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">requirements to conduct post-marketing studies or clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">warning letters or untitled letters; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">refusal to approve pending applications or supplements to approved applications that we submit; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">recalls or market withdrawals of products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">fines, restitution, or disgorgement of profits or revenues; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">suspension or withdrawal of marketing approvals; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">refusal to permit the import or export of our products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">product seizure; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">injunctions, consent decrees, or the imposition of civil or criminal penalties. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, the FDA&#8217;s policies may change, and additional government regulations may be enacted that could prevent, limit, or delay regulatory approval of a product candidate. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may lose any marketing approval that we may have obtained, which would adversely affect our business, prospects, and ability to achieve or sustain profitability.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also cannot predict the likelihood, nature, or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. The policies of the FDA and of other comparable regulatory authorities may change and additional government regulations may be enacted that could prevent, limit, or delay regulatory approval of a product candidate. For example, the results of the 2020 U.S. Presidential election may impact our business and industry. Namely, the previous presidential administration took several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA&#8217;s ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. It is difficult to predict whether or how these actions will be implemented, or whether they will be rescinded and replaced under the new presidential administration. The policies and priorities of the new administration are unknown and could materially impact the regulatory framework governing our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may be subject to enforcement action, and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition, and results of operations. Furthermore, noncompliance by us or any collaborator with regulatory requirements, including safety monitoring or pharmacovigilance, may also result in significant financial penalties, which would adversely affect our business. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We received Fast Track designation by the FDA for FX-322 and may seek Fast Track designation by the FDA for any future product candidates, but we might not receive such a designation. However, such designation may not lead to a faster development or regulatory review or approval process. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2019, FX-322 received Fast Track designation by the FDA. If a drug is intended for the treatment of a serious condition and nonclinical or clinical data demonstrate the potential to address an unmet medical need for this condition, a drug sponsor may qualify for FDA Fast Track designation. Fast Track designation provides increased opportunities for sponsor meetings with the FDA during preclinical and clinical development, in addition to the potential for rolling review once a marketing application is filed. The FDA has broad discretion whether to grant Fast Track designation, and we may not receive such a designation for all of the product candidates for which we may request it. Moreover, even if we receive Fast Track designation, Fast Track designation does not ensure that we will receive marketing approval or that approval will be granted within any particular time frame. We may not experience a faster development or regulatory review or approval process with Fast Track designation compared to conventional FDA procedures. In addition, the FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program. Fast Track designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may seek a Breakthrough Therapy designation for FX-322 and our other product candidates, but we might not receive such designation, and even if we do, such designation may not lead to a faster development or regulatory review or approval process. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may seek a Breakthrough Therapy designation for FX-322 if results from our ongoing clinical trials support such designation and we may seek a Breakthrough Therapy designation for other product candidates we may develop. A Breakthrough Therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA may also be eligible for priority review if supported by clinical data at the time the NDA is submitted to the FDA. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Designation as a Breakthrough Therapy is within the discretion of the FDA. Accordingly, even if we believe that a product candidate meets the criteria for designation as a Breakthrough Therapy, the FDA may disagree and instead determine not to make such a designation. Even if we receive Breakthrough Therapy designation, the receipt of such designation may not result in a faster development or regulatory review or approval process compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if a product candidate qualifies as a Breakthrough Therapy, the FDA may later decide that it no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Potential product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any products that we may develop. </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The use of any product candidate we may develop in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by patients, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated adverse effects. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">impairment of our business reputation and significant negative media attention; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">withdrawal of participants from our clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">significant costs to defend the litigation; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">distraction of management&#8217;s attention from our primary business; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">substantial monetary awards to patients or other claimants; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">inability to commercialize a product candidate; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">product recalls, withdrawals or labeling, marketing or promotional restrictions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">decreased market demand for any product; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">loss of revenue. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The product liability insurance we currently carry, and any additional product liability insurance coverage we acquire in the future, may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If we obtain marketing approval for any product candidate, we intend to acquire insurance coverage to include the sale of commercial products; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. A successful product liability claim, or series of claims, brought against us could cause our share price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operation and business, including preventing or limiting the commercialization of any product candidates we develop. </p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The COVID-19 pandemic has caused and could continue to cause disruptions to our business, including our preclinical studies, clinical trials and operations and could adversely impact our financial condition and results of operations.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the World Health organization designated the outbreak of the novel strain of coronavirus, known as COVID-19, as a global pandemic. This virus has and continues to spread globally and governments and businesses around the world have taken unprecedented actions to mitigate the spread of COVID-19, including, but not limited to, shelter-in-place orders, business closures, quarantines, border closures, significant restrictions on travel, social distancing practices as well as restrictions that prohibit many employees from going to work. The pandemic, and government measures taken in response, have had a significant impact, both direct and indirect, on business and commerce, as worker shortages have occurred; supply chains have been disrupted; facilities and production have been suspended; and demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and services, such as travel, has fallen. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 23, 2020, the governor of Massachusetts ordered the closure of all non-essential businesses, effective March 24, 2020 through April 7, 2020, which was subsequently extended through May 18, 2020. The governor of Massachusetts has since implemented a phased re-opening plan. Since December 2020, several vaccines combating COVID-19 have been granted emergency use authorization by the FDA and are being administered.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In light of recent developments relating to the COVID-19 pandemic, the focus of healthcare providers and hospitals has been on fighting the virus and vaccinating the public and we have been required to take steps consistent with the FDA&#8217;s updated industry guidance for conducting clinical trials issued on March 18, 2020. The majority of our employees have continued to work from home, while nearly a quarter to one-third of our workforce, mainly consisting of laboratory employees, have periodically worked in rotating teams to ensure on the continuation of essential experiments. Our </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Farmington</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> CT research site, co-located with the University of Connecticut, has </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">resumed</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> activity</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> at a fifty percent rate </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">after having paused activity during the state mandated lock down orders previously in effect, however, we have transitioned k</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ey experiments </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to our offices in </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Woburn, MA and third parties and contract research organizations have been engaged to advance certain projects. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have also</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> taken</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">steps consistent with the FDA&#8217;s updated industry guidance for conducting clinical trials.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:10pt;text-transform:none;font-variant: normal;">It is unknown how long these conditions will last and what the complete effect will be to the Company. If COVID-19 continues to spread in the United States and worldwide, and measures to mitigate the ongoing effects of the pandemic, such as stay home orders and/or advisories persist or are reintroduced, we may continue to experience disruptions and other effects on our business that could severely impact our business, operations, preclinical studies and clinical trials, including: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">delays, difficulties or postponement in enrolling and retaining patients in our clinical trials;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.72%;text-indent:-4.86%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">delays, difficulties or postponement in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.72%;text-indent:-4.86%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of ENT practices and academic centers serving as our clinical trial sites and staff supporting the conduct of our clinical trials;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.72%;text-indent:-4.86%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others or interruption of clinical trial subject visits and study procedures, which may impact the integrity of subject data and clinical study endpoints; </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.72%;text-indent:-4.86%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.72%;text-indent:-4.86%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems; </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.72%;text-indent:-4.86%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">interruptions in planned trials due to restricted or limited operations at our laboratory facility; </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.72%;text-indent:-4.86%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">continual changes to operating requirements and related expenses, limitations in employee resources that would otherwise be focused on the conduct of our preclinical studies and clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people and resulting losses of productivity and employee work culture; </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.72%;text-indent:-4.86%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">risk that participants enrolled in our clinical trials will acquire COVID-19 while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.72%;text-indent:-4.86%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">refusal of the FDA, or other government agencies, to accept data from clinical trials in these affected geographies;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.72%;text-indent:-4.86%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">interruption or delayed to our sourced discovery and clinical activities;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.72%;text-indent:-4.86%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">inability to obtain additional financing or access the financial markets, and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.72%;text-indent:-4.86%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">if any of the CMOs involved in the manufacture and supply of FX-322 experience a delay or disruption due to COVID-19, we may not have sufficient quantities of FX-322 for our planned activities and may not be able to transition to a new CMO in a timely or cost-effective manner, or at all, which would negatively impact our ability to develop and potentially commercialize FX-322.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.43%;text-indent:-4.86%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The global outbreak of COVID-19 continues to rapidly evolve and continues to have indeterminable adverse effects on general commercial activity and the world economy. We had previously observed an impact from COVID-19 as a number of clinical trial sites had informed us that they have temporarily halted enrollment, though we completed enrollment on the Phase 2a clinical trial in September 2020. However, due to the uncertain nature of the effects of the outbreak, particularly in the United States, enrollment, participation and retention in our ongoing and planned trials may be reduced, and for a number of the clinical sites, halted for an unknown period of time. Any reduction in enrollment, participation and retention and any halts may delay our ongoing and planned clinical trials and our development plans for FX-322, which could have an adverse impact on our business and results of operations. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The extent to which COVID-19 may </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">continue to </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">impact our business, preclinical studies, clinical trials (including the completion and timing of our Phase 2a clinical trial</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and Phase 1b clinical trials in ARHL and severe SNHL</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) and operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ongoing and </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ultimate geographic spread of the disease, duration of the outbreak, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">including future waves of infection, new variant strains of the underlying virus, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">travel restrictions and social distancing in the United States and other countries, business closures or business disruptions</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, availability and effectiveness of vaccines</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and the effectiveness of actions taken in the United States and other countries to contain</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">treat</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and mitigate the spread of</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COVID-19</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. In addition, if we or any of the third parties with whom we engage were to experience shutdowns or </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">additional </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively impacted, which could have a material adverse effect on our business and our financial results. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 pandemic has resulted in a widespread health crisis that has adversely affected the economies and financial markets worldwide, resulting in an economic downturn that could continue to significantly impact our business, financial </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">condition</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and results of operations. To the extent the COVID-19 pandemic adversely affects our business, financial </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">condition</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and results of operations, it may also have the effect of heightening many of the other risks described in this &#8220;Risk Factors&#8221; section.</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks related to commercialization </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We face significant competition from biotechnology, pharmaceutical, and medical device companies, and our operating results will suffer if we fail to compete effectively. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The biotechnology, pharmaceutical, and medical device industries are highly competitive and subject to significant and rapid technological change. Our success is highly dependent on our ability to acquire, develop, and obtain marketing approval for new products on a cost-effective basis and to market them successfully. If a product candidate we develop is approved, we will face intense competition from a variety of businesses, including large, fully integrated pharmaceutical companies, specialty pharmaceutical companies, and early-stage companies, particularly if the early-stage company has a collaborative arrangement with a large and established company. We are aware of several companies developing products to treat SNHL through the regeneration of hair cells or through other mechanisms, and we also anticipate that new companies will enter the SNHL market in the future. If we successfully develop and, if approved, commercialize FX-322 for the treatment of SNHL, it may compete, or potentially be used in conjunction, with currently marketed devices, including the hearing aids and cochlear implants currently available and the next generation of improved hearing aids and cochlear implants, and any new therapies that may become available in the future. Furthermore, changes in the regulatory landscape may increase competition from hearing aids. <font style="color:#000000;">The FDA Reauthorization Act of 2017 created a new category of over-the-counter, or OTC, hearing aids which are intended to be available to consumers without first requiring a visit to a medical professional. While the final regulations needed to implement this new category of devices have not yet been issued, if and when they are, obtaining hearing aids may become less expensive and more convenient.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competition could render any product candidate we develop obsolete, less competitive, or uneconomical. Our competitors may, among other things: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">have significantly greater name recognition and financial, manufacturing, marketing, product development, technical, and human resources than we do, with mergers and acquisitions in the biotechnology, pharmaceutical, and medical device industries resulting in even more resources being concentrated in our competitors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">more effectively recruit and retain qualified scientific and management personnel; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">more effectively establish clinical trial sites and patient registration; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">develop and commercialize products that are safer, more effective, less expensive, more convenient, or easier to administer, or have fewer or less severe side effects; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">obtain quicker regulatory approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">better protect their patents and intellectual property or acquire technologies that are complementary to, or necessary for, our programs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">implement more effective approaches to sales, marketing, pricing, coverage, and reimbursement; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">form more advantageous strategic alliances or collaborations. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are not able to effectively compete for any of the foregoing reasons, our business will be materially harmed. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The successful commercialization of any product candidate we develop will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels, and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our or our collaborators&#8217; ability to market those products and decrease our or our collaborators&#8217; ability to generate revenue. </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The availability and adequacy of coverage and reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers, and other third-party payors are essential for most patients to be able to afford prescription medications. Our ability to achieve acceptable levels of coverage and reimbursement for products or procedures using our products by governmental authorities, private health insurers and other organizations will influence our ability to successfully commercialize any product candidates we develop. Obtaining adequate coverage and reimbursement for any product candidate we develop that is administered under the supervision of a physician, which is what we anticipate for FX-322, may be particularly difficult because of the higher prices associated with such products. In addition, we believe that FX-322 is a novel approach to treating hearing loss and, as a result, availability of coverage and reimbursement by payors is highly uncertain, particularly because the cost of existing treatments for SNHL, such as hearing aids, are generally not reimbursed by payors. A decision by a third-party payor not to cover or separately reimburse for our products or procedures using our products could reduce physician utilization of our products once approved. Assuming we obtain coverage for our product candidates or procedures using our products by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the United States or elsewhere will be available for any product we commercialize, and any reimbursement that may become available may be decreased or eliminated in the future. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and the current presidential administration and Congress have introduced several proposals related to drug pricing. Many third-party payors may refuse to provide coverage and reimbursement for particular drugs or biologics when an equivalent generic drug, biosimilar, or a less expensive therapy is available. Although there are currently no FDA approved drugs for the treatment of SNHL, it is possible that a third-party payor may consider FX-322 as substitutable and only offer to reimburse patients for the less expensive product. Even if we show improved efficacy, pricing of existing drugs and medical devices, such as hearing aids, may limit the amount we will be able to charge for any product we commercialize. Payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize a satisfactory return on our investment in our product candidates. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our product candidates and may not be able to obtain a satisfactory financial return on our product candidates. Additionally, our ability to obtain a satisfactory financial return depends on what, if any, proposals related to drug pricing may be implemented and, if implemented, when they might take effect. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will be covered. The Medicare and Medicaid programs increasingly are used as models in the United States for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor, and one third-party payor&#8217;s decision to cover a product does not ensure that other payors will also provide similar coverage. Additionally, the process for determining whether a third-party payor will provide coverage for a product is typically separate from the process for setting the price of such product or establishing the reimbursement rate that the payor will pay for the product once coverage is approved. As a result, the determination of coverage and reimbursement is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases at short notice, and we believe that changes in these rules and regulations are likely. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, increasing efforts by governmental and third-party payors in the United States to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for any product we commercialize. We expect to experience </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pricing pressures in connection with the sale of our product candidates due to the trend toward managed health care, the increasing influence of health maintenance organizations, and additional legislative, administrative, or regulatory changes. The downward pressure on healthcare costs in general, particularly prescription drugs and biologics and surgical procedures and other treatments, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We or our collaborators may also be subject to extensive governmental price controls and other market regulations outside of the United States, and we believe the increasing emphasis on cost-containment initiatives in other countries have and will continue to put pressure on the pricing and usage of medical products. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we or our collaborators are able to charge for products we or our collaborators commercialize. Accordingly, in markets outside the United States, the reimbursement for products we or our collaborators commercialize may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if a product candidate we develop receives marketing approval, it may fail to achieve market acceptance by physicians, patients, third-party payors, or others in the medical community necessary for commercial success. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a product candidate we develop receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors, and others in the medical community. If it does not achieve an adequate level of acceptance, we may not generate significant product revenues or become profitable. The degree of market acceptance of our product candidates, if approved, will depend on several factors, including, but not limited to: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the efficacy and potential advantages compared to alternative treatments; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">effectiveness of sales and marketing efforts; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the cost of treatment in relation to alternative treatments, including any similar generic treatments; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our ability to offer our products for sale at competitive prices; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the convenience and ease of administration compared to alternative treatments; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the strength of marketing and distribution support; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the availability of third-party coverage and adequate reimbursement; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the prevalence and severity of any side effects; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">any restrictions on the use of our product together with other medications. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we expect sales of our product candidates, if approved, to generate substantially all our revenues for the foreseeable future, the failure of our product candidates to find market acceptance would harm our business and could require us to seek additional financing. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are unable to establish sales and marketing capabilities either on our own or in collaboration with third parties, we may not be successful in commercializing any product candidate we develop, if approved. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to market and successfully commercialize any product candidate we develop, if approved, we must build our sales and marketing capabilities or enter into collaborations with third parties for these services. We currently have no sales, marketing or distribution capabilities and as a company have no experience in marketing products. We intend to directly market and commercialize FX-322 for the treatment of SNHL, if approved, in the United States by developing our own sales and marketing force, targeting ear, nose, and throat doctors and audiologists. There are significant expenses and risks involved with establishing our own sales and marketing capabilities, including our ability to hire, train, retain, and appropriately incentivize a sufficient number of qualified individuals, generate sufficient sales leads and provide our sales and marketing team with adequate access to physicians who may prescribe our product, effectively manage a geographically dispersed sales and marketing team, and other unforeseen costs and expenses. Any failure or delay in the development of a product candidate that affects the expected timing of commercialization of the product candidate or results in the failure of the product candidate to be commercialized could result in us having prematurely or unnecessarily incurred costly </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">commercialization expenses. Our investment would be lost if we are unable to retain or reposition our sales and marketing personnel. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also enter into collaborations for the sales and marketing of our product candidates, if approved. To the extent that we depend on collaborators for sales and marketing activities, any revenues we receive will depend upon the success of those collaborators&#8217; sales and marketing teams and the collaborators&#8217; prioritization of our product and compliance with applicable regulatory requirements, and there can be no assurance that the collaborators&#8217; efforts will be successful. For example, under the License and Collaboration Agreement with Astellas, or the Astellas Agreement, we will depend on Astellas to sell and market FX-322 for the treatment of SNHL, if approved, outside of the United States, and we can have no assurance that it will be successful in its efforts or devote sufficient resources to the sale and marketing of FX-322. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unable to build our own sales and marketing team or enter into a collaboration for the commercialization of product candidates we develop, if approved, we may be forced to delay the commercialization of our product candidates or reduce the scope of our sales or marketing activities, which would have an adverse effect on our business, operating results and prospects. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">A variety of risks associated with operating internationally could materially adversely affect our business. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business strategy includes potentially expanding internationally if any of our product candidates receive regulatory approval. Doing business internationally involves several risks, including, but not limited to: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">multiple, conflicting, and changing laws and regulations, such as data privacy and security laws and regulations, tax laws, export and import restrictions, economic sanctions laws and regulations, employment laws, regulatory requirements, and other governmental approvals, permits, and licenses; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">failure by us to obtain and maintain regulatory approvals for the use of our products in various countries; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">additional potentially relevant third-party patent rights; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">complexities and difficulties in obtaining protection and enforcing our intellectual property; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">difficulties in staffing and managing foreign operations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">complexities associated with managing multiple payor reimbursement regimes, government payors, or patient self-pay systems; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">limits in our ability to penetrate international markets; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products, and exposure to foreign currency exchange rate fluctuations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade, and other business restrictions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">certain expenses, including, among others, expenses for travel, translation, and insurance; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">regulatory and compliance risks that relate to maintaining accurate information and control over sales and activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act of 1977, as amended, or the FCPA, its books and records provisions, or its anti-bribery provisions, as well as other applicable laws and regulations prohibiting bribery and corruption. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these factors could significantly harm any future international expansion and operations and, consequently, our results of operations. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks related to our dependence on third </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">parties</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The Astellas Agreement is important to our business. If we or Astellas fail to adequately perform under the Astellas Agreement, or if we or Astellas terminate the Astellas Agreement, the development and commercialization of FX-322 for SNHL outside the United States would be materially delayed and our business would be adversely affected. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Astellas Agreement, Astellas is responsible for the development and commercialization of FX-322 outside of the United States and we are responsible for development and commercialization in the United States. We and Astellas are jointly responsible for conducting global clinical studies and coordinating commercial launch activities. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have received an upfront payment from Astellas of $80.0 million, and we may also receive development milestone payments up to $230.0 million. If the Astellas licensed products are successfully commercialized, we would be eligible for up to $315.0 million in potential commercial milestone payments plus tiered royalties at rates ranging from low- to mid-teen percentages. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Termination of the Astellas Agreement could cause significant delays in our development and commercialization efforts for FX-322 for the treatment of SNHL outside of the United States. If the Astellas Agreement is terminated, we would need to expand our internal capabilities or enter into another agreement to compensate for the loss in funding and clinical development support from Astellas. Any suitable alternative agreement would take considerable time to negotiate and could also be on less favorable terms to us. Whether or not we identify another suitable collaborator, we may need to seek additional financing to continue the development of FX-322, or we may be forced to discontinue development of FX-322, either of which could have a material adverse effect on our business. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We intend to continue to collaborate with third parties for the development and commercialization of our product candidates. We may not succeed in establishing and maintaining collaborations, which may significantly limit our ability to successfully develop and commercialize our other product candidates, if at all. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have entered into the Astellas Agreement for the development and commercialization of FX-322 for the treatment of SNHL outside the United States and may seek collaborations for the development and commercialization of other product candidates. The process of establishing and maintaining collaborative relationships is difficult, time-consuming, and involves significant uncertainty, such as: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">a collaborator may shift its priorities and resources away from our product candidates due to a change in business strategies, or a merger, acquisition, sale, or downsizing; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">a collaborator may seek to renegotiate or terminate its relationships with us due to unsatisfactory clinical results, manufacturing issues, a change in business strategy, a change of control or other reasons; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">a collaborator may cease development in therapeutic areas which are the subject of our collaboration; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">a collaborator may not devote sufficient capital or resources towards our product candidates, or may fail to comply with applicable regulatory requirements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">a collaborator may change the success criteria for a product candidate, thereby delaying or ceasing development of such candidate; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">a significant delay in initiation of certain development activities by a collaborator will also delay payment of milestones tied to such activities, thereby impacting our ability to fund our own activities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">a collaborator could develop a product that competes, either directly or indirectly, with our product candidate; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">a collaborator with commercialization obligations may not commit sufficient financial resources or personnel to the marketing, distribution, or sale of a product; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">a collaborator with manufacturing responsibilities may encounter regulatory, resource, or quality issues and be unable to meet demand requirements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">a collaborator may terminate a strategic alliance; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">a dispute may arise between us and a collaborator concerning the research, development, or commercialization of a product candidate resulting in a delay in milestones or royalty payments or termination of the relationship and possibly resulting in costly litigation or arbitration, which may divert management&#8217;s attention and resources; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">a collaborator may use our products or technology in such a way as to invite litigation from a third party. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any collaborator fails to fulfill its responsibilities in a timely manner, or at all, our research, clinical development, manufacturing, or commercialization efforts related to that collaboration could be delayed or terminated, or it may be necessary for us to assume responsibility for expenses or activities that would otherwise have been the responsibility of our collaborator. If we are unable to establish and maintain collaborations on acceptable terms or to successfully transition away from terminated collaborations, we may have to delay or discontinue further development of one or more of our product candidates, undertake development and commercialization activities at our own expense, or find alternative sources of capital, which would have a material adverse impact on our clinical development plans and business. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our employees and independent contractors, including principal investigators, CROs, consultants, vendors, and any third parties we may engage in connection with development and commercialization may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our employees and independent contractors, including principal investigators, CROs, consultants, vendors, and any third parties we may engage in connection with development and commercialization of our product candidates, could engage in misconduct, including intentional, reckless, or negligent conduct or unauthorized activities that violate applicable laws, rules, and regulations including: the laws and regulations of the FDA or other similar regulatory requirements of other authorities, including those laws that require the reporting of true, complete, and accurate information to such authorities; manufacturing standards; data privacy, security, fraud and abuse, and other healthcare laws and regulations; or laws that require the reporting of true, complete, and accurate financial information and data. Specifically, sales, marketing, and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing, and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. Activities subject to these or other laws could also involve the improper use or misrepresentation of information obtained in the course of clinical trials, creation of fraudulent data in preclinical studies or clinical trials, or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. Additionally, we are subject to the risk that a person or government agency could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us or them and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant civil, criminal, and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid, other U.S. federal healthcare programs or healthcare programs in other jurisdictions, individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We currently rely on third-party contract manufacturing organizations, or CMOs, for the production of clinical supply of FX-322 and intend to rely on CMOs for the production of commercial supply of FX-322, if approved, and for clinical and commercial supply of our future product candidates, as well as to supply raw materials necessary to produce our product candidates. Our dependence on CMOs may impair the development of our product candidates and may impair their commercialization, which would adversely impact our business and financial position. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not own facilities for manufacturing FX-322 or any product candidate. Instead, we rely on and expect to continue to rely on CMOs for the supply of cGMP grade clinical trial materials of FX-322 and any product candidates we develop and, in future, for commercial quantities. Reliance on CMOs may expose us to more risk than if we were to manufacture our product candidates ourselves. If any CMO we engage is unable to provide sufficient supply of any product candidate we develop, we may be unable to arrange for an alternative supply or to do so on commercially reasonable terms or in a timely manner, which could delay any clinical trials, the commercial launch of our product candidates, if approved, or, regarding any commercial supply, result in a shortage in supply that could negatively impact our revenues. For example, we are substantially dependent on the CMO that supplies us with the proprietary glycogen synthase kinase 3, or GSK3, inhibitor that is a key component of FX-322 and the CMO that lyophilizes FX-322 into a powder. While there are other CMOs who are able to supply the GSK3 inhibitor or lyophilize FX-322, manufacture of the GSK3 inhibitor and the lyophilization process require proprietary knowledge or specialized capabilities that only a limited number of CMOs have. As a result, transitioning to a new CMO for either the supply of the GSK3 inhibitor or to conduct the lyophilization process would be particularly time consuming and costly. We have just begun to engage other CMOs as back-up for the manufacture and supply of FX-322. As a result, if any of the CMOs involved in the manufacture and supply of FX-322 experience a delay or disruption, or if we fail to obtain the appropriate approvals to manufacture and supply FX-322 outside the US (e.g., as a result </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of a failure to obtain a waiver under the </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bayh-Dole</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Act</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">), we may not have sufficient quantities of FX-322 for our planned activities and may not be able to transition to a new CMO in a timely or cost-effective manner, or at all, which would negatively impact our ability to develop and potentially commercialize FX-322. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The facilities used to manufacture our product candidates must be inspected by the FDA and comparable foreign regulatory authorities. While we provide oversight of manufacturing activities, we do not and will not control the execution of manufacturing activities by, and are or will be dependent on, our CMOs for compliance with cGMP requirements for the manufacture of our product candidates. As a result, we are subject to the risk that our product candidates may have manufacturing defects that we have limited ability to prevent. If a CMO cannot successfully manufacture material that conforms to our specifications and the regulatory requirements, we will not be able to secure or maintain regulatory approval for the use of our product candidates in clinical trials, or for commercial distribution of our product candidates, if approved. While we have engaged independent auditors to assess the compliance with the protocol that we co-developed with our CMOs regarding the manufacturing process for FX-322, in general, we have limited control over the ability of our CMOs to maintain adequate quality control, quality assurance, and qualified personnel, and we were not involved in developing our CMOs&#8217; policies and procedures. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the FDA or comparable foreign regulatory authority finds deficiencies with or does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval or finds deficiencies in the future, we may need to find alternative manufacturing facilities, which would delay our development program and significantly impact our ability to develop, obtain regulatory approval for, or commercialize our product candidates, if approved. In addition, any failure to achieve and maintain compliance with laws, regulations, and standards related to manufacturing could subject us to risks, including the risk that we may have to suspend the manufacture of our product candidates, that obtained approvals could be revoked, and that the FDA or another governmental regulatory authority may take enforcement actions, including untitled letters, warning letters, seizures, injunctions, or product recalls. Furthermore, CMOs may breach existing agreements they have with us because of factors beyond our control. They may also terminate or refuse to renew their agreement at a time that is costly or otherwise inconvenient for us. If we were unable to find an adequate CMO or another acceptable solution in time, our clinical trials could be delayed, or our commercial activities could be harmed. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We contract for the supply of the active pharmaceutical ingredient, or API, and other raw material necessary to produce FX-322 and we may contract in the future for the supply of API and other raw material for any other product candidate we develop. Supplies of API or other raw material could be interrupted from time to time and we cannot be certain that alternative supplies could be obtained within a reasonable time frame, at an acceptable cost, or at all. The extent to which the COVID-19 pandemic impacts our ability to procure sufficient supplies for the development of our products and product candidates will depend on the severity and duration of the spread of the virus, and the actions undertaken to mitigate the spread of COVID-19 or treat its effects and may cause delays. In addition, a disruption in the supply of API or other raw material could delay the commercial launch of our product candidates, if approved, or result in a shortage in supply, which would impair our ability to generate revenues. Growth in the costs and expenses of API or other raw material may also impair our ability to cost-effectively manufacture our product candidates. In addition, there may be a limited number of suppliers for API or other raw material that we may use to manufacture our product candidates, and we cannot be certain that we will be able to engage such suppliers in a timely manner or at all. If we are unable to do so, clinical development of our product candidates, commercialization for any approved product, or our business could be adversely affected. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finding new CMOs or third-party suppliers involves additional cost and requires our management&#8217;s time and focus. In addition, there is typically a transition period when a new CMO commences work. Although we have not, and do not intend to, begin a clinical trial unless we believe we have on hand, or will be able to obtain, a sufficient supply of our product candidates to complete the clinical trial, any significant delay in the supply of our product candidates or the raw materials needed to produce our product candidates, could considerably delay conducting our clinical trials and potential regulatory approval of our product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of their manufacture of our product candidates, our CMOs and third-party suppliers are expected to comply with and respect the proprietary rights of others. If a CMO or third-party supplier fails to acquire the proper licenses or otherwise infringes the proprietary rights of others in the course of providing services to us, we may have to find alternative CMOs or third-party suppliers or defend against claims of infringement, either of which would significantly impact our ability to develop, obtain regulatory approval for, or commercialize our product candidates, if approved. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We intend to rely on third parties to conduct, supervise, and monitor our clinical trials. If those third parties do not successfully carry out their contractual duties, or if they perform in an unsatisfactory manner, it may harm our business. </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely, and will continue to rely, on CROs, CRO-contracted vendors, and clinical trial sites to ensure the proper and timely conduct of our clinical trials, including our Phase 2a trial and other ongoing and planned clinical trials of FX-322 for the treatment of SNHL. Our reliance on CROs for clinical development activities limits our control over these activities and we were not involved in developing our CRO&#8217;s policies and procedures, but we remain responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol and legal, regulatory, and scientific standards. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and our CROs will be required to comply with the Good Laboratory Practice requirements for our preclinical studies and GCP requirements for our clinical trials, which are regulations and guidelines enforced by the FDA and are also required by comparable foreign regulatory authorities. Regulatory authorities enforce GCP requirements through periodic inspections of trial sponsors, principal investigators, and clinical trial sites. If we or our CROs fail to comply with GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP requirements. In addition, our clinical trials must be conducted with product produced under cGMP requirements. Accordingly, if our CROs fail to comply with these requirements, we may be required to repeat clinical trials, which would delay the regulatory approval process. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our CROs are not our employees, and we do not control whether they devote sufficient time and resources to our clinical trials. Our CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials, or other drug development activities, which could harm our competitive position. We face the risk of potential unauthorized disclosure or misappropriation of our intellectual property by CROs, which may reduce our trade secret protection and allow our potential competitors to access and exploit our proprietary technology. If our CROs do not successfully carry out their contractual duties or obligations, or fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for any other reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize, any product candidate that we develop. As a result, our financial results and the commercial prospects for any product candidate that we develop would be harmed, our costs could increase, and our ability to generate revenue could be delayed. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our relationship with any CROs terminates, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. Switching or adding additional CROs involves substantial cost and requires management&#8217;s time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. While the COVID-19 pandemic and government measures taken in response have had a significant impact on our CROs and their ability to conduct clinical trials, there is potential they will face disruption in the future, which may affect our ability to initiate and complete our clinical trials. Though we intend to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have an adverse impact on our business, financial condition, and prospects. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks related to healthcare laws and other legal compliance matters </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Enacted and future healthcare legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates, if approved, and may affect the prices we may set. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes, and additional proposed changes, to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of health care. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers. Among the provisions of the ACA, those of greatest importance to the biotechnology and pharmaceutical industries include the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">an annual, non-deductible fee payable by any entity that manufactures or imports certain branded prescription drugs and biologic agents; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs and biologics that are inhaled, infused, instilled, implanted, or injected; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">establishment of a Center for Medicare Innovation at the Centers for Medicare&#160;&amp; Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since its enactment, there have been judicial challenges to certain aspects of the ACA, and we expect there will be additional challenges to the ACA in the future. For example, in December 2018, a U.S. District Court judge in the Northern District of Texas ruled that the individual mandate is a critical and inseverable feature of the ACA, and therefore, because it was modified as part of the TCJA, the remaining provisions of the ACA are invalid as well. On December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the district court&#8217;s decision that the individual mandate was unconstitutional but remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. The U.S. Supreme Court is currently reviewing this case, although it is unclear when or how the Supreme Court will rule. It is also unclear how other efforts, if any, to challenge, repeal or amend some or all aspects of the ACA will impact the law, our business or financial condition. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, the Budget Control Act of 2011 resulted in aggregate reductions of Medicare payments to providers of 2% per fiscal year. These reductions went into effect in April 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030, with the exception of a temporary suspension from May 1, 2020 through March 31, 2021, unless additional action is taken by Congress. In addition, in January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws or any other similar laws introduced in the future may result in additional reductions in Medicare and other healthcare funding, which could negatively affect our potential customers and accordingly, our financial operations. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been administration efforts, Congressional inquiries and proposed federal and state legislation designed to bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient assistance programs and reform government program reimbursement methodologies for drugs. Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. We expect that additional U.S. federal healthcare reform measures will be implemented in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, measures designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition, and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. Furthermore, there has been increased interest by third-party payors and governmental authorities in reference pricing systems and publication of discounts and list prices. These reforms could reduce the ultimate demand for our product candidates or put pressure on our product pricing. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In markets outside of the United States, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. We cannot predict the likelihood, nature, or extent of government regulation that may arise from future legislation or administrative action in the United States or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our business operations and current and future relationships with contractors, investigators, healthcare professionals, consultants, third-party payors, patient organizations, customers, and others will be subject to applicable healthcare regulatory laws, which could expose us to penalties.</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business operations and current and future arrangements with contractors, investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell, and distribute our product candidates, if approved. Such laws include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving, or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order, or recommendation of, any good, facility, item or service for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. The U.S. federal Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other hand; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the U.S. federal false claims, including the civil False Claims Act, or FCA, which, among other things, impose criminal and civil penalties, including through civil whistleblower or </font><font style="font-style:italic;color:#000000;">qui tam</font><font style="color:#000000;"> actions, against individuals or entities for knowingly presenting, or causing to be presented, to the U.S. federal government claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. A claim includes &#8220;any request or demand&#8221; for money or property presented to the federal government. In addition, pharmaceutical manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation: </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics, and medical devices; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">federal price reporting laws, which require manufacturers to calculate and report complex pricing metrics to government programs, where such reported prices may be used in the calculation of reimbursement and/or discounts on approved products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the U.S. federal legislation commonly referred to as the Physician Payments Sunshine Act, enacted as part of the ACA, and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics, and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to the government information related to certain payments and other transfers of value to physicians (as defined by statute) and teaching hospitals, as well as ownership and investment interests held by such physicians and their immediate family members. Beginning in 2022, such obligations will include payments and other transfers of value provided in the previous year to certain other healthcare professionals, including physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiology assistants and certified nurse midwives;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">analogous U.S. state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales, and marketing arrangements </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; </font><font style="color:#000000;">and </font><font style="color:#000000;">state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities</font><font style="color:#000000;">;</font><font style="color:#000000;"> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">similar healthcare laws and regulations in the European Union, or EU, and other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">laws and regulations prohibiting bribery and corruption such as the FCPA, which, among other things, prohibits U.S. companies and their employees and agents from authorizing, promising, offering, or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations or foreign government-owned or affiliated entities, candidates for foreign public office, and foreign political parties or officials thereof. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available under such laws, it is possible that some of our business activities, including our consulting agreements and other relationships with healthcare providers, some of whom receive stock or stock options as compensation for their services, could be subject to challenge under one or more of such laws. Ensuring that our current and future internal operations and business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance, or case law involving applicable fraud and abuse or other healthcare laws and regulations. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to actions including the imposition of civil, criminal, and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid, and other federal healthcare programs, individual imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements, or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of noncompliance with these laws, and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government-funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, defending against any such actions can be costly, time consuming, and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The global data protection landscape is rapidly evolving, and we are or may become subject to numerous state, federal and foreign laws, requirements and regulations governing the collection, use, disclosure, retention, and security of personal data, such as information that we may collect in connection with clinical trials in the U.S. and abroad. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business, affect our ability to operate in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us to comply with federal, state or foreign laws or regulation, our internal policies and procedures or our contracts governing our processing of personal information could result in negative publicity, government investigations and enforcement actions, claims by third parties and damage to our reputation, any of which could have a material adverse effect on our operations, financial performance and business.</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As our operations and business grow, we may become subject to or affected by new or additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities. In the U.S., HIPAA imposes, among </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:8pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other things, certain standards relating to the privacy, security, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">transmission</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and breach reporting of individually identifiable health information. Certain states have also adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. In addition, the </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CCPA</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> went into effect on January 1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability, and many similar laws have been proposed at the federal level and in other states. Further, the </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CPRA</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> recently passed in California. The CPRA will impose additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It will also create a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The majority of</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the provisions will go into effect on January 1, 2023, and additional compliance investment and potential business process changes may be required. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event that</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> we are subject to or affected by HIPAA, the CCPA, the CPRA or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition.</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, the GDPR applies to companies established in the EEA, as well as to companies that are not established in the EEA and which collect and use personal data in relation to (i)&#160;offering goods or services to, or (ii)&#160;monitoring the behavior of, individuals located in the EEA. If we conduct clinical trial programs in the EEA (whether the trials are conducted directly by us or through a clinical vendor or collaborator), or enter into research collaborations involving the monitoring of individuals in the EEA, or market our products to individuals in the EEA, we will be subject to the GDPR. The GDPR puts in place stringent operational requirements for processors and controllers of personal data, including, for example, high standards for obtaining consent from individuals to process their personal data (or reliance on another appropriate legal basis), the provision of robust and detailed disclosures to individuals about how personal data is collected and processed (in a concise, intelligible and easily accessible form), a comprehensive individual data rights regime (including access, erasure, objection, restriction, rectification and portability), maintaining a record of data processing, data export restrictions governing transfers of data from the EEA, short timelines for data breach notifications to be given to data protection regulators or supervisory authorities (and in certain cases, affected individuals) of significant data breaches, and limitations on retention of information. The GDPR also puts in place increased requirements pertaining to health data and other special categories of personal data, as well as a definition of pseudonymized (i.e., key-coded) data. Further, the GDPR provides that EEA member states may establish their own laws and regulations limiting the processing of genetic, biometric, or health data, which could limit our ability to collect, use, and share such data and/or could cause our costs to increase. In addition, there are certain obligations if we contract third-party processors in connection with the processing of personal data. If our or our collaborators&#8217; or service providers&#8217; privacy or data security measures fail to comply with the GDPR requirements, we may be subject to litigation, regulatory investigations, enforcement notices requiring us to change the way we use personal data, or fines of up to 20&#160;million Euros or up to 4% of our total worldwide annual revenue of the preceding financial year, whichever is higher, as well as compensation claims by affected individuals, including class-action type litigation, negative publicity, reputational harm and a potential loss of business and goodwill. Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the United States, and the efficacy and longevity of current transfer mechanisms between the EU and the United States remains uncertain. For example, in 2016, the EU and United States agreed to a transfer framework for data transferred from the EU to the United States, called the Privacy Shield, but the Privacy Shield was invalidated in July 2020 by the Court of Justice of the European Union. Further, from January 1, 2021, companies have to comply with the GDPR and also the United Kingdom GDPR, or the UK GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The UK GDPR mirrors the fines under the GDPR, i.e., fines up to the greater of &#8364;20 million (&#163;17.5 million) or 4% of global turnover. The relationship between the United Kingdom and the European Union in relation to certain aspects of data protection law remains unclear, and it is unclear how United Kingdom data protection laws and regulations will develop in the medium to longer term, and how data transfers to and from the United Kingdom will be regulated in the long term. Currently there is a four to six-month grace period agreed in the EU and United Kingdom Trade and Cooperation Agreement, ending June 30, 2021 at the latest, whilst the parties discuss an adequacy decision. However, it is not clear whether (and when) an adequacy decision may be granted by the European Commission enabling data transfers from EU member states to the United Kingdom long term without additional measures. These changes may lead to additional costs and increase our overall risk exposure.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we work to comply with applicable laws, regulations and standards, our contractual obligations and other legal obligations, these requirements are evolving and may be modified, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">interpreted</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and applied in an inconsistent manner from one jurisdiction to another, and may conflict with one another or other legal obligations with which we must comply. Any failure or perceived failure by us or our employees, representatives, contractors, consultants, collaborators, or other third parties to comply with such requirements or adequately address privacy and security concerns, even if unfounded, could result in additional cost and liability to us, damage our reputation, and adversely affect our business and results of operations.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are subject to environmental, health and safety laws and regulations, and we may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operations, including our development, testing and manufacturing activities, are subject to numerous environmental, health and safety laws and regulations. These laws and regulations govern, among other things, the controlled use, handling, release, and disposal of and the maintenance of a registry for, hazardous materials and biological materials, such as chemical solvents, human cells, carcinogenic compounds, mutagenic compounds, and compounds that have a toxic effect on reproduction, laboratory procedures and exposure to blood-borne pathogens. If we fail to comply with such laws and regulations, we could be subject to fines or other sanctions. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As with other companies engaged in activities similar to ours, we face a risk of environmental liability inherent in our current and historical activities, including liability relating to releases of or exposure to hazardous or biological materials. Environmental, health and safety laws and regulations are becoming more stringent. We may be required to incur substantial expenses in connection with future environmental compliance or remediation activities, in which case, the production efforts of our third-party manufacturers or our development efforts may be interrupted or delayed. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks related to our intellectual property </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are unable to obtain, maintain, enforce and protect patent protection for our technology and product candidates or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully develop and commercialize our technology and product candidates may be adversely affected. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success depends in large part on our ability to obtain and maintain protection of the intellectual property we may own solely and jointly with others, or may license from others, particularly patents, in the United States and other countries with respect to any proprietary technology and product candidates we develop. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our technologies and product candidates that are important to our business and by in-licensing intellectual property related to such technologies and product candidates. If we are unable to obtain or maintain patent protection with respect to any proprietary technology or product candidate, our business, financial condition, results of operations and prospects could be materially harmed. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent prosecution process is expensive, time-consuming, and complex, and we may not be able to file, prosecute, maintain, defend, or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we do not have the right to control the preparation, filing, and prosecution of patent applications, or to maintain, enforce, and defend the patents, covering technology that we license from third parties. Therefore, these in-licensed patents, and applications may not be prepared, filed, prosecuted, maintained, defended, and enforced in a manner consistent with the best interests of our business. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent position of pharmaceutical and biotechnology companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. In addition, the scope of patent protection outside of the United States is uncertain and laws of foreign countries may not protect our rights to the same extent as the laws of the United States or vice versa. For example, European patent law restricts the patentability of methods of treatment of the human body more than U.S. law does. With respect to both owned and in-licensed patent rights, we cannot predict whether the patent applications we and our licensors are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors. Further, we may not be aware of all third-party intellectual property rights potentially relating to our product candidates. In addition, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not published at all. Therefore, neither we nor our licensors can know with certainty whether either we or our licensors were the first to make the inventions claimed in the patents and patent applications we own or in-license now or in the future, or that either we or our licensors were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">enforceability, and commercial value of our owned and in-licensed patent rights are uncertain. Moreover, our owned and in-licensed pending and future patent applications may not result in patents being issued </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> protect our technology and product candidates, in whole or in part, or </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents and our ability to obtain, protect, maintain, defend, and enforce our patent rights, narrow the scope of our patent protection and, more generally, could affect the value or narrow the scope of our patent rights. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, we or our licensors may be subject to a third-party pre-issuance submission of prior art to the United States Patent and Trademark Office, or USPTO, or become involved in opposition, derivation, revocation, reexamination, <font style="font-style:italic;">inter partes</font> review, post-grant review, or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize drugs without infringing third-party patent rights. If the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if our owned and in-licensed patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us, or otherwise provide us with any competitive advantage. The issuance of a patent is not conclusive as to its inventorship, scope, validity, or enforceability, and our owned and in-licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. Such proceedings also may result in substantial cost and require significant time from our management and employees, even if the eventual outcome is favorable to us. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. Furthermore, our competitors may be able to circumvent our owned or in-licensed patents by developing similar or alternative technologies or products in a non-infringing manner. As a result, our owned and in-licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing technology and products similar or identical to any of our technology and product candidates. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural<font style="font-weight:bold;font-style:italic;"> </font>expiration of a patent is generally 20 years from its earliest United States non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars. Given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are unable to obtain licenses from third parties on commercially reasonable terms or fail to comply with our obligations under such agreements, our business could be harmed. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our products, in which case we would be required to obtain a license from these third parties. If we are unable to license such technology, or if we are forced to license such technology on unfavorable terms, our business could be materially harmed. If we are unable to obtain a necessary license, we may be unable to develop or commercialize the affected product candidates, which could materially harm our business and the third parties owning such intellectual property rights could seek either an injunction prohibiting our sales or an obligation on our part to pay royalties and/or other forms of compensation. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unable to obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected technology and product candidates, which could</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> significantly</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> harm our business, financial condition, results of operations, and prospects. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, if we fail to comply with our obligations under license agreements, our counterparties may have the right to terminate these agreements, in which event we might not be able to develop, manufacture or market, or may be forced to cease developing, manufacturing or marketing, any product that is covered by these agreements or may face other penalties under such agreements. Such an occurrence could materially adversely affect the value of the product candidate being developed under any such agreement. Termination of these agreements or reduction or elimination of our rights under these agreements, or restrictions on our ability to freely assign or sublicense our rights under such agreements when it is in the interest of our business to do so, may result in our having to negotiate new or reinstated agreements with less favorable terms, cause us to lose our rights under these agreements, including our rights to important intellectual property or technology, or impede, or delay or prohibit the further development or commercialization of, one or more product candidates that rely on such agreements. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of our marketing exclusivity for any product candidates we may develop, our business may be materially harmed. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, the patent term of a patent that covers an FDA-approved drug may be eligible for limited patent term extension, which permits patent term restoration as compensation for the patent term lost during the FDA regulatory review process. The Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Act, permits a patent term extension of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the drug is under regulatory review. Patent extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. In addition, only one patent applicable to an approved drug may be extended, and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. Similar provisions may be available in Europe and certain other non-United States jurisdictions to extend the term of a patent that covers an approved drug. While, in the future, if and when our product candidates receive FDA approval, we expect to apply for patent term extensions on patents covering those product candidates, there is no guarantee that the applicable authorities will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions. We may not be granted patent term extension either in the United States or in any foreign country because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the term of extension, as well as the scope of patent protection during any such extension, afforded by the governmental authority could be less than we request. If we are unable to obtain any patent term extension or the term of any such extension is less than we request, our competitors may obtain approval of competing products following the expiration of our patent rights, and our business, financial condition, results of operations, and prospects could be materially harmed. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is possible that we will not obtain patent term extension under the Hatch-Waxman Act for a United States patent covering any of our product candidates that we may identify even where that patent is eligible for patent term extension, or if we obtain such an extension, it may be for a shorter period than we had sought. Further, for our licensed patents, we may not have the right to control prosecution, including filing with the USPTO, of a petition for patent term extension under the Hatch-Waxman Act. Thus, if one of our licensed patents is eligible for patent term extension under the Hatch-Waxman Act, we may not be able to control whether a petition to obtain a patent term extension is filed, or obtained, from the USPTO. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Also, there are detailed rules and requirements regarding the patents that may be submitted to the FDA for listing in the Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. We may be unable to obtain patents covering our product candidates that contain one or more claims that satisfy the requirements for listing in the Orange Book. Even if we submit a patent for listing in the Orange Book, the FDA may decline to list the patent, or a manufacturer of generic drugs may challenge the listing. If one of our product candidates is approved and a patent covering that product candidate is not listed in the Orange Book, a manufacturer of generic drugs would not have to provide advance notice to us of any abbreviated new drug application filed with the FDA to obtain permission to sell a generic version of such product candidate. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Although we or our licensors are not currently involved in any litigation, we may become involved in lawsuits to protect or enforce our patent or other intellectual property rights, which could be expensive, </font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">time-consuming</font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> and unsuccessful. </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitors and other third parties may infringe, misappropriate or otherwise violate our or our licensors&#8217; issued patents or other intellectual property. As a result, we or our licensors may need to file infringement, misappropriation or other intellectual property related claims, which can be expensive and time-consuming. Any claims we assert against perceived infringers could provoke such parties to assert counterclaims against us alleging that we infringe, misappropriate, or otherwise violate their intellectual property. In addition, in a patent infringement proceeding, such parties could counterclaim that the patents we or our licensors have asserted are invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. Third parties may institute such claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post-grant review, <font style="font-style:italic;">inter partes</font> review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). The outcome following legal assertions of invalidity and unenforceability is unpredictable. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An adverse result in any such proceeding could put one or more of our owned or in-licensed patents at risk of being invalidated or interpreted narrowly and could put any of our owned or in-licensed patent applications at risk of not yielding an issued patent. A court may also refuse to stop the third party from using the technology at issue in a proceeding on the grounds that our owned or in-licensed patents do not cover such technology. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information or trade secrets could be compromised by disclosure during this type of litigation. Any of the foregoing could allow such third parties to develop and commercialize competing technologies and products and have a material adverse impact on our business, financial condition, results of operations, and prospects. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same technology. Our defense of litigation or interference or derivation proceedings may fail and, even if successful, may result in substantial costs, and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development partnerships that would help us bring our product candidates to market. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends upon our ability and the ability of our collaborators to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property and proprietary rights of third parties. There is considerable patent and other intellectual property litigation in the pharmaceutical and biotechnology industries. We may become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our technology and product candidates, including interference proceedings, post grant review, <font style="font-style:italic;">inter partes</font> review, and derivation proceedings before the USPTO and similar proceedings in foreign jurisdictions such as oppositions before the European Patent Office. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our technologies or product candidates that we may identify may be subject to claims of infringement of the patent rights of third parties. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The legal threshold for initiating litigation or contested proceedings is low, so that even lawsuits or proceedings with a low probability of success might be initiated and require significant resources to defend. Litigation and contested proceedings can also be expensive and time-consuming, and our adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we can. The risks of being involved in such litigation and proceedings may increase if and as our product candidates near commercialization and as we gain the greater visibility associated with being a public company. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of merit. We may not be aware of all such intellectual property rights potentially relating to our technology and product candidates and their uses, or we may incorrectly conclude that third party intellectual property is invalid or that our activities and product candidates do not infringe such intellectual property. Thus, we do not know with certainty that our technology and product candidates, or our development and commercialization thereof, do not and will not infringe, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">misappropriate</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or otherwise violate any third party&#8217;s intellectual property. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the discovery, use or manufacture of the product candidates that we may identify or related to our technologies. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that the product candidates that we may develop may be found to infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Moreover, as noted above, there may be existing patents that we are not aware of or that we have incorrectly concluded are invalid or not infringed by our activities. If any third-party patents were held by a court of competent jurisdiction to cover, for example, the manufacturing process of the product candidates that we may develop, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize the product candidates that we may identify. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products, or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may choose to take a license or, if we are found to infringe, misappropriate or otherwise violate a third party&#8217;s intellectual property rights, we could also be required to obtain a license from such third party to continue developing, manufacturing and marketing our technology and product candidates. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us and could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or product. In addition, we could be found liable for significant monetary damages, including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent or other intellectual property right and could be forced to indemnify our customers or collaborators. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. In addition, we may be forced to redesign our product candidates, seek new regulatory approvals, and indemnify third parties pursuant to contractual agreements. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar material adverse effect on our business, financial condition, results of operations, and prospects. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Intellectual property litigation or other legal proceedings relating to intellectual property could cause us to spend substantial resources and distract our personnel from their normal responsibilities. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">financial resources and may also have an advantage in such proceedings due to their more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of intellectual property litigation or other proceedings could compromise our ability to compete in the marketplace. </font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Periodic maintenance, renewal and annuity fees and various other government fees on any issued patent and pending patent application must be paid to the USPTO and foreign patent agencies in several stages or annually over the lifetime of our owned and in-licensed patents and patent applications. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In certain circumstances, we rely on our licensing partners to pay these fees to, or comply with the procedural and documentary rules of, the relevant patent agency. With respect to our patents, we rely on an annuity service, outside firms, and outside counsel to remind us of the due dates and to make payment after we instruct them to do so. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, potential competitors might be able to enter the market with similar or identical products or technology. If we or our licensors fail to maintain the patents and patent applications covering our product candidates, it would have a material adverse effect on our business, financial condition, results of operations, and prospects. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we fail to comply with our obligations in our intellectual property licenses and funding arrangements with third parties, or otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important to our business. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are party to license and funding agreements that impose, and we may enter into additional licensing and funding arrangements with third parties that may impose, diligence, development, and commercialization timelines, milestone payment, royalty, insurance and other obligations on us. Under our existing licensing and funding agreements, we are obligated to pay royalties on net product sales of product candidates or related technologies to the extent they are covered by the agreements. If we fail to comply with such obligations under current or future license and funding agreements, our counterparties may have the right to terminate these agreements or require us to grant them certain rights. Such an occurrence could materially adversely affect the value of any product candidate being developed under any such agreement. Termination of these agreements or reduction or elimination of our rights under these agreements may result in our having to negotiate new or reinstated agreements with less favorable terms, or cause us to lose our rights under these agreements, including our rights to important intellectual property or technology, which would have a material adverse effect on our business, financial condition, results of operations, and prospects. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disputes may arise regarding intellectual property subject to a licensing agreement, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the scope of rights granted under the license agreement and other interpretation related issues; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the sublicensing of patent and other rights under our collaborative development relationships; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the priority of invention of patented technology. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected technology and product candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current or future licensors may have relied on third-party consultants or collaborators or on funds from third parties such that our licensors are not the sole and exclusive owners of the patents and patent applications we in-license. If other third parties have ownership rights to patents and/or patent applications we in-license, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In spite of our best efforts, our licensors might conclude that we have materially breached our license agreements and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize product candidates and technology covered by these license agreements. If these in-licenses are terminated, or if the underlying intellectual property fails to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, products and technologies identical to ours. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.14%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or in-licensed patents, trade secrets, or other intellectual property as an inventor or co-inventor. For example, we or our licensors may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or our or our licensors&#8217; ownership of our owned or in-licensed patents, trade secrets, or other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.14%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to seeking patents for some of our technology and product candidates, we also rely on trade secrets and confidentiality agreements to protect our unpatented know-how, technology, and other proprietary information, to maintain our competitive position. We seek to protect our trade secrets and other proprietary technology, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors, and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. We cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary technology. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Detecting the disclosure or misappropriation of a trade secret and enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside of the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be materially and adversely harmed. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our registered and unregistered trademarks or trade names may be challenged, infringed, circumvented, or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential collaborators or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trade names or trademarks that incorporate variations of our unregistered trade names </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or trademarks. Over the long term, if we are unable to successfully register our trade names and trademarks and establish name recognition based on our trade names and trademarks, then we may not be able to compete effectively, and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trade names and trademarks may be ineffective and could result in substantial costs and diversion of resources and could adversely impact our financial condition or results of operations. </font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Intellectual property rights do not necessarily address all potential threats. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">we, or our license partners or current or future collaborators, might not have been the first to file patent applications covering certain of our or their inventions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or in-licensed intellectual property rights; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">it is possible that our owned and in-licensed pending patent applications or those we may own or in-license in the future will not lead to issued patents; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">we cannot ensure that any of our pending patent applications, if issued, or those of our licensors, will include claims having a scope sufficient to protect our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">we cannot ensure that any patents issued to us or our licensors will provide a basis for an exclusive market for our commercially viable product candidates or will provide us with any competitive advantages; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">we cannot ensure that our commercial activities or product candidates will not infringe upon the patents of others; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">we cannot ensure that we will be able to successfully commercialize our product candidates on a substantial scale, if approved, before the relevant patents that we own, or license expire; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">we may not develop additional proprietary technologies that are patentable; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the patents of others may harm our business; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations, and prospects. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks related to our employees, managing our growth and our operations </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our future success depends on our ability to retain our key personnel and to attract, retain and motivate qualified personnel. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are highly dependent on the expertise of David L. Lucchino, our President and Chief Executive Officer, as well as the other principal members of our management, scientific, and clinical teams. Although we have employment agreements, offer letters or consulting agreements with our executive officers, these agreements do not prevent them from terminating their services at any time. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we lose one or more of our executive officers or key employees, our ability to implement our business strategy successfully could be seriously harmed. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period because of the limited number of individuals in our industry with the breadth of skills and experience required to develop, gain regulatory approval of and commercialize product candidates successfully. Competition </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these additional key personnel on acceptable terms given the competition among numerous biotechnology and pharmaceutical companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be engaged by other companies or organizations and may have commitments that limit their availability. If we are unable to continue to attract and retain highly qualified personnel, our ability to develop and commercialize our product candidates will be limited. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We expect to expand our development, regulatory, and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding COVID-19, we have experienced and expect to continue to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of clinical development, regulatory affairs, quality and sales and marketing. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities or acquire new facilities, and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may engage in transactions that could disrupt our business, cause dilution to our shareholders or reduce our financial resources. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the future, we may enter into transactions to acquire or in-license rights to product candidates, products or technologies, or to acquire other businesses. If we do identify suitable candidates, we may not be able to enter into such transactions on favorable terms, or at all. Any such acquisitions or in-licenses may not strengthen our competitive position, and these transactions may be viewed negatively by analysts, investors, customers, or other third parties with whom we have relationships. We may decide to incur debt in connection with an acquisition, or in-license or issue our common stock or other equity securities as consideration for the acquisition, which would reduce the percentage ownership of our existing stockholders. We could incur losses resulting from undiscovered liabilities of the acquired business that are not covered by the indemnification we may obtain from the sellers of the acquired business. In addition, we may not be able to successfully integrate the acquired personnel, technologies, and operations into our existing business in an effective, timely, and nondisruptive manner. Such transactions may also divert management attention from day-to-day responsibilities, increase our expenses, and reduce our cash available for operations and other uses. We cannot predict the number, timing or size of future acquisitions or in-licenses or the effect that any such transactions might have on our operating results. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our business and operations would suffer in the event of security breaches or system failures. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The U.S. federal and various state and foreign governments have enacted or proposed requirements regarding the collection, distribution, use, security and storage of personally identifiable information and other data relating to individuals. In the ordinary course of our business, we and third parties with which we have relationships will continue to collect and store sensitive data, including clinical trial data, proprietary business information, personal data and personally identifiable information of our clinical trial subjects and employees, in data centers and on networks. The secure processing, maintenance and transmission of this information is critical to our operations. Despite the implementation of security measures, our computer systems, as well as those of our CROs and other contractors and consultants, are vulnerable to damage from computer viruses, unauthorized access, malfeasance, natural and manmade disasters (including hurricanes), terrorism, war, and telecommunication, electrical failures or other disruptions. Attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise.  For instance, companies have experienced an increase in phishing and social engineering attacks from third parties in connection with COVID-19 global pandemic. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. A number of proposed and enacted federal, state and international laws and regulations obligate companies to notify individuals </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of security breaches involving particular personally identifiable information, which could result from breaches experienced by us or by third parties, including collaborators, vendors, contractors, or other organizations with which we have formed strategic relationships. While we do not believe that we have experienced any such system failure, accident, or security breach to date, if such an event were to occur and cause interruptions in our or their operations, it could result in delays and/or material disruptions of our research and development programs. For example, the loss of preclinical or clinical trial data from completed, ongoing, or planned trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we currently rely on third parties for the manufacture of our product candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. Any such access, disclosure, notifications, follow-up actions related to such a security breach or other loss of information could result in legal claims or proceedings, liability under </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">data protection laws</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and significant costs, including regulatory penalties, fines, and legal expenses, and such an event could disrupt our operations, cause us to incur remediation costs, damage our reputation, and cause a loss of confidence in us and our or such third parties&#8217; ability to conduct clinical trials, which could adversely affect our reputation and delay the clinical development of our product candidates.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks related to our common stock </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The market price of our common stock has been volatile and fluctuated and may in future fluctuate substantially, which could result in substantial losses for our stockholders. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The market price of our common stock has been highly volatile and subject to wide fluctuations in response to various factors, some of which are beyond our control. In addition to the factors discussed in this section titled &#8220;Risk factors&#8221; and elsewhere in this Annual Report on Form 10-K, these factors include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">any delay in the ultimate completion of our Phase 2a clinical trial, enrollment or ultimate completion of our Phase 1b clinical studies in ARHL and severe SNHL, and other planned clinical trials of FX-322 for the treatment of SNHL; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the results of the Phase 2a clinical trial, the Phase 1b clinical studies in ARHL and severe SNHL, or other planned clinical trials of FX-322 for the treatment of SNHL or clinical trials of our competitors for the same or similar indication. For example, the price of our common stock decreased significantly following the announcement of our Phase 2a interim results, showing that four weekly injections in subjects with mild to moderately severe SNHL did not demonstrate improvements in hearing measures versus placebo; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our ability to develop additional product candidates based on our PCA platform, including MS; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">any delay in submitting a regulatory filing and any adverse development or perceived adverse development with respect to the regulatory review of such filing; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">failure to successfully develop and commercialize FX-322 for the treatment of SNHL or any future product candidate; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">inability to obtain additional funding; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">regulatory or legal developments in the United States and other countries applicable to our PCA platform or any product candidate: </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">adverse regulatory decisions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">changes in the structure of healthcare payment systems; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">adverse developments concerning our CMOs or CROs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">inability to obtain adequate product supply for our other product candidates, or the inability to do so at acceptable prices; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">introduction of new products, services or technologies by our competitors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our ability to effectively manage our growth; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">failure to meet or exceed financial projections we provide to the public; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">failure to meet or exceed the estimates and projections of the investment community; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">changes in the market valuations of companies similar to us; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">market conditions in the biotechnology and pharmaceutical sectors, and the issuance of new or changed securities analysts&#8217; reports or recommendations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by us or our competitors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the termination of a collaboration agreement, licensing agreement or other strategic arrangement, or the inability to establish additional collaboration arrangements that we need on favorable terms, or at all; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">significant lawsuits, including patent or shareholder litigation, and disputes or other developments relating to our proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our product candidates and PCA platform; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">additions or departures of key scientific or management personnel; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">sales of our common stock by us or our shareholders in the future; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">trading volume of our common stock; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">general economic, industry and market conditions. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the trading prices for common stock of biopharmaceutical companies have been highly volatile as a result of the COVID-19 pandemic. The ongoing COVID-19 pandemic continues to rapidly evolve. The extent to which the outbreak may impact our business and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our directors, executive officers and shareholders affiliated with our directors and executive officers own a significant percentage of our common stock and, if they choose to act together, will be able to exert significant influence over matters subject to shareholder approval. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our directors, executive officers, and shareholders affiliated with our directors and executive officers exert significant influence on us. As of March 19, 2021, these holders beneficially own approximately&#160;15.1% of the voting power of our outstanding common stock. As a result, these holders, acting together, have significant influence over all matters that require approval of our stockholders, including the election of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transactions. The interests of these holders may not always coincide with our corporate interests or the interests of other shareholders, and they may act in a manner with which our shareholders may not agree or that may not be in the best interests of our other shareholders. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be the sole source of gain for our stockholders. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. As a result, capital appreciation, if any, of our common stock will be the sole source of gain on an investment in our common stock for the foreseeable future. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We will incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a public company, and particularly after we no longer qualify as an emerging growth company, we will incur significant legal, accounting and other expenses that we did not incur previously. The Sarbanes-Oxley Act of 2002, or SOX, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of The Nasdaq Stock Market LLC, and other applicable securities rules and regulations impose various requirements on U.S. reporting public companies, including the establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time consuming and costly. For example, we expect that these rules and regulations may make it more expensive for us to obtain director and officer liability insurance, which in turn could make it more difficult for us to attract and retain qualified senior management personnel or members for our board of directors. In addition, these rules and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulations are often subject to varying interpretations, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section&#160;404 of SOX, or Section&#160;404, as a public company, we will be required to furnish a report by our senior management on our internal control over financial reporting, and our independent registered public accounting firm will be required to provide an attestation report on our internal control over financial reporting. However, while we remain an emerging growth company, we will not be required to provide the attestation report. To ensure compliance with Section&#160;404, we are engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants, and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented, and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section&#160;404. If we identify one or more material weaknesses, it could result in an adverse reaction on the price of our common stock in the market due to a loss of confidence in the reliability of our financial statements. Furthermore, if we are unable to conclude that our internal control over financial reporting is effective, our investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock could decline. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company&#8221; and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act, and a &#8220;smaller reporting company&#8221; as defined under the rules promulgated under the Securities Act. As an emerging growth company and a smaller reporting company we may follow reduced disclosure requirements and do not have to make all the disclosures that public companies that are not emerging growth companies or smaller reporting companies do. We will remain an emerging growth company until the earlier of (a) the last day of the fiscal year in which we have total annual gross revenues of $1.07 billion or more; (b) the last day of the fiscal year following the fifth anniversary of the date of the completion of our initial public offering; (c) the date on which we have issued more than $1 billion in nonconvertible debt during the previous three years; or (d) the date on which we are deemed to be a large accelerated filer under the rules of the Securities and Exchange Commission, or SEC, which means the market value of our voting and non-voting common stock that is held by non-affiliates exceeds $700 million as of the last business day of our second fiscal quarter. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">not being required to comply with the auditor attestation requirements of Section 404;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">an exemption from compliance with the requirement of the Public Company Accounting Oversight Board regarding the communication of critical audit matters in the auditor&#8217;s report on the financial statements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">progressively adding to the number of years of audited financial statements required to be included in our periodic reports; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation, stockholder approval of any golden parachute payments not previously approved and having to disclose the ratio of the compensation of our chief executive officer to the median compensation of our employees. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to use the extended transition period for complying with new or revised accounting standards; and as a result of this election, our financial statements may not be comparable to companies that comply with public company effective dates. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also a smaller reporting company, and we will remain a smaller reporting company until the fiscal year following the determination that our voting and non-voting common stock held by non-affiliates is more than $250 million measured on the last business day of our second fiscal quarter, or our annual revenues are more than $100 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is more than $700 </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million measured on the last business day of our second fiscal quarter. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Similar to</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> emerging growth companies, smaller reporting companies are able to provide simplified executive compensation disclosure, are exempt from the auditor attestation requirements of Section 404, and have certain other reduced disclosure obligations, including, among other things, being required to provide only two years of audited financial statements and not being required to provide selected financial data, supplemental financial information or risk factors. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may choose to take advantage of some, but not all, of the available exemptions for emerging growth companies and smaller reporting companies. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our shares price may be more volatile. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Provisions in our restated certificate of incorporation and our amended and restated bylaws or Delaware law may discourage, delay or prevent a merger, acquisition or other change in control of our company that our shareholders may consider favorable, including transactions in which our shareholders might otherwise receive a premium for their shares. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our restated certificate of incorporation and our amended and restated bylaws include certain anti-takeover provisions, including those establishing: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents shareholders from filling vacancies on our board of directors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the ability of our board of directors to alter our bylaws without obtaining stockholder approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the required approval of the holders of at least two-thirds of the shares entitled to vote at an election of directors to adopt, amend or repeal our bylaws or repeal the provisions of our restated certificate of incorporation regarding the election and removal of directors: </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the requirement that a special meeting of stockholders may be called only by the chairman of the board of directors, the chief executive officer, the president, or the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors: and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a shareholders&#8217; meeting, which may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to obtain control of us. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the General Corporation Law of the State of Delaware, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our restated certificate of incorporation </font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and amended and restated bylaws </font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">designates specific courts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us. </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.14%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our restated certificate of incorporation specifies that, unless we consent in writing to the selection of an alternative forum to the fullest extent permitted by law, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (1)&#160;any derivative action or proceeding brought on our behalf, (2)&#160;any action asserting a claim for breach of a fiduciary duty owed by any of our directors, officers, or other employees to us or our stockholders, (3)&#160;any action asserting a claim arising pursuant to any provision of the General Corporation Law of the State of Delaware, our restated certificate of incorporation, or our amended and restated bylaws, (4)&#160;any action to interpret, apply, enforce, or determine the validity of our restated certificate of incorporation or our amended and restated bylaws, or (5)&#160;any action asserting a claim governed by the internal affairs doctrine. Under our restated certificate of incorporation, this exclusive forum provision will not apply to claims which are vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery of the State of Delaware, or for which the Court of Chancery of the State of Delaware does not have subject matter jurisdiction. In addition, our amended and restated bylaws specifies that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended. These exclusive forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. For example, stockholders who do bring a claim in the Court of Chancery could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near the State of Delaware. The Court of Chancery may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments or results may be more favorable to us than to our stockholders. The enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in such action. If a court were to find the choice of forum provisions contained in our amended and restated certificate of incorporation or amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business, financial condition, or results of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">General Risk Factors </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until such time, if ever, as we can generate substantial revenues, we may finance our cash needs through a combination of equity offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or other sources. We do not currently have any committed external source of funds. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that we raise additional capital through the sale of equity or convertible debt securities, our existing stockholders&#8217; ownership interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. In addition, debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, intellectual property, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. Furthermore, any capital raising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to advance research programs, product development activities or product candidates. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate product candidate development or future commercialization efforts. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in either the patent laws or interpretation of patent laws in the United States, including patent reform legislation such as the Leahy-Smith America Invents Act, or the Leahy-Smith Act, could increase the uncertainties and costs </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">surrounding the prosecution of our owned and in-licensed patent applications and the maintenance, enforcement, or defense of our owned and in-licensed issued patents. The Leahy-Smith Act includes </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a number of</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> significant changes to United States patent law. These changes include provisions that affect the way patent applications are prosecuted, redefine prior art, provide more efficient and cost-effective avenues for competitors to challenge the validity of patents, and enable third-party submission of prior art to the USPTO during patent prosecution, and additional procedures to attack the validity of a patent at USPTO-administered post-grant proceedings, including post-grant review, </font><font style="font-style:italic;">inter </font><font style="font-style:italic;">partes</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> review, and derivation proceedings. Assuming that other requirements for patentability are met, prior to March 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March 2013, under the Leahy-Smith Act, the United States transitioned to a first-to-file system in which, assuming that the other statutory requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. As such, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our patent rights and our ability to protect, defend and enforce our patent rights in the future. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not be able to protect our intellectual property and proprietary rights throughout the world. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filing, prosecuting, and defending patents on product candidates in all countries throughout the world would be prohibitively expensive. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States, and even where such protection is nominally available, judicial and governmental enforcement of such intellectual property rights may be lacking. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection or licenses, but enforcement is not as strong as that in the United States. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. In addition, certain jurisdictions do not protect, to the same extent or at all, inventions that constitute new methods of treatment. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations, and prospects may be adversely affected. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be subject to claims by third parties asserting that our employees, </font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">consultants</font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> or contractors have wrongfully used or disclosed confidential information of third parties, or we have wrongfully used or disclosed alleged trade secrets of their current or former employers, or claims asserting we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property. </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our employees, consultants and contractors were previously employed at universities or other pharmaceutical or biotechnology companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants, and contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Litigation may be necessary to defend against these claims. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, while it is our policy to require our employees, consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our intellectual property assignment agreements with them may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial conditions, results of operations, and prospects. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could have a material adverse effect on our competitive business position and prospects. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products, which license may not be available on commercially reasonable terms, or at all, or such license may be non-exclusive. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our management and employees. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We could be subject to securities class action litigation. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the past, securities class action litigation has often been brought against companies following a decline in the market price of their securities. This risk is especially relevant for us because biotechnology and pharmaceutical companies have experienced significant share price volatility in recent years. For example, the price of our common stock decreased significantly following the announcement of our Phase 2a interim results, showing that four weekly injections in subjects with mild to moderately severe SNHL did not demonstrate improvements in hearing measures versus placebo. As a result, we may be more susceptible to these types of lawsuits and legal proceedings than other companies with more stable security prices. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If securities or industry analysts issue an adverse or misleading opinion regarding our common stock, our stock price and trading volume could decline. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading market for our common stock is influenced by the research and reports that industry or securities analysts publish about us or our business. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our clinical studies and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Sales of a substantial number of shares of our common stock, or the perception that substantial sales might occur, could cause the price of our common stock to fall. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of a substantial number of shares of our common stock, or the perception that these sales might occur, could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. The shares of common stock that were sold in the initial public offering of our common stock are freely transferable without restrictions or further registration under the Securities Act of 1933, as amended, or the Securities Act, except for any shares acquired by our affiliates, as defined in Rule 144 under the Securities Act. The remaining shares of our common stock that are outstanding are either unrestricted or restricted as a result of securities laws. In addition, there are shares of common stock that are either subject to outstanding options or reserved for future issuance under our existing equity incentive plans and may become eligible for future sale subject to vesting, and Rule 144 and Rule 701 under the Securities </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Act. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1B_UNRESOLVED_STAFF_COMMENTS"></a>I<a name="ITEM_1B_UNRESOLVED_STAFF_COMMENTS"></a>tem 1B. Unresolved Staff Comments. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_2_PROPERTIES"></a><a name="ITEM_2_PROPERTIES"></a>Item 2. Properties. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Our principal office is located at 19 Presidential Way, Woburn, Massachusetts 01801, where we lease approximately 17,000 square feet of office and laboratory space. We lease this space under a lease that terminates on May 31, 2021. We also lease approximately 2,133&#160;square feet of office and laboratory space at 400&#160;Farmington Avenue, Farmington, Connecticut 06030. This lease is set to terminate on July&#160;31, 2021. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">On January 7, 2020, we entered into an indenture of lease for the lease of approximately 61,307 square feet of office and laboratory space located at 75 Hayden Avenue, Lexington, Massachusetts 02421, which, once occupied, will be our new principal office. The lease term commenced on December 11, 2020 and we expect to move to this new location in the second quarter of 2021.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_3_LEGAL_PROCEEDINGS"></a><a name="ITEM_3_LEGAL_PROCEEDINGS"></a>Item 3. Legal Proceedings. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are not subject to any material legal proceedings. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_4_MINE_SAFETY_DISCLOSURES"></a><a name="ITEM_4_MINE_SAFETY_DISCLOSURES"></a>Item 4. Mine Safety Disclosures.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Management</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Executive officers and directors</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth information regarding our executive officers and directors as of the date of this Annual Report on Form 10-K.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:25.15%;"></td>
<td style="width:1.94%;"></td>
<td style="width:1.52%;"></td>
<td style="width:5.3%;"></td>
<td style="width:1.17%;"></td>
<td style="width:2.38%;"></td>
<td style="width:62.54%;"></td>
</tr>
<tr style="height:10.3pt;">
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Age</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Position</p></td>
</tr>
<tr style="height:3.3pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="middle"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:10.3pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Executive Officers</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:3.3pt;">
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:10.3pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David L. Lucchino</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President, Chief Executive Officer, Director, and Co-Founder</p></td>
</tr>
<tr style="height:3.3pt;">
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:10.3pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Christopher R. Loose, Ph.D.</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Scientific Officer and Co-Founder</p></td>
</tr>
<tr style="height:10.3pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:10.3pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Peter P. Pfreundschuh</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
<tr style="height:3.3pt;">
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:10.3pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Carl P. LeBel, Ph.D.</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Development Officer</p></td>
</tr>
<tr style="height:3.3pt;">
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:10.3pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dana C. Hilt, M.D.</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Medical Officer</p></td>
</tr>
<tr style="height:10.3pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:10.3pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Quentin McCubbin</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Manufacturing Officer</p></td>
</tr>
<tr style="height:3.3pt;">
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:10.3pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Michael D. Bookman</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General Counsel and Secretary</p></td>
</tr>
<tr style="height:3.3pt;">
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:10.3pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk35366256"></a>Wendy S. Arnold</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief People Officer</p></td>
</tr>
<tr style="height:3.3pt;">
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:10.3pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Non-Employee Directors</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:3.3pt;">
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:10.3pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marc A. Cohen</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chairman and Director</p></td>
</tr>
<tr style="height:3.3pt;">
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:10.3pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Timothy J. Barberich</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
<tr style="height:10.3pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:10.3pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cynthia L. Feldmann</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
<tr style="height:3.3pt;">
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:10.3pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Michael Huang</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:25.15%;"></td>
<td style="width:1.94%;"></td>
<td style="width:1.52%;"></td>
<td style="width:5.3%;"></td>
<td style="width:1.17%;"></td>
<td style="width:2.38%;"></td>
<td style="width:62.54%;"></td>
</tr>
<tr style="height:3.3pt;">
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
<td colspan="4" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:10.3pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Robert S. Langer, Sc.D.</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
<tr style="height:3.3pt;">
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:10.3pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Joel S. Marcus</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Executive officers</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">David L. Lucchino<font style="font-style:normal;"> </font><font style="font-style:normal;color:#000000;">has served as our President and Chief Executive Officer and a member of our board of directors since November 2014 and was a co-founder of our company with Dr. Robert S. Langer and Dr. Christopher R. Loose. From December 2014 until June 2016, Mr. Lucchino served as the President and Chief Executive Officer of Entrega Bio, a PureTech Health-founded biotechnology company focused on oral drug delivery technology. Prior to that, Mr. Lucchino co-founded Semprus BioSciences, or Semprus, a biotechnology company, and served as its President and Chief Executive Officer from June 2007 to June 2012. Mr. Lucchino oversaw the development of the company&#8217;s lead medical product, which received FDA clearance in 2012. Semprus was acquired by Teleflex, Inc., or Teleflex, in June 2012. Prior to Semprus, Mr. Lucchino worked at the investment firm Polaris Partners. Mr. Lucchino is the immediate past chairman of the board of directors of MassBio, a non-profit organization that represents and provides services and support for the biotechnology industry in Massachusetts. He is a member of the College of Fellows of the American Institute for Medical and Biological Engineering and was appointed by Governor Charlie Baker as a member of the Commonwealth&#8217;s Economic Planning Council. Mr. Lucchino also serves as a trustee of Mt. Auburn Hospital, a Harvard Medical School facility, a trustee of the Multiple Myeloma Research Foundation, and a member of the Board of Advisors of Life Science Cares. Mr. Lucchino holds an MBA from the Massachusetts Institute of Technology&#8217;s, or MIT&#8217;s, Sloan School of Management, an M.S. from the Newhouse School of Journalism at Syracuse University, and a B.A. in Philosophy and Religious Studies from Denison University. We believe Mr. Lucchino&#8217;s extensive management experience in the biotechnology and pharmaceutical industry qualifies him to serve on our board of directors.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Christopher R. Loose, Ph.D.<font style="font-style:normal;"> </font><font style="font-style:normal;color:#000000;">co-founded our company and has served as our Chief Scientific Officer since January 2016. Prior to our company, Dr. Loose co-founded Semprus with Mr. Lucchino and Dr. Langer and served as its Chief Technology Officer from June 2007 until its acquisition by Teleflex in June 2012. At Semprus, he led the technology team in the development through regulatory clearance of medical products designed to reduce infection and clotting. Prior to Semprus, Dr. Loose worked as a chemical engineer at Merck Research Labs. In 2011, Dr. Loose was awarded the inaugural Peter Strauss Entrepreneurial Award from the Hertz Foundation. Since 2014, Dr. Loose has served as an Associate Professor Adjunct of Urology at the Yale School of Medicine. Dr. Loose is also the Executive Director of Yale University&#8217;s Center for Biomedical and Interventional Technology. Dr. Loose holds a Ph.D. in Chemical Engineering from MIT and a BSE in Chemical Engineering summa cum laude from Princeton University.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Peter P. Pfreundschuh<font style="font-style:normal;"> has served as our Chief Financial Officer since December 2020. He joined our company from UroGen Pharma Ltd., a commercial-stage biopharma company, where he served as chief financial officer, chief compliance officer and corporate secretary from August 2018 to October 2020. He brings to our company more than 20 years of finance, business development, commercial and public company leadership experience in the life sciences and medical device industries. Prior to joining UroGen, Mr. Pfreundschuh was the chief financial officer of Sucampo Pharmaceuticals Inc. from March 2017 to February 2018, where he co-led the sale of the company to Mallinckrodt, was EVP and chief financial officer of Immunomedics Inc. from September 2013 to September 2016, and was chief financial officer of the heart pump maker, CircuLite Inc. Mr. Pfreundschuh also has held senior roles across finance, commercial operations and business development within the pharmaceutical industry at AstraZeneca Pharmaceuticals and Johnson &amp; Johnson. He started his career as an auditor at Ernst &amp; Young, LLP. Mr. Pfreundschuh is a certified public accountant and holds a Master of Business Administration in finance from Rider University. He has completed master&#8217;s coursework in strategic marketing from Northwestern University&#8217;s Kellogg School of Management and received his Bachelor of Science in accounting from Rutgers University. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Carl P. LeBel, Ph.D.<font style="font-style:normal;"> </font><font style="font-style:normal;color:#000000;">has served as our Chief Development Officer since March 2018. In 2017, Dr. LeBel founded LeBel Consulting, LLC, a biopharmaceutical consulting company. Prior to joining our company, from February 2009 until November 2016, Dr. LeBel served as the Chief Scientific Officer of Otonomy, Inc., or Otonomy, a biopharmaceutical company where he was responsible for all research and development activities. From 2008 to 2009, he served as the President and Chief Executive Officer of Akesis Pharmaceuticals, Inc., or Akesis, a virtual metabolic disorders company. Prior to Akesis, Dr. LeBel served as an Executive Director in a variety of research and development management positions for Amgen, Inc., or Amgen, a biopharmaceutical company. Before joining Amgen, Dr. LeBel served as a Research Scientist at Alkermes, Inc. Dr. LeBel is a scientific fellow of the American Academy of Otolaryngology and a full member of the American Association for the Advancement of Science and the Society of Toxicology. Dr. LeBel is a co-inventor on numerous patents in the field of drug delivery for otology-related disorders. He was a National Institute of Environmental </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:normal;color:#000000;">Health Sciences post-doctoral fellow in Molecular Neurotoxicology at the University of California Irvine. Dr. LeBel holds a Ph.D. in Biomedical Sciences and Toxicology from Northeastern University and a B.S. in Chemistry from the University of Detroit.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Dana C. Hilt, M.D.<font style="font-style:normal;"> </font><font style="font-style:normal;color:#000000;">has served as our Chief Medical Officer since August 2019. From October 2016 to August 2019, Dr. Hilt served as Chief Medical Officer for Lysosomal Therapeutics, Inc., or Lysosomal, a life sciences drug development company in the field of neurodegeneration, where he was responsible for all clinical development activity for a product candidate for the treatment of Parkinson&#8217;s Disease. Prior to Lysosomal, beginning in 2006, Dr. Hilt served in the roles of Senior Vice President of Drug Development and Chief Medical Officer for FORUM Pharmaceuticals, Inc., or FORUM, where he oversaw the clinical, chemistry manufacture controls, regulatory and quality control activities for therapies focused on the treatment of cognitive impairment in schizophrenia and Alzheimer&#8217;s disease. Prior to FORUM, Dr. Hilt served as the Chief Medical Officer and Senior Vice President of Clinical Research, Medical Affairs, and Development for Ascend Therapeutics US, LLC, or Ascend, a specialty pharmaceutical company concentrating on women&#8217;s health and transdermal drug delivery. Before joining Ascend, Dr. Hilt served as the Vice President of Clinical Research at Guilford Pharmaceuticals Inc., or Guilford, a biopharmaceutical company engaged in the research, development, and commercialization of drugs that target the acute care market and neurological indications including Parkinson&#8217;s disease and brain cancer. Prior to Guilford, he served as a Director of Clinical Development at Amgen, where he established its clinical neuroscience group. Prior to that, Dr. Hilt served on the staff of the National Institute of Health. He holds an M.D. from Tufts University School of Medicine and a B.S. from the University of Maine.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Quentin McCubbin <font style="font-style:normal;">has served as our Chief Manufacturing Officer since January 2021. He joined our company from Cerevel Therapeutics, a clinical-stage biotechnology company, where he served as Head of Technical Operations for two years. Prior to Cerevel, he spent 19 years at Takeda/Millennium Pharmaceuticals in a variety of roles including six years as Vice President of Pharmaceutical Sciences and Global Head of Process Chemistry. He began his career as a chemist, completing a post-doctoral fellowship at Imperial College in London. He earned his B.S. and Ph.D. in Chemistry from Monash University in Australia. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Michael D. Bookman<font style="font-style:normal;color:#000000;"> has served as Frequency's General Counsel and Secretary since January 2021 and as its Deputy General Counsel and Secretary from September 2019 to January 2021. Prior to his time at Frequency, from October 2012 to August 2019, Mr. Bookman was an Associate at Latham &amp; Watkins LLP, a leading international law firm where he worked on corporate transactional, securities and general business and governance matters, with an emphasis on representing high-growth technology and life sciences companies. Mr. Bookman is also a member of the Boston Bar Association&#8217;s Life Sciences Advisory Committee. He holds a J.D. from the University of Virginia School of Law and a B.B.A., summa cum laude, in finance from the University of Miami.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Wendy S. Arnold <font style="font-style:normal;color:#000000;">has served as our Chief People Officer since February 2020. Ms. Arnold previously served as Senior Vice President, Human Resources at Kaleido Biosciences where she helped to establish the HR infrastructure, compensation, performance and development programs. Prior to Kaleido, she was the head of the HR business partnership function at Moderna Therapeutics, where she helped to lead the HR organization during a period of significant growth, including implementing talent development and engagement initiatives. Prior to that, she was at Celgene Avilomics Research (formerly Avila Therapeutics), where she was responsible for building and developing the HR infrastructure for the company&#8217;s early research and development division. She also held senior HR positions at Inotek Pharmaceuticals and Amylin Pharmaceuticals. Ms. Arnold received her Bachelor of Science degree from Colorado State University.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Non-Employee Directors</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Marc A. Cohen<font style="font-style:normal;"> has served as a member of our board of directors and as Chairman since June 2020 and Executive Chairman from September 2016 to June 2020. Since 2012, Mr. Cohen has served as the Chief Executive Officer of Bublup, Inc., an online knowledge-sharing platform, as well as CoBro Ventures, Inc., an investment management company. Mr. Cohen has also been Executive Chairman of C4 Therapeutics since 2015 and Mana Therapeutics since 2018. Mr. Cohen holds an M.S. in Electrical Engineering from Stanford University and a Bachelor&#8217;s degree in Engineering Science from Harvard University. We believe Mr. Cohen&#8217;s extensive entrepreneurial experience in the life sciences industry qualifies him to serve on our board of directors.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Timothy J. Barberich<font style="font-style:normal;"> has served as a member of our board of directors since September 2016. Mr. Barberich has served on the board of directors of Verastem, Inc. since 2014, and TScan Therapeutics, Inc. since 2019. Mr. Barberich previously served as a director for GI Dynamics, Inc. from 2011 to 2021, Tokai Pharmaceuticals, Inc. from 2009 to 2017, for HeartWare International, Inc. from 2008 to 2016, for Inotek Pharmaceuticals Corporation from 2016 to 2017, and for Neurovance, Inc. from 2010 to 2016. Mr. Barberich is co-founder, and served as the CEO and Chairman of Sepracor Inc. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:normal;">from 1984 to 2009. He holds a B.S. in Chemistry from Kings College. We believe Mr. </font><font style="font-style:normal;">Barberich&#8217;s</font><font style="font-style:normal;"> extensive experience in the life sciences industry qualifies him to serve on our board of directors.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Cynthia L. Feldmann<font style="font-style:normal;"> has served as a member of our board of directors since September 2020. Ms. Feldmann has served as a director of UFPT since June 2017. She chairs the UFPT Audit Committee and serves on the Nominating &amp; Governance Committee. Since 2005, Ms. Feldmann has served on the board of directors of STERIS PLC (NYSE: STE), an NYSE-listed $16 billion provider of infection prevention, decontamination, and health science technologies, products and services. She is a member of STERIS&#8217; Nominating &amp; Governance Committee and Compliance Committee, and was previously Chair of and served on the Audit Committee. Ms. Feldmann also served from 2003 to January 2018 on the board of directors of Hanger Inc. (NYSE: HNGR), a $860 million provider of orthotic and prosthetic services and products, and the largest orthotic and prosthetic managed care network in the U.S. Ms. Feldmann served on the Audit Committee, including as Chair of the Audit Committee, the Compensation Committee and the Quality and Technology Committee of Hanger. Ms. Feldmann currently serves on the board of directors and is the chair of the Finance Committee of Falmouth Academy, an academically rigorous, co-ed college preparatory day school for grades 7 to 12. She was the President and Founder of Jetty Lane Associates, a consulting firm, from 2005 until 2012. Previously, Ms. Feldmann served as Business Development Officer at Palmer &amp; Dodge LLP, a Boston based law firm, with a specialty in serving life sciences companies. From 1994 to 2002, she was a Partner at KPMG LLP, holding various leadership roles in the firm&#8217;s Medical Technology and Health Care &amp; Life Sciences industry groups. Ms. Feldmann is a retired CPA and holds a Masters Professional Director Certification from the American College of Corporate Directors. We believe Ms. Feldmann&#8217;s extensive expertise in auditing and accounting, particularly her experience in the life sciences industry, qualifies her to serve on our board of directors.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Michael Huang<font style="font-style:normal;"> has served as a member of our board of directors since October 2018. Since 2019, Mr. Huang has served as a member of the board of directors of Viracta Therapeutics. Mr. Huang serves as Managing Partner at Taiwania Capital Management Corporation, a venture capital firm. From 2014 to 2017, Mr. Huang served as Chief Executive Officer of NeuroVive Pharmaceutical Asia, Inc., a biopharmaceutical company. Mr. Huang holds an MBA from Rice University, a M.A. in Chemistry from the University of Texas, Arlington, and a B.S. from University of Texas, Austin. We believe Mr. Huang&#8217;s extensive investment experience in the life sciences industry qualifies him to serve on our board of directors.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Robert S. Langer, Sc.D.<font style="font-style:normal;">, </font><font style="color:#000000;font-style:normal;">has served as a member of our board of directors since September 2016. Dr. Langer has served as a David H. Koch Institute Professor at the Massachusetts Institute of Technology since 2005. Dr. Langer currently serves on the board of directors of Rubius Therapeutics, Inc., Moderna, Inc., and Puretech Health plc, and previously served on the board of directors of Momenta Pharmaceuticals, Inc., Kala Pharmaceuticals, Inc., Fibrocell Science, Inc. and Millipore Corp. Dr. Langer holds a Sc.D. in Chemical Engineering from MIT and a B.S. in Chemical Engineering from Cornell University. We believe Dr. Langer&#8217;s pioneering academic work, extensive medical and scientific knowledge, and experience serving on public company boards of directors qualify him to serve on our board of directors.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Joel S. Marcus<font style="font-style:normal;"> </font><font style="color:#000000;font-style:normal;">has served as a member of our board of directors since December 2018. Mr. Marcus currently serves as Executive Chairman and Founder of Alexandria Real Estate Equities, Inc., a real estate investment trust, and Alexandria Venture Investments, the company&#8217;s strategic venture capital platform. Mr. Marcus served as the Chief Executive Officer of Alexandria from 1997 to 2018 and as its Chairman from 2007 to 2018. Mr. Marcus also currently serves on the boards of directors of Applied Therapeutics, Inc., Intra-Cellular Therapies, Inc., and MeiraGTx Holdings plc. He holds a B.A. and J.D. from the University of California, Los Angeles. We believe Mr. Marcus&#8217; extensive investment experience and service on the boards of directors of public life sciences companies qualify him to serve on our board of directors.</font></p><a name="_AEIOULastRenderedPageBreakAEIOU7"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_II"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_II"></a>PAR</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">T II</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"></a>Item 5. Market for <a name="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"></a>Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Market Information</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock is traded under the symbol &#8220;FREQ&#8221; on the Nasdaq Global Select Market. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 19, 2021, there were approximately 116 registered holders of record of our common stock. The actual number of stockholders is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. The number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Dividend Policy</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid any dividends on our capital stock. We currently intend to retain all available funds and any future earnings, if any, to fund the development and expansion of our business and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination to pay dividends will be made at the discretion of our board of directors. Investors should not purchase our common stock with the expectation of receiving cash dividends.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Equity Compensation Plan Information</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides information on our equity compensation plans as of December 31, 2020.</p>
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:8.1pt;">
<td valign="bottom"  style="width:35.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:19.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:18.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:19.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.19%;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of Securities</p></td>
</tr>
<tr style="height:8.1pt;">
<td valign="bottom"  style="width:35.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:19.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:18.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:19.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.39%;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining Available for Future</p></td>
</tr>
<tr style="height:8.1pt;">
<td valign="bottom"  style="width:35.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:19.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of Securities to be</p></td>
<td valign="bottom"  style="width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:18.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:19.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.39%;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Issuance Under Equity</p></td>
</tr>
<tr style="height:8.1pt;">
<td valign="bottom"  style="width:35.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:19.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Issued Upon Exercise of</p></td>
<td valign="bottom"  style="width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:20.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:3.37%;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average Exercise</p></td>
<td colspan="2" valign="bottom"  style="width:19.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.19%;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Compensation Plans</p></td>
</tr>
<tr style="height:8.1pt;">
<td valign="bottom"  style="width:35.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:19.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding Options,</p></td>
<td valign="bottom"  style="width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:20.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:3.37%;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price of Outstanding Options,</p></td>
<td colspan="2" valign="bottom"  style="width:19.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.19%;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(excludes securities</p></td>
</tr>
<tr style="height:8.55pt;">
<td colspan="2" valign="bottom"  style="width:37.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Plan Category</p></td>
<td valign="bottom"  style="width:19.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants and Rights</p></td>
<td valign="bottom"  style="width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:20.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:3.37%;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants and Rights</p></td>
<td colspan="2" valign="bottom"  style="width:19.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.19%;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">reflected in first column) <font style="font-size:6pt;">(1)</font></p></td>
</tr>
<tr style="height:10.45pt;">
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:35.72%; border-top:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity compensation plans approved by</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.4%; border-top:solid 1pt #CFF0FC;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:19.12%; border-top:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:2.08%; border-top:solid 1pt #CFF0FC;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.4%; border-top:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:18.92%; border-top:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.58%; border-top:solid 1pt #CFF0FC;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:18.92%; border-top:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:0.86%; border-top:solid 1pt #CFF0FC;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
<tr style="height:11.5pt;">
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="width:37.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">security holders <font style="font-size:7.5pt;">(2)</font></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:19.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 6,816,798<font style="font-size:7.5pt;">(3)</font></p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="width:3.48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:18.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 10.11<font style="font-size:7.5pt;">(4)</font></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:18.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,099,368<font style="font-size:7.5pt;">(5)</font></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:10.75pt;">
<td colspan="2" valign="bottom"  style="width:37.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity compensation plans not approved by</p></td>
<td valign="bottom"  style="width:19.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:18.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:18.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
<tr style="height:11.5pt;">
<td colspan="2" valign="bottom"  style="width:37.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">security holders</p></td>
<td valign="bottom"  style="width:19.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  style="width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:20.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.79%;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td colspan="2" valign="bottom"  style="width:19.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.19%;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr style="height:11.5pt;">
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="width:37.12%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total<font style="font-size:10pt;font-weight:normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:19.12%; border-bottom:solid 1pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,816,798 </p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="width:3.48%; border-bottom:solid 1pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:18.92%; border-bottom:solid 1pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.11</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.58%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:18.92%; border-bottom:solid 1pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,099,368</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:0.86%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Pursuant to the terms of the 2019 Incentive Award Plan, or the 2019 Plan, the number of shares of common stock available for issuance under the 2019 Plan automatically increases on each January 1 until and including January 1, 2029, by an amount equal to the lesser of: (a) 4% of the shares of common stock outstanding on the final day of the immediately preceding calendar year and (b) such smaller number of shares as is determined by our board of directors. Pursuant to the terms of the 2019 Employee Stock Purchase Plan, or the 2019 ESPP, the number of shares of common stock available for issuance under the 2019 ESPP automatically increases on each January 1 until and including January 1, 2029, by an amount equal to the lesser of: (a) 1% of the shares of common stock outstanding on the final day of the immediately preceding calendar year and (b) such smaller number of shares as is determined by our board of directors.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Consists of the 2014 Stock Incentive Plan, or the 2014 Plan, the 2019 Plan, and the 2019 ESPP.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(3)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Includes 3,942,449 outstanding options to purchase shares of common stock under the 2014 Plan and 2,874,349 outstanding options to purchase stock under the 2019 Plan.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(4)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">As of December 31, 2020, the weighted-average exercise price of outstanding options under the 2014 Plan was $3.02 and the weighted-average exercise price per share of outstanding options under the 2019 Plan was $19.84.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(5)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">As of December 31, 2020, a total of 2,099,368 shares of common stock were available for issuance, consisting of (a) 623,445 shares of common stock available for future issuance under the 2019 ESPP, none of which shares were subject to outstanding purchase rights under the 2019 ESPP and (b) 1,475,923 shares of common stock available for future issuance under the 2019 Plan.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recent Sales of Unregistered Equity Securities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_2_258"></a><a name="_cp_blt_2_265"></a>During the period covered by this Annual Report on Form 10-K, we did not issue any securities which were unregistered under the Securities Act<a name="_cp_blt_2_258"></a><a name="_cp_blt_2_265"></a> and required to be disclosed herein.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Proceeds</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2019, we issued and sold 6,325,000 shares of our common stock in our IPO at a public offering price of $14.00 per share.&nbsp;&nbsp;The offer and sale of all the shares in the IPO were registered under the Securities Act pursuant to a registration statement on Form S-1 (File No. 333-233652), as amended, which was declared effective by the SEC on October 2, 2019.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The $79.7 million in net proceeds we received from the IPO have been invested in cash and cash equivalents. There has been no material change in the expected use of the net proceeds from our IPO as described in our final prospectus, dated October 2, 2019, filed with the SEC pursuant to Rule 424(b) relating to our registration statement on Form S-1 on October 4, 2019.</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_6_SELECTED_FINANCIAL_DATA"></a><a name="ITEM_6_SELECTED_FINANCIAL_DATA"></a>Item 6. Selected Financial Data. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You should read the following selected consolidated financial data together with our consolidated financial statements and the related notes included elsewhere in this Annual Report on Form 10-K and the section titled &#8220;Management&#8217;s discussion and analysis of financial condition and results of operations.&#8221; We have derived the consolidated statement of operations data for the years ended December&#160;31, 2020 and 2019 and the consolidated balance sheet data as of December&#160;31, 2020 and 2019 from our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K. Our historical results are not necessarily indicative of results that may be expected in any future period, and our results for any interim period are not necessarily indicative of results that may be expected for any full year. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="8" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.38%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share amounts)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Consolidated Statements of Operations Data:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,984</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,947</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalty</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,415</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,784</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,119</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,838</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,534</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,622</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,550</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,675</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income (expense)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">994</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,784</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Realized gain on investments</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign exchange (loss) gain</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss before income taxes</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,476</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,746</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income taxes</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(35</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,511</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,746</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cumulative Series C preferred stock dividends</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,054</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,511</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,800</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common stockholders,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; basic and diluted(1)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.82</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.29</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares of common stock outstanding,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; basic and diluted(1)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,253,227</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,649,245</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">See Note 2 within the notes to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K for an explanation and details of the method used to calculate the basic and diluted net loss per share of common stock. </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="8" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.04%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.04%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Consolidated Balance Sheet Data:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.68%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.68%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and short-term</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; investments</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">220,341</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,355</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Working capital(1)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">198,430</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">168,575</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">264,722</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">223,218</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,231</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,860</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(95,399</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(68,888</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; (deficit) equity</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">192,491</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">167,358</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">We define working capital as current assets less current liabilities. See our consolidated financial statements included elsewhere in this Annual Report on Form 10-K for further details regarding our current assets and current liabilities. </p></td></tr></table></div><a name="_AEIOULastRenderedPageBreakAEIOU8"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"></a>Item 7. Management&#8217;s Discussion and Analysis of </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial Condition and Results of Operations. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes and other financial information included elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis contains forward-looking statements that involve risks and uncertainties. You should review the section titled &#8220;Risk factors&#8221; in this Annual Report on Form 10-K for a discussion of important factors that could cause actual results to differ materially from the results described below. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage biotechnology company focused on harnessing the body&#8217;s innate biology to repair or reverse damage caused by a broad range of degenerative diseases and a global leader in the science and development of medicines for inner-ear cellular regeneration and hearing restoration. Our initial focus is on advancing our lead product candidate, FX-322, through clinical studies with the goal of developing and commercializing a medicine to help millions of patients with the most common form of hearing loss and build upon the potential of regenerative therapeutics for hearing.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our initial therapeutic focus is sensorineural hearing loss, or SNHL, which is the most prevalent type of hearing loss. We are developing FX-322 to treat the underlying cause of SNHL, which is the loss of hair cells. FX-322 is designed to regenerate hair cells through the activation of progenitor cells already present in the ear. In our Phase 1/2 clinical trial evaluating FX-322 in 23 patients with stable SNHL, we observed a statistically significant and clinically meaningful improvement in key measures of hearing loss, including word recognition, and clarity of sounds, and FX-322 was observed to be well-tolerated. We commenced dosing of a Phase 2a clinical trial of FX-322 in patients with SNHL in October 2019. <font style="color:#000000;">In September 2020, we completed enrollment of 95 patients across 16 sites in the Phase 2a clinical trial. </font>In March 2021, we announced topline, day-90 interim data from the Phase 2a clinical trial. The results showed that four weekly injections in subjects with mild to moderately severe SNHL did not demonstrate improvements in hearing measures versus placebo. While WR scores increased across all groups, repeated weekly injections appeared to dampen the hearing benefit observed compared to other single injection-studies. The interim results also showed an unexpected apparent level of hearing benefit in the placebo group that did not occur in previous trials and exceeded well-established published standards. No treatment-related serious adverse events were observed in the study. <font style="color:#000000;">We plan to report an analysis of the end of Phase 2a data (210 days) late in the second quarter of 2021.</font> We are also working to identify a product candidate for the treatment of multiple sclerosis, or MS. This program focuses on activating oligodendroglial progenitor cells in the central nervous system to repair the myelin sheath that protects axons and may have the potential to repair damage done by the disease. <font style="color:#000000;">We established an internal research program using PCA to drive remyelination as a potential therapy for MS and have identified compounds that display promising preliminary preclinical results in an </font><font style="font-style:italic;color:#000000;">in vivo</font><font style="color:#000000;"> model of remyelination. Our research efforts are focused on optimizing these compounds and identifying a lead therapeutic candidate to advance into clinical trials. We have obtained worldwide licenses for intellectual property from Scripps and Cambridge Enterprise on approaches to promote remyelination of nerve fibers and are engaged in sponsoring clinical research to validate this approach at Cambridge University.&#160;</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2021, we announced new data from a Phase 1b clinical trial of FX-322 designed to evaluate the impact of injection conditions on tolerability. The data showed hearing improvement from a single injection of FX-322. In the multi-center, randomized study, subjects with mild to severe SNHL (n=33) were injected in one ear with FX-322 with the untreated ear as the control. Hearing function was tested over the course of 90 days following dosing. Thirty-two (n=32) subjects completed the 90 day clinical assessment period and, at day 90 following dosing, thirty-four percent (34%) of these subjects achieved a ten percent (10%) or greater absolute improvement in WR scores in the treated ear, which was clinically meaningful and statistically significant compared to the untreated ear (p &lt;0.05). This included a subset of subjects that more than doubled their WR scores. The single dose had a favorable safety profile and was well tolerated.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.9%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We commenced a Phase 1b clinical trial of FX-322 for age-related hearing loss in October 2020. The clinical trial is a double-blind, placebo-controlled, randomized multicenter safety study of up to 30 individuals aged 66-85 with mild to moderately severe age-related hearing loss. The primary objectives of the Phase 1b study are to assess the local and systemic safety of a single dose of FX-322 and evaluate hearing responses in an older adult cohort. Study participants will be randomized 4:1 to receive either FX-322 or placebo in one ear. Validated measures of hearing including WR, words-in-noise, or WIN, and pure tone audiometry will be used. Safety, otologic and audiologic assessments will be conducted at day 30 and 90 following administration of FX-322 or placebo. We expect to share results from this clinical trial in the second quarter of 2021.</p>
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.14%;">We also commenced a Phase 1b clinical trial of FX-322 in patients aged 18-65 with&#160;severe SNHL&#160;in November 2020.&#160;Severe SNHL is defined as a pure tone average deficit between 71-90 dB. Many&#160;patients&#160;with this clinical </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">profile&#160;typically would be candidates for cochlear implants. This&#160;clinical trial&#160;has a similar design to the age-related Phase 1b&#160;clinical trial&#160;that completed enrollment in October 2020.&#160;</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to&#160;share&#160;results for the age-related Phase 1b study second quarter 2021 and SNHL Phase 1b study in&#160;the third quarter of&#160;2021.</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2019, we completed the initial public offering of our common stock, or the IPO. In the IPO, we issued and sold 6,325,000 shares of our common stock at a price to the public of $14.00 per share, inclusive of the underwriters&#8217; exercise in part of their over-allotment option. We received approximately $79.7 million in net proceeds, after deducting underwriting discounts and commissions and other offering expenses. <font style="color:#000000;">In July 2019, we closed our Series C convertible preferred stock financing in which we issued and sold 39,492,960 shares of our Series C convertible preferred stock for aggregate gross proceeds of approximately $61.7&#160;million. In July 2019, we also entered into a License and Collaboration Agreement, or the Astellas Agreement, with Astellas Pharma Inc., or Astellas, pursuant to which Astellas paid us an upfront payment of $80.0&#160;million. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.9%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, we completed a private placement of our common stock to new and existing investors, or the Private Placement. In the Private Placement, we issued and sold 2,350,108 shares of our common stock at a purchase price of $18.00 per share. We received approximately $40.1 million in net proceeds, after deducting placement agent fees and other offering expenses.&#160;In connection with the Private Placement, we entered into a Registration Rights Agreement, or the Registration Rights Agreement, with the investors purchasing shares in the Private Placement. Pursuant to the Registration Rights Agreement, we filed a registration statement with the Securities and Exchange Commission, or the SEC, which was declared effective on September 3, 2020, registering the resale of the shares sold in the Private Placement.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="margin-left:36pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our formation in 2014, we have devoted substantially all our resources to developing our PCA platform, conducting research and development activities, including product candidate development, recruiting skilled personnel, establishing our intellectual property portfolio, and providing general and administrative support for these operations. We have financed our operations primarily through proceeds from the sale of convertible notes, convertible preferred stock, the common stock and the Astellas Agreement. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our formation, we have incurred significant operating losses and have not generated any revenue from the sale of products. Our ability to generate any product revenue or product revenue sufficient to achieve profitability will depend on the successful development and eventual commercialization of one or more of our product candidates. Our net losses were $26.5&#160;million and $18.7&#160;million for the years ended December&#160;31, 2020 and 2019, respectively. As of December 31, 2020, we had an accumulated deficit of $95.4 million. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our operating expenses to increase substantially in connection with the expansion of our product development programs and capabilities. In addition, we expect to continue to incur significant additional costs associated with operating as a public company. We will not generate revenue from product sales unless and until we successfully complete clinical development, obtain regulatory approval for, and successfully commercialize our product candidates, or until our collaborators do so, which could result in milestone payments or royalties to us. If we obtain regulatory approval for any of our product candidates, we expect to incur significant expenses related to developing our commercialization capability to support product sales, marketing and distribution. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of these anticipated expenditures, we will need additional financing to support our continuing operations. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our cash needs through a combination of public or private equity or debt financings and other sources, which may include current and new collaborations with third parties. Adequate additional financing may not be available to us on acceptable terms, or at all. Our inability to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. We cannot be sure that we will ever generate sufficient revenue to achieve profitability. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the numerous risks and uncertainties associated with the development of therapeutics, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we can generate revenue from product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be required to raise additional capital on terms that are unfavorable to us or we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">COVID-19</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.9%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our offices are located in states that are currently operating under a phased re-opening plan in response to the COVID-19 pandemic. As of the date of the filing of this Annual Report, the majority of our employees continue to work from home, while nearly a quarter to one-third of our workforce, consisting of mainly laboratory personnel, have periodically </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">worked in rotating teams to ensure the continuation of essential experiments</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Our Farmington, CT research site, co-located with the University of Connecticut, has resumed activity at a fifty percent level after a period of paused activity due to state lock down orders previously in effect. Thus, while we have resumed experiments at our Farmington site, we have transitioned certain key experiments to </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> offices in Woburn, MA and third parties and contract research organizations have been engaged to advance certain projects</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. We have</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> also</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> taken steps consistent with the FDA&#8217;s updated industry guidance for conducting clinical trials.</font><font style="color:#000000;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 pandemic, and actions taken to mitigate it, have had and are expected to continue to have an adverse impact on the economies and financial markets of many countries, including the geographical area in which </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">operates</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, which could adversely impact our ability to raise additional capital when needed or on acceptable terms, if at all. In addition, COVID-19 may cause significant disruptions in </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> business or operations, as well as the business and operations of </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> CMOs, CROs and other third parties with whom </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conduct business. The COVID-19 pandemic may also adversely impact </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> clinical trials, which could impede, delay, limit or prevent the clinical development of our product candidates and ultimately lead to the delay or denial of regulatory approval of our product candidates, which would materially adversely affect our business and operations, including </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ability to generate revenue.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">License and collaboration agreements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Astellas Pharma Inc. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2019, we entered into the Astellas Agreement with Astellas, under which we granted Astellas an exclusive, royalty-bearing, sub-licensable, nontransferable license to certain patent rights to research, develop, manufacture, have manufactured, use, seek, and secure regulatory approval for, commercialize, offer for sale, sell, have sold and import, and otherwise exploit licensed products containing both a GSK-3 inhibitor and an HDAC inhibitor, or the Astellas licensed products, including our product candidate FX-322, outside of the United States. We and Astellas have agreed to jointly develop the Astellas licensed products, including carrying out joint studies. Each party has agreed to use commercially reasonable efforts to carry out development activities assigned to it under an agreed-upon development plan. Astellas has agreed to use commercially reasonable efforts to obtain regulatory approval for at least one Astellas licensed product in SNHL and in age-related hearing loss, in each case in one major Asian country and one major European country. We have agreed to use commercially reasonable efforts to obtain regulatory approval for at least one Astellas licensed product in the United States. Astellas has the sole right to commercialize the Astellas licensed products outside of the United States and we have the sole right to commercialize the Astellas licensed products in the United States. Astellas has agreed to use commercially reasonable efforts to commercialize Astellas licensed products in a major Asian country and a major European country following receipt of regulatory approval in such countries. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a consideration for the licensed rights under the Astellas Agreement, Astellas paid us an upfront payment of $80.0 million in July 2019 and has agreed to pay potential development milestones up to $230.0 million. Specifically, we would receive development milestone payments of $65.0 million and $25.0 million upon the first dosing of a patient in Phase 2b clinical trial for SNHL in Europe and Asia, respectively and $100.0 million and $40.0 million upon the first dosing of a patient in a Phase 3 clinical for SNHL in Europe and Asia, respectively. If the Astellas Licensed Products are successfully commercialized, we would be eligible for up to $315.0 million in potential commercial milestone payments and tiered royalties at rates ranging from low to mid-teen percentages. The parties shall share equally, on a 50/50 basis, all out-of-pocket costs and joint study costs for all the joint activities conducted pursuant to the development plans or the joint manufacturing plan. Pursuant to our Exclusive Patent License Agreement, or the MIT License, with the Massachusetts Institute of Technology, or MIT, we are required to pay MIT a royalty on sublicense revenues. A royalty of $16.0 million related to the $80.0 million upfront payment received from Astellas was expensed in the quarter ended September 30, 2019 and paid in November 2019. The $80.0&#160;million upfront payment received from Astellas in July 2019 has been recorded as deferred revenue and is being recognized as revenue, using the input method, over the period in which we will be conducting Phase 2a clinical trials for FX-322. As of December 31, 2020, we have recognized $65.9 million of the $80.0 million since the agreement was executed in 2019. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Massachusetts Institute of Technology </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2016, we entered into the MIT License, with MIT under which we received an exclusive, worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, offer to sell, lease, and import products, or the MIT licensed products, and to develop and perform processes, or the MIT licensed processes, which incorporate the licensed technology for the treatment of disease, including but not limited to the prevention and remediation of hearing loss. We are required to use diligent efforts to develop and commercialize the MIT licensed products or processes, and to make such products or processes reasonably available to the public. We are also subject to certain development obligations with regards to a first MIT licensed product. We have satisfied certain obligations related to preclinical studies and the filing of an IND for a first MIT licensed product with our development activities related to FX-322. Our future development obligations are: (i)&#160;to commence a Phase&#160;II clinical trial for such product within two years of the IND filing for such product, (ii)&#160;to commence a Phase&#160;III clinical trial for such product within five years of the IND filing for such product, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)&#160;to file a New Drug Application, or NDA, or equivalent with the FDA or comparable European regulatory</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> agency for such product within nine years of the IND filing for such product, and (iv)&#160;to make a first commercial sale of such product within 11&#160;years of the IND filing for such product. We also have certain development obligations with regards to a second MIT licensed product. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon entering into the MIT License, we paid a $50&#160;thousand license fee payment and issued shares of our common stock equal to 5% of our then-outstanding capital stock to MIT. We are required to pay certain annual license maintenance fees ranging from $30 thousand to $0.1 million per year prior to first commercial sale of a MIT licensed product and an annual license maintenance fee of $0.2 million every year afterwards, which may be credited to running royalties during the same calendar year, if any. We are also required to make potential milestone payments in an aggregate amount of up to $2.9&#160;million on each MIT licensed product or process. In addition, we agreed to pay a low single-digit royalty on the MIT licensed products and processes and a low-twenties royalty on sub-license revenues. In the year ended December 31, 2019, we paid MIT a $16.0 million royalty on the upfront license fee received from Astellas. See &#8220;Business&#8212;License and collaboration agreements&#8212;Massachusetts Institute of Technology.&#8221; </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Massachusetts Eye and Ear (Formerly Massachusetts Eye and Ear Infirmary) </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2019, we entered into an Non-Exclusive Patent License Agreement, or the MEE License, with the Massachusetts Eye and Ear, or MEE, under which we received a non-exclusive, non-sub-licensable, worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, offer to sell, lease, and import products, and to develop and perform processes that incorporate the licensed technology for the treatment or prevention of hearing loss, or the MEE licensed products. We are obligated to use diligent efforts to develop and commercialize the MEE licensed products. We are also subject to milestone timeline obligations to dose a first patient in a Phase&#160;II trial by December&#160;31, 2020 and to dose a first patient in a Phase&#160;III trial by December&#160;31, 2024. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon entering into the MEE License, we made a $20&#160;thousand license fee payment. We are obligated to pay certain annual license maintenance fees between $5&#160;thousand and $7.5&#160;thousand per each MEE patent family case number included in the licensed MEE patent rights prior to first commercial sale of an MEE licensed product. We are also obligated to pay a minimum annual royalty payment of $15&#160;thousand per each MEE patent family case number included in the licensed MEE patent rights after first commercial sale of an MEE licensed product. We are also obligated to make milestone payments up to $350&#160;thousand on each product or process that incorporates the licensed patent rights. In addition, we have agreed to pay a low single-digit royalty on products and processes that incorporate the licensed patent rights. See &#8220;Business&#8212;License and collaboration agreements&#8212;Massachusetts Eye and Ear.&#8221; </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The Scripps Research Institute (California Institute for Biomedical Research) </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2018, we entered into a license agreement, or the CALIBR License, with the California Institute for Biomedical Research, or CALIBR, a division of Scripps, under which we received an exclusive, worldwide, royalty-bearing license to certain patent rights to make, have made, use, sell, offer to sell, and import products, or the CALIBR licensed products, which incorporate licensed technology for the treatment of MS. We have agreed to use commercially reasonable efforts to develop, manufacture, and sell at least one CALIBR licensed product. We are also subject to certain milestone timeline obligations, which may be extended in certain circumstances as described in the CALIBR License, to: (i)&#160;submit an IND (or equivalent) for a CALIBR licensed product by the 30th month after the effective date of the CALIBR License, (ii)&#160;initiate a Phase&#160;II clinical trial (or equivalent) for a CALIBR licensed product by the fourth anniversary of the effective date of the CALIBR License, and (iii)&#160;initiate a Phase&#160;III clinical trial (or equivalent) for a CALIBR licensed product by the sixth anniversary of the effective date of the CALIBR License. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon entering into the CALIBR License, we made a $1.0&#160;million license fee payment, and are required to make milestone payments in an aggregate amount of up to $26.0&#160;million for each category of CALIBR licensed products. Category 1 is any CALIBR licensed products containing a compound that modulates any muscarinic receptor, and Category 2 is any CALIBR licensed products not included in Category 1 that could differentiate oligodendrocyte precursor cells from <font style="font-style:italic;">in vitro</font> studies and/or are active in animal models relevant to MS. We are also required to pay a mid-single-digit royalty on CALIBR licensed products and a royalty on sub-license revenues ranging from a low-teen percentage to 50%. See &#8220;Business&#8212;License and collaboration agreements&#8212;The Scripps Research Institute (California Institute for Biomedical Research).&#8221; </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The Scripps Research Institute </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2018, we entered into a Research Funding and Option Agreement, or the Scripps option agreement, with Scripps, under which we were granted an exclusive option to acquire an exclusive, sublicensable, worldwide license under certain intellectual property related to the treatment of MS. As consideration for the Scripps option agreement, we are required to make funding payments totaling $0.7 million to Scripps to support its research activities. Scripps has agreed to use reasonable efforts to perform the research program pursuant to the Scripps option agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Scripps option agreement had a one-year term and was renewed for a second year by mutual written agreement.&nbsp;&nbsp;We have the right to terminate by giving 90 days&#8217; advance notice.&nbsp;&nbsp;Scripps has the right to terminate in the event of nonpayment by us that remains uncured for 10 days.&nbsp;&nbsp;Each party has the right to terminate in the event of the other party&#8217;s material breach that remains uncured for 60 days or if the other party becomes bankrupt.  See &#8220;Business&#8212;License and collaboration agreements&#8212;The Scripps Research Institute (California Institute for Biomedical Research).&#8221; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2020, we extended the term of the option agreement through the end of December 2021. As consideration for this extension, we are required to make additional funding payments of $0.6 million to Scripps through December 2021.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have the right to terminate by giving 90 days&#8217; advance notice. Scripps has the right to terminate in the event of nonpayment by us that remains uncured for 10 days. Each party has the right to terminate in the event of the other party&#8217;s material breach that remains uncured for 60 days or if the other party becomes bankrupt.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cambridge Enterprise Limited </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, we entered into an Exclusive Patent License Agreement, or the Cambridge License, with Cambridge, under which we received an exclusive, worldwide, royalty-bearing license to certain patent rights to make, have made, use, sell, offer to sell, and import products, or the Cambridge licensed products, which incorporate licensed technology for the treatment of demyelinating diseases. We also have the right to grant sublicenses under the Cambridge License. Cambridge reserves the right to use for itself (as well as the investors and the funder) and the right to grant nonexclusive licenses to other academic institutions for any academic publication, research and teaching and clinical patient care. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have agreed to use diligent and good faith efforts to develop and commercially exploit at least one Cambridge licensed product. Upon entering into the Cambridge License, we made a $50 thousand license fee payment. We are obligated to pay an annual license fee of $50 thousand. We are also obligated to make milestone payments up to $10.5 million on each Cambridge licensed product. In addition, we have agreed to pay a low single-digit royalty on products that incorporate the licensed patent rights, subject to offset in certain circumstances.  </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Cambridge License continues in effect on a country-by-country basis until the expiration or revocation, without right of further appeal, of all licensed issued patents and filed patent applications, unless terminated earlier. We have the right to terminate for any reason upon 90 days&#8217; prior written notice. Each party has the right to terminate immediately if the other party ceases to carry on its business. Either party may also terminate the Cambridge License for material breach if such breach remains uncured for 30 days. Cambridge may also terminate the Cambridge License if we fail to diligently develop and commercially exploit at least one Cambridge licensed product or we or our affiliates or sub-licensees commence any action against Cambridge to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or not infringed.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comp</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">onents of our results of operations</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have not generated any revenue from product sales and do not expect to generate any revenue from product sales in the foreseeable future. In July 2019, we entered into the Astellas Agreement and received an upfront license fee payment of $80.0 million. In accordance with ASC 606, <font style="font-style:italic;">Revenue Recognition</font>, we are recognizing the $80.0 million as revenue over the period that research and development services and the Phase 2a clinical study for FX-322 are being provided using the input method. For the purpose of revenue recognition, this is the period from execution of the Astellas Agreement to, based on management&#8217;s best estimate, the completion date of the Phase 2a clinical study. In the year ended December 31, 2020, we recognized $37.0 million of the $80.0 million upfront fee as revenue. In the year ended December 31, 2019, we recognized $28.9 million of the upfront fee as revenue. The 2019 amount reflects revenue of $16.0 million equal to the royalty expense under the MIT License as well as $12.9 million from applying the input method to the remaining $64.0 million of the upfront payment.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Royalty</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are required to pay royalties under the MIT License on the receipt of fees for the sublicense of the MIT intellectual property. We expensed the $16.0 million royalty due MIT on the $80.0 million license fee pursuant to the Astellas Agreement in the third quarter of 2019. There were no royalties paid in the year ended December 31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and development expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts and for the development of our product candidate, FX-322. These include the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">salaries, benefits and other related costs, including stock-based compensation expense, for personnel engaged in research and development functions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">expenses incurred under agreements with third parties, including contract research organizations, or CROs, and other third parties that conduct preclinical research and development activities and clinical trials on our behalf; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">costs to manufacture our clinical trial material for use in our preclinical studies and clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">costs of outside consultants, including their fees and related travel expenses; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">costs of laboratory supplies and acquiring, developing and manufacturing preclinical study and clinical trial materials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">option and license payments made to third parties, including MIT, Scripps, MEE and Cambridge, for intellectual property used in research and development activities; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">facility-related expenses, which include direct depreciation costs and expenses for rent and maintenance of facilities and other operating costs if specifically, identifiable to research activities. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expense research and development costs as incurred. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We track external research and development costs, including the cost of services, outsourced research and development, clinical trials, contract manufacturing, laboratory equipment and maintenance, and certain other development costs, by product candidate when the costs are specifically identifiable to a product candidate. Internal and external costs associated with infrastructure resources, other research and development costs, facility-related costs, and depreciation and amortization that are not identifiable to a specific product candidate are included in the platform development, early-stage research, and unallocated expenses category in the table below. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our research and development expenses by product candidate or development program for the years ended December&#160;31, 20</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and 2019</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">: </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ended December 31</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.56%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct research and development expenses by</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; product candidate:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FX-322 external development costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,392</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,294</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.56%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Platform development, early-stage research</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; and unallocated expenses:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee-related costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,140</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,249</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory supplies</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">388</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">395</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outsourced research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,694</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,241</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facility-related costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,392</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,155</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">759</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">450</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other research and development costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,650</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.56%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Platform development, early-stage research and unallocated expenses total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,023</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,490</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.56%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,415</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,784</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.56%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that our research and development expenses will continue to increase substantially for the foreseeable future as we complete our Phase 2a clinical trial and additional clinical trials for FX-322 and continue to discover and develop additional product candidates. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to increased scale, duration and the higher costs associated with later stage clinical trials. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot determine with certainty the duration and costs of future clinical trials of FX-322 or any other product candidate we may develop or if, when, or to what extent we will generate revenue from the commercialization and sale of any product candidate for which we obtain marketing approval. The duration, costs, and timing of clinical trials and development of FX-322 and any other product candidate we may develop will depend on a variety of factors, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the scope, rate of progress, expense and results of clinical trials of FX-322, as well as of any future clinical trials of other product candidates and other research and development activities that we may conduct; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the actual probability of success for our product candidates, including their safety and efficacy, early clinical data, competition, manufacturing capability, and commercial viability; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">significant and changing government regulation and regulatory guidance; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the timing and receipt of any marketing approvals; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the progress of the development efforts of parties with whom we may enter into collaboration agreements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability to secure manufacturing supply through relationships with third parties; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the commercialization of our product candidates, if and when approved; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the expense of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">General and administrative expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in our executive, finance, business development, and administrative functions. General and administrative expenses also include legal fees relating to intellectual property and corporate matters; professional fees for accounting, auditing, tax and consulting services; insurance costs; travel expenses; and facility-related expenses, which </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">include direct depreciation costs and expenses for rent and maintenance of facilities, and other operating costs that are not specifically attributable to research and development activities. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that our general and administrative expenses will increase in the future as we increase our personnel headcount to support our continued research activities and development of product candidates. In addition, due to our IPO in October 2019, we expect to incur increased expenses associated with being a public company, including costs of accounting, audit, legal, regulatory, and&#160;tax-related&#160;services associated with maintaining compliance with the requirements of The Nasdaq Stock Market LLC and the SEC; director and officer insurance costs; and investor and public relations costs. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Interest income </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income consists of interest earned on cash equivalents and short-term investments. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Realized gain on investments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Realized gain on investments represents the gain realized on our marketable securities in the years ended December 31, 2020 and 2019. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Foreign exchange (loss) gain </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign exchange (loss) gain represents the gain or loss recorded as a result of remeasuring the financial statements of our foreign subsidiaries. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income taxes </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception in 2014, we have generated cumulative federal and state net operating loss and research and development credit carryforwards for which we have not recorded any net tax benefit due to uncertainty around utilizing these tax attributes within the respective carryforward periods. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, we had federal net operating loss carryforwards of approximately $67,868 and Massachusetts state operating loss carryforwards of approximately $43,386&#160;which may be available to offset future taxable income. The U.S. federal net operating loss carryforwards include $22,400 available to reduce future taxable income through 2037 and approximately $45,469 which do not expire and are available to reduce future taxable income indefinitely. The state net operating loss carryforwards are available to offset future taxable income through 2040. As of December&#160;31, 2020, we also had federal and Massachusetts research and development tax credit carryforwards of $3,014 and $1,211, respectively, which are available to offset federal and state tax liabilities through 2040 and 2035, respectively. Realization of future tax benefits is dependent on many factors, including our ability to generate taxable income within the net operating loss carryforward period. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as provided under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, respectively, as well as similar state provisions. These ownership changes may limit the number of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section&#160;382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a three-year period. We have completed several financings and have conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception and have determined that an ownership change did occur in March 2017. Accordingly, utilization of $12,400 of the U.S. net operating loss carryforwards which were incurred prior to March 2017 (pre-ownership change) is limited under Section 382. After the Section 382 limitations, we may utilize approximately $10,800 of our pre-ownership change net operating loss carryforwards based upon an annual usage of approximately $1,600 for each of the next five years after the ownership change and approximately $180 for each of the 15 years thereafter. The remaining pre-ownership change net operating losses of approximately $1,600 were written off due to expiration under limitation. The limitation has been determined by first multiplying the value of our stock at the time of the ownership change by the applicable long-term tax-exempt rate. These carryforwards may be subject to further annual limitations under Section&#160;382 in the event of future changes in ownership.&nbsp;&nbsp;Additionally, we have determined an ownership changed occurred in October of 2019 as a result of the IPO.&nbsp;&nbsp;Accordingly, utilization of approximately $46,123 of the U.S. net operating loss carryforwards incurred prior to October 2019 is also limited under Section 382.&nbsp;&nbsp;We have determined we will be able to utilize the entire $46,123 of our pre-ownership change net operating loss carryforwards based upon the limitations calculated from the October 2019 ownership change. These carryforwards may be subject to further annual limitations under Section 382 in the event of future changes in ownership.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Results of operations </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comparison of years ended December 31, 2020 and 2019 </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our results of operations for the years ended December 31, 2020 and 2019: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Increase</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Decrease)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in&#160;thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,984</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,947</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,037</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalty</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,415</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,784</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,631</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,119</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,838</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,281</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,534</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,622</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,912</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,550</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,675</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,875</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">994</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,784</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(790</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Realized gain on investments</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(54</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign exchange (loss) gain</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss before income taxes</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,476</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,746</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,730</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income taxes</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(35</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(35</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,511</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,746</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,765</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue was $37.0 million for the year ended December 31, 2020 compared to $28.9 million for the year ended December 31, 2019. In July 2019, we entered into the Astellas Agreement and received an upfront license fee payment of $80.0 million. In accordance with ASC 606, we are recognizing the $80.0 million as revenue over the period that research and development services and the Phase 2a clinical study for FX-322 are being provided using the input method. In the year ended December 31, 2020, we recognized revenue of $37.0 million applying the input method to the upfront payment. In the year ended December 31, 2019 we recognized revenue of $28.9 million applying the input method to the upfront payment. We expect to recognize the remaining revenue under the Astellas Agreement in 2021. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Royalty Expense</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are required to pay royalties under the MIT License on the receipt of fees for the sublicense of the MIT intellectual property. In the year ended December 31, 2019, we expensed the $16.0 million royalty due MIT on the $80.0 million upfront fee received from Astellas. No royalties were due in the year ended December 31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and development expenses </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Increase</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Decrease)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in&#160;thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct research and development expenses by product</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; candidate:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FX-322 external development costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,392</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,294</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,098</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Platform development, early-stage research and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; unallocated expenses:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee-related costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,140</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,249</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,891</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory supplies</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">388</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">395</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outsourced research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,694</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,241</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,453</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facility-related costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,392</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,155</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">237</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">759</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">450</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">309</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other research and development costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,650</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,650</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Platform development, early-stage research and unallocated expenses total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,023</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,490</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,533</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,415</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,784</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,631</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses for the year ended December 31, 2020 were $37.4 million, compared to $18.8 million for the year ended December 31, 2019. The increase of $18.6 million was primarily due to an increase of $13.5 million in platform development, early-stage research and unallocated expenses and an increase of $5.1 million in FX-322 external research and development costs. </p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The $9.4 million of FX-322 external development costs incurred for the year ended December 31, 2020 consisted primarily of $8.9 million of clinical and development costs associated with the Phase 2a and other related clinical trials of FX-322, including $2.2 million related to drug manufacturing and development, and $0.4 million of third party consulting costs. T<font style="color:#000000;">he $4.3&#160;million of FX-322 external development costs incurred for the year ended December 31, 2019 consisted primarily of $2.1&#160;million of clinical development costs including manufacturing costs for FX-322 to be used in clinical trials, $0.7 million of outside consulting costs, $1.1 million in clinical trial costs and $0.3 million in milestone payments under the MIT License.</font></p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The $28.0 million of platform development, early-stage research and unallocated expenses incurred for the year ended December 31, 2020 consisted primarily of $17.1 million of employee-related costs, including $4.0 million of stock compensation expense, $6.7 million of outsourced research and development expense, and $1.7 million of other research and development costs. This increase of $13.5 million from the year ended December 31, 2019 is primarily attributable to an increase of $8.9 million in employee-related expenses associated with increased headcount to support pre-clinical and clinical development of FX-322 and research on our PCA platform developments and a $1.7 million increase in other research and development expenses, primarily related to consulting on programs excluding FX-322.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">General and administrative expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses were $27.1 million for the year ended December 31, 2020, compared to $14.8 million for the year ended December 31, 2019. General and administrative expenses increased $12.3 million due to an increase of $8.0 million in employee-related costs, including $4.1 million in stock compensation expense, as we increase our general and administrative headcount to manage our growth and the impact of being a public company, and increases of $2.3 million and $1.4 million in directors and officers insurance and public relations expense, respectively. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Interest income </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income was $1.0 million for the year ended December 31, 2020 compared to $1.8&#160;million for the year ended December 31, 2019, due to a decrease in interest rates in the current year. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Realized gain on investments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Realized gain on investments was $84 thousand for the year ended December 31, 2020 compared to $138 thousand for the year ended December 31, 2019 due to a decrease in interest rates in the current year. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Foreign exchange (loss) gain</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign exchange loss was $4 thousand for the year ended December 31, 2020 compared to a gain of $7 thousand for the year ended December 31, 2019. The decrease of $11 thousand was due to differences in foreign exchange remeasurement of the financial statements of our foreign subsidiaries. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and capital resources </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception, we have incurred significant operating losses. We expect to continue to incur significant expenses and operating losses for the foreseeable future as we advance the preclinical and clinical development of our product candidates. We expect that our research and development and general and administrative costs will continue to increase, including in connection with conducting preclinical studies and clinical trials for our product candidates, contracting with contract manufacturing organizations, or CMOs, to support preclinical studies and clinical trials, expanding our intellectual property portfolio, and providing general and administrative support for our operations particularly as we continue to operate as a public company. As a result, we will need additional capital to fund our operations, which we may obtain from additional equity or debt financings, collaborations, licensing arrangements or other sources. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not currently have any approved products and have never generated any revenue from product sales. We have financed our operations primarily through proceeds from the sale of our convertible notes, convertible preferred stock, our IPO, our Private Placement, the upfront payment under the Astellas Agreement, and a Term Loan. To date, we have raised approximately $376.9&#160;million through a combination of convertible notes, convertible preferred stock, the upfront payment under the Astellas Agreement, grants, the IPO, our Private Placement, option exercises and Term Loan. Our cash, cash equivalents and short-term investments totaled $220.3 million as of December 31, 2020. As of December 31, 2020, we had $15.0 million of debt related to the Term Loan.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash flows </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our sources and uses of cash for the periods presented: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in&#160;thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash (used in) provided by operating activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,188</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,216</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in) investing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,402</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,261</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,688</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142,015</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase in cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,902</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">157,970</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash flows for the year ended December 31, 2020 </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Operating activities </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used by operating activities for the year ended December 31, 2020 was $45.2 million, consisting of a net loss of $26.5 million as we incurred expenses associated with our FX-322 program, platform development and early-stage research, and general and administrative expenses. In addition, we had non-cash charges of $11.6&#160;million for depreciation, stock-based compensation expense, and non-cash lease expense. Net cash used in operating activities was also impacted by a net $30.2 million decrease in operating assets and liabilities, including a decrease of $37.0&#160;million in deferred revenues from the upfront payment under the Astellas Agreement, and increases in accounts payable, accrued expenses and prepaid expense and other current assets of $4.3 million, $3.1 million, and $0.6 million, respectively.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Investing activities </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by investing activities for the year ended December 31, 2020 was $10.4 million, which was attributable to $43.4 million of redemptions of available for sale securities, partially offset by $26.3 million of available for sale securities and $6.7 million of purchases of property and equipment, $2.6 million of which is related to the buildout of the Company&#8217;s new Lexington office.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Financing activities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities for the year ended December 31, 2020 was $56.7 million, primarily attributable to $40.1 million in net proceeds from the July 2020 Private Placement, $15.0 million in proceeds from the Term Loan, and $1.5 million in proceeds from the exercise of stock options.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash flows for the year ended December&#160;31, 2019 </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Operating activities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by operating activities for the year ended December 31, 2019 was $34.2&#160;million, primarily consisting of a net loss of $18.7&#160;million as we incurred expenses associated with our FX-322 program, platform development and early-stage research, and general and administrative expenses. In addition, we had non-cash charges of $4.3&#160;million primarily for depreciation, stock-based compensation expense and deferred lease incentives. Net cash used in operating activities was also impacted by a net $48.7 million change in operating assets and liabilities, including an increase of $51.1&#160;million in deferred revenues from the upfront payment under the Astellas Agreement and a $1.5 million increase accrued expenses,&#160;which were partially offset by an increase of $3.3&#160;million in prepaid expenses and other current assets and a $.6 million decrease in accounts payable. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Investing activities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities for the year ended December 31, 2019 was $18.3&#160;million, which was attributable to $1.1 million of purchases of property and equipment and $17.2 million of net purchases of marketable securities. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Financing activities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities for the year ended December 31, 2019 was $142.0&#160;million, consisting of proceeds from our IPO of $79.7 million, the issuance of our Series C convertible preferred stock of $61.7 million, the issuance of additional shares of our Series B convertible preferred stock of $0.3 million, and $0.3 million of proceeds from the exercise of stock options. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Funding requirements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operating expenses increased substantially in the years ended December 31, 2020 and 2019 and are expected to increase substantially in the future in connection with our ongoing activities, particularly as we advance FX-322 through clinical trials and as we research and develop additional product candidates including preclinical activities, studies for INDs, and initiation of human clinical trials. In addition, we expect to incur additional general and administrative costs to build the infrastructure necessary to manage the growth of our research and development efforts and the increased costs associated with operating as a public company. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Specifically, our costs and expenses will increase as we: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">advance the clinical development of FX-322; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">pursue the preclinical and clinical development of other product candidates using our PCA platform, including our program for the treatment of MS; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">in-license or acquire the rights to other products, product candidates or technologies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">maintain, expand, and protect our intellectual property portfolio; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">hire additional personnel in research, manufacturing, and regulatory and clinical development, as well as management personnel; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">expand our operational, financial, investor relations, and management systems and increase personnel, including personnel to support our operations as a public company. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that our existing cash, cash equivalents, and short-term investments, will enable us to fund our operating expenses and capital expenditure requirements into 202</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. We have based this estimate on assumptions that may prove to be incorrect, and we could utilize our available capital resources sooner than we expect. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the numerous risks and uncertainties associated with the research, development, and commercialization of therapeutics, it is difficult to estimate with certainty the amount of our working capital requirements. Our future funding requirements will depend on many factors, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the progress, costs, and results of our clinical development and clinical trials for FX-322; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the progress, costs, and results of our additional research and preclinical development programs, including our program for the treatment of MS; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the outcome, timing and cost of meeting regulatory requirements established by the FDA and comparable foreign regulatory authorities, if applicable, for our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the costs and timing of internal process development, manufacturing activities, and clinical trial management associated with FX-322 and other product candidates we advance through preclinical and clinical development; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability to establish and maintain strategic collaborations, licensing or other agreements and the financial terms of such agreements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the scope, progress, results, and costs of any product candidates that we may derive from our PCA platform or any other product candidates we may develop alone or with collaborators; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the extent to which we in-license or acquire rights to other products, product candidates, or technologies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">additions or departures of key scientific or management personnel; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the costs and timing of preparing, filing, and prosecuting patent applications, maintaining and protecting our intellectual property rights, and defending against any intellectual property-related claims; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales, and distribution for any product candidates for which we or our collaborators obtain marketing approval. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our cash needs through a combination of public or private equity or debt financings and other sources, which may include current and new collaborations with third parties. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through other sources, such as collaboration agreements, strategic alliances, licensing arrangements or marketing and distribution arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, product development, and research programs or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce, or terminate our product development or future commercialization efforts or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual obligations and commitments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of our contractual obligations and commitments as of December&#160;31, 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Payments due by period (in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Less than</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1 year</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1 - 3 years</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> 4 - 6 years</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">More than</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6 years</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease obligations (1)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,456</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,986</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,855</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,048</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,567</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Represents future minimum lease payments under our operating leases for office and laboratory space at our Woburn, Massachusetts,<font style="font-size:12pt;"> </font>Lexington, Massachusetts and Farmington, Connecticut facilities (see Note 17 of notes to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K for additional information on these lease agreements). </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not included future milestone payments under our collaboration and license agreements in the table above since the payment obligations under these agreements are contingent upon future events, such as the achievement of specified product development milestones or generating product sales, and we are unable to estimate the timing or likelihood of achieving these milestones or generating future product sales. We are also required to spend certain minimum amounts on research and development of licensed products or processes under the MIT License, and may have certain funding obligations under the Scripps option agreement, which are not included in the table above. See &#8220;&#8212;License and collaboration agreements&#8221; for more information regarding our payment obligations under these agreements. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also enter into contracts in the normal course of business with CROs, CMOs, universities, and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts generally do not contain minimum purchase commitments and are cancelable by us upon prior written notice although, purchase orders for clinical materials are generally non-cancelable. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including noncancelable obligations of our service providers, up to the date of cancellation or upon completion of a manufacturing run. These payments are not included in the table above as the amount and timing of such payments are not known or are not material.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Critical accounting policies and use of estimates </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our audited consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, revenue, costs and expenses, and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events, and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While our significant accounting policies are described in more detail in the notes to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue recognition</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We account for contracts with customers in accordance with Accounting Standards Codification (&#8220;ASC&#8221;), Topic 606, <font style="font-style:italic;">Revenue from Contracts with Customers</font> (&#8220;ASC 606&#8221;), including all amendments thereto. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as collaborative arrangements and leases. Our disclosure in the accompanying consolidated financial statements reflects the Company&#8217;s accounting policies in compliance with this standard.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under ASC 606, an entity recognizes revenue when or as its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To recognize revenue for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies its performance obligations. We only apply the five-step model to contracts when it is probable that the entity will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services it transfers to the customer. Once a contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract and identifies as a performance obligation each promise to transfer to the customer either (a) a good or service (or bundle of goods and services) that is distinct, or (b) a series of distinct goods and services that are substantially the same and have been the same pattern of transfer to the customer.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We assess whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i)&#160;the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii)&#160;the entity&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract). In assessing whether a promised good or service is distinct, we consider factors such as the research, manufacturing and commercialization capabilities of the collaboration partner (the &#8220;customer&#8221; in this type of arrangement) and the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">availability of the associated expertise in the general marketplace. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> also consider the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct. For each arrangement that results in revenues, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> identif</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">y</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> all performance obligations, which may include, for example, a license to IP and know-how, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">research</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and development activities, and/or manufacturing services. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to any upfront payment, if the consideration promised in a contract includes a variable amount, we estimate the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. We determine the amount of variable consideration by using the expected value method or the most likely amount method. We include the estimated variable consideration in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, we re-evaluate the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an arrangement includes development and regulatory milestone payments, we evaluate whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. If it is probable that a significant revenue reversal will not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our control or of the licensee such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each subsequent reporting period, we re-evaluate the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For contracts that include sales-based royalties (including milestone payments based on the level of sales) promised in the exchange for licenses of intellectual property, and the license is deemed to be the predominant item to which the royalties relate, we recognize royalty revenue and sales-based milestone payments at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied. In determining the transaction price, we adjust the promised amount of consideration for the effects of the time value of money if the timing of payments provides the Company or the Company&#8217;s customer with a significant benefit of financing the transfer of goods and services. We do not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. We assess each of its revenue generating arrangements in order to determine whether a significant financing component exists. We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time.&nbsp;&nbsp;For performance obligations satisfied over time, we measure progress toward completion of its performance obligations using an input method based on our efforts and inputs to satisfy its performance obligations relative to total expected inputs to the satisfaction of that performance obligation.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts received from a customer prior to revenue recognition are recorded as deferred revenue. Amounts received from a customer that are expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability in the accompanying consolidated balance sheets.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accrued research and development expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf, and estimating the level of service performed and the associated costs incurred for the services when we have not yet been invoiced or otherwise notified of the actual costs. Most of our service providers invoice us in arrears for services performed, on a&#160;pre-determined&#160;schedule or when contractual milestones are met; however, some require advance payments. We make estimates of our accrued expenses as of each balance sheet date in our consolidated financial statements based on facts and circumstances known to us at that time. Examples of estimated accrued research and development expenses include fees paid to the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>CROs and other third parties in connection with performing research and development activities and conducting preclinical studies and clinical trials on our behalf;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vendors in connection with preclinical development activities; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>CMOs and other vendors in connection with product manufacturing and development and distribution of preclinical supplies.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We base our expenses related to preclinical studies on our estimates of the services received and efforts expended pursuant to quotes and contracts with CROs that conduct and manage preclinical studies and clinical trials and CMOs that manufacture product for our research and development activities on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. In accruing fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or amount of prepaid expense accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may cause us to report amounts that are too high or too low in any particular period. To date, we have not made any material adjustments to our prior estimates of accrued research and development expenses.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company elected to early adopt ASC 842, <font style="font-style:italic;">Leases</font>, as of January 1, 2020 and elected the transition method under ASU 2016-02 whereby the Company records a right-to-use asset and a lease liability on the consolidated balance sheet for all leases with terms longer than 12 months. The Company also elected to apply the package of practical expedients intended to ease transition. Accordingly, the Company has only applied ASC 842 to leases existing at January 1, 2020. The Company determines if an arrangement is, or contains, a lease at inception. Operating leases are included in operating lease right-of-issue (&#8220;ROU&#8221;) assets, other current liabilities, and operating lease liabilities on the consolidated balance sheets.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments to be made over the lease term. The ROU asset also includes any lease payments made at or before the lease commencement date and excludes lease incentives received. As the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected to not apply the recognition requirements of ASC 842 for short-term leases, which is defined as a lease that, at the lease commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For real estate lease agreements entered into or modified after the adoption of ASC 842 that include lease and non-lease components, the Company has elected to account for the lease and non-lease components, such as common area maintenance charges, as a single lease component.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-based compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We measure stock options and other stock-based awards granted to our employees, directors, consultants, advisors based on the fair value on the date of the grant, awards, net of actual forfeitures, over the requisite service period, which is generally the vesting period of the respective award. For stock-based awards granted to&#160;non-employees,&#160;compensation expense is recognized over the period during which services are rendered by such&#160;non-employees&#160;until completed.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We estimate the fair value of each stock option grant on the date of grant using the Black-Scholes option-pricing model, which uses as inputs the fair value of our common stock and assumptions we make for the volatility of our common stock, the expected term of our stock options, the risk-free interest rate for a period that approximates the expected term of our stock options, and our expected dividend yield.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Determination of fair value of common stock</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the IPO, there had been no public market for our common stock and as such, the estimated fair value of our common stock had been determined by our board of directors as of the date of each option grant, with input from management, taking into consideration our most recently available third-party valuations of common stock at the time of the grants, as well as our board of directors&#8217; assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. Third-party valuations, or valuation reports, were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide,&#160;Valuation of Privately-Held-Company Equity Securities Issued as Compensation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock valuation reports were prepared using a market approach, utilizing either the guideline M&amp;A or guideline public company methodologies. Under the guideline M&amp;A methodology, a set of mergers and acquisitions within the biotechnology and pharmaceutical industries for similar stage companies were reviewed and an applicable equity value was selected to apply to our company. Under the guideline public company methodology, the market capitalizations of similar public companies were analyzed, and an applicable capitalization for our company was selected based on qualitative and quantitative factors.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For each valuation report, an option pricing allocation method, or OPM, was selected to allocate the total equity value across the various securities outstanding at the time of the valuation. The OPM treats common stock and preferred stock as call options on the total equity value of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a company&#8217;s securities changes. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to considering the results of the valuation reports, our board of directors considered various objective and subjective factors to determine the fair value of our common stock as of each grant date, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the prices at which we sold shares of convertible preferred stock and the superior rights and preferences of the convertible preferred stock relative to our common stock at the time of each grant;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the progress of our research and development programs, including the status and results of preclinical studies and clinical trials for our product candidates;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our stage of development and commercialization and our business strategy;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>external market conditions affecting the biotechnology industry and trends within that industry;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our financial position, including cash on hand, and our historical and forecasted performance and operating results;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the lack of an active public market for our common stock and our convertible preferred stock;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the likelihood of achieving a liquidity event, such as an initial public offering, or IPO, or sale of our company considering prevailing market conditions; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the analysis of IPOs and the market performance of similar companies in the biotechnology industry.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumptions underlying these valuations represented management&#8217;s best estimate, which involved inherent uncertainties and the application of management&#8217;s judgment. As a result, if we had used different assumptions or estimates, the fair value of our common stock and our stock-based compensation expense could have been materially different.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recent accounting pronouncements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A description of recent accounting pronouncements that may potentially impact our financial position, results of operations, or cash flows is disclosed below:</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13, <font style="font-style:italic;">Financial Instruments - Credit Losses</font> (Topic 326): Measurement of Credit Losses on Financial Instruments. The FASB has subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">previously recognized credit losses if fair value increases. This standard will become effective for the Company on January 1, 2023. The Company is still evaluating the impact of this standard on its consolidated financial statements.</font><font style="font-size:12pt;color:#000000;">&#160;</font><font style="color:#000000;"> </font><font style="color:#000000;"> </font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued&#160;<font style="color:#000000;">ASU 2019-12</font>&#160;amending accounting guidance that simplifies the accounting for income taxes, as part of its initiative to reduce complexity in the accounting standards. The amendments eliminate certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The amendments also clarify and simplify other aspects of the accounting for income taxes. This standard will become effective for the Company on January 1, 2021. The Company is still evaluating the impact of this standard on its consolidated financial statements.<font style="font-size:12pt;color:#000000;">&#160;</font><font style="color:#000000;">   </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are no other recent accounting pronouncements that we believe will have a material impact on our consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Off-balance sheet arrangements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under SEC rules. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"></a><a name="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"></a>Item 7A. Quantitative and Qualitative Disclosures About Market Risk. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities. Our interest-earning assets consist of cash, cash equivalents and short-term investments, which are denominated in U.S. dollars. We had cash, cash equivalents and short-term investments of $220.3 million, or 83.2% of our total assets, at December 31, 2020. Interest income earned on these assets was $1.0 million for the year ended December 31, 2020. Our interest income is sensitive to changes in the general level of interest rates, primarily U.S. interest rates. Such interest-earning instruments carry a degree of interest rate risk however, if a change by 10% in interest rates were to have immediately occurred on December 31, 2020, such change would not have had a material impact on our financial position or results of operations. We had $15.0 million of debt outstanding as of December 31, 2020.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"></a><a name="ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"></a>Item 8. Financial Statements and Supplementary Data. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our consolidated financial statements, together with the reports of our independent registered public accounting firms, appear at pages&#160;F-1 through F-33 of this Annual Report on Form&#160;10-K for the year ended&#160;December&#160;31, 2020. An index of those financial statements is found in Item 15 of Part IV of this Annual Report on Form 10-K.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"></a>Item 9. Changes in and Disagreements with<a name="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"></a> Accountants on Accounting and Financial Disclosure.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9A_CONTROLS_PROCEDURES"></a><a name="ITEM_9A_CONTROLS_PROCEDURES"></a>Item 9A. Controls and Procedures. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Evaluation of Disclosure Controls and Procedures</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We maintain &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is (1) recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms and (2) accumulated and communicated to our management, including our principal executive and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their control objectives.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer (our principal executive officer and principal financial officer, respectively), evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2020. Based on the evaluation of our disclosure controls and procedures as of December 31, 2020, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Management&#8217;s Annual Report on Internal Control Over Financial </font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Reporting</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with policies or procedures may deteriorate. Our internal control over financial reporting is a process designed under the supervision of our principal executive officer and principal financial officer to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our financial statements for external reporting purposes in accordance with U.S. generally accepted accounting principles.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management, with the participation of Chief Executive Officer and Chief Financial Officer (our principal executive officer and principal financial officer, respectively), conducted an evaluation of the effectiveness of our internal control over financial reporting based on the criteria set forth in &#8220;Internal Control &#8211;Integrated Framework (2013)&#8221; issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, management concluded that our internal control over financial reporting was effective as of December 31, 2020.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Changes in Internal Control over Financial Reporting</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There was no change in our internal control over financial reporting that occurred during the period covered by this Annual Report on Form 10-K that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9B_OR_INFORMATION"></a><a name="ITEM_9B_OR_INFORMATION"></a>Item 9B. Other Information. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None</p><a name="_AEIOULastRenderedPageBreakAEIOU9"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_III"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_III"></a>PART </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">III </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"></a><a name="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"></a>Item 10. Directors, Executive Officers and Corporate Governance. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item 10 will be included in our Definitive Proxy Statement to be filed with the SEC with respect to our 2021 Annual Meeting of Stockholders and is incorporated herein by reference.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_11_EXECUTIVE_COMPENSATION"></a><a name="ITEM_11_EXECUTIVE_COMPENSATION"></a>Item 11. Executive Compensation. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item 11 will be included in our Definitive Proxy Statement to be filed with the SEC with respect to our 2021 Annual Meeting of Stockholders and is incorporated herein by reference.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"></a><a name="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"></a>Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item 12 will be included in our Definitive Proxy Statement to be filed with the SEC with respect to our 2021 Annual Meeting of Stockholders and is incorporated herein by reference.<font style="color:#000000;">&nbsp;&nbsp;</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"></a><a name="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"></a>Item 13. Certain Relationships and Related Transactions, and Director Independence. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item 13 will be included in our Definitive Proxy Statement to be filed with the SEC with respect to our 2021 Annual Meeting of Stockholders and is incorporated herein by reference.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"></a><a name="ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"></a>Item 14. Principal Accounting Fees and Services. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item 14 will be included in our Definitive Proxy Statement to be filed with the SEC with respect to our 2021 Annual Meeting of Stockholders and is incorporated herein by reference<font style="color:#000000;">. </font></p><a name="_AEIOULastRenderedPageBreakAEIOU10"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_IV"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_IV"></a>PART</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> IV</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"></a><a name="ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"></a>Item 15. Exhibits, Financial Statement Schedules. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(1) Financial Statements</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following documents are included on pages F-1 through F-33 attached hereto and are filed as part of this Annual Report on Form 10-K.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:92.36%;"></td>
<td style="width:0.48%;"></td>
<td style="width:7.16%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"><font style="text-decoration:underline;">Report of an Independent Registered Public Accounting Firm</font></a></p></td>
<td colspan="2" valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consolidated financial statements As of December 31, 2020 and 2019</p></td>
<td colspan="2" valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_BALANCE_SHEETS"><font style="text-decoration:underline;">Consolidated balance sheets</font></a></p></td>
<td colspan="2" valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_OPERATIONS"><font style="text-decoration:underline;">Consolidated statements of operations</font></a></p></td>
<td colspan="2" valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_COMPREHENSIVE_LO"><font style="text-decoration:underline;">Consolidated statements of comprehensive income</font></a></p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENT_CONVERTIBLE_PREFE"><font style="text-decoration:underline;">Consolidated statements of convertible preferred stock, non-controlling interest and stockholders&#8217; deficit</font></a></p></td>
<td colspan="2" valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CASH_FLOWS"><font style="text-decoration:underline;">Consolidated statements of cash flows</font></a></p></td>
<td colspan="2" valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"><font style="text-decoration:underline;">Notes to consolidated financial statements</font></a></p></td>
<td colspan="2" valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-8</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(2) Financial Statement Schedules:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the Consolidated Financial Statements or the Notes thereto set forth below beginning on page F-1.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(3) Exhibits.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a list&#160;of&#160;exhibits filed as part of this Annual Report on Form 10-K.<font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:7.62%;"></td>
<td style="width:0.66%;"></td>
<td style="width:39.91%;"></td>
<td style="width:0.83%;"></td>
<td style="width:8.59%;"></td>
<td style="width:0.96%;"></td>
<td style="width:11.49%;"></td>
<td style="width:1.68%;"></td>
<td style="width:8.79%;"></td>
<td style="width:0.95%;"></td>
<td style="width:9.03%;"></td>
<td style="width:1.38%;"></td>
<td style="width:7.91%;"></td>
<td style="width:0.2%;"></td>
</tr>
<tr>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #FFFFFF;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #FFFFFF;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="9" valign="bottom"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated&#160;by&#160;Reference</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;Description</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #FFFFFF;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #FFFFFF;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File&#160;No.</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filing</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed/</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Furnished</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Herewith</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;3.1</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519263787/d796545dex31.htm"><font style="text-decoration:underline;">Restated Certificate of Incorporation of Frequency</font></a><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519263787/d796545dex31.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519263787/d796545dex31.htm"><font style="text-decoration:underline;"> Therapeutics, Inc.</font></a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-39062</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/7/19</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;3.2</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519263787/d796545dex32.htm"><font style="text-decoration:underline;">Amended and Restated Bylaws of Frequency</font></a><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519263787/d796545dex32.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519263787/d796545dex32.htm"><font style="text-decoration:underline;"> Therapeutics, Inc.</font></a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-39062</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9/25/20</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;4.1</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex41.htm"><font style="text-decoration:underline;">Form of Specimen Common Stock Certificate</font></a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-233652</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9/23/19</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;4.2</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519239976/d72917dex42.htm"><font style="text-decoration:underline;">Second Amended and Restated Investors&#8217;</font></a><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519239976/d72917dex42.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519239976/d72917dex42.htm"><font style="text-decoration:underline;"> Rights Agreement, dated as of July 17, 2019</font></a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-233652</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9/6/19</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;4.3 </p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1703647/000119312520293921/d67863dex43.htm"><font style="text-decoration:underline;">Form of Indenture</font></a><font style="text-decoration:underline;"> </font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-3</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-250099</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/16/20</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;4.4</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1703647/000156459020012977/freq-ex43_875.htm"><font style="text-decoration:underline;">Description of Frequency Therapeutics, Inc. Securities</font></a><font style="text-decoration:underline;"> </font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-39062</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/26/20</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1<font style="color:#000000;">&#8224;</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1703647/000119312519239976/d72917dex101.htm"><font style="text-decoration:underline;">2014 Stock Incentive Plan, as amended and form of option agreements thereunder</font></a><font style="text-decoration:underline;"> </font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-233652</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9/6/19</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2<font style="color:#000000;">&#8224;</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex102.htm"><font style="text-decoration:underline;">2019 Incentive Award Plan and form of option</font></a><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex102.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex102.htm"><font style="text-decoration:underline;"> agreements thereunder</font></a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-233652</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9/23/19</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3<font style="color:#000000;">&#8224;</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex103.htm"><font style="text-decoration:underline;">Non-Employee Director Compensation Program</font></a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-233652</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9/23/19</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex105.htm"><font style="text-decoration:underline;">Form of Indemnification Agreement for Directors</font></a><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex105.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex105.htm"><font style="text-decoration:underline;"> and Officers</font></a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-233652</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9/23/19</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:7.62%;"></td>
<td style="width:0.66%;"></td>
<td style="width:39.91%;"></td>
<td style="width:0.83%;"></td>
<td style="width:8.59%;"></td>
<td style="width:0.96%;"></td>
<td style="width:11.49%;"></td>
<td style="width:1.68%;"></td>
<td style="width:8.79%;"></td>
<td style="width:0.95%;"></td>
<td style="width:9.03%;"></td>
<td style="width:1.38%;"></td>
<td style="width:7.91%;"></td>
<td style="width:0.2%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk32847514"></a>10.5.1</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1703647/000156459020012977/exhibit10_51.htm"><font style="text-decoration:underline;">Lease Agreement, dated as of August 24, 2016, as amended, between ARE-MA Region No. 20 and Frequency Therapeutics, Inc. </font></a><font style="text-decoration:underline;"> </font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-39062</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5.1</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/26/20</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5.2</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1703647/000119312520319143/d44798dex101.htm"><font style="text-decoration:underline;">Agreement for Termination of Lease and Voluntary Surrender of Premises, dated as of December 11, 2020, between ARE-MA Region No. 20 and Frequency Therapeutics, Inc. </font></a><font style="text-decoration:underline;"> </font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-39062</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12/16/20</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex107.htm"><font style="text-decoration:underline;">Second Amended and Restated Executive</font></a><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex107.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex107.htm"><font style="text-decoration:underline;"> Employment Agreement, dated as of September</font></a><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex107.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex107.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex107.htm"><font style="text-decoration:underline;"> 20, 2019, between David L. Lucchino and</font></a><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex107.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex107.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex107.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex107.htm"><font style="text-decoration:underline;"> Frequency Therapeutics, Inc.</font></a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-233652</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9/23/19</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1703647/000119312519239976/d72917dex1010.htm"><font style="text-decoration:underline;">Exclusive Patent License Agreement, dated as of December 13, 2016, as amended, between Massachusetts Institute of Technology and Frequency Therapeutics, Inc.</font></a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-233652</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.10</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9/6/19</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.8</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1703647/000119312519239976/d72917dex1011.htm"><font style="text-decoration:underline;">Non-Exclusive Patent License Agreement, dated as of February 7, 2019, between Massachusetts Eye and Ear Infirmary and Frequency Therapeutics, Inc.</font></a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-233652</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.11</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9/6/19</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk32847805"></a>10.9</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519239976/d72917dex1012.htm"><font style="text-decoration:underline;">License and Collaboration Agreement, dated as of</font></a><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519239976/d72917dex1012.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519239976/d72917dex1012.htm"><font style="text-decoration:underline;"> July 16, 2019, between Astellas Pharma, Inc. and</font></a><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519239976/d72917dex1012.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519239976/d72917dex1012.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519239976/d72917dex1012.htm"><font style="text-decoration:underline;"> Frequency Therapeutics, Inc.</font></a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-233652</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.12</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9/6/19</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.10<font style="color:#000000;">&#8224;</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1703647/000119312519251257/d72917dex1013.htm"><font style="text-decoration:underline;">2019 Employee Stock Purchase Plan</font></a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-233652</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.13</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9/23/19</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk32848501"></a>10.11</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1703647/000156459020012977/freq-ex1013_758.htm"><font style="text-decoration:underline;">Indenture of Lease, effective as of January 7, 2020 between HCP/KING 75 Hayden LLC and Frequency Therapeutics, Inc. </font></a><font style="text-decoration:underline;"> </font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-39062</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.13</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/26/20</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.12</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1703647/000119312520196443/d12381dex101.htm"><font style="text-decoration:underline;">Securities Purchase Agreement, dated July 17, 2020, by and among Frequency Therapeutics, Inc. and the Investors named therein. </font></a><font style="text-decoration:underline;"> </font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-39062</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7/21/20</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.13</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1703647/000119312520196443/d12381dex102.htm"><font style="text-decoration:underline;">Registration Rights Agreement, dated July 17, 2020, by and among Frequency Therapeutics, Inc. and the Investors named therein. </font></a><font style="text-decoration:underline;"> </font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-39062</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7/21/20</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1703647/000119312520307216/d32382dex101.htm"><font style="text-decoration:underline;">Employment Agreement, effective December 1, 2020, by and between Frequency Therapeutics, Inc. and Peter P. Pfreundschuh. </font></a><font style="text-decoration:underline;"> </font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-39062</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12/1/20</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.15</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1703647/000119312520318153/d61497dex101.htm"><font style="text-decoration:underline;">Loan and Security Agreement, dated December 11, 2020, by and between Frequency Therapeutics, Inc. and Silicon Valley Bank.</font></a><font style="text-decoration:underline;"> </font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-39062</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12/15/20</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.16</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="freq-ex1016_1057.htm"><font style="text-decoration:underline;">Employment Agreement, effective February 3, 2020, by and between Frequency Therapeutics, Inc. and Wendy S. Arnold.</font></a><font style="text-decoration:none;"> </font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.1</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="freq-ex211_19.htm"><font style="text-decoration:underline;">Subsidiaries of Frequency Therapeutics, Inc.</font></a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.1</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="freq-ex231_7.htm"><font style="text-decoration:underline;">Consent of RSM US, LLP, Independent Registered Public Accounting Firm</font></a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:7.62%;"></td>
<td style="width:0.66%;"></td>
<td style="width:39.91%;"></td>
<td style="width:0.83%;"></td>
<td style="width:8.59%;"></td>
<td style="width:0.96%;"></td>
<td style="width:11.49%;"></td>
<td style="width:1.68%;"></td>
<td style="width:8.79%;"></td>
<td style="width:0.95%;"></td>
<td style="width:9.03%;"></td>
<td style="width:1.38%;"></td>
<td style="width:7.91%;"></td>
<td style="width:0.2%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.1</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="freq-ex311_16.htm"><font style="text-decoration:underline;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.2</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="freq-ex312_22.htm"><font style="text-decoration:underline;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.1</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="freq-ex321_8.htm"><font style="text-decoration:underline;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.2</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="freq-ex322_14.htm"><font style="text-decoration:underline;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.INS</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Instance Document</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">***</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.SCH</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Schema Document</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">***</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.CAL</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Calculation Linkbase Document</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">***</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.DEF</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Extension Definition Linkbase Document</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">***</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.LAB</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Label Linkbase Document</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">***</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.PRE</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Presentation Linkbase Document</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">***</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:92.86%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Filed herewith</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:-4.86%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Furnished herewith</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:-4.86%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">***</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Submitted electronically herewith</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.46%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8224;&#160;&#160;&#160;&#160;&#160;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">A management contract or compensatory plan or arrangement required to be filed as an exhibit pursuant to Item&#160;15(a)(3) of Form&#160;10&#8209;K.</p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_16_FORM_10K_SUMMARY"></a><a name="ITEM_16_FORM_10K_SUMMARY"></a>Item 16. Form 10-K Summary</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p><a name="_AEIOULastRenderedPageBreakAEIOU11"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="SIGNATURES"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="SIGNATURES"></a>SIGNAT</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">URES</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized<font style="font-weight:bold;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FREQUENCY THERAPEUTICS, INC.</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 29, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;David L. Lucchino</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.52%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David L. Lucchino</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President, Chief Executive Officer and Director (Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">POWER OF ATTORNEY </p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each person whose individual signature appears below hereby authorizes and appoints David L. Lucchino and Peter P. Pfreundschuh, and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this annual report on Form 10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;David L. Lucchino</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President, Chief Executive Officer and Director (Principal Executive Officer)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:25%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 29, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">David L. Lucchino</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Peter P. Pfreundschuh</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer (Principal Financial and Accounting Officer)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:25%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 29, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Peter P. Pfreundschuh</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Marc A. Cohen</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chairman and Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:25%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 29, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Marc A. Cohen</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Cynthia L. Feldmann</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 29, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cynthia L. Feldmann</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Timothy J. Barberich</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:25%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 29, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Timothy J. Barberich</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Michael Huang</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:25%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 29, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Michael Huang</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Robert S. Langer</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:25%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 29, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Robert S. Langer, Sc.D.</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Joel S. Marcus</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:25%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 29, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Joel S. Marcus</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"><font style="text-decoration:underline;">Report of an Independent Registered Public Accounting Firm</font></a></p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p></td>
</tr>
<tr>
<td valign="top"  style="width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consolidated financial statements </p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_BALANCE_SHEETS"><font style="text-decoration:underline;">Consolidated balance sheets</font></a></p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</p></td>
</tr>
<tr>
<td valign="top"  style="width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_OPERATIONS"><font style="text-decoration:underline;">Consolidated statements of operations</font></a></p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p></td>
</tr>
<tr>
<td valign="top"  style="width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_COMPREHENSIVE_LO"><font style="text-decoration:underline;">Consolidated statements of comprehensive loss</font></a></p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p></td>
</tr>
<tr>
<td valign="top"  style="width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENT_CONVERTIBLE_PREFE"><font style="text-decoration:underline;">Consolidated statements of convertible preferred stock, non-controlling interest and stockholder&#8217;s equity (deficit)</font></a></p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p></td>
</tr>
<tr>
<td valign="top"  style="width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CASH_FLOWS"><font style="text-decoration:underline;">Consolidated statements of cash flows</font></a></p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</p></td>
</tr>
<tr>
<td valign="top"  style="width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"><font style="text-decoration:underline;">Notes to consolidated financial statements</font></a></p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-8</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-1</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"></a><a name="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"></a>Report of Independent Registered Public Accounting Firm</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:7.14%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the Stockholders and the Board of Directors of Frequency Therapeutics, Inc.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Opinion on the Financial Statements</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:7.14%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited the accompanying consolidated balance sheets of Frequency Therapeutics, Inc. and its subsidiaries (the Company) as of December 31, 2020 and 2019, the related consolidated statements of operations, comprehensive loss, convertible preferred stock, non-controlling interest, and stockholders&#8217; equity (deficit) and cash flows for the years then ended, and the related notes to the consolidated financial statements (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Basis for Opinion</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:7.14%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:7.14%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:7.14%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have served as the Company's auditor since 2017.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ RSM US LLP</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Boston, Massachusetts</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 29, 2021</p><a name="_AEIOULastRenderedPageBreakAEIOU13"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Frequency Therapeutics, Inc.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_BALANCE_SHEETS"></a><a name="CONSOLIDATED_BALANCE_SHEETS"></a>Consolidated Balance Sheets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">220,341</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,158</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term marketable securities</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,197</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,723</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">225,064</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">221,355</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,287</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,762</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right of use assets</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,551</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,820</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">264,722</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">223,218</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities and Stockholders&#8217; Equity</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,506</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,219</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,663</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,239</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,068</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,152</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liabilities</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">397</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current liabilities</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">170</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,634</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,780</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue, net of current portion</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,900</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liabilities, net of current portion</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,597</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term Loan</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term liabilities</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,231</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,860</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217; equity:</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued or</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; outstanding at December 31, 2020 and December 31, 2019, respectively</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $0.001 par value; 200,000,000 shares authorized,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; 33,964,000 and 30,844,507 shares issued and outstanding at December 31, 2020</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; and December 31, 2019, respectively</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">287,829</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">236,161</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated other comprehensive income</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(95,399</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(68,888</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; equity</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">192,491</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">167,358</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and stockholders&#8217; equity</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">264,722</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">223,218</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">See accompanying notes.</p><a name="_AEIOULastRenderedPageBreakAEIOU14"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Frequency Therapeutics, Inc.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_OPERATIONS"></a>Consolidated S<a name="CONSOLIDATED_STATEMENTS_OPERATIONS"></a>tatements of Operations</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,984</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,947</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalty</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,415</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,784</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,119</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,838</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,534</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,622</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,550</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,675</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">994</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,784</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Realized gain on investments</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign exchange (loss) gain</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss before income taxes</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,476</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,746</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for income taxes</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(35</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,511</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,746</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cumulative Series C convertible preferred stock dividends</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,054</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,511</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,800</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common stockholders-basic</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; and diluted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.82</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.29</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares of common stock outstanding-basic</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; and diluted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,253,227</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,649,245</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">See accompanying notes.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Frequency Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_COMPREHENSIVE_LO"></a>Consolidated S<a name="CONSOLIDATED_STATEMENTS_COMPREHENSIVE_LO"></a>tatements of Comprehensive Loss</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,511</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,746</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive (loss) gain:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized (loss) gain on marketable securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total comprehensive (loss) gain</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,538</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,692</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">See accompanying notes.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU16"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Frequency Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENT_CONVERTIBLE_PREFE"></a>Consolidated S<a name="CONSOLIDATED_STATEMENT_CONVERTIBLE_PREFE"></a>tatement of Convertible Preferred Stock, Non-controlling Interest and Stockholder&#8217;s Equity (Deficit)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:4pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series C</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">convertible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">issued</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series C</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">convertible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series B</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">convertible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">issued</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series B</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">convertible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series B-1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">convertible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">issued</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series B-1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">convertible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series A</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">convertible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">issued</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series A</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">convertible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series A-1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">convertible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">issued</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series A-1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">convertible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">controlling</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">interest</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">issued</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">par</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additi-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">onal</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">paid-in</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">capital</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">comprehensive income</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumu-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">lated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">deficit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">stock-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">holders&#8217;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">equity (deficit)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance, December 31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">41,857,005</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">38,224</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">62,528,507</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">46,694</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3,773</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%; border-right:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%; border-left:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2,084,710</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">804</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(49,088</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(48,282</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.88%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.88%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.8%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,609</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,609</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock upon exercise of stock options</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">357,170</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">365</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">366</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Series B convertible preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">288,991</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">266</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Series C convertible preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,492,960</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,687</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accretion of Series C preferred dividend</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,054</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,054</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,054</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Initial public offering of common stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,325,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,690</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,696</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of preferred stock and non-controlling interest into common stock in connection with the IPO</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(39,492,960)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(62,741</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(42,145,996)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(38,490</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10.000)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(62,528,507)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,694</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,000)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,773</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,077,627</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">151,693</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">151,715</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive income</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,746</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,746</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance, December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%; border-right:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%; border-left:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">30,844,507</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">236,161</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(68,888</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">167,358</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.88%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.88%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.8%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,983</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,983</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock upon exercise of stock options</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">769,385</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,544</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,545</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock in Private Placement, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,350,108</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,141</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,143</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive (loss)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,511</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,511</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance, December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%; border-right:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%; border-left:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">33,964,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">287,829</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.26%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(95,399</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">192,491</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%; border-top:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.8%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:4pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">See accompanying notes</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU17"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Frequency Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_CASH_FLOWS"></a>Consolidated S<a name="CONSOLIDATED_STATEMENTS_CASH_FLOWS"></a>tatements of Cash Flows</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from operating activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,511</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,746</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,983</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,609</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,146</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">813</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock for license agreement</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-cash lease expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">434</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred lease incentives</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(160</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating assets and liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(626</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,252</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,287</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(644</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36,984</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,052</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,083</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,490</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash (used in) provided by operating activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,188</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,216</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from investing activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and equipment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,671</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,064</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase of available for sale securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,345</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(282,618</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Redemption of available for sale securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,418</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">265,421</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in) investing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,402</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,261</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from financing activities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of Series B convertible preferred stock, net of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; issuance costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">266</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of Series C convertible preferred stock, net of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; issuance costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,687</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,545</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,062</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from Private Placement, net of issuance costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,143</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from Term Loan</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,688</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142,015</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net increase in cash, cash equivalents, short-term investments, and restricted cash</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,902</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">157,970</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents, short-term investments and restricted cash at</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; beginning of period</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,259</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,289</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents, short-term investments, and restricted cash at end of period</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">222,161</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,259</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Non-cash items:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets in exchange for lease liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,335</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cumulative Series C convertible preferred stock dividends</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,054</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of preferred stock and non-controlling interest into common stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">151,715</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and equipment included in accounts payable and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;accrued expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,145</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">See accompanying notes</p><a name="_AEIOULastRenderedPageBreakAEIOU18"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Frequency Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"></a>Notes to C<a name="NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"></a>onsolidated Financial Statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Amounts in thousands, except share and per share amounts)</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Organization and basis of presentation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Frequency Therapeutics, Inc., together with its wholly owned subsidiaries, Frequency Therapeutics, PTY, LTD, Frequency Therapeutics Securities Corporation and Frequency Therapeutics Japan KK (Frequency Japan) (the Company), headquartered in Woburn, Massachusetts, was incorporated in November 2014 as a Delaware corporation. The Company is a clinical-stage biotechnology company focused on harnessing the body&#8217;s innate biology to repair or reverse damage caused by a broad range of degenerative diseases.&nbsp;&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 20, 2019, the Company effected a 1-for-6.7355 reverse stock split of its common stock. The par value of the common stock was not adjusted as a result of the reverse stock split and the authorized capital was amended to 100,000,000 shares of common stock and 148,724,922 shares of $0.001 par value preferred stock (the Preferred Stock). The reverse stock split resulted in an adjustment to the Series A Convertible  Preferred Stock (Series A Preferred), Series B Convertible Preferred Stock (Series B Preferred) and Series C Convertible Preferred Stock (Series C Preferred) conversion prices to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. The accompanying consolidated financial statements and notes to the consolidated financial statements give retroactive effect to the reverse stock split for all periods presented. Shares of common stock underlying outstanding stock options were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the appropriate securities agreements. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2019, the Company completed the initial public offering of its common stock (the &#8220;IPO&#8221;). In the IPO, the Company issued and sold 6,325,000 shares of its common stock at a price to the public of $14.00 per share, inclusive of the underwriters&#8217; exercise in part of their over-allotment option. The Company received approximately $79.7 million in net proceeds, after deducting underwriting discounts and commissions and other offering expenses. In connection with the IPO, on October 7, 2019 all Preferred Stock and the preferred stock of Frequency Japan converted into 22,077,627 shares of common stock and all outstanding shares of Series A-1 Preferred Stock and B-1 Preferred Stock were forfeited.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 20, 2020, the Company issued and sold an aggregate of 2,350,108 shares of its common stock, par value $0.001 per share, at a purchase price of $18.00 per share to new and existing investors in a private placement for net proceeds of $40.1 million after deducting placement agent fees and offering expenses (the &#8220;Private Placement&#8221;).&#160;In connection with the Private Placement, the Company entered into a Registration Rights Agreement (the &#8220;Registration Rights Agreement&#8221;) with the investors. Pursuant to the Registration Rights Agreement, the Company agreed to prepare and file a registration statement with the Securities and Exchange Commission (the &#8220;SEC&#8221;) within 60 days after the closing of the Private Placement (the &#8220;Initial Filing Date&#8221;) for purposes of registering the resale of the Shares. The Company filed a registration statement (the &#8220;Registration Statement&#8221;) which was declared effective by the SEC on September 3, 2020.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has also agreed, among other things, to indemnify the investors, their officers, directors, managers, employees, agents and any person who controls any investor under the Registration Statement from certain liabilities and to pay all fees and expenses (excluding any underwriting discounts and commissions) incident to the Company&#8217;s obligations under the Registration Rights Agreement.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Uncertainties </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our offices are located in states that are currently operating under a phased re-opening plan in response to the COVID-19 pandemic. As of the date of the filing of this Annual Report, the majority of our employees continue to work from home, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-8</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">while nearly a quarter to one-third of our workforce, consisting of mainly laboratory personnel, have periodically worked in rotating teams to ensure the continuation of essential experiments. Our Farmington, CT research site, co-located with the University of Connecticut, has resumed activity at a fifty percent level after a period of paused activity due to state lock down orders previously in effect. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">W</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">hile we have resumed experiments at our Farmington site, we have transitioned certain key experiments to </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> offices in Woburn, MA and third parties and contract research organizations have been engaged to advance certain projects. We are also have taken steps consistent with the FDA&#8217;s updated industry guidance for conducting clinical trials.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.9%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 pandemic, and actions taken to mitigate it, have had and are expected to continue to have an adverse impact on the economies and financial markets of many countries, including the geographical area in which we operate, which could adversely impact our ability to raise additional capital when needed or on acceptable terms, if at all. In addition, while no significant disruptions have occurred, the COVID-19 pandemic may cause such disruptions in our business or operations, as well as the business and operations of our CMOs, CROs and other third parties with whom we conduct business. The COVID-19 pandemic may also adversely impact the our clinical trials, which could impede, delay, limit or prevent the clinical development of our product candidates and ultimately lead to the delay or<font style="font-weight:bold;"> </font>denial of regulatory approval of our product candidates, which would materially adversely affect our business and operations, including our ability to generate revenue.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liquidity and capital resources </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has funded its operations primarily with proceeds from the sale of its capital stock, convertible notes and amounts received under a collaboration agreement. The Company has incurred recurring losses since its inception. In addition, as of December&#160;31, 2020, the Company had an accumulated deficit of $95,399. The Company expects to continue to generate operating losses for the foreseeable future. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company&#8217;s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurances that additional funding will be available on terms acceptable to the Company, or at all. The Company believes that existing resources will be sufficient to fund planned operations for at least 12 months from the date the financial statements were available to be issued.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2. Summary of significant accounting policies </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of presentation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared in accordance with accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP) that the Company follows to ensure its financial condition, results of operations, and cash flows are consistently reported. References to GAAP issued by the FASB in these notes to the consolidated financial statements are to the FASB <font style="font-style:italic;">Accounting Standards</font> Codification (ASC). </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Principles of consolidation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements include the accounts of Frequency Therapeutics, Inc. and its wholly owned subsidiaries Frequency Therapeutics Securities Corporation, Frequency Therapeutics PTY, LTD and Frequency Japan. All intercompany transactions and balances have been eliminated. Frequency Japan was closed down in February 2021, as further described in Note 19 of notes to consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of estimates </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. On an ongoing basis, the Company&#8217;s management evaluates its estimates, which include but are not limited to management&#8217;s judgments of accrued expenses, revenue recognition, fair value of common stock, valuation of share-based awards, present value of lease liabilities and income taxes. Actual results could differ from those estimates. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-9</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company utilize</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> significant estimates and assumptions in determining the fair value of its common stock in periods prior to the IPO. The Company </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">utilized</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately Held Company Equity Securities Issued as Compensation (the Practice Aid), to estimate the fair value of its common stock. Each valuation methodology includes estimates and assumptions that require the Company&#8217;s judgment. These estimates and assumptions include </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a number of</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to the Company&#8217;s common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale. Significant changes to the key assumptions used in the valuations could have resulted in different fair values of common stock at each valuation date. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comprehensive income (loss) </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Components of comprehensive income or loss, including net income or loss, are reported in the financial statements in the period in which they are recognized. Other comprehensive income or loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss) are reported net of any related tax effect to arrive at comprehensive income (loss). Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and economic events other than those with stockholders which for the years ended December 31, 2020 and 2019 consist of unrealized gain on marketable securities.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segment information </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company&#8217;s chief operating decision-maker, the Company&#8217;s chief executive officer, views the Company&#8217;s operations and manages its business as a single operating segment, which is in the business of discovering and developing small molecule drugs that activate progenitor cells within the body to create healthy tissue. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Foreign currency </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All periods presented are reported in US dollars. The functional currency for entities outside the United States is the US dollar. Realized and unrealized gains and losses from foreign currency transactions are reflected in the consolidated statements of operations as other expense. During the years ended December&#160;31, 2020 and 2019 the Company recorded $(4), and $7<font style="font-size:12pt;">&#160;</font>of foreign currency exchange (losses) gains, respectively. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash and cash equivalents </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with an original maturity of six months or less at acquisition to be cash equivalents which are stated at fair market value. Cash and cash equivalents at December&#160;31, 2020 and 2019 consists entirely of cash and money market funds. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Restricted Cash</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has $1.8 million of restricted cash as of December 31, 2020 which represents a $1.7 million security deposit on the Company's future Lexington, Massachusetts facility and a $0.1 million security deposit on the Company's Woburn, Massachusetts facility. The $0.1 million restricted cash at December 31, 2019 represented the security deposit on the Company's Woburn, Massachusetts facility.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Short-term marketable debt securities</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term marketable securities represent holdings of available-for-sale marketable debt securities in accordance with the Company&#8217;s investment policy. Short-term marketable investments mature within one-year from the balance sheet date. Investments in marketable securities are recorded at fair value, with any unrealized gains and losses reported within accumulated other comprehensive income as a separate component of stockholders&#8217; equity (deficit) until realized or until a determination is made that an other-than-temporary decline in market value has occurred. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion, together with interest on securities sold is determined based on the specific identification method and any realized gains or losses on the sale of investment are reflected as a component of other income (expense).</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-10</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of credit risk and off-balance sheet risk</font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instrument that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. The Company maintains its cash and cash equivalents at several accredited financial institutions, in amounts that exceed federally insured limits. Marketable securities consist of U.S. Treasury securities with maturities of less than twelve months. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which its money market accounts are maintained.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has no significant off-balance sheet such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Significant suppliers </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is dependent on third-party manufacturers to supply products for research and development activities of its programs, including preclinical and clinical testing. In particular, the Company relies and expects to continue to rely on a single manufacturer of its product candidates for use in clinical trials. The Company would be adversely affected by a significant interruption in the supply of product for use in clinical programs. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair value measurements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic&#160;820, <font style="font-style:italic;">Fair Value Measurement</font> (ASC&#160;820), establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The hierarchy defines three levels of valuation inputs, of which the first two are considered observable and the last is considered unobservable: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:9.38%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Quoted prices in active markets for identical assets or liabilities.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:9.38%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Inputs other than quoted prices included within Level&#160;1 that are either directly or indirectly observable,&nbsp;&nbsp; &nbsp;&nbsp;such as quoted market prices, interest rates and yield curves.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:9.38%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 3</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Unobservable inputs developed using estimates or assumptions developed by the Company, which reflect those that a market participant would use in pricing the asset or liability.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying values of other current assets, accounts payable, and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. The fair value of the Company&#8217;s Term Loan is not materially different from the carry value as presented given the Term Loan was issued within one month of December 31, 2020. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property and equipment </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consist of lab equipment, computer equipment, furniture and office equipment and leasehold improvements recorded at cost. These amounts are depreciated using the straight-line method over the estimated useful lives of the assets as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.38%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.38%;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Estimated useful life</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="top"  style="width:72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and office equipment</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="top"  style="width:72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shorter of the estimated useful</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">life or lease term</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheet and related gains or losses are reflected in the consolidated statements of operations.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-11</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Impairment of long-lived assets </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company continually evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company did not recognize any impairment losses for the years ended December&#160;31, 2020 and 2019.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and development costs and accruals </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses include salaries and benefits, materials and supplies, preclinical and clinical trial expenses, stock-based compensation expense, depreciation of equipment, contract services and other outside expenses. The Company has entered into various research and development-related contracts with research institutions, contract research organizations, contract manufacturers and other companies. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. Costs of certain development activities, such as manufacturing, pre-clinical and clinical trial expenses, are recognized based on an evaluation of the progress to completion of specific tasks. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed. Costs incurred in obtaining technology licenses are charged to research and development expense as acquired in-process research and development if the technology licensed has not reached technological feasibility and has no alternative future use.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company elected to early adopt ASC 842, <font style="font-style:italic;">Leases</font> (ASC 842) as of January 1, 2020 and elected the transition method under ASU 2016-02 whereby the Company records a right-to-use asset and a lease liability on the consolidated balance sheet for all leases with terms longer than 12 months. The Company also elected to apply the package of practical expedients intended to ease transition. Accordingly, the Company has only applied ASC 842 to leases existing at January 1, 2020. The Company determines if an arrangement is, or contains, a lease at inception. Operating leases are included in operating lease right-of-issue (&#8220;ROU&#8221;) assets, other current liabilities, and operating lease liabilities on the consolidated balance sheets.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments to be made over the lease term. The ROU asset also includes any lease payments made at or before the lease commencement date and excludes lease incentives received. As the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected to not apply the recognition requirements of ASC 842 for short-term leases, which is defined as a lease that, at the lease commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For real estate lease agreements entered into or modified after the adoption of ASC 842 that include lease and non-lease components, the Company has elected to account for the lease and non-lease components, such as common area maintenance charges, as a single lease component.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Collaborative arrangements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company analyzes its collaborative arrangements to assess whether they are within the scope of ASC 808, <font style="font-style:italic;">Collaborative Arrangements</font> (&#8220;ASC 808&#8221;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship (e.g., a licensing arrangement) where the contracted party has obtained goods or services that are an output of the Company&#8217;s ordinary activities in exchange for a consideration and therefore within the scope of ASC 606, <font style="font-style:italic;">Revenue from Contracts with Customers</font> (&#8220;ASC 606&#8221;). For those </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-12</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">elements of the arrangement that are accounted for pursuant to </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASC</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 606, including those to which </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASC</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 606 is applied by analogy, the Company applies the five-step model described in the Company&#8217;s revenue recognition policy. For elements of collaborative arrangements that are accounted for pursuant to ASC 808, an appropriate and rational recognition method is determined and applied consistently. Reimbursements from the </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">counterparty</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> that are the result of a collaborative relationship with the </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">counterparty</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, instead of a customer relationship, such as co-development or clinical activities, are recorded as a reduction to research and development expense as the services are performed. Similarly, amounts that are owed to a collaboration partner related to the co-development clinical activities are recognized as research and development expense. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company enters into out-licensing agreements that are within the scope of ASC 606. The terms of such out-license agreements include licenses to functional intellectual property (IP), given the functionality of the intellectual property is not expected to change substantially as a result of the licensor&#8217;s ongoing activities. Such arrangements typically include payment of one or more of the following: non-refundable up-front license fees; reimbursement of certain costs; development and regulatory milestone payments and milestone payments based on the level of sales; and royalties on net sales of licensed products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers the economic and regulatory characteristics of the licensed IP, research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace to determine if it has standalone value at the inception of the licensing arrangement, which would make the license distinct. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of any additional good or services promised in the contract, whether the value of the license is dependent on the remaining goods and services, whether there are other vendors that could provide the remaining promise, and whether the license is separately identifiable from the remaining good and services. For licenses that are combined with other goods and services, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of progress and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue is allocated to the licensed IP on a relative standalone selling price basis and, for functional IP, is recognized at a point when the licensed IP is made available for the customer&#8217;s use and benefit, which generally occurs at the inception of the arrangement. However, in cases, where the functionality of the IP is expected to substantively change as a result of activities of the Company that do not transfer additional promised goods or services, or in cases, where there is an expectation that the Company will undertake activities to change the standalone functionality of the IP and the customer is contractually or practically required to use the latest version of the IP, revenue for the license to functional IP is recognized over time. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development and regulatory milestone fees, which are a type of variable consideration, are recognized as revenue to the extent that it is probable that a significant reversal will not occur. The Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into a collaboration arrangement with Astellas Pharma Inc. (&#8220;Astellas&#8221;), as further described in Note 16 of notes to consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue recognition </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for contracts with customers in accordance with ASC 606, including all amendments thereto. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as collaborative arrangements and leases. The Company&#8217;s disclosure within the below sections or elsewhere within these consolidated financial statements reflects the Company&#8217;s accounting policies in compliance with this new standard.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under ASC 606, an entity recognizes revenue when or as its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To recognize revenue for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies its performance obligations. The Company only applies the five-step model to contracts when it is probable that the entity will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services it transfers to the customer. Once a contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and identifies as a performance obligation each promise to transfer to the customer either (a) a </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-13</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">good or service (or bundle of goods and services) that is distinct, or (b) a series of distinct goods and services that are substantially the same and have been the same pattern of transfer to the customer.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company assesses whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i)&#160;the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii)&#160;the entity&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract). In assessing whether a promised good or service is distinct, the Company considers factors such as the research, manufacturing and commercialization capabilities of the collaboration partner (the &#8220;customer&#8221; in this type of arrangement) and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct. For each arrangement that results in revenues, the Company identifies all performance obligations, which may include, for example, a license to IP and know-how, research and development activities, and/or manufacturing services. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to any upfront payment, if the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the estimated variable consideration in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. If it is probable that a significant revenue reversal will not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or of the licensee such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For contracts that include sales-based royalties (including milestone payments based on the level of sales) promised in the exchange for licenses of intellectual property, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestone payments at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied. In determining the transaction price, the Company adjusts the promised amount of consideration for the effects of the time value of money if the timing of payments provides the Company or the Company&#8217;s customer with a significant benefit of financing the transfer of goods and services. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. The Company assesses each of its revenue generating arrangements in order to determine whether a significant financing component exists. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time.&nbsp;&nbsp;For performance obligations satisfied over time, the Company measures progress toward completion of its performance obligations using an input method based on the Company&#8217;s efforts and inputs to satisfy its performance obligations relative to total expected inputs to the satisfaction of that performance obligation.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts received from a customer prior to revenue recognition are recorded as deferred revenue. Amounts received from a customer that are expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability in the accompanying consolidated balance sheets.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-14</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Patent costs </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses in the accompanying consolidated statements of operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-based compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for its stock-based compensation in accordance with ASC Topic&#160;718, <font style="font-style:italic;">Compensation&#8212;Stock Compensation</font> (ASC&#160;718). ASC&#160;718 requires all share-based payments to employees and directors to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company adopted FASB Accounting Standards Update (ASU) 2016-09 which identifies areas for simplification of several areas of share-based payment transactions. The Company treats non-employee grants in a manner consistent with employee grants. The Company estimates the fair value of options granted using the Black-Scholes option pricing model for stock option grants to both employees and non-employees. The Company believes the fair value of the stock options granted to non-employees is more reliably determinable than the fair value of the services provided. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (a)&#160;the expected stock price volatility, (b)&#160;the expected term of the award, (c)&#160;the risk-free interest rate and (d)&#160;expected dividends. Due to the lack of sufficient company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No.&#160;107, Share-Based Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to non-employees, the Company utilizes the contractual term of the share-based payment as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are significant judgments and estimates inherent in the determination of the fair value of the Company&#8217;s common stock prior to the IPO. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to its common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expenses the fair value of its share-based compensation awards to employees and non-employees on a straight-line basis over the requisite service period, which is generally the vesting period. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income taxes </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes using the asset and liability method in accordance with ASC Topic 740, <font style="font-style:italic;">Income Taxes</font> (ASC 740) which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. At December&#160;31, 2020 and 2019, the Company has concluded that a full valuation allowance is necessary for its deferred tax assets (see Note 13). </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net loss per share </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period and, if dilutive, the weighted-average number of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-15</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">potential shares of common stock. Diluted net loss per share is the same as basic net loss per share for the years ended December&#160;31, 20</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20 and</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 201</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> since all potential shares of common stock instruments are anti-dilutive </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as a result of</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the loss for such periods. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s convertible preferred stock contractually entitled the holders of such shares to participate in dividends but did not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reported a net loss, such losses are not allocated to such participating securities. In periods where the Company reported a net loss attributable to common stockholders, diluted net loss per share is the same as basic net loss per share, since dilutive shares of common stock are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for the years ended December&#160;31, 2020 and 2019.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted net loss per share attributable to common stockholders was calculated as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk64651614"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,511</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,800</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares of common stock outstanding-</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,253,227</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,649,245</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common stockholders-</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.82</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.29</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company excluded the following potential shares of common stock from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted Common Stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,093</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,366</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series C Preferred (as converted to common stock)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,172,676</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series B Preferred (as converted to common stock)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,759,079</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A Preferred (as converted to common stock)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,070,574</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of Frequency Japan preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">513,047</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding stock options (as converted to common stock)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,816,798</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,968,672</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,819,891</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,554,414</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently adopted accounting pronouncements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU No. 2016-02, <font style="font-style:italic;">Leases</font> (Topic 842) (&#8220;ASU 2016-02&#8221;), as amended by various subsequently issued ASUs. The standard requires lessees to recognize an operating lease with a term greater than one year on their balance sheets as a right-of-use asset and corresponding lease liability, measured at the present value of the lease payments. Lessees are required to classify leases as either finance or operating leases. If the lease is effectively a financed purchase by the lessee, it is classified as a financing lease, otherwise it is classified as an operating lease. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2018, the FASB also issued ASU 2018-11, <font style="font-style:italic;">Leases</font> (Topic 842): Targeted Improvements (&#8220;ASU 2018-11&#8221;), which permits entities to continue applying legacy guidance in ASC 840, Leases, including its disclosure requirements, in the comparative periods presented in the year that the entity adopts the new leasing standard. The Company adopted the standard on January 1, 2020 using the optional transition method. As such, the consolidated balance sheets and statements of operations for prior periods will not be comparable in the year of adoption of ASC 842. The Company elected the package of practical expedients permitted under the transition guidance within the standard. Accordingly, the Company did not reassess the conclusion of whether the existing arrangements contain a lease, lease classification and initial direct costs under ASC </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-16</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">842. As a result of the adoption of ASC 842, the Company recorded $</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.2</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million of ROU assets and a total of $</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.5</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million of lease liabilities on the consolidated balance sheets as of January 1, 2020. In addition, in the first quarter of 2020 the Company expanded and amended the lease for its Woburn, Massachusetts facility and increased both the ROU asset and lease liability by $</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.0</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million. On December 11, 2020, the Company terminated this lease and remeasured the existing ROU asset and lease liability based on this lease modification, resulting in a $</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.7</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million impact to both the ROU asset and lease liability. As disclosed in Note 16, the Company has </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">entered into</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> a lease for a facility in Lexington Massachusetts which commenced December 11, 2020. In accordance with ASU No. 2016-02, the Company recognized a right-of-use asset and related lease liability at such time.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2016,&#160;the FASB issued ASU No. 2016-01, <font style="font-style:italic;">Financial Instruments - Overall</font> (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. This new standard amended certain aspects of accounting and disclosure requirements for financial instruments, including the requirement that equity investments with readily determinable fair values are to be measured at fair value with any changes in fair value recognized in a company's statements of operations. Prior to adoption of ASU 2016-01, companies recognized changes in fair value in accumulated other comprehensive income (loss), net. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. In addition, a valuation allowance should be evaluated on deferred tax assets related to available- for-sale debt securities in combination with other deferred tax assets.&#160;The Company adopted this new standard on January 1, 2020, using the modified retrospective method, and determined that it did not have a material impact on its financial statements.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently issued accounting pronouncements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company is an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, as amended (Jobs Act). The Jobs Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company elected to avail itself of this extended transition period and, as a result, we will not be required to adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13, <font style="font-style:italic;">Financial Instruments - Credit Losses</font> (Topic 326): Measurement of Credit Losses on Financial Instruments. The FASB has subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. This standard will become effective for the Company on January 1, 2023. The Company is still evaluating the impact of this standard on its consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued&#160;<font style="color:#000000;">ASU 2019-12</font>&#160;amending accounting guidance that simplifies the accounting for income taxes, as part of its initiative to reduce complexity in the accounting standards. The amendments eliminate certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The amendments also clarify and simplify other aspects of the accounting for income taxes. This standard will become effective for the Company on January 1, 2021. The Company is still evaluating the impact of this standard on its consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3. Fair value measurements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s financial assets measures at fair value on a recurring basis by level within the fair value hierarchy at December 31, 2020 and 2019 are summarized as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortization</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Market</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Hierarchy</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gain</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214,522</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214,549</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.04%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214,522</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214,549</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-17</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortization</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Market</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Hierarchy</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Loss) Gain</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,131</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,119</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Government treasury securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,131</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,197</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.04%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,262</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,316</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4. Prepaid expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.4%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent and deposits</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,729</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">801</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grant receivable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">805</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">340</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Insurance</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,552</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,132</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">199</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,723</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5. Property and equipment </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment include the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,166</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,846</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and office equipment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">283</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">257</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">291</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,419</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,419</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,340</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">306</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,499</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,828</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated depreciation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,212</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,066</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,287</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,762</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognized $1,146 and $813 of depreciation expense for the years ended December&#160;31, 2020 and 2019, respectively. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6. Accrued expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consist of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.4%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll and employee related expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,062</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,686</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional fees</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">647</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">435</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third-party research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">874</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Taxes and other</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,663</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,239</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-18</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7. Debt</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 11, 2020, the Company entered into a Loan and Security Agreement (the &#8220;Loan Agreement&#8221;) with a commercial bank for a Term Loan with a principal balance of $15 million. The Company will make monthly interest only payments through November&#160;30, 2022. The principal balance and interest will be repaid in equal monthly installments after the interest only period and continuing through May&#160;1, 2024 (the &#8220;Loan Maturity Date&#8221;). Advances under the Loan Agreement will bear an interest rate equal to the greater of either (i) 1.50% plus the Prime Rate (as reported in<font style="font-style:italic;">&#160;The Wall Street Journal</font>, subject to an interest rate floor of zero) or (ii) 4.75%. Interest related to the Loan Agreement was immaterial for the year ended December 31, 2020. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company may prepay the advance made under the Loan Agreement in whole, at any time subject to a prepayment premium equal to: (a) 2.0% of the then-outstanding principal amount of the advance, if such prepayment occurs on or prior to the first anniversary of the Closing Date; (b) 1.0% of the then-outstanding principal amount of the advance, if such prepayment occurs after the first anniversary of the Closing Date and on or prior to the second anniversary of the Closing Date; and (c) 0.0% of the then-outstanding principal amount of the advance, if such prepayment occurs after the second anniversary of the Closing Date. The prepayment premium is waived if the Term Loan Facility is refinanced by the Bank (in its sole and absolute discretion) on or prior to the Loan Maturity Date.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will pay a final payment of $150,000, which will occur on the earliest of: (i)&#160;the Loan Maturity Date; (ii)&#160;the date that the Company prepays all of the outstanding principal in full; (iii)&#160;the date the loan payments are accelerated due to an event of default; or (iv)&#160;the termination of the Loan Agreement. The Company is recording the final payment as interest expense over the term of the loan. The Term Loan Facility is secured by substantially all of the Company&#8217;s assets, excluding intellectual property.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8. Convertible preferred stock </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2018, the Company had issued 62,528,507 shares of Series A Preferred Stock, 10,000 shares of Series A-1 Preferred Stock, 41,857,005 shares of Series B Preferred Stock, and 10,000 shares of Series B-1 Preferred Stock. In 2019, the Company also issued 288,911 shares of Series B Preferred Stock. On July&#160;17, 2019, the Company authorized and issued 39,492,960 shares of Series&#160;C Preferred for net proceeds of $61,687. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluated the tranched nature of the issuance of these preferred shares as well as the rights, preferences, and privileges of such shares and has concluded that there were no freestanding derivative instruments or any embedded derivatives requiring bifurcation. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2019, in connection with the IPO, all shares of Preferred Stock were automatically converted into common stock.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9. Non-controlling Interest</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2018, the Company issued shares of preferred stock in its subsidiary, Frequency Japan, to a Japanese investor. The Frequency Japan preferred stock held by such investor was convertible, at the option of the holder, into 673,605 shares of Company common stock, adjustable for certain dilutive events, upon an initial public offering of Company common stock, a Company liquidation or upon a 70% vote of the holders of the Preferred Stock. The preferred shares also had a liquidation preference equal to the amount paid for the shares. The Company had the option to acquire the preferred shares of Frequency Japan under certain circumstances and the holder of such preferred shares had the right to require the Company to purchase such shares under certain circumstances, primarily a merger or liquidation. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with this sale of the preferred stock in Frequency Japan, FT-FJ Investment, LLC (FT-FJ), a Delaware limited liability company controlled by the Company, purchased 10,000 shares of the Company&#8217;s Series A-1 Preferred Stock and 10,000 shares of the Company&#8217;s Series B-1 Preferred Stock. FT-FJ also granted to the Japanese investor an irrevocable proxy to vote the shares of Series A-1 and Series B-1 Preferred Stock held by FT-FJ. Each share of Series A-1 Preferred had 236 times the voting power of one share of common stock and each share of Series B-1 Preferred Stock has 217 times the voting power of one share of common stock. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 20, 2019, the Company, Frequency Japan, the Japanese investor, and FT-FJ entered into an agreement pursuant to which, contingent upon the closing of an initial public offering of the Company&#8217;s common stock: (i) the Japanese investor agreed to convert its shares of preferred stock held in Frequency Japan and to terminate its proxy over the shares of Series A-1 and B-1 Preferred Stock held by FT-FJ and (ii) FT-FJ agreed to forfeit its shares of Series A-1 and Series B-1 Preferred Stock. The shares were converted into common stock and the Series A-1 and B-1 preferred shares were forfeited in conjunction with the IPO.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-19</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">0</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">. Stockholders&#8217; </font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">equity</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Preferred stock</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:normal;">The Company has authorized 10,000,000 shares of $0.001 par value preferred stock of which no shares were issued or outstanding as of December 31, 2020.</font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Common stock </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has authorized 200,000,000 shares of $0.001 par value common stock of which 33,964,000 were issued and outstanding as of December 31, 2020. Common shares are voting, and dividends may be paid when, as and if declared by the Board of Directors.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has reserved the following shares of common stock for future issuance as of December 31, 2020 and 2019:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options outstanding</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,816,798</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,968,672</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for future grant under stock option plan</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,475,923</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,859,654</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,292,721</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,828,326</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11. Stock-based compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November&#160;13, 2014, the Company adopted the 2014 Stock Incentive Plan (2014 Plan). All of the Company&#8217;s employees, officers, directors, and consultants are eligible to be granted options to purchase common shares and restricted stock under the terms of the 2014 Plan. The Company reserved an aggregate of 8,550,415 shares of common stock for issuance under the 2014 Plan. As of December&#160;31, 2020, there were no shares of common stock available for future grants under the 2014 Plan.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 17, 2019, the Company&#8217;s board of directors and on September 19, 2019, its stockholders approved and adopted the 2019 Incentive Award Plan (&#8220;the &#8220;2019 Plan&#8221;) which became effective on the day prior to the IPO.&nbsp;&nbsp;Under the 2019 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock and cash-based awards to individuals who are then employees, officers, directors or consultants of the Company, and employees and consultants of the Company&#8217;s subsidiaries.&nbsp;&nbsp;A total of 3,100,000 shares of common stock were approved to be initially reserved for issuance under the 2019 plan.&nbsp;&nbsp;The number of shares under the 2014 Plan subject to outstanding awards as of the effective date of the 2019 Plan that are subsequently canceled, forfeited or repurchased by the Company will be added to the shares reserved under the 2019 Plan.&nbsp;&nbsp;In addition, the number of shares of common stock available for issuance under the 2019 Plan will be automatically increased on the first day of each calendar year during the ten-year term of the 2019 Plan, beginning with January 1, 2020 and ending with January 1, 2029, by the amount equal to 4% of the outstanding number of shares of the Company&#8217;s common stock on December 31, of the preceding calendar year or such lesser amount as determined by the Company&#8217;s board of directors.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All stock option grants are non-statutory stock options except option grants to employees (including officers and directors) intended to qualify as incentive stock options under the Internal Revenue Code of 1986, as amended. Incentive stock options may not be granted at less than the fair market value of the Company&#8217;s common stock on the date of grant, as determined in good faith by the Board of Directors at its sole discretion. Nonqualified stock options may be granted at an exercise price established by the Board of Directors at its sole discretion (which has not been less than fair market value on the date of grant) and the vesting periods may vary. Vesting periods are generally four years and are determined by the Board of Directors. Stock options become exercisable as they vest. Options granted under the 2014 Plan and the 2019 Plan expire no more than ten years from the date of grant. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-20</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock options </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the stock option activity under the 2014 Plan and the 2019 Plan are as follows: </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">exercise</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">term</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">intrinsic</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">exercise</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">term</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">intrinsic</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019 Plan</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">price</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014 Plan</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">price</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,089,334</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.61</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,247,338</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.09</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,015,381</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.17</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(357,170</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.02</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,211</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.09</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,247,338</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.09</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.76</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,287</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,721,334</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.85</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.89</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,051</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,645,859</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.22</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,851</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.93</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(767,534</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.94</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,997</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.72</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,351</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.89</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,874,349</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.84</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.09</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,325</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,942,449</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.02</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.98</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127,090</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable as of December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">564,617</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.48</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.90</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,042</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,337,828</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.57</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.88</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,416</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options unvested as of December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,309,732</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,283</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,604,621</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,674</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock option valuation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumptions that the Company used to determine the grant-date fair value of stock options granted to<font style="font-weight:bold;font-style:italic;"> </font>employees and directors were as follows, presented on a weighted average basis: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.0</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.9</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79.1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79.4</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Risk-Fee Interest Rate<font style="font-style:normal;">: The Company based the risk-free interest rate over the expected term of the options based on the constant maturity of U.S. Treasury securities with similar maturities as of the date of the grant.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expected Term<font style="font-style:normal;">:&nbsp;&nbsp;The expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term).</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expected Volatility<font style="font-style:normal;">: The Company uses an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry that were deemed to be representative of future stock price trends as the Company does not have sufficient trading history for its common stock.&nbsp;&nbsp;The Company will continue to apply this process until a sufficient amount of historical information regarding volatility of its own stock price options becomes available.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expected Dividend Yield<font style="font-style:normal;">: The Company has not paid and does not anticipate paying any dividends in the near future.&nbsp;&nbsp;Therefore, the expected dividend yield was zero.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#8217;s common stock. During the years ended December&#160;31, 2020 and 2019, 769,385 and 357,170 shares were exercised, respectively. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2020 and 2019 was $16,667 and $5,896 respectively.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-21</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">grant date </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fair value of options granted to employees during the years ended December&#160;31, 20</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> was $</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.4</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.05</font><font style="font-size:12pt;">&#160;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">respectively. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total grant date fair value of options vested during the years ended December&#160;31, 2020 and 2019 was $7,907 and $2,990, respectively. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Restricted common stock </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company issued common stock to founders, employees and advisors which was subject to vesting over four years. If any of these individuals ceased to be employed or to provide services to the Company prior to vesting, the Company had the right to repurchase any unvested Common Stock at the price paid by the holder. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the status of restricted common stock as of December&#160;31, 2020 and 2019 is presented below: </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:72.52%;">
<tr style="height:8.85pt;">
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:20.95pt;">
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:8.85pt;">
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested, December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,366</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.36</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:8.85pt;">
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Awarded</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:8.5pt;">
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(67,273</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.29</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:8.85pt;">
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:8.5pt;">
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested, December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,093</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.75</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> The total value of restricted stock awards that vested during the years ended December&#160;31, 2020 and 2019, based on estimated fair values of the stock underlying the restricted stock awards was $20 and $73, respectively. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-based compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense of $9,983 and $3,609 for the years ended December&#160;31, 2020 and 2019 respectively, is included in research and development and general and administrative expenses in the Company&#8217;s consolidated statements of operations and comprehensive loss. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020 and 2019, total unrecognized stock-based compensation expense relating to unvested stock options was $31,006 and $13,820, respectively. This amount is expected to be recognized over a weighted-average period of 3.08 years and 2.76 years, respectively. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12. Employee stock purchase plan </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 20, 2019, the Company&#8217;s board of directors and stockholders approved and adopted the 2019 Employee stock Purchase Plan (the &#8220;ESPP&#8221;) which became effective on the date of the IPO. The ESPP permits participants to purchase common stock through payroll deductions of up to 15% of their eligible compensation. A total of 315,000 shares of common stock were approved to be initially reserved for issuance under the ESPP. In addition, the number of shares of common stock available for issuance under the ESPP will be automatically increased on the first day of each calendar year during the first ten-years of the term of the ESPP, beginning with January 1, 2020 and ending with January 1, 2029, by an amount equal to 1% of the outstanding number of shares of the Company&#8217;s common stock on December 31 of the preceding calendar year or such lesser amount as determined by the Company&#8217;s board of directors. No shares were issued under the ESPP at December 31, 2020.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-22</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">13. Income taxes </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk64656435"></a>Since inception in 2014, the Company has generated cumulative federal and state net operating loss and research and development credit carryforwards for which we have not recorded any net tax benefit due to uncertainty around utilizing these tax attributes within the respective carryforward periods. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the Company had federal net operating loss carryforwards of approximately $67,868 and Massachusetts state operating loss carryforwards of approximately $43,386&#160;which may be available to offset future taxable income. The U.S. federal net operating loss carryforwards include $22,400 available to reduce future taxable income through 2037 and approximately $45,469 which do not expire and are available to reduce future taxable income indefinitely. The state net operating loss carryforwards are available to offset future taxable income through 2040. As of December&#160;31, 2020, the Company also had federal and Massachusetts research and development tax credit carryforwards of $3,014 and $1,211, respectively, which are available to offset federal and state tax liabilities through 2040 and 2035, respectively. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Realization of future tax benefits is dependent on many factors, including the Company&#8217;s ability to generate taxable income within the net operating loss carryforward period. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as provided under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, respectively, as well as similar state provisions. These ownership changes may limit the number of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section&#160;382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has completed several financings and has conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception and has determined that an ownership change did occur in March 2017. Accordingly, utilization of $12,400 of the U.S. net operating loss carryforwards which were incurred prior to March 2017 (pre-ownership change) is limited under Section 382. After the Section 382 limitations, the Company may utilize approximately $10,800 of its pre-ownership change net operating loss carryforwards based upon an annual usage of approximately $1,600 for each of the next five years after the ownership change and approximately $180 for each of the 15 years thereafter. The remaining pre-ownership change net operating losses of approximately $1,600 were written off due to expiration under limitation. The limitation has been determined by first multiplying the value of our stock at the time of the ownership change by the applicable long-term tax-exempt rate. These carryforwards may be subject to further annual limitations under Section&#160;382 in the event of future changes in ownership.&nbsp;&nbsp;Additionally, the Company has determined an ownership changed occurred in October of 2019 as a result of the IPO.&nbsp;&nbsp;Accordingly, utilization of approximately $46,123 of the U.S. net operating loss carryforwards incurred prior to October 2019 is also limited under Section 382.&nbsp;&nbsp;The Company has determined it will be able to utilize the entire $46,123 of its pre-ownership change net operating loss carryforwards based upon the limitations calculated from the October 2019 ownership change. These carryforwards may be subject to further annual limitations under Section 382 in the event of future changes in ownership.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration of all the evidence, both positive and negative, the Company has recorded a valuation allowance against its deferred tax assets at December&#160;31, 2020 and 2019 because the Company&#8217;s management has determined that it is more likely than not that the Company will not recognize the benefits of its federal and state deferred tax assets primarily due to its cumulative loss position and, as a result, a valuation allowance of approximately $26,995 and $16,204 as of December&#160;31, 2020 and 2019 has been established. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has no unrecognized tax benefits. The Company has not, as yet, conducted a study of its research and development credit carryforwards. Such a study may result in an adjustment to the Company&#8217;s research and development credit carryforwards; however, until a study is completed, and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#8217;s research and development credits and, if an adjustment were required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the consolidated balance sheet or consolidated statements of operations if an adjustment were required. The Company has elected to recognize interest and penalties related to income tax matters as a component of income tax expense, of which no interest or penalties were recorded for the years ended December&#160;31, 2020 and 2019. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-23</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company files income tax returns in the U.S. and Massachusetts. The statute of limitations for assessment by the Internal Revenue Service and Massachusetts tax authorities remains open for all years since 2014. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service or state authorities to the extent utilized in a future period. No federal or state tax audits are currently in process. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the Company&#8217;s pre-tax income for the years ended December 31, 2020 and 2019 is as follows:</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:56.02%;">
<tr style="height:10.65pt;">
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:12.7pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Domestic</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,744</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,086</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr style="height:12.7pt;">
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(732</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(714</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr style="height:13.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,476</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,800</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s provision at December 31, 2020 and 2019 consist of the following:</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:55.74%;">
<tr style="height:10.3pt;">
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:12.35pt;">
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:12.35pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp; Federal</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:13.05pt;">
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp; State</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:13.05pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp; Foreign</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:12.35pt;">
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:12.35pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:13.05pt;">
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp; Federal</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:12.35pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp; State</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:13.05pt;">
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp; Foreign</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:12.35pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Deferred</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:12.35pt;">
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total provision (benefit)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate for the years ended December&#160;31, 2020 and 2019 is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:52.54%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S federal statutory income tax rate</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent differences</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.2)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.8</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes, net of federal benefit</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.0</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.0</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credits</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.8</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation deductions</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other items</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.6</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.0</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in deferred tax asset valuation allowance</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40.7)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23.0</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective income tax rate</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;%</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-24</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s deferred tax assets at December&#160;31, 2020 and 2019 consist of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,885</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,253</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credits</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,992</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,138</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangibles</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">360</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">358</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">850</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">686</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,606</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">496</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">189</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liability</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,285</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right of use asset</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,181</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax asset</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,995</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,204</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,995</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,204</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14. Research and license agreements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Massachusetts Institute of Technology </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2016, the Company entered into an exclusive patent license agreement (MIT License Agreement), with the Massachusetts Institute of Technology, (MIT), under which the Company received an exclusive, worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, offer to sell, lease and import products (Licensed Products) and to develop and perform processes (Licensed Processes) which incorporate the licensed technology for the treatment of disease, including but not limited to the prevention and remediation of hearing loss. The Company also has the right to grant sublicenses of its rights under the MIT License Agreement. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is required to use diligent efforts to develop and commercialize the Licensed Products or Processes, and to make such products or processes reasonably available to the public and to spend certain minimum amounts on research and development of Licensed Products and/or Processes each year until the first commercial sale of a Licensed Product and/or a first commercial performance of a Licensed Process. The Company is also subject to certain development obligations with regards to a first Licensed Product. The Company has satisfied certain obligations related to preclinical studies and the filing of an IND for a first Licensed Product with its development activities related to FX-322. The Company&#8217;s future development obligations are: (i) to commence a Phase II clinical trial for such Product, (ii) to commence a Phase III clinical trial for such Product within five years of the IND filing for such product within two years of the IND filing for such product, (iii) to file a New Drug Application or equivalent with the FDA or comparable European regulatory agency for such Product within nine years of the IND filing for such product, and (iv) to make a first commercial sale of such Product within 11 years of the IND filing for such product. The Company also has certain development obligations for as second Licensed Product. In the event that the Company has failed to fulfill the development timeline obligation with respect to a second Licensed Product and fail to cure such breach within ninety (90)&#160;days of written notice by MIT, MIT may restrict the licensed field to the prevention and remediation of hearing loss in humans and animals. The Company does not have the right to control prosecution of the in-licensed patent applications, and its rights to enforce the in-licensed patents are subject to certain limitations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon entering into the MIT License Agreement, the Company paid a $50 license fee payment and issued to MIT shares of our common stock equal to 5% of total then-outstanding capital stock. The Company is required to pay certain annual license maintenance fees which may be credited to running royalties during the same calendar year, if any, and to make potential milestone payments up to $2,900 on each Licensed Product or Licensed Process. In addition, The Company is required to pay a low single-digit royalty on Licensed Products and Licensed Processes and a low-twenties royalty on sublicense revenues. In the year ended December 31, 2019 the Company paid MIT a royalty of $16,000 related to the upfront payment received from Astellas, see Note 15.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-25</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The MIT License Agreement will remain effect until the expiration or abandonment of all issued patents and filed patent applications licensed thereunder remain in effect, unless terminated earlier. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has the right to terminate for any reason upon a </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3-month</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> prior written notice. MIT shall have the right to terminate if the Company ceases to carry on any business related to the MIT License Agreement. MIT may terminate the MIT License Agreement for the Company&#8217;s material breach uncured within ninety </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(90)&#160;days</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (or thirty (</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)&#160;days in the case of nonpayment). MIT may also terminate the MIT License Agreement if the Company or our affiliates commence any action against MIT to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or non-infringed (a patent challenge), or if our sublicensee commences such actions and the Company does not terminate such sublicense within thirty (30)&#160;days after MIT&#8217;s demand. MIT has the right to increase all payments due, instead of terminating the MIT License Agreement in the case of a patent challenge.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2019, the Company entered into an amendment with MIT, updating the diligence milestones for a second Licensed Product. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patents in-licensed by the Company from MIT pursuant to the MIT License claim inventions created by, among others, Dr. Langer, one of the Company&#8217;s directors.&#160;Pursuant to MIT&#8217;s policy on the ownership, distribution and commercial development of MIT technology, or the MIT Policy, inventors of intellectual property invented at MIT, including the inventors of patents licensed to the Company under the MIT License, are entitled to a portion of the net royalty income derived by MIT from such inventions, but not amounts received by MIT from the sale of common stock previously issued by the Company to MIT pursuant to the MIT License. Accordingly, pursuant to the MIT Policy, Dr. Langer is entitled to receive a portion of the amounts the Company pays to MIT under the MIT License, including the Astellas Royalty Payment and future milestone payments or royalties, if any, that the Company may receive pursuant to the Astellas Agreement. Accordingly, Dr. Langer has received $1.98 million and $0.01 million from MIT under the MIT Policy during the years ended December 31, 2020 and 2019, respectively. Refer to Note 18 for all related party disclosures. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The Scripps Research Institute (California Institute for Biomedical Research)</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2018, the Company entered into a license agreement, (CALIBR License Agreement), with the California Institute for Biomedical Research, (CALIBR), under which the Company received an exclusive, worldwide, royalty-bearing license to certain patent rights to make, have made, use, sell, offer to sell, and import products (CALIBR Licensed Products) which incorporate the licensed technology for the treatment of multiple sclerosis. The Company also have the right to grant sublicenses of our rights under the CALIBR License Agreement. CALIBR reserves the right to use for itself and the right to grant non-exclusive licenses to other nonprofit or academic institutions, for any internal research and educational purposes. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is required to use commercially reasonable efforts to develop, manufacture, and sell at least one Licensed Product and does not have the right to control prosecution of the in-licensed patent applications, and to enforce the in-licensed patents are subject to certain limitations. The Company is also subject to certain milestone timeline obligations , which may be extended under certain circumstances as outlined in the CALIBR License Agreement, to: (i) submit an IND (or equivalent) for a CALIBR Licensed Product by the 30th month after the effective date of the CALIBR License Agreement, (ii) initiate a Phase II clinical trial (or equivalent) for a CALIBR Licensed Product by the fourth anniversary of the effective date of the CALIBR License Agreement, and (iii) initiate a Phase III clinical trial (or equivalent) for a CALIBR Licensed Product by the sixth anniversary of the effective date of the CALIBR License Agreement. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon entering into the CALIBR License Agreement, the Company made a $1,000 license fee payment and are required to make milestone payments up to $26,000 for each Category of CALIBR Licensed Products (Category 1 means any CALIBR Licensed Products containing a compound that modulates any muscarinic receptor and Category 2 means any CALIBR Licensed Products not included in Category 1 that could differentiate oligodendrocyte precursors). The Company is also required to pay a middle single-digit royalty on CALIBR Licensed Products and a royalty on sublicense revenues ranging from low-teen percentage to 50%. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The CALIBR License Agreement shall continue in effect until expiration of all Company obligations to pay royalties. Royalties shall be payable on a country-by-country and CALIBR Licensed Product-by-CALIBR Licensed Product basis upon the later of (1)&#160;the expiration or abandonment of all valid claims of the licensed patent rights in such country and (2)&#160;ten years from the first commercial sale of each CALIBR Licensed Product. The Company may terminate the CALIBR License Agreement at will upon a 30-day prior written notice. The Company may also elect to terminate its license to one or more licensed patents in any or all jurisdictions by giving ninety (90)&#160;days&#8217; prior written notice to CALIBR. CALIBR may terminate the CALIBR License Agreement for material breach uncured within thirty (30)&#160;days. CALIBR has the right to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-26</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">terminate or reduce the license to a non-exclusive license if the Company fails to use diligent efforts to develop and commercially exploit CALIBR Licensed Products.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The Scripps Research Institute</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2018, we entered into a Research Funding and Option Agreement, or the Scripps option agreement, with Scripps, under which we were granted an exclusive option to acquire an exclusive, sublicensable, worldwide license under certain intellectual property related to the treatment of MS. As consideration for the Scripps option agreement, we made funding payments totaling $0.7 million to Scripps to support its research activities. Scripps has agreed to use reasonable efforts to perform the research program pursuant to the Scripps option agreement. The Scripps option agreement had a one-year term and was renewed for a second year by mutual written agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2020, the Company extended the term of the option agreement through the end of December 2021. As consideration for this extension, the Company is required to make additional funding payments of $0.6 million to Scripps through December 2021.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has the right to terminate by giving 90 days&#8217; advance notice. Scripps has the right to terminate in the event of nonpayment by us that remains uncured for 10 days. Each party has the right to terminate in the event of the other party&#8217;s material breach that remains uncured for 60 days or if the other party becomes bankrupt.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Massachusetts Eye and Ear (Formerly Massachusetts Eye and Ear Infirmary) </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2019, the Company entered into an Non-Exclusive Patent License Agreement (MEE License Agreement) with the Massachusetts Eye and Ear (MEE) under which it received a non-exclusive, non-sublicensable, worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, offer to sell, lease and import products and to develop and perform processes which incorporate the licensed technology for the treatment or prevention of hearing loss. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is required to use diligent efforts to develop and commercialize the licensed products and MEE has control over the filing, prosecution, enforcement and defense of any licensed patent rights. We met one of our milestone timeline obligations by dosing a first patient in a Phase&#160;II trial by December&#160;31, 2020. We are still subject to a milestone timeline obligation to dose a first patient in a Phase&#160;III trial by December&#160;31, 2024.  </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon entering into the MEE License Agreement, the Company made a $20 license fee payment and is required to pay certain annual license maintenance fees until the first commercial sale and a minimum annual royalty payment after the first commercial sale. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is also required to make milestone payments up to $350 on each product or process which incorporates the licensed patent rights and pay a low single-digit royalty on products and processes that incorporate the licensed patent rights. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The MEE License Agreement shall remain in effect until all issued patents and filed patent applications within the licensed patent rights have expired or been abandoned, unless terminated earlier. The Company has the right to terminate the MEE License Agreement at will by giving thirty (30)&#160;business days advance written notice to MEE. MEE has the right to terminate the MEE License Agreement if the Company fails to make any payment due within thirty (30)&#160;business days after MEE notifies the Company of such failure. MEE shall have the right to terminate if the Company fails to maintain the required insurance. MEE shall also have the right to terminate the MEE License Agreement upon forty-five (45)&#160;business days written notice if the Company becomes insolvent. MEE has the right to terminate for any other default not cured within sixty (60)&#160;business days written notice. MEE also has the right to terminate if the Company or its affiliates challenge the validity of the licensed patent rights. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cambridge Enterprise Limited</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, we entered into an Exclusive Patent License Agreement ( the &#8220;Cambridge License&#8221;) with Cambridge Enterprise Limited (the technology transfer arm of the University of Cambridge)<font style="font-size:12pt;"> </font>(&#8220;Cambridge&#8221;) under which we received an executive worldwide royalty-bearing license to certain patent rights to make, have made, sell, offer to sell and import products, or the (the &#8220;Cambridge License Product&#8221;) which incorporate licensed technology for the treatment of demyelinating diseases.&nbsp;&nbsp;We also have the right to grant nonexclusive licenses to other academic institutions for any academic publication, research and teaching and clinical patient care.&nbsp;&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-27</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> agreed to use diligent and good faith efforts to develop and commercially exploit at least one Cambridge Licensed Product.&nbsp;&nbsp;Upon </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">entering into</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the Cambridge License, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Company</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> made a $</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> license fee payment.&nbsp;&nbsp;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> obligated to pay an annual license fee of $</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> also obligated to make milestone payments up to $</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million on each Cambridge License Product</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;In addition, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Company has</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> agreed to pay a low single-digit royalty on products that incorporate the licensed patent rights, subject to offset in certain circumstances.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Cambridge License continues in effect on a country-by-country basis until the expiration or revocation, without right of further appeal, of all licensed issued patents and filed patent applications, unless terminated earlier.&nbsp;&nbsp;We have the right to terminate for any reason upon 90 days&#8217; prior to written notice.&nbsp;&nbsp;Each party has the right to terminate immediately if the other party ceases to carry on its business.&nbsp;&nbsp;Either party may also terminate the Cambridge License for material breach if such breach remains uncured for 30 days.&nbsp;&nbsp;Cambridge may also terminate the Cambridge License if we fail to diligently develop and commercially exploit at least one Cambridge Licensed Product or we or our affiliates or sub-licenses commence any action against Cambridge to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or not infringed.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Department of Defense </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2018, the Company received a grant (the Grant) from the Department of Defense (DoD) under which the Company is receiving funding to further the Company&#8217;s research and development of a therapeutic drug to treat hearing loss. The Company is receiving funding of $1,596 over two years from the date of the Grant. The Company has determined that the DoD is not considered a customer under ASC 606, therefore funding received from the DoD under the Grant is recorded as a reduction of research and development expenses. The Company has recorded $323 and $845 as a reduction in research and development expenses for the years ended December&#160;31, 2020 and 2019, respectively. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15. Collaboration agreement </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2019, the Company entered into a License and Collaboration Agreement with Astellas (the Astellas Agreement), under which the Company granted Astellas an exclusive, royalty-bearing, sub-licensable, nontransferable license to certain patent rights to research, develop, manufacture, have manufactured, use, seek and secure regulatory approval for, commercialize, offer for sale, sell, have sold and import, and otherwise exploit licensed products containing both a GSK-3 inhibitor and an HDAC inhibitor, (the Astellas Licensed Products), including the product candidate FX-322, outside of the United States. The Company also granted Astellas a right of first negotiation and a right of last refusal if it entered into any negotiation or agreement of any kind (other than an acquisition of all of the stock or assets of the Company) with any third party under which such third party would obtain the right to develop, manufacture, or commercialize Astellas Licensed Products in the United States. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has agreed to conduct Phase 2a clinical studies in the United States. Upon the completion thereof, the Company and Astellas have agreed to jointly develop the Astellas Licensed Products, including carrying out joint studies. Each party has agreed to use commercially reasonable efforts to carry out development activities assigned to it under an agreed-upon development plan. Astellas has agreed to use commercially reasonable efforts to obtain regulatory approval for at least one Astellas Licensed Product in sensorineural hearing loss and in age-related hearing loss, in each case, in one major Asian country and one major European country. The Company has agreed to use commercially reasonable efforts to obtain regulatory approval for at least one Astellas Licensed Product in the United States. Astellas has the sole right to commercialize the Astellas Licensed Products outside of the United States, and the Company has the sole right to commercialize the Astellas Licensed Products in the United States. Astellas has agreed to use commercially reasonable efforts to commercialize Astellas Licensed Products in a major Asian country and a major European country following receipt of regulatory approval in such countries. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The collaboration is governed by a joint steering committee (&#8220;JSC&#8221;) established under the Astellas Agreement and shall be comprised of three representatives each from the Company and Astellas. The JSC shall oversee and coordinate the overall conduct of the development, manufacture and commercialization of the Astellas Licensed Products. All decisions of JSC shall be taken through a unanimous vote with each party&#8217;s representatives collectively having one vote. Both the parties shall be responsible for carrying out the development and manufacturing activities in their defined territory in accordance with the plan as reviewed and approved in the JSC. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As consideration for the licensed rights under the Astellas Agreement, Astellas paid the Company an upfront payment of $80.0&#160;million in July 2019 and has agreed to pay potential development milestone payments up to $230.0&#160;million and commercialization milestones of up to $315.0 million. Specifically, the Company would receive development milestone </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-28</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">payments of $</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.0</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">m</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">illion and </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.0</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million upon the first dosing of a patient in a Phase 2b clinical trial for SNHL in Europe and Asia, respectively and </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100.0</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million and $</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40.0</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million upon the first dosing of a patient in a Phase 3 clinical trial for SNHL in Europe and Asia, respectively. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> If the Astellas Licensed Products are successfully commercialized, the Company would be eligible for up to $</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">315.0&#160;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million in potential commercial milestone payments </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and also</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> tiered royalties at rates ranging from low- to mid-teen percentages. The parties shall share equally, on a 50/50 basis, all out-of-pocket costs and joint study costs for all the joint activities conducted pursuant to the development plans or the joint manufacturing plan. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Astellas Agreement remains in effect until the expiration of all royalty obligations. Royalties are paid on a licensed product-by-licensed product and country-by-country basis until the latest of (i)&#160;the expiration of the last valid claim in the licensed patent rights with respect to such Astellas Licensed Product in such country or (ii) a set number of years from the first commercial sale of such Astellas Licensed Product in such country. Astellas may terminate the Astellas Agreement at will upon 60 days&#8217; written notice. Each party has the right to terminate the Astellas Agreement due to the other party&#8217;s material breach if such breach remains uncured for 90 days (or 45 days in the case of nonpayment) or if the other party becomes bankrupt. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Astellas Agreement is a collaborative agreement that is within the scope of ASC 808. The Company analyzed the joint research and development activities to assess whether they fall within the scope of ASC 808, and will reassess this throughout the life of the arrangement based on changes in the roles and responsibilities of the parties. Based on the terms of the arrangement as outlined above, both parties are deemed to be active participants in the collaboration. Both parties are performing research and development activities in their defined territory and will be performing joint clinical studies in accordance with the development plan and the study protocol approved by the JSC. Additionally, Astellas and the Company are exposed to significant risks and rewards dependent on the commercial success of any product candidates that may result from the collaboration. As such, the collaboration arrangement is deemed to be within the scope of ASC 808. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The arrangement consists of two components; the license of IP and the research and development activities, including committee participation, to support the co-development and research plan. Under the provisions of ASC 808, the Company has determined that it will apply the guidance in ASC 606 to recognize the revenue related to the license since that component of the arrangement is more reflective of a vendor-customer relationship. The Company determined that the license and the related research and development services associated with the Phase 2a clinical study were not distinct from one another, as the license has limited value to Astellas without the performance of the research and development activities and the Phase 2a study is essential to the use of the license. As such, the Company determined that these activities should be accounted for as a single combined performance obligation. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue associated with this single performance obligation is being recognized as the research and development work is performed, using an input method on the basis of research and development costs incurred to date relative to total research and development costs expected to be incurred. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligation. The Company has determined that the period of performance of the research and development services began upon the signing of the Astellas Agreement and will continue until the completion of the Phase 2a clinical trial of FX-322. The transaction price of $80.0 million has been allocated to the single combined performance obligation and will be recognized over such period. Management has analyzed the progress of the Phase 2a clinical trial and has estimated the completion date of such trial and the total costs it expects to incur in performing the trial and is recognizing the $80.0 million upfront fee as revenue over the period from July 2019 until the estimated completion date using the input method. The Company regularly assesses its estimates and to the extent that facts and circumstances dictate, the Company revises its estimates of total cost or completion date and accounts for such change on a prospective basis. The Company was required to pay MIT a royalty of $16.0 million on the $80.0 million of sublicense revenues. The $16.0 million royalty was expensed in the third quarter of 2019.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The $80.0&#160;million upfront payment received from Astellas in July 2019 was initially recorded as deferred revenue and is being recognized as revenue according to the policy described above. In the year ended December 31, 2020, the Company recognized $37.0 million of revenue under the Astellas Agreement. In the year ended December 31, 2019, the Company recorded $28.9 million of revenue under the Astellas Agreement which included $16.0 million related to the royalty payment to MIT and $12.9 million based upon the application of the input method to the remaining $64.0 million to be recognized over the estimated period to completion of the Phase 2a clinical trial for FX-322. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The potential development and regulatory milestone payments are fully constrained until the Company can conclude that achievement of the milestone is probable and that it is probable that recognition of revenue related to the milestone will not result in a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is ultimately resolved and as such these have been excluded from the transaction price. As part of its </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-29</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">evaluation of the constraint, the Company considers numerous factors, including the fact that achievement of the milestones is outside the control of the Company and contingent upon the future success of clinical trials, the licensee&#8217;s efforts, and the receipt of regulatory approval. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the license granted to Astellas and therefore are recognized at the later of when the performance obligation is satisfied, or the related sales of licensed products occur. The Company re-evaluates the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts, at each reporting period and as uncertain events are resolved or other changes in circumstances occur, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Astellas Agreement contains joint research and development activities that are not within the scope of ASC 606. The Company will recognize research and development expense related to the joint study costs for all the joint activities in future periods and reimbursements received from Astellas will be recognized as an offset to research and development expense on the consolidated statement of operations during the development period. In the years ended December 31, 2020 and 2019, the Company invoiced Astellas $1,046 and $186 for joint costs, respectively.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">16. Commitments and contingencies </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Operating leases </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2016, the Company and a related third party (see Note 18) entered into a five-year operating lease for the Company&#8217;s primary office and laboratory space in Woburn, Massachusetts. <font style="color:#000000;">The lease was extended in November 2019 and expires in February 2025. Additionally, the Company amended the lease in November 2019 to add additional laboratory and office space. The commencement date of the additional space occurred in February 2020 and expires in February 2025. The lease agreements do not contain any material residual value guarantees or material restrictive covenants.</font> <font style="font-size:12pt;">&#160;</font>The Company also leases a laboratory facility in Connecticut under an operating lease which expires in 2021.<font style="font-size:12pt;">&#160;&#160;</font> </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 11, 2020, the Company entered into an Agreement for Termination of Lease and Voluntary Surrender of Premises (the &#8220;Lease Termination Agreement&#8221;) with ARE-MA Region No. 20, LLC (the &#8220;Landlord&#8221;). The Lease Termination Agreement provides that the Lease Agreement, dated as of August 14, 2016, by and between the Company and Landlord (as the same may have been amended, the &#8220;Lease&#8221;) will terminate on March 31, 2021, unless the Company elects to extend the term of the Lease. The Company exercised the option to extend the lease until May 31, 2021.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As consideration for the Landlord&#8217;s agreement to enter into the Lease Termination Agreement and accelerate the expiration date of the term of the Lease, the Company has agreed to pay to Landlord a fee of approximately $0.2 million.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 7, 2020 the Company entered into an indenture of lease (the &#8220;Lexington Lease&#8221;) with HCP/KING 75 Hayden LLC, for the lease of approximately 61,307 square feet of rentable area in Lexington, Massachusetts or (the &#8220;Lexington Premises&#8221;).&nbsp;&nbsp;The Lexington Lease commenced on December 11, 2020, (the &#8220;Commencement Date&#8221;).&nbsp;&nbsp;The Company expects to use the Lexington Premises as its new principal executive offices and as a laboratory for research and development, and other related uses.&nbsp;&nbsp;The term of the Lexington Lease, (the &#8220; Initial Term&#8221;), is ten years from the rent commencement date (which is five months following the Commencement Date) and the Initial Term is expected to end on May 31, 2031.&nbsp;&nbsp;The Company also has the option to extend the Initial Term for two additional terms of five years each.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of&#160;December 31, 2020, the Company has $30,551&#160;of operating lease ROU assets, and&#160;$397&#160;and $30,597&#160;of current and non-current lease liabilities, respectively, recorded on the consolidated balance sheets. For the year ended December 31, 2020&#160;the Company recorded $470&#160;of operating lease cost, $510<font style="font-size:12pt;">&#160;</font>of variable lease cost, and $106&#160;of short-term lease cost. The lease expense for the years ended December 31, 2020 and 2019 are $835&#160;and $269, respectively. Cash paid for amounts included in the measurement of lease liabilities for year ended&#160;December 31, 2020&#160;is $484.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other information</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.52%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3 years</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate (1)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.5</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Rate includes the Company&#8217;s Woburn and Lexington leases. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-30</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below reconciles the undiscounted cash flows to the operating lease liability recorded on the consolidated balance sheet as of December 31, 2020. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,928</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,159</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,284</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,412</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,545</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,070</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum lease payments</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,398</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: amount of lease payments representing interest</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,404</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of future lease payments</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,994</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: current lease liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(397</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent lease liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,597</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future aggregate minimum payments under the noncancelable operating leases and short term leases, including the Lexington, MA lease and Connecticut lease, which is not subject to ASC 842, as of December 31, 2020 are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;">
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,986</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,159</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,284</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,412</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,545</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026 and beyond</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,070</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum lease payments</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,456</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Contract commitments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has contracted with a research institution to provide research for a therapeutic drug to treat multiple sclerosis. In September 2020, the Company extended the term of this contract through December 2021. As consideration for this extension, the Company committed to total payments of $0.6 million through December 2021. <font style="font-size:12pt;">&#160;</font> <font style="font-size:12pt;">&#160;</font>&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company enters into contracts in the normal course of business with CROs, CMOs, universities, and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts generally do not contain minimum purchase commitments and are cancelable by us upon prior written notice although, purchase orders for clinical materials are generally non-cancelable. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including non-cancelable obligations of our service providers, up to the date of cancellation or upon the completion of a manufacturing run. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Guarantees </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has identified the guarantees described below as disclosable, in accordance with ASC 460, <font style="font-style:italic;">Guarantees</font>. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving at the Company&#8217;s request in such capacity. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors&#8217; and officers&#8217; insurance coverage that should limit its exposure and enable it to recover a portion of any future amounts paid. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is a party to a number of agreements entered into in the ordinary course of business that contain typical provisions that obligate the Company to indemnify the other parties to such agreements upon the occurrence of certain events. Such indemnification obligations are usually in effect from the date of execution of the applicable agreement for a period equal to the applicable statute of limitations. The aggregate maximum potential future liability of the Company under such indemnification provisions is uncertain. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-31</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases office space </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in Woburn, Massachusetts under</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> a </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">five-year</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> non</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cancelable operating lease</font><font style="color:#000000;">, and has </font><font style="color:#000000;">entered into</font><font style="color:#000000;"> a facility lease in Lexington, Massachusetts. The Company has standard indemnification arrangements under these leases that require it to indemnify the landlord against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation, or nonperformance of any covenant or condition of the lease</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020 and 2019, the Company had not experienced any losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves have been established. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">17. Employee benefit plan </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employees of the Company are eligible to participate in the Company&#8217;s 401(k) retirement plan (the &#8220;401(k) Plan&#8221;). Participants may contribute up to 90% of their annual compensation to the 401(k) Plan, subject to statutory limitations. Under the 401(k) Plan Safe Harbor Match, the Company matches 100% of the first 5% of employee contributions and vests 100% at time of match. For the years ended December 31, 2020 and 2019, the Company made matching contributions of $0.4 million and $0.2 million, respectively. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18. Related party transactions </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s lease for its Woburn, Massachusetts facility, see Note 16, is with an entity affiliated with one of the Company&#8217;s directors and shareholders. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As disclosed in Note 14, the Company entered into the MIT License Agreement in December 2016. <font style="color:#000000;">The patents in-licensed by the Company from MIT pursuant to the MIT License Agreement claim inventions created by, among others, Dr. Langer, one of the Company&#8217;s directors. Accordingly, Dr. Langer has received $1.98 million and $0.01 million from MIT under the MIT Policy during the years ended December 31, 2020 and 2019, respectively.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">19. Subsequent events </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has evaluated subsequent events for recognition, remeasurement and disclosure purposes through March 29, 2021, the date which the consolidated financial statements were available to be issued. The identified subsequent events are as follows; </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 18, 2021, the Company completed the liquidation and dissolution of Frequency Therapeutics Japan KK, the Company&#8217;s Japanese subsidiary. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 23, 2021, the Company announced topline, day-90 data from its FX-322 Phase 2a study. The interim results show that four weekly injections in subjects with mild to moderately severe sensorineural hearing loss did not demonstrate improvements in hearing measures versus placebo. No treatment-related serious adverse events were observed in the study. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company also announced new preliminary data from a parallel study demonstrating hearing improvement from a single injection of FX-322. The single dose showed efficacy that was clinically meaningful and statistically significant compared to the untreated ear, had a favorable safety profile and was well tolerated.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-32</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">20. Selected Quarterly Data (Unaudited) </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table contains quarterly financial information for 2020 and 2019.&nbsp;&nbsp;The Company believes that the following information reflects all normal recurring adjustments necessary for the fair statement of the information for the periods presented.&nbsp;&nbsp;The operating results for any quarter are not necessarily indicative of results for any future period.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except per share amounts)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,264</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,523</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,247</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,950</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">36,984</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,177</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,548</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,588</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,182</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">63,495</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,913</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,025</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,341</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,232</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(26,511</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cumulative series C convertible preferred stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; dividends</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,913</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,025</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,341</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,232</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(26,511</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common shareholders -</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.16</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.19</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.16</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.30</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(0.82</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except per share amounts)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,238</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,709</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">28,947</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,826</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,852</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,813</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,202</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">47,693</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,826</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,852</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(575</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,493</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(18,746</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cumulative series C convertible preferred stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; dividends</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,014</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(1,054</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,826</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,852</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,589</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,533</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(19,800</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common shareholders -</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.24</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.42</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.73</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.19</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(2.29</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:7.14%;text-indent:3.57%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-33</a></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>2
<FILENAME>freq-ex1016_1057.htm
<DESCRIPTION>EX-10.16
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
freq-ex1016_1057.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.16</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:33.33%;"></td>
<td style="width:44.87%;"></td>
<td style="width:21.79%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gqmjb0hqad4j000001.jpg" title="" alt="" style="width:211px;height:48px;"></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#29ADC6;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19 Presidential Way, Suite 203</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#29ADC6;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Woburn, MA 01801</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 19, 2019</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wendy S. Arnold</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64 East Street</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ipswich, MA 01938</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Re:&nbsp;&nbsp;Employment Terms</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dear Wendy:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On behalf of us at Frequency Therapeutics, Inc. (the &#8220;Company&#8221;), I am pleased to offer you full-time employment, subject to the terms and conditions below. We expect that your employment with the Company will commence no later than February 3, 2020 in the Company&#8217;s Woburn, MA offices.&nbsp;&nbsp;You will be employed as Chief People Officer, reporting to David Lucchino, Chief Executive Officer.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Your responsibilities will include but not be limited to:&nbsp;&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Reinforce and build upon a &#8220;check your ego at the door&#8221; culture. (This means supporting our team/teammates, even when one might not get the bulk of the credit one feels they might otherwise deserve.) This approach is fundamental to our culture as team Frequency&#8217;s number one mission is to help patients regain hearing while building value for shareholders. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Develop the overall strategic HR plan and prioritize and implement key HR initiatives.&nbsp;&nbsp; Participate in the development of the organization's plans and programs as a strategic partner, bringing a business perspective as well as the perspective of people and organization.&nbsp;&nbsp; Evaluate and advise on the impact of strategic and growth initiatives on attracting, motivating, developing and retaining our talent.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Act as a trusted advisor and coach to leaders, managers, and employees. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Develop and execute the recruitment strategy and workforce plan to enable our rapid growth.&nbsp;&nbsp; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Coach hiring managers to identify and recruit strong and diverse talent.&nbsp;&nbsp;Design and implement effective and nimble recruiting procedures and practices.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Work with the Leadership Team to design the structure and roles to achieve strategic and growth goals.&nbsp;&nbsp;Advise leaders on optimal staffing and team structure.&nbsp;&nbsp; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Champion, promote, and embed an innovative and inclusive company culture.&nbsp;&nbsp; Implement programs and practices to sustain the culture as the company grows.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Evaluate Frequency&#8217;s current people-related practices and identifies opportunities for improvement.&nbsp;&nbsp;Partners with the CEO, CFO, and General Counsel to develop progressive and competitive compensation and benefits programs to provide motivation, incentives and rewards for strong performance.&nbsp;&nbsp; Contribute to the development of presentations to the Compensation Committee of the Board of Directors.&nbsp;&nbsp;Coordinate with Frequency&#8217;s external compensation consultant to support analyses for the Compensation Committee. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US-DOCS\110928677.1</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manage and facilitate Frequency&#8217;s goal setting and performance assessment process.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Supports continuous leader, manager, and employee development by implementing learning programs to ensure skill development needed to build a high-performing company. Ensure strong people management practices, including feedback and assessment.&nbsp;&nbsp; Work with managers to create career paths that grow and retain talent.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Partner with Legal to develop appropriate policies and programs for effective and compliant management of the people resources of the organization, including employee relations, affirmative action, sexual harassment, employee complaints, external education and career development.&nbsp;&nbsp;Stay abreast of and ensures compliance with new laws and regulations.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Oversee the development and management of HR operations, systems, and processes that will scale as Frequency rapidly grows.&nbsp;&nbsp;Manage the human resource information database (HRIS) and production of necessary reports while ensuring the confidentiality of HR data.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Structure, develop and oversee the HR resources to provide maximum benefit to the organization as it grows.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Identify, hire, and oversee external resources effectively when outside expertise is necessary.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Your compensation will be </font><font style="font-weight:bold;color:#000000;">$</font><font style="font-weight:bold;font-style:italic;color:#000000;">25,666.67 per month</font><font style="color:#000000;"> subject to tax and other withholdings as required by law.&nbsp;&nbsp;In addition, you will be eligible for an annual performance-based bonus with a target amount equal to 35% of your annualized base salary, based on your individual performance and the Company&#8217;s performance during the applicable fiscal year, in accordance with certain milestones to be determined by the board of directors of the Company (the &#8220;Board&#8221;). The Company also agrees to pay the equivalent of your 2019 annual bonus at your previous employer, which is an amount equal to $52,272. Your salary may be adjusted from time to time in accordance with normal business practice and at the sole discretion of the Company. The actual amount of any such annual bonus payable to you will be determined by the Board in its discretion. You must be an active employee of the Company on the date any bonus is paid in order to be eligible for payment of an annual bonus.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">You will be eligible for Frequency Health, Dental, Vision and Disability insurance, in addition to participation in the Company&#8217;s 401(k) the first of the month following your first day of employment. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">You will be eligible for a maximum 15 Paid Time Off days (PTO) per calendar year to be taken at such times as may be approved by the Company. These PTO days are accrued monthly at a rate of 10 hours per month.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">You will be required to execute an Employee Proprietary Information and Inventions Assignment Agreement in the form attached as </font><font style="text-decoration:underline;color:#000000;">Exhibit B</font><font style="color:#000000;">, as a condition of employment. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">You represent that you are not bound by any employment contract, restrictive covenant or other restriction preventing you from entering into employment with or carrying out your responsibilities for the Company, or which is in any way inconsistent with the terms of this letter. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US-DOCS\110928677.1</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">In connection with entering into this letter agreement, following the commencement of your employment with the Company, the Company will recommend to the Board of Directors or its designee that it grant you an option to purchase 130,000 shares of the Company&#8217;s common stock (the &#8220;Stock Option&#8221;) at a per-share exercise price equal to the fair market value of a share of the Company&#8217;s common stock on the date of grant (as determined under the Plan (as defined below)), provided that you are employed by the Company on the date of grant&#160; Subject to your continued employment with the Company through the applicable vesting date, 25% of the shares underlying the Stock Option will vest on the first anniversary of the date you commence employment with the Company and 1/48th of the total number of shares initially underlying the Stock Option will vest on each monthly anniversary thereafter.&#160; The Stock Option will otherwise be subject to the terms and conditions of the Company&#8217;s 2019 Incentive Award Plan (the &#8220;Plan&#8221;) and a stock option agreement to be entered into between you and the Company. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">You agree to provide to the Company, within three days of your hire date, documentation of your eligibility to work in the United States, as required by the Immigration Reform and Control Act of 1986. You may need to obtain a work visa in order to be eligible to work in the United States.&nbsp;&nbsp;If that is the case, your employment with the Company will be conditioned upon your obtaining a work visa in a timely manner as determined by the Company.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">8.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">This offer set forth in this letter is contingent upon the Company completing a background check on you to its satisfaction in accordance with applicable laws. The Company engages a third-party provider to perform background checks and such provider will be reaching out to you under separate cover to provide the background check disclosure and required authorization forms for your review and execution.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">9.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Company shall have the right to terminate your employment without &#8220;Cause&#8221; (as defined on Exhibit A hereto).&nbsp;&nbsp;Termination &#8220;Without Cause&#8221; means the Company&#8217;s termination of your employment for any reason other than for Cause, death or as a result of you becoming permanently disabled (within the meaning of Section 22(e) of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;)).&nbsp;&nbsp;If the Company terminates your employment with the Company Without Cause or you terminate your employment with the Company with Good Reason (as defined on Exhibit A hereto), you shall be entitled to payment of your unpaid base salary earned for the period up to the date of such termination, amounts accrued or payable under any benefit plans and programs of the Company applicable to you up to the date of such termination, subject to and in accordance with the terms of such plans and programs, and amounts payable on account of any unreimbursed business expenses incurred in accordance with Company policy up to the date of such termination.&nbsp;&nbsp;In addition, in the event you deliver to the Company a general release of claims against the Company and its affiliates in a form reasonably acceptable to the Company that becomes effective and irrevocable within sixty (60) days following such termination of employment (&#8220;Release Condition&#8221;) and subject to your compliance with the terms of any confidentiality, non-competition, non-solicitation or other similar restrictive covenants with the Company to which you are subject, the Company will (i) continue to pay your then current base salary, less all applicable withholding taxes and authorized deductions, for a period of twelve (12) months following the date of termination (&#8220;Severance Period&#8221;), (ii) an amount equal to 100% of your annual bonus opportunity, less all applicable taxes and withholdings, in one lump sum within </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US-DOCS\110928677.1</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">14 days of the </font><font style="color:#000000;">satisfaction of the Release Condition, </font><font style="color:#000000;">and (</font><font style="color:#000000;">i</font><font style="color:#000000;">ii) should you timely elect and be eligible to continue receiving group medical and dental coverage pursuant to COBRA, and so long as the Company can provide such benefit without violating the non-discrimination requirements of the law, the Company will pay the portion of the premium for such coverage that is paid by the Company for active and similarly situated employees who receive the same type of coverage, such payment to be made for coverage from the termination date through the earliest of (x) the end of the Severance Period, (y) the date you are no longer eligible for COBRA coverage or (z) the date you become eligible for healthcare coverage from a subsequent employer (and you agree to promptly notify the Company of such eligibility).&nbsp;&nbsp;The remaining balance of any premium cost shall timely be paid by </font><font style="color:#000000;">you</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">10.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Notwithstanding Section 9 hereof, if the Company terminates your employment with the Company Without Cause or you terminate your employment with the Company with Good Reason during the twelve (12) month period commencing on a Change in Control (as defined on Exhibit A hereto), then, subject to your compliance with the Release Condition and with the terms of any confidentiality, non-competition, non-solicitation or other similar restrictive covenants with the Company to which you are subject, in lieu of (and not in addition to) the amounts in Section 9 hereof, (i) the Company will pay you (x) the same benefits as set forth in Section 9 hereof, except that the Severance Period will be twelve (12) months and (y) an amount equal to 100% of your target annual bonus for the year in which the termination occurs, less all applicable taxes and withholdings, in one lump sum within 14 days of the execution of the Release Agreement, and (ii) the vesting and, to the extent applicable, exercisability of each equity award, including all unvested stock options, held by you as of the date the termination occurs will accelerate in respect of one hundred percent (100%) of the shares subject thereto.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">11.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Nothing in this letter or any other prior agreement between you and the Company (collectively, the &#8220;Subject Documents&#8221;) prevents you from reporting possible violations of law or regulation to any governmental agency or entity in accordance with the provisions of and rules promulgated under Section 21F of the Securities Exchange Act of 1934 or Section 806 of the Sarbanes-Oxley Act of 2002, or any other whistleblower protection provisions of state or federal law or regulation (including the right to receive an award for information provided to any such government agencies).&nbsp;&nbsp;Furthermore, in accordance with 18 U.S.C. &#167; 1833, notwithstanding anything to the contrary in any Subject Document: (a) you shall not be in breach of any Subject Document, and shall not be held criminally or civilly liable under any federal or state trade secret law (i) for the disclosure of a trade secret that is made in confidence to a federal, state, or local government official or to an attorney solely for the purpose of reporting or investigating a suspected violation of law, or (ii) for the disclosure of a trade secret that is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal; and (b) if you file a lawsuit for retaliation by the Company for reporting a suspected violation of law, you may disclose the trade secret to your attorney, and may use the trade secret information in the court proceeding, if you file any document containing the trade secret under seal, and do not disclose the trade secret, except pursuant to court order.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">12.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">This letter shall be interpreted to avoid any additional tax under Section 409A of the Code (&#8220;Section 409A&#8221;).&nbsp;&nbsp;If any payment or benefit cannot be provided or made at the time </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US-DOCS\110928677.1</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">specified without incurring sanctions under Section 409A, then such benefit or payment shall be provided in full at the earliest time thereafter, when such </font><font style="color:#000000;">sanctions will not be imposed.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding anything in this letter to the contrary, any compensation or benefit payable under this letter upon your termination of employment shall be payable only upon your &#8220;separation from service&#8221; with the Company within the meaning of Section 409A (a &#8220;Separation from Service&#8221;) and, except as provided below, any such compensation or benefits shall not be paid, or, in the case of installments, shall not commence payment, until the sixtieth (60th) day following your Separation from Service (the &#8220;First Payment Date&#8221;).&nbsp;&nbsp;Any installment payments that would have been made to you during the sixty (60) day period immediately following your Separation from Service but for the preceding sentence shall be paid to you on the First Payment Date and the remaining payments shall be made as provided in this letter.  The right to receive any installment payments under this letter, including without limitation any continuation salary payments that are payable on Company payroll dates, shall be treated as a right to receive a series of separate payments and, accordingly, each such installment payment shall at all times be considered a separate and distinct payment as permitted under Section 409A.&nbsp;&nbsp;Except as otherwise permitted under Section 409A, no payment hereunder shall be accelerated or deferred unless such acceleration or deferral would not result in additional tax or interest pursuant to Section 409A.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding any other provision of this letter to the contrary, and solely if and to the extent necessary for compliance with Section 409A and not otherwise eligible for exclusion from the requirements of Section 409A, if as of the date of your Separation from Service from the Company, you are deemed to be a &#8220;specified employee&#8221; (within the meaning of Section 409A), no payment or other distribution required to be made to you hereunder (including any payment of cash, any transfer of property and any provision of taxable benefits) as a result of your Separation from Service shall be made until the date that is the earlier of (1) the expiration of the six-month period measured from the date of your Separation from Service or (2) the date of your death.&nbsp;&nbsp;Upon the expiration of the foregoing delay period, all payments and benefits delayed pursuant to the foregoing shall be paid to you in a lump sum, and all remaining payments and benefits due under this letter shall be paid or provided in accordance with the normal payment dates specified for them herein.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">13.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Notwithstanding any other provisions of this letter, in the event that any payment or benefit made by the Company or otherwise to you or for your benefit, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise (all such payments and benefits, including the payments and benefits under Section 9 and Section 10 hereof, being hereinafter referred to as the &#8220;Total Payments&#8221;), would be subject (in whole or in part) to the excise tax imposed by Section&#160;4999 of the Code (the &#8220;Excise Tax&#8221;), then the Total Payments shall be reduced (in the order provided in this Section below) to the minimum extent necessary to avoid the imposition of the Excise Tax on the Total Payments, but only if (a) the net amount of such Total Payments, as so reduced (and after subtracting the net amount of federal, state and local income and employment taxes on such reduced Total Payments and after taking into account the phase out of itemized deductions and personal exemptions attributable to such reduced Total Payments), is greater than or equal to (b) the net amount of such Total Payments without such reduction (but after subtracting the net amount of federal, state and local income and employment taxes on such Total Payments and the amount of the Excise Tax to which you would be subject in </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US-DOCS\110928677.1</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">respect of such unreduced Total Payments and after taking into account the phase out of itemized deductions and personal exemptions attributable to such unreduced Total Payments).</font><font style="color:#000000;">&nbsp;&nbsp;</font><font style="color:#000000;">The</font><font style="color:#000000;"> Total Payments shall be reduced in the following order:&nbsp;&nbsp;(</font><font style="color:#000000;">i</font><font style="color:#000000;">) reduction on a pro-rata basis of any cash severance payments that are exempt from Section&#160;409A, (ii) reduction on a pro-rata basis any non-cash severance payments or benefits that are exempt from Section&#160;409A, (iii) reduction on a pro-rata basis of any other payments or benefits that are exempt from Section&#160;409A, and (iv) reduction of any payments or benefits otherwise payable on a pro-rata basis or such other manner that complies with Section 409A; provided, in case of clauses (ii), (iii) and (iv), that reduction of any payments attributable to the acceleration of vesting of Company equity awards shall be first applied to Company equity awards that would otherwise vest last in time.</font><font style="color:#000000;">&nbsp;&nbsp;</font><font style="color:#000000;">All determinations regarding the application of this </font><font style="color:#000000;">Section </font><font style="color:#000000;">shall be made by an accounting firm or consulting group with experience in performing calculations regarding the applicability of Section 280G of the Code and the Excise Tax selected by the Company (the &#8220;</font><font style="color:#000000;">Independent Advisors</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;For purposes of</font><font style="color:#000000;"> these</font><font style="color:#000000;"> determinations, no portion of the Total Payments shall be taken into account which, in the opinion of the Independent Advisors, (</font><font style="color:#000000;">x</font><font style="color:#000000;">) does not constitute a &#8220;parachute payment&#8221; within the meaning of Section 280G(b)(2) of the Code (including by reason of Section 280G(b)(4)(A) of the Code) or (</font><font style="color:#000000;">y</font><font style="color:#000000;">) constitutes reasonable compensation for services actually rendered, within the meaning of Section 280G(b)(4)(B) of the</font><font style="color:#000000;"> </font><font style="color:#000000;">Code, in excess of the &#8220;base amount&#8221; (as defined in Section 280G(b)(3) of the Code) allocable to such reasonable compensation.&nbsp;&nbsp;The costs of obtaining such determination and all related fees and expenses (including related fees and expenses incurred in any later audit) shall be borne by the Company.</font><font style="color:#000000;">&nbsp;&nbsp;</font><font style="color:#000000;">In the event it is later determined that a greater reduction in the Total Payments should have been made to implement the objective and intent of this </font><font style="color:#000000;">Section</font><font style="color:#000000;">, the excess amount shall be returned immediately by </font><font style="color:#000000;">you </font><font style="color:#000000;">to the Company.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">14.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">This letter shall be interpreted and construed in accordance with the laws of the Commonwealth of Massachusetts without regard to any conflicts of laws principles that would result in the application of the laws of another state.&nbsp;&nbsp;While other terms and conditions of your employment may change in the future, the at-will nature of your employment may not be changed, except in a subsequent letter or written agreement, signed by you and the Chief Executive Officer of the Company.&nbsp;&nbsp;This letter may be executed in several counterparts, each of which shall be deemed to be an original, but all of which together will constitute one and the same agreement.&nbsp;&nbsp;Signatures delivered by facsimile or PDF shall be deemed effective for all purposes.&nbsp;&nbsp;This letter contains the entire agreement between you and the Company with respect to the matters covered herein.&nbsp;&nbsp;This letter supersedes all prior and contemporaneous agreements and understanding, oral or written, between you and the Company with respect to the matters herein.&nbsp;&nbsp;This letter may not be amended, nor may any of your rights or obligations as set forth herein be altered, except by a written instrument executed by you, on the one hand, and a duly-authorized officer of the Company acting with the written authorization of the Board, on the other hand.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US-DOCS\110928677.1</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">15.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">If you agree with the employment provisions of this letter, please sign this letter in the space provided below and return it to David L. Lucchino, President and CEO. Please return this signed offer letter by </font><font style="font-weight:bold;color:#000000;">December 27, 2019 by 5PM (EST)</font><font style="color:#000000;"> or the offer will become null and void.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:26.92%;"></td>
<td style="width:30.77%;"></td>
<td style="width:7.69%;"></td>
<td style="width:34.62%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sincerely,</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FREQUENCY THERAPEUTICS, INC.</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ David L. Lucchino</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David L. Lucchino</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and CEO</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accepted and agreed by:</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Wendy S. Arnold</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wendy S. Arnold</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US-DOCS\110928677.1</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:33.33%;"></td>
<td style="width:44.87%;"></td>
<td style="width:21.79%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gqmjb0hqad4j000001.jpg" title="" alt="" style="width:211px;height:48px;"></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#29ADC6;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19 Presidential Way, Suite 203</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#29ADC6;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Woburn, MA 01801</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Exhibit A</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When used in the letter to which this Exhibit A is attached, the following terms shall have the meanings set forth below.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1) &#8220;Cause&#8221; means any of:</p>
<p style="text-align:justify;Background-color:#auto;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) your conviction of, or plea of guilty or nolo contendere to, any crime involving dishonesty or moral turpitude or any felony; or (b) a good faith finding by the Company that you have (i) engaged in willful misconduct or gross negligence that is materially harmful to the business or reputation of the Company, (ii) breached or threatened to breach the terms of any restrictive covenants or confidentiality agreement<font style="font-weight:bold;"> </font>or any similar agreement with the Company, and/or (iii) materially failed to perform your assigned duties, provided, however, in the case of (iii) that the Company provided you with written notice of such failure and a period of 30 days to cure, but you failed to cure such failure.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2) &#8220;Good Reason&#8221; means the occurrence, without your prior written consent, of any of the following events:</p>
<p style="text-align:justify;Background-color:#auto;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) a material reduction in your authority, duties, or responsibilities (other than in connection with a corporate transaction where you continue to hold substantially the same position with respect to the Company&#8217;s business, substantially as such business exists prior to the date of consummation of such corporate transaction, but do not hold such position with respect to the successor or surviving entity in the transaction); (b) the relocation by at least 50 miles of the principal place at which you provide services to the Company; or (c)&#160;a material reduction in your base salary (other than a reduction of less than 10% that is implemented in connection with a contemporaneous reduction in base salaries proportionately affecting other similarly situated employees of the Company). </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To be treated as a resignation for Good Reason, (x) you must provide written notice to the Company of your intention to terminate your employment for Good Reason, describing the grounds for such action, no later than 90 days after the occurrence of such circumstances, (y) you must provide the Company with at least 30 days in which to cure the circumstances, and (z) if the Company is not successful in curing the circumstances, you must end your employment within<font style="font-weight:bold;"> </font>30<font style="font-weight:bold;"> </font>days following the cure period in (y).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3) &#8220;Change in Control&#8221; means a Change in Control as defined in the Company&#8217;s 2019 Incentive Award Plan, as in effect on the date hereof.</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US-DOCS\110928677.1</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Exhibit B</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee Proprietary Information and Inventions Assignment Agreement</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US-DOCS\110928677.1</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>freq-ex211_19.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
freq-ex211_19.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">Exhibit 21.1</font></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:24pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Subsidiaries of Frequency Therapeutics, Inc.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:76%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt #000000;white-space:nowrap;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Legal Name of Subsidiary</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt #000000;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Jurisdiction of Organization</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Frequency Therapeutics Pty Ltd</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Australia</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Frequency Therapeutics Securities Corporation</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Massachusetts</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>freq-ex231_7.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
freq-ex231_7.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 23.1</p>
<p style="Background-color:#FFFFFF;text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<p style="Background-color:#FFFFFF;text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<p style="Background-color:#FFFFFF;text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Consent of Independent Registered Public Accounting Firm</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consent to the incorporation by reference in the Registration Statements (No. 333-233652 and 333-248474) on Form S-1 and Form S-3 (No. 333-250099) of Frequency Therapeutics, Inc. of our report dated March 29, 2021, relating to the consolidated financial statements of Frequency Therapeutics, Inc. and Subsidiaries, appearing in this Annual Report on Form 10-K of Frequency Therapeutics, Inc. for the year ended December 31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ RSM US LLP</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Boston, Massachusetts</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 29, 2021 </p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>freq-ex311_16.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
freq-ex311_16.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.1</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATIONS</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, David L. Lucchino, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">I have reviewed this Annual Report on Form 10-K of Frequency Therapeutics, Inc.;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting</font><font style="Background-color:#FFFFFF;color:#333333;font-size:9.5pt;font-family:Arial;"> </font><font style="font-family:Arial;color:#000000;">(as defined in&#160;Exchange Act Rules 13a-15(f)&#160;and&#160;15d-15(f)) for the registrant and have:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 29, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;David L. Lucchino</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">David L. Lucchino</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">President and Chief <font style="color:#000000;">Executive</font> Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>freq-ex312_22.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
freq-ex312_22.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.2</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATIONS</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Peter Pfreundschuh, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">I have reviewed this Annual Report on Form 10-K of Frequency Therapeutics, Inc.;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting</font><font style="Background-color:#FFFFFF;color:#333333;font-size:9.5pt;font-family:Arial;"> </font><font style="font-family:Arial;color:#000000;">(as defined in&#160;Exchange Act Rules 13a-15(f)&#160;and&#160;15d-15(f)) for the registrant and have:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 29, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Peter Pfreundschuh</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Peter Pfreundschuh</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>freq-ex321_8.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
freq-ex321_8.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.1</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.03%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Annual Report of Frequency Therapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, David L. Lucchino, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.03%;text-indent:-5.03%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 29, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;David L. Lucchino</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">David L. Lucchino</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>freq-ex322_14.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
freq-ex322_14.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.2</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.03%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Annual Report of Frequency Therapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Peter Pfreundschuh, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.03%;text-indent:-5.03%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 29, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Peter Pfreundschuh</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Peter Pfreundschuh</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>gyycud3vz5ad000011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gyycud3vz5ad000011.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" )^ E@# 2(  A$! Q$!_\0
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M #T%+7\Y3?\ !PM^SLUOJL%K.;S4M/9U*6D0G *$AL[%8<$'KG@5];?L5_\
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MI/- %+PQ_P %%O@QXJ^+E_\ !W3KA7\3:?=O9SQBY1B)$?RSF/&1\WJ1TK]
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MB/V0/VJ_V8-<\<_![XFK>R_"_7[C4+:W%R)/)6SN6D4 !N/N-@?E7R+^W/\
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M4O)EE#31M;HC LOS'*Y]:_5/_@ME^PW\<OVI]+\(0_"RVEN'TRZL)+GRXV?
MA=6?IGLOYU[/9?\ !,U/C1_P3Y\-?!WXHV2M\0?#VA>3IZ30AMMY!!$L0(89
M!+;MO&#@]^H!_&7^QQ\5O"&D_#W5'U_]G;5_'NJ:I:2/-JZV4UU_I,T;9E\P
MHQ!W\]<\=Z]Z_8 UKX]^&?VG;O7? 7P\\0>%?!^L:F_GV+1W4<4$$DK9#)M"
M@*K&OJO3?V#_ /@IW^S/JNN>#/AK\-=-UCPI+?2PZ=<SZ6DK"T+L(R"T3$?)
MCOCT]:_;?_@F#^R]^U3X:DUC6_VC? >DZ<]ZDAMB-/CC:-FR5*908(XZ>E '
MX"_M _!KPI\<_P#@J-\+="^(,,EY:7FHZ?-J-F\C$&9I8V<,F<=3@@CVZ5^P
M_P#P7<TNV_95_9C\"^#_ (*V4OA_1=7T^&QU$VC.@:"/-J7=D QOC7>03QNZ
MGFO-/B+_ ,$UOVC]5_X*;^'/CKI=E.O@#3M:ANI&2)A&D*3A\ @;0-HZ5_0+
M^W/^QKX;_;"^!-UX'UVW677+/1$CTF1XP[+>"WY"D\JWG-D<=CR"* /P\_X(
MP_\ !/?]D'XM?L[7WCKXA^';#Q;XKUN&%]2FN[F,26YNHWDN+@22>8=\;@ 9
M& ')/ K\4/VGOV7_ (-_!+_@I)X1TGX8SHFD2^,((VTZWN,JL9O4&W8C$= ?
M\,5],>$/V,?^"O'[(FO^)? /P135Y? ^HW%S!8^6)O+2TD9T0H <#;&>/;\J
M\W^%G_!);_@HCXA_:I\$_&WXPIJ=PMMXBM-1U(7"S.%C%RDLGWCCIG^7I0![
M3_P7'^#'PW6Z^ EP=&3S[JST-IF*C+,YM\Y)Y/J/<C\=#]NKX+?#KPE^P#\!
M]:\/:;]AU&X;23/-"3'N)$;')0CT[_\ UZ_0?_@K%_P3^^/O[1EU\'Y/AY9S
M2IX9M=(CU'9&6PUMY7F9P#C&TGV^M._;7_8 _: ^*'[%'PC^%OA2TFD\5>&A
MIO\ :$:QL2/(V;N,9& #VYH _+GXL?%;Q]X2_88T7PGX;U&[T[1=2TNS@O;E
M)I541S(J2@NIXRAYY[\]\?JO_P $JO\ @FS^QK\3_P!D&U\=>/\ 1;#Q7XN\
M017KZMJT]W"TUB?($ID'F!VD8R.QVY3[A7.6!7V_X5?\$O+_ ,?_ +$+?"7X
MG6HA\;IH9@MY'B_?+>)!MBP2,@[P,>_7V_$>+]CW_@K[^RG<:U\*_@<=:N?A
MY=W%Y#9E#/LCMY794* ' &PCIV&.] 'EJP6W['G_  53T'P#\ ]5E'A#4]6>
M*[TRSN'>)(WGVLA2-B@P./3OZ8^N?%?[.WA#]KK_ (*2VFD_$:RDN;,26CW%
MK([ .',>_*Y .<GZ_H?JS_@F#_P2'^*UK\4V_:*_:X6>Z\<KYEU;+?HTDBW,
MA+*%\S)&'.3Z#D5],^!_V*_C)HG_  43O_C(UI)#X%%Z/L[K&RQ^3&_R<CC&
MT4 ?C?\ \%POV(O@?^S-XK^&VK?!_0V\/ZG;3::9)X&,)=@T9R2A&?QZ5_45
M_P $G]:U+7?V// -YJMP]S="WAB,DCEV*K:PXRQ)-?G!_P %M?V'/C?^U5K?
MA.Y^%EM-/'I\UDUQLC9P!$Z%^F>@%?JG_P $X/A!XO\ @?\ LR>$_ ?C>-HM
M=TU$%RC+M(*V\:'C_>4T ?+_ /P7)@2?]B'QZC[AFSE&48J>1CJ.>]?SD?!"
MPC/_  2HUZT5Y<S)?J"96W@D-C!SD=?\]OZFO^"K/P*\<?M#_LJ>+_A_\/87
MF\0ZC;RI;(BEB6( & ,]Z_$WX3?\$X?VC/#W[ 6I_!_4;.9?&$YNMD9B8,=X
M?;\N,\\?E]* /E'_ ((!_P#!.CX$?&_3/B?XD^+?A[_A)9UDNC;K<2&0(9Y_
M*!!<-C9YN_ISM XS7S_X)^%/A[]F_P#X*_7?A3X6)-HN@Q>(GB6TCE=8]BW)
M4#8&VCC';M]*_H7_ ."'O['WQ@_93\*^.=.^*MO+;W&JNYM!(C)D&Y1QP>^U
M3_G%?"OBW_@G#^T5J?\ P4_N_CW#9SGP))KTEXDOE-L\DW!D^]C'3N3[^M '
M]8?A"YFN_#&AW$[%YI=/MVD8G)9B@R<_I^%?QL?\' ?Q6^(FL_%'PQ\*)]7N
MM(\#7>O0VMU)YTL,,EO). X)!"D$$]3_ %K^RKPM9RZ;X<T>RG!\ZVLH891_
MMJN&]/2OR5_X*H_\$W-*_;.^',UUX<A6#QWIA>[T^YBC G:>,;XBKK\V=XY[
MY_0 ^;/@'_P2U_88UG]AWP_K.J^&]+U#6]6\%?VIJ7BEKJ'SXM1,;?N]IRS
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M<ZUX'M;S4--MVF>2:&*R$DL8P7RH C]\<8KY(D_9<_X+1_%G1[+X(^/6UM?
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MF/,:-=Y_TA.K8SSWY[],5\8?MP:;HM]^P%^SG9S6UI';WFEZ2LTD4*([AH8
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M (.2/A)\.?"7_"D/$&@:;:Z9JG]KZ&OGV<$=L[;9(.2T:J?0'GF@#W[_ (.
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MMXV^)/[-7PG^%-G;N;[P;:6,-P/+)(,$<:D8 &.4_G7])M% 'P?^PC^SI?\
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M_#2=])\=+/)>"WLXS$S3EC(#^[QD%O3//7M7]'-% '\=GP-_X(I_&[Q5\0]
MU?XMZ]J]CI7AZ\BFA5Y)E6:."52H8%N051?6OZR_A5\.=*^%G@S1?"&EG?#I
M=E;VQE(^:0PQA"2>^2"<GK7I%&.^.?7% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% "$@=: <\X/XT,-PQTYK\QOV
MC_VY/%?P/^,>A?#V/PE]MT75;B&*753 7$:RR!=V\C' .?UZ4 ?IOO7<5R<C
MV/\ GO3ZX3PQXST_7/!EOXRGD6&R:Q-[<R=HXTB663TQM#=.!VK\R_C5_P %
M$_$>E^([O1/@=X1/CQ-,G,.I2PVQN?(\MMLI)16QMP: /UN) Z_UHSD9'/\
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M,\YS3LXZ\4 %%&<].:* $#9Z9I:3@>@]:7.>E !1110 4444 %%%% !1110
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MC !<(A/Y<FN] )R?0<Y_&IZ0]#]#_*@#C?'_ /R*FK_]>DO_ * :^0_V3O\
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M <J,=QU]\4#/?FF(6BD.[L<?Y^E+0 4444 %%%% !1110 4444 %%%% !29
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M5_\ KTE_] -?(?[)W_(P^+/^N]Q_Z&:^O/'_ /R*FK_]>DO_ * :^0_V3O\
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ME5I)04^>4TYTTU&,;MNW2W^2/]1^"HPJ.>0Y=",:4VYU(6C&T+IW=K:I:O\
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M?]CZ]6\T"61?%A\3JR$B<W'GX)'KN;^>?PH ^V1GO111F@!,]/<_T)K\?_\
M@H!;V!\<^'7:QMWG+V9\YHU,@)9.0Q&0>M?K_D[@,<9Z_@:_*3]NOPAXG\0>
M,] GT339;R*-K3>Z1LX7:R9Y"G&,'\30!V_Q$U6]TG]DZ..Q9XQ<Z2(Y#&=N
MU'B((X[8]>*\_P#^"9GA+P]'X8\8W<NFZ??W=Y<!YI[FU@N'YN S*?-1P,MC
MGK\O'?/U!8?#BZ\9?LUW'AF^MS'J3:+<I!$RX83Q6H:-0",Y+GCN3VS7Y%_
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M'A*M!<5\.+G6N:X5_$MO:+S/(XAI5?\ 5_./W<[?V?7Z/JM_N>OH?T+>&/\
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MH<JTB*V"#GJP_P _2MNB@"K:V]O:0K;6Z*D2 X55 4#IC XZ8'TKS[Q9\)/
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MO^%>_P#ZT83_ *$>!_\  %_EZ_T]/B_^(=YG_P!%CGB_[F)>7=^7Y=C\I/\
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M_H'6G_?E?\*/]:,)_P!"/ _^ +_+U_IZ'_$.\S_Z++//_!\O+_+\NVOY2?\
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MV:7I[:3;S[)MIBC1D7!QTSG&.E?U"/!%+"UO-&DL++L:-UW(R_W2#G(KCO\
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M +_DC<9_V'K_ -)1..@HHHK^9S]M"BBB@ HHHH **** 'KT;Z?T->R?L]_\
M)0+#_KYC_F*\;7HWT_H:]D_9[_Y*!8?]?,?\Q7T'"7_)5\.?]C;"?^G$>3Q!
M_P B#.O^Q?7_ /26?T-^&/\ D!:=_P!>Z?R%;U8/AC_D!:=_U[I_(5O5_L!A
M/]UPW_8/1_\ 3<3_ #<Q/^\5_P#K[/\ ]*84445T& 4444 %%%% !GI[G^A/
M]*\K\9?&/P-X%OXM-\1:Q;6%U,ZI''-*B,S,<# 9AG/''6O4PN"3SS7\WO\
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M)+=>.^ *^)? /_!6WPS?>)+6S\565Q9:5>2HL5Q+$T<>R1PJG>R@#@]<C_
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MB?\ >*__ %]G_P"E,****Z# **** "BBB@ K^;G_ (*N@GXW^%@!G-[8\?\
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M^;YBXS[KQTK[RU^^DTS1M5U"%#)-:V4\\<8Y9VCC)50.O)':OQC\._"#Q?\
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MYN8G_>*__7V?_I3"BBBN@P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ_Y$.]_ZX-_Z#7X*Q?ZRZ_Z^9?\ T*O\[_I3?\EW@/\ L6O_ -*@?VGX!?\
M)&XS_L/7_I*)Z***_F<_;0HHHH **** "BBB@!Z]&^G]#7LG[/?_ "4"P_Z^
M8_YBO&UZ-]/Z&O9/V>_^2@6'_7S'_,5]!PE_R5?#G_8VPG_IQ'D\0?\ (@SK
M_L7U_P#TEG]#?AC_ ) 6G?\ 7NG\A6]6#X8_Y 6G?]>Z?R%;U?[ 83_=<-_V
M#T?_ $W$_P W,3_O%?\ Z^S_ /2F%%%%=!@%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !7YW?MO_ +,EK\1?#NH?$+PY<PZ9XWTF
MTD^S7\Y5%&V,[/WA(Q]WN?\ ZWZ(U^./_!0K]H+Q)_PD=E^SUX:NIM)N_$TD
M,+ZE!NC<)<!5P9!CH"<9/&30!^#7P)U3]H;X?_&SQ3X9U+Q-;%_$]Q=:=/>F
MZ'ER1R2>7PQ;!^4^OK7]._["_P"SS-\'O"E_K6IWD.H:KXG87\D\)5QFX;S6
M^89^E? %Q_P2OCC^%'_"?S^.KM?&.E:1<^(4G$LC2321)]IPTP^7)VOP7R<=
MR17TQ_P3,^,?BGQ?H7B/P5XKO+B]E\+W#Z?:W$Y9BRVSF,$$YZA#0!^L=%%-
M*Y(.>F.WH<T .HHHH **** "BBB@ I#T/T/\J6D/0_0_RH XWQ__ ,BIJ_\
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M)_NN&_[!Z/\ Z;B?YN8G_>*__7V?_I3"BBBN@P"BBB@ HHHH **** "BBB@
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M^'[;48X+N2">2&+:L^QMQ# =![T ?TL^%_B5X%\:.8_"WB?2];=025L9O-(
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MA5^]7[77_(AWO_7!O_0:_!6+_677_7S+_P"A5_G?]*;_ )+O ?\ 8M?_ *5
M_M/P"_Y(W&?]AZ_])1/1117\SG[:%%%% !1110 4444 /7HWT_H:]D_9[_Y*
M!8?]?,?\Q7C:]&^G]#7LG[/?_)0+#_KYC_F*^@X2_P"2KX<_[&V$_P#3B/)X
M@_Y$&=?]B^O_ .DL_H;\,?\ ("T[_KW3^0K>K!\,?\@+3O\ KW3^0K>K_8#"
M?[KAO^P>C_Z;B?YN8G_>*_\ U]G_ .E,****Z# **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "OQ#_P""B/PL\0Z3\3="^.3VUQ?>
M&=#GMFNK=(WE0B$1ER4 (_'TYK]O*Y?Q?X.\.^.]#NO#WB?3H=3TJ\4K-;3*
M"IR",C(.#SZ4 ?EG<_\ !0CX%2? &ZTAUN(=7U'PU=Z5;Z2L(VO>20B*/<OW
M@=Y!QCJ@KF?^"5_@K7H8/&OC#4[*;3]/UC4)[O3XWB,6^&:4M&<$#/!'-?3#
M?\$\?@G)XD34WT.W.FP3F>"Q(&Q&W;N% QVQTK[6\*>$/#G@C2[?1?#6G0Z=
M96Z)&D,*JN50  ' &>G8>M '644A) !P3[?Y%+0 ASV%!7)!YXI:* "BBB@
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M_P"\5_\ K[/_ -*84445T& 4444 %%%% !1110 4444 %%%% !1110 4444
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M_)5\.?\ 8VPG_IQ'D\0?\B#.O^Q?7_\ 26?T-^&/^0%IW_7NG\A6]6#X8_Y
M6G?]>Z?R%;U?[ 83_=<-_P!@]'_TW$_S<Q/^\5_^OL__ $IA111708!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!SVM>&-'\0^0=
M7M([LVS;H=ZJ=ASG(R.N:_*C_@HS\6+KX1Z';+X=6"XO#Y<$&FJJO,=P &$'
M/?T_F*_7<,#T/\Z_!G_@HKX7\0:9\=?#'Q UNUGO/AY93V9O8#&\EN0OEARP
MP5ZCT_2@#Y=6_P#V@+CX3+\51H\R61MVNFM3:N&6,88DC;G '^>*_3'_ ()C
M_&+4?BSX.UBYU2-+>[TMO)EAVA'+[_+((XY!/IFN_G_:!_9\N/V;-0^SC3H[
M.X\+7=K;Z6(8"[7;6VV,@_?1@Y5L!.B;>C&OFC_@E3I>H23^/M8M[.:RT2ZU
M2XEMD:-HD>%ISLV@@ CD'C.<4 ?MA112#/<4 +0<]J** ('WY Z\C.!VQ]*Y
M+Q%\1? GA&5(?$_B[0=!F<@)'JFI6UH[$] %E=3D^F*G\<:K=Z%X2\0:MIT;
M2ZA9Z;<SV<0&XO<(A,:@8[D_YZU^!=O^R/\ %/\ ;Z\5^+-:^*?C'7_ -CH-
M_)_94=G)=0>?LFVP81#\RG@L>R@GG@4 ?T$:/X@T7Q%:+?:!JUCJUHP!6XL+
MB*YA8'H0\98<CISSVK%\1?$/P/X/*KXJ\5Z'H#-]T:KJ%O9DYZ8$K+G-?C#^
MQAXO\:_ SXY^(/V<K_5[OQ'X>\.B:*/5+F5YRZP$J&WL6["OD[_@H;J7A/\
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M /26?T-^&/\ D!:=_P!>Z?R%;U8/AC_D!:=_U[I_(5O5_L!A/]UPW_8/1_\
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MU+P/XA;XS_%-Y)?B3J#>==I-DLLKG>^2WHW!R<],#T_3QCDY'3 Q0!R?C_\
MY%35_P#KTE_] -?(?[)W_(P^+/\ KO<?^AFOKSQ__P BIJ__ %Z2_P#H!KY#
M_9._Y&'Q9_UWN/\ T,T#6S]/U1]WT444""BBB@ HHHH **** "BBB@ HHHH
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MMN3[P1__ !-/6&-"-D4<8!_@4+^BJ/;\J ) ,#%+110 44ASVXI: (S'SN&
M<YZ8[8J2BB@!N6R1T'KC_P"OBG444 -9=W!QCKC&?ZTFT!3T/![=.*?2'H?H
M?Y4 <;X__P"14U?_ *])?_0#7R'^R=_R,/BS_KO<?^AFOKSQ_P#\BIJ__7I+
M_P"@&OD/]D[_ )&'Q9_UWN/_ $,T#6S]/U1]WT444""BBB@ HHHH ***C:0+
MP??]/SH DHJG+J%A VV>]M8&_NS7$4;?]\NX.<T^*\M9_P#47$,__7&5)/\
MT%C0!9HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^0OVNO^1#O?\ K@W_
M *#7X*Q?ZRZ_Z^9?_0J_>K]KK_D0[W_K@W_H-?@K%_K+K_KYE_\ 0J_SO^E-
M_P EW@/^Q:__ $J!_:?@%_R1N,_[#U_Z2B>BBBOYG/VT**** "BBB@ HHHH
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M9](?Y"OT7K^<>)/^1YF2[8B2_")_HWX:W_U&X;Z_\)U+\Y!1117B'W(4444
M%%%% !1110!\A?M=?\B'>_\ 7!O_ $&OP5B_UEU_U\R_^A5^]7[77_(AWO\
MUP;_ -!K\%8O]9=?]?,O_H5?YW_2F_Y+O ?]BU_^E0/[3\ O^2-QG_8>O_24
M3T445_,Y^VA1110 4444 %%%% #UZ-]/Z&O9/V>_^2@6'_7S'_,5XVO1OI_0
MU[)^SW_R4"P_Z^8_YBOH.$O^2KX<_P"QMA/_ $XCR>(/^1!G7_8OK_\ I+/Z
M&_#'_("T[_KW3^0K>K!\,?\ ("T[_KW3^0K>K_8#"?[KAO\ L'H_^FXG^;F)
M_P!XK_\ 7V?_ *4PHHHKH, HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]#7LG[/?/Q T\?\ 3S'_ $KZ#A+_ )*OAW_L;87_ -.(\GB#_D09U_V+Z_\
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MT +_ /[]-_A1_P -8ZQ_T +_ /[]-_A7VC_P@_A#_H7M+_\  9:/^$'\(?\
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MK MGIC YKHAGO0 44UBP!VC)JE<W,=E;RWEVRQ0P*TDKN0JJHY))[ >O3ZT
M7B0!S^7_ -:@'(X'%<YHGB71?$R2R:->P7J6[[)6@D5PK*V,':<#!&*WT?<=
MOIQ_G\C0!+TZ"BBB@ HHIC]/Q_H: 'T5AZQK%CH%E+J>IS)!9P(7DD<A54 $
MDDGCIV//%>&-^U+\*_[173(]4,UP\ODJ8BC*7W;<9'J: /H^DR#T(KB+#X@^
M%K^6UMX]0MTN+P*T$$DB"5PP!&$)#'KV%=/=:A869"3W$*.2/D,@# '^(C/
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MG$0;9MP .0O;\Z_6?HXQ[Y^IR: )**** "BBB@ HHHH **** "BBB@ HHHH
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M0?S'I6SXR^'V@^.M%M]!UVTBN;&U\LQ12*&4>4J(F 01P$7D#' KOL?I]:3
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MDFGQ(9'G5@4"@$YSG'0>M</JWQT^'6AZ3<:YJ>NVMKIELQ66Y>5 B%3ALLQ
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M=\;OA]XP\8^-O'=Y_:Y\0SQO;3:E LD$+F=GD9+F[A(C! !900. Q7(S]*_
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *09[G/X8I:* "BBB@ I!GGG/X=*6B@ K,U?2+'7+"?3=
M1B$UI<H4EC.,,I!!'(([^E:=% '+^%O"&B>#;*33]"M1:6LDGFM$N I?GG"@
M#/)[9]ZZ5EW8YQCZ_P LT^B@ IK*&ZC_ #^-.HH ;M'I^I_QHVCMD?0TZB@!
M",^H^A/_ .K]*0*>[$CZG^AIU% "!0.0/YTTHI))&[.00>1@]L=_QI]% $:Q
M1H,)&B G)"*%R?4[0*> !T'\Z6B@!FP#)!()[]_TQG\:=C( /.*6B@!  .E!
M /6EHH 3'&.?U_2DV^I)]B:=10!D:UHEAK]A+IFI1">SF&V2)@"&!SGKFH?#
MWAS2O"]@NF:/;BVM%8N(EQ@,>I   K=HH 0@'K_6EHHH ,?7\S2%0>H_4TM%
M %:ZL[:]@DMKJ&.>"52CQR*&4JW4?,#ZU\J>)/V+O@CXH\2IXIU#19TU%)_M
M&V"2.. R;MQS&(\$9_*OK2B@#!\.>&M'\*:7;:1HEG%9V=K&L:+'&BLP4  N
MRJNXX ]JW"H)R<Y[>WT[C\#3J* $ QW)^O-! /)_F?\ &EHH 0#'<GZ\URWB
M[P;H7C?3/[(\0VBWECO\SRG"D;N.?F5AV]*ZJB@#"\.^'=+\+:5;Z-H\'V>P
MM5VPPC&U![   ?@.PK<(S['M_P#JZ4M% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
( !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>gyycud3vz5ad000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gyycud3vz5ad000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .O!E0# 2(  A$! Q$!_\0
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MOXDDU[KHVG#2=%L[ '=Y$2H6'<]S^>:6,E:G&+T965PO7G.+NMKOJ>&^!O\
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M7E[GAHT9/WEU/,[;XNE;%5N=++W07!9)<(Q]<8XKC[2TU/QQXH=\%I9WWS2
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MUJ\^UZA8^=/M"[O-=>!TX# 5G2K0A5<[:&V(PE6KAE2<KR[D_AK_ )%71_\
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M:%=3U2RLFG)$(N;A(S(1C.W<1G&1T]10!?HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ANI)(;.:6&/S94C9DC_O$
M#@?C7RQX6AT3XBZGJ%Q\0/&%U9WWF#R(7F6),'.<%P5 !XVC%?5,\R6]O)/)
MG9&A=L#)P!D\=Z\$OO%?P7\8)+>:YILNFZ@^3(1!(DA;US%D,?=OQH ]$\#>
M$[;P%INI71\37&H:2Z"6)KB3,=O&H)8C!*\]R .@KF)_CPT\L\^A^#-5U32K
M=BLM\I954#O@(P'KR1^%>=^!-'U76K'QUIGAE[V3P_+:2+;>?QYL@D4QCTWL
M@8''J,]JK>#-5T.QT-['6_&OBWP_>6LCJ;.SED6(\Y^55!VMG.0<<_6@#W0?
M%+2KSX<WWB_2H'NEL@!+9ROY;J^5&TG#8^]G(SFN/7]H":YTL7]AX)U&ZAA7
M-Y*LI\JW/IO$9SQ@\A>OXUDV^BZ#8? /Q1J?A^[U&>VU$(76^50Z,D@'8 '.
M>O/\Z[;X0PQ'X'V"F-2)8KKS!C[W[V0<^O  H TK/XK>'KKX?S^+SYZ6MN_E
M2V^T&42\80#."3N!!SC!R<<URMM\<M1G\JZ_X5]K']ERL!'=QLS!@3CC]V%/
M_?5<)\.Y/#Z_![Q0OB<7+:8U]"I%M_K%<[0&3/&1UY[ ]>E07?C1/"6G6?\
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M %%%% !1110 4444 %%02S,EU!$ -LF[/X"IZ "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BH+N9H+5Y5 ++C&?K
M4] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !114%I,T]JDK@!FSG'3K0!/1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !114$4S/=3Q$#;'MQCKR* )Z***
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<C\![FMP^ O#1L?LO]FH!MV^:"?,SZ[O7]*2?PI)JGAE=-UC47N;M7,J784
MQOVQZ@9/7].,43I7CLP?9#K>G"(KL^T"-O.QZ],9]\U/-=64K/KY^97LU&3<
MJ=TTK+33R.:MK:[USP-J5FTCRW6AW):UF_B*KU7/T!_2MS6/%;7WP_M9;4@W
M^J8M513R'/#_ .?]H5U'A[0;;P[I26-NQ<Y+R2MUD8]2?\]JYG1_ ,NF^*S?
M23Q/ID$DDMI &)9';'48P,8]3T%5[2G)MOH[K^O4CZO6A&*CO)6?EY_)77W&
M/XOTRWT1?!]A]E:\B@:020QKN,QS&6 '?)S^=;?A[^RY]9A$7@R[TV1066YF
MMBBJ0/7UJ]XN\/ZIK%_I%YI4UI'+82/)_I)8 DE".@.?NFELH/&ZWT!O;K1F
MM0X\T1!]Q7/.,KUH<U*FM==>OF"HN%=OE=M+:)[)=>ARFE_\(Y_PEWB?_A(/
MLG_'W^Y^T?[S[L?^.U:\-V>FZCXJUZSTQ&?P_-:A'"Y\OS"5^[GO][%;FE>#
M(HM<UN]U6UL+R*]G$EN'3S&C&6)SN7@G(Z>E6O#6@7OAV[O;6.:&31Y'\VW4
ML?-B8XR#Q@C\>WN:<ZL;.SULO3H*EAIWCS15KOIKUW\F<>NJ:OI5C<>"$5WU
M%IA!:3]!Y#9);/L/RS[5Z+HVDV^B:3;Z?;#Y(EP6Q@LW=C]367=:!=S^/;'7
M5DA%K;VIA9"QWECOZ#&,?,.]='6-:HI))==7ZG5A:,H2;ETT7I_7Y!1116!V
M!1110!4U+_D'R_A_,5;JIJ7_ !XR?4?S%6Z "BBB@ KG_''_ ")6J?\ 7+_V
M85T%9?B/39M7\/7NGV[1K+.FU3(2%'(/. :NFTIION95TY4I)=F>?V?_  A'
M_"%Q_;?L7V_[+\^S_6[\<8QWSC^M9^J?:?\ A7WAK^T=V/M9QYO_ #SYQGVQ
M^F*]$T/PIIVGZ59Q76FZ?)>0Q@23+ I+-Z[B,U!XR\.77B.WL(K9[=1!<"20
M3$@,N.@P#77&O'GMTOU/,GA*GL6[*]DK)>:W.1\6_P#"(?V0O]@_9_[5\Y/L
M_P!BSNSGG./;]<4[Q.P7QWHYU#3)=2;^S%\VUBCWL[9DSQ['G\*Z?6?!Z&YL
MM1\/16=AJ%I)D839'(IZA@H_7'<_A#KOA[7[KQ39ZYI4VGQ2P6HA*W#.0&R^
M<87D8;KQ]*(58Z:]]PJ8>I[WN]8[+2RZ^HS0IM/B-[=VOA.YTJ:VMF=99X#&
M'_V0?PJIX,\/V&OZ4==UF-;^]O)'),I)$8!*X Z#I^6*W=+@\7"_3^V+C29+
M$AA(D ?>>..HQUK,C\+:_H,\Z^&M2M5L9G,GV:\4D1D_W2 3Z5',M4G9NW7\
M+FJIOW9.#:5]+):Z:VV\A?$/AW3=#\(:])I\30BXC4O'O)48(Z#M6SX._P"1
M.TG_ *]UK-E\/:_>^'M5M=1U6&XN[U0(T"[88L8Z'&>WI533])\=Z;I\%E;W
MFB>3 @1-WF$X'_ :3M*'*Y:W_0J-Z=534&E:UE;N,B_Y++-_UX_T%<EH]QJ6
MBZMJNOV:F:TM[QHKR 'DQEB<_AZ]OIFO0+7P[J">./[>GEMC$UH(75&;=OP
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MC1RTF3ECOP.F!PU=U<:WI-IJ4.G7.J64-]. 8K:2X199,G VJ3DY(/0=JOT
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M44 %%%% !1110 4444 %%%% !1110!4U+_CQD^H_F*MU4U+_ (\9/J/YBK=
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !533?^0?%^/\S5NJFF_\@^+\?YF@"W1110 4444 %%%% !1110 4444
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M;?#OP[%*NUQIT&0>V4!H Z.BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "JEU_Q\VO^^?Y5;JI=?\
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MW_D'Q?C_ #-6ZJ:;_P @^+\?YF@"W1110 4444 %%%% !1110 4444 %%%%
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M_P")KRBBC^U*W9?C_F']AX?N_P /\CU?_A,= _Y__P#R#)_\31_PF.@?\_\
M_P"09/\ XFO***/[4K=E^/\ F']AX?N_P_R/5_\ A,= _P"?_P#\@R?_ !-'
M_"8Z!_S_ /\ Y!D_^)KRBBC^U*W9?C_F']AX?N_P_P CU?\ X3'0/^?_ /\
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MKRBBC^U*W9?C_F']AX?N_P /\CT^]\6Z'+;,B7V6)''E/Z_2K'_"8Z!_S_\
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M_P")KRBBC^U*W9?C_F']AX?N_P /\CU?_A,= _Y__P#R#)_\31_PF.@?\_\
M_P"09/\ XFO***/[4K=E^/\ F']AX?N_P_R/5_\ A,= _P"?_P#\@R?_ !-'
M_"8Z!_S_ /\ Y!D_^)KRBBC^U*W9?C_F']AX?N_P_P CU?\ X3'0/^?_ /\
M(,G_ ,31_P )CH'_ #__ /D&3_XFO***/[4K=E^/^8?V'A^[_#_(]7_X3'0/
M^?\ _P#(,G_Q-'_"8Z!_S_\ _D&3_P")KRBBC^U*W9?C_F']AX?N_P /\CU?
M_A,= _Y__P#R#)_\35>R\6Z'#9QQR7V&&<CRG]3[5YA11_:E;LOQ_P P_L3#
M]W^'^1ZO_P )CH'_ #__ /D&3_XFC_A,= _Y_P#_ ,@R?_$UY111_:E;LOQ_
MS#^P\/W?X?Y'J_\ PF.@?\__ /Y!D_\ B:/^$QT#_G__ /(,G_Q->444?VI6
M[+\?\P_L/#]W^'^1ZO\ \)CH'_/_ /\ D&3_ .)H_P"$QT#_ )__ /R#)_\
M$UY111_:E;LOQ_S#^P\/W?X?Y'J__"8Z!_S_ /\ Y!D_^)H_X3'0/^?_ /\
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M_P#\@R?_ !-'_"8Z!_S_ /\ Y!D_^)KRBBC^U*W9?C_F']AX?N_P_P CU?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\17 VS7"G]W9+W8G^\!^7'4\4C:-H_PC^$>I"YM_[5#+F[63@74LF$P>N%Y
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M.PI5,.Z<>:^SL51Q:JS44K75T95%%%<YUA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% &CH/_(>L?\ KLO\Z]7KRC0?^0]8_P#79?YUZO7NY3_#EZGS&>_Q
M8^GZA1117K'AA1110 4444 %%%% !4%Y_P >Q^H_G4]07G_'N?J/YT 3T444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,*PV%E!Z$AL$$$@9KB/$!TFQ\!>,M(M=!?0K]+!9YK0.K1,A)"NFTE<$A@>
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M!>?\>Y^H_G0!/1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7!E,,%M$A>2*-]AFR7"B,GH6()["@#;U?1--UZT2VU.T2XACE29 Q(*NIRK
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-<Y81LD$D6T=,YV19QC[S'L<UNKHVK67CB\U>R-E+8ZC#;Q72S2,LD7E;\%
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M4EPMYJ,+&XA#L6*E0,28)."67C&:]/HH XB^TO2M$G\2W?B"ZL[;0]8CM[1
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MSYK_ -]-_C1_PB.C?\^:_P#?3?XUNT4>PI?RK[D'UJO_ #O[V87_  B.C?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)_X6#I/_ #[WO_?"?_%4?\+!TG_GWO?^^$_^*KS:BC^TJ_D']CX7L_O/2?\
MA8.D_P#/O>_]\)_\54%IX[TN"U2)X+PLN<X1<=?]ZO/:*/[2K^0?V/A>S^\]
M)_X6#I/_ #[WO_?"?_%4?\+!TG_GWO?^^$_^*KS:BC^TJ_D']CX7L_O/2?\
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MJ=%%@+E%4Z*+ 7**IT46 N453HHL!<HJG118"Y15.BBP%RBJ=%%@+E%4Z*+
M7**IT46 N54U#_CU_P"!+_.DJ"\_X]S]1_.BP&G12)]Q?I2T@"BBB@ HHHH
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M+?C_ '?B'PY"_P#9%O9F.ZNA&42>0KCOW)QUY.S- 'H'@KQS_P )AJ&OVO\
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MT;)NP<9&0,CT-:59?A_1O[ TF/3A?WEZD3'RY+N3>X7/"YQR .*U* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH XSXA?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ J"\_X]C]1_.IZ@O/\ CV;ZC^=
M&DGW%^E+2)]Q?I2U(PHHHH **** ,[Q!:S7WAO5+2W3?//9RQ1KD#<S(0!D\
M=37*_"+P]JOA?P%#IFLVOV:\6>5S'YBOP3QRI(_6N[HH YGQW/XEC\,S0^$[
M!KG5+C]TLGG1QBW4]7^=AD^F._/:N8LO@[I2_#.3PU=[6U"YQ<37V,L+G'#
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M7^5Y7/521]UAT]:[FN4\8> -+\:26DM]>:E:3VH98I;*X\L@-C<.01S@=LT
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M1TZZU#7X5GBM8KY-L+R?*O0@D^F<YJ#1?L5B^K:/<ZA;[;N%52Y1LQY /?\
MX%^E:<E.2@K+JK^>MNO7<R]I5@ZDDW?W7:U]-+].FJ_X)CZ;I']H:=J-WY_E
M_8T#[=F=^<]\\=/>KUMX9C_LZ&\U+4X;%9QF%63<6'KU%:EK;Z=I'A[5X!JU
MI<7,\7W8Y!C@' 'J>3^E1W(T_P 2Z98.=3M[.YMHO*DCG.T'&.1S4QH045=)
MRMM?S]>Q4L54E-\K:A?>VRMZ=7U+6L:3'<Q^'-,>\5%:.1$G1=RL<)CN.O\
M6N;LM GNM??2G?RVB+>9)MR% [XR.#Q^=:?B6XM8;'1(M/OHYVM XWHP)!&W
M!QVY!Q6KJ]_;1:#)K, V7FIPI"?;&=Q'X<?@*TJ0I3G)O[-F]=U9:??^9E2J
M5J=**C]JZ6FSYGK]VOR.&>$&\:"W8S R;(V"X+\X''O72KX,12L$^K11W9 _
M="(LH)[%LUS=E<?9+^WN=N[R95DV^N"#7H,^JO>3BYLO%%K;6C@$PRHF]/4
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M?_((;_>_QKSRO0_!?_((;_>_QKT<K_C_ "/(SK_=OFOU.EHHHKZ(^3"BBB@
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M\DRN3N8/"\8V\8)RPZD<4 ;M%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '%_$'_CRMO\
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M-AE\9QEBF2.* /0:*XZ#QO<:GXCATO1M'^V6\MC;ZA]L>Y$2+#*3U&TG=@9
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MD#.!TR>!^-<5HOQ%AU+Q+;:+<1Z8LMV)/(-AJL=VRLBEBLBJ 4.T'IN'&,T
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M+N9=Z0+M9V?:/OG"D*O<D4 =917F[^([J/PIXADTKQ)?ZMJUO;!X(;G3!!-
MS9 81>4I9<XZJ>AY-:_A+5H+S4Y[?_A+-0U.X6'?]CO[!+1T7(^<+Y4;$=L\
MCF@#L:*** "L67PY#<>)(-:N;^^F:V):VM'=?(A<IL+* H8G:6ZL1\QK:HH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** .+^(/\ QYV__70?R:O/Z] ^(/\ QYV__70?R:O/Z^=S+^/\D?6Y
M/_NJ]6%%%%<!ZH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3%6-+\-7\?B%=<UK5TU"\AMFMK=8+3[/'&K,I8XW,68[5ZG ]*Z6B@ HHHH
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M*_G9R'_"!:=_?NO^_B_X4?\ "!:=_?NO^_B_X5U]%'U2A_(@_M#%?SLY#_A
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MT47 K>4_]W]:@O(W%I(2.WK6A5>^_P"/&7Z47 EB_P!4G^Z*?38_]4GT%.I
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M_ A_\:/[5A_*P_L*I_.CV6BO&O[;U;_H)WO_ ($/_C1_;>K?]!.]_P# A_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5:TV9[?4[:6,X99%/ZU5J:T_X_(?]\?SJH.TDT1-)Q:9
M[%1117V)^?A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %01?\?=
MQ_P'^53U!%_Q]W'_  '^5 $]%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %07?^K7_?%3U!=_ZM?]\4 3T444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5%<_\
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M>HSS7#_$OPYH/AKQ5X5A\'6HLO$4EVI$-HS9,>0 6&>.>/<;LYQ71:S\1$\
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M'?//7VK,KM[G43I5IX5N\G8L3B0#NI" U*FE1:-X@U#6)%'V.WB\^#GAF?.
M/QR/Q%5+"J4O==EI?RTO?\R(8Z48>^KO6WFU)JWY'!T5<MA_:.M0BY8G[3<*
M)&_WFY_G7HEUJ>FZ9>?86OH[>),*;06;,""/4#G-9T<.JB<G*R7]=T;8G%RH
MR48QYFU?K^B9Y?17=Z//96\OB2YTY4EM4B62)64A3PQQ@\XSFH+;4Y?$GA[5
MTU".)FM8Q+$ZI@J<'_#]35+"QLO>U=_32_7Y$/&R3?N:*U]==;=+=+G%T5VT
M>JSZ1X&TN>V2,S-)(@=USM&]B<?D*9)>OX:\.:9)IT,?FW:EY;ADR<X!V_K^
ME+ZM%*[ET3>G>P_KDV[*'5I:[VO?IIMYG)V5M]LO[>UW[/.E6/=C.,D#./QK
M:B\+^9J>I67VS'V*/?O\K[_&<8SQ^M:]PJ7O_".:Q) D-Y/=HD@48#@/PWZ?
MK5JV_P"1G\2?]>Y_]!%;4\+!-*6NOX6N<]7&U&FXZ63\]5)(\]HKT'2C8:)X
M:LKDW:VLESR\_P!G,A8_W<CIC^A]Z:R:%KNO::4F2>;YC,/):,3  D$@C'45
M'U+1>\KNVGK\_P!#7^T?>E[CY5?77I\K?B<9I5A_:>IP67F>5YK8W[<XXSTJ
M*]MOL=_<6N_?Y,K1[L8S@D9Q^%=KI_B6^NO%*Z?);1"W$K(L8CYCQGG/KQ7)
M:W_R'M1_Z^I?_0C6=6E3C2O%W=[=C2C6JSK<LU963M>_7T*%%=S]@'B3^PM1
M(W#_ %-V3_L9//UP?S%6+VQ@\1:KI6J6Z_Z,79)R?1"2,_7!_,5?U*35XOM;
MSV_*Z,WF,8NTE;>_DU?3YV9Q]E:6$VFWD]Q?>3<Q#]S#M^__ )Z>U1S:7<0Z
M5;ZD^SR)V*I@\Y!(Y'X&NIM;\ZG:^++O.5>-=G^Z X'Z 5+?^(-07P98W8=/
M-N6>*0[!@KEA_(52H4G"[?1O;SMW)>*K*=DMVEJ]KQO;;^OF<O<:1]G\/V>J
M^?N^TNR>5LQMP2.N>>GI697;)JUQI'@72YK58_->5U#.N=HW,>/RJIXC==2\
M.Z7K#QJEU*S1R%1C=@D?^R_K45*$.6\7JDG;[NI='%5.?EFM')I/TO;2WD8V
ME:-+JWG>7=6L'E8SY\A7.<].#Z5:U+PO=Z7I_P!MENK.2(L%'E2$EB?3BLBV
M\I;B)[A&>W61?-"]2N>1]2 :ZW7?LFNZ!_:MF\\,=D5A^SNH"@$@<8[\COVI
M4H4YTI:>\O/^MBJ]2K3K1U]UOM^'S,JS\)ZA>6L=P9+:W67F-9Y-K./88-9=
M_87.FW;VMU&4E7\B/4'N*Z#QYN_MJ#KY/V=?+],9/2E\:9_XE7G;?M?V0>=Z
M_P"<[JJK1A%24=XV^9-#$592@Y-6G?3M8Y6BNS\/:G:6^B+;V][;V&H;RSR3
MQ9$@YQS^7Y&M#38[\>,'>_\ LYDDL3L>W'R.,CGZT0PBDHM2W_#\0J8YP<DX
M[7Z[V^7ZGGE:O]C?\4W_ &O]H_Y;>5Y6S]<Y_I6IX%1O[;N#M.%MF!XZ<BKF
MFZA-IG@+[3!$KR+<D!F7(3/\7]/QI4:$7'FGV?RM8>(Q4XSY*:U3C\[WT\MC
MBJOZO:V5G=I'87GVJ(QAB^,8;G(_E^==#>7)UWP9<:C>PH+JVF"QRJN-X)4$
M?K^E:UU8V]_XZMDN5#I'9"0(PR&()QD=^N?PJHX6ZM%WO:WSO_D1+'<KO)6M
MS77I;R\_(\YHKT>76M%N4FM;_4EGA(*F$V3J4^G&1BLMKH^&O#5A<:;'$\UV
M6,ERR9Z=%_SZ&E+"16O/=+?O]R8X8Z<M/9M-NRO=+ONTNW8Y6PL9M2OHK2#;
MYLA(7<<#@9_I45Q"]M<RP28WQ.4;'3(.*[+1/$-W>^);17MH8#/'MF94P9<
MD&HEUZ-_%SMJY1H+5I8X6\O(0[N"0.O2E["DX)J6[ML-XJNJC3AHHWM?7KY?
MU^!QU%=KKLFI7NB3R)?6%_9HREVA3#ISZ=A7%5C6I>SE;^OU.G#UO;1YFK?U
MZ(****Q.@**** "BBB@ J:T_X_(?]\?SJ&IK3_C\A_WQ_.G'=$R^%GL5%%%?
M9'Y\%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5!%_Q]W'_  '^
M53U!%_Q]W'_ ?Y4 3T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 5!=_P"K7_?%3U!=_P"K3_?% $]%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %17/\ Q[2?
M[IJ6HKC_ (]I/]TT 7;?_CVB_P!P?RJ2H[?_ (]HO]P?RJ2I&%%%% !1110
M454U34[31M+N=2OI/+M;:,R2,%)( ] .2?:LBT\6I+*WV_1M5TFW6-I3=ZA'
M&D(51DEF#G9Q_>Q0!T5%86C^,O#VNZ.-4LM6M#:C8)"\RJ8BYPJN,_*2> #R
M:UWN[:*ZAM9+B)+B8,T43. \@7&XJ.I R,XZ9% $U%<[K'C+2=,M[H6][97E
M];,BR64=VGF+ND5"2!DC&[/2MN&\M;A9F@N895A=HY2D@81NOWE;'0CN#TH
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M\-_VYJ,J6MHMNL\C.XPN0,+DXR22 /4D>M &I165IOB31=6T;^U[/4[22Q4
MR3"9=L1P"5<YPK $9!Z9JUI^J:?JUM]ITV_M;V#.WS;:99%SZ94D4 6Z*S;W
MQ#HFF221W^L:?:/'MWK/<I&5W9VY!/&<''K@TIU_1A?0V)U:P%Y,H:*W-RGF
M2 \@JN<D'VH T:*H7VN:1IEQ%;W^J65I-,<11SW"1L_T!.3^%.U'6=+TB))=
M3U*SLHY#A'N9UC#'T!8C- %VBL;2_$5MJ%OJ=S(8K>VL+IX#.TP*,JJK;\\
M#YOTZU8A\0:+<Z;+J4&KV$MA%GS+I+E&B3'JP.!^= &C16;)XAT2*TFNY-8T
M]+:&4PRS-=($CD !*,<X#8(X//-5-4\9>'M(TFVU2ZU6T^Q7,JQ0S1S*RR$G
M&0<X('4D= "30!NT5G3:_HUMIL6I3ZO816$N/+NGN46)\],.3@_G535?$L&G
MC1'MUCO(-5ODM$ECF&U0T;OO! (8?)C''7K0!N454_M73O[,_M/[?:_V?L\S
M[5YR^5M_O;\XQ[YI]Y?6FGVCW5[=06UL@RTTT@1%^I/% %BBLY-?T:32VU--
M6L&T]#AKM;E#$/J^<?K3X-:TJY@MY[?4[*6&YD\J"2.=665\$[5(.&. 3@>A
MH O45!)?6D5S]GDNH$G\HS>4T@#>6#@MCKM!(R>G-5K'7=(U.&:;3]5L;N*#
M_6O;W"2+'_O$'C\: -"BL^#7M'N89YH-6L)8H(UEF>.Y1A&C#*LQ!X! )!/7
M%2Z=JNG:O;FXTR_M;V$':9+:99%SZ94D4 6Z*S[_ %[1]*FCAU'5K"SEE_U:
M7%RD;/\ 0,1FI-1U?3=(MUN-3U&TLH6.U9+F=8U)] 6(% %RBJ<.K:;<033P
M:A:2PP?ZZ1)E98_E#?,0<#Y2#SV(-&G:OINL0-/IFHVE]$IVM);3+*H/IE2:
M +E%%% 'E6O^!?'_ (IFN-)U7Q/IX\-SW/FN((2MP8]VX1XVXP/4L>@SGI7I
MUG:06%E!9VL8CM[>-8HT'1548 _(5/10 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!P/Q$_X^;#_<?^8KB:[7XB?\
M?5A_N/\ S%<57S68?[S+Y?DC['*O]TA\_P V%%%%<9Z)/97DVGWD=U;L%EC.
M5) /M6Z?&NH_,T=M8QRD8\U(?F_G7-T5K"M4@K1=C&IAZ55WG&YJZ=X@O-.^
MT@+#<)<G,L=PFY6/KC-26?B6]L;NYGA2WV7)S) 4_=Y]AG^M8U%"K5%:SV%+
M#4I7O'?<W;_Q5?:AITEC)#:I Y!Q'&5VX(/'/J*=;>+]1M[6.!X[:X$0Q&\\
M99E_'-8%/BC>:5(HQEW8*HSU)Z57UBKS7YM27A*"CR\JMN;C7,WBJX7[?>V=
MH]O%M5Y#L$ASWYQGZ?E5CQ9JZW<=GI\-T+E+9!YLR])'QC/\_P ZY^\L[C3[
MM[6ZC\N9,;ER#C(R.1QT-04Y5YJ,HO=[_(F.&IN49Q?NK9:6U)()FM[B.9 "
MT;AP#TR#FK=WJ]U=ZP=4RL5R65@8@0 0 !C.?2J%%8J<DK)G0Z<6^9K7;Y'3
M#QSJ8D$@MK$2?Q.(CEOJ<UF1:[=1)J2K'"1J!S+D'Y>2?EY_VCUS6?%#+,Q6
M*-Y"!DA%)P/6F5K+$59:MF,<+0C=1BOZU1M1W,FO+9:=<W%I9Q6D3".5\J#T
MX))Z\#T[UH>(M42/1+'18+Q+HQ*#-+&<J<?=4'OC^@KE:*%7DHM=7I?R$\+%
MSC+I'5+S[B@D'(."*Z*/QIJ:QH)(K2:1!A9I8LN/Q!K&O].NM,G6&\B\N1E#
M@;@>#]#[55J8SJ4FTG8N=*E72<DFNAI6^N75NFH*%B<WZD3,R\C.>1@@#J:9
M8:M/I]K>6\21LEW'Y<A<$D#GIS[U0HI>UGIKM^I3HTVFK;V_#8OS:M//H]MI
MC)&(;=RZ, =Q))//.._I5G3?$M]IMI]D5()[?.5CG3<%/MR*QZ*%6FGS)Z["
ME0I2CRN.E[_,U;OQ!?7NI6U],4+6S*T487"+@@],^U2)XEO([^^O!%!YEXFR
M0%3@#&..:QJ*?MJE[W%]7I6MRZ;?J:^F>)+[2[9K9%AGMR<B*=-R@^W(IE[K
M]]>WT%V6CAD@&(O)3:%_S[U5NM.NK**WEN(MB7">9$=P.Y>.>#QU'6DL=/N]
M3N/(LX3+)C<0"!@>I)XJN>MI3N_0GV>'NZUEZ_F;G_"<:F'$@M[(2<;I!$=S
M#T)S7/W5P]W=S7,@4/-(TC!>@).3BI+ZPN=-N3;W<7ER@ E=P/!^E5J56K5E
M[M1[#HT:,/>I):]C5T_7[W3=.N;&W\ORKC.YB#N4D8)!!X-)8:_>Z;IMS80>
M7Y5QG<6!W+D8)!!]*RZ*E5JBM9[%/#TG>\=]67[+5I["RO;6)(S'>($D+ Y
M&>G/O5JQ\27=CIXL?(M;B!6+()X]VPGTY]S^=48]+U":(2Q6-R\9&0ZPL0?Q
MQ581N9/+",9,XV@<Y],52J586MH3*E1J7ND^K+LVK3SZ/;:8R1B&W<NC '<2
M23SSCOZ43:M//H]MIC)&(;=RZ, =Q))//.._I4,^G7UM'YEQ97$4?]Z2)E'Y
MD56J7.:T?:WR*C3I-7CWO\S4TK7KO2$EC@2"2*4Y>.:/<"?YU)J?B2^U.U%J
MZP06X.XQP)M!/OR:I/IFH10F:2QN4B R7:%@OYXJ"&":XD$<$3RR'HJ*6)_
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M%_Q]W'_ ?Y5/4$7_ !]W'_ ?Y4 3T444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5!=_<3_KH*GJ"[^XG_704 3T444
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M**^R/SX**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J"+_C[N/\
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M$JZ$,...#6/=^"=-M_#NHZ;HVFV*B]E6::*]\R2*5AM!)^;*L0H^8<@_-R:
M,2_U7Q!X6\4V5K=:ZVK63Z;>WCPR6T4<K-$J$ E%'R\G& /XLYXQ4\/^(/&5
M[/H]^;75;FVOGB-Q'-;6D=JD3CEXF20R?*#D;MV0#P,\:/AGP)/8>)H];O[>
MRMF@MI((HK>[GNWDWE<EY9@&( 7 7&!N)K?L?!/AW3+^.\L]/\J2%B\2":0Q
M1,002D1;8AY/( ZT <[I>KZ[!K]NOB34=0L'GO'ACM/L$;6<@);RU2906!(
M.689.1@4>/Y;N\\4>'M"6R>^L[N.XF>T^T>1'<21A-JROUV ,S$ ') X-=#:
M^"/#UGJ$5]#8OYT,GFQ*]S*\<;]-RQLQ13R>0*T-8T+3=>MD@U*U$RQOYD;!
MV1XVZ;E=2&4^X(H \KU74!964'ABR\.G26DUB&"_LM/N@$G62)G15E^7:KE
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5-:?\?D/^^/YU#5K387N-3MHHQEFD4?K503<DD1-I1;9Z]1117V)^?A1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %01?\?=Q_P'^53U!%_Q]W'_
M  '^5 $]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %07?W(_\ KH*GJ"[^Y'_UT% $]%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %1S_ /'O)_NG^524R;_4
M2?[I_E0!:M?^/2'_ '%_E4M0VG_'I#_N#^535(PHHHH **** "BBB@ HHHH
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M?] R\_[\M_A1_86K?] R\_[\M_A7LE%']E0_F8?V[4_D1XW_ &%JW_0,O/\
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MV%JW_0,O/^_+?X5[)11_94/YF']NU/Y$>-_V%JW_ $#+S_ORW^%']A:M_P!
MR\_[\M_A7LE%']E0_F8?V[4_D1XW_86K?] R\_[\M_A2+HNJ.H9-.NF4]"(6
M_P *]EJIIO\ R#XOQ_F:/[*A_,P_MVI_(CR;^PM6_P"@9>?]^6_PH_L+5O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M445QGHA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !6MX=U)].U>%@Q\J1@DB]B#_AUK)J:
MT_X_(?\ ?'\ZNE)PFI(RK0C4IRC+9H]BHHHK[ ^!"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *@B_X^[C_ (#_ "J>H(O^/NX_X#_*@">BBB@
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MMSNW<#G:,X[=:]1TG3;?1M(L],M%VV]I"L,8]E&/SH N4444 %%%% !1110
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M$5W,BK'/ABI*88MC(/4"MJN$^$ND:=I_@6TNK.R@@N+K?Y\D: -+ME<+N/?
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MZYSQB@#O:*IZ5JEEK6F6^I:=-YUI<+NBDVE=PSCH0".G<5<H **** "BBB@
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M1161L%36G_'Y#_OC^=0U-:?\?D/^^/YTX[HF7PL]BHHHK[(_/@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "H(O^/NX_P" _P JGJ"+_C[N/^ _
MRH GHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ J"ZZ1?\ 75:GJ"ZZ1?\ 75: )Z*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *1_N-]*6D;[A^E $EA_QXQ?
M2K-5K#_CQB^G]:LU(PHHHH **** "BJ&M:@-*T6\OFFMH?(B+B2Y8B-3VW$
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MX[9Y76ZO)KQ_,(.'E<LP& .,GC^9K,@\=:'<7$<$?]J;Y'"+NTB[49)P,DQ
M >YXK*\?:U=VNJZ!HEO)J$::DT[R_P!FJ#<R")5(C0GA,EP2V1@*>10!W-%>
M77$\]UH-UI>BP^*A>V^H6KWUI<WK?;([<MN/ERF7&UE1AP_7/2ND\&7>GFXU
M#3X5UV"^@\MY[76;F2:1%;.UE+.Z[3@_=;MS0!UM%%% !1110 4444 %%%%
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M#(4;G)^[P2<8S6KH6@6F@6T\5L\\TEQ,9[BXN)-\DTA &YC] !@  8X%:E%
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M110 4444 %%%% !4$7_'W<?\!_E4]01?\?=Q_P !_E0!/1110 4444 %%%%
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M9Y-17K/_  B&@_\ /@/^_K_XT?\ "(:#_P ^ _[^O_C1_95;NOQ_R#^W,/\
MRO\ #_,\FHKUG_A$-!_Y\!_W]?\ QH_X1#0?^? ?]_7_ ,:/[*K=U^/^0?VY
MA_Y7^'^9Y-17K/\ PB&@_P#/@/\ OZ_^-'_"(:#_ ,^ _P"_K_XT?V56[K\?
M\@_MS#_RO\/\SR:BO6?^$0T'_GP'_?U_\:/^$0T'_GP'_?U_\:/[*K=U^/\
MD']N8?\ E?X?YGDU%>L_\(AH/_/@/^_K_P"-'_"(:#_SX#_OZ_\ C1_95;NO
MQ_R#^W,/_*_P_P SR:BO6?\ A$-!_P"? ?\ ?U_\:/\ A$-!_P"? ?\ ?U_\
M:/[*K=U^/^0?VYA_Y7^'^9Y-17K/_"(:#_SX#_OZ_P#C1_PB&@_\^ _[^O\
MXT?V56[K\?\ (/[<P_\ *_P_S/)J*]9_X1#0?^? ?]_7_P :/^$0T'_GP'_?
MU_\ &C^RJW=?C_D']N8?^5_A_F>345ZS_P (AH/_ #X#_OZ_^-'_  B&@_\
M/@/^_K_XT?V56[K\?\@_MS#_ ,K_  _S/)J*]9_X1#0?^? ?]_7_ ,:/^$0T
M'_GP'_?U_P#&C^RJW=?C_D']N8?^5_A_F>345ZS_ ,(AH/\ SX#_ +^O_C1_
MPB&@_P#/@/\ OZ_^-']E5NZ_'_(/[<P_\K_#_,\FHKUG_A$-!_Y\!_W]?_&C
M_A$-!_Y\!_W]?_&C^RJW=?C_ )!_;F'_ )7^'^9Y-17K/_"(:#_SX#_OZ_\
MC1_PB&@_\^ _[^O_ (T?V56[K\?\@_MS#_RO\/\ ,\FHKUG_ (1#0?\ GP'_
M ']?_&C_ (1#0?\ GP'_ ']?_&C^RJW=?C_D']N8?^5_A_F>345ZS_PB&@_\
M^ _[^O\ XT?\(AH/_/@/^_K_ .-']E5NZ_'_ "#^W,/_ "O\/\SR:BO6?^$0
MT'_GP'_?U_\ &C_A$-!_Y\!_W]?_ !H_LJMW7X_Y!_;F'_E?X?YGDU%>L_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M63[>2LFNYZF=3L!<?9S?6PGWA/+,J[MQZ#&<Y]JSM'U];O2TN]2>TM'DE:-
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MYR!SFI4%9713J.[M+;T.WHHHKG.L**** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "HO._TOR-O_ "SW[L^^*EJI_P Q;_MA_P"S4 6Z***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MBN9OL]NTNW=MQQG'>I:J:E_R#Y?P_F* +=%%% !1110 4444 %%%% !1110
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MU<S!S)O.>P8#%=9;2&:UAE8 ,Z!CCIR*4H-14NY<*T93<%NB6BBBH-0HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** *D_P#R$+7Z/_*K=5)O^0A:_1_Y5;H **** "BBB@#S[QK<0VGC
MGPU<7$BQPQLS.[' 49%6_%7C'1IO#]W96-S'?7=W&8(H807.6&,_AG-=7>:7
MI^H,K7MA:W+(,*9H5<K],BFVNCZ78R^;::;9V\G]^&!4/Y@5T*I"T;K5'%+#
MU>:?*U:7W[6//;ZPFTN?X?V=Q_KHY6WCT):,X_#.*T=?7PC?Z_<FXU2;3-6@
MPCSPR&,MP,<XP<<#L>*[>>RM;F:&:XMH998#NB>2,,8SQRI/3H.GI4=WI6G7
M[!KRPM;EAP#-"KD?F*?M]4WY[>;N2\&TFE9IVW\E8\TBEU;7]'\1Z);W[ZM:
MP)&]O=,F&<A@Q7/?.#^7O73Z#XVT(Z':QW5Y':7$$2QRPR@@J5&...>G:NJM
M[:WM(1%;010QCHD:!0/P%5KC1=*NYO.N=,LYI?[\D"LWYD4I582T:T'##5:;
M4HRN[6UOWNNM]#C/%5XNNZ-I?B'2HGN;?3KSS9(VC(+*I&3@]1Q^1]C6X?'O
MAH6/VK^TD(V[O* /F9]-OK^E=&B)&BHBJJ*,!5& !5+^P]($_GC2K'SLY\S[
M.F[/UQ4\\&K26Q?L:L9.<)*[M?3JNJU.0\': ]_X6U;[?$T,6KRNZ1D<HIZ-
MCUSR/H*YVQGO=<CTSP5<HRFSNG^UMZQ)T'ZD?@M>P57CL+.*[DNXK2!+F08D
MF6,!W'NW4]!^56L1JVUZ>1G+ KEC&+VT?FKW_,X+XD1VYU;PQ%/.UK;>;(KR
MQMM,:YCY![8%7-!B\,V.KPR6GBF[O)V_=I#/=AU8MQTVCFNOO--L-1V?;K&V
MNO+SL\^)7VYZXR..@_*H(O#^BP3)-#I%A'*AW*Z6R J?4$#BDJR]FH.XWA9>
MV=56UMWZ(\_T>/Q"_BWQ3_8,MC'B['G?:@W/S/MVX!]_TK3\!K)>ZUJVJ:I<
M,=;4_9YK<IM\I!CIZ@E1^7O7;P65K;3336]M#%+.=TKQQA3(>>6(Z]3U]:%L
M;1+Q[Q;6!;IUVM.(QO8<<%NN.!^5.5=235M["IX-P<6Y7LV[=-;[>9YSJ6@V
MQ^)]OIF]Q87H%_-;C[C.N_MZ$@_F:]-J!K*U>\2\:VA:Z1=BSF,%U7G@-U Y
M/YU/6=2HYI>2-Z%!4G)KJ[A11161T!1110!4U'_CQ?ZC^8JW534?^/%_J/YB
MK= !1110 5S_ (X_Y$K5/^N7_LPKH*CG@ANH&@N(HYHG&&CD4,K?4&JA+EDF
M15ASP<>Z//-#L?&5[X6LX+6_TN"PEMPJ-M8RJA'TQG\:J^,]%30/#&@Z;:2;
MVCO,B1QC<YR<D=AG]*].AABMX4A@B2*)!A410JJ/0 =*CNK&TO0@N[6"X$;;
MD$L8?:?49Z&MUB&IWMH<<L"G2Y;ZVM=_H>:^)AXC>6PTWQ->VD.E7<P62>S0
MD CD*Q8#'^3SBE\6VM@/B#I=M>7LMA9IIP7SHI-C* 9,#)!]A7I5U:6U["8;
MNWBN(B<E)4#KGZ&J]QHNE7C(USIEE.R($0RP*Q51T R.![4XXA*VEM]B:F";
MO9WNUOY=/0Y;1+70%>[L]-\27%]<W=N\2QW%R) .#R  *J^"_$-AH6DG0M9D
M6PO;.1P1*" X+$YST/7'T KLK;1-)LIUGM=+LH)ESB2*W16&?<"I+O3-/U J
M;VQMKDJ, S0J^/S%2ZL7=.]F:1P]2-I1LFK][69ROB+Q#INN>$->CT^9IA;Q
MJ'<(0IR1T/>G>%_%&A6GA?3;>XU2VCFC@571GY4^E=4-.LA9M9BSMQ:M]Z'R
MEV'_ (#C%5/^$:T'_H":;_X")_A2YZ?+RV=KC=&M[15$U>UNO>YRMM(DOQAD
MDC8,CV 96'0@JM8V@>'(?$=KXBA+"*ZBOR]M..L;Y;]#W_\ K5Z<FG645R+F
M.SMTN @02K$H8*.V<9Q[4ZVL;2S,AM;6" RMND,487>?4XZFJ^L67N]E^!'U
M+FE>>JNW]YYGX4O-0N_B.%U6,I?6]DT$I/\ $5/WOQ!%+X>T^;5-#\965O@S
M2W#! >Y!)Q^.,5Z7]CM?MGVS[-#]JV[/.\L;]OINZX]J+:QM+,R&UM8(#*VZ
M0Q1A=Y]3CJ:<L0GLK;?@3# M64I7W_%6.0\+>,=&@\/VME?W*6-W9QB"6&8%
M3E1C/XXS]:9XD\86U[X5E71FDEGO9S90_(5+'^(KGKP?_'A7676CZ9>R^;=Z
M=:7$G]^6!6/YD4\Z;8,\#FRMBUO_ *DF)<Q?[O''X5'/3YN:S-?8U_9^SYE:
MUMM3S+5--U^+PI96B>&6M3I1$ZW:WL;L",ECM'/)YP/05:\2:W;ZD/!6KLZQ
MQ-="24D\1E63=^ (->F$ @@@$'@@U0.@Z.T"0-I-@848LL9MDVJ3U(&."<#\
MJM8A73DN_P")E+!22:A+=+?R:MLD0VOB?0[VYCMK;5+:6:0X1%?))K6K/@T'
M1[6=9[?2;&&5#E9([=%9?H0*T*YY<M_=.VG[2WOV^04445)H%5+'[L__ %V:
MK=5+'[L__79J +=%%% !1110 4444 %>4^!XO%$FE7AT2XTV.V^V.&%T&W;]
MJYQ@'C&/UKU:H+6RM;&-H[.VAMXV;>RPQA 6]2!WX%:PJ<D6K;G-6H>TG&5[
M6OMYG"ZAX=ET3P3XAN;R[^U:A? 27$@&%R&X _,TWP[X(MM0\.V%V^KZQ$TL
M*L4BN0J+[ ;>!7?SP0W4#07$4<T3C#1R*&5OJ#2PPQ6\*0P1)%$@PJ(H55'H
M .E7]8ERVZW,_J5/G3:T2M^-SS/PSJR^'?A_K=T&+2I?R1P[CDLY5 ,_S_"J
M\.B^(&\%2:,?"[.\[^>;MKZ,-O)R&V]>G&,^M>D_V-I1B\K^S+/R_,\W9Y"X
MW_WL8^][]:O53Q"O=+K<SC@6THREHE;2W7?=,\[CUW0-=\&6$?B5RK^8;=GP
M=R2H/O9'(R,?G5 :A_8NLZ7;^'?$<^J0W$XC>SE;S0JDC//;]/YUZ.-*TY4F
M1=/M0L[;I0(5Q(?5N.3]:+32=-L'+V>GVENY&"T,*H?T%)5H*]EIVZ#>$JNU
MVKJVNM]/F>6_9]*N/'/B :IK%QIJ";Y&AG$9<YZ'(.:[WPHVD0VLUGI>L2ZE
MA_-=IIA(ZY &,@#CC^=:$V@:-<S/-/I-A+*YRSO;(S,?4DCFIK/2]/T]F:RL
M+6V9QAC#"J%OK@4JE93C;4JAA94I\VF[[WU.6^*/_(G'_KX3^M=98_\ (/MO
M^N2_R%+=6=K?0^3=VT-Q%G.R9 ZY]<&IE4*H50 H&  .!6;G>"CV.B-)JK*I
MW27W7%HHHK,V"BBB@ HHHH *J#_D*G_KC_6K=5!_R%6_ZX_UH MT444 %%%%
M !1110 5Y1X-C\2NNJ'0Y].CA%VWF"Z#9+>V >,5ZO4%K8VED'%I:P6XD;<X
MBC";CZG'4UK3J<D6K;G-6H.K.,KVM?\ $Y >')]'\-^);^_NQ=:E?6DS3.JX
M5<(V /S_ )5F>$_!EMJ?ABQO'U;5X6E5B8X+D*BX8C@;?:O1I8HYHGBE19(W
M4JZ.,A@>H([BFV]O!:0+!;0QPPI]V.-0JK] *KZQ+E?<CZE3YT[:)?C>]SSG
MPS>Q>&+#Q?.SO*MG=LB&5LM(P+*N3W).,_C5/3=,\02^$[RR?PRURVIDSM=M
M?1HQ8\JVT\\=<9]>E>E/HVER)*DFFV;K-)YDH:!2'?\ O'CD\GD^M70,# Z5
M;Q"NVEJ_T,XX%V492T2:TMU>NZ?0\YT_6]'O_ \=AXHRIMYQ92Y!W(P!VMQR
M.!C/J#GK6;<WT.@369\,>)KB_P#,G6/^SY&\T%3U^G8=,\^U>FC3-/#3L+&V
MW7'^N/DKF7_>XY_&FVNCZ993>=::=9V\G]^*!5/Y@4*O!-Z?+H)X2HTE=777
M6_YGFNJ0:;/\3=975-5GTZ$0QE9(9A&6;9'QD@]L_E78^$_[%MS<6VEZW-J3
MOB1A/.)&4#CC &!S6O<Z'I%Y.T]UI=E/,^-TDMNC,<# R2,]*?::3INGR-)9
M:?:6TC#:6AA5"1Z9 J9UE*"CKLBZ6%E3JN>FK;ZWU,SQ5XIM?#&G^;)B2ZER
M((,_>/J?0"L/P=)ITVJOJ-[JUM=Z]?*1Y<;Y$2 9V+] .?I^)["\TO3]096O
M;"UN6084S0JY7Z9%1VVAZ19SK/:Z7903)G;)%;HK#(P<$#/2IC."AR]67.E5
ME64VURK9?KZE^BBBL3K"BBB@ HHHH *J:C_QXO\ 4?S%6ZJ:C_QXO]1_,4 6
MZ*** "BBB@ HHHH *X?XK?\ (HQ_]?:?^@M7<5!=V5K?P^3>6T-Q$#N"31AQ
MGUP:NE/DFI=C'$4G5I2@NIQU[H/C+6[9K#4]3TR&RE(\TVR,7(!SCD#^=9?B
MG2(9/&/AG2$FGA@6V\E9(GQ(JKD#!QUXKTRH)+&TFNH[J6U@DN(O]7*T8+I]
M#U%:QKM/[S"I@XRC:]WIOKHG>QYCXY\)0:-X<-W'J>J7#><J[+F<.G.>V!S6
MIXYN;K5]=L/#]A:->^21=W4*R!-P'12QX''\Q7=75G:WT/DW=M#<19SLF0.N
M?7!HCLK2*ZDNH[6%+B48DF6,!W'N>IIK$;.6K5R98)7DH.RE:_RN>;ZG?ZOI
M7BRP\1W^AG3+9L6ER1<I,'4YY.W&,#_T$5>UE?!]_KEU*VKRZ7JL+;'FAD,>
MX@#!SC!_#!XKN[FUM[V!H+JWBGA;!,<J!E./8U!/HVEW007&FV<P10J^9 K;
M0.@&1P*%66CM:W;_ ((/"2U2::;OJNORL>;)JU]?>%_%-G+?MJ-C:HH@O'7!
M;+=,]_\ /K4>BV/AF31;-[OQ9?VUP8@9(4O JH?0#;Q7J/\ 9]E]C-G]DM_L
MK#!A\H;#_P !QBJG_"-:#_T!--_\!$_PJOK$;-)6]#-X&=TVT[*VM^]_^ 7H
M;NWN+1;N&57MV7>L@/!'K7G_ (BOO"7B&(:I_;LT%Y;1$0"-RC*PR1\N,YSZ
M5Z'##%;PI#!$D42#"HBA54>@ Z53DT/29I_/ETNR>8G/F-;H6S]<5C3G&$KZ
MG57I3JPY=/.]S.\%7E_?^$[.XU$LT[!L.W5UR<$_A_C704@      X %+42?
M-)LVIQ<(*+=[!1114EA1110 4444 5+'[L__ %V:K=5+'[L__79JMT %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!4F_P"0C;?1OY5;JI-_R$;;Z-_*K= !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% %34?^/)OJ/YU;JIJ/_'FW^\/Y
MU;H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *J6/W)O^NS5;JI8?<F_Z[-0!;HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ JH/^0JW_7$?SJW50?\ (5;_
M *XC^= %NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "JFH_P#'DWU'\ZMU4U'_ (\V_P!X?SH MT444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5+'[DW
M_79JMU4L/N3?]=FJW0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% %27_D(V_P#NM5NJDO\ R$;?_=:K= !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %3
M4?\ CT/^\O\ .K=5-1_X]#_O+_.K= !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !52P_U<O\ UU:K=5+#_5R_]=6H
M MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 547_D*/_UR'\ZMU47_ )"C_P#7(?SH MT444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 54U'_CT/\ O+_.K=5-
M1_X]#_O+_.@"W1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!4L/]7+_P!=6JW52P_U<O\ UU:K= !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P#L:/\ A8W_ %"O_)C_ .QH_M##?S?@_P#(/[*Q?\GXK_,[JBN%_P"%C?\
M4*_\F/\ [&C_ (6-_P!0K_R8_P#L:/[0PW\WX/\ R#^RL7_)^*_S.ZHKA?\
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M,?\ V-'_  L;_J%?^3'_ -C1_:&&_F_!_P"0?V5B_P"3\5_F=U17$Q?$2)G
MFTUT7U6;<?RP*Z:PUBUU*W\ZU8.O<9Y4^XK6EB:55V@[F%?!UZ"O4C9?UV-"
MBH?/_P!G]://_P!G]:WL<Q-14/G_ .S^M'G_ .S^M%@)J*A\_P#V?UH\_P#V
M?UHL!-14/G_[/ZT>?_L_K18":BH?/_V?UH\__9_6BP$U%0^?_L_K1Y_^S^M%
M@)J*A\__ &?UH\__ &?UHL!-14/G_P"S^M'G_P"S^M%@)J*A\_\ V?UH\_\
MV?UHL!-52P_U4O\ UU:I?/\ ]G]:K64NV)_EZR,>M %^BH?/_P!G]://_P!G
M]:+ 345#Y_\ L_K1Y_\ L_K18":BH?/_ -G]://_ -G]:+ 345#Y_P#L_K1Y
M_P#L_K18":BH?/\ ]G]://\ ]G]:+ 345#Y_^S^M'G_[/ZT6 FHJ'S_]G]:/
M/_V?UHL!-14/G_[/ZT>?_L_K18":BH?/_P!G]://_P!G]:+ 345#Y_\ L_K1
MY_\ L_K18":BH?/_ -G]://_ -G]:+ 345#Y_P#L_K1Y_P#L_K18":JB_P#(
M4D_ZY#^=2^?_ +/ZU667_B8NVW_EF!U]Z +]%0^?_L_K1Y_^S^M%@)J*A\__
M &?UH\__ &?UHL!-14/G_P"S^M'G_P"S^M%@)J*A\_\ V?UH\_\ V?UHL!-1
M4/G_ .S^M'G_ .S^M%@)J*A\_P#V?UH\_P#V?UHL!-14/G_[/ZT>?_L_K18"
M:BH?/_V?UH\__9_6BP$U%0^?_L_K1Y_^S^M%@)J*A\__ &?UH\__ &?UHL!-
M14/G_P"S^M'G_P"S^M%@)J*A\_\ V?UH\_\ V?UHL!-534?^/3_@2_SJ7S_]
MG]:K7TNZVQMQ\P[^] %^BH?/_P!G]://_P!G]:+ 345#Y_\ L_K1Y_\ L_K1
M8":BH?/_ -G]://_ -G]:+ 345#Y_P#L_K1Y_P#L_K18":BH?/\ ]G]://\
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M]1V/:@#.UWQGX=\,WMI9ZSJL-I<79Q"CACGG&20"%&>YP*WJ\F^+.J>'=/\
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M44 %0+_Q_2?[@J>JZ?\ '])_N"@"Q1110 4444 %%%% !1110 4444 %%%%
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MW<DGIP.>*DT7XPZKJ.KV%I>^ -7LK>^E6.&YRS*=QP&^9%&._7UH ]7HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MRQ-PR2*&4_4&LRT\*^'=/NA=66@Z7;7 .1+#9QH^?J!F@#YY\66FOZ0GP_\
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MZ?96UG #GR[>)8U_)0!46G:)I.CM,VF:79633D&8VUND9D(SC=M SC)Z^IH
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M_P"^* )Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** %T[_ (]?^!M_.K=5-._X]/\ @1_G5NI&%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!P7Q%_
MU^G_ .Z_\Q7$5VWQ%_X^-/\ ]U_YBN)KYK,/]YE\OR1]CE7^Z0^?YL****XS
MT0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "IK7_C[A_P!\?SJ&IK0$WD( _C'\Z<=T3+X6>Q4445]D
M?GP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4%G_J/^!'^=3U!
M9_\ 'O\ \"/\Z )Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *@3_C]E_W14]01_\ 'Y-_NB@">BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H+O_5I_OBIZ
M@N_N)_UT% $]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% "Z=_QZ#_ 'C_ #JW533O^/,?[Q_G5NI&%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MVYA_Y7^'^9Y-17K/_"(:#_SX#_OZ_P#C1_PB&@_\^ _[^O\ XT?V56[K\?\
M(/[<P_\ *_P_S/)J*]9_X1#0?^? ?]_7_P :/^$0T'_GP'_?U_\ &C^RJW=?
MC_D']N8?^5_A_F>345ZS_P (AH/_ #X#_OZ_^-'_  B&@_\ /@/^_K_XT?V5
M6[K\?\@_MS#_ ,K_  _S/)J*]9_X1#0?^? ?]_7_ ,:/^$0T'_GP'_?U_P#&
MC^RJW=?C_D']N8?^5_A_F>345ZS_ ,(AH/\ SX#_ +^O_C1_PB&@_P#/@/\
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MW?UH\I/[OZT7 K459\I/[OZT>4G]W]:+@5J*L^4G]W]:/*3^[^M%P*U01_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% %0_\A5?^N)_G5NJA_Y"J_\ 7$_SJW0 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!4OON0_\ 79:MU4OON0_]
M=EJW0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 54T[_CS7ZG^=6ZJ:=_QY+]3_.@"W1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !52'_D(W/T7^56ZJ0_\
MA&Y^B_RH MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 54OON0_P#79:MU4OON0_\ 79: +=%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %33O\ CS7Z
MG^=6ZJ:=_P >2_4_SJW0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% %0_\ (5'_ %Q_K5NJA_Y"H_ZX_P!:MT %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 5+[[L'_79:MU4OONP?]=EJW0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 54T[_CQ3ZG^9JW533O\ CQ3ZG^9H
M MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 54A_Y"%U]$_E5NJD'_ "$+KZ)_*@"W1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !52^^[!_UV6K=5+[[L'_7
M9: +=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% %33O^/%/J?YFK=5-._X\4^I_F:MT %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!4_YBH_ZX?\
MLU6ZB\G_ $OS]W\&S;CWS4M !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% %2^Z6_\ UW6K=13P^<(_FQL</TZXJ6@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ JIIO_'C']3_,U;J*VA^SP+%NW8SSC'>@"6BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JD'_(0N_HG\JMU$D.R
MXEEW9\S'&.F* ):*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *J7W2W_P"NZU;J*>'SA'\V-CA^G7% $M%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %3
M3?\ CQC^I_F:MU%;0_9X%BW;L9YQCO4M !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
C%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>gyycud3vz5ad000015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gyycud3vz5ad000015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '7 =H# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4M)2T >0ZGX:O]0^.=Q<R6,W]F3Z2]NUQL^3+(1C/K7%> _
MFOV=KXLEU#3KI98M,EL[-74_.6SPGJ./UKZ2HH ^>[_P'K=_\'?#0339GOM+
MG>6:Q;*NZ%CD#WZ5I>%-&MM3\9Z?-:> ;NPM;0"66\U">0-'(/[@S@\U[E10
M!\]3Z9K$GBG7H_$WA;5=>NYI6&FLKG[,BG..X '3\JCM/"^O)\!-2T=](NUU
M :B&$'EG<RY'(]17T310!X]\3-"U74/A-X?L++3YY[N&6W,D,:99<1D'(]C7
MK5BK)I]LK AEB4$'L<"IZ* .1^(>HW]IX<-CI,$LFHZE(+2%D4D1[OO.2.@
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M&HZRLQ6.<3.+>12>IVGTKZ'\-::ND>&["Q6UCM!#$ 8(W+K&3R0">3R:U:*
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M4 %%%% !24M)0 M)110 4444 %%%% ",Z(NYV"J.Y.*1)8W&4=6QUP<UY_\
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M;6BP?9XCY0W;ERQ^<9/-2Z#XIU6\DT,3W8GMYKV[@-PL04744:Y1\=OPZXH
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M06%Y>6M@<7EU H*0G&2.3EL Y.*Z6VN(KNVBN('#Q2H'1AT((R#0!(JJBA5
M  P .U1):6\<[SI!&LSCYI H#-]34U% $,UE:W+(T]O%*R<J70$K],U'=:98
MWQ4W=G!.5Z&6,-C\ZM44 -6*-(Q&B*J 8"@< 56@TK3[:8SP65O%*>KI$H8_
MB!5NB@""YL;2]C\NZMHIT'\,J!A^M,:QA6QDM+=1;1LA4>2 NS(ZC'0U:HH
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MC"2W9Y#J%I:7?Q-\1B\\,7&N!(K79Y;#]UE#GJPZ_P!*VO%%M!H/AC3=<TN
MZ;?:?C[/9'DS!S\UN0,Y)/Y$5V%CH4%CKVIZNDDC3:@(A(IQM78"!C\Z;=Z!
M;W^NVFJ74DDGV-3Y$!QL1SU?'=L<#TKE-#F?"6IV$'AU_%>K7R?:M1?-Q(0<
M0D$@0@=1MZ?7)JQX@TZP\0V(UN"WFUH+;E;:S6;9'G)^< X^;C&?;BMNP\.6
MVFZMJ%Y;22"*^822VIP8Q(.K@=B>]0ZIX7^V:FNI6.I7.G77D^1(T(5E=,Y
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MB@!:RO$G_(LZI_UZ2_\ H)K4K+\2_P#(LZI_UZ2?^@FJA\2$]CF?A+_R)?\
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M4M !2TE+0 E%%% 'CNF?\G,ZI_V#Q_Z"M>Q5X[IG_)S.J?\ 8/'_ *"M>Q4
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MK(H6DI:2@ HHHH **** "BBB@ I:2EH 2BBB@ I:2EH 2BBB@ HHHH ****
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M2@>=$?XEQ7:9% 'CNF?\G,ZI_P!@\?\ H*U[%7CNE_\ )S.J?]@\?^@K7L5
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M3SDG^=>^LP52Q. !DFO'M+_Y.9U3_L'C_P!!6N^\=ZM_8_A&^G5L2R)Y,?\
MO-Q_+)_"JA%RDHKJ)NRN<IX&5O$/CO6?$<G,<3&*#\>!_P".C]:]/KD_ASI!
MTGP?:[AB6YS</_P+I^F*ZRM<3)2J-+9:?<3!6CJ%%+25@6%%%% !112T )12
MT4 )12T4 )12T4 )12TE !12TE !12T4 )12TE !12T4 )112T )2T44 )11
M10 444M "4444 %%%% !12TE !2T44 )2T44 %%%% !1110 4E+24 %%+24
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M^%W^!?\ H*2?]^&H_P"%W^!?^@I)_P!^&H ]$HKSO_A=_@7_ *"DG_?AJ/\
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MU8#K]>M<C%XN\=?#&=;7Q99OK&CCA-0AY91[G^C?G0!ZC_P@WA7_ *%W3/\
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M%%% !12TE !1110 4444 %%%% !112T )1110 4M)2T )1110 4444 %%%%
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MM)2T )2TE% "T444 )12T4 %8GB/PS8^)H+2*^,H6UN4N8_+;'S+TS[5MTE
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MUO"T>S3(FC\]F&-S@\?E5_PA\/;G2]/U71-?^P:CHL]R;BWBV'=N+$G=G\*
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M110 4444 %%%% !1110 4M)10 4444 %+24M "4444 %+244 %%%% !1110
MM)110 M%)2T %%)2T %%%% !1110 4E%% "TE%% !1110 4444 %+110 E%%
M% "T444 )1110 M)110 4444 %+110 E%%% !2T44 )1110 M)110 4444 %
M%%% !1110 4M%% "4444 %+110 E%%% !1110 4444 %%%% !1110 M%%% "
/4M%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>gyycud3vz5ad000006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gyycud3vz5ad000006.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_X0!*17AI9@  34T *@    @  P$:  4
M   !    ,@$;  4    !    .@$H  ,    !  (        #P     $   /
M     0  _]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$!_\  $0@!' )% P$1  (1 0,1 ?_$ !X  0 " P$! 0$!
M       &!P0%" ," 0D*_\0 5!   04  @$# P(#! 0("P$1! $" P4&  <1
M$A,A"!0Q%2(605$C,F%Q"21"@1<S4E>1EZ'6)28U0U-B<K'!T? 8-&."DB=$
M5%65\7.#DZ*CPN'_Q  = 0$  04! 0$             !0$"! 8' P@)_\0
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MXOM-4=+6Z5;*];"HK2 P7#'@"&5MNV1CVAD')\D4DS!ML'JF@7%@&FA)N;8
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M*4XI7SY_<C?ZM<O_ $*U/_\ ;BE?7%*QV/\ ]8GB_FV."7_=+[L:?]L"_/\
M\EXI61Q2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<
M4IQ2G%*<4IQ2G%*<4K1:.]&SE419$NB3VVN2!DTJ0122MCDF<LLWI>L(PX\,
MYATZ1R*,",23[;TA5J^<LL<,4DTKK'%%&\DDCG:B(BEG9F]%5023Z 9JY$:1
MTC12SR,J(J@DLS'"@ >I)P/C7)-G9&W=C+;V<I3IO=B6+Q#"A@JD1$M#% #(
MDF#_ (C/'98*,R99:W(4GZB09]W_ .%B-=Q[5=4?7[F2YNI9;70[)PL42JO5
MDE8-TT1'RLFHW"K*V6'3L+96=\!9#=]!L+%=*A6"%4GU.Z0EV;)2.,,-[.RG
M<MI Q10%(>YG*JASL,&JF/AEAD 9!#+7+-*DP#'E3TDAC61-E:X=6RV.XNX8
MFCJ6=8-+*>HQ7Z<^M:(35!XRPW-]9[Y9K;0]!RZ1H2YAG94 ;9 JFZUJ[54
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M/=;ZF82L-L:VTU%$=>;+[Z6GO+S<'29?!F3V$;O>@=!KK#"5Q 5A8_=DBDZ
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M5UMBHK6>'>T,I!RZ7/G5Q52BJ5M++ZQ0\_UZ7M;_ *^LY#:\G1"&U.-L+3=
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M(28<*[DTZS'M4MXGB35;<*@<EWTVW5G=HGE8L3?B!V*+'$XMQNCBE2(A363
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MF6R>4" O@+\^OHQFZUPU&JI((''FR23GN"%P,=A@@G/KN^%2,3Z&ALN%U/\
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M)U(;^WR 6!*J+A#N<SN#M,$@D@=7=8\Q/+&N]6E_8:K"R2H9;F1=KVLI&0"
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MN:J?,C_[RJ57O6;TJ6:;!RL6";%Z$Y*R)W[6RY#2$$:#*3A1^5<VLKA3"\A
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M(G*V;^*-]6CJ3=(]%\_<RZ'036CY%556=[GN5RJJJI71@88M>(* %!&*$"-
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M'_")V']]G,O 2U?V*148\+3V4+517Q+>A$)Z?[-7*5TYQ2N/OJH/@U5ST?\
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M)E]LG4^C2W*>S'.2JV9*D"9P=.\9Z@=UOI<;<(J7=WCN9)%/LL3'U"0-UQC
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MEELG;'V4=Y[B LV!U9+=,^>N@^"[]-EQIK$+()3?6Y[%QTXX[E5][HL,,R@
M_5I,_ 2HSU$$*_LGKX!&M46AZSU%R Q?E&&P28C."$1JOGP^*IO;@?U(OGVC
M9$\^'.\PGT=0I)XAB+<BUT>ZFB)[B4S6-JK#/8B&>9#ZD2$=B14GXQD9-'D"
MDCKZC;Q/CLT>R[G*GT.988G^],^@KL*XN*V@K2K:V*8("'&DDTKFOD>OJ<V.
M*&""%DA!11$KF0"!C13%%DR1##0RSRQQN[==W=M8V\MW=S)!;PH7DD<X4#@
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M%7^?A//%*12,FCCFB=ZHY6-DC<B*B.8]J.:Y$5$7PK514\HB_/%*^^*5QMK
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M[E!<S)"/K+;<2#''>;E:XMYW4LL$L:K#M2;9G=+R=AVP$5M<2Q;HH7<!([C
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MNKSE@6YB>W<X67:#P>?.A*\%>7V["2?L$J V]A70'9UPMYLEJFR>NMQS!T=
MJ>$746@##)9Y&KY5SJ_/6%>P&5OI1/URTC>CGL8L?0OI"U5Y]1CTF-_J+&..
M:= <;[R=-Z!_>(;5XVCYP3<R;@<*1J/A#3UCM)+^1<RW+&.$D?9MXGPQ4_\
MF3HZN.?W"X(!8&MYO<L"9@V2R0AB^AALD+WPD3D21LF0*.5BME@B8/+%,01
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M"+;AQV35@MJB<M\8:S0S"$$ "%E"!E V\RNL8GP0+/X8D)29%$A"M%(@8*9
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M.-TA4VX). L[-6K^HC$ WV+*N(HRHS:!/U>,H:>)88*\16EW#_MIH"6%_9U
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M&4!N9AA*7\R?<6^@<[X5Y4CE\IV8^#GO'$^H:C.7'(CB"^4'C&79E'8#RJO
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M@1'"BO<9:2I*9- ,Q$]4DAMC*Z$6)J>M[YHXV(KE3EO,49.-S*K-@#EW))P
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MZK$0H:&42,P0*IC*,['"JKLZ,<^F8P>^%.*CFL)!N/4CV*I9BP<%5&<ED57
M'_/ZC)%2O%3ZR-YM7+EUC'@]6A02.3["P%J]/;W9('V56>YA,D$,@I+'C74.
M1N&0QHHN=?+ZP!9J#3K[SHD.XKB;IX,+B.XEF9.FDC%B RLH2=;27 4B '*+
M%27ML C-)@,3%O'UB!X4C#AW3R@X9<&$W,9/>;D,ULT][$]L@DLDI5:_P,>
M_P!QDX3U5TK7H*2UDH%D(Z9T[(IHH9?+Y(9V>W/(U<^QU%[?=97O4FT^0=&Y
MM9-Q: $EA/;QR_N+J!G::(@+O+21R$QS29Q+FS28"ZM#''>(>K!<(%VRG 4Q
M3,G[V"546-\EMH5)$\\:FO T3[8F4:1S)?9D:YDC/*QRL<B2#SL_JR6-S)XO
M4GE$<QWA'(BIA7=NUK<2P.ROTV&V1?L2QL \4R>NR6-DE3/.UAGFLNWF6XAC
MF *[QYE/VD=25DC/]Z-PR-SW!%8SE\-5?2KOA?VM\>7?X)ZE:WROX^7(G]51
M/GF/7O4(N@29)XG0M:ID@I$$Z^VV> &DFB<%+60>IGADMJ03#+++Z8W3I7K*
MQR.J@DBHKO$^^/'4:.2/E0P6.9#"R ?S.'.6 !RJL.8T862(LBA7)"B2-SM)
M',;B12?> 4 /H02I&'8&_=;>2D]3]?U"*CI=I39YMHUWESEH8:(>TN?6SPC9
M1K"5 : UCU1%&O'KX<Y$:O8O$^K-!X0TZ)'Q+J]M9V[G)WBW:T6>Z;'JKJJV
M[^F+GT.,<ZT*P6;Q!>.P^KT^:YE4<;>J+@Q0C/H8R6G3'<P < DBN^<>KI%:
M@1J6$K;.9/5"USTJXG(OH9%\L6P5BIX<08GJ6"54]4 #V1Q)$\DWWK1R2QY'
M\'P'JW;NWH?1./5LOO\ Q']0?\O>.>0,;!\Z(]8V,DFD;X];8T;XC1414];Y
M',C:[PK5]OUK*K7(](U9^[EQX],GW?Y^[^OPQ3UQ\CY^?2OC[E&.:DT4L".<
MC&R/]MT2O=\-:KXI'^WZE\-:LR1M>]S8V.=(YK74S[QC\L?GG(^\@#W$TKPL
M G$LCG&<V&Q$]4@)#O/I1SD3W!B/3\R EHUL94*^?[L1,2,+&%FAHRYP1PR\
MJW]5/]UNS#UX/=5(9QSC(]1[_N_O#T_(\$U[A%L.%A*8UT:2M7UQ2)XD@FC<
MZ*<>5$^$F'G9)!*B*J))&Y$543SRH.X C(!SP>XP2"#\000?B*J1@XX./4=C
M\1\#4UZQLWTVZGKE<UE=L*J21S5_:UNCSWM.'=$UOA)"K7/D'(7+(BN07*@1
M,<C6>GG0?H^U P:C<Z:Q^JOH#<1J3VNK7:K!1PNZ:W<LY.3LM$ [&M.\86:R
MV<%X >I;2=%B,<P3[F&[/98IU&T#@M<N3S73[7>$_DK?_K\?[^=A#8^(]17-
M\5R+HMW6=2=[=CDF^R@FZQ/5E\ULK_;:MK6%=A9NPE1$1/+W5E301/5?*^B&
M)//CPB:%=ZK#H/BG6))5'3U32]"N@&EV W$$FL6<S#CDF""T4_\  *VZWL)M
M7T'35CSOL;_5H"<$_4RQZ;<QCOQB66Y/'?=77,[)WL5()VP/5/A[H4F1%_DO
MH5[//^7E.=$K4:Y+^I_(;Z7KZ7L"ET4-E=].6P?;.;J!LY! 829DXR9+(1IJ
M'SOFB,SA5T+-7_:/;9)*T/\ LW2LFC?/S\\_"E6+0UW:&GHZ;24G=-$937]5
M7W547%UB"L95;:"1&A$,7^*5\MF&GCD3Y7X=Q2LFPP?;%J =5G]M49(%D&2
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M1Q2G\)=Q_P#/!3?]6 /_ 'HXI3^$NY/^>"F_ZKP?^]'%*?PEW'_SP4W_ %8
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M%I"9"KI!SWDTTT<^H6MX-.Y:*W$;QPN0,H[LXBCN"<$DE\#("_5[E>%$;*/
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M6M17.5$15XI40RHDY1-QK3HI(2M&X.*N&GB="17Y>J:0E&(1&_TR,(+F-L]
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M NR**,851DD_$LS$L[L2SN6=V9F)/.YYYKJ:2>XD:6:5MSR.<LQ[?<   %4
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MQ1(722/\>&10Q,\KX:U//AK4\-8QJJOPUK5543@D*,GA1C/N"C[@3P/0 GT
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M,68*!"I!A$0\*.1J/E>C?4]WGT11HJ^J6:14],4,:.EE=X9&QSU1JT+!1EB
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M?A45%\*B_"IQ2J RU9_P-[,7#B>6=7;TNPGP8J^?9PVR9 5<V^&#1$](^9T
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M%LD90GZNZ?I2^"O!%MIVDXG?0])6)':,'?=;P]]=M%QY99);J^Z;;EV[DD#
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M7>W3-1EWW&TBTN7Y>< $M;RG^.;OTI#AI?,KEI=@DB=54NF5O[/CS\>4_/\
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MU;OOAF7<IQAA@E61U;#))&P9)8V >.161@&4BN7W$$MK-);S*%EB;:X!# \
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M,5LC8B6N1\)$?LE"$02O&,!,A7RX<X R*8(T95]8Y<$T#OF-56.TZ*.XB25
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IE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>gyycud3vz5ad000010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gyycud3vz5ad000010.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" (-!YX# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHS0 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M112'...O^?6@!:@N;JWM(FFNID@B7[TDC;5'XU3UC5;;1-*O=6O6"6UA;O<3
ML3@!4'//UK\?OBC^T+\3_C+X_G\%_"DSOIT%P]M)-;%M@.X+R5R!]/Z<4 ?L
M%9:OIFH\65[!<D=1&X)XXZ5I5^'BZ_\ M&? WQEH5OXCCU&[L+V>+SBHD=0D
MCKG..!@'G_)/ZAW?Q^\'>&/!5CXD\3WJVTC6<<L]OYBK/OV L-K9.<Y&,=J
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M![7]GSXP?#[2?A]J!BEN)+07T5M(3O9BFX,$/J#G(SGC%'Q3;Q!\8_B+X?\
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MH **** "BBB@ HHHH **** "D)P"3T )/T%+45PK/!,B??:*14_WF1@OZD4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P &MA_\?H_X2;PY_P!#!HG_ (-;#_X_0!MT5B?\)-X<_P"A@T3_ ,&MA_\
M'Z/^$F\.?]#!HG_@UL/_ (_0!MT5B?\ "3>'/^A@T3_P:V'_ ,?H_P"$F\.?
M]#!HG_@UL/\ X_0!MT5B?\)-X<_Z&#1/_!K8?_'Z/^$F\.?]#!HG_@UL/_C]
M &W16)_PDWAS_H8-$_\ !K8?_'Z7_A)?#IZ:_HO_ (-;'_X_0!M4T]1\V.G'
MKS]>_2L?_A)?#HZZ_HH_[BMC_P#'Z/\ A(_#IY_MW13[_P!J6)_7SZ -A\XX
MSU[9I2<#IGVK%_X27PY_T']$_P#!K8__ !^K<.KZ5<@M;ZGI\ZCJT-Y;2C\T
MD84FTM6TEYZ!Y]"[C.#]T\YXY_I3ZS9M9TBVYN-5TV >LU]:Q?\ H<JU6_X2
M7PX>FOZ)_P"#6Q_^/T)IZIIKRU!.^VOH;=&<]*Q/^$E\.?\ 0?T3_P &MA_\
M?J>+6]%E_P!3JVER_P#7*_M'_P#0)33_ *_+^OF)M+5M)>>AJ49[=_2LA_$&
MA1G;)K6DQD=0^HV:$?4-,"*C_P"$E\.9_P"0_HF?^PI89_\ 1]%[[#3OJM5W
M1MY_3K[49K$_X23PYR?[?T3'?_B:6'Z_OZ/^$E\.?]!_1/\ P:V'_P ?H VZ
M*Q/^$F\-GIX@T0_]Q6P_^2*/^$F\.?\ 0P:)_P"#6P_^/T ;><]**Q/^$E\-
MCIK^B?\ @UL/_C]'_"3>'/\ H8-$_P#!K8?_ !^@#;HK$_X2;PY_T,&B?^#6
MP_\ C]'_  DWAS_H8-$_\&MA_P#'Z -NBL3_ (2;PY_T,&B?^#6P_P#C]'_"
M3>'/^A@T3_P:V'_Q^@#;HK$_X2;PY_T,&B?^#6P_^/T?\)-X<_Z&#1/_  :V
M'_Q^@#;HK$_X2;PY_P!#!HG_ (-;#_X_1_PDWAS_ *&#1/\ P:V'_P ?H VZ
M0G Z9]JQ?^$F\.?]#!HG_@UL/_C]+_PDGAW_ *#^B_\ @TL?_C] &R#D=,>U
M&3D#''K6,?$GAT==>T49]=4L1_[7H/B3PZ.NOZ*/KJEB/_:] &U16+_PDOAT
M]-?T7_P:V/\ \?H/B3PZ.NOZ*/KJEB/_ &O0!M?A29.<8./7\/I6+_PDWAS_
M *&#1/\ P:V'_P ?I?\ A)?#O7^W]%Q_V%;'_P"/T ;5'OCFL3_A)?#G_0?T
M3_P:V/\ \?H_X2;PY_T,&B?^#6P_^/T ;0)/4$?Y^E+6)_PDWAS_ *&#1/\
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M_1_PDWAS_H8-$_\ !K8?_'Z -NBL3_A)O#G_ $,&B?\ @UL/_C]'_"3>'/\
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M_A_XHU#2;&2<(T=O<2QJ1OQT1@#7]X3_ '&_W6_D:_S3O^#I!0?VB-*RH/\
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M2@U9+6U]=3Z#TO\ X*Z?MHW1^UIXOUQ[(')E%S=E0N<YSN('7U[].3F/6?\
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MDJ>8?7\?3P2E3ES0I2J-+FFU>R6N^^[/#8_^"S'[6]M)<0S^/]8\U2P"F\N
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M1_A1L7^ZO_?(_P *.9]W]X'ZW?\ #Z?]K?\ Z'_6/_ VY_\ BJ/^'T_[6_\
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MXB\8:TUN70EA=71&W.3_ !$XP<^V?Q/Z2_ #_@K#\=]6\-7,&J>+=0GU,6V
MKW,Q82;>>"V>O\Z_&+X'>'K/QKI,.F1VD(E>+:&:-<Y(]<=B!BOI?X=?#&3P
M%XHF;4OEM7)8#&$PW)]!CGH?3\_E\[S>=>%3"2G*C4HOF@J<K3J)-=O^#O?R
M/YZ\8/$BA++LZX?AF-7)>(<HE#$X-4)2C5QD8RC)P5FKW5TU?6[.R^.G_!7W
M]JKPSXHO+.#Q?J\$$MRZQ8N+@* 7( ^]@#D<BJ'@W_@J!^UWXEL9+\>.M8*A
M V/MESV'3[W7I[_2OG/]ISX>:9XCUF*[TQ8&*L7^15/(/MZ_J?RKQ+P9J5YX
M<D?1C"BA1LRR@< [>F/0^GKZ5WTLUK3RNA[!N&(A!>T]HW=135V^K>FN^MS]
M X+XTJY_P#D^.RNO&6;?5::S&E6E+GA4I\L)RFI:^]9OSNM]S[CU+_@J/^V8
MTL\%GXRUMQ$6'RW5UG"^OS>GU/([UXSX@_X+!_MB:)<M;W'CO6X70X93=W(_
M3?VP>/H*Y>R\1Z)H2S3ZE%:L\J,3N5>K#GK^?\C7PY\9-2TO5M7NKRRCA59&
M? 15 ZX&,>XZ?XFN[*LSQ6*KNG4I6IJ.E17UDK)W_P _O/M.'.(<UQ^-KX3%
M8!T\/1IQ=/%6;C6EHI)7_#33[C[@F_X+4?M;G&WQ_K.5Q_R^W'/ '][\:@;_
M (+5?M<;3CQ_K(..?]-N/3G^+UK\F7C ).Q<#O@?2JTL:8X1<G/8>HKZ2[[O
M[S[N+]Z[ZO7^O74_6'_A]A^UUNVGX@:S_P"!MQZ9Z>937_X+6_M=#&/B#K(Z
M_P#+Y<>W_32OR+**)/N+_P!\CTQ_2DD1>/E7O_"/;VJ]>1W\K>FAJFGM;0_7
M'_A]=^UU_P!%!UG_ ,#+C_XY1_P^N_:Z_P"B@ZS_ .!EQ_\ '*_(K8O]U?\
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MQ<.(L10IX=W7[K#UTI/$.S^Q^MO3A;G_ (+4_M9[54>/=8!.!_Q^W'J?]O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6/4=>_!_"N?_ &I/A39>*OA5_P )<TT>M:I;L)S< K*ZE<-URS=N/7O7Y?\
MQD_;SUC6M*C\/>#IGATRU@2.W2%RJ@HN 0 1C/\ B.M2_!_]NJ[MO"]SX6^(
M$S7-E,I7$[E@,@]CT_J<U^$4N#N*:-:CGTI0GC?[2GB*]"R^L2P=2HI>Q4_B
M]R+LHW/YO_U*XYIXJ'&,IS6)6*G7>74O?QBPM65W02>K=K)J^FQ^GO[.?C^Z
MN_@G?^%;BS\B*WM)89I"NT(%78<D]/7GKBE,'A_X>?"?6/&'A[PK#K^LFYF8
MSI"DKA]S' PK-D?7N>AZ?GQ:?MK>!O#WAWQ+HVBB-#J4$L=L4(&&D##C'O\
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M(****HD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ1_NG\/YBH: )]P]1^=&X>H_.H** 'N<GCT_QIE%% !14H08Y'/^?0TUP!C
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M!]!_*EH **** "BBB@ HHHH *0]#]#_*EI#T/T/\J (**** "DW#U'YTM5Z
M)]P]1^=0444V]$NU_P 0"BG( 3SZ5)L7T_G_ (T@%'0?0?RJ>W?9*K8SS4-2
M1$!P3[_RIK=>H&],%DB!!VL><=NOX_UY_*O:/V># GCW28[M@4.H0#+'& '7
M/7]?\BO"5W2R)@_*-O\ G_/Y$UU.A:I<:!JUC?6;%)8KB-\J<$$$'VZ8_#/8
M9J*]&6(H8G#P=G.A.TO-JVC\F]NAYN;X-XW*,PR^E)PJXS"U*<9V_AN44_\
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MJG_7TO\ .O\ 38JXNZN92T=NUOR044451(4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 U_N-_NM_(U_FB?\'2_P#R<3I?_7R?_0Z_TNW^XW^Z
MW\C7^:)_P=+_ /)Q.E_]?)_]#J)[?/\ 1@?RX1?<'^>PJ2HXON#_ #V%25D
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #7^XW^ZW
M\C7^:)_P=+_\G$Z7_P!?)_\ 0Z_TNW^XW^ZW\C7^:)_P=+_\G$Z7_P!?)_\
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MK%)731"21P"<>U)DGKDT,,$BDK=+W5*ZN_O]?G;\C *DE^X?\]C4=22_</\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P"8M4Y22IS_ )X-7*IR_</^>QIT^OR_44WM\_T/ZH?^#4W_ ).@U+_KY_\
M9A7^FW7^9)_P:F_\G0:E_P!?/_LPK_3;K0A[_)?D@HHHH$%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% #7^XW^ZW\C7^:)_P=+_\
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M<G=6VM;:_=[ZJ_EJCFX]R-YC#*D_YX_SGK5N=XYXQ@8/KQ_GC_/-*%!0KQD
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M #1/^#I?_DXG2_\ KY/_ *'43V^?Z,#^7"+[@_SV%25'%]P?Y["I*R ****
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MU\R?^C5K^69/^/*V_P"N:?R%8S^)_+\D2Y6E:W5?C\B&BBBI*"BBB@ HHHH
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MB@04444 %5Y^WX?UJQ5>?M^']:"H[_=_Z4BC<?ZB;_KF_P#(U_5U_P &PO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MV*_S)_\ @U/_ .3H-4_Z^E_G7^FQ6L-OG^B,9_$_E^2"BBBK)"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!K_<;_ '6_D:_S0?\
M@Z;_ .3BM,_Z^O\ VHU?Z7S_ '&_W6_D:_S0?^#IO_DXK3/^OK_VHU9U.GS_
M $ _EKB^X/\ /85)4<7W!_GL*DK, HHHH :S;<<=:;YGM^O_ -:B3M^/]*CH
M D\SV_7_ .M2,V1C'?\ SVIE% !1110 4444 %%%% !1110 \/@8Q^O_ -:E
M+Y!&.OO_ /6J.B@ IRMMSQUIM% $GF>WZ_\ UJ<IW#I[>M0U*G3\?Z"A>>P$
MBKD\<=^!6YIMW%:RQF3Y@&7KTX.>^/\ ]0)]JQHAEP,9S_B*=)M,HB"G)Q]?
M;/OT_P YK2,5/FC>U]K^I2BI^X_M:+MK_7]/;[N^&?CW0;#2HUD$:R!!UV#)
MP>/Y^G:O)?BQXBL]8OFEM-I7<W"X([@XP?QKP[3;R>UQ&K2*!@?>Z8_'^?J:
MO7\SR*'WEB3W.>H_3->10RFEA\<\4Y2E*3O9O2UU?6_=[=M=#YZCD5'"YE/&
MJ4_:5+IWDW&RM:RO97VLNOX5F&V(MC!X/IUY_P#K>W2J1))]_P :LO(3$H)S
MGM^'?O56-MS@=_T]/K^E>F_=YI6T;LG;IHEOU_K<]V&O-Y-ZORLO6_X&S8V$
MUP56)2Q8CC'7J<=/SZ_X[4V@7EG$)YX716]5./7\L?A^E>E?"K1[._U&W%T4
M";ESNQ^O3U[U]$?%/PSH-IX;66!H?,\D'Y<9SM[>OKZ8[5XN(S14,7##^SD^
M>4;R5[=+'R>9<24,#FN"RQQDZN-E:+49-;J_1K?STN?!<R^3(&SCYNAX]#[5
MU^E>*+JPB98G;:1C X_^MU//?C\N-U;?]I945L!CTSC]!VI;8OY7S AN>OKS
M_7UKU)QC."E*/,G:W,D^J=VOGOL?3SA&I2@I1NNETM]&[Z:O09XAU6XU&9C(
M[$%L\D^@_0'I7"W$#,3C)P3_ "]>_P"GX5T]Z"6)'0$Y/ZUB2Y_\>/\ G^==
M$4HTU:*LTK=HJRLO4UBE&,4E966W0HPD@;2/;\AG-6*A3[P_'^1J:I*(GZ_A
M_4TRGOU_#^IIE !5>?M^']:L57G[?A_6@J._W?\ I2*]%%%!L*.H^H_G5X=!
M]!_*J2C)'MS^M71P /04&=1NR7>_Z"T444&:"BBB@ HHHH **** "BBB@ HH
MHH **** "J\_;\/ZU8JO/V_#^M!4=_N_]*11N/\ 43?]<W_D:_JZ_P"#87_D
MK=K_ -?4/_HY:_E%N/\ 43?]<W_D:_JZ_P"#87_DK=K_ -?4/_HY::W7JOS*
MJ=/G^A_I=)]Q?]U?Y"G4U/N+_NK_ "%.K<S"BBB@#_-6_P"#FEE3XR7QZYNI
M/S+CT'M7\LMG)&;: EN#&O3Z5_4G_P '-G_)9;__ *^I/_1E?RO6BYLX#V\I
M/KT%9R:O\*T_X']:W%9/=:_\-_E_6M]7=&"2&ZGO09$ SN!]JI!=O3/-/49(
M!_SQ4W7\OXO^O\_S+1[:_P##?Y?UK>R!OR>G3MZY_6K]L!N7.,$Y].A'^%4T
M4   8R!ZU<BX(SU&<?7/^%23.6NFFEG]R.ULDMQ""<9Q^N._;';I_*N,U10;
MM]O3)'3IC&/\/PJZ)Y(P "?SX]\#_$?2LRY=I)=Q]\UG&/+)[VM97_K?OZ&$
M(.$VU.\6FE?I>S\]G_6YG8VJW?/_ .K^M,4 GDX_S[U8E4!#@=QZU5K0Z(MM
M:ZZ_H@HHHH*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JNQ._&./H?P
M_I5BH7^\?P_D* &T444 36R[YE4]\?S_ /K5T,[") H;H!G^8_4_7BN>MVVS
M(W?('Z__ *ZU90TSKR><?X\?AUZ=35QBYZ:V6NVVU[>>WYB:7,GK;KUUT7R?
M^1[W\!;VY/C#3(8;@P9NH1N#8XWKCG(S^'I^7]<?P#LR_P +K&.2<7,LUG$"
M2V<DQ=\D^_X_2OXTO"FL7'AK5+.^MR5DCFC?(X^ZV>H/X=S@U_3S_P $^OC1
M<>//#EMH]R6=[6*-,9+= !WS]>X/\_PKQNRW%5\EIXZA%.C@ZD:M2R7.W%IJ
M[W:NOZN?S-XY9)5>9Y'Q HQ6"BY8*LTES4G4BHJI)VNTV[:L\6_:B\*:EIOB
M*YN%A<0-+(V0IP<D]^G3MGMBORK^,"3+$[Y;@'/!'3C/Z=1^?I_21^T3X+LM
M=L)BUL&F(?#!.>Y[+V]O7'T_$'X[_#0V5O=_(0 'P".V<]",=OPS6?AYG]/,
M<JRV<X\M6C&-*46T[I<J4M-?O/QWP?XEP.0<?XKAW&U(0E7E_LL[64X2::U:
MWNU\.Y\1?!N:ROO%EO:ZA(JQ&XC4ER,8W ,<GCCG..G7M7UY\>1I/A[1M.72
M;U")8X]ZQNI R ,'!]__ -=?GG+'J?A[7FEL1(LB3Y!4X.5)P1C_ #WSS79:
MSXF\0^(H;>UU&29B JH'9L@C _PZ_K7ZIBLMEB,;0Q<:T504$YT]-6DK2WZ:
M^6JU/ZUSKA*>9\39)GL,>XX7+83<\$G'V=9U8)*375Q>M[=+GU-\/O$>FVFG
M12W5XH!*E\N!QW')Z?4_X#;^)_B?P/J/AR6.V>W>\,;?,&3);;UX]>1_6OBU
M])\7"V$=H+DQD#&PL1C@]N/7^7-4(/"GC"^FVM'>OZK^\/&<GV]1^N>:Y5E=
M!8A5_K<5RSYK1:3TMI):?C]QQ8C@C*ZV=4<[GF\J%?#U.=485H4XRC[MHU(\
MR;2Z77SN84VFR-=220IE&E8C R-K'C_.<=>E6KKPY//#O\O(P<]<\#V'Z_I7
M9Z?HFIQW*V$]K()5(R&4Y)&03^E:OB"671+8PS1%&9<99>?N^GU]?3O7M_6'
M*=.G"49-I-:ZM:*ZMO??]3[EXINI2A"49S<8\MI*[CI:UMTUK>[]3YMU>T%J
M[*WR]<#Z\'WSFL11V'//;GM^O^1VK6\0W9O+E\'D%AZ?Y_STK)MEYQ[8'7L/
M_KUZU*_+&3[_ '[7OO\ I^9[,+N,7)V:CJM[MVZ^7RW,6<8E;W)/2HJLW2E9
MFSW)_G5:LFVVV^^GI9'2OACZ?H%%%% PHHHH **** "BBB@ HHHH **** "B
MBB@ J.7[A_SV-25'+]P_Y[&@#^IS_@U/_P"3H-4_Z^E_G7^FQ7^9/_P:G_\
M)T&J?]?2_P Z_P!-BM8;?/\ 1&,_B?R_)!1115DA1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 U_N-_NM_(U_F>_\'3__ "<5I?\
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M1<+&=T606 [KSQCM7\5Y[3S+(/$*MB*6'C.>(Q'/3A&_*X5)16G=Z];Z7/\
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MQ/Y?D@HHHJR0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC%2Q]*G)N',KRJ<]E#E2W??T1^.,'A2Z:U$QB;(7+_*?8GZ]SGVZ>F+=Z=L
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MY::W7JOS*J=/G^A_I=)]Q?\ =7^0IU-3[B_[J_R%.K<S"BBB@#_-/_X.;/\
MDLM__P!?4G_HROY7K/\ X];?_KDG\J_JA_X.;/\ DLM__P!?4G_HROY7K/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MGM=C8.%5_O#&#_G/MS61$K+E4I)/;3=K31_UVL?16@>*]-0Z>%C2&998P7&
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/N+_ +J_R%.K<S"BBB@#_-%_X.<9-OQGO@<?\?4F.#VD/I7\K=A+_H]MR/\
M5+V/]VOZGO\ @YT_Y+1??]?4O_HVOY5[(D6MOC_GDG\JRGNO3_,#JHY.%QC@
M\\^_Z59#@N#D?G]:PDG*J.O/_P"OL1ZU,EP2Z@D@9Z\_XU &Y4J=/Q_H*I!^
M!AN.W/\ ]>I8W8G /'^?P_.DU>WDTR>9:7O9M7?;9_U_PU[=0O\ >/X?R%.5
MNQYSC'2F-U/UIC^%;:+^OU$HHHH,IN[T[!11102%%%% !1110 4444 %%%%
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M+OQGJ]UJL%U%.7V(' SGMGIGT_SUK]]_VK?!=YXEL_M$*!HY8GD*J 2 P/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 R3_5R?[C?^@FO\SO_@Z<_P"3BM,_Z^1_Z&:_TQ)/
M]7)_N-_Z":_S._\ @Z<_Y.*TS_KY'_H9J)IV3[?\ #^6J+[@_P ]A4E1Q?<'
M^>PJ2L@&LQ&,>],WGV_S^-+)V_'^E1T 3*Q.<^U.J%20?3D9J;.>E !1110
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M_P">:V4DC+A >2=J\?T/8_\ UZT5/GMRK=Z??UO^&W8F<E9\D5T>J]+K3?\
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MT6G1C3P^'_LVA0HX.$8J$:*BH..BT4?=:5^VO32UO-;E/*G>,]0>G_ZJKO\
M=/X?S%6[YO,NY9.N3^O2JK ["?\ /'/]*T3N[]TKKL[+;U.Q;)N]VMND=KKY
MO\OD05%-]S\14M13?<_$512W7JOS*E%%%!N%%%% !1110 4444 %%%% !111
M0 5'+]P_Y[&I*CE^X?\ /8T ?U.?\&I__)T&J?\ 7TO\Z_TV*_S)_P#@U/\
M^3H-4_Z^E_G7^FQ6L-OG^B,9_$_E^2"BBBK)"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<_2NFC8RE-PVG QT'/7'^?4US=N,."JDMD?SS_G-;JF21E5 0V.I]P/8>O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZU##]]&0".=XHWT>PF_.W_ L;-N\JS0R$G;O (YX4G/8>A] .WI7[P_\$X]
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% ",-RE?4$?F,5_,[_P %3O\ @ACH_P"W
MU\1;;QG>79A>"428[=01_+\?I7],=%&Z::N!_"<O_!ISX;4 ?V@?\CZ5*O\
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M (A._#G_ $$#_G\*0?\ !ISX;!)_M!N?\^E?W844<GF_Z_I_TM3G?;^OZO\
MTM?X45_X-//#8(/]H'\JF'_!J!X;7I?MS[?_ %Z_NHHIJ"7GZD-W=S^%C_B%
M"\.?\_Y_+_Z]'_$*%X<_Y_S^7_UZ_NGHI\J[?U_2_J[$?PK?\0G_ (;8_P#(
M0(S[8%(W_!I[X:QC^T2<@]*_NJHI<JM:W^8'\*'_ !"=^'/^@@?\_A2'_@TY
M\-G&=1;\O_K5_=A12Y/-_P!?T_Z6M\[73^M/^#_2U_A-_P"(3CPU_P!!%O\
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M]%+D\W_7]/\ I:OG?;^OZO\ TM?X4/\ B$[\.?\ 00/^?PH_XA._#G_00/\
MG\*_NOHHY/-_U_3_ *6ISOM_7]7_ *6O\*'_ !"=^'/^@@?\_A1_Q"=^'/\
MH('_ #^%?W7T4<GF_P"OZ?\ 2U.=]OZ_J_\ 2U_A0_XA._#G_00/^?PH_P"(
M3OPY_P!! _Y_"O[KZ*.3S?\ 7]/^EJ<[[?U_5_Z6O\*'_$)WX<_Z"!_S^%'_
M !"=^'/^@@?\_A7]U]%')YO^OZ?]+4YWV_K^K_TM?X4/^(3OPY_T$#_G\*/^
M(3OPY_T$#_G\*_NOHHY/-_U_3_I:G.^W]?U?^EK_  H_\0G7AO\ Z"+?E_\
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MOB:YKVOY;+8Y,DX0X=X>J8NKE.64<-/&RYL1*RFYO39R7NO3H?QJZQ_P;/\
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MIKX:;_F(GMU^OT_H:C_XA,_#7_00_3_[&O[N**I*RL0W=W/X1_\ B$S\-?\
M00_3_P"QH_XA,_#7_00_3_[&O[N**8C^$?\ XA,_#7_00_3_ .QJ,_\ !I?X
M:.?^)CU]CW_#^M?W>44#3:V/X0/^(2SPU_T$1_WR::W_  :5^&2,'4>/93].
M_'>O[P:*!\TNY_,I_P $HO\ @A3HO_!/SXH77CVTO3.T\N\ \_=Z=>N.GT]N
MG]-=%% FV]PHHHH$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
A10 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>gyycud3vz5ad000016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gyycud3vz5ad000016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (* ^H# 2(  A$! Q$!_\0
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MHH 2EI*6@!**** "BBB@ HHHH **** "BBB@ I:2B@!:*3BB@ HHHH ****
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M>B>$YM9\"ZSK>EY36=(U>2X@=/O,HP2OZ9_"M3X:Z_>ZWJGCK6XHS'?3:>)
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M35(_B7X;O3!X>T>2(!6@LKKYKB$\?=QSQ3/ &G:!J'Q4\:C5X+::=;A_*2X
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M?IGQ0\+ZK;ZI=07K+:Z: 9YY(RJ$'IM/?.*\+N[>[C_9[L?M(=8I=6W0!O\
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MJH\SL 8H^[#/>L6T\2:MX[^'$6H>$KJ"UU=F591* 1&P^^.0?PJI!XFU_P
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M 'J30 ^BH8[RWFE:*.:-Y%4.55@2%/0_0U-0 444M "44M% "444M "444M
M"444M "44M)0 44M% "44M)0 44M)0 4444 %%%+0 E%%+0 E%%+0 E+110
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MHI: $HI:* $HHHH **** "BBEH \H^-NG:S=>$[RZBU,6^DVT2M):HGS3/O
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M:E_WZ7_&N^\(>++'QGHHU73DF2#S&CQ,H#9&,_SKYMNO&5K<?$*+Q?!X5/\
M8T"^28/+&UN",GC;GO\ A7TAX-US1?$/A^&_T)8X[5R08E0(8W[@@=ZN6BV$
M=!12TE0,**** %I*6DH ***6@!**** "BBB@ HHHH **** %I*6N;\4>-M)\
M)M;17OVB:YN<^5;6L1DD8#J<#L* .CHKEO\ A8/AX^$#XF%V3IX.P_(=^_.-
MFWKNSVJQX6\9Z5XM2Y^P>?'-:L%GM[F(QR)GID>AH Z&O(/@Y_R-GCK_ +")
M_P#0GKU_->0?!S_D;/'7_81/_H3T >OT&N;O?'OAO3[V:TN=1"3PL4=?*<X(
MZC(%<SXE^(T=[!'IGA9GN;ZZ.P2+&1LSZ9'WOY5M##U)/8ESBNIZ/'-%+N\N
M1'VL5;:V<'T/O3Z\:@@U_P"&-Y;WMR?M>G7>/M2H<A7/7_@7H>]=PGQ+\*L@
M)U(J2,X,+Y'Z54\-):P]Y=T)5%UT9UM'%4=)UBQURP^V:?.)H"Q3=M(Y'7@U
MP&DZ1?>)=<\32R^)-8M?LFIO!!';W&U$4*I'RD>]8--.S+/3:*X31?%UY::7
M?VFI13ZCJ6GZ@=/!MXQNN"0&1CV7Y3R>G%61\0(H8-2^WZ7=VMUIWE-<P$J^
M(W. X8'! YS]*0'949%90UVW;Q#'HT8:2=K;[2S+]U$S@9^ISCZ5S&M3W>K^
M/1H+ZM<Z9906(NE-NXC>=RV/O'LOI[T =YD45Y7IOB74/$UOI6B+J4D<DUY=
M07%[;X5Y(H.A4]BV5R1[UU7A*YO(-0UG0[R\DO/[.F3R9Y<;VC==P#'N1R,T
M =5112T )1110 4444 %%%% !112T )12TE !1110 44M)0 4444 %%8WBBQ
MU74-%:#1KP6EV74B0DCY1U&17E42^-I?%<OAU=?D%W&F]G,QV8P#Z9[UT4J"
MJ)OF2L1*?*]CVZBLKPY::C8Z)!;ZM="ZO%SOE!SGDXY^E:M825G8M!1112 *
M**6@!*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2EI*6@!****
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M.?+,CEMN?88KI:!10 4444 %+WI*7O0 E+24M "4444 %%%% !1110 4444
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MLVH:99W4BKM#S0JY ],D5HTM &+'X0\.0RI+%H>G)(C!E9;9 5(Z$<5LT44
M%+24M "4444 %%%% "TE+24 %%%% "TE+24 %+24M "4444 %%%% !1110 4
M444 +7D_Q6A#^(O#\NM65W>>%X_,-S';HS8EQ\I8+SBO6*:0&X- 'SVFCZR_
MP[BOH+"[_LW3==%Y96LBGS1:#K@=>^:[7P TNO?$+Q+XKCM+FWTZYBAMK<W$
M91GV@9.#]*]/V\8I0,=* /.=4^"7A'5]4NM1N5O?/N9#))MN,#)ZX&*YWX&6
M,6FZWXQL8-WDV]X(DW')VJ6 S7M!KR#X.?\ (V>.O^PB?_0GH ]?I:2EH 2B
MBB@ HHHH **** "EI*6@ I*6DH *6DI: $HHHH **** "BBB@ I:2EH *CE=
M(XF>1PB*"68G  I+BXBM;=YYY$CBC&YW8X %>5:IK.I_$;56T;0]T&D1D?:+
M@C&\>I]O1>_>M:5)U'?9+=DRE8\G\8V1@\0:KJN@:O??9(V++*"P//7YL]"<
MX/>K_P .O!.L>-]0MM3O=4NVLHCF:21BQ/\ L D]?Y4>)=4EO[O5/">AWL.G
MZ)I^4N)'!+WL@.#D@<\YP. ,55\'_$:_^'=Q;VBWT>KZ1(&9[2/AH6R>A(X/
M?C(YKIJ3_P"7D5Y7_7^M"8KHV?54:+%$L:DX50!D\\5F:UXET;P];M/JNHV]
MJ@&?WC\GZ#J:\G&M_%;QZG_$IT^+P]ILG2>;(<KZY(S^0K5T;X%Z2LRWGB74
M+O6KT_,_F.5CS^>3^=<)H5=2^-[:E,UCX+T"[U6Z)PLKH0@]\#G\\55_X0/X
MB^-V5_%FOC3;%N39VAYQZ8''YDU[!IVDZ?I-LMOI]G!:PJ,!(D"C]*N4 >8R
M? OP?_8,]A%!,MS(/EO7<M(K>OI^%>;Q:+XTOO%DWPSF\5-]B@A#.^W@Q8!V
M^O0]":]X\86WB&Z\/R1>&+J*VU,NI624 KMSSU!KR"/X<_%6'Q/+XC35]-&J
M2Q^6\^X<K@#&-F.PH ZRY^!'A*728+: 7-O=PIC[9%)\[-ZL.E87]C_%3X?(
M3IEZGB+2X^1#*"9 OT)S^1->K>%H-:MO#UM%X@N([C5%!\Z2, *>3C& .V.U
M;% 'EF@_''0KR=;+7;:XT2^SM9;A24S_ +V./Q%>F6E[;7UNL]K<13Q,,AXW
M# _B*RM?\'Z#XFMS#JVFP7&1PY7#K]&'(KS2[^#VN>&K@WW@+Q%<6S Y^QW+
M?(WMGH?Q% 'LYZ5\\_%+P[XXTNQU36KGQ'YNCFYW1V@=B55F^48(QQFMZV^+
M?B/PK=+9>/?#DT2]!>VJ_*WOCH?P/X5A>)?%VM_&">\\.>%K6W32DVN\MRX1
MY,'(//09'0"JC)Q=T+<ZCX9>&/&ME=:=JFJ>(1<Z1):;DM [' 91MXQCBO71
M7D/@/QKK6C:];>!O%]@EM="$+97$?W9 !P#V/ ZBO7A2;;U8Q:***0!1110
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M 4:@0 !T^9Z]@KQ_X.?\C9XZ_P"PB?\ T)Z /8*6DHH **** "BBB@ HHHH
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M[N_T6RN;A\;I98@S''O3;/P9X:T^[CN[/0[&"XB.4DCA 93[&MRB@!:2BB@
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M>0?!S_D;/'7_ &$3_P"A/0!Z_2TE+0 E%%% !1110 4444 %+24M !24M)0
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MRP2[$K1-$?,N68;6&#P:31?AAX=T#4QJ%BEV)PK*/,N68888/!JBSL0Z$X#
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MX=\0:@+V^2[,PC6,>7=,HPHP.!2ZU\,?#NOW,,]ZEV7BA6%?+N64;5&!T[T
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M_P V.C\/S?YA2TE%;&H4M)10 M)110 M%)10 M)110 M)110 4444 %+244
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MB?UKHZYS0O\ D8M<_P"NJ?UKHJ*'P?-_FPH_#\W^84M)16QJ%+244 +2444
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M%=I)<:5<&00OLE1T*/&WH5/(K9D_U3?2@#R+]G__ ) 6O?\ 82;^5>P5X_\
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M6DI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2EI*6@#C-?\
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MZ_\ (5C/^)'YF4_XD?F=)1116QJ%%%% !1110 4444 %%%% !2TE+0 E%%%
M!2TE+0 E%%% !1110 M)2TE !1110 M)2TE !2TE+0 E%%% !1110 4444 %
M%%% "TE+7)>+O&4WA^]L=,T[2)]4U2]W&*"-@BA5ZEF/2@#K**\]C^*UB?"%
MQK$NGW$=[!=?86T\D;S<'H@/0CWK5\'^-&\276H:=?:9+IFK:>R_:+5W#X##
M(((ZB@#K37D'P<_Y&SQU_P!A$_\ H3UZVT\0R#(@([%A7D?P;(/BOQR1R#J)
MY'^\U 'L%+24M "4444 1W$RV]K+.V2L:%R!UP!FO/A\8M$_Y\=0_P"^4_\
MBJ]!N)8X+:6:;B*-"S\9X R:\$\;?$/P;JNI:-+IMPABMYMT^+8K\N5]N>AK
MHPZI.5JGYD3YK>Z>HZ5\0](U6PU"\"7%O#8H'D,P SG. ,$\\5QNFX\2ZI=^
M-?$C"#1;')ACD/R_+T'OCOZFJDVLVOQ.\0_V;H3+!H=GB6ZF">7N']X\?4#\
M36;?/+\5/$D/A3P_FV\(Z4P^TSIP)<>GK[?B:TE*%*-X;R_!?\$FSD]>A8T/
M3[WXQ>,#XAU6)XO#%@Y6SMGX$Q'K_7\J]T1%155%"J!@ #@"JNF:;::1IT%A
M8PK#;0($C11P *N5QFH4E+24 %!Z44&@#GO#7_'_ *U_U]FNAKGO#/\ Q^ZS
M_P!?9_E70UC0_AKY_F94?@^_\SG_  __ ,A;7#_T\C^5=!6!X?\ ^0GK9_Z>
MOZ5OT4/@^_\ ,=+X?O\ S"BBBMC0*6DI: "DI:2@ HHHH 6DI:2@ HHHH **
M** "BBB@ HHHH *6DI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH 2EI*6@!**** "BBB@#R[XN>,-0TF.UT/3(;R-[T9N;RW@:0P19P=N/XCS
M7.WL.GGP)H.H>&M,U$VF@ZJDUQ'/;E9I!_')CJ>U>YT8[4 >9_#L2:SXU\5>
M*4MYX;"^:*&V,\90R!%P6P>W2K=Y\&?!-S//=2Z:YEE9I&/GMR2<GO7H(&!@
M#BFR?ZIOI0!Y!^SVBQ>'M;C485-0*CZ 5[#7D'[/_P#R M=_["3?RKU^@ I:
M2EH ***AN+F&TMY+BXE2*&,;GD=L*H]2: ):*Q/^$Q\-_P#0>T[_ ,"5_P :
MO6VL:=>64EY;7UO-;1YWRQR JN.N30!/=W4%C:2W5U*D4$2EW=S@*!U)KPVZ
MN-2^-OB8V5HTMKX/L9<RR\@W!']3V]!S3]:U;4_C)XE;P_H4DEOX8M'_ -,O
M!_RVQZ>OL/QKI_$&JVWA/3+7P=X3@ O741XBY://<_[9]>W6M*=.527*B922
M5V5_$.I;S!X$\'P+&BCRIFBX5%'5<^G]X_A7=^%_#5IX9TI;2W :0_--,1S(
MW^'H*H>"O!\/AG3]TF)-1F&9YNO_  $>W\ZZJM*M1)>SI[+\11B[\SW"BBBN
M<L**** "E[TE+WH 2N:\&_\ 'OJ7_7Z_\A72US?@W_CVU#_K\?\ D*QG_$C\
MS&?\2/S.DHHHK8V"BBB@ HHHH **** "BBB@ I:2EH 2BBB@ I:2EH 2BBB@
M HHHH 6DI:2@ HHHH 6DI:2@ I:2EH 2BBB@ HHHH **** "BBB@!:\\^*'C
M^/P?96]I:F+^U[[*0/+]R%>AD8^@KT.L^^T/2]3D62_T^UN7485IH@Q ].:
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M*YOP;_QY7W_7X_\ 2L9_Q(_,QG_$C\SI****V-@HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** %I*6DH **** "BBB@ HHHH
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M"\.G-UK/_7ZW\A6[3H_ ATO@_KN%%%%:F@4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4M)2T %%%% !1110 4444 %%%% !1110 4444
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MZ'VKIFI4X-VMT6M]/+_,A-29Z:!@4445YYL%%%% !1110 4444 %+WI*7O0
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MRJ-<TA));'/>)_B#KOQ"N3;1^;IN@;O]5$<23#W/?Z=/K76^%_#GB;^S%L=
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MNY\+Z9;_ /+O<:K;QW [%,DX/MD"H/#L$6G_ !RU^TL8DBM7TV%Y(XQA0P(
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MMU<_]/K?R%=!7/\ A?[VJ_\ 7Z_\A704Z'\-"H_ @HHHK4U"EI*6@ I*6DH
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M[^/_ (UYK\6_ ?AKPZ/#W]E:8EO]JOQ%-M=CN7CCDT >L?\ "S?!?_0QV/\
MWW1_PLWP7_T,=C_WW5$?!WP)C_D Q?\ ?Q_\:/\ A3O@3_H Q?\ ?Q_\: +W
M_"S?!?\ T,=C_P!]T?\ "S?!?_0QV/\ WW5'_A3O@/\ Z $7_?Q_\:/^%.^
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M4*W_ $..K?\ ?7_UZ/\ A0K?]#CJW_?7_P!>N<L]CWI_>7\Z-Z?WE_.O'/\
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M_G7S9\.?AQ<>-_#\VI3^)M2MF2Y:$(CD@@8YY/O78?\ "A6_Z''5O^^O_KT
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MXZM_WU_]>@#V/>G]Y?SHWI_>7\Z\<_X4,W_0XZM^?_UZ/^%#-_T..K?]]?\
MUZ /8]Z?WE_.EWI_>7\Z\;_X4,W_ $..K?\ ?7_UZYCQ_P#"^?P;X2N=:A\4
M:G</"Z*(W<@'<V.QH ^C*6L7PD[/X0T=W8LQLXB68Y).T5M4 %%%% !1110
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MM=NS>1Z?=26]O=!<-=@'"X ZDGBI?A)KVNZY)XC;7I9#/#?!5@8\0 C.T>U
M'IE)110 M%)10 M%%)0 4M)10 M%)10 4444 %%%% !2TE% "TR2-)4:.1%=
M&&&5AD$>AI])0!%]DM_LWV;R(_(V[?*VC;CTQTQ3;6RM;&$0VEM%;Q@YV1(%
M'Y"IZ*  ]*Y+PCX'C\)ZKK=]'>O<'5+CSV5D"^7R3CWZUL^)-<@\-^'K[5[A
M2T=K&7*CJQ[#\37)>$O'VJ:KX@BT?7M'33I[NT%[9F.7>'C]#Z&@#T&EI**
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M2W27%[I-Y#=12Q/N4*[\JI[C:V*]JB?S(4D QN4'\Z '4M)10 4444 %%%%
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MOG<2 '*E(PWRM^%>XTM ''_$O0;_ ,2>!;W2]-C62ZE9"JLP4'# GDUSVO\
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M=*6@!***6@!*6DI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
,B@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>gqmjb0hqad4j000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gqmjb0hqad4j000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !& 24# 2(  A$! Q$!_\0
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M'53ZCWJ2RM_LEA;VV[=Y,2Q[L8S@ 9J42(59@ZE5SDYZ8I&EC1 [2(JGHQ;
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G1M]<K_SLW418XU1%"HHPH'0"G445V;',%%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>gyycud3vz5ad000012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gyycud3vz5ad000012.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" )" X0# 2(  A$! Q$!_\0
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M*44@YSU(([UYUJW_  5K^ MF(FM[B6:-I%1YD4O&N6P<L.!0!^LE%?F)K?\
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M!\<_V(+V_P!*N+NVU.TTO-S<,'1RT</S'=P3S[Y]* /V#^'7Q6\,?%"S:_\
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M/V6?!+:G-)*\<&FA6WMNX$?7'//?\*_1C]O7]FKQG\;]*\ VWAU'=]#-C]I
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M9=PP0!V]^W>@/ZL?FS^W-^R_\4/@?\2?A]>>/_&\OBJ&_N+-XC)<-.JCS57
MW,W1E(Z=17=_M>_$KQ5I_P"S]X5\,6LEQ!I,UK9QOY;.BR(54%?E]1QC/]0?
MU:_X*1?LK>._V@/%G@C4O"JRO!HK6;3!5+*OER*S=B.@8_G4WQ1_80E^)/[/
M&E>%+BW7_A*=,L(/+8Q_/]HB0=?E)/(H _#;2/@-/X_^"6G3>&/ UZ^NW-K$
MZZU$DF=Y"DN) ,\$D\G/]/TA^%32_L]_LLQVGQMEDO;41_N;*\=G9U"\1 .2
M2?X<5S/@/X-?MH?#+3XO NAZ+%+HEF5AAD>WR?)5MO4K_<QTK[8^*G[)7CSX
MZ?L\6WASQ4K6OBFSA69(XE*AI0NXJ0!_>!S_ "H _"WX\_&OX<>,_A_K0\*_
M ^XLXFE/E>(XK1UCP&^642A ,?Q9#<YKZI_9(\0ZE?\ [*WBRSFN919II5WY
M=NTC$Q8A;"X).-O3V_E/_P ,:?M31^#-0^&,?A^T.B',$5V;13.T>=H._9G.
MTC^E?7'P&_8C^(O@+X.>(O"6HQNM[J5A<1JNPC][-&XQC']XCMZYH ^,_P#@
MEG^R/\/_ (Q>+OB!XG\769OFL=6NI$$CL^")SMX)['C^M._X*4>$=)\&?';X
M0>&=(C:VTRQU[3U@A1V55"3+@8!QV_*OU'_X)N?LS>,OV?7\:?\ "4H\:ZQ>
MW$L&Y2N0[LPQQ[UY+^W/^QSX_P#C7\:? WB[0(I'T_1M6MKNX(5B D<RN<D
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MC!D39$%39@$CD<>WO@5^:W_!,O\ X)O_ !!^!?Q,O_%?Q'2:ZA>^>6+[4K,
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M,=^V/>G44 ,V+V4#Z #^E+M7.=JYZYP,TI.,#UI: &LJMRRAL<C*@D?3/>C
M(Y4?B!3J* (PB8P I/K@$]_\3BE**P =5?']Y0>G3KGI3@ .@H.>W% "$94A
M<#MQV^F.E,$>!C/Z?_JJ0 #I2T -V+W4'W(%!YP"N5/!&,CMBG4$XYH 9L4#
M 4+_ +H _D*7:N.5!QW('\Z4'/(I: &@ C:2&'H<'CT/K2>6@((51UR HYR,
M4X*!T'\Z6@!NQ?[H_(>Q_I2>6F,!5'T !_/%/HH 8R;@HST_7_..E(T2'^$
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MS[_:@_8@T_\ :2\3:?K&LZR8;"RN8[D63,VQBA# ;0<'IZ5]@?##P#IOPO\
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MZ7XC1IA]J9)%9RN1YF2,_P - '[E^)/VAOASX7U!-.O]2#3.P5C"594SQEL
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M (2V^_Z!K?\ ?+T =]17 _\ "6WW_0-;_OEZ/^$MOO\ H&M_WR] '?45P/\
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MN!_X2V^_Z!K?]\O1_P );??] UO^^7H [ZBN!_X2V^_Z!K?]\O1_PEM]_P!
MUO\ OEZ .^HK@?\ A+;[_H&M_P!\O1_PEM]_T#6_[Y>@#OJ*X'_A+;[_ *!K
M?]\O1_PEM]_T#6_[Y>@#OJ0C/!K@O^$MOO\ H&M_WR]'_"6WW_0-;_OEZ .^
M'''I17 _\);??] UO^^7H_X2V^_Z!K?]\O0!WI7)!YXI:X'_ (2V^_Z!K?\
M?+T?\);??] UO^^7H [ZBN!_X2V^_P"@:W_?+T?\);??] UO^^7H [ZD QD^
MM<%_PEM]_P! UO\ OEZ/^$MOO^@:W_?+T =]17 _\);??] UO^^7H_X2V^_Z
M!K?]\O0!WU%<#_PEM]_T#6_[Y>C_ (2V^_Z!K?\ ?+T =Z%P2>>:6N!_X2V^
M_P"@:W_?+T?\);??] UO^^7H [ZBN!_X2V^_Z!K?]\O1_P );??] UO^^7H
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M_P );??] UO^^7H [ZBN!_X2V^_Z!K?]\O1_PEM]_P! UO\ OEZ .^HK@?\
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M"/RHO^>4?_?"_P"%'E1?\\H_^^%_PJ2B@"/RHO\ GE'_ -\+_A1Y47_/*/\
M[X7_  J2B@"/RHO^>4?_ 'PO^%'E1?\ /*/_ +X7_"I** (_*B_YY1_]\+_A
M1Y47_/*/_OA?\*DHH C\J+_GE'_WPO\ A1Y47_/*/_OA?\*DHH C\J+_ )Y1
M_P#?"_X4>5%_SRC_ .^%_P *DHH C\J+_GE'_P!\+_A1Y47_ #RC_P"^%_PJ
M2B@"/RHO^>4?_?"_X4>5%_SRC_[X7_"I** (_*B_YY1_]\+_ (4>5%_SRC_[
MX7_"I** (_*B_P">4?\ WPO^%'E1?\\H_P#OA?\ "I** (_*B_YY1_\ ?"_X
M4>5%_P \H_\ OA?\*DHH C\J+_GE'_WPO^%'E1?\\H_^^%_PJ2B@"/RHO^>4
M?_?"_P"%'E1?\\H_^^%_PJ2B@"/RHO\ GE'_ -\+_A1Y47_/*/\ [X7_  J2
MB@"/RHO^>4?_ 'PO^%'E1?\ /*/_ +X7_"I** (_*B_YY1_]\+_A1Y47_/*/
M_OA?\*DHH C\J+_GE'_WPO\ A1Y47_/*/_OA?\*DHH C\J+_ )Y1_P#?"_X4
M>5%_SRC_ .^%_P *DHH C\J+_GE'_P!\+_A1Y47_ #RC_P"^%_PJ2B@"/RHO
M^>4?_?"_X4>5%_SRC_[X7_"I** (_*B_YY1_]\+_ (4>5%_SRC_[X7_"I**
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_L7BSU;]:/L7BSU;]: /2/-7U_E_C1YJ^O\ +_&O-_L7BSU;]:/L7BSU;]:
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M_P O\:/-7U_E_C7F_P!B\6>K?K1]B\6>K?K0!Z1YJ^O\O\:/-3U_4?XUYO\
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M/_?Y/_BJ/^$[\)?]!NQ_[_)_\57\J?\ PT-\4/\ H*W'_@1)_C1_PT-\4/\
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M=\GWKZ=C)'!.<\?X?UK^ILBS19UD^79M&FZ4<?A:6)C3>\(U$GROS6MOZO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1)_^?G^= '2_VM9_\]!^=']K6?\ ST'YUS7_  B3_P#/S_.C_A$G_P"?G^=
M'2_VM9_\]!^=']K6?_/0?G7-?\(D_P#S\_SH_P"$2?\ Y^?YT =+_:UG_P ]
M!^=']K6?_/0?G7-?\(D__/S_ #H_X1)_^?G^= '2_P!K6?\ ST'YT?VM9_\
M/0?G7-?\(D__ #\_SH_X1)_^?G^= '2_VM9_\]!^=']K6?\ ST'YUS7_  B3
M_P#/S_.C_A$G_P"?G^= '2_VM9_\]!^=']K6?_/0?G7-?\(D_P#S\_SH_P"$
M2?\ Y^?YT =+_:UG_P ]!^=']K6?_/0?G7-?\(D__/S_ #H_X1)_^?G^= '2
M_P!K6?\ ST'YT?VM9_\ /0?G7-?\(D__ #\_SH_X1)_^?G^= '2_VM9_\]!^
M=']K6?\ ST'YUS7_  B3_P#/S_.C_A$G_P"?G^= '2_VM9_\]!^=']K6?_/0
M?G7-?\(D_P#S\_SH_P"$2?\ Y^?YT =+_:UG_P ]!^=']K6?_/0?G7-?\(D_
M_/S_ #H_X1)_^?G^= '2_P!K6?\ ST'YT?VM9_\ /0?G7-?\(D__ #\_SH_X
M1)_^?G^= '2_VM9_\]!^=']K6?\ ST'YUS7_  B3_P#/S_.C_A$G_P"?G^=
M'2_VM9_\]!^=']K6?_/0?G7-?\(D_P#S\_SH_P"$2?\ Y^?YT =+_:UG_P ]
M!^=']K6?_/0?G7-?\(D__/S_ #H_X1)_^?G^= '2_P!K6?\ ST'YT?VM9_\
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M/\Z/^$2?_GY_G0!TO]K6?_/0?G1_:UG_ ,]!^=<U_P (D_\ S\_SH_X1)_\
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M#Z5_/2I/FW&1_P MY,\'^]Q7^=WTCTO^(BN7; QVU_E5O4_TB^C6O^-<0?\
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M[ E^<#_27Z-2<O#>FE_T%3?R4F,?K^']33*>_7\/ZFF5^ ']!A1110 4444
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MDV?_ #S'Y4?V39_\\Q^5 '*_\)?-_P ^I_(_X4?\)?-_SZG\C_A75?V39_\
M/,?E1_9-G_SS'Y4 <K_PE\W_ #ZG\C_A1_PE\W_/J?R/^%=5_9-G_P \Q^5'
M]DV?_/,?E0!RO_"7S?\ /J?R/^%'_"7S?\^I_(_X5U7]DV?_ #S'Y4?V39_\
M\Q^5 '*_\)?-_P ^I_(_X4?\)?-_SZG\C_A75?V39_\ /,?E1_9-G_SS'Y4
M<K_PE\W_ #ZG\C_A1_PE\W_/J?R/^%=5_9-G_P \Q^5']DV?_/,?E0!RO_"7
MS?\ /J?R/^%'_"7S?\^I_(_X5U7]DV?_ #S'Y4?V39_\\Q^5 '*_\)?-_P ^
MI_(_X4?\)?-_SZG\C_A75?V39_\ /,?E1_9-G_SS'Y4 <K_PE\W_ #ZG\C_A
M1_PE\W_/J?R/^%=5_9-G_P \Q^5']DV?_/,?E0!RO_"7S?\ /J?R/^%'_"7S
M?\^I_(_X5U7]DV?_ #S'Y4?V39_\\Q^5 '*_\)?-_P ^I_(_X4?\)?-_SZG\
MC_A75?V39_\ /,?E1_9-G_SS'Y4 <K_PE\W_ #ZG\C_A1_PE\W_/J?R/^%=5
M_9-G_P \Q^5']DV?_/,?E0!RO_"7S?\ /J?R/^%'_"7S?\^I_(_X5U7]DV?_
M #S'Y4?V39_\\Q^5 '*_\)?-_P ^I_(_X4?\)?-_SZG\C_A75?V39_\ /,?E
M1_9-G_SS'Y4 <K_PE\W_ #ZG\C_A1_PE\W_/J?R/^%=5_9-G_P \Q^5']DV?
M_/,?E0!RO_"7S?\ /J?R/^%'_"7S?\^I_(_X5U7]DV?_ #S'Y4?V39_\\Q^5
M '*_\)?-_P ^I_(_X5(GBN9B@^S'YF"_=/K_ /6KIO[)L_\ GF/RIRZ79JP8
M1C@YZ4UNO4'?H?F3^WUKDEQX7:%HB@$)7H?3\/\ ]?M7X&$@2S\C'G/S]6)K
M^@W_ (*!V5JGA%G" /\ 9]W3OMQU_*OY[F!#S@_\]W_++5_G;](W_DXL[;?4
ME^<3_2?Z,S:\-Z=]7]8FOQLW]]_ZU%?J/I_C3*<W\/\ NBFU^ '] A1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5O2'\O5[1@/NR1G'_
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M6D(!QGMTI: "D8D#@9Y]#2*V[/'2G4 -5=OXX_"G444 %%%% !1110 4444
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MGV@@@=,$G\J^D+5WEABE<;6DC5RGIN /]: )\@''>EHQ[?I49W%CC/&.^.U
M$E-#$L1Z9_G2G)''!IJ[QP0._.??\?Y4 /HI,GT'Y_\ UJ,GT'Y__6H 6BDR
M?0?G_P#6HR?0?G_]:@!:*3)]!^?_ -:C)]!^?_UJ %HI,GT'Y_\ UJ,GT'Y_
M_6H 6BDR?0?G_P#6HR?0?G_]:@!:*3)]!^?_ -:C)]!^?_UJ %HI,GT'Y_\
MUJ,GT'Y__6H 6BDR?0?G_P#6HR?0?G_]:@!:*3)]!^?_ -:C)]!^?_UJ %HI
M,GT'Y_\ UJ,GT'Y__6H 6BDR?0?G_P#6HR?0?G_]:@!:*3)]!^?_ -:C)]!^
M?_UJ %HI,GT'Y_\ UJ,GT'Y__6H 6BDR?0?G_P#6HR?0?G_]:@!:*3)]!^?_
M -:C)]!^?_UJ %HI,GT'Y_\ UJ,GT'Y__6H 6BDR?0?G_P#6HR?0?G_]:@!:
M*3)]!^?_ -:C)]!^?_UJ %HI,GT'Y_\ UJ,GT'Y__6H 6BDR?0?G_P#6HR?0
M?G_]:@!:*3)]!^?_ -:C)]!^?_UJ %HI,GT'Y_\ UJ,GT'Y__6H 6BDR?0?G
M_P#6HR?0?G_]:@!:*3)]!^?_ -:C)]!^?_UJ %HI,GT'Y_\ UJ,GT'Y__6H
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M!^?_ -:C)]!^?_UJ %HI,GT'Y_\ UJ"6[ ?G_P#6'\Z %HI 6[@?G_\ 6/\
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MH"KG< ,^H_+M2GH<],4W/&$.3_3\>.M #Z*!G SU[T4 %%%% !1110 4444
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MBN8_X2FQ]Z/^$IL?>@#IZ*YC_A*;'WH_X2FQ]Z .GHKF/^$IL?>C_A*;'WH
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MT5S'_"4V/O1_PE-C[T =/17,?\)38^]'_"4V/O0!T]%<Q_PE-C[T?\)38^]
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MFI?</T]3CZ^_?/;OWK4HH Y7_A%K3^]_G\J/^$6M/[W^?RKJ<#.>]+0!RO\
MPBUI_>_S^5'_  BUI_>_S^5=510!RO\ PBUI_>_S^5'_  BUI_>_S^5=510!
MRO\ PBUI_>_S^5'_  BUI_>_S^5=510!RO\ PBUI_>_S^5'_  BUI_>_S^5=
M510!RO\ PBUI_>_S^5'_  BUI_>_S^5=510!RO\ PBUI_>_S^5'_  BUI_>_
MS^5=510!RO\ PBUI_>_S^5'_  BUI_>_S^5=510!RO\ PBUI_>_S^5'_  BU
MI_>_S^5=510!RO\ PBUI_>_S^5'_  BUI_>_S^5=510!RO\ PBUI_>_S^5'_
M  BUI_>_S^5=510!RO\ PBUI_>_S^5'_  BUI_>_S^5=510!RO\ PBUI_>_S
M^5'_  BUI_>_S^5=510!RO\ PBUI_>_S^5'_  BUI_>_S^5=510!RO\ PBUI
M_>_S^5'_  BUI_>_S^5=510!RO\ PBUI_>_S^5'_  BUI_>_S^5=510!RO\
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M_)Q9?]@2_.!_I)]&O_DVU/\ ["I?^E,:_7\/ZFF4]^OX?U-,K\ /Z$"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "K^B?\AJS_ .NL7_H:
MU0J_HG_(:L_^NL7_ *&M5#XZ?_7RG_Z7$F?\.K_U[D?T]?L:?\DCT[_<MO\
MT6U?6]?)'[&G_)(]._W+;_T6U?6]?ZP\!_\ )&\.?]BK#?\ I)_D7XA?\EOQ
M-_V-L3^:"BBBOK3XT**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG0OV7_$>K>*I]7^(-_%J=E([[(P59EC8].N>A.?PK[P<D8QQU_I49,F[;V_
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MJ<(XP<A%!^E/HH _-?\ X*#(G_"(D[1DV_7'?&:_GL'^MN#ZSN1^9%?T+?\
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M+^5'E1_W%_*I** (_*C_ +B_E1Y4?]Q?RJ2B@"/RH_[B_E1Y4?\ <7\JDHH
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MSV\V/_T-:HD9X-6])4MJUFJ<'S(__1@_QJH?Q*7G5I_+WU_704_X=7_KW/\
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M_P"@A_X\?\:/[!\3_P#00_\ 'C_C0!Z117F_]@^)_P#H(?\ CQ_QH_L'Q/\
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M\T?_ $M'Y7XF?P\M_P 57_VT^>!T'T'\J6D'0?0?RI:_I-[OU?YGY&%%%%(
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MO^?B/_OH?XT?VE9?\_$?_?0_QKF_^$/M_P#GXD_,_P"-'_"'V_\ S\2?F?\
M&@#I/[2LO^?B/_OH?XT?VE9?\_$?_?0_QKF_^$/M_P#GXD_,_P"-'_"'V_\
MS\2?F?\ &@#I/[2LO^?B/_OH?XT?VE9?\_$?_?0_QKF_^$/M_P#GXD_,_P"-
M'_"'V_\ S\2?F?\ &@#I/[2LO^?B/_OH?XT?VE9?\_$?_?0_QKF_^$/M_P#G
MXD_,_P"-'_"'V_\ S\2?F?\ &@#I/[2LO^?B/_OH?XT?VE9?\_$?_?0_QKF_
M^$/M_P#GXD_,_P"-'_"'V_\ S\2?F?\ &@#I/[2LO^?B/_OH?XT?VE9?\_$?
M_?0_QKF_^$/M_P#GXD_,_P"-'_"'V_\ S\2?F?\ &@#I/[2LO^?B/_OH?XT?
MVE9?\_$?_?0_QKF_^$/M_P#GXD_,_P"-'_"'V_\ S\2?F?\ &@#I/[2LO^?B
M/_OH?XT?VE9?\_$?_?0_QKF_^$/M_P#GXD_,_P"-'_"'V_\ S\2?F?\ &@#I
M/[2LO^?B/_OH?XT?VE9?\_$?_?0_QKF_^$/M_P#GXD_,_P"-'_"'V_\ S\2?
MF?\ &@#I/[2LO^?B/_OH?XT?VE9?\_$?_?0_QKF_^$/M_P#GXD_,_P"-(?!\
M'&+F3WY--;J^W]?U_D!6\?:A9GP9XDQ<1Y&E7/\ $#UC/^3Z5_#-^U8ZR_&?
MQ:RN&SJ,_P".97'^?I^-?V\^._"5NO@WQ(1<29_LJY/)[B-AUSTYXK^'_P#:
MCLA:_&3Q8@<M_P 3&?KZ>:_K7]"^ E_K>=M7O[*A9)7^TK=5Y]?D?EGB;_!R
MVW\\^GDK_J>!#@ >@I:**_I-[OU/R(****0!1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %0S G9C^\#^1!J<$CD5%(Q4*!W;_#_  IK=>J_,#^@
M_P#X(S7%O!JU_P";,B$C/S''4?7V/ZU_2 =1LA_R\Q'Z,#7\U7_!'/1HM2UB
M_+3,F ,A3CIG/OGG_.,#^C)O"%N>?M,O?J3^G-?QEXM_\EKF'_7NA_Z2?T%P
M/_R3F$_QU+>EU?\ $Z+^T[$=;F,?\"'^-']I67_/Q'_WT/\ &N:/@VV;K<R\
M>YI?^$/M_P#GXD_,_P"-?F9]<=&=3L1R;B/_ +Z'^-*NIV+8Q<1\\#YA_0GT
MKF_^$/MB"#<2\CC!/^-.C\(6R%3]HE.TY')]?K0!\ _\% KRVD\)LBS(6%O@
MX/M7\^72:XQR#.YR/J<?R_"OWW_;]T"*W\+&596.Z L<G_9&0?\ Z]?@1@K)
M.B<@328/_ N?7T[>_:O\[OI&_P#)Q96V^I+??[/ZG^D_T:$GX;4[J\OK,G;;
M:3;U_ :_7\/ZFF4]\X"GT']13<_*%[#\Z_ #^@1**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *O:*0-9M">@DC)_[[6J-7=(42:Q:*>!YD
M8S_P-?\ &JA_$I_]?*?_ *6B9_PZO_7N7Y'].G[&UY:K\)-/#3Q@JEN2"<8
MC;G_ #^=?6/]I67_ #\1_P#?0_QKXS_8Z\.6\_PEL7,\@+QPHP4YQN3=G\,8
MKZG_ .$/MA@?:9/0<G_&O]8N!+?ZF\-V_P"A5AK^7NG^17B$V^-^)^W]K8FW
MWJYTO]I67_/Q'_WT/\:/[2LO^?B/_OH?XUS?_"'V_P#S\2?F?\:/^$/M_P#G
MXD_,_P"-?6'QQTG]I67_ #\1_P#?0_QH_M*R_P"?B/\ [Z'^-<W_ ,(?;_\
M/Q)^9_QH_P"$/M_^?B3\S_C0!TG]I67_ #\1_P#?0_QH_M*R_P"?B/\ [Z'^
M-<W_ ,(?;_\ /Q)^9_QH_P"$/M_^?B3\S_C0!TG]I67_ #\1_P#?0_QH_M*R
M_P"?B/\ [Z'^-<W_ ,(?;_\ /Q)^9_QH_P"$/M_^?B3\S_C0!TG]I67_ #\1
M_P#?0_QH_M*R_P"?B/\ [Z'^-<W_ ,(?;_\ /Q)^9_QH_P"$/M_^?B3\S_C0
M!TG]I67_ #\1_P#?0_QH_M*R_P"?B/\ [Z'^-<W_ ,(?;_\ /Q)^9_QH_P"$
M/M_^?B3\S_C0!TG]I67_ #\1_P#?0_QH_M*R_P"?B/\ [Z'^-<W_ ,(?;_\
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M:O\ .[Z1G_)Q)?\ 8$OSB?Z2?1K?_&MJ?_85+_TI@_7\/ZFF4]^OX?U-,K\
M/Z$"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "K^B?\AJS
M_P"NL7_H:U0J_HG_ "&K/_KK%_Z&M5#XZ?\ U\I_^EQ)G_#J_P#7N1_3U^QI
M_P DCT[_ '+;_P!%M7UO^%?)/[&@Q\(]._W;<?E&U?6U?ZP\!_\ )&\.?]BK
M#?\ I)_D7XA?\EOQ/_V-L3^:"BBBOK3XT**** "BBB@ HHHH **** "BBB@
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M +6\0?\ /$_]\'_"C^UO$'_/$_\ ?!_PKO/+3^Z*/+3^Z* .#_M;Q!_SQ/\
MWP?\*/[6\0?\\3_WP?\ "N\\M/[HH\M/[HH X/\ M;Q!_P \3_WP?\*/[6\0
M?\\3_P!\'_"N\\M/[HH\M/[HH X/^UO$'_/$_P#?!_PH_M;Q!_SQ/_?!_P *
M[SRT_NBCRT_NB@#R7Q-+XAU?0=5TM("7O;.:!?EQS(A ]^OM7\\OQD_X):?$
MOQ]X[UKQ);V;F+4+J28'8>CNSYSM.>O%?TY-&HP509!]*<&/'RG]?\*^GX;X
MMS?A6>)GE52$)8J,(U>>+EI!W5M5^O<\?-LCP.=*C'&PE)4')PY7;67?N?R>
M'_@D'\4>UG)CW5O\*3_AT'\4O^?-_P#OEO\ "OZQZ*^N_P"(Q<9?]!-#I_R[
M?E_>\OQ9XG^HF0?] \O_  +T_P D?R<?\.@_BE_SYO\ ]\M_A1_PZ#^*7_/F
M_P#WRW^%?UCT4?\ $8N,O^@FA_X+?E_>\OQ8?ZB9!_T#R_\  O3_ "1_)Q_P
MZ#^*7_/F_P#WRW^%'_#H/XI?\^;_ /?+?X5_6/11_P 1BXR_Z":'_@M^7][R
M_%A_J)D'_0/+_P "]/\ )'\G'_#H/XI?\^;_ /?+?X4?\.@_BE_SYO\ ]\M_
MA7]8]%'_ !&+C+_H)H?^"WY?WO+\6'^HF0?] \O_  +T_P D?R<?\.@_BE_S
MYO\ ]\M_A1_PZ#^*7_/F_P#WRW^%?UCT4?\ $8N,O^@FA_X+?E_>\OQ8?ZB9
M!_T#R_\  O3_ "1_)Q_PZ#^*7_/F_P#WRW^%'_#H/XI?\^;_ /?+?X5_6/11
M_P 1BXR_Z":'_@M^7][R_%A_J)D'_0/+_P "]/\ )'\G'_#H/XI?\^;_ /?+
M?X4?\.@_BE_SYO\ ]\M_A7]8]%'_ !&+C+_H)H?^"WY?WO+\6'^HF0?] \O_
M  +T_P D?R<?\.@_BE_SYO\ ]\M_A1_PZ#^*7_/F_P#WRW^%?UCT4?\ $8N,
MO^@FA_X+?E_>\OQ8?ZB9!_T#R_\  O3_ "1_)Q_PZ#^*7_/F_P#WRW^%'_#H
M/XI?\^;_ /?+?X5_6/11_P 1BXR_Z":'_@M^7][R_%A_J)D'_0/+_P "]/\
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M* "BBB@ HHSCKQ1F@ HHHH **,T4 %%%% !1110 4444 (3CDTH.>:.O444
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MHJ"6XAA4O+(J*.2S$ #ZDXHN!/16$WB;0%)5M5L@0<$&>,$'T()I/^$G\/\
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M9[B"6#"Q@EB0ZJ.@))([5P/[0W_!0>^\"^+;KP-\*O"4OCC6+20PW36*-<M
MP)#96,.%((QG;D8)[5]J?%?1=!\*^#_$_B/0],L-/UB/2[O:;."&"1]T$F65
M(E4@]^ %_05_-Y^R9JOQ<U+]H;XDZQX3M(]=NS?WI>"^C%R8OWLG"JX?';V%
M 'Z=_!K_ (*0:]J_C:T\%?%7P7/X5>\ECBAN[V-[?#2-C&YP@."< $G%=?\
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MK[OS7!_#KP1IOPY\&Z-X0TJ-(K/2+6."(1J%4[553T &?EY_2NZ3[H_'^9H
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MG/8_C6]\ /CU\4O@5X3LM"TKX7_Z=<1Q+=W8LMS.Y"[V<F,DY)).?K7] ]%
M'S?^S_\ %+Q;\4-%>_\ %&CG2+A%#B,Q>5DY';:H/?M7T>O QZ9_F:6B@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
AHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>gyycud3vz5ad000013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gyycud3vz5ad000013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +?!A # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[]/1RL/:(V:*QO[9?_GF?^_3T?VR_P#SS/\ WZ>CE8>T1LT5C?VR_P#SS/\
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MN/\ P'D_^)H^W1?W+C_P'D_^)H LT56^W1?W+C_P'D_^)H^W1?W+C_P'D_\
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M 8<__'Q+_OG^=1U)/_Q\2_[Y_G4=;HXWN%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!H?\ ,'_S_>K/K0_Y@_\ G^]6?4QZ
MESZ>@44451 4444 %%%% !115'6;JYL=#O[NS@-Q=06\DD$(0L9'"DJN!R<G
M XH O45RD7B&]GEMK&WNK26_N)MC![*6'[,@1G)>-GW$G  Y7KGM1!XGN[?5
MUL]3%JD44LUK<3HK*/-6))XV&2<*8R^0<D%>M*X[,ZNBN-TOQ=J%_8VT<UK#
M!JEQ?1PB$J<+"Z";<1G.1%D9SC>/PKLJ=Q-6"BBB@ HHHH **** "BBB@ HH
MHH D@_X^(O\ ?'\ZW*PX/^/B+_?'\ZW*SF;TM@HHHJ#4**** "BBB@ HHHH
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M% !1110!1O\ 3;'4 GVVRMKGR\[/.B5]N>N,CCH/RJ'_ (1K0?\ H":;_P"
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MV3_KH/Y&@"_1110 4444 %%%% !1110!3U+_ (]U_P!_^AK+K4U+_CW7_?\
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MB@ HHHH **** )(/^/B+_?'\ZW*PX/\ CXB_WQ_.MRLYF]+8****@U"BBB@
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M45=FW17$_P#"T=$_Y]=0_P"_:?\ Q=:.C^-M/UVXG@LK:\\V&!IMKHHW $#
MPQYY%6Z4TKM$*O3;LF=+17">%?'%_KNNFQN+*%(F5F#1!LIC^]D\^G:N[I3@
MX.S*IU(U%>(4445!8445SGBOQ5_PC$=JWV+[3YY88\W9MQCV.>M.,7)V1,YJ
M"YI;'1T5S6H>)YK?P9'KL%F#)(JD1DEE3)QDD8X_+M2>#/$EUXCLKB6[MDB>
M%PH:,$*V1[D\CZ]Q5>SERN1/M8N2CU9TU%%%0:!1110 4444 %%%% !1110
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M !\2_P"^?YU'6Z.-[A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 :'_,'_S_ 'JSZT/^8/\ Y_O5GU,>I<^GH%%%%40%%%%
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MT(PNZ:LSRGQWK>E^(+JQ;3/,EG12COL(R#C:N#R2#G\^]>C^&-(_L3P_:V;
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M1_C_ "-;%9SW-Z7PA1114&H4444 %%%% !1110 4444 %%%% !1110 4444
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MBC[-!_SQC_[Y% :$M%1?9H/^>,?_ 'R*/LT'_/&/_OD4!H2T5%]F@_YXQ_\
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M'_WR* T):*B^S0?\\8_^^11]F@_YXQ_]\B@-#5_Y@_\ G^]6?5G[%:_V5O\
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M@AB4)W$94_AZ%SR.5'<45Q<_B&2&WOXXH].NKDQ6SZ;)'$1'<>=\BDC<<@2
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M 4444 %%%% !1110 4444 %%%% !1110 50U7_CV3_KH/Y&K]4-5_P"/9/\
MKH/Y&@"_1110 4444 %%%% !1110!3U+_CW7_?\ Z&LNM34O^/=?]_\ H:RZ
MUAL<U7X@HHHJB HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH L6/\ Q^1_C_(UL5CV/_'Y'^/\C6Q6<]S>E\(4445!J%%%% !1110
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M 4444 %%%% !1110!H?\P?\ S_>K/K0_Y@_^?[U9]3'J7/IZ!1115$!1110
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M%%0:A1110 4444 %%07EY;Z?:/=74GEPIC<VTG&3@<#GJ:R?^$RT#_G_ /\
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M'_C\C_'^1K8K'L?^/R/\?Y&MBLY[F]+X0HHHJ#4**** "BBB@ HHHH ****
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M0Q8?(IP?4$CBE75KY4V"X/ (#%06 /4!L9JD>M%>![2:T39R%S2O^0G#^/\
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M@5X2TBQDJ,-SD]*[BBBMJ5%4Y2:>[N<U;$.K&$6OA5@HHHK8YPHHHH ****
M"BBB@ HHHH **** "J&J_P#'LG_70?R-7ZH:K_Q[)_UT'\C0!?HHHH ****
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MA609",@RW/;G'ZT3Q%*#Y9228J>%KU(\T(MHZ>BJ.DZK!K-E]KMTD6/<5Q(
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M'_'Q%_OC^=;E9S-Z6P4445!J%%%% !1110!A>,O^14O?^ ?^AK7D]>L>,O\
MD5+W_@'_ *&M>3UX.:?QEZ?JSZG(_P#=WZ_H@KK/A]_R'Y_^O5O_ $)*Y.NL
M^'W_ "'Y_P#KU;_T)*YL'_'CZG9F'^ZS]#TFBBBOISXH**** "BBB@ HHHH
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M7%5\SFG^\/T1]MD7^Z+U85U'@]6;[;B1DQL^Z!S][U%<O75>#/\ E^_[9_\
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M_P#$U9HH K?9IO\ G^N/^^8__B:/LTW_ #_7'_?,?_Q-6:* *WV:;_G^N/\
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M_B:/LTW_ #_7'_?,?_Q-6:* *WV:;_G^N/\ OF/_ .)H^S3?\_UQ_P!\Q_\
MQ-6:* *WV:;_ )_KC_OF/_XFGQPR(^YKJ60?W6"X_114U% !1110 4444 %%
M%% !1110 4444 %%%% $;]*DJ-^E24 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4-5_
MX]D_ZZ#^1J_5#5?^/9/^N@_D: +]%%% !1110 4444 %%%% %/4O^/=?]_\
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M?[K+_$_R05U7@S_E^_[9_P#LU<K75>#/^7[_ +9_^S5AEO\ O4?G^3.K.?\
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MU7KX-)TM3YC-92CB79]$6+N_O+]U>\NY[EU& TTA<C\Z]=^$O_(JW7_7Z_\
MZ E>-5[+\)?^15NO^OU__0$HQBM1T%E3;Q-WV9O^,O\ D5+W_@'_ *&M>3UZ
MQXR_Y%2]_P" ?^AK7D]?%9I_&7I^K/U'(_\ =WZ_H@KK/A]_R'Y_^O5O_0DK
MDZZSX??\A^?_ *]6_P#0DKFP?\>/J=F8?[K/T/2:***^G/B@HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH C?I4E1OTJ2@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ JAJO_'LG_70?R-7ZH:K_P >R?\ 70?R- %^BBB@ HHH
MH **** "BBB@"GJ7_'NO^_\ T-9=:FI?\>Z_[_\ 0UEUK#8YJOQ!1115$!11
M10 4444 %%%% '/^+_\ D$Q?]=Q_Z"U<57:^+_\ D$Q?]=Q_Z"U<57S.:?[P
M_1'VN1?[FO5A75>#/^7[_MG_ .S5RM=5X,_Y?O\ MG_[-49;_O4?G^3-<Y_W
M&?R_-'2W?_'E/_US;^5<E76W?_'E/_US;^5<E79F_P <?0^,H[,*N:5_R$X?
MQ_D:IU<TK_D)P_C_ "->?AOXT/5?F:2^%G3T445]:<@4444 %%%% %BQ_P"/
MR/\ '^1K8K'L?^/R/\?Y&MBLY[F]+X0HHHJ#4**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH PY_^/B7_?/\ZCJ2?_CXE_WS_.HZW1QO<***
M* "BBB@ HHHH **** ,KQ)_R +K_ (!_Z$*\_KT#Q)_R +K_ (!_Z$*\_KYW
M-_XZ]/U9]AP]_NLO\3_)!75>#/\ E^_[9_\ LU<K75>#/^7[_MG_ .S5AEO^
M]1^?Y,ZLY_W&?R_-'5UQAZUV=<8>M>AF_P!CY_H?%T>H5<TK_D)P_C_(U3JY
MI7_(3A_'^1KR\-_&AZK\S67PLZ>BBBOK3D"BBB@ HHHH T/^8/\ Y_O5GUH?
M\P?_ #_>K/J8]2Y]/0****H@*\^^)W_,+_[:_P#LE>@UY_\ $WKI7;_6_P#L
ME;X;^*CCQ_\ N\OE^://J*ZNV\&Q:K:&;1M5%XZ3QPN'MFB7+]U8GYL=3P#C
M\,TO$/AZ/0@@6XNI7+E#YMDT*''=6).X5Z*JP;Y5N>%+#5(QYVM/5'9_#?\
MY%VX_P"OMO\ T!*V_$G_ " +K_@'_H0K$^&__(NW'_7VW_H"5M^)/^0!=?\
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M7_D5;K_K]?\ ] 2C&_P@RG_>5Z,W_&7_ "*E[_P#_P!#6O)Z]8\9?\BI>_\
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MZ37:_P"-BWBN5M-7U25O-7[G>T5Q_AS6-7C\1W^@:Y/#<2V\(N$N44)E..H
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MC3?-=O2ROT04445D= 4444 %4-5_X]D_ZZ#^1J_5#5?^/9/^N@_D: +]%%%
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MBO5/FSU'X;_\B[<?]?;?^@)6WXD_Y %U_P  _P#0A6)\-_\ D7;C_K[;_P!
M2MOQ)_R +K_@'_H0KP<P^"IZ/\C[')OCH>J_,\_HHHKXH_33H/"'_(6E_P"N
M!_\ 0EKM:XKPA_R%I?\ K@?_ $):[6OILK_W=>K/B<]_WQ^B.,/6B@]:*^=.
M0N:5_P A.'\?Y&NGKF-*_P"0G#^/\C73U]!E/\%^OZ(YZWQ!1117IF04444
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MN?%'J-%>6Y/J:U/#I/\ ;UMR?XO_ $$UST\RYYJ/+OY_\ #OJ***], HHHH
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MVYC]VR2*?UB%TEKZ+N3]4J)-RLM]VEMO8Z&BN.&L:V/%EU!'I[RA8<BU^TJ
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M'K(NH[N:ZMXP&L(@VXN\G7)Z!2?3VK1\,Z+I?BCQMXYN-?L;>_N(;Q;*-+E
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MT->9AOXT/5?F:2V9U%%1>:__ #[R?FO^-'FO_P ^\GYK_C7UIR6):*B\U_\
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MT&Y!A=1\O)(_O#WKP<P^"IZ/\C[')E[U#U7YG!T445\4?IIT'A#_ )"TO_7
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MYZUU]%:2PZDWKH]6C.&+<8KW5S)63_KU.>L[:=?'.H7#0R"![9560H=I/R\
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MT445ZI\V>H_#?_D7;C_K[;_T!*V_$G_( NO^ ?\ H0K$^&__ "+MQ_U]M_Z
ME;?B3_D 77_ /_0A7@YA\%3T?Y'V.3?'0]5^9Y_1117Q1^FG0>$/^0M+_P!<
M#_Z$M=K7%>$/^0M+_P!<#_Z$M=K7TV5_[NO5GQ.>_P"^/T1QAZT4'K17SIR%
MS2O^0G#^/\C73US&E?\ (3A_'^1KIZ^@RG^"_7]$<];X@HHHKTS(**** "BB
MB@"2#_CXB_WQ_.MRL.#_ (^(O]\?SK<K.9O2V"BBBH-3@_BU_P BK:_]?J?^
M@/7C5>R_%K_D5;7_ *_4_P#0'KQJO8P7\(^6S;_>7Z(*]E^$O_(JW7_7Z_\
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M_P!_^AK+K4U+_CW7_?\ Z&LNM8;'-5^(****H@**** "BBB@ HHHH Y_Q?\
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MFOQ)'J][-OG5'#@!%6-,$<8(3=]6/>NFH **** "BBB@ HHHH **** ,.?\
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M6JRPWR><HEU)D;16"*=L;RF('I\VT!93G/#X[8KOP,  DG'<]Z=P:L8'B_\
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MW_D/6O\ P+_T$UYV'_BQ]5^8SOZ***^G$%%%% !1110 4444 %%%% !1110
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MCI;O_CRG_P"N;?RKDJZV[_X\I_\ KFW\JY*NS-_CCZ'QE'9A5S2O^0G#^/\
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M*^*/TTZ#PA_R%I?^N!_]"6NUKBO"'_(6E_ZX'_T):[6OILK_ -W7JSXG/?\
M?'Z(XP]:*#UHKYTY"YI7_(3A_'^1KIZYC2O^0G#^/\C73U]!E/\ !?K^B.>M
M\04445Z9D%%%% !1110!)!_Q\1?[X_G6Y6'!_P ?$7^^/YUN5G,WI;!1114&
MIP?Q:_Y%6U_Z_4_] >O&J]E^+7_(JVO_ %^I_P"@/7C5>Q@OX1\MFW^\OT05
M[+\)?^15NO\ K]?_ - 2O&J]E^$O_(JW7_7Z_P#Z E&-_A!E/^\KT9O^,O\
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *H:K_Q[)_UT'\C5^J&J_\
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M'\?Y&O+PW\:'JOS-9?"SIZ***^M.0**** "BBB@#0_Y@_P#G^]6?6A_S!_\
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M-#6]5.M:O<7Y@C@\URP2, 8Y[D 9/J>]>H^"/^1/L?\ MI_Z,:O'J]A\$?\
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M +-7*UU7@S_E^_[9_P#LU89;_O4?G^3.K.?]QG\OS1U=<8>M=G7&'K7H9O\
M8^?Z'Q='J%7-*_Y"</X_R-4ZN:5_R$X?Q_D:\O#?QH>J_,UE\+.GHHHKZTY
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M-=/7,:5_R$X?Q_D:Z>OH,I_@OU_1'/6^(****],R"BBB@ HHHH D@_X^(O\
M?'\ZW*PX/^/B+_?'\ZW*SF;TM@HHHJ#4X/XM?\BK:_\ 7ZG_ * ]>-5[+\6O
M^15M?^OU/_0'KQJO8P7\(^6S;_>7Z(*]E^$O_(JW7_7Z_P#Z E>-5[+\)?\
MD5;K_K]?_P! 2C&_P@RG_>5Z,W_&7_(J7O\ P#_T-:\GKUCQE_R*E[_P#_T-
M:\GKXG-/XR]/U9^I9'_N[]?T05UGP^_Y#\__ %ZM_P"A)7)UUGP^_P"0_/\
M]>K?^A)7-@_X\?4[,P_W6?H>DUY:?O'ZUZE7EI^\?K7HYI]CY_H?%"5J>'?^
M0]:_\"_]!-9=:GAW_D/6O_ O_037G8?^+'U7YC._HHHKZ<04444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% $;]*DJ-^E24 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+_G\M_\ OZ/\:LT4 <]-=6YGD(GB(+'!WCUJ/[3!_P ]H_\ OL59G_X^)?\
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M*/M,'_/:/_OL5+17UNIR:$7VF#_GM'_WV*/M,'_/:/\ [[%2T4:AH1?:8/\
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M7S_-GQV:_P"^3^7Y(\VHHHKPCSS4\._\AZU_X%_Z":[^N \._P#(>M?^!?\
MH)KOZ]O+/X3]?T0@HHHKT0"BBB@##G_X^)?]\_SJ.I)_^/B7_?/\ZCK='&]P
MHHHH **** //OB=_S"_^VO\ [)7G]>@?$[_F%_\ ;7_V2O/Z]7#?PD?-X_\
MWB7R_)!7J/PW_P"1=N/^OMO_ $!*\NKU'X;_ /(NW'_7VW_H"5.*_AEY=_'^
M1M^)/^0!=?\  /\ T(5Y_7H'B3_D 77_  #_ -"%>?U\5F_\=>GZL_4>'O\
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M0 4444 %%%% !1110 4444 %4-5_X]D_ZZ#^1J_5#5?^/9/^N@_D: +]%%%
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M ,?D?X_R-;%9SW-Z7PA1114&H5Y=\8?^8+_VW_\ :=>HUY=\8?\ F"_]M_\
MVG73A/XR_KH<&9_[K+Y?FC@(] UF6!9X])OWA9=RR+;.5(]0<=*SJ[#3];DM
M/"=]=3WZR7LL:Z?:0;QNBBZLVT'IC@$CM7'UZT)2;=SYBK"$5'EZGO/PZ_Y$
M33?^VO\ Z->K?C+_ )%2]_X!_P"AK53X=?\ (B:;_P!M?_1KU;\9?\BI>_\
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M0 4444 %%%% !1110 4444 %4-5_X]D_ZZ#^1J_5#5?^/9/^N@_D: +]%%%
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M ,?D?X_R-;%9SW-Z7PA1114&H5Y=\8?^8+_VW_\ :=>HUY=\8?\ F"_]M_\
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MU'X;_P#(NW'_ %]M_P"@)4XK^&7EW\?Y&WXD_P"0!=?\ _\ 0A7G]>@>)/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP?\ NB^?YL^.S7_?)_+\D>;4445X1YYJ>'?^0]:_\"_]!-=_7 >'?^0]:_\
M O\ T$UW]>WEG\)^OZ(04445Z(!1110!AS_\?$O^^?YU'4D__'Q+_OG^=1UN
MCC>X4444 %%%% 'GWQ._YA?_ &U_]DKS^O0/B=_S"_\ MK_[)7G]>KAOX2/F
M\?\ [Q+Y?D@KU'X;_P#(NW'_ %]M_P"@)7EU>H_#?_D7;C_K[;_T!*G%?PR\
MN_C_ "-OQ)_R +K_ (!_Z$*\_KT#Q)_R +K_ (!_Z$*\_KXK-_XZ]/U9^H\/
M?[K+_$_R05U7@S_E^_[9_P#LU<K75>#/^7[_ +9_^S5AEO\ O4?G^3.K.?\
M<9_+\T=77&'K79UQAZUZ&;_8^?Z'Q='J%7-*_P"0G#^/\C5.KFE?\A.'\?Y&
MO+PW\:'JOS-9?"SIZ***^M.0**** "BBB@#0_P"8/_G^]6?6A_S!_P#/]ZL^
MICU+GT] HHHJB KS[XG?\PO_ +:_^R5Z#7GWQ._YA?\ VU_]DK?#?Q4<>/\
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M[Q^M>CFGV/G^A\4)6IX=_P"0]:_\"_\ 03676IX=_P"0]:_\"_\ 037G8?\
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M -DKS^O0/B=_S"_^VO\ [)7G]>KAOX2/F\?_ +Q+Y?D@KV'P1_R)]C_VT_\
M1C5X]7L/@C_D3['_ +:?^C&K/&? O4VRO^,_3]4'B_\ Y!,7_7<?^@M7%5VO
MB_\ Y!,7_7<?^@M7%5\1FG^\/T1^IY%_N:]6%=5X,_Y?O^V?_LU<K75>#/\
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MLOE^:/+Z***]H^2/>?AU_P B)IO_ &U_]&O5OQE_R*E[_P  _P#0UJI\.O\
MD1--_P"VO_HUZM^,O^14O?\ @'_H:U\UCOAJ_/\ 4^]RG>A_V[^AY/1117R)
M^@G=?#C_ )B?_;+_ -GKL=2_Y!=W_P!<7_\ 037'?#C_ )B?_;+_ -GKL=2_
MY!=W_P!<7_\ 037T.#_W1?/\V?'9K_OD_E^2/-J***\(\\U/#O\ R'K7_@7_
M *":ZJ[\0V-CXCT_0[@NEU?Q220,0-C;,97.<[B#D<=%/X\KX=_Y#UK_ ,"_
M]!-;/B#PM)KNLQ77GK D5C)%%*N3)#.98I(Y%'0A3'SSSTZ$U[>6?PGZ_HA%
MV/Q3I4FM:IIAG$<FEQ12W4TA"Q)YF[ W$]1MY[<CG.<3OXAT2.WBN'UC3U@F
M+"*1KE K[3AMIS@X/7'2N4/@*ZMK_P"U6MQ;S-'%:.?M!(^U3QS3R2-)@' 8
MS9!&<,.F ,W;'PK>IXM37KO[&NZ6:9X(F9A&S111J5)49)$9R<#KWKT0-H>)
M]$;4[73EU.U:YNX?/@5901(F0 5.<'.>!WYQT-5_#'BO3O$VE6-S!<VJWES:
MI<R627*R20A@"00,'@G&<"LO2?#.JZ1K=M>QFRFB$E^DD9E9#'%<70F0K\AR
M0HP5X&3]ZI-'\*7>FZ9X.MB]L'T5-MT8R</F!HSLXYR[ \XZ9ZT 1:IKPL=1
M>.;3;[RGN?(2X CV,['Y0 7W<G SC&3UQS6)=>/[2V^PYTZ\_P!)NIK9PSQ*
M8FB+JV3OV_>CZD@8R<\8K1O]/UBZ\6&ZN8+*73[:;-K']J=2AZ-(R^60S\D
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M.O[H#J6Y^7H>M5[CQ/H=O927C:K9M!$Z1N\<ROM9C@ X/^0">U<Y>>#]4O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J&J_\
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M01@@ZO=\_P#D6HO^%:Z)_P ]M3_\&EU_\=KLJ*;2ENB.5'&_\*UT3_GMJ?\
MX-+K_P".TJ?#?1XV#)<:HK#H1JMV#_Z-KL:*2C%=%]P<J.3_ .$ T[_G_P!9
M_P#!O>?_ !VC_A -._Y_]9_\&]Y_\=KK**KF8<B.3_X0#3O^?_6?_!O>?_':
M/^$ T[_G_P!9_P#!O>?_ !VNLHHYF'(CD_\ A -._P"?_6?_  ;WG_QVC_A
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M1QT9=9O 1^/FU8_X0W2_^?K7/_![>_\ QZN@HJDDM@.?_P"$-TO_ )^M<_\
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M+;=Y$FL1;OO;-8NES^4E=;1248IW2"4YR5FV_F<O_P (%I'_ #]ZY_X.[O\
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M_#S:ZZBI;;W+C!1VT.(_X59X>_Z?_P#P977_ ,=H_P"%6>'O^G__ ,&5U_\
M':[>BHY(=E]QK[2?\S^]G&0_#31+=R\$VIQ,1@E-4N@<?A+4_P#P@&G?\_\
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M>WO_ ,>H_P"$-TO_ )^M<_\ ![>__'JZ"BJ Y_\ X0W2_P#GZUS_ ,'M[_\
M'J/^$-TO_GZUS_P>WO\ \>KH** .?_X0W2_^?K7/_![>_P#QZK6G^';+3;H7
M$$^INX!&+G5+F=.?]F21E_'%:U% !1110 4444 %%%% !1110 4444 %%%%
M$;]*DJ-^E24 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+%<Y%>@UXAIFBB+Q'H1\$>%_$WA]X;Q6U%M0:1;9K<9WH0[L')[;>GUZ>WT
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 1OTJ2HWZ5)0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 50U7_CV3_KH/Y&K]4-5_X]D_ZZ#^1H OT444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5A:CX-\/ZOKMMK6H
M:<MQ?VVWR9'E?:NTDK\F=I())Y'>MVB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** ,*'P;X?@\2R>(DTY3JTF2;AY7;&1@
MX4DJO QP!6[110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %80\&^'QXG/B0Z<K:N>1</*[;3MVY"D[0=H R!6[10 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &%8>#= TS7[
MG7+33PNIW)8R7#2NY^8Y; 8D+D^@%;M%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5A/X-T"7Q,/$<FGB35EP5G>5V"D+M!"D
M[0< #(%;M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% $;]*DJ-^E24 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4-5_X]D_
MZZ#^1J_5#5?^/9/^N@_D: +]%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!&_2I*C?I4E !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !5#5?\ CV3_ *Z#^1J_5#5?^/9/^N@_D: +]%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% $5Q<06EM)<W,T<,$2EY)9&"JBCDDD\
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M:!X@CUKP_P#VU+$MI:,TK1L\H(,*,P60G P&4;O8'K7#K\-]='@7[,=2L_\
MA*1=BY%]EMG$?D 9QN_U/M][\Z]#L=,CT[0[?2[1V@CM[=8(G3!9 %P",@C(
M]P1[4 0Z=XET'6+EK;2];TV^G52YBM;N.5@H(&<*2<9(Y]ZR];\3ZEH4K7%U
MHB?V0MS#;FY^V#SF\QE0,L04Y4,PX+!N"<5J:=I5[8W+2W'B#4M00J5$5U';
MJH.1\W[N)#GCUQSTKGM2T;Q/?>+UU">TTF]TNT*MI]K)?R0^6_>5U$+!G_N\
MX7ZG- &AHOB#5M;O[LPZ39QZ;;7T]FUP]\_FL8F*EA'Y6,$C^_5VXUX6OBNU
MT6>WV1W5G)<0W1DX9XV4-'MQ_=8-G/KZ5SB>#[]_$5GJ T[0=+D@O#<37^F[
MEGNT.[,;KL'#9&XEVZ9P#5_Q]X6OO$^E6R:5=QV>H6\Q,<\A( C=&CD' /)1
MSCW H H:;\2X-4\*76LP:9()X[Z.SALVEPTQE*>4V=O 99%;H<#/7%;]QXOT
M*TU3^SI[X)<+(L3D1.8HY&^ZCRA=BL<C 8@G(]16$_@)D\<:;J=K-#%H]O%$
MTUIR&:>%'CB8<8P%DYY_@6HK[P7J\UIK.AP3V/\ 8VKWK7<UQ(S_ &B$.P:1
M%4#:W(^5MPV@]#B@#H1XRT#[9J5J;\K)IH8WC-#(L<& "=SE=O0C'//.,X-4
MM-\=:?K'BZ/0K&*5\V+WCRS1R0LN'10/+= 2"'R&Z<=ZH3>!KJ[T7Q782W4,
M;:MJ(O;:1<MLVB(H'! _BBY ['K5C3M%\13>/8?$.KKI4,$6F/9+#9S22,7:
M1&W$LB\':>.WOUH T+7Q?97/BW4?#WV>\CFLHXY&G:VD\HA@Q.7V[5 V\$D!
MNV<&BV\<^&KM+AX]414@@-RSRQO$K1#@R(6 #K_M+D<CU%4-0\*WUUXBUR:.
M2W_L[7-/2RN6,C+-;[5D4,@"D-GS.Y7&.]95GX#OOL<4&IV>FWC6=D]K;O-J
M-W*LNY0IS&QVQJ5'(&[G!!&* -C4_B%I.G6-O=K;ZE.DMY%:%1I\Z,ID(PVU
MD!(P<C ^;H,FMG5?$.EZ)HHU?4[AK6Q^3,DD+@KO("@KC<#DCJ..^*XW_A"/
M$#Z3-$][ IBOK2]L;&6]FN8HC"P8KYTB[PKX'&TA<<9YK2^(5GJVH^"(8;:U
M5]2-Y9N8X5:9$83(2> "4&"2<#@=J -BV\8:#<VM[<K?^5'8H'N1<Q/ \:D9
M#%9%#8/8XP>V:@;QYX;CTNZU&74&BM[62..<2VTJ21ER FZ-E#@-G@XP?7BN
M?UKP-K'BF34+W5+FSLKR2U@M[6*TDDDC7RYO.W.Q",<L , #:,X)/-)=^!-0
MU*VFFF@LH-0DN+/YSJ-S=!H89A(06D'7K@!>_)H TY_'L1\56&B6.G7,HN(!
M<S7%Q#/ (HBP&[!B.>YRQ51C&[/%:-KXW\.WGG&'4"1% ]SN>"1!)$OWGC+*
M!(H]4W=O455U;PI-JWB>\O)9D2QN]#DTM]C'S59WR6'&,8/7/7M6//X-U_5+
M.RM=1FTR-=+L)[:U>V=\W$DD)B#."H\M0IY4;^>_&* -S_A/_#9L+.]%[.;>
M]D,=JPLIR9V";_D&S+<=P.3QUXI;?Q_X9NIHHX=18F240;FMI56.4G CD8KB
M-\\;7(/3CFJJ>%+U#X)_>6V-"4BY 8_/_HYB^3CGYCGG''Y51N_!.I3^&O$.
MG)/:"?4M;74(6+MM6,31/ACMR&Q&W !&2.: .BG\7:%;:O\ V7+?A;KS5A/[
MIS&LC#*HT@&Q7.1A203D<<UE>)_B-HWAZTO6C9KR[M'6)H4218_,) V&8(45
ML'.TG/'2LQ_ %U_:&I0.(+S2=1U$WTGFZA=1-'N8.R^4AV-AA\K97'&0<5!K
M'@CQ)+X>UCP[ILNDMI]_?->)<7,DBRH&E$K(5"$'YLX;/3 QWH [S5=7L-$L
MQ=:A/Y43.(TPK.SN>BJJ@LS'T )JG;>+=#NULS#?;C=W+6D2&)U83*I8HRD9
M1@ 3A@/U%0^)M$O-2FTK4-.D@%]I=T;B**Y)$4H9&1E8@$J<,<-@X(Z&N??P
M5K#WG]O&:Q.M'54U$VP=Q;;5@\GR]^W=G;SOV]?X: -?6?'ND:1$7"W5V8]2
M339EM[:1C%*VTGHO. ZG ZYP,GBKS>+-'74([#SYS<OLRBVDQ\K> 5$A"XC)
M!'#X-<JO@G7I=*U-KF;3AJ,^O1:S#''(_E83RL1LQ7(^X1N"GL<=A;U#PQKM
MYKT>J6BV.F74CP-<7=K?S[G"8W(\.T1S C<H9L$ CCB@#3MO'.DMI5O?7<OE
MFYN)X((;>.6X>7RG9&*HJ;SC;D_+@9ZGJ8-*^(6DW^CRZI.WD6_]H365L(P\
M[W.PD!D15W'(&[ !P*R=)\%:YH#:9?V4FG7%_:_;898)I76)XIYS*I5PA*L/
MES\I!Y'O56U^'FMPQ6E]-<V;ZG;:E>W9A@N9[>&5+@@D"1!O0C QPPZCF@#T
M"RUC3]1TD:I:722V15G\T9  7.[(/((P00>000:SX?&>@SP7TPO)$6QMS=SB
M:VEC80@$F159077@\J"*9I&@7&E^&;VSMFBL=1NS-,TL4LEPJ3OG#YE)9L<$
MYP"0>!FN0;P'XEO9K^:^FLA)/X?N=+#'4)[@O-+MQ(=Z (I(.54<>] ':Z1X
MNT37;A(-/NW>62'[1&LEO)%YL? WIO4;UY'*Y'-.U;Q7HNAW(M]0O"DOE^:R
MQPR2^6F<;WV*=B\'YFP.#SQ6>OAN\77/"MZ)(!%I%C/;3J&.69TB V\<C,9Z
MX[5%J6@:W#KVJZCHKZ?(NK6T<$ZWK.I@9 RAUV@[QAN4.WD?>YH J:M\2;?3
MO$$^G0:;<W=M:68N[FZCBF8!"&*[-D3*P(7[Q95YX)(($OAWQZ-8:U^W646G
M+<6,M_F264%(4*?,?,B08^<Y.<<<;@<BK8^ ;K3(M2MK>ZAD@F\/PZ3 TC'=
MO19!N88P%.\=,]^*CN_AY=ZC!9VMS=PQP)X:?1Y7B9BPE)C(91@97Y#U()]*
M ->Y\?Z*-*NKRSF,S0>2=D\4T =9)!&K*6CRRDGAE!'N.M:3>*]&75ETQKIU
MN7E\A2T$@C,G]P2;=F[@_+NS6#J^A^*_$'AFXTJ^_L6 [K4Q&"25@YCF1W8D
MJ-H*IPH#8/\ %5'5_!_B?5-7B>6\M9[6+68;^.62^F4I D@81"!5\O< " Q)
M)]NM '5:%XBCUBSU.ZEA6UCL+ZYM'9I,@B%RI<G QG&<=O4UF:G\1M%L= NM
M7@2^NX;<1G"64R;U<X#*S( 5Z_,..V>15G0?#]UI6E:W:W'V69[[4+RZC4DE
M"DKEE5^!V."!G\:YD^ -:GT+6-*^U6]C97-JD5K9)>374,<B.&#@R &-2 %V
M+D"@#M[?Q#IEU=FT265+E;07C0S6\D3K"690Q#*".5;@\\=*IR>-?#\5C8WG
MVUY(K^$SVRPVTLCO&,9?8JE@HR,D@ 5EWNA^))=:_MRVCTI;VYTTZ?<P27$A
MCBQ(S(Z,(\O]\Y4A<\<BJ6C>#M>\.)HUW8/IMS>VVD)I=U%/*Z1G:Q971PA/
M4G(*C(QR,4 ;/A3QQIWBBTMW3;!<W"3RQ0[BP>*.9HMX?: >0#CJ-P^M:8\2
MZ.= 77/MJC36QLG*,-^6VC:,9.3P,#G(QG->:W7A+6+3PSHGA^-YE\0174[-
M?6-NYMTM[EY!,/,8!5(1@=IYW*N,XS7H6LZ#'=>%?[%M+&SFA1(XX[>YD=(P
MJ$8^9!N4C P1T.#0!#+XRL/-TP0),ZWL\L)66WFBE7RXFD;$9CW,<*.#C.>,
MG@U])^(&C:EX:CUR875E \ODJDUM)N=]Q 6,;?WA.T\)GN#R#69IO@[7HM4T
M6\OK^*6*PU">Y$$EU)<-#$\!C6-977=)AB3EL<' Z53C\ ZU'HFEV/GV>_1;
MV2XM'2ZFC^THYDW!R@#1-AP 5+]#V.* .\TS5[#6;#[;87 F@W,C':59&7@J
MRL RL.X(!K-A\::'=+/]FN)Y9(K=KE8_LDH::->K1@K^\&<#*9ZBE\.Z%)I.
MG7NZ.&UOKV5IIFBN9;D;]H4-NE.6( '8 XZ5S6E^#O$?_"0Z3J&L7-K*+*TN
M+>>9;Z:9YWD"CS CJ$C^[RJ\>YXP =1X<\21^*?#46KZ?:S1F6/<D-U&\0W;
M<@;BOS+R/G4,.N,XK"'CG5#X=U#6#I&F11Z;=7%K=B;5)% :)]GR$0$ON/0$
M*>@[UL^"])U+0?#-IH^H_96^PQK!#+;R,WFHHP&8,HVD^@)^M8D'A;6+2RU&
MQDT_0=5L;[4KN\DMKV1P,22[XSGRV&0,Y&WKC#<4 =9I%Y>W^B6MY>V L;R:
M(2/:&7?Y1/(4M@<],\<5RL?Q NO+F@N-'@34EUC^R(XDO286D\H2;C*8P5&"
M1]TG.,#GC2\/^$O[-TG2X=0O[RXO+('#0WL\<7WRP4QAPKJH(4;P20!FL*^\
M ZC<S7\K-I]U#-KC:E]@N6;R+F(PK&$E^4X(8;APPX'7L =3X<\0'75U".6U
M%M=Z?=&UN$27S8]X56RCX&X88=0""#D5GQ_$GPG*D;KJ<GERLR1.UG,%D<'!
M1"4PSY_A&3[5+X/\.7'AY-2\U;2WBO+D316%EGR+4;%!5,@=2"QP ,GH*R+'
MP1J-MX;\*:<\UH9M(U8WUPRLVUD_?<+\O+?O%Z@=#S0!T<?BW0Y-'FU47P6T
M@E\B7S(G21)<@>68R X?D87&3D8'(JO)XZ\.0Z=]OEU!HX1<K:,KV\JR),WW
M4:,KO4D<\@=O6L:[\$ZE+>ZI?0W-JMPVLPZK8JY8H3'"L923 XS\W(SC@\XQ
M45QX*U?4M676;R6QBO)=4L[J6WBD=HT@MPP"ABH+N=YY*J.@[4 :FJ?$+1M/
M\/SZO$+NZ2"YCM98$M95EC=RH&]&4,G#9&X#/ &20#'-\1-+M/$$^FWD-U#%
M'8Q7JR_9IF<JQ8'=$(]T87:"2V.O.*J:YX)U#59?%317-LG]J-8R6NXM\K6Y
M#$/QP"5 R,\?E6C9:#JC>)=3UF]%G&U[ID-KY4,K2;)%:0GDHN5PZ\XSUX%
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MN;)VCL,<5S\7@.ZN=3MYI].T/28U25+R71]RM?K)&R%738H49;=RSG(&#WH
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M3KVQ%EJ>G,@GA6;S4*N-R.CX7((!Z@$$$5BZG\0QIOAC5=3;2GDOK#46T_[
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M$(IPH[D\5S^N?$2#3=9L-/L=/GU%;FU^VO/#',R"#*_,GEQ/O.&SV4<989%
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M*,"R@E3R"&P>G3FN:@\$>(#<7FJW$^F+JG]LIJEM%&TA@($/E&-R5!!VD_,
M><''45Z/10!P%SX,U.]>^U&]M=,N=0OKR*X,"WD\"6XCC*)Y<R+O#\G+;1D'
M&*H7?P^\17MC(EUJEM=7+Z'=Z=YLTCDAY95:,%MI+*JKM+'YCC..:].HH XC
MQ'X,N-9F@9YT2UCT2ZT^;R\F3=($P4&,$?(>I':LG1SX@UCQ;X::\TU(;71X
M9EFG%M/%O9HM@/[V-<9./E0N.N6X%>FT4 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 1OTJ2H
MWZ5)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 50U7_CV3_KH/Y&K]4=5&;9/]\?R- %
MZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"*XN(+2
MVDN;F:.&")2\DLC!511R22> !ZT6]Q!=VT=S;31S02J'CEC8,KJ>001P0?6H
MM2TVTUC3+G3K^$3VES&8Y8R2-RGKR.1]1S1INFVFCZ9;:=80B"TMHQ'%&"3M
M4=.3R?J>: +5<MJ'B^>Q\5?V*NB7LT?V9Y_M:1R,F5 .W"H2>N,C(S@=3@=3
M10!PEO\ $:6XTZSE;0IK2\OKY[*WAO93#'N4.<M(4( (3&%#')Q6X?$%U;76
MC6>HV,-M>:C<20^6MR9 -D;/N5@GS?=Z-LZ_@9_$5C=ZA9);P6&E:A S?O[7
M4LA)%[88*V"#ZJ?PKE])\"ZE87^B3M<6JP6.I7-V;5)'9+>*2$QK%$2,D G/
M.T<G '2@#=TCQWX;UV6U33[]Y/M>X6SO;2QI,5Y95=U"LPP<J#D8Z58@\7Z%
M<ZF=/BOMTVYT#F)Q$S)RZK*5V,PP<@,2,'TKG=.\$ZE9^%?!FEO/:>?HE]'<
MW+*[;754E4A/ER3F0=0.]2Z=X5URS\//X3>;3_[#,,]O]K5I#=-%(K!1LP%5
M@6Y;<<XZ#- &]I/BS1-<NVM=/O?-F\OS55HGC\R/.-\98 2+G'S+D<CGFJ5W
MXCU9O%EUH6E:397#6UK%<R375^\ (=G  "POTV>HZU0\,^$+W3K[3IM4BMI&
MTRW:"WN(]0NI68D!2?+D.R,%1RHW<XP1BK-SX-^W^-[[6KNXN$M9K*&WB6TO
MY[>3<C.6+>6RY&&&,D]^!0 W5O''_".79MM=T\0-+:K+9M;SF87<W :!,JIW
MABNW(^8'/&"!T<<VH2:0D[6<$>H-"&-LUP?+63'W3($)QGC(7\*Y;Q#X,OO$
MFH[[C4/LMKI\*G2##(S21W(P?/DR/F(P !DY!;/)K6&DZA):Q:E+($\0);[=
MJ7UP;+S=I&3$&567G/*Y_$9H H:5XJUK4;S6;8:!:R'3=L?F6FHF1)9SUB!>
M),%1RQYQTY/ 6V\5:Q/>ZAI7]@0G6+-89##'?AH2DN[#&0H",;#D;">1C/:E
M:>&M?L=4U/6=/M-#TV\N+,Q)9V\KM!-.7W>?*1&IR.>BDG)RWI#9:%XRTWPY
M?6]C%H\6MW9#S:G+J$DK2N>&<CR %P.%'(''&!R =+X<U]];&HPW%HMK>:==
M&UN(TE\U-VU6!5\+D88=0"#G(K*O_B-HT%]IUG8LU[+>:@EB&"2)'R2&9)"F
MR0J>H4_E6AX7TBXTO17TZZL+6T&2=UO>O<M,S?>=W:-#O)YSS7+Q>"_$L5AX
M;T7S-).F:'J$-PMQYD@FFBC)P-FS:K8//S')_N]* .MC\7Z%+JPTQ+\&X,I@
M4^4XB:4=8Q+C87X/RAL\'BJ=QX[T8:7J-[9S-<+96TEQO:"9(9 G7;+L*L,\
M97=]*QX?!6L)86F@-/8G1;341?)<AW^TN!,9EC*[=H.XX+[CD#[H/-4)O &N
MR:;JMA:26.FV=W83VXLX;V>:WDE?[KA'7$ !W<)G.: .IN/'OAZRN);6[O)(
M[BWBCEN52VFD6%77<&9E3 7'\1P!WQ5K4O%VAZ3<)!=WO[QXA-B&%YMD9Z.V
MQ3L3@_,V!P>:QXO"5^DGBIC+;?\ $WL(;:W^9OE9(6C);C@9(Z9XK!:RUKP;
M<M]BMA?27NEVMK/FUN)426&,IN1HXV#*0>5?8.GS#)H ]'TW4K35],MM1L)?
M.M+F,212;2NY3T." 1^(JU6!X(TZZTCP-HFGWL?EW5O9QI*F<[6"C(_"M^@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBCR* */F7/\ SWE_[[-'F7/_ #WE_P"^S5[R*/(H I"2Y_Y[R_\ ?9IP\UP
M\CL/1F)JWY'M3Q#0!?HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "DQ2T4 ,VTFRI** (]@HV"I** (]@HV"I** (]@H
MV"I** (]@HV"I** (]@HV"I** (]@HV"I** (]@HV"I** (]@HV"I** (]@H
MV"I** (]@HV"I** (]@HV"I** (]@HV"I** (]@HV"I** (]@HV"I** (]@H
MV"I** (]@HV"I** (]@HV"I** (]@HV"I** (]@HV"I** (]@HV"I** (]@H
MV"I** (]@HV"I** (]@HV"I** (]@HV"I** (]@HV"I** (]@HV"I** (]@I
M=M/HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
C HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>gyycud3vz5ad000007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gyycud3vz5ad000007.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" (C!W@# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M??%3P3\-+,7OB_6(=-B9=RJS(9"/78SH>>WM2E'EMK>_E_7_  X)WU\_\O\
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M-A( 5EC*_P 0R,A6;'YT.,DKM-+S7]=PO?;4ZZJMQ=VEO_Q\7,,'?]Y*D?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[718Y?LYNM&B@V [,N85W#!QT!''7^KO+EIM2UNFMKV75=27\4O3\=+'R?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_5C\@?@S^Q'XY\0>.[7XA?&35)-7\B>.XA@NY#+AT8-PLA/<=@<<5]4_M:?
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MZH/M=KU^TP8]?.C_ /BJ075L>ES W_;6,_R:BS[/[A<T?YH_>BQ32>0N.O\
M]?M^%1_:+?\ Y[P_]_4_^*I?M$!Z31'_ +:)_C19]G]W]=U]X^:/=?>B3 ]!
M^5+4)N;<=9X1]94_^*IIN[4=;FW'UFC'_LU%GV?W!S1_F7WK^NJ+%&.^.?7%
M5OMMG_S]VW_?^+_XJG"[M3TN8#])H_\ XJBS[/[A<\?YH_>B>BH/M5M_S\0?
M]_8__BJ7[1;_ //>'_OZG_Q5%GV?W?UW0^9=U]Y(K;L\=*=4/VFW_P">\/\
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MMXKD--"LC ./,R1@$>I['VQP*_>#]GC]H;0OBOH%I%-=Q1:S'%&LD3.-[MM
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M$'_?V/\ ^*H^U6PZW$ _[:Q__%46?9_<'-'^9?>OZZK[R?'?'/KBBH?M-O\
M\]X?^_J?_%4?:;?_ )[P_P#?U/\ &BS[/[OZ[K[PYEW7WDV<=:*K&YM<8-S!
MUZ^=$/ZTHNK;H+B X])HS_)J+/L_N%S1_FC]Z+&>W?THJ S6X.XSQ#ZRICIC
MUH%U;'I<0'Z2QG_V:BS[/[A\T>Z^]?UU1/14'VJV_P"?B#_O]'_\52_:;?\
MY[P_]_4_^*HL^S^[^NZ#F7=?>B:BJYN[4=;FW'UFC'_LU+]JMNOVB#'KYL?_
M ,519]GTZ?UN'-'NOO7]=43YQUHJO]IMGX%Q ?I-'_\ %'UI?M-N.MQ!_P!_
M8_\ XJBS[/[@YH]U]Z)\T56\^WR2+F'/IYD9_P#9O6G_ &BW_P">\/\ W]3_
M .*HU[/^K?Y_B@YEW7WHD9L>_P"/2@M@@?K^=1>=;@[O/BYSUE3'KZTANK4\
M&Y@'_;:/_P"*HL^S^X.9=U]Z+%%0"XM\#$\./^NJ?_%4[[1 >DT7_?Q/\:+/
ML_N_KN@YEW7WHEHJ W$ ZW$*_P#;2/\ #J:!/#_S\1'_ (''_1J+/L_N_KNO
MO#F7=?>B>C-1&> \>=%S_P!-$_QH$L('^MCQZ[U[_C2U[?U_37WAS+NOO)<Y
MZ<T5 LUN,XGB/_;1.WXT[SH@<F:/'IO3C\<T:]@NNZ'EL$#'7'\Z=FH?M$ Z
MS0_]_$_QIHGMU))N(><_\M$[\_WJ->W]?TU]X<R[K[R=3D9QWI:A^T6__/>'
M_OZG_P 52^?!_P ]HO\ OXG^-&O8.9=U]Y+14?G0GI+'_P!]K_C1YT/_ #UC
M_P"^U_QIV?9_=_7=?>%UW1)14)N+<<&>$'WD0?\ LU(+FW/2X@/TEC_^*I:Z
M:/\ X'?[] YEW7WHGHJ+SX3TFB/_ &T3_&BG9]G]W]=U]X<R[K[S\(O"7[2W
MQ O=1BAN-6N-AD .Z5^F>_/?\^OO74_$WXQ?$M;-)]&U>X#>4&/ERR#^$]<'
M)'\ORKY$\):WI$UT/+9?,5_E&1Z\?7GWY_4>HW_C*WLE"7;1M'MVX<@ CIW/
M^<U^SU<!A8XF/^QTW;E?+[)6>U]/RZ'\:X3B3,<1EM2EBLUQ"GJXU88B?6W7
MF/(=5_:;^-=A=-!/X@O8CN/6:4<9]S^6<^]"_M3?%BRC$\WBBZ/MY\OY_>_#
MOG]:NZZW@W7Y#+(;=)6.1C:/ITQZ\C/>N0F^&^G:H=RS)]EQGY2.@('8X/T%
M>M1IY;R_O<OHI/2-Z,=]'9:=E^I\E+%\0J=66"SW'U%=_%BZKLU;7X[^>VGS
M.VTK]KWXGWSJJZ_=, <'][)^.?F]/4?EQCW&'X^?$ZYT#^TEURY5@N[_ %L@
M)QWZ]NH_P%?,7AWP)X;L]5ALDD0.[@') 'WN.2?S'_ZJ]=\>PVGA/PZL,$T3
M(\7 1_4,>GJ./_U5PUZ.6SJTH4\'17-4C_R[CJER_P!W5J__  QWY?FO$U/"
MXBMB\YQ4X0B[R^LS]UZ=>:^^_D,'[3?Q0>Y^SIXAN=^=N//DSU.#][Z?YQ4-
MQ^T=\7+>Y ;7KL*QR!YT@'7ZX[>G/\_E@:FL-ZMZA^<G<!^/ QTXZ>G]=E?$
MXOKC9<J%PN%) [=._N!^'->K++L"FE]1H:Q7_+N"WM=[:/MIYZGEPXKS6:DJ
MN;Y@I1=H-8FK:6UF_>U7YKR/I1/VH_BC'<QQ'7KI@2H(\Z0_>./[Q_I].*[3
M7_VC/B/%HD4\7B&X2:4# \Y\\C''S<9'M^5?&D=Q&+])&P8\@YX[9)_D/KU]
M:7Q[XKAATR-+5CYD2YP#D9'_ .OOC\>*Y:^4X2=2G['!4>E_W<;:6WTU]//L
M['13XKS6G@\5.MG&.M%)1MB*G-TV=WI9M=^Y[1>?';XU">*['BJ]2$_-M^T2
MX(/U;'/N/PKBM?\ VD?CG#,6MO$U]L .,7$V"2,@\-]/Q-?-UG\2]0FD2"Z1
MS A R.>!CKVX_/BNYL_%&FZI-#"J* S#?NQVQUR>^/PKT/[*HT4JD\#A>9I7
M3I4VK:;:/5VMK??J>$^)<=BY<U'/,TIS;2UQ=9*]HZ?%9;'J6@_M5_&P'R;O
MQ%?%V8*,S2],^N[\.,C\LGZ,T+XY?%S^S%U&ZU^\,>T/DS2#.!_O<D_AGK[5
MXII'AGPMJ=K#+$D7VK"M\H7[RC/J>ISCW]J[K6+VTT[0DTU=BD+M'0-P#UZ'
MOWSSZYKS\1# UIJE' 4(23]ZU&*_EOT[W7EVV/H\JS#/:$'/$YWC9)J\+XJL
MUTY=Y/O^FY0\2?M3_%7SFAM_$%U'L;&1,XZ'_>]^_P#]>JNE_M8?%5(6CN/$
M%T6Q@'SI"?0 ?,>W/Z'->)^(+&!6>=70EB2.1G)R??\ KZ=ZYBP$4LP5P.#V
MXSR.G^?IFNFGEF <&_J=!V>G[J-]+:[=[?=W/+GQ+Q)#&3:S?&N":T^LU+<M
MTE]KM9,^L[']I#XM741GC\0W3$MD()I#Q[<_3M^-=58_M$?%NXC57U:[5NY\
MR0_^S?B?_K5\W:-?6VG2Q[E&SC*D<<X_#'T]LU[+I6HZ;?0AHEC!PN1@9_'W
MY%>;7P&"IMR>#I=[JG'3;2UO\M.I[^!SC-ZLHSGG&,4FE?\ VFIRZJ/1RM?M
M_F=UXK^/GQ8M?"TUW;ZW=B<1LP82R9! SV;MZD=!TQ7Y_P"N_M?_ !]MM0FB
M7Q3?QQJ[?\O$PP,CL6[#OWK]$D\/VNL^&+I'A!00N1E>"0I]O\]1S7Y8_%W2
MK73-=O;:!$3#NO3H,]/K@\C@YZUW\.X?+YUZE.I@<--2V<J496U6CTM=_KWN
M>+QSB^(\%@*.*HYWF5)2E=.GBJJ3M9VTG_5SW#PA^V1\8EFA:_\ %EXZY&X-
M<R>O0Y;D\_KUK[5\+?MA^*;S38A<:[)YFP98S-DDCOR/?-?C)IEJ\SJH? W
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M>M>E?#C3UG64K$"5^\0.^,GGJ.1^O2OHE@,MI85P>"PW,HIW=*'-?U:71/\
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MK="(3-&$4MC); ]>>^?\Y/E'BOP9=:7))?P1^99DELJ,C&3CMZ=NN/UYJ-+
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MMO9)79+16?\ VMI8X.I:>#_U^6__ ,<H_M;2O^@GI_\ X&6W_P <K+ZQA_\
MG_1_\&P_^2+]E5_Y]5/_  "7^1H45G_VMI7_ $$]/_\  RV_^.4?VMI7_03T
M_P#\#+;_ ..4?6,/_P _Z/\ X-A_\D'LJO\ SZJ?^ 2_R-"BL_\ M;2O^@GI
M_P#X&6W_ ,<H_M;2O^@GI_\ X&6W_P <H^L8?_G_ $?_  ;#_P"2#V57_GU4
M_P# )?Y&A16?_:VE?]!/3_\ P,MO_CE']K:5_P!!/3__  ,MO_CE'UC#_P#/
M^C_X-A_\D'LJO_/JI_X!+_(T**S_ .UM+_Z"5A_X&6^/S\S%']K:5_T$]/\
M_ RV_P#CE'UC#_\ /^C_ .#8?_)![*K_ ,^JG_@$O\C0HK/_ +6TK_H)Z?\
M^!EM_P#'*/[6TK_H)Z?_ .!EM_\ '*/K&'_Y_P!'_P &P_\ D@]E5_Y]5/\
MP"7^1H45G_VMI7_03T__ ,#+;_XY1_:VE_\ 02L/_ NWQ^?F8H^L8?\ Y_T?
M_!L/_D@]E5_Y]5/_  "7^1H45G_VMI7_ $$]/_\  RV_^.4?VMI7_03T_P#\
M#+;_ ..4?6,/_P _Z/\ X-A_\D'LJO\ SZJ?^ 2_R-"BL_\ M;2O^@GI_P#X
M&6W_ ,<H_M;2O^@GI_\ X&6W_P <H^L8?_G_ $?_  ;#_P"2#V57_GU4_P#
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MM=1$L<L8;R5(+ 9QU]>>WK^'M%I%G97EO'$$ DP.OJ,#V].O;CI7H-I;7%E
ML5NHP1@\#TQW&2>GO_.O,Q=2-I*]FM+>7N[>>K_#<^@PN"J/DG[1RA&,'SQV
M;]W31]=>Z/I[PA/:W/A:X1@%?[*P)/\ >V'_ /43UP?I7Y7?'OPM>S>)=0GM
MD9D\QSD+[G)X!SQCC^N*_0[0-1?3]$E$K%=T9W9..PS].YZ5Y3J\WA74KN07
ML<<SR,=Q(#'KSG\\?C[$5PY/6GA<5.JHN4%V732VG_ MYIGN<28*EFF48?!5
MZRHSA!.TG9ZJWKZ=;6W/RWMX-2TV<[XY,9P?D;KG!''IS_\ 6-=!:ZP\+AFW
M $C<"".Y]3WX_P#U&OT?M_A[\.-38+)!$I?'50.2?\X]/RK.U;]G+PMJ,;-I
M/E\C(V@#KD_AV_'I7TSS["UY>SJTG1:=N>2W6GWW_K7;\XI\"YE0CSX'%TJT
M7\%-M<W32SZ-6Y>G0^>?AUKLDSPK!?M%AE)C#$=^GT]/ZFOH3Q-J$ESI"[W\
MSRX^7ZY^7@YY^OU_"O-=:^!FJ^#;=M1T\2N8_P!YMCRV5!)'3UZ>A!Z>E+PY
M>:YKEM/I4\$RRC=&"ZL,GICGCV_^L.?-J.A7Q4:M.<94UK*2:M=6WO;^G\CV
ML'_:.7X>6 Q%&:Q%964+-J6UFOD]=3G?^$D:WF,90A X&[!QUY_+Z].];<_C
M'1X[8&>X5'QC!/?&",^O/;O^=9T_AR>QNGM=0@?)).=I_G^O^<BE=?#BUU]6
M2V,BOSZC'KGZ=??FO1OADE)N*3:]_1)/1?A;^MC@;SBE.="C3IRJ:WCRWDMM
M]K,9+KGA[4E.^YCW/P/F'4G&/ZGWXK(DL(8YA+8W(;)#* W8G./\_F1C' >(
M/AY?Z',(UEDX;C!//Y'_ #QZYJK&=8L#'B1FVJ,Y/ Z8X/IQZUO&CS:TZL:G
M-=<L=;II7^2\_7>YXWUK%.IRXS"PIU:<N:36DDU;36W7\['V?X<O+?7/#K:+
MJ4BE_)VKO/7Y>#SSG_#M7@6O_"6]LKNXN+)"T4DA92#_  D^P[@\<<?A7.^&
M=8\2R7H97<(I' /&!GTZ]B/TKZ:T&YUO5+#$T1.U<9*YSQW./SYY_&O)E*KE
MW-&-2\:DG>-]KV;7W[:??L?24IX;.X0]KAI1KT5RQG:_,E9I:K?\?Q/&M-T3
M^Q=/EN+R4H\*YP20>.QQQ_GWKP;7OB=-%J[PVMPVV.3'#, <<<'/YYK[JO\
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M.X(Y-'G>90#Y1Z\^M94\43O<JD@'SL!SSD$G/!_/Z]^W0^#K=TTZ49_=M'@
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M?]._)'>_\+C^+7_0U7?_ '_E_P#BJ/\ A<GQ:''_  E=X,]OM$W_ ,57!4P
MGENHQC_(H_UEXF_Z*7/]+?\ ,WQO]W_I[Y+\0_L3(W;_ (1,H_\ #?AM-O\
MIWY+^KGH/_"XOBT>GBF\/_;>7_XJD_X7'\6O^AJN_P#O_+_\57!Y*C.< _3M
M3%).<\]/3^E"XEXF_P"BES_H_P#D;8W^[_T]WT6GJ/\ L3)/^A)E'K_9^&MT
M_P"G?DOZ9WW_  N/XL_]#5>?]_Y?_BJ7_A<?Q:_Z&J[_ ._\O_Q5<%12_P!9
M>)E_S4O$'?7-L;?HU_R]\D+^Q<C_ .A)E'_AOPWE_P!._)'>_P#"X_BU_P!#
M5=_]_P"7_P"*H_X7'\6O^AJN_P#O_+_\57!4Y<9^;I^/]*?^LO$W_12\0?\
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M=Q^! SUXK\Y!>6=N'!==X+!N1G.<?ASU]NF:^RR!?['-Q@W-5GK;1*RM^/\
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M;>Q;G1;TE"3M=K31;?)GCOQ U.\U#)8MD':#D]/K]!Z8Y-<UX>T2"[M7EGD
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M;T1K2K1E@J4%.5.4&DU?3H[+3?\ S\[/D+\7$A+22L67/RD]"/R[G'3/-7]
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MQ$H.2O*2=T[[-6N[:?\ !.P86MWH/EW$(<PQ$$D#C /\J\GM--B@O&N+638
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M744$LC8W@8.>>>>/J ?SK2\>Z?';P6\S1;AMZ^O&#_CU^O&*I>&[+9JD,LS
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M;5WZ^7EOW=.$7[>C5=JL;I1OV:M9K6_Z]#AQYUIM>%RNT $*<9QU''^.36C
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MH[O$2CL2#@XYSW],=/?I[=;=27(D29G[COVSG)^H]^>OO6SJL-K/HR7)0&<
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M7IZ<_P#ZZ^=?$FB33:BL=L6W.02 ,X&?;/8<G\Z^K_$>DKYDDP3Z?C_^K/\
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MD)NQG@=LC\/_ -59L6KHMR8&3+;S@_B#UZG_ ":XY*I&?(DFMD]?EY:;;_\
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M/\+^B?\ 7<V6/Q;KX=PJ6M)1FHK9)I:]6M-?7HCZ%UJ.,:?]KGB51(N[..O
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MF26\1 )Y((7_ "1^/6O(M*UZ.P=PRC/S 'KZ<C\/Z_CZCX5UJ+4["\M'8%I
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M<)OB4E\!CG)SG.17XL.JNNW!&>X)_P C\ZK0PRV^?+N+@9["9P._8G_/%=7
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M]!_7I7DFLH+MDD9_E689)XP,_KTZ^]=Q<RF./+*2'&.GL.^/_P!?>N-UD*8
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M9BH4YSGM^?KUQ_C6)J6E3KJ4S(SL5;YEY.!_GMU'7DUZAX.U"VBWJ-KDI@C
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M(0XC! SZ+Z=\_KDYYKRZ'59);9GX. ?ID9_QS4VE:^VJ^"GA9LLHP!^&/?\
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M0,@<\FOS[7RMT[^=_P!#^A!:^(OVW/\ D0H_]R3^;U]NY[=Z^,OVS=&UC6?
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M_P *U^)W_0IWW_?B7_"C_A6WQ./7PG??]^)?\*'D>?.W_"#G>BLO^$O&;?\
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M_P"@KFOQ7T748I3LD89R3@GW/7\L?A^?[,_ML3M!\)[IU7=S+@>^U?\ ./\
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M)#M#9R, ^O?U_ 8_R*YN65O?2<=]M;[^OE_P6>E0<)I\E135[J*W5[;?\/\
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M/DEB9.:CS>ZG:][7VZ_U\CL/M?G1^7./3G..>_/'^?S.+=E4;:%&W([#N?\
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MPUEB$YTT_>;WMI:S_K8YYY?A,5^_P<E[>I\$'HME>_\ 6GG>QX0)X;DI(>.
M3SC]/?O]:ENHK66)<$ CIC'I_@.ON*ZW4_!%M:W;I;W:XR<(" >.V,\9.><^
MW%4M/\(&\O5M))_+#MM!+=>>,$]_I_@*Z75P\U[9*>FK2OTLTWY_/YGE5,-B
MH35.:IW;LK:M-VZ]O\O,\QU))&5HX0[9X&!GG'Y>WKFL_3O"FNZE,GV9)!EN
M#@CO^73/O^-?<VE_ :)='-YL%Q((O,X ;/&?KUQ^8->6WMX_AB]EM7L/(^SL
M0KF/&=N1U(ZG\Q]:(YI3K1E0HP3J:+7>^EN_]/0WJ\.5Z7LJ^8/EH32<:B37
M*K)ZM+KTU6ES$\.?#'4$ABFUMPL2[6.6QQP<_P!/\YKU(ZSIGA[[+::=#%,$
M*J3@$]O3]?\ ]=>(ZY\1-9N)?+CF98,[ H)''^>GT_"MGPI<O=7,4MVN_P P
MC ;)[YZ_AS_D5R5:-=I5:LTY;66B2V5^MWZ7OJ=V#QF&HSI4,'%J?,HJ<E?F
MVZ[VWMJ?5XUFQGT'[7-I\.X)N)V+G(&<?R_QKQ-_'!DU)K6T@")N*G QC!YZ
M#T[_ *UZ3>WEM;:&(W4!'3&/8C&.PZ<9]QUS7D<&F1RWOVJ"W."V2P'49)].
MX_SBN&BTXU7.3:C+W4]KZ=7^&GY'TV9XG$PEA%3Y;N$5/D2[)OF26^KU_'1,
MM7R7-Q<>>-PRN[ )_D/<U#;LQE"74:2*.N\$]_?UKIX8&&]V0E53'TX_R>/R
MKS/5-5D2\E7.Q Q'IWQCMZ=3ZUK3O.2Y7[VEFM7NK;>5['F8JHZ$7*I&Z;3E
M%KW'MI\_R9I7VG>&-2O!;W*Q1NQVX& 26(&?\^F:]$\-^!/"VCO'J ,88J-A
M^7G/Y?IV_&OGB*RO-5UJ"2W=B%E4G!/3.>W'/7W[X%>SZK?#3K6UM6G_ 'P1
M 5).<XYSU/7'I58N$Y*G"-23>]1)NZ:Y=;=EV>[W.;*Z^'KO$5JV7PHPINT:
MC23;;C:VE[KR_/0\T^+?A#4;B]DU;3-\L/) 0%L#@XXSQD?G^0\8MK\V-K(F
MHQ$.@(/F#&#U_B]/3W]Z^V-"O;:.TSJJB6"0='&X8(XZ^WXUYI\0/AUHWBB*
M6;2WCM222=N%SGGH,?A^&*Z<%CXTG["I"3C'132=NFK?]:G#F&52JN6,P\O>
MFK^SD][I6=K_ / /E%/$D)N@L6-K/C (Z9 _''3CZ<8KT"U:*XMUGP,%=W'0
M=>OX8_.N3USX2:OH $EFDEWN;@KENI)['KT_7MS6SI>A>);72S'+83!MO'R,
M,9_+MW _ICV6Z%50]G.SM>5VD]UT]-/F?)8>AF$:]6.(ISG&Z]G*,967SVW]
M?R'WNH6_$1(.,C\<Y/?Z^G]*QVAAU"X2+/ (Z<\ C Z^G>LZ?2=;FE9!9R[Q
MD'ANI'_U_0<5Z#X-\":U<SK+/;2(,ALL&Z @\Y/IC'OWK*KRTH_Q(JZNVWIT
MZ?Y=_,UI8;$8FO"/LY651)MQVO;LMMO)Z'S]\8I]2BM+;3]/5V& "5!]0.WY
M^G3BN0\&V]];K%'?;E+%2<Y'/&>OXCT%?5OQ,\(LC0+]C.Y=N7V'VSSR#CZ=
M_>O,8=!1IDCVX8;1]W&/\/QQ7=A\1&5"*45*ZZ/1[:OMIV\FCR<;DN+AF[Q7
MM'RT[*$>B3M?RW_X;37V;PQ%H1T@?:74S[/ER1]['Y_R^M5YX86+I&@:-B0.
M!P/\]/PSDURWV-K.%%#D<#!Z8Q_G/'2M"RO7M</-ED&#S]>OY=/_ *PKRI4I
M<TI<S^)V2O?5[+MKTMT^9]-'%1:A0=.,E:+G*UVGI>[\F76T2.UA:9PJ!N1Q
MCID_0C_/O7-37:V>YU/R<Y(_$?RZ?_7K:UC5VO$$<;X3'W<X'N.#],?R[UQD
MP\QS&[?( /EZ9Z_T.,_3KWZZ,7-*+T;:WOY?C;?^D<]?DIJ3I*7-JUK[JVM?
MY/\ /78BF\4QHDB0Q@LQ.<\D\D?4]?\ />[X:UZXM[ZWF,SJKS#*!L+@D9X&
M.WT^O7/%ZK:HCCR8R/?L/R[U)8K<)) RH65&4Y'..0?;Z8_/L*WE34(S<HWT
MLKN_:]EV_7L>1#$5XU5-R^&4=KZ^]'\X^EOO/IGQ9"VJ6EK- ,JR N5&?X3G
M..G/)]^N*\:U?2H(87WA7[8XXX/MUSV_QKVK3M1CN?!TI(!GCA.T_P 0*KQW
MR,>WTKYRN[^ZFGFBE<\2,>_0$\<C''^??DPLWSR2NE&24=K)Z?I?^MO6SCV<
M72K22G'$T8SLM;.T4T^NCOI\BA8VMG8SF7(SNS@X'0YZ=SP#G')X[UU=KK7F
MN!!&!L(RV.,<_7\_TK@[B&9Y 5R1N/KR!GGC/<?A^-=/9NB6OEQQ[90AW-R<
M_P">GL:ZZVL];2T6KZK3RM_2^7AT*[5O9I1@G\+5NUWZ^GXGM,,RZKX=DB.&
ME"=.IXX_SC\Z\Y$GV/=:R?*P^4@\?U'//''YUM>")=0>Y$2Q/+$QVD $CD]^
MPZ]#_.O2=3^%T^K-]KAS'(XSMZ$9YZ<=^G3@YKRO:4\+4G&4[QJNZ5]%LM6W
M_3/J:>%Q..PT*V&@E.E&T[_:^'1;;[?K<\<9H&0K)M96Y/KZ?T_R:Y_7)H(K
M;R[7!)'.WMGOGGW/Z5ZG-\)]:2<H[.(@/O=N_.<^W!XXJA<_"J<AU,Q.#SD_
M3OTZ\YX_4FNR%?"2L^?5VNTU:]X]+Z?BSS9Y=CK6E@[2LVF]%>RLU_P/*ROO
MY[\/=3M[?4I(KQBP8' ZX)'H/YC\NE:6O:@+;5)FMTD,4K<$#WZ]!Z_TKU+P
M;\([*QO/M]]<*4!!VD_0'C../_UBO4O^$(\*ZI(8@(@V<*?ESGU!_4_D.:XL
M1BZ$:T91C*44]H[/:_XZ_P!:=V&R7,:F70BZE-5YU+J+:YHQT;M=[6?IH?*%
MO=7-]*L:!PI/( //UP,9_P Y->N>$["2TEBE6!F<8R2G_P!;MR>_\\^P:;\*
M]#MKQ0LL9)8$+\OX=/K^?Y'V2#P;H6DV.XQ1F1HSAL#@X.#GV_2N/$YK3=/D
MIQDFVE+IO;9-=_QZGLY7PSBXU%5=2#<-9:Z:<NOY;??L?'/BN5GU .Y57*D8
MR..!V]:XF]MC.Z,K,XZD'MQ]>Y^AKJ?BIHFK0:V]U9([V@<GY<D;2?;\L?H2
M:YC0KM&"QW1^?H1W';TSG]?QKT\.XRH4I)KFY4VHZR3:3^5OT9XF82E3QM>G
M.,K2E;G:T=G]F6S[Z=R*WNK73'<S+MXSG&!G.?Z=<]:R9?%Z,TD4'(8E?Z?A
M_GGTWM>BL[F(I&HWXSN'?Y<?CC)]?Z5YC'8K:W&TCC=UQWR>_3'^>]=$?9R=
MZBDY=;+=*R_/\=CR:[KT7"-)KE<E)O3?W4U_5KV.YTZ]9Y4+=69< XQGC_/]
M*]'E&+>)I NTD9Z9 R._X>F?Y5YO:367E( RK*F".GU^N>#^)'!KHX;Z\U&)
M+6V5I6#*H"AB?3!Q_GGH:B?*E)I65M.9_EM<]+!<T*<YQ:G.3T4=;.37;?5:
M?F>I:E>FX\->7M0QHG!/H%_F>/4<@^M>-:;=V32S1OC>"0#Q_A]<5]#?\*^U
M*Z\(1R"1DF=%+1=\$>G!!Q@?2O#W^''B"&>4V]E+*V\_,JG!.>O?W'7K^=<=
M&MAK<G.E[VS>S3BUN_Z]4=^987'U)8.:I2E'V7-/EA=I))]%VMI^77EM8@MO
M-60'G.1CU]?;)]Q]:@MTN9;J Q;BJLO/X_A[=S6E>^'?$$$@BN+"4,#QE22>
M?_KUI:=I&NQS0HNFRG+I\VPX"D@>GZ#_ !KOYTX/DDFDG=)]++?Y;?B>*\)B
M98FFHTJL4YQ=N22NE;>Z\_O[=-KQI9RS^'K?S259$&/P& ?K_DU[!^PI:QK\
M5823N=95(SCKN7'U^M<CX^TB]C\*V[O;M&WE+OR#D=,^F<>G_P"NNO\ V&_W
M7Q8A^?GSDW9QV9>F?2O*Q3C+*,=[R?[N6B=T]MT?69+1=+C;A[FNI.O2O%KT
M_%^MM#ZT_;YCE&OZ 0, 26Q&/JOMG'?U]Z^M/@_9:?K'P,M[/6B$L&L8UD9N
M!L\L DL>./?I^E?,/[>TL8UOP]O7C?:C/_?/?'OWKZ3\.*T/[,PGM!M?^S!\
MRX!SY.1R/\\U^?8N_P#8>3T54E3Y\4TK+X;S6O\ E^??]ZRR$9<><95*BC5I
MT<I;EAW\-2/LT^5]?5>1\]:G\#OV;KN\N9+_ %*T2=W8R@RH,,6R>?J3U/-?
M4?P4\"_#CPGH.KIX(N(9XA8S?-$P;^ GJ.>V,?CQW_"+Q]XB\2IK>H)#>3H!
M._21QCYS[CMT[\?2OU,_82N-6U#PSJS7MP\^;"7)+EL'8?4\_AS]1BO2S[*,
M1A\KIXF>:U*\'*B_JS3T7N6OZW[^=G8\7@'BS)LSXI67X;A:C@*]-8F"QB<5
M)\L9+1?%NM_EKU^-=8@@U3]J!;*=$>.355\Q7'R_Z\\8/MW],]Z_4+X_Z[)X
M/^'6FZ9I6;6)["$/Y7RJ<H,_=Q[<_K7Y3?$2\N?#O[2=QJT43;;?5220#@8G
M//?@#TQ]*_6WQ?H2?&GX0V5SIWSZE!I\9,:G+9$:]NO)''?\ZSSBT*F0UJW*
M\/*G2YDFFHV4;.5FUKV_R,^!U.>$\0<%036;5,;BW0E&RE*G[6>D=+N\;Z+_
M ()^/OB3P_=^+]06[=C(I8M(3\QZYSD^_?KZ5PFM^!RL\%E!*?WK!=N3MRV!
MTYQ_]8<=:^A-3\/^,/"NH3Z7)HDX6)R@<Q/SSC(.W&#6/=^"_$URT>H75C-:
MJ2&B=E8?-E<'G _,5]11QTO<4:E+DC'W(IK9I<MDKN^R5MEWZ_EN.R6I5J58
MO!XFIBG).JG":E*4914[MJR5EUT>GH?3_P"S_P#LM>$K3P5+XS\5!9C%%YVT
M .<!=V,8]_;FO-?CMI?P6NM-":"C6^J1$IC;M&X>V,]@.IYZ<U]$?!3XB:UX
M/\,OHGB?2I-1TJ=!$"R,R!7&/< 8_I6[\4O@-X2^(/A"[\6>'=.6PGB@>X(4
M;/FVES]>1]#7Q,L;B:.;3EF5:M*E.I^X]E/]VHMI)32>_P NMS]CGD.%QG"4
M*/#F7Y;]:H8.^88;%T)_79R23DZ-9VCTE9GY/&6&QM&A(1D (C/&[;T]SGGW
M_P .76YM'<E -X/<<9^G;.?\.U7]:\/>((=8OK+R96BLYGA& V#M)4>N>WO_
M #JA_P (OK$(,JV4W.3]UN?T]OP'?IG]*I2I>SIU(U8N,X+1RO=^5M;[?UJ?
MSMB8UHU53CAYPE&].=/E;<:JE9Z]K::?*YR7B2\M-I60*LH! Z ]?3GKGC\*
M\LF^TZK=1V%A!*YE;9E4)'S-P2<'_/Z_0UC\'M6\42B\NR]L@8$JW ]>AQ^/
MZ]J]X\/_  ]\'>"K 3W:0W-\JDAB$9@P7MR>A'Y^W-7+,889:)U*DOA:]ZU[
M6?EO^1C#AK&YA-2Q$H4,(G&=2_NS:7+H]4_*V_0\U\*?"C48?!K2$#[0T)D$
M>,-]W)RIQS^';IGIY6;2\L;V6TO8678S#E2 <' /.,9Y ]J]W_X6)J5MXA%G
M!&?[,+[,!<*$)(Q@#&,'CCG]*](N?!_A[QGY4EO)%'=S*N\+M#;B#DGIWSV^
MN*X%BZ^$GSXB+J4ZK3NM>2]MWM_6FI]!_8^7XFG&C@*KC6P_N14W_$:6R[J^
MNG>Q\>W;0L#&H7'/4#N,>_Y\_P!:Y.:);F0PIMR. /7G]?<9_I7U)X]^!%WH
M]K]LMK@G<I(VGMVZ'].OMWKP0> M>@F#1Q2/R<'!.<GK_(CG/85ZN'QE.2YH
M27(U;5K9V7WK=W]#YW,\JQ^%JT\/6IN;DM.2+=KI+6VW3^MN2$JZ=F.?CC@\
M?TZ_3KT%9MSJ'S@HQ"$\X([\=N^:]#O_ (:^(;Y58VLN<#L<<Y_#/X\U:T[X
M+ZO=F..='B#]201CGGJ, XSQ_C6SK8**YI3NUK:ZT=E;KJG]_3TX:>6YFY*A
M"E*-KN,G%I+2-M;='\O+J>9'48W0( 6P.H//4GW]>OK^5=)X=T74_$EW%964
M$A9V"J0A(Y(]OUQCUKWO2O@+9:;"LU[<!V W%6(/X$'CG_.*]V^&GA[0M+O8
MT@M$:5"H$FP=L<C@'CG@>E>;B<SA3O.DVIVT<K*+T6VG6]OR/>R_A7'8C$4(
M8RI34)23<8_$_AV3U[W>KUV/-?"'P4U32X9I=64*DL?\?'##T/IGD?CTKC=0
M^!VE7&ISW'G*@:0L0&P.3D_S_*OK#XJ:U/IUE^XN54B/&Q2!@$# .,>_XU\>
MZAXVU5)',<K-\W./8]>WI^!XKS<'7S#%N=>%549-Z>[+5*WZ:W_,^@S;!9+@
M*D,'.@ZTJ<4Y;.UTMWW_ "6Z[R2? &RN[B-;>6/:2,G([$^N<_T'>O:="_9H
MT>VL4N7:-YE0-@$$D@ ^G?/T_.O&(?'.HF&.2.^,4T9W%-W/J1^?J./:O4_!
MWQFO[>5!J<F+9,(S,3AAD GGL?7'Y5OB5FWLO:1KQE'JK.^GEN[K31=CERW_
M %851^UP_)--1@I6<4WRV;Z+:]W9&/XEL(?#I_LV/=%LRF5XR!A?0'@#MQ7.
M6T\!CV.P:0YP6/J?TZ>OZ5[GXNBT/QSI_P#:6D.DMRL>YE3&<@ G@<\'Z>W>
MOF6Y@G343;3.UJT;8 /!."1W_/\ #\KPC=2DI5(N%5?$FM7:UGZ-]?QZ"S*C
M+!XCGP\E/#54G"<;."VO%6TTO:W1^ECJ-0-D+8\@NJ\X/Y?J/\:ZOX8>)FL;
MX1Q@8! SWX/Y_P!.W&:\LEN8[#SA<2>;O! 8D>A /IW_ #[<',?@[4'&N*(B
M1!O#;L\ $X_#K_6G.A.="JYN\7LN_P G]WD<N&QL</F5&NN7FC%*:6O\K;M;
M_@:].OO?QNSXBTII&4*50_,!SP!W_/T_3-?&6D17ML\T0+& ,PSC(ZX!]AC_
M /7TKZR\>ZQ93Z*\'VE1)Y?()&<[>G4D=0<=_:OEJPUB&"6:U;#L7.#C.<G'
M7Z8_$"JRB/+2Y+6C%NRFK);7T:Z]^_FS+B6O3Q.9T*ZJ**=--\K6K=GKY^NU
MBS;>$I]8>6]DF(C@RVUF(R%.[\>X_P .E=[\.OB/#X!\0PK<>9]F,J1,0#M/
MS*"?Z^G<>M97AU9]0F=#<?9+;)W9. PY]QZ'U].]=??Z%X/>!(IY83< AA+E
M0=_7(Y'?VQ736G3J\]&I"4J<UM!?#+2VW3^M3DPM#$X6K2QN#J4E4C43E[22
MNZ=TY+=:_<E=H^Q?$5KX?^(?AV/6+%8'D>'S#DJ2#LY]\]_PKXQUFU32-3GA
M?8%5V  QV)P!CC!K:L?%U]X<TJ6RTJ\::((51%?< /;!ST''?\!6)9^&=<\8
M W\A<,SEB.G!)^G]?Y5QX/!T\)S7JMT[WC&3\UHT?09ICL/F=2A.G1OBZ:C&
MKR1O&6BNVTK-7ZL\L\5:U]FOHY;?.U6'"@\\C/\ /%06EYJ>M31LJOY1*C&#
MCMW_ %_+G Q7N,GPTTTQJ-2D6.5/O;R,YX'<Y].WUK6_X1SP_P"&K)+B&>*9
MB!\@*$9_ \]N*ZI8O#)Q4(5)U$KQM%O1/KOV_70\"658Z-:I6G.%.G4<9<C:
M4DE;TZ>=W8D^"UKI-C\0]#-^Q2X,T)4'@YW@]>I[_J1S7]-7P_:-O">D&+[A
MMX\?]^TK^97X?)8:I\3="N1((REQ!A.1GYQC@=Q_6OZ8_AL O@W10O(%M'R.
M0?W:'(K\WX^GSO R:LY0;:Z+;0_I'P%=J6=TXQCR0KQM-6<I:1NG8[JDR"<=
MZ,CU%+CV_2OS<_HL8P!/^UC@?Y_'O4,UM;W*;+JWAG0?PRQI(O'^RP8?I5GW
MQS36!(X)&,\>M*48R3C.*E%[QDDTUV:::?S0U*47>+<6MFFTU\T90T+0R21I
M&F\]3]BMA_[3S^E+_8.B?] C3?\ P"M__C=:BG(X&.:=6'U3"?\ 0+A__!-+
M_P"0\C7ZQB/^?];_ ,&S_P#DC)_L'1/^@1IO_@%;_P#QNC^P=$_Z!&F_^ 5O
M_P#&ZUJ*/J>$_P"@7#_^"*7_ ,CY+[@^L8C_ )_UO_!L_P#Y(R?[!T3_ *!&
MF_\ @%;_ /QNC^P=$_Z!&F_^ 5O_ /&ZUJ*/J>$_Z!</_P""*7_R/DON#ZQB
M/^?];_P;/_Y(R?[!T3_H$:;_ . 5O_\ &Z/[!T3_ *!&F_\ @%;_ /QNM:BC
MZGA/^@7#_P#@BE_\CY+[@^L8C_G_ %O_  ;/_P"2,G^P=$_Z!&F_^ 5O_P#&
MZ/[!T3_H$:;_ . 5O_\ &ZUJ*/J>$_Z!</\ ^"*7_P CY+[@^L8C_G_6_P#!
ML_\ Y(R?[!T3_H$:;_X!6_\ \;H_L'1/^@1IO_@%;_\ QNM:BCZGA/\ H%P_
M_@BE_P#(^2^X/K&(_P"?];_P;/\ ^2,G^P=$_P"@1IO_ (!6_P#\;H_L'1/^
M@1IO_@%;_P#QNM:BCZGA/^@7#_\ @BE_\CY+[@^L8C_G_6_\&S_^2,G^P=$_
MZ!&F_P#@%;__ !NC^P=$_P"@1IO_ (!6_P#\;K6HH^IX3_H%P_\ X(I?_(^2
M^X/K&(_Y_P!;_P &S_\ DC)_L'1/^@1IO_@%;_\ QNC^P=$_Z!&F_P#@%;__
M !NM:BCZGA/^@7#_ /@BE_\ (^2^X/K&(_Y_UO\ P;/_ .2,G^P=$_Z!&F_^
M 5O_ /&Z/[!T3_H$:;_X!6__ ,;K6HH^IX3_ *!</_X(I?\ R/DON#ZQB/\
MG_6_\&S_ /DC)_L'1/\ H$:;_P" 5O\ _&Z^:?VJ]*T:V^%FHO'I5C'*3)LD
MCMHHV3$8)P44$Y..N>GO7U97S!^UG_R2R^^LW_HM:^"\4,-A8>'G&$EAL.FL
MBQMFJ%*Z_=I77NZ-:6>ZLFM4CZK@>O7EQ?PZG6K-/-<+=>UGK[_^+_AS^>J]
MXU*YP,#S),#\34=37HSJ-T<]'D/3W/\ A^M0$@ D\ <DU_A!6=ZU;LJM3[N9
MO\#_ %/AK3H^=*G_ .DH7..M=/X'\$:]\1M>MM$T*UGE\R98YY%1BFPM@G<
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M)N]Y.VW^1[Y::FL=@\V<.%;'4]L\_P"<<9]*XL^(&>Y<R.1\QZG ]OIUS_\
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MM2]I[-J,HW7*[M)._6UUIT.2@M@UL$V#U.![=, 8YKF+WPXDERMQ$K+*)%P
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M1WQZ_H/6O6[O4YI$+&?C!VCKQQ^77W''//-8UOXGN=,GCW2%HY6QG/ &>O\
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MA5%8>M&4IK7E:M9^=W;0]N^=4<7C,SH9DX5L?3]C7J-ZU*+LG]RT^[N>7?\
M""R>)X[B],9,EP2_3G+9;.1]?7M[BOHGX,>)_$_PIL;NTM5?R9XVC;&1\K
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MX6KO1[#/V<?V<- ^%&A6MU<VD,VLSQ(\KR(I:-R >I P<]!7UG12$$]#BO\
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MW_2H(_ 'C*7 =I"&.><GZ<?3H?S]:^A-:O+6UN8TTZT7S'9=JJ@))W=.%_\
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M_-?6O#4=WJ]U-9L[;';R6')!!.TJ1_G\LUZ-)\2_%?C5'CO=1F-M)EF1G8
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M6BUGJ$@6*!2[L<!0">N#^OUI^L:9<>"-+W36#0RA,G]V<@Y]<<=?Q]LYKG_
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MK!JI.'-%^]ILET79:_UWUCF5.K2HT8WA5IJT5=KF;MY;=5Z&^?$$6Q4E)!
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M=.F>/Q[=\\UZ5J'@+4[R\:Q16\Q7*[?H0./Y?_7J.;X,Z\0N(6RN#W)XR>W
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MOG@W?EM9.]GN[;]#"&=U,)C)X2.$IX>%2FDY)QM*]M%Y[ZW^1W.L7A@U%0
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MQV!XP/3KSBNODMI=!MK>[UN)HIB S!QM89]CC!/_ -<>@^KOA7X#'PYG2_\
M%&DC[#-((T:6,;1D_P"V,=_;GMBO;OB;^S58?$?1(_$.D%(K>YC$D<<97 !
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MUX1RNEC<JC@\UY(1QM.%H3:5DYKJ^_X;GX*^/?V7/BCI4:WL$E[+;NV05WL
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MG\^YZF$\6N"Z^+CA95E2A2M%8EJ\&[I63NDGZ7_S_9F^\5G0]9M+?8Q,C("
M.1R.P]#CUZ8/7GZ_\.7AOM(M;@@@N@/(YQ@=??K7YK_##XM>%_BE<:;JKO$T
M\HBD,1*[E8D'&.HQT]\]Z_2OP_Y7]E6GD*%C\M=H'3[J^G\J^$SG#5,*Z4*U
M!T*JOSJ6\FM-%T77YG[9P?CJ681Q&(PN+IXG"3C&5#D6L8OE=I??HUYFR1D8
MH P,"EHKPS[@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI'S!<YX'J..WI4_P>_;-\)?%6TLM.\07D=M.-B,)6523QD?,1Z?3'Z_5FO\
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M$_?Y6ERK_+KN?IE;P\P\Z]?$QQE*G2K8&,(1K37[J<H1E*HVWTW6BLD?DQ\
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M).VEEK?HO\COXOA3X U'Q%=7]C!;23,&)\M5(W<\?GZ]_P *\)^*_P !-/\
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M^>37Z>_VGX%U:XGL=.CMGO$5AL&S<'&!T S_ (=J\UUOP++K#S6<]F&M9"0
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M]X_"WX#7?C#18=/\8QEHG099U.1ZG/KCZ=:[OPE\&=.T.Z6:ULUZC;A <?3
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M4J=.4(TX7;C&*44DK[?U\NW)P,T@8'@9H).0,9!Z\4N .@'Y5^9G]*"T444
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M[_K7>/XJDN?"ZVWF;8UCP.<#ISCD#\A7E&GWOGWDBGD;B,G'7/7GKR/YFN'
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M;M]YSGB3QIJ]K/;M:W=[Y\Y_TK]ZQ&YOO9Y_#%/TG65OK^,7P+M+M!=N3N)
MR3T!.3UKNO'_ (6M-'O[J-H5Q&Y"':..<#''I^H^M8&C^'HY(X+M%',BC..@
MW?YZ'M[UUQ>%E0C65XK>,DK6T6B:U273_,\.K2Q[QZHXF?M)4JBBTVVD[KWK
M7NK[M^KWW[Z^T$:?I#7MKO8NA8!>G()^GTSBO!I+33=9N+J/6T&/F5=P&>I
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M7D9?9L!W\;OE'//J,_TS7QKXZ^)6LWFZ*SFD@"<?(Q&<9';L>]>-/KNJW/\
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MS66(Y,/1_<87 QE?VK5ES3L^J6_F?N_X:U71O$ZB_P!.EBE7^+80<'\#^/\
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M2(RA]SY7(QG(;T/![#O7R/XG\>^*O$5T^HW>J73S[VD56DDR#G(QD^O)XY_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!)+ZTC<02>7%N168X;A1GJ?\/K7PC\*_ &N^(_$\[V%M<+9I>!EEVML*A_O
M]@1_]:J'Q2\.?%G7O$6E2037 TV6[3[2JR.$,32#(.#C&W/4=_2OU?\ @WX6
M\.>%O VE2SQ6D=^;*(W4C-&K&41@N23SDGKG^M>Q*M#)L!"U95YXQM>S2<N1
MZ*S7?LSXK!8#_7//G/%4)9;A\K?/[23Y77U3LGY_T]R7Q9;IX1^#MS!<S!)X
M=/).\D'(C/?/7KSZ=?;\8-"^)EK<^+M1M=2F62U;4&CV[@?E:3';KU[<<=Q7
MW5^W#\9X]%\(-I.AW8DDN(FA=8I V,J5/"D'N1SBOQE^%G_$[\?06^H7+1B]
MO(Y7W,0 6?/))Z\]*]CA;+)3R[&XBM'E5Y5$]FMGIW;W_K7Y7Q.XDIT^)LGR
M;+Y*K3PWLJ5;W_=DY<JC&<O/:S_X?]B(/V>K3Q_H^GZUX;8*LJH[A><;@,Y_
M'/YUR7C;]C+Q&]A)J$&7$$+,549)VJ<C'7/'M[5]F?#7Q#X-^&?@S3EU+6($
M1H(2H,\?&4![GW[]_;%>D6'QR^'.H,UI_:UO,DP*;3.A#!\<?>[^_KQBOF%F
MN;X>I.>&IU:N&IUGR5)1<ER1DN:VENUG?;\?TF/"/".8X2G',*V'PV.K8>$I
M4UB(>Y4E%--1OK=^7W;G\^-[\,M33Q'/X=O-,NMT<IC,GE-M^]M[CW/Y>G%?
M7G[//[.>J^%O$\7B)(9UMF4.R@-L*=<8Z8YY]_>OT@\0^%?A->W)UM%TU9YC
MYGF!X<Y8YS_@?7-=IH/B#X?:/IWDI<V8*IM4>;%CV'!!_P \UZ&.XMQ.)P[P
MU/#UHQG%1FO9O66E_N?Y]KL\')?##*L!F4<;BLTH5'0K>TH3C5BO<3TC)7N[
M>:ZV/A7XW_"O3?&=Y$MG;I:WZE 6*!2[ CH>,\FM3X(_ G7-+U6./5(?,M1M
MV%DR-O'Z<=N #FL_]I3XI1:)KECJ&@M']GAD1I6B8'*AAR=IYZ=3]:]N^#7[
M47PZN]%MI=:OH8+](E1][HI+ #.22.<Y.1Z9S4REF<<GHQITIU:,KRA%)N46
M[;JU[?ATZ'5@\+PI6XMQ;Q&*H8>O2Y7S3J1C1K*-M4W9/97?^1[=XD^&%E)X
M2U*RMK=!=21.L7R#()3  .!CGT']37P3IO[+'C74-3O)6DE6%YI&3(. &8XZ
MYSU/M^5?=][^T=\,9ONZO;%#C_ELG0?C_P#J]^*IZ3^T/\-KN^_L^PU6W^T2
MD+&%FC^\3A>0?4\^WOS7C8?%9Q@Z$G]6JQ4Y^][2+22LNZZ+\C[+.,MX-SC$
M898C,,)"E2M3BJ&)@G.6EKI>=EK:_J?E9\5O"7B#X,ZO%;WER6CG=58%O4X'
MX]/\*M:1X)O/B%IHO[>&218T#NR D=,G) []OQ["O0OVU_#GC+Q9K.GW>C0/
M=V,TL3+)%F0;2P(Y4'J/_K"OJC]D[P!=:7X'\O7++#W%N$)E0KRR 'J,YY[&
MOIJF:*AE%#%N5-XAZ2BM);KI=/3M]W0_+\!P[+,N+\QR&%*O2RJA[]&I4IMT
MY0M=-5-5*[U].W3\\K_PGKND)*^B6DYDLR5EV*Q/RG!Z ^G;C-6]-\6[+,QZ
MY)Y%X@*LDK888]0??Z<?7)_6ZR^&&@Z=<:BTME!.MXSX!56QNSVQR<'C!/X"
MOE3XE_L@KXEO[O5]/<VB.&>.)/E&3SP!QUYXQS6%'B#!8API8N:AK']Y9)JZ
M6GRW_4]#,_#_ #?+:<L5EK>(G*<XU,)%>ZHP^"44MFTE^N[/D+PAX_TG_A+K
M6RO;F#[))*BEF<;1N)R>?8^YZ9]#^I_PZ\ ^#9[>VU^PNK9C(B/\C+P< ],X
M/^>G&/S6M_V.-9L;JXU+4;QK6"U+2K,S[/\ 5Y(Y..WY^U<0?CQXQ^&.HZAX
M:TF^GOK>P1U0AW<9C..,$^G\\"NC'X&GFL?9Y9BM;14G>Z6BZ[+KYMZ=3R^'
M\XQ'"<JN(XJRU*%6K_LZD[235K<L=7JNO>WH?O%;ZYHMDR6+7=JK!=NTE=Q[
M#OSV_P ]>*\4>,?!G@".?Q!>WUD&16D*;TR0 6 Z@Y]\9SQCM7YH?!;QGX\^
M*5CJ'B6>:[26T21UC_> ' .,9X]!^=?$7QY^)GQ0U'Q1J6C:G<WEOIL#2( 3
M(%95.".3SQ^G6O&P?"CQ.+J86>(LZ-O:V=I3O:[6NJ=EHOTT^USOQ3IY=DU+
M,:.5SG]8O]3G/X8-6Y6]M-G^NY[K^T]^UK%XI\7Q2>%F*1VET S1,0"%?GIQ
MTZ>OY5]??LY_MB>%-:\.V'AOQ5+;)/&$C=[EE/8+D[@?\?Y#\%;O6+:.1]Q$
MMQD[B>6+$]SCW_SS7,:MXFU[387FTB6:UF*Y1XBX.X@\C:1]1T]>W/WE;A+
MXO 4,)R>Q]A)*%3:3V7-ZOST/Y\PWBYGF5YYBL\J5_K3Q?NXG I/V3CS)J,5
MJKI:?(_JVUSX\_#+PKIS7UEJ6G/&4:79#)&,\;L$+W_+/3N*\,C_ &_? "W,
MT+1Q'R"5#\<[25R/K[<]Z_ _X8W_ (Z\66LD>MZQ>O .=LDLF-H_WCC'T&.O
M;BNZ;08OM4L5M(9)(2?-/))())SW)/7T_KXG^I67T:DZ5?%3J2C&_-=N/+I9
M,^ZEXW\28JC2Q67Y?0P="IHJ=2*<Y227-RK1KO?_ "/TP_:+_:1\(_%[PDUE
MID""Y((#@<G/ YX['_.,U^<T,4.F!'EED3YB3ABH[^_O^5=7X8TQ9PUN5PP
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M52$K2C3:M[T':RZ%?PG]CUV>'SDVR-(%0$8[G'7MGTJ7Q]9:SH>J6L(W?89
M,8X&#C\\@G\_:LWPW<I!JEJ(UV+%(K?+QGD9S@=/K[]N*^@/&MA:ZWX?AU+
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M;3^F?*]U:1SW#33!C,[9)/4$^_'U_P YKVGX7$6VJ6T"X'G.H],9( _+U_\
MK5PMUIR_:2S#;AAT_+VYSCZ\^E=9X<:2POK:>+.Z-E*].,<@<>Y_I7;BY?N9
M1Y8V35M'9_#IUZ'SV5TY87,,/4E)RDL0[M[R3L[]>]OT/7/B3I#6>I0$G<LL
M8;CT([XR?7KBO#]1B83-Y0(YRV ?RZC\J]D\4:K>:DD5S.I)CCPO'&!T(/\
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MC!Y_7T[\Y]_QS/"WAJRUC6_M-RH:*&3?DXP0#GCVX/;\/3S>]\0,ZLBRYW$
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M/D:D9QA*<XS47I%N+MS:=7_70[SPS<M/NWACU _/MQUKIKL@1D$E>O7^O/\
MGZ5S/A#"QNTHQM[D=/Z?7T_*M;4;A)MX4X XX([<G^58;U.9K3=NU^J6_P#G
MYKT]"E4<<+#J]--=+I:+U\K&1=.%4Y?/&/7\_P!1CZU6T[]_-LV[P1@C /&.
MAQ^'Y]\UC7]XD;;';C)[^XSW_P XY ZT:'X@L[*] F9?+8XR3T_'@^@Q6TXO
MD<E!/31V3VMMY[?F<,L1!5X*N^52DK7>CVLFNW3;0ZK6/"FFW=K(?*42L#SM
M'7ZC\2,?G7%Z5HJ:=.T0'R!NA^O/';I7?7^K13X>V<;&Y.#].V>X/^ -<_,P
M:3S$.3P>/SZ'GT__ %U-&=J2C>3M9J[;:OR]/7SN:8C"X.M5C.G&$91W44DI
M/W;7MY/3?\S;L(H8Y,,@93G/'7_'O^%<KXFL;5KDN(P$;.>,=_RS@\_2NGTZ
M>(.HD89X'/<Y_P#KFL;Q=/%&K."!GH1Z_P"3GK3]YSO>=M&[+?6/]>OH:5X4
MWAFO9P<8KEUCKNE=W6EOS]3Q'Q-X<A8![<99CDA>.<Y_KQ7(VGA>Y%S [ @;
M^1]2/T_SZUZ2+Y&8AFWY/0D'N?7Z\?Y%6H[F'S8S@ !L_A[?KW_PKUJ=>2AR
MVEHKZ^?ZVZ>>NA\C++L!5J2J<T4W)72VO>-DEV\K:/[SK=,T=;:WMG"_,L:Y
M]\CZ=?<__7KIX8HF8"4#'_UL?KW_  -9EOJ48M4 &1M'(Z_Y]_7VYJQ;>=*/
M-_Y9L>#[GO\ 7\>U>9*:E-W?,[WL_E]WY]SZFBJ$(4_9P^%122TC]GIMIY^?
MRZ"YL["YM&B95.5.>!SU'K[\_P!.WD>L?"^TU%;B>W3YP"V0.YY]/?\ G7?W
M%P85X8D')[\>G\O_ -52Z?JTD8=<%E?(.>G3GW]<?C3C4E!KEE)+:T=EJM^P
M8K X+&MO%T(2NN7F44I;)>O3U6Z/!=%T"?2KI[>9&,:O@9]B!_\ 7_ESS7K%
M@D:18P2 ,\9_+ID_T]^VCJ$5K*Y94 =_FSCWR?3W_K6;#LC9@#T[?E@?TZ_E
M6SK>U:OJE%:OK^'ZZ,\W#8:C@8SHT+*G*7,I2WBM-.K\ON[HP]3M3(^^#*29
MR".,8''/OC@=^G>H$UW5M.55>5F1#SD\$#'X5T)CEG;Y5.,^G3./0<5!JNG(
M(5$BX#CDD?Y_R*4I4(OEE:;=DFHWY7I_5]AJ%1*5:-24)1U6K4>FZ6E]V_+H
M/M_B; D/DS. V,$9YSS[<_AU^G6W;^,;&6171=S,3R!SGKZ?C^77I7BNL>&W
M:X\RW8[<\A0<<?3MQ@<5T/AS39$ECSDX(# _CG^O\^35O"X;V6FKWO:]MMW9
M_?;\CCPN:YE4KJE53Y>;W9KW5962\O-_CT/4+[7(;W'[O##'7/OG@^P_2OL+
M]F'XR:;X7=M#O)X;871V;Y"!C=A>?\\=A7Q^=-MRBN<!\ $#^OX?3Z9Z<OK6
MCZC#MN])GEAF1U<-$Q4_*2?][TQS7GXG#8/&8:6$D]962J;6U2T]+?TCZO+L
MXQ62XRGFD.:;H-<]."O*:]V^FC_JZML?T+^$#:W<ZZK:W*W<4H#AHR&7YL'M
MGU ''OCO2?$GP_H/B/3;@ZW+'% L;EO,('8_WL?Y'3M7P/\ LJ_M%:%X6T:/
M1_&U^?,A55+SR<@(%_O'GH?K^-97[4_[4N@:I&^F>"=1)67*N89>Q&.JGW_S
MW_/%DF8K-:="E3J^PA-<M>,?=:7+]K;[_P#-G[S4XXR"7"[S#$5\-.5>#<\!
M4J)8AU9)>[);K56O<^8/B_H^@:/XIN8-&ECEMEFDQY9!Y#=P._7]>W7B;&96
M"*#@<#KVY_S^//7%<):ZG/J4SW%Y<O/-(Y;,C%B22Q]3^'KQ^.E]N-LVT9W'
M\_Y@?YQ7Z/&"C3IT*M_:P5E/H_AZZ7O;\&O7^=JF8X;&8ROBZ-&.&H59K]U&
M7,EJGTV3^=]NAZ_IL2S<,0=O/;K_ "[?_7]8M5CC=3'R<9Y'UQ[_ .?2O/M+
M\8P63[+I]JD@$DXX(]>V,5=U/Q=IS$/;2J<CG#+WYZ\8_GC\JS^K5(SOR3E>
M2TWU[K?^OF="Q>"E!T_:QYE9N'-9I63][^NWD4YM-7S7*=>>.<CD]1V]_;IU
MQ4]O;R0R#G!!&,_Y&?7K_*J%EJJW5RN&!WG Z>OY=Q7275O)$$N7X0\D_@#_
M /7_  KJJ)\L%*/+;I;72V_]6Z(YJ?)+GG23LMVU>*OLD^GR\]-C4CNI)8Q%
M*V=H&"?7/'<?YSZUB:C9-(<@;L^X./?T[].:1KV,HOED9SZCK_G/O[5M::T<
MQ_>,I7H03[]L_P ^GM7+-:M6=M'IHOZO_5S>%7VR5/26NG7LOT5M=?Q.>%HX
MC1 ,9(SGK^'/_P!:M:QL7R55=V 3QD\#\,=?\BNO:RLV1"70#MT_Q_E6C8V]
MI#O<-&>,#..Y_P#U?IS2]NU;=)*UWTVU^[I^?3IHX&G&6KLGOT:V_KT:Z[^8
M7%HOG.LHVX;!'^<#-+#8_/B(Y4]AUX&.>V.O]:V]9M)%N99" $9LJ1@#'.,?
MET_E4VEPQH-[NA/'\6?Z_AZ4E=^]S-K=:V_X?9$>P=Y).+:O=*W-926K^5GT
MZ'1Z'IV_39U8?,5;]1C\N.,5Y[>6'EW#H1CYVZY]<Y[9[^_([5ZU:ZCI]I92
MR/-&,*2<,,]/?WZ9]J\LU#4[>YN7FA92F6QSZFLL.KU*C?,FW:]K:66E_P ?
M^"=6*4'1PJE*$N6UXIJ3T4>B\TNWXD$5E!D CYLCG_/3_/%=SH.GN&#9^3L.
MWMZ<_P"<YKA4N&<90<9!SUZ$?YZUWFAWZ+&BR.%!/&3M_#MSQ^M=%>K*,4X^
M\]K+?H_5_(RI/#QJIN,DWI%V:2E>*UTV_P""=C-$&B,9&>,8QWP/\:Y#4-&0
MJQ4<G)Q@'GW_ *U[!86-A-I4ETT\9<*2H#C)XZ=<].17"WJ*-SAE(R>-W]/R
M/IVSZ>=3K5/:V:D]=.UM-/R_SUT]W$85>QIU)U(2YXIIJ5[;>G]=[' 6&F*)
M-I3YMX(X/J/\./;VKTV^N(+?03;.!O\ *(&>O(QWY'3T[^IXY2WD1+R-3@98
M9[=3_P#K_P#K5O\ B* &SB=2<%1GTZ_4?B.M;U&YU*3:?*I*VFC^'??>S^_3
M4YL,O80Q#MS<\>72-TEW7=O>_38\0,$GVB<OT9\C.??VST^O'I3)K(M&S1 9
MVDG _P ]_P#Z]=PUI:GG*Y'#=.N/_K< <9_&FV]I H?G*N,*/YXQZ_YYKJ=>
MS:L]+*RV2:C=?UY7/$^K*3:=F]=5KUOVWO\ @M]&)X MDF=XG^5U#>F21TQ_
MD9SWJWK \O4)H5.-IQVQW/Z=,=,UK>&M--M<F:(D @G@]L8]/P_R:;J5M#+?
MR$G]XYY_/ S^/.?Y<XXXNV)G)*RZ7Z:+3?OUZ>AZ$*/)@*:<W&2EVL];66VO
MY;' W<'[S+?,3^)']/TK1\,VDT>I1R(F &ZXZ]?\_A6S/I*Q.)&.?P[]O?IZ
MXKHM$MRMS%L08R.P_'GIGW_45K4K)TY)VC?[GM:WW+8SI8>7MX/;5;[]/N_X
M)A>-K59G1G7]X%].>0>W^1ZUYQ'8N58D';GCCTZ?B/\ &O5_&C@3KNP&QP/I
MZ_D?\>E<C !+$0H'49]L#_#G/4"JPM_8OFOS/5:[)6L_G9]=B,51BZ]6$>6_
M(F[+5RTN_77=KOVN7],<#3I($SNV8P!_^O\ QY%<9/:E9Y_,7 +<9Z$9S^@_
M'OZUZEHNFVXA:1F&2#QD=OKU_7I^-<SKMM"\K+& !GDCODXZ?Y[]:F*NY-<R
MU6M[-^?]>A-2C:G34FDDMF_32WGK:WWG+6FF1NI/RC(]1SV_K_\ 6I+:VETZ
MY,R8*YR0/7-:<,?DJ%#''U/^>PK3LH[>3+7#?+U_$=CS6NJ5O>MH_P 5^'<Y
ME2A=<EE4TL].7E=K>2>GX[6T(+N\6]@*R'!QC!X_3UYY]:X&ZLW:7;$"2Q&,
M<>V/>NVU*.$RC[,<KST/^>A''^<Y;RI!*FT;G_STY[>GUK>$5%:*W?IK;]'J
M16O4485):T]');/TEYZ;7_0DT31"K)),#N# \]>^.O?H?K7I=S?LNF&SQA=I
M&<=L>OO[=JY[3V>4H2N <=O;_P"O[?C6_K-JT5B9$&>.3WSCW&/7/]._+5DN
M=*_56ZZZ6T\CT<)3Y</46&C9<C<U]J3LKWTW[7[GA.N:<C2N8P<DG. ?TQ^O
MYUT/P\LYDU0"([6XXX'0U!.'GE*1J68DYXS_ )QWY&,UTWAV!]+O4N6 #Y48
MXYR?0=Q^7M73"3]G*\OLZ<W5:=]&_78\JAA;XNC6LH6FE)WLK77Q>JMYZ==3
M8\2V<L=ZS2=3U.._MT[\CU^M<PVGB8;R0>1QCK@9^N??I7H?BS+6\5TP_P!8
M /PQG^7J:XNUCEFD&P'!^O1O8>Y_^OVKEHM.G?F5^;79NRZW^?\ P3TL73A"
MM*Z3E>*C=?9ZM=/\C?T+348"!&"F7@].AZ9[]ZXCQIHC:;=XW;B_/X_RSSGK
MU[UWVGV]S#=P%,X!![\8ZY_/G'2LSQA:RW&H1O/G:%SD\=../?D?3IUYK7#U
M%"O%7W5]M[6O=^?GU["Q%&$L%-3[QC%K2*V;N_OO?M;8\=@LIC,K@,!T[8/8
M_C_4>U=9&-GD+@YWKS@8QQZCGTS6A%##'D8'0XQ]>,_X#ZCK6S864%R\6\@#
M?QGZ^_MT_"G6K)^T5KWDKQO>VW3?ITM_EPX2A)\L9N+LKI1:M&-ULNK^7FS7
MUG31=Z#'*,$I&.,9)^7/\\CVSZ9KS6PL#$K2[,$$@<9.<\=>GZ?TKW:_M(K;
M3 N]2NWIN']T<X_/Z\'UKAULA-&1"JX+G]2<8QCT_P :RPV(E"$^:\;M+SMI
MT?3]#T,;0BY4.6TWRI>[;FO9;V_#Y=SGM,\0^(-/OHQ8WLL*H5'RR$ #KT[>
MN,=?0\UU_BJ\UO7=/5M0NWGP@X+ENW89_#_Z]9X\/>6XE<@'.3[9QU_'\SV
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MBHQ#39"R/YQ 3G ;);CI_@.M?E5\9-?_ &;=6\,WNI6,6CC5+F-S"R&#S"[
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M],#U.?J>.M>$6^R'40B/M._C!P3^7OQZ=*]HA\/'5=(:>1QO5>#G.>/QY/\
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M4WHVD_\ @O7[CHA:M++&LS;DP._3KUSSR,?4<5L64:0W(6,; #][IT'7_/\
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M4XN/M;6=[>OR\G_D9RQ#PW)3BW=\O,VM;)).W_#^>YZ =1@F==X^5E![=_\
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MGO\ YR3SZ_A7JX>24+/W5:]O/2_R;5U\CYO,L/3KR3CTD[?*VZO;RV\_3G]
MB<R;=Q)SC/7&#]/?Z$5W7]C/=8(.6'OV^O\ GCZU0TRRAM9MJ#L>O_U^.<?S
MQVKLK>X2W&YNN"/;/;TKCKR?.I0V>U];VMTW_+T.W"82%.@G+>ZZ^?;TTW.-
MUKP9+<V,LL65DB3(.>O!R>/?G\Z^=[C4K_3KR6TG:0;) HW'CKUY_7\!Z5]I
MZ?>+?.;=UR),KTXYR.O^?6O+_B!\-%$K7D<8'F;GR![?3CD^W^/7AL7%R4)O
M6RWLKZ+2]OS^_4Y<YR:I5I?6<#-QJ1BG4Y;IR6FC].GY'->#KM[CRFWDOP<<
M]<_TKV6[BNKNS6'>>5_H/RXZ&OGGPR9M"U#;=AO*#';D' P>.:^AK#58[R*-
MH^FWCZ$=?\<^^*C%QO4E)646N^VB\]OON=&25KX>5"M)QE>,9-O=^ZO7<YV;
M1KR"+Y7)8]N>OY8_( ?6N+OM3UG29#S)M!..3SC)^OKQ]*]?N[@1[7? !.1^
M( Y_SU]JYK5H(-0C)*)T!''7_P#5]:Y858QDH25X75Y+7MIM;;K]YVXO!M0:
MH5W2ENI1WL[=-/+_ (>QQ&F^,-3U"583*P ..I]0.,?0_7O7H$$NL+Y3+,Y0
MGGDX(_#V_P  17G']F-I\XFB7HV> ?7G_(__ %>F:'K$+0JEP!\H'4=^<^G]
M?3D5>)E2>D*7NV2B^FR[]4<N!EB8S]GB*[FX/>[O-.UGOWO?IZ7.@O[#4-3L
MHPDK!]N?QZ8)QGU'<GBO,)O^$@TV]>V,DC(,XY/3V_3V':O;-.U"VG*B)E '
M7GCGVZ#_ /765K:V_G^:%0L>X /OWSW_ ,^O'1KM:2IJU[7W22MUZ=O6QZN(
MH>U@JE&K[.JU:6MKK35=KZNW]+P/5=5\01R-#YD@1^",L1_^OMV]ZS;#Q+-:
MW MKH,F3]YLC/U[^^/KWS7L<^GVEW,DCJHP 3@#ZY_F/RQ7->,O">G/8+=6P
M"S*!RH[CCL!Z#!KTJ56A/W9047:S:MIMIM^/IUU/!K8''4U+$T<1*;I>]*+V
M>J5M?S6W;:_1Z#K%G<1*IPQ(P.GZ<>OOTJ]JZW9A!M&9#U&..A[8 _'V_*O+
MO"L4\,T:R$@*,#W//]/KFO9%E5H0C8Z?TX]^N/IW/ISU*48.3C%33:O9ZI.W
MX?\ !/5PDY8C#2E-\DK>EI>[MYZ_GJM3F[/Q#XDL8")+B0P(""-QQQ[ XSQC
M^7I7-CXJ20WYM[F7"!B#DX]OT^G'6O48;2TGLI_/0;<,2?S)YS^'_P!<5\S^
M-O#UNUS,]B<-DD8SGN?Z?7!Z\BG@WAZLG3G#DDW9273;7\K+_ASAS>MF&!PM
M.I3K2K034N5/1+3W4NKZZ=F>]VOC6SU"6$VDBO*2#A3GTZ>^?\CK7H=_K\DV
ME11&(EPH!;'/3_ZWY?2OA?P-?7>C^(85O&D:W#J#NSC&>1U_SFOLC^WK"YMH
MS&%P57';DC\_\X]*6,P<J52'*^>',F]E9>Z[>>ZWN;Y)G-;-,/*53FHN'N\C
MT;22UMY_/3;J8+:QY)9)<Y)SCTZ=/3Z]N<X)YM0:S;D;C,HQU&>W7W&./3UK
M,U?3&OHWN+3LIZ=,X)^GX=<=>*\$UJ;7M,NI%;S/*)(XSCN>GT_/GUK6EA55
M?NZMVNKVM9+7]?QZZZXK,:F7J,XT>>+=G/?FVU]>J_R/L/2_$EC';>:LZ\<$
M9'KCCGWZ?3\:AOXKVX\Y&&#SGKG!S_4&OD6SU[41$ LLGWN02P_B^O7C'!_*
MO7?"MY?W4 W,V0.O/<__ &/-95,MC&\I5+6Z+7MI_7_#&#SZ6/G[+D?+3L]5
MUTTOW36WX]O8+N_AA7=)*K;>V<],=CW]!^?>LNU\810W<<:N%^;J<<<X&>O_
M -?IQ6')I-W,#)([$<X&?H?7W_3KFN+U_2;VSM9KN'>2@)& <Y&#GI^OZ#I7
M)[&FW&,I+E;MK:]M+;]_ZU.VOC,13C]8IP<N2S:]+7MMI9>CTM8]6\2WL%["
M+D3AGP. 0??/Y=?\:Y'3M9B5A$>.?F.1UZ<Y]N?QKY:NOB;J%G<-;7)FV*[)
M\V<8''<\=,=./PQ7I/AG6AK$2O$XWO@]1QQ^/Y>U>P\N5*DI6DN>-UVM9:7V
M_K30\>EQ!1Q>,E"G[E5))J7NW;LM/EVT/H4ZO'8V[3B<;"O"Y[_GQT/X8K@;
MSQ0DTKE&#9/K[@^OMGD=?>K-IHUU?VYC>1L=@>V>W?GN.*SHO!-T9I-I./Q'
M'(_SP?YUPT525U-6:U6^EM?3>_K<]#%5L14Y%",G:UWZV5_R_P""5X?%4"3%
M9W"*>Y( ZXSSZ9]^U2W'C32;4$F[CV_[W/7\L$9[?CWKB_%WA>YMP>64\\KZ
M_D.>_J/6O%=6\*ZM-$[0SS$?> RW/!'3VXSU_'.:]+#X'#8B'M'5<6W:TO5?
M-WV6WH?.YEFN/P*2AAG+W5+FUN[V=M-/7KZW/K"/Q%I-[:B:VN49SCY592>O
M^&/\BI8WCN )UPQ !/0DG )QWKY$\"VFNV.I21ZA).;="2N[=C@__6_D.U?2
MFBWK2QLD.3MR#GM^..OX<]ZXL7@XT6U3K.3OY\O32_3MKY=K&^4YW5S"%J^'
M=*6R=FF]KO\ X?Y]ST+2-;@CNHHI9 OS 'D#'X''_P"KZ<=UK>N:8D$<7VA"
M&4%ER,<C/.#R0>*\$2W>2\#9=6SD@<8QUQ^(-2>)--N8=-:_6:5MB$XW'J!Q
M[]_H*X_9TYSI1U^**E+9INVKZW_#KN>[_:&(P]&LZ5--1@^9]>56YFMMT=>V
ML:':RNPN(O,8MM&1D9R>_?IVXIL6M13NLBR@C> ,'K@C'Z_3\J^0#J5W-J39
MFF'SD8).#SSU/L..XZ>M>M>'VOY_+5'<XP1G)X'/3\,_6O2K8!4H.2G=N*23
MTO>VOWWZ?@?/9=Q%/%5YTXT&E&HG)-=+K:UM-?\ /N?3/B&Z$FCVTDDP"X!'
M.> ,#_//TSFN,L?$%G:OAIERJGTZ]?\ /;CZ8QVCU?5;3[*Y<I$HQC/& .A[
MUY]JNBZA;!F#2;L^_3GM^)Z=JX\)0IM2C+W;/37?;YVWOJM3W,RS"MI7IT'*
M$()ZJVNFVGXZ_F>S6_Q TV"Z'FS(@4G!R.<?EZ_EUQBN*\7_ !/T^XODBBN$
MQP,@J.I Q]>.O&?:O#[_ $G4KMU,<SJ5)#8)'IGTYXQ_GGRWQ#I&KVM^DCO,
MR!AD\],^O.>,\GM^0]?#9=AJCM*7O)/E>U]NOE]RWUZ?*YCQ/F*P:C'"ODE4
MCM=M;7\_6WYGUU9:Y!=HCB<'//#9YQQQS]<ULS:U<6L2FW5F.>HR?7GC/X__
M %Z\.\&%)8K97E.X;=P)SZ<8^O?_ .M7T):6<<MEMC4.P0CIDYZC\??VY]*\
MZOAZ=*I)MZ-\M_NWLU?7KKU/;RS%5\?AE)+V,W!-=]%&_P!_^7F0/K^JS6#3
M.6>-%)89)QQWZ^OT]^N.53XCIIYQ,X3#D8)QT/OGZC_.>_\ #ELTBW=I=H/+
M?<!N' _/GG^F.G%>9>-/ -G<O((&(;YF!7U.>P_#T%88?V%2JZ=2/73?7;]=
M.NW7<Z,8L;A\'#$8:7/73Y5KU27GOI^%CJ+?XIVFH 1)(K,W=<9Y)]B?UXS^
M=NX\07CPYBW%6&?7Z'_Z]?*\^CZEX<N?-7S&C1@ ,'L<CK^?XYY[^N^$_%)O
MX4AE4;N%.X=L\\=/IQS7?/!4X6G2:<8V;?3II\GY(\C 9Y7Q'M,/C7.EB-H\
MRWE=+=];7UU[FU->7CRM,%)<G.3U'(XZ\\^V??O7G_B3QEJVGAMXD"A2<G/3
M'N/\./6O>8$TY8"[JA<C/;KCYL?4]OZ<5YUXNT[2M1A>-E0$AES@#\/I^(]J
M="I"-2,94U9NW7=-?"_/\/SZL?AL53PDG0Q4N>I'F?6^B]V]]];=^QR/@/XI
M117?F7K;\=<GIW/7IV_KP,5Z7+XZLO$%Y(D<BJ,   ]B/\X]>O;->&Z1\/@U
M^6MI!Y#MSSZ\CI[]?\36_J'@/6?#%S%J*[S;2L""N2,$]_P_^OUK?$4<#.M)
MQ2A4Y;R;W:T]WS=_P/$R_&9U2PG)5A*=.%1NI)7D^337K_5[7UOZ=.51#(@S
MWXSSU&1[=_\ Z]9USXHCTF+S';;M )&<9QS_ (?_ %ZMZ=/%+9HLQVN5&0>.
M<=?>L35?#L&K12IOQP<=!],^OKQR.?6N.C3BZT5-63M9]+7UU\]=/^ >S4>(
MJ4E7PS:J2BI<NN_Z/\KD<?Q1M;\-;F[6,C@#=@\9Z<]>/_9:SI/$<E[*42X\
MP*<C:WX ^V,=,?R&>#3X6/+>LT4SAB_ 4G&<]NGY]1[5JZQX2U3PK!%,N]U<
M#)Y/YY^H]Z])T<%SJ%.:YNJM97M'Y;?=VV/!EC<XJ*HL32E*-/6ZN_<5EMWV
MT9W4&J:G)%Y4+L2>,CL>?ISTQ@=N*T[+0]3O-TTN\\%LG)_+UX_SZ\9X1UD-
M(J38+YY#CG'Y\]B>_K7T/X;N%NQY2HO(] <\?3_/YUYM>L\+*48TKQORRETL
M[:^MO/<][*'_ &E%*I4TA&R5^UM&NC/!]:T>:=FMHU/FX/(Z\\?3VZ_X'QK6
MO"M[;W&"K[RV>IP<,>OKTS[=>#7U[XHCM-%N6G<+N8$@>_'4<_3\\\BO*]0U
M&SO9&E*KD$L.G./ISWZ_SK?"5ZB5X1NHN\;:VV_%W^75G%FN585S;G4C"I%/
MEN^VGWM?Y'@$]AJ-BT)\N3:A#'KZC\NG<=Z^@/"E[%JMA LY^>!5&T]<@#I_
MB!Q68WV.X3$J)S\H(&.O0X.,_I@UWGAOPE&;&2XLY%R03@'ZD8'8\< >V3Z;
MXO%*5!RG2Y9N2U5[ZN*./)L!5P]67LZBG"I><H-V;T5WZ]?-^6I;8PE%4*"<
M_P"'Y?X?3%$FGI(F[ P>X]^,>V/Z'MTRY9FLG:*8C>K?Y_STJM-XA$,+)G'7
M!_/I^78UPQ]H^65--ZK1?A?M\_\ ,]SVM&G->UM*,=[[*]OD]?\ AM3D/B!X
M>M(M/^T1;2[ G@<\CT'X?A7C.@QR6FIQNIV*".<D#/Z'L/K7M&O7(U&Q^5]Q
M R1GMCH!D]\\X'M7!V-C#,WRX$BGGH#QTYZ]OIZ<\U[.'JSEAIJI"W3O;;2^
M^VB_!GQ^848RS&-3#J&OO)IZVT>G2^ZV/;+*>9[2*17Y55)_3_/3C]!O'5GF
MLO*<]!C)_I[CK_*N.T.["P);-R>A]>@^F?R[=JZ-K5F!48"D9STYQ]/?KQZ9
MS7CU8RA%RY?=N]M];6[^GD[GUV JXBO3;C.2Y8*%V[)M))ZN_P#7X\]>ZZD.
M(B> >3G& #S_ /KI\6J0SIF.4!NO49&..V>>GL3GZUR7BVTEL@" V9/N[0><
MGU'^?;%<7$-4M561O,"D\9S[XQGFNBGAU5C%W3;4;=7K:R^[3IJ[GCULQQ%"
ML\/_ !)OK'51O;=][?+YV/6%U[[)?P%B&VL 3UR/7O\ S[9->W+JUC?:9'+\
MOF"/K\N>G'^?7H.E?(PN;B:2)V#9!&3^7UR?;TKT_3]5GCM44;]H '3CL#_G
M_'C'$8:,>6^G1VWU^[7RMZJRN=N4YE*G*LIM\THZVOIM^MCIM8O!AQ'Q][H<
M?G^5>3:SJ]Q"ZB,-D./7GGKTQT^E>AND]]%N@@EE;OL4MCKG..G;^E<9>Z7<
MR3JAMW#E@ I4@Y!(Z8[^V!6N'A1IODG:3C&]F[;V:TWO:^_^1CF<\1-PJTHU
M(1E-*,U'1O39[-[K39['01>*+[^RHD=ROR8R2>/E'?'/7_/2O)]2U.6>]W-+
MO^<\Y]?\_P"/M[S;?#/Q)J>B->+IUU]GCCW%Q"VW&/7&.@&..>U>4OX0>.:8
M2JRR(Y!5\@@KG Q586MAG*HZ7LU*+:G9IVV336_EZ66ESGS;#YI4C1^L4:T8
MU(1E3E.,H*2M'7:S?5:_Y%C3)!+ ,G)P._/'Y?3BMZ\MUU33_LBMA@#]?3@_
MS_0UFZ3IWV9VB=3DMA>.Y/05[SX,^"7BKQ-!<:GIT$DEM'$9"0I(V@'G=@_I
M^=7B,11I1C.52$(MJ/.W97=DM]WV.G+<NQ>/I0PN&HSJSDK2C%7=E'5\JZ))
M_=N<%^SAILUC\9= C&647=MQUY$@&?7\S_2O[0_A;D>!="R""+.+@_\ 7*,^
ME?RA?LW^$K"Q^.&E6>K;4N;>]B5@_!RLFT\'GGZ5_6SX-@@M_#6D16V#$MG#
MMQT_U:_X5^,>)^+C6Q."I1BU[.G\5M))K=?+;]#^P/HR934RW Y_*52#C/$I
M*DK<U)Q:34K:IIIZ,Z;-&:0C(Q0!@8K\I/ZK%HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH _./_@II)-%\ ;Z6W=XYHVG970E2,*F.1[U_(G>_$+Q
M67>UGU&X:*)G5%,SD##$#@GIQ_C7]>G_  4LB,OP"U #KF<?^.(:_CKUFT\N
MZG+#'[R3IP/O'M^6>O6OZ#\*J<*F45_:0ISY<3+EYZ<9.+:6J;3^7XG\ _2E
MK8BEQCA(T*U6E[7*J,9^RJRAIINEIW9^AG[ GCCQ5XN^(T?A75[PW.BRS+%)
M;R'>I1C@C#9ZXX]?K7Z5_M&?LK:->>+-&N_"FF"W-QM>Z>&, $D9;.T?6OPD
M_9X^)U_\(O&EGXBM00GVI#*PX^7<,_3C/Z\\U_0;X;_;C^$^N>#(-2U>YMSK
M=O:D$22+N$@CP.K9^]QT]<#!JN+,+FN$SFGC\OP\I494O93HT$_9RFTE[24$
M[7UU_P R?";,^%\UX,Q&0\48Z@L90K^WI5\;.+E&C!\RA3G*\KK9).U_(_'C
M]H[X:#X8>*%N)F!91N:+CM@G(_3GOQ@=_&H?'&E:A%# +=5< +RO4_ET_D/6
MNL_:J^--O\3_ !S>7>GR[[/S9!&%;*[ >.G8@8_7'>OF73?.EN(C "7#+@?C
M^!]/P%?89=@L14RS"3Q<G2Q$8N;BOABFMO7^NI^(<29O@J7$N94,C4:V7>W5
M-5-'SV:5U^C[?<_H1=$M+M1<QQC>^"  ,_X@X/\ 3O74^'O"=];S?;U@=HD7
MTXP.?\XZD?A4>E6S:=X>AOKK[Y0-CU].#W]O_P!==)X8^*5I;NVGWD:>2?D+
M,!P&X]?\X&.N:Y\5]9C2:I<]1IM3W?NZ):^FFOR\_=P>'R^$J-:O.-&I4C&:
M5U'WFDTVK=/ZN>.^-==EEU^VM60K&LJJPQC&.#T[<?YS7TY826"^!D>UP\P@
M7<!@D$+Z#OS^N*Y74_!&C>*OM6KV/EED0RC;VXSQU]^_X5QF@^(H])EN-'GE
MW1QN8]K-P,':.O'3_(YPKK$8>,*2?M*#A.I%]-$[+O?5O3O8UPZKY3CL4\3R
M2HYA"U&JVOA5N][/^6^_XGEWC:229?F.QBS97H0,\=>,].N#61I%]/;V_E++
MA6[ ].,]R,<]_P#(]-USPXOB2>7[ 06;( 3G!/TR/3/^<\A#X UZSF-L89))
M68X55+'OV Z?05Z,94I4E&I*,'R\S4[1<597]$K]^G6Q\OB,%CUC)U\-2G6C
M-MQE33E;;W='OTMY=[&[I=XZE-S9W=L_7)Z^O4^M=?JM_$FD8\W:V"2,X.?K
MG^1_*N,&D7^D%1?P20XY D4ID]>X'I^?K7FOBWQ-<?;%LH6<(>,#('T'KGGG
M^O-<_P!6IUJE-TY1GR^_=:K=??U=M]$=U;'U,%@YO%QE"HURNFURSU2WC???
M^E8[*Q\520W'E[_E0D9SD$9/J>N*?KGB.WU I!O4N2!M&,^GL>_&?UKR827*
MQ,_S;B,\#D^G^!S7)VUW?-K WNQ7?P"3T[>H]O\ #FN^GA5*I*JE9PA:[VT2
M_P"#UZ;'S]3/,1"C3H-RC3JR4>5)_"VM>^FFK_37VG4[9OLJ2;SM49QG.![>
MV>W?'X5G1++]EDD1^=I!'YY/^1VK?L+674;-5DS]T8 SZ<]N3S^OM3#9):HT
M0Y8@[A^AS],_D>:E2C'W+MRBTWZ*W=?T_(Z'0:M42]VI3T[=/GTU_ \-U*!V
MNY68'D\]>>N.WI_]>A2RQ^6..O!]<8'^(KT&ZTA)9F?:,Y);Z_A^A/3VYK'U
M#2/+B\P#WXX[=.G_ -:O4I5Z<N6*=FHV5^^GZ_U8^<J8:K"K4JM*4&G%6W5[
M6=O^!W?33GK.\-HC@$[FSSP/0#'YY_\ U9JW8ZB9[N)96./,SR??W^F.V,5F
M26K[6(!&#QS_ ).?J/PZ54B22.17Z'</; X[9[C'Y4K4YRDN76*]Y]-;):Z:
M+2ZUMZG+"I7I\L;/EBU=O;=.ZOIHK?,Z_P 93I;_ &=XGP"@S@D9X'I^(]_Y
M>;7EP)4))W'!'Z?Y/>M'Q#>27'EHS9P!CUX&?SY]/I[<[&I==ISGGCIUSZ_C
M6E*DU3=I+KKON]-.EM/4Y,PQGUC$3;5DXI?-**M?_AS6TV:X@@+19Z^XZ\@_
ME^I_&NZ\/>)I;,MN^]SG)Y[\=N_MW[56T&WL5T]VN,;]IZX[?7VQ^'K7/)*B
M7LQ3&SD+CIZ>W%.7LZE-QE%NWE:STMK^7]7Z:,ZV'CAG3E;GAK'JM=?3;_A]
M3T(ZVUU?":4X0'.,]>0>?U'Y>E=):W\=RQ\ML =O0\^X]>@KQXWOWAG&-QSC
MT/K3-,\026UWY98["W/IR>OIV_'/>N:IA8N,+.UEIY[;_P!/L>A#,HT*E/GD
M[U+-/>VRT^]Z7=M;'JFO7DAM3"C' ]#]<G@GKGOZ#/3->1ZQ*T**S]B23^/4
M?IT_IQU]WK$5QA4(+E>>^3M^OMQZUQ>ON)(_FX//Y\_ET&#TZ\U>'IV7+-.V
ME^VEM_QZ6^9S9I5]M"<W45K+5/WOL[+YZ^I%::M<.AB#GRL'C)';GZ9'L.*W
MM%U=].D+Q9!/7DY.<Y^O8?U/%<#9S,K!>.OY=_Z?I79Z4L<TB;L<$Y_+_(]:
MWG"+4KK1VTVMMJ>-@\154H<LI2Y6N5MZWTV?=,]>T[QC-) J@[91GYO\"?3'
M&/\ ]726_B[4%389FY!YW9[=>G!QG_&O%[B\ALY55#C''7&>G;'UKJ]%NHKF
M!Y9& V@G!.,@<8Q^/;K7G3H4DDU!WD]='9[6_P"!Y].WU^"S+$N4N:K)-1M*
MS=EMY[=/DC4NO$UTM\SR2L<L2.3ZX[__ %Z[+P7J\>K^(;.*YY0,N23QQ]:\
M8U.]M6F)B.6!(/3G'!]..!R/YUL>$=6:SU.&92001C'X=<X]NGO2EA;4Y\K]
MYQ:ZM[+37M8K"YE4ACJ3G6=2E*M!S4I737-'6[NM.G;7S/L+XD>)K6&QATJ!
MQY:)T!P,[>..G;T/?\?GD>)+W2=0@U"V=D\MU/!([Y'YYY[\?E9\1ZK_ &A(
MD@<DA5[Y[G(_^L/\*YBY/GP*A +<=NN.W3/4#UKDPN$I4J"A-?'S<SMOM;?Y
M=V>_FF:5L3BVZ=11C1E#V;I[N$;.-VG_ ,!?(^J]9\5W?BCP7!<><6E6$ \\
M\+G^IY_3(X^>I-<N[..9&<[P6&<]^@YSVQ]>.*FB\33:5HGV-<M\O(Z@ ]NO
MMW%><RZI/>R29&%9SZ]__KGW]N^8PF%E25:,(I4DTU;?5J__  +ZD9OF\L1#
M#3E7D\4X\DFGZ+?96?E?\#N=/\?W-F2)&,F[(&<GK[?3ISZ5T#^-7N+1BXS(
M_*$]0.WX>G?'TKRK["JJDAP6SG'].P]S]*GDN&B"#'(8#'MQZ_3_ .MW/14P
M]*>L8J_+VT6VKTM^AY-#,L;2A/VN(DHI_:?33N]^R]=ST9_B(^@6>ZX)(E!
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MM9>C^[\>>KF5."Y)RU;C9?.+2MM_7W?:>@>++6;PO-IEZX$S(5CW$9QCCK[
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M4YP=JL4'<9((X'IGM_/KZ\K/?_:C]EE;.YARQR.3]>H].O'3H*F\47OENTB
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M*%*=2ZC'G>TGY:_-'QV/V93'\9[+PY)I3-I/F!9)#%E,9QGD8X(Z>_XCQ?\
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MWMQ^?Z_YP:]%2]7^SKB!3AV# >_7WX)Y^GYUY'J"S^8ZYPV3M.><D\<?B?\
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M(SV//;U_P]*\,FDD0*ZDD >Y_P \'ZGWQ7T9#X2USQ+;-;V]K/)"BY+)&Q
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.W3%<3?SK:WK>:>2!\I^ON<?J.3Q45OK4R3(",A"/R ZDY_/ KG?$%U]LO\
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MX62QU>>UE9=B2/M8].#Z].O_ -;BO:_A1\+9_B)XI@\-6NV1I_E&/FZX _\
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MX&U02/O8[#K_ "S7+1XNRV?UFAB*;IUZ.(]C&@]YQYK:*W6VIZN-\)N)Z-/
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M[>S?#?\ 9<USQ]#/J+Q2):JA9),?>[]>G^/TKV3]O+Q!X8\)-:V&B"V2\B9
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M>(;>RL[:0VS,-[A"5V@COCN.I_ ]:]+%8NEAZ4JV(DH0A%3OU=[/E2ZM]?\
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M\EKIJ?U^_$7P)\)?CJ;+6-5O[&[@@A@=]\D+=LG[W/ Q^5>#_%_Q+^SS\+?
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MT[:6[6?KUN?K3XA\*>#_ -H#PC;6NH?9WF>W1-SE"<E #R>3ZGZ<]*Y[P/\
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MZS=VR7,MU,%9< L[#CU'([=^G;UKX67#%!8OVOM5##.7/*@FN5R5FU]_2W_
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MC^G/?TK^G;X9A!X*T,1_=^R18_[]I7Y[X@XJ.+I955IZQ=#66EF[+MVU_P"
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MQ#[-Y?92O5/?_)S7\V">,[RX\37.KW<CJ[7TLL;(V "TF1^7/H0><5]+P_\
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MW\KIZ>9_-<>+<XP_%.(SJ&)J8?%YGBY\]2$G%KFE>$;)ZQY7;7R['Z9^*_\
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MB/XZ\?-<6!N/LTMSD-M;: 7Z_3'Y'L:^AOA%^QYX<\$I;:KX\FA\^!8I6-P
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M*IS67,TTE;7J-^+/B%;6YCTJWDR$CP54^@[_ )=>:\B\.:[J<NL6]E K?O)
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M*+4=;:MIOMH_F>C?#'PSI]UJ#//,H4$.5+ =!G'/Y]^_M75>.M0TG2IU@@9
M$8*<8^F3Q[_I[5X_X0CUJ"X>:-Y(8R><DKQDGKGL#^/KUKG?B%K2)<".:?\
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M(\KT73VA$MY?YGG(+;GR3GD]23[''I]>?*O$\']J7EP2ORQEL =!@YXQ]/\
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M']:\=U_66T[Q2\XN/WK7!888# WY^G8^GOCM]!IX?O\ XG>&!'8AKBZAA'"
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M*=2  =!0-V3D\=O\XKY8_3Q:*** "BBB@ HHHH **** "BBB@ HHHH ****
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M!-8\"?&Y=2M+<S:(UYOWA2T?E[SWQMQCKSTYK\POV9?CSKGPD\2Z=J5M>RK
MURKW2^80&7>I;(R!_P#7/<5_1I\/_P!N?X9^(/#-O=7]QI\5]%8YD9VC\PS*
MF6Y/)).?3-<G$D.(LDQN/J8-U<5ALPI^S<4G+V5TDW&W57T:TMN>UX=5?#GC
M+)LFEG3P^4YOD>)A5IUI.,95J=-J24N:W,K:>A\:_M_>"/#OA'PYIR0PPPW3
M11#*;=Q8*.H'/)Z?_7Q7Y"63.LFQE/EL 5.#R,9QS[8_/TS7VC^UO\?K?XT>
M+;C3[&7?IUA,PC9&W(55N.F1ZGK_ (5\G-/9;8HHE#,,1YZ\].WMC'Y5]!P]
M0Q6#RK"TL6W[5IU&Y7NN=)I3;ZK1(^!\1\=EV<\5XZMD[HK T*D:=*=.*2J.
MDTI-):-.77KZ'6^')XGL[NU7&^5"%[XZXY_^MZ^E>%^,M*\J>:.X7Y=[.#ST
MR2,&O>M.L4T*U^W3Y/G E,^C#H><=,?3ZUR6M06?B02Q *LV#M/?!_IGZ=>.
M*]?"594ZSJ)KDD[*V^ZTOMIY]/4^.S'#O$8.E3J./M87Y(?9DG9J_GIM;3T/
M._ /CR7P[./L<S6]U;-^X>,D-N!(7!'.<\CK] ,Y][G_ &L?BC):_P!DMK%\
M(MIC4^9)PO3^]SZ=QVKY:MO#<MEXGAM)(W;S)=JD9P<D8]/;Z]!7:^(M&N-,
MU2 2)LC*H<%<9'0YR!C_ #U'%=F)PV7UZL/;4859S7,IS2<HO1:/3\>GX>9E
M69Y_EV$Q-##8S$X"A3JJ$X8><HQE&25^:VFSMINF5_&GB;Q#XKE(U"^GNWN<
MY\QG8@GGN?PX[^_-8D'PNOC8"\:(XQY@;;@],_Y_G7H^G:3:7IBG("^4 >1Z
M<_Y_SCURPU"V>R>R?RM@B*@X'=2!]..>W3L#6=3%/"TU1PT.6G!\MXK=.U]E
MM>UV:1RN&8SK8C'U/:U*L5*E*<W*5TEJV]>;7H8?PU^'%MJ7@[5+FY4&6UBD
MVYQD%%/0GKSZ=N!VKS#P3J_V#Q=<:/(<1BX>(#CH'*@#H.W\^@KZ4\.ZQ;Z+
MX2UM48(728#) '*D5\(2^)EL_&RWD9^9[XEF&>AD]>,]1],YK#+EB,14QSES
M.-K4_5I/L];=CHS:6"RG#</SH)0KJ\*[35ZM/GM[RNOQ/L;Q3X.>0)>V:%ED
M4,<#.>_;/7Z>OL*\YT[P'J']L07TD;*HE4@#(Z-G'.#SC..?6OHG1O%6GZEX
M8M-J*TI@7<Q&>=@/]?4^W'%<Y#J<DDI(3$<3EL[<>_TZ9YZ<&N/#8FM&E7I2
M2E+G<==6UHNNS1]%B,OR^O/"5[R?/"%3W4KQFDI:/RW^XO\ B>ZGL=$B@!V.
ML(4#.#PO;W^@X/Y4O[.WAV[\:^([JSFDW1ERKHS<$9/J<8//Y=^:\"^)_P 1
MYO[0CL86^5?D.#Q[Y]^OX\>IJ;X0^-_&OAS4YM2\-PSW#9+R>2"<#KD[0>/7
M\NN:TE@Z_P#9]>"]G3G6]Z%2;M9Z:*]M-%N]_N.>AGN!GQ/@J=2&(KT*5H8B
MG2A?6-KIVL[VCV_.Q_0?X3\*:)\(_AIJ6M65O;)J(M9?F0IO)V'D;1G/X\C!
MK\3OBKXKO_%OCG5+Z[>0F6>78IR?^6G'?M_GV]<\+_M(>/\ XA:HGP\N6GCN
M;LBW:%BV[=(0/NG'.3C_ #FO<-1_8I\56.G2>+=4+^6T8N2"IX#+OYSTZGMT
MY^GRN HT\AQ-66:XB-7%XM7IM-.Z=K)7\FOZN?K&?8FMQOEV"PW"V#K_ -E9
M2G''T^1QC3JJ*4I3TWW>ORT/F7X<S7VDQ_:),^21T.>1]./\CG.#7K_A;3DO
M/$$>N3QB6")][Y (4 [L_AC\/SKRC5)GTG4'T&/ ,,K1$@=""1C_ ">W2OHK
MX4:%=W>G75G.I+7496,D'/S# QQP>>OMCTKKQDU3I3K*48<\;:V:Y)67D]F_
MFK]K?.Y1AZU5T<O@I2^IU5):<S52$D^5WZ7]=O4\H_:4^(&C^(=)30=-1//B
MB\H[ "0<8_,8/MV'0BBHO&OP%UG3]<EU&Y29[>61G 8$C!9F^@P.WT[YR5V9
M;7P6$PE*E3KRDFN9MR:]YM7TYO.YY>?9/FN;9G7Q.+IQIU%)4HQC35O9P<5!
MWMJ^]OS1\MZ[#?7T&R=#MQW'7CG'IT]:XO1K>YL-40VJEF+KDJ#GJ/H>G^<U
M[+KVL6,UN5C58R%)Z 9Z >_8_2KOPM\*#6M;CNG3S+97#'C(XYZ?Y_#G/K1K
M>PPDY5*<>6+=^C:NM%\ORZ'SM3+E7S2AAZ<G*K)I-?:2=GS/TW.ZT31;[4+"
M.:>W)W*"Q9?5>^1^(!.:S-2@O;"8VUC=O:EB5*QL5_D1Z>_;@BO?/%NM:7X4
MTLVT%NH?R@O P1\OT&#TQZ?G7RQ>^)6O[\RC@ER<>V?IT[>O:O'HSJ8R4ZD4
ME1>R>J>UK)W['T^-ITL#[+#RDY55RJ4HNTEHM'U6JV^[4Z>S\.-"&O\ 5)OM
M6<L3*2QZ9[D^^:^;OBOJ]I-=M9VR(JJ6!(X&!D'ZYQ].,=Z^B+[5;N?2F102
MH3&?^ CVZ>WO7R+XRL+M[^:X*.P+-QSWSVSGG]<\8KULL52.)49N*IVT2LE>
M\>E]'KY=TNA\IQ15E0P2I8:#J5*MI2E+5I:7WOMTO\]=Y? MY:+(;1\%W;IQ
MU[8_,=?Y5]S?"KXOZ_\ #26W%GYCVC,FY1G:$&%Z#@#'^-?$GPX\,/?:G'<.
MICPP/(QQG_/]??ZTN],CT^Q665@$$8SG.1C_ .M_AFEFT*5>I/#R2E&>\&M7
MI':Z_.Y7!M?,,!AHX[#U72J4IKE:;6FFCLDUVL]'H?H=%^USX?30Q=S1Q_VH
M(2<8&[<1V_'G\C7QY\4/VFO%OC1[BWM+BXMK7YU5D9E&WG'0^GI_6O-/!7PZ
MNOB)>,FEM(ZH3N5&8CCV&??KQC'>F?$+PJOP^26ROTVR^61\XP<_CG)[=<U\
MY@,JR>CB_9\G-73YN22O:[[:['Z)FO%7%>/RMUJV(>'P-E"52%X.H]/B:2<O
M5]]4?&WQ2UO4+^Z;[?=R7<KN#^\8MU/N3WZCC%:G@'39;^T0*@S'@].<@#IT
MZ?AG%<QXDB34;Z6=C\N[*]Q^I[>O/7O75?#^ZU""^2WMXV>)WV\#(P>GUZ #
MJ#R/2OO)J,,"X+W(Q2M%*RTMHDO(_#J3J5L[G4JR=7VDE9[S:=MWJ]9;M^O<
M_37]E[XP6W@N5-&UBY$,+E8L,V%(;Y>Y P?3^=?H%JOA/X5^/+9=9OK;3I?-
M0.TTGE%CN4,<DC/]>GO7XD7GAS4K=H=1CD>*3"RX5BI!&/0C&#_+&<]>OB^*
M7CVRTY=(M;VX$041K^\;'' 'KGGUXZU^>8_(XXG%+%X6JZ4I-*HXR:;VN].W
MZ>I^^\/<;2RO _V5F^64<90@E*A&K'GTLK12::7G;7\#]/-8^)/PD^#5A<1:
M&+*.]6-@GDF/._!QC: >H_I7X^?M._M&>)/B5JL]D+B:+3@[K'M9PA3)4#@]
M"/YUTM[X>USQ!;2ZEK%Y-(Y5GVM(Y/KCDGU_SQ7S)X[LXH+H1;.8WZXSGMGI
MZCBO:R3)L+@L2L1-O$8FZ<).\E%I+=OY^;[V/CN.>-,[S#!3P]"A#+,IFHPI
MX;#+DYX.2C:7+:^CNU9?J3_"NW_L_P 06&J3-MS<PL6/!^^ISGJ>W)[\@U_0
M)I=@GCGX%R6]J_F3G3@J ?,2?)Z#KGH..>O;.*_ GPU#)-%;^3&?W<D;;AGM
MC'3WZYQ].P_9/]ECXG6":';Z!J5W'&L:A"DC@9^7!X)Z$Y'^36'%\9UI4,:H
MRD\-4YFEKHG'W4>IX/U\+A*F8Y3BI*%',J3C&HW9.I4BKW;T?Q:[]#\CO&OA
M_P 1^%_&FHZ,;.X-Q/?2+$OE.0<N0/X?0C&/Y5]=? G]FGQIXSN+6^UZV>TT
M^0JP>52@*<'/( Z$#\>E?IUK7PI^#VN:K_PD^J&P6ZC)N!(PBP67G)SU_ GJ
M,9YKPKXS?M-^'OAUIY\/>$FM2T*&*-[<(""!M!W*,_YXZ&O-?$>)S7#4<+E^
M#Y<3[L)8B:_AI63M=6?Y?>K_ $5/P]RCAW&XG->(,RA7P$<1.MA\)"<7S\WO
M*+2?3:_WZGQA^UM\//"'PQTB."TN8'U,(58(ZEMWT'/7/0?F*^3/@YXA?3M3
ML;P DM)&P)/7YE(_G^';TKB?CK\1_$GC_P 1FYU2[DEBDN"8U9V*X)R.O^?U
MQI^";::P33[K83$AC8MCC 89'OD=O>OL,-@JV'R>4*]9XFO/WIRE_-)+W(K>
MVMEIOY;_ (IF6=X?->+<7B,EP?U' 82K3C1I])\DU^]6^_IW=M#]RKYF\7?!
M,S#/G16&[(ZC$9_'I_GI7X^ZMXDN=,U_4+*5?,\B9U(?V=@.#Q[]^.M?L5^S
M_=V'C#X7S:/'(GVB2Q,*IP6W%&7I^/3C'7/6ORE^/WP*\=Z!\2KBTTS3KNXA
MU6[)26*-RJ"23(Z C'.>V!7RG#U2E0Q>-PN*JQHQG5E9S:7NIIM;KNM-7YGZ
M[XC4\RQ62\/9[@J$\5[3#T,-45&+J)2M%>\H\W7J]=^YR]IXTU'4[B#2](M6
M:XG<1_NE+8W$#G'OR#_2NB^(GP,\26OAQ?%>K!H%,8EP^5/3=T;'KW_QK[;_
M &;?V6[?PE"GBOQVH0)$ETOVE0-IP'Q\^.>HSCK^=?./[;WQU2:]_P"$-\,3
M1'3XW$!2#:!MW%#D+QV_3IU%>A0S26+SE8+++SPU)KVM:UXNUN:S?Z;W/F<?
MP]1R;@[%9OQ14_>5TE@<)>U559*].3A=-)2=]5^)8_8A\-67B3Q!/',1+Y,A
M7:QST8<<Y],=/SQ72?M=ZA:^#?%EOI\<*(OF!=H"C(#8Z#'7L<>QK/\ ^"><
ML=OXAN!(X$TC;R"<'<V">N.^>_6NU_;J^#/B77]2;QE9^:;*T8R$+NQA,GMZ
M^PKCJXA0XI=.<_9TZD$H*6TI-):=-[^=NVQZ>$PF*GX3TL?@*?ML73KRJU'%
M<TXT8V;3NKV4=^]K:GQF_C+3(8_M#VB/)M##"9/7V]<GU_3GU7X2>%O$_P 5
M]<CM[*VFCTL$&0[6";!UYQ@#CU_"O-_V9? TWQ-\62Z'J>FS&&"7RC(R$K\K
M8ZD>WZ],9K]JO#?P^T#X&^"KS4[6"&WECM)LLR+G<8SQGKQG'/I^6_$.8QRV
MI'"8?7&5+>S?-S1O.VNAP<!\-XSBJ$<ZQ=Z.3X5REB8N/(YRI6<E?3FO;TZ'
MY!_M=?#_ ,-> +>QM+)HO[44)]I"%=^[Y2=W'KU],^G%>J?L2:E:7M_:V#H)
M5DB",& /WACW'/UKXQ_:1\;WGCOXB:G)+.9;<SRK& Q*C#\8 XZ$?0=#WKZ8
M_8;N%L?'%G8N,%M@&>?8?49P?S]Z];'82MA^&%'$/FQ*HNM*2::DZB5DO\/7
MMKU/!RC,<'BO%**P%-4< L33PRCRI*I[/W+[6DWIY6]#W3]L+PMH_AG48[^*
M*.%[D*QP IRP&3T_SGO7RIX5U/1M/DCO99U7 #?>&3T/'0]>?Z>OUY_P4&L]
M05+*6WMY9TV1'Y%)QD#T'3GJ*_-#P;X>\8^-->LM!L])O5BEDC1I51]NUB%.
M3CO[]1Z5SY'*G5R:%?%R2I1@U\2>RBM;NZT_"QZ'&]9X#C2OA,-@:E9XFI%8
M=0ISM"<FM?=3BM=7Y'TKXL\2WGBS2[FT\.++.8XV#;%+ 8&.H['D\5^</BJ\
M\4^'?% 2Z>9"UV-R?,, L<\'I@$YK^@/PQ\&?#'P7^%E[KOB.*/^T&LC*1.%
M+;C$6Z,3@YXZ>HQ7X7_$SQ'9>+/B/=75O$HLDU)X@%7"X\PX/ ZX/\LX->GP
MMC,)B<1CUA:5Z4*4HJJU>+=MM>NOX=-CY;Q,R7$95@\IQ.8YA*GFF(J4Y4J$
M':5*,G'E4DM?[KYK?J?HW\!-!@\:_#>\U-V,LUG:LSJW/W8\G/Y\=O;%?/NK
M:5I\FK7B!Q')'<2ILZ9VMZ8]1^'?K7WW^QMX$35_ .HVVF./]*M7#1CK\T?.
M!_GH*_/+X]6]W\._B=J.E7"M$AN)26;('+GGGC'7_P"OV\O+\1[?-LPPBY8U
M:;YZ<=F]NEEU[?EM])GV#^I<'\,9QC,,JL:J5.K67-)\WN^_*R[:ZZ^IM:%%
M'IMXKF<JBL.C9) ]A^/7OQ7:>/;?5]9\,R2Z1%+)'%!EG"D\ 'DD?0?TS7 _
M!GP_K/Q2\66=CI\,EQ9F:,3% S*%W?-G ';/^/K^M'C[X=^#/A=\*+I+\6\=
M_+I9&V4*&\SR^>#SG/&."?Y9YGF*R[&X2$H>TK5JD%*,;2M=Q[;;KUOL:\,Y
M)B>(<FS/&TI^PRRG1J.-62<8N4(W7*WU=E_6_P"!GA"2]U3Q4NE74CY2Y1)5
M8D ?. ??U].*_:G2O@O:6_P<M]3ML._V-)) .< KN)X_'_.*_%>PNUL_B1JE
MY 0L$U_NA?\ AV^=QCMP#VZ>U?T9_ ^-/$_P#N8?-6>X&E[40$%@QB(P.^>/
M3&1UZUOQE7K48Y7B:5J=.=6ESJ*MRJT=)6MT=NFQGX+X'"YA6XAR_$4_;U*5
M+$J"?VO9N34HWU=VEZGXQ>*_"NE2ZI<QP3A+F.4AU4C.X'!Z?4^I^IZ;/PXT
M6*PU=)+^?;%'(&4LP.[:<\9[GKQQSV[<A\2H-2\*^.]>344DM4-Y)Y9ERH8;
MSC:".?;'YU;^%UOK7Q(\8:=HVD.\J?:HTF\K)^7<-V<>W7N<?7'>W5GEJQ$Z
MB5"5)2<UR]EI??6RT^9\_0=.IGZP^&P2CC%F+PT:,FTY-344^31O:]_+>YZQ
M\4M2AOIH([9G-L@ 8X.U@ 1UR1C&.?YUQ?@#7K7P[K]GMF $]PH8 \?,P_(?
MU[5]R_'OX0>'? /PQ@NKC:NLFS+,&QO#B/ZY/(Z_RK\I_#&HF]U^*-V(>*Y8
M)\V,8D^4]1T KCRNM3S'!8M4X^Y#FC=JW_;R=M?/U/:XEHXKASB'!4L4HQKU
MYTY.,&_W?,H^ZU>ZMY[>ED?</QBT"\U.SL]>L6=XO*60E>0>"W;]?7-?.L?B
M>:*WDMIX_N;AEAUP2!@X..0>/Y8K](/#?@.;6O@U+J4R^>T-H64$;B%6//'^
M>.W'3\]-7CTG^U;C3W58YHY75@1@_*_?D9_B]/<US93BZ#5?"\G-.@W#W4WL
MT[O2^[_3R/1XJRRI@?J&.A-Q69TH57S:IMI*R>W7^KW/=/@M?P3P2S&((=I[
M#KCKV[YX_&N"^,OB=+#4G/FA<MP _)Y[_3C@FM7PMXLT/PIIDD >-9W1E3GD
ML>G?Z8Z=^U?*7Q>3Q?JVI-JHL[HZ6[%DE"OY>PMG.>F..#[_ $KIPN&]KCY3
MJM4X-63EHI/317UO_P -HSQ\US1X/A^%#"_OJ].5ZT::<N2]M9<J=EKU_-GT
M#\+O&IN-8CBFE(BE*QCGJ3D?7/W>W?/O7J/Q:\)>([#2W\06=DTEG*GF>9L)
MPN-V<_3!Z]1]!7R[\!K;^V?$FFVDC[<74 ;GH=R\?3C]:_:7XN^&+?3?@W;,
MZ1O$MDN\[025\H>W/Z\5Y^:UXY7F>"HKWH5ZB4EWUC:VVZM8^FX0P%;/^&,U
MQ>(:O@Z'M%?7EY5TZZZW_%'XE^$]9:77HY[I65XKD J1P,-T'T([_B:^Z[KQ
MS:GPO##@?)"!C(' 0#Z>QY],U\>9T);V[DMPD;QW+%F&!T8D].!GWYKHU\0_
MVLT.@:9FYN9QL1(R68'G& /QQT]^HKT\QHTL55ISA&5-4%&=1O11M;?8^1R7
M&5<MP^+A"K&I4QE27)!M.6LK*"BM>VBT^6AYGXO\2K=>(CY;!469B>?0\$XQ
M^/MCFOHSP.)?%GAY]+L,SW!B("KECG;Z?C_(8/6OE_XC^!]<\)SBZU.UGMS/
MEE:564?-D_Q?7Z>_8?:W["%E97^OVR7[K*LN,*^&SG '!S^7/Z5695J5/*UC
M:+C-86TTUKS<MG9V^[\]A\-T\7C>)HY)CE+#2QL[2C45FE.W*TG_ #)Z'S%X
MGBUWP=?SZ;J5O)&H9BH92.,XSSZ_K[FNX^%-Q%K,S&0?.& 7(SW&/P'M^'K7
MTM^VWX(A\/\ B/\ M-;;;9S(,%4 4@\YXP#Q_P#7S7R/\/-5M-#O8+D2*L3D
M%@3@<GG]!_7ZX8;%2Q^ ^NV=Z\.:T>CLNB_R_-G;F.6O(.):^78FHU0PU:R<
M^L;IIWUT_/H?5_B>6TAT,P2R")ECQR<=% [XZ^V,_A7R=%XE^RZ^+>RE\R=I
M5"E6)Y+^Q]^O\J]'^+_C&UU3P\QT*42WBP?-'$PW$XY!"G(/6OB+X>^)]1C\
M>6K:U;RPA+R(?O@PW#S!ZC_/(YZ5IEN7REAJ\OM-.23>K>EE9ZW^1Q\4<14J
M&;Y70H\TJ%:5.$:T8N25^5-MJZBUKO9+4_2?Q+I&L-X0M=0UF!_L\J*V]E)&
MTC.<G(&0>IP/:OFZZ;1[>5EA8,YS\O0#K@>Q_P X%?KGJGA;2?'/P"@N[2!#
M+;:>CGRUYRL(.<C)ZK^/Y5^/-TNF6>MZC9W!"RVUR\8#'GY7QWXZ?CZ8K@R/
M&.M/%4=.>A4G%IK1.Z[7W]-%8^IXLRB655\JJ1G'%TLSPBKNM/3V;45*T9/K
MJ[:]/-'1^ [.2Z\0QRF &)90=Q7 'S9ZX],$GU_&O1_C9XS?3M'33;:0@B/!
M*'(&!@C(^OK]/6N%LO'NC:'Y5I91I->RLH4( 7+%L<8'N/;^GT!>?L]ZUX_^
M'=QXWU /91) TZB4%,J%W<$X!]CSG&.M=&*G3I8K#XC'1E&"FH0I_P [DTM%
MO_P^M]#R<NPN*S#+\UPN4-SQ,:,ZM6<4[4HP5VW+9.RZM,^4/A5X\NH+K[.T
M[N)7((+$<$L/7G@C^7;->R>-?A]X@U+2/^$JM(':VVF1G5<^I.3T].?Y5\K:
M3;6^A^*)-+BN%,D4Q0R!@!E7(Z_@#_2OW(^"O@VU\5_!*YM9Q'=2_8'=2%#$
M'RL@9_/&*C/\6L!5P^(I1Y:53E3NK<J=OQV-^ \DJ<34<1E>+K.=?#4*\O:1
MEO.&RW;U:U7R1^'>LS7]H\;CS//C.,8/!S_CV-?0?P4>2.\_MO5W(V(&0.>X
MP1@-U[9__7GC_BQ+I?@7QEJ-AJUIY<4,TFPNN 1O*C&0/2K_ ,)KF_\ BIXG
ML/#?ARWDCM?M,0DDB#!3&77.2!_=[<^E>C6F\1EL<1*"E0C3YYU$U9Q23=WO
M96MUW/F,NI/"Y_\ 4H2<ZZQ3PRP]FYJ<9<D9);^=[?<C=^,_BN]\3W<D,<,B
MVT#;8WV, 0N,<].WK7GO@KQ#+H<Z)<G=!*XC()XQTQSP>,CKVS[U][?M2?#W
MPM\,/AYIT1CCCUMK6/SG8 .9#&<\]^?3\:_)>/Q,\D\,+R8!NP%Y.=NX=QZ<
M\_7ZU&3RI9C@.?#P:I1YHQOM>/5>5TMM==3NXTHXSAS.HTL?6C5KS5.;46N:
M,9\MHN-]XIV[Z7\C]M?A/\(O"WC7X7ZUKGV2"2\>WD=7*KNR8RPYQGL??'/K
M7YP?$#P3I]KJ&HZ9(429)Y54<#&"V,#&>/\ 'ZU^KO[)$^_X+:@(<SS/I\A"
M#YCS >W/^?<U^.?QZ\63Z5\3-4ANW^S%+JX)1R4X#G''H<>GYYKQL@K8JKFF
M:X=5)3C15HIN_+9K17Z:6NCZ_CJ&5X7A3AC,YT526)P<E5FHJ*<G*/Q-+?6Z
M;]#H?A1X?TOPSJ#WVI3)A"2FY@.[8QGZ^_3W%8'QFU2;4KUY[-)6LB-@95.S
M&."#TP,<5S?P]EUWXF>);+0-$AEN8YIHTDF@+,JJ6 ))48''&<YSWQ7Z>_&+
MX%^$/AU\#K:YUF&-=;:R21I)%&\OL!/)YSNS^([5ZF,Q5'+\PPO/^\Q&)G&$
MJ2;;C?E]YI=/DM]//Y3*,DK<1\,9AB,O_P!FRW+:3KSK24DJMFKPYNNFUF].
M_3\S/A-J[:9J%NL;_-)-$"F?[SC(([>G3UZU^NOQ"^%^G>-O@3:ZLEC$MY!8
MI(\P0;R1'NZXSQ@YSS]*_$3PCJR6?BX2(VZT2\CVG^' D'/7&< >E?T8_#*Z
MM?%O[/E[;6>V69-)(6,88[O)8#'7))'X^_%>7Q?.IA\3@:M%27[R'/);6;3]
M[T6GY>?U/A+3H9QA.(<MK<LX0PE54E)*7-*"TY4]F[?Y,_"O2K.#3-<N+.[N
M/W-K.496;*C9)CH3CIST^AKWKQ3XPT!/#$5CI,P^V>4%5(3N9GVX P.>WK^%
M?&WQ>N/%GAGQOK]H=(NU634)DC?RW (:1L$?+S^!ZXK[(_8K_9U\1_%#6K;7
M?%5K=1Z/!,LK_:%;RR@^8_?XQC],9[5[.8TX4,#1S>O5ARTZ4)TX*46Y3M%O
M1.[?1:?AO\9D57&YCGU?A#+L!5GBJ\YT'7G3G%82FIN]3F:TBEK>_P M#X*\
M5W?B"WUW[3>I-'&TH9/,5ER#G!YQVQ_GFOU$_8&U_3]2UF.QU-DE$SA/+D(.
M=VT<@G\,'M7@_P#P4*M?!/@KQ98^'_#$4"R0A893"JJ=ZY4Y*]#^OL*\=_9/
M\9ZAX3\>Z#,\S)!/>0@Y; P9%Z\XZ9ZXXJ\P3SWARI6I1]@_J_M(<RM*=K7M
MUUMIUM^'/DDI<'>)M++,1C/KRIXZ-'%RTE"#ERIQZQTNU>^_D?HU^VO\-5\/
M>((?$MII:1Z=)ES*L8VD$%L[@/\ ]=?"FD7>@*KZC+;P,PR06"G&/<\^^/S[
MU^X/[5/AUOB1\ [:_P!'MOM=ZNE"4^2@:3/DY_A!.1GVY_.OYO!8?$%M;N/"
ML>A7ZR-/)"&$<G]_9_=_S[5Y'",I8W+ZE*M747@DXS<IV:4;]W_GZZGV?BW@
MH\.<2X;'X;"2KT,WBJF$]E0YXJK5C&SO"+6CU]3Z>TKQ)=>.[T^%M$@>5Y"(
M1'&A90&.,<#'':O#OCM\%_$_PPO+/4M6@:!+MXW"L"N Q!'&?0_GBOU\_8G_
M &8K;P?H_P#PG7C6T-M<K"+L&[3 &U=P'S^WIWKX\_X*+?$?3?&_BBWT31I8
M#!IT@BQ"% .Q@O;Z9P/2M,NSMU\_AE^ CS8"SCB9+7FJ*UY7:_7OJ<>?\'?5
M/#O^W.)9J.<8BK&IE]%M0FJ%2W+S0;YM%;IZH]3_ ."=OQ/FF\01^& V(YEB
MA()P#D8(P3W)[=Q6U_P4;\)OX0URVUBQWQI>,LDKQJ<88*QR0!W)/ZX]/AS]
ME'QA+\./B)IFINQ$,D\(.20O4+^1_E^5?NU\8_A5I?[4/P_LY8)(S?2VR>4_
M!(+1C\>I'T.:\O.YT\EXFI9A+W</5@HU916BNU?ROZGU7 ]'$<:^%V-X=C*-
M7,\#6E4P%.4FFN76*[J+MJE;31W9_.MX?UV_\3:UIVC:1+/-/<7$4,H3<V-Q
M"D\=,9YY^N>_[G>%?AE#\,/V;M2U:^C62]OM,ED82X#AFM\D8.3G/TKA_P!G
M?_@GE9_"CQ1+XI\73QS6T4_VE#-@JBJV\=3V ]!Z#CI;_;A^/6E>'/"5WX(\
M.74,\!A> + RX0;"G(7/3'':EFN9X;/\?@<'D,ZGU93@\4VK1DX<KWZ?UN=?
M"7"^8\"<-YYQ!QG*C#,ZV$Q.&P.#A.+]G"<'%.,9.]Y*VMMS^?[Q7JQN?B#J
M-Z28U74+D@#IQ*QXQ7[E_P#!/#XO6(A3PS<W"D7,)B\MGP#YB!,<]\'L/;-?
M@%=_:;W6IIRK,\]T[9'^TW_U_P"=?8?P+\7:I\,M?TK7$D>.&-X6<%F (R*^
MTXERJCB\H6#A;ZY"C'V-1[<Z4;_/:^_3Y_A7AGQ/+A_B]9M:V"GBI1Q,6O><
M*LTFO/3=-:ZGVQ_P4%^#.L>'_%-QXYT6V=[:Y#3N8(V; ;+$_*.>#U_/W^)?
M@/X!\4?%OQMINE_9+EK%)X/M!DB<!=K#.25QCKUK^@SP/XR^&GQ[\$6B>+[B
MQE#V\44J3&,LH\ODG<<Y]>G3\KFF^&OV?/@@;C6M!N]*2<)(Y5?)WAURR@8.
M>HQ@8Y]:_.,/Q/B\!E[RFMAJE3'T_P!Q"K&$G>+LK[65E]_<_HG-O"C+<_S_
M  O%>%SJAA,BQ=6..Q>#=6"O)VG*\6^O735Z'(_%?5="_9__ &?Y/#BS1VU[
M-I2IA& ?>T&#C!SSGO\ UY_F5U?5CJ_C/5]1GD:0SWLDT;$DGYG+<9/Z]/I7
MZ>_M>_'@?%F^U+3+&5C86R2)"8W)1E3*KC'!X'0?4$<5^5.@1QMXC>*]^6/S
M-@9O]XXSU/KWS7V?!>7O+L'7Q6+4IXK%<TY7^)1E9J_7]%N?D?C)Q'#.<_RW
M+<LFI9+ET'A(6^!RHV@Y+2WO6NG^)^P7_!/+X@"RU^33KNXVQLPC19'P#Z<$
M\\FOUS\;?##PQX]6-]1TNUNO.Y\Z1$8\]P2.>>>.GI@U_.=\,=6N_ 6N6FNZ
M7.5MHI$DDV-@,HPW./4#D'U]>GZH^&?V^/#-OI-O:7GE_:;>W",2W.]1@]3W
M_P#KU\GQ1D6-J8^&/RM5&Y.\U!M:OO:WR_,_5?#'B_)<-PVN'^(YTXX;#U'6
MI*NDU*+Y6DN9==%HCZOL?A+\,_A!:2^()=.TZU>W!E#@1(P(R00<#D8^G?/.
M!^.W[<7[5D_C2>X\(:'=/_94+26^4;*!067J#C&.,<Y_GV?QU_:RUGXJ2OHO
MAZ62*U?,;^4Q 8'(.<=^N?KUK\W_ (H>&KNQ1[Z8R232[Y&W$L=QZDD\\>OK
MQFO4X9R-+&0Q6:WK8GF3A&;<K2TMI=[=_N/EO%#Q IU\KQ>2<'T(8?+'3D\1
M4HPC352&G-K!1YF_ZV.%\&6%QJ$CA/WC%B68\\DD]>3V^O\ .OUB_8R^-Y\
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MM[-NVO\ GY'K0JXR.$E3JUZ>,A.7.O>3=)7U7R71+<=X\9K70=-M]ORA(PW
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MOM^]VSUQQ[>Y_2N2U<Q3M)C[@X!QV'T]?J:]$9M4_P"$91[C3)[:W9%82NC
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MZO5H#INGW;Q@,_EMC')R0>WX\\?KS3]7N++PK:9B@\R15."H^[@>V>2>WX<
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M_%2"W8>$M7NL0X6()*^U2,$8VL<8[?7O7XS^#M0%IJL43N LS@'/'7'TP?\
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M//9FV[B3QG)&!C_(KTG2O#%J)P4&_:QQSG!_$D=NPZ5P7Q@2:ULOLODL4=<
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M070A4M\H!SM&??J<G/.?QKC/ T=O<7VYD!6)B!QUQP/Y#I[=*^0G'#5)NO\
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M1^1'7MZ9KY3\-:7-=3R/)&0ZMD9!!Z]1D=/TK]$O@-X4L+G2WN+U5,ZQDHC
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M3>/]-AW3P6AN%55))Q&'XX_S[$\_GE'KHAOI;;4+9(Y[>Z>,[U ;]VVT\?\
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MEE=K%'86L\RR,FT1KF1MQQ@*._\ 0=*X+4?^"G?@:ZTBZ%M- EV$;RQN7=N
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MSRW$XRJU*@G%V7Q)R2?*NEWZ?F>*Z2/(*LGRLN.1],_YY^N>M=9F+4PL;/\
MO@5'S'GW[_3MWKE-'E25L/P5Y.01U_J,=?:M*:.:"Y$MLQ Y)(Z=?\/\*ZIV
M<Y73TV45LO/IZ^OS/+PTX^RBHJ]*=O=ETVWZ;?TC:OK"*UC56/..,?B.OUQV
MZ_D-?X=:N_ACQ5I>M0<&SNXYF(XP%<$_CP/R/) JSINE?V]8-,TV9(EZ=\_C
MCG)QQG\\5/X>\*W5U<7,91@D>?FYY&#G_P#7_P#JKGE6H0H5*->UIIQ<>ZDD
MM^G=]_0]:A2Q%/%X7%8/2I"4:E":NU>G9VTO=)IW7;L?MCH__!2K2-!\#V6D
MR3K]MM+'R -_S!A%M &6'3_'K7YC_%/]H?Q9\=_%5_&=0NA82R.L<0D=D*DG
M&!G;R,?B,8KY \4V:6%_)$[.VQRNW>V.#Z>F17HGP:LXYO$%JWF;4:<;@>XR
M/_U#Z=R*\'#<-Y/E$*V8X6G^_FG:;5W!R>LHK6SUW['W.;^)'%?%U7+>'\SS
M%T<)2G"E6A1<H2G"*C%*5K7O;:W5ECQ9X>?2/#UU;2HPFD#'<1AFST/0=3S7
M#_L_:_\ \(_XEFMY'*M),V!G'5B!WZ]./?BON#XJ^!4U6U@6QCWDVQ9BJ]PF
M2/UX_2O@#PY8GP_\3(K&\S%B["_-\N<OP/ISZ_A7J8&M#%X/%X:;:FJ;J1>S
MF][_ (6M?L?+YY@*V39]E5>G^[HPQ$(*I9VY9<E_>=KR?S5S]'+Z:2*W&K2S
MDQF+>(V;@\$C&?7CKGVP*^4O&VO3ZMJC,23!&>%S\IVGC'Y?YZU[1XZU:6+3
M;&VMI28);=0=I[;>^/<]?_KU\X:D_P!FF$LS':S#@@<@G\/U_P :X\JH6YJD
MHQDTVE=7Y'%K9WWNNW_!]KBC,)RFJ$:LG14(2DT]:FD6XR[KOY(]:^$?BR;P
M1XOT?Q)!NB2.]M_,*Y4;5=,YZ=A_^NOWQ^+?@;3?VL?@?H&I^'KFVN-<L-/@
M;R]Z/)YD<(R,<G@_0]>]?SY&2VNO"P:T3]]&N]2OWMPZ'\__ -?8_4/[)_[2
M/COP/J,&D_VA,-.C<*8&=F0H,#:%/'3ZU\]Q'E-;&2IYQ@*T:6/R^3<8V;]K
M'1<JMMHM]+GWGAMQ7@<E^L\,YUAJM?A_BBA%573?^YU;K][&_G=JUFFGW1H:
ME^SI\7]-G.A&QN"XN?(4")RNP$J".,8Q[5^JO[+?PS'P ^'M_P"(_',UO;W\
MEK))%&[JL@8QLV,'G(/IST_#P;Q[^W3H7AM5>XT.*>_:+(F\A21+C[_W,]>?
M7GG%?%?CC]K+QU\5;TVPO)H-'9BJVRLR*$.1MVC:O0#^OMXE;#<19_1I4,51
MH8' IQEB:S=ZE5JW-R):ZVZW[6U1^@X/,?#O@3,Y9CE^88K.<U5%T,MPLT^2
MA&2]V4Y?S1_0]NUCXBV'COX^6E]%,&5=85%RW&!-QCVQ^';GBON7]M3Q1JGA
MWX:^&!I.H2VCR64)'V>1DSF-/[I!]?3/O7XTZ%8ZOI7BJR\4VJR,EO<)=/U.
M2I#GU]._?G'<?2'QJ_:&U'XM>']*T!K61'TF&.$MAN?+"KW ]/\ ]6:US')_
M:8_)?9<E3"X.+IU)27V$DDY*SU?2_P"!QY-QC.GP_P 7T\SG6PN8YQB?;9?R
M-\TXN:;M.-[:66YS7P<^*?C=?&6C1W.N:A+%+J<",&GD92"XX(+#CGJ0>/U^
M[/V]K>YU3P-X4NTEW/);6LCL6RQ*JC$DD_45^87@6ZN=$U:UU.>%A]AN$N0"
M#_"=W'3TQ^61Z>Q?'?\ :=N?B5HECX>AC,;:=$L"GD9VJ%^O4=LC/Y5OC<LE
M/.\MQ.#A2C1H.]248V>T=)6[WZOKT,<FXIPV"X)XARS-,7B9XO,(TW@XSG*<
MW*+U4&VU'?;MN?H1^RKXQT#XF_!W4/A9/>P)JD%F\,*2RJ"SA&4* QSU('Y#
MKFORZ^+OP)^(7PT\?:NDMC<W%A=WTA@>"*1T:-Y&*G*KCI]?RKQ'X<?$'QU\
M/?$2ZUX=OIX'CF$TRI(ZAUW9*D \@].>F:_3'P9^WYX,U>QM[3XA^%(M7U*U
M14>XFMU=F=>K;F0^G)/T]:RQ&6YIDN88O$972AC</C)1KU\-=*4)Z/W;].J_
M(TP?$/"_'6193E?$N(J\/9UD=.5#!YC4O.AB,,M%[2,-6X+5I^I\&^+/!>N:
M)IEAK5W8RVX8HZ^9$R%CG/\ $HSSZ_H#7Z:_LK?M 6VB^ _^$9\303QZ5<1K
M TL2-C#@*3D9'X]\>IKYP_:$^/'A'XNZ3#IWA;0X])BMAE1'"$Z?11U&>HK0
M^!/[0GPM\!^&VT+QIH$-_-&!B5T5CN3IR0>_TS^)%99I0Q>:Y1"&+RNL\1*N
MI2I4914X033BX-Z75M7^)MPQB,HX6XRJ2RSB/#PP53!<D\QKTIO!XR?*N:GR
M+WUS=_,^DOVEOV<_#?B/P3)\0_#>ISSV30FZ:&=FPNX-(0 ?3_#GU_'&71=)
MU&>\LK=D\VVF>)L8ZJ2#P/\ 'V K]#_CW^WAX=\6^#7\ ^"+)=.LS"8"J#:"
M"FW' 'K_ )ZU^5FDZG=:?X@N)I)&"WDK2L22?F<DY]/6O4X7PN;4LOKQQ\I4
MG":6"I5K>U5%.-N9Q2NWW/F?%'..%<5Q%@:V1>QQ-*O27]J5L.I>P^L.VM/G
MO))O>^F_8^E_AG\*"NH0ZBI0I$X=@?0$'Z].Y_6N$_:)\0BQU&.STURLT:&,
M^6><C R,'US^7Y=[X(\8:E9/+'%.7CF&%4'/7 ]__K9]17E7CS1+K4_$@O;N
M%G1W)(89SD]N/R_*O5PUWCI3Q?+^Z2Y%&UI+3?3UO8^4S7V$.'_8Y32G"I4K
MP52>G+%2L^9?Y]]CQKP)/K5SK,$C//)NE&XMG@[L^_;\NE??8OQ%X8CA(4W!
MB +-@MT ^OX?Y/!?#;X;6MU!+?I (S$K-C:.J@GKT]^_;J<5PGQ-\;OX6DFM
M%)^3>@7D'CIQ_7\.#Q6F*DLPK0IX>,5.,D[+;=6O9?\ #WZF&6TI\-Y3/&9A
M4G-8E<J=[Q3DE;XNOKW9T>0]V"),R;AD@\CYAZ'GGCK]!7T=IUK<VOAB.^W;
M\QCH<G].W7.:^#/ ?BZYUV6>1V)8EB"><<\<$_3\S7U5X0\8ZA'#_9EXAGMF
MPB*0=N<=1P/ZUS9C@JT)4O:.+Y$I3COHN6Z7GIU_![^KD&9X;$0G54:DXU&E
M3:>SNNWG_FS@_B1?:M/93+8RS([YX4L".W0=_P"GUKY*\3Z[J$6G+9:@T[R+
M(?O9/7..O3&,^WZ5^F8\ QZS%)>RQB*-OF1&'4''0=^OY=#7E_BWX#:?JMM]
MJ2W5G5B>%';." .W;]?6G@<XP5*4(58.GR-)N*79+?U_!?=CGG#6:YASUL/4
ME:JK>S;?L[.VEMK_ ->1\A^"-)FUNWA\A)%&%R0#Z#)S[>GM7UM\*?#$6E7K
MRS.1(0"2PP?\X]"./TW?AWX#T[2IX]*-H(Y&&-Q7OG KI+_3;S2_$(TVUMG9
M20#(HZ Y'/'\^W;BLLPS&G7J581J2]G*-XZ^ENVO_#=SHR3AU971PV(Q-'VN
M)BU&K;2,:EU;Y6WU3N97B?PW-J>IK)!@Q^8-Q]03U/\ G^M>K6_PATB_\,^;
M.\1N'BY7C<"5]/P_/TQ3;?P[>+'&6?#RKT/9NHX_^M75:+I6LVLX%Q<LUIGA
M,D@#MQG'^./6O#Q.)J-4>6NXJD[[_$E;3U_ST/M,#EN&]M7K8C#RG'$Z-25X
MP;2LXZ?UY:'-?#;P?8^%IKFVC?,C[@BD\<YZ?CU]@?<5P7C6RUN'Q(\@BD-J
MS_/M5B N?7'?\NV*^EET-#,E["?F7!8KT//(/OZ^OZ'H(=$LK]6-Y:"5I/E#
ME<\GCJ<^W^-<E/,/9UY5WK&<>6?-NMOA_P ]SV5D:J86GA(2=%4W[2BXZ7AH
M[/H_^ ?*4T^C6EBL\>[[8(P"I'._'H??/3K^I\F6P\0>(M4=H1<B%7&T*&QM
MSZ 8_'OQ7V]J7PGL68SI:@HS XP3QGT[?2M3PMX8T;0;ZWBFLD<3.%)*#CD#
MN.?P[_6M89KA:49.,>>35FY[:V\N[O\ TSSI\,XS$8FG3K2C2H1<5&<-.?6-
MW+7=_P"6C/!="^$>H:[I48NC('C(8[\@Y '4$ CU_P XK[3^#ME_PB&D'37S
M*P78JGZ=>G?')_R)=2L(K&[@2P58H)5!.U0 -W0<>Y__ %UVFB:0+7_2&^;=
M@CMVSCT]/S_+QL;CZE>C[*5W!3YU;[+=M(]M7H?<Y-D5#*\7&IA8IUZ;]G*J
MFVI1LKW[O]4;FGZ?%->O=M"B.7R#C!P3D>I]/\\45J69'G[0VT8X7Z'Z^E%>
M'5?O*Z4FHK5ZM[/]/ZZ_;X9*,';^=\SZN5E=OS/R<_MGQEJ8:&75+XJ<@_O7
M/'3U]!S^>*\?\?PSVUI,EY>23SL&X=BQSAAW/X&OI_58(/#5G-/(N6*EEX!/
M(SU _P XKXL\<:K<ZMJ<Q+'RMYP,D#&3CUYZ\_KZ_IN5U5*M*<(4X0Y?><86
M<EII>WDK:_>?S7Q%S8'!6K8BMB*L](JI.4[7LKI7OO=_\,>8^&-(DU36E4+_
M ,M,$X[YZ_A_GM7V1\+&B^'_ (KL]7N)&1$,;DYP,+@^Q]>1GCI[>#_#K39$
MU=&6$OF3KC.<GGG!_P YKZ8UOPW)J%G&R QS; H .#S^OM_]:NC,ZE+%I4:B
M_=33BX^6G-\U;MW/%X8P,L'06,H4VZ]*M]8C)J]IIJ23TOHU]Q^E'A7]J?X>
M:RMKINJQVMTZ!$/VC8^,#&/FSV'U'/TKJ/%_[07PQ\.64EUH]G817QA+1M L
M8??CCE>>O&>V#CJ*_'B/P3JVE.EXBRI\V?,#,.>>O;O_ (]ZZ&WTBZOMT]_=
M,\<2Y(9V(^7)Y!/H!['ZU\E+A?*HS]I"M6<(IQ]G[1N,G)KW+)[;:)>I^PX;
MQ'X@E0G&MAL/]8M'EKSIKGIP@E%M-J^JZW_S-;]H3]H#Q7XYCOXA>7%OIYWB
M+;*P!4DX& ?3K^GI7YR:? ^HZW,]Q(T[M([;Y#DY)'//.<G_ ":]O^+OB2".
M1M,LV "Y5MI],YSC->+^&[9TU"&9W(5Y%))]"><]N_Y>M?>930^J9>J=*G&A
M!1]U*-I-/EO=[M_I]Q_/7%^:8G/L^IU\=BJF(G0Q$:CA.3<+JR44KV2[V73H
MS]//V*_$\OACQ#!I[S>5;W#!2';:F#CKR.F?3OZU]I?M7? O4/BSH]M)X=_?
M7#Q*W[H;_F*@GIGW/]:_+C0-0N="6QO])E9)X]C;HS@DKCN.^1^N:^Z_AI^V
M+=:#8QZ?K41FDB15$D@+9VC'\0/7W_7DU\5G>"QOU[#YGEB7M*3M-=9.ZUM^
MO_#'[GP;G>0UN&WPKQ%*<<%43E&HEM%M-Q3Z6^^W4YKX(?L-7-E/!>^-<1&W
MVL!,-J_(=W\0_P#U]Z^LOBO\2_"?P3\!W&@:++:+="T,0:W9-^0N!G:1S^GY
MU\Z>//VR]3UJWGL='B-N\H8)+&I7J!C! !_7]:_.[XB>*O$^OW%Y=Z[?2SQ2
M;F17D8@9!]?P _KGF:659EFN-IXC-*DG2BXR5&]XO6/2[Z]/+<[<7Q/PSPAE
M>*P?!^$E*O*C*C];DO?5U\2F[NZN^I\X_&KQOK/C/Q7=W4TTDJ3W#.FYBV%9
MSCOZ'^?X^_\ [)20Z;XST62]95WWD)&[@<NOK_GU.:^2-5).J/*7W@2C:,YP
M >OT_P DU] > KG4M+FTS6[-' M98I#M#?P$-VZ<#GZ]Z_0LPA2_LAX6,5!N
MGR+2U]$K=%]_ZV/YTX<S"M/B>.8XRI4Q-2&(56I!7?*E4C)Z:WTO_P .?L[^
MV'HVLZA\-;"\T9)IX_L2MB ,V1Y8/\(]\_KSW_'+P]H'B779AI1T^]$TTQCY
MADZE@,'*]/J>,8K]H_@I\?/!7C[PQ:>'?&TEOF"W2!HY]A_AV'.[]>>:]/OM
M$^ ?A>.?7[9=.66!3/&,0\MC=[]^:_,\!FM;):-; O!N<E4E.C4Y6[REJEII
MUT/Z;SSA; <<XK"<187/L-A<&L)"EB\-B)J,TH*/-%+F6NG3JCY"^ _[(VB6
MN@R:YXT)MF-LTX\\;%^[G&6'^1^.?SQ_:ZG\%^'/$\VF>%)897MI2LAB*MRK
M8ZC_ #P?:OT*^._[8&FW7A/4?#GA8);21QS6\<T.%.T!E!!4>G/&>N<#O^%?
MBB[U/Q#KM[?:A<O/---(S,S%R=TF<_,3SSZG\>M?3<+8;,L;BJN8XZI*E0E'
M]W1U2Z/9Z]GIOIMK;\L\3<UX>RK)\!PYPU0HUV[+%X^*NW*.DE%W=[M=/G>Q
M^D'P(^&/BCQQX!DUS2%:1H;<R%5R3@*">!G/3C\37D?B'4]<T+6[O2M1\U)H
M7975\J,J3D '^F<]SC-?HO\ \$[ \7@6\@F820&T8>6W((*'C'.>O _^O7R/
M^V%H=_I_CJ_O[#27AMS,[/*D1 (+')) [XZ]<?6LL'C95^(,7@JT4Z?-+DDO
M=M9K2][W_I(ZL?D:POAYDG$F$G6]K>-/%TX\TFXNRYU%/YV/(K+QH;<A71#C
MN1R2>Y/?KG\<^]2:MK&H^((6&GP2RA1R85+8 [Y7../QX_&O)?#MKK7B_5;?
M1])LY9II'6)F5')4MP2<#@=^P['%?LC^S]^S#IW@_P !WFO>-+=)&FMWD_?A
M<QYC)'#_ %[?_JZLVS'"Y+*D\0KUJ]2-.E3@^:5G:S]'\_S/-X3R7,^+*]3#
MX;GC@J2J3K8JJG",81@FE>R6KTW[:=OQJU6]N=.8K?%T.>5DR"/7(_/_ .OS
M7:_#(_\ "0^)-/TZU8,T\B# YX+<8]^1U]^M87[3]]HMK\0+ZPT21/LD=S*@
M6/&!SP/E! P:S_V;]2:Q^)V@>8^Z-KF'@^AD&.WTS^G->S5A)Y/7Q?)RS=/G
MC'NK+1JU]]?Q/B<-5Y.+J.65&JM*GC?JTYIM^[&45H]59Z_(_0OXN?"Z_P#
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MA^:"BJ;Y5&*Y;;[;MN_WG59 ..]+2$9]CZXY% X&,Y]Z^=/T$6BBB@ HHHH
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M,RX?AEDZV$IX:->I7HP=.E4HQBI1J^TDK-VUT:\M#X;TZ:%XWCFZMG!/^/\
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M1F8!9-A&TY[Y[$?7G'] W_!-K5]%\>_#;6O!VMF+;=6TT(24*=VZ/8,;N?\
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MB&:RMVMYX 1@J2R]L#U'?VZ>]:.@SV-]JZ1"%!YS9/R@=3SD >QSG/YU;O\
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MS)NZ?]>1RFB^&K+2=LJ L(^5^7N._;\_0_6M\V%GXBG6VC@!N%P!A>YSZ#/
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MV)_Q]NG-?.\U1RE4E:--:)+2_P -WKOO;[S]*AAZ<<)3I0@I32BFVO>OI?\
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M:WLET-[]O?X^> YO!VJ>%XGMI]0<31JZ%6(8AAD8)[\_7TS7X3_!7Q'-X?\
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M!O@IH5NK:!K=&M64-Q'L'W2.IQU__5\9Z?\ MG^.[K2WTTS3[I(S'YF7!&>
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MIHWBR:U>]AMTC=+MU/"@#&&8^GX=/:O89/BC\%- L[K6K:VT=7@5VW1K"'W
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M1L]UN]_3_ASJS;$9CG&$JU<VS#$X_$ZPA4JU'-1O;2.MK*_WO0^,?#_AZ?\
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M2BE*D *G ]L>OK_GCCBL>7P+$YW<;<?F,_UP<#^@KKC5TM[65K?"NB]WTO\
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M/^>:RQXFU758)(#YFR0$,1G;S]./\CIS7J7CGPA#?QW%WI\8:0NS<#)ZD\X
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MO>\[I/6]GW_/[SU8J;K5)N"IKFLHQ2M9)6OW7EO^!W5KJVFZAI;6]XJ>:L9
M'&<E<#\\<_7-<EX?4OXCCM8>(V?">F,\>N>G7WSQ65:6S>=]HWD1$XVY.!G
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MZLKJ3Y;3OIK=ZZW_ ,TM3TPRK 2HP6R3P?Z?G6GH(M+B[(N<!R1LS]<C_/\
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MXO\ "WR]&7M>6/2=-N+E(\N8F/RKSG:?S^M? GC#4)]5UFZ9PQQ(=B=3@'C
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M]1M[N-6*%U>1@.N"">??V_F:]*^*"W]SJPD"L4DDXQDCD^Q[9_\ U5Z;\/-
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MV3VUWWMUW[=&?%YE36,Q</9Q52<*J]Q:I6E%:]DON_,]T%G8W.@P16J#S$B
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M11C5I.E5@JD94WRQ=FKJUFNOH>;X<SK8+$K$X.I'"XFEBH3]M+>,>97Z[/\
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MW3TMU6I^6_Q)U/[=JT[VGS1Q2$'8<CAB/_K]\UPVD:C(-0@,I*!7&>QP"/\
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M,?R_E14S:NE>DE%Q5N^EDDUY]#"CPUA[RHXF[A4K<T):WU<6[>5].^^FYJ>
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M]/QZ=/ISSWKIX/#H>-AJ&(L+W(&3CU/(Q@_48KB;JT33M158)LQ%N"",=?\
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M$^_7VS6U!IODQ@[1T],@\>]7)98Y(1(I_P!7CTYQCT]OJ>M26-XUVIC"@@'
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M8V=2S[%&0.?K_+WKBH-.EC!D*G8.3QG'!S]/3\1ZU!_PF]_+&(3;DKNP/EX
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M>/7(Z5T]OX=U6UB!,<C+MS@ D<>_U[=..V:]8TK29?M"R7Z?*&!RP[ Y]/\
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MNG.>>:_'B;3S;W)>V8B8-E)!]Y",D$$=/;_)/NOPY^/WBGX=ND5SJ=W<6ZD
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M/4]!]<GL*Z:<6V[QC'E6CNK[+IH^OR^9R8[,)4I4Z>'A4KPERIRL^3HGRO\
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M\1_2-^V78R7_ ,*;R*( L/.//IL7U]Q7\^C:4#/<0NBJ5=PW_?9^GN>]?KO
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M>]Z]K>9@ZEXL>QNHP8)-G&X@<#IU[=_\/6NB\.>+/"VJ71AOD5;@?ZK.,[^
M!SR23^G7BJ'B*TBEMR(K=&9@<,%!/S \].W'L.N.Q\XTCPE<-J*7C$Q".0L
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MA!IKX9)*Z[[].Y%''/;7&"<J.<9'O[_T_&M22_FE*6Z1DEB,<>X&3P,<Y_Q
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MR6G?ST\M33$>UQ'N0E4481M>[5UT;\M%Y?(\H6"XBU(-=!Y$:0<DEAUP#_\
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M SU^N,^W0GIN:CH^BR*EZ85::3G=CN<GV.>_3OCZ]/=>(CXHD$$Z^6B@[!C
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M(.HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]7))+I;\O,\_T:\M;NYE:^MPWF,3G&.I'3CWZY]L5K2:?IRS-(+?]TYZ;>W
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MDFXW>NFUOZ^1Q_Q+C8:):MLW1[1GCC_]>#TS_A7@=C=PPWJ+", 8##WY]/\
M)S]*^NO$UC9W_AF2.8KNAB) .,G"G^77')KXQ>%K;4;AXD<HDC*K!3C(;'7H
M!CWZ>E=^6:T9J3LM5=]=E;T^\^>S^$J.-PU6,>=5(Q=X_9=E^NWKZGJVFZM_
MI2;SA<XY]\9Q_GU^M>I1:A#(L>W!4*,]!GC^9Q^7(XKP;1+6]U"7>%(0$')Q
M[=^3_P#6R.O->FQQO:PJ&D!10 W(R!]?\!T_&IKT(*=HSYK]M6MOS7WK\>C
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MS^9C0M N]7O8[E[1MD+AB2IQ@$'DXZ?7/]*]*UZQ74;:.""##PH%.%'4 9Y
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MV?L*VBT\S^>+5M?U::*2)+>0Q,""N#R/P'USTXK>\/Z%H^I>'KF.2Q U$JS
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M\$P<CX._"P'U'P^\) _F-(S3C\#_ (+-][X0?"X_7X?^$S_/2:[Y<?863O\
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M(W$=3XN-\M>]_P#8<9UM_>\G^1_"-HNF:U<70(LY6)]%;U&>A_D.N.V**_O
MA_9=_9GMVW6_[.WP*@;^]#\(_ $3?FGA]316%7Q:PDY)K*<2E;9UZ6^FUEHK
M+;I<Z\+]$C-J-/EGQ?@)RO=RC@L2D]NCEO='NM%%%?AY_<04444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
B444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>gyycud3vz5ad000009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gyycud3vz5ad000009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (K T # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ I,T&FYH ?12"EH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M**** "BBB@ HHHH **** "BBB@ HHHH ***JZC?PZ9I\UY<;C'$,D(,LQ/
M'J20!]::3;L@*^LZW::)!&\^^265ML,$>"\A[XSV'4D\#\JY:;Q/KDQ)C:RM
M@6R%$32$#T+%AG_OD5FW%Q)?WTFH7*;;B50H3.1$O9 ?YGN<GT 9NKU:6%A"
M/O*[,)3;>ALQ>+-8CE!E@L;B,J<JN^$@\8.<OD=>,"MBT\8:5.=MR\EA)G&+
ML!5/&>'!*^O&<\=*X_=0P5U*L RL,$$<$4YX6E+I82J21Z?17FMA=7FDG&GW
M1CBS_P >\@WQ=SPN05Y)/RD>^:Z?3_%]K*?+U*,6,G_/1GW0G_@?&W_@0'/
MS7%4PDX:K5&JFF='129HS7*6+1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M472E9G1&2:%HI*6LB@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MFKSE<YN_L-6@7(L9KAA]X*P"J/K7(7>L7X<QE!;,,Y 3#<^YY_+%>J*TL?\
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M:3 M4QJ?4;GBLP,_4L&VV$X\QU3'J">1^6:HJ,WS9_A08_$G/\A5R[;=<6Z
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M_3O7.1I@!06;U+'))[D^]>OE.#YW[>:T6WK_ ,#\_0Y<56Y5R(MPH#@ 8 Z
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M5^"]1)M7TF9LO;#= 3_%#V&23DJ>/H5KBQE&Z]HOF:TY=#K**2EKS#8****
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M_>PV/IM/_P!:O35KWLOBE1OW/*QDFZENPNVFD5+3'Z5W'*5)JI[0JA5 "@8
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M*^H>YY@RPXLH!Z1K_*K0ZU%'P*E%)[@2K3Q48J05 $@Z44T4M(!#3#3C3#3
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M6.$<@?0\_P!<?A2:@N)K?_?/_H+4EEQ>2@=T4GZY89_0?E3[[YKF!!VW.3[
M8_\ 9OTI_: @LO\ 5LF"/+8K@CH.WZ8J\HK.B8^>&&X*UQMZ=<)C\LC]*TEZ
MT2 AFC#,I)/RG./7Z_S_  K-8JK3)G 6=#R>!DJ?YYJS,[B\,A+;%E6+:,X
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MC_(']#]>-2H:L M%)14@+2TE% "T444 %%%% "T444 %)2TE !1110 4444
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M]<9/YI4V*N^P%.&WDA63S91([MN+!-O8#IGVJL@:.XFA( 4GS(SZY^]^O/\
MP(5IL.*S[X>6$N>1Y3?-@$Y4\'IZ=?PJD[@1S0B3:P8I(ARCCJI_P]15FTOA
M,S0R#9.@RR]B/4>HICK5>6,2)M8D=PRG!4^H-/= :P-+FL^SN)CNBN!\Z8Q(
M!PX]?8^HJ\&J&K 24M,%.J0'44E+0 4X4VEH D%+3!3J0"$4TT\TTT ,HI32
M4P-[PI_R%)?^N)_]"6NPKC_"G_(4E_ZXG_T):["O*Q?\4Z*?PA1117*6%%%%
M !1110 4444 %%%% !1110 444E "T444 ,DC2:-HY%W*PP17)WEJ]G<M$W(
MZJ?45U]4=4M!=6C$ F2,%DQW]JPKT^>-UNC6E/E=F<M1117G':%%%% !6;KY
M8:+.Z#+1E'_[Y8'^E:59NOEO[$N%7J^U.G]Y@/ZUT83_ 'B'JOS,ZOP/T,J<
M<TU*?-UIB5]GT/&'T"DI10!(M2K42U*M2P)!2TE+4@--1FG&F&F@&TE%)5 !
MIM*324 )12TE,!1UJ=.*K@U*K4F!/FHW?%-+\5"[4D@(YR&4JP!!&"#WK/"^
M5>(L8Q&R'* _*N,<@?C5F>58T9W8*HY)-56;[/#->3;0P7C(^Z.P/X]?_K5H
MM$!R_BB[\[4! K I$,<>O?\ 'K6$*DN)GN+B29R2SG))/-,%?)XFK[6K*9[E
M&')!1'"G@4T5(!7.:C@*D IHIXI#"EI*6@8E)124 %--*::: $I#2TE #328
MIU)0(9BDIU)3 ::::<:::8AIIIIQIIH$)1124 +3A3:44P)[=BDRR*,E#OQ]
M.?Z5]4:-8MIFAZ?8.X=K6VCA+ 8#%5 S^E?,WAVS6_U^PM)"1'/<1PR8(!*.
MP5L>^"?YU]35O16C9QXEZI&9JN@Z=K #74 \]1A+A/ED3KC![CD\'(]JX?5/
M#VIZ,DDT@6[LHU+-<1##H !RZ?GRN>F2!7I=%=U'$SIZ;HY)03/)$<$!E(*D
M9!!ZU,KUT.O^%1:PR7FD6Y902TEFGIW,8]?]GOVP>#RT,J31K)&P9&&017K4
MZD:L>:)SN+B]2X&S4@JNK5,K530BPM/(XJ-#4F>*@9FWZ(MS93,OW)2N[!.
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MY"DO_7$_^A+785Q_A3_D*2_]<#_Z$M=A7EXO^*=%/X0HHHKE+"BBB@ HHHH
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ML3^/RK71E<>;$I]K_P"0L4[4F0/UI*4C)HQ7U)Y0E/44@%/44 /44\4T4^I
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MBG\(4445REA1110 4444 %%%% !1110 E+110 4444 %%%% !112&@!:***
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MJ2NA****!BT4E% "TM)10 M%)2T@%HI** %HI*6@ I:2B@8M+3:6@!:*2EH
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MBI,4F*=P(R*JR2$721\;61C^(*_XFK3RQ+((C(@D89"%N3^%4KL 2P2XSLD
M)[X;Y?YD?E51 L,9%A;RE+3-A8U SN<G"C\217J6G6::?IUM9QDE((UC!/4X
M&,GWKSO28!<:WID+DA&N YQWV*SC_P >45Z<.E>;CY:J/S-J2ZBT445YQJ07
MEE:ZA:O;7EO%<0/]Z.5 RGN.#[UY-XG^#K!I+KP_.64Y8VDS<CJ?E<]>P ;\
M6KV"BIE%2W*C.47='R7?:?>:;=/;7MM)!,GWDD4@CW^GOTJK7U=JNB:;K=OY
M&HV<5PHSM+#YE]U/4'W%>8>(/@P=SSZ#>#!Y^S7/;K]UQ^  (^IK&5%K8ZX8
MA/XCR"BM+5M!U31+L6VH64T$C'"!EX?I]TCANHZ$]:S:Q::W.A-/8****!BT
M444@"EI** %HHHH 6BDI: "EI** %I:2EH 44H%==X?^''B#7)@9+1["U!PT
MUVA0]NB'#'KUX'!YKUC0?AIX?T1DF>#[;=+TEN/F .<Y"] >.N,UI&E)F,Z\
M8[:GC&@^#M<\1$-8V3>0?^7B7Y(^_0]^F. ?>O5O#?PITS2GCN=1<WURIW*&
M&$4\]%_+J3TXQ7H( 48   ["EK>-.,3EG6E(;'&D2!(U"J.@ IU%%:&(4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 4=7TR'6--ELYN-PRCXYC<?=8>X/^%>=203VEPUI
M>*J74?WE4\,.S+ZJ?_K'D&O4ZJWFFV.H;/MMG;W&S.SSHE?;GKC(]A75A\2Z
M6CV(G#F//](LVO)5U5XO,TVV8[&V9S(/X_=1D@$9Y!/;-=<A#*&4@J1D$=#6
MS%$D,:QQHJ1H JJHP% Z #TK(O;4::#/ A^RYS)&HSY7^T!Z>H_'UKBQLI59
M<_3L=%!J*Y2>S.+E??-:=9=DP:XC92"I&00>#Q6I6>'^$*WQ!1116YD%%%%
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MV/G#:=N[!QZXJ2"WFN9!'!&TLA.%1!EF^@')KZ?MO"?A^SE66WT:QCD7[KK
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M'*%%%%<A84444 %%%% !1110 4444 %%%% !2'/:EHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3(T="^Z
M4N&;*@@?+[<=J?10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %)2T4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
$ '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>gyycud3vz5ad000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gyycud3vz5ad000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *T!@8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"D5U;.U@<'!QVI:J6/WKC_KJ: +=%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHJK?ZE::7;B>\E\J,MM#;2W/X ^E*4E%7;L.,7)\L5=EJBL/_ (3#0O\
MG^/_ 'YD_P#B:GM/$FDW]REM;7>^5_NKY3C/XD5FJ])NRDOO-GA:\5=P?W,U
M:***U, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK,E
MUN"'78=):*3S94W!\?+W_P *F4E&U^I<(2G?E6VIIT4451 444R61(8GED.$
M12S''0"ANVK!*X^BL/\ X3#0?^?[_P @R?\ Q-6K3Q!I-\X2WOHF<]%;*D_@
M<5G&M3D[*2^\WEAJT5>4&ODS2HHJ*>Y@M8C)<31Q(.K.P JVTE=F*3;LB6BL
M=?%.B-+Y8U"+=ZD$#\R,5K1R)*@>-U=#R&4Y!I1G&7PNY<Z52'QQ:]4.HHJG
M%JME/J$MC%<!KF(9=,'C\>E-R2=F2HRE=I;%RBBBF2%%%4[[5++33$+N<1&5
MMJ9!.3^%)R45=E1C*3M%79<HHHIDA1110 4444 %%%% !1110 4444 %%%%
M!1110 4450O=42ROK*U:-F:Z<HK \+CUI.2CN5&$INT2_1113)"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH R/%/_(K:E_UP:J_A6UMG\*Z8S6\3,8%R2@)-6/%/_(K:E_UP:N;
M\/\ C*RLO#]C:R6.I.T4(4M';Y4_0YJXIN+L#Z?UV-WQ!X;L-2TV8K;QPW2*
M7BFC7:RL.1R*=X2U*74_"]I=SDM+M*NQ[E21G]*R+WQ%J6NVSV.B:1>1M,"C
M7-T@C6,'@GJ:Z+1],31M$@L$;=Y28+>IZD_G2U47<-VC'3QS9/:+(MK<27+R
M.B6L(WN0IQN]A6[;7XETM+ZYB>S4IO=)N#&/>N7^'=E$EA?7FT&:6[=-V.0H
M[?F34GQ"N'33;&U"2/%<W2K*D?WG4<[1]:;2O9"1-_PFIN&9]-T34;VW4X\]
M(\*?IZUJZ-K]GK:2"#S(YXCB6"9=KI]16=%XEEAB2*+PQK"(@VJH@4 #\ZS&
MGO+WQAIFHVNB:C:8W17+S18#(>F<'M3Y4] .ETC6H]4GO;<PM!<6<OER1LV3
M[,/8UILP12S$!0,DGM7(ZLO]A>,K+5E^6UOA]EN?0-_"3_GM5SQE=S+I<>FV
MA_TO49!;QX[ _>/TQ_.IM>UNH^NI<TS7%U329]12V=((R_E[C_K%7N/0&K&B
MZDFKZ/;W\<1B28$A"<XP2/Z4PV4>G>&Y+.$82&V9![X4UB>'KA[3X:Q7$?WX
MK65U^H+4.UFU_6X*]T7-2\6VMG>M8VEM<:A>+]^*V3=L^IJ.U\96YNX[74K"
M[TR60X0W"81CZ;J7P-90VWABVN% ::Z!FED[L23_ "J_XDL8+_P_>Q3J"!$S
MJ2/ND#((INT79@O>V+>HWJZ=IMQ>LA=88RY4'&<4FF7RZEIEO>JA19T#A2<D
M9KE[6[EO?A9)-.2T@M'0L>IVY /Z5M^%?^15TS_KW6AQM<5]B37M:30K%+J2
M%I0\JQ[5..O>KE[?6^G64EW=2B.&,99C7-?$/_D 0?\ 7U'6AXLTB?6M DM;
M5E$RLLB*QP&([&E963\_\A]2BOC*XF7S;;PYJDUL>1*(\9'J!6UH^L0:U:M/
M#%/%L;8Z31[64^E8D'C!K.-(M6T6_LV4;6=(M\8Q[CM^==!IVIV.JVWVBPG2
M:,GDKP0?<'D&FUY"+E4=8U*/2-)N;Z3&(D) ]3V'YU>KAO&&I6MUKVG:)<W$
M<-HKBXNFD; ('1?\^U2E=V'MJ9QTVXT;1=/\4,K-?+.9[OU>.3J/P&/SKT:"
M:.X@CGB8-'(H92.X-8MUK_AN\LIK2;5;(PRH48>:.A&*S? .J)-8W&DF=9I+
M&0JDBG(>,G@C_/I5N[3\A&SJ'B"VTS5H+*Y&Q)(7F,S-A5"UEGQI)(#+::!J
M=Q:C_EL(L CU JKXCL(=1\?:%;W #1>4[E3T;;D@?F*[0    8 Z 5.B28^M
MC-T;7;'7+=I;1VW(<21.-KH?0BH]4\06^E:G96=PF%N0[&4L J!1DYK%U!%T
MWXB:7-; (;Z-XYU7^+ X)_3\JA\86<5_XL\.VTXS$[/N![@8.*:2;7F)Z7+I
M\:--F2PT/4KRV'_+=(B P]1ZUJZ-X@L=<C?[,SI-&<202KM=/J*U%544*H"J
M!@ #@5R6N0)8>-=#OK<;);IV@F"_QKC@GZ9_E25F[!TN:VI^(K72M3M[2Z&Q
M)8GE,Q;A0OMWINC^(?[9N72+3KR&W"[EN)H]JO\ 2L;Q%90W_CS0(9U#1B.1
MRIZ';R,_B*["5O*@=E'W5) HT44Q];&-J_BBSTNZ6S2*>\O6&1;VR;F ]_2J
M4?C6.*9(]5TN^TU9#A99D^3/N>U0^ ($ETNXU23Y[N[N',CGJ #@"NFO[.'4
M+&:UN$#12(5((_6AVCHPW)_,0Q^8&!3&[<#QCUKF&\:)/(PTO2;_ %!%.#+%
M&0A^A--\ 7;R>%@L[Y6WD>,.Q_A%3+XMM#E-+TK4+V%#CS+6 >7^!)%/EL[!
MT+&C^*+75KM[)X)[.]0;C;W"[6(]16I?ZA:Z79O=7DRQ0IU8]_8#N:XJ^U-K
M[QAX?F.E7MC()70O<1A?,4CH,'G']:O:[&NI>.M'TVX&ZUCB:Y*'H[#.,_3%
M'+L(E'C265?.M_#VJ2VO7SA'C(]0*V](UJRUNU,]FY.T[7C<89#Z$5?  & ,
M 5'%;00/(\4,<;2-N<JH!8^I]:5T,XJRUFTT;Q+XDEN68L\\:QQ1KN>0[3P!
M5Y_&QML27VA:G:VI/^N>/@?45!X?LH9?'GB&\= TL3HB$C[N1R?TKKYX8[B"
M2&5 \;J592."#0VDEZ+\@ZL2VN(;NWCN+>19(9%W(Z]"*Q=3\5VUC>FQM;:X
MU"] RT-LF[9]3VK-\%3O;^#+AAE_LSS; ?0<@5G>$=9>QT<2+H6IW4]P[22W
M,40(D)/KFGRJ[#5(W[/Q?!)>1VFHV-UIDTIQ']I7"N?0-ZUMWU];:;927=W(
M(X8QEF-<CKVIR:UI$]F_AK5P[+F)S /D<=#U]:MZGI>H:YX(M82I2_18Y6CE
MXW,O53]:&D"W!?&5Q*OFV_AS5);8\B41XR/4"MO1]7@UFT-Q#%/%M8HR3)M9
M2*PX?&1M$6+5M%U"S91AG6+?&/Q';\*Z'3M2LM5MOM%A.DT1/)7C!]QU!H:\
MA%NBBBH&%%%% !1110 4444 %%%% !1110 4444 %%%% !52Q^]<?]=35NJE
MC]ZX_P"NIH MT444 %%%% !1110 4444 %%%% !1110 4444 %<YXSYTRT!_
MY_(_ZUT=<UXVW?V3:[,;_M:;<],X-<^*_A/^NIU8+_>(^IO_ &6W_P">$7_?
M IRV\*-N6&-6'0A0*Q?+\5?\]]*_[Y>KNG+K"R/_ &E)9LF/D\@,#GWS5QG=
MVY6B9TW&-^=/YC;[6[?3M0BMK@;5>)I3*3PH';%)IFM?VG.RQV-U%"%RLTJ;
M5;Z5EZS:QWGC+28YE#((V<J>AQR/UKIG.R)F ^ZI(%13E.4I-O1,NI&E"G&R
M]Z2_5F5J/B"WL;D6L<,UW=$9\F!=Q'U]*A@\3Q?:$@O[*YL&D.$:9?E)],UB
M^'-3>WM9KC^RK^YFN)69YHHP0>>F<]JT-3U-]2TZ:UDT#4SO4A281P>QZUBJ
M\G'G4OE;]3I>%A"7LW&_G?\ 0Z5W6-"[L%51DL3P!6 ?%232,NGZ;>7L:G!E
MC3"_@:SM4FO/^$,L(+H2133RI!+N&"!SU^N!76VUO%:6\<$"!(T&U5%;<TZD
MK1=DK>NISNG3HQYIKF;;2[:=3#E\7VD5G)*T$R7$; /;2C8XSW]Q6Y/.(+26
MX*DB-"Y'K@9KF/'=I"^EQ714":.4*&[D'M70:C_R![K_ *]W_P#0324ZBYU)
M[#J4Z3A3G!6YF[_@.TV]74=.@O%0HLJ[@I.<5'J^I+I.GM=O&9%5E7:#CJ<5
M7\,?\BU8?]<_ZFJOC/\ Y%R3_KI'_P"A"JG.2H\ZWL3"E%XKV;VYK?B;WF*(
MO,8A5QN))Z"L%O%*RR,-/TV\O8U.#+&F%/T]:9XMG>'PVJ)N_?.D;;>N#R?Y
M8IUOK36MO'!#X?U-(T4*H$(Z?G45*OON"=K>5RZ-!>S]HX\UWWML7M,URUU-
MWB59(;F/[\$R[6'O4FJZHFE10R21EQ+*L7!QC/>L"[N;B]UC3KNWT>_@FBE"
MR2218!C/!!P:L>-H_-TNVC)P'N47/UI.M/V4FMU^)2PT/;0B]%+=7O8L2^)U
M:1Q8:=>7J(<&2)/D/T/>K6E:[:ZJTD2+)#<1_?AE7#"M"&&.WA2&)0L:#"@=
MA7/ZDHA\::1+&-K2I(CD?Q #C-6W4@TV[INVW<S@J-6\(QLTFT[]M=3;OK^V
MTVU:XNI1'&/S)] .YK%_X2F5E\U-$U!K?KYFSMZXIE_&M_XVL[6?F&W@,X0]
M&;.*Z:A.=1OE=DM!.-*E&/-'F;5][6,K^WK>71I=2M$:=8AEX_NL,=0:O6=W
M'?6<-U$?DE4,/;VIRVT"+(J0HHD)+@*!N)ZYK!\.N=/OKW0Y"<0MYMOGO&>W
MX57-*,TI=?S_ .#^A/)3G3DX+5:_+_@,U=6U./2;$W,B&0E@J1J>6)[5%]CF
MGUR"_E15CBM]J+G)#L>?TK/G/]K^+(K<#=;:</,?T,AZ#\*Z.B/[QMO9/3Y?
M\'\@G:C%)?$UKZ/;\/S,K4]=@TZ=+80S7-TXW"&%<G'J:J)XG9)$6\TB^ME<
MA0YCW#FH;V*^TGQ%/JL%F][;W$:JZQGYX\8' ].*M6_BG3II%AN%GM)&. MS
M&5R?KTK)5).5I2Y==K?UN;JC#D3C#FTU:>OW=+>:-RJNI_\ (*O/^N#_ /H)
MJU574_\ D%7G_7!__03715^!^AQ4_C7J9/A.WA?PU:,T,;,0<DJ#W-7M2T.P
MU&U>.2WC5R/ED10&4]B#7.>'O$EK8Z';V\EK>NR Y:.'<IY['-7Y_$=W?1M!
MI.E79F<;1).@15]^M<L:M%TE%ZZ;'H5:&(6(E..FKUO;J3>'-49_#DDUV^YK
M0NCN>X7G/Y55TC36UY_[8U8>8CD_9K=C\B+V..YJ6?2'T[P3=6:-OF\IGD8?
MQ'J?\*U-"ECFT&Q>(C;Y*CCL0,&JA%RE&%3HE]__  !5)QC&=2EUE:_E^ERP
MVG63Q>6UI 4QC;Y8JOIFC0:2\_V9Y!%*P(B+95/I6C173R1OS6U.'VL^5QOH
MRGJM^FF:9/=O@^6N5'J>P_.N1-C-H^FV&NLI-T)3)=>K(_4?A5WQ'?VUQKEC
MI=Q/'%;1MYUPSM@''1?\^M:MUK&A7=I+;2ZC:F.1"C#S!T-<=1QJ2D[JZV]=
M_P#@'?14Z,(VBWS:OTVM^;^XUHY$EB61"&1P&4CN#3JYKP=J"SV,M@95DDLW
M**RG(=.Q%=+773FJD%)=3AKTG2J.#Z!7'R6:>*=4U&5N;>VC-O;GMO[M^=;/
MB34QI6BS3!L2N/+B'^T?\.35/0]0T;2](@MO[2M?, W2'S!RQY-<]5PG/V<G
MHM_T_KT.K#QJ4Z3K03N]%^O^1:\,Z@]]I*I/G[3;DPR@]<CBKFK:BNE:=)>/
M&9%CQ\H."<FN;@U.SM/&6ZTNHI;;4% D$; A9!T/X_UK4\8_\BQ=?\!_F*2K
M/V$I)ZQO^ YT%]9@FK1G9V]=T$_B:(2F&RL[F]E4#>(5RJGT)]:DL/$EO=W8
MM+B">SNC]V.=<;OH:M:-:166D6T,( 'EAB1_$2,DUG^,+:.309;CA9K8K)&_
M<'(JYNK"+J-[="8*A.I[)1W=KWU^[8U=1O5T[3I[QD+K$NXJ#C-9DWB>$%8[
M2TN+R<H&9(%R$R,X)]:-:E:?P7<2O]Y[8,?J<59\/6<-EH=JD2CYXP[MW8D9
M)IRE.55PB[*R?YDQA2A1YYJ[O;\""S\36\]VMI=VT]C</]Q9UP&^AK3O;H65
MC-=,I81(7*@]<5G>*+2*YT"Y9P-\*^9&_=2/2HI[A[KP0T\O^LDL]S'U.VDZ
MDXJ46]4KIC]G3GRSBK)NS7^0T^*X&CB^S6=S=3O&':*%=VS/8GUK7NKZWL;,
MW5TXBC R=W7Z?6L_PK:QVWAVTV* TB;V/J35+5P+[Q?IMA,,V\<9GVGHS<XS
M],4<]2,$V]7;Y%.E2E6<(JRC>[ZNQ(/%,CCS8=%U"2W_ .>@3J/7%:NFZK::
MM 9;5R2IPZ,,,A]"*N@8&!7,W"K8>.;)H %%[$RS*.A(&0?K3;G3:YG=/0B*
MI5DU&/*TF][[=S0U'7[>PN1:I!<7-T1GRH$R0/>JB>*ECF2/4-.N[%7.%DE7
MY<^YJY?:U:6-WY"PS7-V5!,=O'N8#MFL?7=8>[T2ZADT74(U9/OR1 *I]3S6
M=6JXWDI;=+&M"A&?*G3WZWU]4CK>HR*P[OQ-!%=-:V=M<7TZ??6!<A3Z$U&U
MW-!X%6Y1CYHLUPW?. ,U9\,VD5KH%KY8&Z1!([=V)YK64Y2GR1=M+F,:4*<7
M.:O9V2([/Q)#/=I:7=K<6,[_ '%G7 ;V!JKXCD2'6]$ED8(B3,68G@#%=#)!
M%,4,D:.4.Y2RYVGU%<WXIMDN]7T2"091YSN'J..*BJIJGJ[NZ_-&F&=.59.*
MLK._7H]B=O%!?+VFDW]S /\ EJL> 1ZCUK1TK6+75X6>W+*R'$D;C#(?<5?
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M"ZGJUO)%]A@%O"L@(W/_ !-S7<T4*5D-ZE;4 6TVZ5023"X '?@UC^$;4_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *J6/WKC_KJ:MU4L?O7'_74T 6Z*** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *J6/WKC_KJ:MU4L?O7'_74T 6Z*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *J6/WKC_KJ:MU4L?O7'_74T 6Z*** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *J6/WKC_ *ZFK=5+'[UQ_P!=30!;HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ JI8_>N/^NIJW52Q^]<?]=30!;HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ JI8_>N/^NIJW52Q^]<?]=30!;HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ JI8_>N/^NIJW52Q^]<?]=30!;HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JI8_>N/\
MKJ:MU4L?O7'_ %U- %NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH AN+A;=-[*[ L%PBY/)Q3+Z\6PLY
M+EHY)%09*QKEC^%2RAFB8(X1B,*Q&<&JTDT]G9P[HWNILJC^6 ,GNWL* +44
MJR1QN#C>NX \'%/K.D219;;S8A<3;F43(H7R@>^"?H*;]K?3;+S;^>.2"*/Y
M[@<$MG'W10!IT4U'#JK+R",@TZ@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ***0G% "T50O-6M[-)#\TKQLBM'$-S MTXJ:<W#
M1S)!L23:/+=^03[B@"S1423*TLD0SNCQNXXYJ0$'I0 M%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4\UO-<?9896BC<"2V?[REF.7!/4>@K;L=0M]1MA/;2;T)(Z8((Z@T 6J***
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MR<]#2V,BR7L[P,X=F"36\S8$87(R@QT/ZTYX[<O=/:A9PN5DM#@*\G!SSWH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5XE^QVH$UP7"]9)"!5CJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[HTBDVY;.#[''O4;^7&8Y65[Z_MX"\;*-NX-Z?P]JO&4KY,@DBCA/#*>I)Z
M$'&<T 2])>-@RN2/XC4%LUI?.M[&FYTW1AV4@CGD<TT3K.8+FWMQ(&)1I&^0
MHO?KSU%6#+YELTEJ8Y6P=GS?*3]10!/138]Q1=X ;'(!X!IU !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,DW
MD#RR <C.1GCO3CTJ&.W07,EPKN6<!2-V5&/04 !MT-VESEMZH4 W'&"0>GX4
MB>=]IDWM&8=HV #Y@>^:=Y;"X,GFML*X\OC /K5"R5HKIY[FW,=U<,5)C)9-
MJ_=)].#0! MLM\SWTSH'BDRLEHY)9%Y"MZ_2ISODBNX;]HWB*_(T8(D"L/3J
M"/6H=/#LS(J0FVDF:59K1L# (P&]2><T$1FX:YD7$S(Q^T0C#)&#D @\^O:@
M!V!'9&WV_;K1 R29.74!>F/XC^76FO+]ELG:T0W,$:K&+11AD'?W)P>E22VI
M>YAG?)F#/Y4D0P$4KQO&>:IF<33-+,-D<:D1:A P*G@;LCL<C'X4 ,LHTAM/
ML\)^U6+ E[:8?O(4] O4\^M21S3V4<DGF-J5H6R8@H,L1)&%QZ >O-5[AEWI
MJ,LJ6TJ@(E_$=T<PYX8#MQW[U*LH\N-I)4TV\FD.)44;+@C@$^H.<XSF@"1X
M+::S>&+;>62DAHU.Z1)"W4'MC)JK=0J]K%;W+?;K-#L^V1'][ P[G'\ZG241
M7&+@I87\KG:R?ZNX SMS^?3K2(UQ$_G2,+*Z\PKY(8>5<MC(QZ$^M %:5[A5
M@%Q*UY:QN&CO[8_-&P_OJ.H]:>SL]I<EY+9H92#]L5 8YSR CKVQZU @\N8O
M9N-+U-^6LYC^ZE)]/<^HI/W]K<-)%$MCJ,Q&ZVG;_1YO4J?6@!;34;K2A,X5
MGA!11;'A%)Q_JWZ$8YQ766]U!=1;X94D4$J2IS@CJ*Y>XA@?2S9_9524/G[)
M<$B-G)R=C?3.,4ENK62*UO#=1JD(1DQB16=\EB3\I Q0!U]%9%GJY=]LZC8[
M2>6Z@CA>Q!YS]*M'5+3;D3*QW%0H^\6'4 =<T 7:*Q+J[U18)9EC2$>7F-"A
MD;< <@X_"LP>*[BQOH;?4(T>-E!DEC5E,6<?>!H ZZBHX9H[B%989%DC895E
M.0:>S!1DD4 +29 &2:S+W64MUVVT+W<S#*I&/EQZEN@%4KF>>ZCE;<'0@A(T
M;"&-E^\W]['^SZT 7YM41ITMK4B1Y"R^8.4C8#HW^%58)YY9BEPJS)&5D6=T
MQUX(5>HQSR:4P^1;QS/'%^XV2.YCPO0[F0#G./6HH(6C\Z<SM#YQ8//*<R,H
M&5*^@'/&* %2U9T='F>VDD?#$8,APWRD8X (R.E3+'#'*U_=116LCYB?<<LP
MSA<GWJ5I S(]N%S-#Q>D ].F1W[F@)#)=PW04RL\!4S@_( .>GUH 2U\Z6'R
M[>$VT*Q&-))!F0$' X/48YJ5&@#QW$2^=-*OE&91Q\N>OH,YJJ;J:XGMI+2,
MS-&0LDCY2,JW5E]3Q4DT,3M$DTLDZO/OA$2X"$#/)7M]: &M<175B8+Q5EE6
M54ECM26V'.1G^M33/),\UJ]U% THQ T3?O,#J>:K6UP\S+'<O#;73%R]O$P9
MI ..O4&H+&(VUO$L4*V=JL9R9CNF1R<#U'- &D)2\,K,OV>5&\E)9E'S=,'Z
M$GI5>6PBOKFYCN'FE4QJC1."L1(YR*=(C0O+LMY[MGE3>)6PH_VESQQ[=Z?<
MSXFG5KT(J;#Y<2YD7)[]>#]* )@DR6D6Z6.%HN9-BY&T=AGI21&(ND9#NT48
M9)Y%X.>.OK38;62'4YI8U3[/.N]V+'=O& ,#H!@5));1O:-;W<OFI*Q'S87.
M3P.* )(QYD7DW!260*-^%PI_"I^.E5XFN!=R1M$@MU5?+<-R3WR/RJ7RP9O-
MW-G;MQGC\J )**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ JI8_>N/\ KJ:MU4L?O7'_ %U- %NBBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MEMIUK',N45I+<8W>ON* -K-%9D6@Z8L2B33[1G"@,PA49-/_ +"TG_H&VO\
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M--_Y\XORH OT50_L33?^?.+\J/[$TW_GSB_*@"_15#^Q--_Y\XORH_L33?\
MGSB_*@"_15#^Q--_Y\XORH_L33?^?.+\J +]%4/[$TW_ )\XORH_L33?^?.+
M\J +]%4/[$TW_GSB_*C^Q--_Y\XORH OT50_L33?^?.+\J/[$TW_ )\XORH
MOT50_L33?^?.+\J/[$TW_GSB_*@"_2&LJZTNP@@,D>F+,P(^1.IYJ4Z/I@QF
MTA&3@9% %B/[1]HE69X3$W^K500WOG_ZU-LV@-L8[52J1,4 ((P1]:I_V%IJ
MGS'LX9)!G:=N#CTJ!])TVX$<#6L,+RQDO$?O@8QP0>H- %R2P@EMTDNXD22-
MQ,QAR/F'?CDU5:>X-KY4+0:FI4^;&S!'VMTXZ=/7K2G1=.@6VBCBMPH.#YH)
M9U ['/6H)]*TLZ?<RW.G16_)7)D"[AG"G=VS0 K$3)-#9S1R,[$-97G V@8(
M7N!GO@BF",29MG(^<\V=UV51C,9^N.:K7&B:<RNEUI\=U'$IDWHA5T_NJI_B
M/7G-/E\/:3<&6&2&&Z!'FF"0 21*1QMQSU]: *ZS/);R6+HUQD<Z??G;+@?W
M&_B_SS44BY,10W-R83C,8Q=6@(Z'^\/PJDEC8/;1P?V>-1MR,-$Z[;J#MT[C
MWQ4[:'83^4MN@OH5PF^,A+BW/J?4>H(H VS,K307+*;M8CY<=U!RR'!W>8!P
M /2J15KR;SYG55"[EU*P?@@?PN.:I+I-O.8#$D;+NPES9IGK_P ]8^WU_E2/
MIUM;744CV]K:%@0LT(WVTQ_VAU4^^: +DZSI/]MN6$# @"]LCE7Y.!(OH.YJ
M1GS<QM.3:S;CLO+/F"3_ 'QVS[_G5:;1=,\S[3&D%C,7"@,08+DXY[]#GK59
M='TF"?YK)-*NV; C?+V\_P#3'Y&@#;O;2":ZMKF6$^:TN(KNS' '4%_8GZU4
MO;>20I?+(]SY:L3?6# /@=%*<AA4$NCZ3;2I"(TTZ=L/YBH6MY#CD<\?AD&@
MZ/86EU%+/8I9J%,CS6PW6[XZ;AU'^>: "::*^,<TBQ7TJH-MQ92".Y08[IG.
M>O\ A5LO#)?V["ZMI)("H5+Y#%,O')#<9Z^E4_LUC*@+6%O< X/VO3'^=".0
M<=1^M7TG!TH(;J&>,1[BNI1E6P3@ G@#N.E #_#\KP17JS(8Y?M1W;Y"X487
M&2?4=*34-2C-TMS:E&D2(H=S[>I&WN,9^E9$D T][II(+==.N(T$S6DP_=GH
M& /.#G'YUD?:'BACDMK-\.H7*C*8R"/N\@Y&.><4 5O$EP9M:,,(9@N5C97!
M#!N>,=N2*UK+5(],M)XKZ!5*@,(Y2N=VP9&#DC)Q63;/#;7$FK7I3[078+8J
MF"2?8_P\GK6->SRWEY-<3 +)(Y)51@ ^F* .O7Q=;*PMQ'+*J/O27(W#Y<$J
M. "/3I3V\36MZL$ER"DL";HY&VECAN3GL3@=N*X^*WN"_FQP;@%R3V Z9XKJ
M=(\.21G8XAG5M\<\;("N/X3GN#C@^M "MJNIZI>R1M&MQ;2LCQB:,B+Y03U[
M'(Q[FN@T/[6L4TS0%(P$\@3N0BH<,P'^[S@X[5GVGA/3+..62XA@G>95#Q20
MB1@PY*X7C.T>M3+INDM+-<'2+.T.8W4WH'0C!(3^'KCZT ;H%Q<'S(;EGR#+
M!, !$<\!2 <MCK2CS#<Q7<:-+(#Y$Q9S&B@=6"GKR*S#H6FM)<"&QMWG64.B
M7$("A<#.P 9(P??FH9/#MC<27%U)8P1V[*@6*Y15CV\$G  ((]S0!L%?,N0?
M/EE\J<JL<2[53Y>C>H]_>DM84:U%L#%;PR(T;P6W.Q^_SCIQ["L^32=*WF.+
M38[N2.=6*I$J!%;ISC# "IKK0M)%M(UW!96T/S*YCC5>"?E.X]#0!I6RR1NB
M.(X=I*!2=[2H!P<\<_G5>-"@D:QM7>21I) ]P2 K],<\@'VJ*#2])7?:PZ>I
M:!!M9T(5\CC#=#[XJ!K>Q1MKZ=&SJBB6"%"[HS=\],4 :KJ2ZK=W**L\?EB#
M@9;O@]3QFID189$1(0%$>/,XXQC />LAM+TFS(\V*T6UB0+N<Y</VR?I4$/A
M^P=(6CL?/#;HY&NB5(4$D-MQSSC'M0!H2F7R+FVNF:YE>WR8HDV CD<'U/UJ
M\@A@B4;57RH^ 3EE7'_UJQCH5G<QAMD)DB1DFABX1G([GJ*>^BZ>L]FQM$C=
MAM=5B+@\="W89[T :)U&-HK>:-'D@FR3*!A8UQG+9Z"I_+D8R[I24<?* ,;>
M.QK'L]"TRTC,%Q! 6EE;RP\FXN.N.?Y58;2[(7B0KI<9B*%FFSPI[#% &H@$
M<84L<*.K'^=*KJZAD8,I&00<@UF+H-ANE\RV@=&/RKLQ@8Z=>:D30=*C142Q
MA55&  .!0!HT50_L33?^?.+\JNQQI%&L<:A4484#L* '4444 %%%% !1110
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M** "JEC]ZX_ZZFK=5+'[UQ_UU- %NBBB@ HHHH **** "BBB@ HHHH ****
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MLY4,-R]0#TH ?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.>*@AGM)K:(12217,)W?9G?:4SQB-_7V- &G%;0_9H;349()+>16= [<H,D
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M101U(!P10! MU-/!<?;+19[21MD+0 N70^H[55#6<\'V,73P6[2?9VMI@#D
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M8[5&!;&.:2ULS<?:2DD@885P>,_-QP!TITUTUNKM//'"B[^(QN8KP P^GT-
M%AY##;>==RI"B9,F#\N.W-5YI([>T6WM[62[*!66,\Y!/7<W!QUZYIKKY0+I
M:SW;OY<;[VX9?[V#QQWXJ9(KYDB\V>.)EF)81KD.G.%YZ'&* &33R0DM=7D5
MO&)EV;<9(/\ "V?4^E1R*;4^7:VDMS-'\P>5N,.WS ,?Y4B/I?GR7\,9GDFD
M$+NBE\,/4=L>M6H);R:1&E@6"(JP96;+9S\N,<8(YH 06TSR$W%T<++YD2Q?
M)A<=&]:B@%LB3R:?;!GE!G5R"%=SD=3T/%$;6N^"?S9+J:-F@\Q.<$GD,!QV
M'TJ4-=W"747EFTVMMAER'W#'WL?XT /\J>20^;/M4[&5(^"I'49[@U7AO+22
M9FLXC.9G*R21C*AE'\1[>E22/:)=B8AI+F("([ 25#<\@4L7VB:.91#]C*S?
M*0%;>O'..V>10!-&\KV\+3X@E.-R AN?3-,AO;.6_FMXG5KA #* IX],FH[B
MRM9I3-<NTGDN)E#.<1D#J *GAGBG0R6^&W*&#XP&STY[T 6:*J:=]N^R_P#$
MP,1GW'_59VXSQ5N@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ KBK?PC>M%=.+DV-U)J%RQD0[O,MI7R5..AQ@@]0?QKM:*.MPOI8
MXZX\-7:1:HME!$J_:K:>TBWA5=8E3Y?]G[I%5-1TG7=;NM<N9-,6T6ZT1[&W
MC>=&<R$L?FP<#J.YKO**-_Z\K#3MM_6MSEK/3-1T_P 4K>BT$UO<Z=;VDC+(
MH,#1F0DD'J#O[9Z5B0V>I:-J/AB)=/CNKFWM[OS(?-56 ++RC'C/(ZD=^:]$
MHIMMDV.'CT#5XM1;Q!]CA:Y>^-R=-\T?*AA$60_W?,P,^G)&>]/O=$U;4(M0
MU$V:07,UQ:2QV7G*2RPN&.YA\H<\CJ1P.:[6BD,XJ^TS6O[8EU2"WO2M[!&K
MV]O=0HT++GABP(*\]CUSP:M:#X;ETK6X+@VZK!%I4=JI\T2%'\QF90< XY'.
M!T%=7133L#U7]?UT.+CT75+"WTV>*R$\EGJ-S,;=)54F.0OMP2<?Q XKLU)*
M@L,$CD9Z4M%('J[A1110 51NM'TV^F\ZZL;>:3&-\D8)Q5ZB@#+_ .$:T3_H
M%6G_ 'Z%'_"-:)_T"K3_ +]"M2B@#+_X1K1/^@5:?]^A1_PC6B?] JT_[]"M
M2B@#+_X1K1/^@5:?]^A1_P (UHG_ $"K3_OT*U** ,K_ (1O1/\ H%6G_?H4
M?\(WHA_YA5I_WZ%:A(SMR,D9Q4<*-#"$:1Y"/XFZF@#(7PSI@O)"VF6!MRHV
M 0#<#WS^E5+G0M#9+B.?3;40[PJ-;Q9<8 )S@<5N(1,!>(D@DV%51R5_,?UJ
MG(SQV.%,-CJ%X<J&.X&3'Z\"@#-D\,Z2T<S3Z9;7%G*$\N)+<!U]<GK[U&GA
MW17EB%KIUI<VTC997A!5%7@@''7..#[U>F-T@1I66/5!;D"7!\@G/0^_^-36
M\<I@:X:(6U\JM'M+?NW8\Y SSD_C0!B2:!I#.\.G6-J\L2EIK.:,!R&]&ZK_
M "J./PYH6H7<L:Z;;.;<H@41['A..3N_CZ5G-;ZW?ZLEK<)):[?G$A/[P+_$
M%8?>'L?:KUS<&RL+>6[G::=2K)+RBC!(QQR&(]>* ,^#2M'2XEV6<4RK$4-Q
M'  8VS_''_6HI-%TZRM6G>PM,L"5=(@UM/D#[PYV&M ZA#=:C=W%W%)"T3?)
M=0J5DB7L)%[CWYID,<EG 0DR()VRDJC-K<9[,/X30!#<^']#D>.1+&U(DQFW
M=0 YQUBD[?3VK.3PSIMU?RPRZ; K '"A!YT7H67HX]Q6I/;G]W9):B"9VWFP
ME.8IO4QOV-2X5Y_D:646H.8A\MS;?0_Q#^E ',0Z%8VSQ^?9VUW;^8420 )^
M3=C[&KL^BZ=&UTC6MLI'(D6 'KVDC[?[PJ]YUO/;3.9XU:0A6N"GRR9_AE3^
M$_[5%W*=/F@&HPRF-E&PAOF3IRCC[R^QH I2Z=I\*6\@TJ'-Q&51U"E=WMV8
M>QYI(]/T6.!@MG90S,Q5K>2/]W(/QY1OTJ=$,-E=%;H2V32[T;9NB)ZX8=4/
MN*KQPQWFH>5.I:-Q@*)0TF".JMT;GL: )+CPII,K1/:6:6UXQ!6UE((<#^X_
M3UZTKZ#9V4S""R@CU!B D,T2+N]<Y^5OPQ3X0\%M<:?'<AX@,H9%.Z+'7*'D
M?45.U]=MIT<DJ)?0HRK\X\Q![AA\RGV- ")I6BAB=3TJ&POD8!GMU #<9)VG
M@CZ4L5O:^:T5M!I&HJJYD2: 0LH!^GO5Z4RZOI"E+*08+%#&5G5CG)'S<BLZ
M2QEAM(91I\5O*Q=)=ZL/,[=N!P0?K0!=_L+0=Q^U>#HH\DDM ZD8'I@BKJ:)
MX5CCV_V6\88^40R\KNYSU]NM8EH;.5G22.:.\B9@D2SG,F[.[&1P.I_&FLMP
MER6G5XK+*-M64;U!&W)/4X7/TH R_B'8>'8_!%[+86C)<20I(I?LI< ?G73Z
M7IFEKIVGH_AV.1C;HS-E0!M3(/XUROQ&6./PGJ!$:*##%' ^_<SQB088=L&N
MML;.SMMHN$@-Y+;H;?!8[QLPR')QDCM[T#+EOH'A(7S)'I-DMP'"E'(/WAG(
M'X]*LQ^&=$;;%%962&*1U(2V!^7^[STZBJ/G)O6" 11RS!?LK(J[F'\).0<;
M2-OO5R)=32W4.UQ(\K9;YL%5'<=.<]1Z4"'MX<T)D16TU6/DA@PC"!B"/R8U
M"VD:)]FF>VTBP27RA.-\8?&3\W3TQVHALA</L:Y>2:(Y5FBR$+<C//8Y_,5H
MHDT<\**UT5;.?+C0*@/8_0\_C0!F_P!@:2\ADCL!(J.["-+55!  ^0DC\C4O
M_"/Z!#;P>=I-L LF09PN[IDGW(]/:M1#<2.ZR6DZ"4G)\X?+CICTS4"QWS,S
MKIL",4,R&23<5F/!'TQZ4 4X]!T>7#"RM75T>1%BM@-RG&.?4?UI(_#&FN3C
M0;88\M=UP =Z]3P.C"M2[?4(W;[/-:[3L"(PY&#\_P"E0I>13RHHU"20X:Y4
M11\/%T Z<_SH JS>&=&BLY6OK:S2,!MSI$$VC/!SZXJ*71O#9B:2'0HKHAD!
M"P#/3(/-;2V]NR1@PR3#R2!YG.1D'!SWZ?E3BMW*2%*01M",<99'_EB@#$&@
MV\K1N-#T^VC69A*)$!)C'0C'>G1>&?#^RWCEM8;EI)#+%((A@XYQD#&/K6RT
MUFD^UY@7G/D[=V02 >,=N*11);PK!9VJI'%(J ,<#9QDC_/:@#+'AO3A)LAT
M.PBC24 EHU^9,9)&!US44FB>&H(9)+FTM93:2;G*PC*YZ @>QK6F*10R2W5P
M\GV>7S<1CE1V4@=:G*%+E##;QE)B3,_0]./KZ4 8<F@Z?(S+8Z%9("4?S981
MM<'KC'.<>M2GPGH$]PPDM+9V1Q((U4+LX]NWUK6CMYV(:>X;*RLZ"/Y1M[*?
M6H8)+%[Z:>VC+SL_D32*IX*CO[4 4H-#\.N4%OI%JR2;F#I -N0><GUS3!X8
MTT"Z^TV5BL;-^Y9(5!1<=\]\UJ*UT]B3% EO-NP$<Y&,]>/45)<B!899+@YB
MVC<",CCVH RXO#N@I</ -+@:0J'9FA!'IUZ=NE%IX=TTP_Z9H^GQR;R $0$$
M9X[=:UV9Y4D2,F-BOR28R,GO^%(+8/;11W+><Z$,7(QEAWH I?\ "-Z)_P!
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ME% &7_PC6B?] JT_[]"C_A&M$_Z!5I_WZ%:E% &7_P (UHG_ $"K3_OT*/\
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MR?LJJ6.#DYZC)&:T+6YBD$)$M[ABT0$D9&3UR>.WK0!1_P"$=TQ8U6/2()I
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M;B.QOKE=Q!^:WNQWQV'_ ->L^&Z1%F,EPT6QMBSA<O&#T60?QI[\U*T;^;!
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ML;1RHK?,..">.]3I<:I:QF>QNS+ #M>.20?+M'+ ANF<UL36 G/F"UC:":5
MD[S[O,4'A<8X&,UDWNEV^_<D,<#*-TI)CV\DD## >E %^T\56]S*(9;B,0LB
M@DS.KY ]QW;CK7065V9W;>FT>9N8BY# -CD<=O;WKSZ\@@T]H)S:V[VTJ*5E
M!92&QS]UCSGVJ)[B"XB +R!68RNZOP6YR<,!_.@#T=UN)(&5+:565,!?M.,D
MGG)'?OFDDM+I;BYE@@@+A5\AY)&.XXPVX?2N,M-3DMKQY;>6:YDEP\BS0GGC
M@_(>/E-;NF^(+6:-8[E(TN$5HEC,C+E,?[>.21CF@#<CCN5DYN+>*%)1L5$Z
MIC[OMSZ5'=W.GVSI;WUWND\T.BL>023MZ=OK445G9I'F#22ZG8?E=2"0,CJW
M:KS.Y?<+ E^ 68KTQGU]>* (DF2**1[&P=F:?$B[?+)/=^>HJTJW/VUV9T-L
M8P%3'S!NYSZ5 YU)IXS&+=(<J7#9+8YW#^6#3X[>XW;KBZ9@)&*A!M&T] ?7
M'K0!&8(X+13>W3R^2_F>8YV^N,X[<U-'''96[16MMA8QE43 !SZ4HBMK<LQ*
M@L%1B[9SCIUID>I6\Y3R=\H:1H]RH<*5ZYH =*MU)*Z(ZQPF,;9!RX;//'3&
M*?+'""\TH&-F&W'C:.>E,AENY)%,ENL414[@6RP.>.G&,4V.RV!3-<33;0P.
M]N&!]0.* %.H0"W@FB#S13$!&B4L.>_L*C6&[NX"MVWV=UF)7R'^\H/ .1W'
M44_[1;6KQ6D2'J%"1H2$!SC..@XJ$?VI/<#?Y5M;C>K ?,Y[*0>@]: )X].L
MXI(GBMT1H00FT?=W=?SJP&+[U 92. 2.ON*HPS6]N)%C>2XF1DCF91N;=@ $
M]NE:/ YH AM(IH;98YYS/(/O2%0,_@*GHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M% !1110 4444 %%%% !1110 4444 %%%% !52Q^]<?\ 74U;JI8_>N/^NIH
MMT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1135+%B"N,'CWH B
M^R0?:OM7E+Y^W;YF.<>E16R@SSSK=-,CM@)D%8R."!^-6ZK;9%M)/LT*0S'<
M55P,;O4X]>M %>W\IHKF999+L"5B$8#Y"/X5Z=Z\4\:7$@\47L<;7,4.8W$,
MKG*$HI/&?4FO:[D*]B(;]"B&/?-+$VU5(P>N<UXGXYDBE\87KPR"2(K%L<'.
M1Y28YKLP*_>/T/*SAM4%;O\ HS$:^NW38]U.R^AD)%#7ETZJKW,S*IR 7) J
M;3]*O-3\XVD:,(5#2%Y50*"<=6([TE]IEYIWEFYB"K("4='5U;'7!4D5Z?NW
ML?/6J<O-K8B>]NY4V274SKZ-(2*&O;IMNZYF.TY7,AX^E05+]GF^S?:?*;R-
M^SS,<;L9QGUQ561*E)[,<UY=-()&N9BZ]&+G(_&FFXG)8F:0[_O?,?F^M+<P
M"WF\L313?*#OB)*\C..0.14L&GS7&GW=ZC(([79O!)R=QP,4O=M<?OWL0>?,
M<_O9.1@_,>E+]JN,*//EPGW1O/R_2K-AI%[J44TMK&ACAV^8SS)&%STY8CTJ
M.^TV[TYT6ZB"^8NY&5U=6'L5)!I7C>W4=JG+S:V(A<S@,!-)\_WOG/S?6AKF
M=D5&GD*+T4N<"HJ*JR(YI=R=[V[D38]U,R_W3(2*1[JXD4*]Q*RKT#.2!4-%
M%D'-+N3/=W,@ >XE8+T#.3BD:XG<@M-(Q7H2Q.*BHHL@YI=RP+^\ P+N<?20
MT@O;L-N%U,&YY$ASS4%%%D'-+N3B]NQ)Y@NIM^,;O,.<?6G'4+TXS=W'!R/W
MAZ_G5:E R0,@9[FBR#FEW+ U&^'2\N!GG_6M_C1_:-]_S^7'_?UO\:CN81;W
M#PB:*8*<>9$25;Z9 J*DDF-RDG9LM?VE?_\ /[<_]_6_QI4U34$8,M]<AAT(
ME;_&JE%/E787/+N>L>"?&,5_ITUEK3!Y8V#"5USO4GJWT/>NM-VG]I6MK]J,
MCJNYG$BC?G[H(QR#[5Y7\-8HY_$YBFC62-H6W*PR#Q7L"0AKO'E&/R2/F$8"
MN,' !Z\5X^*@H5+(^JRVK*KATY[K0R1(8KUUMYUWS@QI'))(RK(O+@#MQWIO
MDV^I1,UJ6:,J(4C?>,2*#R=WH._K5Z\MXHE$K1.)%N@T3>=M+%L X/IC(Q[4
MR6\$,U^_[L10.A9C*_#<<$ <#'IUKF.\Y?6X[*984 N)=H*QB,H<[<Y8AAG^
M$YJL\BQ6T,T1BN+,("=T&T(6.<,$/7/M78%%,J&6W9I7,KI''.QW1^N#QSD<
M'IFJ4>EP?9(YH$NDB9T#1.L;CY3]XY/3MUH Y22W(3Y8S;RNA#29(4KG!X=>
M/3K4MW]J:80+;3/'][S5.[(/H!N4C'M6S<"TM+V61O,B:,$,RP2!)')R#\I(
M*^V*R$$T]]OCGCED89'DE3@ \##;6'T!H ?IEY=6USMMD)@,TC[68J0H7&/E
M[]>,=:Z2#7;%H4N9Y;N,1L$95?S!QGD[<GGW]*Q)I9E=8VVQ2*!\SL=V.^/,
MXR>G#551+>'SW6!HF6-W)@#*XZ;3R>0/8T =U;WVGS%##>J=A(VF7DD^H-3&
MS@>(1R.\BE2IW2'Y@3GUKAX]6B^TJUS#;7T   \U1OC. .6Z]<_>Q]:ZBTN+
M2=%D&GS+^]2,8 8 @<$8)&!TS0!H2160!DD2,X"Y+<\+T_(T?:3RL%M(W+#.
M-HR/KZ^M1)A(U>VT_!#&,AL*0N3S],_SIT=U(=IN&@A/EY= ^65N_P"&* ))
M/M4@<!E@"NI5_O;EX)!';N*C>*%7CCGFED,KML#$X.0<KQQC&>M1P^5MB@DD
MFNW,!/F$?+(I]<?+DU+.MW+"8[8);MA=KN V/48]0* &B6]>69$ME@C5"$ED
M8$ENW [5';9218KF]-S=*&F4)\F5/'0<$?6I&A6VM4DO+R1UA5O,=C@.#_>
MXJ1$$*F*UME4)'^[;@+_ +OK0 I$IC22WB2)W8-()!SCOT[U%;PR6T+M-<27
MDRYST'?(&.F>:)_,%G%-<7/V=HB'F\KD'U'(SBI9#+F06T*AR PD?&UORYSC
MVH M#I2TU2"."#@TZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@],X]J;*XDCBCOXB%G78RJ \8;/'/7-0>6TD=XDX2>:)?+7[,VV4H<'!]":
M+<1:,B-9'?;&9"DH^;).1\W08Y&*C5V<02);CR[M?WHA .UB/O%L\CM5AOG_
M -5(285(> $?,2. WI042WA0INCAB3!@C4$?3 '\J /*/$T"CXS>$-.A8F&W
MAWIAB2 2W<]_EZUZT[HL2-<%899/D!SR">P->5W=M"OQ_P!,BAC"16M@,*HX
M7.[_ .*KU:1X@C/<*%CC8$,^,=N: )!$I1 _SE.06'.?7ZT%U#A,G<02./\
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MJ6HVKYHY#;N,#;R*LW(B9X!)&SGS,H0,[3@\FB0S&Y4;(C:["7+'Y@>W'3%
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M>)/LBB24% I;><X/W=^S&37 5:L=2N]-E:2TF\MG7:V5#!A[@@@T.@NG]?\
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MYH O%V\X)Y;%2,[\C /IZU)42,S,X:,H%;"DD?,/6I: "BBB@ HHHH ****
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M:JS-:VY:\N4B@<?)YS8SC/'/]*EG$CVLOV-XUF8?*Y&5W>^*SFU#RF%KJUN
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M@6V#,DP;@''1P,;AG-7$M[1(!<K&JQ(HEBD09V\?-M7'&?ZT?6JW</[-PO\
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MY 7/6EAV9EEBM"JK,S2-<9!X'WESV_*LN+Q%X?2X4OK5C,SJP#>?'Y<0X^7
M/K^/%5M<\4Z,FAW-Q'K%A-=0V\J\7 4'*G.%SST&* ,;X+'[5X2U*]< M>:E
M-*<C.<A:]#M!+]D GDBE?GYHEPI'85Y;\+=5T32? -C)<:A;"Z621O)-PJD;
MFQR"?0 \UWR^*= $K@Z]IOEX 5!.H(/?G- &M9(8[.-#"L.!_JT;(7\:L5B0
M^)?#<$2Q1ZSIZHO 'VE?\:D_X2OP]_T&]/\ _ A?\: ->HIX4GB,<@RIZX.*
MS/\ A*O#W_0;T_\ \"%_QJ%?%>B))*TNN::8\CRPDZY [YYYYH T@ [M-=0I
M&8'/EN7SQZ^U13P[(G>&U#LD@EC59-N]CU)JC)XM\-R2FUDU6R963<295*8S
MC!.<9]JAN/$_A^Y8V@UC3Q" #(6F7:RGLI##!XH NL4O?-D$,T9=OLS-YFP@
M?WA^)P#4<KSCR2FZ+AH0CQB0+CDLQ!XR!CKWK%N==TS^T9&M?$.FH0RRH#*=
MI.-N"<[<8';GO43>)]%LD9)-2T^5Y;QI=PND81YZ.0"#B@#=AVW%M"50);H?
M,M1!,0TN,G&T@?E5,(LR*D_DFXDWS+'*ODNB$],KQG-9EOXKT..WV6^M0;GF
M;=<S3(!"3_$@;JI_K5:XU_0OL>W2];M1.TV;AY+A4+=<D!\@@]<#VH @OM.<
M7C"\Q;/(<H)0 OTWKQQ_M"LLV$NG3^7<(JS [@O5)5]B.,_0U-<>)]-6:2\@
MU6V&YR&V3*HD [F-R0?PQ47_  D>D_:DN?[4MHXYC\R0RJ5S[PMSCZ'% $J2
M12N[12&*,\IOR0&_V9.JGV(ISSLQ\N:'%VG61%W,Z^I7[KC'<55U#4M*6Y+0
MZMI^)%PA@F!5#[H3N4\?3VJHNNZ9DRW%[8ET^611("DG^UP<9^A!]J .AB2+
M?$TKJD+_ '%=B8BWHK#YHS[&MK3=0O+:5H9;\1DCY8=07( _V9 <&N';7].M
ME:2'58&V8#IYZGCMU^\/8C(K7L-<T2"\=TUJRMS*N[*RK- >^&0\QF@#T&"Y
MNW&76R53_$DQ/T[4DETD8W7%['Q ?,AA&23_ 'AWKC&\6:(AWW%MI%T?[]G=
M1L/Q&<UL6/BW0Y(II(I-.M'"CR_-N(P6)['!XH U[ (8$^RVKLJP?NI[@_,W
M/W3GYJ=<^86(FN<YB#K;0<,S*<M@]2#P,53;Q)H3NC/XDL5"2;MJW" $8QM/
M/-01^*/#-DL4=I?V3J92I(G7Y,\DY)Z?2@#57[1=;WBMQ:/)&I$[J"V>ZD>U
M(S6\4UU) IN[R/#-"'R0<8&,\+Q6?-K_ (?N8VCN?$%@5\T.@CN50C'0$@\T
MU/&&CSJSP:GIT#+-M?SYE^=1W&#^5 &O.IRTUU,$M?)VO$>Q/?/Z4MQ'-/!-
M;1,;9/+ CN%.2/7CV_K63/XG\-VYFN8]3LIIG"AD6Z7YA]"<5*?$GA][@N?$
M%@8S'M,/VA-OUZ_A0!KE/F2:%8F=L!G/4K]13YKA(#&')S(X1< GDUA6OBO1
MS;LLVK:5#(I(14N5*@=NXJQ'XKT':!)K>G%P!N(G4 GVYH VZ*QE\6>'6&5U
MS3B/47*?XT[_ (2OP]_T&]/_ / A?\: ->BLC_A*_#W_ $&]/_\  A?\:/\
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M1\%)!]UP0""I[CF@"Q1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ7R710!]>1:MIVO6#:9JNHV=OJMF<Q3"=?F..&!S^=4TUFWN;HW[7UK#KUD
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M=5]JDH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MWMM*"#\LKL^U>G4Y%#M:_P#77_@$O^OP,36?A[_9&@KJ;7&J.9V(M8GTETW
M,%_>$M^[8DG P<XZ\URTVB:M;745K/I=[%<3?ZJ*2W=7?_=!&3^%=WX>\3:/
MIR^#C<W";K.&\CF.&)MWD9]CG'/&0>.?QK5T_P 5VNG:KH<5[J^E7-M%J8N6
MFBFN9W@ 4@G=)T!SR!Z"AJS_ *_KS&>8+H6L/=BT32KYKDIY@A%NY?;_ 'MN
M,X]Z;#HNJW-Q+;P:9>2SQ$+)&D#,R$] 0!D5WGAWQ9%=:'K5I?:HL6K75VD_
MVN\GF031@'Y"\9W#!.0.G-37WC()I_B98]6MUOYK2SMXI[%Y09PC-N^=_F)
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M $09O%%N;*;%KK6GG*/_ ,],?_7IP9O$2K-"S6FOZ>,,O_/3%0SL-;MEU6Q
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MX72!S)*6#,92O YZ'\_TIZLT2QI*YDD8XW*F 3U_"@">BD%+0 4444 %%%%
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M*6VR5P,N,@\$X_2FV5O$T;3V\%LWGB19);9RAQGC ]<]:67SH!?$2:@H699
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M#R98SM229?E?CKQR13 TK".=_-@\K?\ Z,I!\P#@?XTL3B5/,N694N@ MO,
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M(N[8Z5=2J0)%.ZTF/H1SP: *T\;6\C2M;16RR]8E;=:7/T;^$_4U3=Y8WB:
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M-C3KBV>]GN$FD+-L+%@2<\'L*C?QGHK7-L62]C-L2%&, @C'(SS0!HQSB"6
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MT];BXC>*/8H6W";F3MCCK5RW:4M+YGE[0WR!,Y ]_>@"Q1110 4444 %%%%
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M;^!O^6^CJW'<A!59'\U+#Y%9IM)EBY./N[L?RJ311(FL:*TGW;BP>+/KC?\
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ME+U! ],\_B:K1R2:7=K<0';>V;_.,\2)V;\C^M75%N'+R872-2'.W_EC*/\
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M+19$4G/\//\ .N\XRG8:3';6^N0N1*_]GK*'(R06&ZK%M%METZ8DLLVD2*5
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MW8B@"MKD^F::DL4EW;6PF8.8DMQ(['G)(]_PKBM4O;%9A-I$NQWE/RHAC.W
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MDCR589&01^AH DHHHH **** "BBB@ JI8_>N/^NIJW52Q^]<?]=30!;HHHH
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M.34%_B/3TW+G&C(!STRXH CU%@EO=HI(/]G6T;?B0:?J;I#_ &\O."MLB_7
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MEF]CNIK26!4M+>.-(''\7R\UJU'&Y;=E&7#$#/?WJ2@ HHHH **** "BBB@
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MY&XC!'<\]*7]?F/^OR.X-U;B)93<1"-_NN7&&XSP?H*K7FMZ98:>;^YOH$M
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M5BY^T +JSH6%Q)T[8^;VJSN,$]K'C_4ZO(..?2D8I%H\,BKEH=7.X]N^/Y4
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ML:H8B!\I_O9ZY-6Z *']B6'_ #RD_P"_S_XT?V)8?\\I/^_S_P"-:%% &?\
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MW],>] '$:GH^E16GB"VA>\\P1B<K]IDQR!R/FYY'>N<N+6T9W;=<?OM)4_\
M'S)]X8_VO:NRU6[674+VSA2(I<::9$D51EL>_IBN2@B(33FVY\ZQEC.?4;J
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MS6G110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %86O:9"=&U>5%/FSP;FYSDH"1Q6[6=J)O&62&&%7A>WDRV?F#X^4 >]
M'$WL[3WFHF0C=<:0LGU(&?Z54AD,KRH&XGT4D\=U!_\ B:DEMY;:ZTT.K;I]
M)DB(?@@A6./Y5%IB!IM').?M%A/#GW'F4 6?#\)DU5U)Q]HT@8/7LH_I4NF.
M(XO"TG.=\T#9'N:3PRX_MO1O]O3W0\>CM_A59YVMM.M&(_X]-7=03Z')H ?H
M>V+4-(+-E4N[B$'/TQ5*%0DVDJ2"B:A-"6[$$K2N[6<UQ(^ MEJP;'LV[/\
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MDK^5&-,DE+ _<#R$Y_(UVEDD,<5BBJ\^R#]W<D9XP.I]30!I44#I10 4444
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M_P#7H ;IT@D^QDG)DUDOGU  _P :LZ<QN!8W!3)DUIF+8]ABJ>E;5.AXR?\
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M>X"'$>F1QCV+*H'\ZA\KR--ORZXV:= BG_>;-2WR-Y&MQ@?ZR2V08/TP/TH
MH6B&TT36(GRCR);H >OS8/\ *I]4B)EOH^_VFVCXXS\AJ34HP)=0A^;<;ZWC
MP>X"_P#UJ6YW3:G=;"2'U2-#CK\H- #5*Q26P^7<=4FD)/;;51HW32M,DQ\S
M"YF/Y 5=@42.LV0=HO+C\#P#^=)=X2VLTC',6F#C'1G8?XT 1)#MMY8>2S6<
M*%1U^=P<5J-$C74LD*XSJD42(3P0BTN5_M*5F!8M>VUN".VP9-1:?/YM]8R8
MQ')>75QCV"@4 30E#IFD*2"OVJXF;WV[C_2H+1A;0VCO\NS39YR#V+-P:K-,
M8=,T]D)W?8KF0#TW$\_K4TUP%2\0@ 0:1'$I8==V/\: +=[,RV]HJIS%HY;/
MIN"BJMZ46"_B7#86TM0P_,U'J5VF-07=@)806Z@\<G!_I5.Q4?V#;L[-NN-2
M3#$\D** -</%ME4JH636@"".RUEM>^9.ERL@YFNK@#OC& ?TJ);V0):NI5@;
MFXN"/4@<?UJI"T<<&UW4,;,JON6<_P!#0!9BA86=ZP&=MI%!G'4L0?\ &M"Z
MM-UW<*02HN[:V4 >BU9CM%DGGMAG9)?P0GZ(N35^VBCN;ZTF;(6?4)I_J$!
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M<8)%&]6LYT)&9=; ('<#FH;B<SWX(&T2ZN 5]=@ JH9MT5K(N0TE_<2C\!0
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M '$;_P#1[]HY8F633HDSO&0P"Y7'K@&J>J2VJ7,WDR(=R6SC:<\A1N%>A_\
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M/<5++K%DTT\RSDF2_BDQM/\ JU[_ ,Z[X^&-$/72[;_OB@^%]$(P=+M_^^:
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MFGZ1J%FD^CJ9XU(MYDF+-@+DG'XUVH\+:(/^8;!TQ]VHF\'Z$P/^@(,^A(H
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MU6QMXOWK%9%LIH\E>LC$X_3%>G_V-IG_ #X6WI_JA2?V-IA&/[/ML?\ 7(4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !12"EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *JV7_+Q_P!=F_I5JJME_P O'_79OZ4
M6J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2DK"[#@A213Z9*"T+@#)*D"D]AK<X;2/[?OO"RZR/$,HF\MY/*DAC,?RYX.
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M)/;7IZ6].IKT445B=04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU$J4%HDB."&.V@C@B7;'&H55SG '2I***DM*VB"BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>gyycud3vz5ad000014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gyycud3vz5ad000014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +>!DD# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)67?^NAS.C)^X\5VSPPI'%(S+#$V^.-BASMX'<>@K4\.11#P-;2+&@=K,@L
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 8=YI]U+XPTR_2+-M!!*DC[A\I/3C.:-%T^ZM-:URXGBV17,Z/"VX'< N#
MT/'XUN457.[6(]FKW^?X6,33["Y@\5:Q>R1;;>X2 1/N!W%5(/'4?C3;/3[J
M+QCJ5^\6+6:WC2-]PY(ZC&<UNT4<[#V:_&YPO@^[UBU\/H(=,%[;/)(8F2=4
M9/G((8-[C.1ZU=?0M2ET+799T1M3U,9\E'&U !A5R<#@=ZZ2PL+;3+1;6SB\
MN%22%W$X).3R>>IJS5RJ>\VD9QH^ZE)F1<:0=0\*#2IR8W>V6,G.=K #'Y$5
M2%SXF73OL8TJ/[4$\L7?VE?+SC&_'WO?&*Z2BI4S1T^SL<W<>&FC\&Q:5:OF
M[M );>7.,3*=P(],DD?C3]$TBX:POYM7C"7NI,WGJK9V)C:J@\]!_.NAHH]I
M*UA>RBG<XJRT2?3;06<WA73]0>(;4NU\I1(.Q8,,@^O6K^HZ/<RZ1I,-M8VT
M,D-]#//%;82- "=Q&<?XUTU%-U&W<2HQ2L8?BS3[K4]%%O9Q>9+Y\;[=P' ;
M)ZFG^*[&YU+PW=6EI'YD[F/:NX#.'4GD\= :V:*E3:MY%."=_,YG6M">37(]
M6ATZUU%3%Y,UK<;>F<AU+9&1T^E3Z18E=1,Y\.6.FQHGR.HC,NX]>4& ,>];
M]%/G=K"]DN:YA^%M/NM.L+J*[B\MWNY95&X'*D\'@U!IFD7<<OB%9T\I+Z9C
M"VX'*E<9X/'XUT=%'.[M]P5-))=CG_#":G8V%OIE[IOE);QE?M G5E<@\8 Y
MZ>M=!114R=W<J,>56"BBBD4%%%% !1110 4444 %%%% !1110 4444 %%%%
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M*H]![4^BBLS8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,6FZ=;V4(Q'"@0>_J?QJ90Y47"IS,S)=3F?Q6;)+A8;*SM3/=$@88D\ D]
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG_?5 $E%1^?#_P ]4_[ZH\^'_GJG_?5 $E%1^?#_ ,]4_P"^J//A_P">J?\
M?5 $E%1^?#_SU3_OJCSX?^>J?]]4 245'Y\/_/5/^^J//A_YZI_WU0!)14?G
MP_\ /5/^^J//A_YZI_WU0!)14?GP_P#/5/\ OJCSX?\ GJG_ 'U0!)14?GP_
M\]4_[ZH\^'_GJG_?5 $E%1^?#_SU3_OJCSX?^>J?]]4 245'Y\/_ #U3_OJC
MSX?^>J?]]4 245'Y\/\ SU3_ +ZH\^'_ )ZI_P!]4 245'Y\/_/5/^^J//A_
MYZI_WU0!)14?GP_\]4_[ZH\^'_GJG_?5 $E%1^?#_P ]4_[ZH\^'_GJG_?5
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MGP_\]4_[ZH DHJ/SX?\ GJG_ 'U1Y\/_ #U3_OJ@"2BH_/A_YZI_WU1Y\/\
MSU3_ +ZH DHJ/SX?^>J?]]4>?#_SU3_OJ@"2BH_/A_YZI_WU1Y\/_/5/^^J
M)**C\^'_ )ZI_P!]4>?#_P ]4_[ZH DHJ/SX?^>J?]]4>?#_ ,]4_P"^J )*
M*C\^'_GJG_?5'GP_\]4_[ZH DHI P894@@]Q2T %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5G:U!>
MW.G&.P2SDFW E+M2T; =1Q6C133L[DRCS)HX/_A";W4/[2FN_L-A)<PHD45D
MIV*RL&#MTYR,?0UJ6.D:S=Z]::GKCV:FRB9(8[8L=S,,,QSTX[5U%%:.M)F$
M<)3B[K_A];_F%%%%9'2%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M< 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !114#^:'0"088D?=]J )
MZ*1<A0"<GUQ2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %<-XK\6[?,T[39/F^[+,IZ>R_XUW->%5YN95YTXJ,>I[&3X6G6G*<]>6WZ
MA1117@GU05L>'_$%QH=WN7+VSG][%GK[CWK'HJH3E"2E%ZF=2G&K%PFKIGMM
ME>V^H6B7-M('B<<$=O8^]6*Y/X??\@"?_KZ;_P!!2NLKZFA4=2FIOJ?$8JDJ
M-:5-;)A1116I@%%%% !1110 444$X&3TH **I6^KV%W8R7L-TC6L98/,>%&.
MO)[>]0Z9XATG69)(]/OHYWCY91D$#UP>WO5<LNQ'M(72NM=C3HHHJ2PHHHH
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M-$R<G:H&:V=9-;?TT<D<))-7E?;IV=U8?1117.=P4UE+#AROT IU% $?EO\
M\]G_ "'^%'EO_P ]G_(?X5)10!'Y;_\ /9_R'^%'EO\ \]G_ "'^%244 1^6
M_P#SV?\ (?X4>6__ #V?\A_A4E% $?EO_P ]G_(?X4>6_P#SV?\ (?X5)10!
M'Y;_ //9_P A_A1Y;_\ /9_R'^%244 1^6__ #V?\A_A1Y;_ //9_P A_A4E
M0R-*K+@IAFP,@_XT .\M_P#GL_Y#_"CRW_Y[/^0_PIZ[L?,03["EH C\M_\
MGL_Y#_"CRW_Y[/\ D/\ "I** (_+?_GL_P"0_P */+?_ )[/^0_PJ2B@"/RW
M_P">S_D/\*/+?_GL_P"0_P *DHH C\M_^>S_ )#_  H\M_\ GL_Y#_"I** (
M_+?_ )[/^0_PH\M_^>S_ )#_  J2B@"/RW_Y[/\ D/\ "CRW_P">S_D/\*DH
MH C\M_\ GL_Y#_"CRW_Y[/\ D/\ "I** (_+?_GL_P"0_P */+?_ )[/^0_P
MJ2B@"/RW_P">S_D/\*/+?_GL_P"0_P *DHH C\M_^>S_ )#_  H\M_\ GL_Y
M#_"I** (_+?_ )[/^0_PH\M_^>S_ )#_  J2B@"/RW_Y[/\ D/\ "CRW_P">
MS_D/\*DHH C\M_\ GL_Y#_"CRW_Y[/\ D/\ "I** (_+?_GL_P"0_P */+?_
M )[/^0_PJ2B@"/RW_P">S_D/\*/+?_GL_P"0_P *DHH C\M_^>S_ )#_  H\
MM_\ GL_Y#_"I*:SJF,YY] 30 WRW_P">S_D/\*/+?_GL_P"0_P *5)DD^Z2<
MC/W2*?0!'Y;_ //9_P A_A1Y;_\ /9_R'^%244 1^6__ #V?\A_A1Y;_ //9
M_P A_A4E% $?EO\ \]G_ "'^%'EO_P ]G_(?X5)10!'Y;_\ /9_R'^%'EO\
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M10!'Y;_\]G_(?X4>6_\ SV?\A_A4E% $?EO_ ,]G_(?X4>6__/9_R'^%244
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MM=$/A1RU/C=PHHHJB HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH)) _*M6MZ;O!,YJJM-KS"BBBK,PHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (X_OR_[_\
M05)4<?WY?]_^@J2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MO"J]UKPJO'S;['S_ $/H<A_Y>?+]0KHM(M;*VL[2[N[9;F6[N?)AC<G8J@@,
MQ'<Y/2N=K<T34Q&BV5Q8R7D*RB>,1$[XV'<>HZ<5YM!Q4]3V,4I.G[OSZ#KR
MPM'M=9DCC,<UE>8!!^4QLQ4+CVQ6#71:W>R26T\5MIEQ:6TTQFGDF4[I&)XS
MQ@ $]*YVG7Y5*R#"N3A>7]:+]=3TGX??\@"?_KZ;_P!!2NLKD_A]_P @"?\
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MUH /-/\ SRD_(?XT>:?^>4GY#_&I:* (O-/_ #RD_(?XT>:?^>4GY#_&I:*
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M?Q[IB_=@N6_X"H_K6BFCZ<GW=/MA_P!LA5A+.!/N6T*_2,#^E/EQ+WDE\O\
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MVSF=&:XGD,LI4<;CV'/0  5HHQ;/R,OUIU+6T8J*LC"<G*7,PHHHIDA1110
M4444 %%%% !7&7<%[=ZI-IDT=YY$EV9Y9%SL\D+P 1_+U KLZXR^UC5'U.94
MU*.QMDNC;9:)6"_*2&8GUQ7-B7&RN=F#4G)\MMNO_ -WPR;@^'[7[3O\P!@-
M^=VW<<9_#%:U9GA^[FOM$MYYY#)*VX,^T#=AB,C'&*TZUI6]G&W8PKW]K*_=
MA1116AD<UXPBO(]-DO[.[U))(DVK;V0!WL3P2,$X'?VK#M-2OM0MM!TFVUJ5
MGO1+)=7@7$@V#)09'&.GZUU6JZ/=W]S'/::S=V+*FPI&%9&&<YVGO[UG_P#"
M%6D=A:Q6UY<PWEM*TR7@(+EV^]GL0>./:NF$X*"3//JTJLJCE%:>N^JVUZK0
M=X9O+P:CJ^CWMRUTUA(GESN &9'7(#8[BNEK*T30XM&CG(GEN;FYD\R>XE/S
M.>WT ]*U:QJ-.5T==",HP2EO_5@HHHJ#48TA4X\MV]P*;YI_YY2?D/\ &I:*
M (O-/_/*3\A_C1YI_P">4GY#_&I:* (O-/\ SRD_(?XT>:?^>4GY#_&I:* (
MO-/_ #RD_(?XT>:?^>4GY#_&I:* (O-/_/*3\A_C1YI_YY2?D/\ &I:* (O-
M/_/*3\A_C1YI_P">4GY#_&I:* (O-/\ SRD_(?XT>:?^>4GY#_&I:* (O-/_
M #RD_(?XT>:?^>4GY#_&I:* (O-/_/*3\A_C1YI_YY2?D/\ &I:* (O-/_/*
M3\A_C1YI_P">4GY#_&I:* (O-/\ SRD_(?XT>:?^>4GY#_&I:* (O-/_ #RD
M_(?XT>:?^>4GY#_&I:* (O-/_/*3\A_C1YI_YY2?D/\ &I:* (O-/_/*3\A_
MC1YI_P">4GY#_&I:* (O-/\ SRD_(?XT>:?^>4GY#_&I:* (O-/_ #RD_(?X
MT>:?^>4GY#_&I:* (O-/_/*3\A_C1YI_YY2?D/\ &I:* (O-/_/*3\A_C1YI
M_P">4GY#_&I:* (O-/\ SRD_(?XT>:?^>4GY#_&I:* (O-/_ #RD_(?XT>:?
M^>4GY#_&I:* (O-/_/*3\A_C1YI_YY2?D/\ &I:* (O-/_/*3\A_C1YI_P">
M4GY#_&I:* (O-/\ SRD_(?XT>:?^>4GY#_&I:* (O-/_ #RD_(?XT>:?^>4G
MY#_&I:* (O-/_/*3\A_C1YI_YY2?D/\ &I:* (O-/_/*3\A_C1YI_P">4GY#
M_&I:* (O-/\ SRD_(?XT>:?^>4GY#_&I:* (O-/_ #RD_(?XT>:?^>4GY#_&
MI:* (O-/_/*3\A_C1YI_YY2?D/\ &I:* (O-/_/*3\A_C1YI_P">4GY#_&I:
M* (O-/\ SRD_(?XT>:?^>4GY#_&I:* (O-/_ #RD_(?XT>:?^>4GY#_&I:*
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M'/@H[1D_5I?D8!\=2R\6FD2R?5S_ $%-_P"$A\37(_T?1P@]7C;^I%=2%8#
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M+AL_-$OE C>$VYR2>GXU=K6%^5<VYA5Y>=\NUPHHHJB HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* (I))$Y"*1D#[V.IQZ4]2Q'S* ?8YILW^K'^\O\Q4E !1110 4444 %%%%
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MCVK;CD62-9$8,C ,I'<&IC-2T+G3E!78^BBBK,PHHHH **** "BBB@ HHHH
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M47V>+^[^IH^SQ?W?U- $M1R?ZV'_ 'C_ "-)]GB_N_J:CD@C\V+Y?XCW/H:
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M_P!W]30!+147D1_W3^9IK10J,M@#U+$4 3T5G2WVDP?ZV\MT]C,/\:HS>)-
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M "BBB@ HHHH CM_^/>/_ '14E1V__'O'_NBI* "BBB@ HHHH **** "BBB@
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MY,3+>27HO\PY\%':$GZNWY'.'QEJ4YQ::)(<]"=S?R I#J?C"Y_U=C% #W*
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MUR<4 .HJ/,_]V/\ [Z/^%&9_[L?_ 'T?\* )**CS/_=C_P"^C_A29F_NQ_\
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M5'F?^['_ -]'_"C,_P#=C_[Z/^% $E%1YG_NQ_\ ?1_PHS/_ '8_^^C_ (4
M245'F?\ NQ_]]'_"C,_]V/\ [Z/^% $E%1YG_NQ_]]'_  HS/_=C_P"^C_A0
M!)14>9_[L?\ WT?\*,S_ -V/_OH_X4 245'F?^['_P!]'_"C,_\ =C_[Z/\
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M  H DHJ/,_\ =C_[Z/\ A1F?^['_ -]'_"@"2BH\S_W8_P#OH_X4F9O[L?\
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M.+;3IY#Z,P'\LTS_ (2G7;CBUT0C/0LC-_A72+'*G")"H_V<C^E.V3GJ(_\
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M]'_"C,_]V/\ [Z/^% $E%1YG_NQ_]]'_  HS/_=C_P"^C_A0!)14>9_[L?\
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M97)_#[_D 3_]?3?^@I765]'@_P"!'T/CLP_WJ?J%9?B*TN+[1)K>U!:1BOR
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MUZ_C6O45O;Q6EO'! @2*,;54=A4M:P3C%)F-22E-R75A1115$!1110 4444
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M4E5X)X?L\?[U/NC^(5)Y\/\ SU3_ +Z% $E%1^?#_P ]4_[Z%'GP_P#/5/\
MOH4 245'Y\/_ #U3_OH4>?#_ ,]4_P"^A0!)14?GP_\ /5/^^A1Y\/\ SU3_
M +Z% $E%1^?#_P ]4_[Z%'GP_P#/5/\ OH4 245'Y\/_ #U3_OH4>?#_ ,]4
M_P"^A0!)14?GP_\ /5/^^A1Y\/\ SU3_ +Z% $E%1^?#_P ]4_[Z%'GP_P#/
M5/\ OH4 245'Y\/_ #U3_OH4>?#_ ,]4_P"^A0!)14?GP_\ /5/^^A1Y\/\
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M0I<SM8:A%.]B2BH_/A_YZI_WT*//A_YZI_WT*11)14?GP_\ /5/^^A1Y\/\
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M]"CSX?\ GJG_ 'T* "?_ %?_  )?YBI*KS3P^7_K4^\O\0]14GGP_P#/5/\
MOH4 245'Y\/_ #U3_OH4>?#_ ,]4_P"^A0!)14?GP_\ /5/^^A1Y\/\ SU3_
M +Z% $E%1^?#_P ]4_[Z%'GP_P#/5/\ OH4 245'Y\/_ #U3_OH4>?#_ ,]4
M_P"^A0!)14?GP_\ /5/^^A1Y\/\ SU3_ +Z% $E%1^?#_P ]4_[Z%'GP_P#/
M5/\ OH4 245'Y\/_ #U3_OH4>?#_ ,]4_P"^A0!)14?GP_\ /5/^^A1Y\/\
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M$@95=Q],T 1P_P#+3_?-2U#%YBLVZ/ 9LYW5-0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% $=O_P >\?\ NBI*CM_^/>/_
M '14E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1110 4444 %%%% !44O6/_?']:EJ*7K'_OC^M $M%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !41@5F!+/D'(^8U+10 BC:,9)^II:** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HJKJ&H6^EV;W=T7$*$ E$+GGCH.:H2>*='BTB#5'NL
M6MP=L)V-N<YQ@+C/:J4)/9$2J0B[2=C9HJEI>K66LVOVFQG$L8;:W!!5O0@\
M@U=I--.S*C)25UL%%%%(84444 %%%% !1110 4444 %%%% !1110!%_R\G_<
M'\ZEJ+_EY/\ N#^=2T %%%% !1110 4444 %%%% #9/]4_\ NFB/_5)_NBB3
M_5/_ +IHC_U2?[HH =1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M  H\M_\ GL_Y#_"I** (_+?_ )[/^0_PH\M_^>S_ )#_  J2B@"/RW_Y[/\
MD/\ "CRW_P">S_D/\*DHH C\M_\ GL_Y#_"CRW_Y[/\ D/\ "I** (_+?_GL
M_P"0_P *BEC?,?[Y_OCL/?VJS44O6/\ WQ_6@!?+?_GL_P"0_P */+?_ )[/
M^0_PJ2B@"/RW_P">S_D/\*/+?_GL_P"0_P *DHH C\M_^>S_ )#_  H\M_\
MGL_Y#_"I** (_+?_ )[/^0_PH\M_^>S_ )#_  J2B@"/RW_Y[/\ D/\ "CRW
M_P">S_D/\*DHH C\M_\ GL_Y#_"CRW_Y[/\ D/\ "I** (_+?_GL_P"0_P *
M/+?_ )[/^0_PJ2B@"/RW_P">S_D/\*/+?_GL_P"0_P *DHH C\M_^>S_ )#_
M  H\M_\ GL_Y#_"I** (_+?_ )[/^0_PH\M_^>S_ )#_  J2B@"/RW_Y[/\
MD/\ "CRW_P">S_D/\*DHH C\M_\ GL_Y#_"CRW_Y[/\ D/\ "I** (_+?_GL
M_P"0_P */+?_ )[/^0_PJ2B@"/RW_P">S_D/\*/+?_GL_P"0_P *DHH C\M_
M^>S_ )#_  H\M_\ GL_Y#_"I** (_+?_ )[/^0_PH\M_^>S_ )#_  J2B@"/
MRW_Y[/\ D/\ "CRW_P">S_D/\*DHH C\M_\ GL_Y#_"CRW_Y[/\ D/\ "I**
M (_+?_GL_P"0_P */+?_ )[/^0_PJ2B@"/RW_P">S_D/\*/+?_GL_P"0_P *
MDHH C\M_^>S_ )#_  H\M_\ GL_Y#_"I** (_+?_ )[/^0_PH\M_^>S_ )#_
M  J2B@"/RW_Y[/\ D/\ "CRW_P">S_D/\*DHH C\M_\ GL_Y#_"CRW_Y[/\
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M+0!'Y;_\]G_(?X4>6_\ SV?\A_A4E% $?EO_ ,]G_(?X4>6__/9_R'^%244
M1^6__/9_R'^%'EO_ ,]G_(?X5)10!'Y;_P#/9_R'^%'EO_SV?\A_A4E% $,D
M;^6W[Y^A[#_"B.-_+7]\_0=A_A4DG^J?_=-$?^J3_=% #?+?_GL_Y#_"CRW_
M .>S_D/\*DHH C\M_P#GL_Y#_"CRW_Y[/^0_PJ2B@"/RW_Y[/^0_PH\M_P#G
ML_Y#_"I** (_+?\ Y[/^0_PH\M_^>S_D/\*DHH C\M_^>S_D/\*/+?\ Y[/^
M0_PJ2B@"/RW_ .>S_D/\*/+?_GL_Y#_"I** (_+?_GL_Y#_"CRW_ .>S_D/\
M*DHH C\M_P#GL_Y#_"CRW_Y[/^0_PJ2B@"/RW_Y[/^0_PH\M_P#GL_Y#_"I*
M* (_+?\ Y[/^0_PH\M_^>S_D/\*DHH C\M_^>S_D/\*/+?\ Y[/^0_PJ2B@"
M%H688,SXR#T'^%.\M_\ GL_Y#_"I** (_+?_ )[/^0_PH\M_^>S_ )#_  J2
MB@"/RW_Y[/\ D/\ "CRW_P">S_D/\*DHH C\M_\ GL_Y#_"CRW_Y[/\ D/\
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M(7!)8^II:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)5B?-<Y.2#CG]*EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ K!EU"Q\26\]GIVL2V[Q$--)
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M^5'FG_GE)^5244 1^:?^>4GY4>:?^>4GY5)10!'YI_YY2?E1YI_YY2?E4E%
M$?FG_GE)^5'FG_GE)^5244 1^:?^>4GY4>:?^>4GY5)10 BG<N<$>QI:** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!"0
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MV@CGTZ![:.YQM6,K\X7/OZ<UT'@+S?\ A#[3S-^W<_E;^OE[CM_2B=+EC?\
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M&!'#GT)_I7)HVH7&O:M)9BQ$BZ1(KKIA)C#?P@GN]*%)2BW<*N)E3FERZ/\
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M/ZU<Z"BGJ9T\9*;CIO;UUOJO([.BBBN8[PHHHH **** "BBB@ HHHH ****
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MWAN[=X+B-9(G&&1AD$5+10Y-N["%.,59=3,N?#NC7DB27&F6LCHH4,T8S@<
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !137=(XVDD94102S,<
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(J?6M)AUO2IK&9F0/@I(O5&!R&'T-9%UIGB74[ Z;>7EA%;R#9/<0!_-D3N
MI&%)'7D]:J+5EK:S,JD6I2?+>ZM^>A>T"]GN/"-C>2J7G-JK'/5B%Z_CC]:I
M> XD'A2VN^&GNV>:>3N[ECU_E6I';7UK?6<-H;5=)B@\MXV!\W</N[>V.G7W
MK+M-'UK0_.MM(FL9K!Y&DACNRZM!N.2!M!W+GG''6BZ::3WU_,+2C*,FKV37
MSTU&^&%%IKWB/3H<"UAN8Y8U4<*9$W,!Z $=*Y@RNO@/4(%8JMSK+02,.R-(
M,_X?C7<Z#HQTBVF,T_VB\NI3/<3;=NYSV [ =JSK+PH3X<U'2=0D0B[N9)E>
M$D[,L"IY Y! K15(J3?I^!C*A4<%%+I+Y7V7Z&IJNG6DWARZL&A1;86[*J8X
M7 X(^G6H/"-U+>>$M,GG),C0 $GJ<<9_2J,^F>)[W33I=S?6"0NOERW<8?S7
M3H?E/ )'?/>NBM+6*RLX;6!=L,*"-!Z # K*5E"U[ZG3!.53GM96M_7I^I-1
M1161T!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% &5XEO)]/\-:A=VLGESPPLR-@'!^
MAXK+LK;Q/?:1#?-K4<-S)$)$@%JACY&0&/7)[D8Z]*N^,?\ D3M6_P"O=JSM
M,@\4)H-K;VUSIK1F!!%<2AQ(BE1C*@88@=\CIR*WA_#OIOU..JVZUG>UNC\S
M8\.ZO_;FB0WK1B*4EDEC'174X./;C/XU%J U'[8_V?7;*TCP,0RVH=EX]=X_
ME5K1-)AT328;"%V<1Y+2-U=B<DG\:6YT32;V=I[K2[*>9L9DEMT9CCW(J+Q4
MVUL:J-1THJ6_75K\ANE"[ E^U:G;7W(VF"'R]G7K\S9S_2L;6%6\\>:)9SJ&
MMXH9;E4/1I!P#^'6N@L]-L=.#BRLK:V#XW^1$J;L=,X'-4-<T:;49+.]LKA;
M?4+)RT+NN58$89&'H13C)<]R:D)>R2WLT^_7S,[QR!!86&HQ@"ZM;V(Q-WY.
M"OT([>U=--!#<Q&*>))8SU1U# _@:P'T?5M6U"SEUF6S2TM)!,MO:EF\R0?=
M+%@.!UQBKEPGB#=J7V>73]K*HL=X8%#_ !%^#^&*;M91OL*-U*4W%V?Z+?\
M0RO&,T>I0)X:M%$M]=,C' XMXPP)<GMTP/K4WB\8/AT9)QK$')^CU5T71_$6
MC12%;?29[J=M\]S+=2EY6]_W?3T%:VL:7=ZK%HY!@26TOHKJ<;CMPH.X*<<\
MGC.*JZBTD]$9VE.,I-:NVGDF4/%G_(6\,_\ 81'_ *":ZFL;7-(N-2OM(GA>
M)5LKL3R!R02N,<8'7\JV:SDTXQ1T4XM5)M];?D%%%%9FP4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!%;VUO:1^7;010QDEML:!1D]3@=ZEHHH!*VB"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** &30Q7$+PSQ)+$XPR.H96'H0>
MM*B+&BHBA44855& !Z"G44!;6X4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MR53?CW^Z"/>M:VBU/1I]0C@TXWD5Q</<PR),B8+]5<,01@]QFDXQZ#4YO?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
B444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>gyycud3vz5ad000005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gyycud3vz5ad000005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )T!'@# 2(  A$! Q$!_\0
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MA\/_ !$N],L-T=A-8?:3!N)57# 9&?Q_.J_A?0['Q;8W&NZW$;N>ZF=8U=V
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)S]UJ_8PI4??C)QTN[>2Z>GD='1117*>B%%%% !1110 4444 %%%% !1110
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M8****104444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6+>XR>3@?*Q^H_4&NSK-JSL:)W5PHHHI#"BBB@ HHHH **** "BBB@ HHHH
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M44 %%%% !1110 4444 %%%% !1110 445!>7<%A93W=S((X($,DCGHJ@9)H
M\G^.'B*%+"V\-+(VZX(GN0A_@!^53]6&?^ UX#J/E*B1+N"2/U+'CUK>\7:_
M)KGB&\U65_GN')1.NU0/E ^@ KF)5FNFCB4$_-N.:VM96.>_-*Y:N8XHX$47
M!8CYE!'3%9DEV9)03P@[ TV[$L<[I+P>N!T(JNJEFPO)J6RXQT+1N$88V#/K
MGI5JVOYC(L0<*IZ57M]-GG3><1IV+\9^E7FTN."V\QYAO W%6&*:4MQ2<=BU
M/-%):2).2VU>>>]4H8]-*;9$DSC[^ZG6,EM/%)&05F(X!Z8]JB8Q+(<D;5[
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ML\LLAEFGE(+R.>YQQT &/:M"IJ2YI71I0ING"S_KM^ 4445F;!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5Y-\;?%0L-+M?#L.#+J&7N/\
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MV\$>XJTNYG*78^VJ*Y?X?>*H_%_@ZSU+<#<*/*N5':1>OY\'\:ZBLC8****
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M,;5"X>X48'0>4>*Z.L))*S74[:<I-R4NC_1/]0HHHJ#4**** "BBB@ HHHH
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MR;,6]TZ6VS(H)B]3VJ.RB6XO88V^Z6&?I5O4K\7)\L<*#R >*9IL;&[C< [
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MQLZ<#UIW@_Q#HZ>&](L6U.U%UY*1^291NW=,8]:ATURWCK_3-8UW[1QGIO\
MI_F=%J%W<VD:-;:?->LQP5B=%*^_S$5GZ/XAFUA8YETFY@M'W8N)9(]N02,8
M#9ZC'2MRN5\/6,>J> %L9?N3B="?3,CX/U'6ICR\NJ+FYJHDGT;MITM_F=26
M5?O,!]32*Z,6"LI*G! /2O.KF>XUK0=6O;Q")--TU[-@1_R\$?O2/^^4'XFK
M@^P'4;$^%O)-P+.?[08,9QL^3S?]KS,?>YZ^]7['S,UBKO1:?CO;8[D.A8J&
M4LO4 \BJ&L:L-(MH9?LTMP\TZ01QQD EFZ=2!7#:(D)FT,P7>G)>B5?-6W@?
M[4W!\Q9CNSZY+#KC%='XW:-=-T]IK@VT8U& M,K!3&,G+9/ Q1[)*:B'UARI
M2FM+&A8ZZ;C4187>GW-C<O&9(UF*,)%! ."K$9&1Q[UJAT+E ZEAU /(KA+>
M:-O$<3:+JTNL2O:3)(\KB3[/QE2&  7<P ([_A5#14B+Z&8[O3DO_.7S5A@?
M[6QQ^\64[LXZY)&,X]J;HK?8B.):T>NOEY?)[GHEM=&:$R2Q- 0[+MD(SA21
MG@]#C/XU,'0IO#+MQG=GC%>?V-I;WUUHL%S$LL+7^HEHV&5;#L0".XSCBB2&
M"V6ZMI(U318-<Q<1 ?NTC,*D CH$\P@D=*3I*]K_ -7*6)=KM?U9/L>@*ZN,
MJP88SP<UEW^M/;ZA]@L[">^NA&)76-E18U)(!+,0,D@X'M61X9.F'Q1K9TD1
M?93%;X\D?NR?WF=N.,?3C.:-<DTHZ_MO[NXTBY6%?(OXY_*69<G*9/RG:>Q]
M:2@E*Q3K-T^9.VMOZ9J0^)+.2S6>6.:!_M2V;PR*-T<I(&#@XQR#D'I6QN7!
M.X8'7GI7GMU<K?Z*DNI2PWUC:ZM D=_+$JK+#E=Q/&,#)4D<'%2WFHV-EIWB
M^TEGBCFG+M!%D;I%:W4*5'<<'ITQ5.C?;^MB%BFOB_K?_([MY$0#<RC/3)ZU
M0TS5QJD%G/%;2K#<V_GAV(PO(^4\YSS].*Y?_B4_VI=?\)!Y.TV4'V+S_P"Y
MM^;R\_Q;O3GI5&S^U?V5IWV'=]J_X1R?RMOWMVZ/&/>DJ2L#Q+O_ %?=(]&5
MT8L%=25." >E4[_5(; VX<%VFN$M\*1E2_0GVKB-'2'^T-*;3+O2Q<>6^Y+*
M!A(Z[#D3'<<?-@Y;G=45N-&^P^'=GE?VT+Z'[5_SW\S=^\\SOC=Z^V*?L5<'
MBFXZ*WS]/\ST.YG: 1%8'EWR*AVD?*#_ !'/85+YB;@N]=QZ#/)K#\4?ZO2?
M^PI;_P#H5<S/IUF/#&L:EY"?;8]4E:.X(^>/%QQM/4#KP/4U$::DDS2I7<)-
M);*YW&JZA'I6E7-_*C/';QEV5>I ]*IVNK:A<3QI)H-W!&_65Y8BJ\=P')_2
MHO&7_(FZM_U[-4UAICV)6YEUB_GC6/E+ATV#CKPHZ?6DDN2[*E*;J\JVLNWF
M1KXGL_[*N+R6.6*6WE,$EJ0#+YN<! !U+<8QUS6Q$[/"CO&8W902A()4^G%<
M'<>;=:G_ ,)E!:*]A;L%$6T[YXE# S@>HR=O^R#ZBNKCGU.ZO(I[633Y-)D"
MNKY?S&4CJ.W7]*J<$MOZ\B*564G[W_#KN:E%%%8G4%%%% !7EWQS\6?V#X+.
MF6\FV\U0F$8/*Q#[Y_'A?Q->H$A023@#DDU\@?$SQ%-XR\=7<\08VT#>1;*?
M^>:GK^)R?QII";L<7"KRRX4\CFM._*>7"59MQ.W'X57CB6T?!C\V7T!^[6C!
M;2W2AW6%=IRH(Z5K%:6,9/6YM0J(8$4#A5 _*E?:ZY(!J$3,&"/C(QRM2\,I
M /6N@Y3+FT:$NTC,0@R0 .E8,C Q,>>#A2.GO737N$MI95+;U4X&3C/TKEMP
M5=FT$@UA4LCII-M:A;6DUV2L2YQU/I6DUC&ENL4AP1SD#\ZAM'=$W"1HU)Z)
MQFKT86ZC^>0YC89<=2I]?7G^=**5AR;N5DN'AVJD8RF51E')_P YK/9MTC9X
M /2M%V;<3&P^=3M!&>/2LLMND!SUZFE(J)9^T,MI) I^1R#@U3!7N#^=:4$U
MOL\OREYZLPR:K75KY8\V/)C)_*DUH-/6P3/%+"C1Q)%L&&P>6JONY/;TIIX.
M*FM1'YZF0X7U/:ENQ[(UGFB^UJ\D1.U -X[U)<1DP2W5NWR*!G'?UJ%KXY\N
M+"1]L#D_C4FGS%[N2/=A73E<<$UK=;&-FM3,@N2FU&/RBKD.H_9H_P!V,L2>
M33;^&V@G5(A^\4[G8GCZ54N91/*650N3D@"HUB792'-<>8S-(H9F.234+7,K
M!8PY*KPH]*8QP,402F">.8 $HP;!J;EV-2RT*XN?WDY\I#ZCYC^%9UW;FUNI
M(#SM. ?7TKJ)=7MXX4D9C\XR%7DU@:A=K?3^:L978N,GG-7.,4M#*$I-Z[%%
MO3TJ2#:&#,,JO)%/2T=T#LP4'MWJ2*UW2G()C7T/)J$F:MHNQW5FZ[65D8C'
M/(J"Y5UL1^\8HS\#M4@M[=D^:)T]]^:IW#LF;=7)BSN&:IO34A)7T);&9D29
M=V,+N7ZUM.8[ZR29) OR$8]#7+Y(Z=ZUM$D#&6W;[K8(!Z9IPET%./VC)VMO
M*D'(//M6[")%L&BB=  O\/4GWJ&^CW:DJ6Z*9!]\XX_&D.G7<:LPF3GJ%/-"
M33!M-(A@E5#N/S.#P":T4G6210<$@_(,=*JZ8&DDS-")(U/S,1]VK-[IT[2>
M9:2+L/0$X(IQO:Y,K7LS*N;F2:8ER<^E>M? 3Q=_9OB*;P_<R8M]1&Z')X69
M1_[,./J!7CLJM'(5<$,#@@TZTO)[&\@N[:0QSP2+)&XZJP.0?SK-FR5MC[SH
MK#\'^(X?%?A33]9AP#/&/-0?P2#AE_ @UN5!84444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <UXLC@D?2R]\EE
M<I<%K:2:+?"7VGY7SP,C.#GKTKF-1N;B;1?$-O\ 9[(3QR6[W=S8%FBE0D;L
MKG((4?, >F:]'GMX+J%H;B&.:)NJ2*&4_@:2WM+:TA\FVMXH8O[D:!5_(5M"
MJHI:'+5P[G)N]K_Y6_K[CBXE,OB'1&_M32GD4L8DT^U8%H]IR"0Y 7Z]P*@6
M%_MX\&;3Y"WWVKIQ]D_U@7_OOY:[BVTZQLG=[6SMX&?[S11*I;ZX'-3>3%Y_
MG^6GG;=GF;1NV]<9]*?M1?5M-^OX=5^!P,?VA?$'B$37NDV\AFRRZA 79H-H
MVX.\#;C/&.N:;IUE!-)X-@ED%Y;@7;1F2(J&4#*_*V3@<8SZ"NZN=.LKUE:[
ML[>=D^Z98E8K],BI3!$7C<Q(7CR$8J,KGKCTH]MI_7:PEA==7_5T_P!#AG2:
M#QIJR+<Z7:8@A%NM[ 6'DA>1'\R@ -G(K;\%QK'H3"*Y2X@-Q*T31Q&- I;H
M@)/R@YQS6U=6%G?!1=VD%P%.5$T8?'TS4Z(L:!$4*JC  & !4RJ<T;%TZ')/
MF]?Q.7TRSMI_&WB26:".1P+= 74'"F/D<^O'Y5RT E72/"O[VVAM4N;I=]TA
M>%9-["/<,CMNQSP:]/6&))'D6-%DDQO8* 6QTR>]1FSM6MC;&VA-N>L10;3D
MYZ=.M4JUOP_*Q,L+=:/O^+3_ $.#EFBM)O$-W<3VM^HL56ZMK")XD8DD*6?<
M?FP2#CG%,NI9%U/PTDESI (O(_*@L$)*(5(Y<M]WH,8&?PKOX+*TM8#!;VT,
M,)SF..,*IS[#BHX=*TZW7;#86L2[P^$A5?F'0\#J/6G[9=B7A9=_ZO?^OO.4
MTJRMCIWBJ[,$9N/MMV!*5!8 +T![=3^9J#1;:&YUCPQYT22>7H0=0PSAOD&?
MR)KN5MX4215AC"R$LX"C#$]2?7-(EM!&R,D$:LB>6A5 "J^@]!QTJ?:[E?5M
MO+_.YY[?1)#'K<?E@:='K<#W<:CY?*VH7R!VS@FM2:XTBX\?:&VG26TDPAG$
MC6Y!&W8-H)'XXKH]1T^2>SF2PF6SN9&#^:(PP8C'##^($#!K-TW0;I-6AU"^
M:R3[,CI!!90E$!?&YCD\D@ 57M$U=_UH9NA*,K)=4_N=P\;?\BVW_7S;_P#H
MU*I:;)IT.O\ B(:NUNMRTP(-P0,V^P;<9_A^]G'>NLEABG39+&DB9!VNH(R.
M14-SI]E>LC75G;SLGW3+$K;?ID<5$9I1Y7_6W^1O.BW/G7];_P"9Y]8Q(VF:
M(Z7Z64Z371T[[7#OB>(MPISC!VXQSG'2I3-:W>DWUO=M:V$L.IQ$WEFIEMI)
MB 0Q!X Z!L\9Q7?W%I;7</DW-O%-%_<D0,OY&D2RM8[7[*EM"MOC'E",!,?3
MI5^V6YDL(UI?I^EOZL<SX?NI/^$GNK6YBTZ:Z-JLC7E@2%90V KKT#<DCVKK
M:@M;&TL4*6EK#;H3DK%&$!/X5/64Y*3NCII0<(V84445!H%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4C!6'S $>]+5'5--AU2U6"X\QHE<2-$
MK "7'\+9ZJ3V]J:WU%*]M"VJ1<,BI[$"D1(N2BIR<G:!UKD-(L4NSKFE2QR:
M6CR1R?8HF&(XR.2I'&'VD$#ISWI^F6%M>ZK?2:(GV'2VM&MFFM@$667/WT'0
M[1D;NY/?%:.FE?4YU6;M:._]?UL=:%C,A<!2XX)'4>U.VKC&T8ZXQ7(Z?86"
M^)K5="MTCAL4=+ZXC&%E)7 C)_C8'YB>V/4UL:MJ%W'J%CIMAY*W%T)',LRE
MEC1 ,G:",DEACD4G#6R+C5]UR:ZV_K\C6R <$CFFI'$I+1H@+<DJ!S7+S-?G
MQ!H0U%(1.DETH:'.V1?+X;!)*Y],FJ^D:IJ5S;:/8Z;%8VJSZ<;ABT3,L6&
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M",X8=_Q%.463"4;E;34C9RCL"<?*OK4O]B^;=-^]"Q9[<GZ5&;&ZBFREM.,
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M_</G_P#B*/\ A)]._N7P_P"W"?\ ^(HY)=@]I#N;-%8W_"3Z;_T^_P#@#/\
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M(J74[O4-1M;J2QT-U9(%4274"^83O!*JC?>P 3SP2!UKJZ*7M-M =!:V>_\
MP?\ ,X,V5_<:E=3B+5)XI-*N(%EO%56,A*D*%4#;T[CG\*UUL+A6\*XMV M0
M1-@?ZO\ <%>?QP*Z6BFZK81PZ77^MS"\*1SVVCFSN;::&6":4'S%P'!=F!4]
MQ@BN<A-Q?^']5T:WTV=I;F_N%2X"CR@#,<NS9X*XZ=>!BO0*@M;2"SC:.WC"
M*\C2, 3RS$DG\230JEFW8'0NE&^B5CC-7M]5N#K5KY.H!I=RV\5I%&L,RE
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBM[Y5!LP^+KU\HX#?EU'N*+7"]C[&HID4B31)+$X>-U#*RG@@]#3Z@L****
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M26 OA#' -@Q*PZG/*YR  #S6SDS!01!H_@[5;Z_U2TDMIX9["V:9HS'\S/\
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M>W7RY(F#=%8^E6';_1)"#R1BM8Z&4M6:%E=1PVS&1L <Y/4GZ?E5:;67;B)
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MO6:=MC7ENM3H'F24[VXQZU1:4I)YL8#JO4-TJQ:6D3+^]?)]JFOK=(M.D"#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN(U)WHNWU4=*89G.!Z5]&G]G;12I!US4.?\ 83_"H_\ AG+1?^@[J'_?M/\
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M[_T!(/\ P._^PHY6'.OZ3-BBL?[=KO\ T!(/_ [_ .PH^W:[_P! 2#_P._\
ML*.5ASK^DS8HK'^W:[_T!(/_  ._^PH^W:[_ - 2#_P._P#L*.5ASK^DS8HK
M'^W:[_T!(/\ P._^PH^W:[_T!(/_  ._^PHY6'.OZ3-BBL?[=KO_ $!(/_ [
M_P"PH^W:[_T!(/\ P._^PHY6'.OZ3-BBL?[=KO\ T!(/_ [_ .PH^W:[_P!
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHKF_'/B%?#?A:ZNP^VXD'E0?[Y[_ (#)_"FE=V$W979X#\8/&$NM^.7M;:=A
M8Z=F"/:V SY^=OSX_P" UP=]>W#C:L\F!_MFM"]TV>Z</ 8YB#\Q$@+'COTY
MS6-(I5BAZJ<$5JXN*L8J2D[A;RS@Y,\O_?9HN;J8L +B3KV<\4Y?E7ZU2(_?
ML&. 3G-2]BEJS>TXR3.H$TC-CDESQ70Q3/:6^UI9"0>3N-<Q8W10JL2< <UI
M?;'N8P( I;G)8]!ZUO!I(YZB;93\01R_+>P3R8<X=0Q_.L#[5<?\]Y?^^S76
M+"&+><?/=AA4?[HKCW!$C @*03D>E95%K<VI2NK$ZW5Q@CSY?^^S3UNY^\\N
M#_MFJJ]:?M8*2.QQUK,T)8GO9G*1RS,1U^<X%217<D$R^<TDB@\@2GD5#'<S
M0\(P [CUIS212')0 ^PR*>@.YIK<VES'L2[EA<GI*Q_F*'M9[=-[W$A5ONL)
M"0?H:RMT<AV!%W=FSBK%CJ36;>6P\VV<_/$_(_#WJDT]R&I+8L-=R+"5,LI9
MQ\WSGM54S7'F+LN)3GL'.:M:M;V]N89;23=%,I95/\--L9D@BP/OMR6[T-:V
M8)Z71-&]\.6DE4>K,:@?4+B"9ML[Y)_B.13IKDN2-V:IL26]?K0_(%KN7!JE
MPRE6ED"GKM<_RJPFIW!VI)=2LN,*2Y_*LU(AVP*FCA7S5+#<F1N7U%";!I&O
M97S^85-Q)NR0/G-7[BZFCM$*R2,JD9^<BH(HK/?^X2/;GTY%2WS"*U\S@9R3
MQ6Z5D<[=V12WDSS-^]E /^T:8MS<%\&>3&0/O&H0VY5D'>I<9PXZ ?K4C*^J
MWL[6,F)Y <C(WGUI+#4Y[;3QMF;S!&6!=SCO4%ZN^WD'M5!Y$^PH<99HP@]L
M$YJ&[.YHE>-AO]HW+2F1KB9G/))<\T->W3<F>7(_VS53C)(Z4X@]^N.#6=S:
MQ:-[<@8^TR'VW&BYFO!'#*TT@5UX(<\X-4SUS5F-O/@2 N% ?.3T&: V(Q=7
M'/[^7I_?-)]JN/\ GXE_[[-+!"'N&C=@, CKWJ'!W$#G'I2'<F%U<?\ /Q+_
M -]FD^U7'_/Q+_WV:AI54NP5>I]30!.MS<X.+B7/IO/-=()9K46-FT\GF2.)
M9?G/7KC^0K#TB 3Z@F1E(_G8_3I^N*M"Y-WKR2'H"<#VP:TAHKF4]7;L=7'>
M2L/]<_\ WT:?]JF/_+:3_OHUE6[D[_8U;$@!VUT)G*T7EN)O^>TG_?1H^VS
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M[10'F*NWH>E6+F.)DQ&J_P#?-6H.US-U%>QD?;;C'_'Q+_WV:/M]S_S\2_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?!/09-*F V>1BMEM--KL*28E!S\W (J?9;"95GV2D_W\=?3(/\Z?(Q>T70Q
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M6@::U:U*6<90%6ZLQ)R3QQZ5TFY=VW<-P&2,\TM'M)![*)SUOI6N*EK:SZG
M+2W9<R0Q%9IE7HK'.!GN1UK9OX[F:PGBM)EAN'0K'(PR$)[XJQ12<FV4H)*Q
MS&D:+KFD116\5WIOD!PTI^SOYDG/S$L6Y8^M*GA[4;>74(K:[M$M[V9Y6F:$
MF=-_50<X..Q/3TKI596!*L#@XX-+3]I*Y*I1M8HZ-8OINC6EC(ZNUO$(RRC
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M/TJU5>PMFM+""W=UD>- K.J! Q[G:.!]*L5B[7T.E7MJ%%%%(84444 %%%%
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MM?EFN;>UTJS%U--;BZ8RR^6L<9Z9.#R?3%9.DZS+9VVIW4]JXDDU@0&%I/\
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MUY?:5]GT^X=5643AGCW'"EUQP#D="<9KHZEQ:W*C)2V"BBBD4%%%% !1110
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M^AK(3[V?2LY*SU-8.ZT/1+F?^Q_"*:7K6NPSW4VKPW,!L[I;I[2-0PDE#*2
M6RN%R"=N>*LP[O#]QXEU+4_$UGJEC?V,]O $O5FEOGD&(RT8)9"IPQ+ ;<8%
M>8GDU-=3QSNC1P)"%0*0AX)]:5BKD%%%7-,L'U"]2$*Q4?-)MZA?QH2N[";2
M5V545V^ZI;'H*F$$[ %8B<DC@5H:RL=M<&VMHVBC &5/4TTO/!80$S1[6!**
M%^9/QJ^6SL3S72:(;*Q>:785SCD@]!]:Z2TTNUC7YP"??I6997$=O:+AAO8[
MG-..JL'SG(K2/+'<RGS2>AJRZ3:2(=T,>.Q48(KG[_3&L<O&VZ-N_I6E!?L[
M$,WRD422;T,;$%3Q3DHR1,7*+U,.2Y><L648X ./2G/OL;Q=A!8 '!'K3KJ)
M(E6!.&1CNR?I4$LLT\PD(+-Z"LC=:DC+);E7D!"N.?<5+;HZ71%JY9AG##TJ
MI-,\I&\YP,#BG6EP]O)NC;:V,&DFK@T[%U!+J%RJ._S$8W8]*S[J"2"X9''S
M9Z5I6JRQVTMTKA.-HSU;FHGO$+F2>#S+@D%&)X'&/QJFE;4E-IZ&_I&DI9P+
M)(N9W )X^[["M%E'TKDVU"ZFCC0MCRAU1L%O<UT6FW1NK8;C\Z<-[^AK:$EL
MCGJ1DO>93UN*(68D< .K84_SKE)3ER1TKHO$=PI1( <L#DUS9!SSS6-5^\;T
M5[HY&"G)J39G:Y;:I/7TJ'C%31@M\@/6H1JS3L^;"[1'W/Y9;)&.*R&^;-:Y
M8QZ*[$XDY3/KDUD <54NA$.HP5W'PL\6#PCXVM+F67;97/\ HUUGH$8\-^!P
M?IFN'(Q^-.1@#@C-0:'WL"",@Y!HKS[X/>+1XH\$PQS2;K[3\6T^3R0!\C?B
M./J#7H-24%%%% !1110 4444 9.LV-Q>76DR0J"MM>"63)QA=K#\>2*IVVDW
M<6@:U:-&!-=3731#<.0^=O/;K71457.[6(=--W.6@T[4])N;.^MK1;HFPBM;
MF 2A&5DZ,">".2#5<Z)J\^DZBTL,*7LFHI>Q1"3*D+L(7=_P$C-=C15>T9/L
M5L<P+/5-4UZWO+VQ6TM4MIH"GG!W!;;R<<<XXQZ<TVRA\0V>FVNCQ6T4?D;8
M_M_F*5\M3U"'G<1Q@\9[UU-%+GZ6'[);W.(D\-26ES?*/#]GJ?GS/-!<2.JE
M-QSM<'G .>F>*OII.H:3=V-]9VL%RR6GV6XMX2(@/FW;DSQU)X-=113=1O<2
MHQ6QAZ!::A#=ZI=:A"D+W<ZR(B/N 4(!C/J,8JMKVF75WK-O.]B=1T]82AM1
M.(PLF<[R"0&XXKI:*7.[W&Z:<>4XA/#FHKI6JVRV5O ;F[@FABA<;%52I([<
M@+Z<FM_4M.FN]=TFX5 ;>!9UF.[!&] !6Q10ZC8*E%*W];W.*GTS7U\+2^'8
M;&*0(AB2[\]0KQ@Y'R]0V./3OFNR8/Y)5"%?;A21D T^BE*38XP43B$T&_EO
M;.5=(@T^]CF5KB^MIPJ2*#\V$')W>A'?K5PV6M6?]L65M8Q317\TDT=R9@HC
MWJ 0R]3C';K[5U=%5[1D*BELSE+;2]3TIM*OH+5;F6+3TLKFW$H4C&""I/!P
M<]ZB.AZM>0:E//'#!>27L5Y;)YFY<HJX4D?3!/KS7844>T8_8QV.:\C5]3U_
M3;NZTY;2UMDE5U,ZNQ+KC/';]?I6/#X6GM++^SU\/:=<SJ2L>H2E=I7/#,OW
ML@=A^==[10JC6PG1B]S%L-,FM?$5W<E%%L]I##&5P.5W9&.PY%2>'[&XL+2Z
MCN%"M)>32K@@_*SDC]*UJ*ER;+4$G<R;:QGC\4:A?,H$$UO"B-GDE2V>/Q%9
M/]AW_P#P@?\ 97E+]K\S=MWC&//W]>G2NLHI\[_KR$Z:?X_B<EJVA7]W_P )
M%Y42G[;]F\C+@;MF-WTJXUOJ>E:S?W-E9+>P7Q5\><(S%(%VG.>JD 'CGVKH
M:*.=VM_7]:![)7NOZW_S,CPS97>GZ(EO>A!<>;*[[#D?,[-Q^=9]YHUY<ZOK
M$1A!LM4MDC^T"09B958<KU/)'2NGHHYW=L?LURJ/8Y2>TUO5=.M](N[&*WC5
MH_M%T)PRNJ$'Y%'.3@=<8KJZ**3E<<8\H4445)04444 %%%% !1110 4444
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M8*YJH\1#8Q72M!;2)S:IN/0KP:I_81O^0G_=;J*EP&JB,-E*'!&*GMKZ2W;
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M\6:C=M$1!+;0HC]B07R/U%:+EY3%\_-IM_P"/_A)[:33K&YM[>>>:^)6"V4
M.2N=V<G  QR<T^+Q) L=[]O@EL9K./S98I,-E#T92"0P[?6L2PTO4M-L]%OO
ML3RR6;7"3VRLN_9(Y(9<G!(P#C/>GW^D7_B.34[IK9[)9+-;:V2<C<Y#[\L
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_%8\7^";.^D<&\B'D70[^8O?\1@_C77U)04444 %%%% !1110 4444 %%%%
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M9"C8((],U!H>M? GQ4VD^+6TF;Y;34EVY[+*/NG\<D?B*^G:^'O#]R;/41<
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MI/M1)IA%-$EU)NM(2RA/-;*#'W5%4XB[M]GP&4G'S=*M7,WVF>-F4!%   Z
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %4-/OI;N699%0",X&T&B
MBGT$]R_1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
2444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>gyycud3vz5ad000008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gyycud3vz5ad000008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +G!9\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#$\0Z]+HOV)8+'[9-=S
M>4B><(^>W)!HL-3UVXO8XKSP[]D@;.Z;[:DFWC^Z!D\\5E>.4EEN=!C@F\B9
MKX!)=H;8>QP>N/2MC3-.UFUNC)?Z[]NAVD"+[(D7/KD'-:I14+^O<P;DZEE>
MVG;]2]'J5C,\:17ML[2$A%6526(Z@<\XH;4K%;L6C7ML+D](3*N\_P# <YKC
M_"&F0_V%?ZA!;QMJ1FG$4K*"RD9 "GMU[>M<S:1^?H3QS2>&8I"6$CW;2+=J
M^>23USGTXJE23;5]B95I))VWO^!ZW<7-O:0F:YGBAB'5Y'"@?B:CAU"RN'1(
M+RWE=TWJJ2JQ9>F1@\CWKB[U8X_$6BQ^)989;-;+"2.<PO/W))XZ>OM3M)_L
MC_A8\@T;R?)^Q'?Y&/+W[A]W''3'2E[)6^_\!^V=_N]=;':PW5O<1-+!<12Q
MJ2"Z.& (Z\BB.[MI;7[5'<0O;D9\U7!3'UZ5Q7AW6-/TSP[J-K>W<4%S%/,#
M"[ .<],#J?PK&F^T#P'X>*^3]D\]O/\ /W>5G>=N_;SMSFCV6OW?B#KV_'\#
MTRUOK.^1GM+J"X53@F&0.!^51/K&EQ)NDU*S1=Y3+3J!N'4=>OM7&Z%;S/XI
MM9X+KPY'LC82Q:6[9D3W&,9!P>QJ;PIHFF7\&KSWEE#<2-?31[I5#;5'IGIU
M/(HE3C'5A&K*5DE_5CM_,3R_,WKLQG=GC'KFJL>K:;-%++%J%H\<0S(ZS*0G
MU.>*\[1V;P+I2W+2-IL>H%+K!)Q$&. ?;_ZU=3;0>$;G4DAL19-=20.@6TZ%
M",-NV\?GS1*FE<<:K;2V.B^TP?9OM/G1_9]N_P W<-NWKG/3'O3XY(YHEEB=
M7C<;E93D$>H->=12W$MHG@IV8SI=^4[^ML/GS^7%>B*BQPB.-0JJN% Z #I4
M3BHJ_P#5BZ<W-V^_U.?M_$=Q+::WJ'D1M9V#LD*C*M(4'S9/(QGIQ6OIM]_:
M&DVU_P"7Y?G1"39NSC(SC-<?I./^%7ZC_?V7&_ZY/_UJFT3PQ]I\.V5Q_;NM
MQ>9;JWEQ7>U%XZ 8X%7.$4GTM;\C.,Y\RZWO^9MZ1XEM=0T5-2NVAL(WD:,"
M688R#ZG'I5K^UK2\BECTO4+&>[$99$657Y'J%.<5Q^A7FF:?\.UGU2"&YC2>
M3RXI4#;WR< 9[^_UK2\'6FEPRRW8N=-?5+H;FAM'3$*?W%"_ADTYTTN:W04*
MLGRKN;GA_53K.BP7K($E8%94'17!P<>U:=<SX)_X\=2V_P"K_M&;9],BNFK.
MHDI:&M)MQU"BBBH- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH BFM;>X:-IX(I6B;?&70,4;U&>AJ6BB@"*"V@M8S';P
M1PH26*QH%&3U.!44FF6$MT+J2QMGN!TE:)2X_'&:M44[L5EL17%K;W<1BN8(
MIXSU25 P_(UCQ:";?Q5%J-NEO#9QV9MQ%&-I#;L\ #&/QK=HH4FMA2BGN57T
MVPENA=265L]P.DK1*7'XXS4D=I;0VPMHK>*.  @1*@"X/MTJ:BB['97N5K73
M[*QW?8[.WM]WWO)B5,_7 J2"VM[976W@BB5V+L(T"[F/4G'?WJ6BB[8))$,-
MI;6\!@@MXHH3G,:(%7GKP*K'3H[*TG_L>ULK6Y<?*?*"J3_M;>35^BB["R,'
M1]&O(M5N=7U:2V>_F01!;92$1!Z9Y)/%;U%%$I-BC%16AB:3HCZ?+JEO*(9M
M/NIC-'&WS$;A\RL",8K8CBCAA6&*-(XE&U450 !Z 4^BAMO<(Q4=BFVD::]L
MMLVG6C6ZMN6(P*5!]0,8S47]D6=G'++IFG6,%V4*QNL2IR?4J,XK1HHNQ\JW
ML9GA_2CHVBV]DS*\J@M*Z]&<G)K3HHHDVW=A&*BK(****0PHHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!MD(]>,C/?&!6RG%'.Z<F;<$B2V\<D;;HW4,K>H(X-24V-%BC6-%"HH"J!V
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MJ5?"^G#3I[.0SRF>3S9+B23,I<=&W#H1VQ6W/!/R_P"#_EH8>SJ->?\ P/\
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M%% !1110 45#=7=M8VYN+NXBMX5*J9)G"*"2 !D\<D@#W(J:@ HHHH ****
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MJ^/?^A6TC_P;M_\ &:Z^B@#D/[5\>_\ 0K:1_P"#=O\ XS1_:OCW_H5M(_\
M!NW_ ,9KKZ* .0_M7Q[_ -"MI'_@W;_XS1_:OCW_ *%;2/\ P;M_\9KKZ* /
M.K6#QY;>*=1UO_A'M(8WMO! 8?[58;/++G.?*YSO].U:W]J^/?\ H5M(_P#!
MNW_QFNOHH Y#^U?'O_0K:1_X-V_^,T?VKX]_Z%;2/_!NW_QFNOHH Y#^U?'O
M_0K:1_X-V_\ C-']J^/?^A6TC_P;M_\ &:Z^B@#D/[5\>_\ 0K:1_P"#=O\
MXS1_:OCW_H5M(_\ !NW_ ,9KKZ* .0_M7Q[_ -"MI'_@W;_XS1_:OCW_ *%;
M2/\ P;M_\9KKZ* .0_M7Q[_T*VD?^#=O_C-9/AZ#QYH%C<6P\/:1/YUY/=;C
MJK+CS9"^W_5'IG&:]%HH Y#^U?'O_0K:1_X-V_\ C-']J^/?^A6TC_P;M_\
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MU?'O_0K:1_X-V_\ C-=?10!R']J^/?\ H5M(_P#!NW_QFC^U?'O_ $*VD?\
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MKX]_Z%;2/_!NW_QFNOHH Y#^U?'O_0K:1_X-V_\ C-']J^/?^A6TC_P;M_\
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MU]6?_I5%78UQWQ2_Y)_>?]?5G_Z515V- !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !12$A022 !R2>U06M]9WP8VEW!<!#AC%('P??% 7+%%
M%% ''?%+_DG]Y_U]6?\ Z515V-<=\4O^2?WG_7U9_P#I5%78T %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 <_XU\S_A%[G;NV;D\[;U\O<-WZ
M51A^Q?\ "<6']C^1Y7V)OM/V?&W;QLSCCZ5UI 8$$ @\$'O4%K8V=B&%I:06
MX<Y811A,GWQ6D9V5O7\58RG3YI7]/P=RQ11169J>7?$;4_$TOAR\MKKPW;V^
MF?;;8?;5U(.VT7,>UO+V#K@<;N,]\5ZC7'?%+_DG]Y_U]6?_ *515V- !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <=\4O^2?W
MG_7U9_\ I5%78UQWQ2_Y)_>?]?5G_P"E45=C0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 45B1^*+(C4#<PW-G]@56F$ZKT;.,;2<YQ^M2Z=
MK]OJ-V;0V]U:7/EB58KJ,(73^\,$_P"-5R2)YX]S6HHHJ2CCOBE_R3^\_P"O
MJS_]*HJ[&N.^*7_)/[S_ *^K/_TJBKL: "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** ..^*7_)/[S_KZL__ $JBKL:X[XI?\D_O/^OJS_\
M2J*NQH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MNM_^>G_CIK'HHY$'M6;'VZW_ .>G_CIH^W6__/3_ ,=-8]%'(@]JS8^W6_\
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MNM_^>G_CIK'HHY$'M6;'VZW_ .>G_CIH^W6__/3_ ,=-8]%'(@]JS8^W6_\
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ME45:=:0,:O0****LQ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*O\ R3R^_P"OFS_]*HJTZT@8U>@44459B%%%% !1110 4444 %%%% !1110
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MNO\ GX;_ +Y7_"C[9=?\_#?]\K_A1R,/;(VZ*Q/MEU_S\-_WRO\ A1]LNO\
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M#?\ ?*_X4?;+K_GX;_OE?\*.1A[9&W16)]LNO^?AO^^5_P */MEU_P _#?\
M?*_X4<C#VR-NBL3[9=?\_#?]\K_A1]LNO^?AO^^5_P *.1A[9&W16)]LNO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5U/AO_D'2?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M21[/*8?,%Y&<8[5U-56OS:HC#VY-&OD%%%%9&X4444 %%%% !1110!PWQ?\
M^28:I_UUM?\ TIBKS>O2/B__ ,DPU3_KK:_^E,5>;UWX/9GC9KO'YA1117:>
M0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M***[3R HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% '#?%__ ))AJG_76U_]*8J\WKTCXO\ _),-4_ZZVO\ Z4Q5YO7?
M@]F>-FN\?F%%%%=IY 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M &G_ -,?_'O_ *U']I_],?\ Q[_ZU'*P]I$T**S_ .T_^F/_ (]_]:C^T_\
MIC_X]_\ 6HY6'M(FA16?_:?_ $Q_\>_^M1_:?_3'_P >_P#K4<K#VD30HK/_
M +3_ .F/_CW_ -:C^T_^F/\ X]_]:CE8>TB:%%9_]I_],?\ Q[_ZU']I_P#3
M'_Q[_P"M1RL/:1-"BL_^T_\ IC_X]_\ 6H_M/_IC_P"/?_6HY6'M(FA16?\
MVG_TQ_\ 'O\ ZU']I_\ 3'_Q[_ZU'*P]I$T**S_[3_Z8_P#CW_UJ/[3_ .F/
M_CW_ -:CE8>TB:%%9_\ :?\ TQ_\>_\ K4?VG_TQ_P#'O_K4<K#VD30HK/\
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MV[<7C#&<_P "5S8N+5,]#+)IXC3LSMJ***\L^C"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ J*XMH+N$PW,$<T1ZI(@93^!J6B@"
M&"UM[:#R(+>**'_GG&@5?R'%-M;&SL0PM+2"W#G+"*,)D^^*L44[L5D%%%%(
M9POQC_Y)9JW_ %TMO_2B*O&*]G^,?_)+-6_ZZ6W_ *415XQ7I8#:1X&=_%#Y
M_H%%%%>B>$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !7LOPE_Y%6Z_Z_7_] 2O&
MJ]E^$O\ R*MU_P!?K_\ H"5R8W^$>GE/^\KT9WE%%%>.?4A1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!POQC
M_P"26:M_UTMO_2B*O&*]G^,?_)+-6_ZZ6W_I1%7C%>E@-I'@9W\4/G^@4445
MZ)X04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_C'_ ,DLU;_KI;?^E$5>,5Z6 VD>!G?Q0^?Z!1117HGA!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %=%>^+[^?2M-L+26YLDM(3$YBN6 FZ<D#']>M<[14
MRBI6OT-(5)P347:YM>'O$#Z'JLM^\+73R0O&0TFTY;OG!HT'Q =&6ZMYK2.]
ML;M0L]O(Q7=CH01T/O6+12=.+O=;E1KU(VL]KO[]SH]1\417%C!IVFZ9'I^G
MQ3"=H5E,C2/ZECS4DWC2X/BZ77H+5$\Y!');2-O5DP 03@=<5S%%3[*';O\
MB5]:J]^W;IM^9T]WXKM%TNZL-&T6+3%N\"X?SVE9U]!D?**MQ^.+1GL;N^T"
M&ZU.T542Z-PR@A>A* 8S[^M<;11[&']7'];JWW_!6^ZUCII?%WF?\)!_H./[
M7*_\M?\ 58)_V?FZ^U5+;Q'):^&UTJ&';(EZ+M+@/T(  &W'MUS6)135*"5K
M=OPV$\35;NWW_'<[:'QW81ZG'JS^&H&U3_EI<"Y8!N,$A,$ X[\UR%[<_;+^
MXNMFSSI6DVYSC))QFH**(4XP=T*IB*E16D_/9&QXCUW_ (2#4(KO[-Y'EP)#
MMW[L[<\YP/6M2;QU<'6K+48+-$\BT%I)#(^]9D[YX&,_TKDZ*/90LE;8%B:J
M;DGJ[?AL;VIZSI%S:F/3O#L-C*SAS,;EY2,=@#@ >U;D?Q!M!JD6K2>'8WU)
M4V/<?:F&X8Q\JX(7]>]<+12=&#5G^;*CBZL7=-?<NGR_$V[WQ!]L\-V^D?9=
MGDW+S^;YF<[L\8Q[]<U>M/&/V5=!'V#=_9)<_P"NQYN[_@/R_K7+44_90M:P
MOK-7FYKZVM^-S?TKQ+_9FN:AJ7V3S?M:2IY?F8V;SGKCG'TKH]"EL=4\.6EM
MJ\FAW(MMPA6[OWM98@3T.%.X5Y[14RHQ:TT_X!5/%SB]=5KIZVO^1UGCW5K/
M4]6M4L7B>.UMEA+0C]WGKA?85%I?B>PM?#HT;4=$^WPB<S@_:VBP2,?PC/ZU
MS%%-4HJ"@Q3Q4W5=5:-_EMU.HM_%5C87<O\ 9^A1PZ?<P^5=6<ER\@EY."&/
M*D9HN?%MK]DAT^PT."UTU9A-/;-,TAG([,QP<5R]%'L87O\ JP^M5;63_!?Y
M:7Z]SKI?&5E%I4VGZ;H*VL,Y7SEDO))E90<X /W<\\CUH/C*RMM-N[72M!6R
M>ZC:.1C>/(@#=<(> :Y&BE["']-C^N5NC_!?AH%%%%;'*%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:\PKTL!M(\#._BA\_P! HHHKT3P@HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]+ ;2/ SOXH?/] HHHKT3P@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]E^$O\
MR*MU_P!?K_\ H"5XU7LOPE_Y%6Z_Z_7_ /0$KDQO\(]/*?\ >5Z,[RBBBO'/
MJ0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***J0
MZII]PDKP7]K*L7,A296"?7!XHL%RW15>VO[.\B:6UNX)XTX9XI P'U(HM;ZS
MO@QM+N"X"'#&*0/@^^*=F*Z+%%%%(9POQC_Y)9JW_72V_P#2B*O&*]G^,?\
MR2S5O^NEM_Z415XQ7I8#:1X&=_%#Y_H%%%%>B>$%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3?\ OX__ ,17LM%'UVJ']DX;L_O/&O\ A4NO?\_>F_\ ?Q__ (BC_A4NO?\
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M /B*]EHH^NU0_LG#=G]YXU_PJ77O^?O3?^_C_P#Q%'_"I=>_Y^]-_P"_C_\
MQ%>RT4?7:H?V3ANS^\\:_P"%2Z]_S]Z;_P!_'_\ B*/^%2Z]_P _>F_]_'_^
M(KV6BCZ[5#^R<-V?WGC7_"I=>_Y^]-_[^/\ _$4?\*EU[_G[TW_OX_\ \17L
MM%'UVJ']DX;L_O/&O^%2Z]_S]Z;_ -_'_P#B*/\ A4NO?\_>F_\ ?Q__ (BO
M9:*/KM4/[)PW9_>>-?\ "I=>_P"?O3?^_C__ !%'_"I=>_Y^]-_[^/\ _$5[
M+11]=JA_9.&[/[SQK_A4NO?\_>F_]_'_ /B*/^%2Z]_S]Z;_ -_'_P#B*]EH
MH^NU0_LG#=G]YXU_PJ77O^?O3?\ OX__ ,11_P *EU[_ )^]-_[^/_\ $5[+
M11]=JA_9.&[/[SQK_A4NO?\ /WIO_?Q__B*/^%2Z]_S]Z;_W\?\ ^(KV6BCZ
M[5#^R<-V?WGC7_"I=>_Y^]-_[^/_ /$4?\*EU[_G[TW_ +^/_P#$5[+11]=J
MA_9.&[/[SQK_ (5+KW_/WIO_ '\?_P"(H_X5+KW_ #]Z;_W\?_XBO9:*/KM4
M/[)PW9_>>-?\*EU[_G[TW_OX_P#\11_PJ77O^?O3?^_C_P#Q%>RT4?7:H?V3
MANS^\\:_X5+KW_/WIO\ W\?_ .(H_P"%2Z]_S]Z;_P!_'_\ B*]EHH^NU0_L
MG#=G]YXU_P *EU[_ )^]-_[^/_\ $4?\*EU[_G[TW_OX_P#\17LM%'UVJ']D
MX;L_O/&O^%2Z]_S]Z;_W\?\ ^(H_X5+KW_/WIO\ W\?_ .(KV6BCZ[5#^R<-
MV?WGC7_"I=>_Y^]-_P"_C_\ Q%'_  J77O\ G[TW_OX__P 17LM%'UVJ']DX
M;L_O/&O^%2Z]_P _>F_]_'_^(H_X5+KW_/WIO_?Q_P#XBO9:*/KM4/[)PW9_
M>>-?\*EU[_G[TW_OX_\ \11_PJ77O^?O3?\ OX__ ,17LM%'UVJ']DX;L_O/
M&O\ A4NO?\_>F_\ ?Q__ (BC_A4NO?\ /WIO_?Q__B*]EHH^NU0_LG#=G]YX
MU_PJ77O^?O3?^_C_ /Q%'_"I=>_Y^]-_[^/_ /$5[+11]=JA_9.&[/[SQK_A
M4NO?\_>F_P#?Q_\ XBC_ (5+KW_/WIO_ '\?_P"(KV6BCZ[5#^R<-V?WGC7_
M  J77O\ G[TW_OX__P 11_PJ77O^?O3?^_C_ /Q%>RT4?7:H?V3ANS^\\:_X
M5+KW_/WIO_?Q_P#XBC_A4NO?\_>F_P#?Q_\ XBO9:*/KM4/[)PW9_>>-?\*E
MU[_G[TW_ +^/_P#$4?\ "I=>_P"?O3?^_C__ !%>RT4?7:H?V3ANS^\\:_X5
M+KW_ #]Z;_W\?_XBC_A4NO?\_>F_]_'_ /B*]EHH^NU0_LG#=G]YXU_PJ77O
M^?O3?^_C_P#Q%'_"I=>_Y^]-_P"_C_\ Q%>RT4?7:H?V3ANS^\\:_P"%2Z]_
MS]Z;_P!_'_\ B*/^%2Z]_P _>F_]_'_^(KV6BCZ[5#^R<-V?WGC7_"I=>_Y^
M]-_[^/\ _$4?\*EU[_G[TW_OX_\ \17LM%'UVJ']DX;L_O/&O^%2Z]_S]Z;_
M -_'_P#B*/\ A4NO?\_>F_\ ?Q__ (BO9:*/KM4/[)PW9_>>-?\ "I=>_P"?
MO3?^_C__ !%'_"I=>_Y^]-_[^/\ _$5[+11]=JA_9.&[/[SQK_A4NO?\_>F_
M]_'_ /B*/^%2Z]_S]Z;_ -_'_P#B*]EHH^NU0_LG#=G]YXU_PJ77O^?O3?\
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M_P"%2Z]_S]Z;_P!_'_\ B*]EHH^NU0_LG#=G]YXU_P *EU[_ )^]-_[^/_\
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M_'_^(KV6BCZ[5#^R<-V?WGC7_"I=>_Y^]-_[^/\ _$4?\*EU[_G[TW_OX_\
M\17LM%'UVJ']DX;L_O/&O^%2Z]_S]Z;_ -_'_P#B*/\ A4NO?\_>F_\ ?Q__
M (BO9:*/KM4/[)PW9_>>-?\ "I=>_P"?O3?^_C__ !%'_"I=>_Y^]-_[^/\
M_$5[+11]=JA_9.&[/[SQK_A4NO?\_>F_]_'_ /B*/^%2Z]_S]Z;_ -_'_P#B
M*]EHH^NU0_LG#=G]YXU_PJ77O^?O3?\ OX__ ,11_P *EU[_ )^]-_[^/_\
M$5[+11]=JA_9.&[/[SQK_A4NO?\ /WIO_?Q__B*/^%2Z]_S]Z;_W\?\ ^(KV
M6BCZ[5#^R<-V?WGC7_"I=>_Y^]-_[^/_ /$5W_@?P[=^&=%FLKV2"21[AI08
M6)&"JCN!S\IKIJ*SJ8FI4CRR-J& HT)\\-PHHHK [0HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1E5AA@"/0
MBEHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
(H **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>gyycud3vz5ad000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gyycud3vz5ad000004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,7!(L# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI<T4VV*TDC 5AGUKU.+>(D$A#/M&XCH32Z7'UL/HHHH **** "BBB@ HHHH
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M<>&M:U&PT^*V\+0V)M77S) 4627U.>XK8^*&GM%I]AJ\+^7<VY\HD'D@C_\
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M:*PWJ[A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%&:0.K9VL#
MCK@T +12%@%+$@ =3FEZC(H **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH C\[_IG)_WS1YW_ $SD_P"^:DHH C\[_IG)_P!\T>=_TSD_[YJ2B@"/SO\
MIG)_WS1YW_3.3_OFI** (_._Z9R?]\T>=_TSD_[YJ2B@"/SO^F<G_?-'G?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !111VH **\BU-F_M2ZY/\ K6[^]5-S
M>I_.O'EFUFUR?C_P#VHY/S)/G_#_ ()[117B^YO4_G1N;U/YTO[7_N?C_P
M?]C?W_P_X)[117B^YO4_G1N;U/YT?VO_ '/Q_P" ']C?W_P_X)[117B^YO4_
MG7I/@TD^'H\_\]&_G73A<?[>?)RV^9S8O+_J]/GYK_+_ ()OT445Z!YH4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !2'H:6D/0T >0ZG_R%+K_KJW\ZJU:U/_D*
M77_75OYU5KX^I\;/M*?P(****@L**** "O2/!?\ R+Z_]=6_I7F]>D>"_P#D
M7U_ZZM_2O2RO^/\ (\S-OX'S.AHHHKZ$^;"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M':BCM0!Y#JG_ "%;K_KJW\ZJ5;U3_D*W7_75OYU4KX^I\;/M*?P+T"BBBH+"
MBBB@ KTGP;_R+T?_ %T;^=>;5Z3X-_Y%Z/\ ZZ-_.O2RO^/\CS,V_@?,Z"BB
MBOH3YL**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ I#T-+2'H: /(=3_ .0I=?\
M75OYU5JUJ?\ R%+K_KJW\ZJU\?4^-GVE/X$%%%%06%%%% !7I'@O_D7U_P"N
MK?TKS>O2/!?_ "+Z_P#75OZ5Z65_Q_D>9FW\#YG0T445]"?-A1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS>O2/!?_ "+Z_P#75OZ5Z65_Q_D>9FW\#YG0T445]"?-A1110 4444 %%%%
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M_GHO_?- $E%1[9?^>B_]\T;9?^>B_P#?- $E%1[9?^>B_P#?-&V7_GHO_?-
M$E':H]LO_/1?^^:3;+C_ %B_]\T >3:I_P A6Z_ZZM_.JE6M3S_:EUGKYK?S
MJK7Q]3XV?:4_@7H%%%%06%%%% !7I/@W_D7H_P#KHW\Z\VKT;P>)#X?CVN /
M,;M[UZ65_P ?Y'F9M_ ^9T=%1[9?^>B_]\T;9?\ GHO_ 'S7T)\V245'ME_Y
MZ+_WS1ME_P">B_\ ?- $E%1[9?\ GHO_ 'S1ME_YZ+_WS0!)14>V7_GHO_?-
M&V7_ )Z+_P!\T 245'ME_P">B_\ ?-&V7_GHO_?- $E%1[9?^>B_]\T;9?\
MGHO_ 'S0!)14>V7_ )Z+_P!\T;9?^>B_]\T 245'ME_YZ+_WS1ME_P">B_\
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MA=Y/- '345S,/C"*YLKS4(;=FL;:$,SDX+2'^ #VZ$U(^MZGI^FSZAJME;)
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MG_L;3+_[,N;V5(RF_P"YNSSG'/2J&E:IJHUK6S>B+[';/EL2D^6 @.%&/QH
MZVBN/L_&IGN+)I!8_9[R01I'%<;IHR>A9?\ #I72ZE!<7-D\5M=-:NW655!8
M#OC/0^]#T5P6]BW17$6U_=6OPX\Y+B1K@NT2S.<L,R%<Y]:FGL&T/5],33II
MMUXDD4@DE9P[!"P;D]<BAZ M3L:,@]*X&WO;_2V:,BXBFN(%4BY<D"49WR<G
MA0/Z5UFAM9?V:D=E<BX6/AWSDENIS[T :5%%% !1110 4444 %%%% !30BJ"
M H /7 ZTZB@   & ,"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H[44=J /(=4_Y"MU_
MUU;^=5*MZI_R%;K_ *ZM_.JE?'U/C9]I3^!>@4445!84444 %>D^#?\ D7H_
M^NC?SKS:O2?!O_(O1_\ 71OYUZ65_P ?Y'F9M_ ^9T%%%%?0GS84444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!Y_*H6M=?FL;B"2]LXY)$VQRPQL"GJ>3UQTK:HH Y:/P<EO:7NGVUQLL+J$
MQD$E91CYP??&34TFC:MJ6F36.IW5MY9C"QF&,YW @ACGZ=*Z.B@#$L-.OQNB
MOH]/$)C,;&WC(9LC&?:JNDZ)J.EK;V@.GR6L!PLK1'S2O8>F?>NEHH Y.?PW
MJOV2^TVVO;>.PNG:0,R$NNXY*^F,]ZNS>'I);BXE$Z@2Z=]C V]#S\WTYK?H
MHMI8.MS";0I/LVBQ^<N=-(+<??PFWCTKBK"6*SNOM<7V*;4S<MBTDMV-P,MS
MSGKCOBO4J*=];A;2QEZUI;:S9PVKNJ0F57G0C.]1SMJE)X3L8+^RO-*@M[*:
MWERY1,>8A&"O%=#12 Y%O#6KBTN].2^MOL5W,TDA,9WHK-D@=C5G5-!O=1:&
MVS9BTB9&CE*'SHPN. ??'6NEHH YA]"U6UEOX],N[=+:^<R/YJ$O&S##$8ZU
M8M?#26EW;-'-^XAL3:;2.3D@YK?HH Y*'PUJOV>QLYKVW^R6,RR1[8SND /&
M?3CTJ\NB72:MJ3^;$UAJ*_O5(.]3MV\=JWZ* .<TG1]2TT6]JW]GR6T'RB7R
MB)64=/;/O6U?)=O:LMD\*3'H95)7'X59HH>H+0Y6T\,WP\.SZ/>W=NT3 F*2
M)"&5BV[)R?6K5II.IS:G:WFJW%N_V-2(E@4C<Q&"QS[=JZ"B@#!GT"2]CU"2
MZF4W-R-D; 9$2 Y '\S5G1]+FL);NXN)8WFN64L(U(4!5 &/RK5HH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *.U%':@#R'5/\
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M1110 4444 %%%% !1110 4444 %(>AI:0]#0!Y#J?_(4NO\ KJW\ZJU:U/\
MY"EU_P!=6_G56OCZGQL^TI_ @HHHJ"PHHHH *](\%_\ (OK_ -=6_I7F]>D>
M"_\ D7U_ZZM_2O2RO^/\CS,V_@?,Z&BBBOH3YL**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH ***175L[6!QUP: %HI"RA2Q( '4YI<Y&10 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4=J
M*.U 'D.J?\A6Z_ZZM_.JE6]4_P"0K=?]=6_G52OCZGQL^TI_ O0****@L***
M* "O2?!O_(O1_P#71OYUYM7I/@W_ )%Z/_KHW\Z]+*_X_P CS,V_@?,Z"BBB
MOH3YL**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ I#T-+2'H: /(=3_Y"EU_UU;^
M=5:M:G_R%+K_ *ZM_.JM?'U/C9]I3^!!1114%A1110 5Z1X+_P"1?7_KJW]*
M\WKTCP7_ ,B^O_75OZ5Z65_Q_D>9FW\#YG0T445]"?-A1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %17,)N+:2)99(2XQOCQN'TS4M1W$1GMWB$LD188WQD!E^F: .,MY);'P=J
M@AEDW)<R1J[.2P!;'6EO]*^R7UI:Z2?(>\M9%D 8@.1@@GWZC/O6W:>&+6UM
MKJV:[O+B"Y!\Q)I%(R>I& .:DL= CL[C[0]Y<W,RQ^5$\S ^6OH, ?F: .:5
MVBN9-/N(Y(K-IPSV\)\PDA0?+&/7&XUVMG<0W=I'/;G,3KE>,<50_P"$?M?L
MD,*RSI)$YD$ZL/,+GJ22"#G/I5^TM8K&TCMH01'&,#)R:.@$],,F#C8Y^@I]
M% $?G?\ 3.3_ +YH\[_IG)_WS4E% $?G?],Y/^^:/._Z9R?]\U)10!'YW_3.
M3_OFCSO^F<G_ 'S4E% $?G?],Y/^^:/._P"F<G_?-244 1^=_P!,Y/\ OFCS
MO^F<G_?-244 1^=_TSD_[YH\[_IG)_WS4E% $?G?],Y/^^:/._Z9R?\ ?-24
M4 1^=_TSD_[YH\[_ *9R?]\U)10!'YW_ $SD_P"^:/._Z9R?]\U)10!'YW_3
M.3_OFCSO^F<G_?-244 1^=_TSD_[YH\[_IG)_P!\U)10!'YW_3.3_OFCSO\
MIG)_WS4E% $?G?\ 3.3_ +YH\[_IG)_WS4E% $?G?],Y/^^:/._Z9R?]\U)1
M0!'YW_3.3_OFD\[_ *9R?]\U+1VH \@U,YU2Z/\ TU;^=5:MZI_R%;K_ *ZM
M_.JE?'U/C9]I3^!>@4445!84444 %>C>#Y-OA^,;'/SMT'O7G->D^#?^1>C_
M .NC?SKTLK_C_(\S-OX'S-SSO^F<G_?-'G?],Y/^^:DHKZ$^;(_._P"F<G_?
M-'G?],Y/^^:DHH C\[_IG)_WS1YW_3.3_OFI** (_._Z9R?]\T>=_P!,Y/\
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M'UI:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *.U%':@#R'5/^0K=?\ 75OYU4JWJG_(5NO^NK?SJI7Q]3XV?:4_@7H%
M%%%06%%%% !7I/@W_D7H_P#KHW\Z\VKTGP;_ ,B]'_UT;^=>EE?\?Y'F9M_
M^9T%%%%?0GS84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2'H:6D/0T >0ZG_R%
M+K_KJW\ZJU:U/_D*77_75OYU5KX^I\;/M*?P(****@L**** "O2/!?\ R+Z_
M]=6_I7F]>D>"_P#D7U_ZZM_2O2RO^/\ (\S-OX'S.AHHHKZ$^;"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *.U%':@#R'5/^0K=?\ 75OYU4JWJG_(5NO^
MNK?SJI7Q]3XV?:4_@7H%%%%06%%%% !7I/@W_D7H_P#KHW\Z\VKTGP;_ ,B]
M'_UT;^=>EE?\?Y'F9M_ ^9T%%%%?0GS84444 %%%% !1110 4444 %%%% !1
M110 44=J\\OO%>K07T\23($1RH^0=*Y\1B84$G/J=.&PL\0VH=#T.BO-/^$P
MUC_GNG_?L4?\)AK'_/=/^_8KE_M2AV9U_P!DU^Z_KY'I=%>:?\)AK'_/=/\
MOV*/^$PUC_GNG_?L4?VI0[,/[)K]U_7R/2Z*\T_X3#6/^>Z?]^Q1_P )AK'_
M #W3_OV*/[4H=F']DU^Z_KY'I=%8_AJ_N-2TA;BY8-(789 QP*V*[Z<U.*FN
MIYU2#IS<'N@HHHJR HHHH **** "BBB@ HHHH **** "D/0TM(>AH \AU/\
MY"EU_P!=6_G56K6I_P#(4NO^NK?SJK7Q]3XV?:4_@04445!84444 %>D>"_^
M1?7_ *ZM_2O-Z](\%_\ (OK_ -=6_I7I97_'^1YF;?P/F=#1117T)\V%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4=J*.U 'D.
MJ?\ (5NO^NK?SJI5O5/^0K=?]=6_G52OCZGQL^TI_ O0****@L**** "O2?!
MO_(O1_\ 71OYUYM7I/@W_D7H_P#KHW\Z]+*_X_R/,S;^!\SH****^A/FPHHH
MH **** "BBB@ HHHH **** "BBB@ /2O(=3_ .0I=?\ 75OYUZ\>E>0ZG_R%
M+K_KJW\Z\C-O@B>SD_QR*E%%%>&>\%%%% !1110!Z1X+_P"1>7_KJU=#7/>"
M_P#D7E_ZZM70U]7A/X$/0^1QG^\3]6%%%%=!S!1110 4444 %%%% !1110 4
M444 %(>AI:0]#0!Y#J?_ "%+K_KJW\ZJU:U/_D*77_75OYU5KX^I\;/M*?P(
M****@L**** "O2/!?_(OK_UU;^E>;UZ1X+_Y%]?^NK?TKTLK_C_(\S-OX'S.
MAHHHKZ$^;"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BJ>JWXTS3)[LKO,:Y"YZGH!^=8
M-QKVJ:2P6_CMYO.@:6+RE*[6&,J>>1SUH ZJBN9B\07<X>SB$$E\TH2-X\^7
MMP"7//;./K72KD*-QR<<F@!:**3(]: %HI,CU%&1ZB@!:*3(]11D>HH 6BDR
M/449'J* %HI,CU%&1ZB@!:*3(]11D>HH 6BDR/449'J* %HI,CU%&1ZB@!:*
M3(]11D>HH 6BDR/449'J* %HI,CU%&1ZB@!:*3(]11D>HH 6BDR/449'J* %
MHI,CU%&1ZB@!:*3(]11D>HH 6CM29'J*,CU% 'D6J?\ (5NO^NK?SJI5S4P?
M[4NN#_K6_G53:?0_E7Q]3XV?:4W[B]!**7:?0_E1M/H?RJ2[B44NT^A_*C:?
M0_E0%Q*])\&_\B]'_P!=&_G7F^T^A_*O2/!O'AZ//'[QOYUZ.5_Q_D>9FW\#
MYG044F1ZBC(]17T)\V+129'J*,CU% "T4F1ZBC(]10 M%)D>HHR/44 +129'
MJ*,CU% "T4F1ZBC(]10 M%)D>HHR/44 *>E>0ZG_ ,A2Z_ZZM_.O721CJ*\C
MU,'^U+K@_P"M;^=>1FWP1/9R?XY%.BEVGT/Y4;3Z'\J\0]ZXE%+M/H?RHVGT
M/Y4!<2BEVGT/Y4;3Z'\J N>C^"_^1>7_ *ZM70USW@SCP^N>/WC5T&1ZBOJL
M)_ AZ'R.,_CS]6+129'J*,CU%=!S"T4F1ZBC(]10 M%)D>HHR/44 +129'J*
M,CU% "T4F1ZBC(]10 M%)D>HHR/44 +2'H:,CU%!(P>10!Y#J?\ R%+K_KJW
M\ZJU;U('^T[K@_ZUOYU5VGT/Y5\?4^-GVE-^XA**7:?0_E1M/H?RJ2[B44NT
M^A_*C:?0_E0%Q*](\%_\B^O_ %U;^E><;3Z'\J]'\&<>'USQ^];^E>CE?\?Y
M'F9K_ ^9T-%)D>HHR/45]"?-BT4F1ZBC(]10 M%)D>HHR/44 +129'J*6@ H
MHHH **** "BBB@ HHHH **** "BBB@ HJKJ.I66DV;7=_<QV]NA :1S@#) '
MZD#\:Q/$7C6Q\-R0+/9:E=+,AD#V=JTJ@#U(Z&@#I:*X?0OBEH_B&]MK>PT_
M5V6X?8LYLV\L'W;H!7<4 %%4IM7T^WU:VTJ6Z1+ZY1I(8#G<ZKU(^E7: "BN
M>\3>*XO#=[HEM);/,=5O5M%*L!L)[G\ZZ&@ HHKC=:\<W-CXG.A:5H-UJMS%
M$LUR89%41*QP/O'DT =E16/XC\3:?X6TM;_4C*$DD$4<<49=Y'()"@#J>#^5
M9WAKQ[I7B;4+C3H8;RSU"!0[VU[ 8GVGN : .IHK@)OB_P"&X;AOW6HO8I+Y
M+:@MHQMPV<??KO8Y$FB26-@R. RL#P0: '4444 %%07EY;Z?937EW*L5O AD
MDD;HJCDFLO5?%6G:7X?CUO\ ?75G*4"-;1ERP8X!QZ<T ;=%-1@\:N 0&&1D
M4Z@ HHJC8:QI^J3WD%E=)-)9S&"X5<YC<=5- %ZBBB@ HHHH **** "BBB@
MHHHH **** "BBB@#.URQDU+1KBUB($CKE,],@Y'\JS+:#4+_ %2UN[RP-M%9
MP,FQG5C*[8SC';CO7244 <E+H=XZ1WC6H,CRDR6L3A-L>#M4'@<'D^M=!I,%
MQ;:7;PW3;ID3#'.?UJ[10 5!%&CABR@G>W7ZU/44'W6_WV_G0 OD1?W!1Y$7
M]P5)10!'Y$7]P4>1%_<%244 1^1%_<%'D1?W!4E% $?D1?W!1Y$7]P5)10!'
MY$7]P4>1%_<%244 1^1%_<%'D1?W!4E% $?D1?W!1Y$7]P5)10!'Y$7]P4>1
M%_<%244 1^1%_<%'D1?W!4E% $?D1?W!1Y$7]P5)10!'Y$7]P4>1%_<%244
M1^1%_<%'D1?W!4E% $?D1?W!1Y$7]P5)10!'Y$7]P4>1%_<%244 1^1%_<%'
MD1?W!4E% %<V%H3DV\1)_P!D4GV"S_Y]HO\ OD59HI<J'S/N5OL%G_S[1?\
M?(H^P6?_ #[1?]\BK-%'*@YGW*WV"S_Y]HO^^11]@L_^?:+_ +Y%6:*.5!S/
MN5OL%G_S[1?]\BI%MH$7:D2J/0"I:*+)!=LC\B+^X*/(B_N"I**8B/R(O[@H
M\B+^X*DHH C\B+^X*/(B_N"I** (_(B_N"F111E6RH/S&IZCA^ZW^\: #R(O
M[@H\B+^X*DHH C\B+^X*/(B_N"I** (_(B_N"CR(O[@J2B@"/R(O[@J,V%H3
MDV\1)_V15BBDTF--K8K?8+/_ )]HO^^11]@L_P#GVB_[Y%6:*.5!S/N5OL%G
M_P ^T7_?(H^P6?\ S[1?]\BK-%'*@YGW*WV"S_Y]HO\ OD4?8+/_ )]HO^^1
M5FBCE0<S[D2VT"+A(E4>@&*7R(O[@J2BF(C\B+^X*/(B_N"I** (_(B_N"CR
M(O[@J2B@"/R(O[@H\B+^X*DHH C\B+^X*/(B_N"I** (_(B_N"CR(O[@J2B@
M"/R(O[@H\B+^X*DHH C\B+^X*/(B_N"I** *YL+0G)MXB3_LBD^P6?\ S[1?
M]\BK-%+E0^9]RM]@L_\ GVB_[Y%'V"S_ .?:+_OD59HHY4',^Y6^P6?_ #[1
M?]\BC[!9_P#/M%_WR*LT4<J#F?<K?8+/_GVB_P"^14BVT"#"1*H] ,5+119(
M+MD?D1?W!1Y$7]P5)13$1^1%_<%'D1?W!4E% $?D1?W!1Y$7]P5)10!'Y$7]
MP4D PC = QJ6HX?NM_O&@"2BBB@ HHHH **** "BBB@ HHHH **** /+/C!\
M/]8\91V=SH[1>=:H5*;MLCY8< E@H &6YYRHKJ/!WARX\*^ TTBZDBDFA24L
M\6<-DDYY)YYY]ZZNF31^;!)'G&]2N?3(H \Q^'&IG1?@C)J@3>UG%=3A/[Q5
MF('Z5CKI7B6?X?-XX;QAJB:H+<WPMUE_T8*,G9Y?3&*] \*^#4T+P/\ \(U>
MSK>1.LJ2LJ% RR$Y&,GL:Y9/ACXD32CX;'C#'AD_+Y/V0>?Y><^7OST[9_2@
M#E;C3KCQ7\1?">H'6]4M'U?2WN,PS;3;D+RL?H#WK;\=7UA8ZVUC=>-/$27$
M5N@CLM)5B\9VCYY"O4D\X)[UT_B'P#=W%WHE_P"&]4CTN\TF%K:(RP>:K1L
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M'A >*?[=N_MA_>^3D>5MSTQ7HVD7C:AH]G=N,--$KD>Y%.P7+M%%%( HHHH
M**** "BBB@ HHHH **** "HYYH[:"2>5ML<:EF.,X J2J&M_\@*__P"O=_\
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M]CML(&?8D<_A1K&N:?H-J+C4)C&C':H"EBQ] !7/^'K_ $GP]X*LKF,RRPR
M;VBC+L7/7(%:,VJ?VMHHU#2M,^VRH^(XKE?+(/<_-0] 6I)HOBW1]>\T65PV
M^(;G21"I ]:HCXB>&S?"U^V/DMM$AB;9GZUSGA%@WCO43JT!L]2F3Y;54'E[
M?KGFG>+HX/$.JV?AS1K:,O!)OGEC4!8AZ9%';S#N=AK7BO2-!\L7MPV^1=R)
M&A<D>O':K.BZ]IVOVIN-.G\Q5.&!!#*?<&J6MW6F>'M'%Q=QQR2)%Y,>5!=S
MC@"LGX=:'<Z;I]S?7:>5)>OYBP_W%[4+J#V1VM%%% !1110 4444 %1P_=;_
M 'C4E1P_=;_>- $E%%% !1110 4444 %%%% !1110 4444 %%<AXN\:2:%J=
MAHNEZ:VI:U?JSQ6_F"-51>K,QZ#@_D:R;?XG31Z7XA75-'-GK6B0B:6S\X.L
MBG&&5AVY'YB@#T6BO+[/XIZMY>DZGJGA:2QT'4I8X8KMIP75G^ZQ7KM/;VYJ
MYJ_Q"UN/QE>>&M"\,G4[JWC24N9Q&H0]<D\ \C'- 'HE07=]:6*(]W<Q0([B
M-6E<*&8] ,]S7!W7Q UN]UB[TOPSX9.HSZ>JB^>2X6-(Y",F-2?O$<BN>\5^
M+;?QAX(TJ\CMY+6X@UV""YMI?O12*W(H ]<BOK2:[FM(KF)[B$ RQ*X+(#TR
M.V:L5Y;I&I6VC?$OQ_J5XVVWM;2VED('. K'CWJ2'XGZQ"++4]4\+O::!>RK
M'%="X5I$W'"LZ=0#0!Z=4%K>VM]&TEI<PW"*Y1FB<, PZCCN*X74OB#JLNOW
M^F>%_#K:PNF8^VRB=4 8C.Q ?O-_455^!\QN?!-Y.T;1F34[ARC=5R0<&@#T
MK()(!&1UI:\QM-:L-$\2?$34K:PE-U810RSEYR5F^5R !CY>A_.F6?Q3UEK?
M3-6U'PI)9Z#?RI"ET;@%P6X#%>NTG]* /4:*H:SJL&B:)>ZK<!FAM86F95ZD
M 9P/K7'Z1XP\6ZK8RW?_  B*I!-:-<64J7J$.>,*W/RD@Y_"@#O4C2)=L:*@
M)SA1CFG5Y%\/_&7BM_"U]?:KI;7%G;"YE^VR7:LQ923Y>WK@'C/M73:EX_;3
M_AG;>+_L =IHXG^S[^!O([T =O4%O>VMV\R6US#,T+^7*(W#%&]#CH?:N,UO
MQUJ:>(&T/PUH)U6^@@6>Z+3"-(E/09/5CZ5PW@_QK<:)!KFKW6DR1QW>OB&Z
MC=L-;;E R?7!H ]SHKFM1\5_9?&6D>'K:V%Q)>Q//,X?'DQ@<-COD\5TM "%
ME7&2!GID]:6O&/B3I_@"ROM5NO$6KW<VMRP[[: RN3#Q\@0*, 9]:Z;0_#5S
MXL^&.AV7B.]O%8QJ\XAF*M,O\*N>_&,T >@*P894@CU!I:\G\(:9;>'/B_J6
MB>'WE&CI8+)=0&4ND4Y(V]3P2,UZQ0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !44'W6_WV_G4M10?=;_ 'V_G0!+1110 4444 %%%% &&WAQ
M6\7+K_VD[EA\KR=G'USG^E6]<TH:WHUQI[3&$3+C>%W8Y]*T:*.E@ZW.0O\
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M #5Z!10!QFM^!)]:N;.X;79HY;:,(&\K<2P_B^]P:UM T+4-(EE:]UVYU)7
M"K*N GTY-;;ND:[G957U)Q3NO2@ HHHH **** "BBB@ J.'[K?[QJ2HX?NM_
MO&@"2BBB@ HHHH 9+$DT3Q2#<C@JP]17"_\ "O;^U$UMIGB*XM=/F8EH-F<
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MA"PU6\5@T'F&"+[BYZ#WI/$5W=2^-6L#X@?2K86X<-D8)_&J/]LN?B%_;/\
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M/]JW.HVL6GE0PN6E'EL#TP>ASVQ7,ZW\4/#>G>%I]:L=3L[\(=D<4<P#._\
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M\I(IO)=PH.0",XJKX:\86EYI%HVJ:A:QWT^?DW!<\\<=J.M@Z7.LHHZC(HH
M**** "BBB@ HHHH **** "HX?NM_O&I*CA^ZW^\: )**** "BBB@ HHHH **
M** "BBB@ HKCM>\5ZI8^)8M&TS38KJ62/>-\FVEU#Q+KNDZ"NHWVD1(RR[9H
MUESM3^\,4=+AUL=A17*2^,?M.KZ;8:3"ETUV@ED8M@1IZ_6NID8I&S*NY@,A
M1WH =17 ZEXP\2:,T5UJ&BP16$DFS ERX^M;NL:IKJ"'^Q=+CN%>/S&EFDVJ
M/;'K1TN!T-%<?X>\87FMZ5?R?V=G4+0[3 C<.?J>E4U\9:WI^OV>GZWI4$$=
MV<1M%)N(HZV#I<[RBBN+U;QU+9:Y;V%OILC0O.(6GERH)[[?6CK8.ESM**QO
M$6O'0[-9([.:ZGDSLCC'H,DD]A4?AC7WUWP^-3GA6$[F!1#G % &[17&Z?XW
MFU'Q5#I:Z:\-O*C,DLV59@.X'I77ROY<3OC.U2<4=+AUL/HKSR#QYK<]C<ZE
M'HL$EC;2%)"LQ# #OC%6[GQJ[ZEH3VTD<5A?*6F\T#*CZ]J .XHJE8:OIVJ(
M[V-[#<+&<.8W!V_6JZ>)=$DO/LB:I:M<$[0@D')]* -6BL^_US2]+D6.^OX+
M=W^ZLC@$U)=:MI]E:+=W-[!%;O\ =D9QAOIZT 7**K6.H6>I0>?97,5Q%G&Z
M-LC-9GB7Q"=!M T5E-=SN"51!P .I8]A0] 6IN45SNE>()]4\'OK'E)%-Y;L
M%!R 153PUXQM+S1[1]5U"UCOIB1LW!<\\<=J+:V#I<ZVBCJ,BB@ HHHH ***
M* "BBB@ HHHH *CA^ZW^\:DJ.'[K?[QH DHHHH **** "BBB@ HHHH ****
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M"+3?[-W\-YC>9L^F,9KD?$>MV_BO6/[#2_M[33+=\W,\L@7S".RYZUZ8  H
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MW:QS/"VZ-F'*GVJVRJR%& *D8(/>J;$CR;QCY,<<.JQ>(DU-%G#QV4CAE_
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ML?8OWE]#5<^#_#YFBF_LJW#Q?=PM-ZNX+1%O0#*?#]@9\^;Y"[L]>E:-(
M , =!2TV[NXDK*P4444AA1110 4444 %%%% !4</W6_WC4E1P_=;_>- $E%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !2,H92K %2,$'O2T4 1PP16T*Q01)'&O"HBX _
M"I*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
1BB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>gyycud3vz5ad000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gyycud3vz5ad000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -K!@,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT[F7MIN/-SZ]K'K%]J0CT"XU*T9) L#2QD\@\9%>>VGQ0OU,AO+2W<;/W:Q
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M>#CW.*^%_P#R +C_ *[G^0KN*:D:1C$:*H]%&*=3J3YY.0J5/V<%$Y/XB_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 3 ]!2T44 %%%
M% !1110 4444 %%%% !1110 4444 (RJPPR@CT(H55484 #T I:* "BBB@ H
MHHH **** "BBB@ HHHH **** "F>3%NW>6F[UQS3Z* "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *3 /4"EHH **** "BBB@ HHHH **** "BBB@ I" >H
MI:* #ITHHHH **** "BBB@ I, = *6B@ HHHH 3 /4"EHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBFEU'>@!U%1^:N<4GG<_=-%A71+13!*I-.# ]#0.X
MM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(6 ZT +13
M=ZYZTN0>AH 6BBB@ HHHH **** "BD) ZTTRCMS0%Q]%1;I&Z#%+B3'7F@5R
M2BHMT@/3-+YP[@BG8+HDHIH=3WIU(84444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M 6(MKKT.:!*1]X8J6FO]TTQ6&F912^:.U(B#8,BG[1Z4!J,,H'8TGG_[)J3
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M 'J:0N@ )90#T.:YCQ#J=MJG@FZNK23=&P7V(.X<&LC6Y6;PAI"C(Q)'S^%
MKH[QY50<GFJ[QR7/4[5I]M !"A;D[15FJVV)LY;E1;-D;(E;Z9I^R<-PXQZ5
M8HI78U!+8K[[A?X 10+A@?FC858HHN%GW(1<H3CI3Q-&>C"E**>JBF&WC/\
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M133$I]:;Y">]/0-20L .M1ERQPM(T049%2(05XH%J]!%C[GDT^BBD58****
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M<HMSY;CR_P"+/-1>%=4T[2;&>RU%UM[J.1BXD'WJ["'3;&WG,\-G!',>KK&
MQ_&DN-,L+MP]S96\SCHSQ@FFW=W!12.*TE/M;^(=1@C*V4L;B/(P&.#R*U_
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M?:(AAAZCUKH*\J7[1X8\0]3A&P?]I#7J-O,EQ;I-&<JXR#0!)3'3^)>M/HH
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M444 %%%% !12%U'4BHGN8E[Y^E.PFTMR1VVJ33%PB&1R ,9)/:J_VR.20 Y
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M6.1MC _PMVKTH'-(H4UPU_\ Z)X\C=N%E _45W-<AXUM'"V^HPCYX6PV/TH
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M7UO38]._M WD1M?^>H.151/%>C372VL-_"\S<!=W4^E%JCOOYB<J$;;:;?\
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M%)YD['Y5P/>IPJCH!2T706?5E8PS./FDQ]*:+%023(Y)]ZMT4<S%R1ZD'V;
MP':F_9CVD;\ZLT478^1%<0./^6A/UI#'.#PXJS11<.5%<_:!TP:3SIAUC_*K
M-%%PY?,K?:L?>C84?;H,X+$?458P/2J]Q$ORL$'6FK,4N9*Z8[[7%V-'VN/W
M_*I%C3&0HYI=B_W12T'[Q%]KC]_RH^UQ>_Y5+L7^Z*-B_P!T4:!:1%]KB]3^
M5.%Q&>Y_*G^6G]T4>6G]T4:![PS[1'_>I1/&?XQ2^3&>JBFFWB/\(HT#WB*1
MU$ZNK ^O-6<*>P-5VLH6[$?2D^S.GW)3]#3T)7,GL3F&,]5%,-K$>U,WSI]Y
M0WTIPN5_B!%&H[QZA]F4# 8BD$#KTD)^M3"16Z,*=2NQ\L2MY=P#PXI2;@#@
M U8HHN'+YE82S_Q(*0W3KUB8_05:HQ1=!RON4(;E5=BX89/I5M9HVZ,*<44]
M5%1-##NQPK'H,T[IB2DB;(/0TM5C;$#Y'(H_?H>Q%*P^9]46:*K?:'7[\?Y5
M(+A"<9P:+,.9$M%-#JW1@:=2*# ]**** &E%;JH-1M;1D=,?2IJ*+B:3."\9
M:$8)%U*V!VGB0#L>QK9\*:ZNHV?D3-_I,0P?]H>M=!/#'<P/#*H9'&"#7F6J
M:?=^&-76:!B(]V8W]1Z&@9ZC4%U;1W=K)!*N5<8-4-#UN'6+4.A"RJ/G3/(-
M:U 'G]F[^'M4DTV]&;28_(QZ<]ZGU.Q>V#,GS1L,JPKI]7TBWU:U,,PPP^ZX
MZJ:Y6*[N] D^PZK&9;0G"2XS@4 84T$<Z;9%S_2JO]BR^63$P9>P;K78OI5O
M=K]HL)$D4\[<U4DMY8?E>-E_"@#BI=/EC;!B;/MS48LKDG"QR?EBNQ,29)VC
M-0B"5CRV/I0!SL6E7+GYY0@]S6O8Z/# PD9O,8=STK1BT^>;CRF;T(%:-OHQ
MA0O<RK#'U.X\T 4TC:1PB*2QZ 5>GE@T&U\Z4A[MAA$':H+G7+:S_P!&TN(R
MSMQOQDU:T;PW--<C4-7)>4\I$>WUH D\+Z1-YCZM? FXFY4'^$5U=(  , 8%
M+0 5SGBO7!IEF8(6_P!)E&!C^$>M7M;UJ#1[0O(092/D3/)->=007OB/5B6)
M9W.6;LHH O>$]'.HZA]HF&88CDY[FO2QA0 . *S++28=.LEAB8K@<D=S5A+5
MF&7E8T[(AR=[6++2HO5A3#<IG"Y)I1;1CMGZT\(HZ 4:#]X@\Z5ON1X^M+Y<
MS?>;'TJQ11<.7NR 6RYRQ)-2K&B]%%.HHNQJ*04F >U+12&,,2'JHIAMHSVQ
M4U%.[%RIE<VW&%8BJ\R3H0$DY/2KY(4$GM4$0\R0R'IVIID2BMD1"UF(RTQS
MWHJ[11S,?LXA1114EA112,P49)Q0 M02M&.-H+4AD>4X08'K3XX53D\MZT]B
M&[[%?[()FW.,#T%3K:PH.$%344.3!0BAH11T4?E3L444BPHHHH ***3(]10
MM%-,B#JP_.F&>,#.ZBPKHEHJ 749.!DTU[O;TC8_2G9BYX]RS4<DB+UP3Z54
M>\E/"Q,!ZXIT<D2@,X.X^HI\I/M$]$.,;3]5"K]*D6SA4?<!/K3Q/&?XJ>&4
M]"*+L:C$C^SQ?W*/L\7]VI:*5V5RHC\B/^Z*7R8_[HI]%%V%D,\F/^Z*/)C_
M +HI]%*["R&>3'_=%'DQ_P!VGT4[L+(A-K"W6,56O+.(65P5!7]VW3Z5?I"
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MI9VXC0#W-0FVN7;+R_A5^BCFML)PONRKMN$X7;BG>9..J9JQ11<?+YD G?\
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M1110 4444 %%%% !1129 ZD4 +13#+&.K"F?:8\X!S3LQ<R)J*@-RH/W3^5
MN,CA#19BYT3T56-Q)VB-1M/<]HJ.5B<T6I) @]ZCCB).]^M5%DF#EI8R35Q+
ME& R<'T--IHE24GJ344@8'H0:6I-0HHHH ***JWVHVFG0^;=3+&O8$\GZ"@"
MU3))8XEW2.J*.['%</J7CJ5R8].BV#H)'&3^ K+CTO7]<?S)?-*G^*5L#\J
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M\I[&K23S8^>+%-Q)C43W+-%0"Y'=2*<MQ&?XJ5F5S(EHIHD0]&%.I%!1110
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M<E;[IJ"T^XWUI'NB%XC8U#:W04E'4ID\9IV=B7./,B_12 @C(.:6I- HHHH
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M1112&)M!Z@4TPQGJHI]% K(@-LF/ER/I2?9V PKD58HIW8N1%;%PO0@TOG2
MX,9^M6**+AR]F0"Y7."",5(LT;=&%.*J>H%1M;QD=,?2C0/>),CU%+FJ;V;=
M8Y"*CCCFW;'D.1^M.R)YVG9HO[@.XIIEC'5Q4?V93]XDT[[/'_=I:%>\(;F+
M^]0;E!V-/$,8_A%+L7T%&@>\0_:U_NM^5+]H!_A-3;1Z48'I1H%I=RK-.Q&!
M&34,5XT3%'C;;V-:-(54]0*=T2X2O>Y''<1R=#@^AJ7-1&WC/\('TIA@=?\
M5O\ @:6A5Y+<L457\V5/OKGZ4];A#P3@^]%@YD2T4@(/0TM(H**** "BBB@
MHHHH , ]152XLHW^95PP]*MT4TVA2BI*S*L$<1&"OS"I_)C_ +HJ.6,J?,3K
MWJ2.0.OOWION3%):,78@_A'Y4NT>@I:*DL3 ]*:T2./F44^B@+%<Q/&<QG\*
M5;C!PXP:GIK(K#D4[]R>6VPH8$9!S2U7,#+S&V/:@3,G$B_C1;L'-;<L44U9
M%8<&G4B@HHHH ***0L!U(H 1_NFDB&$J.:XC1<%J=#(CI\IIVT)NKDM%%%(H
M**** "BBB@ HHHH **** "J\OS7*+CIS5BH.MS]*:)D3T444B@HHHH ****
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MSL68U2Y+>YH G>ZFD;?)*S-Z9IF]G;ESSV%-RH!'7/ZU(C(BY;"_SH F&1@
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MFM8O[*$8*S!AN+8^M;1=0<%@/J:;C:PHS4K^0M%8OB*[UBUAMVT>VCG=I0)
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M5]5O%M=&O;E6&8X'8?4 XI6=[%N:2;/(ESXC^(O/S1O<_P#CB_\ UA7M"IM
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M4BM\6=68J"5@&#Z<+7;R65K-<QW$EO&\T?W)&4%E^AH2RM8[I[I+>-;AQAI
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M9@(FR1TIELZ^2OS"GT)O[Q/1112*"BBB@ HHHH **** "BBB@ HHHH ****
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MX?N8@6_O-R:!G':-X-N+O;->9BCZ[3U-=Y96-O80"*WC55'H.M6:* "BBB@
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M7CU.;5/ MY+<'=*@*%O7'>MSPU_R+EC_ -<A54ZO/4TVLF*KA_94GS?$I6_
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M?RI]% $+6R$<9%--NV<K(15BBG=D\J*VRX7HP/UI=\XZH#5BBBX<OF5GN6C
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M,?2GBV3.22:FHHNPY4,6-%Z**=@>E+12*$**W50?J*KR:=9R_?MHF^JBK-%
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M94D?2J;+.L@B#G![XK6JMUO/H*M29E."Z$<-HW5W8U96"-?X:DHJ6VRU!(3
M'04M%%(H**** "BBB@ KG_$/A>WUB,RQ 17:CAQT;V-=!145*<:D>62T-:5:
M=&:G!V9XE>V5QI]RUO<QE)%['O[BJ]>Q:SHEKK5MY<ZXD'W)!U6O+M7T:ZT:
MZ,5PN5/W)!T85\_BL'*@[K6)]7@<QAB5RO27;_(SJ***XCTA0<$$=J]CL))F
MT^WD7#*T:G]*\;KU[PQ-YWANR;.<1[3^'%>KE4K3DO(\'/87IPEV9H"Y /S@
MK4JNK_=(-*55NH!J(VZ_P_+]*]S0^9]Y$U%4Y?M$7W3N%1+?2;B-A)'44^5O
M8EU$G9FC155;B5QD1D4XM.>BBE8KG18K,U^SFO\ 1+BVMP#*X 4$X[U;VW!'
M4"D\F8]9*F=-3BXOJ73JN$E-+8AT:T>ST>UMYE DCC"L!SS57Q'I+ZMIZ1PR
M!)HG$D9/3(K1%NW>0FC[*,Y+-^=3*E&4.1[%1Q%2-7VJ6M[G(ZI9^(]6T[[-
M<+:QJF#A6Y<BKFK:9<75MH\<00M:L#+\W3 '^%=)]G3'.32BVC'\-9?58:W;
M=[?@;_7JNG+%*U_QT,7Q/;R:CHK6UO@REE(!..E4=4TZ:5;&\LG"7MJ@7GHW
M'2NJ\I/[HI=BC^$5<J%.3;?6WX&=/$UH148VTO\ CN<I9W.O-?QO=>5!;K]Y
M(QG=3)K;4;?Q!/J.EB"47"@,LIQMKK3$AZJ*C-K%G(4 ^U)T(-*[=UK>X1Q-
M2,KQ4;6M:VAB7FF7MUXCTR_V)Y<*?O2&Z'!Z5#-I&J:9J\]]I!BD2XYDAD.!
MFM_R'3[CGZ&E\R9/O+GZ4GAH/5/6]REC:D4DUI:UNEKW,32]'OWU=M6U5T\_
M;LCCCZ**E\.:9=:=+J#7"A1-.73!SD5L+<H>#E?K4H96Z$&G'#Q@TUTO^(2Q
M<ZB:TL[+TMV.?M=)ND\3ZA>N MO/'M1@W/:LZRT;6=-BFM(K6SF1V)%Q)U&?
M:NRHJ/JL.C?7\318VILTGM^&QR=AH5];^%+VPD1?M$K,5 ;@YQ6[HMK+9:-:
MVTP DCC"L <\U<66-MVUU.WK@]*5'2091@P]0<U=.C&#7+VM]Q%;$5*J:DMW
M?YCJ***V.8**** "BBB@ J&2+G>G#5-10)JY'%+OX/#"I*AECYWK]ZG12!Q@
M\,.U,2?1DE%%%(H**** "BBB@"-)D?H<?6I*B>!&[8/M4>V:+[IW"G9$W:W+
M-%0K<*3AOE/O4H(/0TK#33V%HHHH&%%%% !1110 4444 5YOEF1P/8U8J&Y7
M,>?3FI(VW1J?:F]B5NT.HHHI%!1110 4444 %%%% !1110 4444 %5G^6\3W
M%6:KS\31GWQ31,MBQ1112*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!
MKG"$TD0PGUI)3P!ZT\< 4Q=1:***0PHHHH **** "BBB@ HHHH @O+6.]M);
M:4?)(NTUPA^']U]JVBZ3R,_>QSBN_>9$ZFHO/9SA$/XUSU\'2KM.:V.K#YA5
MPR:IO<P%T;4]&4'2;OS81U@GZ?@:H:QXQN;:T-N+5K:^/!W<@#U%==Y4KGYW
MP/05Y[X[M7AU>&3GRWB !]P3FN3&QEAZ+E2;7E_6QVY=..+Q"C7BGUOU?KW.
M<-[<^<\OGR!W.YB&QDUU7ACQ-=27<=A>3%T<X1SU!]*XZK.GN(]1MG9MJK(K
M%O0 UX6&Q%2E44DSZ7%X2E7HN,ET/8OL:-RY+'WIPM(1_ *6WNH+J(202I(I
M[J<U-D5]@I75TSX)TTG9HC\A/2D,$9[5+13NPY5V(#:QGM0+5!TS4]%%V+EC
MV(?LXQPQ%-^S,#Q(:L4478<B*QBF!^62F2M<Q],&KE(0#UHN)P[&89IW?8%P
MWK4\-O(W,KDCTJ10/MC<=JLU3?8F,+ZLC6%%Z"I***@U2L%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 57N_P#5J/5JL57N>6C'O36Y,]B<<**6
MBBD4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5KGEXU]
M35FJS_-=K_LTT3+8L]J***104444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 57B&;AV_"K!Z5!;CYG/J::V)>Z)Z***104444 %%%% !1110
M 4444 %<5XXUJ 6YTR-$DF8Y=B,[/I[UVM9#>&-(DE:22T5W8Y9F)))KGQ,*
ME2')#J=>#J4J555*J;MM8\AHKV%?#FCITTZW_%*F71M-3[MC /\ @ KS%E4^
MLD>V\\I=(,\8KT_P+*7\.A#G]W*R_P!?ZUO+8VB?=M81_P  %3)&D8PB*H]%
M&*ZL+@70GS\US@QV9QQ-+V:C;7N.HHHKT3R JLRJET#C[PQ5FJ]SD;&'8TT3
M+:Y. !TI:0'(!I:105G:KI7]J+&/M<]OL)YA;&?K6C14RBIJTBH3E"7-'<X'
M3]*FO->O[!]4O5CML;6#\GZUT<]Z/#UK;VHCNKV1@=I R3]36?H?_(YZS^%2
M>(M5N;75;2S6<6D$JY:X*Y_"O/IVIT>=:-NWX^9ZU7FK5U3>JLG;;IY:ES3?
M$D-_>FREMI;6YQD))W%07OBVWLM0GLFMI7ECP%"<[S6%;S++XUT_;J!O< @R
M;<#H>*TM-C1_'NI,R@E8QMR.G2G"O5FDD];M7^03PM&$G*4=.6]M=[V]33OO
M$EO8V]NSPR-<3J&2!?O?C5&7QG'!L2?3KB*5V "/QP>^:KZTW]E>+;?5+F-G
MM&CV;@,[#6?XIUNRU4V<=H&?9*"TFW 'M2J8B<>;WK-.UOU'0PE.;A[C::NW
M?;R.KU37K;2_+1D>6XE&4AC&2:AT_P 20WEX+2>VFM+AAE4E'WOI7/Z^DMGX
MGM[V2>2WMY(@JSJN[8<5-;I::EK=I_Q.I+N:$[TQ'Q],U2Q%1U;>=K:;?F0L
M)1]BI/JKWUT?W6&CQ-J"^)94^QW#Q!,"V!Y'3YNE=I$YDB5RI4L 2I[5R$]W
M!IGCR2>\?RH7M\*Y'&>/\*Z^&6.>%)8F#(XRI'<5KA&[24I7=V88V,;0<863
M2U.3O)[S7]=FTVSG-O:VW$LBCYB:L#PQ>6<\4MCJLW##S%F.015..<>&?$]X
MUXK"TO&WI*!D ]>:V9/%6DK+%%%<>>\C!0(E)Q65+V<ES57[U^_F;U%5C:-"
M-X6[7OIK<BU'7AIERMHJ/=7+#/E1CD#WJ33?$D-],]O)!);W"C)CD'.*YS4!
M)I_BZXFGNY+2*X7,<X3(QZ5=TN&TO_$"7":L]W- A)/EX!!XQFB&(J2J6?>U
MM/\ AR98.E&CS:[7OKO]UO(;X=D!.O9;J[8S]#5[P.2= Y.?WK?SK/T"-7.O
MY[.V/R-6O!<;G0MR-C]ZW'XTL+\</\+_ #1>,NH5/6/Y'5T56WSI]Y<^XI?M
M:#[^5KTK,\;F74L45$+B)NCBG>:G]X4K#NA]%0M<QJ<9I#=+CA2:=F+F7<GH
MJOY\A'RQFDW7##A0*+!S(LU7F4*=ZG##]:3RYV'+X^E!M-P^=V--:";;6P^*
MXCE7AAGTJ:J)TY <HQ!J18YXA@-N'O0TN@E*7VD6J*KBX*_ZQ"*E65'Z-2LR
MU),?11FBD,**** &/&KCD5$8GC.8VR/0U8HIW$XID*S\X<;34N01D&D:-7'(
MJA.);<EE8E!VII7)<G%:FC15"&:X<@!, CJ:F*7#'[X HM8%.^R+-(64=2*@
M-N[=9#2_9E/WB32LAWEV'M/&O5A3#=(.@)_"G^1'_=IP11T HT#WBI--*RX2
M,X-1V]T\>U)5(]ZT,"D,:'JHIW5K$N#O>XJL&'!S2U7: J<QL1[4"=D.)%_&
ME;L5S6W+%%-5U8<&G4B@HHHH **** "BBB@ HHHH *@N1D(?0YJ>H+HXBZ]Z
M:W)EL3#I2TU#E ?:G4B@HHHH **** "BBB@ HHHH **** "BBD) ZF@!:0D
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MY"H!G)YJQ5?[]U_NTT3+:Q.JA1@4M%%(H**** "BBB@ HHHH *0J&&",TM%
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M0?6EK.ANY(UQ)&:MI<QN!SC/K0XM#C-,FHI P/0BEJ2PHHHH **** "BBB@
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M_NKCZU,L:+T44ZBZ"S>[*X@=CEW/TIZP(O;/UJ6BB[!10@ '04M%%(H****
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M 4444 %%%% !1110 4444 %%%% $9_UE25$?]?CVJ6@2"BBB@84444 %%%%
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M** "BBB@ HHHH **** (?^7C\*FJ+_EO^%2TV)!1112&%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 'I44/\1]34C?=-,A&$_&GT%U)****0PHH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"(\S@>@J6HDR78U
M+38D%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !113'D6,
M?,<4 -DY(%2U0DO$\P8Z"IXKN.0XR*IIV(4XMEBBD# ]"*6I+"BBB@ HHHH
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M,J:P)M+O+1R8/WD?IWKAQ-"3?-$[Z%:,H*#=FBUI<IT^?*N0AZCK71KK5M%
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MHHK<YR%U59%.T<U,*CE!VY':GJ<J#3$MQ:***0PHHHH **** "BBB@ HHHH
M**** "BBB@ HI"RJ.2!437*#A<D^U.PFTMR:D+!1R<5!OF?[JX%1O:R28+2'
MZ"BW<ER?1$J2*\I.X5/5 6)#95V%3AIHQ\PW =Q3:7049-?$BQ142W"-U.#[
MU+D'I4EII[!1110,**** "BBB@ HHHH **8TJ+U85%]ISPBDT[,3DD6*BF;[
MH!'6HR)Y%QG;4)LG/+2,6]::2ZD2D^B+PZ4M5(X9XAP^X4[SI5^^GY4K#Y^Z
M+-%0"Y3@'()J02HW1A19E*28^BC(HI#"BBB@ HHHH **C:9%ZM49N&;[B$T[
M,ER2+%,:5%'+"H=DTGWFVCVIZVR Y/-%D%V]D(;G/"*2:;B>3OM%6 JCH!2T
M7#E;W93^P@MN9B3[T];*(')%6:*.9BY(]B'[,F, D?C3?L[#[LAJQ11=CY45
M]EP.C@T!YQ]Y0?I5BBBX<OF5_M##[T9%*+J,]<BI\4THIZJ*- M+N()48<,*
M=D'H:C-O&1C&/I3&MOEPCD4:!>78F+J.II=ZGO6>\%Q&/]9GZU)'9N3F20GV
M%.R[DJ<F[6++3HO>H_/9_N(?J:D6!%[9^M28'I2T*M)E;RYG^\V!Z"GK;H.N
M3]:FHHN'*A JKT I:**104444 %%?/T_B[Q"MQ*HUB[ #D >8?6H_P#A,/$7
M_09O/^_AKN^HS[GCO.:7\K/H6BOGK_A,/$7_ $&;S_OX:/\ A,/$7_09O/\
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M]5W"G+<(>#Q]:\ _X2_Q%_T&;S_OX::?%FOMUU>[/_;0T?49=Q?VQ36R9]#
M@]#2U\\#Q9X@7IJ]V/\ MH:=_P )?XB_Z#-Y_P!_#2^H3[E?VS2_E9]"T5\\
M_P#"7>(?^@Q>?]_#2_\ "8>(O^@S>?\ ?PT?4)]Q_P!LTOY6?0M,:5%ZM7SX
M?%WB$]=8N_\ OX:;_P )5KW_ $%KK_OX:?U"7<3SFGTBSZ!-SGA%)II\]_\
M9%>!#Q=XA'36+L?]M#2_\)AXB_Z#-Y_W\-'U&7=$_P!L4WNG^![\+;/WV)J1
M8D7H*^??^$P\1?\ 09O/^_AH_P"$P\1?]!F\_P"_AH^HS[C6;T5]EGT+17SU
M_P )AXB_Z#-Y_P!_#1_PF'B+_H,WG_?PTOJ$^Y7]LTOY6?0M%?/7_"8>(O\
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M7O;9G.W/%7['6]^WX&:Q=DE;927WC:***W.(**** "BBB@ HHHH *][\ _\
M(E:?_NM_,UX)7O7@+_D2K#_=;^9KBQW\->IZ^3_QGZ?Y'0QYWL:EJ*'E2:EK
MRV?1K8****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F2_<Q
MZT^HY><"A">PY!A *=2#I2T#"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **8TBH.341F=^(U_$T["<DB<D <FH6N!G" L?:@0,QS(V?:I515'
MHT%JR'9++]YMH]!3Q @ZC)]ZEHHN'*A@C44X #H*6BD589)&DL;1NH96&"#7
MFVO:--HEZ)X2WDLV4<?PGTKTRH+NTAO;=H)T#(PY%<F+PL<1"W5;,[,'BY8>
M=]T]T8?AWQ$FHQ""=@MPH_[ZKH2>*\SUC1+K0[L2Q%C#G*2+V^M;^@^*XYPM
MO?'9)T5^Q^M<N%QLHR]CB-)+\3IQ>"4H^WP^L7^!TMU:QW41209]#Z5E!KG2
MSLD4R6YZ'TK<1U=<J00>]#*'4JP!!]:]&5-3U//IU7%<K5T9:BWNEWPN 3VI
MK6\J]L_2I)M'B9M\+&)O:JY@U2WX1UD4>M<<\/W1T1DG\,OO Q-TVD?A31;.
M?X6/X4INM37@VX/X4W[5JC\"''X5G]77F:+G[K[R5+*3OP/>GF.WMQF60'V!
MJM]GU2<X9MH^M6(=$7.ZXD+GTK2&'[(B4DOBE]Q ]_+<'R;.,X/&15RRTL0M
MYLYWRG\A5Z*WCA4+&H4>U35U0HI:LPG6TY8*R$' H--9@,Y.*YC7?%<5JK6]
MF0\_0MV6BM7A1CS38J%"I6GR05RUX@\01Z5"8HR&N6'"_P!WW-<-96=UK-_@
M$N[MEW/:BTM+O6;[ W.[G+.>U>CZ1I$.E6P1!ES]YO6O+ITYXZHJM32"V1ZU
M2I3P%-TJ;O-[OL3Z=81:=9I!&.@Y/K5NBBO:2ML>(VV[L****!!1110 4444
M %%%% !1110 4444 %%%% $4?S.S5+6=%]HB;D;E[XJVEPAX/!]ZIHB,DUJ3
M44@(/0TM26%%%% !1110 4444 %%%-9U4<G% #J*KM<\X12:39-)]X[13L3S
M+H3-*B]3526ZE=BL2''J:L+;HO)Y/O4FQ?04U9":D_(I123H<,F1WQ5E;E#U
MX^M2@ =!2-&C=5%#:8*+2T8H93T(I:@-L/X6*FDVSIT.X4K#NUNBQ15?[05.
M'0CWJ19XVZ-19@I)DE%)D'I2TB@HI,@=:C>X1>^3[4";2):0D#J:@\R5_NK@
M>] @9N9')]J=A<U]A[7"+QG)]J9YDK_=7'UJ58D7H*?1=!9O<KB!F.9')]JE
M6)$Z"GT47&HI"8'I1@>E+12&)@'J*8T*-U6I** LF0&V7^%B,4GES(>'R*L4
M4[LGE17\R91\R9^E*+E<X8$5/2%5/4"BZ"SZ,8LT;=&%/!!Z&HVMXSVQ]*BD
MMV _=N11H*\D6LCUI"P'4UF-]H!";^O>IX;9B<R.QI\HE-MV2+#7"+WS]*9Y
MLC_<3'N:E6)%Z**?2T*LWN5_*E<_.^!Z"GK;H/?ZU+11=ARH0*!T%+112*"B
MBB@ HHHH **** "F-$C]13Z* *YMR.8W(-&^:/[R[A[58HIW)Y>Q"MPAX/!]
MZE!!Z'--:)&Z@5"T!09C8C':C0/>1\VW/_'U-_OM_.HJEN/^/F7_ 'S_ #J*
MOH%L?#O<****8@HHHH ='&\LBQQJ6=CA5'4FKZZ#JS/(BZ=<%H_O 1GBDT'_
M )&#3_\ KX3_ -"%=SXN\7:MI_C(VEI<&*WA9,QJ.'S@G-93G)248K<ZJ5*F
MZ;J5&U9I:>=S@K?2=0NW=+>RGD9#A@J'@U6FAEMY6BFC:.1>"K#!%>F>/O$N
MI:/JUO;Z=-]F5HA-(8P!O8^OY4:]:6VJ^)?"\]TB@WL2F;C 8]:SA7D[-K1F
MU3!PBY1C*[C;TU_X<\^BT74Y[?SXK"X>+&=X0XJ]X2TV#5/%-I87L;&&0L'7
M.#PI/]*Z'Q%XOUW3_%4UK:R-#!;R;(K=5^5E'3COFMVYM((/BCHT\4:Q2W$)
MDE0=FV&DZTN75;IV^X:PM-3M%WY6D[KSL>;:K8B'7KNRM(V94F9(T')QFHKO
M2=0L8Q)=6<T*'HSH0*](\.6\"ZOXHU$NB74$A$<C+N\L'.6Q_GI26.MV#QW5
MMK/B./4+29""C1'*'U''%+V\DK)7LD6\'!MRE*UV[;65G_6QYE;6MQ>2B*VA
M>60_PHN33[O3KRP8+=VLL)/3>I&:[NPG?0/AR^I:4!]JGN?+DG"Y*+S_ (#\
MZYJ^\5:OJFC?8[YA/#YFX3.F6!],UK&I*4M%HG8YI4*<(+G;YFK^1D75C=6+
M(MU \)==RAQC(]:<;"YBCMYYH'2"<X1R,!OI78_$L$W&DN!\IM!@]C3_ !,C
M1^"?"ZNI5LG@_A2C6;47W=OS'/"I2G&_PJ_Y?YF3XXT:RT74K2&QC*));+(P
M+9RQ)K&_L74_LWVG[!<>3C._RSC%>F:I9VU]\1M%BNE5HQ9JX5NA(SBFW&NM
M;>(9#-XFC2))2K69A.T+G[O2L85I**2U?_!.JKA(.<I-V5TM+=EWL>5P6T]U
M,(H(GED/147)J>[TG4+!0UU9S0J>[H0*[O3M=T+3?$>M?9IC!#=JOD721Y\H
M\YX[<G]*J^(H=7NO#<MU'KZ:KIL<@,F.&4]L_G6OMI<RTLM##ZK#D;4KM7VM
MT_KH<%5]=&U)K<7(L;@P==^PXQ5SPA:07OBK3[>Y ,329(/0X!(%=#K?C'7K
M7Q7-;02,D,,WEI;!?E9<XQCOFKE.2FHQ7F8TZ4'3=2HW:]M#-\<Z+9:)J-K#
M8QLB20!V!;/-8BZ+J;VWVE;"X,.,[Q&<5Z5XBM(-0^(^B07:CRFBW,AZ$C)
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M'"O4_6N=IT<;RN$C1G<]%49)H=.#ES-:B5>JH<B>AU-GXZN8M.AL[S3[2^6
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M!MO<BCX<BI:B;B4'UJ6FR4%%%%(84444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% $<J@KDTV&%47/K2RDDA14HZ4^A-DV%%%%(
MH**** "BBB@ HHHH **** "BBB@ HHHH 0G S4<63ECWITAPE*@P@% NHZBB
MB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%-<X0F@!L6#DBI*CBQ
MLR.]24,2V"BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'S)
M<_\ 'U-_OM_.HJEN?^/J;_?;^=15]"MCX5[A1113$%%%% $UJ(6NX1<EA 7
MD*=0O?%=[I^E>%-5NET^"PU*,R<1W3@X)KC= N+2TUZRGODWVR2@R#&>*])C
MU."/Q$E\_BF#^SVDRELBXP.P/H*YJ[>R/0P48M-RMNM[?JSDM)\'"Y\1:C9W
MD_EVFG%C-*.I ]/PJ64>"+RWN(8/M5G+&A,4S_,)".V*T+?Q)IUMXQUV*ZDW
MZ=J):,RISC(QG]:SIO#GANR@N+B;Q MPNT^1' OSY[9J.:3LYW6BV_$U<(13
M5))ZN]^W3^D=%IUSH*_#>61[&=K-9PLL8?YF? Y'M7/^'M,T_5++Q'<I'+'%
M!$SP)O(P,$@''7M4OARZTV_\&WN@W=^EE*T_FI)(."./\*?X=GT_2++Q-9MJ
M$,@> I"^<>;\IZ4I)Q4[7O\ \,5"2FZ3E:UG?;?4S]2T2RE\%V6MZ<A5U?RK
MI<YY]?\ /K3+G1K+3?!EI>W:,;^]DW1C/W8QWQ_GK5GP-JEDHOM&U654L+M,
M[G. K#_$?RJ+Q3K=I?\ BNWV 2:99,D2*O1D4C=CZUI[_/R=+W^7;[S!JE[+
MVNE[6MY]_N_$TK&R\(W,T-HEAJ4@D(7[400 3WJ3P_IMCH'Q%?3+A))Y%<?9
MI <;<C//X&M2[U.UFU2&^M?$T%MIHVG[*B88 =L5AZKK=E#\45U1)EEM%:/,
MB'(QL -91<I-K75,Z)JG32EI=27;;[W^)7\8#3=0\2R66G6DL>H/=F.61FRK
ML3C@=N:TKC0/#>BSIIUY:7]W<8'FSQ*=J$^E9_B-;"RUT>(-/U6"Z=[L3B!1
M\R\YYKH+W5+;7)5OK+Q4-.1U'F6\J\J>^*+M0BE>W7?<=H.K4<K7OIMMKYV.
M)\5^'_\ A'M56&.0R6\R"6%B.=I['WK2\#:#IVN#4O[0R%@B#*X.-O7)K(\3
M7IN]595U*6_AB&V.608/O^M=1\,O)\K7/M&1#]F&_']WG-:S<E0;;U.:E&G+
M&**7NWV^1'8:?X.UR[.E6:W<%R01%.YR'(]JB\+>$[.]O-:L]4RKV8*^8#C8
M1G)_2K.D:?X<\/ZD-8?78[F.++0P(OSD]LU'H&O6TS>*+J[GC@>\A<QJQQDD
M' %9R<K2Y&]OQ-X1I\T/:I7OT[6Z_,IPZ%HVO^(H+#1'F2UCC+7,T@Y(!ZC]
M*N067@K4-1_LB!;N.9F\N.Z+<,WTK"\':Y%H.N>?<*3;31F&7'4 ]_TKH+/2
M/#6FZPNKMK\4MM$_FQP*OSYZ@&JFG%V;=K:>IG1<9QYHQC>^M^B\OZN4]+\$
MI_;&IQZK.8[/31NE=.KCJ,?A5_1=/\&>(-62SMX;J"09*AVXE _E4>G>,;2\
MUK65U&)UT_4EVDJ,F, 8!/X5H^$-)\.V/B2*2SU-[ZX(;RD5,!!CDL:B4II-
MSO>W3\36G"DY)4DFKN]][7TM\C!TGPI:W^M:LUPTD>G:?(VX(,LV"< ?E5^/
MPYH6OV]S%I=K>V-Y#&73SP=L@%)HGB.UT[7]=LKJ=H;>]F?;<)UC;)P:EO+D
MV-E<S'QH9WV'R8X4Y)]#1)U+[]%8<(T4GHGJ[[?+=K\"IH/A_1)?!UQJNK"5
M6@N"K%#R0,?+BDDT30-<\.7U_HB3V]Q9+O>.5L[E_P#U5#;ZE:_\*RO+1[E/
MM;W>\1D_,1QSBD\(:A:6GA_Q!%<7$<<DUL5C5C@L=IX%5+GM*5WH_P#(S@Z5
MX4VE9IW[]1MII5F?AW+J<HD,J704@.<%<C/'2NGUF[\/IX'TF2>PG>T?(@C5
M_F0X/4US4&H6B_"ZXL3<1BZ:Y#"+/S$9'.*NPRZ5XA\$Z?IL^J16-Q9,=PE&
M=PYZ4JB;=W?27X6*HRC%*,;7</+>YGZ+H&E0^'VU[7'E-NS[(8(^KFIKK0M$
MUK0+K5- \Z&6TYFMY3GCU%2:9>Z5JWA<^'=1O1:R6\Q>WN"/E;KU_.I#<Z1X
M4\-W]E9Z@FH7]\ C-&/E5?\ )-.3E=[WOIVL3"%/E5TN6VKZW_K8DM/#_ANW
M\(:=K.JF52^=ZQG)D.3@5PMX8&O)C:AA;ESY8;J%SQ75:S?VDWP^T2TCN(VN
M(G8R1@\KUZUQU;4D[R;?5G+B91Y81BELK^MCMK;0=%T70+75-?\ .FENQF&W
MB../>J5[I>B:K?:?#X?FE$MV^QX)1_J_?-:@N](\6>'+"RO-073[ZQ78K2#*
MN/\ (%9TITCPMJNF76FWS7US ^Z<J,(1[?@:SBY<SO>^OIY&\XPY%RI<MEKU
MOU\[FS-H7A>PO1I4]IJ,TH(1[M%.U6_PJ3PQH;^'_B2;(OOC\AGC?^\IZ5:O
M+^VU2Z^W6?BX6=O)\S6\B_,OJ!63X=UJ!?'[7-WJAFMHXVCCN)_ER.U9+G<7
M?L[G1)4HU(M)?$K-6V^^_P!Y/X7_ .09XP_W&_\ 9JJZ1X<TJ#PM#K-_;75\
MTSE1%;_P#WH\.ZE96^G^*$FN8T:X1A$&/W_O=*9X<2./2XWM/%@T^<DF6"5?
ME'TJGS*_3;\B(N#4$TG\7;OYG/Z__9'VF/\ LF"YA7;^\2?J#[5D5V7CK4].
MOA8PVTT=U=0IB>YC3:'-<;712;<-3@Q,5&JTFOD%%%%:G.%%%% !7O?@#_D2
M]/\ ]UOYFO!*][\ ?\B7I_\ NM_,UQ8[^&O4]?)_XS]/U1TM%%%>4?2!1110
M 4444 ,:-&Z@5$;<CE&(JQ13N)Q3*^^:/[R[A[4W[;'TZ'WJU52:W!!.T&FK
M/<B2DEH(;Y5.#S]*>))91E5P#W-1PVH !VC-7%&T8H=N@14GN0BWSR[$FI51
M5Z"G44KLM12"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7T&$%.JE%.00K BK@8'H:&K#C)-"T444B@HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /F2Y_P"/J;_?;^=15I^(;%]-\07UJXQLF;;[J3D'\JS*
M^@B[I-'P\XN,FF%%%%40%%%% !1110 4444 %%%% !1110 4444 %%%% !6U
MH7B&70X+^*.%9!=Q>4Q)^[U_QK%HJ914E9EPG*$E*.Z"BBBJ("BBB@#5T+79
M]!NGFAAAF$B['25-P(K<D\?S);R)I^F6=E+*NUI8D^;\*XZBLY4H2=VC>GB*
MM-<L785F+,68Y).2:2BBM#$****!!1110 4444 %%%% !1110 4444 %%%%
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M10 5%*<D*.]2$@=:A616F//2FA-]"8# Q2T44AA1110 4444 %%%% !1110
M4444 %%,:0#WIN7?IP*=A7)"P'4U5EN&)*H#4XB'<YIQ1?2A6$TVBE$TB\8)
MYZU;652!GBGA0.@I"@/:ANXHQ:%!!Z4M1&+'W3BC,B]1F@JY+13!*#UXIP(/
M0TAW%HHHH **** "BBD) ZF@!:*C,H[<TF7;H,46%<D) ZFF&4=N:3RL_>-2
M!0.@IAJ1[G;H,4"(G[QJ6BBX6&"-0,8H\E/2GT4@LAHC4=J:8AVXJ2B@+(BP
MZ^]*)>S#%24A /44PL 8'H:6HS$.QQ2?.OO0%^Y+13!*._%.!!Z4AW%HHHH
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M5R0D#K49D)X44HC)Y8T\ #H*8:LC"%N6-2!0O04M%($@HHHH&%%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(5!ZBEHH B*,O*FH
MFNMK;2,&K559U!)XJEKN1*Z6@HN0/O$5)YP(^49JDB@GD5?0 *,"AI(4&V-S
M(W3B@1D_>-2T4KEV&"-1VI^!112&%%%% !1110 4444 -90W6F;63H<BI:*!
M6&+(#UX-/J.0#&<4D1/K3"^MB6BBBD,**** "BBB@ HHHH ***C=B.] #\@4
MTR =*A!)Z^M3(HQTIDIM[%-VD<D8P*;&[1D @X]15UU![4B*N>E/FT(Y'?<>
MK!A3J@D&#Q4D9)'-*QHGK8?1112&%%%% !1110 4444 %%%% !1110 4444
M%%%1R$CH: 82RA!UJFUP3*#V%/E ;!/-)M7TJTD8RDVR>*<.<9J>J:(HY YJ
M16(/6DT7&3ZEBBD!R*6I+"BBB@ HHHH **** "BBB@ HHHH **** "F&113)
M"<]:(P#VIV)OK87+MTX%*(_4YJ2BD.P8 Z4444#"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>26
<FILENAME>freq-20201231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Instance Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-26T19:12:56.2451531+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 5da74deaf6894583a1f70c65f38043d1 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xbrli:xbrl xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2020-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:freq="http://www.frequencytx.com/20201231" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="freq-20201231.xsd" />
  <xbrli:unit id="U_iso4217USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_xbrlishares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_iso4217USD_xbrlishares">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="U_xbrlipure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_utrsqft">
    <xbrli:measure>utr:sqft</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_freqTerm">
    <xbrli:measure>freq:Term</xbrli:measure>
  </xbrli:unit>
  <xbrli:context id="C_0001703647_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_20200630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_20210319">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-03-19</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesB1ConvertiblePreferredStockMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesA1ConvertiblePreferredStockMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesCConvertiblePreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesB1ConvertiblePreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesA1ConvertiblePreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_20190919_20190920">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-09-19</xbrli:startDate>
      <xbrli:endDate>2019-09-20</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_20190920">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-09-20</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20191001_20191031">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-10-01</xbrli:startDate>
      <xbrli:endDate>2019-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20191031">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20200720_20200720">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-07-20</xbrli:startDate>
      <xbrli:endDate>2020-07-20</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20200720">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-07-20</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtStatementGeographicalAxis_freqLexingtonMassachusettsFacilityMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">freq:LexingtonMassachusettsFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtStatementGeographicalAxis_freqWoburnMassachusettsFacilityMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">freq:WoburnMassachusettsFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtStatementGeographicalAxis_freqWoburnMassachusettsFacilityMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">freq:WoburnMassachusettsFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_freqLabEquipmentMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">freq:LabEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareDevelopmentMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_freqFurnitureAndOfficeEquipmentMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">freq:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_freqUnvestedRestrictedCommonStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">freq:UnvestedRestrictedCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_freqUnvestedRestrictedCommonStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">freq:UnvestedRestrictedCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_freqSeriesCPreferredAsConvertedToCommonStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">freq:SeriesCPreferredAsConvertedToCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_freqSeriesBPreferredAsConvertedToCommonStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">freq:SeriesBPreferredAsConvertedToCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_freqSeriesAPreferredAsConvertedCommonStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">freq:SeriesAPreferredAsConvertedCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_freqConversionOfFrequencyJapanPreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">freq:ConversionOfFrequencyJapanPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_freqOutstandingStockOptionsAsConvertedToCommonStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">freq:OutstandingStockOptionsAsConvertedToCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_freqOutstandingStockOptionsAsConvertedToCommonStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">freq:OutstandingStockOptionsAsConvertedToCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_20200101">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-01-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_20201211">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-11</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtStatementGeographicalAxis_freqWoburnMassachusettsFacilityMember_20200101_20200331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">freq:WoburnMassachusettsFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201811Member_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201811Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201601Member_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapLongtermDebtTypeAxis_freqTermLoanMember_us-gaapTypeOfArrangementAxis_freqLoanAndSecurityAgreementMember_20201211">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">freq:TermLoanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-11</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapLongtermDebtTypeAxis_freqTermLoanMember_us-gaapTypeOfArrangementAxis_freqLoanAndSecurityAgreementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">freq:TermLoanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapLongtermDebtTypeAxis_freqTermLoanMember_us-gaapTypeOfArrangementAxis_freqLoanAndSecurityAgreementMember_20201211_20201211">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">freq:TermLoanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-11</xbrli:startDate>
      <xbrli:endDate>2020-12-11</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapLongtermDebtTypeAxis_freqTermLoanMember_us-gaapTypeOfArrangementAxis_freqLoanAndSecurityAgreementMember_us-gaapVariableRateAxis_us-gaapPrimeRateMember_20201211_20201211">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">freq:TermLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-11</xbrli:startDate>
      <xbrli:endDate>2020-12-11</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapDebtInstrumentAxis_freqPrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMember_us-gaapLongtermDebtTypeAxis_freqTermLoanMember_us-gaapTypeOfArrangementAxis_freqLoanAndSecurityAgreementMember_20201211_20201211">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">freq:TermLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">freq:PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-11</xbrli:startDate>
      <xbrli:endDate>2020-12-11</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapDebtInstrumentAxis_freqPrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMember_us-gaapLongtermDebtTypeAxis_freqTermLoanMember_us-gaapTypeOfArrangementAxis_freqLoanAndSecurityAgreementMember_20201211_20201211">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">freq:TermLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">freq:PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-11</xbrli:startDate>
      <xbrli:endDate>2020-12-11</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapDebtInstrumentAxis_freqPrepaymentOccursAfterSecondAnniversaryOfClosingDateMember_us-gaapLongtermDebtTypeAxis_freqTermLoanMember_us-gaapTypeOfArrangementAxis_freqLoanAndSecurityAgreementMember_20201211_20201211">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">freq:TermLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">freq:PrepaymentOccursAfterSecondAnniversaryOfClosingDateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-11</xbrli:startDate>
      <xbrli:endDate>2020-12-11</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesCConvertiblePreferredStockMember_20190717">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-07-17</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtConsolidatedEntitiesAxis_srtSubsidiariesMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtConsolidatedEntitiesAxis_srtSubsidiariesMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqDelawareLimitedLiabilityCompanyMember_us-gaapStatementClassOfStockAxis_freqSeriesA1ConvertiblePreferredStockMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:DelawareLimitedLiabilityCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqDelawareLimitedLiabilityCompanyMember_us-gaapStatementClassOfStockAxis_freqSeriesB1ConvertiblePreferredStockMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:DelawareLimitedLiabilityCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqDelawareLimitedLiabilityCompanyMember_us-gaapStatementClassOfStockAxis_freqSeriesA1ConvertiblePreferredStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:DelawareLimitedLiabilityCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqDelawareLimitedLiabilityCompanyMember_us-gaapStatementClassOfStockAxis_freqSeriesB1ConvertiblePreferredStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:DelawareLimitedLiabilityCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20141113">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">freq:TwoThousandAndFourteenStockIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-11-13</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">freq:TwoThousandAndFourteenStockIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20190917">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">freq:TwoThousandAndNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-09-17</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">freq:TwoThousandAndNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtRangeAxis_srtMaximumMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">freq:TwoThousandAndFourteenStockIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">freq:TwoThousandAndNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">freq:TwoThousandAndFourteenStockIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">freq:TwoThousandAndNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">freq:TwoThousandAndFourteenStockIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">freq:TwoThousandAndFourteenStockIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">freq:TwoThousandAndNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20190919_20190920">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-09-19</xbrli:startDate>
      <xbrli:endDate>2019-09-20</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20190920">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-09-20</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20201230_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-30</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtStatementGeographicalAxis_stprMA_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtStatementGeographicalAxis_stprMA_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtStatementGeographicalAxis_stprMA_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtRangeAxis_srtMinimumMember_us-gaapIncomeTaxAuthorityNameAxis_us-gaapInternalRevenueServiceIRSMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapIncomeTaxAuthorityNameAxis_us-gaapInternalRevenueServiceIRSMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapIncomeTaxAuthorityNameAxis_us-gaapInternalRevenueServiceIRSMember_20170228">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapIncomeTaxAuthorityNameAxis_us-gaapInternalRevenueServiceIRSMember_20170331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapIncomeTaxAuthorityNameAxis_us-gaapInternalRevenueServiceIRSMember_20191031">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqMassachusettsInstituteOfTechnologyMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_freqPatentLicenseAgreementMember_20161201_20161231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">freq:PatentLicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-12-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqMassachusettsInstituteOfTechnologyMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqMassachusettsInstituteOfTechnologyMember_20161231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqMassachusettsInstituteOfTechnologyMember_20161201_20161231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-12-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqMassachusettsInstituteOfTechnologyMember_srtRangeAxis_srtMaximumMember_20161201_20161231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-12-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqMassachusettsInstituteOfTechnologyMember_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_srtProductOrServiceAxis_us-gaapRoyaltyMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:AstellasPharmaLimitedLiabilityCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtTitleOfIndividualAxis_srtDirectorMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtTitleOfIndividualAxis_srtDirectorMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqCaliforniaInstituteForBiomedicalResearchMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_freqPatentLicenseAgreementMember_20180901_20180930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:CaliforniaInstituteForBiomedicalResearchMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">freq:PatentLicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-09-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqCaliforniaInstituteForBiomedicalResearchMember_20180930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:CaliforniaInstituteForBiomedicalResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqCaliforniaInstituteForBiomedicalResearchMember_srtRangeAxis_srtMaximumMember_20180901_20180930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:CaliforniaInstituteForBiomedicalResearchMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-09-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqCaliforniaInstituteForBiomedicalResearchMember_20180901_20180930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:CaliforniaInstituteForBiomedicalResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-09-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqCaliforniaInstituteForBiomedicalResearchMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:CaliforniaInstituteForBiomedicalResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqScrippsOptionAgreementMember_20180901_20180930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:ScrippsOptionAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-09-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqScrippsOptionAgreementMember_20200901_20200930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:ScrippsOptionAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-09-01</xbrli:startDate>
      <xbrli:endDate>2020-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqScrippsOptionAgreementMember_srtStatementScenarioAxis_srtScenarioForecastMember_20200901_20211231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:ScrippsOptionAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-09-01</xbrli:startDate>
      <xbrli:endDate>2021-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqScrippsOptionAgreementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:ScrippsOptionAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqMassachusettsEyeAndEarMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_freqNonExclusivePatentLicenseAgreementMember_20190201_20190228">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">freq:NonExclusivePatentLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:MassachusettsEyeAndEarMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-02-01</xbrli:startDate>
      <xbrli:endDate>2019-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqMassachusettsEyeAndEarMember_20190228">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:MassachusettsEyeAndEarMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqMassachusettsEyeAndEarMember_srtRangeAxis_srtMaximumMember_20190201_20190228">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:MassachusettsEyeAndEarMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-02-01</xbrli:startDate>
      <xbrli:endDate>2019-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqMassachusettsEyeAndEarMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:MassachusettsEyeAndEarMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqMassachusettsEyeAndEarMember_20190201_20190228">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:MassachusettsEyeAndEarMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-02-01</xbrli:startDate>
      <xbrli:endDate>2019-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqCambridgeEnterpriseLimitedMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_freqPatentLicenseAgreementMember_20191201_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:CambridgeEnterpriseLimitedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">freq:PatentLicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-12-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqCambridgeEnterpriseLimitedMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:CambridgeEnterpriseLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqCambridgeEnterpriseLimitedMember_20191201_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:CambridgeEnterpriseLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-12-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqCambridgeEnterpriseLimitedMember_srtRangeAxis_srtMaximumMember_20191201_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:CambridgeEnterpriseLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-12-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqCambridgeEnterpriseLimitedMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:CambridgeEnterpriseLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtProductOrServiceAxis_us-gaapGrantMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_freqResearchAndDevelopmentMember_20180601_20180630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">freq:ResearchAndDevelopmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-06-01</xbrli:startDate>
      <xbrli:endDate>2018-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtProductOrServiceAxis_us-gaapGrantMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtProductOrServiceAxis_us-gaapGrantMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190701_20190731">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:AstellasPharmaLimitedLiabilityCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-07-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190701_20190731">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:AstellasPharmaLimitedLiabilityCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-07-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_freqPhase2bClinicalTrialMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190701_20190731">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:AstellasPharmaLimitedLiabilityCompanyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">freq:Phase2bClinicalTrialMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-07-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_srtStatementGeographicalAxis_srtAsiaMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_freqPhase2bClinicalTrialMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190701_20190731">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:AstellasPharmaLimitedLiabilityCompanyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">freq:Phase2bClinicalTrialMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-07-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_freqPhase3ClinicalTrailMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190701_20190731">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:AstellasPharmaLimitedLiabilityCompanyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">freq:Phase3ClinicalTrailMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-07-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_srtStatementGeographicalAxis_srtAsiaMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_freqPhase3ClinicalTrailMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190701_20190731">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:AstellasPharmaLimitedLiabilityCompanyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">freq:Phase3ClinicalTrailMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-07-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:AstellasPharmaLimitedLiabilityCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:AstellasPharmaLimitedLiabilityCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190701_20190930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:AstellasPharmaLimitedLiabilityCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-07-01</xbrli:startDate>
      <xbrli:endDate>2019-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190701_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:AstellasPharmaLimitedLiabilityCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-07-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:AstellasPharmaLimitedLiabilityCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_srtProductOrServiceAxis_us-gaapRoyaltyMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:AstellasPharmaLimitedLiabilityCompanyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:AstellasPharmaLimitedLiabilityCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtStatementGeographicalAxis_stprMA_20161231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtStatementGeographicalAxis_stprCT_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtStatementGeographicalAxis_stprMA_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtCounterpartyNameAxis_freqAREMARegionNo20LLCMember_us-gaapTypeOfArrangementAxis_freqLeasesTerminationAgreementMember_20201211_20201211">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:AREMARegionNo20LLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LeasesTerminationAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-11</xbrli:startDate>
      <xbrli:endDate>2020-12-11</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapTypeOfArrangementAxis_freqLeasesTerminationAgreementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LeasesTerminationAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtCounterpartyNameAxis_freqHaydenLLCMember_us-gaapLeaseContractualTermAxis_freqLexingtonLeaseMember_20200107">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:HaydenLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">freq:LexingtonLeaseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-01-07</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtCounterpartyNameAxis_freqHaydenLLCMember_us-gaapLeaseContractualTermAxis_freqLexingtonLeaseMember_20200107_20200107">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:HaydenLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">freq:LexingtonLeaseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-07</xbrli:startDate>
      <xbrli:endDate>2020-01-07</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_20200101_20200331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_20200401_20200630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_20200701_20200930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-07-01</xbrli:startDate>
      <xbrli:endDate>2020-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_20201001_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-10-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_20190701_20190930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-07-01</xbrli:startDate>
      <xbrli:endDate>2019-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_20191001_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-10-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_20190101_20190331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_20190401_20190630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <dei:DocumentType id="F_000000" contextRef="C_0001703647_20200101_20201231">10-K</dei:DocumentType>
  <dei:AmendmentFlag id="F_000001" contextRef="C_0001703647_20200101_20201231">false</dei:AmendmentFlag>
  <dei:DocumentAnnualReport id="F_000002" contextRef="C_0001703647_20200101_20201231">true</dei:DocumentAnnualReport>
  <dei:DocumentPeriodEndDate id="F_000003" contextRef="C_0001703647_20200101_20201231">2020-12-31</dei:DocumentPeriodEndDate>
  <dei:DocumentTransitionReport id="F_000004" contextRef="C_0001703647_20200101_20201231">false</dei:DocumentTransitionReport>
  <dei:DocumentFiscalYearFocus id="F_000005" contextRef="C_0001703647_20200101_20201231">2020</dei:DocumentFiscalYearFocus>
  <dei:CurrentFiscalYearEndDate id="F_000006" contextRef="C_0001703647_20200101_20201231">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus id="F_000007" contextRef="C_0001703647_20200101_20201231">FY</dei:DocumentFiscalPeriodFocus>
  <dei:EntityCentralIndexKey id="F_000008" contextRef="C_0001703647_20200101_20201231">0001703647</dei:EntityCentralIndexKey>
  <dei:EntityFileNumber id="F_000009" contextRef="C_0001703647_20200101_20201231">001-39062</dei:EntityFileNumber>
  <dei:EntityRegistrantName id="F_000010" contextRef="C_0001703647_20200101_20201231">Frequency Therapeutics, Inc.</dei:EntityRegistrantName>
  <dei:EntityIncorporationStateCountryCode id="F_000011" contextRef="C_0001703647_20200101_20201231">DE</dei:EntityIncorporationStateCountryCode>
  <dei:EntityTaxIdentificationNumber id="F_000012" contextRef="C_0001703647_20200101_20201231">47-2324450</dei:EntityTaxIdentificationNumber>
  <dei:EntityAddressAddressLine1 id="F_000013" contextRef="C_0001703647_20200101_20201231">19 Presidential Way</dei:EntityAddressAddressLine1>
  <dei:EntityAddressAddressLine2 id="F_000014" contextRef="C_0001703647_20200101_20201231">2nd Floor</dei:EntityAddressAddressLine2>
  <dei:EntityAddressCityOrTown id="F_000015" contextRef="C_0001703647_20200101_20201231">Woburn</dei:EntityAddressCityOrTown>
  <dei:EntityAddressStateOrProvince id="F_000016" contextRef="C_0001703647_20200101_20201231">MA</dei:EntityAddressStateOrProvince>
  <dei:EntityAddressPostalZipCode id="F_000017" contextRef="C_0001703647_20200101_20201231">01801</dei:EntityAddressPostalZipCode>
  <dei:CityAreaCode id="F_000018" contextRef="C_0001703647_20200101_20201231">866</dei:CityAreaCode>
  <dei:LocalPhoneNumber id="F_000019" contextRef="C_0001703647_20200101_20201231">389-1970</dei:LocalPhoneNumber>
  <dei:Security12bTitle id="F_000020" contextRef="C_0001703647_20200101_20201231">Common Stock, $0.001 par value per share</dei:Security12bTitle>
  <dei:TradingSymbol id="F_000021" contextRef="C_0001703647_20200101_20201231">FREQ</dei:TradingSymbol>
  <dei:SecurityExchangeName id="F_000022" contextRef="C_0001703647_20200101_20201231">NASDAQ</dei:SecurityExchangeName>
  <dei:EntityWellKnownSeasonedIssuer id="F_000023" contextRef="C_0001703647_20200101_20201231">Yes</dei:EntityWellKnownSeasonedIssuer>
  <dei:EntityVoluntaryFilers id="F_000024" contextRef="C_0001703647_20200101_20201231">No</dei:EntityVoluntaryFilers>
  <dei:EntityCurrentReportingStatus id="F_000025" contextRef="C_0001703647_20200101_20201231">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityInteractiveDataCurrent id="F_000026" contextRef="C_0001703647_20200101_20201231">Yes</dei:EntityInteractiveDataCurrent>
  <dei:EntityFilerCategory id="F_000027" contextRef="C_0001703647_20200101_20201231">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:EntitySmallBusiness id="F_000028" contextRef="C_0001703647_20200101_20201231">true</dei:EntitySmallBusiness>
  <dei:EntityEmergingGrowthCompany id="F_000029" contextRef="C_0001703647_20200101_20201231">true</dei:EntityEmergingGrowthCompany>
  <dei:EntityExTransitionPeriod id="F_000030" contextRef="C_0001703647_20200101_20201231">false</dei:EntityExTransitionPeriod>
  <dei:EntityShellCompany id="F_000031" contextRef="C_0001703647_20200101_20201231">false</dei:EntityShellCompany>
  <dei:EntityPublicFloat id="F_000032" contextRef="C_0001703647_20200630" decimals="-5" unitRef="U_iso4217USD">625800000</dei:EntityPublicFloat>
  <dei:EntityCommonStockSharesOutstanding id="F_000033" contextRef="C_0001703647_20210319" decimals="INF" unitRef="U_xbrlishares">34177771</dei:EntityCommonStockSharesOutstanding>
  <dei:IcfrAuditorAttestationFlag id="F_000034" contextRef="C_0001703647_20200101_20201231">false</dei:IcfrAuditorAttestationFlag>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000035" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">220341000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000036" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">200158000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent id="F_000037" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">17197000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="F_000038" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">4723000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="F_000039" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">4000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000040" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">225064000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000041" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">221355000</us-gaap:AssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000042" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">7287000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000043" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">1762000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:OperatingLeaseRightOfUseAsset id="F_000044" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">30551000</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:RestrictedCashNoncurrent id="F_000045" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">1820000</us-gaap:RestrictedCashNoncurrent>
  <us-gaap:RestrictedCashNoncurrent id="F_000046" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">101000</us-gaap:RestrictedCashNoncurrent>
  <us-gaap:Assets id="F_000047" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">264722000</us-gaap:Assets>
  <us-gaap:Assets id="F_000048" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">223218000</us-gaap:Assets>
  <us-gaap:AccountsPayableCurrent id="F_000049" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">5506000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent id="F_000050" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">1219000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="F_000051" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">6663000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="F_000052" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">3239000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:ContractWithCustomerLiabilityCurrent id="F_000053" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">14068000</us-gaap:ContractWithCustomerLiabilityCurrent>
  <us-gaap:ContractWithCustomerLiabilityCurrent id="F_000054" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">48152000</us-gaap:ContractWithCustomerLiabilityCurrent>
  <us-gaap:OperatingLeaseLiabilityCurrent id="F_000055" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">397000</us-gaap:OperatingLeaseLiabilityCurrent>
  <us-gaap:OtherLiabilitiesCurrent id="F_000056" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">170000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000057" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">26634000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000058" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">52780000</us-gaap:LiabilitiesCurrent>
  <us-gaap:ContractWithCustomerLiabilityNoncurrent id="F_000059" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">2900000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
  <us-gaap:OperatingLeaseLiabilityNoncurrent id="F_000060" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">30597000</us-gaap:OperatingLeaseLiabilityNoncurrent>
  <us-gaap:LongTermLoansFromBank id="F_000061" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">15000000</us-gaap:LongTermLoansFromBank>
  <us-gaap:LongTermDebtNoncurrent id="F_000062" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">180000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:Liabilities id="F_000063" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">72231000</us-gaap:Liabilities>
  <us-gaap:Liabilities id="F_000064" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">55860000</us-gaap:Liabilities>
  <us-gaap:PreferredStockValue id="F_000065" xsi:nil="true" contextRef="C_0001703647_20201231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:PreferredStockValue id="F_000066" xsi:nil="true" contextRef="C_0001703647_20191231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommonStockValue id="F_000067" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">34000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue id="F_000068" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">31000</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapital id="F_000069" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">287829000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital id="F_000070" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">236161000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="F_000071" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">27000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="F_000072" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">54000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000073" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">-95399000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000074" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">-68888000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="F_000075" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">192491000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="F_000076" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">167358000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000077" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">264722000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000078" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">223218000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000079" contextRef="C_0001703647_20201231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000080" contextRef="C_0001703647_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized id="F_000081" contextRef="C_0001703647_20201231" decimals="INF" unitRef="U_xbrlishares">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized id="F_000082" contextRef="C_0001703647_20191231" decimals="INF" unitRef="U_xbrlishares">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued id="F_000083" contextRef="C_0001703647_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued id="F_000084" contextRef="C_0001703647_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding id="F_000085" contextRef="C_0001703647_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding id="F_000086" contextRef="C_0001703647_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000087" contextRef="C_0001703647_20201231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000088" contextRef="C_0001703647_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="F_000089" contextRef="C_0001703647_20201231" decimals="INF" unitRef="U_xbrlishares">200000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="F_000090" contextRef="C_0001703647_20191231" decimals="INF" unitRef="U_xbrlishares">200000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="F_000091" contextRef="C_0001703647_20201231" decimals="INF" unitRef="U_xbrlishares">33964000</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="F_000092" contextRef="C_0001703647_20191231" decimals="INF" unitRef="U_xbrlishares">30844507</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="F_000093" contextRef="C_0001703647_20201231" decimals="INF" unitRef="U_xbrlishares">33964000</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="F_000094" contextRef="C_0001703647_20191231" decimals="INF" unitRef="U_xbrlishares">30844507</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000095" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">36984000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000096" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">28947000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RoyaltyExpense id="F_000097" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">16000000</us-gaap:RoyaltyExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000098" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">37415000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000099" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">18784000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000100" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">27119000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000101" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">14838000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses id="F_000102" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">64534000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000103" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">49622000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss id="F_000104" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-27550000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_000105" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-20675000</us-gaap:OperatingIncomeLoss>
  <us-gaap:InvestmentIncomeInterest id="F_000106" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">994000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest id="F_000107" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1784000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:RealizedInvestmentGainsLosses id="F_000108" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">84000</us-gaap:RealizedInvestmentGainsLosses>
  <us-gaap:RealizedInvestmentGainsLosses id="F_000109" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">138000</us-gaap:RealizedInvestmentGainsLosses>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax id="F_000110" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-4000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax id="F_000111" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">7000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="F_000112" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-26476000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="F_000113" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-18746000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeTaxExpenseBenefit id="F_000114" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">35000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:NetIncomeLoss id="F_000115" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-26511000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000116" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-18746000</us-gaap:NetIncomeLoss>
  <us-gaap:TemporaryEquityDividendsAdjustment id="F_000117" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1054000</us-gaap:TemporaryEquityDividendsAdjustment>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000118" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-26511000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000119" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-19800000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000120" contextRef="C_0001703647_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-0.82</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000121" contextRef="C_0001703647_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-2.29</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000122" contextRef="C_0001703647_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">32253227</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000123" contextRef="C_0001703647_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">8649245</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax id="F_000124" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-27000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax id="F_000125" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">54000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent id="F_000126" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-27000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent id="F_000127" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">54000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:ComprehensiveIncomeNetOfTax id="F_000128" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-26538000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="F_000129" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-18692000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000130" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">41857005</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests id="F_000131" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20181231" decimals="-3" unitRef="U_iso4217USD">38224000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000132" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesB1ConvertiblePreferredStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">10000</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests id="F_000133" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesB1ConvertiblePreferredStockMember_20181231" decimals="-3" unitRef="U_iso4217USD">9000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000134" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">62528507</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests id="F_000135" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_20181231" decimals="-3" unitRef="U_iso4217USD">46694000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000136" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesA1ConvertiblePreferredStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">10000</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests id="F_000137" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesA1ConvertiblePreferredStockMember_20181231" decimals="-3" unitRef="U_iso4217USD">8000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
  <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests id="F_000138" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20181231" decimals="-3" unitRef="U_iso4217USD">3773000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
  <us-gaap:CommonStockSharesOutstanding id="F_000139" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">2084710</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="F_000140" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="-3" unitRef="U_iso4217USD">2000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="F_000141" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231" decimals="-3" unitRef="U_iso4217USD">804000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="F_000142" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231" decimals="-3" unitRef="U_iso4217USD">-49088000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="F_000143" contextRef="C_0001703647_20181231" decimals="-3" unitRef="U_iso4217USD">-48282000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000144" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">3609000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000145" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">3609000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000146" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">357170</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000147" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000148" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">365000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000149" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">366000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <freq:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues id="F_000150" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">288991</freq:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues id="F_000151" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">266000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
  <freq:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues id="F_000152" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesCConvertiblePreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">39492960</freq:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues id="F_000153" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesCConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">61687000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
  <freq:ConvertiblePreferredStockAccretionOfDividend id="F_000154" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1054000</freq:ConvertiblePreferredStockAccretionOfDividend>
  <freq:ConvertiblePreferredStockAccretionOfDividend id="F_000155" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1054000</freq:ConvertiblePreferredStockAccretionOfDividend>
  <us-gaap:TemporaryEquityAccretionOfDividends id="F_000156" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesCConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1054000</us-gaap:TemporaryEquityAccretionOfDividends>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000157" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">6325000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000158" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">6000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000159" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">79690000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000160" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">79696000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <freq:TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering id="F_000161" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesCConvertiblePreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">-39492960</freq:TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering>
  <freq:TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering id="F_000162" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesCConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-62741000</freq:TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering>
  <freq:TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering id="F_000163" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">-42145996</freq:TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering>
  <freq:TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering id="F_000164" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-38490000</freq:TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering>
  <freq:TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering id="F_000165" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesB1ConvertiblePreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">-10.000</freq:TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering>
  <freq:TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering id="F_000166" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesB1ConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-9000</freq:TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering>
  <freq:TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering id="F_000167" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">-62528507</freq:TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering>
  <freq:TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering id="F_000168" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-46694000</freq:TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering>
  <freq:TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering id="F_000169" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesA1ConvertiblePreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">-10000</freq:TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering>
  <freq:TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering id="F_000170" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesA1ConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-8000</freq:TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering>
  <freq:TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering id="F_000171" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-3773000</freq:TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering>
  <freq:StockIssuedDuringPeriodSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering id="F_000172" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">22077627</freq:StockIssuedDuringPeriodSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering>
  <freq:StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering id="F_000173" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">22000</freq:StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering>
  <freq:StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering id="F_000174" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">151693000</freq:StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering>
  <freq:StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering id="F_000175" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">151715000</freq:StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax id="F_000176" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">54000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax id="F_000177" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">54000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:NetIncomeLoss id="F_000178" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-18746000</us-gaap:NetIncomeLoss>
  <us-gaap:CommonStockSharesOutstanding id="F_000179" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">30844507</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="F_000180" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">31000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="F_000181" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231" decimals="-3" unitRef="U_iso4217USD">236161000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="F_000182" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231" decimals="-3" unitRef="U_iso4217USD">54000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="F_000183" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231" decimals="-3" unitRef="U_iso4217USD">-68888000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000184" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">9983000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000185" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">9983000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000186" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">769385</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000187" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000188" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1544000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000189" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1545000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000190" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">2350108</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000191" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000192" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">40141000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000193" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">40143000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax id="F_000194" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-27000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax id="F_000195" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-27000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:NetIncomeLoss id="F_000196" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-26511000</us-gaap:NetIncomeLoss>
  <us-gaap:CommonStockSharesOutstanding id="F_000197" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">33964000</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="F_000198" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="-3" unitRef="U_iso4217USD">34000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="F_000199" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231" decimals="-3" unitRef="U_iso4217USD">287829000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="F_000200" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231" decimals="-3" unitRef="U_iso4217USD">27000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="F_000201" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231" decimals="-3" unitRef="U_iso4217USD">-95399000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:ProfitLoss id="F_000202" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-26511000</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="F_000203" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-18746000</us-gaap:ProfitLoss>
  <us-gaap:ShareBasedCompensation id="F_000204" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">9983000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="F_000205" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">3609000</us-gaap:ShareBasedCompensation>
  <us-gaap:Depreciation id="F_000206" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1146000</us-gaap:Depreciation>
  <us-gaap:Depreciation id="F_000207" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">813000</us-gaap:Depreciation>
  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims id="F_000208" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">54000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
  <freq:NonCashLeaseExpenses id="F_000209" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">434000</freq:NonCashLeaseExpenses>
  <freq:DeferredLeaseIncentives id="F_000210" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">160000</freq:DeferredLeaseIncentives>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="F_000211" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">626000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="F_000212" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">3252000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="F_000213" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">4287000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="F_000214" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-644000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInContractWithCustomerLiability id="F_000215" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-36984000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
  <us-gaap:IncreaseDecreaseInContractWithCustomerLiability id="F_000216" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">51052000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities id="F_000217" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">3083000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities id="F_000218" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1490000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000219" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-45188000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000220" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">34216000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000221" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">6671000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000222" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1064000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt id="F_000223" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">26345000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt id="F_000224" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">282618000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
  <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt id="F_000225" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">43418000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
  <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt id="F_000226" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">265421000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000227" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">10402000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000228" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-18261000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock id="F_000229" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">266000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock id="F_000230" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesCConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">61687000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000231" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1545000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000232" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">80062000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement id="F_000233" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">40143000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <us-gaap:ProceedsFromIssuanceOfLongTermDebt id="F_000234" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">15000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="F_000235" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">56688000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="F_000236" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">142015000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect id="F_000237" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">21902000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect id="F_000238" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">157970000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations id="F_000239" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">200259000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations id="F_000240" contextRef="C_0001703647_20181231" decimals="-3" unitRef="U_iso4217USD">42289000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations id="F_000241" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">222161000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
  <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability id="F_000242" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">31335000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
  <freq:NonCashDividendOnCumulativeConvertiblePreferredStock id="F_000243" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1054000</freq:NonCashDividendOnCumulativeConvertiblePreferredStock>
  <us-gaap:ConversionOfStockAmountIssued1 id="F_000244" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">151715000</us-gaap:ConversionOfStockAmountIssued1>
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid id="F_000245" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">2145000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <dei:DocumentsIncorporatedByReferenceTextBlock id="F_000246" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Portions of the Proxy Statement for the registrant&amp;#8217;s&amp;#160;2021&amp;#160;Annual Meeting of Stockholders are incorporated by reference into Part&amp;#160;III of this Annual Report on Form 10-K.&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock id="F_000247" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;1. Organization and basis of presentation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Frequency Therapeutics, Inc., together with its wholly owned subsidiaries, Frequency Therapeutics, PTY, LTD, Frequency Therapeutics Securities Corporation and Frequency Therapeutics Japan KK (Frequency Japan) (the Company), headquartered in Woburn, Massachusetts, was incorporated in November 2014 as a Delaware corporation. The Company is a clinical-stage biotechnology company focused on harnessing the body&amp;#8217;s innate biology to repair or reverse damage caused by a broad range of degenerative diseases.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On September 20, 2019, the Company effected a 1-for-6.7355 reverse stock split of its common stock. The par value of the common stock was not adjusted as a result of the reverse stock split and the authorized capital was amended to 100,000,000 shares of common stock and 148,724,922 shares of $0.001 par value preferred stock (the Preferred Stock). The reverse stock split resulted in an adjustment to the Series A Convertible  Preferred Stock (Series A Preferred), Series B Convertible Preferred Stock (Series B Preferred) and Series C Convertible Preferred Stock (Series C Preferred) conversion prices to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. The accompanying consolidated financial statements and notes to the consolidated financial statements give retroactive effect to the reverse stock split for all periods presented. Shares of common stock underlying outstanding stock options were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the appropriate securities agreements. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In October 2019, the Company completed the initial public offering of its common stock (the &amp;#8220;IPO&amp;#8221;). In the IPO, the Company issued and sold 6,325,000 shares of its common stock at a price to the public of $14.00 per share, inclusive of the underwriters&amp;#8217; exercise in part of their over-allotment option. The Company received approximately $79.7 million in net proceeds, after deducting underwriting discounts and commissions and other offering expenses. In connection with the IPO, on October 7, 2019 all Preferred Stock and the preferred stock of Frequency Japan converted into 22,077,627 shares of common stock and all outstanding shares of Series A-1 Preferred Stock and B-1 Preferred Stock were forfeited.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On July 20, 2020, the Company issued and sold an aggregate of 2,350,108 shares of its common stock, par value $0.001 per share, at a purchase price of $18.00 per share to new and existing investors in a private placement for net proceeds of $40.1 million after deducting placement agent fees and offering expenses (the &amp;#8220;Private Placement&amp;#8221;).&amp;#160;In connection with the Private Placement, the Company entered into a Registration Rights Agreement (the &amp;#8220;Registration Rights Agreement&amp;#8221;) with the investors. Pursuant to the Registration Rights Agreement, the Company agreed to prepare and file a registration statement with the Securities and Exchange Commission (the &amp;#8220;SEC&amp;#8221;) within 60 days after the closing of the Private Placement (the &amp;#8220;Initial Filing Date&amp;#8221;) for purposes of registering the resale of the Shares. The Company filed a registration statement (the &amp;#8220;Registration Statement&amp;#8221;) which was declared effective by the SEC on September 3, 2020.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has also agreed, among other things, to indemnify the investors, their officers, directors, managers, employees, agents and any person who controls any investor under the Registration Statement from certain liabilities and to pay all fees and expenses (excluding any underwriting discounts and commissions) incident to the Company&amp;#8217;s obligations under the Registration Rights Agreement.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Uncertainties &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&amp;#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Our offices are located in states that are currently operating under a phased re-opening plan in response to the COVID-19 pandemic. As of the date of the filing of this Annual Report, the majority of our employees continue to work from home, while nearly a quarter to one-third of our workforce, consisting of mainly laboratory personnel, have periodically worked in rotating teams to ensure the continuation of essential experiments. Our Farmington, CT research site, co-located with the University of Connecticut, has resumed activity at a fifty percent level after a period of paused activity due to state lock down orders previously in effect. While we have resumed experiments at our Farmington site, we have transitioned certain key experiments to our offices in Woburn, MA and third parties and contract research organizations have been engaged to advance certain projects. We are also have taken steps consistent with the FDA&amp;#8217;s updated industry guidance for conducting clinical trials.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.9%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The COVID-19 pandemic, and actions taken to mitigate it, have had and are expected to continue to have an adverse impact on the economies and financial markets of many countries, including the geographical area in which we operate, which could adversely impact our ability to raise additional capital when needed or on acceptable terms, if at all. In addition, while no significant disruptions have occurred, the COVID-19 pandemic may cause such disruptions in our business or operations, as well as the business and operations of our CMOs, CROs and other third parties with whom we conduct business. The COVID-19 pandemic may also adversely impact the our clinical trials, which could impede, delay, limit or prevent the clinical development of our product candidates and ultimately lead to the delay or&lt;font style="font-weight:bold;"&gt; &lt;/font&gt;denial of regulatory approval of our product candidates, which would materially adversely affect our business and operations, including our ability to generate revenue.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Liquidity and capital resources &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has funded its operations primarily with proceeds from the sale of its capital stock, convertible notes and amounts received under a collaboration agreement. The Company has incurred recurring losses since its inception. In addition, as of December&amp;#160;31, 2020, the Company had an accumulated deficit of $95,399. The Company expects to continue to generate operating losses for the foreseeable future. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company&amp;#8217;s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurances that additional funding will be available on terms acceptable to the Company, or at all. The Company believes that existing resources will be sufficient to fund planned operations for at least 12 months from the date the financial statements were available to be issued.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock id="F_000248" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2. Summary of significant accounting policies &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Basis of presentation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP) that the Company follows to ensure its financial condition, results of operations, and cash flows are consistently reported. References to GAAP issued by the FASB in these notes to the consolidated financial statements are to the FASB &lt;font style="font-style:italic;"&gt;Accounting Standards&lt;/font&gt; Codification (ASC). &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Principles of consolidation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The consolidated financial statements include the accounts of Frequency Therapeutics, Inc. and its wholly owned subsidiaries Frequency Therapeutics Securities Corporation, Frequency Therapeutics PTY, LTD and Frequency Japan. All intercompany transactions and balances have been eliminated. Frequency Japan was closed down in February 2021, as further described in Note 19 of notes to consolidated financial statements. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Use of estimates &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of the Company&amp;#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. On an ongoing basis, the Company&amp;#8217;s management evaluates its estimates, which include but are not limited to management&amp;#8217;s judgments of accrued expenses, revenue recognition, fair value of common stock, valuation of share-based awards, present value of lease liabilities and income taxes. Actual results could differ from those estimates. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company utilized significant estimates and assumptions in determining the fair value of its common stock in periods prior to the IPO. The Company utilized various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately Held Company Equity Securities Issued as Compensation (the Practice Aid), to estimate the fair value of its common stock. Each valuation methodology includes estimates and assumptions that require the Company&amp;#8217;s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to the Company&amp;#8217;s common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale. Significant changes to the key assumptions used in the valuations could have resulted in different fair values of common stock at each valuation date. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Comprehensive income (loss) &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Components of comprehensive income or loss, including net income or loss, are reported in the financial statements in the period in which they are recognized. Other comprehensive income or loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss) are reported net of any related tax effect to arrive at comprehensive income (loss). Comprehensive loss includes net loss as well as other changes in stockholders&amp;#8217; equity that result from transactions and economic events other than those with stockholders which for the years ended December 31, 2020 and 2019 consist of unrealized gain on marketable securities.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Segment information &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company&amp;#8217;s chief operating decision-maker, the Company&amp;#8217;s chief executive officer, views the Company&amp;#8217;s operations and manages its business as a single operating segment, which is in the business of discovering and developing small molecule drugs that activate progenitor cells within the body to create healthy tissue. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Foreign currency &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All periods presented are reported in US dollars. The functional currency for entities outside the United States is the US dollar. Realized and unrealized gains and losses from foreign currency transactions are reflected in the consolidated statements of operations as other expense. During the years ended December&amp;#160;31, 2020 and 2019 the Company recorded $(4), and $7&lt;font style="font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;of foreign currency exchange (losses) gains, respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all highly liquid investments with an original maturity of six months or less at acquisition to be cash equivalents which are stated at fair market value. Cash and cash equivalents at December&amp;#160;31, 2020 and 2019 consists entirely of cash and money market funds. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Restricted Cash&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has $1.8 million of restricted cash as of December 31, 2020 which represents a $1.7 million security deposit on the Company&apos;s future Lexington, Massachusetts facility and a $0.1 million security deposit on the Company&apos;s Woburn, Massachusetts facility. The $0.1 million restricted cash at December 31, 2019 represented the security deposit on the Company&apos;s Woburn, Massachusetts facility.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Short-term marketable debt securities&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term marketable securities represent holdings of available-for-sale marketable debt securities in accordance with the Company&amp;#8217;s investment policy. Short-term marketable investments mature within one-year from the balance sheet date. Investments in marketable securities are recorded at fair value, with any unrealized gains and losses reported within accumulated other comprehensive income as a separate component of stockholders&amp;#8217; equity (deficit) until realized or until a determination is made that an other-than-temporary decline in market value has occurred. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion, together with interest on securities sold is determined based on the specific identification method and any realized gains or losses on the sale of investment are reflected as a component of other income (expense).&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Concentration of credit risk and off-balance sheet risk&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instrument that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. The Company maintains its cash and cash equivalents at several accredited financial institutions, in amounts that exceed federally insured limits. Marketable securities consist of U.S. Treasury securities with maturities of less than twelve months. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which its money market accounts are maintained.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has no significant off-balance sheet such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Significant suppliers &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is dependent on third-party manufacturers to supply products for research and development activities of its programs, including preclinical and clinical testing. In particular, the Company relies and expects to continue to rely on a single manufacturer of its product candidates for use in clinical trials. The Company would be adversely affected by a significant interruption in the supply of product for use in clinical programs. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Fair value measurements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic&amp;#160;820, &lt;font style="font-style:italic;"&gt;Fair Value Measurement&lt;/font&gt; (ASC&amp;#160;820), establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The hierarchy defines three levels of valuation inputs, of which the first two are considered observable and the last is considered unobservable: &lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.86%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:9.38%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Quoted prices in active markets for identical assets or liabilities.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.86%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:9.38%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Inputs other than quoted prices included within Level&amp;#160;1 that are either directly or indirectly observable,&amp;nbsp;&amp;nbsp; &amp;nbsp;&amp;nbsp;such as quoted market prices, interest rates and yield curves.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.86%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:9.38%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Unobservable inputs developed using estimates or assumptions developed by the Company, which reflect those that a market participant would use in pricing the asset or liability.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&amp;#160;3. A financial instrument&amp;#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying values of other current assets, accounts payable, and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. The fair value of the Company&amp;#8217;s Term Loan is not materially different from the carry value as presented given the Term Loan was issued within one month of December 31, 2020. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Property and equipment &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment consist of lab equipment, computer equipment, furniture and office equipment and leasehold improvements recorded at cost. These amounts are depreciated using the straight-line method over the estimated useful lives of the assets as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.38%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.38%;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated useful life&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Software&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and office equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shorter of the estimated useful&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;life or lease term&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheet and related gains or losses are reflected in the consolidated statements of operations.&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Impairment of long-lived assets &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company continually evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company did not recognize any impairment losses for the years ended December&amp;#160;31, 2020 and 2019.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Research and development costs and accruals &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses include salaries and benefits, materials and supplies, preclinical and clinical trial expenses, stock-based compensation expense, depreciation of equipment, contract services and other outside expenses. The Company has entered into various research and development-related contracts with research institutions, contract research organizations, contract manufacturers and other companies. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. Costs of certain development activities, such as manufacturing, pre-clinical and clinical trial expenses, are recognized based on an evaluation of the progress to completion of specific tasks. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed. Costs incurred in obtaining technology licenses are charged to research and development expense as acquired in-process research and development if the technology licensed has not reached technological feasibility and has no alternative future use.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company elected to early adopt ASC 842, &lt;font style="font-style:italic;"&gt;Leases&lt;/font&gt; (ASC 842) as of January 1, 2020 and elected the transition method under ASU 2016-02 whereby the Company records a right-to-use asset and a lease liability on the consolidated balance sheet for all leases with terms longer than 12 months. The Company also elected to apply the package of practical expedients intended to ease transition. Accordingly, the Company has only applied ASC 842 to leases existing at January 1, 2020. The Company determines if an arrangement is, or contains, a lease at inception. Operating leases are included in operating lease right-of-issue (&amp;#8220;ROU&amp;#8221;) assets, other current liabilities, and operating lease liabilities on the consolidated balance sheets.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ROU assets represent the Company&amp;#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&amp;#8217;s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments to be made over the lease term. The ROU asset also includes any lease payments made at or before the lease commencement date and excludes lease incentives received. As the Company&amp;#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected to not apply the recognition requirements of ASC 842 for short-term leases, which is defined as a lease that, at the lease commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For real estate lease agreements entered into or modified after the adoption of ASC 842 that include lease and non-lease components, the Company has elected to account for the lease and non-lease components, such as common area maintenance charges, as a single lease component.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Collaborative arrangements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company analyzes its collaborative arrangements to assess whether they are within the scope of ASC 808, &lt;font style="font-style:italic;"&gt;Collaborative Arrangements&lt;/font&gt; (&amp;#8220;ASC 808&amp;#8221;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship (e.g., a licensing arrangement) where the contracted party has obtained goods or services that are an output of the Company&amp;#8217;s ordinary activities in exchange for a consideration and therefore within the scope of ASC 606, &lt;font style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt; (&amp;#8220;ASC 606&amp;#8221;). For those elements of the arrangement that are accounted for pursuant to ASC 606, including those to which ASC 606 is applied by analogy, the Company applies the five-step model described in the Company&amp;#8217;s revenue recognition policy. For elements of collaborative arrangements that are accounted for pursuant to ASC 808, an appropriate and rational recognition method is determined and applied consistently. Reimbursements from the counterparty that are the result of a collaborative relationship with the counterparty, instead of a customer relationship, such as co-development or clinical activities, are recorded as a reduction to research and development expense as the services are performed. Similarly, amounts that are owed to a collaboration partner related to the co-development clinical activities are recognized as research and development expense. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company enters into out-licensing agreements that are within the scope of ASC 606. The terms of such out-license agreements include licenses to functional intellectual property (IP), given the functionality of the intellectual property is not expected to change substantially as a result of the licensor&amp;#8217;s ongoing activities. Such arrangements typically include payment of one or more of the following: non-refundable up-front license fees; reimbursement of certain costs; development and regulatory milestone payments and milestone payments based on the level of sales; and royalties on net sales of licensed products. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers the economic and regulatory characteristics of the licensed IP, research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace to determine if it has standalone value at the inception of the licensing arrangement, which would make the license distinct. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of any additional good or services promised in the contract, whether the value of the license is dependent on the remaining goods and services, whether there are other vendors that could provide the remaining promise, and whether the license is separately identifiable from the remaining good and services. For licenses that are combined with other goods and services, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of progress and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue is allocated to the licensed IP on a relative standalone selling price basis and, for functional IP, is recognized at a point when the licensed IP is made available for the customer&amp;#8217;s use and benefit, which generally occurs at the inception of the arrangement. However, in cases, where the functionality of the IP is expected to substantively change as a result of activities of the Company that do not transfer additional promised goods or services, or in cases, where there is an expectation that the Company will undertake activities to change the standalone functionality of the IP and the customer is contractually or practically required to use the latest version of the IP, revenue for the license to functional IP is recognized over time. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Development and regulatory milestone fees, which are a type of variable consideration, are recognized as revenue to the extent that it is probable that a significant reversal will not occur. The Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has entered into a collaboration arrangement with Astellas Pharma Inc. (&amp;#8220;Astellas&amp;#8221;), as further described in Note 16 of notes to consolidated financial statements. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Revenue recognition &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for contracts with customers in accordance with ASC 606, including all amendments thereto. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as collaborative arrangements and leases. The Company&amp;#8217;s disclosure within the below sections or elsewhere within these consolidated financial statements reflects the Company&amp;#8217;s accounting policies in compliance with this new standard.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under ASC 606, an entity recognizes revenue when or as its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To recognize revenue for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i)&amp;#160;identify the contract(s) with a customer; (ii)&amp;#160;identify the performance obligations in the contract; (iii)&amp;#160;determine the transaction price, including variable consideration, if any; (iv)&amp;#160;allocate the transaction price to the performance obligations in the contract; and (v)&amp;#160;recognize revenue when (or as) the entity satisfies its performance obligations. The Company only applies the five-step model to contracts when it is probable that the entity will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services it transfers to the customer. Once a contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and identifies as a performance obligation each promise to transfer to the customer either (a) a good or service (or bundle of goods and services) that is distinct, or (b) a series of distinct goods and services that are substantially the same and have been the same pattern of transfer to the customer.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company assesses whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i)&amp;#160;the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii)&amp;#160;the entity&amp;#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract). In assessing whether a promised good or service is distinct, the Company considers factors such as the research, manufacturing and commercialization capabilities of the collaboration partner (the &amp;#8220;customer&amp;#8221; in this type of arrangement) and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct. For each arrangement that results in revenues, the Company identifies all performance obligations, which may include, for example, a license to IP and know-how, research and development activities, and/or manufacturing services. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In addition to any upfront payment, if the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the estimated variable consideration in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. If it is probable that a significant revenue reversal will not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or of the licensee such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For contracts that include sales-based royalties (including milestone payments based on the level of sales) promised in the exchange for licenses of intellectual property, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestone payments at the later of (i)&amp;#160;when the related sales occur, or (ii)&amp;#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied. In determining the transaction price, the Company adjusts the promised amount of consideration for the effects of the time value of money if the timing of payments provides the Company or the Company&amp;#8217;s customer with a significant benefit of financing the transfer of goods and services. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. The Company assesses each of its revenue generating arrangements in order to determine whether a significant financing component exists. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time.&amp;nbsp;&amp;nbsp;For performance obligations satisfied over time, the Company measures progress toward completion of its performance obligations using an input method based on the Company&amp;#8217;s efforts and inputs to satisfy its performance obligations relative to total expected inputs to the satisfaction of that performance obligation.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts received from a customer prior to revenue recognition are recorded as deferred revenue. Amounts received from a customer that are expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability in the accompanying consolidated balance sheets.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Patent costs &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses in the accompanying consolidated statements of operations. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Stock-based compensation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for its stock-based compensation in accordance with ASC Topic&amp;#160;718, &lt;font style="font-style:italic;"&gt;Compensation&amp;#8212;Stock Compensation&lt;/font&gt; (ASC&amp;#160;718). ASC&amp;#160;718 requires all share-based payments to employees and directors to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company adopted FASB Accounting Standards Update (ASU) 2016-09 which identifies areas for simplification of several areas of share-based payment transactions. The Company treats non-employee grants in a manner consistent with employee grants. The Company estimates the fair value of options granted using the Black-Scholes option pricing model for stock option grants to both employees and non-employees. The Company believes the fair value of the stock options granted to non-employees is more reliably determinable than the fair value of the services provided. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (a)&amp;#160;the expected stock price volatility, (b)&amp;#160;the expected term of the award, (c)&amp;#160;the risk-free interest rate and (d)&amp;#160;expected dividends. Due to the lack of sufficient company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No.&amp;#160;107, Share-Based Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to non-employees, the Company utilizes the contractual term of the share-based payment as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;There are significant judgments and estimates inherent in the determination of the fair value of the Company&amp;#8217;s common stock prior to the IPO. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to its common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company expenses the fair value of its share-based compensation awards to employees and non-employees on a straight-line basis over the requisite service period, which is generally the vesting period. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Income taxes &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for income taxes using the asset and liability method in accordance with ASC Topic 740, &lt;font style="font-style:italic;"&gt;Income Taxes&lt;/font&gt; (ASC 740) which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&amp;#8217;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. At December&amp;#160;31, 2020 and 2019, the Company has concluded that a full valuation allowance is necessary for its deferred tax assets (see Note 13). &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Net loss per share &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. Diluted net loss per share is the same as basic net loss per share for the years ended December&amp;#160;31, 2020 and 2019 since all potential shares of common stock instruments are anti-dilutive as a result of the loss for such periods. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s convertible preferred stock contractually entitled the holders of such shares to participate in dividends but did not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reported a net loss, such losses are not allocated to such participating securities. In periods where the Company reported a net loss attributable to common stockholders, diluted net loss per share is the same as basic net loss per share, since dilutive shares of common stock are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for the years ended December&amp;#160;31, 2020 and 2019.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic and diluted net loss per share attributable to common stockholders was calculated as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.06%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss attributable to common stockholders&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26,511&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19,800&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average shares of common stock outstanding-&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,253,227&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,649,245&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share attributable to common stockholders-&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.82&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.29&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company excluded the following potential shares of common stock from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.06%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested restricted Common Stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,093&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70,366&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series C Preferred (as converted to common stock)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,172,676&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series B Preferred (as converted to common stock)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,759,079&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A Preferred (as converted to common stock)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,070,574&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Conversion of Frequency Japan preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;513,047&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding stock options (as converted to common stock)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,816,798&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,968,672&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,819,891&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,554,414&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Recently adopted accounting pronouncements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016, the FASB issued ASU No. 2016-02, &lt;font style="font-style:italic;"&gt;Leases&lt;/font&gt; (Topic 842) (&amp;#8220;ASU 2016-02&amp;#8221;), as amended by various subsequently issued ASUs. The standard requires lessees to recognize an operating lease with a term greater than one year on their balance sheets as a right-of-use asset and corresponding lease liability, measured at the present value of the lease payments. Lessees are required to classify leases as either finance or operating leases. If the lease is effectively a financed purchase by the lessee, it is classified as a financing lease, otherwise it is classified as an operating lease. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2018, the FASB also issued ASU 2018-11, &lt;font style="font-style:italic;"&gt;Leases&lt;/font&gt; (Topic 842): Targeted Improvements (&amp;#8220;ASU 2018-11&amp;#8221;), which permits entities to continue applying legacy guidance in ASC 840, Leases, including its disclosure requirements, in the comparative periods presented in the year that the entity adopts the new leasing standard. The Company adopted the standard on January 1, 2020 using the optional transition method. As such, the consolidated balance sheets and statements of operations for prior periods will not be comparable in the year of adoption of ASC 842. The Company elected the package of practical expedients permitted under the transition guidance within the standard. Accordingly, the Company did not reassess the conclusion of whether the existing arrangements contain a lease, lease classification and initial direct costs under ASC 842. As a result of the adoption of ASC 842, the Company recorded $1.2 million of ROU assets and a total of $1.5 million of lease liabilities on the consolidated balance sheets as of January 1, 2020. In addition, in the first quarter of 2020 the Company expanded and amended the lease for its Woburn, Massachusetts facility and increased both the ROU asset and lease liability by $1.0 million. On December 11, 2020, the Company terminated this lease and remeasured the existing ROU asset and lease liability based on this lease modification, resulting in a $1.7 million impact to both the ROU asset and lease liability. As disclosed in Note 16, the Company has entered into a lease for a facility in Lexington Massachusetts which commenced December 11, 2020. In accordance with ASU No. 2016-02, the Company recognized a right-of-use asset and related lease liability at such time.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January 2016,&amp;#160;the FASB issued ASU No. 2016-01, &lt;font style="font-style:italic;"&gt;Financial Instruments - Overall&lt;/font&gt; (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. This new standard amended certain aspects of accounting and disclosure requirements for financial instruments, including the requirement that equity investments with readily determinable fair values are to be measured at fair value with any changes in fair value recognized in a company&apos;s statements of operations. Prior to adoption of ASU 2016-01, companies recognized changes in fair value in accumulated other comprehensive income (loss), net. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. In addition, a valuation allowance should be evaluated on deferred tax assets related to available- for-sale debt securities in combination with other deferred tax assets.&amp;#160;The Company adopted this new standard on January 1, 2020, using the modified retrospective method, and determined that it did not have a material impact on its financial statements.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Recently issued accounting pronouncements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company is an &amp;#8220;emerging growth company&amp;#8221; as defined in the Jumpstart Our Business Startups Act of 2012, as amended (Jobs Act). The Jobs Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company elected to avail itself of this extended transition period and, as a result, we will not be required to adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;font style="font-style:italic;"&gt;Financial Instruments - Credit Losses&lt;/font&gt; (Topic 326): Measurement of Credit Losses on Financial Instruments. The FASB has subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. This standard will become effective for the Company on January 1, 2023. The Company is still evaluating the impact of this standard on its consolidated financial statements.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, the FASB issued&amp;#160;&lt;font style="color:#000000;"&gt;ASU 2019-12&lt;/font&gt;&amp;#160;amending accounting guidance that simplifies the accounting for income taxes, as part of its initiative to reduce complexity in the accounting standards. The amendments eliminate certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The amendments also clarify and simplify other aspects of the accounting for income taxes. This standard will become effective for the Company on January 1, 2021. The Company is still evaluating the impact of this standard on its consolidated financial statements.&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
  <us-gaap:FairValueDisclosuresTextBlock id="F_000249" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;3. Fair value measurements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s financial assets measures at fair value on a recurring basis by level within the fair value hierarchy at December 31, 2020 and 2019 are summarized as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.74%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Market&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Hierarchy&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gain&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;214,522&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;214,549&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.04%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;214,522&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;214,549&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.74%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Market&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Hierarchy&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Loss) Gain&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;200,131&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;200,119&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. Government treasury securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,131&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;66&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,197&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.04%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;217,262&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;217,316&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <freq:PrepaidExpensesAndOtherCurrentAssetsTextBlock id="F_000250" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;4. Prepaid expenses &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid expenses and other current assets consisted of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Rent and deposits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;63&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,729&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;801&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant receivable&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;805&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounts receivable&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;340&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Insurance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,552&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,132&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;102&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;199&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.4%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,723&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</freq:PrepaidExpensesAndOtherCurrentAssetsTextBlock>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock id="F_000251" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;5. Property and equipment &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment include the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,166&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,846&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and office equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;283&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;257&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Software&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;291&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,419&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,419&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,340&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;306&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,499&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,828&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,212&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,066&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.66%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,287&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,762&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognized $1,146 and $813 of depreciation expense for the years ended December&amp;#160;31, 2020 and 2019, respectively. &lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock id="F_000252" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;6. Accrued expenses &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses consist of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Payroll and employee related expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,062&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,686&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;647&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;435&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Third-party research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;874&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;118&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Taxes and other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;80&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.4%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,663&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,239&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
  <us-gaap:DebtDisclosureTextBlock id="F_000253" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;7. Debt&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On December 11, 2020, the Company entered into a Loan and Security Agreement (the &amp;#8220;Loan Agreement&amp;#8221;) with a commercial bank for a Term Loan with a principal balance of $15 million. The Company will make monthly interest only payments through November&amp;#160;30, 2022. The principal balance and interest will be repaid in equal monthly installments after the interest only period and continuing through May&amp;#160;1, 2024 (the &amp;#8220;Loan Maturity Date&amp;#8221;). Advances under the Loan Agreement will bear an interest rate equal to the greater of either (i) 1.50% plus the Prime Rate (as reported in&lt;font style="font-style:italic;"&gt;&amp;#160;The Wall Street Journal&lt;/font&gt;, subject to an interest rate floor of zero) or (ii) 4.75%. Interest related to the Loan Agreement was immaterial for the year ended December 31, 2020. &lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company may prepay the advance made under the Loan Agreement in whole, at any time subject to a prepayment premium equal to: (a) 2.0% of the then-outstanding principal amount of the advance, if such prepayment occurs on or prior to the first anniversary of the Closing Date; (b) 1.0% of the then-outstanding principal amount of the advance, if such prepayment occurs after the first anniversary of the Closing Date and on or prior to the second anniversary of the Closing Date; and (c) 0.0% of the then-outstanding principal amount of the advance, if such prepayment occurs after the second anniversary of the Closing Date. The prepayment premium is waived if the Term Loan Facility is refinanced by the Bank (in its sole and absolute discretion) on or prior to the Loan Maturity Date.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company will pay a final payment of $150,000, which will occur on the earliest of: (i)&amp;#160;the Loan Maturity Date; (ii)&amp;#160;the date that the Company prepays all of the outstanding principal in full; (iii)&amp;#160;the date the loan payments are accelerated due to an event of default; or (iv)&amp;#160;the termination of the Loan Agreement. The Company is recording the final payment as interest expense over the term of the loan. The Term Loan Facility is secured by substantially all of the Company&amp;#8217;s assets, excluding intellectual property.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
  <freq:TemporaryEquityTextBlock id="F_000254" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;8. Convertible preferred stock &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2018, the Company had issued 62,528,507 shares of Series A Preferred Stock, 10,000 shares of Series A-1 Preferred Stock, 41,857,005 shares of Series B Preferred Stock, and 10,000 shares of Series B-1 Preferred Stock. In 2019, the Company also issued 288,911 shares of Series B Preferred Stock. On July&amp;#160;17, 2019, the Company authorized and issued 39,492,960 shares of Series&amp;#160;C Preferred for net proceeds of $61,687. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company evaluated the tranched nature of the issuance of these preferred shares as well as the rights, preferences, and privileges of such shares and has concluded that there were no freestanding derivative instruments or any embedded derivatives requiring bifurcation. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In October 2019, in connection with the IPO, all shares of Preferred Stock were automatically converted into common stock.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;</freq:TemporaryEquityTextBlock>
  <us-gaap:MinorityInterestDisclosureTextBlock id="F_000255" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;9. Non-controlling Interest&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2018, the Company issued shares of preferred stock in its subsidiary, Frequency Japan, to a Japanese investor. The Frequency Japan preferred stock held by such investor was convertible, at the option of the holder, into 673,605 shares of Company common stock, adjustable for certain dilutive events, upon an initial public offering of Company common stock, a Company liquidation or upon a 70% vote of the holders of the Preferred Stock. The preferred shares also had a liquidation preference equal to the amount paid for the shares. The Company had the option to acquire the preferred shares of Frequency Japan under certain circumstances and the holder of such preferred shares had the right to require the Company to purchase such shares under certain circumstances, primarily a merger or liquidation. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with this sale of the preferred stock in Frequency Japan, FT-FJ Investment, LLC (FT-FJ), a Delaware limited liability company controlled by the Company, purchased 10,000 shares of the Company&amp;#8217;s Series A-1 Preferred Stock and 10,000 shares of the Company&amp;#8217;s Series B-1 Preferred Stock. FT-FJ also granted to the Japanese investor an irrevocable proxy to vote the shares of Series A-1 and Series B-1 Preferred Stock held by FT-FJ. Each share of Series A-1 Preferred had 236 times the voting power of one share of common stock and each share of Series B-1 Preferred Stock has 217 times the voting power of one share of common stock. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On August 20, 2019, the Company, Frequency Japan, the Japanese investor, and FT-FJ entered into an agreement pursuant to which, contingent upon the closing of an initial public offering of the Company&amp;#8217;s common stock: (i) the Japanese investor agreed to convert its shares of preferred stock held in Frequency Japan and to terminate its proxy over the shares of Series A-1 and B-1 Preferred Stock held by FT-FJ and (ii) FT-FJ agreed to forfeit its shares of Series A-1 and Series B-1 Preferred Stock. The shares were converted into common stock and the Series A-1 and B-1 preferred shares were forfeited in conjunction with the IPO.&lt;/p&gt;</us-gaap:MinorityInterestDisclosureTextBlock>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock id="F_000256" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;10. Stockholders&amp;#8217; equity &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Preferred stock&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;font style="font-weight:normal;"&gt;The Company has authorized 10,000,000 shares of $0.001 par value preferred stock of which no shares were issued or outstanding as of December 31, 2020.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Common stock &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has authorized 200,000,000 shares of $0.001 par value common stock of which 33,964,000 were issued and outstanding as of December 31, 2020. Common shares are voting, and dividends may be paid when, as and if declared by the Board of Directors.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has reserved the following shares of common stock for future issuance as of December 31, 2020 and 2019:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.16%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,816,798&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,968,672&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.16%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares available for future grant under stock option plan&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,475,923&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,859,654&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.16%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,292,721&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,828,326&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock id="F_000257" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;11. Stock-based compensation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On November&amp;#160;13, 2014, the Company adopted the 2014 Stock Incentive Plan (2014 Plan). All of the Company&amp;#8217;s employees, officers, directors, and consultants are eligible to be granted options to purchase common shares and restricted stock under the terms of the 2014 Plan. The Company reserved an aggregate of 8,550,415 shares of common stock for issuance under the 2014 Plan. As of December&amp;#160;31, 2020, there were no shares of common stock available for future grants under the 2014 Plan.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On September 17, 2019, the Company&amp;#8217;s board of directors and on September 19, 2019, its stockholders approved and adopted the 2019 Incentive Award Plan (&amp;#8220;the &amp;#8220;2019 Plan&amp;#8221;) which became effective on the day prior to the IPO.&amp;nbsp;&amp;nbsp;Under the 2019 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock and cash-based awards to individuals who are then employees, officers, directors or consultants of the Company, and employees and consultants of the Company&amp;#8217;s subsidiaries.&amp;nbsp;&amp;nbsp;A total of 3,100,000 shares of common stock were approved to be initially reserved for issuance under the 2019 plan.&amp;nbsp;&amp;nbsp;The number of shares under the 2014 Plan subject to outstanding awards as of the effective date of the 2019 Plan that are subsequently canceled, forfeited or repurchased by the Company will be added to the shares reserved under the 2019 Plan.&amp;nbsp;&amp;nbsp;In addition, the number of shares of common stock available for issuance under the 2019 Plan will be automatically increased on the first day of each calendar year during the ten-year term of the 2019 Plan, beginning with January 1, 2020 and ending with January 1, 2029, by the amount equal to 4% of the outstanding number of shares of the Company&amp;#8217;s common stock on December 31, of the preceding calendar year or such lesser amount as determined by the Company&amp;#8217;s board of directors.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All stock option grants are non-statutory stock options except option grants to employees (including officers and directors) intended to qualify as incentive stock options under the Internal Revenue Code of 1986, as amended. Incentive stock options may not be granted at less than the fair market value of the Company&amp;#8217;s common stock on the date of grant, as determined in good faith by the Board of Directors at its sole discretion. Nonqualified stock options may be granted at an exercise price established by the Board of Directors at its sole discretion (which has not been less than fair market value on the date of grant) and the vesting periods may vary. Vesting periods are generally four years and are determined by the Board of Directors. Stock options become exercisable as they vest. Options granted under the 2014 Plan and the 2019 Plan expire no more than ten years from the date of grant. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Stock options &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of the stock option activity under the 2014 Plan and the 2019 Plan are as follows: &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;exercise&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;term&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;intrinsic&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;exercise&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;term&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;intrinsic&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019 Plan&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2014 Plan&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,089,334&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.61&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,247,338&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14.09&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,015,381&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.17&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(357,170&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.02&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26,211&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.09&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,247,338&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14.09&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.76&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,287&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,721,334&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.85&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.89&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;65,051&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,645,859&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24.22&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,851&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18.93&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(767,534&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.94&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16,997&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22.72&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11,351&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.89&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,874,349&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19.84&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.09&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,325&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,942,449&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.02&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.98&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;127,090&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options exercisable as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;564,617&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17.48&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.90&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,042&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,337,828&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.57&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.88&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76,416&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options unvested as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,309,732&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,283&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,604,621&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,674&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Stock option valuation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The assumptions that the Company used to determine the grant-date fair value of stock options granted to&lt;font style="font-weight:bold;font-style:italic;"&gt; &lt;/font&gt;employees and directors were as follows, presented on a weighted average basis: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.9&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;79.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;79.4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Risk-Fee Interest Rate&lt;font style="font-style:normal;"&gt;: The Company based the risk-free interest rate over the expected term of the options based on the constant maturity of U.S. Treasury securities with similar maturities as of the date of the grant.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Expected Term&lt;font style="font-style:normal;"&gt;:&amp;nbsp;&amp;nbsp;The expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term).&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Expected Volatility&lt;font style="font-style:normal;"&gt;: The Company uses an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry that were deemed to be representative of future stock price trends as the Company does not have sufficient trading history for its common stock.&amp;nbsp;&amp;nbsp;The Company will continue to apply this process until a sufficient amount of historical information regarding volatility of its own stock price options becomes available.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Expected Dividend Yield&lt;font style="font-style:normal;"&gt;: The Company has not paid and does not anticipate paying any dividends in the near future.&amp;nbsp;&amp;nbsp;Therefore, the expected dividend yield was zero.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&amp;#8217;s common stock for those stock options that had exercise prices lower than the fair value of the Company&amp;#8217;s common stock. During the years ended December&amp;#160;31, 2020 and 2019, 769,385 and 357,170 shares were exercised, respectively. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2020 and 2019 was $16,667 and $5,896 respectively.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted-average grant date fair value of options granted to employees during the years ended December&amp;#160;31, 2020 and 2019 was $16.41 and $4.05&lt;font style="font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The total grant date fair value of options vested during the years ended December&amp;#160;31, 2020 and 2019 was $7,907 and $2,990, respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Restricted common stock &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company issued common stock to founders, employees and advisors which was subject to vesting over four years. If any of these individuals ceased to be employed or to provide services to the Company prior to vesting, the Company had the right to repurchase any unvested Common Stock at the price paid by the holder. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of the status of restricted common stock as of December&amp;#160;31, 2020 and 2019 is presented below: &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:72.52%;"&gt;
&lt;tr style="height:8.85pt;"&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:20.95pt;"&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;average fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:8.85pt;"&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested, December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70,366&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.36&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:8.85pt;"&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Awarded&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:8.5pt;"&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(67,273&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.29&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:8.85pt;"&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:8.5pt;"&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.12%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested, December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,093&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.75&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; The total value of restricted stock awards that vested during the years ended December&amp;#160;31, 2020 and 2019, based on estimated fair values of the stock underlying the restricted stock awards was $20 and $73, respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Stock-based compensation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense of $9,983 and $3,609 for the years ended December&amp;#160;31, 2020 and 2019 respectively, is included in research and development and general and administrative expenses in the Company&amp;#8217;s consolidated statements of operations and comprehensive loss. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2020 and 2019, total unrecognized stock-based compensation expense relating to unvested stock options was $31,006 and $13,820, respectively. This amount is expected to be recognized over a weighted-average period of 3.08 years and 2.76 years, respectively. &lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <freq:EmployeeStockPurchasePlanDisclosureTextBlock id="F_000258" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;12. Employee stock purchase plan &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On September 20, 2019, the Company&amp;#8217;s board of directors and stockholders approved and adopted the 2019 Employee stock Purchase Plan (the &amp;#8220;ESPP&amp;#8221;) which became effective on the date of the IPO. The ESPP permits participants to purchase common stock through payroll deductions of up to 15% of their eligible compensation. A total of 315,000 shares of common stock were approved to be initially reserved for issuance under the ESPP. In addition, the number of shares of common stock available for issuance under the ESPP will be automatically increased on the first day of each calendar year during the first ten-years of the term of the ESPP, beginning with January 1, 2020 and ending with January 1, 2029, by an amount equal to 1% of the outstanding number of shares of the Company&amp;#8217;s common stock on December 31 of the preceding calendar year or such lesser amount as determined by the Company&amp;#8217;s board of directors. No shares were issued under the ESPP at December 31, 2020.&lt;/p&gt;</freq:EmployeeStockPurchasePlanDisclosureTextBlock>
  <us-gaap:IncomeTaxDisclosureTextBlock id="F_000259" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;13. Income taxes &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Since inception in 2014, the Company has generated cumulative federal and state net operating loss and research and development credit carryforwards for which we have not recorded any net tax benefit due to uncertainty around utilizing these tax attributes within the respective carryforward periods. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2020, the Company had federal net operating loss carryforwards of approximately $67,868 and Massachusetts state operating loss carryforwards of approximately $43,386&amp;#160;which may be available to offset future taxable income. The U.S. federal net operating loss carryforwards include $22,400 available to reduce future taxable income through 2037 and approximately $45,469 which do not expire and are available to reduce future taxable income indefinitely. The state net operating loss carryforwards are available to offset future taxable income through 2040. As of December&amp;#160;31, 2020, the Company also had federal and Massachusetts research and development tax credit carryforwards of $3,014 and $1,211, respectively, which are available to offset federal and state tax liabilities through 2040 and 2035, respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Realization of future tax benefits is dependent on many factors, including the Company&amp;#8217;s ability to generate taxable income within the net operating loss carryforward period. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as provided under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, respectively, as well as similar state provisions. These ownership changes may limit the number of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section&amp;#160;382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has completed several financings and has conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception and has determined that an ownership change did occur in March 2017. Accordingly, utilization of $12,400 of the U.S. net operating loss carryforwards which were incurred prior to March 2017 (pre-ownership change) is limited under Section 382. After the Section 382 limitations, the Company may utilize approximately $10,800 of its pre-ownership change net operating loss carryforwards based upon an annual usage of approximately $1,600 for each of the next five years after the ownership change and approximately $180 for each of the 15 years thereafter. The remaining pre-ownership change net operating losses of approximately $1,600 were written off due to expiration under limitation. The limitation has been determined by first multiplying the value of our stock at the time of the ownership change by the applicable long-term tax-exempt rate. These carryforwards may be subject to further annual limitations under Section&amp;#160;382 in the event of future changes in ownership.&amp;nbsp;&amp;nbsp;Additionally, the Company has determined an ownership changed occurred in October of 2019 as a result of the IPO.&amp;nbsp;&amp;nbsp;Accordingly, utilization of approximately $46,123 of the U.S. net operating loss carryforwards incurred prior to October 2019 is also limited under Section 382.&amp;nbsp;&amp;nbsp;The Company has determined it will be able to utilize the entire $46,123 of its pre-ownership change net operating loss carryforwards based upon the limitations calculated from the October 2019 ownership change. These carryforwards may be subject to further annual limitations under Section 382 in the event of future changes in ownership.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration of all the evidence, both positive and negative, the Company has recorded a valuation allowance against its deferred tax assets at December&amp;#160;31, 2020 and 2019 because the Company&amp;#8217;s management has determined that it is more likely than not that the Company will not recognize the benefits of its federal and state deferred tax assets primarily due to its cumulative loss position and, as a result, a valuation allowance of approximately $26,995 and $16,204 as of December&amp;#160;31, 2020 and 2019 has been established. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has no unrecognized tax benefits. The Company has not, as yet, conducted a study of its research and development credit carryforwards. Such a study may result in an adjustment to the Company&amp;#8217;s research and development credit carryforwards; however, until a study is completed, and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&amp;#8217;s research and development credits and, if an adjustment were required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the consolidated balance sheet or consolidated statements of operations if an adjustment were required. The Company has elected to recognize interest and penalties related to income tax matters as a component of income tax expense, of which no interest or penalties were recorded for the years ended December&amp;#160;31, 2020 and 2019. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company files income tax returns in the U.S. and Massachusetts. The statute of limitations for assessment by the Internal Revenue Service and Massachusetts tax authorities remains open for all years since 2014. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service or state authorities to the extent utilized in a future period. No federal or state tax audits are currently in process. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the Company&amp;#8217;s pre-tax income for the years ended December 31, 2020 and 2019 is as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:56.02%;"&gt;
&lt;tr style="height:10.65pt;"&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12.7pt;"&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Domestic&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(25,744&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19,086&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12.7pt;"&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(732&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(714&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:13.45pt;"&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26,476&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19,800&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s provision at December 31, 2020 and 2019 consist of the following:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:55.74%;"&gt;
&lt;tr style="height:10.3pt;"&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12.35pt;"&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12.35pt;"&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Federal&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:13.05pt;"&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; State&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:13.05pt;"&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Foreign&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12.35pt;"&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12.35pt;"&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:13.05pt;"&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Federal&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12.35pt;"&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; State&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:13.05pt;"&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Foreign&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12.35pt;"&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total Deferred&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12.35pt;"&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total provision (benefit)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the U.S. federal statutory income tax rate to the Company&amp;#8217;s effective income tax rate for the years ended December&amp;#160;31, 2020 and 2019 is as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:52.54%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.34%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.46%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td style="border:none;padding:0;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S federal statutory income tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.46%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.2)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.8&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.46%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State income taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.0&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.46%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11.2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.8&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.46%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock compensation deductions&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.46%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other items&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.0&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.46%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in deferred tax asset valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(40.7)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(23.0&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;%&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td style="border:none;padding:0;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s deferred tax assets at December&amp;#160;31, 2020 and 2019 consist of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,885&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,253&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,992&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,138&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangibles&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;360&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;358&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;850&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;686&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,606&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;496&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;142&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;189&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fixed assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;56&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,285&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right of use asset&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7,181&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax asset&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,995&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,204&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26,995&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16,204&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <freq:ResearchAndLicenseAgreementsDisclosureTextBlock id="F_000260" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;14. Research and license agreements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Massachusetts Institute of Technology &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2016, the Company entered into an exclusive patent license agreement (MIT License Agreement), with the Massachusetts Institute of Technology, (MIT), under which the Company received an exclusive, worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, offer to sell, lease and import products (Licensed Products) and to develop and perform processes (Licensed Processes) which incorporate the licensed technology for the treatment of disease, including but not limited to the prevention and remediation of hearing loss. The Company also has the right to grant sublicenses of its rights under the MIT License Agreement. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is required to use diligent efforts to develop and commercialize the Licensed Products or Processes, and to make such products or processes reasonably available to the public and to spend certain minimum amounts on research and development of Licensed Products and/or Processes each year until the first commercial sale of a Licensed Product and/or a first commercial performance of a Licensed Process. The Company is also subject to certain development obligations with regards to a first Licensed Product. The Company has satisfied certain obligations related to preclinical studies and the filing of an IND for a first Licensed Product with its development activities related to FX-322. The Company&amp;#8217;s future development obligations are: (i) to commence a Phase II clinical trial for such Product, (ii) to commence a Phase III clinical trial for such Product within five years of the IND filing for such product within two years of the IND filing for such product, (iii) to file a New Drug Application or equivalent with the FDA or comparable European regulatory agency for such Product within nine years of the IND filing for such product, and (iv) to make a first commercial sale of such Product within 11 years of the IND filing for such product. The Company also has certain development obligations for as second Licensed Product. In the event that the Company has failed to fulfill the development timeline obligation with respect to a second Licensed Product and fail to cure such breach within ninety (90)&amp;#160;days of written notice by MIT, MIT may restrict the licensed field to the prevention and remediation of hearing loss in humans and animals. The Company does not have the right to control prosecution of the in-licensed patent applications, and its rights to enforce the in-licensed patents are subject to certain limitations. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon entering into the MIT License Agreement, the Company paid a $50 license fee payment and issued to MIT shares of our common stock equal to 5% of total then-outstanding capital stock. The Company is required to pay certain annual license maintenance fees which may be credited to running royalties during the same calendar year, if any, and to make potential milestone payments up to $2,900 on each Licensed Product or Licensed Process. In addition, The Company is required to pay a low single-digit royalty on Licensed Products and Licensed Processes and a low-twenties royalty on sublicense revenues. In the year ended December 31, 2019 the Company paid MIT a royalty of $16,000 related to the upfront payment received from Astellas, see Note 15.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The MIT License Agreement will remain effect until the expiration or abandonment of all issued patents and filed patent applications licensed thereunder remain in effect, unless terminated earlier. The Company has the right to terminate for any reason upon a 3-month prior written notice. MIT shall have the right to terminate if the Company ceases to carry on any business related to the MIT License Agreement. MIT may terminate the MIT License Agreement for the Company&amp;#8217;s material breach uncured within ninety (90)&amp;#160;days (or thirty (30)&amp;#160;days in the case of nonpayment). MIT may also terminate the MIT License Agreement if the Company or our affiliates commence any action against MIT to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or non-infringed (a patent challenge), or if our sublicensee commences such actions and the Company does not terminate such sublicense within thirty (30)&amp;#160;days after MIT&amp;#8217;s demand. MIT has the right to increase all payments due, instead of terminating the MIT License Agreement in the case of a patent challenge. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2019, the Company entered into an amendment with MIT, updating the diligence milestones for a second Licensed Product. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The patents in-licensed by the Company from MIT pursuant to the MIT License claim inventions created by, among others, Dr. Langer, one of the Company&amp;#8217;s directors.&amp;#160;Pursuant to MIT&amp;#8217;s policy on the ownership, distribution and commercial development of MIT technology, or the MIT Policy, inventors of intellectual property invented at MIT, including the inventors of patents licensed to the Company under the MIT License, are entitled to a portion of the net royalty income derived by MIT from such inventions, but not amounts received by MIT from the sale of common stock previously issued by the Company to MIT pursuant to the MIT License. Accordingly, pursuant to the MIT Policy, Dr. Langer is entitled to receive a portion of the amounts the Company pays to MIT under the MIT License, including the Astellas Royalty Payment and future milestone payments or royalties, if any, that the Company may receive pursuant to the Astellas Agreement. Accordingly, Dr. Langer has received $1.98 million and $0.01 million from MIT under the MIT Policy during the years ended December 31, 2020 and 2019, respectively. Refer to Note 18 for all related party disclosures. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;The Scripps Research Institute (California Institute for Biomedical Research)&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In September 2018, the Company entered into a license agreement, (CALIBR License Agreement), with the California Institute for Biomedical Research, (CALIBR), under which the Company received an exclusive, worldwide, royalty-bearing license to certain patent rights to make, have made, use, sell, offer to sell, and import products (CALIBR Licensed Products) which incorporate the licensed technology for the treatment of multiple sclerosis. The Company also have the right to grant sublicenses of our rights under the CALIBR License Agreement. CALIBR reserves the right to use for itself and the right to grant non-exclusive licenses to other nonprofit or academic institutions, for any internal research and educational purposes. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is required to use commercially reasonable efforts to develop, manufacture, and sell at least one Licensed Product and does not have the right to control prosecution of the in-licensed patent applications, and to enforce the in-licensed patents are subject to certain limitations. The Company is also subject to certain milestone timeline obligations , which may be extended under certain circumstances as outlined in the CALIBR License Agreement, to: (i) submit an IND (or equivalent) for a CALIBR Licensed Product by the 30th month after the effective date of the CALIBR License Agreement, (ii) initiate a Phase II clinical trial (or equivalent) for a CALIBR Licensed Product by the fourth anniversary of the effective date of the CALIBR License Agreement, and (iii) initiate a Phase III clinical trial (or equivalent) for a CALIBR Licensed Product by the sixth anniversary of the effective date of the CALIBR License Agreement. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon entering into the CALIBR License Agreement, the Company made a $1,000 license fee payment and are required to make milestone payments up to $26,000 for each Category of CALIBR Licensed Products (Category 1 means any CALIBR Licensed Products containing a compound that modulates any muscarinic receptor and Category 2 means any CALIBR Licensed Products not included in Category 1 that could differentiate oligodendrocyte precursors). The Company is also required to pay a middle single-digit royalty on CALIBR Licensed Products and a royalty on sublicense revenues ranging from low-teen percentage to 50%. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The CALIBR License Agreement shall continue in effect until expiration of all Company obligations to pay royalties. Royalties shall be payable on a country-by-country and CALIBR Licensed Product-by-CALIBR Licensed Product basis upon the later of (1)&amp;#160;the expiration or abandonment of all valid claims of the licensed patent rights in such country and (2)&amp;#160;ten years from the first commercial sale of each CALIBR Licensed Product. The Company may terminate the CALIBR License Agreement at will upon a 30-day prior written notice. The Company may also elect to terminate its license to one or more licensed patents in any or all jurisdictions by giving ninety (90)&amp;#160;days&amp;#8217; prior written notice to CALIBR. CALIBR may terminate the CALIBR License Agreement for material breach uncured within thirty (30)&amp;#160;days. CALIBR has the right to terminate or reduce the license to a non-exclusive license if the Company fails to use diligent efforts to develop and commercially exploit CALIBR Licensed Products. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;The Scripps Research Institute&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In September 2018, we entered into a Research Funding and Option Agreement, or the Scripps option agreement, with Scripps, under which we were granted an exclusive option to acquire an exclusive, sublicensable, worldwide license under certain intellectual property related to the treatment of MS. As consideration for the Scripps option agreement, we made funding payments totaling $0.7 million to Scripps to support its research activities. Scripps has agreed to use reasonable efforts to perform the research program pursuant to the Scripps option agreement. The Scripps option agreement had a one-year term and was renewed for a second year by mutual written agreement.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In September 2020, the Company extended the term of the option agreement through the end of December 2021. As consideration for this extension, the Company is required to make additional funding payments of $0.6 million to Scripps through December 2021.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has the right to terminate by giving 90 days&amp;#8217; advance notice. Scripps has the right to terminate in the event of nonpayment by us that remains uncured for 10 days. Each party has the right to terminate in the event of the other party&amp;#8217;s material breach that remains uncured for 60 days or if the other party becomes bankrupt.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Massachusetts Eye and Ear (Formerly Massachusetts Eye and Ear Infirmary) &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2019, the Company entered into an Non-Exclusive Patent License Agreement (MEE License Agreement) with the Massachusetts Eye and Ear (MEE) under which it received a non-exclusive, non-sublicensable, worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, offer to sell, lease and import products and to develop and perform processes which incorporate the licensed technology for the treatment or prevention of hearing loss. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is required to use diligent efforts to develop and commercialize the licensed products and MEE has control over the filing, prosecution, enforcement and defense of any licensed patent rights. We met one of our milestone timeline obligations by dosing a first patient in a Phase&amp;#160;II trial by December&amp;#160;31, 2020. We are still subject to a milestone timeline obligation to dose a first patient in a Phase&amp;#160;III trial by December&amp;#160;31, 2024.  &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon entering into the MEE License Agreement, the Company made a $20 license fee payment and is required to pay certain annual license maintenance fees until the first commercial sale and a minimum annual royalty payment after the first commercial sale. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is also required to make milestone payments up to $350 on each product or process which incorporates the licensed patent rights and pay a low single-digit royalty on products and processes that incorporate the licensed patent rights. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The MEE License Agreement shall remain in effect until all issued patents and filed patent applications within the licensed patent rights have expired or been abandoned, unless terminated earlier. The Company has the right to terminate the MEE License Agreement at will by giving thirty (30)&amp;#160;business days advance written notice to MEE. MEE has the right to terminate the MEE License Agreement if the Company fails to make any payment due within thirty (30)&amp;#160;business days after MEE notifies the Company of such failure. MEE shall have the right to terminate if the Company fails to maintain the required insurance. MEE shall also have the right to terminate the MEE License Agreement upon forty-five (45)&amp;#160;business days written notice if the Company becomes insolvent. MEE has the right to terminate for any other default not cured within sixty (60)&amp;#160;business days written notice. MEE also has the right to terminate if the Company or its affiliates challenge the validity of the licensed patent rights. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Cambridge Enterprise Limited&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, we entered into an Exclusive Patent License Agreement ( the &amp;#8220;Cambridge License&amp;#8221;) with Cambridge Enterprise Limited (the technology transfer arm of the University of Cambridge)&lt;font style="font-size:12pt;"&gt; &lt;/font&gt;(&amp;#8220;Cambridge&amp;#8221;) under which we received an executive worldwide royalty-bearing license to certain patent rights to make, have made, sell, offer to sell and import products, or the (the &amp;#8220;Cambridge License Product&amp;#8221;) which incorporate licensed technology for the treatment of demyelinating diseases.&amp;nbsp;&amp;nbsp;We also have the right to grant nonexclusive licenses to other academic institutions for any academic publication, research and teaching and clinical patient care.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has agreed to use diligent and good faith efforts to develop and commercially exploit at least one Cambridge Licensed Product.&amp;nbsp;&amp;nbsp;Upon entering into the Cambridge License, the Company made a $50 license fee payment.&amp;nbsp;&amp;nbsp;The Company is obligated to pay an annual license fee of $50. The Company is also obligated to make milestone payments up to $10.5 million on each Cambridge License Product.&amp;nbsp;&amp;nbsp;In addition, the Company has agreed to pay a low single-digit royalty on products that incorporate the licensed patent rights, subject to offset in certain circumstances. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Cambridge License continues in effect on a country-by-country basis until the expiration or revocation, without right of further appeal, of all licensed issued patents and filed patent applications, unless terminated earlier.&amp;nbsp;&amp;nbsp;We have the right to terminate for any reason upon 90 days&amp;#8217; prior to written notice.&amp;nbsp;&amp;nbsp;Each party has the right to terminate immediately if the other party ceases to carry on its business.&amp;nbsp;&amp;nbsp;Either party may also terminate the Cambridge License for material breach if such breach remains uncured for 30 days.&amp;nbsp;&amp;nbsp;Cambridge may also terminate the Cambridge License if we fail to diligently develop and commercially exploit at least one Cambridge Licensed Product or we or our affiliates or sub-licenses commence any action against Cambridge to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or not infringed.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Department of Defense &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2018, the Company received a grant (the Grant) from the Department of Defense (DoD) under which the Company is receiving funding to further the Company&amp;#8217;s research and development of a therapeutic drug to treat hearing loss. The Company is receiving funding of $1,596 over two years from the date of the Grant. The Company has determined that the DoD is not considered a customer under ASC 606, therefore funding received from the DoD under the Grant is recorded as a reduction of research and development expenses. The Company has recorded $323 and $845 as a reduction in research and development expenses for the years ended December&amp;#160;31, 2020 and 2019, respectively. &lt;/p&gt;</freq:ResearchAndLicenseAgreementsDisclosureTextBlock>
  <us-gaap:CollaborativeArrangementDisclosureTextBlock id="F_000261" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;15. Collaboration agreement &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2019, the Company entered into a License and Collaboration Agreement with Astellas (the Astellas Agreement), under which the Company granted Astellas an exclusive, royalty-bearing, sub-licensable, nontransferable license to certain patent rights to research, develop, manufacture, have manufactured, use, seek and secure regulatory approval for, commercialize, offer for sale, sell, have sold and import, and otherwise exploit licensed products containing both a GSK-3 inhibitor and an HDAC inhibitor, (the Astellas Licensed Products), including the product candidate FX-322, outside of the United States. The Company also granted Astellas a right of first negotiation and a right of last refusal if it entered into any negotiation or agreement of any kind (other than an acquisition of all of the stock or assets of the Company) with any third party under which such third party would obtain the right to develop, manufacture, or commercialize Astellas Licensed Products in the United States. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has agreed to conduct Phase 2a clinical studies in the United States. Upon the completion thereof, the Company and Astellas have agreed to jointly develop the Astellas Licensed Products, including carrying out joint studies. Each party has agreed to use commercially reasonable efforts to carry out development activities assigned to it under an agreed-upon development plan. Astellas has agreed to use commercially reasonable efforts to obtain regulatory approval for at least one Astellas Licensed Product in sensorineural hearing loss and in age-related hearing loss, in each case, in one major Asian country and one major European country. The Company has agreed to use commercially reasonable efforts to obtain regulatory approval for at least one Astellas Licensed Product in the United States. Astellas has the sole right to commercialize the Astellas Licensed Products outside of the United States, and the Company has the sole right to commercialize the Astellas Licensed Products in the United States. Astellas has agreed to use commercially reasonable efforts to commercialize Astellas Licensed Products in a major Asian country and a major European country following receipt of regulatory approval in such countries. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The collaboration is governed by a joint steering committee (&amp;#8220;JSC&amp;#8221;) established under the Astellas Agreement and shall be comprised of three representatives each from the Company and Astellas. The JSC shall oversee and coordinate the overall conduct of the development, manufacture and commercialization of the Astellas Licensed Products. All decisions of JSC shall be taken through a unanimous vote with each party&amp;#8217;s representatives collectively having one vote. Both the parties shall be responsible for carrying out the development and manufacturing activities in their defined territory in accordance with the plan as reviewed and approved in the JSC. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As consideration for the licensed rights under the Astellas Agreement, Astellas paid the Company an upfront payment of $80.0&amp;#160;million in July 2019 and has agreed to pay potential development milestone payments up to $230.0&amp;#160;million and commercialization milestones of up to $315.0 million. Specifically, the Company would receive development milestone payments of $65.0 million and $25.0 million upon the first dosing of a patient in a Phase 2b clinical trial for SNHL in Europe and Asia, respectively and $100.0 million and $40.0 million upon the first dosing of a patient in a Phase 3 clinical trial for SNHL in Europe and Asia, respectively.  If the Astellas Licensed Products are successfully commercialized, the Company would be eligible for up to $315.0&amp;#160;million in potential commercial milestone payments and also tiered royalties at rates ranging from low- to mid-teen percentages. The parties shall share equally, on a 50/50 basis, all out-of-pocket costs and joint study costs for all the joint activities conducted pursuant to the development plans or the joint manufacturing plan. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Astellas Agreement remains in effect until the expiration of all royalty obligations. Royalties are paid on a licensed product-by-licensed product and country-by-country basis until the latest of (i)&amp;#160;the expiration of the last valid claim in the licensed patent rights with respect to such Astellas Licensed Product in such country or (ii) a set number of years from the first commercial sale of such Astellas Licensed Product in such country. Astellas may terminate the Astellas Agreement at will upon 60 days&amp;#8217; written notice. Each party has the right to terminate the Astellas Agreement due to the other party&amp;#8217;s material breach if such breach remains uncured for 90 days (or 45 days in the case of nonpayment) or if the other party becomes bankrupt. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Astellas Agreement is a collaborative agreement that is within the scope of ASC 808. The Company analyzed the joint research and development activities to assess whether they fall within the scope of ASC 808, and will reassess this throughout the life of the arrangement based on changes in the roles and responsibilities of the parties. Based on the terms of the arrangement as outlined above, both parties are deemed to be active participants in the collaboration. Both parties are performing research and development activities in their defined territory and will be performing joint clinical studies in accordance with the development plan and the study protocol approved by the JSC. Additionally, Astellas and the Company are exposed to significant risks and rewards dependent on the commercial success of any product candidates that may result from the collaboration. As such, the collaboration arrangement is deemed to be within the scope of ASC 808. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The arrangement consists of two components; the license of IP and the research and development activities, including committee participation, to support the co-development and research plan. Under the provisions of ASC 808, the Company has determined that it will apply the guidance in ASC 606 to recognize the revenue related to the license since that component of the arrangement is more reflective of a vendor-customer relationship. The Company determined that the license and the related research and development services associated with the Phase 2a clinical study were not distinct from one another, as the license has limited value to Astellas without the performance of the research and development activities and the Phase 2a study is essential to the use of the license. As such, the Company determined that these activities should be accounted for as a single combined performance obligation. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue associated with this single performance obligation is being recognized as the research and development work is performed, using an input method on the basis of research and development costs incurred to date relative to total research and development costs expected to be incurred. The transfer of control occurs over this time period and, in management&amp;#8217;s judgment, is the best measure of progress towards satisfying the performance obligation. The Company has determined that the period of performance of the research and development services began upon the signing of the Astellas Agreement and will continue until the completion of the Phase 2a clinical trial of FX-322. The transaction price of $80.0 million has been allocated to the single combined performance obligation and will be recognized over such period. Management has analyzed the progress of the Phase 2a clinical trial and has estimated the completion date of such trial and the total costs it expects to incur in performing the trial and is recognizing the $80.0 million upfront fee as revenue over the period from July 2019 until the estimated completion date using the input method. The Company regularly assesses its estimates and to the extent that facts and circumstances dictate, the Company revises its estimates of total cost or completion date and accounts for such change on a prospective basis. The Company was required to pay MIT a royalty of $16.0 million on the $80.0 million of sublicense revenues. The $16.0 million royalty was expensed in the third quarter of 2019.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The $80.0&amp;#160;million upfront payment received from Astellas in July 2019 was initially recorded as deferred revenue and is being recognized as revenue according to the policy described above. In the year ended December 31, 2020, the Company recognized $37.0 million of revenue under the Astellas Agreement. In the year ended December 31, 2019, the Company recorded $28.9 million of revenue under the Astellas Agreement which included $16.0 million related to the royalty payment to MIT and $12.9 million based upon the application of the input method to the remaining $64.0 million to be recognized over the estimated period to completion of the Phase 2a clinical trial for FX-322. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The potential development and regulatory milestone payments are fully constrained until the Company can conclude that achievement of the milestone is probable and that it is probable that recognition of revenue related to the milestone will not result in a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is ultimately resolved and as such these have been excluded from the transaction price. As part of its evaluation of the constraint, the Company considers numerous factors, including the fact that achievement of the milestones is outside the control of the Company and contingent upon the future success of clinical trials, the licensee&amp;#8217;s efforts, and the receipt of regulatory approval. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the license granted to Astellas and therefore are recognized at the later of when the performance obligation is satisfied, or the related sales of licensed products occur. The Company re-evaluates the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts, at each reporting period and as uncertain events are resolved or other changes in circumstances occur, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Astellas Agreement contains joint research and development activities that are not within the scope of ASC 606. The Company will recognize research and development expense related to the joint study costs for all the joint activities in future periods and reimbursements received from Astellas will be recognized as an offset to research and development expense on the consolidated statement of operations during the development period. In the years ended December 31, 2020 and 2019, the Company invoiced Astellas $1,046 and $186 for joint costs, respectively.&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock id="F_000262" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;16. Commitments and contingencies &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Operating leases &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2016, the Company and a related third party (see Note 18) entered into a five-year operating lease for the Company&amp;#8217;s primary office and laboratory space in Woburn, Massachusetts. &lt;font style="color:#000000;"&gt;The lease was extended in November 2019 and expires in February 2025.&lt;/font&gt; Additionally, the Company amended the lease in November 2019 to add additional laboratory and office space. The commencement date of the additional space occurred in February 2020 and expires in February 2025. The lease agreements do not contain any material residual value guarantees or material restrictive covenants. &lt;font style="font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;The Company also leases a laboratory facility in Connecticut under an operating lease which expires in 2021.&lt;font style="font-size:12pt;"&gt;&amp;#160;&amp;#160;&lt;/font&gt; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On December 11, 2020, the Company entered into an Agreement for Termination of Lease and Voluntary Surrender of Premises (the &amp;#8220;Lease Termination Agreement&amp;#8221;) with ARE-MA Region No. 20, LLC (the &amp;#8220;Landlord&amp;#8221;). The Lease Termination Agreement provides that the Lease Agreement, dated as of August 14, 2016, by and between the Company and Landlord (as the same may have been amended, the &amp;#8220;Lease&amp;#8221;) will terminate on March 31, 2021, unless the Company elects to extend the term of the Lease. The Company exercised the option to extend the lease until May 31, 2021.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As consideration for the Landlord&amp;#8217;s agreement to enter into the Lease Termination Agreement and accelerate the expiration date of the term of the Lease, the Company has agreed to pay to Landlord a fee of approximately $0.2 million.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On January 7, 2020 the Company entered into an indenture of lease (the &amp;#8220;Lexington Lease&amp;#8221;) with HCP/KING 75 Hayden LLC, for the lease of approximately 61,307 square feet of rentable area in Lexington, Massachusetts or (the &amp;#8220;Lexington Premises&amp;#8221;).&amp;nbsp;&amp;nbsp;The Lexington Lease commenced on December 11, 2020, (the &amp;#8220;Commencement Date&amp;#8221;).&amp;nbsp;&amp;nbsp;The Company expects to use the Lexington Premises as its new principal executive offices and as a laboratory for research and development, and other related uses.&amp;nbsp;&amp;nbsp;The term of the Lexington Lease, (the &amp;#8220; Initial Term&amp;#8221;), is ten years from the rent commencement date (which is five months following the Commencement Date) and the Initial Term is expected to end on May 31, 2031.&amp;nbsp;&amp;nbsp;The Company also has the option to extend the Initial Term for two additional terms of five years each.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of&amp;#160;December 31, 2020, the Company has $30,551&amp;#160;of operating lease ROU assets, and&amp;#160;$397&amp;#160;and $30,597&amp;#160;of current and non-current lease liabilities, respectively, recorded on the consolidated balance sheets. For the year ended December 31, 2020&amp;#160;the Company recorded $470&amp;#160;of operating lease cost, $510&lt;font style="font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;of variable lease cost, and $106&amp;#160;of short-term lease cost. The lease expense for the years ended December 31, 2020 and 2019 are $835&amp;#160;and $269, respectively. Cash paid for amounts included in the measurement of lease liabilities for year ended&amp;#160;December 31, 2020&amp;#160;is $484.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other information&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.52%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average remaining lease term&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.52%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.3 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average discount rate (1)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.86%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.57%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;"&gt;(1)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Rate includes the Company&amp;#8217;s Woburn and Lexington leases. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The table below reconciles the undiscounted cash flows to the operating lease liability recorded on the consolidated balance sheet as of December 31, 2020. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,928&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,159&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,284&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,412&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,545&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,070&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total minimum lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;47,398&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: amount of lease payments representing interest&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16,404&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Present value of future lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,994&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: current lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(397&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.56%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Noncurrent lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,597&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Future aggregate minimum payments under the noncancelable operating leases and short term leases, including the Lexington, MA lease and Connecticut lease, which is not subject to ASC 842, as of December 31, 2020 are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,986&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,159&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,284&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,412&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,545&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2026 and beyond&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,070&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.56%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total minimum lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;47,456&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Contract commitments &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has contracted with a research institution to provide research for a therapeutic drug to treat multiple sclerosis. In September 2020, the Company extended the term of this contract through December 2021. As consideration for this extension, the Company committed to total payments of $0.6 million through December 2021. &lt;font style="font-size:12pt;"&gt;&amp;#160;&lt;/font&gt; &lt;font style="font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&amp;nbsp;&amp;nbsp; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company enters into contracts in the normal course of business with CROs, CMOs, universities, and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts generally do not contain minimum purchase commitments and are cancelable by us upon prior written notice although, purchase orders for clinical materials are generally non-cancelable. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including non-cancelable obligations of our service providers, up to the date of cancellation or upon the completion of a manufacturing run. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Guarantees &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has identified the guarantees described below as disclosable, in accordance with ASC 460, &lt;font style="font-style:italic;"&gt;Guarantees&lt;/font&gt;. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving at the Company&amp;#8217;s request in such capacity. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors&amp;#8217; and officers&amp;#8217; insurance coverage that should limit its exposure and enable it to recover a portion of any future amounts paid. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is a party to a number of agreements entered into in the ordinary course of business that contain typical provisions that obligate the Company to indemnify the other parties to such agreements upon the occurrence of certain events. Such indemnification obligations are usually in effect from the date of execution of the applicable agreement for a period equal to the applicable statute of limitations. The aggregate maximum potential future liability of the Company under such indemnification provisions is uncertain. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company leases office space in Woburn, Massachusetts under a five-year non-cancelable operating lease&lt;font style="color:#000000;"&gt;, and has entered into a facility lease in Lexington, Massachusetts. The Company has standard indemnification arrangements under these leases that require it to indemnify the landlord against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation, or nonperformance of any covenant or condition of the lease&lt;/font&gt;. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2020 and 2019, the Company had not experienced any losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves have been established. &lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock id="F_000263" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;17. Employee benefit plan &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Employees of the Company are eligible to participate in the Company&amp;#8217;s 401(k) retirement plan (the &amp;#8220;401(k) Plan&amp;#8221;). Participants may contribute up to 90% of their annual compensation to the 401(k) Plan, subject to statutory limitations. Under the 401(k) Plan Safe Harbor Match, the Company matches 100% of the first 5% of employee contributions and vests 100% at time of match. For the years ended December 31, 2020 and 2019, the Company made matching contributions of $0.4 million and $0.2 million, respectively. &lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock id="F_000264" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;18. Related party transactions &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s lease for its Woburn, Massachusetts facility, see Note 16, is with an entity affiliated with one of the Company&amp;#8217;s directors and shareholders. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As disclosed in Note 14, the Company entered into the MIT License Agreement in December 2016. &lt;font style="color:#000000;"&gt;The patents in-licensed by the Company from MIT pursuant to the MIT License Agreement claim inventions created by, among others, Dr. Langer, one of the Company&amp;#8217;s directors. Accordingly, Dr. Langer has received $1.98 million and $0.01 million from MIT under the MIT Policy during the years ended December 31, 2020 and 2019, respectively.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:SubsequentEventsTextBlock id="F_000265" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;19. Subsequent events &lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has evaluated subsequent events for recognition, remeasurement and disclosure purposes through March 29, 2021, the date which the consolidated financial statements were available to be issued. The identified subsequent events are as follows; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On February 18, 2021, the Company completed the liquidation and dissolution of Frequency Therapeutics Japan KK, the Company&amp;#8217;s Japanese subsidiary. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On March 23, 2021, the Company announced topline, day-90 data from its FX-322 Phase 2a study. The interim results show that four weekly injections in subjects with mild to moderately severe sensorineural hearing loss did not demonstrate improvements in hearing measures versus placebo. No treatment-related serious adverse events were observed in the study. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company also announced new preliminary data from a parallel study demonstrating hearing improvement from a single injection of FX-322. The single dose showed efficacy that was clinically meaningful and statistically significant compared to the untreated ear, had a favorable safety profile and was well tolerated.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:QuarterlyFinancialInformationTextBlock id="F_000266" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;20. Selected Quarterly Data (Unaudited) &lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table contains quarterly financial information for 2020 and 2019.&amp;nbsp;&amp;nbsp;The Company believes that the following information reflects all normal recurring adjustments necessary for the fair statement of the information for the periods presented.&amp;nbsp;&amp;nbsp;The operating results for any quarter are not necessarily indicative of results for any future period.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="18" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June 30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="18" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands, except per share amounts)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total revenue&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,264&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,523&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,247&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,950&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,984&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,177&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,548&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,588&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,182&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;63,495&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,913&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,025&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,341&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10,232&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26,511&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cumulative series C convertible preferred stock&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; dividends&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss attributable to common stockholders&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,913&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,025&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,341&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10,232&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26,511&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share attributable to common shareholders -&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.16&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.19&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.16&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.30&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.82&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="18" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June 30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="18" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands, except per share amounts)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total revenue&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,238&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,709&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,947&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,826&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,852&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,813&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,202&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;47,693&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,826&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,852&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(575&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,493&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(18,746&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cumulative series C convertible preferred stock&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; dividends&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(40&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,054&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss attributable to common stockholders&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,826&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,852&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,589&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,533&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19,800&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share attributable to common shareholders -&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3.24&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3.42&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.73&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.19&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.29&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock id="F_000267" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Basis of presentation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP) that the Company follows to ensure its financial condition, results of operations, and cash flows are consistently reported. References to GAAP issued by the FASB in these notes to the consolidated financial statements are to the FASB &lt;font style="font-style:italic;"&gt;Accounting Standards&lt;/font&gt; Codification (ASC). &lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:ConsolidationPolicyTextBlock id="F_000268" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Principles of consolidation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The consolidated financial statements include the accounts of Frequency Therapeutics, Inc. and its wholly owned subsidiaries Frequency Therapeutics Securities Corporation, Frequency Therapeutics PTY, LTD and Frequency Japan. All intercompany transactions and balances have been eliminated. Frequency Japan was closed down in February 2021, as further described in Note 19 of notes to consolidated financial statements. &lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <us-gaap:UseOfEstimates id="F_000269" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Use of estimates &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of the Company&amp;#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. On an ongoing basis, the Company&amp;#8217;s management evaluates its estimates, which include but are not limited to management&amp;#8217;s judgments of accrued expenses, revenue recognition, fair value of common stock, valuation of share-based awards, present value of lease liabilities and income taxes. Actual results could differ from those estimates. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company utilized significant estimates and assumptions in determining the fair value of its common stock in periods prior to the IPO. The Company utilized various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately Held Company Equity Securities Issued as Compensation (the Practice Aid), to estimate the fair value of its common stock. Each valuation methodology includes estimates and assumptions that require the Company&amp;#8217;s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to the Company&amp;#8217;s common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale. Significant changes to the key assumptions used in the valuations could have resulted in different fair values of common stock at each valuation date. &lt;/p&gt;</us-gaap:UseOfEstimates>
  <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock id="F_000270" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Comprehensive income (loss) &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Components of comprehensive income or loss, including net income or loss, are reported in the financial statements in the period in which they are recognized. Other comprehensive income or loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss) are reported net of any related tax effect to arrive at comprehensive income (loss). Comprehensive loss includes net loss as well as other changes in stockholders&amp;#8217; equity that result from transactions and economic events other than those with stockholders which for the years ended December 31, 2020 and 2019 consist of unrealized gain on marketable securities.&amp;nbsp;&amp;nbsp;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
  <us-gaap:SegmentReportingPolicyPolicyTextBlock id="F_000271" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Segment information &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company&amp;#8217;s chief operating decision-maker, the Company&amp;#8217;s chief executive officer, views the Company&amp;#8217;s operations and manages its business as a single operating segment, which is in the business of discovering and developing small molecule drugs that activate progenitor cells within the body to create healthy tissue. &lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock id="F_000272" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Foreign currency &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All periods presented are reported in US dollars. The functional currency for entities outside the United States is the US dollar. Realized and unrealized gains and losses from foreign currency transactions are reflected in the consolidated statements of operations as other expense. During the years ended December&amp;#160;31, 2020 and 2019 the Company recorded $(4), and $7&lt;font style="font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;of foreign currency exchange (losses) gains, respectively. &lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock id="F_000273" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all highly liquid investments with an original maturity of six months or less at acquisition to be cash equivalents which are stated at fair market value. Cash and cash equivalents at December&amp;#160;31, 2020 and 2019 consists entirely of cash and money market funds. &lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy id="F_000274" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Restricted Cash&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has $1.8 million of restricted cash as of December 31, 2020 which represents a $1.7 million security deposit on the Company&apos;s future Lexington, Massachusetts facility and a $0.1 million security deposit on the Company&apos;s Woburn, Massachusetts facility. The $0.1 million restricted cash at December 31, 2019 represented the security deposit on the Company&apos;s Woburn, Massachusetts facility.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
  <us-gaap:MarketableSecuritiesPolicy id="F_000275" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Short-term marketable debt securities&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term marketable securities represent holdings of available-for-sale marketable debt securities in accordance with the Company&amp;#8217;s investment policy. Short-term marketable investments mature within one-year from the balance sheet date. Investments in marketable securities are recorded at fair value, with any unrealized gains and losses reported within accumulated other comprehensive income as a separate component of stockholders&amp;#8217; equity (deficit) until realized or until a determination is made that an other-than-temporary decline in market value has occurred. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion, together with interest on securities sold is determined based on the specific identification method and any realized gains or losses on the sale of investment are reflected as a component of other income (expense).&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
  <us-gaap:ConcentrationRiskCreditRisk id="F_000276" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Concentration of credit risk and off-balance sheet risk&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instrument that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. The Company maintains its cash and cash equivalents at several accredited financial institutions, in amounts that exceed federally insured limits. Marketable securities consist of U.S. Treasury securities with maturities of less than twelve months. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which its money market accounts are maintained.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has no significant off-balance sheet such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <freq:SignificantSuppliersPolicyTextBlock id="F_000277" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Significant suppliers &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is dependent on third-party manufacturers to supply products for research and development activities of its programs, including preclinical and clinical testing. In particular, the Company relies and expects to continue to rely on a single manufacturer of its product candidates for use in clinical trials. The Company would be adversely affected by a significant interruption in the supply of product for use in clinical programs. &lt;/p&gt;</freq:SignificantSuppliersPolicyTextBlock>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy id="F_000278" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Fair value measurements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic&amp;#160;820, &lt;font style="font-style:italic;"&gt;Fair Value Measurement&lt;/font&gt; (ASC&amp;#160;820), establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The hierarchy defines three levels of valuation inputs, of which the first two are considered observable and the last is considered unobservable: &lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.86%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:9.38%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Quoted prices in active markets for identical assets or liabilities.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.86%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:9.38%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Inputs other than quoted prices included within Level&amp;#160;1 that are either directly or indirectly observable,&amp;nbsp;&amp;nbsp; &amp;nbsp;&amp;nbsp;such as quoted market prices, interest rates and yield curves.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.86%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:9.38%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Unobservable inputs developed using estimates or assumptions developed by the Company, which reflect those that a market participant would use in pricing the asset or liability.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&amp;#160;3. A financial instrument&amp;#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying values of other current assets, accounts payable, and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. The fair value of the Company&amp;#8217;s Term Loan is not materially different from the carry value as presented given the Term Loan was issued within one month of December 31, 2020. &lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock id="F_000279" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Property and equipment &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment consist of lab equipment, computer equipment, furniture and office equipment and leasehold improvements recorded at cost. These amounts are depreciated using the straight-line method over the estimated useful lives of the assets as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.38%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.38%;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated useful life&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Software&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and office equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shorter of the estimated useful&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;life or lease term&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheet and related gains or losses are reflected in the consolidated statements of operations.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock id="F_000280" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Impairment of long-lived assets &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company continually evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company did not recognize any impairment losses for the years ended December&amp;#160;31, 2020 and 2019.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
  <us-gaap:ResearchAndDevelopmentExpensePolicy id="F_000281" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Research and development costs and accruals &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses include salaries and benefits, materials and supplies, preclinical and clinical trial expenses, stock-based compensation expense, depreciation of equipment, contract services and other outside expenses. The Company has entered into various research and development-related contracts with research institutions, contract research organizations, contract manufacturers and other companies. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. Costs of certain development activities, such as manufacturing, pre-clinical and clinical trial expenses, are recognized based on an evaluation of the progress to completion of specific tasks. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed. Costs incurred in obtaining technology licenses are charged to research and development expense as acquired in-process research and development if the technology licensed has not reached technological feasibility and has no alternative future use.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:LesseeLeasesPolicyTextBlock id="F_000282" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company elected to early adopt ASC 842, &lt;font style="font-style:italic;"&gt;Leases&lt;/font&gt; (ASC 842) as of January 1, 2020 and elected the transition method under ASU 2016-02 whereby the Company records a right-to-use asset and a lease liability on the consolidated balance sheet for all leases with terms longer than 12 months. The Company also elected to apply the package of practical expedients intended to ease transition. Accordingly, the Company has only applied ASC 842 to leases existing at January 1, 2020. The Company determines if an arrangement is, or contains, a lease at inception. Operating leases are included in operating lease right-of-issue (&amp;#8220;ROU&amp;#8221;) assets, other current liabilities, and operating lease liabilities on the consolidated balance sheets.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ROU assets represent the Company&amp;#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&amp;#8217;s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments to be made over the lease term. The ROU asset also includes any lease payments made at or before the lease commencement date and excludes lease incentives received. As the Company&amp;#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected to not apply the recognition requirements of ASC 842 for short-term leases, which is defined as a lease that, at the lease commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For real estate lease agreements entered into or modified after the adoption of ASC 842 that include lease and non-lease components, the Company has elected to account for the lease and non-lease components, such as common area maintenance charges, as a single lease component.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
  <us-gaap:CollaborativeArrangementAccountingPolicy id="F_000283" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Collaborative arrangements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company analyzes its collaborative arrangements to assess whether they are within the scope of ASC 808, &lt;font style="font-style:italic;"&gt;Collaborative Arrangements&lt;/font&gt; (&amp;#8220;ASC 808&amp;#8221;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship (e.g., a licensing arrangement) where the contracted party has obtained goods or services that are an output of the Company&amp;#8217;s ordinary activities in exchange for a consideration and therefore within the scope of ASC 606, &lt;font style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt; (&amp;#8220;ASC 606&amp;#8221;). For those elements of the arrangement that are accounted for pursuant to ASC 606, including those to which ASC 606 is applied by analogy, the Company applies the five-step model described in the Company&amp;#8217;s revenue recognition policy. For elements of collaborative arrangements that are accounted for pursuant to ASC 808, an appropriate and rational recognition method is determined and applied consistently. Reimbursements from the counterparty that are the result of a collaborative relationship with the counterparty, instead of a customer relationship, such as co-development or clinical activities, are recorded as a reduction to research and development expense as the services are performed. Similarly, amounts that are owed to a collaboration partner related to the co-development clinical activities are recognized as research and development expense. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company enters into out-licensing agreements that are within the scope of ASC 606. The terms of such out-license agreements include licenses to functional intellectual property (IP), given the functionality of the intellectual property is not expected to change substantially as a result of the licensor&amp;#8217;s ongoing activities. Such arrangements typically include payment of one or more of the following: non-refundable up-front license fees; reimbursement of certain costs; development and regulatory milestone payments and milestone payments based on the level of sales; and royalties on net sales of licensed products. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers the economic and regulatory characteristics of the licensed IP, research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace to determine if it has standalone value at the inception of the licensing arrangement, which would make the license distinct. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of any additional good or services promised in the contract, whether the value of the license is dependent on the remaining goods and services, whether there are other vendors that could provide the remaining promise, and whether the license is separately identifiable from the remaining good and services. For licenses that are combined with other goods and services, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of progress and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue is allocated to the licensed IP on a relative standalone selling price basis and, for functional IP, is recognized at a point when the licensed IP is made available for the customer&amp;#8217;s use and benefit, which generally occurs at the inception of the arrangement. However, in cases, where the functionality of the IP is expected to substantively change as a result of activities of the Company that do not transfer additional promised goods or services, or in cases, where there is an expectation that the Company will undertake activities to change the standalone functionality of the IP and the customer is contractually or practically required to use the latest version of the IP, revenue for the license to functional IP is recognized over time. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Development and regulatory milestone fees, which are a type of variable consideration, are recognized as revenue to the extent that it is probable that a significant reversal will not occur. The Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has entered into a collaboration arrangement with Astellas Pharma Inc. (&amp;#8220;Astellas&amp;#8221;), as further described in Note 16 of notes to consolidated financial statements. &lt;/p&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
  <us-gaap:RevenueRecognitionPolicyTextBlock id="F_000284" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Revenue recognition &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for contracts with customers in accordance with ASC 606, including all amendments thereto. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as collaborative arrangements and leases. The Company&amp;#8217;s disclosure within the below sections or elsewhere within these consolidated financial statements reflects the Company&amp;#8217;s accounting policies in compliance with this new standard.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under ASC 606, an entity recognizes revenue when or as its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To recognize revenue for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i)&amp;#160;identify the contract(s) with a customer; (ii)&amp;#160;identify the performance obligations in the contract; (iii)&amp;#160;determine the transaction price, including variable consideration, if any; (iv)&amp;#160;allocate the transaction price to the performance obligations in the contract; and (v)&amp;#160;recognize revenue when (or as) the entity satisfies its performance obligations. The Company only applies the five-step model to contracts when it is probable that the entity will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services it transfers to the customer. Once a contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and identifies as a performance obligation each promise to transfer to the customer either (a) a good or service (or bundle of goods and services) that is distinct, or (b) a series of distinct goods and services that are substantially the same and have been the same pattern of transfer to the customer.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company assesses whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i)&amp;#160;the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii)&amp;#160;the entity&amp;#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract). In assessing whether a promised good or service is distinct, the Company considers factors such as the research, manufacturing and commercialization capabilities of the collaboration partner (the &amp;#8220;customer&amp;#8221; in this type of arrangement) and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct. For each arrangement that results in revenues, the Company identifies all performance obligations, which may include, for example, a license to IP and know-how, research and development activities, and/or manufacturing services. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In addition to any upfront payment, if the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the estimated variable consideration in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. If it is probable that a significant revenue reversal will not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or of the licensee such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For contracts that include sales-based royalties (including milestone payments based on the level of sales) promised in the exchange for licenses of intellectual property, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestone payments at the later of (i)&amp;#160;when the related sales occur, or (ii)&amp;#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied. In determining the transaction price, the Company adjusts the promised amount of consideration for the effects of the time value of money if the timing of payments provides the Company or the Company&amp;#8217;s customer with a significant benefit of financing the transfer of goods and services. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. The Company assesses each of its revenue generating arrangements in order to determine whether a significant financing component exists. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time.&amp;nbsp;&amp;nbsp;For performance obligations satisfied over time, the Company measures progress toward completion of its performance obligations using an input method based on the Company&amp;#8217;s efforts and inputs to satisfy its performance obligations relative to total expected inputs to the satisfaction of that performance obligation.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts received from a customer prior to revenue recognition are recorded as deferred revenue. Amounts received from a customer that are expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability in the accompanying consolidated balance sheets.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <freq:PatentCostsPolicyTextBlock id="F_000285" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Patent costs &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses in the accompanying consolidated statements of operations. &lt;/p&gt;</freq:PatentCostsPolicyTextBlock>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy id="F_000286" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Stock-based compensation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for its stock-based compensation in accordance with ASC Topic&amp;#160;718, &lt;font style="font-style:italic;"&gt;Compensation&amp;#8212;Stock Compensation&lt;/font&gt; (ASC&amp;#160;718). ASC&amp;#160;718 requires all share-based payments to employees and directors to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company adopted FASB Accounting Standards Update (ASU) 2016-09 which identifies areas for simplification of several areas of share-based payment transactions. The Company treats non-employee grants in a manner consistent with employee grants. The Company estimates the fair value of options granted using the Black-Scholes option pricing model for stock option grants to both employees and non-employees. The Company believes the fair value of the stock options granted to non-employees is more reliably determinable than the fair value of the services provided. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (a)&amp;#160;the expected stock price volatility, (b)&amp;#160;the expected term of the award, (c)&amp;#160;the risk-free interest rate and (d)&amp;#160;expected dividends. Due to the lack of sufficient company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No.&amp;#160;107, Share-Based Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to non-employees, the Company utilizes the contractual term of the share-based payment as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;There are significant judgments and estimates inherent in the determination of the fair value of the Company&amp;#8217;s common stock prior to the IPO. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to its common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company expenses the fair value of its share-based compensation awards to employees and non-employees on a straight-line basis over the requisite service period, which is generally the vesting period. &lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:IncomeTaxPolicyTextBlock id="F_000287" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Income taxes &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for income taxes using the asset and liability method in accordance with ASC Topic 740, &lt;font style="font-style:italic;"&gt;Income Taxes&lt;/font&gt; (ASC 740) which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&amp;#8217;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. At December&amp;#160;31, 2020 and 2019, the Company has concluded that a full valuation allowance is necessary for its deferred tax assets (see Note 13). &lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:EarningsPerSharePolicyTextBlock id="F_000288" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Net loss per share &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. Diluted net loss per share is the same as basic net loss per share for the years ended December&amp;#160;31, 2020 and 2019 since all potential shares of common stock instruments are anti-dilutive as a result of the loss for such periods. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s convertible preferred stock contractually entitled the holders of such shares to participate in dividends but did not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reported a net loss, such losses are not allocated to such participating securities. In periods where the Company reported a net loss attributable to common stockholders, diluted net loss per share is the same as basic net loss per share, since dilutive shares of common stock are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for the years ended December&amp;#160;31, 2020 and 2019.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic and diluted net loss per share attributable to common stockholders was calculated as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.06%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss attributable to common stockholders&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26,511&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19,800&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average shares of common stock outstanding-&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,253,227&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,649,245&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share attributable to common stockholders-&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.82&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.29&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company excluded the following potential shares of common stock from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.06%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested restricted Common Stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,093&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70,366&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series C Preferred (as converted to common stock)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,172,676&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series B Preferred (as converted to common stock)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,759,079&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A Preferred (as converted to common stock)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,070,574&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Conversion of Frequency Japan preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;513,047&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding stock options (as converted to common stock)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,816,798&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,968,672&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,819,891&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,554,414&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="F_000289" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Recently adopted accounting pronouncements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016, the FASB issued ASU No. 2016-02, &lt;font style="font-style:italic;"&gt;Leases&lt;/font&gt; (Topic 842) (&amp;#8220;ASU 2016-02&amp;#8221;), as amended by various subsequently issued ASUs. The standard requires lessees to recognize an operating lease with a term greater than one year on their balance sheets as a right-of-use asset and corresponding lease liability, measured at the present value of the lease payments. Lessees are required to classify leases as either finance or operating leases. If the lease is effectively a financed purchase by the lessee, it is classified as a financing lease, otherwise it is classified as an operating lease. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2018, the FASB also issued ASU 2018-11, &lt;font style="font-style:italic;"&gt;Leases&lt;/font&gt; (Topic 842): Targeted Improvements (&amp;#8220;ASU 2018-11&amp;#8221;), which permits entities to continue applying legacy guidance in ASC 840, Leases, including its disclosure requirements, in the comparative periods presented in the year that the entity adopts the new leasing standard. The Company adopted the standard on January 1, 2020 using the optional transition method. As such, the consolidated balance sheets and statements of operations for prior periods will not be comparable in the year of adoption of ASC 842. The Company elected the package of practical expedients permitted under the transition guidance within the standard. Accordingly, the Company did not reassess the conclusion of whether the existing arrangements contain a lease, lease classification and initial direct costs under ASC 842. As a result of the adoption of ASC 842, the Company recorded $1.2 million of ROU assets and a total of $1.5 million of lease liabilities on the consolidated balance sheets as of January 1, 2020. In addition, in the first quarter of 2020 the Company expanded and amended the lease for its Woburn, Massachusetts facility and increased both the ROU asset and lease liability by $1.0 million. On December 11, 2020, the Company terminated this lease and remeasured the existing ROU asset and lease liability based on this lease modification, resulting in a $1.7 million impact to both the ROU asset and lease liability. As disclosed in Note 16, the Company has entered into a lease for a facility in Lexington Massachusetts which commenced December 11, 2020. In accordance with ASU No. 2016-02, the Company recognized a right-of-use asset and related lease liability at such time.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January 2016,&amp;#160;the FASB issued ASU No. 2016-01, &lt;font style="font-style:italic;"&gt;Financial Instruments - Overall&lt;/font&gt; (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. This new standard amended certain aspects of accounting and disclosure requirements for financial instruments, including the requirement that equity investments with readily determinable fair values are to be measured at fair value with any changes in fair value recognized in a company&apos;s statements of operations. Prior to adoption of ASU 2016-01, companies recognized changes in fair value in accumulated other comprehensive income (loss), net. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. In addition, a valuation allowance should be evaluated on deferred tax assets related to available- for-sale debt securities in combination with other deferred tax assets.&amp;#160;The Company adopted this new standard on January 1, 2020, using the modified retrospective method, and determined that it did not have a material impact on its financial statements.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Recently issued accounting pronouncements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company is an &amp;#8220;emerging growth company&amp;#8221; as defined in the Jumpstart Our Business Startups Act of 2012, as amended (Jobs Act). The Jobs Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company elected to avail itself of this extended transition period and, as a result, we will not be required to adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;font style="font-style:italic;"&gt;Financial Instruments - Credit Losses&lt;/font&gt; (Topic 326): Measurement of Credit Losses on Financial Instruments. The FASB has subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. This standard will become effective for the Company on January 1, 2023. The Company is still evaluating the impact of this standard on its consolidated financial statements.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, the FASB issued&amp;#160;&lt;font style="color:#000000;"&gt;ASU 2019-12&lt;/font&gt;&amp;#160;amending accounting guidance that simplifies the accounting for income taxes, as part of its initiative to reduce complexity in the accounting standards. The amendments eliminate certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The amendments also clarify and simplify other aspects of the accounting for income taxes. This standard will become effective for the Company on January 1, 2021. The Company is still evaluating the impact of this standard on its consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <freq:PropertyAndEquipmentTableTextBlock id="F_000290" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment consist of lab equipment, computer equipment, furniture and office equipment and leasehold improvements recorded at cost. These amounts are depreciated using the straight-line method over the estimated useful lives of the assets as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.38%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.38%;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated useful life&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Software&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and office equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shorter of the estimated useful&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;life or lease term&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</freq:PropertyAndEquipmentTableTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock id="F_000291" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic and diluted net loss per share attributable to common stockholders was calculated as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.06%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss attributable to common stockholders&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26,511&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19,800&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average shares of common stock outstanding-&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,253,227&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,649,245&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share attributable to common stockholders-&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.82&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.29&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock id="F_000292" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company excluded the following potential shares of common stock from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.06%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested restricted Common Stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,093&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70,366&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series C Preferred (as converted to common stock)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,172,676&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series B Preferred (as converted to common stock)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,759,079&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A Preferred (as converted to common stock)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,070,574&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Conversion of Frequency Japan preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;513,047&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding stock options (as converted to common stock)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,816,798&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,968,672&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,819,891&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,554,414&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock id="F_000293" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s financial assets measures at fair value on a recurring basis by level within the fair value hierarchy at December 31, 2020 and 2019 are summarized as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.74%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Market&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Hierarchy&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gain&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;214,522&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;214,549&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.04%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;214,522&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;214,549&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.74%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Market&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Hierarchy&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Loss) Gain&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;200,131&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;200,119&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. Government treasury securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,131&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;66&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,197&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.04%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;217,262&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;217,316&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
  <freq:SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock id="F_000294" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid expenses and other current assets consisted of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Rent and deposits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;63&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,729&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;801&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant receivable&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;805&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounts receivable&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;340&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Insurance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,552&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,132&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;102&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;199&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.4%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,723&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</freq:SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock>
  <us-gaap:PropertyPlantAndEquipmentTextBlock id="F_000295" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment include the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,166&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,846&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and office equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;283&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;257&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Software&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;291&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,419&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,419&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,340&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;306&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,499&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,828&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,212&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,066&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.66%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,287&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,762&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock id="F_000296" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses consist of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Payroll and employee related expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,062&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,686&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;647&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;435&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Third-party research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;874&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;118&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Taxes and other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;80&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.4%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,663&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,239&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <freq:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock id="F_000297" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has reserved the following shares of common stock for future issuance as of December 31, 2020 and 2019:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.16%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,816,798&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,968,672&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.16%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares available for future grant under stock option plan&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,475,923&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,859,654&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.16%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,292,721&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,828,326&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</freq:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock id="F_000298" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of the stock option activity under the 2014 Plan and the 2019 Plan are as follows: &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;exercise&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;term&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;intrinsic&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;exercise&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;term&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;intrinsic&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019 Plan&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2014 Plan&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,089,334&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.61&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,247,338&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14.09&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,015,381&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.17&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(357,170&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.02&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26,211&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.09&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,247,338&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14.09&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.76&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,287&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,721,334&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.85&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.89&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;65,051&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,645,859&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24.22&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,851&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18.93&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(767,534&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.94&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16,997&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22.72&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11,351&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.89&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,874,349&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19.84&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.09&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,325&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,942,449&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.02&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.98&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;127,090&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options exercisable as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;564,617&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17.48&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.90&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,042&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,337,828&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.57&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.88&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76,416&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options unvested as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,309,732&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,283&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,604,621&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,674&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock id="F_000299" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The assumptions that the Company used to determine the grant-date fair value of stock options granted to&lt;font style="font-weight:bold;font-style:italic;"&gt; &lt;/font&gt;employees and directors were as follows, presented on a weighted average basis: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.9&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;79.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;79.4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock id="F_000300" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of the status of restricted common stock as of December&amp;#160;31, 2020 and 2019 is presented below: &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:72.52%;"&gt;
&lt;tr style="height:8.85pt;"&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:20.95pt;"&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;average fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:8.85pt;"&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested, December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70,366&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.36&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:8.85pt;"&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Awarded&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:8.5pt;"&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(67,273&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.29&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:8.85pt;"&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:8.5pt;"&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.12%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested, December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,093&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.75&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
  <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock id="F_000301" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the Company&amp;#8217;s pre-tax income for the years ended December 31, 2020 and 2019 is as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:56.02%;"&gt;
&lt;tr style="height:10.65pt;"&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12.7pt;"&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Domestic&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(25,744&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19,086&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12.7pt;"&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(732&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(714&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:13.45pt;"&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26,476&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19,800&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
  <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock id="F_000302" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s provision at December 31, 2020 and 2019 consist of the following:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:55.74%;"&gt;
&lt;tr style="height:10.3pt;"&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12.35pt;"&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12.35pt;"&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Federal&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:13.05pt;"&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; State&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:13.05pt;"&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Foreign&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12.35pt;"&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12.35pt;"&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:13.05pt;"&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Federal&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12.35pt;"&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; State&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:13.05pt;"&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Foreign&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12.35pt;"&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total Deferred&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12.35pt;"&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total provision (benefit)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock id="F_000303" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the U.S. federal statutory income tax rate to the Company&amp;#8217;s effective income tax rate for the years ended December&amp;#160;31, 2020 and 2019 is as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:52.54%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.34%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.46%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td style="border:none;padding:0;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S federal statutory income tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.46%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.2)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.8&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.46%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State income taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.0&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.46%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11.2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.8&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.46%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock compensation deductions&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.46%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other items&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.0&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.46%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in deferred tax asset valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(40.7)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(23.0&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;%&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td style="border:none;padding:0;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock id="F_000304" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s deferred tax assets at December&amp;#160;31, 2020 and 2019 consist of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,885&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,253&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,992&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,138&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangibles&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;360&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;358&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;850&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;686&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,606&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;496&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;142&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;189&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fixed assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;56&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,285&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right of use asset&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7,181&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax asset&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,995&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,204&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26,995&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16,204&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:LeaseCostTableTextBlock id="F_000305" contextRef="C_0001703647_20200101_20201231">
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other information&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.52%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average remaining lease term&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.52%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.3 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average discount rate (1)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.86%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.57%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;"&gt;(1)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Rate includes the Company&amp;#8217;s Woburn and Lexington leases. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
  <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock id="F_000306" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The table below reconciles the undiscounted cash flows to the operating lease liability recorded on the consolidated balance sheet as of December 31, 2020. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,928&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,159&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,284&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,412&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,545&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,070&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total minimum lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;47,398&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: amount of lease payments representing interest&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16,404&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Present value of future lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,994&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: current lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(397&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.56%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Noncurrent lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,597&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
  <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock id="F_000307" contextRef="C_0001703647_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Future aggregate minimum payments under the noncancelable operating leases and short term leases, including the Lexington, MA lease and Connecticut lease, which is not subject to ASC 842, as of December 31, 2020 are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,986&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,159&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,284&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,412&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,545&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2026 and beyond&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,070&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.56%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total minimum lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;47,456&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
  <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock id="F_000308" contextRef="C_0001703647_20200101_20201231">
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table contains quarterly financial information for 2020 and 2019.&amp;nbsp;&amp;nbsp;The Company believes that the following information reflects all normal recurring adjustments necessary for the fair statement of the information for the periods presented.&amp;nbsp;&amp;nbsp;The operating results for any quarter are not necessarily indicative of results for any future period.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="18" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June 30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="18" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands, except per share amounts)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total revenue&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,264&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,523&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,247&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,950&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,984&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,177&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,548&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,588&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,182&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;63,495&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,913&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,025&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,341&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10,232&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26,511&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cumulative series C convertible preferred stock&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; dividends&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss attributable to common stockholders&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,913&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,025&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,341&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10,232&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26,511&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share attributable to common shareholders -&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.16&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.19&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.16&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.30&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.82&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="18" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June 30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="18" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands, except per share amounts)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total revenue&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,238&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,709&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,947&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,826&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,852&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,813&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,202&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;47,693&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,826&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,852&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(575&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,493&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(18,746&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cumulative series C convertible preferred stock&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; dividends&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(40&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,054&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss attributable to common stockholders&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,826&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,852&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,589&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,533&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19,800&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share attributable to common shareholders -&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3.24&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3.42&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.73&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.19&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.29&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
  <dei:EntityIncorporationDateOfIncorporation id="F_000309" contextRef="C_0001703647_20200101_20201231">2014-11-30</dei:EntityIncorporationDateOfIncorporation>
  <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 id="F_000310" contextRef="C_0001703647_20190919_20190920" decimals="6" unitRef="U_xbrlipure">0.148467</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
  <us-gaap:StockholdersEquityReverseStockSplit id="F_000311" contextRef="C_0001703647_20200101_20201231">1-for-6.7355</us-gaap:StockholdersEquityReverseStockSplit>
  <us-gaap:CommonStockSharesAuthorized id="F_000312" contextRef="C_0001703647_20190920" decimals="INF" unitRef="U_xbrlishares">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized id="F_000313" contextRef="C_0001703647_20190920" decimals="INF" unitRef="U_xbrlishares">148724922</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000314" contextRef="C_0001703647_20190920" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000315" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20191001_20191031" decimals="INF" unitRef="U_xbrlishares">6325000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:SharesIssuedPricePerShare id="F_000316" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20191031" decimals="INF" unitRef="U_iso4217USD_xbrlishares">14.00</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering id="F_000317" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20191001_20191031" decimals="-5" unitRef="U_iso4217USD">79700000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="F_000318" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20191001_20191031" decimals="INF" unitRef="U_xbrlishares">22077627</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000319" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20200720_20200720" decimals="INF" unitRef="U_xbrlishares">2350108</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000320" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20200720" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:SharesIssuedPricePerShare id="F_000321" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20200720" decimals="INF" unitRef="U_iso4217USD_xbrlishares">18.00</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000322" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20200720_20200720" decimals="-5" unitRef="U_iso4217USD">40100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:RestrictedCashNoncurrent id="F_000323" contextRef="C_0001703647_srtStatementGeographicalAxis_freqLexingtonMassachusettsFacilityMember_20201231" decimals="-5" unitRef="U_iso4217USD">1700000</us-gaap:RestrictedCashNoncurrent>
  <us-gaap:RestrictedCashNoncurrent id="F_000324" contextRef="C_0001703647_srtStatementGeographicalAxis_freqWoburnMassachusettsFacilityMember_20201231" decimals="-5" unitRef="U_iso4217USD">100000</us-gaap:RestrictedCashNoncurrent>
  <us-gaap:RestrictedCashNoncurrent id="F_000325" contextRef="C_0001703647_srtStatementGeographicalAxis_freqWoburnMassachusettsFacilityMember_20191231" decimals="-5" unitRef="U_iso4217USD">100000</us-gaap:RestrictedCashNoncurrent>
  <freq:FairValueOfTermLoan id="F_000326" contextRef="C_0001703647_20201231" decimals="INF" unitRef="U_iso4217USD">0</freq:FairValueOfTermLoan>
  <freq:FairValueOfTermLoanIssuedTerm id="F_000327" contextRef="C_0001703647_20200101_20201231">P1M</freq:FairValueOfTermLoanIssuedTerm>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000328" contextRef="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_freqLabEquipmentMember_20200101_20201231">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000329" contextRef="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareDevelopmentMember_20200101_20201231">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000330" contextRef="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_freqFurnitureAndOfficeEquipmentMember_20200101_20201231">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives id="F_000331" contextRef="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20200101_20201231">Shorter of the estimated useful
life or lease term</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
  <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse id="F_000332" contextRef="C_0001703647_20200101_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
  <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse id="F_000333" contextRef="C_0001703647_20190101_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000334" contextRef="C_0001703647_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_freqUnvestedRestrictedCommonStockMember_20200101_20201231" decimals="0" unitRef="U_xbrlishares">3093</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000335" contextRef="C_0001703647_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_freqUnvestedRestrictedCommonStockMember_20190101_20191231" decimals="0" unitRef="U_xbrlishares">70366</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000336" contextRef="C_0001703647_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_freqSeriesCPreferredAsConvertedToCommonStockMember_20190101_20191231" decimals="0" unitRef="U_xbrlishares">1172676</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000337" contextRef="C_0001703647_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_freqSeriesBPreferredAsConvertedToCommonStockMember_20190101_20191231" decimals="0" unitRef="U_xbrlishares">4759079</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000338" contextRef="C_0001703647_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_freqSeriesAPreferredAsConvertedCommonStockMember_20190101_20191231" decimals="0" unitRef="U_xbrlishares">7070574</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000339" contextRef="C_0001703647_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_freqConversionOfFrequencyJapanPreferredStockMember_20190101_20191231" decimals="0" unitRef="U_xbrlishares">513047</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000340" contextRef="C_0001703647_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_freqOutstandingStockOptionsAsConvertedToCommonStockMember_20200101_20201231" decimals="0" unitRef="U_xbrlishares">6816798</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000341" contextRef="C_0001703647_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_freqOutstandingStockOptionsAsConvertedToCommonStockMember_20190101_20191231" decimals="0" unitRef="U_xbrlishares">5968672</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000342" contextRef="C_0001703647_20200101_20201231" decimals="0" unitRef="U_xbrlishares">6819891</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000343" contextRef="C_0001703647_20190101_20191231" decimals="0" unitRef="U_xbrlishares">19554414</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:OperatingLeaseRightOfUseAsset id="F_000344" contextRef="C_0001703647_20200101" decimals="-5" unitRef="U_iso4217USD">1200000</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:OperatingLeaseRightOfUseAsset id="F_000345" contextRef="C_0001703647_20201211" decimals="-5" unitRef="U_iso4217USD">1700000</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:OperatingLeaseLiability id="F_000346" contextRef="C_0001703647_20200101" decimals="-5" unitRef="U_iso4217USD">1500000</us-gaap:OperatingLeaseLiability>
  <us-gaap:OperatingLeaseLiability id="F_000347" contextRef="C_0001703647_20201211" decimals="-5" unitRef="U_iso4217USD">1700000</us-gaap:OperatingLeaseLiability>
  <freq:IncreaseDecreaseInOperatingLeaseRightOfUseAssets id="F_000348" contextRef="C_0001703647_srtStatementGeographicalAxis_freqWoburnMassachusettsFacilityMember_20200101_20200331" decimals="-5" unitRef="U_iso4217USD">1000000</freq:IncreaseDecreaseInOperatingLeaseRightOfUseAssets>
  <freq:IncreaseDecreaseInOperatingLeaseLiability id="F_000349" contextRef="C_0001703647_srtStatementGeographicalAxis_freqWoburnMassachusettsFacilityMember_20200101_20200331" decimals="-5" unitRef="U_iso4217USD">1000000</freq:IncreaseDecreaseInOperatingLeaseLiability>
  <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted id="F_000350" contextRef="C_0001703647_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201811Member_20201231">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
  <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate id="F_000351" contextRef="C_0001703647_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201811Member_20201231">2020-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
  <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted id="F_000352" contextRef="C_0001703647_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201601Member_20201231">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
  <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate id="F_000353" contextRef="C_0001703647_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201601Member_20201231">2020-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
  <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect id="F_000354" contextRef="C_0001703647_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201601Member_20201231">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000355" contextRef="C_0001703647_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231" decimals="-3" unitRef="U_iso4217USD">214522000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000356" contextRef="C_0001703647_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" unitRef="U_iso4217USD">214522000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000357" contextRef="C_0001703647_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231" decimals="-3" unitRef="U_iso4217USD">27000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000358" contextRef="C_0001703647_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" unitRef="U_iso4217USD">27000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000359" contextRef="C_0001703647_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231" decimals="-3" unitRef="U_iso4217USD">214549000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000360" contextRef="C_0001703647_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" unitRef="U_iso4217USD">214549000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000361" contextRef="C_0001703647_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231" decimals="-3" unitRef="U_iso4217USD">200131000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="F_000362" contextRef="C_0001703647_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231" decimals="-3" unitRef="U_iso4217USD">12000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000363" contextRef="C_0001703647_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231" decimals="-3" unitRef="U_iso4217USD">200119000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000364" contextRef="C_0001703647_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231" decimals="-3" unitRef="U_iso4217USD">17131000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000365" contextRef="C_0001703647_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">217262000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000366" contextRef="C_0001703647_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231" decimals="-3" unitRef="U_iso4217USD">66000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000367" contextRef="C_0001703647_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">54000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000368" contextRef="C_0001703647_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231" decimals="-3" unitRef="U_iso4217USD">17197000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000369" contextRef="C_0001703647_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">217316000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <freq:PrepaidRentAndDepositsCurrent id="F_000370" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">63000</freq:PrepaidRentAndDepositsCurrent>
  <freq:PrepaidResearchAndDevelopmentExpenseCurrent id="F_000371" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">1729000</freq:PrepaidResearchAndDevelopmentExpenseCurrent>
  <freq:PrepaidResearchAndDevelopmentExpenseCurrent id="F_000372" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">801000</freq:PrepaidResearchAndDevelopmentExpenseCurrent>
  <us-gaap:GrantsReceivableCurrent id="F_000373" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">805000</us-gaap:GrantsReceivableCurrent>
  <freq:PrepaidAccountsReceivableCurrent id="F_000374" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">340000</freq:PrepaidAccountsReceivableCurrent>
  <us-gaap:PrepaidInsurance id="F_000375" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">2552000</us-gaap:PrepaidInsurance>
  <us-gaap:PrepaidInsurance id="F_000376" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">2132000</us-gaap:PrepaidInsurance>
  <us-gaap:OtherAssetsCurrent id="F_000377" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">102000</us-gaap:OtherAssetsCurrent>
  <us-gaap:OtherAssetsCurrent id="F_000378" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">199000</us-gaap:OtherAssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000379" contextRef="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20201231" decimals="-3" unitRef="U_iso4217USD">4166000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000380" contextRef="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20191231" decimals="-3" unitRef="U_iso4217USD">1846000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000381" contextRef="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231" decimals="-3" unitRef="U_iso4217USD">283000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000382" contextRef="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20191231" decimals="-3" unitRef="U_iso4217USD">257000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000383" contextRef="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20201231" decimals="-3" unitRef="U_iso4217USD">291000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000384" contextRef="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231" decimals="-3" unitRef="U_iso4217USD">1419000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000385" contextRef="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231" decimals="-3" unitRef="U_iso4217USD">1419000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000386" contextRef="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231" decimals="-3" unitRef="U_iso4217USD">4340000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000387" contextRef="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20191231" decimals="-3" unitRef="U_iso4217USD">306000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000388" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">10499000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000389" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">3828000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="F_000390" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">3212000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="F_000391" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">2066000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="F_000392" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">5062000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="F_000393" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">2686000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent id="F_000394" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">647000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent id="F_000395" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">435000</us-gaap:AccruedProfessionalFeesCurrent>
  <freq:AccruedThirdPartyResearchAndDevelopmentExpensesCurrent id="F_000396" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">874000</freq:AccruedThirdPartyResearchAndDevelopmentExpensesCurrent>
  <freq:AccruedThirdPartyResearchAndDevelopmentExpensesCurrent id="F_000397" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">118000</freq:AccruedThirdPartyResearchAndDevelopmentExpensesCurrent>
  <freq:AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent id="F_000398" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">80000</freq:AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent>
  <us-gaap:DebtInstrumentFaceAmount id="F_000399" contextRef="C_0001703647_us-gaapLongtermDebtTypeAxis_freqTermLoanMember_us-gaapTypeOfArrangementAxis_freqLoanAndSecurityAgreementMember_20201211" decimals="-6" unitRef="U_iso4217USD">15000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentPaymentTerms id="F_000400" contextRef="C_0001703647_us-gaapLongtermDebtTypeAxis_freqTermLoanMember_us-gaapTypeOfArrangementAxis_freqLoanAndSecurityAgreementMember_20200101_20201231">The Company will make monthly interest only payments through November 30, 2022. The principal balance and interest will be repaid in equal monthly installments after the interest only period and continuing through May 1, 2024 (the &#8220;Loan Maturity Date&#8221;)</us-gaap:DebtInstrumentPaymentTerms>
  <us-gaap:DebtInstrumentFrequencyOfPeriodicPayment id="F_000401" contextRef="C_0001703647_us-gaapLongtermDebtTypeAxis_freqTermLoanMember_us-gaapTypeOfArrangementAxis_freqLoanAndSecurityAgreementMember_20200101_20201231">monthly</us-gaap:DebtInstrumentFrequencyOfPeriodicPayment>
  <freq:DebtInstrumentInterestOnlyPaymentMaturityDate id="F_000402" contextRef="C_0001703647_us-gaapLongtermDebtTypeAxis_freqTermLoanMember_us-gaapTypeOfArrangementAxis_freqLoanAndSecurityAgreementMember_20201211_20201211">2022-11-30</freq:DebtInstrumentInterestOnlyPaymentMaturityDate>
  <us-gaap:DebtInstrumentMaturityDate id="F_000403" contextRef="C_0001703647_us-gaapLongtermDebtTypeAxis_freqTermLoanMember_us-gaapTypeOfArrangementAxis_freqLoanAndSecurityAgreementMember_20201211_20201211">2024-05-01</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 id="F_000404" contextRef="C_0001703647_us-gaapLongtermDebtTypeAxis_freqTermLoanMember_us-gaapTypeOfArrangementAxis_freqLoanAndSecurityAgreementMember_us-gaapVariableRateAxis_us-gaapPrimeRateMember_20201211_20201211" decimals="4" unitRef="U_xbrlipure">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
  <freq:DebtInstrumentFloorInterestRatePercentage id="F_000405" contextRef="C_0001703647_us-gaapLongtermDebtTypeAxis_freqTermLoanMember_us-gaapTypeOfArrangementAxis_freqLoanAndSecurityAgreementMember_20201211" decimals="2" unitRef="U_xbrlipure">0.00</freq:DebtInstrumentFloorInterestRatePercentage>
  <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 id="F_000406" contextRef="C_0001703647_us-gaapLongtermDebtTypeAxis_freqTermLoanMember_us-gaapTypeOfArrangementAxis_freqLoanAndSecurityAgreementMember_20200101_20201231" decimals="4" unitRef="U_xbrlipure">0.0475</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
  <freq:DebtInstrumentPrepaymentPremiumPercentage id="F_000407" contextRef="C_0001703647_us-gaapDebtInstrumentAxis_freqPrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMember_us-gaapLongtermDebtTypeAxis_freqTermLoanMember_us-gaapTypeOfArrangementAxis_freqLoanAndSecurityAgreementMember_20201211_20201211" decimals="3" unitRef="U_xbrlipure">0.020</freq:DebtInstrumentPrepaymentPremiumPercentage>
  <freq:DebtInstrumentPrepaymentPremiumPercentage id="F_000408" contextRef="C_0001703647_us-gaapDebtInstrumentAxis_freqPrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMember_us-gaapLongtermDebtTypeAxis_freqTermLoanMember_us-gaapTypeOfArrangementAxis_freqLoanAndSecurityAgreementMember_20201211_20201211" decimals="3" unitRef="U_xbrlipure">0.010</freq:DebtInstrumentPrepaymentPremiumPercentage>
  <freq:DebtInstrumentPrepaymentPremiumPercentage id="F_000409" contextRef="C_0001703647_us-gaapDebtInstrumentAxis_freqPrepaymentOccursAfterSecondAnniversaryOfClosingDateMember_us-gaapLongtermDebtTypeAxis_freqTermLoanMember_us-gaapTypeOfArrangementAxis_freqLoanAndSecurityAgreementMember_20201211_20201211" decimals="3" unitRef="U_xbrlipure">0.000</freq:DebtInstrumentPrepaymentPremiumPercentage>
  <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid id="F_000410" contextRef="C_0001703647_us-gaapLongtermDebtTypeAxis_freqTermLoanMember_us-gaapTypeOfArrangementAxis_freqLoanAndSecurityAgreementMember_20201211" decimals="-3" unitRef="U_iso4217USD">150000000</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
  <us-gaap:TemporaryEquitySharesIssued id="F_000411" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">62528507</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued id="F_000412" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesA1ConvertiblePreferredStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">10000</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued id="F_000413" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">41857005</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued id="F_000414" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">288911</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued id="F_000415" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesB1ConvertiblePreferredStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">10000</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000416" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesCConvertiblePreferredStockMember_20190717" decimals="INF" unitRef="U_xbrlishares">39492960</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued id="F_000417" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesCConvertiblePreferredStockMember_20190717" decimals="INF" unitRef="U_xbrlishares">39492960</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000418" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesCConvertiblePreferredStockMember_20190717" decimals="-3" unitRef="U_iso4217USD">61687000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion id="F_000419" contextRef="C_0001703647_srtConsolidatedEntitiesAxis_srtSubsidiariesMember_20181231" decimals="INF" unitRef="U_xbrlishares">673605</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <freq:PercentageOfVoteOfHoldersOfPreferredStock id="F_000420" contextRef="C_0001703647_srtConsolidatedEntitiesAxis_srtSubsidiariesMember_20180101_20181231" decimals="INF" unitRef="U_xbrlipure">0.70</freq:PercentageOfVoteOfHoldersOfPreferredStock>
  <freq:PreferredStockSharesPurchased id="F_000421" contextRef="C_0001703647_deiLegalEntityAxis_freqDelawareLimitedLiabilityCompanyMember_us-gaapStatementClassOfStockAxis_freqSeriesA1ConvertiblePreferredStockMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">10000</freq:PreferredStockSharesPurchased>
  <freq:PreferredStockSharesPurchased id="F_000422" contextRef="C_0001703647_deiLegalEntityAxis_freqDelawareLimitedLiabilityCompanyMember_us-gaapStatementClassOfStockAxis_freqSeriesB1ConvertiblePreferredStockMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">10000</freq:PreferredStockSharesPurchased>
  <us-gaap:PreferredStockVotingRights id="F_000423" contextRef="C_0001703647_deiLegalEntityAxis_freqDelawareLimitedLiabilityCompanyMember_us-gaapStatementClassOfStockAxis_freqSeriesA1ConvertiblePreferredStockMember_20200101_20201231">Each share of Series A-1 Preferred had 236 times the voting power of one share of common stock</us-gaap:PreferredStockVotingRights>
  <us-gaap:PreferredStockVotingRights id="F_000424" contextRef="C_0001703647_deiLegalEntityAxis_freqDelawareLimitedLiabilityCompanyMember_us-gaapStatementClassOfStockAxis_freqSeriesB1ConvertiblePreferredStockMember_20200101_20201231">Each share of Series B-1 Preferred Stock has 217 times the voting power of one share of common stock</us-gaap:PreferredStockVotingRights>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000425" contextRef="C_0001703647_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231" decimals="INF" unitRef="U_xbrlishares">6816798</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000426" contextRef="C_0001703647_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191231" decimals="INF" unitRef="U_xbrlishares">5968672</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000427" contextRef="C_0001703647_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20201231" decimals="INF" unitRef="U_xbrlishares">1475923</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000428" contextRef="C_0001703647_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20191231" decimals="INF" unitRef="U_xbrlishares">1859654</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000429" contextRef="C_0001703647_20201231" decimals="INF" unitRef="U_xbrlishares">8292721</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000430" contextRef="C_0001703647_20191231" decimals="INF" unitRef="U_xbrlishares">7828326</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000431" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20141113" decimals="INF" unitRef="U_xbrlishares">8550415</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant id="F_000432" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="F_000433" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20190917" decimals="INF" unitRef="U_xbrlishares">3100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <freq:PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance id="F_000434" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20200101_20201231">P10Y</freq:PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum id="F_000435" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription id="F_000436" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20200101_20201231">In addition, the number of shares of common stock available for issuance under the 2019 Plan will be automatically increased on the first day of each calendar year during the ten-year term of the 2019 Plan, beginning with January 1, 2020 and ending with January 1, 2029, by the amount equal to 4% of the outstanding number of shares of the Company&#8217;s common stock on December 31, of the preceding calendar year or such lesser amount as determined by the Company&#8217;s board of directors.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="F_000437" contextRef="C_0001703647_20200101_20201231">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod id="F_000438" contextRef="C_0001703647_srtRangeAxis_srtMaximumMember_20200101_20201231">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000439" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20181231" decimals="INF" unitRef="U_xbrlishares">2089334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000440" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">1247338</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000441" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">3015381</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000442" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">357170</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod id="F_000443" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">26211</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000444" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20191231" decimals="INF" unitRef="U_xbrlishares">1247338</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000445" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20191231" decimals="INF" unitRef="U_xbrlishares">4721334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000446" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">1645859</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000447" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">1851</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000448" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">767534</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod id="F_000449" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">16997</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod id="F_000450" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">11351</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000451" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20201231" decimals="INF" unitRef="U_xbrlishares">2874349</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000452" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20201231" decimals="INF" unitRef="U_xbrlishares">3942449</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="F_000453" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20201231" decimals="INF" unitRef="U_xbrlishares">564617</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="F_000454" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20201231" decimals="INF" unitRef="U_xbrlishares">2337828</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber id="F_000455" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20201231" decimals="INF" unitRef="U_xbrlishares">2309732</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber id="F_000456" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20201231" decimals="INF" unitRef="U_xbrlishares">1604621</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000457" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20181231" decimals="2" unitRef="U_iso4217USD_xbrlishares">0.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="F_000458" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">14.09</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="F_000459" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">4.17</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="F_000460" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">1.02</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice id="F_000461" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">1.09</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000462" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">14.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000463" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">2.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="F_000464" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">24.22</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="F_000465" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">18.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="F_000466" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">1.94</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice id="F_000467" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">22.72</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice id="F_000468" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">6.89</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000469" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">19.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000470" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">3.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="F_000471" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">17.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="F_000472" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">2.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="F_000473" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20190101_20191231">P9Y9M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="F_000474" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20190101_20191231">P8Y10M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="F_000475" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20200101_20201231">P9Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="F_000476" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20200101_20201231">P7Y11M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 id="F_000477" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20200101_20201231">P8Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 id="F_000478" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20200101_20201231">P7Y10M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="F_000479" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20191231" decimals="-3" unitRef="U_iso4217USD">4287000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="F_000480" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20191231" decimals="-3" unitRef="U_iso4217USD">65051000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="F_000481" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20201231" decimals="-3" unitRef="U_iso4217USD">44325000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="F_000482" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20201231" decimals="-3" unitRef="U_iso4217USD">127090000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 id="F_000483" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20201231" decimals="-3" unitRef="U_iso4217USD">10042000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 id="F_000484" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20201231" decimals="-3" unitRef="U_iso4217USD">76416000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue id="F_000485" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20201231" decimals="-3" unitRef="U_iso4217USD">34283000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue id="F_000486" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20201231" decimals="-3" unitRef="U_iso4217USD">50674000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_000487" contextRef="C_0001703647_20200101_20201231" decimals="3" unitRef="U_xbrlipure">0.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_000488" contextRef="C_0001703647_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000489" contextRef="C_0001703647_20200101_20201231">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000490" contextRef="C_0001703647_20190101_20191231">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000491" contextRef="C_0001703647_20200101_20201231" decimals="3" unitRef="U_xbrlipure">0.791</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000492" contextRef="C_0001703647_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.794</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000493" contextRef="C_0001703647_20200101_20201231" decimals="3" unitRef="U_xbrlipure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000494" contextRef="C_0001703647_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000495" contextRef="C_0001703647_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">769385</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000496" contextRef="C_0001703647_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">357170</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="F_000497" contextRef="C_0001703647_20200101_20201231" decimals="0" unitRef="U_iso4217USD_xbrlishares">16667</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="F_000498" contextRef="C_0001703647_20190101_20191231" decimals="0" unitRef="U_iso4217USD_xbrlishares">5896</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000499" contextRef="C_0001703647_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">16.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000500" contextRef="C_0001703647_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">4.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue id="F_000501" contextRef="C_0001703647_20200101_20201231" decimals="0" unitRef="U_iso4217USD_xbrlishares">7907</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue id="F_000502" contextRef="C_0001703647_20190101_20191231" decimals="0" unitRef="U_iso4217USD_xbrlishares">2990</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="F_000503" contextRef="C_0001703647_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20200101_20201231">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="F_000504" contextRef="C_0001703647_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">70366</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod id="F_000505" contextRef="C_0001703647_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">67273</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="F_000506" contextRef="C_0001703647_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">3093</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue id="F_000507" contextRef="C_0001703647_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">0.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue id="F_000508" contextRef="C_0001703647_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">0.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue id="F_000509" contextRef="C_0001703647_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">1.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue id="F_000510" contextRef="C_0001703647_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">73000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue id="F_000511" contextRef="C_0001703647_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">20000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000512" contextRef="C_0001703647_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">9983000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000513" contextRef="C_0001703647_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">3609000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions id="F_000514" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">31006000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions id="F_000515" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">13820000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="F_000516" contextRef="C_0001703647_20200101_20201231">P3Y29D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="F_000517" contextRef="C_0001703647_20190101_20191231">P2Y9M3D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <freq:PercentageOfEligibleEmployeeCompensation id="F_000518" contextRef="C_0001703647_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20190919_20190920" decimals="2" unitRef="U_xbrlipure">0.15</freq:PercentageOfEligibleEmployeeCompensation>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000519" contextRef="C_0001703647_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20190920" decimals="INF" unitRef="U_xbrlishares">315000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <freq:PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance id="F_000520" contextRef="C_0001703647_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20190919_20190920">P10Y</freq:PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum id="F_000521" contextRef="C_0001703647_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20190919_20190920" decimals="INF" unitRef="U_xbrlipure">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod id="F_000522" contextRef="C_0001703647_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20201230_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
  <us-gaap:IncomeTaxExpenseBenefit id="F_000523" contextRef="C_0001703647_20190101_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:OperatingLossCarryforwards id="F_000524" contextRef="C_0001703647_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231" decimals="-3" unitRef="U_iso4217USD">67868000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards id="F_000525" contextRef="C_0001703647_srtStatementGeographicalAxis_stprMA_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231" decimals="-3" unitRef="U_iso4217USD">43386000</us-gaap:OperatingLossCarryforwards>
  <freq:NetOperatingLossCarryforwardsExpirationWithLimitation id="F_000526" contextRef="C_0001703647_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231" decimals="-3" unitRef="U_iso4217USD">22400000</freq:NetOperatingLossCarryforwardsExpirationWithLimitation>
  <freq:OperatingLossCarryforwardsExpirationYear id="F_000527" contextRef="C_0001703647_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231">2037</freq:OperatingLossCarryforwardsExpirationYear>
  <freq:NetOperatingLossCarryforwardsExpirationWithoutLimitation id="F_000528" contextRef="C_0001703647_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231" decimals="-3" unitRef="U_iso4217USD">45469000</freq:NetOperatingLossCarryforwardsExpirationWithoutLimitation>
  <freq:OperatingLossCarryforwardsExpirationYear id="F_000529" contextRef="C_0001703647_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231">2040</freq:OperatingLossCarryforwardsExpirationYear>
  <freq:TaxCreditCarryforwardExpirationYear id="F_000530" contextRef="C_0001703647_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231">2040</freq:TaxCreditCarryforwardExpirationYear>
  <freq:TaxCreditCarryforwardExpirationYear id="F_000531" contextRef="C_0001703647_srtStatementGeographicalAxis_stprMA_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231">2035</freq:TaxCreditCarryforwardExpirationYear>
  <us-gaap:TaxCreditCarryforwardAmount id="F_000532" contextRef="C_0001703647_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231" decimals="-3" unitRef="U_iso4217USD">3014000</us-gaap:TaxCreditCarryforwardAmount>
  <us-gaap:TaxCreditCarryforwardAmount id="F_000533" contextRef="C_0001703647_srtStatementGeographicalAxis_stprMA_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231" decimals="-3" unitRef="U_iso4217USD">1211000</us-gaap:TaxCreditCarryforwardAmount>
  <freq:CumulativeChangeInOwnershipPercentage id="F_000534" contextRef="C_0001703647_srtRangeAxis_srtMinimumMember_us-gaapIncomeTaxAuthorityNameAxis_us-gaapInternalRevenueServiceIRSMember_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.50</freq:CumulativeChangeInOwnershipPercentage>
  <freq:PeriodOfCumulativeChangeInOwnership id="F_000535" contextRef="C_0001703647_us-gaapIncomeTaxAuthorityNameAxis_us-gaapInternalRevenueServiceIRSMember_20200101_20201231">P3Y</freq:PeriodOfCumulativeChangeInOwnership>
  <us-gaap:OperatingLossCarryforwards id="F_000536" contextRef="C_0001703647_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapIncomeTaxAuthorityNameAxis_us-gaapInternalRevenueServiceIRSMember_20170228" decimals="-3" unitRef="U_iso4217USD">12400000</us-gaap:OperatingLossCarryforwards>
  <freq:OperatingLossCarryforwardsUsageAfterOwnershipChange id="F_000537" contextRef="C_0001703647_us-gaapIncomeTaxAuthorityNameAxis_us-gaapInternalRevenueServiceIRSMember_20170331" decimals="-3" unitRef="U_iso4217USD">10800000</freq:OperatingLossCarryforwardsUsageAfterOwnershipChange>
  <freq:OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange id="F_000538" contextRef="C_0001703647_us-gaapIncomeTaxAuthorityNameAxis_us-gaapInternalRevenueServiceIRSMember_20170331" decimals="-3" unitRef="U_iso4217USD">1600000</freq:OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange>
  <freq:OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange id="F_000539" contextRef="C_0001703647_us-gaapIncomeTaxAuthorityNameAxis_us-gaapInternalRevenueServiceIRSMember_20170331" decimals="-3" unitRef="U_iso4217USD">180000</freq:OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange>
  <freq:RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration id="F_000540" contextRef="C_0001703647_us-gaapIncomeTaxAuthorityNameAxis_us-gaapInternalRevenueServiceIRSMember_20170331" decimals="-3" unitRef="U_iso4217USD">1600000</freq:RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration>
  <us-gaap:OperatingLossCarryforwards id="F_000541" contextRef="C_0001703647_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapIncomeTaxAuthorityNameAxis_us-gaapInternalRevenueServiceIRSMember_20191031" decimals="-3" unitRef="U_iso4217USD">46123000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit id="F_000542" contextRef="C_0001703647_20200101_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
  <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit id="F_000543" contextRef="C_0001703647_20190101_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
  <us-gaap:DeferredTaxAssetsValuationAllowance id="F_000544" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">26995000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance id="F_000545" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">16204000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:UnrecognizedTaxBenefits id="F_000546" contextRef="C_0001703647_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefits id="F_000547" contextRef="C_0001703647_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense id="F_000548" contextRef="C_0001703647_20200101_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense id="F_000549" contextRef="C_0001703647_20190101_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic id="F_000550" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-25744000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic id="F_000551" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-19086000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign id="F_000552" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-732000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign id="F_000553" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-714000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments id="F_000554" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-26476000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments id="F_000555" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-19800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:CurrentFederalTaxExpenseBenefit id="F_000556" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">35000</us-gaap:CurrentFederalTaxExpenseBenefit>
  <us-gaap:CurrentIncomeTaxExpenseBenefit id="F_000557" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">35000</us-gaap:CurrentIncomeTaxExpenseBenefit>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="F_000558" contextRef="C_0001703647_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="F_000559" contextRef="C_0001703647_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential id="F_000560" contextRef="C_0001703647_20200101_20201231" decimals="3" unitRef="U_xbrlipure">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
  <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential id="F_000561" contextRef="C_0001703647_20190101_20191231" decimals="3" unitRef="U_xbrlipure">-0.028</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes id="F_000562" contextRef="C_0001703647_20200101_20201231" decimals="3" unitRef="U_xbrlipure">0.030</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes id="F_000563" contextRef="C_0001703647_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.040</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch id="F_000564" contextRef="C_0001703647_20200101_20201231" decimals="3" unitRef="U_xbrlipure">0.112</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch id="F_000565" contextRef="C_0001703647_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.018</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
  <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost id="F_000566" contextRef="C_0001703647_20200101_20201231" decimals="3" unitRef="U_xbrlipure">0.051</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
  <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost id="F_000567" contextRef="C_0001703647_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent id="F_000568" contextRef="C_0001703647_20200101_20201231" decimals="3" unitRef="U_xbrlipure">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent id="F_000569" contextRef="C_0001703647_20190101_20191231" decimals="3" unitRef="U_xbrlipure">-0.010</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance id="F_000570" contextRef="C_0001703647_20200101_20201231" decimals="3" unitRef="U_xbrlipure">-0.407</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance id="F_000571" contextRef="C_0001703647_20190101_20191231" decimals="3" unitRef="U_xbrlipure">-0.230</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards id="F_000572" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">17885000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards id="F_000573" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">13253000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch id="F_000574" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">3992000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch id="F_000575" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">1138000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets id="F_000576" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">360000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
  <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets id="F_000577" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">358000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost id="F_000578" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">850000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost id="F_000579" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">686000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities id="F_000580" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">48000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
  <us-gaap:DeferredTaxAssetsDeferredIncome id="F_000581" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">3606000</us-gaap:DeferredTaxAssetsDeferredIncome>
  <us-gaap:DeferredTaxAssetsDeferredIncome id="F_000582" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">496000</us-gaap:DeferredTaxAssetsDeferredIncome>
  <us-gaap:DeferredTaxAssetsOther id="F_000583" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">142000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsOther id="F_000584" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">189000</us-gaap:DeferredTaxAssetsOther>
  <freq:DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment id="F_000585" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">56000</freq:DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment>
  <freq:DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment id="F_000586" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">36000</freq:DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment>
  <freq:DeferredTaxAssetsLeasingArrangements id="F_000587" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">7285000</freq:DeferredTaxAssetsLeasingArrangements>
  <freq:DeferredTaxAssetsRightOfUseAssets id="F_000588" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">7181000</freq:DeferredTaxAssetsRightOfUseAssets>
  <us-gaap:DeferredTaxAssetsGross id="F_000589" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">26995000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsGross id="F_000590" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">16204000</us-gaap:DeferredTaxAssetsGross>
  <freq:LicenseAgreementEnteredDate id="F_000591" contextRef="C_0001703647_deiLegalEntityAxis_freqMassachusettsInstituteOfTechnologyMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_freqPatentLicenseAgreementMember_20161201_20161231">2016-12</freq:LicenseAgreementEnteredDate>
  <freq:DescriptionOfFutureDevelopmentObligations id="F_000592" contextRef="C_0001703647_deiLegalEntityAxis_freqMassachusettsInstituteOfTechnologyMember_20200101_20201231">The Company&#8217;s future development obligations are: (i) to commence a Phase II clinical trial for such Product, (ii) to commence a Phase III clinical trial for such Product within five years of the IND filing for such product within two years of the IND filing for such product, (iii) to file a New Drug Application or equivalent with the FDA or comparable European regulatory agency for such Product within nine years of the IND filing for such product, and (iv) to make a first commercial sale of such Product within 11 years of the IND filing for such product.</freq:DescriptionOfFutureDevelopmentObligations>
  <freq:LicenseFeePayment id="F_000593" contextRef="C_0001703647_deiLegalEntityAxis_freqMassachusettsInstituteOfTechnologyMember_20161231" decimals="-3" unitRef="U_iso4217USD">50000</freq:LicenseFeePayment>
  <freq:PercentageOfSharesOfCommonStockIssued id="F_000594" contextRef="C_0001703647_deiLegalEntityAxis_freqMassachusettsInstituteOfTechnologyMember_20161201_20161231" decimals="INF" unitRef="U_xbrlipure">0.05</freq:PercentageOfSharesOfCommonStockIssued>
  <freq:MilestonePayments id="F_000595" contextRef="C_0001703647_deiLegalEntityAxis_freqMassachusettsInstituteOfTechnologyMember_srtRangeAxis_srtMaximumMember_20161201_20161231" decimals="-3" unitRef="U_iso4217USD">2900000</freq:MilestonePayments>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000596" contextRef="C_0001703647_deiLegalEntityAxis_freqMassachusettsInstituteOfTechnologyMember_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_srtProductOrServiceAxis_us-gaapRoyaltyMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">16000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <freq:DescriptionOfConditionsToTerminateLicenseAgreement id="F_000597" contextRef="C_0001703647_deiLegalEntityAxis_freqMassachusettsInstituteOfTechnologyMember_20200101_20201231">The Company has the right to terminate for any reason upon a 3-month prior written notice. MIT shall have the right to terminate if the Company ceases to carry on any business related to the MIT License Agreement. MIT may terminate the MIT License Agreement for the Company&#8217;s material breach uncured within ninety (90) days (or thirty (30) days in the case of nonpayment). MIT may also terminate the MIT License Agreement if the Company or our affiliates commence any action against MIT to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or non-infringed (a patent challenge), or if our sublicensee commences such actions and the Company does not terminate such sublicense within thirty (30) days after MIT&#8217;s demand. MIT has the right to increase all payments due, instead of terminating the MIT License Agreement in the case of a patent challenge.</freq:DescriptionOfConditionsToTerminateLicenseAgreement>
  <freq:RightToTerminateAgreementUponPriorWrittenNotice id="F_000598" contextRef="C_0001703647_deiLegalEntityAxis_freqMassachusettsInstituteOfTechnologyMember_20161201_20161231">P3M</freq:RightToTerminateAgreementUponPriorWrittenNotice>
  <freq:RightToTerminateAgreementIfBreachRemainsUncured id="F_000599" contextRef="C_0001703647_deiLegalEntityAxis_freqMassachusettsInstituteOfTechnologyMember_20161201_20161231">P90D</freq:RightToTerminateAgreementIfBreachRemainsUncured>
  <freq:RightToTerminateAgreementIncaseOfNonpayment id="F_000600" contextRef="C_0001703647_deiLegalEntityAxis_freqMassachusettsInstituteOfTechnologyMember_20161201_20161231">P30D</freq:RightToTerminateAgreementIncaseOfNonpayment>
  <us-gaap:PaymentForManagementFee id="F_000601" contextRef="C_0001703647_srtTitleOfIndividualAxis_srtDirectorMember_20200101_20201231" decimals="-4" unitRef="U_iso4217USD">1980000</us-gaap:PaymentForManagementFee>
  <us-gaap:PaymentForManagementFee id="F_000602" contextRef="C_0001703647_srtTitleOfIndividualAxis_srtDirectorMember_20190101_20191231" decimals="-4" unitRef="U_iso4217USD">10000</us-gaap:PaymentForManagementFee>
  <freq:LicenseAgreementEnteredDate id="F_000603" contextRef="C_0001703647_deiLegalEntityAxis_freqCaliforniaInstituteForBiomedicalResearchMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_freqPatentLicenseAgreementMember_20180901_20180930">2018-09</freq:LicenseAgreementEnteredDate>
  <freq:LicenseFeePayment id="F_000604" contextRef="C_0001703647_deiLegalEntityAxis_freqCaliforniaInstituteForBiomedicalResearchMember_20180930" decimals="-3" unitRef="U_iso4217USD">1000000</freq:LicenseFeePayment>
  <freq:MilestonePayments id="F_000605" contextRef="C_0001703647_deiLegalEntityAxis_freqCaliforniaInstituteForBiomedicalResearchMember_srtRangeAxis_srtMaximumMember_20180901_20180930" decimals="-3" unitRef="U_iso4217USD">26000000</freq:MilestonePayments>
  <freq:PercentageOfSharesOfCommonStockIssued id="F_000606" contextRef="C_0001703647_deiLegalEntityAxis_freqCaliforniaInstituteForBiomedicalResearchMember_20180901_20180930" decimals="INF" unitRef="U_xbrlipure">0.50</freq:PercentageOfSharesOfCommonStockIssued>
  <freq:DescriptionOfConditionsToTerminateLicenseAgreement id="F_000607" contextRef="C_0001703647_deiLegalEntityAxis_freqCaliforniaInstituteForBiomedicalResearchMember_20200101_20201231">The Company may terminate the CALIBR License Agreement at will upon a 30-day prior written notice. The Company may also elect to terminate its license to one or more licensed patents in any or all jurisdictions by giving ninety (90) days&#8217; prior written notice to CALIBR. CALIBR may terminate the CALIBR License Agreement for material breach uncured within thirty (30) days. CALIBR has the right to terminate or reduce the license to a non-exclusive license if the Company fails to use diligent efforts to develop and commercially exploit CALIBR Licensed Products.</freq:DescriptionOfConditionsToTerminateLicenseAgreement>
  <freq:RightToTerminateAgreementUponPriorWrittenNotice id="F_000608" contextRef="C_0001703647_deiLegalEntityAxis_freqCaliforniaInstituteForBiomedicalResearchMember_20180901_20180930">P30D</freq:RightToTerminateAgreementUponPriorWrittenNotice>
  <freq:RightToTerminateLicensedPatentsUponPriorWrittenNotice id="F_000609" contextRef="C_0001703647_deiLegalEntityAxis_freqCaliforniaInstituteForBiomedicalResearchMember_20180901_20180930">P90D</freq:RightToTerminateLicensedPatentsUponPriorWrittenNotice>
  <freq:RightToTerminateAgreementIfBreachRemainsUncured id="F_000610" contextRef="C_0001703647_deiLegalEntityAxis_freqCaliforniaInstituteForBiomedicalResearchMember_20180901_20180930">P30D</freq:RightToTerminateAgreementIfBreachRemainsUncured>
  <freq:LicenseAgreementEnteredDate id="F_000611" contextRef="C_0001703647_deiLegalEntityAxis_freqScrippsOptionAgreementMember_20180901_20180930">2018-09</freq:LicenseAgreementEnteredDate>
  <freq:FundingPaymentsMadeAsConsiderationToSupportResearchActivities id="F_000612" contextRef="C_0001703647_deiLegalEntityAxis_freqScrippsOptionAgreementMember_20180901_20180930" decimals="-5" unitRef="U_iso4217USD">700000</freq:FundingPaymentsMadeAsConsiderationToSupportResearchActivities>
  <freq:TermOfAgreement id="F_000613" contextRef="C_0001703647_deiLegalEntityAxis_freqScrippsOptionAgreementMember_20180901_20180930">P1Y</freq:TermOfAgreement>
  <freq:LicenseAgreementExtendedDate id="F_000614" contextRef="C_0001703647_deiLegalEntityAxis_freqScrippsOptionAgreementMember_20200901_20200930">2021-12</freq:LicenseAgreementExtendedDate>
  <freq:AdditionalFundingPaymentsMadeAsConsiderationToSupportResearchActivities id="F_000615" contextRef="C_0001703647_deiLegalEntityAxis_freqScrippsOptionAgreementMember_srtStatementScenarioAxis_srtScenarioForecastMember_20200901_20211231" decimals="-5" unitRef="U_iso4217USD">600000</freq:AdditionalFundingPaymentsMadeAsConsiderationToSupportResearchActivities>
  <freq:DescriptionOfConditionsToTerminateLicenseAgreement id="F_000616" contextRef="C_0001703647_deiLegalEntityAxis_freqScrippsOptionAgreementMember_20200101_20201231">The Company has the right to terminate by giving 90 days&#8217; advance notice. Scripps has the right to terminate in the event of nonpayment by us that remains uncured for 10 days. Each party has the right to terminate in the event of the other party&#8217;s material breach that remains uncured for 60 days or if the other party becomes bankrupt.</freq:DescriptionOfConditionsToTerminateLicenseAgreement>
  <freq:RightToTerminateAgreementUponPriorWrittenNotice id="F_000617" contextRef="C_0001703647_deiLegalEntityAxis_freqScrippsOptionAgreementMember_20180901_20180930">P90D</freq:RightToTerminateAgreementUponPriorWrittenNotice>
  <freq:RightToTerminateAgreementIncaseOfNonpayment id="F_000618" contextRef="C_0001703647_deiLegalEntityAxis_freqScrippsOptionAgreementMember_20180901_20180930">P10D</freq:RightToTerminateAgreementIncaseOfNonpayment>
  <freq:RightToTerminateAgreementIfBreachRemainsUncured id="F_000619" contextRef="C_0001703647_deiLegalEntityAxis_freqScrippsOptionAgreementMember_20180901_20180930">P60D</freq:RightToTerminateAgreementIfBreachRemainsUncured>
  <freq:LicenseAgreementEnteredDate id="F_000620" contextRef="C_0001703647_deiLegalEntityAxis_freqMassachusettsEyeAndEarMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_freqNonExclusivePatentLicenseAgreementMember_20190201_20190228">2019-02</freq:LicenseAgreementEnteredDate>
  <freq:LicenseFeePayment id="F_000621" contextRef="C_0001703647_deiLegalEntityAxis_freqMassachusettsEyeAndEarMember_20190228" decimals="-3" unitRef="U_iso4217USD">20000</freq:LicenseFeePayment>
  <freq:MilestonePayments id="F_000622" contextRef="C_0001703647_deiLegalEntityAxis_freqMassachusettsEyeAndEarMember_srtRangeAxis_srtMaximumMember_20190201_20190228" decimals="-3" unitRef="U_iso4217USD">350000</freq:MilestonePayments>
  <freq:DescriptionOfConditionsToTerminateLicenseAgreement id="F_000623" contextRef="C_0001703647_deiLegalEntityAxis_freqMassachusettsEyeAndEarMember_20200101_20201231">The Company has the right to terminate the MEE License Agreement at will by giving thirty (30) business days advance written notice to MEE. MEE has the right to terminate the MEE License Agreement if the Company fails to make any payment due within thirty (30) business days after MEE notifies the Company of such failure. MEE shall have the right to terminate if the Company fails to maintain the required insurance. MEE shall also have the right to terminate the MEE License Agreement upon forty-five (45) business days written notice if the Company becomes insolvent. MEE has the right to terminate for any other default not cured within sixty (60) business days written notice. MEE also has the right to terminate if the Company or its affiliates challenge the validity of the licensed patent rights.</freq:DescriptionOfConditionsToTerminateLicenseAgreement>
  <freq:RightToTerminateAgreementUponPriorWrittenNotice id="F_000624" contextRef="C_0001703647_deiLegalEntityAxis_freqMassachusettsEyeAndEarMember_20190201_20190228">P30D</freq:RightToTerminateAgreementUponPriorWrittenNotice>
  <freq:RightToTerminateAgreementIncaseOfNonpayment id="F_000625" contextRef="C_0001703647_deiLegalEntityAxis_freqMassachusettsEyeAndEarMember_20190201_20190228">P30D</freq:RightToTerminateAgreementIncaseOfNonpayment>
  <freq:RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent id="F_000626" contextRef="C_0001703647_deiLegalEntityAxis_freqMassachusettsEyeAndEarMember_20190201_20190228">P45D</freq:RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent>
  <freq:RightToTerminateAgreementIfBreachRemainsUncured id="F_000627" contextRef="C_0001703647_deiLegalEntityAxis_freqMassachusettsEyeAndEarMember_20190201_20190228">P60D</freq:RightToTerminateAgreementIfBreachRemainsUncured>
  <freq:LicenseAgreementEnteredDate id="F_000628" contextRef="C_0001703647_deiLegalEntityAxis_freqCambridgeEnterpriseLimitedMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_freqPatentLicenseAgreementMember_20191201_20191231">2019-12</freq:LicenseAgreementEnteredDate>
  <freq:LicenseFeePayment id="F_000629" contextRef="C_0001703647_deiLegalEntityAxis_freqCambridgeEnterpriseLimitedMember_20191231" decimals="-3" unitRef="U_iso4217USD">50000</freq:LicenseFeePayment>
  <freq:AnnualLicenseFee id="F_000630" contextRef="C_0001703647_deiLegalEntityAxis_freqCambridgeEnterpriseLimitedMember_20191201_20191231" decimals="-3" unitRef="U_iso4217USD">50000</freq:AnnualLicenseFee>
  <freq:MilestonePayments id="F_000631" contextRef="C_0001703647_deiLegalEntityAxis_freqCambridgeEnterpriseLimitedMember_srtRangeAxis_srtMaximumMember_20191201_20191231" decimals="-2" unitRef="U_iso4217USD">10500</freq:MilestonePayments>
  <freq:DescriptionOfConditionsToTerminateLicenseAgreement id="F_000632" contextRef="C_0001703647_deiLegalEntityAxis_freqCambridgeEnterpriseLimitedMember_20200101_20201231">We have the right to terminate for any reason upon 90 days&#8217; prior to written notice.  Each party has the right to terminate immediately if the other party ceases to carry on its business.  Either party may also terminate the Cambridge License for material breach if such breach remains uncured for 30 days.  Cambridge may also terminate the Cambridge License if we fail to diligently develop and commercially exploit at least one Cambridge Licensed Product or we or our affiliates or sub-licenses commence any action against Cambridge to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or not infringed.</freq:DescriptionOfConditionsToTerminateLicenseAgreement>
  <freq:RightToTerminateAgreementUponPriorWrittenNotice id="F_000633" contextRef="C_0001703647_deiLegalEntityAxis_freqCambridgeEnterpriseLimitedMember_20191201_20191231">P90D</freq:RightToTerminateAgreementUponPriorWrittenNotice>
  <freq:RightToTerminateAgreementIfBreachRemainsUncured id="F_000634" contextRef="C_0001703647_deiLegalEntityAxis_freqCambridgeEnterpriseLimitedMember_20191201_20191231">P30D</freq:RightToTerminateAgreementIfBreachRemainsUncured>
  <freq:AmountOfFundingReceivedAsGrant id="F_000635" contextRef="C_0001703647_srtProductOrServiceAxis_us-gaapGrantMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_freqResearchAndDevelopmentMember_20180601_20180630" decimals="-3" unitRef="U_iso4217USD">1596000</freq:AmountOfFundingReceivedAsGrant>
  <freq:GrantTermPeriod id="F_000636" contextRef="C_0001703647_srtProductOrServiceAxis_us-gaapGrantMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_freqResearchAndDevelopmentMember_20180601_20180630">P2Y</freq:GrantTermPeriod>
  <freq:IncreaseDecreaseInResearchAndDevelopmentExpense id="F_000637" contextRef="C_0001703647_srtProductOrServiceAxis_us-gaapGrantMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">323000</freq:IncreaseDecreaseInResearchAndDevelopmentExpense>
  <freq:IncreaseDecreaseInResearchAndDevelopmentExpense id="F_000638" contextRef="C_0001703647_srtProductOrServiceAxis_us-gaapGrantMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">845000</freq:IncreaseDecreaseInResearchAndDevelopmentExpense>
  <us-gaap:ProceedsFromCollaborators id="F_000639" contextRef="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190701_20190731" decimals="-5" unitRef="U_iso4217USD">80000000</us-gaap:ProceedsFromCollaborators>
  <us-gaap:ContractWithCustomerLiabilityRevenueRecognized id="F_000640" contextRef="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190701_20190731" decimals="-5" unitRef="U_iso4217USD">230000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
  <freq:ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones id="F_000641" contextRef="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190701_20190731" decimals="-5" unitRef="U_iso4217USD">315000000</freq:ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones>
  <us-gaap:ContractWithCustomerLiabilityRevenueRecognized id="F_000642" contextRef="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_freqPhase2bClinicalTrialMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190701_20190731" decimals="-5" unitRef="U_iso4217USD">65000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
  <us-gaap:ContractWithCustomerLiabilityRevenueRecognized id="F_000643" contextRef="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_srtStatementGeographicalAxis_srtAsiaMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_freqPhase2bClinicalTrialMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190701_20190731" decimals="-5" unitRef="U_iso4217USD">25000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
  <us-gaap:ContractWithCustomerLiabilityRevenueRecognized id="F_000644" contextRef="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_freqPhase3ClinicalTrailMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190701_20190731" decimals="-5" unitRef="U_iso4217USD">100000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
  <us-gaap:ContractWithCustomerLiabilityRevenueRecognized id="F_000645" contextRef="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_srtStatementGeographicalAxis_srtAsiaMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_freqPhase3ClinicalTrailMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190701_20190731" decimals="-5" unitRef="U_iso4217USD">40000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
  <freq:RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization id="F_000646" contextRef="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190701_20190731" decimals="-5" unitRef="U_iso4217USD">315000000</freq:RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization>
  <freq:AgreementTerminationNoticePeriod id="F_000647" contextRef="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190701_20190731">P60D</freq:AgreementTerminationNoticePeriod>
  <freq:RightToTerminateAgreementIfBreachRemainsUncured id="F_000648" contextRef="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190701_20190731">P90D</freq:RightToTerminateAgreementIfBreachRemainsUncured>
  <freq:RightToTerminateAgreementIncaseOfNonpayment id="F_000649" contextRef="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190701_20190731">P45D</freq:RightToTerminateAgreementIncaseOfNonpayment>
  <freq:RevenueRecognitionTransactionPrice id="F_000650" contextRef="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">80000000</freq:RevenueRecognitionTransactionPrice>
  <us-gaap:AccruedRoyaltiesCurrent id="F_000651" contextRef="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20201231" decimals="-5" unitRef="U_iso4217USD">16000000</us-gaap:AccruedRoyaltiesCurrent>
  <us-gaap:RoyaltyExpense id="F_000652" contextRef="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190701_20190930" decimals="-5" unitRef="U_iso4217USD">16000000</us-gaap:RoyaltyExpense>
  <freq:UpfrontFeeRecognizedAsRevenue id="F_000653" contextRef="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190701_20201231" decimals="-5" unitRef="U_iso4217USD">80000000</freq:UpfrontFeeRecognizedAsRevenue>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000654" contextRef="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">28900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000655" contextRef="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">37000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000656" contextRef="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_srtProductOrServiceAxis_us-gaapRoyaltyMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">16000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <freq:RevenueFromContractWithCustomerApplicationInputMethod id="F_000657" contextRef="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">12900000</freq:RevenueFromContractWithCustomerApplicationInputMethod>
  <us-gaap:RevenueRemainingPerformanceObligation id="F_000658" contextRef="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20191231" decimals="-5" unitRef="U_iso4217USD">64000000</us-gaap:RevenueRemainingPerformanceObligation>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000659" contextRef="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1046000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000660" contextRef="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">186000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:LesseeOperatingLeaseTermOfContract id="F_000661" contextRef="C_0001703647_srtStatementGeographicalAxis_stprMA_20161231">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
  <freq:LeaseExpirationYear id="F_000662" contextRef="C_0001703647_srtStatementGeographicalAxis_stprCT_20200101_20201231">2021</freq:LeaseExpirationYear>
  <us-gaap:LesseeOperatingLeaseOptionToExtend id="F_000663" contextRef="C_0001703647_srtStatementGeographicalAxis_stprMA_20200101_20201231">The lease was extended in November 2019 and expires in February 2025.</us-gaap:LesseeOperatingLeaseOptionToExtend>
  <freq:OperatingLeaseAgreementAmendedDate id="F_000664" contextRef="C_0001703647_srtStatementGeographicalAxis_stprMA_20200101_20201231">2019-11</freq:OperatingLeaseAgreementAmendedDate>
  <freq:OperatingLeaseAgreementCommencementDate id="F_000665" contextRef="C_0001703647_srtStatementGeographicalAxis_stprMA_20200101_20201231">2020-02</freq:OperatingLeaseAgreementCommencementDate>
  <freq:OperatingLeaseAgreementExpirationDate id="F_000666" contextRef="C_0001703647_srtStatementGeographicalAxis_stprMA_20200101_20201231">2025-02</freq:OperatingLeaseAgreementExpirationDate>
  <us-gaap:LeaseExpirationDate1 id="F_000667" contextRef="C_0001703647_srtCounterpartyNameAxis_freqAREMARegionNo20LLCMember_us-gaapTypeOfArrangementAxis_freqLeasesTerminationAgreementMember_20201211_20201211">2021-03-31</us-gaap:LeaseExpirationDate1>
  <freq:OperatingLeaseTerminationFee id="F_000668" contextRef="C_0001703647_us-gaapTypeOfArrangementAxis_freqLeasesTerminationAgreementMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">200000</freq:OperatingLeaseTerminationFee>
  <us-gaap:NetRentableArea id="F_000669" contextRef="C_0001703647_srtCounterpartyNameAxis_freqHaydenLLCMember_us-gaapLeaseContractualTermAxis_freqLexingtonLeaseMember_20200107" decimals="INF" unitRef="U_utrsqft">61307</us-gaap:NetRentableArea>
  <freq:OperatingLeaseCommencementDate id="F_000670" contextRef="C_0001703647_srtCounterpartyNameAxis_freqHaydenLLCMember_us-gaapLeaseContractualTermAxis_freqLexingtonLeaseMember_20200107_20200107">2020-12-11</freq:OperatingLeaseCommencementDate>
  <us-gaap:LesseeOperatingLeaseTermOfContract id="F_000671" contextRef="C_0001703647_srtCounterpartyNameAxis_freqHaydenLLCMember_us-gaapLeaseContractualTermAxis_freqLexingtonLeaseMember_20200107">P10Y</us-gaap:LesseeOperatingLeaseTermOfContract>
  <us-gaap:LeaseExpirationDate1 id="F_000672" contextRef="C_0001703647_srtCounterpartyNameAxis_freqHaydenLLCMember_us-gaapLeaseContractualTermAxis_freqLexingtonLeaseMember_20200107_20200107">2031-05-31</us-gaap:LeaseExpirationDate1>
  <freq:OperatingLeaseNumberOfAdditionalExtensionTerms id="F_000673" contextRef="C_0001703647_srtCounterpartyNameAxis_freqHaydenLLCMember_us-gaapLeaseContractualTermAxis_freqLexingtonLeaseMember_20200107" decimals="INF" unitRef="U_freqTerm">2</freq:OperatingLeaseNumberOfAdditionalExtensionTerms>
  <freq:OperatingLeasesAdditionalExtensionTerm id="F_000674" contextRef="C_0001703647_srtCounterpartyNameAxis_freqHaydenLLCMember_us-gaapLeaseContractualTermAxis_freqLexingtonLeaseMember_20200107_20200107">P5Y</freq:OperatingLeasesAdditionalExtensionTerm>
  <us-gaap:OperatingLeaseCost id="F_000675" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">470000</us-gaap:OperatingLeaseCost>
  <us-gaap:VariableLeaseCost id="F_000676" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">510000</us-gaap:VariableLeaseCost>
  <us-gaap:ShortTermLeaseCost id="F_000677" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">106000</us-gaap:ShortTermLeaseCost>
  <us-gaap:OperatingLeaseExpense id="F_000678" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">835000</us-gaap:OperatingLeaseExpense>
  <us-gaap:OperatingLeaseExpense id="F_000679" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">269000</us-gaap:OperatingLeaseExpense>
  <us-gaap:OperatingLeasePayments id="F_000680" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">484000</us-gaap:OperatingLeasePayments>
  <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 id="F_000681" contextRef="C_0001703647_20201231">P10Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
  <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent id="F_000682" contextRef="C_0001703647_20201231" decimals="3" unitRef="U_xbrlipure">0.085</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths id="F_000683" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">2928000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo id="F_000684" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">4159000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree id="F_000685" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">4284000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour id="F_000686" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">4412000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive id="F_000687" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">4545000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive id="F_000688" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">27070000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue id="F_000689" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">47398000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
  <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount id="F_000690" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">16404000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
  <us-gaap:OperatingLeaseLiability id="F_000691" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">30994000</us-gaap:OperatingLeaseLiability>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent id="F_000692" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">2986000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears id="F_000693" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">4159000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears id="F_000694" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">4284000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears id="F_000695" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">4412000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears id="F_000696" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">4545000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter id="F_000697" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">27070000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue id="F_000698" contextRef="C_0001703647_20201231" decimals="-3" unitRef="U_iso4217USD">47456000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:LongTermPurchaseCommitmentAmount id="F_000699" contextRef="C_0001703647_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">600000</us-gaap:LongTermPurchaseCommitmentAmount>
  <us-gaap:LesseeOperatingLeaseTermOfContract id="F_000700" contextRef="C_0001703647_srtStatementGeographicalAxis_freqWoburnMassachusettsFacilityMember_20201231">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
  <us-gaap:LossContingencyLossInPeriod id="F_000701" contextRef="C_0001703647_20200101_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:LossContingencyLossInPeriod>
  <us-gaap:LossContingencyLossInPeriod id="F_000702" contextRef="C_0001703647_20190101_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:LossContingencyLossInPeriod>
  <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent id="F_000703" contextRef="C_0001703647_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.90</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
  <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch id="F_000704" contextRef="C_0001703647_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">1.00</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
  <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent id="F_000705" contextRef="C_0001703647_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.05</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
  <us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage id="F_000706" contextRef="C_0001703647_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">1.00</us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount id="F_000707" contextRef="C_0001703647_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">400000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount id="F_000708" contextRef="C_0001703647_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">200000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000709" contextRef="C_0001703647_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">7264000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000710" contextRef="C_0001703647_20200401_20200630" decimals="-3" unitRef="U_iso4217USD">8523000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000711" contextRef="C_0001703647_20200701_20200930" decimals="-3" unitRef="U_iso4217USD">11247000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000712" contextRef="C_0001703647_20201001_20201231" decimals="-3" unitRef="U_iso4217USD">9950000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <freq:OperatingAndNonOperatingExpensesNet id="F_000713" contextRef="C_0001703647_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">12177000</freq:OperatingAndNonOperatingExpensesNet>
  <freq:OperatingAndNonOperatingExpensesNet id="F_000714" contextRef="C_0001703647_20200401_20200630" decimals="-3" unitRef="U_iso4217USD">14548000</freq:OperatingAndNonOperatingExpensesNet>
  <freq:OperatingAndNonOperatingExpensesNet id="F_000715" contextRef="C_0001703647_20200701_20200930" decimals="-3" unitRef="U_iso4217USD">16588000</freq:OperatingAndNonOperatingExpensesNet>
  <freq:OperatingAndNonOperatingExpensesNet id="F_000716" contextRef="C_0001703647_20201001_20201231" decimals="-3" unitRef="U_iso4217USD">20182000</freq:OperatingAndNonOperatingExpensesNet>
  <freq:OperatingAndNonOperatingExpensesNet id="F_000717" contextRef="C_0001703647_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">63495000</freq:OperatingAndNonOperatingExpensesNet>
  <us-gaap:NetIncomeLoss id="F_000718" contextRef="C_0001703647_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">-4913000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000719" contextRef="C_0001703647_20200401_20200630" decimals="-3" unitRef="U_iso4217USD">-6025000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000720" contextRef="C_0001703647_20200701_20200930" decimals="-3" unitRef="U_iso4217USD">-5341000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000721" contextRef="C_0001703647_20201001_20201231" decimals="-3" unitRef="U_iso4217USD">-10232000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000722" contextRef="C_0001703647_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">-4913000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000723" contextRef="C_0001703647_20200401_20200630" decimals="-3" unitRef="U_iso4217USD">-6025000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000724" contextRef="C_0001703647_20200701_20200930" decimals="-3" unitRef="U_iso4217USD">-5341000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000725" contextRef="C_0001703647_20201001_20201231" decimals="-3" unitRef="U_iso4217USD">-10232000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000726" contextRef="C_0001703647_20200101_20200331" decimals="2" unitRef="U_iso4217USD_xbrlishares">-0.16</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000727" contextRef="C_0001703647_20200401_20200630" decimals="2" unitRef="U_iso4217USD_xbrlishares">-0.19</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000728" contextRef="C_0001703647_20200701_20200930" decimals="2" unitRef="U_iso4217USD_xbrlishares">-0.16</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000729" contextRef="C_0001703647_20201001_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-0.30</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000730" contextRef="C_0001703647_20190701_20190930" decimals="-3" unitRef="U_iso4217USD">24238000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000731" contextRef="C_0001703647_20191001_20191231" decimals="-3" unitRef="U_iso4217USD">4709000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <freq:OperatingAndNonOperatingExpensesNet id="F_000732" contextRef="C_0001703647_20190101_20190331" decimals="-3" unitRef="U_iso4217USD">5826000</freq:OperatingAndNonOperatingExpensesNet>
  <freq:OperatingAndNonOperatingExpensesNet id="F_000733" contextRef="C_0001703647_20190401_20190630" decimals="-3" unitRef="U_iso4217USD">6852000</freq:OperatingAndNonOperatingExpensesNet>
  <freq:OperatingAndNonOperatingExpensesNet id="F_000734" contextRef="C_0001703647_20190701_20190930" decimals="-3" unitRef="U_iso4217USD">24813000</freq:OperatingAndNonOperatingExpensesNet>
  <freq:OperatingAndNonOperatingExpensesNet id="F_000735" contextRef="C_0001703647_20191001_20191231" decimals="-3" unitRef="U_iso4217USD">10202000</freq:OperatingAndNonOperatingExpensesNet>
  <freq:OperatingAndNonOperatingExpensesNet id="F_000736" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">47693000</freq:OperatingAndNonOperatingExpensesNet>
  <us-gaap:NetIncomeLoss id="F_000737" contextRef="C_0001703647_20190101_20190331" decimals="-3" unitRef="U_iso4217USD">-5826000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000738" contextRef="C_0001703647_20190401_20190630" decimals="-3" unitRef="U_iso4217USD">-6852000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000739" contextRef="C_0001703647_20190701_20190930" decimals="-3" unitRef="U_iso4217USD">-575000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000740" contextRef="C_0001703647_20191001_20191231" decimals="-3" unitRef="U_iso4217USD">-5493000</us-gaap:NetIncomeLoss>
  <us-gaap:TemporaryEquityDividendsAdjustment id="F_000741" contextRef="C_0001703647_20190701_20190930" decimals="-3" unitRef="U_iso4217USD">1014000</us-gaap:TemporaryEquityDividendsAdjustment>
  <us-gaap:TemporaryEquityDividendsAdjustment id="F_000742" contextRef="C_0001703647_20191001_20191231" decimals="-3" unitRef="U_iso4217USD">40000</us-gaap:TemporaryEquityDividendsAdjustment>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000743" contextRef="C_0001703647_20190101_20190331" decimals="-3" unitRef="U_iso4217USD">-5826000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000744" contextRef="C_0001703647_20190401_20190630" decimals="-3" unitRef="U_iso4217USD">-6852000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000745" contextRef="C_0001703647_20190701_20190930" decimals="-3" unitRef="U_iso4217USD">-1589000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000746" contextRef="C_0001703647_20191001_20191231" decimals="-3" unitRef="U_iso4217USD">-5533000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000747" contextRef="C_0001703647_20190101_20190331" decimals="2" unitRef="U_iso4217USD_xbrlishares">-3.24</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000748" contextRef="C_0001703647_20190401_20190630" decimals="2" unitRef="U_iso4217USD_xbrlishares">-3.42</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000749" contextRef="C_0001703647_20190701_20190930" decimals="2" unitRef="U_iso4217USD_xbrlishares">-0.73</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000750" contextRef="C_0001703647_20191001_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-0.19</us-gaap:EarningsPerShareBasicAndDiluted>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>27
<FILENAME>freq-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-26T19:12:56.2451531+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 5da74deaf6894583a1f70c65f38043d1 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:freq="http://www.frequencytx.com/20201231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.frequencytx.com/20201231" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" namespace="http://xbrl.sec.gov/country/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" namespace="http://fasb.org/srt/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd" namespace="http://fasb.org/srt-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" namespace="http://fasb.org/srt-types/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" namespace="http://fasb.org/us-gaap/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" namespace="http://fasb.org/us-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" namespace="http://fasb.org/us-types/2020-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.frequencytx.com/20201231/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="freq-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="freq-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="freq-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="freq-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" id="Role_StatementConsolidatedStatementsOfOperations">
        <link:definition>100030 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" id="Role_StatementConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>100040 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/StatementConsolidatedStatementOfConvertiblePreferredStockNonControllingInterestAndStockholderSEquityDeficit" id="Role_StatementConsolidatedStatementOfConvertiblePreferredStockNonControllingInterestAndStockholderSEquityDeficit">
        <link:definition>100050 - Statement - Consolidated Statement of Convertible Preferred Stock, Non-controlling Interest and Stockholder&apos;s Equity (Deficit)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100060 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureOrganizationAndBasisOfPresentation" id="Role_DisclosureOrganizationAndBasisOfPresentation">
        <link:definition>100070 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100080 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100090 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosurePrepaidExpenses" id="Role_DisclosurePrepaidExpenses">
        <link:definition>100100 - Disclosure - Prepaid Expenses</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment" id="Role_DisclosurePropertyAndEquipment">
        <link:definition>100110 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureAccruedExpenses" id="Role_DisclosureAccruedExpenses">
        <link:definition>100120 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureDebt" id="Role_DisclosureDebt">
        <link:definition>100130 - Disclosure - Debt</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStock" id="Role_DisclosureConvertiblePreferredStock">
        <link:definition>100140 - Disclosure - Convertible Preferred Stock</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureNonControllingInterest" id="Role_DisclosureNonControllingInterest">
        <link:definition>100150 - Disclosure - Non-controlling Interest</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockholdersEquity" id="Role_DisclosureStockholdersEquity">
        <link:definition>100160 - Disclosure - Stockholders&apos; Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100170 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureEmployeeStockPurchasePlan" id="Role_DisclosureEmployeeStockPurchasePlan">
        <link:definition>100180 - Disclosure - Employee Stock Purchase Plan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100190 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureResearchAndLicenseAgreements" id="Role_DisclosureResearchAndLicenseAgreements">
        <link:definition>100200 - Disclosure - Research and License Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCollaborationAgreement" id="Role_DisclosureCollaborationAgreement">
        <link:definition>100210 - Disclosure - Collaboration Agreement</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100220 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureEmployeeBenefitPlan" id="Role_DisclosureEmployeeBenefitPlan">
        <link:definition>100230 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions" id="Role_DisclosureRelatedPartyTransactions">
        <link:definition>100240 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>100250 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyDataUnaudited" id="Role_DisclosureSelectedQuarterlyDataUnaudited">
        <link:definition>100260 - Disclosure - Selected Quarterly Data (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100270 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100280 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100290 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosurePrepaidExpensesTables" id="Role_DisclosurePrepaidExpensesTables">
        <link:definition>100300 - Disclosure - Prepaid Expenses (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentTables" id="Role_DisclosurePropertyAndEquipmentTables">
        <link:definition>100310 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureAccruedExpensesTables" id="Role_DisclosureAccruedExpensesTables">
        <link:definition>100320 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockholdersEquityTables" id="Role_DisclosureStockholdersEquityTables">
        <link:definition>100330 - Disclosure - Stockholders&apos; Equity (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100340 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100350 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100360 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyDataUnauditedTables" id="Role_DisclosureSelectedQuarterlyDataUnauditedTables">
        <link:definition>100370 - Disclosure - Selected Quarterly Data (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" id="Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails">
        <link:definition>100380 - Disclosure - Organization and Basis of Presentation - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100390 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails">
        <link:definition>100400 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
        <link:definition>100410 - Disclosure - Summary of Significant Accounting Policies - Schedule of Basic And Diluted Net Loss per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
        <link:definition>100420 - Disclosure - Summary of Significant Accounting Policies - Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails" id="Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails">
        <link:definition>100430 - Disclosure - Fair Value Measurements - Schedule of Financial Assets Measured on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosurePrepaidExpensesSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" id="Role_DisclosurePrepaidExpensesSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>100440 - Disclosure - Prepaid Expenses - Summary of Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" id="Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
        <link:definition>100450 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" id="Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails">
        <link:definition>100460 - Disclosure - Property and Equipment - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" id="Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails">
        <link:definition>100470 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" id="Role_DisclosureDebtAdditionalInformationDetails">
        <link:definition>100480 - Disclosure - Debt - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails" id="Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails">
        <link:definition>100490 - Disclosure - Convertible Preferred Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureNonControllingInterestAdditionalInformationDetails" id="Role_DisclosureNonControllingInterestAdditionalInformationDetails">
        <link:definition>100500 - Disclosure - Non-controlling Interest - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" id="Role_DisclosureStockholdersEquityAdditionalInformationDetails">
        <link:definition>100510 - Disclosure - Stockholders&apos; Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails" id="Role_DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails">
        <link:definition>100520 - Disclosure - Stockholders&apos; Equity - Schedule of Common Stock Shares Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
        <link:definition>100530 - Disclosure - Stock-based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnder2014PlanAnd2019PlanDetails" id="Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnder2014PlanAnd2019PlanDetails">
        <link:definition>100540 - Disclosure - Stock-based Compensation - Summary of Stock Option Activity under 2014 Plan and 2019 Plan (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfGrantDateFairValueOfStockOptionsGrantedOnWeightedAverageBasisDetails" id="Role_DisclosureStockBasedCompensationSummaryOfGrantDateFairValueOfStockOptionsGrantedOnWeightedAverageBasisDetails">
        <link:definition>100550 - Disclosure - Stock-based Compensation - Summary of Grant-date Fair Value of Stock Options Granted on Weighted Average Basis (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStatusOfRestrictedCommonStockDetails" id="Role_DisclosureStockBasedCompensationSummaryOfStatusOfRestrictedCommonStockDetails">
        <link:definition>100560 - Disclosure - Stock-based Compensation - Summary of Status of Restricted Common Stock (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureEmployeeStockPurchasePlanAdditionalInformationDetails" id="Role_DisclosureEmployeeStockPurchasePlanAdditionalInformationDetails">
        <link:definition>100570 - Disclosure - Employee Stock Purchase Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100580 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationPreTaxIncomeDetails" id="Role_DisclosureIncomeTaxesScheduleOfReconciliationPreTaxIncomeDetails">
        <link:definition>100590 - Disclosure - Income Taxes - Schedule of Reconciliation Pre-tax Income (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionDetails" id="Role_DisclosureIncomeTaxesScheduleOfProvisionDetails">
        <link:definition>100600 - Disclosure - Income Taxes - Schedule of Provision (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails" id="Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails">
        <link:definition>100610 - Disclosure - Income Taxes - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails" id="Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails">
        <link:definition>100620 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureResearchAndLicenseAgreementsAdditionalInformationDetails" id="Role_DisclosureResearchAndLicenseAgreementsAdditionalInformationDetails">
        <link:definition>100630 - Disclosure - Research and License Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails" id="Role_DisclosureCollaborationAgreementAdditionalInformationDetails">
        <link:definition>100640 - Disclosure - Collaboration Agreement - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100650 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeasesDetails" id="Role_DisclosureCommitmentsAndContingenciesScheduleOfLeasesDetails">
        <link:definition>100660 - Disclosure - Commitments and Contingencies - Schedule of Leases (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfReconcilesUndiscountedCashFlowsToOperatingLeaseLiabilityRecordedOnConsolidatedBalanceSheetDetails" id="Role_DisclosureCommitmentsAndContingenciesScheduleOfReconcilesUndiscountedCashFlowsToOperatingLeaseLiabilityRecordedOnConsolidatedBalanceSheetDetails">
        <link:definition>100670 - Disclosure - Commitments and Contingencies - Schedule of Reconciles the Undiscounted Cash Flows to the Operating Lease Liability Recorded on the Consolidated Balance Sheet (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfReconcilesUndiscountedCashFlowsToOperatingLeaseLiabilityRecordedOnConsolidatedBalanceSheetDetails2" id="Role_DisclosureCommitmentsAndContingenciesScheduleOfReconcilesUndiscountedCashFlowsToOperatingLeaseLiabilityRecordedOnConsolidatedBalanceSheetDetails2">
        <link:definition>100680 - Disclosure - Commitments and Contingencies - Schedule of Reconciles the Undiscounted Cash Flows to the Operating Lease Liability Recorded on the Consolidated Balance Sheet (Details)2</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumPaymentsUnderNoncancelableOperatingLeasesAndShortTermLeasesDetails" id="Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumPaymentsUnderNoncancelableOperatingLeasesAndShortTermLeasesDetails">
        <link:definition>100690 - Disclosure - Commitments and Contingencies - Schedule of Future Aggregate Minimum Payments Under Noncancelable Operating Leases and Short Term Leases (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformationDetails" id="Role_DisclosureEmployeeBenefitPlanAdditionalInformationDetails">
        <link:definition>100700 - Disclosure - Employee Benefit Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>100710 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyDataUnauditedScheduleOfQuarterlyFinancialInformationDetails" id="Role_DisclosureSelectedQuarterlyDataUnauditedScheduleOfQuarterlyFinancialInformationDetails">
        <link:definition>100720 - Disclosure - Selected Quarterly Data (Unaudited) - Schedule of Quarterly Financial Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="freq_OperatingAndNonOperatingExpensesNet" name="OperatingAndNonOperatingExpensesNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="freq_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_ConvertiblePreferredStockAccretionOfDividend" name="ConvertiblePreferredStockAccretionOfDividend" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="freq_TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" name="TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" name="TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="freq_StockIssuedDuringPeriodSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" name="StockIssuedDuringPeriodSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" name="StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="freq_SeriesCConvertiblePreferredStockMember" name="SeriesCConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_SeriesBConvertiblePreferredStockMember" name="SeriesBConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_SeriesB1ConvertiblePreferredStockMember" name="SeriesB1ConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_SeriesA1ConvertiblePreferredStockMember" name="SeriesA1ConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_NonCashLeaseExpenses" name="NonCashLeaseExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="freq_DeferredLeaseIncentives" name="DeferredLeaseIncentives" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="freq_NonCashDividendOnCumulativeConvertiblePreferredStock" name="NonCashDividendOnCumulativeConvertiblePreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="freq_PrepaidExpensesAndOtherCurrentAssetsTextBlock" name="PrepaidExpensesAndOtherCurrentAssetsTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_TemporaryEquityTextBlock" name="TemporaryEquityTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_EmployeeStockPurchasePlanDisclosureTextBlock" name="EmployeeStockPurchasePlanDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_ResearchAndLicenseAgreementsDisclosureTextBlock" name="ResearchAndLicenseAgreementsDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_SignificantSuppliersPolicyTextBlock" name="SignificantSuppliersPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_PatentCostsPolicyTextBlock" name="PatentCostsPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_PropertyAndEquipmentTableTextBlock" name="PropertyAndEquipmentTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" name="SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" name="ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_LexingtonMassachusettsFacilityMember" name="LexingtonMassachusettsFacilityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_WoburnMassachusettsFacilityMember" name="WoburnMassachusettsFacilityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_FairValueOfTermLoan" name="FairValueOfTermLoan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="freq_FairValueOfTermLoanIssuedTerm" name="FairValueOfTermLoanIssuedTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_LabEquipmentMember" name="LabEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_FurnitureAndOfficeEquipmentMember" name="FurnitureAndOfficeEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_UnvestedRestrictedCommonStockMember" name="UnvestedRestrictedCommonStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_SeriesCPreferredAsConvertedToCommonStockMember" name="SeriesCPreferredAsConvertedToCommonStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_SeriesBPreferredAsConvertedToCommonStockMember" name="SeriesBPreferredAsConvertedToCommonStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_SeriesAPreferredAsConvertedCommonStockMember" name="SeriesAPreferredAsConvertedCommonStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_ConversionOfFrequencyJapanPreferredStockMember" name="ConversionOfFrequencyJapanPreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_OutstandingStockOptionsAsConvertedToCommonStockMember" name="OutstandingStockOptionsAsConvertedToCommonStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="freq_IncreaseDecreaseInOperatingLeaseLiability" name="IncreaseDecreaseInOperatingLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="freq_PrepaidRentAndDepositsCurrent" name="PrepaidRentAndDepositsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="freq_PrepaidResearchAndDevelopmentExpenseCurrent" name="PrepaidResearchAndDevelopmentExpenseCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="freq_PrepaidAccountsReceivableCurrent" name="PrepaidAccountsReceivableCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent" name="AccruedThirdPartyResearchAndDevelopmentExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="freq_AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent" name="AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="freq_DebtInstrumentFloorInterestRatePercentage" name="DebtInstrumentFloorInterestRatePercentage" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="freq_DebtInstrumentInterestOnlyPaymentMaturityDate" name="DebtInstrumentInterestOnlyPaymentMaturityDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_LoanAndSecurityAgreementMember" name="LoanAndSecurityAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_TermLoanMember" name="TermLoanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMember" name="PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMember" name="PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_PrepaymentOccursAfterSecondAnniversaryOfClosingDateMember" name="PrepaymentOccursAfterSecondAnniversaryOfClosingDateMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_DebtInstrumentPrepaymentPremiumPercentage" name="DebtInstrumentPrepaymentPremiumPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_PercentageOfVoteOfHoldersOfPreferredStock" name="PercentageOfVoteOfHoldersOfPreferredStock" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_DelawareLimitedLiabilityCompanyMember" name="DelawareLimitedLiabilityCompanyMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_PreferredStockSharesPurchased" name="PreferredStockSharesPurchased" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_TwoThousandAndFourteenStockIncentivePlanMember" name="TwoThousandAndFourteenStockIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_TwoThousandAndNineteenIncentiveAwardPlanMember" name="TwoThousandAndNineteenIncentiveAwardPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" name="PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_PercentageOfEligibleEmployeeCompensation" name="PercentageOfEligibleEmployeeCompensation" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_IncomeTaxesDisclosureLineItems" name="IncomeTaxesDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_IncomeTaxesDisclosureTable" name="IncomeTaxesDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_TaxCreditCarryforwardExpirationYear" name="TaxCreditCarryforwardExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_NetOperatingLossCarryforwardsExpirationWithLimitation" name="NetOperatingLossCarryforwardsExpirationWithLimitation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="freq_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation" name="NetOperatingLossCarryforwardsExpirationWithoutLimitation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="freq_OperatingLossCarryforwardsUsageAfterOwnershipChange" name="OperatingLossCarryforwardsUsageAfterOwnershipChange" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange" name="OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange" name="OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration" name="RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="freq_CumulativeChangeInOwnershipPercentage" name="CumulativeChangeInOwnershipPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_PeriodOfCumulativeChangeInOwnership" name="PeriodOfCumulativeChangeInOwnership" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" name="DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="freq_DeferredTaxAssetsLeasingArrangements" name="DeferredTaxAssetsLeasingArrangements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="freq_DeferredTaxAssetsRightOfUseAssets" name="DeferredTaxAssetsRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="freq_LicenseAgreementEnteredDate" name="LicenseAgreementEnteredDate" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_MassachusettsInstituteOfTechnologyMember" name="MassachusettsInstituteOfTechnologyMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_PatentLicenseAgreementMember" name="PatentLicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_AstellasPharmaLimitedLiabilityCompanyMember" name="AstellasPharmaLimitedLiabilityCompanyMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_CaliforniaInstituteForBiomedicalResearchMember" name="CaliforniaInstituteForBiomedicalResearchMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_ScrippsOptionAgreementMember" name="ScrippsOptionAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_NonExclusivePatentLicenseAgreementMember" name="NonExclusivePatentLicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_MassachusettsEyeAndEarMember" name="MassachusettsEyeAndEarMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_CambridgeEnterpriseLimitedMember" name="CambridgeEnterpriseLimitedMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_ResearchAndDevelopmentMember" name="ResearchAndDevelopmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_DescriptionOfFutureDevelopmentObligations" name="DescriptionOfFutureDevelopmentObligations" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_LicenseFeePayment" name="LicenseFeePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="freq_PercentageOfSharesOfCommonStockIssued" name="PercentageOfSharesOfCommonStockIssued" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_MilestonePayments" name="MilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="freq_RightToTerminateAgreementUponPriorWrittenNotice" name="RightToTerminateAgreementUponPriorWrittenNotice" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_RightToTerminateAgreementIfBreachRemainsUncured" name="RightToTerminateAgreementIfBreachRemainsUncured" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_RightToTerminateAgreementIncaseOfNonpayment" name="RightToTerminateAgreementIncaseOfNonpayment" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_DescriptionOfConditionsToTerminateLicenseAgreement" name="DescriptionOfConditionsToTerminateLicenseAgreement" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice" name="RightToTerminateLicensedPatentsUponPriorWrittenNotice" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_FundingPaymentsMadeAsConsiderationToSupportResearchActivities" name="FundingPaymentsMadeAsConsiderationToSupportResearchActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="freq_TermOfAgreement" name="TermOfAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_LicenseAgreementExtendedDate" name="LicenseAgreementExtendedDate" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_AdditionalFundingPaymentsMadeAsConsiderationToSupportResearchActivities" name="AdditionalFundingPaymentsMadeAsConsiderationToSupportResearchActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent" name="RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_AnnualLicenseFee" name="AnnualLicenseFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="freq_IncreaseDecreaseInResearchAndDevelopmentExpense" name="IncreaseDecreaseInResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="freq_AmountOfFundingReceivedAsGrant" name="AmountOfFundingReceivedAsGrant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="freq_GrantTermPeriod" name="GrantTermPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones" name="ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization" name="RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="freq_LicenseAndCollaborationAgreementMember" name="LicenseAndCollaborationAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_Phase2bClinicalTrialMember" name="Phase2bClinicalTrialMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_Phase3ClinicalTrailMember" name="Phase3ClinicalTrailMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_AgreementTerminationNoticePeriod" name="AgreementTerminationNoticePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_RevenueRecognitionTransactionPrice" name="RevenueRecognitionTransactionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="freq_UpfrontFeeRecognizedAsRevenue" name="UpfrontFeeRecognizedAsRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="freq_RevenueFromContractWithCustomerApplicationInputMethod" name="RevenueFromContractWithCustomerApplicationInputMethod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="freq_LeaseExpirationYear" name="LeaseExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_OperatingLeaseAgreementAmendedDate" name="OperatingLeaseAgreementAmendedDate" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_OperatingLeaseAgreementCommencementDate" name="OperatingLeaseAgreementCommencementDate" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_OperatingLeaseAgreementExpirationDate" name="OperatingLeaseAgreementExpirationDate" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_LeasesTerminationAgreementMember" name="LeasesTerminationAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_AREMARegionNo20LLCMember" name="AREMARegionNo20LLCMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_HaydenLLCMember" name="HaydenLLCMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_LexingtonLeaseMember" name="LexingtonLeaseMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_OperatingLeaseTerminationFee" name="OperatingLeaseTerminationFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="freq_OperatingLeaseCommencementDate" name="OperatingLeaseCommencementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_OperatingLeaseNumberOfAdditionalExtensionTerms" name="OperatingLeaseNumberOfAdditionalExtensionTerms" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="freq_OperatingLeasesAdditionalExtensionTerm" name="OperatingLeasesAdditionalExtensionTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>28
<FILENAME>freq-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-26T19:12:56.2451531+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 5da74deaf6894583a1f70c65f38043d1 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="freq-20201231.xsd#TemplateLink" roleURI="http://www.frequencytx.com/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="freq-20201231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLoansFromBank" xlink:type="locator" xlink:label="us-gaap_LongTermLoansFromBank" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_PreferredStockValue" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_CommonStockValue" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_AdditionalPaidInCapital" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermLoansFromBank" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermDebtNoncurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10210.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10220.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10230.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10240.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="freq-20201231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense" xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:type="locator" xlink:label="us-gaap_RealizedInvestmentGainsLosses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDividendsAdjustment" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDividendsAdjustment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_TemporaryEquityDividendsAdjustment" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10040.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InvestmentIncomeInterest" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_RealizedInvestmentGainsLosses" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10100.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_RoyaltyExpense" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10130.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" xlink:href="freq-20201231.xsd#Role_StatementConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="freq-20201231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="freq-20201231.xsd#freq_DeferredLeaseIncentives" xlink:type="locator" xlink:label="freq_DeferredLeaseIncentives" />
    <link:loc xlink:href="freq-20201231.xsd#freq_NonCashLeaseExpenses" xlink:type="locator" xlink:label="freq_NonCashLeaseExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10090.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="10100.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="freq_NonCashLeaseExpenses" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="freq_DeferredLeaseIncentives" order="10170.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10180.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="10210.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails" xlink:href="freq-20201231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosurePrepaidExpensesSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="freq-20201231.xsd#Role_DisclosurePrepaidExpensesSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosurePrepaidExpensesSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance" xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" />
    <link:loc xlink:href="freq-20201231.xsd#freq_PrepaidAccountsReceivableCurrent" xlink:type="locator" xlink:label="freq_PrepaidAccountsReceivableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantsReceivableCurrent" xlink:type="locator" xlink:label="us-gaap_GrantsReceivableCurrent" />
    <link:loc xlink:href="freq-20201231.xsd#freq_PrepaidResearchAndDevelopmentExpenseCurrent" xlink:type="locator" xlink:label="freq_PrepaidResearchAndDevelopmentExpenseCurrent" />
    <link:loc xlink:href="freq-20201231.xsd#freq_PrepaidRentAndDepositsCurrent" xlink:type="locator" xlink:label="freq_PrepaidRentAndDepositsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="freq_PrepaidRentAndDepositsCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="freq_PrepaidResearchAndDevelopmentExpenseCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_GrantsReceivableCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="freq_PrepaidAccountsReceivableCurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="freq-20201231.xsd#Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:href="freq-20201231.xsd#Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails">
    <link:loc xlink:href="freq-20201231.xsd#freq_AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="freq_AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="freq-20201231.xsd#freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent" xlink:type="locator" xlink:label="freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="freq_AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationPreTaxIncomeDetails" xlink:href="freq-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfReconciliationPreTaxIncomeDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationPreTaxIncomeDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionDetails" xlink:href="freq-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfProvisionDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="10080.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails" xlink:href="freq-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10070.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails" xlink:href="freq-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails">
    <link:loc xlink:href="freq-20201231.xsd#freq_DeferredTaxAssetsRightOfUseAssets" xlink:type="locator" xlink:label="freq_DeferredTaxAssetsRightOfUseAssets" />
    <link:loc xlink:href="freq-20201231.xsd#freq_DeferredTaxAssetsLeasingArrangements" xlink:type="locator" xlink:label="freq_DeferredTaxAssetsLeasingArrangements" />
    <link:loc xlink:href="freq-20201231.xsd#freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" xlink:type="locator" xlink:label="freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="freq_DeferredTaxAssetsLeasingArrangements" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="freq_DeferredTaxAssetsRightOfUseAssets" order="10120.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfReconcilesUndiscountedCashFlowsToOperatingLeaseLiabilityRecordedOnConsolidatedBalanceSheetDetails" xlink:href="freq-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfReconcilesUndiscountedCashFlowsToOperatingLeaseLiabilityRecordedOnConsolidatedBalanceSheetDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfReconcilesUndiscountedCashFlowsToOperatingLeaseLiabilityRecordedOnConsolidatedBalanceSheetDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="10080.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfReconcilesUndiscountedCashFlowsToOperatingLeaseLiabilityRecordedOnConsolidatedBalanceSheetDetails2" xlink:href="freq-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfReconcilesUndiscountedCashFlowsToOperatingLeaseLiabilityRecordedOnConsolidatedBalanceSheetDetails2" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfReconcilesUndiscountedCashFlowsToOperatingLeaseLiabilityRecordedOnConsolidatedBalanceSheetDetails2">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumPaymentsUnderNoncancelableOperatingLeasesAndShortTermLeasesDetails" xlink:href="freq-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumPaymentsUnderNoncancelableOperatingLeasesAndShortTermLeasesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumPaymentsUnderNoncancelableOperatingLeasesAndShortTermLeasesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyDataUnauditedScheduleOfQuarterlyFinancialInformationDetails" xlink:href="freq-20201231.xsd#Role_DisclosureSelectedQuarterlyDataUnauditedScheduleOfQuarterlyFinancialInformationDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyDataUnauditedScheduleOfQuarterlyFinancialInformationDetails">
    <link:loc xlink:href="freq-20201231.xsd#freq_OperatingAndNonOperatingExpensesNet" xlink:type="locator" xlink:label="freq_OperatingAndNonOperatingExpensesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="freq_OperatingAndNonOperatingExpensesNet" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>29
<FILENAME>freq-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-26T19:12:56.2451531+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 5da74deaf6894583a1f70c65f38043d1 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="freq-20201231.xsd#TemplateLink" roleURI="http://www.frequencytx.com/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/StatementConsolidatedStatementOfConvertiblePreferredStockNonControllingInterestAndStockholderSEquityDeficit" xlink:href="freq-20201231.xsd#Role_StatementConsolidatedStatementOfConvertiblePreferredStockNonControllingInterestAndStockholderSEquityDeficit" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/StatementConsolidatedStatementOfConvertiblePreferredStockNonControllingInterestAndStockholderSEquityDeficit">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="freq-20201231.xsd#freq_StockIssuedDuringPeriodSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" xlink:type="locator" xlink:label="freq_StockIssuedDuringPeriodSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" />
    <link:loc xlink:href="freq-20201231.xsd#freq_TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" xlink:type="locator" xlink:label="freq_TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" />
    <link:loc xlink:href="freq-20201231.xsd#freq_TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" xlink:type="locator" xlink:label="freq_TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" />
    <link:loc xlink:href="freq-20201231.xsd#freq_StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" xlink:type="locator" xlink:label="freq_StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAccretionOfDividends" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAccretionOfDividends" />
    <link:loc xlink:href="freq-20201231.xsd#freq_ConvertiblePreferredStockAccretionOfDividend" xlink:type="locator" xlink:label="freq_ConvertiblePreferredStockAccretionOfDividend" />
    <link:loc xlink:href="freq-20201231.xsd#freq_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="freq_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="freq-20201231.xsd#freq_SeriesA1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesA1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_SeriesB1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesB1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_SeriesCConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesCConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesCConvertiblePreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesBConvertiblePreferredStockMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesB1ConvertiblePreferredStockMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesAConvertiblePreferredStockMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesA1ConvertiblePreferredStockMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="11420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="11540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" order="11780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="11900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="12140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="12260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="freq_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="12320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="freq_ConvertiblePreferredStockAccretionOfDividend" order="12980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityAccretionOfDividends" order="13340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="13700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="13940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="freq_StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" order="14420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="freq_TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" order="14440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="freq_TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" order="14460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="freq_StockIssuedDuringPeriodSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" order="14660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="14780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="15140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="freq-20201231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountIssued1" />
    <link:loc xlink:href="freq-20201231.xsd#freq_NonCashDividendOnCumulativeConvertiblePreferredStock" xlink:type="locator" xlink:label="freq_NonCashDividendOnCumulativeConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="freq-20201231.xsd#freq_DeferredLeaseIncentives" xlink:type="locator" xlink:label="freq_DeferredLeaseIncentives" />
    <link:loc xlink:href="freq-20201231.xsd#freq_NonCashLeaseExpenses" xlink:type="locator" xlink:label="freq_NonCashLeaseExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="freq-20201231.xsd#freq_SeriesCConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesCConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10220.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesBConvertiblePreferredStockMember" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesCConvertiblePreferredStockMember" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="freq_NonCashLeaseExpenses" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="freq_DeferredLeaseIncentives" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="10950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="11150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" order="11190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="11350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="11470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="11510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="11550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="11590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="11630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="11710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="11790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="freq_NonCashDividendOnCumulativeConvertiblePreferredStock" order="11830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_ConversionOfStockAmountIssued1" order="11870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="11910.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" xlink:href="freq-20201231.xsd#Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="locator" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10940.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="freq-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:loc xlink:href="freq-20201231.xsd#freq_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="locator" xlink:label="freq_IncreaseDecreaseInOperatingLeaseLiability" />
    <link:loc xlink:href="freq-20201231.xsd#freq_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:type="locator" xlink:label="freq_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:loc xlink:href="freq-20201231.xsd#freq_FairValueOfTermLoanIssuedTerm" xlink:type="locator" xlink:label="freq_FairValueOfTermLoanIssuedTerm" />
    <link:loc xlink:href="freq-20201231.xsd#freq_FairValueOfTermLoan" xlink:type="locator" xlink:label="freq_FairValueOfTermLoan" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201601Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201811Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201811Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="freq-20201231.xsd#freq_WoburnMassachusettsFacilityMember" xlink:type="locator" xlink:label="freq_WoburnMassachusettsFacilityMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_LexingtonMassachusettsFacilityMember" xlink:type="locator" xlink:label="freq_LexingtonMassachusettsFacilityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="freq-20201231.xsd#freq_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="freq_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="freq-20201231.xsd#freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="freq_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="freq_SummaryOfSignificantAccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="freq_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_StatementGeographicalAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="freq_LexingtonMassachusettsFacilityMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="freq_WoburnMassachusettsFacilityMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="freq_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201811Member" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201601Member" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="freq_FairValueOfTermLoan" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="freq_FairValueOfTermLoanIssuedTerm" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="freq_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="freq_IncreaseDecreaseInOperatingLeaseLiability" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="11110.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails" xlink:href="freq-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_FurnitureAndOfficeEquipmentMember" xlink:type="locator" xlink:label="freq_FurnitureAndOfficeEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareDevelopmentMember" xlink:type="locator" xlink:label="us-gaap_SoftwareDevelopmentMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_LabEquipmentMember" xlink:type="locator" xlink:label="freq_LabEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="freq-20201231.xsd#freq_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="freq_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="freq-20201231.xsd#freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="freq_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="freq_SummaryOfSignificantAccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="freq_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="freq_LabEquipmentMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="freq_FurnitureAndOfficeEquipmentMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="10240.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="freq-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="freq-20201231.xsd#freq_OutstandingStockOptionsAsConvertedToCommonStockMember" xlink:type="locator" xlink:label="freq_OutstandingStockOptionsAsConvertedToCommonStockMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_ConversionOfFrequencyJapanPreferredStockMember" xlink:type="locator" xlink:label="freq_ConversionOfFrequencyJapanPreferredStockMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_SeriesAPreferredAsConvertedCommonStockMember" xlink:type="locator" xlink:label="freq_SeriesAPreferredAsConvertedCommonStockMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_SeriesBPreferredAsConvertedToCommonStockMember" xlink:type="locator" xlink:label="freq_SeriesBPreferredAsConvertedToCommonStockMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_SeriesCPreferredAsConvertedToCommonStockMember" xlink:type="locator" xlink:label="freq_SeriesCPreferredAsConvertedToCommonStockMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_UnvestedRestrictedCommonStockMember" xlink:type="locator" xlink:label="freq_UnvestedRestrictedCommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="freq_UnvestedRestrictedCommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="freq_SeriesCPreferredAsConvertedToCommonStockMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="freq_SeriesBPreferredAsConvertedToCommonStockMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="freq_SeriesAPreferredAsConvertedCommonStockMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="freq_ConversionOfFrequencyJapanPreferredStockMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="freq_OutstandingStockOptionsAsConvertedToCommonStockMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10220.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails" xlink:href="freq-20201231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10040.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_2" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_2" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="11210.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="freq-20201231.xsd#Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10500.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" xlink:href="freq-20201231.xsd#Role_DisclosureDebtAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" />
    <link:loc xlink:href="freq-20201231.xsd#freq_DebtInstrumentPrepaymentPremiumPercentage" xlink:type="locator" xlink:label="freq_DebtInstrumentPrepaymentPremiumPercentage" />
    <link:loc xlink:href="freq-20201231.xsd#freq_DebtInstrumentFloorInterestRatePercentage" xlink:type="locator" xlink:label="freq_DebtInstrumentFloorInterestRatePercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:loc xlink:href="freq-20201231.xsd#freq_DebtInstrumentInterestOnlyPaymentMaturityDate" xlink:type="locator" xlink:label="freq_DebtInstrumentInterestOnlyPaymentMaturityDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPaymentTerms" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:loc xlink:href="freq-20201231.xsd#freq_PrepaymentOccursAfterSecondAnniversaryOfClosingDateMember" xlink:type="locator" xlink:label="freq_PrepaymentOccursAfterSecondAnniversaryOfClosingDateMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMember" xlink:type="locator" xlink:label="freq_PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMember" xlink:type="locator" xlink:label="freq_PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember" xlink:type="locator" xlink:label="us-gaap_PrimeRateMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:type="locator" xlink:label="us-gaap_VariableRateDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:type="locator" xlink:label="us-gaap_VariableRateDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:type="locator" xlink:label="us-gaap_VariableRateAxis" />
    <link:loc xlink:href="freq-20201231.xsd#freq_TermLoanMember" xlink:type="locator" xlink:label="freq_TermLoanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <link:loc xlink:href="freq-20201231.xsd#freq_LoanAndSecurityAgreementMember" xlink:type="locator" xlink:label="freq_LoanAndSecurityAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="freq_LoanAndSecurityAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_2" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="freq_TermLoanMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain_2" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_PrimeRateMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_2" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="freq_PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMember" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="freq_PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMember" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="freq_PrepaymentOccursAfterSecondAnniversaryOfClosingDateMember" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPaymentTerms" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="freq_DebtInstrumentInterestOnlyPaymentMaturityDate" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="freq_DebtInstrumentFloorInterestRatePercentage" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="freq_DebtInstrumentPrepaymentPremiumPercentage" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" order="11220.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:href="freq-20201231.xsd#Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:loc xlink:href="freq-20201231.xsd#freq_SeriesB1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesB1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_SeriesA1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesA1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_SeriesCConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesCConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesAConvertiblePreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesBConvertiblePreferredStockMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesCConvertiblePreferredStockMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesA1ConvertiblePreferredStockMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesB1ConvertiblePreferredStockMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10480.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureNonControllingInterestAdditionalInformationDetails" xlink:href="freq-20201231.xsd#Role_DisclosureNonControllingInterestAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureNonControllingInterestAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockVotingRights" xlink:type="locator" xlink:label="us-gaap_PreferredStockVotingRights" />
    <link:loc xlink:href="freq-20201231.xsd#freq_PreferredStockSharesPurchased" xlink:type="locator" xlink:label="freq_PreferredStockSharesPurchased" />
    <link:loc xlink:href="freq-20201231.xsd#freq_PercentageOfVoteOfHoldersOfPreferredStock" xlink:type="locator" xlink:label="freq_PercentageOfVoteOfHoldersOfPreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:loc xlink:href="freq-20201231.xsd#freq_DelawareLimitedLiabilityCompanyMember" xlink:type="locator" xlink:label="freq_DelawareLimitedLiabilityCompanyMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain_2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="freq-20201231.xsd#freq_SeriesB1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesB1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_SeriesA1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesA1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SubsidiariesMember" xlink:type="locator" xlink:label="srt_SubsidiariesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_SubsidiariesMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesA1ConvertiblePreferredStockMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesB1ConvertiblePreferredStockMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_2" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="freq_DelawareLimitedLiabilityCompanyMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="freq_PercentageOfVoteOfHoldersOfPreferredStock" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="freq_PreferredStockSharesPurchased" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockVotingRights" order="10430.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails" xlink:href="freq-20201231.xsd#Role_DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:type="locator" xlink:label="us-gaap_StockCompensationPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="freq-20201231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:loc xlink:href="freq-20201231.xsd#freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" xlink:type="locator" xlink:label="freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="freq-20201231.xsd#freq_TwoThousandAndNineteenIncentiveAwardPlanMember" xlink:type="locator" xlink:label="freq_TwoThousandAndNineteenIncentiveAwardPlanMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_TwoThousandAndFourteenStockIncentivePlanMember" xlink:type="locator" xlink:label="freq_TwoThousandAndFourteenStockIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="freq_TwoThousandAndFourteenStockIncentivePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="freq_TwoThousandAndNineteenIncentiveAwardPlanMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="11200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11240.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnder2014PlanAnd2019PlanDetails" xlink:href="freq-20201231.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnder2014PlanAnd2019PlanDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnder2014PlanAnd2019PlanDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="freq-20201231.xsd#freq_TwoThousandAndFourteenStockIncentivePlanMember" xlink:type="locator" xlink:label="freq_TwoThousandAndFourteenStockIncentivePlanMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_TwoThousandAndNineteenIncentiveAwardPlanMember" xlink:type="locator" xlink:label="freq_TwoThousandAndNineteenIncentiveAwardPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="freq_TwoThousandAndNineteenIncentiveAwardPlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="freq_TwoThousandAndFourteenStockIncentivePlanMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="12000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="12180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="12390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="12570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="12750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="12930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="14010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="14190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="14760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="14970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="15330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="15510.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStatusOfRestrictedCommonStockDetails" xlink:href="freq-20201231.xsd#Role_DisclosureStockBasedCompensationSummaryOfStatusOfRestrictedCommonStockDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStatusOfRestrictedCommonStockDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="10690.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureEmployeeStockPurchasePlanAdditionalInformationDetails" xlink:href="freq-20201231.xsd#Role_DisclosureEmployeeStockPurchasePlanAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureEmployeeStockPurchasePlanAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:loc xlink:href="freq-20201231.xsd#freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" xlink:type="locator" xlink:label="freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="freq-20201231.xsd#freq_PercentageOfEligibleEmployeeCompensation" xlink:type="locator" xlink:label="freq_PercentageOfEligibleEmployeeCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="freq_PercentageOfEligibleEmployeeCompensation" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="10280.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="freq-20201231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" />
    <link:loc xlink:href="freq-20201231.xsd#freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration" xlink:type="locator" xlink:label="freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration" />
    <link:loc xlink:href="freq-20201231.xsd#freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange" xlink:type="locator" xlink:label="freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange" />
    <link:loc xlink:href="freq-20201231.xsd#freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange" xlink:type="locator" xlink:label="freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange" />
    <link:loc xlink:href="freq-20201231.xsd#freq_OperatingLossCarryforwardsUsageAfterOwnershipChange" xlink:type="locator" xlink:label="freq_OperatingLossCarryforwardsUsageAfterOwnershipChange" />
    <link:loc xlink:href="freq-20201231.xsd#freq_PeriodOfCumulativeChangeInOwnership" xlink:type="locator" xlink:label="freq_PeriodOfCumulativeChangeInOwnership" />
    <link:loc xlink:href="freq-20201231.xsd#freq_CumulativeChangeInOwnershipPercentage" xlink:type="locator" xlink:label="freq_CumulativeChangeInOwnershipPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:loc xlink:href="freq-20201231.xsd#freq_TaxCreditCarryforwardExpirationYear" xlink:type="locator" xlink:label="freq_TaxCreditCarryforwardExpirationYear" />
    <link:loc xlink:href="freq-20201231.xsd#freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation" xlink:type="locator" xlink:label="freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation" />
    <link:loc xlink:href="freq-20201231.xsd#freq_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="freq_OperatingLossCarryforwardsExpirationYear" />
    <link:loc xlink:href="freq-20201231.xsd#freq_NetOperatingLossCarryforwardsExpirationWithLimitation" xlink:type="locator" xlink:label="freq_NetOperatingLossCarryforwardsExpirationWithLimitation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:type="locator" xlink:label="us-gaap_InternalRevenueServiceIRSMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember" xlink:type="locator" xlink:label="us-gaap_ResearchMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_MA" xlink:type="locator" xlink:label="stpr_MA" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="freq-20201231.xsd#freq_IncomeTaxesDisclosureTable" xlink:type="locator" xlink:label="freq_IncomeTaxesDisclosureTable" />
    <link:loc xlink:href="freq-20201231.xsd#freq_IncomeTaxesDisclosureLineItems" xlink:type="locator" xlink:label="freq_IncomeTaxesDisclosureLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="freq_IncomeTaxesDisclosureTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="freq_IncomeTaxesDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="freq_IncomeTaxesDisclosureTable" xlink:to="srt_StatementGeographicalAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_MA" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="freq_IncomeTaxesDisclosureTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_2" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="freq_IncomeTaxesDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_2" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_InternalRevenueServiceIRSMember" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="freq_IncomeTaxesDisclosureTable" xlink:to="srt_RangeAxis" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="freq_NetOperatingLossCarryforwardsExpirationWithLimitation" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="freq_OperatingLossCarryforwardsExpirationYear" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="freq_TaxCreditCarryforwardExpirationYear" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="freq_CumulativeChangeInOwnershipPercentage" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="freq_PeriodOfCumulativeChangeInOwnership" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="freq_OperatingLossCarryforwardsUsageAfterOwnershipChange" order="11120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange" order="11160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange" order="11200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration" order="11240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" order="11350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="11390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="11460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" order="11500.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureResearchAndLicenseAgreementsAdditionalInformationDetails" xlink:href="freq-20201231.xsd#Role_DisclosureResearchAndLicenseAgreementsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureResearchAndLicenseAgreementsAdditionalInformationDetails">
    <link:loc xlink:href="freq-20201231.xsd#freq_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="freq_IncreaseDecreaseInResearchAndDevelopmentExpense" />
    <link:loc xlink:href="freq-20201231.xsd#freq_GrantTermPeriod" xlink:type="locator" xlink:label="freq_GrantTermPeriod" />
    <link:loc xlink:href="freq-20201231.xsd#freq_AmountOfFundingReceivedAsGrant" xlink:type="locator" xlink:label="freq_AmountOfFundingReceivedAsGrant" />
    <link:loc xlink:href="freq-20201231.xsd#freq_AnnualLicenseFee" xlink:type="locator" xlink:label="freq_AnnualLicenseFee" />
    <link:loc xlink:href="freq-20201231.xsd#freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent" xlink:type="locator" xlink:label="freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent" />
    <link:loc xlink:href="freq-20201231.xsd#freq_AdditionalFundingPaymentsMadeAsConsiderationToSupportResearchActivities" xlink:type="locator" xlink:label="freq_AdditionalFundingPaymentsMadeAsConsiderationToSupportResearchActivities" />
    <link:loc xlink:href="freq-20201231.xsd#freq_LicenseAgreementExtendedDate" xlink:type="locator" xlink:label="freq_LicenseAgreementExtendedDate" />
    <link:loc xlink:href="freq-20201231.xsd#freq_TermOfAgreement" xlink:type="locator" xlink:label="freq_TermOfAgreement" />
    <link:loc xlink:href="freq-20201231.xsd#freq_FundingPaymentsMadeAsConsiderationToSupportResearchActivities" xlink:type="locator" xlink:label="freq_FundingPaymentsMadeAsConsiderationToSupportResearchActivities" />
    <link:loc xlink:href="freq-20201231.xsd#freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice" xlink:type="locator" xlink:label="freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForManagementFee" xlink:type="locator" xlink:label="us-gaap_PaymentForManagementFee" />
    <link:loc xlink:href="freq-20201231.xsd#freq_RightToTerminateAgreementIncaseOfNonpayment" xlink:type="locator" xlink:label="freq_RightToTerminateAgreementIncaseOfNonpayment" />
    <link:loc xlink:href="freq-20201231.xsd#freq_RightToTerminateAgreementIfBreachRemainsUncured" xlink:type="locator" xlink:label="freq_RightToTerminateAgreementIfBreachRemainsUncured" />
    <link:loc xlink:href="freq-20201231.xsd#freq_RightToTerminateAgreementUponPriorWrittenNotice" xlink:type="locator" xlink:label="freq_RightToTerminateAgreementUponPriorWrittenNotice" />
    <link:loc xlink:href="freq-20201231.xsd#freq_DescriptionOfConditionsToTerminateLicenseAgreement" xlink:type="locator" xlink:label="freq_DescriptionOfConditionsToTerminateLicenseAgreement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="freq-20201231.xsd#freq_MilestonePayments" xlink:type="locator" xlink:label="freq_MilestonePayments" />
    <link:loc xlink:href="freq-20201231.xsd#freq_PercentageOfSharesOfCommonStockIssued" xlink:type="locator" xlink:label="freq_PercentageOfSharesOfCommonStockIssued" />
    <link:loc xlink:href="freq-20201231.xsd#freq_LicenseFeePayment" xlink:type="locator" xlink:label="freq_LicenseFeePayment" />
    <link:loc xlink:href="freq-20201231.xsd#freq_DescriptionOfFutureDevelopmentObligations" xlink:type="locator" xlink:label="freq_DescriptionOfFutureDevelopmentObligations" />
    <link:loc xlink:href="freq-20201231.xsd#freq_LicenseAgreementEnteredDate" xlink:type="locator" xlink:label="freq_LicenseAgreementEnteredDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember" xlink:type="locator" xlink:label="us-gaap_GrantMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_ResearchAndDevelopmentMember" xlink:type="locator" xlink:label="freq_ResearchAndDevelopmentMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_CambridgeEnterpriseLimitedMember" xlink:type="locator" xlink:label="freq_CambridgeEnterpriseLimitedMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_MassachusettsEyeAndEarMember" xlink:type="locator" xlink:label="freq_MassachusettsEyeAndEarMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_NonExclusivePatentLicenseAgreementMember" xlink:type="locator" xlink:label="freq_NonExclusivePatentLicenseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember" xlink:type="locator" xlink:label="srt_ScenarioForecastMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:type="locator" xlink:label="srt_StatementScenarioAxis" />
    <link:loc xlink:href="freq-20201231.xsd#freq_ScrippsOptionAgreementMember" xlink:type="locator" xlink:label="freq_ScrippsOptionAgreementMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_CaliforniaInstituteForBiomedicalResearchMember" xlink:type="locator" xlink:label="freq_CaliforniaInstituteForBiomedicalResearchMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:type="locator" xlink:label="srt_DirectorMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember" xlink:type="locator" xlink:label="us-gaap_RoyaltyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="freq-20201231.xsd#freq_AstellasPharmaLimitedLiabilityCompanyMember" xlink:type="locator" xlink:label="freq_AstellasPharmaLimitedLiabilityCompanyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="freq-20201231.xsd#freq_PatentLicenseAgreementMember" xlink:type="locator" xlink:label="freq_PatentLicenseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="freq-20201231.xsd#freq_MassachusettsInstituteOfTechnologyMember" xlink:type="locator" xlink:label="freq_MassachusettsInstituteOfTechnologyMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="dei_LegalEntityAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="freq_MassachusettsInstituteOfTechnologyMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="freq_PatentLicenseAgreementMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_RangeAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_CounterpartyNameAxis" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_2" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="freq_AstellasPharmaLimitedLiabilityCompanyMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_ProductOrServiceAxis" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_2" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_TitleOfIndividualAxis" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_2" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="freq_CaliforniaInstituteForBiomedicalResearchMember" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="freq_ScrippsOptionAgreementMember" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_StatementScenarioAxis" order="11140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_2" order="11150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="11170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="11190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="freq_NonExclusivePatentLicenseAgreementMember" order="11310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="freq_MassachusettsEyeAndEarMember" order="11370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="freq_CambridgeEnterpriseLimitedMember" order="11690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="freq_ResearchAndDevelopmentMember" order="12050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GrantMember" order="12110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_LicenseAgreementEnteredDate" order="12180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_DescriptionOfFutureDevelopmentObligations" order="12230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_LicenseFeePayment" order="12280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_PercentageOfSharesOfCommonStockIssued" order="12300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_MilestonePayments" order="12320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="12340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_DescriptionOfConditionsToTerminateLicenseAgreement" order="12390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_RightToTerminateAgreementUponPriorWrittenNotice" order="12410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_RightToTerminateAgreementIfBreachRemainsUncured" order="12430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_RightToTerminateAgreementIncaseOfNonpayment" order="12450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_PaymentForManagementFee" order="12500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice" order="12750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_FundingPaymentsMadeAsConsiderationToSupportResearchActivities" order="12840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_TermOfAgreement" order="12860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_LicenseAgreementExtendedDate" order="12910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_AdditionalFundingPaymentsMadeAsConsiderationToSupportResearchActivities" order="12930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent" order="13300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_AnnualLicenseFee" order="13440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_AmountOfFundingReceivedAsGrant" order="13600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_GrantTermPeriod" order="13660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_IncreaseDecreaseInResearchAndDevelopmentExpense" order="13720.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails" xlink:href="freq-20201231.xsd#Role_DisclosureCollaborationAgreementAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <link:loc xlink:href="freq-20201231.xsd#freq_RevenueFromContractWithCustomerApplicationInputMethod" xlink:type="locator" xlink:label="freq_RevenueFromContractWithCustomerApplicationInputMethod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="freq-20201231.xsd#freq_UpfrontFeeRecognizedAsRevenue" xlink:type="locator" xlink:label="freq_UpfrontFeeRecognizedAsRevenue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense" xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedRoyaltiesCurrent" />
    <link:loc xlink:href="freq-20201231.xsd#freq_RevenueRecognitionTransactionPrice" xlink:type="locator" xlink:label="freq_RevenueRecognitionTransactionPrice" />
    <link:loc xlink:href="freq-20201231.xsd#freq_RightToTerminateAgreementIncaseOfNonpayment" xlink:type="locator" xlink:label="freq_RightToTerminateAgreementIncaseOfNonpayment" />
    <link:loc xlink:href="freq-20201231.xsd#freq_RightToTerminateAgreementIfBreachRemainsUncured" xlink:type="locator" xlink:label="freq_RightToTerminateAgreementIfBreachRemainsUncured" />
    <link:loc xlink:href="freq-20201231.xsd#freq_AgreementTerminationNoticePeriod" xlink:type="locator" xlink:label="freq_AgreementTerminationNoticePeriod" />
    <link:loc xlink:href="freq-20201231.xsd#freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization" xlink:type="locator" xlink:label="freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization" />
    <link:loc xlink:href="freq-20201231.xsd#freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones" xlink:type="locator" xlink:label="freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" xlink:label="us-gaap_ProceedsFromCollaborators" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember" xlink:type="locator" xlink:label="us-gaap_RoyaltyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AsiaMember" xlink:type="locator" xlink:label="srt_AsiaMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:type="locator" xlink:label="srt_EuropeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="freq-20201231.xsd#freq_Phase3ClinicalTrailMember" xlink:type="locator" xlink:label="freq_Phase3ClinicalTrailMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_Phase2bClinicalTrialMember" xlink:type="locator" xlink:label="freq_Phase2bClinicalTrialMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="freq-20201231.xsd#freq_AstellasPharmaLimitedLiabilityCompanyMember" xlink:type="locator" xlink:label="freq_AstellasPharmaLimitedLiabilityCompanyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="freq-20201231.xsd#freq_LicenseAndCollaborationAgreementMember" xlink:type="locator" xlink:label="freq_LicenseAndCollaborationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="freq_LicenseAndCollaborationAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="freq_AstellasPharmaLimitedLiabilityCompanyMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="freq_Phase2bClinicalTrialMember" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="freq_Phase3ClinicalTrailMember" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementGeographicalAxis" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_AsiaMember" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="11480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="11510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" order="11530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" order="11680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="11700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones" order="11720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization" order="11820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="freq_AgreementTerminationNoticePeriod" order="11870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="freq_RightToTerminateAgreementIfBreachRemainsUncured" order="11890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="freq_RightToTerminateAgreementIncaseOfNonpayment" order="11910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="freq_RevenueRecognitionTransactionPrice" order="11960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccruedRoyaltiesCurrent" order="11980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RoyaltyExpense" order="12000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="freq_UpfrontFeeRecognizedAsRevenue" order="12020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="12070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="freq_RevenueFromContractWithCustomerApplicationInputMethod" order="12150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="12190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="12260.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="freq-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyLossInPeriod" xlink:type="locator" xlink:label="us-gaap_LossContingencyLossInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="freq-20201231.xsd#freq_OperatingLeasesAdditionalExtensionTerm" xlink:type="locator" xlink:label="freq_OperatingLeasesAdditionalExtensionTerm" />
    <link:loc xlink:href="freq-20201231.xsd#freq_OperatingLeaseNumberOfAdditionalExtensionTerms" xlink:type="locator" xlink:label="freq_OperatingLeaseNumberOfAdditionalExtensionTerms" />
    <link:loc xlink:href="freq-20201231.xsd#freq_OperatingLeaseCommencementDate" xlink:type="locator" xlink:label="freq_OperatingLeaseCommencementDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetRentableArea" xlink:type="locator" xlink:label="us-gaap_NetRentableArea" />
    <link:loc xlink:href="freq-20201231.xsd#freq_OperatingLeaseTerminationFee" xlink:type="locator" xlink:label="freq_OperatingLeaseTerminationFee" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:loc xlink:href="freq-20201231.xsd#freq_OperatingLeaseAgreementExpirationDate" xlink:type="locator" xlink:label="freq_OperatingLeaseAgreementExpirationDate" />
    <link:loc xlink:href="freq-20201231.xsd#freq_OperatingLeaseAgreementCommencementDate" xlink:type="locator" xlink:label="freq_OperatingLeaseAgreementCommencementDate" />
    <link:loc xlink:href="freq-20201231.xsd#freq_OperatingLeaseAgreementAmendedDate" xlink:type="locator" xlink:label="freq_OperatingLeaseAgreementAmendedDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:loc xlink:href="freq-20201231.xsd#freq_LeaseExpirationYear" xlink:type="locator" xlink:label="freq_LeaseExpirationYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="freq-20201231.xsd#freq_WoburnMassachusettsFacilityMember" xlink:type="locator" xlink:label="freq_WoburnMassachusettsFacilityMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_LexingtonLeaseMember" xlink:type="locator" xlink:label="freq_LexingtonLeaseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:loc xlink:href="freq-20201231.xsd#freq_HaydenLLCMember" xlink:type="locator" xlink:label="freq_HaydenLLCMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_AREMARegionNo20LLCMember" xlink:type="locator" xlink:label="freq_AREMARegionNo20LLCMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="freq-20201231.xsd#freq_LeasesTerminationAgreementMember" xlink:type="locator" xlink:label="freq_LeasesTerminationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CT" xlink:type="locator" xlink:label="stpr_CT" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_MA" xlink:type="locator" xlink:label="stpr_MA" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_MA" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CT" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="freq_LeasesTerminationAgreementMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_CounterpartyNameAxis" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="freq_AREMARegionNo20LLCMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="freq_HaydenLLCMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain_2" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="freq_LexingtonLeaseMember" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="freq_WoburnMassachusettsFacilityMember" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="freq_LeaseExpirationYear" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="freq_OperatingLeaseAgreementAmendedDate" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="freq_OperatingLeaseAgreementCommencementDate" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="freq_OperatingLeaseAgreementExpirationDate" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="freq_OperatingLeaseTerminationFee" order="11100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_NetRentableArea" order="11150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="freq_OperatingLeaseCommencementDate" order="11170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="freq_OperatingLeaseNumberOfAdditionalExtensionTerms" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="freq_OperatingLeasesAdditionalExtensionTerm" order="11250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="11300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="11340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="11380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="11420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_VariableLeaseCost" order="11460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ShortTermLeaseCost" order="11500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="11540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="11580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount" order="11650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LossContingencyLossInPeriod" order="11750.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="freq-20201231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForManagementFee" xlink:type="locator" xlink:label="us-gaap_PaymentForManagementFee" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:type="locator" xlink:label="srt_DirectorMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_TitleOfIndividualAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PaymentForManagementFee" order="10120.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>30
<FILENAME>freq-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-26T19:12:56.2461528+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 5da74deaf6894583a1f70c65f38043d1 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="freq-20201231.xsd#freq_OperatingAndNonOperatingExpensesNet" xlink:type="locator" xlink:label="freq_OperatingAndNonOperatingExpensesNet" />
    <link:label xml:lang="en-US" xlink:label="freq_OperatingAndNonOperatingExpensesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating and non-operating expenses net.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_OperatingAndNonOperatingExpensesNet" xlink:to="freq_OperatingAndNonOperatingExpensesNet_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address Address Line</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address City Or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address State Or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well Known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Icfr Auditor Attestation Flag</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right of use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, net of current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities, net of current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLoansFromBank" xlink:type="locator" xlink:label="us-gaap_LongTermLoansFromBank" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermLoansFromBank_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLoansFromBank" xlink:to="us-gaap_LongTermLoansFromBank_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermLoansFromBank_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Loans From Bank</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued or outstanding at December 31, 2020 and December 31, 2019, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value; 200,000,000 shares authorized, 33,964,000 and 30,844,507 shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Including Portion Attributable To Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, authorized shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, issued shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, outstanding shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, authorized shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, issued shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, outstanding shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Income And Comprehensive Income [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Excluding Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense" xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RoyaltyExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RoyaltyExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:type="locator" xlink:label="us-gaap_RealizedInvestmentGainsLosses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RealizedInvestmentGainsLosses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Realized gain on investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealizedInvestmentGainsLosses" xlink:to="us-gaap_RealizedInvestmentGainsLosses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RealizedInvestmentGainsLosses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Realized Investment Gains Losses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign exchange (loss) gain</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transaction Gain Loss Before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Provision for income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDividendsAdjustment" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDividendsAdjustment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityDividendsAdjustment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cumulative Series C convertible preferred stock dividends</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityDividendsAdjustment" xlink:to="us-gaap_TemporaryEquityDividendsAdjustment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityDividendsAdjustment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Dividends Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss attributable to common stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss Available To Common Stockholders Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common stockholders-basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares of common stock outstanding-basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive (loss) gain:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized (loss) gain on marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total comprehensive (loss) gain</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="freq_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="freq_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity, stock issued during period, shares, new issues.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="freq_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:loc xlink:href="freq-20201231.xsd#freq_ConvertiblePreferredStockAccretionOfDividend" xlink:type="locator" xlink:label="freq_ConvertiblePreferredStockAccretionOfDividend" />
    <link:label xml:lang="en-US" xlink:label="freq_ConvertiblePreferredStockAccretionOfDividend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock accretion of dividend.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_ConvertiblePreferredStockAccretionOfDividend" xlink:to="freq_ConvertiblePreferredStockAccretionOfDividend_lbl" />
    <link:loc xlink:href="freq-20201231.xsd#freq_TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" xlink:type="locator" xlink:label="freq_TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="freq_TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock shares conversion of preferred stock and non-controlling interest into common stock in connection with initial public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" xlink:to="freq_TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering_lbl" />
    <link:loc xlink:href="freq-20201231.xsd#freq_TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" xlink:type="locator" xlink:label="freq_TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="freq_TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock value conversion of preferred stock and non-controlling interest into common stock in connection with initial public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" xlink:to="freq_TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering_lbl" />
    <link:loc xlink:href="freq-20201231.xsd#freq_StockIssuedDuringPeriodSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" xlink:type="locator" xlink:label="freq_StockIssuedDuringPeriodSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="freq_StockIssuedDuringPeriodSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares conversion of preferred stock and non-controlling interest into common stock in connection with initial public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_StockIssuedDuringPeriodSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" xlink:to="freq_StockIssuedDuringPeriodSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering_lbl" />
    <link:loc xlink:href="freq-20201231.xsd#freq_StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" xlink:type="locator" xlink:label="freq_StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="freq_StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value conversion of preferred stock and non-controlling interest into common stock in connection with initial public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" xlink:to="freq_StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_SeriesCConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesCConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="freq_SeriesCConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series C convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_SeriesCConvertiblePreferredStockMember" xlink:to="freq_SeriesCConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_SeriesCConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_SeriesCConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series C Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesBConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="freq_SeriesBConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_SeriesBConvertiblePreferredStockMember" xlink:to="freq_SeriesBConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_SeriesBConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_SeriesBConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series B Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_SeriesB1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesB1ConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="freq_SeriesB1ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B-1 convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_SeriesB1ConvertiblePreferredStockMember" xlink:to="freq_SeriesB1ConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_SeriesB1ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B-1 Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_SeriesB1ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series B1 Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesAConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="freq_SeriesAConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_SeriesAConvertiblePreferredStockMember" xlink:to="freq_SeriesAConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_SeriesAConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_SeriesAConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_SeriesA1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesA1ConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="freq_SeriesA1ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A-1 convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_SeriesA1ConvertiblePreferredStockMember" xlink:to="freq_SeriesA1ConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_SeriesA1ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A-1 Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_SeriesA1ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A1 Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-controlling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional-paid in Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Share Based Compensation Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of options (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Value New Issues</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible preferred stock (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_ConvertiblePreferredStockAccretionOfDividend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accretion of Series C preferred dividend</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_ConvertiblePreferredStockAccretionOfDividend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Accretion Of Dividend</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAccretionOfDividends" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAccretionOfDividends" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityAccretionOfDividends_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accretion of Series C preferred dividend</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAccretionOfDividends" xlink:to="us-gaap_TemporaryEquityAccretionOfDividends_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityAccretionOfDividends_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Accretion Of Dividends</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in initial public offering or private placement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in initial public offering or private placement (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock and non-controlling interest into common stock in connection with the IPO</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Conversion Of Preferred Stock And Non Controlling Interest Into Common Stock In Connection With Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock and non-controlling interest into common stock in connection with the IPO (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Shares Conversion Of Preferred Stock And Non Controlling Interest Into Common Stock In Connection With Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock and non-controlling interest into common stock in connection with the IPO</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Value Conversion Of Preferred Stock And Non Controlling Interest Into Common Stock In Connection With Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_StockIssuedDuringPeriodSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock and non-controlling interest into common stock in connection with the IPO (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_StockIssuedDuringPeriodSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Preferred Stock And Non Controlling Interest Into Common Stock In Connection With Initial Public Offering</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance (in shares)</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_NonCashLeaseExpenses" xlink:type="locator" xlink:label="freq_NonCashLeaseExpenses" />
    <link:label xml:lang="en-US" xlink:label="freq_NonCashLeaseExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non cash lease expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_NonCashLeaseExpenses" xlink:to="freq_NonCashLeaseExpenses_lbl" />
    <link:loc xlink:href="freq-20201231.xsd#freq_DeferredLeaseIncentives" xlink:type="locator" xlink:label="freq_DeferredLeaseIncentives" />
    <link:label xml:lang="en-US" xlink:label="freq_DeferredLeaseIncentives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred lease incentives.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_DeferredLeaseIncentives" xlink:to="freq_DeferredLeaseIncentives_lbl" />
    <link:loc xlink:href="freq-20201231.xsd#freq_NonCashDividendOnCumulativeConvertiblePreferredStock" xlink:type="locator" xlink:label="freq_NonCashDividendOnCumulativeConvertiblePreferredStock" />
    <link:label xml:lang="en-US" xlink:label="freq_NonCashDividendOnCumulativeConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non cash dividend on cumulative convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_NonCashDividendOnCumulativeConvertiblePreferredStock" xlink:to="freq_NonCashDividendOnCumulativeConvertiblePreferredStock_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for license agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Stock And Warrants For Services Or Claims</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_NonCashLeaseExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash lease expense</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_NonCashLeaseExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Lease Expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_DeferredLeaseIncentives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deferred lease incentives</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_DeferredLeaseIncentives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Lease Incentives</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Contract With Customer Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash (used in) provided by operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of available for sale securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Available For Sale Securities Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redemption of available for sale securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale Of Available For Sale Securities Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of convertible preferred stock, net of issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Convertible Preferred Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from Private Placement, net of issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Private Placement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from Term Loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Long Term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase in cash, cash equivalents, short-term investments, and restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents, short-term investments and restricted cash at beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents, short-term investments, and restricted cash at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash items:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing And Financing Items [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets in exchange for lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Right Of Use Asset Obtained In Exchange For Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_NonCashDividendOnCumulativeConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative Series C convertible preferred stock dividends</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_NonCashDividendOnCumulativeConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Dividend On Cumulative Convertible Preferred Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountIssued1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConversionOfStockAmountIssued1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock and non-controlling interest into common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountIssued1" xlink:to="us-gaap_ConversionOfStockAmountIssued1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConversionOfStockAmountIssued1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Stock Amount Issued1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of property and equipment included in accounts payable and accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred But Not Yet Paid</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated By Reference [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation And Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:type="locator" xlink:label="freq_PrepaidExpensesAndOtherCurrentAssetsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="freq_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid expenses and other current assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="freq_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses And Other Current Assets [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payables And Accruals [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Accrued Liabilities And Other Liabilities Disclosure Current [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_TemporaryEquityTextBlock" xlink:type="locator" xlink:label="freq_TemporaryEquityTextBlock" />
    <link:label xml:lang="en-US" xlink:label="freq_TemporaryEquityTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_TemporaryEquityTextBlock" xlink:to="freq_TemporaryEquityTextBlock_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_TemporaryEquityTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_TemporaryEquityTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncontrollingInterestAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncontrolling Interest [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestAbstract" xlink:to="us-gaap_NoncontrollingInterestAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-controlling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestDisclosureTextBlock" xlink:to="us-gaap_MinorityInterestDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minority Interest Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&apos; Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_EmployeeStockPurchasePlanDisclosureTextBlock" xlink:type="locator" xlink:label="freq_EmployeeStockPurchasePlanDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="freq_EmployeeStockPurchasePlanDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock purchase plan disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_EmployeeStockPurchasePlanDisclosureTextBlock" xlink:to="freq_EmployeeStockPurchasePlanDisclosureTextBlock_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compensation And Retirement Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_EmployeeStockPurchasePlanDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_EmployeeStockPurchasePlanDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_ResearchAndLicenseAgreementsDisclosureTextBlock" xlink:type="locator" xlink:label="freq_ResearchAndLicenseAgreementsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="freq_ResearchAndLicenseAgreementsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and license agreements disclosure text block.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_ResearchAndLicenseAgreementsDisclosureTextBlock" xlink:to="freq_ResearchAndLicenseAgreementsDisclosureTextBlock_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_ResearchAndLicenseAgreementsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and License Agreements</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_ResearchAndLicenseAgreementsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And License Agreements Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Benefit Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pension And Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="locator" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selected Quarterly Data (Unaudited)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Accounting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Income (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transactions And Translations Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term Marketable Debt Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk and Off-balance Sheet Risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_SignificantSuppliersPolicyTextBlock" xlink:type="locator" xlink:label="freq_SignificantSuppliersPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="freq_SignificantSuppliersPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant suppliers.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_SignificantSuppliersPolicyTextBlock" xlink:to="freq_SignificantSuppliersPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_SignificantSuppliersPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Suppliers</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_SignificantSuppliersPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Suppliers Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Financial Instruments Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Or Disposal Of Long Lived Assets Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Costs and Accruals</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Leases Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Accounting Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Policy [Text Block]</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_PatentCostsPolicyTextBlock" xlink:type="locator" xlink:label="freq_PatentCostsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="freq_PatentCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Patent costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_PatentCostsPolicyTextBlock" xlink:to="freq_PatentCostsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_PatentCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patent Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_PatentCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Patent Costs Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Option And Incentive Plans Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_PropertyAndEquipmentTableTextBlock" xlink:type="locator" xlink:label="freq_PropertyAndEquipmentTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="freq_PropertyAndEquipmentTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Property and equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_PropertyAndEquipmentTableTextBlock" xlink:to="freq_PropertyAndEquipmentTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_PropertyAndEquipmentTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_PropertyAndEquipmentTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property And Equipment Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Basic and Diluted Net Loss per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computation of Diluted Net Loss per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Financial Assets Measured at Fair Value on Recurring Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:type="locator" xlink:label="freq_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="freq_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of prepaid expenses and other current assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="freq_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Prepaid Expenses and Other Current Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Prepaid Expenses And Other Current Assets Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" xlink:type="locator" xlink:label="freq_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="freq_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of common stock shares reserved for future issuance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" xlink:to="freq_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Common Stock Shares Reserved for Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Common Stock Shares Reserved For Future Issuance Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity under 2014 Plan and 2019 Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Grant-date Fair Value of Stock Options Granted on Weighted Average Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Status of Restricted Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Sharebased Compensation Restricted Stock And Restricted Stock Units Activity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation Pre-tax Income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Income Before Income Tax Domestic And Foreign Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Provision</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Components Of Income Tax Expense Benefit Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deferred Tax Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciles the Undiscounted Cash Flows to the Operating Lease Liability Recorded on the Consolidated Balance Sheet</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Maturity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Aggregate Minimum Payments Under Noncancelable Operating Leases and Short Term Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Quarterly Financial Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Quarterly Financial Information Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="locator" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">I P O [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsidiary Sale Of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Date of incorporation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationDateOfIncorporation" xlink:to="dei_EntityIncorporationDateOfIncorporation_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation Date Of Incorporation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split ratio</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Stock Split Conversion Ratio1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split, description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Reverse Stock Split</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock shares issued and sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from issuance of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Initial Public Offering</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of common stock issued upon conversion of preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel">Net proceeds from issuance of common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="freq_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="freq_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="freq_SummaryOfSignificantAccountingPoliciesLineItems_lbl" />
    <link:loc xlink:href="freq-20201231.xsd#freq_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="freq_SummaryOfSignificantAccountingPoliciesTable" />
    <link:label xml:lang="en-US" xlink:label="freq_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_SummaryOfSignificantAccountingPoliciesTable" xlink:to="freq_SummaryOfSignificantAccountingPoliciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Geographical [Domain]</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_LexingtonMassachusettsFacilityMember" xlink:type="locator" xlink:label="freq_LexingtonMassachusettsFacilityMember" />
    <link:label xml:lang="en-US" xlink:label="freq_LexingtonMassachusettsFacilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lexington Massachusetts facility.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_LexingtonMassachusettsFacilityMember" xlink:to="freq_LexingtonMassachusettsFacilityMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_LexingtonMassachusettsFacilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lexington Massachusetts facility</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_LexingtonMassachusettsFacilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lexington Massachusetts Facility [Member]</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_WoburnMassachusettsFacilityMember" xlink:type="locator" xlink:label="freq_WoburnMassachusettsFacilityMember" />
    <link:label xml:lang="en-US" xlink:label="freq_WoburnMassachusettsFacilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Woburn Massachusetts facility.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_WoburnMassachusettsFacilityMember" xlink:to="freq_WoburnMassachusettsFacilityMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_WoburnMassachusettsFacilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Woburn Massachusetts Facility</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_WoburnMassachusettsFacilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Woburn Massachusetts Facility [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments For New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Adoption [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201811Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201811Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201811Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update 2018-11</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201811Member" xlink:to="us-gaap_AccountingStandardsUpdate201811Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201811Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201811 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201601Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201601Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update 2016-01</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201601Member" xlink:to="us-gaap_AccountingStandardsUpdate201601Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201601Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201601 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Foreign currency exchange (losses) gains</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_FairValueOfTermLoan" xlink:type="locator" xlink:label="freq_FairValueOfTermLoan" />
    <link:label xml:lang="en-US" xlink:label="freq_FairValueOfTermLoan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of term loan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_FairValueOfTermLoan" xlink:to="freq_FairValueOfTermLoan_lbl" />
    <link:loc xlink:href="freq-20201231.xsd#freq_FairValueOfTermLoanIssuedTerm" xlink:type="locator" xlink:label="freq_FairValueOfTermLoanIssuedTerm" />
    <link:label xml:lang="en-US" xlink:label="freq_FairValueOfTermLoanIssuedTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of term loan issued term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_FairValueOfTermLoanIssuedTerm" xlink:to="freq_FairValueOfTermLoanIssuedTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_FairValueOfTermLoan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of term loan</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_FairValueOfTermLoan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Term Loan</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_FairValueOfTermLoanIssuedTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of term loan issued term</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_FairValueOfTermLoanIssuedTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Term Loan Issued Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_LabEquipmentMember" xlink:type="locator" xlink:label="freq_LabEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="freq_LabEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lab equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_LabEquipmentMember" xlink:to="freq_LabEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_LabEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lab Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_LabEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lab Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareDevelopmentMember" xlink:type="locator" xlink:label="us-gaap_SoftwareDevelopmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SoftwareDevelopmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Software</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareDevelopmentMember" xlink:to="us-gaap_SoftwareDevelopmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SoftwareDevelopmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Software Development [Member]</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_FurnitureAndOfficeEquipmentMember" xlink:type="locator" xlink:label="freq_FurnitureAndOfficeEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="freq_FurnitureAndOfficeEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Furniture and office equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_FurnitureAndOfficeEquipmentMember" xlink:to="freq_FurnitureAndOfficeEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_FurnitureAndOfficeEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Office Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_FurnitureAndOfficeEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Office Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, estimated useful lives</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold improvements, estimated useful lives</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Estimated Useful Lives</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Long Lived Assets Held For Use</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss Available To Common Stockholders Basic [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss attributable to common stockholders</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted Other Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average shares of common stock outstanding- basic and diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_UnvestedRestrictedCommonStockMember" xlink:type="locator" xlink:label="freq_UnvestedRestrictedCommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="freq_UnvestedRestrictedCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested Restricted Common Stock [Member].</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_UnvestedRestrictedCommonStockMember" xlink:to="freq_UnvestedRestrictedCommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_UnvestedRestrictedCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested Restricted Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_UnvestedRestrictedCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Restricted Common Stock [Member]</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_SeriesCPreferredAsConvertedToCommonStockMember" xlink:type="locator" xlink:label="freq_SeriesCPreferredAsConvertedToCommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="freq_SeriesCPreferredAsConvertedToCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series C Preferred As Converted To Common Stock [Member].</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_SeriesCPreferredAsConvertedToCommonStockMember" xlink:to="freq_SeriesCPreferredAsConvertedToCommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_SeriesCPreferredAsConvertedToCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C Preferred (as converted to common stock)</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_SeriesCPreferredAsConvertedToCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series C Preferred As Converted To Common Stock [Member]</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_SeriesBPreferredAsConvertedToCommonStockMember" xlink:type="locator" xlink:label="freq_SeriesBPreferredAsConvertedToCommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="freq_SeriesBPreferredAsConvertedToCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B Preferred as converted to common stock member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_SeriesBPreferredAsConvertedToCommonStockMember" xlink:to="freq_SeriesBPreferredAsConvertedToCommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_SeriesBPreferredAsConvertedToCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Preferred (as converted to common stock)</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_SeriesBPreferredAsConvertedToCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series B Preferred As Converted To Common Stock [Member]</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_SeriesAPreferredAsConvertedCommonStockMember" xlink:type="locator" xlink:label="freq_SeriesAPreferredAsConvertedCommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="freq_SeriesAPreferredAsConvertedCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A Preferred as converted to common stock member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_SeriesAPreferredAsConvertedCommonStockMember" xlink:to="freq_SeriesAPreferredAsConvertedCommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_SeriesAPreferredAsConvertedCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Preferred (as converted to common stock)</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_SeriesAPreferredAsConvertedCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A Preferred As Converted Common Stock [Member]</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_ConversionOfFrequencyJapanPreferredStockMember" xlink:type="locator" xlink:label="freq_ConversionOfFrequencyJapanPreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="freq_ConversionOfFrequencyJapanPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of Frequency Japan preferred stock member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_ConversionOfFrequencyJapanPreferredStockMember" xlink:to="freq_ConversionOfFrequencyJapanPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_ConversionOfFrequencyJapanPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of Frequency Japan Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_ConversionOfFrequencyJapanPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Frequency Japan Preferred Stock [Member]</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_OutstandingStockOptionsAsConvertedToCommonStockMember" xlink:type="locator" xlink:label="freq_OutstandingStockOptionsAsConvertedToCommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="freq_OutstandingStockOptionsAsConvertedToCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Outstanding stock options as converted to common stock member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_OutstandingStockOptionsAsConvertedToCommonStockMember" xlink:to="freq_OutstandingStockOptionsAsConvertedToCommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_OutstandingStockOptionsAsConvertedToCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding Stock Options (as converted to common stock)</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_OutstandingStockOptionsAsConvertedToCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Outstanding Stock Options As Converted To Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities excluded from computation of earnings per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:type="locator" xlink:label="freq_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" />
    <link:label xml:lang="en-US" xlink:label="freq_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in operating lease right of use assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:to="freq_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_lbl" />
    <link:loc xlink:href="freq-20201231.xsd#freq_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="locator" xlink:label="freq_IncreaseDecreaseInOperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="freq_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in operating lease liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="freq_IncreaseDecreaseInOperatingLeaseLiability_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in right-of-use asset</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Right Of Use Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in lease liability</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adopted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Adopted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adoption date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Adoption Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, immaterial effect</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Immaterial Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type Categorization [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government Treasury Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U S Treasury Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recurring Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortization Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Gain</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Market Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_PrepaidRentAndDepositsCurrent" xlink:type="locator" xlink:label="freq_PrepaidRentAndDepositsCurrent" />
    <link:label xml:lang="en-US" xlink:label="freq_PrepaidRentAndDepositsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Rent and deposits.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_PrepaidRentAndDepositsCurrent" xlink:to="freq_PrepaidRentAndDepositsCurrent_lbl" />
    <link:loc xlink:href="freq-20201231.xsd#freq_PrepaidResearchAndDevelopmentExpenseCurrent" xlink:type="locator" xlink:label="freq_PrepaidResearchAndDevelopmentExpenseCurrent" />
    <link:label xml:lang="en-US" xlink:label="freq_PrepaidResearchAndDevelopmentExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid research and development expense current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_PrepaidResearchAndDevelopmentExpenseCurrent" xlink:to="freq_PrepaidResearchAndDevelopmentExpenseCurrent_lbl" />
    <link:loc xlink:href="freq-20201231.xsd#freq_PrepaidAccountsReceivableCurrent" xlink:type="locator" xlink:label="freq_PrepaidAccountsReceivableCurrent" />
    <link:label xml:lang="en-US" xlink:label="freq_PrepaidAccountsReceivableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid accounts receivable current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_PrepaidAccountsReceivableCurrent" xlink:to="freq_PrepaidAccountsReceivableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_PrepaidRentAndDepositsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent and deposits</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_PrepaidRentAndDepositsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Rent And Deposits Current</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_PrepaidResearchAndDevelopmentExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_PrepaidResearchAndDevelopmentExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Research And Development Expense Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantsReceivableCurrent" xlink:type="locator" xlink:label="us-gaap_GrantsReceivableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GrantsReceivableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivableCurrent" xlink:to="us-gaap_GrantsReceivableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GrantsReceivableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Grants Receivable Current</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_PrepaidAccountsReceivableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_PrepaidAccountsReceivableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Accounts Receivable Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance" xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Insurance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Insurance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lab Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Office Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Software</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Software And Software Development Costs [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in Progress</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Construction In Progress [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation expense</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent" xlink:type="locator" xlink:label="freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent" />
    <link:label xml:lang="en-US" xlink:label="freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued third-party research and development expenses current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent" xlink:to="freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent_lbl" />
    <link:loc xlink:href="freq-20201231.xsd#freq_AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="freq_AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="freq_AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued income taxes and other accrued liabilities, current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent" xlink:to="freq_AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payroll and employee related expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees Current</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Third-party research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Third Party Research And Development Expenses Current</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Taxes and other</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Income Taxes And Other Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_DebtInstrumentFloorInterestRatePercentage" xlink:type="locator" xlink:label="freq_DebtInstrumentFloorInterestRatePercentage" />
    <link:label xml:lang="en-US" xlink:label="freq_DebtInstrumentFloorInterestRatePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument floor interest rate percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_DebtInstrumentFloorInterestRatePercentage" xlink:to="freq_DebtInstrumentFloorInterestRatePercentage_lbl" />
    <link:loc xlink:href="freq-20201231.xsd#freq_DebtInstrumentInterestOnlyPaymentMaturityDate" xlink:type="locator" xlink:label="freq_DebtInstrumentInterestOnlyPaymentMaturityDate" />
    <link:label xml:lang="en-US" xlink:label="freq_DebtInstrumentInterestOnlyPaymentMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument interest only payment maturity date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_DebtInstrumentInterestOnlyPaymentMaturityDate" xlink:to="freq_DebtInstrumentInterestOnlyPaymentMaturityDate_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_LoanAndSecurityAgreementMember" xlink:type="locator" xlink:label="freq_LoanAndSecurityAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="freq_LoanAndSecurityAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Loan and security agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_LoanAndSecurityAgreementMember" xlink:to="freq_LoanAndSecurityAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_LoanAndSecurityAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_LoanAndSecurityAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loan And Security Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Longterm Debt Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Longterm Debt Type [Domain]</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_TermLoanMember" xlink:type="locator" xlink:label="freq_TermLoanMember" />
    <link:label xml:lang="en-US" xlink:label="freq_TermLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_TermLoanMember" xlink:to="freq_TermLoanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_TermLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_TermLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:type="locator" xlink:label="us-gaap_VariableRateAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:type="locator" xlink:label="us-gaap_VariableRateDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember" xlink:type="locator" xlink:label="us-gaap_PrimeRateMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrimeRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prime Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrimeRateMember" xlink:to="us-gaap_PrimeRateMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrimeRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prime Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Name [Domain]</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMember" xlink:type="locator" xlink:label="freq_PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMember" />
    <link:label xml:lang="en-US" xlink:label="freq_PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepayment Occurs on or Prior to First Anniversary of Closing Date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMember" xlink:to="freq_PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayment Occurs on or Prior to First Anniversary of Closing Date</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepayment Occurs On Or Prior To First Anniversary Of Closing Date [Member]</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMember" xlink:type="locator" xlink:label="freq_PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMember" />
    <link:label xml:lang="en-US" xlink:label="freq_PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepayment Occurs After First Anniversary of Closing Date and On or Prior to Second Anniversary of Closing Date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMember" xlink:to="freq_PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayment Occurs After First Anniversary of Closing Date and On or Prior to Second Anniversary of Closing Date</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepayment Occurs After First Anniversary Of Closing Date And On Or Prior To Second Anniversary Of Closing Date [Member]</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_PrepaymentOccursAfterSecondAnniversaryOfClosingDateMember" xlink:type="locator" xlink:label="freq_PrepaymentOccursAfterSecondAnniversaryOfClosingDateMember" />
    <link:label xml:lang="en-US" xlink:label="freq_PrepaymentOccursAfterSecondAnniversaryOfClosingDateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepayment Occurs After Second Anniversary of Closing Date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_PrepaymentOccursAfterSecondAnniversaryOfClosingDateMember" xlink:to="freq_PrepaymentOccursAfterSecondAnniversaryOfClosingDateMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_PrepaymentOccursAfterSecondAnniversaryOfClosingDateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayment Occurs After Second Anniversary of Closing Date</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_PrepaymentOccursAfterSecondAnniversaryOfClosingDateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepayment Occurs After Second Anniversary Of Closing Date [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principal balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Face Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPaymentTerms" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentPaymentTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment terms, description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPaymentTerms" xlink:to="us-gaap_DebtInstrumentPaymentTerms_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentPaymentTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Payment Terms</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Frequency of interest-only payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:to="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Frequency Of Periodic Payment</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_DebtInstrumentInterestOnlyPaymentMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Monthly interest only payments due</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_DebtInstrumentInterestOnlyPaymentMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Interest Only Payment Maturity Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan maturity date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Maturity Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, Interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Basis Spread On Variable Rate1</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_DebtInstrumentFloorInterestRatePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest rate floor percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_DebtInstrumentFloorInterestRatePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Floor Interest Rate Percentage</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_DebtInstrumentPrepaymentPremiumPercentage" xlink:type="locator" xlink:label="freq_DebtInstrumentPrepaymentPremiumPercentage" />
    <link:label xml:lang="en-US" xlink:label="freq_DebtInstrumentPrepaymentPremiumPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument prepayment premium percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_DebtInstrumentPrepaymentPremiumPercentage" xlink:to="freq_DebtInstrumentPrepaymentPremiumPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_DebtInstrumentPrepaymentPremiumPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument prepayment premium percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_DebtInstrumentPrepaymentPremiumPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Prepayment Premium Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument final payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Periodic Payment Terms Balloon Payment To Be Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity By Class Of Stock [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity By Class Of Stock [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_SeriesAConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series A Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_SeriesBConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series B Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_SeriesCConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series C Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_SeriesA1ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series A-1 Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_SeriesB1ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series B-1 Preferred Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, issued shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, authorized shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, net proceeds from shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Carrying Amount Attributable To Parent</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_PercentageOfVoteOfHoldersOfPreferredStock" xlink:type="locator" xlink:label="freq_PercentageOfVoteOfHoldersOfPreferredStock" />
    <link:label xml:lang="en-US" xlink:label="freq_PercentageOfVoteOfHoldersOfPreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of vote of the holders of preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_PercentageOfVoteOfHoldersOfPreferredStock" xlink:to="freq_PercentageOfVoteOfHoldersOfPreferredStock_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock By Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidated Entities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidated Entities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ConsolidatedEntitiesDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SubsidiariesMember" xlink:type="locator" xlink:label="srt_SubsidiariesMember" />
    <link:label xml:lang="en-US" xlink:label="srt_SubsidiariesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Frequency Japan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SubsidiariesMember" xlink:to="srt_SubsidiariesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_SubsidiariesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiaries [Member]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:label xml:lang="en-US" xlink:label="dei_LegalEntityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LegalEntityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_DelawareLimitedLiabilityCompanyMember" xlink:type="locator" xlink:label="freq_DelawareLimitedLiabilityCompanyMember" />
    <link:label xml:lang="en-US" xlink:label="freq_DelawareLimitedLiabilityCompanyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Delaware Limited Liability Company.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_DelawareLimitedLiabilityCompanyMember" xlink:to="freq_DelawareLimitedLiabilityCompanyMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_DelawareLimitedLiabilityCompanyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LLC(FT-FJ)</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_DelawareLimitedLiabilityCompanyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Delaware Limited Liability Company [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible preferred Stock, shares issued upon conversion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Shares Issued Upon Conversion</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_PercentageOfVoteOfHoldersOfPreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Voting percentage of preferred stock holder</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_PercentageOfVoteOfHoldersOfPreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Vote Of Holders Of Preferred Stock</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_PreferredStockSharesPurchased" xlink:type="locator" xlink:label="freq_PreferredStockSharesPurchased" />
    <link:label xml:lang="en-US" xlink:label="freq_PreferredStockSharesPurchased_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock, shares purchased.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_PreferredStockSharesPurchased" xlink:to="freq_PreferredStockSharesPurchased_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_PreferredStockSharesPurchased_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares purchased</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_PreferredStockSharesPurchased_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Purchased</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockVotingRights" xlink:type="locator" xlink:label="us-gaap_PreferredStockVotingRights" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockVotingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, voting rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockVotingRights" xlink:to="us-gaap_PreferredStockVotingRights_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockVotingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Voting Rights</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred Stock, value per share</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, outstanding shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:type="locator" xlink:label="us-gaap_StockCompensationPlanMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Available for Future Grant Under Stock Option Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockCompensationPlanMember" xlink:to="us-gaap_StockCompensationPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Compensation Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares of common stock reserved for future issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_TwoThousandAndFourteenStockIncentivePlanMember" xlink:type="locator" xlink:label="freq_TwoThousandAndFourteenStockIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="freq_TwoThousandAndFourteenStockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and fourteen stock incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_TwoThousandAndFourteenStockIncentivePlanMember" xlink:to="freq_TwoThousandAndFourteenStockIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_TwoThousandAndFourteenStockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2014 Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_TwoThousandAndFourteenStockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Fourteen Stock Incentive Plan [Member]</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_TwoThousandAndNineteenIncentiveAwardPlanMember" xlink:type="locator" xlink:label="freq_TwoThousandAndNineteenIncentiveAwardPlanMember" />
    <link:label xml:lang="en-US" xlink:label="freq_TwoThousandAndNineteenIncentiveAwardPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and nineteen incentive award plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_TwoThousandAndNineteenIncentiveAwardPlanMember" xlink:to="freq_TwoThousandAndNineteenIncentiveAwardPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_TwoThousandAndNineteenIncentiveAwardPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_TwoThousandAndNineteenIncentiveAwardPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Nineteen Incentive Award Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares reserved for issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares available for future grants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" xlink:type="locator" xlink:label="freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Period for automatic increase in common stock available for future issuance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" xlink:to="freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of authorized shares reserved for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period for automatic increase in common stock available for future issuance</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Period For Automatic Increase In Common Stock Available For Future Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of shares issued from outstanding number of shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock future issuance, description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Description</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options expiration period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of shares, Beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares, Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares, Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of shares, Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, Options exercisable as of December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, Options unvested as of December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted average exercise price, Beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average exercise price, Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Options exercisable as of December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Options unvested as of December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term (in years), Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term (in years), Options exercisable as of December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, Options exercisable as of December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, Options unvested as of December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate intrinsic value of stock options exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant date fair value of stock options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total grant date fair value of stock options vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of shares, Unvested, December 31, 2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, Awarded</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares, Vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of shares, Unvested, December 31, 2020</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted average fair value, Unvested, December 31, 2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average fair value, Awarded</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average fair value, Vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average fair value, Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average fair value, Unvested, December 31, 2020</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total value of restricted stock awards, vested based on estimated fair value of stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total unrecognized stock-based compensation expense relating to unvested stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized unvested stock options, weighted-average period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_PercentageOfEligibleEmployeeCompensation" xlink:type="locator" xlink:label="freq_PercentageOfEligibleEmployeeCompensation" />
    <link:label xml:lang="en-US" xlink:label="freq_PercentageOfEligibleEmployeeCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of eligible employee compensation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_PercentageOfEligibleEmployeeCompensation" xlink:to="freq_PercentageOfEligibleEmployeeCompensation_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Employee Stock Purchase Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_PercentageOfEligibleEmployeeCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of eligible employee compensation</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_PercentageOfEligibleEmployeeCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Eligible Employee Compensation</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Period for automatic increase in common available for future issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_IncomeTaxesDisclosureLineItems" xlink:type="locator" xlink:label="freq_IncomeTaxesDisclosureLineItems" />
    <link:label xml:lang="en-US" xlink:label="freq_IncomeTaxesDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="freq_IncomeTaxesDisclosureLineItems_lbl" />
    <link:loc xlink:href="freq-20201231.xsd#freq_IncomeTaxesDisclosureTable" xlink:type="locator" xlink:label="freq_IncomeTaxesDisclosureTable" />
    <link:label xml:lang="en-US" xlink:label="freq_IncomeTaxesDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_IncomeTaxesDisclosureTable" xlink:to="freq_IncomeTaxesDisclosureTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_IncomeTaxesDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_IncomeTaxesDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Disclosure [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Country [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">State And Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_MA" xlink:type="locator" xlink:label="stpr_MA" />
    <link:label xml:lang="en-US" xlink:label="stpr_MA_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Massachusetts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_MA" xlink:to="stpr_MA_lbl" />
    <link:label xml:lang="en-US" xlink:label="stpr_MA_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">MASSACHUSETTS</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember" xlink:type="locator" xlink:label="us-gaap_ResearchMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:type="locator" xlink:label="us-gaap_InternalRevenueServiceIRSMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InternalRevenueServiceIRSMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Internal Revenue Service</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InternalRevenueServiceIRSMember" xlink:to="us-gaap_InternalRevenueServiceIRSMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InternalRevenueServiceIRSMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Internal Revenue Service I R S [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_IncomeTaxesDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_IncomeTaxesDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net tax benefit</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_TaxCreditCarryforwardExpirationYear" xlink:type="locator" xlink:label="freq_TaxCreditCarryforwardExpirationYear" />
    <link:label xml:lang="en-US" xlink:label="freq_TaxCreditCarryforwardExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carryforward expiration year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_TaxCreditCarryforwardExpirationYear" xlink:to="freq_TaxCreditCarryforwardExpirationYear_lbl" />
    <link:loc xlink:href="freq-20201231.xsd#freq_NetOperatingLossCarryforwardsExpirationWithLimitation" xlink:type="locator" xlink:label="freq_NetOperatingLossCarryforwardsExpirationWithLimitation" />
    <link:label xml:lang="en-US" xlink:label="freq_NetOperatingLossCarryforwardsExpirationWithLimitation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Net operating loss carryforwards expiration with limitation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_NetOperatingLossCarryforwardsExpirationWithLimitation" xlink:to="freq_NetOperatingLossCarryforwardsExpirationWithLimitation_lbl" />
    <link:loc xlink:href="freq-20201231.xsd#freq_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="freq_OperatingLossCarryforwardsExpirationYear" />
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_OperatingLossCarryforwardsExpirationYear" xlink:to="freq_OperatingLossCarryforwardsExpirationYear_lbl" />
    <link:loc xlink:href="freq-20201231.xsd#freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation" xlink:type="locator" xlink:label="freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation" />
    <link:label xml:lang="en-US" xlink:label="freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Net operating loss carryforwards expiration without limitation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation" xlink:to="freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_NetOperatingLossCarryforwardsExpirationWithLimitation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards expire through 2037</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_NetOperatingLossCarryforwardsExpirationWithLimitation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Operating Loss Carryforwards Expiration With Limitation</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards expiration year</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards without expiration</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Operating Loss Carryforwards Expiration Without Limitation</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_TaxCreditCarryforwardExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards expiration year</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_TaxCreditCarryforwardExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Expiration Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Amount</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_OperatingLossCarryforwardsUsageAfterOwnershipChange" xlink:type="locator" xlink:label="freq_OperatingLossCarryforwardsUsageAfterOwnershipChange" />
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLossCarryforwardsUsageAfterOwnershipChange_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Loss Carryforwards Usage After Ownership Change.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_OperatingLossCarryforwardsUsageAfterOwnershipChange" xlink:to="freq_OperatingLossCarryforwardsUsageAfterOwnershipChange_lbl" />
    <link:loc xlink:href="freq-20201231.xsd#freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange" xlink:type="locator" xlink:label="freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange" />
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards annual usage for next each five years after ownership change.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange" xlink:to="freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange_lbl" />
    <link:loc xlink:href="freq-20201231.xsd#freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange" xlink:type="locator" xlink:label="freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange" />
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards annual usage for next each after five years and thereafter after ownership change.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange" xlink:to="freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange_lbl" />
    <link:loc xlink:href="freq-20201231.xsd#freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration" xlink:type="locator" xlink:label="freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration" />
    <link:label xml:lang="en-US" xlink:label="freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining pre ownership change in operating loss carryforwards written off due to expiration.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration" xlink:to="freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration_lbl" />
    <link:loc xlink:href="freq-20201231.xsd#freq_CumulativeChangeInOwnershipPercentage" xlink:type="locator" xlink:label="freq_CumulativeChangeInOwnershipPercentage" />
    <link:label xml:lang="en-US" xlink:label="freq_CumulativeChangeInOwnershipPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cumulative change in ownership percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_CumulativeChangeInOwnershipPercentage" xlink:to="freq_CumulativeChangeInOwnershipPercentage_lbl" />
    <link:loc xlink:href="freq-20201231.xsd#freq_PeriodOfCumulativeChangeInOwnership" xlink:type="locator" xlink:label="freq_PeriodOfCumulativeChangeInOwnership" />
    <link:label xml:lang="en-US" xlink:label="freq_PeriodOfCumulativeChangeInOwnership_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Period of cumulative change in ownership.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_PeriodOfCumulativeChangeInOwnership" xlink:to="freq_PeriodOfCumulativeChangeInOwnership_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_CumulativeChangeInOwnershipPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative change in ownership percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_CumulativeChangeInOwnershipPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Change In Ownership Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_PeriodOfCumulativeChangeInOwnership_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period of cumulative change in ownership</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_PeriodOfCumulativeChangeInOwnership_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Period Of Cumulative Change In Ownership</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLossCarryforwardsUsageAfterOwnershipChange_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards, utilization after ownership change</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLossCarryforwardsUsageAfterOwnershipChange_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Usage After Ownership Change</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating loss carryforwards, utilization after five years after ownership change</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Annual Usage For Next Each Five Years After Ownership Change</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards, utilization after 15 years thereafter after ownership change</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Annual Usage For Next Each After Five Years And Thereafter After Ownership Change</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining pre ownership change in operating loss carryforwards written off due to expiration</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Remaining Pre Ownership Change In Operating Loss Carryforwards Written Off Due To Expiration</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal and state deferred tax benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal State And Local Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and penalties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Income Tax Penalties And Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Domestic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Domestic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Foreign</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="locator" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal State And Local Tax Expense Benefit [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current State And Local Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Foreign Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal State And Local Tax Expense Benefit [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred State And Local Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Foreign Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Deferred</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense Benefit</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total provision (benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S federal statutory income tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent differences</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income taxes, net of federal benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation State And Local Income Taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Tax Credits Research</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock compensation deductions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other items</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Other Reconciling Items Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in deferred tax asset valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective income tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Continuing Operations</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" xlink:type="locator" xlink:label="freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets liabilities property plant and equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" xlink:to="freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_lbl" />
    <link:loc xlink:href="freq-20201231.xsd#freq_DeferredTaxAssetsLeasingArrangements" xlink:type="locator" xlink:label="freq_DeferredTaxAssetsLeasingArrangements" />
    <link:label xml:lang="en-US" xlink:label="freq_DeferredTaxAssetsLeasingArrangements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets leasing arrangements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_DeferredTaxAssetsLeasingArrangements" xlink:to="freq_DeferredTaxAssetsLeasingArrangements_lbl" />
    <link:loc xlink:href="freq-20201231.xsd#freq_DeferredTaxAssetsRightOfUseAssets" xlink:type="locator" xlink:label="freq_DeferredTaxAssetsRightOfUseAssets" />
    <link:label xml:lang="en-US" xlink:label="freq_DeferredTaxAssetsRightOfUseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets right of use assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_DeferredTaxAssetsRightOfUseAssets" xlink:to="freq_DeferredTaxAssetsRightOfUseAssets_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards Research</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangibles</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Goodwill And Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Deferred Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Other</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed assets</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Liabilities Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_DeferredTaxAssetsLeasingArrangements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_DeferredTaxAssetsLeasingArrangements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Leasing Arrangements</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_DeferredTaxAssetsRightOfUseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Right of use asset</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_DeferredTaxAssetsRightOfUseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Right Of Use Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_LicenseAgreementEnteredDate" xlink:type="locator" xlink:label="freq_LicenseAgreementEnteredDate" />
    <link:label xml:lang="en-US" xlink:label="freq_LicenseAgreementEnteredDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement entered date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_LicenseAgreementEnteredDate" xlink:to="freq_LicenseAgreementEnteredDate_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_MassachusettsInstituteOfTechnologyMember" xlink:type="locator" xlink:label="freq_MassachusettsInstituteOfTechnologyMember" />
    <link:label xml:lang="en-US" xlink:label="freq_MassachusettsInstituteOfTechnologyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Massachusetts Institute of Technology.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_MassachusettsInstituteOfTechnologyMember" xlink:to="freq_MassachusettsInstituteOfTechnologyMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_MassachusettsInstituteOfTechnologyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MIT</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_MassachusettsInstituteOfTechnologyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Massachusetts Institute Of Technology [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets By Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Major Class Name [Domain]</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_PatentLicenseAgreementMember" xlink:type="locator" xlink:label="freq_PatentLicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="freq_PatentLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Patent license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_PatentLicenseAgreementMember" xlink:to="freq_PatentLicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_PatentLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patent License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_PatentLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Patent License Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Agreement Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_AstellasPharmaLimitedLiabilityCompanyMember" xlink:type="locator" xlink:label="freq_AstellasPharmaLimitedLiabilityCompanyMember" />
    <link:label xml:lang="en-US" xlink:label="freq_AstellasPharmaLimitedLiabilityCompanyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Astellas pharma limited liability company.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_AstellasPharmaLimitedLiabilityCompanyMember" xlink:to="freq_AstellasPharmaLimitedLiabilityCompanyMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_AstellasPharmaLimitedLiabilityCompanyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Astellas Pharma LLC</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_AstellasPharmaLimitedLiabilityCompanyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Astellas Pharma Limited Liability Company [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product Or Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Products And Services [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember" xlink:type="locator" xlink:label="us-gaap_RoyaltyMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RoyaltyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyMember" xlink:to="us-gaap_RoyaltyMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RoyaltyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Royalty [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual With Relationship To Entity [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:type="locator" xlink:label="srt_DirectorMember" />
    <link:label xml:lang="en-US" xlink:label="srt_DirectorMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dr. Langer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_DirectorMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Director [Member]</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_CaliforniaInstituteForBiomedicalResearchMember" xlink:type="locator" xlink:label="freq_CaliforniaInstituteForBiomedicalResearchMember" />
    <link:label xml:lang="en-US" xlink:label="freq_CaliforniaInstituteForBiomedicalResearchMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">California Institute for Biomedical Research.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_CaliforniaInstituteForBiomedicalResearchMember" xlink:to="freq_CaliforniaInstituteForBiomedicalResearchMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_CaliforniaInstituteForBiomedicalResearchMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CALIBR</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_CaliforniaInstituteForBiomedicalResearchMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">California Institute For Biomedical Research [Member]</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_ScrippsOptionAgreementMember" xlink:type="locator" xlink:label="freq_ScrippsOptionAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="freq_ScrippsOptionAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Scripps option agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_ScrippsOptionAgreementMember" xlink:to="freq_ScrippsOptionAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_ScrippsOptionAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scripps Option Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_ScrippsOptionAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Scripps Option Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:type="locator" xlink:label="srt_StatementScenarioAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementScenarioAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementScenarioAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Scenario [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Scenario Unspecified [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember" xlink:type="locator" xlink:label="srt_ScenarioForecastMember" />
    <link:label xml:lang="en-US" xlink:label="srt_ScenarioForecastMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario Forecast</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ScenarioForecastMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Scenario Forecast [Member]</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_NonExclusivePatentLicenseAgreementMember" xlink:type="locator" xlink:label="freq_NonExclusivePatentLicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="freq_NonExclusivePatentLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-exclusive patent license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_NonExclusivePatentLicenseAgreementMember" xlink:to="freq_NonExclusivePatentLicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_NonExclusivePatentLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-Exclusive Patent License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_NonExclusivePatentLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Exclusive Patent License Agreement [Member]</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_MassachusettsEyeAndEarMember" xlink:type="locator" xlink:label="freq_MassachusettsEyeAndEarMember" />
    <link:label xml:lang="en-US" xlink:label="freq_MassachusettsEyeAndEarMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Massachusetts eye and ear.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_MassachusettsEyeAndEarMember" xlink:to="freq_MassachusettsEyeAndEarMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_MassachusettsEyeAndEarMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MEE</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_MassachusettsEyeAndEarMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Massachusetts Eye And Ear [Member]</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_CambridgeEnterpriseLimitedMember" xlink:type="locator" xlink:label="freq_CambridgeEnterpriseLimitedMember" />
    <link:label xml:lang="en-US" xlink:label="freq_CambridgeEnterpriseLimitedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cambridge Enterprise Limited.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_CambridgeEnterpriseLimitedMember" xlink:to="freq_CambridgeEnterpriseLimitedMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_CambridgeEnterpriseLimitedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cambridge</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_CambridgeEnterpriseLimitedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cambridge Enterprise Limited [Member]</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_ResearchAndDevelopmentMember" xlink:type="locator" xlink:label="freq_ResearchAndDevelopmentMember" />
    <link:label xml:lang="en-US" xlink:label="freq_ResearchAndDevelopmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and Development.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_ResearchAndDevelopmentMember" xlink:to="freq_ResearchAndDevelopmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_ResearchAndDevelopmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_ResearchAndDevelopmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember" xlink:type="locator" xlink:label="us-gaap_GrantMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantMember" xlink:to="us-gaap_GrantMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Grant [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research And Development Arrangement Contract To Perform For Others [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_LicenseAgreementEnteredDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement entered date</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_LicenseAgreementEnteredDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Entered Date</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_DescriptionOfFutureDevelopmentObligations" xlink:type="locator" xlink:label="freq_DescriptionOfFutureDevelopmentObligations" />
    <link:label xml:lang="en-US" xlink:label="freq_DescriptionOfFutureDevelopmentObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of future development obligations.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_DescriptionOfFutureDevelopmentObligations" xlink:to="freq_DescriptionOfFutureDevelopmentObligations_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_DescriptionOfFutureDevelopmentObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of future development obligations</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_DescriptionOfFutureDevelopmentObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Future Development Obligations</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_LicenseFeePayment" xlink:type="locator" xlink:label="freq_LicenseFeePayment" />
    <link:label xml:lang="en-US" xlink:label="freq_LicenseFeePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License fee payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_LicenseFeePayment" xlink:to="freq_LicenseFeePayment_lbl" />
    <link:loc xlink:href="freq-20201231.xsd#freq_PercentageOfSharesOfCommonStockIssued" xlink:type="locator" xlink:label="freq_PercentageOfSharesOfCommonStockIssued" />
    <link:label xml:lang="en-US" xlink:label="freq_PercentageOfSharesOfCommonStockIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of shares of common stock issued.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_PercentageOfSharesOfCommonStockIssued" xlink:to="freq_PercentageOfSharesOfCommonStockIssued_lbl" />
    <link:loc xlink:href="freq-20201231.xsd#freq_MilestonePayments" xlink:type="locator" xlink:label="freq_MilestonePayments" />
    <link:label xml:lang="en-US" xlink:label="freq_MilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_MilestonePayments" xlink:to="freq_MilestonePayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_LicenseFeePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License fee payment</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_LicenseFeePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Fee Payment</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_PercentageOfSharesOfCommonStockIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of shares of common stock issued</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_PercentageOfSharesOfCommonStockIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Shares Of Common Stock Issued</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_MilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_MilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_RightToTerminateAgreementUponPriorWrittenNotice" xlink:type="locator" xlink:label="freq_RightToTerminateAgreementUponPriorWrittenNotice" />
    <link:label xml:lang="en-US" xlink:label="freq_RightToTerminateAgreementUponPriorWrittenNotice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Right to terminate agreement upon prior written notice.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_RightToTerminateAgreementUponPriorWrittenNotice" xlink:to="freq_RightToTerminateAgreementUponPriorWrittenNotice_lbl" />
    <link:loc xlink:href="freq-20201231.xsd#freq_RightToTerminateAgreementIfBreachRemainsUncured" xlink:type="locator" xlink:label="freq_RightToTerminateAgreementIfBreachRemainsUncured" />
    <link:label xml:lang="en-US" xlink:label="freq_RightToTerminateAgreementIfBreachRemainsUncured_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Right to terminate agreement if breach remains uncured.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_RightToTerminateAgreementIfBreachRemainsUncured" xlink:to="freq_RightToTerminateAgreementIfBreachRemainsUncured_lbl" />
    <link:loc xlink:href="freq-20201231.xsd#freq_RightToTerminateAgreementIncaseOfNonpayment" xlink:type="locator" xlink:label="freq_RightToTerminateAgreementIncaseOfNonpayment" />
    <link:label xml:lang="en-US" xlink:label="freq_RightToTerminateAgreementIncaseOfNonpayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Right to terminate agreement incase of nonpayment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_RightToTerminateAgreementIncaseOfNonpayment" xlink:to="freq_RightToTerminateAgreementIncaseOfNonpayment_lbl" />
    <link:loc xlink:href="freq-20201231.xsd#freq_DescriptionOfConditionsToTerminateLicenseAgreement" xlink:type="locator" xlink:label="freq_DescriptionOfConditionsToTerminateLicenseAgreement" />
    <link:label xml:lang="en-US" xlink:label="freq_DescriptionOfConditionsToTerminateLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of conditions to terminate license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_DescriptionOfConditionsToTerminateLicenseAgreement" xlink:to="freq_DescriptionOfConditionsToTerminateLicenseAgreement_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_DescriptionOfConditionsToTerminateLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of conditions to terminate license agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_DescriptionOfConditionsToTerminateLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Conditions To Terminate License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_RightToTerminateAgreementUponPriorWrittenNotice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right to terminate agreement upon prior written notice</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_RightToTerminateAgreementUponPriorWrittenNotice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Right To Terminate Agreement Upon Prior Written Notice</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_RightToTerminateAgreementIfBreachRemainsUncured_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right to terminate agreement if breach remains uncured</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_RightToTerminateAgreementIfBreachRemainsUncured_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Right To Terminate Agreement If Breach Remains Uncured</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_RightToTerminateAgreementIncaseOfNonpayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right to terminate agreement incase of nonpayment</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_RightToTerminateAgreementIncaseOfNonpayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Right To Terminate Agreement Incase Of Nonpayment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForManagementFee" xlink:type="locator" xlink:label="us-gaap_PaymentForManagementFee" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentForManagementFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment to director</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentForManagementFee" xlink:to="us-gaap_PaymentForManagementFee_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentForManagementFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payment For Management Fee</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice" xlink:type="locator" xlink:label="freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice" />
    <link:label xml:lang="en-US" xlink:label="freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Right to terminate licensed patents upon prior written notice.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice" xlink:to="freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right to terminate licensed patents upon prior written notice</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Right To Terminate Licensed Patents Upon Prior Written Notice</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_FundingPaymentsMadeAsConsiderationToSupportResearchActivities" xlink:type="locator" xlink:label="freq_FundingPaymentsMadeAsConsiderationToSupportResearchActivities" />
    <link:label xml:lang="en-US" xlink:label="freq_FundingPaymentsMadeAsConsiderationToSupportResearchActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Funding payments made as consideration to support research activities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_FundingPaymentsMadeAsConsiderationToSupportResearchActivities" xlink:to="freq_FundingPaymentsMadeAsConsiderationToSupportResearchActivities_lbl" />
    <link:loc xlink:href="freq-20201231.xsd#freq_TermOfAgreement" xlink:type="locator" xlink:label="freq_TermOfAgreement" />
    <link:label xml:lang="en-US" xlink:label="freq_TermOfAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Term of agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_TermOfAgreement" xlink:to="freq_TermOfAgreement_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_FundingPaymentsMadeAsConsiderationToSupportResearchActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Funding payments as consideration to support research activities</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_FundingPaymentsMadeAsConsiderationToSupportResearchActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Funding Payments Made As Consideration To Support Research Activities</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_TermOfAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement term</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_TermOfAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Term Of Agreement</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_LicenseAgreementExtendedDate" xlink:type="locator" xlink:label="freq_LicenseAgreementExtendedDate" />
    <link:label xml:lang="en-US" xlink:label="freq_LicenseAgreementExtendedDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement extended date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_LicenseAgreementExtendedDate" xlink:to="freq_LicenseAgreementExtendedDate_lbl" />
    <link:loc xlink:href="freq-20201231.xsd#freq_AdditionalFundingPaymentsMadeAsConsiderationToSupportResearchActivities" xlink:type="locator" xlink:label="freq_AdditionalFundingPaymentsMadeAsConsiderationToSupportResearchActivities" />
    <link:label xml:lang="en-US" xlink:label="freq_AdditionalFundingPaymentsMadeAsConsiderationToSupportResearchActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional funding payments made as consideration to support research activities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_AdditionalFundingPaymentsMadeAsConsiderationToSupportResearchActivities" xlink:to="freq_AdditionalFundingPaymentsMadeAsConsiderationToSupportResearchActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_LicenseAgreementExtendedDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement extended date</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_LicenseAgreementExtendedDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Extended Date</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_AdditionalFundingPaymentsMadeAsConsiderationToSupportResearchActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional funding payments made as consideration to support research activities</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_AdditionalFundingPaymentsMadeAsConsiderationToSupportResearchActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Funding Payments Made As Consideration To Support Research Activities</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent" xlink:type="locator" xlink:label="freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent" />
    <link:label xml:lang="en-US" xlink:label="freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Right to terminate agreement upon prior written notice if insolvent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent" xlink:to="freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right to terminate agreement upon prior written notice if insolvent</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Right To Terminate Agreement Upon Prior Written Notice If Insolvent</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_AnnualLicenseFee" xlink:type="locator" xlink:label="freq_AnnualLicenseFee" />
    <link:label xml:lang="en-US" xlink:label="freq_AnnualLicenseFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual license fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_AnnualLicenseFee" xlink:to="freq_AnnualLicenseFee_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_AnnualLicenseFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual license fee</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_AnnualLicenseFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Annual License Fee</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="freq_IncreaseDecreaseInResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="freq_IncreaseDecreaseInResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in research and development expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:to="freq_IncreaseDecreaseInResearchAndDevelopmentExpense_lbl" />
    <link:loc xlink:href="freq-20201231.xsd#freq_AmountOfFundingReceivedAsGrant" xlink:type="locator" xlink:label="freq_AmountOfFundingReceivedAsGrant" />
    <link:label xml:lang="en-US" xlink:label="freq_AmountOfFundingReceivedAsGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of funding received as grant.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_AmountOfFundingReceivedAsGrant" xlink:to="freq_AmountOfFundingReceivedAsGrant_lbl" />
    <link:loc xlink:href="freq-20201231.xsd#freq_GrantTermPeriod" xlink:type="locator" xlink:label="freq_GrantTermPeriod" />
    <link:label xml:lang="en-US" xlink:label="freq_GrantTermPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant term period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_GrantTermPeriod" xlink:to="freq_GrantTermPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_AmountOfFundingReceivedAsGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount of funding received as grant</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_AmountOfFundingReceivedAsGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amount Of Funding Received As Grant</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_GrantTermPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant term period</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_GrantTermPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Grant Term Period</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_IncreaseDecreaseInResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Decrease in research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_IncreaseDecreaseInResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Research And Development Expense</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones" xlink:type="locator" xlink:label="freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones" />
    <link:label xml:lang="en-US" xlink:label="freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer liability revenue recognized from commercialization milestones.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones" xlink:to="freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones_lbl" />
    <link:loc xlink:href="freq-20201231.xsd#freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization" xlink:type="locator" xlink:label="freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization" />
    <link:label xml:lang="en-US" xlink:label="freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue recognition potential commercial milestone payments eligible upon successful commercialization.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization" xlink:to="freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_LicenseAndCollaborationAgreementMember" xlink:type="locator" xlink:label="freq_LicenseAndCollaborationAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="freq_LicenseAndCollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License and collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_LicenseAndCollaborationAgreementMember" xlink:to="freq_LicenseAndCollaborationAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_LicenseAndCollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and Collaboration Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_LicenseAndCollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License And Collaboration Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others Type [Domain]</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_Phase2bClinicalTrialMember" xlink:type="locator" xlink:label="freq_Phase2bClinicalTrialMember" />
    <link:label xml:lang="en-US" xlink:label="freq_Phase2bClinicalTrialMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Phase 2b clinical trial.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_Phase2bClinicalTrialMember" xlink:to="freq_Phase2bClinicalTrialMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_Phase2bClinicalTrialMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Phase 2b Clinical Trial</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_Phase2bClinicalTrialMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Phase2b Clinical Trial [Member]</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_Phase3ClinicalTrailMember" xlink:type="locator" xlink:label="freq_Phase3ClinicalTrailMember" />
    <link:label xml:lang="en-US" xlink:label="freq_Phase3ClinicalTrailMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Phase 3 clinical trail.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_Phase3ClinicalTrailMember" xlink:to="freq_Phase3ClinicalTrailMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_Phase3ClinicalTrailMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Phase 3 Clinical Trial</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_Phase3ClinicalTrailMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Phase3 Clinical Trail [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:type="locator" xlink:label="srt_EuropeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_EuropeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Europe</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EuropeMember" xlink:to="srt_EuropeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_EuropeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Europe [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AsiaMember" xlink:type="locator" xlink:label="srt_AsiaMember" />
    <link:label xml:lang="en-US" xlink:label="srt_AsiaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asia</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_AsiaMember" xlink:to="srt_AsiaMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_AsiaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asia [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" xlink:label="us-gaap_ProceedsFromCollaborators" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromCollaborators_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments received under collaboration agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCollaborators" xlink:to="us-gaap_ProceedsFromCollaborators_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromCollaborators_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Collaborators</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognized potential development milestone payments to receive</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Revenue Recognized</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognized commercialization milestone payments to receive</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Revenue Recognized From Commercialization Milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential commercial milestone payments eligible to receive upon successful commercialization</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Potential Commercial Milestone Payments Eligible Upon Successful Commercialization</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_AgreementTerminationNoticePeriod" xlink:type="locator" xlink:label="freq_AgreementTerminationNoticePeriod" />
    <link:label xml:lang="en-US" xlink:label="freq_AgreementTerminationNoticePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement termination notice period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_AgreementTerminationNoticePeriod" xlink:to="freq_AgreementTerminationNoticePeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_AgreementTerminationNoticePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement termination notice period</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_AgreementTerminationNoticePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Termination Notice Period</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_RevenueRecognitionTransactionPrice" xlink:type="locator" xlink:label="freq_RevenueRecognitionTransactionPrice" />
    <link:label xml:lang="en-US" xlink:label="freq_RevenueRecognitionTransactionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue recognition transaction price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_RevenueRecognitionTransactionPrice" xlink:to="freq_RevenueRecognitionTransactionPrice_lbl" />
    <link:loc xlink:href="freq-20201231.xsd#freq_UpfrontFeeRecognizedAsRevenue" xlink:type="locator" xlink:label="freq_UpfrontFeeRecognizedAsRevenue" />
    <link:label xml:lang="en-US" xlink:label="freq_UpfrontFeeRecognizedAsRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront fee recognized as revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_UpfrontFeeRecognizedAsRevenue" xlink:to="freq_UpfrontFeeRecognizedAsRevenue_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_RevenueRecognitionTransactionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction price allocated to single combined performance obligation</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_RevenueRecognitionTransactionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Transaction Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedRoyaltiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued upfront payment related to sub License revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Royalties Current</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_UpfrontFeeRecognizedAsRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront fee recognized as revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_UpfrontFeeRecognizedAsRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Fee Recognized As Revenue</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_RevenueFromContractWithCustomerApplicationInputMethod" xlink:type="locator" xlink:label="freq_RevenueFromContractWithCustomerApplicationInputMethod" />
    <link:label xml:lang="en-US" xlink:label="freq_RevenueFromContractWithCustomerApplicationInputMethod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue from contract with customer application input method.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_RevenueFromContractWithCustomerApplicationInputMethod" xlink:to="freq_RevenueFromContractWithCustomerApplicationInputMethod_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_RevenueFromContractWithCustomerApplicationInputMethod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue from contract with customer application input method</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_RevenueFromContractWithCustomerApplicationInputMethod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Application Input Method</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue remaining performance obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Remaining Performance Obligation</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_LeaseExpirationYear" xlink:type="locator" xlink:label="freq_LeaseExpirationYear" />
    <link:label xml:lang="en-US" xlink:label="freq_LeaseExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease expiration year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_LeaseExpirationYear" xlink:to="freq_LeaseExpirationYear_lbl" />
    <link:loc xlink:href="freq-20201231.xsd#freq_OperatingLeaseAgreementAmendedDate" xlink:type="locator" xlink:label="freq_OperatingLeaseAgreementAmendedDate" />
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLeaseAgreementAmendedDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease agreement amended date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_OperatingLeaseAgreementAmendedDate" xlink:to="freq_OperatingLeaseAgreementAmendedDate_lbl" />
    <link:loc xlink:href="freq-20201231.xsd#freq_OperatingLeaseAgreementCommencementDate" xlink:type="locator" xlink:label="freq_OperatingLeaseAgreementCommencementDate" />
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLeaseAgreementCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease agreement commencement date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_OperatingLeaseAgreementCommencementDate" xlink:to="freq_OperatingLeaseAgreementCommencementDate_lbl" />
    <link:loc xlink:href="freq-20201231.xsd#freq_OperatingLeaseAgreementExpirationDate" xlink:type="locator" xlink:label="freq_OperatingLeaseAgreementExpirationDate" />
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLeaseAgreementExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease agreement expiration date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_OperatingLeaseAgreementExpirationDate" xlink:to="freq_OperatingLeaseAgreementExpirationDate_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Lease Description [Table]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CT" xlink:type="locator" xlink:label="stpr_CT" />
    <link:label xml:lang="en-US" xlink:label="stpr_CT_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Connecticut</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CT" xlink:to="stpr_CT_lbl" />
    <link:label xml:lang="en-US" xlink:label="stpr_CT_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">CONNECTICUT</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_LeasesTerminationAgreementMember" xlink:type="locator" xlink:label="freq_LeasesTerminationAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="freq_LeasesTerminationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease termination agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_LeasesTerminationAgreementMember" xlink:to="freq_LeasesTerminationAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_LeasesTerminationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Termination Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_LeasesTerminationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leases Termination Agreement [Member]</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_AREMARegionNo20LLCMember" xlink:type="locator" xlink:label="freq_AREMARegionNo20LLCMember" />
    <link:label xml:lang="en-US" xlink:label="freq_AREMARegionNo20LLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">ARE-MA Region No. 20, LLC.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_AREMARegionNo20LLCMember" xlink:to="freq_AREMARegionNo20LLCMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_AREMARegionNo20LLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ARE-MA Region No. 20, LLC</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_AREMARegionNo20LLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">A R E M A Region No20 L L C [Member]</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_HaydenLLCMember" xlink:type="locator" xlink:label="freq_HaydenLLCMember" />
    <link:label xml:lang="en-US" xlink:label="freq_HaydenLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Hayden LLC.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_HaydenLLCMember" xlink:to="freq_HaydenLLCMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_HaydenLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Hayden LLC</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_HaydenLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Hayden L L C [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_LexingtonLeaseMember" xlink:type="locator" xlink:label="freq_LexingtonLeaseMember" />
    <link:label xml:lang="en-US" xlink:label="freq_LexingtonLeaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lexington lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_LexingtonLeaseMember" xlink:to="freq_LexingtonLeaseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_LexingtonLeaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lexington Lease</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_LexingtonLeaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lexington Lease [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Lease Description [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Term Of Contract</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_LeaseExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease, expiration year</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_LeaseExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease, description of option to extend</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Option To Extend</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLeaseAgreementAmendedDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease agreement amended date</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLeaseAgreementAmendedDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Agreement Amended Date</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLeaseAgreementCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease commencement date</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLeaseAgreementCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Agreement Commencement Date</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLeaseAgreementExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration date</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLeaseAgreementExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Agreement Expiration Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date1</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_OperatingLeaseTerminationFee" xlink:type="locator" xlink:label="freq_OperatingLeaseTerminationFee" />
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLeaseTerminationFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease termination fee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_OperatingLeaseTerminationFee" xlink:to="freq_OperatingLeaseTerminationFee_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLeaseTerminationFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment of fee to landlord</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLeaseTerminationFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Termination Fee</link:label>
    <link:loc xlink:href="freq-20201231.xsd#freq_OperatingLeaseCommencementDate" xlink:type="locator" xlink:label="freq_OperatingLeaseCommencementDate" />
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLeaseCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease commencement date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_OperatingLeaseCommencementDate" xlink:to="freq_OperatingLeaseCommencementDate_lbl" />
    <link:loc xlink:href="freq-20201231.xsd#freq_OperatingLeaseNumberOfAdditionalExtensionTerms" xlink:type="locator" xlink:label="freq_OperatingLeaseNumberOfAdditionalExtensionTerms" />
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLeaseNumberOfAdditionalExtensionTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease number of additional extension terms.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_OperatingLeaseNumberOfAdditionalExtensionTerms" xlink:to="freq_OperatingLeaseNumberOfAdditionalExtensionTerms_lbl" />
    <link:loc xlink:href="freq-20201231.xsd#freq_OperatingLeasesAdditionalExtensionTerm" xlink:type="locator" xlink:label="freq_OperatingLeasesAdditionalExtensionTerm" />
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLeasesAdditionalExtensionTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating leases additional extension term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_OperatingLeasesAdditionalExtensionTerm" xlink:to="freq_OperatingLeasesAdditionalExtensionTerm_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetRentableArea" xlink:type="locator" xlink:label="us-gaap_NetRentableArea" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetRentableArea_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rentable area of office space</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetRentableArea" xlink:to="us-gaap_NetRentableArea_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetRentableArea_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Rentable Area</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLeaseCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease commencement date</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLeaseCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Commencement Date</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLeaseNumberOfAdditionalExtensionTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of additional lease extension terms</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLeaseNumberOfAdditionalExtensionTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Number Of Additional Extension Terms</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLeasesAdditionalExtensionTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease extension term</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLeasesAdditionalExtensionTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Additional Extension Term</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Operating lease ROU assets</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Current lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Non-current lease liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short term lease cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Lease Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Remaining Lease Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Discount Rate Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due After Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total minimum lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: amount of lease payments representing interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Present value of future lease payments</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: current lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel">Noncurrent lease liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Four Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Five Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026 and beyond</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due Thereafter</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total minimum lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitment payments related to research</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentAmount" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Purchase Commitment Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyLossInPeriod" xlink:type="locator" xlink:label="us-gaap_LossContingencyLossInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingencyLossInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Losses related to indemnification obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyLossInPeriod" xlink:to="us-gaap_LossContingencyLossInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingencyLossInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency Loss In Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum percentage of employee contribution to retirement plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Maximum Annual Contributions Per Employee Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of employer matching contribution</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Matching Contribution Percent Of Match</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of employee annual compensation matched by the employer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Matching Contribution Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employers matching contribution vesting percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:to="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employers Matching Contribution Annual Vesting Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employers matching contribution</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_OperatingAndNonOperatingExpensesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_OperatingAndNonOperatingExpensesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating And Non Operating Expenses Net</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>31
<FILENAME>freq-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-26T19:12:56.2461528+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 5da74deaf6894583a1f70c65f38043d1 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/role/TemplateLink" xlink:href="freq-20201231.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="freq-20201231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="freq-20201231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLoansFromBank" xlink:type="locator" xlink:label="us-gaap_LongTermLoansFromBank" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermLoansFromBank" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="freq-20201231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="freq-20201231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDividendsAdjustment" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDividendsAdjustment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:type="locator" xlink:label="us-gaap_RealizedInvestmentGainsLosses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense" xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_RoyaltyExpense" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_RealizedInvestmentGainsLosses" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_TemporaryEquityDividendsAdjustment" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" xlink:href="freq-20201231.xsd#Role_StatementConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/StatementConsolidatedStatementOfConvertiblePreferredStockNonControllingInterestAndStockholderSEquityDeficit" xlink:href="freq-20201231.xsd#Role_StatementConsolidatedStatementOfConvertiblePreferredStockNonControllingInterestAndStockholderSEquityDeficit" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/StatementConsolidatedStatementOfConvertiblePreferredStockNonControllingInterestAndStockholderSEquityDeficit">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="freq-20201231.xsd#freq_StockIssuedDuringPeriodSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" xlink:type="locator" xlink:label="freq_StockIssuedDuringPeriodSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" />
    <link:loc xlink:href="freq-20201231.xsd#freq_TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" xlink:type="locator" xlink:label="freq_TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" />
    <link:loc xlink:href="freq-20201231.xsd#freq_TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" xlink:type="locator" xlink:label="freq_TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" />
    <link:loc xlink:href="freq-20201231.xsd#freq_StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" xlink:type="locator" xlink:label="freq_StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAccretionOfDividends" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAccretionOfDividends" />
    <link:loc xlink:href="freq-20201231.xsd#freq_ConvertiblePreferredStockAccretionOfDividend" xlink:type="locator" xlink:label="freq_ConvertiblePreferredStockAccretionOfDividend" />
    <link:loc xlink:href="freq-20201231.xsd#freq_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="freq_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="freq-20201231.xsd#freq_SeriesA1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesA1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_SeriesB1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesB1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_SeriesCConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesCConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesCConvertiblePreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesBConvertiblePreferredStockMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesB1ConvertiblePreferredStockMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesAConvertiblePreferredStockMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesA1ConvertiblePreferredStockMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" order="11770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="11890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="12130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="12250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="freq_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="12310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="freq_ConvertiblePreferredStockAccretionOfDividend" order="12970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityAccretionOfDividends" order="13330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="13690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="13930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="freq_StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" order="14410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="freq_TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" order="14430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="freq_TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" order="14450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="freq_StockIssuedDuringPeriodSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" order="14650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="14770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="15130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_li0l2" order="15490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_li0l2" order="15850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_li0l2" order="16210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_li0l2" order="16450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="freq-20201231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountIssued1" />
    <link:loc xlink:href="freq-20201231.xsd#freq_NonCashDividendOnCumulativeConvertiblePreferredStock" xlink:type="locator" xlink:label="freq_NonCashDividendOnCumulativeConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="freq-20201231.xsd#freq_DeferredLeaseIncentives" xlink:type="locator" xlink:label="freq_DeferredLeaseIncentives" />
    <link:loc xlink:href="freq-20201231.xsd#freq_NonCashLeaseExpenses" xlink:type="locator" xlink:label="freq_NonCashLeaseExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="freq-20201231.xsd#freq_SeriesCConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesCConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesBConvertiblePreferredStockMember" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesCConvertiblePreferredStockMember" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="freq_NonCashLeaseExpenses" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="freq_DeferredLeaseIncentives" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="11620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="11780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="freq_NonCashDividendOnCumulativeConvertiblePreferredStock" order="11820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_ConversionOfStockAmountIssued1" order="11860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="11900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureOrganizationAndBasisOfPresentation" xlink:href="freq-20201231.xsd#Role_DisclosureOrganizationAndBasisOfPresentation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureOrganizationAndBasisOfPresentation">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="freq-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureFairValueMeasurements" xlink:href="freq-20201231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureFairValueMeasurements">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosurePrepaidExpenses" xlink:href="freq-20201231.xsd#Role_DisclosurePrepaidExpenses" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosurePrepaidExpenses">
    <link:loc xlink:href="freq-20201231.xsd#freq_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:type="locator" xlink:label="freq_PrepaidExpensesAndOtherCurrentAssetsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="freq_PrepaidExpensesAndOtherCurrentAssetsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment" xlink:href="freq-20201231.xsd#Role_DisclosurePropertyAndEquipment" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureAccruedExpenses" xlink:href="freq-20201231.xsd#Role_DisclosureAccruedExpenses" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureAccruedExpenses">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureDebt" xlink:href="freq-20201231.xsd#Role_DisclosureDebt" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureDebt">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStock" xlink:href="freq-20201231.xsd#Role_DisclosureConvertiblePreferredStock" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStock">
    <link:loc xlink:href="freq-20201231.xsd#freq_TemporaryEquityTextBlock" xlink:type="locator" xlink:label="freq_TemporaryEquityTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="freq_TemporaryEquityTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureNonControllingInterest" xlink:href="freq-20201231.xsd#Role_DisclosureNonControllingInterest" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureNonControllingInterest">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncontrollingInterestAbstract" xlink:to="us-gaap_MinorityInterestDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockholdersEquity" xlink:href="freq-20201231.xsd#Role_DisclosureStockholdersEquity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockholdersEquity">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockBasedCompensation" xlink:href="freq-20201231.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockBasedCompensation">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureEmployeeStockPurchasePlan" xlink:href="freq-20201231.xsd#Role_DisclosureEmployeeStockPurchasePlan" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureEmployeeStockPurchasePlan">
    <link:loc xlink:href="freq-20201231.xsd#freq_EmployeeStockPurchasePlanDisclosureTextBlock" xlink:type="locator" xlink:label="freq_EmployeeStockPurchasePlanDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="freq_EmployeeStockPurchasePlanDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="freq-20201231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureIncomeTaxes">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureResearchAndLicenseAgreements" xlink:href="freq-20201231.xsd#Role_DisclosureResearchAndLicenseAgreements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureResearchAndLicenseAgreements">
    <link:loc xlink:href="freq-20201231.xsd#freq_ResearchAndLicenseAgreementsDisclosureTextBlock" xlink:type="locator" xlink:label="freq_ResearchAndLicenseAgreementsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="freq_ResearchAndLicenseAgreementsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCollaborationAgreement" xlink:href="freq-20201231.xsd#Role_DisclosureCollaborationAgreement" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCollaborationAgreement">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="freq-20201231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureEmployeeBenefitPlan" xlink:href="freq-20201231.xsd#Role_DisclosureEmployeeBenefitPlan" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureEmployeeBenefitPlan">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions" xlink:href="freq-20201231.xsd#Role_DisclosureRelatedPartyTransactions" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSubsequentEvents" xlink:href="freq-20201231.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSubsequentEvents">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyDataUnaudited" xlink:href="freq-20201231.xsd#Role_DisclosureSelectedQuarterlyDataUnaudited" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyDataUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="locator" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="freq-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:loc xlink:href="freq-20201231.xsd#freq_PatentCostsPolicyTextBlock" xlink:type="locator" xlink:label="freq_PatentCostsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:loc xlink:href="freq-20201231.xsd#freq_SignificantSuppliersPolicyTextBlock" xlink:type="locator" xlink:label="freq_SignificantSuppliersPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="freq_SignificantSuppliersPolicyTextBlock" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="freq_PatentCostsPolicyTextBlock" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="freq-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:loc xlink:href="freq-20201231.xsd#freq_PropertyAndEquipmentTableTextBlock" xlink:type="locator" xlink:label="freq_PropertyAndEquipmentTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="freq_PropertyAndEquipmentTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:href="freq-20201231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosurePrepaidExpensesTables" xlink:href="freq-20201231.xsd#Role_DisclosurePrepaidExpensesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosurePrepaidExpensesTables">
    <link:loc xlink:href="freq-20201231.xsd#freq_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:type="locator" xlink:label="freq_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="freq_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentTables" xlink:href="freq-20201231.xsd#Role_DisclosurePropertyAndEquipmentTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureAccruedExpensesTables" xlink:href="freq-20201231.xsd#Role_DisclosureAccruedExpensesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureAccruedExpensesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockholdersEquityTables" xlink:href="freq-20201231.xsd#Role_DisclosureStockholdersEquityTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockholdersEquityTables">
    <link:loc xlink:href="freq-20201231.xsd#freq_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" xlink:type="locator" xlink:label="freq_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="freq_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables" xlink:href="freq-20201231.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="freq-20201231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:href="freq-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyDataUnauditedTables" xlink:href="freq-20201231.xsd#Role_DisclosureSelectedQuarterlyDataUnauditedTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyDataUnauditedTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" xlink:href="freq-20201231.xsd#Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="locator" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="freq-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:loc xlink:href="freq-20201231.xsd#freq_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="locator" xlink:label="freq_IncreaseDecreaseInOperatingLeaseLiability" />
    <link:loc xlink:href="freq-20201231.xsd#freq_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:type="locator" xlink:label="freq_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:loc xlink:href="freq-20201231.xsd#freq_FairValueOfTermLoanIssuedTerm" xlink:type="locator" xlink:label="freq_FairValueOfTermLoanIssuedTerm" />
    <link:loc xlink:href="freq-20201231.xsd#freq_FairValueOfTermLoan" xlink:type="locator" xlink:label="freq_FairValueOfTermLoan" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
    <link:loc xlink:href="freq-20201231.xsd#freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="freq_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201601Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201811Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201811Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="freq-20201231.xsd#freq_WoburnMassachusettsFacilityMember" xlink:type="locator" xlink:label="freq_WoburnMassachusettsFacilityMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_LexingtonMassachusettsFacilityMember" xlink:type="locator" xlink:label="freq_LexingtonMassachusettsFacilityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="freq-20201231.xsd#freq_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="freq_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="freq_SummaryOfSignificantAccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_StatementGeographicalAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="freq_LexingtonMassachusettsFacilityMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="freq_WoburnMassachusettsFacilityMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201811Member" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201601Member" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_SummaryOfSignificantAccountingPoliciesTable" xlink:to="freq_SummaryOfSignificantAccountingPoliciesLineItems" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="freq_FairValueOfTermLoan" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="freq_FairValueOfTermLoanIssuedTerm" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="freq_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="freq_IncreaseDecreaseInOperatingLeaseLiability" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails" xlink:href="freq-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="freq-20201231.xsd#freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="freq_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_FurnitureAndOfficeEquipmentMember" xlink:type="locator" xlink:label="freq_FurnitureAndOfficeEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareDevelopmentMember" xlink:type="locator" xlink:label="us-gaap_SoftwareDevelopmentMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_LabEquipmentMember" xlink:type="locator" xlink:label="freq_LabEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="freq-20201231.xsd#freq_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="freq_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="freq_SummaryOfSignificantAccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="freq_LabEquipmentMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="freq_FurnitureAndOfficeEquipmentMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_SummaryOfSignificantAccountingPoliciesTable" xlink:to="freq_SummaryOfSignificantAccountingPoliciesLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="freq-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="freq-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:href="freq-20201231.xsd#freq_OutstandingStockOptionsAsConvertedToCommonStockMember" xlink:type="locator" xlink:label="freq_OutstandingStockOptionsAsConvertedToCommonStockMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_ConversionOfFrequencyJapanPreferredStockMember" xlink:type="locator" xlink:label="freq_ConversionOfFrequencyJapanPreferredStockMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_SeriesAPreferredAsConvertedCommonStockMember" xlink:type="locator" xlink:label="freq_SeriesAPreferredAsConvertedCommonStockMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_SeriesBPreferredAsConvertedToCommonStockMember" xlink:type="locator" xlink:label="freq_SeriesBPreferredAsConvertedToCommonStockMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_SeriesCPreferredAsConvertedToCommonStockMember" xlink:type="locator" xlink:label="freq_SeriesCPreferredAsConvertedToCommonStockMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_UnvestedRestrictedCommonStockMember" xlink:type="locator" xlink:label="freq_UnvestedRestrictedCommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="freq_UnvestedRestrictedCommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="freq_SeriesCPreferredAsConvertedToCommonStockMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="freq_SeriesBPreferredAsConvertedToCommonStockMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="freq_SeriesAPreferredAsConvertedCommonStockMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="freq_ConversionOfFrequencyJapanPreferredStockMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="freq_OutstandingStockOptionsAsConvertedToCommonStockMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails" xlink:href="freq-20201231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10060.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10060.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosurePrepaidExpensesSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="freq-20201231.xsd#Role_DisclosurePrepaidExpensesSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosurePrepaidExpensesSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance" xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" />
    <link:loc xlink:href="freq-20201231.xsd#freq_PrepaidAccountsReceivableCurrent" xlink:type="locator" xlink:label="freq_PrepaidAccountsReceivableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantsReceivableCurrent" xlink:type="locator" xlink:label="us-gaap_GrantsReceivableCurrent" />
    <link:loc xlink:href="freq-20201231.xsd#freq_PrepaidResearchAndDevelopmentExpenseCurrent" xlink:type="locator" xlink:label="freq_PrepaidResearchAndDevelopmentExpenseCurrent" />
    <link:loc xlink:href="freq-20201231.xsd#freq_PrepaidRentAndDepositsCurrent" xlink:type="locator" xlink:label="freq_PrepaidRentAndDepositsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="freq_PrepaidRentAndDepositsCurrent" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="freq_PrepaidResearchAndDevelopmentExpenseCurrent" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_GrantsReceivableCurrent" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="freq_PrepaidAccountsReceivableCurrent" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidInsurance" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="freq-20201231.xsd#Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:href="freq-20201231.xsd#Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:href="freq-20201231.xsd#Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="freq-20201231.xsd#freq_AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="freq_AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="freq-20201231.xsd#freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent" xlink:type="locator" xlink:label="freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="freq_AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" xlink:href="freq-20201231.xsd#Role_DisclosureDebtAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" />
    <link:loc xlink:href="freq-20201231.xsd#freq_DebtInstrumentPrepaymentPremiumPercentage" xlink:type="locator" xlink:label="freq_DebtInstrumentPrepaymentPremiumPercentage" />
    <link:loc xlink:href="freq-20201231.xsd#freq_DebtInstrumentFloorInterestRatePercentage" xlink:type="locator" xlink:label="freq_DebtInstrumentFloorInterestRatePercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:loc xlink:href="freq-20201231.xsd#freq_DebtInstrumentInterestOnlyPaymentMaturityDate" xlink:type="locator" xlink:label="freq_DebtInstrumentInterestOnlyPaymentMaturityDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPaymentTerms" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:loc xlink:href="freq-20201231.xsd#freq_PrepaymentOccursAfterSecondAnniversaryOfClosingDateMember" xlink:type="locator" xlink:label="freq_PrepaymentOccursAfterSecondAnniversaryOfClosingDateMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMember" xlink:type="locator" xlink:label="freq_PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMember" xlink:type="locator" xlink:label="freq_PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember" xlink:type="locator" xlink:label="us-gaap_PrimeRateMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:type="locator" xlink:label="us-gaap_VariableRateDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:type="locator" xlink:label="us-gaap_VariableRateAxis" />
    <link:loc xlink:href="freq-20201231.xsd#freq_TermLoanMember" xlink:type="locator" xlink:label="freq_TermLoanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <link:loc xlink:href="freq-20201231.xsd#freq_LoanAndSecurityAgreementMember" xlink:type="locator" xlink:label="freq_LoanAndSecurityAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="freq_LoanAndSecurityAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="freq_TermLoanMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_PrimeRateMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="freq_PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMember" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="freq_PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMember" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="freq_PrepaymentOccursAfterSecondAnniversaryOfClosingDateMember" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPaymentTerms" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="freq_DebtInstrumentInterestOnlyPaymentMaturityDate" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="freq_DebtInstrumentFloorInterestRatePercentage" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="freq_DebtInstrumentPrepaymentPremiumPercentage" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:href="freq-20201231.xsd#Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <link:loc xlink:href="freq-20201231.xsd#freq_SeriesB1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesB1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_SeriesA1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesA1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_SeriesCConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesCConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesAConvertiblePreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesBConvertiblePreferredStockMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesCConvertiblePreferredStockMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesA1ConvertiblePreferredStockMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesB1ConvertiblePreferredStockMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityLineItems" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureNonControllingInterestAdditionalInformationDetails" xlink:href="freq-20201231.xsd#Role_DisclosureNonControllingInterestAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureNonControllingInterestAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockVotingRights" xlink:type="locator" xlink:label="us-gaap_PreferredStockVotingRights" />
    <link:loc xlink:href="freq-20201231.xsd#freq_PreferredStockSharesPurchased" xlink:type="locator" xlink:label="freq_PreferredStockSharesPurchased" />
    <link:loc xlink:href="freq-20201231.xsd#freq_PercentageOfVoteOfHoldersOfPreferredStock" xlink:type="locator" xlink:label="freq_PercentageOfVoteOfHoldersOfPreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="freq-20201231.xsd#freq_DelawareLimitedLiabilityCompanyMember" xlink:type="locator" xlink:label="freq_DelawareLimitedLiabilityCompanyMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="freq-20201231.xsd#freq_SeriesB1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesB1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_SeriesA1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesA1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SubsidiariesMember" xlink:type="locator" xlink:label="srt_SubsidiariesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncontrollingInterestAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_SubsidiariesMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesA1ConvertiblePreferredStockMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesB1ConvertiblePreferredStockMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="freq_DelawareLimitedLiabilityCompanyMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="freq_PercentageOfVoteOfHoldersOfPreferredStock" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="freq_PreferredStockSharesPurchased" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockVotingRights" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:href="freq-20201231.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails" xlink:href="freq-20201231.xsd#Role_DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:type="locator" xlink:label="us-gaap_StockCompensationPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="freq-20201231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:loc xlink:href="freq-20201231.xsd#freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" xlink:type="locator" xlink:label="freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="freq-20201231.xsd#freq_TwoThousandAndNineteenIncentiveAwardPlanMember" xlink:type="locator" xlink:label="freq_TwoThousandAndNineteenIncentiveAwardPlanMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_TwoThousandAndFourteenStockIncentivePlanMember" xlink:type="locator" xlink:label="freq_TwoThousandAndFourteenStockIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="freq_TwoThousandAndFourteenStockIncentivePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="freq_TwoThousandAndNineteenIncentiveAwardPlanMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnder2014PlanAnd2019PlanDetails" xlink:href="freq-20201231.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnder2014PlanAnd2019PlanDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnder2014PlanAnd2019PlanDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="freq-20201231.xsd#freq_TwoThousandAndFourteenStockIncentivePlanMember" xlink:type="locator" xlink:label="freq_TwoThousandAndFourteenStockIncentivePlanMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_TwoThousandAndNineteenIncentiveAwardPlanMember" xlink:type="locator" xlink:label="freq_TwoThousandAndNineteenIncentiveAwardPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="freq_TwoThousandAndNineteenIncentiveAwardPlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="freq_TwoThousandAndFourteenStockIncentivePlanMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="11990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="12170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="12380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="12560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="12740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="12920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="13100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="14000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="14180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="14750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="14960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="15320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="15500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfGrantDateFairValueOfStockOptionsGrantedOnWeightedAverageBasisDetails" xlink:href="freq-20201231.xsd#Role_DisclosureStockBasedCompensationSummaryOfGrantDateFairValueOfStockOptionsGrantedOnWeightedAverageBasisDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfGrantDateFairValueOfStockOptionsGrantedOnWeightedAverageBasisDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStatusOfRestrictedCommonStockDetails" xlink:href="freq-20201231.xsd#Role_DisclosureStockBasedCompensationSummaryOfStatusOfRestrictedCommonStockDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStatusOfRestrictedCommonStockDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureEmployeeStockPurchasePlanAdditionalInformationDetails" xlink:href="freq-20201231.xsd#Role_DisclosureEmployeeStockPurchasePlanAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureEmployeeStockPurchasePlanAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:loc xlink:href="freq-20201231.xsd#freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" xlink:type="locator" xlink:label="freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="freq-20201231.xsd#freq_PercentageOfEligibleEmployeeCompensation" xlink:type="locator" xlink:label="freq_PercentageOfEligibleEmployeeCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="freq_PercentageOfEligibleEmployeeCompensation" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="freq-20201231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" />
    <link:loc xlink:href="freq-20201231.xsd#freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration" xlink:type="locator" xlink:label="freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration" />
    <link:loc xlink:href="freq-20201231.xsd#freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange" xlink:type="locator" xlink:label="freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange" />
    <link:loc xlink:href="freq-20201231.xsd#freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange" xlink:type="locator" xlink:label="freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange" />
    <link:loc xlink:href="freq-20201231.xsd#freq_OperatingLossCarryforwardsUsageAfterOwnershipChange" xlink:type="locator" xlink:label="freq_OperatingLossCarryforwardsUsageAfterOwnershipChange" />
    <link:loc xlink:href="freq-20201231.xsd#freq_PeriodOfCumulativeChangeInOwnership" xlink:type="locator" xlink:label="freq_PeriodOfCumulativeChangeInOwnership" />
    <link:loc xlink:href="freq-20201231.xsd#freq_CumulativeChangeInOwnershipPercentage" xlink:type="locator" xlink:label="freq_CumulativeChangeInOwnershipPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:loc xlink:href="freq-20201231.xsd#freq_TaxCreditCarryforwardExpirationYear" xlink:type="locator" xlink:label="freq_TaxCreditCarryforwardExpirationYear" />
    <link:loc xlink:href="freq-20201231.xsd#freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation" xlink:type="locator" xlink:label="freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation" />
    <link:loc xlink:href="freq-20201231.xsd#freq_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="freq_OperatingLossCarryforwardsExpirationYear" />
    <link:loc xlink:href="freq-20201231.xsd#freq_NetOperatingLossCarryforwardsExpirationWithLimitation" xlink:type="locator" xlink:label="freq_NetOperatingLossCarryforwardsExpirationWithLimitation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="freq-20201231.xsd#freq_IncomeTaxesDisclosureLineItems" xlink:type="locator" xlink:label="freq_IncomeTaxesDisclosureLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:type="locator" xlink:label="us-gaap_InternalRevenueServiceIRSMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember" xlink:type="locator" xlink:label="us-gaap_ResearchMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_MA" xlink:type="locator" xlink:label="stpr_MA" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="freq-20201231.xsd#freq_IncomeTaxesDisclosureTable" xlink:type="locator" xlink:label="freq_IncomeTaxesDisclosureTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="freq_IncomeTaxesDisclosureTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureTable" xlink:to="srt_StatementGeographicalAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_MA" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_InternalRevenueServiceIRSMember" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureTable" xlink:to="srt_RangeAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureTable" xlink:to="freq_IncomeTaxesDisclosureLineItems" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="freq_NetOperatingLossCarryforwardsExpirationWithLimitation" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="freq_OperatingLossCarryforwardsExpirationYear" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="freq_TaxCreditCarryforwardExpirationYear" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="freq_CumulativeChangeInOwnershipPercentage" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="freq_PeriodOfCumulativeChangeInOwnership" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="freq_OperatingLossCarryforwardsUsageAfterOwnershipChange" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationPreTaxIncomeDetails" xlink:href="freq-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfReconciliationPreTaxIncomeDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationPreTaxIncomeDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionDetails" xlink:href="freq-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfProvisionDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="locator" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails" xlink:href="freq-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails" xlink:href="freq-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="freq-20201231.xsd#freq_DeferredTaxAssetsRightOfUseAssets" xlink:type="locator" xlink:label="freq_DeferredTaxAssetsRightOfUseAssets" />
    <link:loc xlink:href="freq-20201231.xsd#freq_DeferredTaxAssetsLeasingArrangements" xlink:type="locator" xlink:label="freq_DeferredTaxAssetsLeasingArrangements" />
    <link:loc xlink:href="freq-20201231.xsd#freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" xlink:type="locator" xlink:label="freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="freq_DeferredTaxAssetsLeasingArrangements" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="freq_DeferredTaxAssetsRightOfUseAssets" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureResearchAndLicenseAgreementsAdditionalInformationDetails" xlink:href="freq-20201231.xsd#Role_DisclosureResearchAndLicenseAgreementsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureResearchAndLicenseAgreementsAdditionalInformationDetails">
    <link:loc xlink:href="freq-20201231.xsd#freq_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="freq_IncreaseDecreaseInResearchAndDevelopmentExpense" />
    <link:loc xlink:href="freq-20201231.xsd#freq_GrantTermPeriod" xlink:type="locator" xlink:label="freq_GrantTermPeriod" />
    <link:loc xlink:href="freq-20201231.xsd#freq_AmountOfFundingReceivedAsGrant" xlink:type="locator" xlink:label="freq_AmountOfFundingReceivedAsGrant" />
    <link:loc xlink:href="freq-20201231.xsd#freq_AnnualLicenseFee" xlink:type="locator" xlink:label="freq_AnnualLicenseFee" />
    <link:loc xlink:href="freq-20201231.xsd#freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent" xlink:type="locator" xlink:label="freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent" />
    <link:loc xlink:href="freq-20201231.xsd#freq_AdditionalFundingPaymentsMadeAsConsiderationToSupportResearchActivities" xlink:type="locator" xlink:label="freq_AdditionalFundingPaymentsMadeAsConsiderationToSupportResearchActivities" />
    <link:loc xlink:href="freq-20201231.xsd#freq_LicenseAgreementExtendedDate" xlink:type="locator" xlink:label="freq_LicenseAgreementExtendedDate" />
    <link:loc xlink:href="freq-20201231.xsd#freq_TermOfAgreement" xlink:type="locator" xlink:label="freq_TermOfAgreement" />
    <link:loc xlink:href="freq-20201231.xsd#freq_FundingPaymentsMadeAsConsiderationToSupportResearchActivities" xlink:type="locator" xlink:label="freq_FundingPaymentsMadeAsConsiderationToSupportResearchActivities" />
    <link:loc xlink:href="freq-20201231.xsd#freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice" xlink:type="locator" xlink:label="freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForManagementFee" xlink:type="locator" xlink:label="us-gaap_PaymentForManagementFee" />
    <link:loc xlink:href="freq-20201231.xsd#freq_RightToTerminateAgreementIncaseOfNonpayment" xlink:type="locator" xlink:label="freq_RightToTerminateAgreementIncaseOfNonpayment" />
    <link:loc xlink:href="freq-20201231.xsd#freq_RightToTerminateAgreementIfBreachRemainsUncured" xlink:type="locator" xlink:label="freq_RightToTerminateAgreementIfBreachRemainsUncured" />
    <link:loc xlink:href="freq-20201231.xsd#freq_RightToTerminateAgreementUponPriorWrittenNotice" xlink:type="locator" xlink:label="freq_RightToTerminateAgreementUponPriorWrittenNotice" />
    <link:loc xlink:href="freq-20201231.xsd#freq_DescriptionOfConditionsToTerminateLicenseAgreement" xlink:type="locator" xlink:label="freq_DescriptionOfConditionsToTerminateLicenseAgreement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="freq-20201231.xsd#freq_MilestonePayments" xlink:type="locator" xlink:label="freq_MilestonePayments" />
    <link:loc xlink:href="freq-20201231.xsd#freq_PercentageOfSharesOfCommonStockIssued" xlink:type="locator" xlink:label="freq_PercentageOfSharesOfCommonStockIssued" />
    <link:loc xlink:href="freq-20201231.xsd#freq_LicenseFeePayment" xlink:type="locator" xlink:label="freq_LicenseFeePayment" />
    <link:loc xlink:href="freq-20201231.xsd#freq_DescriptionOfFutureDevelopmentObligations" xlink:type="locator" xlink:label="freq_DescriptionOfFutureDevelopmentObligations" />
    <link:loc xlink:href="freq-20201231.xsd#freq_LicenseAgreementEnteredDate" xlink:type="locator" xlink:label="freq_LicenseAgreementEnteredDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember" xlink:type="locator" xlink:label="us-gaap_GrantMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_ResearchAndDevelopmentMember" xlink:type="locator" xlink:label="freq_ResearchAndDevelopmentMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_CambridgeEnterpriseLimitedMember" xlink:type="locator" xlink:label="freq_CambridgeEnterpriseLimitedMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_MassachusettsEyeAndEarMember" xlink:type="locator" xlink:label="freq_MassachusettsEyeAndEarMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_NonExclusivePatentLicenseAgreementMember" xlink:type="locator" xlink:label="freq_NonExclusivePatentLicenseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember" xlink:type="locator" xlink:label="srt_ScenarioForecastMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:type="locator" xlink:label="srt_StatementScenarioAxis" />
    <link:loc xlink:href="freq-20201231.xsd#freq_ScrippsOptionAgreementMember" xlink:type="locator" xlink:label="freq_ScrippsOptionAgreementMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_CaliforniaInstituteForBiomedicalResearchMember" xlink:type="locator" xlink:label="freq_CaliforniaInstituteForBiomedicalResearchMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:type="locator" xlink:label="srt_DirectorMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember" xlink:type="locator" xlink:label="us-gaap_RoyaltyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="freq-20201231.xsd#freq_AstellasPharmaLimitedLiabilityCompanyMember" xlink:type="locator" xlink:label="freq_AstellasPharmaLimitedLiabilityCompanyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="freq-20201231.xsd#freq_PatentLicenseAgreementMember" xlink:type="locator" xlink:label="freq_PatentLicenseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="freq-20201231.xsd#freq_MassachusettsInstituteOfTechnologyMember" xlink:type="locator" xlink:label="freq_MassachusettsInstituteOfTechnologyMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="dei_LegalEntityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="freq_MassachusettsInstituteOfTechnologyMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="freq_PatentLicenseAgreementMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_CounterpartyNameAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="freq_AstellasPharmaLimitedLiabilityCompanyMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_ProductOrServiceAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_TitleOfIndividualAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="freq_CaliforniaInstituteForBiomedicalResearchMember" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="freq_ScrippsOptionAgreementMember" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_StatementScenarioAxis" order="10030.12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="freq_NonExclusivePatentLicenseAgreementMember" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="freq_MassachusettsEyeAndEarMember" order="11360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="freq_CambridgeEnterpriseLimitedMember" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="freq_ResearchAndDevelopmentMember" order="12040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GrantMember" order="12100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" order="12160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_LicenseAgreementEnteredDate" order="12170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_DescriptionOfFutureDevelopmentObligations" order="12220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_LicenseFeePayment" order="12270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_PercentageOfSharesOfCommonStockIssued" order="12290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_MilestonePayments" order="12310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="12330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_DescriptionOfConditionsToTerminateLicenseAgreement" order="12380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_RightToTerminateAgreementUponPriorWrittenNotice" order="12400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_RightToTerminateAgreementIfBreachRemainsUncured" order="12420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_RightToTerminateAgreementIncaseOfNonpayment" order="12440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_PaymentForManagementFee" order="12490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice" order="12740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_FundingPaymentsMadeAsConsiderationToSupportResearchActivities" order="12830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_TermOfAgreement" order="12850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_LicenseAgreementExtendedDate" order="12900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_AdditionalFundingPaymentsMadeAsConsiderationToSupportResearchActivities" order="12920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent" order="13290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_AnnualLicenseFee" order="13430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_AmountOfFundingReceivedAsGrant" order="13590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_GrantTermPeriod" order="13650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_IncreaseDecreaseInResearchAndDevelopmentExpense" order="13710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails" xlink:href="freq-20201231.xsd#Role_DisclosureCollaborationAgreementAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <link:loc xlink:href="freq-20201231.xsd#freq_RevenueFromContractWithCustomerApplicationInputMethod" xlink:type="locator" xlink:label="freq_RevenueFromContractWithCustomerApplicationInputMethod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="freq-20201231.xsd#freq_UpfrontFeeRecognizedAsRevenue" xlink:type="locator" xlink:label="freq_UpfrontFeeRecognizedAsRevenue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense" xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedRoyaltiesCurrent" />
    <link:loc xlink:href="freq-20201231.xsd#freq_RevenueRecognitionTransactionPrice" xlink:type="locator" xlink:label="freq_RevenueRecognitionTransactionPrice" />
    <link:loc xlink:href="freq-20201231.xsd#freq_RightToTerminateAgreementIncaseOfNonpayment" xlink:type="locator" xlink:label="freq_RightToTerminateAgreementIncaseOfNonpayment" />
    <link:loc xlink:href="freq-20201231.xsd#freq_RightToTerminateAgreementIfBreachRemainsUncured" xlink:type="locator" xlink:label="freq_RightToTerminateAgreementIfBreachRemainsUncured" />
    <link:loc xlink:href="freq-20201231.xsd#freq_AgreementTerminationNoticePeriod" xlink:type="locator" xlink:label="freq_AgreementTerminationNoticePeriod" />
    <link:loc xlink:href="freq-20201231.xsd#freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization" xlink:type="locator" xlink:label="freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization" />
    <link:loc xlink:href="freq-20201231.xsd#freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones" xlink:type="locator" xlink:label="freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" xlink:label="us-gaap_ProceedsFromCollaborators" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember" xlink:type="locator" xlink:label="us-gaap_RoyaltyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AsiaMember" xlink:type="locator" xlink:label="srt_AsiaMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:type="locator" xlink:label="srt_EuropeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="freq-20201231.xsd#freq_Phase3ClinicalTrailMember" xlink:type="locator" xlink:label="freq_Phase3ClinicalTrailMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_Phase2bClinicalTrialMember" xlink:type="locator" xlink:label="freq_Phase2bClinicalTrialMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="freq-20201231.xsd#freq_AstellasPharmaLimitedLiabilityCompanyMember" xlink:type="locator" xlink:label="freq_AstellasPharmaLimitedLiabilityCompanyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="freq-20201231.xsd#freq_LicenseAndCollaborationAgreementMember" xlink:type="locator" xlink:label="freq_LicenseAndCollaborationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="freq_LicenseAndCollaborationAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="freq_AstellasPharmaLimitedLiabilityCompanyMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="freq_Phase2bClinicalTrialMember" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="freq_Phase3ClinicalTrailMember" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementGeographicalAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_AsiaMember" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" order="11670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="freq_AgreementTerminationNoticePeriod" order="11860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="freq_RightToTerminateAgreementIfBreachRemainsUncured" order="11880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="freq_RightToTerminateAgreementIncaseOfNonpayment" order="11900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="freq_RevenueRecognitionTransactionPrice" order="11950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccruedRoyaltiesCurrent" order="11970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RoyaltyExpense" order="11990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="freq_UpfrontFeeRecognizedAsRevenue" order="12010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="12060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="freq_RevenueFromContractWithCustomerApplicationInputMethod" order="12140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="12180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="12250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="freq-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyLossInPeriod" xlink:type="locator" xlink:label="us-gaap_LossContingencyLossInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="freq-20201231.xsd#freq_OperatingLeasesAdditionalExtensionTerm" xlink:type="locator" xlink:label="freq_OperatingLeasesAdditionalExtensionTerm" />
    <link:loc xlink:href="freq-20201231.xsd#freq_OperatingLeaseNumberOfAdditionalExtensionTerms" xlink:type="locator" xlink:label="freq_OperatingLeaseNumberOfAdditionalExtensionTerms" />
    <link:loc xlink:href="freq-20201231.xsd#freq_OperatingLeaseCommencementDate" xlink:type="locator" xlink:label="freq_OperatingLeaseCommencementDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetRentableArea" xlink:type="locator" xlink:label="us-gaap_NetRentableArea" />
    <link:loc xlink:href="freq-20201231.xsd#freq_OperatingLeaseTerminationFee" xlink:type="locator" xlink:label="freq_OperatingLeaseTerminationFee" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:loc xlink:href="freq-20201231.xsd#freq_OperatingLeaseAgreementExpirationDate" xlink:type="locator" xlink:label="freq_OperatingLeaseAgreementExpirationDate" />
    <link:loc xlink:href="freq-20201231.xsd#freq_OperatingLeaseAgreementCommencementDate" xlink:type="locator" xlink:label="freq_OperatingLeaseAgreementCommencementDate" />
    <link:loc xlink:href="freq-20201231.xsd#freq_OperatingLeaseAgreementAmendedDate" xlink:type="locator" xlink:label="freq_OperatingLeaseAgreementAmendedDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:loc xlink:href="freq-20201231.xsd#freq_LeaseExpirationYear" xlink:type="locator" xlink:label="freq_LeaseExpirationYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:loc xlink:href="freq-20201231.xsd#freq_WoburnMassachusettsFacilityMember" xlink:type="locator" xlink:label="freq_WoburnMassachusettsFacilityMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_LexingtonLeaseMember" xlink:type="locator" xlink:label="freq_LexingtonLeaseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:loc xlink:href="freq-20201231.xsd#freq_HaydenLLCMember" xlink:type="locator" xlink:label="freq_HaydenLLCMember" />
    <link:loc xlink:href="freq-20201231.xsd#freq_AREMARegionNo20LLCMember" xlink:type="locator" xlink:label="freq_AREMARegionNo20LLCMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="freq-20201231.xsd#freq_LeasesTerminationAgreementMember" xlink:type="locator" xlink:label="freq_LeasesTerminationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CT" xlink:type="locator" xlink:label="stpr_CT" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_MA" xlink:type="locator" xlink:label="stpr_MA" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_MA" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CT" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="freq_LeasesTerminationAgreementMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_CounterpartyNameAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="freq_AREMARegionNo20LLCMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="freq_HaydenLLCMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="freq_LexingtonLeaseMember" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="freq_WoburnMassachusettsFacilityMember" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="freq_LeaseExpirationYear" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="freq_OperatingLeaseAgreementAmendedDate" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="freq_OperatingLeaseAgreementCommencementDate" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="freq_OperatingLeaseAgreementExpirationDate" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="freq_OperatingLeaseTerminationFee" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_NetRentableArea" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="freq_OperatingLeaseCommencementDate" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="freq_OperatingLeaseNumberOfAdditionalExtensionTerms" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="freq_OperatingLeasesAdditionalExtensionTerm" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_VariableLeaseCost" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ShortTermLeaseCost" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LossContingencyLossInPeriod" order="11740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeasesDetails" xlink:href="freq-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfLeasesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeasesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfReconcilesUndiscountedCashFlowsToOperatingLeaseLiabilityRecordedOnConsolidatedBalanceSheetDetails" xlink:href="freq-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfReconcilesUndiscountedCashFlowsToOperatingLeaseLiabilityRecordedOnConsolidatedBalanceSheetDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfReconcilesUndiscountedCashFlowsToOperatingLeaseLiabilityRecordedOnConsolidatedBalanceSheetDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveVerboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumPaymentsUnderNoncancelableOperatingLeasesAndShortTermLeasesDetails" xlink:href="freq-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumPaymentsUnderNoncancelableOperatingLeasesAndShortTermLeasesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumPaymentsUnderNoncancelableOperatingLeasesAndShortTermLeasesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformationDetails" xlink:href="freq-20201231.xsd#Role_DisclosureEmployeeBenefitPlanAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="freq-20201231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForManagementFee" xlink:type="locator" xlink:label="us-gaap_PaymentForManagementFee" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:type="locator" xlink:label="srt_DirectorMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_TitleOfIndividualAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PaymentForManagementFee" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyDataUnauditedScheduleOfQuarterlyFinancialInformationDetails" xlink:href="freq-20201231.xsd#Role_DisclosureSelectedQuarterlyDataUnauditedScheduleOfQuarterlyFinancialInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyDataUnauditedScheduleOfQuarterlyFinancialInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDividendsAdjustment" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDividendsAdjustment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="freq-20201231.xsd#freq_OperatingAndNonOperatingExpensesNet" xlink:type="locator" xlink:label="freq_OperatingAndNonOperatingExpensesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="freq_OperatingAndNonOperatingExpensesNet" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityDividendsAdjustment" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703586989976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 19, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001703647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Frequency Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-2324450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Address Line</a></td>
<td class="text">19 Presidential Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">2nd Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">Woburn<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">01801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">389-1970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">FREQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 625.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,177,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portions of the Proxy Statement for the registrant&#8217;s&#160;2021&#160;Annual Meeting of Stockholders are incorporated by reference into Part&#160;III of this Annual Report on Form 10-K.</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703587161176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 220,341<span></span>
</td>
<td class="nump">$ 200,158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,723<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">225,064<span></span>
</td>
<td class="nump">221,355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">7,287<span></span>
</td>
<td class="nump">1,762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets</a></td>
<td class="nump">30,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,820<span></span>
</td>
<td class="nump">101<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">264,722<span></span>
</td>
<td class="nump">223,218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">5,506<span></span>
</td>
<td class="nump">1,219<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">6,663<span></span>
</td>
<td class="nump">3,239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">14,068<span></span>
</td>
<td class="nump">48,152<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">26,634<span></span>
</td>
<td class="nump">52,780<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="nump">30,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLoansFromBank', window );">Term Loan</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">72,231<span></span>
</td>
<td class="nump">55,860<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued or outstanding at December 31, 2020 and December 31, 2019, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 200,000,000 shares authorized, 33,964,000 and 30,844,507 shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">287,829<span></span>
</td>
<td class="nump">236,161<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(95,399)<span></span>
</td>
<td class="num">(68,888)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">192,491<span></span>
</td>
<td class="nump">167,358<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 264,722<span></span>
</td>
<td class="nump">$ 223,218<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansFromBank">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of loans from a bank with maturities initially due after one year or beyond the operating cycle if longer, excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansFromBank</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703586975192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 20, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized shares</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">148,724,922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued shares</a></td>
<td class="nump">33,964,000<span></span>
</td>
<td class="nump">30,844,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding shares</a></td>
<td class="nump">33,964,000<span></span>
</td>
<td class="nump">30,844,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703587004696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement Of Income And Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 36,984,000<span></span>
</td>
<td class="nump">$ 28,947,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">37,415,000<span></span>
</td>
<td class="nump">18,784,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">27,119,000<span></span>
</td>
<td class="nump">14,838,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">64,534,000<span></span>
</td>
<td class="nump">49,622,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(27,550,000)<span></span>
</td>
<td class="num">(20,675,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">994,000<span></span>
</td>
<td class="nump">1,784,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Realized gain on investments</a></td>
<td class="nump">84,000<span></span>
</td>
<td class="nump">138,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange (loss) gain</a></td>
<td class="num">(4,000)<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(26,476,000)<span></span>
</td>
<td class="num">(18,746,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="num">(35,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(26,511,000)<span></span>
</td>
<td class="num">(18,746,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDividendsAdjustment', window );">Cumulative Series C convertible preferred stock dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,054,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (26,511,000)<span></span>
</td>
<td class="num">$ (19,800,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders-basic and diluted</a></td>
<td class="num">$ (0.82)<span></span>
</td>
<td class="num">$ (2.29)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares of common stock outstanding-basic and diluted</a></td>
<td class="nump">32,253,227<span></span>
</td>
<td class="nump">8,649,245<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121605123&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.3(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDividendsAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accretion of temporary equity during the period due to cash, stock, and in-kind dividends. This item is an adjustment to net income necessary to derive net income apportioned to common stockholders and is to be distinguished from Temporary Equity, Accretion of Dividends (Temporary Equity, Accretion of Dividends).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDividendsAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703671221992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement Of Income And Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (26,511)<span></span>
</td>
<td class="num">$ (18,746)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Other comprehensive (loss) gain:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on marketable securities</a></td>
<td class="num">(27)<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total comprehensive (loss) gain</a></td>
<td class="num">(27)<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (26,538)<span></span>
</td>
<td class="num">$ (18,692)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703585166008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Convertible Preferred Stock, Non-controlling Interest and Stockholder's Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Non-controlling Interest</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional-paid in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Series C Convertible Preferred Stock</div></th>
<th class="th"><div>Series B Convertible Preferred Stock</div></th>
<th class="th"><div>Series B-1 Convertible Preferred Stock</div></th>
<th class="th"><div>Series A Convertible Preferred Stock</div></th>
<th class="th"><div>Series A-1 Convertible Preferred Stock</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Beginning Balance at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,224<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 46,694<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,857,005<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">62,528,507<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Dec. 31, 2018</a></td>
<td class="num">$ (48,282)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (49,088)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,084,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">3,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">$ 366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options (in shares)</a></td>
<td class="nump">357,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">357,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,687<span></span>
</td>
<td class="nump">$ 266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of convertible preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,492,960<span></span>
</td>
<td class="nump">288,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_ConvertiblePreferredStockAccretionOfDividend', window );">Accretion of Series C preferred dividend</a></td>
<td class="num">$ (1,054)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,054)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionOfDividends', window );">Accretion of Series C preferred dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in initial public offering or private placement</a></td>
<td class="nump">79,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">79,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in initial public offering or private placement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering', window );">Conversion of preferred stock and non-controlling interest into common stock in connection with the IPO</a></td>
<td class="nump">151,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">151,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering', window );">Conversion of preferred stock and non-controlling interest into common stock in connection with the IPO (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,492,960)<span></span>
</td>
<td class="num">(42,145,996)<span></span>
</td>
<td class="num">(10.000)<span></span>
</td>
<td class="num">(62,528,507)<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering', window );">Conversion of preferred stock and non-controlling interest into common stock in connection with the IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,773)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (62,741)<span></span>
</td>
<td class="num">$ (38,490)<span></span>
</td>
<td class="num">$ (9)<span></span>
</td>
<td class="num">$ (46,694)<span></span>
</td>
<td class="num">$ (8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_StockIssuedDuringPeriodSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering', window );">Conversion of preferred stock and non-controlling interest into common stock in connection with the IPO (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,077,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(18,746)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,746)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 167,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">236,161<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="num">(68,888)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">30,844,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,844,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 9,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">$ 1,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options (in shares)</a></td>
<td class="nump">769,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">769,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in initial public offering or private placement</a></td>
<td class="nump">$ 40,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">40,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in initial public offering or private placement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,350,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(26,511)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,511)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 192,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 287,829<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="num">$ (95,399)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">33,964,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,964,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_ConvertiblePreferredStockAccretionOfDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock accretion of dividend.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_ConvertiblePreferredStockAccretionOfDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_StockIssuedDuringPeriodSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares conversion of preferred stock and non-controlling interest into common stock in connection with initial public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_StockIssuedDuringPeriodSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value conversion of preferred stock and non-controlling interest into common stock in connection with initial public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity, stock issued during period, shares, new issues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock shares conversion of preferred stock and non-controlling interest into common stock in connection with initial public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock value conversion of preferred stock and non-controlling interest into common stock in connection with initial public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of accretion of temporary equity during the period due to unpaid dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703590666904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (26,511)<span></span>
</td>
<td class="num">$ (18,746)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">9,983<span></span>
</td>
<td class="nump">3,609<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">1,146<span></span>
</td>
<td class="nump">813<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Issuance of common stock for license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_NonCashLeaseExpenses', window );">Non-cash lease expense</a></td>
<td class="nump">434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_DeferredLeaseIncentives', window );">Deferred lease incentives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(160)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(626)<span></span>
</td>
<td class="num">(3,252)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">4,287<span></span>
</td>
<td class="num">(644)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(36,984)<span></span>
</td>
<td class="nump">51,052<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">3,083<span></span>
</td>
<td class="nump">1,490<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) provided by operating activities</a></td>
<td class="num">(45,188)<span></span>
</td>
<td class="nump">34,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(6,671)<span></span>
</td>
<td class="num">(1,064)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchase of available for sale securities</a></td>
<td class="num">(26,345)<span></span>
</td>
<td class="num">(282,618)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Redemption of available for sale securities</a></td>
<td class="nump">43,418<span></span>
</td>
<td class="nump">265,421<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">10,402<span></span>
</td>
<td class="num">(18,261)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">1,545<span></span>
</td>
<td class="nump">80,062<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from Private Placement, net of issuance costs</a></td>
<td class="nump">40,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from Term Loan</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">56,688<span></span>
</td>
<td class="nump">142,015<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents, short-term investments, and restricted cash</a></td>
<td class="nump">21,902<span></span>
</td>
<td class="nump">157,970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents, short-term investments and restricted cash at beginning of period</a></td>
<td class="nump">200,259<span></span>
</td>
<td class="nump">42,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents, short-term investments, and restricted cash at end of period</a></td>
<td class="nump">222,161<span></span>
</td>
<td class="nump">200,259<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets in exchange for lease liabilities</a></td>
<td class="nump">31,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_NonCashDividendOnCumulativeConvertiblePreferredStock', window );">Cumulative Series C convertible preferred stock dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,054<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Conversion of preferred stock and non-controlling interest into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment included in accounts payable and accrued expenses</a></td>
<td class="nump">$ 2,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=freq_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=freq_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,687<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_DeferredLeaseIncentives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred lease incentives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_DeferredLeaseIncentives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_NonCashDividendOnCumulativeConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash dividend on cumulative convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_NonCashDividendOnCumulativeConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_NonCashLeaseExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash lease expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_NonCashLeaseExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=freq_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=freq_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=freq_SeriesCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=freq_SeriesCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703588124808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Organization and basis of presentation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Frequency Therapeutics, Inc., together with its wholly owned subsidiaries, Frequency Therapeutics, PTY, LTD, Frequency Therapeutics Securities Corporation and Frequency Therapeutics Japan KK (Frequency Japan) (the Company), headquartered in Woburn, Massachusetts, was incorporated in November 2014 as a Delaware corporation. The Company is a clinical-stage biotechnology company focused on harnessing the body&#8217;s innate biology to repair or reverse damage caused by a broad range of degenerative diseases.&nbsp;&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 20, 2019, the Company effected a 1-for-6.7355 reverse stock split of its common stock. The par value of the common stock was not adjusted as a result of the reverse stock split and the authorized capital was amended to 100,000,000 shares of common stock and 148,724,922 shares of $0.001 par value preferred stock (the Preferred Stock). The reverse stock split resulted in an adjustment to the Series A Convertible  Preferred Stock (Series A Preferred), Series B Convertible Preferred Stock (Series B Preferred) and Series C Convertible Preferred Stock (Series C Preferred) conversion prices to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. The accompanying consolidated financial statements and notes to the consolidated financial statements give retroactive effect to the reverse stock split for all periods presented. Shares of common stock underlying outstanding stock options were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the appropriate securities agreements. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2019, the Company completed the initial public offering of its common stock (the &#8220;IPO&#8221;). In the IPO, the Company issued and sold 6,325,000 shares of its common stock at a price to the public of $14.00 per share, inclusive of the underwriters&#8217; exercise in part of their over-allotment option. The Company received approximately $79.7 million in net proceeds, after deducting underwriting discounts and commissions and other offering expenses. In connection with the IPO, on October 7, 2019 all Preferred Stock and the preferred stock of Frequency Japan converted into 22,077,627 shares of common stock and all outstanding shares of Series A-1 Preferred Stock and B-1 Preferred Stock were forfeited.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 20, 2020, the Company issued and sold an aggregate of 2,350,108 shares of its common stock, par value $0.001 per share, at a purchase price of $18.00 per share to new and existing investors in a private placement for net proceeds of $40.1 million after deducting placement agent fees and offering expenses (the &#8220;Private Placement&#8221;).&#160;In connection with the Private Placement, the Company entered into a Registration Rights Agreement (the &#8220;Registration Rights Agreement&#8221;) with the investors. Pursuant to the Registration Rights Agreement, the Company agreed to prepare and file a registration statement with the Securities and Exchange Commission (the &#8220;SEC&#8221;) within 60 days after the closing of the Private Placement (the &#8220;Initial Filing Date&#8221;) for purposes of registering the resale of the Shares. The Company filed a registration statement (the &#8220;Registration Statement&#8221;) which was declared effective by the SEC on September 3, 2020.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has also agreed, among other things, to indemnify the investors, their officers, directors, managers, employees, agents and any person who controls any investor under the Registration Statement from certain liabilities and to pay all fees and expenses (excluding any underwriting discounts and commissions) incident to the Company&#8217;s obligations under the Registration Rights Agreement.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Uncertainties </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our offices are located in states that are currently operating under a phased re-opening plan in response to the COVID-19 pandemic. As of the date of the filing of this Annual Report, the majority of our employees continue to work from home, while nearly a quarter to one-third of our workforce, consisting of mainly laboratory personnel, have periodically worked in rotating teams to ensure the continuation of essential experiments. Our Farmington, CT research site, co-located with the University of Connecticut, has resumed activity at a fifty percent level after a period of paused activity due to state lock down orders previously in effect. While we have resumed experiments at our Farmington site, we have transitioned certain key experiments to our offices in Woburn, MA and third parties and contract research organizations have been engaged to advance certain projects. We are also have taken steps consistent with the FDA&#8217;s updated industry guidance for conducting clinical trials.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.9%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 pandemic, and actions taken to mitigate it, have had and are expected to continue to have an adverse impact on the economies and financial markets of many countries, including the geographical area in which we operate, which could adversely impact our ability to raise additional capital when needed or on acceptable terms, if at all. In addition, while no significant disruptions have occurred, the COVID-19 pandemic may cause such disruptions in our business or operations, as well as the business and operations of our CMOs, CROs and other third parties with whom we conduct business. The COVID-19 pandemic may also adversely impact the our clinical trials, which could impede, delay, limit or prevent the clinical development of our product candidates and ultimately lead to the delay or<font style="font-weight:bold;"> </font>denial of regulatory approval of our product candidates, which would materially adversely affect our business and operations, including our ability to generate revenue.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liquidity and capital resources </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has funded its operations primarily with proceeds from the sale of its capital stock, convertible notes and amounts received under a collaboration agreement. The Company has incurred recurring losses since its inception. In addition, as of December&#160;31, 2020, the Company had an accumulated deficit of $95,399. The Company expects to continue to generate operating losses for the foreseeable future. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company&#8217;s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurances that additional funding will be available on terms acceptable to the Company, or at all. The Company believes that existing resources will be sufficient to fund planned operations for at least 12 months from the date the financial statements were available to be issued.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703592302504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2. Summary of significant accounting policies </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of presentation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared in accordance with accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP) that the Company follows to ensure its financial condition, results of operations, and cash flows are consistently reported. References to GAAP issued by the FASB in these notes to the consolidated financial statements are to the FASB <font style="font-style:italic;">Accounting Standards</font> Codification (ASC). </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Principles of consolidation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements include the accounts of Frequency Therapeutics, Inc. and its wholly owned subsidiaries Frequency Therapeutics Securities Corporation, Frequency Therapeutics PTY, LTD and Frequency Japan. All intercompany transactions and balances have been eliminated. Frequency Japan was closed down in February 2021, as further described in Note 19 of notes to consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of estimates </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. On an ongoing basis, the Company&#8217;s management evaluates its estimates, which include but are not limited to management&#8217;s judgments of accrued expenses, revenue recognition, fair value of common stock, valuation of share-based awards, present value of lease liabilities and income taxes. Actual results could differ from those estimates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company utilized significant estimates and assumptions in determining the fair value of its common stock in periods prior to the IPO. The Company utilized various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately Held Company Equity Securities Issued as Compensation (the Practice Aid), to estimate the fair value of its common stock. Each valuation methodology includes estimates and assumptions that require the Company&#8217;s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to the Company&#8217;s common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale. Significant changes to the key assumptions used in the valuations could have resulted in different fair values of common stock at each valuation date. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comprehensive income (loss) </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Components of comprehensive income or loss, including net income or loss, are reported in the financial statements in the period in which they are recognized. Other comprehensive income or loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss) are reported net of any related tax effect to arrive at comprehensive income (loss). Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and economic events other than those with stockholders which for the years ended December 31, 2020 and 2019 consist of unrealized gain on marketable securities.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segment information </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company&#8217;s chief operating decision-maker, the Company&#8217;s chief executive officer, views the Company&#8217;s operations and manages its business as a single operating segment, which is in the business of discovering and developing small molecule drugs that activate progenitor cells within the body to create healthy tissue. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Foreign currency </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All periods presented are reported in US dollars. The functional currency for entities outside the United States is the US dollar. Realized and unrealized gains and losses from foreign currency transactions are reflected in the consolidated statements of operations as other expense. During the years ended December&#160;31, 2020 and 2019 the Company recorded $(4), and $7<font style="font-size:12pt;">&#160;</font>of foreign currency exchange (losses) gains, respectively. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash and cash equivalents </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with an original maturity of six months or less at acquisition to be cash equivalents which are stated at fair market value. Cash and cash equivalents at December&#160;31, 2020 and 2019 consists entirely of cash and money market funds. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Restricted Cash</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has $1.8 million of restricted cash as of December 31, 2020 which represents a $1.7 million security deposit on the Company's future Lexington, Massachusetts facility and a $0.1 million security deposit on the Company's Woburn, Massachusetts facility. The $0.1 million restricted cash at December 31, 2019 represented the security deposit on the Company's Woburn, Massachusetts facility.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Short-term marketable debt securities</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term marketable securities represent holdings of available-for-sale marketable debt securities in accordance with the Company&#8217;s investment policy. Short-term marketable investments mature within one-year from the balance sheet date. Investments in marketable securities are recorded at fair value, with any unrealized gains and losses reported within accumulated other comprehensive income as a separate component of stockholders&#8217; equity (deficit) until realized or until a determination is made that an other-than-temporary decline in market value has occurred. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion, together with interest on securities sold is determined based on the specific identification method and any realized gains or losses on the sale of investment are reflected as a component of other income (expense).</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of credit risk and off-balance sheet risk</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instrument that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. The Company maintains its cash and cash equivalents at several accredited financial institutions, in amounts that exceed federally insured limits. Marketable securities consist of U.S. Treasury securities with maturities of less than twelve months. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which its money market accounts are maintained.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has no significant off-balance sheet such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Significant suppliers </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is dependent on third-party manufacturers to supply products for research and development activities of its programs, including preclinical and clinical testing. In particular, the Company relies and expects to continue to rely on a single manufacturer of its product candidates for use in clinical trials. The Company would be adversely affected by a significant interruption in the supply of product for use in clinical programs. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair value measurements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic&#160;820, <font style="font-style:italic;">Fair Value Measurement</font> (ASC&#160;820), establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The hierarchy defines three levels of valuation inputs, of which the first two are considered observable and the last is considered unobservable: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:9.38%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Quoted prices in active markets for identical assets or liabilities.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:9.38%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Inputs other than quoted prices included within Level&#160;1 that are either directly or indirectly observable,&nbsp;&nbsp; &nbsp;&nbsp;such as quoted market prices, interest rates and yield curves.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:9.38%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 3</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Unobservable inputs developed using estimates or assumptions developed by the Company, which reflect those that a market participant would use in pricing the asset or liability.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying values of other current assets, accounts payable, and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. The fair value of the Company&#8217;s Term Loan is not materially different from the carry value as presented given the Term Loan was issued within one month of December 31, 2020. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property and equipment </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consist of lab equipment, computer equipment, furniture and office equipment and leasehold improvements recorded at cost. These amounts are depreciated using the straight-line method over the estimated useful lives of the assets as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.38%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.38%;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Estimated useful life</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="width:72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td valign="top" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="top" style="width:72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="width:72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and office equipment</p></td>
<td valign="top" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="top" style="width:72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shorter of the estimated useful</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">life or lease term</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheet and related gains or losses are reflected in the consolidated statements of operations.</p></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Impairment of long-lived assets </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company continually evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company did not recognize any impairment losses for the years ended December&#160;31, 2020 and 2019.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and development costs and accruals </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses include salaries and benefits, materials and supplies, preclinical and clinical trial expenses, stock-based compensation expense, depreciation of equipment, contract services and other outside expenses. The Company has entered into various research and development-related contracts with research institutions, contract research organizations, contract manufacturers and other companies. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. Costs of certain development activities, such as manufacturing, pre-clinical and clinical trial expenses, are recognized based on an evaluation of the progress to completion of specific tasks. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed. Costs incurred in obtaining technology licenses are charged to research and development expense as acquired in-process research and development if the technology licensed has not reached technological feasibility and has no alternative future use.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company elected to early adopt ASC 842, <font style="font-style:italic;">Leases</font> (ASC 842) as of January 1, 2020 and elected the transition method under ASU 2016-02 whereby the Company records a right-to-use asset and a lease liability on the consolidated balance sheet for all leases with terms longer than 12 months. The Company also elected to apply the package of practical expedients intended to ease transition. Accordingly, the Company has only applied ASC 842 to leases existing at January 1, 2020. The Company determines if an arrangement is, or contains, a lease at inception. Operating leases are included in operating lease right-of-issue (&#8220;ROU&#8221;) assets, other current liabilities, and operating lease liabilities on the consolidated balance sheets.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments to be made over the lease term. The ROU asset also includes any lease payments made at or before the lease commencement date and excludes lease incentives received. As the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected to not apply the recognition requirements of ASC 842 for short-term leases, which is defined as a lease that, at the lease commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For real estate lease agreements entered into or modified after the adoption of ASC 842 that include lease and non-lease components, the Company has elected to account for the lease and non-lease components, such as common area maintenance charges, as a single lease component.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Collaborative arrangements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company analyzes its collaborative arrangements to assess whether they are within the scope of ASC 808, <font style="font-style:italic;">Collaborative Arrangements</font> (&#8220;ASC 808&#8221;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship (e.g., a licensing arrangement) where the contracted party has obtained goods or services that are an output of the Company&#8217;s ordinary activities in exchange for a consideration and therefore within the scope of ASC 606, <font style="font-style:italic;">Revenue from Contracts with Customers</font> (&#8220;ASC 606&#8221;). For those elements of the arrangement that are accounted for pursuant to ASC 606, including those to which ASC 606 is applied by analogy, the Company applies the five-step model described in the Company&#8217;s revenue recognition policy. For elements of collaborative arrangements that are accounted for pursuant to ASC 808, an appropriate and rational recognition method is determined and applied consistently. Reimbursements from the counterparty that are the result of a collaborative relationship with the counterparty, instead of a customer relationship, such as co-development or clinical activities, are recorded as a reduction to research and development expense as the services are performed. Similarly, amounts that are owed to a collaboration partner related to the co-development clinical activities are recognized as research and development expense. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company enters into out-licensing agreements that are within the scope of ASC 606. The terms of such out-license agreements include licenses to functional intellectual property (IP), given the functionality of the intellectual property is not expected to change substantially as a result of the licensor&#8217;s ongoing activities. Such arrangements typically include payment of one or more of the following: non-refundable up-front license fees; reimbursement of certain costs; development and regulatory milestone payments and milestone payments based on the level of sales; and royalties on net sales of licensed products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers the economic and regulatory characteristics of the licensed IP, research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace to determine if it has standalone value at the inception of the licensing arrangement, which would make the license distinct. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of any additional good or services promised in the contract, whether the value of the license is dependent on the remaining goods and services, whether there are other vendors that could provide the remaining promise, and whether the license is separately identifiable from the remaining good and services. For licenses that are combined with other goods and services, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of progress and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue is allocated to the licensed IP on a relative standalone selling price basis and, for functional IP, is recognized at a point when the licensed IP is made available for the customer&#8217;s use and benefit, which generally occurs at the inception of the arrangement. However, in cases, where the functionality of the IP is expected to substantively change as a result of activities of the Company that do not transfer additional promised goods or services, or in cases, where there is an expectation that the Company will undertake activities to change the standalone functionality of the IP and the customer is contractually or practically required to use the latest version of the IP, revenue for the license to functional IP is recognized over time. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development and regulatory milestone fees, which are a type of variable consideration, are recognized as revenue to the extent that it is probable that a significant reversal will not occur. The Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into a collaboration arrangement with Astellas Pharma Inc. (&#8220;Astellas&#8221;), as further described in Note 16 of notes to consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue recognition </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for contracts with customers in accordance with ASC 606, including all amendments thereto. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as collaborative arrangements and leases. The Company&#8217;s disclosure within the below sections or elsewhere within these consolidated financial statements reflects the Company&#8217;s accounting policies in compliance with this new standard.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under ASC 606, an entity recognizes revenue when or as its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To recognize revenue for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies its performance obligations. The Company only applies the five-step model to contracts when it is probable that the entity will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services it transfers to the customer. Once a contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and identifies as a performance obligation each promise to transfer to the customer either (a) a good or service (or bundle of goods and services) that is distinct, or (b) a series of distinct goods and services that are substantially the same and have been the same pattern of transfer to the customer.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company assesses whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i)&#160;the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii)&#160;the entity&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract). In assessing whether a promised good or service is distinct, the Company considers factors such as the research, manufacturing and commercialization capabilities of the collaboration partner (the &#8220;customer&#8221; in this type of arrangement) and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct. For each arrangement that results in revenues, the Company identifies all performance obligations, which may include, for example, a license to IP and know-how, research and development activities, and/or manufacturing services. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to any upfront payment, if the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the estimated variable consideration in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. If it is probable that a significant revenue reversal will not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or of the licensee such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For contracts that include sales-based royalties (including milestone payments based on the level of sales) promised in the exchange for licenses of intellectual property, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestone payments at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied. In determining the transaction price, the Company adjusts the promised amount of consideration for the effects of the time value of money if the timing of payments provides the Company or the Company&#8217;s customer with a significant benefit of financing the transfer of goods and services. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. The Company assesses each of its revenue generating arrangements in order to determine whether a significant financing component exists. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time.&nbsp;&nbsp;For performance obligations satisfied over time, the Company measures progress toward completion of its performance obligations using an input method based on the Company&#8217;s efforts and inputs to satisfy its performance obligations relative to total expected inputs to the satisfaction of that performance obligation.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts received from a customer prior to revenue recognition are recorded as deferred revenue. Amounts received from a customer that are expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability in the accompanying consolidated balance sheets.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Patent costs </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses in the accompanying consolidated statements of operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-based compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for its stock-based compensation in accordance with ASC Topic&#160;718, <font style="font-style:italic;">Compensation&#8212;Stock Compensation</font> (ASC&#160;718). ASC&#160;718 requires all share-based payments to employees and directors to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company adopted FASB Accounting Standards Update (ASU) 2016-09 which identifies areas for simplification of several areas of share-based payment transactions. The Company treats non-employee grants in a manner consistent with employee grants. The Company estimates the fair value of options granted using the Black-Scholes option pricing model for stock option grants to both employees and non-employees. The Company believes the fair value of the stock options granted to non-employees is more reliably determinable than the fair value of the services provided. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (a)&#160;the expected stock price volatility, (b)&#160;the expected term of the award, (c)&#160;the risk-free interest rate and (d)&#160;expected dividends. Due to the lack of sufficient company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No.&#160;107, Share-Based Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to non-employees, the Company utilizes the contractual term of the share-based payment as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are significant judgments and estimates inherent in the determination of the fair value of the Company&#8217;s common stock prior to the IPO. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to its common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expenses the fair value of its share-based compensation awards to employees and non-employees on a straight-line basis over the requisite service period, which is generally the vesting period. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income taxes </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes using the asset and liability method in accordance with ASC Topic 740, <font style="font-style:italic;">Income Taxes</font> (ASC 740) which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. At December&#160;31, 2020 and 2019, the Company has concluded that a full valuation allowance is necessary for its deferred tax assets (see Note 13). </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net loss per share </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. Diluted net loss per share is the same as basic net loss per share for the years ended December&#160;31, 2020 and 2019 since all potential shares of common stock instruments are anti-dilutive as a result of the loss for such periods. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s convertible preferred stock contractually entitled the holders of such shares to participate in dividends but did not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reported a net loss, such losses are not allocated to such participating securities. In periods where the Company reported a net loss attributable to common stockholders, diluted net loss per share is the same as basic net loss per share, since dilutive shares of common stock are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for the years ended December&#160;31, 2020 and 2019.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted net loss per share attributable to common stockholders was calculated as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,511</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,800</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares of common stock outstanding-</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; basic and diluted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,253,227</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,649,245</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common stockholders-</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; basic and diluted</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.82</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.29</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company excluded the following potential shares of common stock from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted Common Stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,093</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,366</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series C Preferred (as converted to common stock)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,172,676</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series B Preferred (as converted to common stock)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,759,079</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A Preferred (as converted to common stock)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,070,574</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of Frequency Japan preferred stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">513,047</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding stock options (as converted to common stock)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,816,798</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,968,672</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,819,891</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,554,414</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently adopted accounting pronouncements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU No. 2016-02, <font style="font-style:italic;">Leases</font> (Topic 842) (&#8220;ASU 2016-02&#8221;), as amended by various subsequently issued ASUs. The standard requires lessees to recognize an operating lease with a term greater than one year on their balance sheets as a right-of-use asset and corresponding lease liability, measured at the present value of the lease payments. Lessees are required to classify leases as either finance or operating leases. If the lease is effectively a financed purchase by the lessee, it is classified as a financing lease, otherwise it is classified as an operating lease. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2018, the FASB also issued ASU 2018-11, <font style="font-style:italic;">Leases</font> (Topic 842): Targeted Improvements (&#8220;ASU 2018-11&#8221;), which permits entities to continue applying legacy guidance in ASC 840, Leases, including its disclosure requirements, in the comparative periods presented in the year that the entity adopts the new leasing standard. The Company adopted the standard on January 1, 2020 using the optional transition method. As such, the consolidated balance sheets and statements of operations for prior periods will not be comparable in the year of adoption of ASC 842. The Company elected the package of practical expedients permitted under the transition guidance within the standard. Accordingly, the Company did not reassess the conclusion of whether the existing arrangements contain a lease, lease classification and initial direct costs under ASC 842. As a result of the adoption of ASC 842, the Company recorded $1.2 million of ROU assets and a total of $1.5 million of lease liabilities on the consolidated balance sheets as of January 1, 2020. In addition, in the first quarter of 2020 the Company expanded and amended the lease for its Woburn, Massachusetts facility and increased both the ROU asset and lease liability by $1.0 million. On December 11, 2020, the Company terminated this lease and remeasured the existing ROU asset and lease liability based on this lease modification, resulting in a $1.7 million impact to both the ROU asset and lease liability. As disclosed in Note 16, the Company has entered into a lease for a facility in Lexington Massachusetts which commenced December 11, 2020. In accordance with ASU No. 2016-02, the Company recognized a right-of-use asset and related lease liability at such time.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2016,&#160;the FASB issued ASU No. 2016-01, <font style="font-style:italic;">Financial Instruments - Overall</font> (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. This new standard amended certain aspects of accounting and disclosure requirements for financial instruments, including the requirement that equity investments with readily determinable fair values are to be measured at fair value with any changes in fair value recognized in a company's statements of operations. Prior to adoption of ASU 2016-01, companies recognized changes in fair value in accumulated other comprehensive income (loss), net. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. In addition, a valuation allowance should be evaluated on deferred tax assets related to available- for-sale debt securities in combination with other deferred tax assets.&#160;The Company adopted this new standard on January 1, 2020, using the modified retrospective method, and determined that it did not have a material impact on its financial statements.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently issued accounting pronouncements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company is an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, as amended (Jobs Act). The Jobs Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company elected to avail itself of this extended transition period and, as a result, we will not be required to adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13, <font style="font-style:italic;">Financial Instruments - Credit Losses</font> (Topic 326): Measurement of Credit Losses on Financial Instruments. The FASB has subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. This standard will become effective for the Company on January 1, 2023. The Company is still evaluating the impact of this standard on its consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued&#160;<font style="color:#000000;">ASU 2019-12</font>&#160;amending accounting guidance that simplifies the accounting for income taxes, as part of its initiative to reduce complexity in the accounting standards. The amendments eliminate certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The amendments also clarify and simplify other aspects of the accounting for income taxes. This standard will become effective for the Company on January 1, 2021. The Company is still evaluating the impact of this standard on its consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703587966616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3. Fair value measurements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s financial assets measures at fair value on a recurring basis by level within the fair value hierarchy at December 31, 2020 and 2019 are summarized as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortization</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Market</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Hierarchy</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gain</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214,522</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214,549</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.04%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214,522</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214,549</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortization</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Market</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Hierarchy</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Loss) Gain</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,131</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,119</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Government treasury securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,131</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,197</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.04%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,262</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,316</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p></div>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703590118616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense And Other Assets Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_PrepaidExpensesAndOtherCurrentAssetsTextBlock', window );">Prepaid Expenses</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4. Prepaid expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.4%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent and deposits</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,729</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">801</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grant receivable</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">805</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">340</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Insurance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,552</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,132</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">199</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,723</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,000</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_PrepaidExpensesAndOtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_PrepaidExpensesAndOtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703666550008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5. Property and equipment </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment include the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,166</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,846</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and office equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">283</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">257</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">291</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,419</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,419</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,340</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">306</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,499</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,828</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated depreciation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,212</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,066</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,287</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,762</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognized $1,146 and $813 of depreciation expense for the years ended December&#160;31, 2020 and 2019, respectively. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703675949672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6. Accrued expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consist of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.4%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll and employee related expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,062</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,686</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional fees</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">647</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">435</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third-party research and development expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">874</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Taxes and other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,663</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,239</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703674434120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7. Debt</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 11, 2020, the Company entered into a Loan and Security Agreement (the &#8220;Loan Agreement&#8221;) with a commercial bank for a Term Loan with a principal balance of $15 million. The Company will make monthly interest only payments through November&#160;30, 2022. The principal balance and interest will be repaid in equal monthly installments after the interest only period and continuing through May&#160;1, 2024 (the &#8220;Loan Maturity Date&#8221;). Advances under the Loan Agreement will bear an interest rate equal to the greater of either (i) 1.50% plus the Prime Rate (as reported in<font style="font-style:italic;">&#160;The Wall Street Journal</font>, subject to an interest rate floor of zero) or (ii) 4.75%. Interest related to the Loan Agreement was immaterial for the year ended December 31, 2020. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company may prepay the advance made under the Loan Agreement in whole, at any time subject to a prepayment premium equal to: (a) 2.0% of the then-outstanding principal amount of the advance, if such prepayment occurs on or prior to the first anniversary of the Closing Date; (b) 1.0% of the then-outstanding principal amount of the advance, if such prepayment occurs after the first anniversary of the Closing Date and on or prior to the second anniversary of the Closing Date; and (c) 0.0% of the then-outstanding principal amount of the advance, if such prepayment occurs after the second anniversary of the Closing Date. The prepayment premium is waived if the Term Loan Facility is refinanced by the Bank (in its sole and absolute discretion) on or prior to the Loan Maturity Date.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will pay a final payment of $150,000, which will occur on the earliest of: (i)&#160;the Loan Maturity Date; (ii)&#160;the date that the Company prepays all of the outstanding principal in full; (iii)&#160;the date the loan payments are accelerated due to an event of default; or (iv)&#160;the termination of the Loan Agreement. The Company is recording the final payment as interest expense over the term of the loan. The Term Loan Facility is secured by substantially all of the Company&#8217;s assets, excluding intellectual property.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703585157112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_TemporaryEquityTextBlock', window );">Convertible Preferred Stock</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8. Convertible preferred stock </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2018, the Company had issued 62,528,507 shares of Series A Preferred Stock, 10,000 shares of Series A-1 Preferred Stock, 41,857,005 shares of Series B Preferred Stock, and 10,000 shares of Series B-1 Preferred Stock. In 2019, the Company also issued 288,911 shares of Series B Preferred Stock. On July&#160;17, 2019, the Company authorized and issued 39,492,960 shares of Series&#160;C Preferred for net proceeds of $61,687. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluated the tranched nature of the issuance of these preferred shares as well as the rights, preferences, and privileges of such shares and has concluded that there were no freestanding derivative instruments or any embedded derivatives requiring bifurcation. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2019, in connection with the IPO, all shares of Preferred Stock were automatically converted into common stock.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:12pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_TemporaryEquityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_TemporaryEquityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703675076792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-controlling Interest<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDisclosureTextBlock', window );">Non-controlling Interest</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9. Non-controlling Interest</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2018, the Company issued shares of preferred stock in its subsidiary, Frequency Japan, to a Japanese investor. The Frequency Japan preferred stock held by such investor was convertible, at the option of the holder, into 673,605 shares of Company common stock, adjustable for certain dilutive events, upon an initial public offering of Company common stock, a Company liquidation or upon a 70% vote of the holders of the Preferred Stock. The preferred shares also had a liquidation preference equal to the amount paid for the shares. The Company had the option to acquire the preferred shares of Frequency Japan under certain circumstances and the holder of such preferred shares had the right to require the Company to purchase such shares under certain circumstances, primarily a merger or liquidation. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with this sale of the preferred stock in Frequency Japan, FT-FJ Investment, LLC (FT-FJ), a Delaware limited liability company controlled by the Company, purchased 10,000 shares of the Company&#8217;s Series A-1 Preferred Stock and 10,000 shares of the Company&#8217;s Series B-1 Preferred Stock. FT-FJ also granted to the Japanese investor an irrevocable proxy to vote the shares of Series A-1 and Series B-1 Preferred Stock held by FT-FJ. Each share of Series A-1 Preferred had 236 times the voting power of one share of common stock and each share of Series B-1 Preferred Stock has 217 times the voting power of one share of common stock. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 20, 2019, the Company, Frequency Japan, the Japanese investor, and FT-FJ entered into an agreement pursuant to which, contingent upon the closing of an initial public offering of the Company&#8217;s common stock: (i) the Japanese investor agreed to convert its shares of preferred stock held in Frequency Japan and to terminate its proxy over the shares of Series A-1 and B-1 Preferred Stock held by FT-FJ and (ii) FT-FJ agreed to forfeit its shares of Series A-1 and Series B-1 Preferred Stock. The shares were converted into common stock and the Series A-1 and B-1 preferred shares were forfeited in conjunction with the IPO.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703665257304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Deficit</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10. Stockholders&#8217; equity </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Preferred stock</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:normal;">The Company has authorized 10,000,000 shares of $0.001 par value preferred stock of which no shares were issued or outstanding as of December 31, 2020.</font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Common stock </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has authorized 200,000,000 shares of $0.001 par value common stock of which 33,964,000 were issued and outstanding as of December 31, 2020. Common shares are voting, and dividends may be paid when, as and if declared by the Board of Directors.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has reserved the following shares of common stock for future issuance as of December 31, 2020 and 2019:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options outstanding</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,816,798</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,968,672</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for future grant under stock option plan</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,475,923</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,859,654</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,292,721</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,828,326</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703592048008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11. Stock-based compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November&#160;13, 2014, the Company adopted the 2014 Stock Incentive Plan (2014 Plan). All of the Company&#8217;s employees, officers, directors, and consultants are eligible to be granted options to purchase common shares and restricted stock under the terms of the 2014 Plan. The Company reserved an aggregate of 8,550,415 shares of common stock for issuance under the 2014 Plan. As of December&#160;31, 2020, there were no shares of common stock available for future grants under the 2014 Plan.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 17, 2019, the Company&#8217;s board of directors and on September 19, 2019, its stockholders approved and adopted the 2019 Incentive Award Plan (&#8220;the &#8220;2019 Plan&#8221;) which became effective on the day prior to the IPO.&nbsp;&nbsp;Under the 2019 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock and cash-based awards to individuals who are then employees, officers, directors or consultants of the Company, and employees and consultants of the Company&#8217;s subsidiaries.&nbsp;&nbsp;A total of 3,100,000 shares of common stock were approved to be initially reserved for issuance under the 2019 plan.&nbsp;&nbsp;The number of shares under the 2014 Plan subject to outstanding awards as of the effective date of the 2019 Plan that are subsequently canceled, forfeited or repurchased by the Company will be added to the shares reserved under the 2019 Plan.&nbsp;&nbsp;In addition, the number of shares of common stock available for issuance under the 2019 Plan will be automatically increased on the first day of each calendar year during the ten-year term of the 2019 Plan, beginning with January 1, 2020 and ending with January 1, 2029, by the amount equal to 4% of the outstanding number of shares of the Company&#8217;s common stock on December 31, of the preceding calendar year or such lesser amount as determined by the Company&#8217;s board of directors.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All stock option grants are non-statutory stock options except option grants to employees (including officers and directors) intended to qualify as incentive stock options under the Internal Revenue Code of 1986, as amended. Incentive stock options may not be granted at less than the fair market value of the Company&#8217;s common stock on the date of grant, as determined in good faith by the Board of Directors at its sole discretion. Nonqualified stock options may be granted at an exercise price established by the Board of Directors at its sole discretion (which has not been less than fair market value on the date of grant) and the vesting periods may vary. Vesting periods are generally four years and are determined by the Board of Directors. Stock options become exercisable as they vest. Options granted under the 2014 Plan and the 2019 Plan expire no more than ten years from the date of grant. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock options </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the stock option activity under the 2014 Plan and the 2019 Plan are as follows: </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">exercise</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">term</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">intrinsic</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">exercise</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">term</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">intrinsic</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019 Plan</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014 Plan</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2018</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,089,334</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.61</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,247,338</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.09</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,015,381</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.17</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(357,170</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.02</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,211</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.09</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,247,338</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.09</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.76</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,287</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,721,334</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.85</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.89</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,051</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,645,859</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.22</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,851</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.93</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(767,534</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.94</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,997</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.72</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,351</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.89</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,874,349</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.84</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.09</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,325</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,942,449</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.02</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.98</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127,090</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable as of December 31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">564,617</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.48</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.90</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,042</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,337,828</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.57</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.88</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,416</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options unvested as of December 31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,309,732</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,283</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,604,621</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,674</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock option valuation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumptions that the Company used to determine the grant-date fair value of stock options granted to<font style="font-weight:bold;font-style:italic;"> </font>employees and directors were as follows, presented on a weighted average basis: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.9</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79.1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79.4</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Risk-Fee Interest Rate<font style="font-style:normal;">: The Company based the risk-free interest rate over the expected term of the options based on the constant maturity of U.S. Treasury securities with similar maturities as of the date of the grant.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expected Term<font style="font-style:normal;">:&nbsp;&nbsp;The expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term).</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expected Volatility<font style="font-style:normal;">: The Company uses an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry that were deemed to be representative of future stock price trends as the Company does not have sufficient trading history for its common stock.&nbsp;&nbsp;The Company will continue to apply this process until a sufficient amount of historical information regarding volatility of its own stock price options becomes available.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expected Dividend Yield<font style="font-style:normal;">: The Company has not paid and does not anticipate paying any dividends in the near future.&nbsp;&nbsp;Therefore, the expected dividend yield was zero.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#8217;s common stock. During the years ended December&#160;31, 2020 and 2019, 769,385 and 357,170 shares were exercised, respectively. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2020 and 2019 was $16,667 and $5,896 respectively.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average grant date fair value of options granted to employees during the years ended December&#160;31, 2020 and 2019 was $16.41 and $4.05<font style="font-size:12pt;">&#160;</font>respectively. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total grant date fair value of options vested during the years ended December&#160;31, 2020 and 2019 was $7,907 and $2,990, respectively. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Restricted common stock </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company issued common stock to founders, employees and advisors which was subject to vesting over four years. If any of these individuals ceased to be employed or to provide services to the Company prior to vesting, the Company had the right to repurchase any unvested Common Stock at the price paid by the holder. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the status of restricted common stock as of December&#160;31, 2020 and 2019 is presented below: </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:72.52%;">
<tr style="height:8.85pt;">
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:20.95pt;">
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:8.85pt;">
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested, December 31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,366</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.36</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:8.85pt;">
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Awarded</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:8.5pt;">
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(67,273</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.29</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:8.85pt;">
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:8.5pt;">
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested, December 31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,093</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.75</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p></div>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> The total value of restricted stock awards that vested during the years ended December&#160;31, 2020 and 2019, based on estimated fair values of the stock underlying the restricted stock awards was $20 and $73, respectively. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-based compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense of $9,983 and $3,609 for the years ended December&#160;31, 2020 and 2019 respectively, is included in research and development and general and administrative expenses in the Company&#8217;s consolidated statements of operations and comprehensive loss. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020 and 2019, total unrecognized stock-based compensation expense relating to unvested stock options was $31,006 and $13,820, respectively. This amount is expected to be recognized over a weighted-average period of 3.08 years and 2.76 years, respectively. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703593368424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Stock Purchase Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_EmployeeStockPurchasePlanDisclosureTextBlock', window );">Employee Stock Purchase Plan</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12. Employee stock purchase plan </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 20, 2019, the Company&#8217;s board of directors and stockholders approved and adopted the 2019 Employee stock Purchase Plan (the &#8220;ESPP&#8221;) which became effective on the date of the IPO. The ESPP permits participants to purchase common stock through payroll deductions of up to 15% of their eligible compensation. A total of 315,000 shares of common stock were approved to be initially reserved for issuance under the ESPP. In addition, the number of shares of common stock available for issuance under the ESPP will be automatically increased on the first day of each calendar year during the first ten-years of the term of the ESPP, beginning with January 1, 2020 and ending with January 1, 2029, by an amount equal to 1% of the outstanding number of shares of the Company&#8217;s common stock on December 31 of the preceding calendar year or such lesser amount as determined by the Company&#8217;s board of directors. No shares were issued under the ESPP at December 31, 2020.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_EmployeeStockPurchasePlanDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee stock purchase plan disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_EmployeeStockPurchasePlanDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703665212440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">13. Income taxes </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since inception in 2014, the Company has generated cumulative federal and state net operating loss and research and development credit carryforwards for which we have not recorded any net tax benefit due to uncertainty around utilizing these tax attributes within the respective carryforward periods. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the Company had federal net operating loss carryforwards of approximately $67,868 and Massachusetts state operating loss carryforwards of approximately $43,386&#160;which may be available to offset future taxable income. The U.S. federal net operating loss carryforwards include $22,400 available to reduce future taxable income through 2037 and approximately $45,469 which do not expire and are available to reduce future taxable income indefinitely. The state net operating loss carryforwards are available to offset future taxable income through 2040. As of December&#160;31, 2020, the Company also had federal and Massachusetts research and development tax credit carryforwards of $3,014 and $1,211, respectively, which are available to offset federal and state tax liabilities through 2040 and 2035, respectively. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Realization of future tax benefits is dependent on many factors, including the Company&#8217;s ability to generate taxable income within the net operating loss carryforward period. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as provided under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, respectively, as well as similar state provisions. These ownership changes may limit the number of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section&#160;382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has completed several financings and has conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception and has determined that an ownership change did occur in March 2017. Accordingly, utilization of $12,400 of the U.S. net operating loss carryforwards which were incurred prior to March 2017 (pre-ownership change) is limited under Section 382. After the Section 382 limitations, the Company may utilize approximately $10,800 of its pre-ownership change net operating loss carryforwards based upon an annual usage of approximately $1,600 for each of the next five years after the ownership change and approximately $180 for each of the 15 years thereafter. The remaining pre-ownership change net operating losses of approximately $1,600 were written off due to expiration under limitation. The limitation has been determined by first multiplying the value of our stock at the time of the ownership change by the applicable long-term tax-exempt rate. These carryforwards may be subject to further annual limitations under Section&#160;382 in the event of future changes in ownership.&nbsp;&nbsp;Additionally, the Company has determined an ownership changed occurred in October of 2019 as a result of the IPO.&nbsp;&nbsp;Accordingly, utilization of approximately $46,123 of the U.S. net operating loss carryforwards incurred prior to October 2019 is also limited under Section 382.&nbsp;&nbsp;The Company has determined it will be able to utilize the entire $46,123 of its pre-ownership change net operating loss carryforwards based upon the limitations calculated from the October 2019 ownership change. These carryforwards may be subject to further annual limitations under Section 382 in the event of future changes in ownership.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration of all the evidence, both positive and negative, the Company has recorded a valuation allowance against its deferred tax assets at December&#160;31, 2020 and 2019 because the Company&#8217;s management has determined that it is more likely than not that the Company will not recognize the benefits of its federal and state deferred tax assets primarily due to its cumulative loss position and, as a result, a valuation allowance of approximately $26,995 and $16,204 as of December&#160;31, 2020 and 2019 has been established. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has no unrecognized tax benefits. The Company has not, as yet, conducted a study of its research and development credit carryforwards. Such a study may result in an adjustment to the Company&#8217;s research and development credit carryforwards; however, until a study is completed, and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#8217;s research and development credits and, if an adjustment were required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the consolidated balance sheet or consolidated statements of operations if an adjustment were required. The Company has elected to recognize interest and penalties related to income tax matters as a component of income tax expense, of which no interest or penalties were recorded for the years ended December&#160;31, 2020 and 2019. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company files income tax returns in the U.S. and Massachusetts. The statute of limitations for assessment by the Internal Revenue Service and Massachusetts tax authorities remains open for all years since 2014. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service or state authorities to the extent utilized in a future period. No federal or state tax audits are currently in process. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the Company&#8217;s pre-tax income for the years ended December 31, 2020 and 2019 is as follows:</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:56.02%;">
<tr style="height:10.65pt;">
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:12.7pt;">
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Domestic</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,744</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,086</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr style="height:12.7pt;">
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(732</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(714</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr style="height:13.45pt;">
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,476</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,800</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s provision at December 31, 2020 and 2019 consist of the following:</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:55.74%;">
<tr style="height:10.3pt;">
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:12.35pt;">
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:12.35pt;">
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp; Federal</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:13.05pt;">
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp; State</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:13.05pt;">
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp; Foreign</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:12.35pt;">
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:12.35pt;">
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:13.05pt;">
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp; Federal</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:12.35pt;">
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp; State</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:13.05pt;">
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp; Foreign</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:12.35pt;">
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Deferred</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:12.35pt;">
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total provision (benefit)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate for the years ended December&#160;31, 2020 and 2019 is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:52.54%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S federal statutory income tax rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent differences</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.2)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.8</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes, net of federal benefit</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.0</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credits</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.8</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation deductions</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other items</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.6</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.0</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in deferred tax asset valuation allowance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40.7)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23.0</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective income tax rate</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;%</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s deferred tax assets at December&#160;31, 2020 and 2019 consist of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,885</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,253</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credits</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,992</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,138</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangibles</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">360</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">358</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">850</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">686</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,606</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">496</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">189</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liability</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,285</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right of use asset</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,181</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax asset</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,995</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,204</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,995</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,204</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703665134408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research And Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_ResearchAndLicenseAgreementsDisclosureTextBlock', window );">Research and License Agreements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14. Research and license agreements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Massachusetts Institute of Technology </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2016, the Company entered into an exclusive patent license agreement (MIT License Agreement), with the Massachusetts Institute of Technology, (MIT), under which the Company received an exclusive, worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, offer to sell, lease and import products (Licensed Products) and to develop and perform processes (Licensed Processes) which incorporate the licensed technology for the treatment of disease, including but not limited to the prevention and remediation of hearing loss. The Company also has the right to grant sublicenses of its rights under the MIT License Agreement. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is required to use diligent efforts to develop and commercialize the Licensed Products or Processes, and to make such products or processes reasonably available to the public and to spend certain minimum amounts on research and development of Licensed Products and/or Processes each year until the first commercial sale of a Licensed Product and/or a first commercial performance of a Licensed Process. The Company is also subject to certain development obligations with regards to a first Licensed Product. The Company has satisfied certain obligations related to preclinical studies and the filing of an IND for a first Licensed Product with its development activities related to FX-322. The Company&#8217;s future development obligations are: (i) to commence a Phase II clinical trial for such Product, (ii) to commence a Phase III clinical trial for such Product within five years of the IND filing for such product within two years of the IND filing for such product, (iii) to file a New Drug Application or equivalent with the FDA or comparable European regulatory agency for such Product within nine years of the IND filing for such product, and (iv) to make a first commercial sale of such Product within 11 years of the IND filing for such product. The Company also has certain development obligations for as second Licensed Product. In the event that the Company has failed to fulfill the development timeline obligation with respect to a second Licensed Product and fail to cure such breach within ninety (90)&#160;days of written notice by MIT, MIT may restrict the licensed field to the prevention and remediation of hearing loss in humans and animals. The Company does not have the right to control prosecution of the in-licensed patent applications, and its rights to enforce the in-licensed patents are subject to certain limitations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon entering into the MIT License Agreement, the Company paid a $50 license fee payment and issued to MIT shares of our common stock equal to 5% of total then-outstanding capital stock. The Company is required to pay certain annual license maintenance fees which may be credited to running royalties during the same calendar year, if any, and to make potential milestone payments up to $2,900 on each Licensed Product or Licensed Process. In addition, The Company is required to pay a low single-digit royalty on Licensed Products and Licensed Processes and a low-twenties royalty on sublicense revenues. In the year ended December 31, 2019 the Company paid MIT a royalty of $16,000 related to the upfront payment received from Astellas, see Note 15.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The MIT License Agreement will remain effect until the expiration or abandonment of all issued patents and filed patent applications licensed thereunder remain in effect, unless terminated earlier. The Company has the right to terminate for any reason upon a 3-month prior written notice. MIT shall have the right to terminate if the Company ceases to carry on any business related to the MIT License Agreement. MIT may terminate the MIT License Agreement for the Company&#8217;s material breach uncured within ninety (90)&#160;days (or thirty (30)&#160;days in the case of nonpayment). MIT may also terminate the MIT License Agreement if the Company or our affiliates commence any action against MIT to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or non-infringed (a patent challenge), or if our sublicensee commences such actions and the Company does not terminate such sublicense within thirty (30)&#160;days after MIT&#8217;s demand. MIT has the right to increase all payments due, instead of terminating the MIT License Agreement in the case of a patent challenge. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2019, the Company entered into an amendment with MIT, updating the diligence milestones for a second Licensed Product. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patents in-licensed by the Company from MIT pursuant to the MIT License claim inventions created by, among others, Dr. Langer, one of the Company&#8217;s directors.&#160;Pursuant to MIT&#8217;s policy on the ownership, distribution and commercial development of MIT technology, or the MIT Policy, inventors of intellectual property invented at MIT, including the inventors of patents licensed to the Company under the MIT License, are entitled to a portion of the net royalty income derived by MIT from such inventions, but not amounts received by MIT from the sale of common stock previously issued by the Company to MIT pursuant to the MIT License. Accordingly, pursuant to the MIT Policy, Dr. Langer is entitled to receive a portion of the amounts the Company pays to MIT under the MIT License, including the Astellas Royalty Payment and future milestone payments or royalties, if any, that the Company may receive pursuant to the Astellas Agreement. Accordingly, Dr. Langer has received $1.98 million and $0.01 million from MIT under the MIT Policy during the years ended December 31, 2020 and 2019, respectively. Refer to Note 18 for all related party disclosures. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The Scripps Research Institute (California Institute for Biomedical Research)</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2018, the Company entered into a license agreement, (CALIBR License Agreement), with the California Institute for Biomedical Research, (CALIBR), under which the Company received an exclusive, worldwide, royalty-bearing license to certain patent rights to make, have made, use, sell, offer to sell, and import products (CALIBR Licensed Products) which incorporate the licensed technology for the treatment of multiple sclerosis. The Company also have the right to grant sublicenses of our rights under the CALIBR License Agreement. CALIBR reserves the right to use for itself and the right to grant non-exclusive licenses to other nonprofit or academic institutions, for any internal research and educational purposes. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is required to use commercially reasonable efforts to develop, manufacture, and sell at least one Licensed Product and does not have the right to control prosecution of the in-licensed patent applications, and to enforce the in-licensed patents are subject to certain limitations. The Company is also subject to certain milestone timeline obligations , which may be extended under certain circumstances as outlined in the CALIBR License Agreement, to: (i) submit an IND (or equivalent) for a CALIBR Licensed Product by the 30th month after the effective date of the CALIBR License Agreement, (ii) initiate a Phase II clinical trial (or equivalent) for a CALIBR Licensed Product by the fourth anniversary of the effective date of the CALIBR License Agreement, and (iii) initiate a Phase III clinical trial (or equivalent) for a CALIBR Licensed Product by the sixth anniversary of the effective date of the CALIBR License Agreement. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon entering into the CALIBR License Agreement, the Company made a $1,000 license fee payment and are required to make milestone payments up to $26,000 for each Category of CALIBR Licensed Products (Category 1 means any CALIBR Licensed Products containing a compound that modulates any muscarinic receptor and Category 2 means any CALIBR Licensed Products not included in Category 1 that could differentiate oligodendrocyte precursors). The Company is also required to pay a middle single-digit royalty on CALIBR Licensed Products and a royalty on sublicense revenues ranging from low-teen percentage to 50%. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The CALIBR License Agreement shall continue in effect until expiration of all Company obligations to pay royalties. Royalties shall be payable on a country-by-country and CALIBR Licensed Product-by-CALIBR Licensed Product basis upon the later of (1)&#160;the expiration or abandonment of all valid claims of the licensed patent rights in such country and (2)&#160;ten years from the first commercial sale of each CALIBR Licensed Product. The Company may terminate the CALIBR License Agreement at will upon a 30-day prior written notice. The Company may also elect to terminate its license to one or more licensed patents in any or all jurisdictions by giving ninety (90)&#160;days&#8217; prior written notice to CALIBR. CALIBR may terminate the CALIBR License Agreement for material breach uncured within thirty (30)&#160;days. CALIBR has the right to terminate or reduce the license to a non-exclusive license if the Company fails to use diligent efforts to develop and commercially exploit CALIBR Licensed Products. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The Scripps Research Institute</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2018, we entered into a Research Funding and Option Agreement, or the Scripps option agreement, with Scripps, under which we were granted an exclusive option to acquire an exclusive, sublicensable, worldwide license under certain intellectual property related to the treatment of MS. As consideration for the Scripps option agreement, we made funding payments totaling $0.7 million to Scripps to support its research activities. Scripps has agreed to use reasonable efforts to perform the research program pursuant to the Scripps option agreement. The Scripps option agreement had a one-year term and was renewed for a second year by mutual written agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2020, the Company extended the term of the option agreement through the end of December 2021. As consideration for this extension, the Company is required to make additional funding payments of $0.6 million to Scripps through December 2021.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has the right to terminate by giving 90 days&#8217; advance notice. Scripps has the right to terminate in the event of nonpayment by us that remains uncured for 10 days. Each party has the right to terminate in the event of the other party&#8217;s material breach that remains uncured for 60 days or if the other party becomes bankrupt.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Massachusetts Eye and Ear (Formerly Massachusetts Eye and Ear Infirmary) </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2019, the Company entered into an Non-Exclusive Patent License Agreement (MEE License Agreement) with the Massachusetts Eye and Ear (MEE) under which it received a non-exclusive, non-sublicensable, worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, offer to sell, lease and import products and to develop and perform processes which incorporate the licensed technology for the treatment or prevention of hearing loss. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is required to use diligent efforts to develop and commercialize the licensed products and MEE has control over the filing, prosecution, enforcement and defense of any licensed patent rights. We met one of our milestone timeline obligations by dosing a first patient in a Phase&#160;II trial by December&#160;31, 2020. We are still subject to a milestone timeline obligation to dose a first patient in a Phase&#160;III trial by December&#160;31, 2024.  </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon entering into the MEE License Agreement, the Company made a $20 license fee payment and is required to pay certain annual license maintenance fees until the first commercial sale and a minimum annual royalty payment after the first commercial sale. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is also required to make milestone payments up to $350 on each product or process which incorporates the licensed patent rights and pay a low single-digit royalty on products and processes that incorporate the licensed patent rights. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The MEE License Agreement shall remain in effect until all issued patents and filed patent applications within the licensed patent rights have expired or been abandoned, unless terminated earlier. The Company has the right to terminate the MEE License Agreement at will by giving thirty (30)&#160;business days advance written notice to MEE. MEE has the right to terminate the MEE License Agreement if the Company fails to make any payment due within thirty (30)&#160;business days after MEE notifies the Company of such failure. MEE shall have the right to terminate if the Company fails to maintain the required insurance. MEE shall also have the right to terminate the MEE License Agreement upon forty-five (45)&#160;business days written notice if the Company becomes insolvent. MEE has the right to terminate for any other default not cured within sixty (60)&#160;business days written notice. MEE also has the right to terminate if the Company or its affiliates challenge the validity of the licensed patent rights. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cambridge Enterprise Limited</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, we entered into an Exclusive Patent License Agreement ( the &#8220;Cambridge License&#8221;) with Cambridge Enterprise Limited (the technology transfer arm of the University of Cambridge)<font style="font-size:12pt;"> </font>(&#8220;Cambridge&#8221;) under which we received an executive worldwide royalty-bearing license to certain patent rights to make, have made, sell, offer to sell and import products, or the (the &#8220;Cambridge License Product&#8221;) which incorporate licensed technology for the treatment of demyelinating diseases.&nbsp;&nbsp;We also have the right to grant nonexclusive licenses to other academic institutions for any academic publication, research and teaching and clinical patient care.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has agreed to use diligent and good faith efforts to develop and commercially exploit at least one Cambridge Licensed Product.&nbsp;&nbsp;Upon entering into the Cambridge License, the Company made a $50 license fee payment.&nbsp;&nbsp;The Company is obligated to pay an annual license fee of $50. The Company is also obligated to make milestone payments up to $10.5 million on each Cambridge License Product.&nbsp;&nbsp;In addition, the Company has agreed to pay a low single-digit royalty on products that incorporate the licensed patent rights, subject to offset in certain circumstances. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Cambridge License continues in effect on a country-by-country basis until the expiration or revocation, without right of further appeal, of all licensed issued patents and filed patent applications, unless terminated earlier.&nbsp;&nbsp;We have the right to terminate for any reason upon 90 days&#8217; prior to written notice.&nbsp;&nbsp;Each party has the right to terminate immediately if the other party ceases to carry on its business.&nbsp;&nbsp;Either party may also terminate the Cambridge License for material breach if such breach remains uncured for 30 days.&nbsp;&nbsp;Cambridge may also terminate the Cambridge License if we fail to diligently develop and commercially exploit at least one Cambridge Licensed Product or we or our affiliates or sub-licenses commence any action against Cambridge to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or not infringed.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Department of Defense </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2018, the Company received a grant (the Grant) from the Department of Defense (DoD) under which the Company is receiving funding to further the Company&#8217;s research and development of a therapeutic drug to treat hearing loss. The Company is receiving funding of $1,596 over two years from the date of the Grant. The Company has determined that the DoD is not considered a customer under ASC 606, therefore funding received from the DoD under the Grant is recorded as a reduction of research and development expenses. The Company has recorded $323 and $845 as a reduction in research and development expenses for the years ended December&#160;31, 2020 and 2019, respectively. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_ResearchAndLicenseAgreementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and license agreements disclosure text block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_ResearchAndLicenseAgreementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703591998200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration Agreement</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15. Collaboration agreement </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2019, the Company entered into a License and Collaboration Agreement with Astellas (the Astellas Agreement), under which the Company granted Astellas an exclusive, royalty-bearing, sub-licensable, nontransferable license to certain patent rights to research, develop, manufacture, have manufactured, use, seek and secure regulatory approval for, commercialize, offer for sale, sell, have sold and import, and otherwise exploit licensed products containing both a GSK-3 inhibitor and an HDAC inhibitor, (the Astellas Licensed Products), including the product candidate FX-322, outside of the United States. The Company also granted Astellas a right of first negotiation and a right of last refusal if it entered into any negotiation or agreement of any kind (other than an acquisition of all of the stock or assets of the Company) with any third party under which such third party would obtain the right to develop, manufacture, or commercialize Astellas Licensed Products in the United States. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has agreed to conduct Phase 2a clinical studies in the United States. Upon the completion thereof, the Company and Astellas have agreed to jointly develop the Astellas Licensed Products, including carrying out joint studies. Each party has agreed to use commercially reasonable efforts to carry out development activities assigned to it under an agreed-upon development plan. Astellas has agreed to use commercially reasonable efforts to obtain regulatory approval for at least one Astellas Licensed Product in sensorineural hearing loss and in age-related hearing loss, in each case, in one major Asian country and one major European country. The Company has agreed to use commercially reasonable efforts to obtain regulatory approval for at least one Astellas Licensed Product in the United States. Astellas has the sole right to commercialize the Astellas Licensed Products outside of the United States, and the Company has the sole right to commercialize the Astellas Licensed Products in the United States. Astellas has agreed to use commercially reasonable efforts to commercialize Astellas Licensed Products in a major Asian country and a major European country following receipt of regulatory approval in such countries. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The collaboration is governed by a joint steering committee (&#8220;JSC&#8221;) established under the Astellas Agreement and shall be comprised of three representatives each from the Company and Astellas. The JSC shall oversee and coordinate the overall conduct of the development, manufacture and commercialization of the Astellas Licensed Products. All decisions of JSC shall be taken through a unanimous vote with each party&#8217;s representatives collectively having one vote. Both the parties shall be responsible for carrying out the development and manufacturing activities in their defined territory in accordance with the plan as reviewed and approved in the JSC. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As consideration for the licensed rights under the Astellas Agreement, Astellas paid the Company an upfront payment of $80.0&#160;million in July 2019 and has agreed to pay potential development milestone payments up to $230.0&#160;million and commercialization milestones of up to $315.0 million. Specifically, the Company would receive development milestone payments of $65.0 million and $25.0 million upon the first dosing of a patient in a Phase 2b clinical trial for SNHL in Europe and Asia, respectively and $100.0 million and $40.0 million upon the first dosing of a patient in a Phase 3 clinical trial for SNHL in Europe and Asia, respectively.  If the Astellas Licensed Products are successfully commercialized, the Company would be eligible for up to $315.0&#160;million in potential commercial milestone payments and also tiered royalties at rates ranging from low- to mid-teen percentages. The parties shall share equally, on a 50/50 basis, all out-of-pocket costs and joint study costs for all the joint activities conducted pursuant to the development plans or the joint manufacturing plan. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Astellas Agreement remains in effect until the expiration of all royalty obligations. Royalties are paid on a licensed product-by-licensed product and country-by-country basis until the latest of (i)&#160;the expiration of the last valid claim in the licensed patent rights with respect to such Astellas Licensed Product in such country or (ii) a set number of years from the first commercial sale of such Astellas Licensed Product in such country. Astellas may terminate the Astellas Agreement at will upon 60 days&#8217; written notice. Each party has the right to terminate the Astellas Agreement due to the other party&#8217;s material breach if such breach remains uncured for 90 days (or 45 days in the case of nonpayment) or if the other party becomes bankrupt. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Astellas Agreement is a collaborative agreement that is within the scope of ASC 808. The Company analyzed the joint research and development activities to assess whether they fall within the scope of ASC 808, and will reassess this throughout the life of the arrangement based on changes in the roles and responsibilities of the parties. Based on the terms of the arrangement as outlined above, both parties are deemed to be active participants in the collaboration. Both parties are performing research and development activities in their defined territory and will be performing joint clinical studies in accordance with the development plan and the study protocol approved by the JSC. Additionally, Astellas and the Company are exposed to significant risks and rewards dependent on the commercial success of any product candidates that may result from the collaboration. As such, the collaboration arrangement is deemed to be within the scope of ASC 808. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The arrangement consists of two components; the license of IP and the research and development activities, including committee participation, to support the co-development and research plan. Under the provisions of ASC 808, the Company has determined that it will apply the guidance in ASC 606 to recognize the revenue related to the license since that component of the arrangement is more reflective of a vendor-customer relationship. The Company determined that the license and the related research and development services associated with the Phase 2a clinical study were not distinct from one another, as the license has limited value to Astellas without the performance of the research and development activities and the Phase 2a study is essential to the use of the license. As such, the Company determined that these activities should be accounted for as a single combined performance obligation. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue associated with this single performance obligation is being recognized as the research and development work is performed, using an input method on the basis of research and development costs incurred to date relative to total research and development costs expected to be incurred. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligation. The Company has determined that the period of performance of the research and development services began upon the signing of the Astellas Agreement and will continue until the completion of the Phase 2a clinical trial of FX-322. The transaction price of $80.0 million has been allocated to the single combined performance obligation and will be recognized over such period. Management has analyzed the progress of the Phase 2a clinical trial and has estimated the completion date of such trial and the total costs it expects to incur in performing the trial and is recognizing the $80.0 million upfront fee as revenue over the period from July 2019 until the estimated completion date using the input method. The Company regularly assesses its estimates and to the extent that facts and circumstances dictate, the Company revises its estimates of total cost or completion date and accounts for such change on a prospective basis. The Company was required to pay MIT a royalty of $16.0 million on the $80.0 million of sublicense revenues. The $16.0 million royalty was expensed in the third quarter of 2019.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The $80.0&#160;million upfront payment received from Astellas in July 2019 was initially recorded as deferred revenue and is being recognized as revenue according to the policy described above. In the year ended December 31, 2020, the Company recognized $37.0 million of revenue under the Astellas Agreement. In the year ended December 31, 2019, the Company recorded $28.9 million of revenue under the Astellas Agreement which included $16.0 million related to the royalty payment to MIT and $12.9 million based upon the application of the input method to the remaining $64.0 million to be recognized over the estimated period to completion of the Phase 2a clinical trial for FX-322. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The potential development and regulatory milestone payments are fully constrained until the Company can conclude that achievement of the milestone is probable and that it is probable that recognition of revenue related to the milestone will not result in a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is ultimately resolved and as such these have been excluded from the transaction price. As part of its evaluation of the constraint, the Company considers numerous factors, including the fact that achievement of the milestones is outside the control of the Company and contingent upon the future success of clinical trials, the licensee&#8217;s efforts, and the receipt of regulatory approval. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the license granted to Astellas and therefore are recognized at the later of when the performance obligation is satisfied, or the related sales of licensed products occur. The Company re-evaluates the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts, at each reporting period and as uncertain events are resolved or other changes in circumstances occur, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Astellas Agreement contains joint research and development activities that are not within the scope of ASC 606. The Company will recognize research and development expense related to the joint study costs for all the joint activities in future periods and reimbursements received from Astellas will be recognized as an offset to research and development expense on the consolidated statement of operations during the development period. In the years ended December 31, 2020 and 2019, the Company invoiced Astellas $1,046 and $186 for joint costs, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703665134408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">16. Commitments and contingencies </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Operating leases </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2016, the Company and a related third party (see Note 18) entered into a five-year operating lease for the Company&#8217;s primary office and laboratory space in Woburn, Massachusetts. <font style="color:#000000;">The lease was extended in November 2019 and expires in February 2025.</font> Additionally, the Company amended the lease in November 2019 to add additional laboratory and office space. The commencement date of the additional space occurred in February 2020 and expires in February 2025. The lease agreements do not contain any material residual value guarantees or material restrictive covenants. <font style="font-size:12pt;">&#160;</font>The Company also leases a laboratory facility in Connecticut under an operating lease which expires in 2021.<font style="font-size:12pt;">&#160;&#160;</font> </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 11, 2020, the Company entered into an Agreement for Termination of Lease and Voluntary Surrender of Premises (the &#8220;Lease Termination Agreement&#8221;) with ARE-MA Region No. 20, LLC (the &#8220;Landlord&#8221;). The Lease Termination Agreement provides that the Lease Agreement, dated as of August 14, 2016, by and between the Company and Landlord (as the same may have been amended, the &#8220;Lease&#8221;) will terminate on March 31, 2021, unless the Company elects to extend the term of the Lease. The Company exercised the option to extend the lease until May 31, 2021.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As consideration for the Landlord&#8217;s agreement to enter into the Lease Termination Agreement and accelerate the expiration date of the term of the Lease, the Company has agreed to pay to Landlord a fee of approximately $0.2 million.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 7, 2020 the Company entered into an indenture of lease (the &#8220;Lexington Lease&#8221;) with HCP/KING 75 Hayden LLC, for the lease of approximately 61,307 square feet of rentable area in Lexington, Massachusetts or (the &#8220;Lexington Premises&#8221;).&nbsp;&nbsp;The Lexington Lease commenced on December 11, 2020, (the &#8220;Commencement Date&#8221;).&nbsp;&nbsp;The Company expects to use the Lexington Premises as its new principal executive offices and as a laboratory for research and development, and other related uses.&nbsp;&nbsp;The term of the Lexington Lease, (the &#8220; Initial Term&#8221;), is ten years from the rent commencement date (which is five months following the Commencement Date) and the Initial Term is expected to end on May 31, 2031.&nbsp;&nbsp;The Company also has the option to extend the Initial Term for two additional terms of five years each.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of&#160;December 31, 2020, the Company has $30,551&#160;of operating lease ROU assets, and&#160;$397&#160;and $30,597&#160;of current and non-current lease liabilities, respectively, recorded on the consolidated balance sheets. For the year ended December 31, 2020&#160;the Company recorded $470&#160;of operating lease cost, $510<font style="font-size:12pt;">&#160;</font>of variable lease cost, and $106&#160;of short-term lease cost. The lease expense for the years ended December 31, 2020 and 2019 are $835&#160;and $269, respectively. Cash paid for amounts included in the measurement of lease liabilities for year ended&#160;December 31, 2020&#160;is $484.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other information</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.52%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3 years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate (1)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.5</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;">(1)</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rate includes the Company&#8217;s Woburn and Lexington leases. </p></td></tr></table></div></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below reconciles the undiscounted cash flows to the operating lease liability recorded on the consolidated balance sheet as of December 31, 2020. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,928</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,159</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,284</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,412</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,545</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,070</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum lease payments</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,398</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: amount of lease payments representing interest</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,404</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of future lease payments</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,994</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: current lease liabilities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(397</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent lease liabilities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,597</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future aggregate minimum payments under the noncancelable operating leases and short term leases, including the Lexington, MA lease and Connecticut lease, which is not subject to ASC 842, as of December 31, 2020 are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;">
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,986</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,159</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,284</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,412</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,545</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026 and beyond</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,070</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum lease payments</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,456</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Contract commitments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has contracted with a research institution to provide research for a therapeutic drug to treat multiple sclerosis. In September 2020, the Company extended the term of this contract through December 2021. As consideration for this extension, the Company committed to total payments of $0.6 million through December 2021. <font style="font-size:12pt;">&#160;</font> <font style="font-size:12pt;">&#160;</font>&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company enters into contracts in the normal course of business with CROs, CMOs, universities, and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts generally do not contain minimum purchase commitments and are cancelable by us upon prior written notice although, purchase orders for clinical materials are generally non-cancelable. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including non-cancelable obligations of our service providers, up to the date of cancellation or upon the completion of a manufacturing run. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Guarantees </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has identified the guarantees described below as disclosable, in accordance with ASC 460, <font style="font-style:italic;">Guarantees</font>. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving at the Company&#8217;s request in such capacity. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors&#8217; and officers&#8217; insurance coverage that should limit its exposure and enable it to recover a portion of any future amounts paid. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is a party to a number of agreements entered into in the ordinary course of business that contain typical provisions that obligate the Company to indemnify the other parties to such agreements upon the occurrence of certain events. Such indemnification obligations are usually in effect from the date of execution of the applicable agreement for a period equal to the applicable statute of limitations. The aggregate maximum potential future liability of the Company under such indemnification provisions is uncertain. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases office space in Woburn, Massachusetts under a five-year non-cancelable operating lease<font style="color:#000000;">, and has entered into a facility lease in Lexington, Massachusetts. The Company has standard indemnification arrangements under these leases that require it to indemnify the landlord against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation, or nonperformance of any covenant or condition of the lease</font>. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020 and 2019, the Company had not experienced any losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves have been established. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703592043688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">17. Employee benefit plan </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employees of the Company are eligible to participate in the Company&#8217;s 401(k) retirement plan (the &#8220;401(k) Plan&#8221;). Participants may contribute up to 90% of their annual compensation to the 401(k) Plan, subject to statutory limitations. Under the 401(k) Plan Safe Harbor Match, the Company matches 100% of the first 5% of employee contributions and vests 100% at time of match. For the years ended December 31, 2020 and 2019, the Company made matching contributions of $0.4 million and $0.2 million, respectively. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703592034360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18. Related party transactions </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s lease for its Woburn, Massachusetts facility, see Note 16, is with an entity affiliated with one of the Company&#8217;s directors and shareholders. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As disclosed in Note 14, the Company entered into the MIT License Agreement in December 2016. <font style="color:#000000;">The patents in-licensed by the Company from MIT pursuant to the MIT License Agreement claim inventions created by, among others, Dr. Langer, one of the Company&#8217;s directors. Accordingly, Dr. Langer has received $1.98 million and $0.01 million from MIT under the MIT Policy during the years ended December 31, 2020 and 2019, respectively.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703665311816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">19. Subsequent events </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has evaluated subsequent events for recognition, remeasurement and disclosure purposes through March 29, 2021, the date which the consolidated financial statements were available to be issued. The identified subsequent events are as follows; </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 18, 2021, the Company completed the liquidation and dissolution of Frequency Therapeutics Japan KK, the Company&#8217;s Japanese subsidiary. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 23, 2021, the Company announced topline, day-90 data from its FX-322 Phase 2a study. The interim results show that four weekly injections in subjects with mild to moderately severe sensorineural hearing loss did not demonstrate improvements in hearing measures versus placebo. No treatment-related serious adverse events were observed in the study. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company also announced new preliminary data from a parallel study demonstrating hearing improvement from a single injection of FX-322. The single dose showed efficacy that was clinically meaningful and statistically significant compared to the untreated ear, had a favorable safety profile and was well tolerated.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703592069176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Data (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Selected Quarterly Data (Unaudited)</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">20. Selected Quarterly Data (Unaudited) </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table contains quarterly financial information for 2020 and 2019.&nbsp;&nbsp;The Company believes that the following information reflects all normal recurring adjustments necessary for the fair statement of the information for the periods presented.&nbsp;&nbsp;The operating results for any quarter are not necessarily indicative of results for any future period.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except per share amounts)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,264</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,523</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,247</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,950</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">36,984</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total expenses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,177</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,548</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,588</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,182</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">63,495</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,913</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,025</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,341</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,232</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(26,511</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cumulative series C convertible preferred stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; dividends</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,913</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,025</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,341</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,232</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(26,511</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common shareholders -</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; basic and diluted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.16</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.19</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.16</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.30</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(0.82</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except per share amounts)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,238</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,709</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">28,947</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total expenses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,826</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,852</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,813</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,202</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">47,693</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,826</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,852</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(575</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,493</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(18,746</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cumulative series C convertible preferred stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; dividends</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,014</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(1,054</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,826</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,852</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,589</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,533</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(19,800</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common shareholders -</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; basic and diluted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.24</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.42</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.73</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.19</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(2.29</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703586797272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of presentation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared in accordance with accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP) that the Company follows to ensure its financial condition, results of operations, and cash flows are consistently reported. References to GAAP issued by the FASB in these notes to the consolidated financial statements are to the FASB <font style="font-style:italic;">Accounting Standards</font> Codification (ASC). </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Principles of consolidation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements include the accounts of Frequency Therapeutics, Inc. and its wholly owned subsidiaries Frequency Therapeutics Securities Corporation, Frequency Therapeutics PTY, LTD and Frequency Japan. All intercompany transactions and balances have been eliminated. Frequency Japan was closed down in February 2021, as further described in Note 19 of notes to consolidated financial statements. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of estimates </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. On an ongoing basis, the Company&#8217;s management evaluates its estimates, which include but are not limited to management&#8217;s judgments of accrued expenses, revenue recognition, fair value of common stock, valuation of share-based awards, present value of lease liabilities and income taxes. Actual results could differ from those estimates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company utilized significant estimates and assumptions in determining the fair value of its common stock in periods prior to the IPO. The Company utilized various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately Held Company Equity Securities Issued as Compensation (the Practice Aid), to estimate the fair value of its common stock. Each valuation methodology includes estimates and assumptions that require the Company&#8217;s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to the Company&#8217;s common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale. Significant changes to the key assumptions used in the valuations could have resulted in different fair values of common stock at each valuation date. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (loss)</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comprehensive income (loss) </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Components of comprehensive income or loss, including net income or loss, are reported in the financial statements in the period in which they are recognized. Other comprehensive income or loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss) are reported net of any related tax effect to arrive at comprehensive income (loss). Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and economic events other than those with stockholders which for the years ended December 31, 2020 and 2019 consist of unrealized gain on marketable securities.&nbsp;&nbsp;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segment information </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company&#8217;s chief operating decision-maker, the Company&#8217;s chief executive officer, views the Company&#8217;s operations and manages its business as a single operating segment, which is in the business of discovering and developing small molecule drugs that activate progenitor cells within the body to create healthy tissue. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Foreign currency </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All periods presented are reported in US dollars. The functional currency for entities outside the United States is the US dollar. Realized and unrealized gains and losses from foreign currency transactions are reflected in the consolidated statements of operations as other expense. During the years ended December&#160;31, 2020 and 2019 the Company recorded $(4), and $7<font style="font-size:12pt;">&#160;</font>of foreign currency exchange (losses) gains, respectively. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash and cash equivalents </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with an original maturity of six months or less at acquisition to be cash equivalents which are stated at fair market value. Cash and cash equivalents at December&#160;31, 2020 and 2019 consists entirely of cash and money market funds. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Restricted Cash</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has $1.8 million of restricted cash as of December 31, 2020 which represents a $1.7 million security deposit on the Company's future Lexington, Massachusetts facility and a $0.1 million security deposit on the Company's Woburn, Massachusetts facility. The $0.1 million restricted cash at December 31, 2019 represented the security deposit on the Company's Woburn, Massachusetts facility.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Short-term Marketable Debt Securities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Short-term marketable debt securities</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term marketable securities represent holdings of available-for-sale marketable debt securities in accordance with the Company&#8217;s investment policy. Short-term marketable investments mature within one-year from the balance sheet date. Investments in marketable securities are recorded at fair value, with any unrealized gains and losses reported within accumulated other comprehensive income as a separate component of stockholders&#8217; equity (deficit) until realized or until a determination is made that an other-than-temporary decline in market value has occurred. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion, together with interest on securities sold is determined based on the specific identification method and any realized gains or losses on the sale of investment are reflected as a component of other income (expense).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Off-balance Sheet Risk</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of credit risk and off-balance sheet risk</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instrument that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. The Company maintains its cash and cash equivalents at several accredited financial institutions, in amounts that exceed federally insured limits. Marketable securities consist of U.S. Treasury securities with maturities of less than twelve months. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which its money market accounts are maintained.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has no significant off-balance sheet such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_SignificantSuppliersPolicyTextBlock', window );">Significant Suppliers</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Significant suppliers </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is dependent on third-party manufacturers to supply products for research and development activities of its programs, including preclinical and clinical testing. In particular, the Company relies and expects to continue to rely on a single manufacturer of its product candidates for use in clinical trials. The Company would be adversely affected by a significant interruption in the supply of product for use in clinical programs. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair value measurements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic&#160;820, <font style="font-style:italic;">Fair Value Measurement</font> (ASC&#160;820), establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The hierarchy defines three levels of valuation inputs, of which the first two are considered observable and the last is considered unobservable: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:9.38%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Quoted prices in active markets for identical assets or liabilities.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:9.38%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Inputs other than quoted prices included within Level&#160;1 that are either directly or indirectly observable,&nbsp;&nbsp; &nbsp;&nbsp;such as quoted market prices, interest rates and yield curves.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:9.38%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 3</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Unobservable inputs developed using estimates or assumptions developed by the Company, which reflect those that a market participant would use in pricing the asset or liability.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying values of other current assets, accounts payable, and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. The fair value of the Company&#8217;s Term Loan is not materially different from the carry value as presented given the Term Loan was issued within one month of December 31, 2020. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property and equipment </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consist of lab equipment, computer equipment, furniture and office equipment and leasehold improvements recorded at cost. These amounts are depreciated using the straight-line method over the estimated useful lives of the assets as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.38%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.38%;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Estimated useful life</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="width:72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td valign="top" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="top" style="width:72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="width:72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and office equipment</p></td>
<td valign="top" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="top" style="width:72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shorter of the estimated useful</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">life or lease term</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheet and related gains or losses are reflected in the consolidated statements of operations.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Impairment of long-lived assets </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company continually evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company did not recognize any impairment losses for the years ended December&#160;31, 2020 and 2019.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs and Accruals</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and development costs and accruals </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses include salaries and benefits, materials and supplies, preclinical and clinical trial expenses, stock-based compensation expense, depreciation of equipment, contract services and other outside expenses. The Company has entered into various research and development-related contracts with research institutions, contract research organizations, contract manufacturers and other companies. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. Costs of certain development activities, such as manufacturing, pre-clinical and clinical trial expenses, are recognized based on an evaluation of the progress to completion of specific tasks. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed. Costs incurred in obtaining technology licenses are charged to research and development expense as acquired in-process research and development if the technology licensed has not reached technological feasibility and has no alternative future use.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company elected to early adopt ASC 842, <font style="font-style:italic;">Leases</font> (ASC 842) as of January 1, 2020 and elected the transition method under ASU 2016-02 whereby the Company records a right-to-use asset and a lease liability on the consolidated balance sheet for all leases with terms longer than 12 months. The Company also elected to apply the package of practical expedients intended to ease transition. Accordingly, the Company has only applied ASC 842 to leases existing at January 1, 2020. The Company determines if an arrangement is, or contains, a lease at inception. Operating leases are included in operating lease right-of-issue (&#8220;ROU&#8221;) assets, other current liabilities, and operating lease liabilities on the consolidated balance sheets.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments to be made over the lease term. The ROU asset also includes any lease payments made at or before the lease commencement date and excludes lease incentives received. As the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected to not apply the recognition requirements of ASC 842 for short-term leases, which is defined as a lease that, at the lease commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For real estate lease agreements entered into or modified after the adoption of ASC 842 that include lease and non-lease components, the Company has elected to account for the lease and non-lease components, such as common area maintenance charges, as a single lease component.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaborative Arrangements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Collaborative arrangements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company analyzes its collaborative arrangements to assess whether they are within the scope of ASC 808, <font style="font-style:italic;">Collaborative Arrangements</font> (&#8220;ASC 808&#8221;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship (e.g., a licensing arrangement) where the contracted party has obtained goods or services that are an output of the Company&#8217;s ordinary activities in exchange for a consideration and therefore within the scope of ASC 606, <font style="font-style:italic;">Revenue from Contracts with Customers</font> (&#8220;ASC 606&#8221;). For those elements of the arrangement that are accounted for pursuant to ASC 606, including those to which ASC 606 is applied by analogy, the Company applies the five-step model described in the Company&#8217;s revenue recognition policy. For elements of collaborative arrangements that are accounted for pursuant to ASC 808, an appropriate and rational recognition method is determined and applied consistently. Reimbursements from the counterparty that are the result of a collaborative relationship with the counterparty, instead of a customer relationship, such as co-development or clinical activities, are recorded as a reduction to research and development expense as the services are performed. Similarly, amounts that are owed to a collaboration partner related to the co-development clinical activities are recognized as research and development expense. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company enters into out-licensing agreements that are within the scope of ASC 606. The terms of such out-license agreements include licenses to functional intellectual property (IP), given the functionality of the intellectual property is not expected to change substantially as a result of the licensor&#8217;s ongoing activities. Such arrangements typically include payment of one or more of the following: non-refundable up-front license fees; reimbursement of certain costs; development and regulatory milestone payments and milestone payments based on the level of sales; and royalties on net sales of licensed products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers the economic and regulatory characteristics of the licensed IP, research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace to determine if it has standalone value at the inception of the licensing arrangement, which would make the license distinct. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of any additional good or services promised in the contract, whether the value of the license is dependent on the remaining goods and services, whether there are other vendors that could provide the remaining promise, and whether the license is separately identifiable from the remaining good and services. For licenses that are combined with other goods and services, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of progress and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue is allocated to the licensed IP on a relative standalone selling price basis and, for functional IP, is recognized at a point when the licensed IP is made available for the customer&#8217;s use and benefit, which generally occurs at the inception of the arrangement. However, in cases, where the functionality of the IP is expected to substantively change as a result of activities of the Company that do not transfer additional promised goods or services, or in cases, where there is an expectation that the Company will undertake activities to change the standalone functionality of the IP and the customer is contractually or practically required to use the latest version of the IP, revenue for the license to functional IP is recognized over time. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development and regulatory milestone fees, which are a type of variable consideration, are recognized as revenue to the extent that it is probable that a significant reversal will not occur. The Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into a collaboration arrangement with Astellas Pharma Inc. (&#8220;Astellas&#8221;), as further described in Note 16 of notes to consolidated financial statements. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue recognition </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for contracts with customers in accordance with ASC 606, including all amendments thereto. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as collaborative arrangements and leases. The Company&#8217;s disclosure within the below sections or elsewhere within these consolidated financial statements reflects the Company&#8217;s accounting policies in compliance with this new standard.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under ASC 606, an entity recognizes revenue when or as its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To recognize revenue for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies its performance obligations. The Company only applies the five-step model to contracts when it is probable that the entity will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services it transfers to the customer. Once a contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and identifies as a performance obligation each promise to transfer to the customer either (a) a good or service (or bundle of goods and services) that is distinct, or (b) a series of distinct goods and services that are substantially the same and have been the same pattern of transfer to the customer.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company assesses whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i)&#160;the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii)&#160;the entity&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract). In assessing whether a promised good or service is distinct, the Company considers factors such as the research, manufacturing and commercialization capabilities of the collaboration partner (the &#8220;customer&#8221; in this type of arrangement) and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct. For each arrangement that results in revenues, the Company identifies all performance obligations, which may include, for example, a license to IP and know-how, research and development activities, and/or manufacturing services. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to any upfront payment, if the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the estimated variable consideration in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. If it is probable that a significant revenue reversal will not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or of the licensee such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For contracts that include sales-based royalties (including milestone payments based on the level of sales) promised in the exchange for licenses of intellectual property, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestone payments at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied. In determining the transaction price, the Company adjusts the promised amount of consideration for the effects of the time value of money if the timing of payments provides the Company or the Company&#8217;s customer with a significant benefit of financing the transfer of goods and services. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. The Company assesses each of its revenue generating arrangements in order to determine whether a significant financing component exists. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time.&nbsp;&nbsp;For performance obligations satisfied over time, the Company measures progress toward completion of its performance obligations using an input method based on the Company&#8217;s efforts and inputs to satisfy its performance obligations relative to total expected inputs to the satisfaction of that performance obligation.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts received from a customer prior to revenue recognition are recorded as deferred revenue. Amounts received from a customer that are expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability in the accompanying consolidated balance sheets.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_PatentCostsPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Patent costs </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses in the accompanying consolidated statements of operations. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-based compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for its stock-based compensation in accordance with ASC Topic&#160;718, <font style="font-style:italic;">Compensation&#8212;Stock Compensation</font> (ASC&#160;718). ASC&#160;718 requires all share-based payments to employees and directors to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company adopted FASB Accounting Standards Update (ASU) 2016-09 which identifies areas for simplification of several areas of share-based payment transactions. The Company treats non-employee grants in a manner consistent with employee grants. The Company estimates the fair value of options granted using the Black-Scholes option pricing model for stock option grants to both employees and non-employees. The Company believes the fair value of the stock options granted to non-employees is more reliably determinable than the fair value of the services provided. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (a)&#160;the expected stock price volatility, (b)&#160;the expected term of the award, (c)&#160;the risk-free interest rate and (d)&#160;expected dividends. Due to the lack of sufficient company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No.&#160;107, Share-Based Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to non-employees, the Company utilizes the contractual term of the share-based payment as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are significant judgments and estimates inherent in the determination of the fair value of the Company&#8217;s common stock prior to the IPO. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to its common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expenses the fair value of its share-based compensation awards to employees and non-employees on a straight-line basis over the requisite service period, which is generally the vesting period. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income taxes </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes using the asset and liability method in accordance with ASC Topic 740, <font style="font-style:italic;">Income Taxes</font> (ASC 740) which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. At December&#160;31, 2020 and 2019, the Company has concluded that a full valuation allowance is necessary for its deferred tax assets (see Note 13). </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net loss per share </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. Diluted net loss per share is the same as basic net loss per share for the years ended December&#160;31, 2020 and 2019 since all potential shares of common stock instruments are anti-dilutive as a result of the loss for such periods. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s convertible preferred stock contractually entitled the holders of such shares to participate in dividends but did not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reported a net loss, such losses are not allocated to such participating securities. In periods where the Company reported a net loss attributable to common stockholders, diluted net loss per share is the same as basic net loss per share, since dilutive shares of common stock are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for the years ended December&#160;31, 2020 and 2019.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted net loss per share attributable to common stockholders was calculated as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,511</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,800</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares of common stock outstanding-</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; basic and diluted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,253,227</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,649,245</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common stockholders-</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; basic and diluted</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.82</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.29</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company excluded the following potential shares of common stock from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted Common Stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,093</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,366</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series C Preferred (as converted to common stock)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,172,676</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series B Preferred (as converted to common stock)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,759,079</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A Preferred (as converted to common stock)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,070,574</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of Frequency Japan preferred stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">513,047</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding stock options (as converted to common stock)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,816,798</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,968,672</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,819,891</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,554,414</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently adopted accounting pronouncements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU No. 2016-02, <font style="font-style:italic;">Leases</font> (Topic 842) (&#8220;ASU 2016-02&#8221;), as amended by various subsequently issued ASUs. The standard requires lessees to recognize an operating lease with a term greater than one year on their balance sheets as a right-of-use asset and corresponding lease liability, measured at the present value of the lease payments. Lessees are required to classify leases as either finance or operating leases. If the lease is effectively a financed purchase by the lessee, it is classified as a financing lease, otherwise it is classified as an operating lease. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2018, the FASB also issued ASU 2018-11, <font style="font-style:italic;">Leases</font> (Topic 842): Targeted Improvements (&#8220;ASU 2018-11&#8221;), which permits entities to continue applying legacy guidance in ASC 840, Leases, including its disclosure requirements, in the comparative periods presented in the year that the entity adopts the new leasing standard. The Company adopted the standard on January 1, 2020 using the optional transition method. As such, the consolidated balance sheets and statements of operations for prior periods will not be comparable in the year of adoption of ASC 842. The Company elected the package of practical expedients permitted under the transition guidance within the standard. Accordingly, the Company did not reassess the conclusion of whether the existing arrangements contain a lease, lease classification and initial direct costs under ASC 842. As a result of the adoption of ASC 842, the Company recorded $1.2 million of ROU assets and a total of $1.5 million of lease liabilities on the consolidated balance sheets as of January 1, 2020. In addition, in the first quarter of 2020 the Company expanded and amended the lease for its Woburn, Massachusetts facility and increased both the ROU asset and lease liability by $1.0 million. On December 11, 2020, the Company terminated this lease and remeasured the existing ROU asset and lease liability based on this lease modification, resulting in a $1.7 million impact to both the ROU asset and lease liability. As disclosed in Note 16, the Company has entered into a lease for a facility in Lexington Massachusetts which commenced December 11, 2020. In accordance with ASU No. 2016-02, the Company recognized a right-of-use asset and related lease liability at such time.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2016,&#160;the FASB issued ASU No. 2016-01, <font style="font-style:italic;">Financial Instruments - Overall</font> (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. This new standard amended certain aspects of accounting and disclosure requirements for financial instruments, including the requirement that equity investments with readily determinable fair values are to be measured at fair value with any changes in fair value recognized in a company's statements of operations. Prior to adoption of ASU 2016-01, companies recognized changes in fair value in accumulated other comprehensive income (loss), net. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. In addition, a valuation allowance should be evaluated on deferred tax assets related to available- for-sale debt securities in combination with other deferred tax assets.&#160;The Company adopted this new standard on January 1, 2020, using the modified retrospective method, and determined that it did not have a material impact on its financial statements.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently issued accounting pronouncements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company is an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, as amended (Jobs Act). The Jobs Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company elected to avail itself of this extended transition period and, as a result, we will not be required to adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13, <font style="font-style:italic;">Financial Instruments - Credit Losses</font> (Topic 326): Measurement of Credit Losses on Financial Instruments. The FASB has subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. This standard will become effective for the Company on January 1, 2023. The Company is still evaluating the impact of this standard on its consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued&#160;<font style="color:#000000;">ASU 2019-12</font>&#160;amending accounting guidance that simplifies the accounting for income taxes, as part of its initiative to reduce complexity in the accounting standards. The amendments eliminate certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The amendments also clarify and simplify other aspects of the accounting for income taxes. This standard will become effective for the Company on January 1, 2021. The Company is still evaluating the impact of this standard on its consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_PatentCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Patent costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_PatentCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_SignificantSuppliersPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Significant suppliers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_SignificantSuppliersPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703592201320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_PropertyAndEquipmentTableTextBlock', window );">Property And Equipment</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consist of lab equipment, computer equipment, furniture and office equipment and leasehold improvements recorded at cost. These amounts are depreciated using the straight-line method over the estimated useful lives of the assets as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.38%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.38%;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Estimated useful life</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="width:72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td valign="top" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="top" style="width:72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="width:72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and office equipment</p></td>
<td valign="top" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="top" style="width:72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shorter of the estimated useful</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">life or lease term</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Net Loss per Share</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted net loss per share attributable to common stockholders was calculated as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,511</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,800</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares of common stock outstanding-</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; basic and diluted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,253,227</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,649,245</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common stockholders-</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; basic and diluted</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.82</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.29</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Computation of Diluted Net Loss per Share</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company excluded the following potential shares of common stock from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted Common Stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,093</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,366</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series C Preferred (as converted to common stock)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,172,676</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series B Preferred (as converted to common stock)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,759,079</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A Preferred (as converted to common stock)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,070,574</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of Frequency Japan preferred stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">513,047</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding stock options (as converted to common stock)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,816,798</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,968,672</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,819,891</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,554,414</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_PropertyAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_PropertyAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703592069176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Financial Assets Measured at Fair Value on Recurring Basis</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s financial assets measures at fair value on a recurring basis by level within the fair value hierarchy at December 31, 2020 and 2019 are summarized as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortization</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Market</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Hierarchy</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gain</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214,522</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214,549</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.04%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214,522</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214,549</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortization</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Market</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Hierarchy</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Loss) Gain</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,131</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,119</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Government treasury securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,131</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,197</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.04%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,262</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,316</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703592192488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense And Other Assets Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock', window );">Summary of Prepaid Expenses and Other Current Assets</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.4%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent and deposits</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,729</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">801</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grant receivable</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">805</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">340</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Insurance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,552</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,132</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">199</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,723</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,000</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703674429896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment include the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,166</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,846</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and office equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">283</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">257</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">291</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,419</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,419</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,340</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">306</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,499</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,828</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated depreciation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,212</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,066</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,287</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,762</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703592034360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consist of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.4%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll and employee related expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,062</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,686</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional fees</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">647</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">435</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third-party research and development expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">874</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Taxes and other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,663</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,239</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703593382824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock', window );">Schedule of Common Stock Shares Reserved for Future Issuance</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has reserved the following shares of common stock for future issuance as of December 31, 2020 and 2019:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options outstanding</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,816,798</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,968,672</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for future grant under stock option plan</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,475,923</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,859,654</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,292,721</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,828,326</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of common stock shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703588118616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity under 2014 Plan and 2019 Plan</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the stock option activity under the 2014 Plan and the 2019 Plan are as follows: </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">exercise</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">term</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">intrinsic</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">exercise</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">term</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">intrinsic</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019 Plan</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014 Plan</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2018</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,089,334</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.61</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,247,338</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.09</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,015,381</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.17</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(357,170</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.02</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,211</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.09</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,247,338</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.09</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.76</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,287</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,721,334</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.85</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.89</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,051</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,645,859</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.22</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,851</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.93</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(767,534</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.94</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,997</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.72</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,351</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.89</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,874,349</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.84</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.09</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,325</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,942,449</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.02</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.98</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127,090</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable as of December 31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">564,617</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.48</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.90</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,042</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,337,828</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.57</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.88</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,416</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options unvested as of December 31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,309,732</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,283</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,604,621</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,674</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Grant-date Fair Value of Stock Options Granted on Weighted Average Basis</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumptions that the Company used to determine the grant-date fair value of stock options granted to<font style="font-weight:bold;font-style:italic;"> </font>employees and directors were as follows, presented on a weighted average basis: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.9</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79.1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79.4</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Status of Restricted Common Stock</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the status of restricted common stock as of December&#160;31, 2020 and 2019 is presented below: </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:72.52%;">
<tr style="height:8.85pt;">
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:20.95pt;">
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:8.85pt;">
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested, December 31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,366</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.36</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:8.85pt;">
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Awarded</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:8.5pt;">
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(67,273</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.29</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:8.85pt;">
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:8.5pt;">
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested, December 31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,093</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.75</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703592330424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Reconciliation Pre-tax Income</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the Company&#8217;s pre-tax income for the years ended December 31, 2020 and 2019 is as follows:</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:56.02%;">
<tr style="height:10.65pt;">
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:12.7pt;">
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Domestic</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,744</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,086</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr style="height:12.7pt;">
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(732</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(714</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr style="height:13.45pt;">
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,476</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,800</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Provision</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s provision at December 31, 2020 and 2019 consist of the following:</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:55.74%;">
<tr style="height:10.3pt;">
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:12.35pt;">
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:12.35pt;">
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp; Federal</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:13.05pt;">
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp; State</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:13.05pt;">
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp; Foreign</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:12.35pt;">
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:12.35pt;">
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:13.05pt;">
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp; Federal</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:12.35pt;">
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp; State</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:13.05pt;">
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp; Foreign</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:12.35pt;">
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Deferred</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:12.35pt;">
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total provision (benefit)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate for the years ended December&#160;31, 2020 and 2019 is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:52.54%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S federal statutory income tax rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent differences</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.2)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.8</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes, net of federal benefit</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.0</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credits</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.8</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation deductions</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other items</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.6</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.0</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in deferred tax asset valuation allowance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40.7)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23.0</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective income tax rate</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;%</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s deferred tax assets at December&#160;31, 2020 and 2019 consist of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,885</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,253</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credits</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,992</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,138</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangibles</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">360</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">358</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">850</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">686</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,606</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">496</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">189</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liability</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,285</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right of use asset</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,181</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax asset</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,995</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,204</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,995</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,204</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703592219464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Leases</a></td>
<td class="text">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other information</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.52%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3 years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate (1)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.5</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;">(1)</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rate includes the Company&#8217;s Woburn and Lexington leases. </p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Reconciles the Undiscounted Cash Flows to the Operating Lease Liability Recorded on the Consolidated Balance Sheet</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below reconciles the undiscounted cash flows to the operating lease liability recorded on the consolidated balance sheet as of December 31, 2020. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,928</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,159</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,284</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,412</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,545</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,070</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum lease payments</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,398</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: amount of lease payments representing interest</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,404</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of future lease payments</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,994</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: current lease liabilities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(397</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent lease liabilities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,597</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Future Aggregate Minimum Payments Under Noncancelable Operating Leases and Short Term Leases</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future aggregate minimum payments under the noncancelable operating leases and short term leases, including the Lexington, MA lease and Connecticut lease, which is not subject to ASC 842, as of December 31, 2020 are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;">
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,986</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,159</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,284</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,412</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,545</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026 and beyond</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,070</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum lease payments</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,456</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703674430728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Data (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Schedule of Quarterly Financial Information</a></td>
<td class="text">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table contains quarterly financial information for 2020 and 2019.&nbsp;&nbsp;The Company believes that the following information reflects all normal recurring adjustments necessary for the fair statement of the information for the periods presented.&nbsp;&nbsp;The operating results for any quarter are not necessarily indicative of results for any future period.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except per share amounts)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,264</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,523</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,247</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,950</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">36,984</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total expenses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,177</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,548</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,588</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,182</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">63,495</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,913</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,025</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,341</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,232</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(26,511</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cumulative series C convertible preferred stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; dividends</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,913</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,025</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,341</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,232</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(26,511</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common shareholders -</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; basic and diluted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.16</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.19</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.16</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.30</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(0.82</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except per share amounts)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,238</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,709</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">28,947</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total expenses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,826</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,852</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,813</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,202</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">47,693</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,826</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,852</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(575</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,493</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(18,746</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cumulative series C convertible preferred stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; dividends</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,014</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(1,054</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,826</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,852</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,589</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,533</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(19,800</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common shareholders -</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; basic and diluted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.24</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.42</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.73</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.19</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(2.29</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121640914&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703586700088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 20, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 20, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 30,  2014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.148467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-6.7355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,724,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,545<span></span>
</td>
<td class="nump">$ 80,062<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95,399<span></span>
</td>
<td class="nump">$ 68,888<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,350,108<span></span>
</td>
<td class="nump">6,325,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from issuance of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number of common stock issued upon conversion of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,077,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares issued and sold</a></td>
<td class="nump">2,350,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price per share | $ / shares</a></td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock | $</a></td>
<td class="nump">$ 40,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703586826424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 11, 2020</div></th>
<th class="th"><div>Jan. 01, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency exchange (losses) gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,000)<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,820,000<span></span>
</td>
<td class="nump">101,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_FairValueOfTermLoan', window );">Fair value of term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_FairValueOfTermLoanIssuedTerm', window );">Fair value of term loan issued term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,551,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,994,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201811Member', window );">Accounting Standards Update 2018-11</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, accounting standards update, immaterial effect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=freq_LexingtonMassachusettsFacilityMember', window );">Lexington Massachusetts facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=freq_WoburnMassachusettsFacilityMember', window );">Woburn Massachusetts Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_IncreaseDecreaseInOperatingLeaseRightOfUseAssets', window );">Increase in right-of-use asset</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_IncreaseDecreaseInOperatingLeaseLiability', window );">Increase in lease liability</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_FairValueOfTermLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of term loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_FairValueOfTermLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_FairValueOfTermLoanIssuedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of term loan issued term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_FairValueOfTermLoanIssuedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_IncreaseDecreaseInOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in operating lease right of use assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_IncreaseDecreaseInOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121329987&amp;loc=SL120154346-209984<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120320025-210437<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120320025-210437<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120240428&amp;loc=SL120254526-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120254519-210437<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121329987&amp;loc=SL120154346-209984<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120320025-210437<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120320025-210437<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120254519-210437<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120240428&amp;loc=SL120254526-165497<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=112272810&amp;loc=d3e31010-122693<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121605123&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201811Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201811Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=freq_LexingtonMassachusettsFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=freq_LexingtonMassachusettsFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=freq_WoburnMassachusettsFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=freq_WoburnMassachusettsFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703581050024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Assets (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=freq_LabEquipmentMember', window );">Lab Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=freq_FurnitureAndOfficeEquipmentMember', window );">Furniture and Office Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Leasehold improvements, estimated useful lives</a></td>
<td class="text">Shorter of the estimated useful
life or lease term<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68071081&amp;loc=d3e1205-110223<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=freq_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=freq_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=freq_FurnitureAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=freq_FurnitureAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703585378840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Basic And Diluted Net Loss per Share Attributable to Common Stockholders (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (10,232)<span></span>
</td>
<td class="num">$ (5,341)<span></span>
</td>
<td class="num">$ (6,025)<span></span>
</td>
<td class="num">$ (4,913)<span></span>
</td>
<td class="num">$ (5,533)<span></span>
</td>
<td class="num">$ (1,589)<span></span>
</td>
<td class="num">$ (6,852)<span></span>
</td>
<td class="num">$ (5,826)<span></span>
</td>
<td class="num">$ (26,511)<span></span>
</td>
<td class="num">$ (19,800)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares of common stock outstanding- basic and diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,253,227<span></span>
</td>
<td class="nump">8,649,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders-basic and diluted</a></td>
<td class="num">$ (0.30)<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.73)<span></span>
</td>
<td class="num">$ (3.42)<span></span>
</td>
<td class="num">$ (3.24)<span></span>
</td>
<td class="num">$ (0.82)<span></span>
</td>
<td class="num">$ (2.29)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703585390104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">6,819,891<span></span>
</td>
<td class="nump">19,554,414<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=freq_UnvestedRestrictedCommonStockMember', window );">Unvested Restricted Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">3,093<span></span>
</td>
<td class="nump">70,366<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=freq_SeriesCPreferredAsConvertedToCommonStockMember', window );">Series C Preferred (as converted to common stock)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,172,676<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=freq_SeriesBPreferredAsConvertedToCommonStockMember', window );">Series B Preferred (as converted to common stock)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,759,079<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=freq_SeriesAPreferredAsConvertedCommonStockMember', window );">Series A Preferred (as converted to common stock)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,070,574<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=freq_ConversionOfFrequencyJapanPreferredStockMember', window );">Conversion of Frequency Japan Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">513,047<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=freq_OutstandingStockOptionsAsConvertedToCommonStockMember', window );">Outstanding Stock Options (as converted to common stock)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">6,816,798<span></span>
</td>
<td class="nump">5,968,672<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=freq_UnvestedRestrictedCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=freq_UnvestedRestrictedCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=freq_SeriesCPreferredAsConvertedToCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=freq_SeriesCPreferredAsConvertedToCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=freq_SeriesBPreferredAsConvertedToCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=freq_SeriesBPreferredAsConvertedToCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=freq_SeriesAPreferredAsConvertedCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=freq_SeriesAPreferredAsConvertedCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=freq_ConversionOfFrequencyJapanPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=freq_ConversionOfFrequencyJapanPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=freq_OutstandingStockOptionsAsConvertedToCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=freq_OutstandingStockOptionsAsConvertedToCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703585279400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Financial Assets Measured on Recurring Basis (Details) - Recurring Basis - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortization Cost</a></td>
<td class="nump">$ 214,522<span></span>
</td>
<td class="nump">$ 217,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Market Value</a></td>
<td class="nump">214,549<span></span>
</td>
<td class="nump">217,316<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortization Cost</a></td>
<td class="nump">214,522<span></span>
</td>
<td class="nump">200,131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Market Value</a></td>
<td class="nump">$ 214,549<span></span>
</td>
<td class="nump">200,119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Government Treasury Securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortization Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Market Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,197<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703674684408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense And Other Assets Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_PrepaidRentAndDepositsCurrent', window );">Rent and deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_PrepaidResearchAndDevelopmentExpenseCurrent', window );">Research and development expenses</a></td>
<td class="nump">$ 1,729<span></span>
</td>
<td class="nump">801<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivableCurrent', window );">Grant receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">805<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_PrepaidAccountsReceivableCurrent', window );">Accounts receivable</a></td>
<td class="nump">340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Insurance</a></td>
<td class="nump">2,552<span></span>
</td>
<td class="nump">2,132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total</a></td>
<td class="nump">$ 4,723<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_PrepaidAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid accounts receivable current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_PrepaidAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_PrepaidRentAndDepositsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rent and deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_PrepaidRentAndDepositsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_PrepaidResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid research and development expense current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_PrepaidResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703581035048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">$ 10,499<span></span>
</td>
<td class="nump">$ 3,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(3,212)<span></span>
</td>
<td class="num">(2,066)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">7,287<span></span>
</td>
<td class="nump">1,762<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">4,166<span></span>
</td>
<td class="nump">1,846<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Office Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">283<span></span>
</td>
<td class="nump">257<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">1,419<span></span>
</td>
<td class="nump">1,419<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">$ 4,340<span></span>
</td>
<td class="nump">$ 306<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703586807528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 1,146<span></span>
</td>
<td class="nump">$ 813<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703586625912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and employee related expenses</a></td>
<td class="nump">$ 5,062<span></span>
</td>
<td class="nump">$ 2,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">647<span></span>
</td>
<td class="nump">435<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent', window );">Third-party research and development expenses</a></td>
<td class="nump">874<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent', window );">Taxes and other</a></td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 6,663<span></span>
</td>
<td class="nump">$ 3,239<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued income taxes and other accrued liabilities, current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued third-party research and development expenses current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703585218488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Additional Information (Details) - Loan Agreement - Term Loan - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 11, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal balance</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPaymentTerms', window );">Payment terms, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company will make monthly interest only payments through November 30, 2022. The principal balance and interest will be repaid in equal monthly installments after the interest only period and continuing through May 1, 2024 (the &#8220;Loan Maturity Date&#8221;)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment', window );">Frequency of interest-only payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">monthly<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_DebtInstrumentInterestOnlyPaymentMaturityDate', window );">Monthly interest only payments due</a></td>
<td class="text">Nov. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Loan maturity date</a></td>
<td class="text">May  01,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_DebtInstrumentFloorInterestRatePercentage', window );">Interest rate floor percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Debt instrument final payment</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=freq_LoanAndSecurityAgreementMember', window );">Prepayment Occurs on or Prior to First Anniversary of Closing Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_DebtInstrumentPrepaymentPremiumPercentage', window );">Debt instrument prepayment premium percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=freq_LoanAndSecurityAgreementMember', window );">Prepayment Occurs After First Anniversary of Closing Date and On or Prior to Second Anniversary of Closing Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_DebtInstrumentPrepaymentPremiumPercentage', window );">Debt instrument prepayment premium percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=freq_LoanAndSecurityAgreementMember', window );">Prepayment Occurs After Second Anniversary of Closing Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_DebtInstrumentPrepaymentPremiumPercentage', window );">Debt instrument prepayment premium percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=freq_LoanAndSecurityAgreementMember', window );">Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, Interest rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_DebtInstrumentFloorInterestRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument floor interest rate percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_DebtInstrumentFloorInterestRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_DebtInstrumentInterestOnlyPaymentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument interest only payment maturity date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_DebtInstrumentInterestOnlyPaymentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_DebtInstrumentPrepaymentPremiumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument prepayment premium percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_DebtInstrumentPrepaymentPremiumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the frequency of periodic payments (monthly, quarterly, annual).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFrequencyOfPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=freq_LoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=freq_LoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=freq_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=freq_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=freq_PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=freq_PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=freq_PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=freq_PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=freq_PrepaymentOccursAfterSecondAnniversaryOfClosingDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=freq_PrepaymentOccursAfterSecondAnniversaryOfClosingDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703585308072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Preferred Stock - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jul. 17, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=freq_SeriesAConvertiblePreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,528,507<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=freq_SeriesBConvertiblePreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, issued shares</a></td>
<td class="nump">288,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,857,005<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=freq_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,492,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, authorized shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,492,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Preferred stock, net proceeds from shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=freq_SeriesA1ConvertiblePreferredStockMember', window );">Series A-1 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=freq_SeriesB1ConvertiblePreferredStockMember', window );">Series B-1 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=freq_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=freq_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=freq_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=freq_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=freq_SeriesCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=freq_SeriesCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=freq_SeriesA1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=freq_SeriesA1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=freq_SeriesB1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=freq_SeriesB1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703585173336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-controlling Interest - Additional Information (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=freq_SeriesA1ConvertiblePreferredStockMember', window );">Series A-1 Preferred Stock | LLC(FT-FJ)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_PreferredStockSharesPurchased', window );">Preferred stock, shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockVotingRights', window );">Preferred stock, voting rights</a></td>
<td class="text">Each share of Series A-1 Preferred had 236 times the voting power of one share of common stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=freq_SeriesB1ConvertiblePreferredStockMember', window );">Series B-1 Preferred Stock | LLC(FT-FJ)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_PreferredStockSharesPurchased', window );">Preferred stock, shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockVotingRights', window );">Preferred stock, voting rights</a></td>
<td class="text">Each share of Series B-1 Preferred Stock has 217 times the voting power of one share of common stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember', window );">Frequency Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preferred Stock, shares issued upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">673,605<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_PercentageOfVoteOfHoldersOfPreferredStock', window );">Voting percentage of preferred stock holder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_PercentageOfVoteOfHoldersOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vote of the holders of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_PercentageOfVoteOfHoldersOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_PreferredStockSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock, shares purchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_PreferredStockSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=freq_SeriesA1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=freq_SeriesA1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=freq_DelawareLimitedLiabilityCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=freq_DelawareLimitedLiabilityCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=freq_SeriesB1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=freq_SeriesB1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703586738920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 20, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">148,724,922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued shares</a></td>
<td class="nump">33,964,000<span></span>
</td>
<td class="nump">30,844,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding shares</a></td>
<td class="nump">33,964,000<span></span>
</td>
<td class="nump">30,844,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703585134920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Common Stock Shares Reserved for Future Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="nump">8,292,721<span></span>
</td>
<td class="nump">7,828,326<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="nump">6,816,798<span></span>
</td>
<td class="nump">5,968,672<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Shares Available for Future Grant Under Stock Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="nump">1,475,923<span></span>
</td>
<td class="nump">1,859,654<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703583963592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 17, 2019</div></th>
<th class="th"><div>Nov. 13, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for issuance</a></td>
<td class="nump">8,292,721<span></span>
</td>
<td class="nump">7,828,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="nump">769,385<span></span>
</td>
<td class="nump">357,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Aggregate intrinsic value of stock options exercised</a></td>
<td class="nump">$ 16,667<span></span>
</td>
<td class="nump">$ 5,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of stock options granted</a></td>
<td class="nump">16.41<span></span>
</td>
<td class="nump">4.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Total grant date fair value of stock options vested</a></td>
<td class="nump">$ 7,907<span></span>
</td>
<td class="nump">$ 2,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized stock-based compensation expense relating to unvested stock options</a></td>
<td class="nump">$ 31,006<span></span>
</td>
<td class="nump">$ 13,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized unvested stock options, weighted-average period</a></td>
<td class="text">3 years 29 days<span></span>
</td>
<td class="text">2 years 9 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 9,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total value of restricted stock awards, vested based on estimated fair value of stock</a></td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=freq_TwoThousandAndFourteenStockIncentivePlanMember', window );">2014 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,550,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock, shares available for future grants</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="nump">767,534<span></span>
</td>
<td class="nump">357,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Aggregate intrinsic value of stock options exercised</a></td>
<td class="nump">$ 1.94<span></span>
</td>
<td class="nump">$ 1.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=freq_TwoThousandAndNineteenIncentiveAwardPlanMember', window );">2019 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of authorized shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance', window );">Period for automatic increase in common stock available for future issuance</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of shares issued from outstanding number of shares</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Common stock future issuance, description</a></td>
<td class="text">In addition, the number of shares of common stock available for issuance under the 2019 Plan will be automatically increased on the first day of each calendar year during the ten-year term of the 2019 Plan, beginning with January 1, 2020 and ending with January 1, 2029, by the amount equal to 4% of the outstanding number of shares of the Company&#8217;s common stock on December 31, of the preceding calendar year or such lesser amount as determined by the Company&#8217;s board of directors.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="nump">1,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Aggregate intrinsic value of stock options exercised</a></td>
<td class="nump">$ 18.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period for automatic increase in common stock available for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=freq_TwoThousandAndFourteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=freq_TwoThousandAndFourteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=freq_TwoThousandAndNineteenIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=freq_TwoThousandAndNineteenIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703580932632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Stock Option Activity under 2014 Plan and 2019 Plan (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares, Exercised</a></td>
<td class="num">(769,385)<span></span>
</td>
<td class="num">(357,170)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercised</a></td>
<td class="nump">$ 16,667<span></span>
</td>
<td class="nump">$ 5,896<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=freq_TwoThousandAndNineteenIncentiveAwardPlanMember', window );">2019 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Beginning balance</a></td>
<td class="nump">1,247,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Granted</a></td>
<td class="nump">1,645,859<span></span>
</td>
<td class="nump">1,247,338<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares, Exercised</a></td>
<td class="num">(1,851)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares, Forfeited</a></td>
<td class="num">(16,997)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Ending balance</a></td>
<td class="nump">2,874,349<span></span>
</td>
<td class="nump">1,247,338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of shares, Options exercisable as of December 31, 2020</a></td>
<td class="nump">564,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of shares, Options unvested as of December 31, 2020</a></td>
<td class="nump">2,309,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Beginning balance</a></td>
<td class="nump">$ 14.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted</a></td>
<td class="nump">24.22<span></span>
</td>
<td class="nump">$ 14.09<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercised</a></td>
<td class="nump">18.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Forfeited</a></td>
<td class="nump">22.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Ending balance</a></td>
<td class="nump">19.84<span></span>
</td>
<td class="nump">$ 14.09<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Options exercisable as of December 31, 2020</a></td>
<td class="nump">$ 17.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term (in years), Outstanding</a></td>
<td class="text">9 years 1 month 2 days<span></span>
</td>
<td class="text">9 years 9 months 3 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term (in years), Options exercisable as of December 31, 2020</a></td>
<td class="text">8 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Outstanding</a></td>
<td class="nump">$ 44,325<span></span>
</td>
<td class="nump">$ 4,287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, Options exercisable as of December 31, 2020</a></td>
<td class="nump">10,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate intrinsic value, Options unvested as of December 31, 2020</a></td>
<td class="nump">$ 34,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=freq_TwoThousandAndFourteenStockIncentivePlanMember', window );">2014 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Beginning balance</a></td>
<td class="nump">4,721,334<span></span>
</td>
<td class="nump">2,089,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,015,381<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares, Exercised</a></td>
<td class="num">(767,534)<span></span>
</td>
<td class="num">(357,170)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares, Forfeited</a></td>
<td class="num">(11,351)<span></span>
</td>
<td class="num">(26,211)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Ending balance</a></td>
<td class="nump">3,942,449<span></span>
</td>
<td class="nump">4,721,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of shares, Options exercisable as of December 31, 2020</a></td>
<td class="nump">2,337,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of shares, Options unvested as of December 31, 2020</a></td>
<td class="nump">1,604,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Beginning balance</a></td>
<td class="nump">$ 2.85<span></span>
</td>
<td class="nump">$ 0.61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercised</a></td>
<td class="nump">1.94<span></span>
</td>
<td class="nump">1.02<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Forfeited</a></td>
<td class="nump">6.89<span></span>
</td>
<td class="nump">1.09<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Ending balance</a></td>
<td class="nump">3.02<span></span>
</td>
<td class="nump">$ 2.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Options exercisable as of December 31, 2020</a></td>
<td class="nump">$ 2.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term (in years), Outstanding</a></td>
<td class="text">7 years 11 months 23 days<span></span>
</td>
<td class="text">8 years 10 months 20 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term (in years), Options exercisable as of December 31, 2020</a></td>
<td class="text">7 years 10 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Outstanding</a></td>
<td class="nump">$ 127,090<span></span>
</td>
<td class="nump">$ 65,051<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, Options exercisable as of December 31, 2020</a></td>
<td class="nump">76,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate intrinsic value, Options unvested as of December 31, 2020</a></td>
<td class="nump">$ 50,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=freq_TwoThousandAndNineteenIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=freq_TwoThousandAndNineteenIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=freq_TwoThousandAndFourteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=freq_TwoThousandAndFourteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703587931608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Grant-date Fair Value of Stock Options Granted on Weighted Average Basis (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">79.10%<span></span>
</td>
<td class="nump">79.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703586664776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Status of Restricted Common Stock (Details) - Restricted Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, Unvested, December 31, 2019 | shares</a></td>
<td class="nump">70,366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of shares, Vested | shares</a></td>
<td class="num">(67,273)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, Unvested, December 31, 2020 | shares</a></td>
<td class="nump">3,093<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average fair value, Unvested, December 31, 2019 | $ / shares</a></td>
<td class="nump">$ 0.36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value, Vested | $ / shares</a></td>
<td class="nump">0.29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average fair value, Unvested, December 31, 2020 | $ / shares</a></td>
<td class="nump">$ 1.75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703586945304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Employee Stock Purchase Plan - Additional Information (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 20, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="nump">8,292,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,828,326<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">2019 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_PercentageOfEligibleEmployeeCompensation', window );">Percentage of eligible employee compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">315,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance', window );">Period for automatic increase in common available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of shares issued from outstanding number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_PercentageOfEligibleEmployeeCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of eligible employee compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_PercentageOfEligibleEmployeeCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period for automatic increase in common stock available for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703581798328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Feb. 28, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Net tax benefit</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit', window );">Federal and state deferred tax benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">26,995,000<span></span>
</td>
<td class="nump">16,204,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Interest and penalties</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Internal Revenue Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_PeriodOfCumulativeChangeInOwnership', window );">Period of cumulative change in ownership</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_OperatingLossCarryforwardsUsageAfterOwnershipChange', window );">Operating loss carryforwards, utilization after ownership change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange', window );">Operating loss carryforwards, utilization after five years after ownership change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange', window );">Operating loss carryforwards, utilization after 15 years thereafter after ownership change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration', window );">Remaining pre ownership change in operating loss carryforwards written off due to expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Internal Revenue Service | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_CumulativeChangeInOwnershipPercentage', window );">Cumulative change in ownership percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 67,868,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_NetOperatingLossCarryforwardsExpirationWithLimitation', window );">Net operating loss carryforwards expire through 2037</a></td>
<td class="nump">$ 22,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation', window );">Net operating loss carryforwards without expiration</a></td>
<td class="nump">$ 45,469,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_TaxCreditCarryforwardExpirationYear', window );">Tax credit carryforwards expiration year</a></td>
<td class="text">2040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Internal Revenue Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,123,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 3,014,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">2040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 43,386,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_TaxCreditCarryforwardExpirationYear', window );">Tax credit carryforwards expiration year</a></td>
<td class="text">2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Massachusetts | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 1,211,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_CumulativeChangeInOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative change in ownership percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_CumulativeChangeInOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_IncomeTaxesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income taxes disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_IncomeTaxesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_NetOperatingLossCarryforwardsExpirationWithLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net operating loss carryforwards expiration with limitation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_NetOperatingLossCarryforwardsExpirationWithLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net operating loss carryforwards expiration without limitation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards annual usage for next each after five years and thereafter after ownership change.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards annual usage for next each five years after ownership change.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_OperatingLossCarryforwardsUsageAfterOwnershipChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards Usage After Ownership Change.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_OperatingLossCarryforwardsUsageAfterOwnershipChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_PeriodOfCumulativeChangeInOwnership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of cumulative change in ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_PeriodOfCumulativeChangeInOwnership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining pre ownership change in operating loss carryforwards written off due to expiration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_TaxCreditCarryforwardExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_TaxCreditCarryforwardExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703588017368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation Pre-tax Income (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (25,744)<span></span>
</td>
<td class="num">$ (19,086)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(732)<span></span>
</td>
<td class="num">(714)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Total</a></td>
<td class="num">$ (26,476)<span></span>
</td>
<td class="num">$ (19,800)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703588041768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Provision (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision (benefit)</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703587057208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Permanent differences</a></td>
<td class="num">(0.20%)<span></span>
</td>
<td class="num">(2.80%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development tax credits</a></td>
<td class="nump">11.20%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock compensation deductions</a></td>
<td class="nump">5.10%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other items</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in deferred tax asset valuation allowance</a></td>
<td class="num">(40.70%)<span></span>
</td>
<td class="num">(23.00%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703585326152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 17,885<span></span>
</td>
<td class="nump">$ 13,253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits</a></td>
<td class="nump">3,992<span></span>
</td>
<td class="nump">1,138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangibles</a></td>
<td class="nump">360<span></span>
</td>
<td class="nump">358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">850<span></span>
</td>
<td class="nump">686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">3,606<span></span>
</td>
<td class="nump">496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_DeferredTaxAssetsLeasingArrangements', window );">Lease liability</a></td>
<td class="nump">7,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_DeferredTaxAssetsRightOfUseAssets', window );">Right of use asset</a></td>
<td class="num">(7,181)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax asset</a></td>
<td class="nump">26,995<span></span>
</td>
<td class="nump">16,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">$ (26,995)<span></span>
</td>
<td class="num">$ (16,204)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_DeferredTaxAssetsLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_DeferredTaxAssetsLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets liabilities property plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_DeferredTaxAssetsRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets right of use assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_DeferredTaxAssetsRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703576546280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and License Agreements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">16 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Feb. 28, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,950,000<span></span>
</td>
<td class="nump">$ 11,247,000<span></span>
</td>
<td class="nump">$ 8,523,000<span></span>
</td>
<td class="nump">$ 7,264,000<span></span>
</td>
<td class="nump">$ 4,709,000<span></span>
</td>
<td class="nump">$ 24,238,000<span></span>
</td>
<td class="nump">$ 36,984,000<span></span>
</td>
<td class="nump">$ 28,947,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Dr. Langer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForManagementFee', window );">Payment to director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,980,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_IncreaseDecreaseInResearchAndDevelopmentExpense', window );">Decrease in research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 323,000<span></span>
</td>
<td class="nump">845,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=freq_ResearchAndDevelopmentMember', window );">Research and Development | Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_AmountOfFundingReceivedAsGrant', window );">Amount of funding received as grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,596,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_GrantTermPeriod', window );">Grant term period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=freq_MassachusettsInstituteOfTechnologyMember', window );">MIT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_DescriptionOfFutureDevelopmentObligations', window );">Description of future development obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company&#8217;s future development obligations are: (i) to commence a Phase II clinical trial for such Product, (ii) to commence a Phase III clinical trial for such Product within five years of the IND filing for such product within two years of the IND filing for such product, (iii) to file a New Drug Application or equivalent with the FDA or comparable European regulatory agency for such Product within nine years of the IND filing for such product, and (iv) to make a first commercial sale of such Product within 11 years of the IND filing for such product.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_LicenseFeePayment', window );">License fee payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_PercentageOfSharesOfCommonStockIssued', window );">Percentage of shares of common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_DescriptionOfConditionsToTerminateLicenseAgreement', window );">Description of conditions to terminate license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company has the right to terminate for any reason upon a 3-month prior written notice. MIT shall have the right to terminate if the Company ceases to carry on any business related to the MIT License Agreement. MIT may terminate the MIT License Agreement for the Company&#8217;s material breach uncured within ninety (90) days (or thirty (30) days in the case of nonpayment). MIT may also terminate the MIT License Agreement if the Company or our affiliates commence any action against MIT to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or non-infringed (a patent challenge), or if our sublicensee commences such actions and the Company does not terminate such sublicense within thirty (30) days after MIT&#8217;s demand. MIT has the right to increase all payments due, instead of terminating the MIT License Agreement in the case of a patent challenge.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_RightToTerminateAgreementUponPriorWrittenNotice', window );">Right to terminate agreement upon prior written notice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_RightToTerminateAgreementIfBreachRemainsUncured', window );">Right to terminate agreement if breach remains uncured</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_RightToTerminateAgreementIncaseOfNonpayment', window );">Right to terminate agreement incase of nonpayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=freq_MassachusettsInstituteOfTechnologyMember', window );">MIT | Astellas Pharma LLC | Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=freq_MassachusettsInstituteOfTechnologyMember', window );">MIT | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=freq_MassachusettsInstituteOfTechnologyMember', window );">MIT | Patent License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_LicenseAgreementEnteredDate', window );">License agreement entered date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2016-12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=freq_CaliforniaInstituteForBiomedicalResearchMember', window );">CALIBR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_LicenseFeePayment', window );">License fee payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_PercentageOfSharesOfCommonStockIssued', window );">Percentage of shares of common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_DescriptionOfConditionsToTerminateLicenseAgreement', window );">Description of conditions to terminate license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company may terminate the CALIBR License Agreement at will upon a 30-day prior written notice. The Company may also elect to terminate its license to one or more licensed patents in any or all jurisdictions by giving ninety (90) days&#8217; prior written notice to CALIBR. CALIBR may terminate the CALIBR License Agreement for material breach uncured within thirty (30) days. CALIBR has the right to terminate or reduce the license to a non-exclusive license if the Company fails to use diligent efforts to develop and commercially exploit CALIBR Licensed Products.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_RightToTerminateAgreementUponPriorWrittenNotice', window );">Right to terminate agreement upon prior written notice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_RightToTerminateAgreementIfBreachRemainsUncured', window );">Right to terminate agreement if breach remains uncured</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice', window );">Right to terminate licensed patents upon prior written notice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=freq_CaliforniaInstituteForBiomedicalResearchMember', window );">CALIBR | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=freq_CaliforniaInstituteForBiomedicalResearchMember', window );">CALIBR | Patent License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_LicenseAgreementEnteredDate', window );">License agreement entered date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2018-09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=freq_ScrippsOptionAgreementMember', window );">Scripps Option Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_LicenseAgreementEnteredDate', window );">License agreement entered date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2018-09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_DescriptionOfConditionsToTerminateLicenseAgreement', window );">Description of conditions to terminate license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company has the right to terminate by giving 90 days&#8217; advance notice. Scripps has the right to terminate in the event of nonpayment by us that remains uncured for 10 days. Each party has the right to terminate in the event of the other party&#8217;s material breach that remains uncured for 60 days or if the other party becomes bankrupt.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_RightToTerminateAgreementUponPriorWrittenNotice', window );">Right to terminate agreement upon prior written notice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_RightToTerminateAgreementIfBreachRemainsUncured', window );">Right to terminate agreement if breach remains uncured</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_RightToTerminateAgreementIncaseOfNonpayment', window );">Right to terminate agreement incase of nonpayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_FundingPaymentsMadeAsConsiderationToSupportResearchActivities', window );">Funding payments as consideration to support research activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_TermOfAgreement', window );">Agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_LicenseAgreementExtendedDate', window );">License agreement extended date</a></td>
<td class="text">2021-12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=freq_ScrippsOptionAgreementMember', window );">Scripps Option Agreement | Scenario Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_AdditionalFundingPaymentsMadeAsConsiderationToSupportResearchActivities', window );">Additional funding payments made as consideration to support research activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=freq_MassachusettsEyeAndEarMember', window );">MEE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_LicenseFeePayment', window );">License fee payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_DescriptionOfConditionsToTerminateLicenseAgreement', window );">Description of conditions to terminate license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company has the right to terminate the MEE License Agreement at will by giving thirty (30) business days advance written notice to MEE. MEE has the right to terminate the MEE License Agreement if the Company fails to make any payment due within thirty (30) business days after MEE notifies the Company of such failure. MEE shall have the right to terminate if the Company fails to maintain the required insurance. MEE shall also have the right to terminate the MEE License Agreement upon forty-five (45) business days written notice if the Company becomes insolvent. MEE has the right to terminate for any other default not cured within sixty (60) business days written notice. MEE also has the right to terminate if the Company or its affiliates challenge the validity of the licensed patent rights.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_RightToTerminateAgreementUponPriorWrittenNotice', window );">Right to terminate agreement upon prior written notice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_RightToTerminateAgreementIfBreachRemainsUncured', window );">Right to terminate agreement if breach remains uncured</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_RightToTerminateAgreementIncaseOfNonpayment', window );">Right to terminate agreement incase of nonpayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent', window );">Right to terminate agreement upon prior written notice if insolvent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">45 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=freq_MassachusettsEyeAndEarMember', window );">MEE | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=freq_MassachusettsEyeAndEarMember', window );">MEE | Non-Exclusive Patent License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_LicenseAgreementEnteredDate', window );">License agreement entered date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2019-02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=freq_CambridgeEnterpriseLimitedMember', window );">Cambridge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_LicenseFeePayment', window );">License fee payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_DescriptionOfConditionsToTerminateLicenseAgreement', window );">Description of conditions to terminate license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">We have the right to terminate for any reason upon 90 days&#8217; prior to written notice.  Each party has the right to terminate immediately if the other party ceases to carry on its business.  Either party may also terminate the Cambridge License for material breach if such breach remains uncured for 30 days.  Cambridge may also terminate the Cambridge License if we fail to diligently develop and commercially exploit at least one Cambridge Licensed Product or we or our affiliates or sub-licenses commence any action against Cambridge to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or not infringed.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_RightToTerminateAgreementUponPriorWrittenNotice', window );">Right to terminate agreement upon prior written notice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_RightToTerminateAgreementIfBreachRemainsUncured', window );">Right to terminate agreement if breach remains uncured</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_AnnualLicenseFee', window );">Annual license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=freq_CambridgeEnterpriseLimitedMember', window );">Cambridge | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=freq_CambridgeEnterpriseLimitedMember', window );">Cambridge | Patent License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_LicenseAgreementEnteredDate', window );">License agreement entered date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2019-12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_AdditionalFundingPaymentsMadeAsConsiderationToSupportResearchActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional funding payments made as consideration to support research activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_AdditionalFundingPaymentsMadeAsConsiderationToSupportResearchActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_AmountOfFundingReceivedAsGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of funding received as grant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_AmountOfFundingReceivedAsGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_AnnualLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual license fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_AnnualLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_DescriptionOfConditionsToTerminateLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of conditions to terminate license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_DescriptionOfConditionsToTerminateLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_DescriptionOfFutureDevelopmentObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of future development obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_DescriptionOfFutureDevelopmentObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_FundingPaymentsMadeAsConsiderationToSupportResearchActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Funding payments made as consideration to support research activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_FundingPaymentsMadeAsConsiderationToSupportResearchActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_GrantTermPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant term period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_GrantTermPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_IncreaseDecreaseInResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_IncreaseDecreaseInResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_LicenseAgreementEnteredDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement entered date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_LicenseAgreementEnteredDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_LicenseAgreementExtendedDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement extended date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_LicenseAgreementExtendedDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_LicenseFeePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License fee payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_LicenseFeePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_PercentageOfSharesOfCommonStockIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of shares of common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_PercentageOfSharesOfCommonStockIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_RightToTerminateAgreementIfBreachRemainsUncured">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right to terminate agreement if breach remains uncured.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_RightToTerminateAgreementIfBreachRemainsUncured</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_RightToTerminateAgreementIncaseOfNonpayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right to terminate agreement incase of nonpayment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_RightToTerminateAgreementIncaseOfNonpayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_RightToTerminateAgreementUponPriorWrittenNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right to terminate agreement upon prior written notice.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_RightToTerminateAgreementUponPriorWrittenNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right to terminate agreement upon prior written notice if insolvent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right to terminate licensed patents upon prior written notice.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_TermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_TermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForManagementFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount paid to managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForManagementFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=freq_ResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=freq_ResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=freq_MassachusettsInstituteOfTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=freq_MassachusettsInstituteOfTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=freq_AstellasPharmaLimitedLiabilityCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=freq_AstellasPharmaLimitedLiabilityCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=freq_PatentLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=freq_PatentLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=freq_CaliforniaInstituteForBiomedicalResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=freq_CaliforniaInstituteForBiomedicalResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=freq_ScrippsOptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=freq_ScrippsOptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=freq_MassachusettsEyeAndEarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=freq_MassachusettsEyeAndEarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=freq_NonExclusivePatentLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=freq_NonExclusivePatentLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=freq_CambridgeEnterpriseLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=freq_CambridgeEnterpriseLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703581211288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreement - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">18 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,950<span></span>
</td>
<td class="nump">$ 11,247<span></span>
</td>
<td class="nump">$ 8,523<span></span>
</td>
<td class="nump">$ 7,264<span></span>
</td>
<td class="nump">$ 4,709<span></span>
</td>
<td class="nump">$ 24,238<span></span>
</td>
<td class="nump">$ 36,984<span></span>
</td>
<td class="nump">28,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,415<span></span>
</td>
<td class="nump">18,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=freq_LicenseAndCollaborationAgreementMember', window );">License and Collaboration Agreement | Astellas Pharma LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Payments received under collaboration agreement</a></td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_AgreementTerminationNoticePeriod', window );">Agreement termination notice period</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_RightToTerminateAgreementIfBreachRemainsUncured', window );">Right to terminate agreement if breach remains uncured</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_RightToTerminateAgreementIncaseOfNonpayment', window );">Right to terminate agreement incase of nonpayment</a></td>
<td class="text">45 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_RevenueRecognitionTransactionPrice', window );">Transaction price allocated to single combined performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued upfront payment related to sub License revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_UpfrontFeeRecognizedAsRevenue', window );">Upfront fee recognized as revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,000<span></span>
</td>
<td class="nump">28,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_RevenueFromContractWithCustomerApplicationInputMethod', window );">Revenue from contract with customer application input method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue remaining performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,046<span></span>
</td>
<td class="nump">186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=freq_LicenseAndCollaborationAgreementMember', window );">License and Collaboration Agreement | Astellas Pharma LLC | Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=freq_LicenseAndCollaborationAgreementMember', window );">License and Collaboration Agreement | Astellas Pharma LLC | Phase 2b Clinical Trial | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized potential development milestone payments to receive</a></td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=freq_LicenseAndCollaborationAgreementMember', window );">License and Collaboration Agreement | Astellas Pharma LLC | Phase 2b Clinical Trial | Asia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized potential development milestone payments to receive</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=freq_LicenseAndCollaborationAgreementMember', window );">License and Collaboration Agreement | Astellas Pharma LLC | Phase 3 Clinical Trial | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized potential development milestone payments to receive</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=freq_LicenseAndCollaborationAgreementMember', window );">License and Collaboration Agreement | Astellas Pharma LLC | Phase 3 Clinical Trial | Asia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized potential development milestone payments to receive</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=freq_LicenseAndCollaborationAgreementMember', window );">License and Collaboration Agreement | Maximum | Astellas Pharma LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized potential development milestone payments to receive</a></td>
<td class="nump">230,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones', window );">Revenue recognized commercialization milestone payments to receive</a></td>
<td class="nump">315,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization', window );">Potential commercial milestone payments eligible to receive upon successful commercialization</a></td>
<td class="nump">$ 315,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_AgreementTerminationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement termination notice period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_AgreementTerminationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with customer liability revenue recognized from commercialization milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_RevenueFromContractWithCustomerApplicationInputMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue from contract with customer application input method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_RevenueFromContractWithCustomerApplicationInputMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue recognition potential commercial milestone payments eligible upon successful commercialization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_RevenueRecognitionTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue recognition transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_RevenueRecognitionTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_RightToTerminateAgreementIfBreachRemainsUncured">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right to terminate agreement if breach remains uncured.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_RightToTerminateAgreementIfBreachRemainsUncured</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_RightToTerminateAgreementIncaseOfNonpayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right to terminate agreement incase of nonpayment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_RightToTerminateAgreementIncaseOfNonpayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_UpfrontFeeRecognizedAsRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront fee recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_UpfrontFeeRecognizedAsRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=freq_LicenseAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=freq_LicenseAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=freq_AstellasPharmaLimitedLiabilityCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=freq_AstellasPharmaLimitedLiabilityCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=freq_Phase2bClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=freq_Phase2bClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AsiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AsiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=freq_Phase3ClinicalTrailMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=freq_Phase3ClinicalTrailMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703581887336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 11, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 07, 2020 </div>
<div>ft&#178; </div>
<div>Term</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease ROU assets</a></td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,551,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">397,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,597,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">470,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">510,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short term lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">835,000<span></span>
</td>
<td class="nump">$ 269,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">484,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Commitment payments related to research</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyLossInPeriod', window );">Losses related to indemnification obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=freq_HaydenLLCMember', window );">Hayden LLC | Lexington Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 31,  2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Rentable area of office space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_OperatingLeaseCommencementDate', window );">Lease commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 11,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_OperatingLeaseNumberOfAdditionalExtensionTerms', window );">Number of additional lease extension terms | Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_OperatingLeasesAdditionalExtensionTerm', window );">Lease extension term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=freq_LeasesTerminationAgreementMember', window );">Lease Termination Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_OperatingLeaseTerminationFee', window );">Payment of fee to landlord</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=freq_LeasesTerminationAgreementMember', window );">Lease Termination Agreement | ARE-MA Region No. 20, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">Mar. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_MA', window );">Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lease, description of option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The lease was extended in November 2019 and expires in February 2025.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_OperatingLeaseAgreementAmendedDate', window );">Lease agreement amended date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2019-11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_OperatingLeaseAgreementCommencementDate', window );">Lease commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2020-02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_OperatingLeaseAgreementExpirationDate', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2025-02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CT', window );">Connecticut</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_LeaseExpirationYear', window );">Lease, expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=freq_WoburnMassachusettsFacilityMember', window );">Woburn Massachusetts Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_LeaseExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_LeaseExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_OperatingLeaseAgreementAmendedDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease agreement amended date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_OperatingLeaseAgreementAmendedDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_OperatingLeaseAgreementCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease agreement commencement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_OperatingLeaseAgreementCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_OperatingLeaseAgreementExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease agreement expiration date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_OperatingLeaseAgreementExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_OperatingLeaseCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease commencement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_OperatingLeaseCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_OperatingLeaseNumberOfAdditionalExtensionTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease number of additional extension terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_OperatingLeaseNumberOfAdditionalExtensionTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_OperatingLeaseTerminationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease termination fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_OperatingLeaseTerminationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_OperatingLeasesAdditionalExtensionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating leases additional extension term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_OperatingLeasesAdditionalExtensionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum amount the entity agreed to spend under the long-term purchase commitment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyLossInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of loss pertaining to the specified contingency that was charged against earnings in the period, including the effects of revisions in previously reported estimates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyLossInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net rentable area for properties owned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=freq_HaydenLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=freq_HaydenLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=freq_LexingtonLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=freq_LexingtonLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=freq_LeasesTerminationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=freq_LeasesTerminationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=freq_AREMARegionNo20LLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=freq_AREMARegionNo20LLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=freq_WoburnMassachusettsFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=freq_WoburnMassachusettsFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703665204952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Leases (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">10 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">8.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703584944376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Reconciles the Undiscounted Cash Flows to the Operating Lease Liability Recorded on the Consolidated Balance Sheet (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 11, 2020</div></th>
<th class="th"><div>Jan. 01, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 2,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">4,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">4,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">4,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2025</a></td>
<td class="nump">4,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">27,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">47,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: amount of lease payments representing interest</a></td>
<td class="num">(16,404)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of future lease payments</a></td>
<td class="nump">30,994<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current lease liabilities</a></td>
<td class="num">(397)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Noncurrent lease liabilities</a></td>
<td class="nump">$ 30,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703665179880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Future Aggregate Minimum Payments Under Noncancelable Operating Leases and Short Term Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2021</a></td>
<td class="nump">$ 2,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2022</a></td>
<td class="nump">4,159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2023</a></td>
<td class="nump">4,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2024</a></td>
<td class="nump">4,412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2025</a></td>
<td class="nump">4,545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">2026 and beyond</a></td>
<td class="nump">27,070<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">$ 47,456<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703593490488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum percentage of employee contribution to retirement plan</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Percentage of employer matching contribution</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Percentage of employee annual compensation matched by the employer</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage', window );">Employers matching contribution vesting percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employers matching contribution</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employer's matching contributions to a defined contribution plan that vests in a given year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703592273240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Dr. Langer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForManagementFee', window );">Payment to director</a></td>
<td class="nump">$ 1,980<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForManagementFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount paid to managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForManagementFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139703586505544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Data (Unaudited) - Schedule of Quarterly Financial Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 9,950<span></span>
</td>
<td class="nump">$ 11,247<span></span>
</td>
<td class="nump">$ 8,523<span></span>
</td>
<td class="nump">$ 7,264<span></span>
</td>
<td class="nump">$ 4,709<span></span>
</td>
<td class="nump">$ 24,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,984<span></span>
</td>
<td class="nump">$ 28,947<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_OperatingAndNonOperatingExpensesNet', window );">Total expenses</a></td>
<td class="nump">20,182<span></span>
</td>
<td class="nump">16,588<span></span>
</td>
<td class="nump">14,548<span></span>
</td>
<td class="nump">12,177<span></span>
</td>
<td class="nump">10,202<span></span>
</td>
<td class="nump">24,813<span></span>
</td>
<td class="nump">$ 6,852<span></span>
</td>
<td class="nump">$ 5,826<span></span>
</td>
<td class="nump">63,495<span></span>
</td>
<td class="nump">47,693<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(10,232)<span></span>
</td>
<td class="num">(5,341)<span></span>
</td>
<td class="num">(6,025)<span></span>
</td>
<td class="num">(4,913)<span></span>
</td>
<td class="num">(5,493)<span></span>
</td>
<td class="num">(575)<span></span>
</td>
<td class="num">(6,852)<span></span>
</td>
<td class="num">(5,826)<span></span>
</td>
<td class="num">(26,511)<span></span>
</td>
<td class="num">(18,746)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDividendsAdjustment', window );">Cumulative Series C convertible preferred stock dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40)<span></span>
</td>
<td class="num">(1,014)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,054)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (10,232)<span></span>
</td>
<td class="num">$ (5,341)<span></span>
</td>
<td class="num">$ (6,025)<span></span>
</td>
<td class="num">$ (4,913)<span></span>
</td>
<td class="num">$ (5,533)<span></span>
</td>
<td class="num">$ (1,589)<span></span>
</td>
<td class="num">$ (6,852)<span></span>
</td>
<td class="num">$ (5,826)<span></span>
</td>
<td class="num">$ (26,511)<span></span>
</td>
<td class="num">$ (19,800)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders-basic and diluted</a></td>
<td class="num">$ (0.30)<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.73)<span></span>
</td>
<td class="num">$ (3.42)<span></span>
</td>
<td class="num">$ (3.24)<span></span>
</td>
<td class="num">$ (0.82)<span></span>
</td>
<td class="num">$ (2.29)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_OperatingAndNonOperatingExpensesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating and non-operating expenses net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_OperatingAndNonOperatingExpensesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDividendsAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accretion of temporary equity during the period due to cash, stock, and in-kind dividends. This item is an adjustment to net income necessary to derive net income apportioned to common stockholders and is to be distinguished from Temporary Equity, Accretion of Dividends (Temporary Equity, Accretion of Dividends).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDividendsAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>104
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M;$U\9YVZTR)[+$29,ZE^_BDA./[0-43ZQ56N2$^VQ$VVT,3N-X@RGN;HS+N
M)AVJET0P ;3L \+>'+ZU^46JH-(TNJV&)IS_PW)8NN+U*5?*U!4A$4S;2D/K
MQNL'1#6"Z8=5]\!:KP-4U]8-GN)T#GM4-:P;B\L7Z[=PQF(.#"Y50S-V-6O
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M+!@%\$8 WF^$T*\WYGCO<)R[^A=02P,$%     @ O(!]4LU/TEC> @  ,0H
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MX90-JA; ]PLIS>&F7J"=VZ?_ U!+ P04    " "\@'U2<M7%I,<"  "3!P
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MRPRG)BAK@/=+*<U^8P-4<WC\#U!+ P04    " "\@'U2[&;0L.L&  "K(@
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MX$#(F7# $/]I07(?P&EO;XP[AU<#[ ^:8>K'-VOPS8+X_M)ZQZJ,6XX )Y:
M4EN_(A 55(C,XD5LK;BC$E]&SGJ@DMB/:=Y@FH>S059C%T\%A\,->6W>VSNF
M YOCJ"71Z)DC6W&E(*CJ[05XI[+RY,O.Q6&M]"3OTF@ 0X?(<9AX-JQ:<VWY
MN9,^6G/(0^!J.!GV((IG4PF3=D,2-'JI^):)_.CL>A=I-ER!<($W*G/8WJL2
MI.^$E)Q'KV\4)0D9\%7+T9@&H=]FF=Q9@MJR)_90> /EL,1)I)#9]!QA?]0X
MC8<"JB5W'&;W)J 4W_-JYP<8>YR3SF?Q.<3^N 1'@TYL>1XGSSE1[7A[_EZ,
M29\@HQZ+>D;A>#Z4$2W9XS#;?SZ*3"LL7;GQB8S7AC[)C^,$SV;G5GC$("9X
M0$YQ*P=X^JJ*0E1 +*\01]P2.PXS^W*GL@VSJ0S4#JX"!YDGE];\QTYL!^C\
M#O?Y?)RFT_-RPS<,1^E0KK34C\/<?T1M0;,]$X7-:"=&FL&%YL!&PX?;UP.H
ME6B<G(/WC9N1%,_\\$FK'22L'5]XSLNM$_M?,8#TU00$#9\'IV<8E(00G@/P
M6]DA^&5)YJ_D?,'J-0/W*2"*(W)N1G\8U*QP# -FM&)&R*N2;"4JJ'%>GF2D
MU1X2UIZEDAGG^3&9!XHIKX_Z6H.37J1Z1LV@IQ^@>])*$@E+TBGNI1)[:!;1
MLF"9J_,N7$T/5C0695+[M9_T!2F.<#Q0EI)6D$A8D$X1?N6J1']+YBWNB4=Q
MDB@:D!S22@YYH>1TL\$72UY0?0%)TK2G,YYA.(;N-1D WPH-"3<>%CR4KNI0
MPSI#+FIS+/_O@8R@9KI >B.5&1OKWSJ]R_JY%0H%MTID]FV"G>@UL]^3$#SO
MI[JGOTFF\^G0&;4J1\(JMWB563ZK$#/H@:]%5=E#M5K)E9"YU]B^Z)$H(LG\
MW-K^N)B0V4 K25IQ)&%Q?)VQWC.TUG);V@?M[.LC(5#\G!<!OG&G_CA]Z]+*
M*(V"!-YT@,+P,DC5M-4V&M8V]U)S+%?CG>UHZU9*V)X\<[U6W?"Z;.DT5S[O
MT+YL44SI0,;25K5HN 5;[,I=P6RGB>[A:*!P6P#MPGDJ(VP-L57'/J+NT'-A
M2<G_XFY!^\T6M D#Y1GMO \+Z]W"X=&'^N8<D8VWRAZ=K(R216$32E00EQ"#
M]D(^IXH+ZE-%/!VB0]H*'GU&\)ZOABU=%KO<U3I [J=-I1O*7M DT?Z+.(+C
M(?RM'-*P'!XBX@XM.A&Q;/Q_WW?HZ4:MZ-'TM]9.M%4H&E:H4.TT&/4OKTP6
MU"--Z4 #1UO!H6'!:5+S%P^B)7LZ_ZT'$;=L&X>;EM]]$(?MNRF1XK3S]J7&
M/>E\^"BY6KOO01JY/*R_(#1/FV].M^Y+R]GS.WRYJ+\<M<O4'[(^,05"KX'G
M5[!D]'X*2:?J;T/UC9%;]WGE01HC2W>YX2SGR@Z _Z^D-,<;NT'SA>[F?U!+
M P04    " "\@'U2!(;11'D-   Y(@  &    'AL+W=O<FMS:&5E=',O<VAE
M970X+GAM;*U:76\;-Q;]*X0W6#3 6)9D)T[:)(#M)-BTS<:(TP:+Q3Y0,QR)
MS<QP2G(DN[]^S[TDYT.6O7G8AZ;2#'EY/\\]E_*KG;'?W$8I+V[KJG&OCS;>
MMS^>G+A\HVKI9J95#=Z4QM;2XZM=G[C6*EGPIKHZ6<[GST]JJ9NC-Z_XV;5]
M\\ITOM*-NK;"=74M[=VEJLSN]='B*#WXK-<;3P].WKQJY5K=*/];>VWQ[:27
M4NA:-4Z;1EA5OCZZ6/QX>4;K><'O6NW<Z+,@2U;&?*,O'XK71W-22%4J]R1!
MXG];=:6JB@1!C3^CS*/^2-HX_IRDOV?;8<M*.G5EJJ^Z\)O71R^.1*%*V57^
ML]G]0T5[GI&\W%2._Q6[L/;\Y9'(.^=-'3=#@UHWX?_R-OIAM.'%_($-R[AA
MR7J'@UC+M]++-Z^LV0E+JR&-/K"IO!O*Z8:"<N,MWFKL\V\^V;5L]%\RN*@I
MQ*5TV@E3BFNKG&H\OWEUXG$6[3C)H]S+('?Y@-S%4GPTC=\X\:XI5#$5< (E
M>TV72=/+Y:,2WZI\)DX7F5C.E_-'Y)WVEI^RO-/OL?S*-,Y4N@C?+N"'L?GB
M4RG>ZT8VN9:5N,%#A;ST3OS[8N6\16;]YQ&%SGJ%SEBAL_][*!Z52V7]HVME
MKEX?M23(;M71F\5,W#MOE<YKQ[:_M^K/3C7YG?BR45:VJO,Z=YGXT.2S3'BS
M5A[/D;9^(S1\LMN8JKH39M>H K6^<KK0TFJ%+0^)NO[RKTS\^N7M0RO$C<H[
MJSV$(%*V-790^H$=/\M6-N*77\0/PP)^]E3\ 'TAIL:7NZ>9V #*_NRD]<I"
M8=V(KV;5V283'Z5S,M]T3GD/)7?2X6T>CP]+_VFVJE[!^N5\<2:P0(JWJI([
M:97(!T5GI%LZ4FA:EB-*.I?5L?/ /K'2QJM\TYC*K.^P-:PL#1  )\'4C;2-
M<DXW:T'JKTQQ]_>_O5@NSG\BK1HH1#)XMS= RU9J*XS%IZVR3HE"UG1.+EG@
MZ@XJK*R1A;"RP7,$O5!KU2A2>(OEVBE@G4.6-/!^ZY.95'Z+EYD8^5"HL@3&
M0JP4BV/TB>/GL_/39\_ZLP%B^3?AVDI[.HB2!!;6L(K?!.^TTHJMK#K6A:2/
ME[#S&^.%+/X )M)1Y$2D*< W;3AT'&4(O9.=WQBK_\+.7+;:HXQ)I$09 YW(
M98OY/)N'_X2#MQ57PD0)$K8X>Y&=+\^RE\OE:-F3^6P^7XQL0 65RE)"A:V<
M<]?]PQMZ^#08?DCM8%C(,:1QL)H@AS0E43>**DI<$'!AN]>KZIY\\4._JG^#
M?(\/+[]KZ^5H*]L?GU]]U^ZK\>Z<-W S;ZW.\9H3M:3^C%BVUJ!<J%H0FT+E
MEO*/["=SFX[3#YY^(#00M<)JYSHHT;5X/AP7W"SS6%540GD/]UA>]LCN!F0G
M6Y%P0<N0CO]KRYH*QRJ/LF*J$>LB"3@49Q2+D%4E6OC+%"X!KRIFXN:PH1WR
MU59L!"@63F\*^AQ>FI;\!P@&E(T=ZA4 &4'H<JJ<6!*0WJJHZ*VR.2H^!B83
MNA2RA8:Y1'BSP_* A1RCD*3PKBW@$Q4: 1T 0*U=*DZ(PWZK":C<@.9R;55P
MWPP-17S*O8EPNH<Q%+Q*D>_I*;#3D_?;;@4E<0:2C%UR'UU"Z1%6+N<_?;C^
MQ)\6/SWE\^@5GDV/BEE$?D+$"_$\.UT^V\.%>Z?(D,-P7XIWKYMXLC@#/%"0
M@X2,?%=UCEP?W<-AW<$I2)&(ZT-4X%\@2\(YPG5DTC'RQ@1,"&&?-AFK<@7Y
M17#\K:Y#T)Z<OYR=@T=6%=4A!#?@_5B0*U4@[K*$ J@^9(HG?_9JT1?TA-QT
MJ3C(>GB*\XV^&V8!?234+<8&;B ?N!:;R,+[[&"WFR'DYZ&S<#GLXTE*V7U4
MA4/VNGLL^P"=",1RF<W/S[/GR_/'0)W.G%13OS0AZ/'BH%*7!YYSL:"P2Z6Y
MD-% ?^[@^M [Z=_'DHW0?HVB6%.A0(%E=OILGBWF+QY)OFS4>%(G&G(M9&9G
M\XU,%1Z2\L4D*2EM&PQ1I(FZU8Y#KN%,'&$=USAMWI)>;04VR:E' #9.(99\
M-I\M^AS;3ZEA+_@(25 J)M!^ZDPJ]SH>?9VV3^KX4(+=V[%'6II$^&"X%)_5
M6A.59QD\FB+J"9PFFCRZ,FDUJ-&[<":N.^LZ.33Q1R5-M66<9)[2$K=#N,AE
MI4;S)1HTDM,WI$&%$7NF7>]ND0I$^J[Z$IX8>//N:F(&0O]\#@)YYV(PN1U6
MQD7$/>CL*>Q&N'ZO*]J#057U)U &(3M;XT)R!V-")L0V):L>)T-7G$(=>:%X
MV T/QJZ?XP9K-SK?,#$$ :DDI4?HX834X,RLP;LK@JV!$Y^&LI[JM"%R63D3
M X<J1+6N(TB22]>.9B=D1Z'J1I=WTUS)$M"7)<J5OA<:B!Y>U;)!Z= GA9YH
M[A1U;"ZF$%\Z'V7MJ!@VAFH#E*1R_#R=$)#]?A;V/A&E-;7 V5XB_I66*\2N
M3R'*0WG'N-G7[U"VZA;=C8&4COR^'O*4>J(N1A0WNK*?<@S:Z5H&@O. ]OLU
M-!._-=$$5GUO"L-P^D<D:%:[;T&G;K(CPBQ6* G:%:>UP"3I?>2GT_$-005=
MMW>QSY,G,K'J/$\PE:XUTQB#H((25J9E?Z\"QU%>,]XBWPF->ZDT*]*@9[;!
M!;2YI>&%*!<T_*92T!M5983'/@(BS_-$O927]FZ0"/685.F!M:V)6#2L#HJI
MJZ*W^R&*<X '3*9P>%(4.E+V-%;A9=D1G+<J1(6 SQJ"?ZQ!?R4&#<=V:)F-
MKV)^3%RQ0^L0U->1\\+I->H#YE/'&(XCHBS1TUBY\684+%BJ&_F>(#.-VR'M
MTA<HXD.:%LE@ Q<Q94([)3=JU(HWG ?$QF05+TRXW)U*QQU6MPZIC@C<=Q1*
MML >;J<I;JR(;DHKD3YP6!=Q7MUZN@;=JE'$CM$'B([3- /FD\IS)MYM54,$
M_E -M3$0!QPFJ*FX+@?_=V4']3">:#>4 [!$-3P9T!PS[4XQ8.2<,.<T8"(,
M(.E PG"Z3.@2IH7S*I.GJQ0&;$Q;&^(K='W2)TC,I$1'B8=L>.ZPZI@NIR.K
M8#I+0PU2KB?A5Y]^__#V&+02>@)I=3X3%_U,4D2.19_+T)KX&\R^:)H.L?K,
M/@[&UO(/8RG]L<; CAY\&6$UF8Q#Z0XZF+XQ-8U.&^K1#:,'-(\73;32-.H8
M9]DB":2M"$6N,AXV(P7#2[I;Q^Y*KN@^B3)T5.D;N55Q?J2<QCJ2$WP*$ B.
M\TK6/,DBC2BIXD!+6LL$$H@[_$UMFI#<ZCB54<C>2UM#C#=(@*LO0^TY(!DI
M>YSBV%..WQK-TW=PUU6D9WGG,VZ-=+]14].FUDJ+F*26NO1L6TYY65&.1L8A
MHX4,9N$*J]]:!,=S_E!"?1.%V<$BBUSAB7JK3>=X8(W=?":^<E1V*G@O:3.R
MFQ0R$\NCL6D/6@Y"1+ZC*Z58(@3"8R$4Y5'&C^\6+R*J4OQIN$N=E;LU;!N<
M;$;7M"X<OE(H<=6LT8NX%\MBRR">]$#546-#]+XJ+B:F(D%O^4U1L:G6I2R;
M<,7W;R]ZM.C:(E9GZ&=BW>DPXQ-IP^[$Z0= Q8!?)7JV7WI98"=Y,"0H N71
M#C5/.]K';-[(,!"1YN3.//3+29WQ0KX:"[<J&D@$KYG0CQ66FCKY=+BMJ25*
M(R!R'6X5 -#A;GIH%R1@K<S:RG83>@:@33 ",CU4$9%"=>,)I-#D%C2A1(NZ
M(/2CEFDES?('.B8!*Q!"T44D_,H_5>6@EW3W$BY1PH6,)[[%XTX2TL.+F?0=
MD"S;M:-\,3FC:9$=QD3XXB[<#%,#V$SVPVRR8]6![0,A6,&^LV=T#;M3 '_I
M @]*R^2$ 22$N_KX"7NN/G\:7QE,:X 3$;2U)C_'%.O%/I!8K']@V_LQ(*7H
MY+T,G48.:^%\8E25!"MBAD:&MMS*?)QWHH!QZXQFM??I#3/)RJ=KETK)(K4D
M/H7$_ZI!&0I&OV:XED;=0V:^QU8)-(E64352_@ZN!45!5FO"?7)=/XAS#Z+S
MTOC$MP;QD'AMD(_N<,-E)Y==I"W]%5)JN[FI8@_BP7Y@V?N:HI8XWT@$/E!1
M85RDV0!QS!6K0A_BO=4DHR5GRUN<'::KQ:%;DX 05"==3:Q-$0=$]H<?&)Z\
M?):=OGPYU2L B=O'D?B;AQJQC*@J81PS T-0K+@:RXXX61 </HNM3C5N)IR+
MR%.BZ(Q+9/3WP $1: 8LM1?JB3VC'W_N"4V29(CG&%]"P@?PQ+-U^+5G $\Z
M<8!+JC_=_](V.J>EFXR@7U_R/(5A&HOC.5$XA&C%Z"0=: >9E C>8#9E-7F=
M.216RZW4%3N;L)ROD,=P.)D-,RJCA(OC8*]4I5&G\;3^.FNHK72:ZZ@WZSAV
M\N!"5)*:^JC&RG ,JMAYL5B*.ORRW9<8$\G (@_\+L 7@H-9XY\J9N+0[\8G
MHY_S,76L^8\67&A6X9?]_FG_=Q$7X<\!AN7ACRH^2KO6L*!2);;.9^?/CC#K
M\A\JA"_>M/S' 2OCO:GY(_T@JBPMP/O2 !?B%SJ@_VN1-_\%4$L#!!0    (
M +R ?5+O$N+G>28   N!   8    >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL
MY3W;<MLXEN_^"E9V:M>NHA5;<>*D;U5.TME)5U^\[62FMK;V@2(AB1.*U!"D
M'?77[[D!.*!(R>F>F9=]22P)! [._0;PFX>F_637QG3)YTU5VV^?K+MN^]73
MIS9?FTUF9\W6U/#+LFDW60<?V]53NVU-5M!#F^KI_.+BQ=--5M9/OON&OKMM
MO_NFZ;NJK,UMF]A^L\G:W6M3-0_?/KE\XK[XM5RM._SBZ7??;+.5N3/=Q^UM
M"Y^>^EF*<F-J6S9UTIKEMT]N+K]Z?87C:<!?2O-@U=\)[F31-)_PP_OBVR<7
M")"I3-[A#!G\=V_>F*K"B0",O\N<3_R2^*#^V\W^CO8.>UEDUKQIJK^61;?^
M]LG+)TEAEEE?=;\V#W\VLI_G.%_>5);^31YX[-6S)TG>VZ[9R,, P::L^?_L
ML^!!/?#R8N*!N3PP)[AY(8+R;=9EWWW3-@])BZ-A-OR#MDI/ W!EC42YZUKX
MM83GNN_NF!A)LTSNRE5=+LL\J[OD)L^;ON[*>I7<-E69E\9^\[2#]?"II[G,
M_9KGGD_,?3E/?FKJ;FV3[^O"%/$$3P%0#^W<0?MZ?G#&MR:?)<\NTV1^,;\X
M,-\SO_MG--^SB?E&MIG\S\W"=BUPR_\>6.#*+W!%"US]4]![>.[Y+%'36S5]
M%J;?NFV]SFQI<2#(KC5UEY%0?%@;&KW99O4.Q^=-;>&1(NM,D2S+.JOS,JL2
M"^,-R&)GDW5V;Y*%,37.M,U:&%?6-$E;P&@##-RM-0CP;%UD;6$3"TIFL4LZ
M6/2=GUKAXLZ/?-W ?\GINYN[UV<S@A+_Q ELLC*U:;.JVN$B9HN Z@VW)<R[
MK6#+I_]Y<W-[!LME':WYAK>9+)L*=)%-NB8![=*W)BEAVK!9P$%1(GI24#L6
MQ)OP!GJP):39- $PDSRSZV1)$P$2"'&E[0!% !@@IFD!L%GRJUF:U@!::#D$
M*"FM[0%FAPC<%R 0_K8FJ9N.1^)/QVF!"\M@FF<4E[<!(["-,*FC__%EX/FJ
M+PRM(ZBFN=ZUYN\];&Z'\[39UO1=F0-ZWM<@IH@CQ.O#ND%:-0\U3&_[A2V+
M,FN1)<<?3^Y,WK> ?QCQIFD!D1G38F+X[8?_3I,?/[RE!<.8'S*@]2RYJ2H
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M=*Z#*FU[_H,SD(GO7/$G<#*?-:5L;^Y%6)+,1#W>F.9JSN!1AE]B?,'(S'M
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M"6='W(>NV=+K[A=-US4;^G-M,K#3. !^7S;@)<@'7 #?PDK@??=_4$L#!!0
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MJAZ2M6/DP@VFF30TYIR9TW<%E0V@_4Q*LW%L@O9+-?X)4$L#!!0    ( +R
M?5+9<'C:A@(  ( %   9    >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;*54
M2V_;, R^ZU<(QHY=;,M)FQ1)@*3MMAZ*!>T>AV$'Q:9CH;+D27+3_?M1LN.E
MV!H,V$427Q\_4J+F>VT>;07@Z',ME5U$E7/-91S;O(*:VY%N0*&EU*;F#D6S
MBVUC@!<AJ)8Q2Y+SN.9"1<MYT&W,<JY;)X6"C:&VK6MN?JY!ZOTB2J.#XE[L
M*N<5\7+>\!T\@/O<; Q*\8!2B!J4%5I1 ^4B6J67Z['W#PY?!.SMT9GZ2K9:
M/WKAMEA$B2<$$G+G$3AN3W %4GH@I/&CQXR&E#[P^'Q ?Q=JQUJVW,*5EE]%
MX:I%-(UH 25OI;O7^P_0US/Q>+F6-JQTW_E.6$3SUCI=]\'(H!:JV_ESWX>C
M@&GR2@#K UC@W24*+*^YX\NYT7MJO#>B^4,H-40C.:'\I3PX@U:!<6ZY,=!P
M4=";9[QF"W8>.T3UMCCO$=8= GL%(67T3BM767JC"BA> L1(9^#$#IS6["3B
M->0CFJ5GE"4L.8&7#35F 2_[MQKI2A7THZO T)6UX"R]:HT!Y>BWU=8Z@P_E
M^XFLXR'K.&0=_T=G3R.,1_0  CW(GPJ.Q>A03-Y7P;NB<HV38QV@N:3H0$LM
M<02%VET2[##46XS!+K\4?,MQ26?D/F A>@&-ML)9\I:<9ZBVP$U>]:8G'.NF
M]JX'1B0]NV S,DU2\MYP-!C$%T]\*P$1ILF$K/)<MPHI'EFR<8+66V5;C,F!
ML+/)A.&:9HR$NR)IPD@ZFY%/VG%)WI QILG"GB1_?27QT5348'9A]GU?,'<W
M((-V^%Y6W53]=N_^ICMN=D)9*J'$T&1T,8FHZ>:]$YQNPHQMM<.)#<<*OT@P
MW@'MI=;N(/@$PZ>[_ 502P,$%     @ O(!]4O-8OAX$ P  708  !D   !X
M;"]W;W)K<VAE971S+W-H965T,3(N>&ULI55-;]LX$+WS5Q#:H&@!P9(HQ592
MVX"3MM@%6L!HNKN'H@=:&EE$*5(EJ3C>7[]#RE$=H,D>]L+/F?=F'C6CY4&;
M[[8%</2AD\JNHM:Y_CI);-5"Q^U,]Z#PIM&FXPZW9I_8W@"O@U,G$Y:F\Z3C
M0D7K93C;FO52#TX*!5M#[=!UW!QO0.K#*LJBQX//8M\Z?Y"LESW?PQVX/_NM
MP5TRH=2B V6%5M1 LXHVV?5-X>V#P5\"#O9L37TF.ZV_^\T?]2I*?4 @H7(>
M@>-T#[<@I0?",'Z<,*.)TCN>KQ_1/X3<,9<=MW"KY=^B=NTJ*B-:0\,'Z3[K
MP^]PRN?2XU5:VC#2PVA;I!&M!NMT=W+&"#JAQID_G'0X<RB?<V G!Q;B'HE"
ME.^XX^NET0=JO#6B^45(-7AC<$+Y1[ES!F\%^KGUUN#[&G>D7-7T_8]!]*BX
M6R8.L;U%4IUP;D8<]@Q.QN@GK5QKZ7M50_T4(,&@ILC88V0W[$7$=U#-:)[%
ME*4L?0$OGS+- U[^7YEN)5>.;L[SI5\W.^L,?B+?7F J)J8B,!7_6],7<7P]
M7MN>5["*L. LF'N(UI<S^@0?IAR>.1:JDD,-U+5 &RVQ"H7:7Q.4%[H=&"_Q
MTXW7&X?LBGSDNY] Y((4<3:?XYS%93$G'P:CA!L,!$+=-**",W-6YH1=+LB=
M;MR!&R#L*B.O?BM9QMZ2CX"5U&I94]'U1M^#=[$(7"#M.-YJA4\RC,4K%$6S
M/:I@,8J\2$F>SLD7[;@D61H75U<DCTM6DDU5#=T@N8,:BQ-EJP3W".1U'B,S
M>4->LSC%+-Z07^L54P4^UT7,RD7(=3%GY N*=ZN[GJLCMJ)*[Y7X!QDNLC@K
MY@'@HLQR%.$)*84';)[6ZVZ"_D?@QE+P%4+/-0_?>(#QNL=(87L(_4H>9_17
MGV1R5O(=F'UH;)96>E!NK/[I=.J=F[%E_#0?&^\G;O9"62JA0==TMKB,J!F;
MV;AQN@\-9*<=MJ.P;+'_@_$&>-]H[1XWGF#ZHZS_!5!+ P04    " "\@'U2
MF>WB388"  !;!0  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6REE,UR
MFS 0@.\\A89V>G(-"$Q(:GO&3M)I#YGQ)&E[Z/0@PV*8"(E*<FR_?5<"$V?:
M^-*+I)5VO_V15M.=5$^Z C!DWW"A9WYE3'L5!#JOH&%Z+%L0>%)*U3"#HMH$
MNE7 "F?4\("&81HTK!;^?.KV5FH^E5O#:P$K1?2V:9@Z+('+W<R/_./&?;VI
MC-T(YM.6;> !S+=VI5 *!DI1-R!T+0514,[\172U3*R^4_A>PTZ?K(G-9"WE
MDQ6^%C,_M $!A]Q8 L/I&:Z!<PO",'[W3']P:0U/UT?Z9Y<[YK)F&JXE_U$7
MIIKYF4\**-F6FWNY^P)]/A/+RR77;B2[3C>.?9)OM9%-;XP1-+7H9K;OZW!B
MD(5O&-#>@+JX.T<NRAMFV'RJY(XHJXTTNW"I.FL,KA;V4AZ,PM,:[<Q\D>=J
M"P6YW>,U:]#3P"#5G@5Y3UAV!/H&(:+D3@I3:7(K"BA> P(,9XB)'F-:TK/$
M&\C')(Y&A(8T/,.+AQQCQXO?X*W8@:TY:+(0!7$),Z[)S\5:&X6OXM<9%\G@
M(G$NDO\HXWE".B9'"/20OS=RB=V@#9$E,1604G)LJEILKCRL&31K4+9NKP5;
M1!RB2P_KH-"","P#-"V7!P!L+,[,B0_OO3<9A2G%F8[2+/562I:@;1,R3DI
MC32Y\))XXCU6M2H^MDR9 V(T,)57#E[ ,W9[B[UK7KC91>)%4>8]LCUF8M4D
MYJ"\+/0^O,MH1#]YC](PCH[349K&.,<C&E_^ZW:"DP??@-JXMK;EV0K3O?UA
M=_@Y%EW#O*AWW\X=4YM::,*A1--P?#'QB>I:N1.,;%W[K*7!9G3+"G\_4%8!
MSTLIS5&P#H;_=/X'4$L#!!0    ( +R ?5(?2DZ[P 0  +X+   9    >&PO
M=V]R:W-H965T<R]S:&5E=#$T+GAM;+56VW+;-A#]E1WU,O*,*U&T76=\F_&E
MF;93MYXD;1XZ?8#(E8@:!!@ M**_[UF0HN58<=.'/M@B0>S9LP>[BSU;.7\?
M*N9('VMCP_FHBK$YF4Y#47&MPL0U;/%EX7RM(E[]<AH:SZI,1K69YEGV_;16
MVHXNSM+:G;\X<VTTVO*=I]#6M?+K*S9N=3Z:C38+;_2RBK(PO3AKU)+?<OR]
MN?-XFPXHI:[9!NTL>5Z<CRYG)U>'LC]M^$/S*FP]DT0R=^Y>7GXJST>9$&+#
M110$A9\'OF9C! @T/O28H\&E&&X_;]!?I]@1RUP%OG;FO2YC=3YZ-:*2%ZHU
M\8U;_<A]/$>"5S@3TG]:=7OSXQ$5;8BN[HW!H-:V^U4?>QVV#%YEGS'(>X,\
M\>X<)98W*JJ+,^]6Y&4WT.0AA9JL04Y;.92WT>.KAEV\N.%Y/)M&(,G[M.BM
MKCJK_#-6LYQNG8U5H!]LR>53@"DH##SR#8^K_$7$&RXF=##;ISS+LQ?P#H:X
M#A+>P0MQT8T.A7&A]4Q_7LY#],B!OUX /QS #Q/XX7\4[66KXPDE5K]9_!9<
MS]G3K(]XGV+%=.WJ1MDUL8WLN21MHR-%OSB%]+4EO>6B]3JNZ7+IF5$:D<9B
M]^U7K_(\.TW[AD]I<7:ZAX2*%5 *5]?L"ZT,TMC>$PH:J^_8UYV#?EOCM2UT
MDW8990LFMZ"O9T=(/F-01Q-ZM\5TA46DXSU3+?E@UL(9W$,D9_'6J+5P"0C/
MNW99T:_NH8O\($N1YQW><Z\2[X"5W,P97:!16M:)/[38_.@T1&5,YTHM8)7T
M_(0+>^W*!%S 3MM6V^5 [%:MJ3N,P^>BWJK8"8\:XXVP$[HL'X1KH!95T+E\
M>@8;X@I2VT<Z'BA]!#A@,8.!$M;0FG$.>!KK/9I-CK)OJ#%M2)ON/-HAO1'C
ML0HBAO,QI4G2\#T4("2<M/*?7>LMX+?/JD:$C2BX3FBJ(X_EDC\? +!7E3.\
M3RJ2H$3A$-KYWVBKE-*SPTR[\5CKMAYB.P'1/<HGB *1"3S^['>X''!>MA3]
M'T]>U:X%1K^QI[=/>@%W1;7MQA6H@X!3)>0P /"_UW&A?1">%JW>!]PR&[AK
M] %Q)P=X2N.YB/O_L'I,OR\BD_)Q1R2!D:3EOX<BYN-BC[+_/9PO8[2IYV<Y
MH0.M%"Q+<296CZWGM2JTD?+2DM4+;8542?,N4:^D6XV1B!K%'9"+*68UQV,+
M_4HT><]RQ>_MTO%Y_>[H8%(3BL2QH2'^U/:R_2Q#IUI5&NJDO4D7\23HJ&RC
M4X=9G*22W>T2&:?[CZ6<>:Q03=L=O],+:HN#3I[=YP<9%JTQ"? I(I,1OT/'
M5;CU5%%@_I%V4U+9<JI7],Z'/KY^>CD5T<;ZH8/#<6/.4&EFZJD\[0E/]4M'
M5CA?=LV4/U$1?6IH>_P1HV1 9 ]]1HFKC0\AWR'OSHL@=U^7%.@^HDS$58:V
MOB59STD:].SX%!*$P#'LPW%AVD10N!B9"*4_-1ZSK8_KR:Z18+HU4^'>7*;)
M,>#F0/ETX]6P.@RGE]U,]KB]FVQOE5_BAB+#"YAFD^.C$?EN6NQ>HFO2A#9W
M$?->>JPP8+.7#?B^<"YN7L3!,+)?_ -02P,$%     @ O(!]4B(]PMUK P
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M!?V*0,L;:'UFJ&4T W;0_BXY_PM02P,$%     @ O(!]4GF)^-TP P  -P<
M !D   !X;"]W;W)K<VAE971S+W-H965T,3<N>&ULE55-DZ,V$+WS*[I(*KE0
M!N0O/+%=-9[95'+8JJEU/@ZI'&1HC&I 8B5AK_/KTQ(VRR0[D\T!T$>_I_=:
MJ+4^*_UL*D0+GYI:FDU86=O>Q;')*VRXF:@6)<V42C?<4E<?8]-JY(4'-77,
MDF01-US(<+OV8T]ZNU:=K87$)PVF:QJN+SNLU7D3IN%MX(,X5M8-Q-MURX^X
M1_MK^Z2I%P\LA6A0&J$D:"PWX7UZMYNY>!_PF\"S&;7!.3DH]>PZ/Q>;,'&"
ML,;<.@9.GQ,^8%T[(I+Q\<H9#DLZX+A]8__1>R<O!V[P0=6_B\)6FS +H<"2
M=[7]H,X_X=7/W/'EJC;^#><^EK$0\LY8U5S!I* 1LO_R3]<\C !9\@J 70',
MZ^X7\BH?N>7;M59GT"Z:V%S#6_5H$B>DVY2]U30K"&>W>ZORYTK5!6KS/;S[
MV E[6<>6F-U\G%]9=CT+>X4E9?!>25L9>"<++%X2Q"1IT,5NNG;L3<9'S"<P
M32-@"4O>X)L./J>>;_H*7^\,_K@_&*OI5_CS#<[9P#GSG+.ORMTCEB(7]DO)
M>YLF328PIOKNFXRERQ\ >\E/])NBUEB <4'P2X7PH)J6RPM4W #O;*6T^(L"
MTB1*$O^ J;A& ZJ$;Y-)DJ30<@TG7G<([3\(*>9<B;P"J6ZP,VH$84Q'04H#
M'69CN2R$/ +WI+0]V!Q0#ULT<9H:.F;_*9(E7Z4R'],-$J?3:+68>>Q8(VG[
M?R+[=>D%)V4)$7F*0IQ$@;(P=,(N<*!4<5'0RB@C1^E"1$EG/J^Y2]_A I9\
M[A37A5]/:*HU2IO)O_S3:JA/A'& 4M54"YW.S_Y?V*5:"V5GNZM!+G-\S9(7
MQ9)T=1>,YUYV7&#@@H)]G\[6540S3EFPB+)T$2U763"G%&?18LF"_35-)RYJ
M?JAQ+.RHN;30T7'7MTWRK-#67 9I-%L2#YM2*YNOHL5\%F016[%HR=)@&64L
MBZ9L\:5#&(^*68/ZZ$NVH01UTO9U;1@=;H7[OAA^#N^OE/=<'P7YK+$D:#)9
MSD/0?9GN.U:UOC0>E*5"ZYL5W6RH70#-ETK96\<M,-R5V[\!4$L#!!0    (
M +R ?5*WXA-I8PP  /,B   9    >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM
M;+U:V8[;R!5]UU<0'4_0#;#9)+50\@:TETD<8,9&>^Q!$.2AFBQ)%9,L3179
MLN;K<^XMDB*UM#V#("\2EZJ[G+N7]'RKS1>[EK+ROA9Y:5]<K*MJ\_3FQJ9K
M60@;Z(TL\6:I32$JW)K5C=T8*3+>5.0W<1C.;@JARHN7S_G9!_/RN:ZK7)7R
M@_%L713"[%[)7&]?7$07[8,[M5I7].#FY?.-6,F/LOJT^6!P=]-1R50A2ZMT
MZ1FY?'%Q&SU]-:'UO."SDEO;N_9(DWNMO]#-N^S%14@"R5RF%5$0^'J0KV6>
M$R&(\5M#\Z)C21O[URWU'UEWZ'(OK'RM\U]55JU?7,POO$PN19U7=WK[=]GH
M,R5ZJ<XM?WI;MS:)+[RTMI4NFLV0H%"E^Q9?&QQZ&^;AF0UQLR%FN1TCEO*-
MJ,3+YT9O/4.K08TN6%7>#>%424;Y6!F\5=A7O?Q8Z?3+->F5>:]U 5M;07 ]
MOZE G=;<I VE5XY2?(92%'L_Z;):6^]MF<EL2. &8G6RQ:ULK^)'*;Z1:>"-
M(]^+PSA\A-ZXTW7,],;GZ"F;YMK61GKOEP-MO3N9BXHAL)7U/JZ%D0Z3#V('
M%\2S?]W>V\K B?[]B"233I()2S+Y'Z#^*"6*V:=V(U+YX@)!::5YD!<OHRCP
M^BS2OJKO2^]G_2"+>VF\:$S@1A/?J]:2)1'ESA.9WA 8](S>.EK>NS(%$H@A
M[T,N2N^27]'E5>#=YKFGEWTJ?_W+/(Z29]:3Q2;7.RFMCQ5+E4J#JTP9A*6F
M2U&2@*5%& D"&M![,E<K=9]+K]+>O?16!F\@$,2"!I:>;FJ3KJ$<Z59 *TLF
MLTP,WY51*6VP+'@-?S0L6R5-85M!._D#[Y>>]@V*&6AY8K4R<@7/H#US?SH-
M_4DT;9GA6<N=^2!%>LK:6@"H'M,>GUO>!+]V\+>^S?!#[2U]E/H<??$@5"X(
M%N*TK"OR9,;&GF8'4W^4,*6S=<*V7O@GK72OA<F(8V<9QE(/*"Q:"@H<6::U
MSL$7:S<;HQUHV:'_+'J><[LE-LY_B'<</J-5S24OII=\'SV[\K9KE:[A JDH
MX!7+I>0D3F+1MDSLO(U1  ,>00_>?7@?>)_Z4#AZ0_\NL(UA:W!MW,IO888N
M,E4N6@QE=;PZ=*KC)S"!JAI_UF3/EASYM[#K)A8%(< NK,I,/:BL%KF%GIH=
M'_O*;T2,!W7[\3(,.\>_HW 476>"U-;W5F5*&"4MW!3B58(C>NQ'8>B'87C.
M*=EG._.[>%5 0HD\[P73^=A8>)LN!LN:'0T\&FXGW)ID_0^@(%[H,BSTRE2Y
M:H$5G8Y[=\F:"![X!.Y$Q:"3\O*W&BX*B5.2,)>93R(OI>*\8Z!(FW$R[WXW
M<*>M0O*#UB++' +TLI&_T[\^=LH <4&;%#F:\] C_1]/ >< 9?4ZL6KT$'#F
ME VBRA2]&VG1Q-!2&5MQ)(&7%(@V+)1E)HRWD_C(:D/HNNQ97O,S2J-'>/I@
MME)E2:NWJEI[_Q!EC3[/:Y*<<TQGJQ/OD54:7$6A:\0F+ (7!)R3'UI>?7.?
M@NJ49P_@P\4@^39[*-XE4QWJKJE[!2*YM#!C*Q@\+),$ 4KQH3,\DD]=D>QG
MG#9W"\[ZY35TJV L0#+(2Y[\FB(''VP",/LHOX19\YHU:#,&P]TQOX+A8;[&
M00E9M=R1)JI+S4.>>X]ZAXVFA"GNY(,L:U(UXVB*%O.93S20FXERT,OS0V*4
M<$M=]4LY0H]0I2!L_% H@X7F"P:1!Y'7\GL-Z@J!"W"F[A]82 $SK3/B *]K
M[/6JM<^;?;VK7%W3B*X,K:*1)'V ;JET@*DNU?<5&RH%;>17:5)ER:U@"0]E
M @&KT*)G?YBY=^D*(/). R#*PQZW$YB=P..*78$>/T 6\I&-1-',G/@/",'
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M>- Y=,R1F4?)@BG@:](GP1,6NA-OIV2>(5L0 _[T6)0?9=/@D"1WI.S3P6&
MF]D(#W-:<@]CCZL(<B!VV[&VI:_?<M,\1M,8ZB]&>*HK6/TI^(@9B'KSFAI
MF=(;3&.N5[:J0-]OVAWT?#_H],>;IKIU /Q"PCB=A@)BH*'AA%M):H&Y\.^=
MX]"^?"K3$> I;S!\ 6(UZ+IJVXX-D'W3=$^%K-;@<CF HU#9]48#51"MMM3A
M]'L55JZML63)1M'#&G754_ISYQ<'YH2K6S[7:4K>6L&;#8U&C5N[EFWO5\T
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MRG@CI"5D&<$8]ELF1[[!CRS&QHKL^F&Y6,1E?OT3;"M55K#"4M0(N%YC?)M
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MD:NO2,\-DLV+A56YQI>T=H>DWTJ;.X$+L5UK+-\J, >CRGC06!@+OPL2B?A
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M[?DH A,PC["IXV&K1!^,?::S",A/50Z5$[?#"$#:M\.Y[7") L>"2OB5;!-
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MYX+VZ0'\OJDJ&SX0@_@_$7C]3U!+ P04    " "\@'U212+:A[$/  #0+P
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MF>OT_V7F9\E1I+YRI4S491^AZ)2]5_VK\<E0[/)).MI]*965="\R!20[\:&
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M.0O]>R1!"VH"2-L#NE]+_+/Q"?C^T1;#JC\KA 9IZRH$42)+F: -"!&>RX<
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MH05XOS#(//&&&#1?2Z_^"U!+ P04    " "\@'U2L4#GV D#  ">!@  &0
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M-(U/3R*P@QL."S)=<*#"$/M9>&SX X+6)_!^;0SM%YY@^B0M?P%02P,$%
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M6J-K,(PF.X,[BN&-T#72[*<ZQ TI"D.EU+4:SN'0",L26" K6 G/LOCEDL5
MJ:!KW-5G:9QFT\E44,]C2%,I.\,=&*#LB?G#Z8""/POZ8?W:N].X!6)NY,L9
M1[8=!OE40PS?FX_D3(%:I#KH++?&]-J-8C2=3E*^'17LJ_OX'[@75$OM[VO%
MT#1^\3P"&K5UW#C3!3W;&\?J&)8-_XZ0O /;*\.WZ+CQ :8?W.8+4$L#!!0
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M!-1$U^BD +!^L4"#O$#RI* _#(@IT0T46D-$,VD":":9,NMD18" "$2XPK1
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M:&5E=#,P+GAM;*55VV[;.!!]UU<,M(LB 0+K8L=.4MN G31I@08(<ND^+/I
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M1D?':>JL2>>.3E_?^$5G<OH_=1Y\5L8<PF_+C>.C9.BL@R0-#KL5DO$PN!O
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M,-X![TNMW9OA$_23>_H/4$L#!!0    ( +R ?5)-,7B*DP(  %P%   9
M>&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;'U446_:,!!^SZ^PLFG:)-8D#J1I
M!TC0=MH>*J&6;0_3'DQR(5$=.[.= O]^9P=2.A5>;)]]]]U]9W\>;Z1ZTB6
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M6V5QB/VRPE<3M'/ \U(I>S!<@N$=7OT#4$L#!!0    ( +R ?5)"(QD;'@4
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M%(/!$5+=2[P;&+ERK]^9-/"6=MTE_+QP93? ^EQ*LQE8 \/OT.7?4$L#!!0
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M#3Y^JNI-JXF1&]</+J3![M(-U]C.@[('<'\II=E/K(+F'X3I?U!+ P04
M" "\@'U2)Q[)53P$   N"@  &0   'AL+W=O<FMS:&5E=',O<VAE970S-RYX
M;6R55EMSZC80?O>OT-"TD\Q0,,;<4F"&),VT,TE/)N0T#YT^R/:"U2-+'$D.
MX=]W5S8NN3'I"ZQU^?;;W6\E3;?:?+,Y@&//A51VULJ=VYQWNS;-H>"VHS>@
M<&:E3<$=?IIUUVX,\,QO*F0W"L-AM^!"M>93/W9GYE-=.BD4W!EFRZ+@9G<!
M4F]GK5YK/W OUKFC@>Y\NN%K6(+[NKDS^-5M4#)1@+)"*V9@-6LM>N<70UKO
M%_PI8&L/;$:1)%I_HX_?LUDK)$(@(76$P/'O"2Y!2@)"&M]KS%;CDC8>VGOT
M:Q\[QI)P"Y=:/HK,Y;/6N,4R6/%2NGN]_0WJ> :$EVII_2_;UFO#%DM+ZW11
M;T8&A5#5/W^N\_"9#5&](?*\*T>>Y15W?#XU>LL,K48T,GRH?C>2$XJ*LG0&
M9P7N<_-+713"89:=95QE[%(K)]0:5"K LM,'GDBP9].N0U^THYO6N!<5;O0!
M;B]BMPB56_:KRB!["=!%D@W3:,_T(CJ*> 5IA_5[;1:%47@$K]]$WO=X_4]$
MOG@3^96PJ=2V-,#^6B36&93/WT>\QHW7V'N-/_"ZQ*[*2@E,K]@-H)SL>[D]
MBD%]>FXW/(59"QO1@GF"UOR+R\$PH:H^1<$'F# H$AS<)RUX]!J%[&?^! 9;
M#KN*^A:C9I*X, >F"'IAI\]VP(U]NR'#M.A2.6:X W;:.PO&G4'P8T#6/0T)
ME<HRPP0B'4QIL>%J]],/XZ@W^L6R1YV41GF=W< SNG78E]ZS[; CR1TTR1U\
M.KGWD&HLI:RI?%5[ZH"EYC9GUW@>X9SVTU\V&!^5ORH*NQ$\$5*XG<<QJ&"&
M5*N8E-529)R +KCD*@6VI/Y[KY#'^3X@GJ,.8PF=CEB.%YS+0\XI<5X=<M8-
MYZIXLN%L7G%.#SDG->?JS.>6DO5&*IT ?WM!U)Y$8S*C(&[W!A,R^VA&XYC,
M&,VX%Y$Y0',0#P(,">^&%0HIB$;M<!0&#]IQ24>7*,JBIKKA.]]X03QJ]R?C
MX :L/6>\\-)"/B]783Q>Y[X_46$(#M:AYH;M.(R#L^"NFF5/7):^^*O24>>^
M<M8/VY-)7#M+2V-HS\O<8>L'I_W)"$'_P%)\N.:$P :3T1'1#AO1#C\MVNN*
M]V*]-K"F=KJMTW:W3P7J&,M$W*B(THOGE7BK@WR9:^/8 S;TD7/F.+.:#6_8
M[(O8%*;T;$ABZ@6C5]*L&%G/B(Z8>K1=GQ:TCC":,Z'-;A=UTNL[2=$EGI9U
M*=ILFXLT9\*B7X</BN0?G*>^6"POV3B.VA_IFG$*R+*5EM1*YY7,3TCHX^'_
M$CJ:0\\N@9U6V:?4?D)ZCP?#]U33/;C#"S!K_U*QS+=_=9TWH\UC:%&] ?Y;
M7KVD;KE9"V71^PJWAIT1GD*F>IU4'TYO_(L@T0[?%][,\4$'AA;@_$IKM_\@
M!\T3<?XO4$L#!!0    ( +R ?5* COPO:00  )$*   9    >&PO=V]R:W-H
M965T<R]S:&5E=#,X+GAM;+U6WV_;-A!^UU]!:,7@ )PM49(M98F!)%VQ#NB0
M->GV,.R!ELXQ%XIT22H__OO=2;;J94TZ#,5>I./I[KN/QX\43^ZMN_4;@, >
M6FW\:;P)87L\F_EZ ZWT4[L%@U_6UK4RX-#=S/S6@6SZI%;/1)+,9ZU4)EZ>
M]+Y+MSRQ7=#*P*5COFM;Z1[/0=O[TSB-]X[WZF83R#%;GFSE#5Q!^+"]=#B:
MC2B-:L%X90USL#Z-S]+C\YSB^X!?%=S[ YO13%;6WM+@;7,:)T0(--2!$"2^
M[N "M"8@I/%QAQF/)2GQT-ZCO^GGCG-920\75O^FFK YC<N8-;"6G0[O[?V/
ML)M/07BUU;Y_LOLAMLAC5G<^V':7C Q:98:W?-CUX2"A3)Y)$+L$T?,>"O4L
M7\L@ER?.WC-'T8A&1C_5/AO)*4.+<A4<?E68%Y97?7^@8;]TT@5P^I$1#IM\
M,+)K%'XY8I-KN=+@CTYF 2M2WJS>H9\/Z.(9]%2P=]:$C6<_F ::OP/,D.K(
M5^SYGHL7$5]#/659RIE(1/("7C;./^OQLF?P/DW[C3+2U$IJ]M8,8B?5O%:^
MUM9W#MCO9RL?',KHCQ?JYF/=O*^;/]=WW%U-IX'9-?L"A\^U_45PVLC'?BMK
M.(UQIWIP=Q OKS? UE;C+E3FA@5:4E;CXN#&]>SC2&$]4E ';4"K[SB3ID$C
MK::,\"YLNY7FD:U *[@#S\)&!GP<5CJ$P1U'<O-,:LT,N37ZZLXYBI3-GRAX
MW/$88* &[_&8Z$OWB%+A81)D (J@OI'W*4GR;<$IVWC6S]V@A >R>) Y#,1"
MZ,=-Z_L$HK^;/9.XRL:&L;C"?BC3J%K2T4$EGV:NNT#2&"I.(VI1]$ZZ>D,:
MC7[J#+ LX=$5;)'V"DO0"#6\&V#,M0U21Q-ED+KM//;7<P8/-680+/,;8B5;
MVV%;CH9PI'$'IH/H5;3@8I[CN^2%R/"=IESD"S0J7A4)OK,YK\I\EP</>)A[
M\%$J>+I81&G.B[R,TCDORA+9\[04F#//>%X5T<_X3T#M^VB2\RK-HJ-H,N>)
M*,@H>):G9*0)%YE ZU4T$8B3DO>B:SL]- W5IU 8%Z2U.W!!D>YP9=;@'!X[
M>,#5MZQ1=ZH!G'KT[3>E2,7W7WSON3$9@E.K;M!SL%BF;5$+/>[&Z@;<?^ _
MHA^LP#-UZ..N#ON.?A"J[C=)HW2'TB/89)K.AP)H5:,U^K)D;Y5$A+;7_RNB
M?5,/+9%C7THT<KY(*G*4O$)E/1%2P4LQC^:\+ 2EE-AFZFA",LH7?%YE!S(:
M@OMEH'A:AL5N-?(J&YJ0EGR1S[^JAB8I3]*<ZN2[3J.CR _7^5^IZ)_T4]PW
MU3"!(MM/H.)EDGQU$653D0\%LFDN]H)99$^%):8"+?:Y7]3LX)K0@KOI+T,>
M2: JAAO#Z!WO6V?#->-3^'!90WG>T']#PQI3D4<1,S=<@(9!L-O^TK&R :\P
MO;G!.R,X"L#O:VO#?D %QEOH\B]02P,$%     @ O(!]4H_W0^_#!   Z1,
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M&?);X5NY[%5EULOM]0Z4V9^'R^SO[X!%"\,2_8_#<[_RW,\]]_=XAOX#W47
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M7#,:,F4GP/-(2O-V8QU4!X^S_P!02P,$%     @ O(!]4FQZ,NG6 @  R@D
M !D   !X;"]W;W)K<VAE971S+W-H965T-#$N>&ULO5;);MLP$+WW*P8ZM4 :
M+796V ;L+&B !#%BI#T4/=#2R")"D0HYJI._+TG9LHLF<GI(+A:7F3=OYM$<
M#I9*/Y@"D>"I%-(,@X*H.@U#DQ98,K.O*I1V)U>Z9&2G>A&:2B/+O%,IPB2*
M#L.2<1F,!GYMJD<#59/@$J<:3%V63#]/4*CE,(B#]<(=7Q3D%L+1H&(+G"'=
M5U-M9V&+DO$2I>%*@L9\&(SCTTG<=P[>XCO'I=D:@TMEKM2#FUQEPR!RC%!@
M2@Z"V<]O/$,A')+E\;@"#=J8SG%[O$:_],G;9.;,X)D2/WA&Q3 X#B##G-6"
M[M3R&ZX2.G!XJ1+&_\)R91L%D-:&5+ERM@Q*+ILO>UH58LOA('[%(5DY))YW
M$\BS/&?$1@.MEJ"=M45S Y^J][;DN'2JS$C;76[]:#1KU "5PXPO),]YRB3!
M.$U5+8G+!4R5X"E' U]A9L]$5@MTUA>&N"T*9G!O,*\%7-OJ&K<S-@;)P.=S
M),:%^3((R1)UX<)T16K2D$I>(14G<*,D%08N9(;9WP"AS;!-,UFG.4DZ$<\Q
MW8=>O =)E$0=>+VV;#V/UW\%[YK-X>*QYI4]H-2!UV_Q^AZOMT.&V]TR_+RV
MOG!%6)I?'9$/VL@'G9E,M?V':WH&)C/ =4I[@*V^=:.O</J^I&4W?@^>D6G3
MP?2P97K8B313.2V9Q@ZHHQ;JZ(/+?=Q&/G[G<G?C[R[W2<OTI!/ILM:24ZW1
M4[W-;8WP36<^CC9W3_3!,L1;]U[\SD+L"+!;B3C9D$VZKQNTC:=0(H.KLM+J
M-SJNG=";BRSN?;0&FTLO[K\Q+;Z5UG]IT!U@5BA-J%U7H@+_P?TD>&Z;F0;A
MB("U+%_**]QJKR7JA7]$&/ %:CIMN]H^5,9->]Z8-Z^<&Z877!H;,+>NT?Z1
MO3QU\W!H)J0JWZSGBFSK]\/"/K90.P.[GRM%ZXD+T#[?1G\ 4$L#!!0    (
M +R ?5+C8ACRXP,  -$-   9    >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM
M;*57VV[;.!#]%4+H0PLTUEVV ]N +[DYVR*H-]MG6J(M(A+I):FX_?L=2K)J
MJ[16V'U(3%+GG.&0,^1P<N3B3::$*/0CSYB<6JE2AUO;EG%*<BP'_$ 8?-EQ
MD6,%7;&WY4$0G)2D/+,]QXGL'%-FS2;EV(N837BA,LK(BT"RR',L?BY(QH]3
MR[5. ]_H/E5ZP)Y-#GA/-D2]'EX$].Q&):$Y89)RA@393:VY>_L\U/@2\!<E
M1WG61MJ3+>=ONO.43"U'3XAD)%9: <//.UF2+--",(V_:TVK,:F)Y^V3^GWI
M._BRQ9(L>?:=)BJ=6B,+)62'BTQ]X\='4OL3:KV89[+\CXXUUK%07$C%\YH,
M,\@IJW[QCWH=S@B@8R9X-<%K$X(K!+\F^'T)04T(^A+"FA#V)40U(>I+&-:$
M85_"J":,^A+&-6'<)D37-LXY[9S3UX;;;'85=%64E"&VP@K/)H(?D=!XT-.-
M,DY+/D0693JC-DK 5PH\-=M4F83X#FWHGM$=C3%3:!['O&"*LCUZX1F-*9'H
M!FT@GY,B(QJ]P)+&:,X2M*)9H4B"OD+^_\&E1 <BT";%@J"Y4H)N"X6W0%(<
M+7F>0QYM%(_?4IXE1$CT<444IIG\! 9>-ROT\<,G] '92&H%B2A#KXPJ^1D&
MH?UGR@N)62(GM@+WM1-V7+NZJ%SUKKCJHR^<J52B.Y:0Q,!?=_-=KT/ AG5O
M%M\[+?["ZU1<D7B ?/<S\AS/,4QHV4W?D /0G:OT53=]7;!.^ETW_0L6G9._
M[^V[.S;0'WK[;J0_]O;=2'_J[;N1OOY_^_[\GY?N(@S]Y@SP2SW_BM[7(B<"
M*RYN.\2"1BPHQ8)K8G *9/H4P*W<CZO<EV>Y;\KA2GU8JNMRX'UVXSJ>[TWL
M]_/,,,!"/W O42L#*G*\\!)U9T %8]>_1-V;+(9^"_5@FGXX&E^B'DWS&H4M
M'Y],%D=>=(E:&U!>%+JMI7@V36P\<IP&=K';8;/;86?HK CC<"_]6_!$C5S4
M&3S?RPJ()#?X'2)R3TZ7 -PWY^&#H#24"FX!N)]N=$4%-Q'T4%+=1*:$K.Q&
M9^[[GA?"W["U3K\#1U$P]H+0O%##QK-AO[30EV/I59\$N>GCVZ*R/#[?6F?0
M"LRE$>2V@FEE1K7"]ZZ7UGTOK0<C:MB:_:,!Y0^"=L(845[02ABCQ5%+Z]F
M\@;>N!4%]EGE!8?HOGP<2%063]4!W(PV[X]Y67:WQA?N[9-K&%_#>Z6J]'[)
M5X\=N(/VE$F4D1V8@C6#3!75 Z+J*'XHZ[XM5U!'ELT4WEQ$: !\WW&N3AUM
MH'G%S?X!4$L#!!0    ( +R ?5)1M;&EU0,  )P0   9    >&PO=V]R:W-H
M965T<R]S:&5E=#0S+GAM;,V8WV_;-A#'_Q5"3RVP12)E259A&["=!.O0+D:,
M;@_#'FCI;!.11)6DXO2_'TG)DG\O& K8+Q%)\8[?XX<^ZC+8</$BUP *O>59
M(8?.6JGRD^O*9 TYE7>\A$*_67*14Z6[8N7*4@!-K5&>N<3S0C>GK'!& SLV
M$Z,!KU3&"I@))*L\I^+'!#*^&3K8V0X\L]5:F0%W-"CI"N:@OI4SH7MNZR5E
M.122\0()6 Z=,?XT)<08V!E_,MC(G38RH2PX?S&=S^G0\8PBR"!1Q@75CU>8
M0I893UK']\:ITZYI#'?;6^^/-G@=S()*F/+L+Y:J]=#I.RB%):TR]<PWOT$3
M4&#\)3R3]B_:-',]!R655#QOC+6"G!7UD[XU&[%C@,,S!J0Q((<&O3,&?F/@
MVT!K93:L>ZKH:"#X!@DS6WLS#;LWUEI'PPJ#<:Z$?LNTG1K-:WR(+]&<K0JV
M9 DM%!HG":\*Q8H5FO&,)0PD^A5->5Y6BMK]UP;W+*L4I.@/?=J^<"E1"0+-
MUU0 &BLEV$+/762 %#>6N3::*YZ\K'F6@I#HPSTHRC+Y47N6QDH.7*5#,L+<
MI)$_J>63,_(Q05]YH=82/10II/L.7+T7[8:0[89,R$6/]Y#<(1__@HA'O!."
MIN\VQ_$%.7[+Q[?^_#/^QAI":O99'W8TAZ023!D8#V])5NF(T:/@^1Z8IR5Z
MH*+0Z"2:M4#^_J(=H\\*<OG/!5F]5E;/RNJ]1Y;L9,%6UM+(2O;/"VQEF7-B
MB9\"7B\<VH5-$GH=A7T<]V,\<%]W.1S/PW$0]'JXUT[<"RUH0PLNAO:M> 5I
MCO6S?@B6F.;N\;VP>V&[1'A+4*-65G0MJ-$1+-^+_0.BQY,BSP_#TSC[;5#]
MBT'-09@8IFBF[P<00H?Q@4H=A<8L#%N=G9(:KS1X/U[8R+A=,[XEOMCKDKUW
M)<+39N6]WR..2!B=X8=W;BC\'H*3GT$0DVY5<E,,NPL!^U=CZ!\Q[$5![$7Q
M&8;==8$OWQ<-P_%/8=AE<AS<%,,N_^/P:@S#$UDT\H+HS+6(N]L!7[X>IA:6
M;-0\"OA>09'\0+_3DA8[8/_KEL1=ZL;]F^+7Y7<<7XU??,0OP+[7BT[C(UWN
M)Y=S_U.EI*)%:K[I+2+T5!II\O__$DF7PPF^)9*D2_.$7.N;IUGYX$LVC.+^
MP7?/B8E!'/;#B!PP=W?JO!S$RI:_AITNU>H*IQUM2^RQ+2P/QB>Z]*X+Y<Y-
M7;=_I6+%])G(8*E=>G>1SK"B+H7KCN*EK2877.G:U#;70'5!9R;H]TO.U;9C
M%FC_(3'Z%U!+ P04    " "\@'U2&F5#AET#  #F"P  &0   'AL+W=O<FMS
M:&5E=',O<VAE970T-"YX;6S-5DUOVS@0_2L#H8<6V%BB_*&XL TD"M(MD.P&
M<=,>BCTPUM@F0I%>DK*;8G_\DK0B*[:L&LBE%UL49Q[?/,Z,9K21ZDDO$0W\
MR+G0XV!IS.IC&.K9$G.J.W*%PN[,I<JIL4NU"/5*(<V\4\[#.(H&84Z9""8C
M_^Y.34:R,)P)O%.@BSRGZOD2N=R, Q*\O+AGBZ5Q+\+):$47.$7SL+I3=A56
M*!G+46@F!2B<CX,+\C$E ^?@+;XRW.C:,[A0'J5\<HO/V3B('"/D.#,.@MJ_
M-:;(N4.R//XM08/J3.=8?WY!O_;!VV >J<94\F\L,\MQ<!Y AG-:<',O-W]B
M&5#?X<TDU_X7-J5M%,"LT$;FI;-ED#.Q_:<_2B%J#J1WQ"$N'>)3';JE0]<'
MNF7FP[JBADY&2FY .6N+YAZ\-M[;1L.$N\:I47:763\SN:9,P5?*"X1;I+I0
M:._(:#B#J<V8K. (<@[73% Q8Y3#A=9HMTO;#.Q-W..L4(J)!5Q2S32\OT)#
M&=<?+,C^WAD\3*_@_;L/\ Z8@"]+66@J,CT*C0W&40IG)?'++?'X"/$KG'6@
M2_Z .(JC!O?T9'<R?.T>6@DK'>-*Q]CC=7^M8RG1A<C@AM%'QIEA6)/L[[ID
MSNHO*=2>3M]O+#Y\-ICK?UK8=2MV7<^N=X3=12Z583^IKYQ4:M.D]Q8B\1"N
M^M>3F/3Z<3P*UW5=F\R2>+ S>\6P5S'LM3)\L!)0SGY:?3[9YM/$;PLPJ!^<
M['$[-.GWFGGU*U[]5E[^7F^I>K(=U5]O$[/^(3.K7&^XQZ[)+.F203/#0<5P
MT,KP5@I\?J%X7=AB@O_@!M?(@;2D3E+!)[]A8I]7[,[?GMCGC==SD-@-9E%$
MNJ3Y>H85P^&IB7TC=5.C2X<'!Y^1(^5$HEU?C]Y:4"7"D8IZ?6[M>T+>7C E
MQGZO.:B8TF[_3LCP",M=MR9QNSJ=:0<^R34JX;YW\$7Y)'Z&J<O7;5Z?4D5D
MUX%)]S>L([+KOZ2] 9]222DY;+ D.5HB9-=D27N7_76RIN2P>PZ.=$ZR:YVD
MO7>>DJQIB9&\#GJX7REA;0AS$["%73"A@>/<^D6=Q :@MD/E=F'DRL]EC]+8
M*<\_+NT@CLH9V/VYE.9EX4:]:K2?_ ]02P,$%     @ O(!]4K9E">N[ @
MV@<  !D   !X;"]W;W)K<VAE971S+W-H965T-#4N>&ULC95=;YLP%(;_BH5V
MT4I;^0ZA(DAILH]>3(N:=KN8=N' 2; *F-DFZ?[];$-0EKBL-PG&YSWO<XZ-
MG1PH>^8%@$ O55GSF54(T=S:-L\*J#"_H0W4<F9+686%'+*=S1L&.->BJK0]
MQYG8%2:UE2;ZW8JE"6U%26I8,<3;JL+LSQV4]#"S7.OXXH'L"J%>V&G2X!VL
M03PU*R9']I E)Q74G- :,=C.K+E[NXA5O [X3N# 3YZ1JF1#Z;,:W.<SRU%
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M@;(.>+Z2TNPW]H+^B<Q> 5!+ P04    " "\@'U2:'M)T9\"  #O!@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6R-5<MNVS 0_!5"R"$!&NME2TY@
M"W#L%NVA@!$G[:'H@996EA!*5$GZ]?==4HK@6+*1B\7'SNSLF%Q.]ER\R0Q
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M&_#Y0DKSN+ 'M_:@/OT;4$L#!!0    ( +R ?5*VRMC/%0,   4,   9
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MDM?][0Z<@3WH6_O]Q;4 QO\OC&0R9)S^:1:'CQ6WBS'<G&/SMX(2U8JDG/D
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M ?A^(J59?[ #5/>T%_\"4$L#!!0    ( +R ?5*ML,S4.08  +LA   9
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M5%>(&>;JSD:N#=3^@C&YG>@ [;^ T4]02P,$%     @ O(!]4AO?0N$) P
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M$L;QA[X5_'_<&UTGG:X3+]$]X+$5( S)65&  I&![M/AISF*PS3^T+<W9P>
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M2ZS_0-D)^+V0TFP[-D!744[_ %!+ P04    " "\@'U2I(@I8GH#  #["@
M&0   'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6R-EMMNVS@0AE^%$'K1 IOH
M9,M281M(;10-T-T-XK2]*'I!RV.+""5Z22IVWGZ'DJ(H%J7VQA;%.7S\10YG
M?A+R464 FIQS7JB%DVE]_.BZ*LT@I^I:'*' F;V0.=4XE =7'2707>64<S?P
MO,C-*2N<Y;QZ=R>7<U%JS@JXDT25>4[E\R?@XK1P?.?EQ3T[9-J\<)?S(SW
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M,^Q.01H#G-\+H5\&IO]I^]WE_U!+ P04    " "\@'U2;EJE'5@-   P2@
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M\X9JKU7M1=7^%=7'^*FQNA//Z'AR>3C#^+,PJ- B('3Z4G-NTW8S>$7A//1
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M<SP?G]0_^MPIEQTSN%+B*T]M-@LF :2X9Z6P=^KX">M\1DXO4<+X7SC6ME$
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MNC5J9T#?]TK9T\0%:/K__!=02P,$%     @ O(!]4MG* .A0 @  ? 4  !D
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M0ERT.L:-CFR'CC2#&Z.I<O!%EUC^31!S4EUFV2:S<;:7<8I%#_KI)\B2+/E
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MP-N((Y@"T( A<=SL@WO[4;C>I\+-+V&CWU!+ P04    " "\@'U2EXJ[',
M   3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!
M5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]I
MSI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z
M3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=
MQ_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( +R
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M5.;IV(GZIUW1%L7U<I19E><7L._&?+<R6ZT^7ZV</_T/4$L#!!0    ( +R
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M/AO_OGG^ E!+ 0(4 Q0    ( +R ?5('04UB@0   +$    0
M  "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ O(!]4@5H@S'O
M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ O(!]4IE<G",0!@  G"<  !,              ( !S0$  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "\@'U2^!=^"&@&  "T&@
M&               @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ O(!]4A.UY*J6!0  VA4  !@              ("!K X  'AL
M+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( +R ?5+-3])8W@(
M #$*   8              " @7@4  !X;"]W;W)K<VAE971S+W-H965T,RYX
M;6Q02P$"% ,4    " "\@'U2,#8F))X$  ###P  &               @(&,
M%P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ O(!]4G+5
MQ:3' @  DP<  !@              ("!8!P  'AL+W=O<FMS:&5E=',O<VAE
M970U+GAM;%!+ 0(4 Q0    ( +R ?5+L9M"PZP8  *LB   8
M  " @5T?  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " "\
M@'U2^^K\"]$&  "M&P  &               @(%^)@  >&PO=V]R:W-H965T
M<R]S:&5E=#<N>&UL4$L! A0#%     @ O(!]4@2&T41Y#0  .2(  !@
M         ("!A2T  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0
M   ( +R ?5+O$N+G>28   N!   8              " @30[  !X;"]W;W)K
M<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " "\@'U26*I0@>T"  "U!@
M&0              @('C80  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+
M 0(4 Q0    ( +R ?5+9<'C:A@(  ( %   9              " @0=E  !X
M;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ O(!]4O-8OAX$
M P  708  !D              ("!Q&<  'AL+W=O<FMS:&5E=',O<VAE970Q
M,BYX;6Q02P$"% ,4    " "\@'U2F>WB388"  !;!0  &0
M@('_:@  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( +R
M?5(?2DZ[P 0  +X+   9              " @;QM  !X;"]W;W)K<VAE971S
M+W-H965T,30N>&UL4$L! A0#%     @ O(!]4B(]PMUK P  T0<  !D
M         ("!LW(  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
M    " "\@'U2X7U>^,$$  "C#   &0              @(%5=@  >&PO=V]R
M:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( +R ?5)YB?C=, ,  #<'
M   9              " @4U[  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL
M4$L! A0#%     @ O(!]4K?B$VEC#   \R(  !D              ("!M'X
M 'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " "\@'U27.==
MJ<(#  !V"   &0              @(%.BP  >&PO=V]R:W-H965T<R]S:&5E
M=#$Y+GAM;%!+ 0(4 Q0    ( +R ?5*OIVF6I@L  /0A   9
M  " @4>/  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @
MO(!]4DOC0%HW$@  4$   !D              ("!))L  'AL+W=O<FMS:&5E
M=',O<VAE970R,2YX;6Q02P$"% ,4    " "\@'U212+:A[$/  #0+P  &0
M            @(&2K0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4
M Q0    ( +R ?5(MX.<#=PL  #D=   9              " @7J]  !X;"]W
M;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ O(!]4K% Y]@) P
MG@8  !D              ("!*,D  'AL+W=O<FMS:&5E=',O<VAE970R-"YX
M;6Q02P$"% ,4    " "\@'U2Y2W%LR$#  #L!@  &0              @(%H
MS   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( +R ?5(&
M]]?*$00  *8(   9              " @<#/  !X;"]W;W)K<VAE971S+W-H
M965T,C8N>&UL4$L! A0#%     @ O(!]4J2OG/1=!   J H  !D
M     ("!"-0  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +R ?5(FPI"7O (  ,4%   9              "
M@80, 0!X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ O(!]
M4DTQ>(J3 @  7 4  !D              ("!=P\! 'AL+W=O<FMS:&5E=',O
M<VAE970S,RYX;6Q02P$"% ,4    " "\@'U2\SM88J@"  "3!0  &0
M        @(%!$@$ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0
M   ( +R ?5)"(QD;'@4  !H-   9              " @2 5 0!X;"]W;W)K
M<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ O(!]4NPU!@JS!   + P
M !D              ("!=1H! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q0
M2P$"% ,4    " "\@'U2)Q[)53P$   N"@  &0              @(%?'P$
M>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( +R ?5* COPO
M:00  )$*   9              " @=(C 0!X;"]W;W)K<VAE971S+W-H965T
M,S@N>&UL4$L! A0#%     @ O(!]4H_W0^_#!   Z1,  !D
M ("!<B@! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " "\
M@'U2<SY#K:<$  "$%   &0              @(%L+0$ >&PO=V]R:W-H965T
M<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( +R ?5)L>C+IU@(  ,H)   9
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M970T-2YX;6Q02P$"% ,4    " "\@'U23YN=8TD#  !T#   &0
M    @($#1 $ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    (
M +R ?5(IWNFO1P(  "X%   9              " @8-' 0!X;"]W;W)K<VAE
M971S+W-H965T-#<N>&UL4$L! A0#%     @ O(!]4FA[2=&? @  [P8  !D
M             ("! 4H! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"
M% ,4    " "\@'U20.1H02<$  "T#P  &0              @('73 $ >&PO
M=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( +R ?5*VRMC/%0,
M  4,   9              " @351 0!X;"]W;W)K<VAE971S+W-H965T-3 N
M>&UL4$L! A0#%     @ O(!]4DR0*=!( P  J@H  !D              ("!
M@50! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " "\@'U2
M#<C<;^0"   J"@  &0              @($ 6 $ >&PO=V]R:W-H965T<R]S
M:&5E=#4R+GAM;%!+ 0(4 Q0    ( +R ?5)85-Z5KP(  -<'   9
M      " @1M; 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%
M  @ O(!]4LCF/WH'!P  LQT  !D              ("! 5X! 'AL+W=O<FMS
M:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " "\@'U2K;#,U#D&  "[(0
M&0              @($_90$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+
M 0(4 Q0    ( +R ?5(&I*F$U@(   D(   9              " @:]K 0!X
M;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ O(!]4B2^M.+/
M @  $0@  !D              ("!O&X! 'AL+W=O<FMS:&5E=',O<VAE970U
M-RYX;6Q02P$"% ,4    " "\@'U2&]]"X0D#  !D"0  &0
M@('"<0$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( +R
M?5+VOCQ0@P4  #H:   9              " @0)U 0!X;"]W;W)K<VAE971S
M+W-H965T-3DN>&UL4$L! A0#%     @ O(!]4JTFJ(6% @  4P8  !D
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M=#8T+GAM;%!+ 0(4 Q0    ( +R ?5(X.NE'> 8  #,A   9
M  " @;^4 0!X;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @
MO(!]4J2#0:+-!0  A!D  !D              ("!;IL! 'AL+W=O<FMS:&5E
M=',O<VAE970V-BYX;6Q02P$"% ,4    " "\@'U2GPJ;?AL"  "Z!   &0
M            @(%RH0$ >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4
M Q0    ( +R ?5(\XW-(:P,  'H*   9              " @<2C 0!X;"]W
M;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @ O(!]4D="3!BJ @
M] 8  !D              ("!9J<! 'AL+W=O<FMS:&5E=',O<VAE970V.2YX
M;6Q02P$"% ,4    " "\@'U2>ZSG/]4"   +"   &0              @(%'
MJ@$ >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( +R ?5+9
MR@#H4 (  'P%   9              " @5.M 0!X;"]W;W)K<VAE971S+W-H
M965T-S$N>&UL4$L! A0#%     @ O(!]4L$P70*L!   GQ(  !D
M     ("!VJ\! 'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q02P$"% ,4
M" "\@'U2LCNO5RP#   6$P  #0              @ &]M $ >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( +R ?5*7BKL<P    !,"   +              "
M 12X 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( +R ?5)=_&RS<P4  +TO   /
M              "  ?VX 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "\
M@'U2K&U05SP"  "O*@  &@              @ &=O@$ >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "\@'U20&L7N@ "  #&*0  $P
M            @ $1P0$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     4 !0
+ .<5  !"PP$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>187</ContextCount>
  <ElementCount>456</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>80</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statement of Convertible Preferred Stock, Non-controlling Interest and Stockholder's Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/StatementConsolidatedStatementOfConvertiblePreferredStockNonControllingInterestAndStockholderSEquityDeficit</Role>
      <ShortName>Consolidated Statement of Convertible Preferred Stock, Non-controlling Interest and Stockholder's Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureOrganizationAndBasisOfPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Prepaid Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosurePrepaidExpenses</Role>
      <ShortName>Prepaid Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureDebt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStock</Role>
      <ShortName>Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Non-controlling Interest</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureNonControllingInterest</Role>
      <ShortName>Non-controlling Interest</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Employee Stock Purchase Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureEmployeeStockPurchasePlan</Role>
      <ShortName>Employee Stock Purchase Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Research and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureResearchAndLicenseAgreements</Role>
      <ShortName>Research and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Collaboration Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCollaborationAgreement</Role>
      <ShortName>Collaboration Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureEmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Selected Quarterly Data (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyDataUnaudited</Role>
      <ShortName>Selected Quarterly Data (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Prepaid Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosurePrepaidExpensesTables</Role>
      <ShortName>Prepaid Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.frequencytx.com/20201231/taxonomy/role/DisclosurePrepaidExpenses</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.frequencytx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureAccruedExpenses</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockholdersEquity</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Selected Quarterly Data (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyDataUnauditedTables</Role>
      <ShortName>Selected Quarterly Data (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyDataUnaudited</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Organization and Basis of Presentation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails</Role>
      <ShortName>Organization and Basis of Presentation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Summary of Significant Accounting Policies - Schedule of Basic And Diluted Net Loss per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Basic And Diluted Net Loss per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Summary of Significant Accounting Policies - Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Fair Value Measurements - Schedule of Financial Assets Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Financial Assets Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Prepaid Expenses - Summary of Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosurePrepaidExpensesSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid Expenses - Summary of Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Property and Equipment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses - Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Debt - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails</Role>
      <ShortName>Debt - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Convertible Preferred Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails</Role>
      <ShortName>Convertible Preferred Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Non-controlling Interest - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureNonControllingInterestAdditionalInformationDetails</Role>
      <ShortName>Non-controlling Interest - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Stockholders' Equity - Schedule of Common Stock Shares Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Common Stock Shares Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Stock-based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Stock-based Compensation - Summary of Stock Option Activity under 2014 Plan and 2019 Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnder2014PlanAnd2019PlanDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Stock Option Activity under 2014 Plan and 2019 Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Stock-based Compensation - Summary of Grant-date Fair Value of Stock Options Granted on Weighted Average Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfGrantDateFairValueOfStockOptionsGrantedOnWeightedAverageBasisDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Grant-date Fair Value of Stock Options Granted on Weighted Average Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Stock-based Compensation - Summary of Status of Restricted Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStatusOfRestrictedCommonStockDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Status of Restricted Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Employee Stock Purchase Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureEmployeeStockPurchasePlanAdditionalInformationDetails</Role>
      <ShortName>Employee Stock Purchase Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Income Taxes - Schedule of Reconciliation Pre-tax Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationPreTaxIncomeDetails</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation Pre-tax Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Income Taxes - Schedule of Provision (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionDetails</Role>
      <ShortName>Income Taxes - Schedule of Provision (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Income Taxes - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>100630 - Disclosure - Research and License Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureResearchAndLicenseAgreementsAdditionalInformationDetails</Role>
      <ShortName>Research and License Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>100640 - Disclosure - Collaboration Agreement - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails</Role>
      <ShortName>Collaboration Agreement - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>100650 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>100660 - Disclosure - Commitments and Contingencies - Schedule of Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>100670 - Disclosure - Commitments and Contingencies - Schedule of Reconciles the Undiscounted Cash Flows to the Operating Lease Liability Recorded on the Consolidated Balance Sheet (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfReconcilesUndiscountedCashFlowsToOperatingLeaseLiabilityRecordedOnConsolidatedBalanceSheetDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Reconciles the Undiscounted Cash Flows to the Operating Lease Liability Recorded on the Consolidated Balance Sheet (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>100690 - Disclosure - Commitments and Contingencies - Schedule of Future Aggregate Minimum Payments Under Noncancelable Operating Leases and Short Term Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumPaymentsUnderNoncancelableOperatingLeasesAndShortTermLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Future Aggregate Minimum Payments Under Noncancelable Operating Leases and Short Term Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>100700 - Disclosure - Employee Benefit Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformationDetails</Role>
      <ShortName>Employee Benefit Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>100710 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="freq-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>100720 - Disclosure - Selected Quarterly Data (Unaudited) - Schedule of Quarterly Financial Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyDataUnauditedScheduleOfQuarterlyFinancialInformationDetails</Role>
      <ShortName>Selected Quarterly Data (Unaudited) - Schedule of Quarterly Financial Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyDataUnauditedTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>freq-20201231.xml</File>
    <File>freq-20201231.xsd</File>
    <File>freq-20201231_cal.xml</File>
    <File>freq-20201231_def.xml</File>
    <File>freq-20201231_lab.xml</File>
    <File>freq-20201231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/stpr/2018-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>109
<FILENAME>0001564590-21-016117-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-21-016117-xbrl.zip
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MZ<N60QK-(74FS>^U<?N OMLM6RZP)6[4-;E+!I/=1FQFS_&K&P>()KX);B)
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M7@2 !M]'435"OX.\!6D/RE$'<<F]B8^Y/EJ 6 +#P@UO$?[^D?%_KX/;B,W
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MM9P,!JMY=@6P;6)-VS!>>L?];N]D(XO"E_#_T:>X!Q,'[-=OH#\CSTF8BS^
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MR@KVV/LEBS#0H"=E@O(=1N%ES:+*8@&E7*?0J8>$^,<6KJH(&Y#'"@9QZ9[
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M^U80?-W/'*!LWS<2E69:0%YJE,([)0N"Y9@8LH$*7!DW ]I-0I&@XIHL<K/
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M1?IR,\\[N^HA"U3+CH 5\2/K]+B[<MA(8/H[3EUPSP4,]48U2Q&.(>>Z+!&
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M,BM?.4H^@1X1=B -A=XZT;8B4+0G\/TAD"(3]JR@9O&B(O)86LY(J)QNL[@
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M7OP3,'F%%ITRFDIM)A)L:0#6HT]V*X>NPZ6 4BU!^)!E$Y0I%PN+7$57T!,
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M3Z>I(X"@I4)WD8K7Q3_>6.JL6;^OG[9][OM"<A*C0>_BX!4?^51B[>+SX."
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MQRW".@#,\Q[J,089ZJEI0I5]9IDCZF'1>K[[Y&!\.X^3+/B?FP7QH=OR&!'
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MIWO LUQ'ALJ/7Q?"HT.-(IE;9T%DW0LW25\9F[ME6\(4)$Y4CG4 &6DJL"6
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M;O<ST\--\[=/?L)"6N['[X&_D]6Z7N_(.L_0XOPD8.C D:/>:)->\R<9QNH
M>H/>A*]C'0V<SVQC,#A;JJP!ZRPSD&"=U6'T6&<=$YRLLY['-7[Z&EHGXAHW
MM=AI^I?U05;$-O:4R<G!92P0:(Z<I 0T^0C69%-,CMV&&%Z8BA+;#D:+-?9W
M34&"%8QQF+""*4$Z-Q4DUB^/\$V'O3ZG;4WU33]CBR930T+LF1H#Q,D:#AT
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MTX.D"'=0UJ#XK9L<)*"4&2[(;H"BCHT? ^^C24"63TV/HY^3Q"%B"MN1%V_
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MM)1?36JPR>M0JDJO1LH/;;+T3B_.0Q#  5H@E!=!&@2)%0.9^$GLW6>45_3
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M2?47!6%P./U#RLXD2:&(L*=(\;<</ S<XJQS/5KS_[/WKLUM&TG;\/>MVO^
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MW"L-5)#@CXC<4M>9=&=)FBV>B $X)::1D.:DMO+AQ<AXI&HQFH>BJFO0P$=
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M!1AG,$Q%<DOJ;I$=Z\*E06I>E4?E=:_GB<@/;AUU*!X/E)?GT:46+5LUO#W
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MF(0L-%L<]E)FEV(P4L!J#16GHD/,Q.D6AR<%"+RM>,"2U\H](2)91I9&K70
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MO,%WJ.<7WW;?O&HY;NJXL/P^C&,X<W &<9XZ:3Y,Z;0Z(E<.,VT[7V#P=$S
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MB#'H[5(KA\_".81U3T&IBT36=GY97#5:33\FX3QV;\7]*SAQ9RN6#_F5%+C
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ME\Z/NKT*CRP?0GR,&$@I# L?+7&%%* *43>3N\VXCCQ]TDP$>P:I%1D(*E8
M*Z(HW:BT;RCD!Z0H-8%0?%/NJ+E'5A0887)9@:08D2JAU!.D#55ZS. ^], I
MJ&0N4),<(2R^TAG([ *VH5UU9#&1:01K=S.3RI8;>F@72P=>.3LRFB,9K0HF
MAA:BB+#TE,#L*X:>Z:PEQ2#/4M 754@+[#6X%IUNBY.F,(\7PD8928^I F.F
ME O#97(/-D]$W=T7I^XRZ^*AB10R#6,$O/(U7 UX9;.+R$<?QA1O^H+\N2[K
MXKSS;%D7-AJ">FVDI->K0Q@%4DB")"M_D'ZF'(,#QG>C/('-CPXZ?$H\&@5
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MAP33B*W(L)@QQ$SWF,6,9:!8'=E\HAJ(.P89-0+8LLO&GF)@-B'3 +?G>@7
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MZ'HYYR3!@ ;Z>B@4Q=?Q1=" O! O)@WE!KN]' D<L+<"ATE*&N_S,6J'/=7
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M,ZNUK$:+E5@LHR>K30,PM%AHL2Y$3N"K/;18PD*',58=BS7H:;H"%4JT6,
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M*%#TL"M* T0/ZIY__D<PP>$%00+Q*IU8>*&].TOT\"H=FCL40#1WB!>:NPM
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M*NL2MQR35;@74M,#&&I&WA8TH"9_6GSE?CY,?O?9W./_2:?P/DR*3\MQ@#O
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MRAS%3A/KFS ;AVGZ1HN85.1.34C"6A%\55@.CS</*XU4PT?1^W(=YZ<]7H$
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MT)K#!XP%F8$I?.+6H5]D>\VQW!P/N /8FW4'NV(=KM1Z+"A;\7%YT-@CY/)
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M*>H^-;M;.35R-[@#8D^+/^M;T<!AJ:C1N#-AN\-9H_IKT%Q_?8S9HZD26K4
M2AR&D/D.=$'Y0X7<.;)@))U]F3V)\F;GUB\C>"^GPCW?R'.H:3KUF%LD<>)K
MT%,4BDV]$19DOVRX7). 4Q\6 _CM%117^+L5.$Q_[UQ@V1#:)@L<;'1WWEI
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M=4BD#]$*X9M(I<$#OYD'XB#CP/AVSKT0 +EA"F\"N67B?DX%.XWOI,>PY"'
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M4[KP=1MZ)^7-:.!CQL4L+%I"FPUB$>I^H$PT@/,()L_?XDBX&\]46%%A96D
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M7 <UCZ?:'=RRE>QU?&MMIG=^T!O2-*7W92!355\GU)")VCBU>>U;E5\++1F
MT)*M%3#)Y#W/"/,?$'2-RGFC+A!E\586"5/=1#XPYCSIV==8":*L)!MHKJ#/
MT24& Y-80[W&IR#,8@V989'N,9VL@]4BI$JUXO3@KT1&79]S.K(EQ821@74Z
MUJ5,C]I :ASTLNL);H#+'9U'[-'0 V29WRM^3Q_4<PC-"NF+7ZB)HI^W!F87
M?:B,A2:E]/3NQ#'\@T=JM\\9%=-3'KZ0,+%1JZMAP,YM2TDO6?N"HQG=N&9'
M]<1+>VIU/\QT40MF=\/EK=1I1] ]XM=6TMCM[('OD.RVX$D8K3%7H4QFKSV#
M/:5MG%N5>J%9@S*Z!KE6E)5SN%(EDE/*H5/>@L9!$ZCJ!%K$=HU]<;U0(W55
M*LK.F<'IIL2LQ31P$[>L1)OHMEI.@QCEY%JMQ[0U-5F/-1)MHFL05J=XLJ[?
M )PZ2?:F+D8P)/7OSC,M1T?E*^,[\-"E>*CM8TY':F6-40$A=;;4Z1"M 2]R
MXZC3F8DFK:;&DW(Z5U%R*-RWLN5^L].G%6KS43<[<OJ 0OU64CH3-CZ1L =A
MF^UUC/O)UZ>L5XC&$(.[M5R_)HZ5;6T=2+7D7H> -*'92/A(C@5>WP"8*;"M
M[V5RB/!-N!H\X*$TI5N<<Y%VVB"@KZI;^!HOVDJ"C(32R<KP^JMP>@,V2!S5
M[*GFSQB7U1=&[JCH9+&7G).<6<WBHP/%7NVF.5(MO2^LP9>7T.9)<B)XDH[1
M-#-%)?0%?;$#KW8.C5DY?6%BUUE/A@@"+PIOA A?HEE&ZLOK"S/G4>4XVC0Q
MM<5UQTO1^J(Y_&*IW?ON&AS0AJO:Z<!;^_S5VQ"G W;M$U@^+#D=T6N?N"*?
MQNDP7_N4J3K(3D<'VZ>S>D[F="BQ??*49OS& <@>!-SV@#884JN3W>N@6:GR
M.CO4]H0]BL9P/_G*L?R=[;*2C.YF7\L51Z"+PXG%F?E3+)UFJR"L(3WSS0]&
MV^5-I-O,&%FKEMAYG42170F=:+^]>F@$8U=4)WC@'SO'X0O_CRV2S3K)/AT4
M\**3NPV :Y?9$X8V73O0.%O(XLV$9MLIOQ/F/E/JOY(@2/+!(["@PE&6'S?T
MY';51M+9TR5B;#FA[!4Q7RO^K"RZ&QN^N@- ).IO*69FV"O$=H+3;*FN-\MO
M^SU(]5":,@F=:*]X"$WQ^]W/"BMQ%60?[7+O="Q5&WSUA-;%\[AK>F<5&54&
MT^F IP$G=0.FTU%- UXJO2:G8Y-FC<7<N78Z-MDH>9+S.*<S( T(VYWQ.WT7
ML\FPE09PM.Y8=@>^261.ZT9EYZDIBK8Z?5NR+A/[P7'CVY+MKMG (#DGZ2Y_
M:-CI2M<4!)"B_%[,OX8^O"H.PH;Q%?'9-;CV_)GF[JVX07!]KZ)X#^CP[\7U
MBYP&Q!='<EV@0,P&GF88:YXEW"^E^[+*U!-6+ 0:;C%T-ERBZ0-:)AR,8WP^
MB3#[7YA.7).%4D!(LP ;0199U=J$W6/$-%9:LE*7W3?$SU!P:Y6<">\=YE?:
M&F(AND]X[V"@>'[%P0)_ 8L^4PH&ZY?1)P;:0&P'88D>=S ":UQC5B^L0TPZ
M][+52.H030,P^C"KJ4-'Y2O#Z34,<QXV>YG3F=W*1I<V,9PXO<1A@[*UZ^'T
MHH<UIE*WU.FU$%M<I;,6IU<^K%&53&F=7O.P0=5.T,.Q4R'Z$24[<3+B>;+M
M%_\(>:YH^:YF*AW,]C<KYNK-@T?/Y^)38U/_\@(ZQVXYTO%=C4KEU>KT?-6$
MK]).[MBAVU*F_3J.Q$5FTRG#4S#.7TA(YO%\Q1"T#LS$S%T8[$!<V;M-CA#\
M-*,L>L9LGG[3XGIDV[HZ-2:W1H;UD9BG4'800.=\GF&&D?"5]<=H*>'VXZ2E
M:MV$8DX@Y@9*ZQ0ZTON%&B;9+:+.I?<*=1*&:0_VIOA^X7ZE+:)>"^\19N/5
MG7K)/4+; LP^>)6JZ$N=ROK*=-K[;I^GS5[N]&J2%:HVA@&GUY%LD+7A*CB]
MDF2%J]R9='HEJ7VN-F<;QBM)=L,(3SC 7H3]?\2(@?[!<HPB]#5$L0^$^OF$
M=/W[-0EAUDG$H603RE+R]:(";13=ETE^H]ATCFE9M]SST+^CX?KCZ@Y?R:W'
M\K)L^*>/>('#&*\NU&/(BWXET>PRYA&=8W;UY@5 ,.C)N8@0BFT(*KZJEG@;
MN('@_#I!%40[+W9OBXN14,,Z<-J=+J5$ON^9;QLO'72R'\3_OL$0^+?_!U!+
M P04    " "\@'U2STXD:#$W  !=Y@, %0   &9R97$M,C R,#$R,S%?9&5F
M+GAM;.U];7/;.I+N]ZW:_^";^;);]R:Q[/@D.35GM^2W,]Y2+)?MG+/S*463
MD,0=BM""I&/-K[\ *1&4Q!<T" *@I*F9C"V+C>XFT&CTRX.__N?;/#AY123R
M<?C;N\&'TW<G*'2QYX?3W]XET7LG<GW_W7_^Q[_^RU__S_OW)]>W=_<G0S?V
M7]&U'[D!CA*"_NWIV[^?_/?EX^ADY(?_>'$B='*-W62.POCD_<DLCA>_?OSX
M\^?/#][$#R,<)#$=+/K@XOG'D_?OUZ2O"'+8'TZNG1B=I/_Y]>3L]&SP_O3\
M_=DOSX.OOP[.?KWXY</9IXO!Q?G@_YZ>_GIZ6B#P1R;%2>$_OYY<?#C],/AP
M\7E0^.*#X_[#F:*3N^OB%SWG\R</.9-?OGS]=/'EW!E,/I^ZOUQ,SK^<?CKW
MBL]?X<62^--9?/)O[K^G+%)YPQ % 5J>W/JA$[J^$YP\K27]?R=WH?OA9!@$
M)X_LL>CD$46(O"+OPXIJ0/7V:[!6'GTE893^^MN[@O;>7DCP 9/IQ[/3T_./
MZV^_6WV=_=6+\P>*7[[XF/TQ_^H.Z9_GZ7<'7[]^_9C^-?]JY)=]D1(=?/SO
M;Z,G=X;FSGOZ5F,J-.,E\G^-T@]'V$U?IX ()Y7?8+^]7W_M/?OH_>#L_?G@
MPUODO:.*.SG)5.<0E^  /:+)2<K^K_%R@7Y[%_GS1<"X2C^;$32IY&:M(S;(
M!2/_%R<(WIVL"']_O-O5K!_&'SU__G'UG8_I Q\[YHH.B$(VS=][:.(D00SC
ML>1QC1SCN>.'T@ROGNZ<WW2<]W,T?T$$R.SFHUUS.J,DB)N\H/>YEF#\EA(H
M<BW*\H2@_Z5\G9T.SK+%^9=G1+]%#?DH-2;;'#'9V#,)W6N6\5NZ%:P?_YBR
MMOE\&4\@FK'SAD,\7V;$GV)*F6U/5YCM1[Y'?_7R#\<3^C'=$F/_)4 /5#Y$
M"/LS=O]QCT/ZMY@2H:Q,[\(8$13%PS#[ZPP''B)/-_^;^/'R&DU\UX^;]/1(
M^?EA@)_-=UG4+S4,?N@ST\UTO_%U]!:CT$/>F@A3INWZ3R5;RQ9@MVRII0MD
MXD0OZ2JA7L_4<18I\Q]1$$?K3](W]_YTL-J _K+Z^,<]BND&C^=HA*-H4\$!
MVP4Q67\8."\H2/VJL@<_:N!U',\0N<+S!4$SMN)?$>> LC.>/#MO$!'$Z-5+
MMKLJV"<_TG=Z%T4)\JX30M_W R(^]IYF#GWIV11A%FL\V9PC=#:43Q/Z_YAR
M.L=A1IE])T0NF^E_^O'LCDUZ)WA(7@+?'4\H1?JLB"HL8E9*S\S48N*09;9P
MTO'^<(($V:9C\XPJTZ^=D]@"3E5:"BLGL16\ZMAI:BWB/?J9_@FT78I2-"A=
M^AI5"K=-4(=L6V9@Z+H$Q>FDO/9??8^Z@"#)A,A)K?M*/[%D#.$%"B.J;$=0
MLE+:4#<PLY0O(CGZQJUA^L?Q(@T6WKS1([D?(:$)VX:Z:2O9E=!UQ,V_:?;O
MI4.986<F>F!*8Z2_$^#!47X,'1H8>O^31#$[RD?/>.AY:3"!.B&.[U'_Q%GX
ML1.D3+YL,_F(Z+J-_!@](?+JNR@3ZQ&Y>)J%)-*7"]%4][SHT&C!P\O>\3B)
M6<C=$_0\Q>AH6QU9H";*C/1=Z 8)8^ !$Z;681P3_R6)';H!/V/J];J[7B]X
MK2@8T<3^V.9=-],R(-&50\B2#CZ<XR2,95Y$&W] R>@ZM/:(8L</D7?CD)".
M'GU;913$):^BH,7^NVXR3UCTWJL*#\(% A#5L\>5;B42<M43TKR[P/DO>5@'
MS^7+$\Y^/1T=DJQ,$YW..*1NRO4JS2DN0@6!_O+^XTR7+[+*.&UQ$0W??* [
M7DM(+J9)W4T4#0>5X0CQN0ZCUX9;Q<QVR>NE8LT*T&O#K6)FN^3U2BVOS>2T
M[)&!$T7C23HNW,R5/=U'KK5;YB(+TE9YEXA6&9[9@4**\=636KD=T5/#'?U1
M3M6%IS>YYE4E0^)N4':(NZ:ZJDL2++7+GID0/*]G9#48KE8P)AXBO[T;G)X.
M3C^<GKX[61 ?$[J3__:.3O@DHASA1>:D4W)I%=:OS&M$;_%-D!+Z[5V$INP'
M_O< 1\C[[5U,=H-$:I516L55JYS-&5FFF-TEPW7TJ5E'78I;4L)8*VRE"<%-
MEHZ+?&&-R!M&7*G$17D_&Y9WLXZR3-B:G0T#W0<N]M?]$;O9P\O%'ISOD=C-
M7CB7>X]F>?-1*1?[3&"/ZXW8@-=]9MB(=[%-E\<;N,A?K-FWA+;JVC@,%H@:
M<<E-FW+8CMU*\(+8Y_:O[?J0(1:-S'*1[=^]A$4NB:5S.4W[H KE;,AY<)E-
MKV*5,HOGKW+Y/^W1<JY*2')A[5_(8M&%+I+.7$N_[*>62LH3<IF_G.V)S*I*
M4=::&0Q,.WBJ-%-?F)3+^VE?9D+W96FYSBY,Q^N4KAZIHL=<%Y_W9;U(U+[F
M2OAZNM]*J*UZ7FOA;+ ORT*NYCW7PUG?'8HV/0^Y%L[[OK%(M*[DPG_=%ZLH
MU&FT%OO\?%\L '#)GW\^B V@3/*O?7_E]K20KG7ZJ?<^N2VMSURC>S%+S7?K
M<X7NA8]C!\1$KM1?^J[4];?$($QRN??F#+F%/K,6\$+\9/37CUORT?'^H1.J
M*1I/KIQH=AO@G[F(+9"6RLA9#)2TP:Z.:M(L+G7SMJ#"^7%"C0B=0 FS-)=)
M?(_COZ.81;! -:;"-/5TPG KFAG/+&B?&MT!2*X&2E+UU<R.TQ>^/LR,PZLL
MI41-5N713X3I%L2U=,,QT,SQY'N$AE%$#?)+EDFZ"V_>W)D33M$M)N,%(I37
M<#I"3H1&OO/B!]1V05Y9JV%T]3S1-W1'7T;$>* [^PIME&[JS,H/7Z*8."ZH
M/19 5,L*I+RP_S&G\=4)F)5[I(P1WZ66C_V!\K?Y0>&;>3;EVH\6.'*"WPE.
M%O0)AE5+'2 _I(MO]0JI0879*9U\6:_IS/6D<A&V#JY1]O^YG.L5\TAWJAOJ
M.L*FI&[.M*Q=%#-&'PAFYM6[7%(S0[G,EUJ*J4R="1C>"82J#BDI(RY"7G1+
MW5&VU3%0X/%DA,/I,R+S:_0"F@<BU,Q)]4#HE(O10^"X:%7YWU*R78KFI"L<
M#-L+MD',I$PM?"1ITG99%RD708*Z0:FY*Z/2II92U3V7G^@>-YX,7QT_8!4B
MU"%EGSPA>F!*.6IC8<5H:Y'86:XK(URZL1.D4& H:2/RTM="G<%X27>"D*$;
M,_=F =YC %3M6JT*;50M=8-2Y^=(I3:JE*H.*7?=;99[I8>:]0D9*)\8/3.2
MI9%T.G]8C/PJB6(\1T0JW@ F;>Q-LLA51.T)M)%9@)@9F:B/MG!\[WKEJ:71
MQPA1FYCF M+P3\OY*C:"&>ES,[$*OLK86PA5J5CG6G.CU?&=[E/^*P %M?+Y
M-I'7E-CJ78JS4OZPEG>?'U#6J< _'4+H]A\Q=R<K((W&Y"IP?%C#/Y"P#EFO
MT8(@UT]#:!!1-I_3@K506JL*X;F*@G9T3U9W3,^  =I()CYC0>]$QO)T,[ZF
MD]S$CZ&7A!2?LLMC5>BGMW@W?<(BZA/&DYT(1$?\H2/^4 W'HW[C#YT)U%(>
M.OZ0:1P'W6 \QD$<S*#2G-M?I-X%!E'O&U':.'I] CMHX2;C<N>^3YWP:J3O
MYBC']6@_P%.GAVG<'##(=75A_XK3I:O-@!#7D/U@)+HT!(S^Y2K\Q7[#UK4*
M:P+"7$U'NU4?PL\U]=E^@!PU.R4DW<*U8[]-ETA.U6I%+.W&D67L-TBJ-;23
M@>7*L-_LJ%9&0\(]5\U7^^U,!_-DI^""Z\-^RZ+&[D(*;;AV[/<46YWA:XNJ
M<IB94_MM:XN2M.(9'E!HQY&[[+<H'6FGJ>*2JZBW1@:J(G 5+M>1_:9&C8X@
M5=FY=L[L-T&M#'%M!3[7@OU^78O^A8IU)-2:D:NHO_%F12HJ].=PL$7[5T^7
M2MGMQN*:.>P5M=F!QX$F>^O2 +4"Z;KDVK'?Q A"M6KNSN4:M-_7T:!!<"]Y
MKK\>1-\%O2%QR *._-H#XP2&=RC"J[<!K^!:LG^)26FI!<!)KIL>Q(I;S: F
MQ!JNB!YX/ZT4(0Q)Q"&5A:V+!L@LMA$$.*)\C\G4"?U_ICL!5<&E$_E1"@\7
M41.;?9I#C]^%$TSFZ8?7[*J&0 Q02_5@1N&VE FC Q1IZSZ-POTBUU13K@\J
MRQ>A=@2CD 45RP=\<,B8I$Y.AM9*W>&T,@=4$R]"3D_)MB >96%WY8%,6'EW
MNY%,S=P*",UV,[B"J+;&M2A[$0\DNWP"/']KB!B?M07,:$6SLT!1SRPL>J\J
MS(TH1?W290H>)O&,^ES_1"#8R29*FO>%-J+4DM&VHC9N-7I$S")G%Y$\+0*8
M*R)$SHQ<U/<O<,$WGD?F_('@0>&TFR6.UB)'R/TPQ:\?/>1GTM(?MH6D'_VX
M">/L"BI,&%)WZL#2E3V>;'PD(A:$FAY#L1F[%V^@;**@I6O_80QGN/"0EL61
MYJG3"7OOS.F/S\0)(R=%#X?W>8I0VT>IV)VU6N1*7B+?\QVR+/ $[F>M)J)Y
MNX2OCI*'=?!<?SNF -\5!+1VY-9>3@QISBTGI'?^CTG&Q3=$G20O"Q B5)C0
ME\O=+Z^_!N^D5CJN,4NQFXV1-1<CT_W98N+AKEYA7B-Z*A Q[G&G=Q?KK:Q/
MO-RD<"V;ODG'S#7PI_9G:)3<B7YJ.%UISWJH=LUR90U,W]?#UP*:.$D0 RQT
MU4(0\["Y"DRO"S%SH%8#1?GM3^\#3F"X]/#+<3/LK_B0$[8J-,'[WGM0:B;L
MAT%"2[Q7V_2^KU(#\C'#/O6NJ]!'2:"8-U7WP!R 55 ;^^]3VSU<]*8,#I=^
MGZPA-"O7)TP!20L N/_W]',/T)7@6JA.J'/!]W%#!%1'<$68/@5I7P<"]3%<
M._9CS;7:) 4,Y9?]W"Z$V[Y.O^RCKRA2W\C[]VVZ )?7I#XE\SD+"DV>_&GH
M4Z99=WF&YL&6/*8&CS4NJ:OH53>@)56]"@32D>A,^S5RI!;&&;7IKD]UQS^B
M1BST'.)%WQ?L4N [*EA,C;X32%RWJ&0\+2E@"4Z'7K9H6<"@:ZULCF6U1H U
M9FV&D8)$KX&S@=_P"Z78"<=;'5KBUX? ">N8>0HN7#9ZF7*M#N6EV"&DI6!L
MOG!\PF+!67/VR']%7C89_H8"[Q83R@^HF$R,H-0ZN:644^=[/&%-Y"/LA-G1
MA?TFO"@:J*CBK T_>M[]9J,P:WQCG6JPJP*K:>B0@,XF1/VQJW1,=UG(@?Q.
M?78&)7F)J!^&GITWB% @LEHNSJG:*<]8;G8 +VH3)&A:MB\#Q;(5".J0[9FR
M.YZL?3NX*.7/]Y5S726K!819NI+OT<^B[TE/=TF893_!Y8A PE([R9_X)2'A
M-R>B%F>6T&V3CN6XJ7<#O,M'@)(4AR/T1@6.L1(FQ8A)S)J(Q(490W_;GBWT
MHQ]/63W<[PA/B;.8T5-](%YHVT"@?SQ+KD\QKM>%:L5A1==? P&YB[.$ CK"
M9;MPFAURO1O/5,/YR% );BO1L<S+V?-B6^D5@!L7HXT%M&5%@V)&"0N83"ZQ
MZ?Q/;8V@&H'[42HLMD]BD ]B3>FP,KD%'$1>_VFX!JI3DR;IW_-Z4=,7CHG5
M1\N=BW#SH<Z>PEFA*NE.]%#4@OU%<[7'>PR.I=ASPZ(>T0LA,G[QG+UOO:W_
M+!47Y37EIJUC]XJICH+WX48Y)<>KTBP&KR&UMWJR*^F+.26N!].'HN[7@F "
MD*O$7G=:E4H:\KQ]J##M1A5E%R9]V7-3 :_)X*JQM\96BVI*[]?:W^FBI(2*
M*VK_C4O[PCM^!=7^.ZUJBC<EKJ6RL/3YR9TA+V$%X3=1[#,9/6J )TG O)>(
M'A=34]QE+;04![TJCH9)J =WM?RRM3+^('4"0,*:,&;+65IS,@%">PJ0TR%7
MZA>P3EYZ["#X-8O;P<M5:LG(500F)$P1X-D-LA.Z)E"N(V")A  E+?!.>!+_
M= AUSEY1@(&""!"1JT5Q7F356O:HT97( I-PF#<A<OLIEZYZLDI6+I>,&6@5
MF1"Y8TW+L:;E6-.B.P$LM#3[4N$B8[Y$=+%I@'M2_=*],OI1&2.S6^,:CZD/
M53&2,@OXK-:4QW3TQ@6.'EP%]N:_6TZ VL,AE]^T_>L^8BATZN<*V=]LA62@
MAY?)]!DF@B&O)ME-9N/)M1\D5,Q[%+/RCS4HRC".B?]"OT3]K&=<  M98:YU
M&4A5SUZOHJP*Q=?1JD5Y]QB3=(%P6*&;-W91+?(8YLR&/&L,EER2])Y)R.%;
MT8!2!]UQ$D<LG9*F5:BZQ^E:CX8KG"7ZHC;>!C">)4E=2I(B,-3M>A[_E[-P
MPDUT.: (4+)RX09$&%)+3K&@('GEPXBVX/NR;(@VTP9*M@7O5]WP+DY6BO?O
M&8)V\5IM:8:%:&EID2TU@PQ)&!ZI;::U;Q)I:V1NMUE=+LL)@-N>NV1#2^HJ
MSSRW% 5^BXOBD7LPZT"!>O5C&KD;1KG*<'=3:,_3 !VO>:S)+/8MR:!CJVK4
M_>8.W;/,A&4:[%<Z0]C[PQ!/O$_)#; &H(>G/N4Z))4A?@KN4]9#4AFBP8P^
M)$"D50&-2-ES7U0'RI",,/;I#JDN'7E%H6>>1!+N?-&:1,I;(;\AA_V>9DNY
M-W[KAT[H^DZ0E7NOON2-PT>F$G8#P:43^9(9HD[&MB3]HU8V'7&$5SH2.SS=
M8L+ ]OF<OT8O<?$2"4"<0)BFEDC)%C>;/!0N"OB=X"CZ'A+D!.R*(=8M+P5,
MJFA FW4C#=JJ:$ +=#/')&:<7>$H3A>M0C64T-8"U%MFO'++!.\C$*-G2K+<
M4X2G'H3([:=<NK(J.2N7RS)FH-D1(7):Y;H+J1<9C5BYH@1\<BT98[8B__!O
M/B+4H9\IFH,UA ]'5@,K;Y>5=**U6'RU%'5(]_WIF:3*7O+]%K[\ZJCHD.(;
M#M'RFT/^@>+;)/0D)*BBH.4ZBS2LNR[IO:+NWI3=ZNG(@9B+4-M'J739@TU.
MH&N_[&FM5BP[:0]#;XU+DB[5G7,W_<(]IL>-XC$<7$B@<-"^Z&@WF*9)3R/#
MU03=* ]W,IE >>K^5A.H7_.XWI#9DWP5R__7F/)*2:NV'BZ[Z0X2H<2]*M&+
MF1)[T8<D?!+<[!MRR>V%\VHG>9U?SZ4W7.QCAST4/=39DWD6LY' XV^91D1/
M\UPUIE'?A$RH)LWTHSFQ76RH3#=ED3QKP.NMLSG545P;<>X%#4YCI+MA397$
MZB4*$2RQ,8J5(=78:Y59J4KL-!G:G8P;5X3I?0>@B*Z.V?!4+$?Z->W1V*\^
MT80^!\ U?9+NL4ZW"D@X3*[])7W:=5I=DY2K3=Q_T%JZMX:S*")9\ JSLK_*
ME>FU'L>2DCQY.4RB%M[#+JFOIZ/IANBU6;I&"[HR_3360G\.4&I(0F^UF::?
M5S(,*J-2-J91A,K4C"MYVRM*.J2YPF$4DR2]6.B.J79*4"21B*ZG<QCHQ&JQ
M?^F$*$%#8PZLA%0 HEI2E@6LLUO_C?TD(50=%1U22* A5SZZGZC!AXH9K!I*
MH5K5\B )332-OKG=0T";%S<R7&0 $+,4C*#I5?$DKD"'9'\+ \#K01YMV'1$
MS2)\7?NC#I)0HS7PJJ93#IW)7.<R]:G/NB6\L( ;;$_"VS36KOVA7$GYZ\^L
M?6JEEG,PFN(/]B0=N]* NL@3OWO8M.N@?;;<;]RK>B%<XJ UW,[2 T//\S,6
M[L())O/5NY:)JHN2LR1XWLBNAK,>X^$N-;ALTCP@.C\\WWUPEJFA1F0>7=(#
M%*:K;/41OD0/CN]MJK+^!"@_AA1<Z=9P!"TRLO2GN9_,Z?@N_<V9BM\ !*"H
M@.-;J@IR1\^!=-^+'ZD5;,UQ+44=$85-=M*$XA,U[(XW#O]PB,^.AXRM@?RL
MJJ.I7\)O3LQ2GLOL2E59F3:I*)A9ZRDP#H/E:JU!.96AJE__>37/>+)E;N3?
M1AU-_1(6K6<+6[Q!Q<![<EP)!/MJ&E)KA-OS,74\232<T/G\A%Q,W<PP]!GZ
M57KIP!7=M?UPRN8T$/2ZQ0CJ)+KU2117#<=NMPG'Y(&YA\^X>^&5,Z-$3X51
M:QELJ0'H,/K7I1QH>#6-ODN@JQUX<WQHBJSL:3WY(G^>^EKPC.O.HSKX+;J'
M\#E2]G0?N=8UIXLC0V?T[K-2=I[Y-R/L ) "2A_34B^#PRG='^=L+<L5 %11
MZ#/WNN;J]NC0^5K^O-R]WG3BL81(5CR['$X)0K"J%B$R6JH7"7'":9;(R&J+
M'?[),_TI<M)HOT2Q$9CT8<FK:]VPN3Z>%)B#+IP* OI]+G#I3NGC^OG>31*
M>1\9KL=I$@@W*/U KO6HFZ^X<47U[5:->LN"6UG&GEV/T94J;():$< GE]Q<
ML:!#9$V)E6J#4.Z;VM.W*V8/:CWT&FG+FK9[L>K;"5P4U_ZUW7!\Q!7G<B[B
MGBW9W? '+VCIQW*M#/Y42%FR3#_U8IG*"5H4T_[E61.!W*A(V@KI<A'W;'F6
MQ=MS83^;!C 36Z U&8=*22LNF?MLNCY;:*&V$[@HKOWUV(TI,:PH0\F58MI8
M=ZB4;A+77'7V;P#M5 ?5A_T%WM(1JV+-"D=G,>W2=2CP9J$1%]G^LFSY=UQ3
M+\858#\(GX "9(H".8".:4>IPSE0);+]G1O2(M<5XG(%[(6I@U9:<_'WPNQ!
M2^-S\7O0R2B_T0&Z&S@8EIWW6*XN-?7I MZ\ZU5ARTZK,2SIXY&304=:'LT7
MF%!/FW6%Q<LKAY EPW=+/<]A'!/_)8F9?7[&#PX!5L=+$-=2BK#)5GIQ;#1,
MXAE#*$>@OJ5&4L;DN8NB1($L:S)2!4JK"\,'E;,?6*DD3*\%MT/%W K0:\'M
ME5IFF\FUF0>*IT&GLT#Q)&C)JR+(N,")HO$D'1=>=EGVM!8PI9CZR,PK*C(
M+1ZK(6+ 0E\NBVR Z\E$J!F0:M<%ALLR,EQ@UB@2AKV& RDX \QO++0H;:Q!
MJ\D8-=LH7&](^U1>5;.-8."N9TTEE4JQFQV3/N%5"8O=[#OV":=*?)(W^_=]
M0J02G^4 N8W?!-,L=XN-?_.@;$^UI :ABY$.7L-C?[:FA> B02RN"N'<G=:H
M[3T.Z>*-Z:>4]G2=BU 8LI4?P))XK80 6KJHBV;V#QQ3WA[]Z2P&HNU64Y'%
M2"@0S"S#0T+<F1.)12!%J,AQEN>6QA,J*/WW;SB@:S-B2+3%X<2Y%*>HZ1:
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M.N2B)AO/4=YF,V)<LP@WN#ZF@=#^R**K:*>""6@)3RT932LGIF?Y& PCT4#
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M!,6P\7\8T?A/V8_+^(Y^B8Q,O_IU!]HNR7D/]YP56L:(,P-F\2V8M-E[4UD
M]=]NZVJJ=V[J8M>QC*]C^A1&*\W-<Q<-!TIOT/1N^7+WQ?2?<P1F_ETXM?E
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M[]/R7QHY8\:D+2*D'BL/;TD>:9P>L4^V:!O$O^&4"X.2@C$,MS0%FUIJ>F;
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M\2..$A8$+Z,5W>(KFB2?<+K<W 5?M;Q$E[15CJL.*R\)R+D ><V@J@@H%#(
M\3!#R*FEOF<&+SE$5B;0U+@CR1YQ_KSB!']+ST08_15]&H017I\'<<36/$E%
MZ#.\"5>AYGOZ86HVS[J'J/MUS[5D L,7-8"C^BJ$#U+F9#D[E/-#5<3.AA ;
MZ;20N3K9\SW%M;P,7Z1I'-[O10W'.\H/X7GV R5,E ?1M18GEB>+9AQ='GB9
M2.#K,#[I/+>$X<R.+:;WB-,<EY=A'3U'IX50*),*5<5"=Q35!4.Y9,!J+1C>
MJ'70\O<:?X2[-W%> ]W]E?'4J*C@NY+"V!44)KW,N [B92PZCZS%P=,UCD5+
M*//[C6Z*K@Z]NSB,< M2',W"<"]-+#MO)OHU.@_<.NXO&%.TC)%D*P]7>9-6
MV?AL4M>3K=<6Q7&^N<L=4G(%69/R""Y6WF]DEQ@07:T3NTX7:]<D;)PZ7"KK
M&5AR ^!&E^*BR]:%<BIN89%41W"=[+8/NMLTL!IPF:KVX.+2[RJ2$P WT>Q6
MJTS*+3#.&Z#V>DWU8ARZZW2TJM52)G"L^CW)M%&MTZ04%YLF)7).\A7&VR[5
MLUF [95T\&M/)/&U2QH-J[9T$TC[HX-.V&:;HUXR3F#RORVJNQ+0/9$*7NVN
MY'HWY!V;-M>9>A]T,&C]35 G"8=0^-K^U%T$X-YG")\^UW"SZ_&*18]+3++?
M.1BLX6:GGXY#,+QN<^K> 76/HX19GY\XW-WXQZ?'8Z;;UU3:SLN\+=[>]3"9
MS.Q9F"9IFWMX+5:.+]PSWCS1+<M]$PUKVY+B5!XQC9N@808_M=3]NQ%,^T86
MS>%OX=L*OYQ_S9(B>%L)]O_7FLF\1N1M\L^TV?GHS .H-*H-OM2!8F>():G!
M*,M$=!0H*H1 N1039/$6)5VR3J:)R3S40\1!:9LF40^5(HNZ-GDQ;R"/DH?1
M:2LVU*XPL$B0)@@YF^D>)-_0YX"DSYD@6G-6XYL6(:Q&R<-,(^G#,/0.A=-^
M=<!2+JGI-;?B\7L;8J;W1[9$/&-S$*&B+ZF)(?<3LFJQUTW82ZM#P4ZD<ZY+
MAD#L7@DNJJ4]T-"0!BH+\2BZX#61U_R$(S;Y$";,8KT-HY#/.OQ%MH'?#)(R
MAV> M'O?R1@*UPEJ+&%XCRIL5%.'P"$B=72X"]6Y3>1%!^M$JSV$TQ6KK_<"
M]&#G ,,SNJ'HVS XWRAXWB!,9=_E\U\C"Z]^W8&R2W+NK5P\,>:FE5LZC:!9
M> L8;3;>U!) Q1_8>>6=]\BF?AD]X23E*S(I@\G3TFX:YKKOHNE^[9-3!E5&
M81 6JJHJJ!"07/LYD]P))GHP>8,#PE-/2H%^"L(HX2ZIM[X9(&2S:>LA[&,_
M+=FA!\8%T8CY1\X7R,R@!AG5TB!H>$@#F8KS"%Y(,AO9<RYHC,.'2+9!63W?
MQ4&4!"N^@N!"<9%.\(;]C>:EH!99<]@TV+CWL8PYVU.L'IFD&'U+&,/OA,O!
M\#$3<*F%=F<$)*ECF#-&%<["+67Y'LE\@HN_<O&:7Y*&T9XM.I?%.E^*)O^.
MR8>3\Z]I'-!X'49!_'R9XFUB7W_$JQ@VBQQO8GG:I-U+0Y*K591RB6"$BC$,
MC8Z(W LVJF+Q7987*Q(8I*BHE#4/7=E?"W%135XD! 92^:10:G9X=((CO-&K
M4=9)PM8D#DA:POF#A#/"#_S1218EKF/Z%"9\]F&P@8T3W0 =^'B'UJ"!T>I;
MC$E^BHDR-B/[PR><FAUC-KYHKNX:(?>S(B^,2'I/SL:T[G9UTUYM@%(M*;4Z
MW;'D'=[N:,RF%EG9YRQ\"M<X6B>+]?_9RQVOCB6K4#/'8)BZCRA_*BL8\DO
M6QR+/J2(F><3CM.05R+;U5]GHW4N%@PWT0"8ZJL:,)AU+RO8Y?7E"H:HY#CE
MA+%X"D(B*^Y5GG5D=;=.@B1<&4\I*J0=1<9A5OZF)114"P2FE!=O+AX492+
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MP%^;D=H3C>P1%N#6(@J@MC<4&=+MJ,9YQR^2C:PP^Z8#<Q.4W*>"E<;UB^
MS83JJF^SE8IB8*GYP'T'->S7BD])D"299RV^AEJ/ZWN(.%!ZDZB'KFB< U_>
M"![ ;+P3F#9S;]<56! .G$ BD<]D;.YBK,9VB>I0S^@V"".MC)R6;UMD?AQ0
M>QW6WX,!'=8./'V3JJI+\Y8LU V\ZQ! U$PX[;QB_HCY.R+U?;HB.=.MM!)Y
M/[M=A>(2(':>>H!2 \W. +S:2C1'KIHY4K!6"5W01D?4!X9^D8P=!8H3MX%B
MF)R5K0V1]QDH3N81*)0!I0::G0%X+8'B9(Q ,<[HB/K 7 >*8\>18IB>G;4-
MT?<:*XZ.9Q(ME%&E)MJ= X)M 8/!-T;(&&> C9C1.S3'06/A-F8,D[,RN"'R
M/B/&8A[Q0AE0:J#9&8#7$BP68X2*<49'U ?F.E X7ETHT+.SMBE7%XNYK"[4
M4:4FVIT#@FT!8YS5Q4@#;,0,QZL+QQ=;\GZ8/VVD$6_W8WRYU4[(P=U*&V'W
MEKA8K625789,]ZMI&,?_:N"U78!UZQ(T4 <785GR1LEKFKNPQHCUK\,Z"%A4
M8VPCZ-Y;FOJ'X1?]<% E+8%4/6G7NOX-F:.JT:WM2M17I6IT+$H%]]#U4+6O
MD> YW ME3)]0PHKJZ XR+J2 I V1J19;E112?2=I^;)5J8PZ,0_Y$I5RV#!<
MH%O]=% SX%1-#K4\E5DOUNN0[\(#<AV$Z\OH--B%:4#T37R D#D&O80]["$*
M=D<[QH_G\V<<83B"&F!42W^@P2%-7!!GQ>:#')?)7*?<;7:5"S-P(W6B%JBI
M,GG=6W1]@*FQCF<#)M'!<2K7O,$IVU+A==YK0-\/NRC8])MNH^C7P\[P)ESU
M=; ;TYT&0*%JJH()0.85.0M4-+F8^FCXBHDCNGT:G0=7ONW@;+&@YO45#^<B
M&YQ">\ISB$7;\6Y#2_#T?G"0JZ;R,?H.G@9Q_,S\;K&E^XBW>2![7F.YM5)K
M^T&&EI_XX.ZL%9X#:=S8BWQKS<PE3C-O/<$/813)%A]L7"L@ZSV/QM3=$]$9
M3"_/<+) <]!S,1<020E1(6)G_>..L\2)NZ3* AR5CC<6L:>%EC.#.* ]6EQ
MWX915E7F.Y QHAO";H_O4"=TN+J\4;*K-FYRTJ;I\/V[220",H/I'S=#]SE/
MA]%Y"]WDCG8<+0K%W <)7O,#!QPE(HGLAI?,2\(4W^+X*5QA63+D!J_H0R2H
MB.HA>N?9OF6Q.77U*YN/_1FSZ2,ACFAFD<N#\%?^,Y %X&CV1\?&\J7;6G%)
M4 C+EWT]=P:ER*@J,RJ$1IG4>>.=BMQ("#[ZB4Y/$;>\:6L=@)]BFFB>^YCR
ML#FE,.,Y?HR"MQBUM@GJ"H>YXD\JT",I1:/A5K:\+1H5-P.&$ 9&+!!A2?QN
MN>.R)>=?<;P*$[U6Q0;$G:/?S<R]VW/N8MW;[$B\WPG?EXSY;^7'5$H$.@(H
M6,*PZP^!,#O4AYU=2) EY&0RH$((&$Z>!49/7MY+W5>0A^;GF8?/;;ZW=/=!
M,.8'O_KL#L+CU9H[B1BEU3O,CKZ[<TD5?K[]OO-Y(0P/MS*!GB-G==7/$>[.
MH^FAF9[)(7\]L)P#WB[/P-S5)S?@8S? /@OZ+L'O?)/JOMO<#W+<$7[@*5YE
MTE?94*ZHMU5BGO>8F]5(F]GRW0]PR^$O-^AL<*QCS-XMZK"9K-O).0O6;>2]
MI"8ZL-*)YN)>0+NGWF[-S@"\KN#:ZF^03L&,UL?>%\0@5L#U7A4=O2D0C9E?
MAD]LBD$[$JQ$HA\,MS1>$X^R"!Y_U>MDD3O^"99+#W70\5J/ UP?G=FAE8G#
MJG2W!HJX\H&4R[U)7TB:55^G^@MEOSV;TD>,+J^7OVM?>[JI(,,6AP<[-88,
M&QDZ;7O:SP>':J^B+\5?YLCP$:)LB$B.$>6#]'.(,<-VC1-XB?_#I!GBT'\P
ME<7Y%^4L\XMILYQ17H;J^]UCYE-)[YIR5C#-?C9Y.5 H;Q[ N8V7TX6N8@=7
M-&';MG2YN0N^ZIPMJ-$SWV>JT'?OL[(VPZI6FR&4M1F^)8PSD$,"+3"IB5+G
M !RI8M9:3X/S1(PI=VS&ULFK(ZC//^5;I?,HO^,\%^^@G#ZX&O.A8]= G$UW
M<%_.><5PK$=S=OBI58WG2XX@>;S"08+/Y:L#I?/QGB\;5A-O(^:E^#M?BJP8
M)T0XJ_RM10*AVGLO&G104?T=FCLLX"Q;K EZS&^9HECX5S>"SN\;VD$'/2^F
MD//*3"$LN$$PAB%@J(K"C$PBL[#\FGT9G<KZ3HQL9S*.;M#0)&X75+28^0TZ
M><8)XA\4PD!O0V%E$=0:C%%;SR\W7,H+0K\DB_LDC8-5JG=CW$?'07&E%KJ>
MRBRQ)3]GA00O]$O.#5J5JS[ VNI==2IP##-C6RG._3JFW O6)\^?$[R^C)9L
MR<<\@6V"5LP?PI3W'3$P/A/J%I6YM;EY."+D!KH1!LK- ]&<.0H*[C_",%@+
MZ*F]TN<'<Q:/^.&#0#D7 )T\(RX"/RDLA$"E%$J1RHMS,PDW87JE^0B^^BUS
ME$HJ'IH5, A([ZOC,?VH1<NT6P]P-)K9LR0K#M:FK';#RTM$JY!@!FYYO'A'
M/<Y.?O@[JC3B2!X?]>'+$B,I17$N)XHRK^2?\I_%_F*7!\G[9_3MGD?),/H.
M\JSHU2B[RMXX!?LE&B YM+T[B@H1Q8U ]8: _7(F<W1[A0^M'5X'!8N]72O%
M\0K.P(@$ \A0-7W!1"'?6W<4=1G9!\[PCDTCH;;EU[]GKNDJ'?=67J4.J]Q;
MJ]YIGUX@Z9@<JG=DN\W?+"PW><K,WX(X#MCL=$'CK'Q:LHQ/21#JU9_7)&R.
MBA:C$1]];&B,"./-JXX%#S$&]/S*#'1JI?-9 4P:V"XWE<2KG#MB[/,*@PE:
MQDA*8)_NYN_>]J!=XL&E+63I22&X7!D+%BCG82^YGWO2UK?^G=>D4$?1G+ R
M\24$EPKB^YF]HE7,)3C#\K^5;5Q6)-3D4$6'JD584^;BX8C_D8G'@E885<\Q
MD@2SJ,9S@$D8W(<$TIF& =+47-?S036?J3*V*.=;/R4HNNQ-=41PJ);K&//>
MC'DDR:(XFU]%YN1"V**=TZIQ< FU"D<?LTG&MTB\$CY,9=;PGDD2I9ES0_5E
M+6/H]6MU"&8&O(*_YV90S,Z9'&+5*A.2%P-F,)+S+U8KGIB<7 ?//'_5SL\/
MB+E$MD'<2ST=P0#M) >H+MH%6:\WMFH//#Q]/E; =3T$UTBN))X L1F=O^HY
MW2<IW>+X*EN^/=LYU@!IESCVLO)QGIE%R!@_X:BO#\"T3J<&;J\+*FAV9D#V
MN6?.7CYRRP5 A023NRNONK5G"[=R@V4]^1W0<QQ@&_3]E)3C#R&QTDG.I%-@
M%W9#LV"K#N> T\!<*'"K,!W9O]3SZ'2\3(?J&#F CCR.I@&I9)^)L]\RGZ6:
MY=*6VP+#*0T -TKT'"_!<]K$3AC^>AD]X<1;JG8O=><0]W#SGZH=YLSA):59
M0#_LP8-*GQ_,*AY=" $B#8SMB/,6<ZM_[,,8,Y%9R$F?KYF6TT6TY@^9=_Q/
M=)Q:AZI%8K(R%R_GM^SKCP$_N!4U621G<8B+<[8PG-@ 8FJNY!G V<A#S]B*
MOH62,<HY(\%:',6>#X,ZCH,NGH*0\%,LGD@1$'R+5_M81)$S?&_GI4.D'6+;
MS\JGOW)W#7+N(N$G8?Q14@@ U&L5<>]S716ESP7C82<NV,N<'PYR*0'B(HS_
M+&J%\3JY8$!S<98;A[ZL3=OJ09 6+_=+Z!N\QMM=WM!@#MYL"CVU5?O<8,X=
M.F...'?IO,L-/)=6WVCXV1./LTGR>);5_DZK;4L,PY$- #?:"8^W YYVYPO#
M7R_"*(A6OLZR>JD[A[B'F_^SK$W.?#9G62K0#WOPH-+G![.*1Q="P#C+JBQ8
MRO<'5J6:C$F[678IL'+OT\722YY.J[4U?".>7K._*?Y^11,HN8NFAM&Q^%9&
M969&T+KTKCZGZ>D$",35BXJ4+IR[0LP]D@7Q<1VX?.L&VS4/@51PQH9.P8.F
MX'!E07 0'G8MVUY=YUVO[-WLD*)KV)H<?#M<Q@\5#&<X-W;B/.B%[=J>!Z:#
M_G@ +0BGO*+1PQV.MS9GQEW47 -7I>[;$3D?=$4#('4]-, ;]+)#-<(':M"[
M.$L)&IR3W)9MMI\3H7&."$8ZR6T[!H+AA 8P&YW^C'?J,^UIS\A>RF7C_\>S
M,9X"PJ]\;W"2QN$JQ6O^BT6TKG]0^4O9K.<P#3OKT7#^=25>6-^P&?Y\L\%Z
M9[]C2V9N6N-*ZB?BA'EJ>RCKB;^1,0B7@KY!R2.-TZ.4SR?R/FDK/^<I6G$Q
M/O%%&+%I(N.FTYK&ZS)D4KDW$?]3$0F5PLK?\;RSYF?5O\^ZC[6]\\B&@?)Q
M(#X0)$<RIYA=C.0L3'8T"<A/,=WOV#?8OWGSG##:XW66)$\CK;79N')-9.::
M<KKLVW.;!G%:N2=4C]%M(1H%*;K'#V$4B0[L&R29O(#(;6KBKN*VD8F\)G-V
M&K/+T)P/ 8DQB"]61X'*8;AIUS4[O3?;?^D%D=:%'H\BHNO,</SP<\K 8@D3
MHTS#B=;%KNHRQ5NSM!-UHA8;4E4F'HO>A9P/E'02;22IL3)G@QHI !-X51*^
MF,^5QP>"\W1Y(C?APV.ZW'Q.L*BLL[Q/@S#BIROY8OF"QL6[2U$LSZ@VAQ4;
M<\@MV'I(U.;"'-'-T9X75)6UZD)>C3C;E8AZJV++0E3>HX_IX"ZLA#J$9<86
M02K&P _Z/_/R5EP4E,O"CQ>+K2K/[2[?/<MJE0K%0!0T,G$SO%KF9-GT[I:M
M1'CW\+[\JJ)AGKM2M1,HH)P?Y,(X%P$MV0>E0N#D&57[U,M"QK(YLV@"?ZQU
MVC! R6)#U4O9@^667>[%R]>ZG?)%=\07;)4N]V'>Y3[D7>[A)2$IHDSU= X;
M47( 9EDO6W!#&;O13PM%U5-1!7$=IGLV-K;YY 4QUR?[]!--_X[3ZR!<ZYWT
MJ=*T.=90X^$AZ6'X(3J_+V'[=_&Z!@6-XH7B3P.0Y9RTC8&: C(7X(NS*%D;
MN,H5Y6P1XXL88\0X(\Y:RX63W(<3O'K[0)_>K7$HW9?]T/1:]M&O9UF+7SYL
M&N]HS!]=GSS?\'D!,XCO\-?TA"CFY&H2U(=-BX&'(H8Y:U3ES7,F"N[3NIX9
MHM1(L;- C_0"=U(!#OW"62/!>^PSC67\$$3A/\7Q*YO3$TK"M?C'(EJS)722
MM^!>;K)CF( 4C8"-#AT=,32/NTX$<&HB58E0321Q_E45BB^V"K%0*1>X[M)N
M[8IZ@6^,?M56XO)+$D(3-DEKS87^>$_D=2VRN)]A:U[(E[8G01**M7%5OA?@
M77U6Y<K1.A%[:1;D,(27,DZY(,AJGH?1PS4;P\JT57$/%8M^KYU4W79M+=B@
MG ^X^54!)JJNN#%F0A%.^0N<TA68:]R&#U&X"5>\4MN!D$:SGAT?<^.TX>NA
M5>U^NPWB9SY]541 +:8-PYZ=6 =UB<:<+2$+9'(%LZRO8,2$-& 34TY %T$8
M_QR0/2[G0Z,IJ)^..;I]=)VBQQDAP:FR-( W$RGA177T-\9LU":%T70S0,BM
MG7F<,"K6]A$'G)M8E<*UL=[PKZ \T,@,A "3Z,RO\(4W''_(?$%<ZF=]Q/+&
MJGD;LU/92DZV$--R#!.J^ECH<W$#S#H[SI4]R-6;\;V=UI$LH*;FRAXCD-?%
MJG?ARV4S6#UHD;5Y0ZW,QO%C:FFW74T#4<8<W&K#!&YJH>_Y1*9Z/8,:O YR
MOR884+NI)A5;S8TTL]D)-RV=)>?-8L\@,:NJ#?W$71=MZ"R(#S"VJ()(M?4Y
MSE38(8KE/9(>70^F.<K]SW4U TJA:P,(RU2\R]'7[)Q05(DU,"Y7LCZR?/H4
M_?0"8G2TU4O&JA%#%UG731<$'P%1S@G>;*" %=50WA@S0*-#\F&?R'S=5OFH
M](QL.64T1[CF;'U)Z$@2?PU0U=;F(]\GNK:<PSM(I[B\+"NI7S\77<?;6J]6
M-D'53RNS7+&!GVZVX]782HE,)KHN"N:XMU-TF_')6-36&\ FM@%8J)JRQIC.
MZOR-YJ5.$JY,R&?.=V\UP^E,IC?,]VH'J-*['-?A-<L=WO+4[_B9;TG29_T;
ME6X"AD>4702]W),4S,3;HO09PG7(("1425-C!,*&!':3J@(Q<S\=).[48TNS
MDNP@3[OJ&%)M=8(, 8=O?S5?9L,81I>I3;BPYG52RF?2E]DK:=,20'V4["K(
M=%-V7C:F\FH\YP4N BC"1O64.,;\\S&,:,R,/I? <E&N1,[<]!3(>RHVU6*%
M,$Q/!T!JH,D9@)4%BYQ?&29@7 W(6<4DAC>_:8Y%G9)3M>>3)K"0W*%UVJ^3
M,4*N6!L]4K)F,4;*\(FFV#+P:A UMR)E)AY>/518__=@1Y-_16=X$ZY"(&%8
M'U1JK-?9 $@.L<O7V)POD/A<2B$:>O&[&W&V<8,)?]!_RCLSW3X&,;X/$KS.
M^\H;'7I;<K(X9+/B[/8LK@1=]C,KA$&9-$B(@TIY4"X0N%G&D>U0MTB-<H*O
M*N=)54ZSDWY;5B/X33MK3_/@D?2*JD S<X<!HS#QASX$9FX 1I$3G31"I\,[
MC_/MCM!GC(4UYM7&>'*6X2K6@*CAP:@.$R_W);D 67'$728"VC$9T+H0 L(U
MBA'*U%C18\Q:5:<1U>W34#Z'L[MXT2)K4P52F8WCDI"54"/;&>2<(=_+F(!-
M+;0]FY!475 4\4A6^LSYBU1;^PN<\<=&AH<%9-_)J\9M\5WPU2[V])(QCS4]
M9)T")?D@Q@AR*%'!BFHH;XRYKD4(H^U7/QVG%N8QSI5V!B4Q5PF??J-RMLWQ
MCT6_NSO<F]S@!#,4>/.BJW E'H,^Q-BJ[)X97</E@"8?+YN47 ;Q8HI(*5!0
MB%'9IZ"4(W?/)8&P93$%G]HH?XQ@7A'L##]A0HW?H Y1LN@JTDO9;>.0W$!%
MC[22&;B%@R)N5$^+<PHMM>8_U;B2B8!*&>SW&Y.,L,TF#P<'9-=Q2@ECQ6M5
MAT]X$<>\OXZ#E\1:9&U.0)39^$AU+)CS<Y <61B!Q@17:J'8&6%(#N![8HY9
M,@;CF=MM*#M5L@AR*GIH/N!H57N?9G@ZJ4/8ZGQ2G9'K$\J<LPB_-=Z0#Q;,
M0*=6.A_IH'U8+,.91H^R9W/V.M^41ATTC7I&YCLP\>@K>5Z0:H>H":M8L#6K
MO.T0+Y"O*0L;Q;7'"8[P)K3N76#.PZ+^A2%/C]<M&5>%>Y;1RF+8@D]=*7RN
M0&>>G@E1><E?ER/''HK79\DCUT&</M^Q57'"5@J\9[O9Z=(0+9OSI7[:CG?S
M,J-&<$-5=N#6D,KX45U=CG.RV2Z)Y32C1=:]38YTG-9EH[ -4W$2T=;MC& <
MCC(PYH;;_7V"_[%GL];YDVG:>S<-BY<,'33=/EPHF"#)!5SH'X2'JJILE)=/
M#0G,7CIU$W%G3E[[MS2,"J8E]3]8ZE<76!RZ_7JZ"/L_]RSVXY@\%ZW#+J,-
MC;?BEL'NX%>;M#EPFJR<PEGPKG1?JW"'?/QK"CZUU/P8T;Y7,*/0KTK1DQG[
MG!0PP2N^$"QM^2Q( _3MYRC8KT/VF^]F8+"]<X:.:N<!H&+XF7!NR?J5-;J2
M/<O_-7)!58K6/=8&.+AW0<!-835A/&R6IZ3,>4!&JF@M-P<][I[S_TQZDU]I
M$VOA;/UT;&[!NNGZ*+\?LJ"XXV7!Z:;>0A>&>RG!1774!QF:XCJRVLIX>I_Y
MG.#EYCQ)0S9KXD3'2YK?-%=^G9)[3V#TN0L4'&"8?X?F:;]>8&F9E I>*BG8
MV^O2&#_RZ[\G+%\Z6"^XU&G:O2M5X>$EQ:7DC++'(=^R'6L"9+^C#2DU5>M<
MX",]R(%9@=WB!W[3?H-W-':R[U$D:''RJ<+ Q\&#8%O=L,)P/#T$J9$B9X$6
MJ0-5L(3C;!<TQN%#)/M2K.KI!-%:_),(RTHL'-""B44_8%.F'KHX2U%0+@L,
M+[6'GCK3]FQA)NT(U],!>#)951( ?G\:)/RA%?\/K^KW%!!^EV:SUE4C:+%2
M4F'@897+^,D,;OY#A3,,)];#D1JI<Q:8D0I<BQ:XP/K<#4[2..072'W:LG=%
M53ZNT5;CZ^6]:L97V )D=]4T@4$OUE'YG.$>]/F&#?0%AI%CP<<@_@VGO)'<
M+5[M8]$H3M_3^ZA8%'_OI.IA#_O(=D1'[),M*MDBT?.I9 [#=Q4@H^I*A M/
MYE45.$H^TSC+*0<G2N7C[9LP^>TTQNLPY3]I7LEUD[&Z]NDBZZ5E3\E,W,D)
M9HAS$\O4Y69S=!\PJ5<,MT>,Y:]@>) *CE1#L8 Q(VUP"9 J@-F62[IE6\YP
M$ZZ"*+W=[W8D9(9BL(53IV58NT2!MI=22!6^*,D90RAUI ,<U54B=)!JTW\%
MH8*K?2F9T<9">H8!8,=Y$83QSP'9X^6FDE/'UL3"2PP6G(H$+8[S5!AX.*%E
M;)'@BS[B@.?<*A0U&NV@5@M%:J3,62!&#L!:;FJ)FP77:=:IUS'=X3A]YN_"
M4[;7Y+M,40',XEQ5G:;%RVM%'C[RRR1GL70MV,)P.VTTJ:E&YX(<:8 FN(I#
ME8(O@$GO<KMC 8(+LXS/PF1'DX L-U<T>K@*G_!ZD238ZJ;#C+Y%?5<#?AYJ
M\!92\%TGYWXDV"/)'X;+6D%/7:A\CC"3 X27,<I%X%,L%P)5T0;@Y>VE-L^_
M\K+_6']AJT3.=7G5&GG/%3NKA59EIQG^Z6*UBO<! >*^.I@.5EUM4>X,\",-
MZ)HU<C.6TZQOKS#S?GS%-DC89@+M)6..40]9][XEV<!P&Q58J(:> $- <NUS
M/D@R C 9=95%;;ZJTKNM4*7IOIQKDX?7>KSU@JY ?$H;485ZO.U:G0MZ9 "X
MP]=\HZ\(GW"TQS=X11^BT/+YG@(QF]7$ '$?:T'!$E5XPG T==2HM@+!(T0Z
MP;&:U#JN"Z^#E/FI6/R;WA+VD3"\=^HFZ>5.4+)#*\X/PE6@ BA445-  :B=
M]TKM"V;VUWR^)2>'0@-8;)8M:ZM=#I>[K-?AI<@X8),S/YTUN.(S(F_Q&D>?
MG:_.S"= .S/; $X=:'J&X.;W\I5FRK5&J%($<;I2""&N,R:Z.2QZN-G<2W32
M<-!;SO_] MP>?RH7!KUZ@JI_TE0]@-GM/(@CMH5,KG$LO-?"(09)F>,R0-J]
M>WS"*;JB"0M/.)8]XF$XB2I<5%-WP*')/"?G5:("P(,^X2^5$Z"81NS'%:XD
MXUBXE#YM<R!U>?DX-.%+ _*,%FNZXX](JD=<-8%@.*,Q\M16ZW-#F>11]4LW
MIBX>Z7>=Q&09--6,G3O^U,+@1$:!E.G!P"!I/R<TU9PPG#,&<5:C#AO5U"%P
MB%IS]A;J.7N0QD+ZAH$$QTF/=U:/>+TGO,Y68R7#ZR:N> 9"2/9L-M(/&-8L
M+$X"S%AZ..K)!.%9;(*US(Z1S%&QS-[!6F;;&@5UA,1,#8 TL.=UY@Z7[M(<
M%A5S !0,%FR)LN9BA4^5=Y_G7U=DO\;K"V8M_(!K+R?10R5;Q@EWW%U8D"MI
M_-3$R_CR #.?L.+<O%HCCEO@7IXIM<2IJH#5A]BYB(C+B*IVUQ[<8 2QIR D
M/*9>T/@VJ#Y@YU??T2HDH2SV[F!I8\K+B549\?:[V"G?264YW-E#MS4*4E1Y
M4L7?*7-Q8[XC%J6ZP<4J.RMJCTP6B,W=8MJB3BX.8O(@+E U]M1%LEDE=3UL
MWV^W0?R\W%S'>!>$ZRSK.<E[@\HR:ZDT9,.#$RL>IF^LS7GZ>2 OY>'A82<E
M0C@326R+J.B NI)2H4"(!>$@QH5]4%>8S-46ZHW-"D/(Q,E?&DA#D*UP,Y&4
MGGS-0@6D/OIER^@7':.??F_8^?;3[3MCOR^,1UK\S/*=L=D+8_]OBR=X50QC
M]\(?R^'U51C<L[4/7PDYV:<,4G6ROAS@XM?],NY%5(7A> ;(MN\=E'0['Q3;
M]@,9@!7./I;]Q4!/Z79+(Y&6*8XO>%E)'#_A-=N.7.Q3MFV]3)(]+W)FNOIW
MP,ITX6?-VL]>H.*O*R$82KAD*!&BH3B3#6W8CG CI$-A)AZ(/8$[XZ&.D9JY
MH71%=2D5$F+)4T91<;6T$BD:RF5SL&$ HI&6"-FKC(M#94R_?RB5V9ZF+88B
M$Z63Q2H-G\+TV<6"QYR;BRG4E+O7/;>TFCPI/>./]M&:;3O9)/D'L286>Q?V
MKQ_$OZ MH:QMJ'5I98?6_.VE)=!TOFFH&E%26A'(.',=/(N7RE^">%W5);^"
M$*-9L#"YE9^YC3DVG-W:D[DD7F/13S';?A^M@Q37;H4V#?L2?\9,D!G>WW#X
M\"C28Y]P'#Q@F+=&3HUO(%C90ONR#&T@B&7B(2%?P\H*$5%%1G A[;XY/91]
M!\1P%M&Z\<GG*$S=+ZH<R^',"IW*Y7DA%J1[T>NXVCJBLK0'&=7\V%]WC/.
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M57(+.??+!V%^)1=8[T;Z\* *B@*H>V*H=B_V?L>&L=PLXICI0_0"T.W%U$'
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MXU#:+_NA:;KLHU^O\$- A,\\JZY06K^FK\\6,AX>!W$&,B8\3VNN?<JF/=H
MI%ARJ%.3)8:VC4I6ZNN)P^^8*;%*P[UI0C'*5NW2+@U T22I*M%9\>,S3((O
M08ROPFW(%A-787 ?$GXN2;=LOGO6K("F2,TXAUZ!NJ?G$)(SREBC@C?*F$,X
M>]/#DNIK%3YNM9GPZO3;B[NCB__\SL6CAM&&D/GYL,E-52FLFE=Z99(GU4'
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MMIQ']XJ<\SPYX%=$F!?QY:^4>9FG.\H_FO0L5%VFZ0Q45<8Q8^(^>A)2O>R
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M/;ZCY69-V8'=,S;T6->">''10DBTB_&!2_&*FOV'05)81#<;M-YCWC6D/#B
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M0UK#^S4I7I\@XAVD7Y/C%M^D!8G[S8(38[*.P!EF\T=U%$U,^UQ(1ZD+PF_
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MGVNE03C!(32G@,YFB.XK-@^/L,G5IX?(C*,7":J0B$=5V726,;D-"6^[TJD
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ML9\/7N<B#:]=2!O;OK)+@)GUX42[!)BY766[!)BYV22[!'PP^^5:^ZJ'IUN
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M@E(<@M33:JOQ]B7H(QL8X^]:7_156]P]XY"F-]UX#EYC!TS)[SA<Q&#1%;S
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M(0 1              "  0    !F<F5Q+3(P,C Q,C,Q+GAM;%!+ 0(4 Q0
M   ( +R ?5)KE2B"FA@  ,$G 0 1              "  ?N[ 0!F<F5Q+3(P
M,C Q,C,Q+GAS9%!+ 0(4 Q0    ( +R ?5*UOY]]I1(  (LD 0 5
M      "  <34 0!F<F5Q+3(P,C Q,C,Q7V-A;"YX;6Q02P$"% ,4    " "\
M@'U2STXD:#$W  !=Y@, %0              @ &<YP$ 9G)E<2TR,#(P,3(S
M,5]D968N>&UL4$L! A0#%     @ O(!]4F6VZ:;/DP  *2\) !4
M     ( ! !\" &9R97$M,C R,#$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( +R
M?5+SO4]4D5H  ,CU!@ 5              "  0*S @!F<F5Q+3(P,C Q,C,Q
>7W!R92YX;6Q02P4&      8 !@"* 0  Q@T#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
